PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Vitarbo, EA; Chatzipanteli, K; Kinoshita, K; Truettner, JS; Alonso, OF; Dietrich, WD				Vitarbo, EA; Chatzipanteli, K; Kinoshita, K; Truettner, JS; Alonso, OF; Dietrich, WD			Tumor necrosis factor alpha expression and protein levels after fluid percussion injury in rats: The effect of injury severity and brain temperature	NEUROSURGERY			English	Article						hyperthermia; hypothermia; inflammation; secondary injury; traumatic brain injury; tumor necrosis factor alpha	CLOSED-HEAD INJURY; TRANSIENT CEREBRAL-ISCHEMIA; TNF-ALPHA; MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; POSTTRAUMATIC HYPOTHERMIA; INFLAMMATORY RESPONSE; CONVERTING ENZYME; CONTUSION; IL-6	OBJECTIVE: Tumor necrosis factor alpha (TNFalpha) is elevated in some models of traumatic brain injury (TBI). However, it is unclear how TNFalpha messenger ribonucleic acid (mRNA) expression and protein levels are affected by injury severity and posttraumatic temperature modification. This study determined the regional and temporal profile of TNFalpha levels after moderate and severe TBI and assessed the effects of posttraumatic hypothermia or hyperthermia on this proinflammatory cytokine. METHODS: Adult male Sprague-Dawley rats were subjected to sham procedures (no injury), moderate fluid-percussion TBI (1.8-2.2 atm), or severe fluid-percussion TBI (2.4-2.6 atm). After 1 to 72 hours of survival, animals were killed, and brain samples, cerebrospinal fluid, and serum were harvested for enzyme-linked immunosorbent assay quantification of TNFalpha levels. In a subsequent study, a 3-hour period of posttraumatic hypothermia (33degreesC) or hyperthermia (39.5degreesC) was applied, followed by immediate killing and cytokine assay. Another group was subjected to moderate TBI (1.8-2.2 atm), followed by killing at 15 minutes or at 1, 3, or 24 hours for TNFalpha reverse transcriptase-polymerase chain reaction analysis. RESULTS: A significant increase in TNFalpha mRNA and protein levels in cellular lysates of injured cortex and ipsilateral hippocampus was noted by I hour after TBI; it was sustained to 3 hours, followed by a rapid decline. Increased injury severity was associated with increased protein levels at remote injury sites and in the injured cerebral cortex at 72 hours. Posttraumatic hypothermia significantly reduced TNFalpha mRNA expression in the hippocampus compared with that in normothermic rats. In contrast, no temperature effects on TNFalpha protein levels were documented. CONCLUSION: Rapid and marked increase in TNFalpha mRNA expression and protein levels follows moderate and severe TBI. Injury severity and posttraumatic temperature play a modest but significant role on TNFalpha expression and protein levels. These findings suggest that the effects of posttraumatic temperature on histopathological and behavioral outcome primarily may involve secondary mediators that do not operate directly through their effect on TNFalpha.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurotrauma Res Ctr, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurotrauma Res Ctr, POB 016960,R-48, Miami, FL 33101 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42133, NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER		Abbas AK, 1991, CELLULAR MOL IMMUNOL; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Floyd RA, 1997, NEUROREPORT, V8, P915, DOI 10.1097/00001756-199703030-00020; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; HUNT JS, 1992, CYTOKINE, V4, P340, DOI 10.1016/1043-4666(92)90076-4; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Karkkainen I, 2000, MOL CELL NEUROSCI, V15, P547, DOI 10.1006/mcne.2000.0848; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Portella G, 2000, ACT NEUR S, V76, P273; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vink R, 2002, EXPERT OPIN INV DRUG, V11, P1375, DOI 10.1517/13543784.11.10.1375; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zhang ZL, 2000, J BIOL CHEM, V275, P15839, DOI 10.1074/jbc.M000604200	54	87	92	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2004	55	2					416	424		10.1227/01.NEU.0000130036.52521.2C			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	844WJ	WOS:000223191500036	15271250				2021-06-18	
J	McDonald, S; Flanagan, S; Martin, I; Saunders, C				McDonald, S; Flanagan, S; Martin, I; Saunders, C			The ecological validity of TASIT: A test of social perception	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; PERFORMANCE SURVEY SCHEDULE; POSITIVE BEHAVIOR SUBSCALE; FRONTAL-LOBE DAMAGE; RIGHT-HEMISPHERE; EXECUTIVE DYSFUNCTION; LANGUAGE DISORDERS; CLINICAL TOOL; IMPAIRMENT	The Awareness of Social Inference Test (TASIT) comprises videoed vignettes in three parts assessing (1) emotion recognition, (2) the ability to understand when a conversational inference such as sarcasm is being made, and (3) the ability to differentiate between different kinds of counterfactual comments (lies and sarcasm). Many adults with traumatic brain injuries perform poorly on TASIT relative to normal control subjects. However, the extent to which poor performance on TASIT predicts poor social functioning is unknown. In this study 21 adults with chronic traumatic brain injuries were tested on TASIT. The TBI participants were video-recorded during a spontaneous encounter with a confederate. Their social behaviour was subsequently rated using the Behavioural Referenced Rating System of Intermediate Social Skills-Revised (BRISS-R). In addition a relative or carer was asked to complete the Social Performance Survey Schedule (SPSS). There were significant associations between TASIT and different aspects of spontaneous social behaviour, in particular, the use of humour and partner-directed behaviour. No correlation was found between TASIT performance and the SPSS either Positive or Negative behaviours. These results confirm that failure to recognise social cues on TASIT translates into observable and reliable difficulties in spontaneous social situations.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ADAMOVICH BLB, 1984, CLIN APHASIOLOGY, V14, P124; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; BEEMAN M, 1993, BRAIN LANG, V44, P80, DOI 10.1006/brln.1993.1006; BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; BOROD JC, 1990, J COMMUN DISORD, V23, P247, DOI 10.1016/0021-9924(90)90003-H; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWNELL HH, 1986, BRAIN LANG, V27, P310, DOI 10.1016/0093-934X(86)90022-2; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CICONE M, 1980, CORTEX, V16, P145, DOI 10.1016/S0010-9452(80)80029-3; FINGERET AL, 1983, PSYCHOL REP, V53, P1175, DOI 10.2466/pr0.1983.53.3f.1175; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Holland A., 1982, CLIN APH P C, P345; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kibby MY, 1998, ARCH CLIN NEUROPSYCH, V13, P523, DOI 10.1016/S0887-6177(97)00038-3; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; LALANDE S, 1992, BRAIN LANG, V42, P165, DOI 10.1016/0093-934X(92)90123-V; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LOHMAN T, 1989, APHASIOLOGY, V3, P685, DOI 10.1080/02687038908249036; LOWE MR, 1985, BEHAV MODIF, V9, P193, DOI 10.1177/01454455850092004; LOWE MR, 1978, BEHAV THER, V9, P535, DOI 10.1016/S0005-7894(78)80126-9; LOWE MR, 1982, PSYCHOL REP, V50, P83, DOI 10.2466/pr0.1982.50.1.83; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1986, BRAIN LANG, V29, P68, DOI 10.1016/0093-934X(86)90034-9; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S., 2002, AWARENESS SOCIAL INF; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Moriyama Y, 2002, ALCOHOL CLIN EXP RES, V26, P1239, DOI 10.1097/01.ALC.0000026103.08053.86; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; Ready RE, 2001, CLIN NEUROPSYCHOL, V15, P314, DOI 10.1076/clin.15.3.314.10269; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; Sbordone RJ, 2001, NEUROREHABILITATION, V16, P199; SCOTT S, 1984, J NEUROL NEUROSUR PS, V47, P840, DOI 10.1136/jnnp.47.8.840; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Tate RL, 2003, NEUROPSYCHOL REHABIL, V13, P43, DOI 10.1080/09602010244000372; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TOMPKINS CA, 1985, BRAIN LANG, V24, P185, DOI 10.1016/0093-934X(85)90130-0; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889	54	87	89	0	23	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL	2004	14	3					285	302		10.1080/09602010343000237			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	829WZ	WOS:000222083400002					2021-06-18	
J	Susco, TM; McLeod, TCV; Gansneder, BM; Shultz, SJ				Susco, TM; McLeod, TCV; Gansneder, BM; Shultz, SJ			Balance recovers within 20 minutes after exertion as measured by the balance error scoring system	JOURNAL OF ATHLETIC TRAINING			English	Article						postural stability; fatigue; recuperation; concussion	MILD HEAD-INJURY; MOTONEURON FIRING RATES; POSTURAL STABILITY; TREADMILL EXERCISE; MUSCLE FATIGUE; CONCUSSION; CONTRACTIONS; PERFORMANCE; COLLEGIATE; MANAGEMENT	Objective: To determine a balance recovery timeline after a functional exertion protocol using the Balance Error Scoring System (BESS). Design and Setting: Five subject groups (4 test, 1 control) were tested 3 times during 1 session: once before the exertion protocol (pretest) and twice after the exertion protocol (posttest I and posttest II). Posttest I occurred at staggered intervals of 0, 5, 10, and 15 minutes, depending on experimental group assignment, and posttest II occurred at 20 minutes. Subjects: One hundred subjects (80 test, 20 control) volunteered to participate in this study. None of the subjects had a balance disorder, mild head injury, or lower extremity injury in the 6 months before testing. Measurements: We assessed balance using the BESS, assigning a score for each stance-surface condition. Results: We found a significant decrease in BESS performance after the exertion protocol in all test groups, with exertion having the greatest effect on the tandem and single-leg stance conditions. All subjects recovered by posttest II, which was administered 20 minutes after cessation of the exertion protocol. Conclusions: Athletic trainers need to be aware of the effect of exertion when administering the BESS after physical activity. Athletic trainers can expect the BESS performance of healthy athletes to return to baseline levels within 20 minutes of rest.	Arizona Sch Hlth Sci, Dept Sports Hlth Care, Mesa, AZ 85206 USA; Washington Univ, St Louis, MO USA; Univ Virginia, Charlottesville, VA USA; Univ N Carolina, Greensboro, NC 27412 USA	McLeod, TCV (corresponding author), Arizona Sch Hlth Sci, Dept Sports Hlth Care, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	McLeod, Tamara/AAU-9435-2020				Adlerton AK, 1996, SCAND J MED SCI SPOR, V6, P211; BAKER AJ, 1993, J APPL PHYSIOL, V74, P2294; Barr WB, 2001, J ATHL TRAINING, V36, P297; BIGLANDRITCHIE BR, 1986, J PHYSIOL-LONDON, V379, P451, DOI 10.1113/jphysiol.1986.sp016263; Borg G., 1998, BORGS PERCEIVED EXER; BYUNG YJ, 1991, ARCH PHYS MED REHAB, V72, P642; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1992, PHYSICAN SPORTSMED, V20, P66; Crowell DH, 2001, J ATHL TRAINING, V36, pS; Derave W, 2002, INT J SPORTS MED, V23, P44, DOI 10.1055/s-2002-19374; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; DIENER HC, 1988, PROG BRAIN RES, V76, P253; Fulco CS, 1999, ACTA PHYSIOL SCAND, V167, P233; FUNDERBURK CF, 1974, J APPL PHYSIOL, V37, P392; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAKKINEN K, 1993, INT J SPORTS MED, V14, P53, DOI 10.1055/s-2007-1021146; HAKKINEN K, 1983, ELECTROEN CLIN NEURO, V55, P436, DOI 10.1016/0013-4694(83)90132-3; HORAK FB, 1990, EXP BRAIN RES, V82, P167; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Lepers R, 1997, EUR J APPL PHYSIOL, V76, P55, DOI 10.1007/s004210050212; MANCUSO JJ, 2002, J ATHL TRAINING, V37, pS10; MARKS R, 1993, PERCEPT MOTOR SKILL, V77, P1195, DOI 10.2466/pms.1993.77.3f.1195; McCrea M, 2001, J ATHL TRAINING, V36, P274; Moyna NM, 2001, MED SCI SPORT EXER, V33, P1404, DOI 10.1097/00005768-200108000-00025; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; Nardone A, 1998, ARCH PHYS MED REHAB, V79, P920, DOI 10.1016/S0003-9993(98)90088-0; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Robertson RJ, 2000, MED SCI SPORT EXER, V32, P2120, DOI 10.1097/00005768-200012000-00024; SELIGA R, 1991, AM IND HYG ASSOC J, V52, P417, DOI 10.1202/0002-8894(1991)052<0417:EOWLAR>2.0.CO;2; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; THOMAS JR, 1975, MED SCI SPORT EXER, V7, P203; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; WOODS JJ, 1987, J NEUROPHYSIOL, V58, P125; Yaggie J. A., 1999, Medicine and Science in Sports and Exercise, V31, pS284, DOI 10.1097/00005768-199905001-01399; YATES JW, 1987, EUR J APPL PHYSIOL, V56, P662, DOI 10.1007/BF00424807	43	87	88	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2004	39	3					241	246					6	Sport Sciences	Sport Sciences	858UF	WOS:000224216800005	15496993				2021-06-18	
J	Kuhtz-Buschbeck, JP; Hoppe, B; Golge, M; Dreesmann, M; Damm-Stunitz, U; Ritz, A				Kuhtz-Buschbeck, JP; Hoppe, B; Golge, M; Dreesmann, M; Damm-Stunitz, U; Ritz, A			Sensorimotor recovery in children after traumatic brain injury: analyses of gait, gross motor, and fine motor skills	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							HEAD-INJURIES; PURDUE PEGBOARD; PERFORMANCE; RELIABILITY; ADOLESCENTS; COORDINATION; CHILDHOOD; SEVERITY; COHORT; ADULTS	The recovery of gait, gross motor proficiency, and hand function was examined in 23 children (13 males, 10 females; age 4 years 7 months to 15 years 10 months) with traumatic brain injury (TBI) over five months of in patient rehabilitation. We used gait analysis, the Gross Motor Function Measure, the Developmental Hand Function Test, and the Purdue Pegboard test. Brain injury had been severe (initial Glasgow Coma Scale GCS <8) in 17 children and moderate (GCS 8-10) in six children. Compared with healthy control children of the same age and sex, repeated gait analyses in ambulatory children with brain injury showed significant reductions of velocity, stride length and cadence, and impaired balance. Spatiotemporal gait variables were correlated with Gross Motor Function Measure scores. Hand function tests revealed deficits in fine motor skills, speed, and coordination. Degree of impairment increased with trauma severity. Despite significant improvements, differences in gait velocity, stride length, and hand function of children with brain injuries and controls were still present about 8 months after TBI. Hand motor skills improved less than gait. Young age at injury was not associated with better recovery.	Univ Kiel, Inst Physiol, D-24098 Kiel, Germany; Mechernich Hosp, Dept Paediat, Mechernich, Germany; Neurol Rehabil Zentrum Kinder & Jugendliche Fried, Bremen, Germany	Kuhtz-Buschbeck, JP (corresponding author), Univ Kiel, Dept Physiol, Motor Control Lab, Olshaussenstr 40, D-24098 Kiel, Germany.		Kuhtz-Buschbeck, Johann/F-7745-2010	Kuhtz-Buschbeck, Johann P/0000-0002-4603-7103			Asikainen I, 1999, EUR J NEUROL, V6, P179, DOI 10.1111/j.1468-1331.1999.tb00011.x; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Drouin LM, 1996, DEV MED CHILD NEUROL, V38, P1007; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Emanuelson IM, 1997, DEV MED CHILD NEUROL, V39, P502; Finger S, 1999, J Hist Neurosci, V8, P269, DOI 10.1076/jhin.8.3.269.1824; FORSSBERG H, 1991, EXP BRAIN RES, V85, P451; GARDNER RA, 1979, J CLIN CHILD PSYCHOL, V8, P156, DOI 10.1080/15374417909532912; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; GOWLAND C, 1995, PHYS THER, V75, P597, DOI 10.1093/ptj/75.7.597; HALEY SM, 1990, J HEAD TRAUMA REHAB, V5, P77; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JEBSEN R H, 1969, Archives of Physical Medicine and Rehabilitation, V50, P311; Johnk K, 1999, RESTOR NEUROL NEUROS, V14, P143; Kennard MA, 1936, AM J PHYSIOL, V115, P138; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; LEMON RN, 1993, EXP PHYSIOL, V78, P263, DOI 10.1113/expphysiol.1993.sp003686; LOEWEN SC, 1988, PHYS THER, V68, P1077, DOI 10.1093/ptj/68.7.1077; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; MELCHERS P, 1991, KAUFMAN ASSESSMENT B; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PATLA AE, 1996, CLIN DISORDERS BALAN, P19; Preis S, 1997, DEV MED CHILD NEUROL, V39, P228; REDDON JR, 1988, PERCEPT MOTOR SKILL, V66, P503, DOI 10.2466/pms.1988.66.2.503; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Stolze H, 1998, GAIT POSTURE, V7, P125, DOI 10.1016/S0966-6362(97)00043-X; SWAINE BR, 1992, ARCH PHYS MED REHAB, V73, P55; TAYLOR N, 1973, ARCH PHYS MED REHAB, V54, P129; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wallen MA, 2001, ARCH PHYS MED REHAB, V82, P642, DOI 10.1053/apmr.2001.22620	42	87	87	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	DEC	2003	45	12					821	828		10.1017/S001216220300152X			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	750NW	WOS:000187003500007	14667074				2021-06-18	
J	Chen, XH; Iwata, A; Nonaka, M; Browne, KD; Smith, DH				Chen, XH; Iwata, A; Nonaka, M; Browne, KD; Smith, DH			Neurogenesis and glial proliferation persist for at least one year in the subventricular zone following brain trauma in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; neural progenitor cell; progressive neurodegeneration; subventricular zone; ventriculomegaly	ADULT-RAT; CELL-PROLIFERATION; DENTATE GYRUS; RODENT HIPPOCAMPUS; NUCLEAR ANTIGEN; GROWTH-FACTOR; EXPRESSION; INJURY; NEUROBLASTS; GENERATION	In several models of traumatic brain injury in rodents, remarkably progressive tissue loss and neuron death has been observed accompanied by expanding ventricles. Here, we explored potential cell proliferation in the subventricular zone (SVZ) in response to this progressive posttraumatic neurodegeneration. Four-month-old rats (n = 57) were subjected to parasagittal fluid-percussion brain injury or sham treatment (no injury), and their brains were harvested at 2 weeks, 2 months, 6 months, and 1 year (n = 6-8/group) after injury or sham treatment. Brain sections (6 mum) were stained with markers of cell proliferation, Ki-67, and proliferative cell nuclear antigen (PCNA) to detect mitotically active cells. In sham animals, we found a typical age-dependent decrease in Ki-67- and PCNA-labelled cells in the SVZ over the course of 1 year. However, in brain-injured animals, this decrease was reversed culminating in a sixfold increase in the number of cells staining with Ki-67 and a threefold increase in cells staining with PCNA by 1 year following injury compared to age-matched controls. Using double labeling, we also determined that many of the cells staining with Ki-67 or PCNA expressed markers selective for neurons (neurofilament protein) and glia (GFAP). These data suggest that there is a persistent proliferation of neurons and glia in the SVZ following brain trauma that does not diminish during aging as found in non-injured animals.	Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Med Ctr, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38104, NS 08803] Funding Source: Medline		Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Calza L, 1998, P NATL ACAD SCI USA, V95, P3209, DOI 10.1073/pnas.95.6.3209; COLTRERA MD, 1991, J HISTOCHEM CYTOCHEM, V39, P23, DOI 10.1177/39.1.1670579; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; GERDES J, 1984, J IMMUNOL, V133, P1710; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKeever PE, 1997, J NEUROPATH EXP NEUR, V56, P798; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Strom RC, 1998, J NEUROSCI, V18, P9948; Szele FG, 1996, J COMP NEUROL, V368, P439, DOI 10.1002/(SICI)1096-9861(19960506)368:3<439::AID-CNE9>3.0.CO;2-6; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Tropepe V, 1997, J NEUROSCI, V17, P7850; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1; YACHNIS AT, 1993, J COMP NEUROL, V334, P356, DOI 10.1002/cne.903340303	30	87	90	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2003	20	7					623	631		10.1089/089771503322144545			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	703KL	WOS:000184278500002	12908924				2021-06-18	
J	Gao, H; Qiao, XX; Cantor, LB; WuDunn, D				Gao, H; Qiao, XX; Cantor, LB; WuDunn, D			Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells	ARCHIVES OF OPHTHALMOLOGY			English	Article							MESSENGER-RNA EXPRESSION; FIBROBLAST GROWTH-FACTOR; OPTIC-NERVE INJURY; IN-VIVO; SURVIVAL; DEGENERATION; ACTIVATION; RECEPTORS; NEURODEGENERATION; NEUROPROTECTION	Objectives: Brimonidine tartrate ophth, an alpha(2)-adrenergic agonist, is widely used as an antiglaucoma agent for lowering intraocular pressure. Recent studies suggest that brimonidine may be neuroprotective for retinal ganglion cells (RGCs) following optic nerve crush injury. Brain-derived neurotrophic factor (BDNF), a potent neuroprotective factor present in the RGCs, promotes RGC survival in culture and following optic nerve injury. We tested the hypothesis that a possible mechanism of brimonidine neuroprotection is through up-regulation of endogenous BDNF expression in the RGCs. Methods: A single dosage of brimonidine tartrate ophth solution (0.85-34muM) was injected intravitreally into Sprague-Dawley rat eyes. The fellow eyes of each animal were injected with balanced salt solution (BSS) and used as control eyes. To determine BDNF messenger RNA expression, animal eyes were enucleated and processed for in situ hybridization, or retinas were isolated and processed for Northern blot analysis using rat BDNF radiolabeled riboprobes. Results: In the control eyes injected with saline, BDNF was present in a minority of the RGCs. Two days after brimonidine injection, the number of BDNF-positive RGCs was increased from 55% to 166%, depending on brimonidine concentrations, when compared with those in the controls. In addition, the BDNF signal intensities in individual RGCs were elevated 50% in brimonidine-injected eyes compared with control eyes. Northern blot revealed a 28% increase of BDNF expression in the brimonidine group compared with the controls (P < .003). No significant difference was observed in BDNF receptor, trk B, expression between brimonidine, or BSS control groups. Conclusions: A single dose of a low concentration of intravitreal brimonidine is sufficient to significantly increase endogenous BDNF expression in RGCs. These results suggest that brimonidine neuroprotection may be mediated through up-regulation of BDNF in the RGCs. The BDNF should be further investigated regarding its role in the neuroprotective effects reported with brimonidine. Clinical Relevance: Brimonidine may be (potentially) used clinically as a neuroprotective agent in optic neuropathy, including glaucoma, and ischemic and traumatic optic neuropathy.	Indiana Univ, Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA; Louisiana State Univ, Ctr Hlth Sci, Dept Anat & Cellular Biol, Shreveport, LA 71105 USA	Gao, H (corresponding author), Baylor Coll Med, Dept Ophthalmol, 6560 Fannin,Suite 2200, Houston, TX 77030 USA.						ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Bautista RD, 1999, INT OPHTHALMOL CLIN, V39, P57, DOI 10.1097/00004397-199903930-00007; Berkowitz BA, 1998, INVEST OPHTH VIS SCI, V39, P391; Bullock R, 1995, ANN NY ACAD SCI, V765, P272, DOI 10.1111/j.1749-6632.1995.tb16584.x; Burke J, 1995, Ann N Y Acad Sci, V763, P78, DOI 10.1111/j.1749-6632.1995.tb32392.x; CARMIGNOTO G, 1989, J NEUROSCI, V9, P1263; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; DOBLE A, 1995, THERAPIE, V50, P319; Gao H, 1997, INVEST OPHTH VIS SCI, V38, P1840; GAO H, 1995, DEV BIOL, V169, P168, DOI 10.1006/dbio.1995.1135; Girkin CA, 2001, SURV OPHTHALMOL, V45, P379, DOI 10.1016/S0039-6257(00)00208-3; Greenfield DS, 1997, J GLAUCOMA, V6, P250; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; Kent AR, 2001, OPHTHALMOLOGY, V108, P784, DOI 10.1016/S0161-6420(00)00654-0; LIU DX, 1994, J NEUROCHEM, V62, P37; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; METSIS M, 1993, P NATL ACAD SCI USA, V90, P8802, DOI 10.1073/pnas.90.19.8802; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; PEREZ MTR, 1995, NEUROSCI LETT, V183, P96, DOI 10.1016/0304-3940(94)11123-Z; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; QIAO X, 1994, INVEST OPHTH VIS SCI, V35, P1497; Qiao XO, 1996, J NEUROSCI, V16, P640; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; RICKMAN DW, 1995, VISUAL NEUROSCI, V12, P215, DOI 10.1017/S0952523800007896; SCHUMAN JS, 1996, SURV OPHTHALMOL S1, V41, P27; SCHWARTZ M, 1999, EUR J OPHTHALMOL, V9, P9; Thanos S, 1989, Fortschr Ophthalmol, V86, P172; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Ugolini G, 1995, BRAIN RES, V704, P121, DOI 10.1016/0006-8993(95)01191-9; UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P907; Walters TR, 1996, SURV OPHTHALMOL, V41, pS19, DOI 10.1016/S0039-6257(96)82028-5; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; Wen R, 1996, J NEUROSCI, V16, P5986; Wheeler LA, 1999, EUR J OPHTHALMOL, V9, pS17, DOI 10.1177/112067219900901S09; Wilensky JT, 1996, SURV OPHTHALMOL, V41, pS3, DOI 10.1016/S0039-6257(96)82026-1; Yoles E, 1999, INVEST OPHTH VIS SCI, V40, P65; Yoles E, 1997, J NEUROTRAUM, V14, P665, DOI 10.1089/neu.1997.14.665; Yoles E, 1998, SURV OPHTHALMOL, V42, P367, DOI 10.1016/S0039-6257(97)00123-9	41	87	94	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9950			ARCH OPHTHALMOL-CHIC	Arch. Ophthalmol.	JUN	2002	120	6					797	803					7	Ophthalmology	Ophthalmology	561MV	WOS:000176145500013	12049586				2021-06-18	
J	Wang, XY; Mori, T; Jung, JC; Fini, ME; Lo, EH				Wang, XY; Mori, T; Jung, JC; Fini, ME; Lo, EH			Secretion of matrix metalloproteinase-2 and-9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase	JOURNAL OF NEUROTRAUMA			English	Article						MAP kinase; mechanical injury; MMP; neuroprotection; primary cortical cultures; rats	ACTIVATED PROTEIN-KINASE; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; GENE KNOCK-OUT; IN-VITRO; MATRIX-METALLOPROTEINASE-9 EXPRESSION; INHIBITION; INTERLEUKIN-1; INCREASE	Matrix metalloproteinases (MMP) are involved in the pathophysiology of brain injury. We recently showed that knockout mice deficient in MMP-9 expression were protected against traumatic brain injury. However, the cellular sources of MMP activity after trauma remain to be fully defined. In this study, we investigated the hypothesis that resident brain cells secrete MMP after mechanical trauma injury in vitro, and mitogen-activated protein (MAP) kinase signal transduction pathways are involved in this response. Rat primary cortical neurons, astrocytes, and co-cultures were subjected to needle scratch mechanical injury, and levels of MMP-2 and MMP-9 in conditioned media were assayed by zymography. MMP-2 and MMP-9 were increased in cortical astrocytes and co-cultures, whereas only MMP-2 was increased in neurons. Western blots showed that phosphorylated extracellular signal regulated kinase (ERK1/2) and p38 were rapidly upregulated in co-cultures after mechanical injury. No change in phosphorylated c-jun N-terminal kinase (JNK) was observed. In-gel kinase assays confirmed this lack of response in the JNK pathway. Treatment with either 10 muM of U0126 (a MAP kinase/ERK1/2 kinase inhibitor) or 10 muM of SB203580 (a p38 inhibitor) had no detectable effect on MMP-2 and MMP-9 levels after mechanical injury. However, combination treatment with both inhibitors significantly reduced secretion of MMP-9. Herein, we demonstrate that (1) resident brain cells secrete MMP after mechanical injury, (2) astrocytes are the main source of MMP-9 activity, and (3) ERK and p38 MAP kinases are upregulated after mechanical injury, and mediate the secretion of MMP-9.	Harvard Univ, Med Sch, Det Neurol, Neuroprot Res Lab, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Neuroprot Res Lab, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Med Sch, Program Neurosci, Charlestown, MA USA; Tufts Univ, Sch Med, New England Eye Ctr, Vis Res Labs, Boston, MA USA; Massachusetts Gen Hosp, Neuroprot Res Lab, Dept Neurol, Boston, MA 02114 USA	Wang, XY (corresponding author), Harvard Univ, Med Sch, Det Neurol, Neuroprot Res Lab, MGH East 149-2322, Charlestown, MA 02129 USA.	wangxi@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038731, R01NS037074, R01NS040529] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS38731, R01-NS37074, R01-NS40529] Funding Source: Medline		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Anthony DC, 1998, J NEUROIMMUNOL, V87, P62, DOI 10.1016/S0165-5728(98)00046-0; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Asahi M, 2001, J NEUROSCI, V21, P7724; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; BRIDGES RJ, 1992, NEUROPHARMACOLOGY, V31, P899, DOI 10.1016/0028-3908(92)90128-C; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Esteve PO, 1998, BBA-MOL CELL RES, V1403, P85, DOI 10.1016/S0167-4889(98)00020-2; Fini ME, 1998, BIOL EXTRAC, P299; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; Hartung HP, 2000, J NEUROIMMUNOL, V107, P140, DOI 10.1016/S0165-5728(00)00225-3; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Jiang Q, 2000, BRAIN RES, V857, P71, DOI 10.1016/S0006-8993(99)02364-1; Katano H, 1999, NEUROREPORT, V10, P2439, DOI 10.1097/00001756-199908200-00002; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; McCawley LJ, 2000, MOL PHARMACOL, V58, P145; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Pagenstecher A, 1998, AM J PATHOL, V152, P729; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; Tsirka SE, 1997, J NEUROSCI, V17, P543; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	54	87	94	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					615	625		10.1089/089771502753754082			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900006	12042096				2021-06-18	
J	Rosenberger, J; Petrovics, G; Buzas, B				Rosenberger, J; Petrovics, G; Buzas, B			Oxidative stress induces proorphanin FQ and proenkephalin gene expression in astrocytes through p38-and ERK-MAP kinases and NF-kappa B	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; mitogen-activated protein kinase; nociceptin; nuclear factor-kappa B; orphanin FQ; oxidative stress	ACTIVATED PROTEIN-KINASE; PREPROENKEPHALIN MESSENGER-RNA; SIGNAL-REGULATED KINASE; BRAIN INJURY; ORPHANIN-FQ; NOCICEPTIN/ORPHANIN FQ; TRANSCRIPTION FACTOR; CULTURED ASTROCYTES; NEUROPEPTIDE GENE; CYCLIC-AMP	Oxidative stress has been implicated in the pathogenesis of stroke, traumatic brain injuries, and neurodegenerative diseases affecting both neuronal and glial cells in the CNS. In this study we have demonstrated that reactive oxygen species (ROS) dramatically induce the expression of two neuropeptide genes, the opioid proenkephalin (pENK) and the opioid-related proorphanin FQ (pOFQ; also known as pronociceptin) in primary astrocytes. Hydrogen peroxide (H2O2) treatment dose-dependently increased pENK and pOFQ mRNA levels with a maximal effect (similar to 15-fold increase) being detected at 50 muM concentration. Exposing the astrocyte cultures to hypoxia and subsequent re-oxygenation also led to a profound elevation of pOFQ and pENK mRNA levels. Western blot analysis and immunocytochemistry revealed that H2O2 treatment elicited the phosphorylation and nuclear translocation of ERK 1/2 and p38 MAP kinases. Blockade of the p38 or the ERK MAP kinase pathways (by SB202190 and PD98059, respectively) prevented the H2O2-induced increase in pENK and pOFQ mRNA levels indicating a central role for these cascades in the regulation of pOFQ and pENK genes In response to oxidative stress. Regulation of pOFQ and pENK gene expression by ERK and p38 activation may be mediated through the transcription factor cAMP-response element binding protein (CREB). We observed CREB phosphorylation in response to H2O2, which was also prevented by SB202190 and PD98059. The nuclear factor-kappaB (NF-kappaB) pathway appears to be involved exclusively in the induction of pOFQ transcription by H2O2, as NF-kappaB inhibitors antagonized the effect of oxidative stress on pOFQ, but not on pENK expression. The profound induction of these genes by oxidative stress and these other factors may suggest a role for orphanin FQ and enkephalin in injury and stress responses of the CNS and neuropathophysiological conditions involving reactive oxygen species.	Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Buzas, B (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.			Petrovics, Gyorgy/0000-0003-3732-284X			Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Andoh T, 1997, NEUROREPORT, V8, P2793, DOI 10.1097/00001756-199708180-00028; Armstead WM, 2000, J NEUROTRAUM, V17, P751, DOI 10.1089/neu.2000.17.751; Armstead WM, 2000, BRAIN RES, V868, P48, DOI 10.1016/S0006-8993(00)02262-9; BORSOOK D, 1994, MOL ENDOCRINOL, V8, P116, DOI 10.1210/me.8.1.116; Buzas B, 1998, J NEUROCHEM, V71, P556; Buzas B, 1999, J NEUROCHEM, V72, P1882, DOI 10.1046/j.1471-4159.1999.0721882.x; BUZAS B, 1998, P38 MAP KINASE NFKB; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Christman JW, 2000, BRAIN PATHOL, V10, P153; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; FAN LS, 1999, MOL PHARMACOL, V55, P658; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Helyes Z, 1997, BRIT J PHARMACOL, V121, P613, DOI 10.1038/sj.bjp.0701209; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P121, DOI 10.1016/S0149-7634(96)00001-2; Kulkarni M, 2000, STROKE, V31, P1990, DOI 10.1161/01.STR.31.8.1990; Laudenbach V, 2001, J CLIN INVEST, V107, P457, DOI 10.1172/JCI9716; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Love S, 1999, BRAIN PATHOL, V9, P119; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Maher P, 2000, CELL MOL LIFE SCI, V57, P1287, DOI 10.1007/PL00000766; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Nose K, 2000, BIOL PHARM BULL, V23, P897; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1996, J BIOL CHEM, V271, P15615, DOI 10.1074/jbc.271.26.15615; SAITO Y, 1997, J NEUROSCI RES, V48, P37; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; Serhan CN, 2001, J IMMUNOL, V166, P3650, DOI 10.4049/jimmunol.166.6.3650; SHINODA H, 1992, DEV BRAIN RES, V67, P205, DOI 10.1016/0165-3806(92)90220-Q; SHINODA H, 1989, SCIENCE, V245, P415, DOI 10.1126/science.2569236; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VILIJN MH, 1988, P NATL ACAD SCI USA, V85, P6551, DOI 10.1073/pnas.85.17.6551; Won JS, 2000, MOL BRAIN RES, V76, P396, DOI 10.1016/S0169-328X(00)00032-2; Xie GX, 1999, GENE, V238, P427, DOI 10.1016/S0378-1119(99)00350-9; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; ZURAWSKI G, 1986, SCIENCE, V232, P772, DOI 10.1126/science.2938259	46	87	90	0	4	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	OCT	2001	79	1					35	44		10.1046/j.1471-4159.2001.00520.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	480YB	WOS:000171489800005	11595755	Bronze			2021-06-18	
J	Chan, RCK				Chan, RCK			Base rate of post-concussion symptoms among normal people and its neuropsychological correlates	CLINICAL REHABILITATION			English	Article							MILD HEAD-INJURY; QUESTIONNAIRE; RELIABILITY; PREDICTION; MODERATE	Objective: To explore the base rate of symptoms similar to those of post-concussion symptoms (PCS) among a group of participants without head injury. The effect of subjective complaints upon cognitive functioning was also examined. Design: A cross-sectional study. Participants: A total of 85 participants without head injury, other identifiable neurological diseases or psychiatric diseases were recruited. Outcome measures: These included Rivermead Post-concussion Symptoms Checklist, Cognitive Failures Questionnaire, Colour Trails Test, Stroop Word-Colour Test, Paced Auditory Serial Addition Test, Symbol Digits Modality Test, Word Fluency Test, Design Fluency Test, Digits Forward and Backward Span Test, and Modified Six Elements Test. Results: A relatively high proportion of the participants reported symptoms similar to those of patients with PCS. These included longer time to think (65.9%), forgetfulness (58.9%), poor concentration (58.9%), fatigue easily (53.5%), and sleep disturbances (50.6%). Gender effect was not significant for either the individual item or the total score of the Rivermead Post-concussion Symptoms Checklist. Moreover, there was no difference found between low symptom reporters and high symptom reporters in terms of attention, working memory, mental fluency, and strategy allocation. Conclusion: The base rates of symptoms were consistent with previous studies among the nonclinical groups. However, persons reporting a high score of concussion-like symptoms did not perform less well than those reporting a low score of symptoms in attention, working memory, mental fluency and strategy allocation.	Univ Hong Kong, Queen Mary Hosp, Dept Psychiat, Lab J2, Hong Kong, Hong Kong, Peoples R China	Chan, RCK (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Psychiat, Lab J2, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; JONESGOTMAN M, 1991, EPILIPSIA, V32, P41; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Miller W., 1992, PHYSICAL MED REHABIL, V6, P547; ODONNELL WE, 1993, J CLIN PSYCHOL, V49, P372, DOI 10.1002/1097-4679(199305)49:3<372::AID-JCLP2270490311>3.0.CO;2-K; Ryan LM, 1999, ARCH CLIN NEUROPSYCH, V14, P42, DOI 10.1093/arclin/14.1.42a; Spreen O., 1998, COMPENDIUM NEUROPSYC; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	21	87	91	0	5	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	JUN	2001	15	3					266	273		10.1191/026921501675253420			8	Rehabilitation	Rehabilitation	437EN	WOS:000168977900006	11386396				2021-06-18	
J	Kamencic, H; Griebel, RW; Lyon, AW; Paterson, PG; Juurlink, BHJ				Kamencic, H; Griebel, RW; Lyon, AW; Paterson, PG; Juurlink, BHJ			Promoting glutathione synthesis after spinal cord trauma decreases secondary damage and promotes retention of function	FASEB JOURNAL			English	Article						central nervous system; functional recovery; neurotrauma; oxidative stress; paraplegia	RANDOMIZED CONTROLLED TRIAL; LIPID-PEROXIDATION PRODUCT; TIRILAZAD MESYLATE; OXIDATIVE STRESS; ISOLATED HEPATOCYTES; N-ACETYLCYSTEINE; INJURY; RAT; METHYLPREDNISOLONE; REDUCTASE	The study aimed to 1) quantify oxidative stress in spinal cord after crush injury at T6, 2) determine whether the administration of the procysteine compound L-2-oxothiazolidine-4-carboxylate (OTC) would up-regulate glutathione (GSH) synthesis and decrease oxidative stress, and 3) determine whether decreased oxidative stress results in better tissue and function retention. We demonstrate that spinal cord compression (5 s with a 50 g aneurysm clip) at T6 in rats results in oxidative stress that is extensive (significant increases in oxidative stress seen at C3 and L4) and rapid in onset. Indices of oxidative stress used were GSH content, protein carbonyl content, and inactivation of glutathione reductase. Administration of OTC resulted in a marked decrease in oxidative stress associated with a sparing of white matter at T6 (16 +/-1.9% retained in OTC-treated animals vs, less than 1% in saline-treated). Behavioral indices in control, saline-treated, and OTC-treated animals after 6 wk were respectively: angle board scores (59 degrees, 32 degrees, and 42 degrees), modified Tarlov score (7, 2.4, and 4.1), and Basso-Beattie-Bresnahan score (21, 5.3, and 12.9). We conclude that administration of OTC after spinal cord trauma greatly decreases oxidative stress and allows tissue preservation, thereby enabling otherwise paraplegic animals to locomote.	Univ Saskatchewan, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Surg Neurosurg, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5E5, Canada	Juurlink, BHJ (corresponding author), Univ Saskatchewan, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.						ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; ANDERSON ME, 1989, FASEB J, V3, P1632; Barker JE, 1996, BRAIN RES, V716, P118, DOI 10.1016/0006-8993(96)00003-0; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blakeman DP, 1998, J BIOCHEM MOL TOXIC, V12, P185, DOI 10.1002/(SICI)1099-0461(1998)12:3<185::AID-JBT7>3.0.CO;2-H; BLAKYTNY R, 1992, BIOCHEM J, V288, P303, DOI 10.1042/bj2880303; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BROWN SA, 1992, J AM VET MED ASSOC, V200, P1849; Burcham PC, 1996, BIOCHEM BIOPH RES CO, V220, P996, DOI 10.1006/bbrc.1996.0521; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Christman JW, 2000, BRAIN PATHOL, V10, P153; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; GALANDIUK S, 1993, ANN SURG, V218, P419, DOI 10.1097/00000658-199310000-00003; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Juurlink BHJ, 1999, NEUROTOX RES, V1, P119, DOI 10.1007/BF03033276; Juurlink BHJ, 1998, GLIA, V22, P371, DOI 10.1002/(SICI)1098-1136(199804)22:4<371::AID-GLIA6>3.0.CO;2-6; KALAYJIAN RC, 1994, J ACQ IMMUN DEF SYND, V7, P369; KHAN M, 1983, CAN J NEUROL SCI, V10, P161, DOI 10.1017/S031716710004484X; Koc RK, 1999, SPINAL CORD, V37, P29, DOI 10.1038/sj.sc.3100732; KOMURO C, 1985, J CHROMATOGR, V338, P209, DOI 10.1016/0378-4347(85)80087-6; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lucas JH, 1998, J NEUROPATH EXP NEUR, V57, P937, DOI 10.1097/00005072-199810000-00006; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; MEISTER A, 1989, GLUTATHIONE CHEM BIO, VA, P367; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; Miyata T, 1998, FEBS LETT, V437, P24, DOI 10.1016/S0014-5793(98)01079-5; Nesathurai S, 1998, J TRAUMA, V45, P1088, DOI 10.1097/00005373-199812000-00021; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1979, SURG NEUROL, V9, P39; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Springer JE, 1997, J NEUROCHEM, V68, P2469; TABATABAIE T, 1994, ARCH BIOCHEM BIOPHYS, V314, P112, DOI 10.1006/abbi.1994.1418; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Tariq M, 1998, J NEUROTRAUM, V15, P239, DOI 10.1089/neu.1998.15.239; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155	46	87	89	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					243	250		10.1096/fj.00-0228com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	WOS:000166312400033	11149912				2021-06-18	
J	Rao, VLR; Dogan, A; Bowen, KK; Todd, KG; Dempsey, RJ				Rao, VLR; Dogan, A; Bowen, KK; Todd, KG; Dempsey, RJ			Antisense knockdown of the glial glutamate transporter GLT-1 exacerbates hippocampal neuronal damage following traumatic injury to rat brain	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						antisense ODN; controlled cortical impact injury; glutamate uptake; hippocampus; knockdown; neuronal death	CONTROLLED CORTICAL IMPACT; OXIDE SYNTHASE EXPRESSION; IN-VIVO; EXTRACELLULAR GLUTAMATE; CELL-DEATH; ISCHEMIA; RELEASE; INHIBITION; SUBTYPE; EXCITOTOXICITY	Traumatic injury to rat brain induced by controlled cortical impact (CCI) results in chronic neuronal death in the hippocampus. In the normal brain, glutamate transporters actively clear the glutamate released synaptically to prevent receptor overactivation and excitotoxicity. Glutamate transporter 1 (GLT-1) is the most abundant and active glutamate transporter, which mediates the bulk of glutamate uptake. CCI injury significantly decreased GLT-1 mRNA (by 49-66%, P < 0.05) and protein (by 29-44%, P < 0.05) levels in the ipsilateral hippocampus, compared with either the respective contralateral hippocampus or the sham-operated control, 24-72 h after the injury, CCI injury in rats infused with GLT-1 antisense oligodeoxynucleotides (ODNs) exacerbated the hippocampal neuronal death and mortality, compared with the GLT-1 sense/random ODN-infused controls. At 7 days after the injury, hippocampal neuronal numbers were significantly lower in the CAI (reduced by 32%, P < 0.05), CA2 (by 45%, P < 0.01), CA3 (by 68%, P < 0.01) and dentate gyrus (by 31%, P < 0.05) in GLT-1 antisense ODN-infused rats, compared with the GLT-1 sense/random ODN-infused controls. This study suggested a role for GLT-1 dysfunction in promoting the hippocampal neuronal death after traumatic brain injury.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA; Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI USA; Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA; Univ Alberta, Dept Psychiat, Edmonton, AB, Canada	Rao, VLR (corresponding author), Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28000, NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028000, P01NS031220] Funding Source: NIH RePORTER		Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Chan H, 2000, NEUROCHEM INT, V37, P243, DOI 10.1016/S0197-0186(00)00026-7; CHOI DW, 1997, PRIMER CEREBROVASCUL, P187; COCCIA C, 1999, SOC NEUR ABSTR, V25; Danbolt NC, 1998, PROG BRAIN RES, V116, P23, DOI 10.1016/S0079-6123(08)60428-8; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; ERECINSKA M, 1987, BIOCHEM PHARMACOL, V36, P3547, DOI 10.1016/0006-2952(87)90001-3; Figiel M, 2000, J NEUROSCI, V20, P3596; Fujita H, 1999, J CEREBR BLOOD F MET, V19, P604, DOI 10.1097/00004647-199906000-00003; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Kanai Y, 1997, NEUROTRANSMITTER TRA, P171; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Knecht K, 1997, NEUROSCI LETT, V229, P201, DOI 10.1016/S0304-3940(97)00444-8; Koura SS, 1998, ACT NEUR S, V71, P244; Lievens JC, 1997, MOL BRAIN RES, V50, P181, DOI 10.1016/S0169-328X(97)00182-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manzoni C, 1997, PHARMACOL RES, V35, P149, DOI 10.1006/phrs.1997.0129; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; Massieu L, 1997, J NEUROCHEM, V69, P1151; MASSIEU L, 1995, J NEUROCHEM, V64, P2262; MASSIEU L, 1999, J NEUROCHEM S, V73; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Miller HP, 1997, J NEUROCHEM, V68, P1564; Mukhin A, 1996, J NEUROSCI, V16, P6012; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2000, NEUROCHEM INT, V36, P531, DOI 10.1016/S0197-0186(99)00153-9; RAO VLR, 1999, J NEUROCHEM S, V73; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; Roettger V, 1996, NEUROSCIENCE, V75, P677, DOI 10.1016/0306-4522(96)00314-4; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sanchez-Carbente MD, 1999, J NEUROCHEM, V72, P129; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Simantov R, 1999, J NEUROCHEM, V73, P1828; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; SUZUKI T, 1999, J NEUROTRAUM, V16, P973; SWANSON RA, 1995, J CEREBR BLOOD F MET, V15, P417, DOI 10.1038/jcbfm.1995.52; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Trotti D, 1996, J BIOL CHEM, V271, P5976, DOI 10.1074/jbc.271.11.5976; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang Y, 1997, J NEUROSCI, V17, P4341; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	63	87	93	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JAN	2001	13	1					119	128		10.1046/j.1460-9568.2001.01367.x			10	Neurosciences	Neurosciences & Neurology	394KJ	WOS:000166523000012	11135010				2021-06-18	
J	Donnemiller, E; Brenneis, C; Wissel, J; Scherfler, C; Poewe, W; Riccabona, G; Wenning, GK				Donnemiller, E; Brenneis, C; Wissel, J; Scherfler, C; Poewe, W; Riccabona, G; Wenning, GK			Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPET study using (123)I-beta-CIT and (123)I-IBZM	EUROPEAN JOURNAL OF NUCLEAR MEDICINE			English	Article						head injury; single-photon emission tomography; nigrostriatal dysfunction; striatal dopamine transporter; striatal D2 receptor	HEALTHY-VOLUNTEERS; DOSIMETRY; RECOVERY; STATE	Structural imaging suggests that traumatic brain injury (TBI) may be associated with disruption of neuronal networks, including the nigrostriatal dopaminergic pathway. However, to date deficits in pre- and/or postsynaptic dopaminergic neurotransmission have not been demonstrated in TBI using functional imaging. We therefore assessed dopaminergic function in ten TBI patients using [(123)I]2-beta-carbomethoxy-3-beta-(4-iodophenyl)tropane (beta-CIT) and [(123)I]iodobenzamide (IBZM) single-photon emission tomography (SPET). Average Glasgow Coma Scale score (+/- SD) at the time of head trauma was 5.8 +/- 4.2. SPET was performed on average 141 days (SD +/- 42) after TBI. The SPET images were compared with structural images using cranial computerised tomography (CCT) and magnetic resonance imaging (MRI). SPET was performed with an ADAC Vertex dual-head camera. The activity ratios of striatal to cerebellar uptake were used as a semiquantitative parameter of striatal dopamine transporter (DAT) and D2 receptor (D2R) binding. Compared with age-matched controls, patients with TBI had significantly Lower striatal/cerebellar beta-CIT and IBZM binding ratios (P less than or equal to 0.01). Overall, the DAT deficit was more marked than the D2R loss. CCT and MRI studies revealed varying cortical and subcortical lesions, with the frontal lobe being most frequently affected whereas the striatum appeared structurally normal in all but one patient. Our findings suggest that nigrostriatal dysfunction may be detected using SPET following TBI despite relative structural preservation of the striatum. Further investigations of possible clinical correlates and efficacy of dopaminergic therapy in patients with TBI seem justified.	Univ Innsbruck Hosp, Dept Nucl Med, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria	Donnemiller, E (corresponding author), Univ Innsbruck Hosp, Dept Nucl Med, Anichstr 35, A-6020 Innsbruck, Austria.			Scherfler, Christoph/0000-0002-4885-5265; Wenning, Gregor/0000-0001-9077-1666			Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kapucu LO, 1998, J NUCL MED, V39, P1703; KUIKKA JT, 1994, EUR J NUCL MED, V21, P53; LARUELLE M, 1994, J CEREBR BLOOD F MET, V14, P982, DOI 10.1038/jcbfm.1994.131; VERHOEFF NPLG, 1993, EUR J NUCL MED, V20, P747, DOI 10.1007/BF00180903; VERHOEFF NPLG, 1991, NUCL MED COMMUN, V12, P687, DOI 10.1097/00006231-199108000-00004; Wenning GK, 1999, MOVEMENT DISORD, V14, P366, DOI 10.1002/1531-8257(199903)14:2<366::AID-MDS1029>3.0.CO;2-D; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Zafonte RD, 1998, BRAIN INJURY, V12, P617	9	87	92	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6997			EUR J NUCL MED	Eur. J. Nucl. Med.	SEP	2000	27	9					1410	1414		10.1007/s002590000308			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	352EN	WOS:000089201700021	11007526				2021-06-18	
J	Engel, S; Schluesener, H; Mittelbronn, M; Seid, K; Adjodah, D; Wehner, HD; Meyermann, R				Engel, S; Schluesener, H; Mittelbronn, M; Seid, K; Adjodah, D; Wehner, HD; Meyermann, R			Dynamics of microglial activation after human traumatic brain injury are revealed by delayed expression of macrophage-related proteins MRP8 and MRP14	ACTA NEUROPATHOLOGICA			English	Article						intracellular signalling; Ki-67; microglia activation; normal brain ischemia	CALCIUM-BINDING PROTEINS; LYMPHOCYTE CHEMOATTRACTANT FACTOR; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS LESIONS; CLASS-II ANTIGENS; CD8(+) T-CELLS; HEAD-INJURY; RAT-BRAIN; CNS; ASTROCYTES	Human traumatic brain injury (TBI) is ideally suited for investigation of the kinetics of human microglial cell activation as the onset of lesion formation is precisely defined. The present study provides evidence of a distinct delay in macrophage/microglia response following TBI. Eighteen brains of patients who had survived TBI for 1 h to 6 months were analysed by immunohistology. Samples of contusional and non-contusional areas were studied using antibodies directed against antigens of microglia/macrophages [major histocompatibility complex class II, CD4, interleukin (IL)-16, macrophage-related protein (MRP) 8 and MRP14]. IL-16, a natural ligand to CD4, was expressed constitutively by numerous microglial cells in all cases throughout the brain. CD4 could be detected regularly on perivascular cells. MRP8 and MRP14, which are only expressed on activated macrophages and microglial cells, could be detected only within brains with a survival time of more than 72 h post TBI. In addition, proliferation of microglia detected by MIB-1 was not present until 72 h. This delayed expression of the activation markers MRP8 and MRP14 and the proliferation marker MIB-1 is comparable to experimental closed head injuries but strictly different from acute activation found in ischemic brains.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Inst Legal Med, D-72076 Tubingen, Germany	Engel, S (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.			Mittelbronn, Michel/0000-0002-2998-052X			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; AKIYAMA H, 1994, J NEUROIMMUNOL, V50, P195, DOI 10.1016/0165-5728(94)90046-9; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; Bernaudin M, 1998, EXP NEUROL, V150, P30, DOI 10.1006/exnr.1997.6728; BO L, 1994, J NEUROIMMUNOL, V51, P135, DOI 10.1016/0165-5728(94)90075-2; Bobryshev YV, 1996, PATHOL RES PRACT, V192, P260, DOI 10.1016/S0344-0338(96)80229-9; BRUCK W, 1995, ANN NEUROL, V38, P788, DOI 10.1002/ana.410380514; CENTER DM, 1995, J LAB CLIN MED, V125, P167; CENTER DM, 1982, J IMMUNOL, V128, P2562; Cruikshank W W, 1998, Int Rev Immunol, V16, P523, DOI 10.3109/08830189809043007; Deininger MH, 1998, HISTOCHEM CELL BIOL, V110, P425, DOI 10.1007/s004180050303; Engel S, 1996, ACT NEUR S, V66, P87; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GOEBELER M, 1995, BIOCHEM J, V309, P419, DOI 10.1042/bj3090419; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Heizmann CW, 1996, MOL CELLS, V6, P629; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; HILT DC, 1988, TRENDS BIOCHEM SCI, V13, P437; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/S0968-0004(06)80021-6; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Krautwald S, 1998, J IMMUNOL, V160, P5874; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuruto-Niwa R, 1998, CELL STRUCT FUNCT, V23, P109, DOI 10.1247/csf.23.109; Laberge S, 1996, J IMMUNOL, V156, P310; LABERGE S, 1995, J IMMUNOL, V155, P2902; Lassmann H., 1997, Journal of Neural Transmission Supplement, V50, P183; MATIAZEK JW, 1997, J IMMUNOL, V158, P5; McKeever PE, 1998, J HISTOCHEM CYTOCHEM, V46, P585, DOI 10.1177/002215549804600504; Moller T, 1997, J NEUROSCI, V17, P615; PERRY VH, 1987, J EXP MED, V166, P1138, DOI 10.1084/jem.166.4.1138; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; QI JF, 1995, J IMMUNOL, V155, P867; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; RENAUD W, 1994, BIOCHEM BIOPH RES CO, V201, P1518, DOI 10.1006/bbrc.1994.1876; RIVA I., 1990, REV ESPANOLA HERPETO, V4, P81; Rostworowski M, 1997, J NEUROSCI, V17, P3664; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; SASAKI A, 1992, NEUROPATH APPL NEURO, V18, P13, DOI 10.1111/j.1365-2990.1992.tb00761.x; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schluesener HJ, 1996, J NEUROSCI RES, V44, P606; SCHLUESENER HJ, 1993, ACTA NEUROPATHOL, V86, P393, DOI 10.1007/BF00369453; SCHMID KW, 1995, HUM PATHOL, V26, P334, DOI 10.1016/0046-8177(95)90067-5; SIEVERS J, 1994, GLIA, V12, P245, DOI 10.1002/glia.440120402; Sorg C, 1992, Behring Inst Mitt, P126; STEVENS A, 1993, J NEUROL SCI, V118, P117, DOI 10.1016/0022-510X(93)90100-D; STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7; Tanaka S, 1998, J NEUROSCI, V18, P6358; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; UNTERHARNSCHEID.F, 1993, PATHOLOGIE NERVENSYS, P396; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5	58	87	91	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	SEP	2000	100	3					313	322		10.1007/s004019900172			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	336MW	WOS:000088307700011	10965802				2021-06-18	
J	Schanke, AK; Sundet, K				Schanke, AK; Sundet, K			Comprehensive driving assessment: Neuropsychological testing and on-road evaluation of brain injured patients	SCANDINAVIAN JOURNAL OF PSYCHOLOGY			English	Article						brain damage; driver's license; neuropsychological tests; on-road driving	OLDER DRIVERS; ALZHEIMER; FITNESS; DISEASE; DAMAGE; STROKE	The study investigates the correspondence between neuropsychological test results and on-road driving performance among 55 patients with a CT-verified brain damage or documented neurological disorder (cerebrovascular accident: 43, traumatic brain injury: 5, multiple sclerosis: 4, other: 3). 5 patients showed unimpaired test profiles and passed the on-road evaluation. 18 patients showed severe neuropsychological deficits contrary to driving and were not recommended for on-road evaluation. Of the remaining 32 patients with some neuropsychological deficits, all 100% in the minor impaired group (n = 8) passed the driving evaluation, compared to 69% in the mildly impaired (n = 16) and 38% in the moderately impaired group (n = 8). Measures of reduced visuoconstructive ability, reaction time, visual attention, and awareness of cognitive impairments, were found to discriminate between groups, it is concluded that neuropsychological assessment of targeted functions provide an ecological valid prediction of driving skill after brain damage, but that on-road evaluation is needed as supplement in cases with ambiguous test findings.	Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; Univ Oslo, Natl Hosp, Dept Psychosomat & Behav Med, Oslo, Norway	Schanke, AK (corresponding author), Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.						ANDERSON W, 1989, CLIN NEUROPSYCHOL, V4, P327; BARR R, 1993, J AM GERIATR SOC, V41, P889, DOI 10.1111/j.1532-5415.1993.tb06199.x; Boake C., 1998, J INT NEUROPSYCH SOC, V4, P75; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; Colsher P L, 1993, Clin Geriatr Med, V9, P365; DICK JPR, 1984, J NEUROL NEUROSUR PS, V47, P496, DOI 10.1136/jnnp.47.5.496; Dobbs AR, 1998, ACCIDENT ANAL PREV, V30, P363, DOI 10.1016/S0001-4575(97)00110-3; FITTEN LJ, 1995, JAMA-J AM MED ASSOC, V273, P1360, DOI 10.1001/jama.273.17.1360; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox G K, 1992, Disabil Rehabil, V14, P140; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; Gimse R, 1997, SCAND J PSYCHOL, V38, P165, DOI 10.1111/1467-9450.00023; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; HOPEWELL CA, 1985, J CLIN EXP NEUROPSYC, V7, P148; JOHANSSON SL, 1993, J UROL PATHOL, V1, P69; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lambert EW, 1992, COGNITIVE REHABI MAY, V10, P32; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LINGS S, 1992, ACTA NEUROL SCAND, V86, P33, DOI 10.1111/j.1600-0404.1992.tb08050.x; Lundberg C, 1998, ACCIDENT ANAL PREV, V30, P371, DOI 10.1016/S0001-4575(97)00111-5; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; MICHON JA, 1908, HUMAN BEHAV TRAFFIC, P485; *NAT HLTH SERV, 1997, GUID ISS HLTH CERT D; QUIGLEY FL, 1983, AM J OCCUPATIONAL TH, V26, P208; REBOK GW, 1994, ALZ DIS ASSOC DIS, V8, P228, DOI 10.1097/00002093-199408040-00002; SCHANKE AK, 1995, J NORWEGIAN MED ASS, V115, P1349; SHORE D, 1990, ARCH PHYSICAL MED RE, V62, P163; Stutts JC, 1998, ACCIDENT ANAL PREV, V30, P337, DOI 10.1016/S0001-4575(97)00108-5; SUNDET K, 1995, SCAND J PSYCHOL, V36, P47, DOI 10.1111/j.1467-9450.1995.tb00967.x; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; World Health Organization, 1980, INT CLASS IMP DIS HA	35	87	89	0	9	BLACKWELL PUBL LTD	OXFORD	108 COWLEY RD, OXFORD OX4 1JF, OXON, ENGLAND	0036-5564			SCAND J PSYCHOL	Scand. J. Psychol.	JUN	2000	41	2					113	121		10.1111/1467-9450.00179			9	Psychology, Multidisciplinary	Psychology	324VR	WOS:000087642500005	10870430				2021-06-18	
J	Skelton, RW; Bukach, CM; Laurance, HE; Thomas, KGF; Jacobs, WJ				Skelton, RW; Bukach, CM; Laurance, HE; Thomas, KGF; Jacobs, WJ			Humans with traumatic brain injuries show place-learning deficits in computer-generated virtual space	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MORRIS WATER MAZE; HEAD-INJURY; TOPOGRAPHICAL DISORIENTATION; SPATIAL LOCALIZATION; STIMULUS-CONTROL; LOBE LESIONS; MEMORY; RATS; HIPPOCAMPUS; TASK	Spatial learning and memory has been linked to the hippocampus and temporal lobes and though these areas are often damaged in traumatic brain injury (TBI), spatial learning deficits after TBI have not received much attention. In the present study, a virtual environment was used to challenge people with TBI to solve a task comparable to the Morris water maze, which in turn has been shown to be highly sensitive to hippocampal and frontal lobe dysfunction in laboratory animals. A regular computer monitor was used to present 12 participants with TBI and 12 age- and sex-matched comparison participants with a computer-generated, three-dimensional "virtual arena maze,'' consisting of a large round arena within a very large square room. Participants were required to learn the place of an invisible target on the floor of the room based solely on distal cues on the walls of the room. Eight of the 12 participants with moderate to severe TBI showed substantial place-learning deficits in comparison to the uninjured participants. Performance in the virtual environment correlated with self-reported frequency of wayfinding problems in everyday life and with scores on a test of episodic memory, the Rivermead Behavioural Memory Task. These data confirm that deficits in spatial learning and memory follow TBI, and suggest that the virtual arena maze may provide a new method for objectively assessing them.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada; Univ So Calif, Los Angeles, CA 90089 USA	Skelton, RW (corresponding author), Univ Victoria, Dept Psychol, Box 3050, Victoria, BC V8W 3P5, Canada.		Skelton, Ronald/E-5605-2012; Bukach, Cindy M/E-7057-2010; Thomas, Kevin Garth Flusk/AAA-8655-2020	Thomas, Kevin Garth Flusk/0000-0002-0807-6101			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BOHBOT V, 1994, NEUR ABSTR, V20, P361; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CORKIN S, 1965, NEUROPSYCHOLOGIA, V3, P339, DOI 10.1016/0028-3932(65)90006-0; DAUM I, 1991, CORTEX, V27, P613, DOI 10.1016/S0010-9452(13)80010-X; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Feigenbaum JD, 1996, NEUROPSYCHOLOGIA, V34, P163, DOI 10.1016/0028-3932(95)00107-7; GAGE FH, 1986, J NEUROSCI, V6, P2837; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Jacobs WJ, 1998, LEARN MOTIV, V29, P288, DOI 10.1006/lmot.1998.1008; Jacobs WJ, 1997, LEARN MOTIV, V28, P521, DOI 10.1006/lmot.1997.0977; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Maguire EA, 1997, PHILOS T R SOC B, V352, P1475, DOI 10.1098/rstb.1997.0134; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; MCDANIEL WF, 1991, BEHAV BRAIN RES, V44, P107, DOI 10.1016/S0166-4328(05)80245-1; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; Milner B., 1970, BIOL MEMORY, P29, DOI 10.1016/B978-0-12-564350-4.50011-7; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; OLSEN GM, 1994, BEHAV NEUROSCI, V108, P681, DOI 10.1037/0735-7044.108.4.681; PANG D, 1989, ASSESSMENT BEHAV CON, P1; Paterson A, 1944, BRAIN, V67, P331, DOI 10.1093/brain/67.4.331; RAPPAPORT M, 1989, ARCH PHYSICAL MED RE, V70, P431; Reid I., 1995, NEUR ABSTR, V21, P1446; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; ROD MR, 1990, CAN J PSYCHOL, V44, P196, DOI 10.1037/h0084242; Sandstrom NJ, 1998, COGNITIVE BRAIN RES, V6, P351, DOI 10.1016/S0926-6410(98)00002-0; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SKELTON RW, 1992, HIPPOCAMPUS, V2, P73, DOI 10.1002/hipo.450020110; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH ML, 1989, NEUROPSYCHOLOGIA, V27, P71, DOI 10.1016/0028-3932(89)90091-2; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUZUKI S, 1980, LEARN MOTIV, V11, P1, DOI 10.1016/0023-9690(80)90018-1; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530	52	87	87	0	9	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2000	22	2					157	175		10.1076/1380-3395(200004)22:2;1-1;FT157			19	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	310QF	WOS:000086838300001	10779831				2021-06-18	
J	Van den Heuvel, C; Blumbergs, PC; Finnie, JW; Manavis, J; Jones, NR; Reilly, PL; Pereira, RA				Van den Heuvel, C; Blumbergs, PC; Finnie, JW; Manavis, J; Jones, NR; Reilly, PL; Pereira, RA			Upregulation of amyloid precursor protein messenger RNA in response to traumatic brain injury: an ovine head impact model	EXPERIMENTAL NEUROLOGY			English	Article						amyloid precursor protein; head injury; experimental animal model; sheep; neuronal cell body; messenger RNA; in situ hybridization; immunocytochemistry	ALZHEIMERS-DISEASE; BETA-PROTEIN; RAT-BRAIN; NERVOUS-SYSTEM; TRANSCRIPTIONAL ACTIVATION; NEUROTROPHIC ACTIVITY; NEURITE OUTGROWTH; SECRETED FORMS; GENE; LOCALIZATION	There is evidence that the amyloid precursor protein (APP) plays an important role in neuronal growth and synaptic plasticity and that its increased expression following traumatic brain injury represents an acute phase response to trauma. We hypothesized that the previously described increased APP expression in response to injury (Van den Heuvel et al., Acta Neurochir. Suppl. 71., 209-211) is due to increased mRNA expression and addressed this by examining the expression of APP mRNA and APP within neuronal cell bodies over time in an ovine head impact model. Twenty-five anesthetized and ventilated 2-year-old Merino ewes sustained a left temporal head impact using a humane stunner and 9 normal sheep were used as nonimpact controls. Following postimpact survival periods of 15, 30, 45, 60, and 120 min, brains were perfusion fixed in 4% paraformaldehyde and examined according to standard neuropathological protocol. APP mRNA and antigen expression were examined in 5-mu m sections by nonisotopic in situ hybridization and APP immunocytochemistry. The percentage of brain area with APP immunoreactivity within neuronal cell bodies in the impacted animals increased with time from a mean of 7.5% at 15 min to 54.5% at 2 h. Control brains showed only very small numbers of weakly APP-positive neuronal cell bodies ranging from 2 to 14% (mean 7%). Increased expression of APP mRNA was first evident in impacted hemispheres at 30 min after impact and progressively increased over time to involve neurons in all sampled regions of the brain, suggesting increased transcription of APP. In contrast, APP mRNA was undetectable in tissue from nonimpacted sheep. These data show that APP mRNA and antigen expression are sensitive early indicators of neuronal injury with widespread upregulation occurring as early as 30 min after head impact. (C) 1999 Academic Press.	Univ Adelaide, Dept Pathol, Adelaide, SA, Australia; Inst Med & Vet Sci, Dept Neuropathol, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Vet Div, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Infect Dis Lab, Adelaide, SA 5000, Australia; Royal Adelaide Hosp, Dept Neurosurg, Adelaide, SA 5000, Australia	Van den Heuvel, C (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA, Australia.			, Corinna/0000-0003-0664-8935			ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ANDREWS EJ, 1993, J AM VET MED ASSOC, V202, P230; ARTHUR J, 1993, J GEN VIROL, V74, P1363, DOI 10.1099/0022-1317-74-7-1363; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; BENDOTTI C, 1988, P NATL ACAD SCI USA, V85, P3628, DOI 10.1073/pnas.85.10.3628; Beyreuther K, 1996, ANN NY ACAD SCI, V777, P74, DOI 10.1111/j.1749-6632.1996.tb34403.x; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CARD JP, 1988, NEURON, V1, P835, DOI 10.1016/0896-6273(88)90131-6; deSilva HAR, 1997, MOL BRAIN RES, V47, P147; DEWJI NN, 1995, MOL BRAIN RES, V33, P245, DOI 10.1016/0169-328X(95)00131-B; Dewji NN, 1996, MOL BRAIN RES, V35, P325, DOI 10.1016/0169-328X(95)00214-D; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; FARBER SA, 1995, J NEUROSCI, V15, P7442; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Griffin WST, 1998, BRAIN PATHOL, V8, P65; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAJIMOHAMMADREZA I, 1994, BRAIN RES, V640, P25, DOI 10.1016/0006-8993(94)91853-8; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Lin L, 1998, NEUROREPORT, V9, P547, DOI 10.1097/00001756-199802160-00030; LOWE J, 1990, NEUROPATH APPL NEURO, V16, P281, DOI 10.1111/j.1365-2990.1990.tb01263.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PALACIOS G, 1992, MOL BRAIN RES, V15, P195, DOI 10.1016/0169-328X(92)90109-O; Panegyres PK, 1998, J NEUROL SCI, V154, P123, DOI 10.1016/S0022-510X(97)00214-1; PEREIRA RA, 1994, J EXP MED, V180, P841, DOI 10.1084/jem.180.3.841; Pierce JES, 1996, J NEUROSCI, V16, P1083; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROCH JM, 1993, ANN NY ACAD SCI, V695, P149, DOI 10.1111/j.1749-6632.1993.tb23044.x; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SANDYSWINSCH DC, 1994, BIOCONTROL SCI TECHN, V4, P269, DOI 10.1080/09583159409355335; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SCOTT JN, 1991, MOL BRAIN RES, V10, P315, DOI 10.1016/0169-328X(91)90090-K; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SMALL DH, 1994, J NEUROSCI, V14, P2117; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Storey E, 1996, BRAIN RES, V735, P217, DOI 10.1016/0006-8993(96)00608-7; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TREJO J, 1994, J BIOL CHEM, V269, P21682; Van Den Heuvel C, 1998, ACT NEUR S, V71, P209; Wallace WC, 1997, MOL BRAIN RES, V52, P213, DOI 10.1016/S0169-328X(97)00259-3; Wallace WC, 1997, MOL BRAIN RES, V52, P201, DOI 10.1016/S0169-328X(97)00258-1; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	64	87	88	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	1999	159	2					441	450		10.1006/exnr.1999.7150			10	Neurosciences	Neurosciences & Neurology	246ED	WOS:000083150700010	10506515				2021-06-18	
J	Tate, RL				Tate, RL			Executive dysfunction and characterological changes after traumatic brain injury: Two sides of the same coin?	CORTEX			English	Article						frontal lobe; brain injury; cognition disorders	CARD SORTING TEST; CLOSED-HEAD INJURY; FRONTAL-LOBE LESIONS; COGNITIVE RISK-TAKING; TEMPORAL LOBECTOMY; PREFRONTAL CORTEX; RELATIVES VIEW; DESIGN FLUENCY; DAMAGE; INFORMATION	This study examined the capacity of neuropsychological variables indicative of dysfunction in the regulation of executive abilities (e.g. noncompliance with rules) to reflect changes in character associated with disturbances in regulatory abilities (e.g. impulsivity). A close relative of 30 participants with traumatic brain injury (TBI) was administered the Current Behaviour Scale (CBS) at admission (rating premorbid character) and six months posttrauma (rating current character). The TBI group was examined neuropsychologically at six months posttrauma, along with 30 nonbrain-damaged (NBD) participants. Significant increases in CBS factors, Loss of Emotional Control and Loss of Motivation, occurred in the TBI group posttrauma. Differences between TBI and NBD groups were found for most executive variables. Those TBI participants with impairments on the neuropsychological Rule Breaking variable showed significant posttrauma increases in Loss of Emotional Control. There was also a trend for individuals with frontal lesions to make rule-breaking and perseverative errors.	Univ Sydney, Dept Med, Rehabil Studies Unit, Royal Rehabil Ctr, Ryde, NSW 1680, Australia	Tate, RL (corresponding author), Univ Sydney, Dept Med, Rehabil Studies Unit, Royal Rehabil Ctr, POB 6, Ryde, NSW 1680, Australia.	state@med.usyd.edu.au					Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Axelrod Bradley N, 1992, Clin Neuropsychol, V6, P143, DOI 10.1080/13854049208401851; Barcelo F, 1997, NEUROPSYCHOLOGIA, V35, P399, DOI 10.1016/S0028-3932(96)00096-6; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Benton A. L., 1994, CONTRIBUTIONS NEUROP; BERMAN KF, 1995, NEUROPSYCHOLOGIA, V33, P1027, DOI 10.1016/0028-3932(95)00035-2; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; Burgess PW, 1996, CORTEX, V32, P241, DOI 10.1016/S0010-9452(96)80049-9; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; CROWE SF, 1992, J CLIN EXP NEUROPSYC, V14, P327, DOI 10.1080/01688639208402832; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Elsass L, 1989, P 14 ANN BRAIN IMP C, P124; Fleming JM, 1996, BRAIN INJURY, V10, P1; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GOLDSTEIN FC, 1989, INTEGRATING THEORY P, P217; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; GURNS S, 1994, BRAIN INJURY, V8, P413, DOI 10.3109/02699059409150993; Heaton R., 1993, WISCONSIN CARD SORTI; HECAEN H, 1964, FRONTAL GRANULAR COR, P335; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kertesz A., 1982, W APHASIA BATTERY; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lishman W. A., 1987, ORGANIC PSYCHIAT; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Luria A. R, 1973, WORKING BRAIN; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; Luria A. R., 1969, HDB CLINICAL NEUROLO, V2, P725; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MILLER L, 1985, NEUROPSYCHOLOGIA, V23, P359, DOI 10.1016/0028-3932(85)90022-3; MILLER L, 1985, NEUROPSYCHOLOGIA, V23, P371, DOI 10.1016/0028-3932(85)90023-5; MILLER LA, 1992, NEUROPSYCHOLOGIA, V30, P69, DOI 10.1016/0028-3932(92)90015-E; Milner B, 1964, FRONTAL GRANULAR COR, P313; Moore W S, 1995, Cardiovasc Surg, V3, P109, DOI 10.1016/0967-2109(95)90882-6; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; NELSON LD, 1989, J CONSULT CLIN PSYCH, V1, P266; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Sichez-Auclair N, 1988, Acta Neurochir Suppl (Wien), V44, P54; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; TATE RL, 1987, SCAND J REHABIL MED, V19, P13; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Varney NR, 1996, ARCH CLIN NEUROPSYCH, V11, P345, DOI 10.1016/0887-6177(95)00015-1; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Walsh K. W, 1991, UNDERSTANDING BRAIN; Wilson, 1991, NATL ADULT READING T; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood R. L., 1987, BRAIN INJURY REHABIL	72	87	89	0	15	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	1999	35	1					39	55		10.1016/S0010-9452(08)70784-6			17	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	177MY	WOS:000079214900003	10213533				2021-06-18	
J	Gillardon, F; Kiprianova, I; Sandkuhler, J; Hossmann, KA; Spranger, M				Gillardon, F; Kiprianova, I; Sandkuhler, J; Hossmann, KA; Spranger, M			Inhibition of caspases prevents cell death of hippocampal CA1 neurons, but not impairment of hippocampal long-term potentiation following global ischemia	NEUROSCIENCE			English	Article						apoptosis; cerebral ischemia; Z-DEVD-FMK; LTP	CEREBELLAR GRANULE NEURONS; ACTIVATION; APOPTOSIS; PROTEASE; EXPRESSION; NECROSIS; CPP32; BRAIN; IAP; RAT	An essential role for caspases in programmed neuronal cell death has been demonstrated in various in vitro studies, and synthetic caspase inhibitors have recently been shown to prevent neuronal cell loss in animal models of focal cerebral ischemia and traumatic brain injury, respectively. The therapeutic utility of caspase inhibitors, however, will depend on preservation of both structural and functional integrity of neurons under stressful conditions. The present study demonstrates that expression and proteolytic activity of caspase-3 is up-regulated in the rat hippocampus after transient forebrain ischemia. Continuous i.c.v. infusion of the caspase inhibitor N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone significantly attenuated caspase-3-like enzymatic activity, and blocked delayed cell loss of hippocampal CA1 neurons after ischemia. Administration of N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val- Asp(OMe)-fluoromethyl ketone, however, did not prevent impairment of induction of long-term potentiation in postischemic CA1 cells, suggesting that caspase inhibition alone does not preserve neuronal functional plasticity. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Max Planck Inst Neurol Forsch, D-50931 Cologne, Germany; Univ Heidelberg, Neurol Klin, Heidelberg, Germany; Univ Heidelberg, Inst Physiol 2, Heidelberg, Germany	Gillardon, F (corresponding author), Boehringer Ingelheim Pharma KG, ZNS Forsch Mol Biol, Binger Str 173, D-55216 Ingelheim, Germany.		Sandkuhler, Jurgen/B-6648-2012	Sandkuhler, Jurgen/0000-0002-5209-485X			Armstrong RC, 1997, J NEUROSCI, V17, P553; Clem RJ, 1997, TRENDS CELL BIOL, V7, P337, DOI 10.1016/S0962-8924(97)01088-X; Deshmukh M, 1997, MOL PHARMACOL, V51, P897; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; FRANK L, 1993, EXP BRAIN RES, V95, P70; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HORI N, 1994, EXP NEUROL, V129, P279, DOI 10.1006/exnr.1994.1170; KIPRIANOVA I, 1999, IN PRESS EXPL NEUROL; Krajewska M, 1997, CANCER RES, V57, P1605; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; MIYAZAKI S, 1993, NEUROL RES, V15, P249; Sakahira H, 1998, NATURE, V391, P96; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	17	87	93	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		1999	93	4					1219	1222		10.1016/S0306-4522(99)00292-4			4	Neurosciences	Neurosciences & Neurology	233PV	WOS:000082436000001	10501444				2021-06-18	
J	Walter, HJ; Berry, M; Hill, DJ; Cwyfan-Hughes, S; Holly, JMP; Logan, A				Walter, HJ; Berry, M; Hill, DJ; Cwyfan-Hughes, S; Holly, JMP; Logan, A			Distinct sites of insulin-like growth factor (IGF)-II expression and localization in lesioned rat brain: Possible roles of IGF binding proteins (IGFBPs) in the mediation of IGF-II activity	ENDOCRINOLOGY			English	Article							HUMAN CEREBROSPINAL-FLUID; CENTRAL-NERVOUS-SYSTEM; AUTORADIOGRAPHIC LOCALIZATION; SELECTIVE AFFINITY; PITUITARY-GLAND; MESSENGER-RNAS; CHOROID-PLEXUS; RECEPTOR; SERUM; HYBRIDIZATION	Although expression of the IGF-II has been demonstrated within the central nervous system (CNS), past studies have failed to reveal its precise roles or responses subsequent to a traumatic injury. To demonstrate that IGF-II, IGFBP, and IGF receptor (-R) expression alters in response to a penetrating CNS injury, we used the techniques of ribonuclease protection assay, in situ hybridization, immunohistochemistry, Western blotting, and RIA. Under normal physiology, IGF-II expression is restricted to the mesenchymal support structures of the brain, including the choroid plexus, where its expression is coincident with that of IGFBP-2. Between 1-7 days post lesion (dpl), in the acute phase following a penetrant wound to the CNS, IGF-II and IGF-IIR protein, but not messenger RNA, were colocalized, with IGF-I, IGF-IR, and IGFBP-1, -2, -3, and -6, to neurons, macrophages, astrocytes, and microglia within the damaged tissue. Within the cerebrospinal fluid (CSF), levels of IGF-II peptide increased to peak at 7 dpl. IGFBP-2, -3, and -6 were also observed within the CSF, with IGFBP-2 predominating and exhibiting an increase in binding efficiency from 7-10 dpl. In the chronic phase of injury (7-14 dpl), an increase in both IGF-II, IGF-IIR and IGFBP-5 messenger RNA and protein was observed specifically and focally in the marginal astrocytes forming the limiting glial membrane of the wound. Thus, our evidence suggests that there are two mechanisms of action for IGF-II within the injured rat brain. During the acute phase, the secretion of IGF-II from the choroid plexus into the CSF is up-regulated, resulting in increased transport of the peptide to the wound. In the CSF, transported IGF-II is complexed to IGFBP-2 and essentially demonstrates an endocrine mode of action with a balance of locally produced IGFBPs modulating its bioactivity in the wound. Later in the wounding response, levels of IGF-II decline in the CSF and the wound neuropil, possibly with the aid of increased IGFBP-5 levels that may help to locally sequester and down-regulate IGF-II activity. Hence, in the chronic phase of the injury response, IGF-II reasserts itself to a predominantly autocrine/paracrine role restricted to the mesenchymal support structures, including the glia limitans, which may help reestablish and maintain tissue homeostasis.	Univ Birmingham, Queen Elizabeth Med Ctr, Dept Med, Wolfson Res Labs, Birmingham B15 2TH, W Midlands, England; Guys Hosp, UMDS, Dept Anat & Cell Biol, London SE1 9RT, England; Lawson Res Inst, Dept Med Physiol & Paediat, London, ON N6A 4V2, Canada; Univ Bristol, Dept Surg, Bristol BS2 8HW, Avon, England	Logan, A (corresponding author), Univ Birmingham, Queen Elizabeth Med Ctr, Dept Med, Wolfson Res Labs, Birmingham B15 2TH, W Midlands, England.	a.logan@bham.ac.uk	Hill, David J/G-3302-2011	Hill, David J/0000-0002-2490-5678; Logan, Ann/0000-0003-3215-5042	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		AUSUBEL FM, 1992, SHORT PROTOCOLS MOL; AYERLELIEVRE C, 1991, DEVELOPMENT, V111, P105; BERRY M, 1998, MONOGRAPH THERAPEUTI, P1; BERRY MM, 1997, GRAYS ANATOMY, P1202; BOHANNON NJ, 1988, BRAIN RES, V444, P205, DOI 10.1016/0006-8993(88)90931-6; BRAR AK, 1993, J NEUROSCI RES, V35, P103, DOI 10.1002/jnr.490350112; CARONI P, 1990, J CELL BIOL, V110, P1307, DOI 10.1083/jcb.110.4.1307; CAUSIN C, 1988, BIOCHEM J, V252, P795, DOI 10.1042/bj2520795; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; CONOVER CA, 1986, BIOCHEM BIOPH RES CO, V139, P501, DOI 10.1016/S0006-291X(86)80019-5; COUCE ME, 1992, ENDOCRINOLOGY, V131, P1636, DOI 10.1210/en.131.4.1636; DEKEYSER J, 1994, SYNAPSE, V17, P196, DOI 10.1002/syn.890170309; DELHANTY PJD, 1993, GROWTH REGULAT, V3, P8; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3051, DOI 10.1210/en.131.6.3051; GIRBAU M, 1989, P NATL ACAD SCI USA, V86, P5868, DOI 10.1073/pnas.86.15.5868; HASELBACHER G, 1982, ENDOCRINOLOGY, V110, P1822, DOI 10.1210/endo-110-5-1822; HILL DJ, 1991, J DEV PHYSIOL, V15, P91; HILL DJ, 1990, EARLY HUM DEV, V21, P49, DOI 10.1016/0378-3782(90)90110-5; Hill J M, 1988, Peptides, V9 Suppl 1, P181, DOI 10.1016/0196-9781(88)90242-2; HOSSENLOPP P, 1986, FEBS LETT, V208, P439, DOI 10.1016/0014-5793(86)81065-1; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAR S, 1993, J COMP NEUROL, V333, P375, DOI 10.1002/cne.903330306; KIESS W, 1987, J BIOL CHEM, V262, P12745; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; KNUSEL B, 1990, J NEUROSCI, V10, P558; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; LOGAN A, 1994, ENDOCRINOLOGY, V135, P2255, DOI 10.1210/en.135.5.2255; Logan Ann, 1994, Progress in Growth Factor Research, V5, P379, DOI 10.1016/0955-2235(94)00008-9; MCKELVIE PA, 1992, J NEUROPATH EXP NEUR, V51, P464, DOI 10.1097/00005072-199207000-00009; MULLER HL, 1994, J CLIN ENDOCR METAB, V79, P428, DOI 10.1210/jc.79.2.428; NILSSON C, 1992, BRAIN RES REV, V17, P109, DOI 10.1016/0165-0173(92)90011-A; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OCRANT I, 1990, ENDOCRINOLOGY, V127, P1260, DOI 10.1210/endo-127-3-1260; OCRANT I, 1993, ANN NY ACAD SCI, V692, P44; OCRANT I, 1988, ENDOCRINOLOGY, V123, P1023, DOI 10.1210/endo-123-2-1023; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; ROGERS SA, 1988, P NATL ACAD SCI USA, V85, P4037, DOI 10.1073/pnas.85.11.4037; ROGHANI M, 1989, FEBS LETT, V255, P253, DOI 10.1016/0014-5793(89)81101-9; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; STEEDMAN HF, 1957, NATURE, V179, P1345, DOI 10.1038/1791345a0; STENVERS KL, 1994, J COMP NEUROL, V339, P91, DOI 10.1002/cne.903390109; TSENG LYH, 1989, MOL ENDOCRINOL, V3, P1559, DOI 10.1210/mend-3-10-1559; VALENTINO KL, 1988, ENDOCRINOLOGY, V122, P2753, DOI 10.1210/endo-122-6-2753; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WERTHER GA, 1989, J NEUROENDOCRINOL, V1, P369, DOI 10.1111/j.1365-2826.1989.tb00131.x	48	87	88	0	1	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	JAN	1999	140	1					520	532		10.1210/en.140.1.520			13	Endocrinology & Metabolism	Endocrinology & Metabolism	149VH	WOS:000077626500067	9886865	Bronze			2021-06-18	
J	Folkerts, MM; Berman, RF; Muizelaar, JP; Rafols, JA				Folkerts, MM; Berman, RF; Muizelaar, JP; Rafols, JA			Disruption of MAP-2 immunostaining in rat hippocampus after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cytoskeleton; dendrite; microtubule; trauma	MICROTUBULE-ASSOCIATED PROTEIN-2; CEREBRAL-ISCHEMIA; CELL-DEATH; VULNERABILITY; MODEL; GROWTH; PATHOPHYSIOLOGY; FOREBRAIN; CALCIUM; SYSTEM	The effects of diffuse brain injury on dendritic morphology in rat hippocampus and cortex were examined in this study using the recently described impact acceleration model of traumatic brain injury (Marmarou et al., 1994). Dendritic structure was visualized using immunostaining of microtubule associated protein-2 (MAP-2). Brains were studied 24, 48, and 72 h after brain injury. Results from immunohistochemistry and light microscopy indicated a time-dependent disruption of dendritic cytoarchitecture in the CA1 subregion and in the hilus of the hippocampus but not in the dentate gyrus or CA3 subregion. Similar disruption was observed in the cortical mantle overlying the hippocampus. Although disruption of dendritic structure was observed at 24 h, the most severe damage was at 48 h after injury with evidence of at least partial recovery of MAP-2 immunostaining by 72 h. In the most severe damage, dendrites appeared to be fragmented, scattered, and unaligned, consisting of irregularly spaced and darkly stained swollen segments. A mixed pattern of immunostaining was observed in somata of hilar cells, with some appearing normal while others stained only faintly, appearing to have lost their typical polygonal shape. Semiquantitative rankings confirmed these qualitative findings. Immediate post-injury behavioral evaluations of injury severity were compared to the degree of disruption of MAP-2 immunostaining. The results of this study indicate that diffuse brain injury is associated not only with axonal damage but also with injury to dendrites.	Univ Calif Davis, Dept Neurol Surg, Neurotrauma Res Labs, Davis, CA 95616 USA; Wayne State Univ, Dept Cell Biol & Anat, Detroit, MI 48201 USA	Berman, RF (corresponding author), Univ Calif Davis, Dept Neurol Surg, Neurotrauma Res Labs, 1 Shields Ave, Davis, CA 95616 USA.						BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRAY D, 1978, P NATL ACAD SCI USA, V75, P5226, DOI 10.1073/pnas.75.10.5226; CACERES A, 1988, MOL BRAIN RES, V3, P233, DOI 10.1016/0169-328X(88)90046-0; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FISCHER I, 1991, EXP CELL RES, V194, P195, DOI 10.1016/0014-4827(91)90354-W; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkerts M. M., 1998, J NEUROTRAUM, V13, P610; FREUND TF, 1992, BRAIN RES BULL, V28, P27, DOI 10.1016/0361-9230(92)90227-O; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HSU M, 1993, J NEUROSCI, V13, P3964; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; JENKINS LW, 1981, ACTA NEUROPATHOL, V55, P205, DOI 10.1007/BF00691320; JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAGLOCZKY Z, 1995, NEUROSCIENCE, V66, P847, DOI 10.1016/0306-4522(94)00613-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; O'Neil BJ, 1996, CARDIAC ARREST SCI P, P84; PARNAVELAS JG, 1974, NATURE, V248, P71, DOI 10.1038/248071a0; Paxinos G, 1986, RAT BRAIN STEREOTAXI; POSTMANTUR RM, 1996, J NEUROPATHOL EXP NE, V55, P68; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; SATO M, 1990, ACTA NEUROPATHOL, V80, P527, DOI 10.1007/BF00294614; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAKEDA M, 1991, ACTA NEUROPATHOL, V82, P346, DOI 10.1007/BF00296545; TOMIMOTO H, 1992, ACTA NEUROPATHOL, V84, P394; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; YAMAMOTO K, 1986, BRAIN RES, V384, P1, DOI 10.1016/0006-8993(86)91212-6; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610	34	87	92	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1998	15	5					349	363		10.1089/neu.1998.15.349			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZL515	WOS:000073441300005	9605349				2021-06-18	
J	Horita, A				Horita, A			An update on the CNS actions of TRH and its analogs	LIFE SCIENCES			English	Article; Proceedings Paper	2nd International Symposium on Membrane Receptors Signal Transduction and Drug Action / 19th Symposium on Biomembrane-Drug Interaction	SEP 24-26, 1997	SAPPORO, JAPAN	Minist Educ Sci Sports & Culture, Japanese Pharmacol Soc, Pharmaceut Soc Japan, Hokkaido Univ, Univ Arizona		thyrotropin releasing hormone; TRH analogs; arousal; amnesia; motor function; spinal cord injury; spinocerebellar injury	THYROTROPIN-RELEASING-HORMONE; VIVO ACETYLCHOLINE-RELEASE; RAT FRONTAL-CORTEX; SPINAL-CORD INJURY; DOSE-RESPONSE; YM-14673; TA-0910; BRAIN; RECEPTOR; MICE	This brief review will discuss the recent literature on several of the central actions of TRH and its analogs. The most prominent of these actions include: (1) the arousal or analeptic effect in drug narcotized animals or in concussion models; (2) the reversal of cognitive deficits produced by various drugs or procedures, and (3) the improvement of several neurological deficits produced in animal models of spinal and/or cerebellar injury. The mediation of these TRH effects by neurotransmitters is discussed. While little has been published on the human neuropsychopharmacology of TRH, and especially of its analogs, the future holds considerable therapeutic promise for these interesting drugs.	Univ Washington, Sch Med, Dept Pharmacol & Psychiat, Seattle, WA 98195 USA	Horita, A (corresponding author), Univ Washington, Sch Med, Dept Pharmacol & Psychiat, Seattle, WA 98195 USA.						BAYLISS DA, 1992, J NEUROPHYSIOL, V68, P1733; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BREESE GR, 1975, J PHARMACOL EXP THER, V193, P11; Callahan AM, 1997, BIOL PSYCHIAT, V41, P264, DOI 10.1016/S0006-3223(97)00372-7; Chizh BA, 1996, EUR J PHARMACOL, V300, P183, DOI 10.1016/0014-2999(95)00869-1; DESHPANDE SB, 1994, EUR J PHARMACOL, V271, P439, DOI 10.1016/0014-2999(94)90804-4; ENGEL WK, 1983, LANCET, V2, P73; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Gershengorn MC, 1996, PHYSIOL REV, V76, P175; GIOVANNINI MG, 1991, BRIT J PHARMACOL, V102, P363, DOI 10.1111/j.1476-5381.1991.tb12179.x; HEINFLINK M, 1995, MOL ENDOCRINOL, V9, P1455, DOI 10.1210/me.9.11.1455; HORITA A, 1986, FASEB J, V45, P795; HORITA A, 1991, LIFE SCI, V49, P595, DOI 10.1016/0024-3205(91)90258-D; HORITA A, 1989, PEPTIDES, V10, P121, DOI 10.1016/0196-9781(89)90087-9; HORITA A, 1975, PHARM BIOCH BEHAV, V5, P111; HUTSON PH, 1990, NEUROSCI LETT, V116, P149, DOI 10.1016/0304-3940(90)90401-T; ITOH Y, 1994, J PHARMACOL EXP THER, V268, P255; ITOH Y, 1994, J PHARMACOL EXP THER, V271, P884; KALIVAS PW, 1980, J PHARMACOL EXP THER, V212, P203; Kinoshita K, 1997, BIOL PHARM BULL, V20, P36; KINOSHITA K, 1994, NEUROPHARMACOLOGY, V33, P1183, DOI 10.1016/S0028-3908(05)80008-5; Kinoshita K, 1996, JPN J PHARMACOL, V71, P139, DOI 10.1254/jjp.71.139; Kinoshita K, 1995, BRIT J PHARMACOL, V116, P3274, DOI 10.1111/j.1476-5381.1995.tb15135.x; KINOSHITA K, 1995, J PHARM, V24, P65; Koenig ML, 1996, BRAIN RES, V730, P143; KRAEMER GW, 1976, PHARMACOL BIOCHEM BE, V4, P709, DOI 10.1016/0091-3057(76)90224-0; Larsson JE, 1996, PEPTIDES, V17, P293, DOI 10.1016/0196-9781(95)02127-2; Mason George A., 1995, P493; MATSUI K, 1994, EUR J PHARMACOL, V254, P295, DOI 10.1016/0014-2999(94)90469-3; MELLOW AM, 1993, BIOL PSYCHIAT, V34, P271, DOI 10.1016/0006-3223(93)90083-P; MIYAMOTO M, 1982, PHARMACOL BIOCHEM BE, V17, P797, DOI 10.1016/0091-3057(82)90363-X; MIYAMOTO M, 1994, EUR J PHARMACOL, V271, P357; MIYAMOTO M, 1993, EUR J PHARMACOL, V238, P181; MOLCHAN SE, 1990, PSYCHOPHARMACOLOGY, V100, P84, DOI 10.1007/BF02245795; Mushiroi Takeshi, 1996, Folia Pharmacologica Japonica, V107, P237, DOI 10.1254/fpj.107.237; Nakayama T, 1996, EUR J PHARMACOL, V316, P157, DOI 10.1016/S0014-2999(96)00614-0; NICOLL RA, 1977, NATURE, V265, P242, DOI 10.1038/265242a0; Ogasawara T, 1996, PHARMACOL BIOCHEM BE, V53, P391, DOI 10.1016/0091-3057(95)02039-X; OGASAWARA T, 1996, PHARM BIOCH BEHAV, V50, P499; OKADA M, 1991, J NEUROCHEM, V56, P1544, DOI 10.1111/j.1471-4159.1991.tb02049.x; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; POPOLI P, 1995, EUR J PHARMACOL, V272, P119, DOI 10.1016/0014-2999(94)00701-8; SANTORI EM, 1981, PSYCHOPHARMACOLOGY, V74, P13, DOI 10.1007/BF00431749; SOBUE I, 1983, J NEUROL SCI, V61, P235, DOI 10.1016/0022-510X(83)90008-4; Stocca G, 1996, PEPTIDES, V17, P1197, DOI 10.1016/S0196-9781(96)00128-3; TOIDE K, 1993, EUR J PHARMACOL, V233, P21, DOI 10.1016/0014-2999(93)90344-H; Ukai Yojiro, 1996, Folia Pharmacologica Japonica, V107, P273, DOI 10.1254/fpj.107.273; YAMAMOTO M, 1989, EUR J PHARMACOL, V166, P545, DOI 10.1016/0014-2999(89)90373-7; YAMAMURA M, 1991, JPN J PHARMACOL, V55, P69, DOI 10.1254/jjp.55.69	51	87	87	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	MAR 27	1998	62	17-18					1443	1448		10.1016/S0024-3205(98)00087-3			6	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	ZE980	WOS:000072850800002	9585116				2021-06-18	
J	Suhr, J; Tranel, D; Wefel, J; Barrash, J				Suhr, J; Tranel, D; Wefel, J; Barrash, J			Memory performance after head injury: Contributions of malingering, litigation status, psychological factors, and medication use	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; WAIS-R; DEFICITS; VALIDITY; FAKING; IMPAIRMENT; CONCUSSION; PROSPECTS; SYMPTOMS; TESTS	Impaired memory test performance can reflect a host of factors, such as head injury/postconcussive syndrome, involvement in litigation, malingering behavior, psychological distress, and medication use. Such factors are important in interpreting memory test performances in patients referred in the context of litigation. We examined memory test performance in mild head-injured patients in litigation, mild to moderate head-injured patients not in litigation, severely head-injured patients not in litigation, depressed patients, and patients with somatization disorders. Findings showed that several memory tests were useful in distinguishing probable malingerers from the other groups. There was a complex interaction among malingering status, psychological status, and medication use in the prediction of memory test results. Although nonneurological factors were related to memory impairment, litigation status alone was not predictive of memory performance. The results emphasize the need to consider nonneurological factors in the interpretation of poor memory performance in patients seen for forensic evaluation.	UNIV IOWA,DEPT PSYCHOL,IOWA CITY,IA 52242	Suhr, J (corresponding author), UNIV IOWA,COLL MED,DEPT NEUROL,IOWA CITY,IA 52242, USA.			Tranel, Daniel/0000-0002-1338-1389; Barrash, Joseph/0000-0001-9827-0110	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS019632] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Beck A.T., 1987, BECK DEPRESSION INVE; BENTON AL, 1961, ARCH GEN PSYCHIAT, V4, P79; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BOONE KB, 1995, J CLIN PSYCHOL, V51, P457, DOI 10.1002/1097-4679(199505)51:3<457::AID-JCLP2270510322>3.0.CO;2-7; Butcher J. N., 1989, MANUAL RESTANDARDIZE; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cullum C, 1991, FORENSIC NEUROPSYCHO, P141; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GUILMETTE TJ, 1994, PERCEPT MOTOR SKILL, V78, P1179, DOI 10.2466/pms.1994.78.3c.1179; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1996, J CLIN EXPT NEUROPSY, V11, P967; Jones R. D., 1996, P395; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; LEESHALEY PR, 1990, PERCEPT MOTOR SKILL, V70, P1379, DOI 10.2466/PMS.70.3.1379-1382; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; Rey A., 1941, ARCH PSYCHOL, V37, P126; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rizzo Matthew, 1996, P1; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; SCHEINBERG P, 1994, ARCH NEUROL-CHICAGO, V51, P650, DOI 10.1001/archneur.1994.00540190024011; Sivan AB., 1992, BENTON VISUAL RETENT; TEASDALE G, 1974, LANCET, V2, P81; TRANEL D, 1996, NEUROPSYCHOLOGICAL A, P81; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	55	87	87	1	10	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1997	19	4					500	514		10.1080/01688639708403740			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	YA413	WOS:A1997YA41300004	9342686				2021-06-18	
J	Reeves, TM; Lyeth, BG; Phillips, LL; Hamm, RJ; Povlishock, JT				Reeves, TM; Lyeth, BG; Phillips, LL; Hamm, RJ; Povlishock, JT			The effects of traumatic brain injury on inhibition in the hippocampus and dentate gyrus	BRAIN RESEARCH			English	Article						traumatic brain injury; paired-pulse inhibition; hippocampus; dentate gyrus; gamma-aminobutyric acid; rat	PAIRED-PULSE DEPRESSION; ACTIVITY-DEPENDENT DISINHIBITION; TRANSIENT CEREBRAL-ISCHEMIA; GABA-MEDIATED INHIBITION; RAT HIPPOCAMPUS; FASCIA-DENTATA; EXTRACELLULAR POTASSIUM; SYNAPTIC TRANSMISSION; COGNITIVE IMPAIRMENT; GLUCOSE-UTILIZATION	Changes in inhibitory neuronal functioning may contribute to morbidity following traumatic brain injury (TBI). Evoked responses to orthodromic paired-pulse stimulation were examined in the hippocampus and dentate gyrus at 2 and 15 days following lateral fluid percussion TBI in adult rats. The relative strength of inhibition was estimated by measuring evoked paired pulses in three afferent systems: the CA3 commissural input to the CA1 region of the hippocampus; the entorhinal cortical input to the ipsilateral CA1 area (temporoammonic system); and the entorhinal input to the ipsilateral dentate gyms (perforant path). In addition to quantitative electrophysiological estimates of inhibitory efficacy, levels of gamma-aminobutyric acid (GABA) were qualitatively examined with immunohistochemical techniques. Effects of TBI on paired-pulse responses were pathway-specific, and dependent on time postinjury. At 2 days following TBI, inhibition of population spikes was significantly reduced in the CA3 commissural input to CA1, which contrasted with injury-induced increases in inhibition in the dentate gyrus seen at both 2 and 15 days postinjury. Low-level stimulation, subthreshold for population spikes, also revealed changes in paired-pulse facilitation of field extracellular postsynaptic potentials (fEPSPs), which depended on fiber pathway and time postinjury. Significant injury-induced electrophysiological changes were almost entirely confined to the hemisphere ipsilateral to injury. Intensity of GABA immunobinding exhibited a regional association with electrophysiological indices of inhibition, with the most pronounced increases in GABA levels and inhibition found in the dentate gyrus. TBI-induced effects showed a regional pattern within the hippocampus which corresponds closely to inhibitory changes reported to follow ischemia and kindling. This degree of similarity in outcome following dissimilar injuries may indicate common mechanisms in the nervous system response to injury.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, DEPT PSYCHOL, RICHMOND, VA 23298 USA	Reeves, TM (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT ANAT, BOX 709, RICHMOND, VA 23298 USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS01750, NS12587, NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, K17NS001750, R01NS020193, P01NS012587] Funding Source: NIH RePORTER		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Brierley JB, 1984, GREENFIELDS NEUROPAT, P125; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; CHANG HS, 1989, STROKE, V20, P1051, DOI 10.1161/01.STR.20.8.1051; CHANG HS, 1989, BRAIN RES, V505, P220, DOI 10.1016/0006-8993(89)91446-7; COLBERT CM, 1992, J NEUROPHYSIOL, V68, P1; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEJONGE M, 1987, BRAIN RES, V412, P318, DOI 10.1016/0006-8993(87)91139-5; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P213; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HERRON CE, 1985, NEUROSCI LETT, V61, P255, DOI 10.1016/0304-3940(85)90473-2; KAMPHUIS W, 1988, BRAIN RES, V440, P205, DOI 10.1016/0006-8993(88)90988-2; KAMPHUIS W, 1992, NEUROSCI LETT, V141, P101, DOI 10.1016/0304-3940(92)90344-7; KAPUR J, 1989, J NEUROPHYSIOL, V61, P417; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY PAT, 1982, J NEUROCHEM, V39, P613, DOI 10.1111/j.1471-4159.1982.tb07937.x; KELLY PT, 1983, BRAIN RES, V258, P338, DOI 10.1016/0006-8993(83)91162-9; KING GL, 1985, J NEUROPHYSIOL, V54, P1295; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.neuro.14.1.379; MARU E, 1987, EXP NEUROL, V96, P46, DOI 10.1016/0014-4886(87)90167-1; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MOTT DD, 1993, J NEUROPHYSIOL, V69, P674; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; REEVES TM, 1995, EXP BRAIN RES, V106, P248; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; ROCK DM, 1986, NEUROSCI LETT, V65, P265, DOI 10.1016/0304-3940(86)90272-7; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Sloviter R S, 1991, Hippocampus, V1, P31, DOI 10.1002/hipo.450010105; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; THOMPSON SM, 1994, PROG NEUROBIOL, V42, P575, DOI 10.1016/0301-0082(94)90044-2; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512; THOMPSON SM, 1988, NEUROSCI LETT, V89, P49, DOI 10.1016/0304-3940(88)90479-X; TITULAER MNG, 1994, NEUROSCIENCE, V59, P817, DOI 10.1016/0306-4522(94)90286-0; TITULAER MNG, 1995, J NEUROCHEM, V64, P2615; TUFF LP, 1983, BRAIN RES, V277, P79, DOI 10.1016/0006-8993(83)90909-5; TUFF LP, 1983, BRAIN RES, V277, P91, DOI 10.1016/0006-8993(83)90910-1; ZHAO DC, 1991, BRAIN RES, V564, P220, DOI 10.1016/0006-8993(91)91457-C	51	87	89	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 16	1997	757	1					119	132		10.1016/S0006-8993(97)00170-4			14	Neurosciences	Neurosciences & Neurology	XC521	WOS:A1997XC52100016	9200506				2021-06-18	
J	Unterberg, AW; Kiening, KL; Hartl, R; Bardt, T; Sarrafzadeh, AS; Lanksch, WR				Unterberg, AW; Kiening, KL; Hartl, R; Bardt, T; Sarrafzadeh, AS; Lanksch, WR			Multimodal monitoring in patients with head injury: Evaluation of the effects of treatment on cerebral oxygenation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	14th Bodensee Symposium on Microcirculation: Small Volume Resuscitation in Head Injury	JUN 14-16, 1996	BODENSEE, GERMANY			cerebral oxygenation; intracranial pressure; cerebral perfusion pressure; traumatic brain injury; multimodal monitoring	ISCHEMIC BRAIN-DAMAGE; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; SATURATION; MANNITOL	Background: Recently, invasive intensive care unit monitoring of cerebral oxygenation has become feasible. The purpose of this study was to investigate the effects of standard therapeutic interventions used in the treatment of intracranial hypertension on cerebral oxygenation and other physiologic parameters in comatose patients. Methods: In the neurosurgical intensive care unit, Ptio(2), and jugular bulb oxygen saturation (Sjvo(2)), arterial blood pressure, intracranial pressure (ICP), and cerebral perfusion pressure (CPP) were prospectively studied (0.1 Hz acquisition rate) with a multimodal monitoring system in 21 patients with severe traumatic brain injury during various treatment modalities: dopamine and mannitol infusion, head positioning, and induced arterial hypocapnia. Results: For baseline CPP values below 40 mm Hg, dopamine infusion was more effective in decreasing ICP and improving Ptio(2) and Sjvo(2) than for initial CPP values above 60 mm Hg. Treatment with mannitol, although improving CPP and lowering ICP, did not affect Ptio(2) and Sjvo(2). CPP in this group, however, was always above 60 mm Hg. Forced hyperventilation to an end-tidal Pco(2) of 21 mm Hg normalized ICP and CPP, but significantly reduced cerebral oxygenation. Conclusion: 4 CPP > 60 mm Hg emerges as the crucial factor guaranteeing sufficient brain oxygenation. Any intervention used to further elevate CPP does not improve cerebral oxygenation, to the contrary, forced hyperventilation even bears the risk of inducing brain ischemia.		Unterberg, AW (corresponding author), HUMBOLDT UNIV BERLIN, VIRCHOW KLINIKUM, DEPT NEUROSURG, VIRCHOW MED CTR, AUGUSTENBURGER PL 1, D-13353 BERLIN, GERMANY.						CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CLARK LC, 1956, T AM SOC ART INT ORG, V2, P41; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAAB MR, 1990, ACT NEUR S, V51, P320; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HARTL R, 1996, IN PRESS CARDIOVASC; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHNEIDER GH, 1993, ACTA NEUROCHIR, P107; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TAKAGI H, 1983, INTRACRANIAL PRESSUR, V5, P729; THEODORSSONNORHEIM E, 1987, COMPUT BIOL MED, V17, P85, DOI 10.1016/0010-4825(87)90003-5; Unterberg A. W., 1995, Journal of Neurotrauma, V12, P405	23	87	89	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1997	42	5		S			S32	S37		10.1097/00005373-199705001-00006			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	XE879	WOS:A1997XE87900007	9191693				2021-06-18	
J	CHAN, PH; EPSTEIN, CJ; LI, Y; HUANG, TT; CARLSON, E; KINOUCHI, H; YANG, G; KAMII, H; MIKAWA, S; KONDO, T; COPIN, JC; CHEN, SF; CHAN, T; GAFNI, J; GOBBEL, G; REOLA, E				CHAN, PH; EPSTEIN, CJ; LI, Y; HUANG, TT; CARLSON, E; KINOUCHI, H; YANG, G; KAMII, H; MIKAWA, S; KONDO, T; COPIN, JC; CHEN, SF; CHAN, T; GAFNI, J; GOBBEL, G; REOLA, E			TRANSGENIC MICE AND KNOCKOUT MUTANTS IN THE STUDY OF OXIDATIVE STRESS IN BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article						TRANSGENIC MICE; KNOCKOUT MUTANTS; FOCAL CEREBRAL ISCHEMIA; TRAUMA; SUPEROXIDE DISMUTASE; OXYGEN FREE RADICALS; CNS INJURY	CU/ZN-SUPEROXIDE-DISMUTASE; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; CORTICAL INFARCTION; OXYGEN RADICALS; NERVOUS-SYSTEM; BLOOD-FLOW; CELLS; NEUROTOXICITY; EDEMA	A rapid increase in the need to explore the molecular basis of cellular function and injury in the central nervous system has led neuroscientists to employ transgenic mouse technology. The successful making of transgenic mice (Tg) overexpressing human CuZn-superoxide dismutase (SOD-1) activity has made it possible to investigate the role of oxygen free radicals in ischemic and traumatic brain injury in a molecular fashion. It has been demonstrated that the 3-fold increase in SOD-1 transgene activity in SOD-1 Tg mice offers protection against cerebral ischemia and reperfusion in two different models of focal cerebral ischemia, as compared to nontransgenic wild-type littermates. Studies involving traumatic brain injury have also demonstrated that acute injuries, including brain edema and blood-brain barrier permeability, are significantly reduced in SOD-1 Tg mice. Furthermore, chronic neurological deficits, such as beam walking, beam balance, and body weight, are significantly improved in these transgenic animals following traumatic brain injury. In addition to the SOD-1 Tg mice being a useful tool for the study of CNS injury, targeted disruption of the mouse gene for mitochondrial manganese SOD (SOD-2) has been successful. These SOD-2 knockout mutant mice, in addition to the recently developed knockout mutants of neuronal nitric oxide synthase (NOS), are believed to offer a unique opportunity to elucidate the oxidative mechanisms in brain injury following stroke and trauma.		CHAN, PH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL & NEUROSURG,521 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.		Copin, Jean-Christophe/K-6890-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, R01NS025372, P01NS014543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG008938] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-08938] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-25372, NS-14543] Funding Source: Medline		AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Chan P.H, 1988, CELLULAR ANTIOXIDANT, VVolume 3, P89; CHAN PH, 1994, ANN NY ACAD SCI, V738, P93; CHAN PH, 1990, STROKE, V21, P80; CHAN PH, 1993, NEUROREPORT, V5, P293, DOI 10.1097/00001756-199312000-00028; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHAN PH, 1994, BRAIN PATHOL, V4, P59; CHAN PH, 1992, NEW INSIGHTS ROLE OX, V7, P277; CHAN PH, 1983, BRAIN RES, V227, P329; CHAN PH, 1995, 19TH PRINC C CER DIS, P153; CHAN PH, 1993, PROG BRAIN RES, V96, P94; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1993, J NEUROSCI, V13, P2651; EDWARDS RH, 1989, CELL, V58, P161, DOI 10.1016/0092-8674(89)90412-1; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; EPSTEIN CJ, 1992, GENE TRANSFER THERAP, P106; EPSTEIN CJ, 1994, P INT ROUND TABLE NE, P239; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HE YY, 1993, AM J PHYSIOL, V265, pH252; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG TT, 1992, FASEB J, V6, P903; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; HUE RT, 1993, FREE RADICAL RES COM, V18, P195; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; KIEDROWSKI L, 1991, J NEUROCHEM, V58, P335; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KINOUCHI H, 1993, J CEREB BLOOD FLO S1, V13, pS30; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KORETSKY AP, 1992, AM J PHYSIOL, V262, pC261; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; LI Y, 1995, IN PRESS NATURE GENE; LI Y, 1994, AM SOC BIOCH MOL BIO, V16; LIEMANHURWITZ J, 1982, P NATL ACAD SCI-BIOL, V79, P2808, DOI 10.1073/pnas.79.9.2808; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU TH, 1989, AM J PHYSIOL, V256, pH589; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P135, DOI 10.1038/jcbfm.1993.16; MIKAWA S, 1995, JCBF M S S, V15, pS729; MIRAULT ME, 1994, ANN NY ACAD SCI, V738, P104; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NAGAFUJI T, 1992, NEUROSCI LETT, V147, P159, DOI 10.1016/0304-3940(92)90584-T; PRADO R, 1993, J CEREBR BLOOD F MET, V13, P720, DOI 10.1038/jcbfm.1993.91; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; ROSENFELD MG, 1988, ANNU REV NEUROSCI, V11, P353, DOI 10.1146/annurev.ne.11.030188.002033; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; SHI YP, 1994, MAMM GENOME, V5, P337, DOI 10.1007/BF00356551; SIESJO BK, 1989, CEREB BRAIN METAB RE, V6, P303; TANAKA K, 1993, NEUROREPORT, V4, P267, DOI 10.1097/00001756-199303000-00010; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; ZHANG FY, 1993, NEUROREPORT, V4, P559, DOI 10.1097/00001756-199305000-00024	64	87	89	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					815	824		10.1089/neu.1995.12.815			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600005	8594209				2021-06-18	
J	PITTS, LH; ROSS, A; CHASE, GA; FADEN, AI				PITTS, LH; ROSS, A; CHASE, GA; FADEN, AI			TREATMENT WITH THYROTROPIN-RELEASING-HORMONE (TRH) IN PATIENTS WITH TRAUMATIC SPINAL-CORD INJURIES	JOURNAL OF NEUROTRAUMA			English	Article						SPINAL CORD INJURY; TRH; HUMAN; BEHAVIORAL OUTCOME	AMYOTROPHIC LATERAL SCLEROSIS; PLATELET-ACTIVATING-FACTOR; EXPERIMENTAL BRAIN TRAUMA; DOSE-RESPONSE; BLOOD-FLOW; BEHAVIORAL DEFICITS; WATER-CONTENT; NALOXONE; RATS; DEXAMETHASONE	Numerous preclinical studies have demonstrated that posttraumatic treatment of spinal cord injury (SCI) with thyrotropin-releasing hormone (TRH) or TRH analogs improves long-term behavioral recovery. The purpose of the present study is to provide preliminary data regarding the safety and potential efficacy of TRH in patients with acute SCI. A total of 20 patients with SCI were classified by clinical examination into complete and incomplete injury groups within 12 h of trauma and randomly assigned in double-blinded fashion to treatment with either TRH (0.2 mg/kg intravenous bolus followed by 0.2 mg/kg/h infusion over 6 h) or vehicle (equal volume physiological saline) placebo. A variety of physiological variables were followed during treatment. Clinical examination included motor and sensory testing, as well as assigning a Sunnybrook score based upon level of function. Patients were examined at 24 h, 72 h, 1 week, 1 month, 4 months, and 12 months after injury. TRH infusions were well tolerated. There appeared to be no discernible treatment effect in patients with complete injuries although data were available from only six such patients at 4 months. For the incomplete injury group, a total of 6 treated and 5 placebo patients had 4-month evaluations. TRH treatment was associated with significantly higher motor, sensory, and Sunnybrook scores than placebo treatment. Because of patients lost to subsequent follow-up, 12-month data were not highly informative. These observations must be interpreted with considerable caution because of the small patient numbers, but together with extensive animal studies they support the need for a larger multicenter clinical trial of TRH.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL & PHARMACOL,WASHINGTON,DC 20007; SAN FRANCISCO GEN HOSP,DEPT NEUROSURG,SAN FRANCISCO,CA 94110			Ross, Amy Miner/W-7789-2019				AKDEMIR H, 1993, RES EXP MED, V193, P297, DOI 10.1007/BF02576237; AKDEMIR H, 1992, RES EXP MED, V192, P177, DOI 10.1007/BF02576273; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; ARIAS MJ, 1987, SURG NEUROL, V28, P335, DOI 10.1016/0090-3019(87)90054-1; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1988, J NEUROSURG, V64, P985; BROOKS BR, 1987, NEUROL CLIN, V5, P143, DOI 10.1016/S0733-8619(18)30939-3; CEYLAN S, 1992, RES EXP MED, V192, P23, DOI 10.1007/BF02576254; CEYLAN S, 1990, RES EXP MED, V190, P111, DOI 10.1007/PL00020013; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P1; DOYLE WK, 1991, CLIN NEUROLOGY, pCH47; ENGEL WK, 1983, LANCET, V2, P73; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1983, NEUROLOGY, V33, P673, DOI 10.1212/WNL.33.6.673; FADEN AI, 1983, PEPTIDES, V4, P631, DOI 10.1016/0196-9781(83)90009-8; FADEN AI, 1992, J PHARMACOL EXP THER, V261, P1064; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P608; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1987, BRAIN RES, V448, P287; FADEN AI, 1993, HDB EXPT PHARM, P325; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HASHIMOTO T, 1989, Japanese Journal of Pharmacology, V49, p312P; HASHIMOTO T, 1991, EUR J PHARMACOL, V203, P25, DOI 10.1016/0014-2999(91)90786-P; HOERLIEIN BF, 1985, J AM ANIM HOSP ASSOC, V2, P67; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; HOLTZ A, 1989, ACTA NEUROL SCAND, V80, P215, DOI 10.1111/j.1600-0404.1989.tb03865.x; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; KOSKINEN LOD, 1989, ANN NY ACAD SCI, V553, P353; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; MILLER SC, 1989, ARCH NEUROL-CHICAGO, V46, P330, DOI 10.1001/archneur.1989.00520390096025; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PRANGE A J JR, 1979, P75; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; RENAUD LP, 1979, SCIENCE, V205, P1275, DOI 10.1126/science.224461; Salzman SK, 1991, J NEUROTRAUM, V8, P45, DOI 10.1089/neu.1991.8.45; TAKAMI K, 1991, JPN J PHARMACOL, V57, P405, DOI 10.1254/jjp.57.405; Tator CH., 1982, EARLY MANAGEMENT ACU, P7; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; WANG GL, 1991, CHINESE MED J-PEKING, V104, P939; Young W, 1985, Cent Nerv Syst Trauma, V2, P109	53	87	89	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1995	12	3					235	243		10.1089/neu.1995.12.235			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RM331	WOS:A1995RM33100001	7473798				2021-06-18	
J	KARCZ, A; HOLBROOK, J; BURKE, MC; DOYLE, MJ; ERDOS, MS; FRIEDMAN, M; GREEN, ED; ISEKE, RJ; JOSEPHSON, GW; WILLIAMS, K				KARCZ, A; HOLBROOK, J; BURKE, MC; DOYLE, MJ; ERDOS, MS; FRIEDMAN, M; GREEN, ED; ISEKE, RJ; JOSEPHSON, GW; WILLIAMS, K			MASSACHUSETTS EMERGENCY-MEDICINE CLOSED MALPRACTICE CLAIMS - 1988-1990	ANNALS OF EMERGENCY MEDICINE			English	Article						MALPRACTICE; RISK MANAGEMENT		Study purpose: To describe the characteristics of malpractice claims against emergency physicians and to identify causes and potential preventability of such claims. Population: Malpractice claims closed in 1988, 1989, and 1990 against emergency physicians insured by the Massachusetts Joint Underwriters Association were compared with claims closed from 1980 to 1987 as investigated in our previous study. Methods: Retrospective review of malpractice claim files by board-certified emergency physicians. Results: The average indemnity and expense per claim were higher in the current study population than in our previous study population (P=.05). Claims in eight high-risk diagnostic areas (chest pain, abdominal pain, fractures, wounds, pediatric fever/meningitis, subarachnoid hemorrhage, aortic aneurysm, and epiglottitis) accounted for 50.8% of claims in this study and 55.5% of total monetary losses. Four claims in this study were related to two instances of failure of an emergency department radiograph follow-up system. The evaluation of patients who were intoxicated contributed to major monetary losses, especially in cases of fractures and head injury. Conclusion: Emergency physicians must have a particular awareness of their great risk exposure for missed myocardial infarction. Addition of dictation or voice-activated record generation systems, departmental protocols for radiograph follow-ups, and holding and re-evaluation of the intoxicated patient will help provide systems supports for reducing the liability of individual emergency physicians.		KARCZ, A (corresponding author), METROWEST MED CTR,DEPT EMERGENCY MED,FRAMINGHAM CAMPUS,FRAMINGHAM,MA 01701, USA.							0	87	88	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	MAR	1993	22	3					553	559		10.1016/S0196-0644(05)81941-9			7	Emergency Medicine	Emergency Medicine	KQ328	WOS:A1993KQ32800008	8442544				2021-06-18	
J	KLONOFF, PS; SNOW, WG; COSTA, LD				KLONOFF, PS; SNOW, WG; COSTA, LD			QUALITY-OF-LIFE IN PATIENTS 2 TO 4 YEARS AFTER CLOSED HEAD-INJURY	NEUROSURGERY			English	Article									ST JOSEPHS HOSP & MED CTR, BARROW NEUROL INST, NEUROPSYCHOL SECT, PHOENIX, AZ 85013 USA; SUNNYBROOK MED CTR, DEPT PSYCHOL, TORONTO M4N 3M5, ONTARIO, CANADA; UNIV VICTORIA, DEPT PSYCHOL, VICTORIA V8W 2Y2, BC, CANADA							BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BERGNER M, 1980, RELEVANCE SOCIAL SCI, P135; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; DENNYBROWN D, 1945, ASS NERV MENT DIS, V24, P467; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GRONWALL D, 1974, LANCET, V2, P605; HERTZOG AR, 1981, J GERONTOL, V36, P472; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JENNETT B, 1979, NURS MIRROR, V1, P30; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KOTTKE FJ, 1982, ARCH PHYS MED REHAB, V63, P60; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, BEHAVIORAL SEQUELAE; LEZAK MD, 1980, FEB M INT NEUR SOC S; LISHMAN WA, ORGANIC PSYCHIATRY P; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; NAJENSON T, 1975, SCAND J REHABIL MED, V7, P101; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; Roueche JR, 1983, COGNITIVE REHABILITA, V1, P4; SISLER GC, 1978, PSYCHIATR CLIN N AM, V1, P137; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; THOMSEN I V, 1981, Journal of Clinical Neuropsychology, V3, P43, DOI 10.1080/01688638108403112; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; Van Zomeren A. H., 1981, REACTION TIME ATTENT	34	87	88	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	1986	19	5					735	743		10.1227/00006123-198611000-00004			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	E7475	WOS:A1986E747500004	3785620				2021-06-18	
J	Oyeniyi, BT; Fox, EE; Scerbo, M; Tomasek, JS; Wade, CE; Holcomb, JB				Oyeniyi, Blessing T.; Fox, Erin E.; Scerbo, Michelle; Tomasek, Jeffrey S.; Wade, Charles E.; Holcomb, John B.			Trends in 1029 trauma deaths at a level 1 trauma center: Impact of a bleeding control bundle of care	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Trauma death; Mortality; Hemorrhage; Temporal distribution	DAMAGE-CONTROL RESUSCITATION; ENDOVASCULAR BALLOON OCCLUSION; EMERGENCY-DEPARTMENT; HEMORRHAGE CONTROL; TOURNIQUET USE; INCREASES; MORTALITY; SURVIVAL; INJURY; TIME	Background: Over the last decade the age of trauma patients and injury mortality has increased. At the same time, many centers have implemented multiple interventions focused on improved hemorrhage control, effectively resulting in a bleeding control bundle of care. The objective of our study was to analyze the temporal distribution of trauma-related deaths, the factors that characterize that distribution and how those factors have changed over time at our urban level 1 trauma center. Methods: Records at an urban Level 1 trauma center were reviewed. Two time periods (2005-2006 and 2012-2013) were included in the analysis. Mortality rates were directly adjusted for age, gender and mechanism of injury. The Mann-Whitney and chi square tests were used to compare variables between periods, with significance set at 0.05. Results: 7080 patients (498 deaths) were examined in 2005-2006, while 8767 patients (531 deaths) were reviewed in 2012-2013. The median age increased 6 years, with a similar increase in those who died. In patients that died, no differences by gender, race or ethnicity were observed. Fall-related deaths are now the leading cause of death. Traumatic brain injury (TBI) and hemorrhage accounted for >91% of all deaths. TBI (61%) and multiple organ failure or sepsis (6.2%) deaths were unchanged, while deaths associated with hemorrhage decreased from 36% to 25% (p < 0.01). Across time periods, 26% of all deaths occurred within one hour of hospital arrival, while 59% occurred within 24 h. Unadjusted mortality dropped from 7.0% to 6.1 (p = 0.01) and in-hospital mortality dropped from 6.0% to 5.0% (p < 0.01). Adjusted mortality dropped 24% from 7.6% (95% CI: 6.9-8.2) to 5.8% (95% CI: 5.3-6.3) and in-hospital mortality decreased 30% from 6.6% (95% CI: 6.0-7.2) to 4.7 (95% CI: 4.2-5.1). Conclusions: Over the same time frame of this study, increases in trauma death across the globe have been reported. This single-site study demonstrated a significant reduction in mortality, attributable to decreased hemorrhagic death. It is possible that efforts focused on hemorrhage control interventions (a bleeding control bundle) resulted in this reduction. These changing factors provide guidance on future prevention and intervention efforts. (C) 2016 Elsevier Ltd. All rights reserved.	[Oyeniyi, Blessing T.; Fox, Erin E.; Scerbo, Michelle; Tomasek, Jeffrey S.; Wade, Charles E.; Holcomb, John B.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Div Acute Care Surg, Dept Surg,Med Sch, Houston, TX 77030 USA	Holcomb, JB (corresponding author), Ctr Translat Injury Res, Dept Surg, 6410 Fannin St UPB 1100, Houston, TX 77030 USA.	John.Holcomb@uth.tmc.edu	Scerbo, Michelle/AAX-2118-2020	holcomb, john/0000-0001-8312-9157	Center for Translational Injury Research; University of Texas Medical School at Houston-Office of the Dean; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	The Center for Translational Injury Research and The University of Texas Medical School at Houston-Office of the Dean.	Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brenner ML, 2013, J TRAUMA ACUTE CARE, V75, P506, DOI 10.1097/TA.0b013e31829e5416; Brown MA, 2009, J EMERG MED, V37, P1, DOI 10.1016/j.jemermed.2007.05.043; Callaway DW, 2015, PREHOSP EMERG CARE, V19, P320, DOI 10.3109/10903127.2014.964893; Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; Duchesne JC, 2011, AM SURGEON, V77, P201; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Grumbach K, 2014, JAMA-J AM MED ASSOC, V311, P1109, DOI 10.1001/jama.2014.705; Gunst Mark, 2010, Proc (Bayl Univ Med Cent), V23, P349; Holcom JB, 2015, JAMA-J AM MED ASSOC, V313, P1463, DOI 10.1001/jama.2014.16802; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Hu GQ, 2010, INJURY PREV, V16, P26, DOI 10.1136/ip.2009.023481; Kragh JF, 2011, J EMERG MED, V41, P590, DOI 10.1016/j.jemermed.2009.07.022; Kragh JF, 2009, ANN SURG, V249, P1, DOI 10.1097/SLA.0b013e31818842ba; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Mangram AJ, 2012, J TRAUMA ACUTE CARE, V72, P119, DOI 10.1097/TA.0b013e318241f0ba; Meislin H, 1997, J TRAUMA, V43, P433, DOI 10.1097/00005373-199709000-00008; Minei JP, 2012, CRIT CARE MED, V40, P1129, DOI 10.1097/CCM.0b013e3182376e9f; Moore LJ, 2015, J TRAUMA ACUTE CARE, V79, P523, DOI 10.1097/TA.0000000000000809; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; National Trauma Insttitue, CAS TRAUM FUND; Norton R, 2013, NEW ENGL J MED, V368, P1723, DOI 10.1056/NEJMra1109343; Pang JM, 2008, INJURY, V39, P102, DOI 10.1016/j.injury.2007.05.022; Passos E, 2014, INJURY, V45, P573, DOI 10.1016/j.injury.2013.11.031; Rhee P, 2008, J TRAUMA, V64, P1093, DOI 10.1097/TA.0b013e31812f6dbc; Rhee P, 2014, ANN SURG, V260, P13, DOI 10.1097/SLA.0000000000000600; Rockett Ian R H, 2012, Am J Public Health, V102, pe84, DOI 10.2105/AJPH.2012.300960; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schwartz DA, 2014, J TRAUMA ACUTE CARE, V76, P134, DOI 10.1097/TA.0b013e3182ab0cfc; Shrestha B, 2015, J TRAUMA ACUTE CARE, V78, P336, DOI 10.1097/TA.0000000000000514; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Singh GK, 2014, AM J PREV MED, V46, pE19, DOI 10.1016/j.amepre.2013.10.017; Tisherman SA, 2014, ANN SURG, V2014; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28; Xu Jiaquan, 2014, NCHS Data Brief, P1	40	86	88	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2017	48	1					5	12		10.1016/j.injury.2016.10.037			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	EF7YF	WOS:000390544600003	27847192	Green Accepted			2021-06-18	
J	Stamm, JM; Koerte, IK; Muehlmann, M; Pasternak, O; Bourlas, AP; Baugh, CM; Giwerc, MY; Zhu, AN; Coleman, MJ; Bouix, S; Fritts, NG; Martin, BM; Chaisson, C; McClean, MD; Lin, AP; Cantu, RC; Tripodis, Y; Stern, RA; Shenton, ME				Stamm, Julie M.; Koerte, Inga K.; Muehlmann, Marc; Pasternak, Ofer; Bourlas, Alexandra P.; Baugh, Christine M.; Giwerc, Michelle Y.; Zhu, Anni; Coleman, Michael J.; Bouix, Sylvain; Fritts, Nathan G.; Martin, Brett M.; Chaisson, Christine; McClean, Michael D.; Lin, Alexander P.; Cantu, Robert C.; Tripodis, Yorghos; Stern, Robert A.; Shenton, Martha E.			Age at First Exposure to Football Is Associated with Altered Corpus Callosum White Matter Microstructure in Former Professional Football Players	JOURNAL OF NEUROTRAUMA			English	Article						age at first exposure; American football; corpus callosum; diffusion tensor imaging; repetitive head impacts	TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURE; HUMAN CEREBRAL-CORTEX; NEUROPSYCHOMETRIC TESTS; RECURRENT CONCUSSION; UNMYELINATED AXONS; YOUTH FOOTBALL; DIFFUSION; CHILDREN; MILD	Youth football players may incur hundreds of repetitive head impacts (RHI) in one season. Our recent research suggests that exposure to RHI during a critical neurodevelopmental period prior to age 12 may lead to greater later-life mood, behavioral, and cognitive impairments. Here, we examine the relationship between age of first exposure (AFE) to RHI through tackle football and later-life corpus callosum (CC) microstructure using magnetic resonance diffusion tensor imaging (DTI). Forty retired National Football League (NFL) players, ages 40-65, were matched by age and divided into two groups based on their AFE to tackle football: before age 12 or at age 12 or older. Participants underwent DTI on a 3 Tesla Siemens (TIM-Verio) magnet. The whole CC and five subregions were defined and seeded using deterministic tractography. Dependent measures were fractional anisotropy (FA), trace, axial diffusivity, and radial diffusivity. Results showed that former NFL players in the AFE <12 group had significantly lower FA in anterior three CC regions and higher radial diffusivity in the most anterior CC region than those in the AFE 12 group. This is the first study to find a relationship between AFE to RHI and later-life CC microstructure. These results suggest that incurring RHI during critical periods of CC development may disrupt neurodevelopmental processes, including myelination, resulting in altered CC microstructure.	[Stamm, Julie M.; Bourlas, Alexandra P.; Baugh, Christine M.; Fritts, Nathan G.; Chaisson, Christine; Cantu, Robert C.; Tripodis, Yorghos; Stern, Robert A.] Boston Univ, CTE Ctr, Sch Med, Boston, MA 02118 USA; [Stamm, Julie M.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Bourlas, Alexandra P.; Chaisson, Christine; Tripodis, Yorghos; Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Stamm, Julie M.; Koerte, Inga K.; Muehlmann, Marc; Pasternak, Ofer; Giwerc, Michelle Y.; Zhu, Anni; Coleman, Michael J.; Bouix, Sylvain; Lin, Alexander P.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Lin, Alexander P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Clin Spect, Boston, MA 02115 USA; [Pasternak, Ofer] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Koerte, Inga K.; Muehlmann, Marc] Univ Munich, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Boston, MA 02115 USA; [Martin, Brett M.; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Chaisson, Christine; Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [McClean, Michael D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; [Cantu, Robert C.] Sports Legacy Inst, Waltham, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA	Stern, RA (corresponding author), Boston Univ, CTE Ctr, Sch Med, 72 East Concord St,B7800, Boston, MA 02118 USA.	bobstern@bu.edu	Shenton, Martha/V-8780-2019; , Bob/ABA-8507-2020; Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 078337, F31 NS 081957, P30 AG13846, UL1-TR000157, P41 EB015902, T32MH019733]; JetBlue Airlines; National Football League (NFL); NFL Players Association; Else Kroner-Fresenius Foundation, Germany; VA Merit AwardUS Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337, F31NS081957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	The authors extend their appreciation to the study participants who make this work possible. This study was supported by the National Institutes of Health (R01 NS 078337; F31 NS 081957 [J.M.S.]; P30 AG13846; UL1-TR000157, P41 EB015902 [O.P.]; T32MH019733 [C.M.B.]), and participant travel was funded by gifts from JetBlue Airlines, the National Football League (NFL), and the NFL Players Association. This study was also partly supported by the Else Kroner-Fresenius Foundation, Germany (I.K., M.M.), and by a VA Merit Award (M.E.S., M.C., L.L., A.Z.).	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Andersen SL, 2008, TRENDS NEUROSCI, V31, P183, DOI 10.1016/j.tins.2008.01.004; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Bardin J, 2012, NATURE, V487, P24, DOI 10.1038/487024a; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Bourlas A. P., 2014, BRAIN INJURY, V28, P517; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Chen Z, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00716; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Dahler D., 2014, CBS NEWS; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Epstein HT, 1999, BRAIN DEV-JPN, V21, P535, DOI 10.1016/S0387-7604(99)00066-2; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Grieve SM, 2011, NEUROIMAGE, V55, P868, DOI 10.1016/j.neuroimage.2010.12.087; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Kaller CP, 2012, NEUROIMAGE, V63, P1454, DOI 10.1016/j.neuroimage.2012.08.032; Kelly AMC, 2009, CEREB CORTEX, V19, P640, DOI 10.1093/cercor/bhn117; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lebel C, 2011, J NEUROSCI, V31, P10937, DOI 10.1523/JNEUROSCI.5302-10.2011; Lebel C, 2010, NEUROIMAGE, V52, P20, DOI 10.1016/j.neuroimage.2010.03.072; Lenroot RK, 2006, NEUROSCI BIOBEHAV R, V30, P718, DOI 10.1016/j.neubiorev.2006.06.001; Lenroot RK, 2009, HUM BRAIN MAPP, V30, P163, DOI 10.1002/hbm.20494; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Council of Youth Sports, 2008, REP TRENDS PART ORG; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; SCHNEIDER GE, 1979, NEUROPSYCHOLOGIA, V17, P557, DOI 10.1016/0028-3932(79)90033-2; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sinopoli KJ, 2014, J NEUROTRAUM, V31, P1843, DOI 10.1089/neu.2014.3326; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stern RA, 2015, NEUROLOGY, V85, P1008; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Uematsu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046970; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu JS, 2013, HUM BRAIN MAPP, V34, P1044, DOI 10.1002/hbm.21491; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	77	86	88	0	41	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1768	1776		10.1089/neu.2014.3822			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500007	26200068	Green Published			2021-06-18	
J	Namjoshi, DR; Cheng, WH; McInnes, KA; Martens, KM; Carr, M; Wilkinson, A; Fan, JJ; Robert, J; Hayat, A; Cripton, PA; Wellington, CL				Namjoshi, Dhananjay R.; Cheng, Wai Hang; McInnes, Kurt A.; Martens, Kris M.; Carr, Michael; Wilkinson, Anna; Fan, Jianjia; Robert, Jerome; Hayat, Arooj; Cripton, Peter A.; Wellington, Cheryl L.			Merging pathology with biomechanics using CHIMERA (Closed-Head Impact Model of Engineered Rotational Acceleration): a novel, surgery-free model of traumatic brain injury	MOLECULAR NEURODEGENERATION			English	Article						Traumatic brain injury; Animal model of traumatic brain injury; Animal model of closed head injury; Diffuse axonal injury; Microglia activation; Neuroinflammation; Tau hyperphosphorylation; Head kinematics; Head injury biomechanics; Impact-acceleration traumatic brain injury model; Surgery-free animal model of traumatic brain injury; Traumatic brain injury biomechanics	DIFFUSE AXONAL INJURY; PROFESSIONAL FOOTBALL; ANGULAR-ACCELERATION; MOUSE MODEL; RAT MODEL; CONCUSSION; MICE; EPIDEMIOLOGY; MECHANISMS; PATHOPHYSIOLOGY	Background: Traumatic brain injury (TBI) is a major health care concern that currently lacks any effective treatment. Despite promising outcomes from many preclinical studies, clinical evaluations have failed to identify effective pharmacological therapies, suggesting that the translational potential of preclinical models may require improvement. Rodents continue to be the most widely used species for preclinical TBI research. As most human TBIs result from impact to an intact skull, closed head injury (CHI) models are highly relevant, however, traditional CHI models suffer from extensive experimental variability that may be due to poor control over biomechanical inputs. Here we describe a novel CHI model called CHIMERA (Closed-Head Impact Model of Engineered Rotational Acceleration) that fully integrates biomechanical, behavioral, and neuropathological analyses. CHIMERA is distinct from existing neurotrauma model systems in that it uses a completely non-surgical procedure to precisely deliver impacts of prescribed dynamic characteristics to a closed skull while enabling kinematic analysis of unconstrained head movement. In this study, we characterized head kinematics as well as functional, neuropathological, and biochemical outcomes up to 14d following repeated TBI (rTBI) in adult C57BL/6 mice using CHIMERA. Results: Head kinematic analysis showed excellent repeatability over two closed head impacts separated at 24h. Injured mice showed significantly prolonged loss of righting reflex and displayed neurological, motor, and cognitive deficits along with anxiety-like behavior. Repeated TBI led to diffuse axonal injury with extensive microgliosis in white matter from 2-14d post-rTBI. Injured mouse brains also showed significantly increased levels of TNF-alpha and IL-1 beta and increased endogenous tau phosphorylation. Conclusions: Repeated TBI using CHIMERA mimics many of the functional and pathological characteristics of human TBI with a reliable biomechanical response of the head. This makes CHIMERA well suited to investigate the pathophysiology of TBI and for drug development programs.	[Namjoshi, Dhananjay R.; Cheng, Wai Hang; Martens, Kris M.; Carr, Michael; Wilkinson, Anna; Fan, Jianjia; Robert, Jerome; Hayat, Arooj; Wellington, Cheryl L.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Namjoshi, Dhananjay R.] Univ British Columbia, Grad Program Neurosci, Vancouver, BC V5Z 1M9, Canada; [McInnes, Kurt A.; Cripton, Peter A.] Univ British Columbia, Dept Mech Engn, Vancouver, BC V5Z 1M9, Canada; [McInnes, Kurt A.; Cripton, Peter A.] Univ British Columbia, Dept Orthopaed, Vancouver, BC V5Z 1M9, Canada; [McInnes, Kurt A.; Cripton, Peter A.; Wellington, Cheryl L.] Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC V5Z 1M9, Canada; [Wellington, Cheryl L.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V5Z 1M9, Canada	Wellington, CL (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.	wcheryl@mail.ubc.ca	Cripton, Peter/AAC-8268-2020; , Jerome/C-6226-2018	Cripton, Peter/0000-0002-5067-0833; McInnes, Kurt/0000-0001-5931-2963; Cheng, Wai Hang/0000-0002-3408-9184; , Jerome/0000-0002-2847-9362; Namjoshi, Dhananjay/0000-0003-1753-5581	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP 123461]; Alzheimer Society Research Program (ASRP) Doctoral Award; ASRP Doctoral Award; Comissao Technica de Atribuicao de Bolsas para Estudos Pos-Graduados Macao	This work was supported by an operating grant from the Canadian Institutes of Health Research to CLW (MOP 123461). DRN was supported by an Alzheimer Society Research Program (ASRP) Doctoral Award (Alzheimer Society of Canada, http://www.alzheimer.ca/en/Research/Alzheimer-Society-Research-Program). WHC is supported by an ASRP Doctoral Award and Comissao Technica de Atribuicao de Bolsas para Estudos Pos-Graduados Macao. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We are indebted to Dr. Peter Davies (Albert Einstein College of Medicine) for the kind gifts of tau antibodies.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; Blume HK, 2011, PHYS MED REH CLIN N, V22, P665, DOI 10.1016/j.pmr.2011.08.007; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Davidsson Johan, 2011, Front Neurol, V2, P41, DOI 10.3389/fneur.2011.00041; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Engelhardt G, 1996, BRIT J RHEUMATOL, V35, P4; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Gerberding JL, 2003, REP C MILD TRAUM BRA; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldstein LE, 2012, SCI TRANSL MED, V4; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li XY, 2010, NEUROSCIENCE, V169, P357, DOI 10.1016/j.neuroscience.2010.04.075; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McIntosh TK, 1996, LAB INVEST, V74, P315; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Nguyen U, 2011, NAT METHODS, V8, P982, DOI [10.1038/nmeth.f.353, DOI 10.1038/NMETH.F.353, DOI 10.1038/nmeth.f.353]; O'Neill RA, 2006, P NATL ACAD SCI USA, V103, P16153, DOI 10.1073/pnas.0607973103; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Peng Y, 2014, INT J CRASHWORTHINES, V19, P105, DOI 10.1080/13588265.2013.805290; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Sevagan G, 2013, P I MECH ENG H, V227, P778, DOI 10.1177/0954411913483430; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIMON P, 1994, BEHAV BRAIN RES, V61, P59, DOI 10.1016/0166-4328(94)90008-6; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Wang HC, 2010, J NEUROTRAUM, V27, P707, DOI 10.1089/neu.2009.1071; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	69	86	87	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1750-1326			MOL NEURODEGENER	Mol. Neurodegener.	DEC 1	2014	9								55	10.1186/1750-1326-9-55			18	Neurosciences	Neurosciences & Neurology	AX6BH	WOS:000347008000001	25443413	DOAJ Gold, Green Published			2021-06-18	
J	Helmer, KG; Pasternak, O; Fredman, E; Preciado, RI; Koerte, IK; Sasaki, T; Mayinger, M; Johnson, AM; Holmes, JD; Forwell, LA; Skopelja, EN; Shenton, ME; Echlin, PS				Helmer, Karl G.; Pasternak, Ofer; Fredman, Eli; Preciado, Ronny I.; Koerte, Inga K.; Sasaki, Takeshi; Mayinger, Michael; Johnson, Andrew M.; Holmes, Jeffrey D.; Forwell, Lorie A.; Skopelja, Elaine N.; Shenton, Martha E.; Echlin, Paul S.			Hockey Concussion Education Project, Part 1. Susceptibility-weighted imaging study in male and female ice hockey players over a single season	JOURNAL OF NEUROSURGERY			English	Article						susceptibility-weighted imaging; ice hockey; sex-based difference; concussion; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; PHYSICIAN-OBSERVED CONCUSSION; WHITE-MATTER INTEGRITY; DIFFUSE AXONAL INJURY; PROFESSIONAL BOXERS; MICROSTRUCTURAL DAMAGE; COGNITIVE DYSFUNCTION; SPORTS CONCUSSION; FOOTBALL PLAYERS; ANISOTROPY	Object. Concussion, or mild traumatic brain injury (mTBI), is a commonly occurring sports-related injury, especially in contact sports such as hockey. Cerebral microbleeds (CMBs), which appear as small, hypointense lesions on T-2*-weighted images, can result from TBI. The authors use susceptibility-weighted imaging (SWI) to automatically detect small hypointensities that may be subtle signs of chronic and acute damage due to both subconcussive and concussive injury. The goal was to investigate how the burden of these hypointensities changes over time, over a playing season, and postconcussion, in comparison with subjects who did not suffer a medically observed and diagnosed concussion. Methods. Images were obtained in 45 university-level adult male and female ice hockey players before and after a single Canadian Interuniversity Sports season. In addition, 11 subjects (5 men and 6 women) underwent imaging at 72 hours, 2 weeks, and 2 months after concussion. To identify subtle changes in brain tissue and potential CMBs, nonvessel clusters of hypointensities on SWI were automatically identified, and a hypointensity burden index was calculated for all subjects at the beginning of the season (BUS), the end of the season (EOS), and at postconcussion time points (where applicable). Results. A statistically significant increase in the hypointensity burden, relative to the BOS, was observed for male subjects with concussions at the 2-week postconcussion time point. A smaller, nonsignificant rise in the burden for female subjects with concussions was also observed within the same time period. There were no significant changes in burden for nonconcussed subjects of either sex between the BUS and BUS time points. However, there was a statistically significant difference in the burden between male and female subjects in the nonconcussed group at both the BUS and BUS time points, with males having a higher burden. Conclusions. This method extends the utility of SWI from the enhancement and detection of larger (> 5 mm) CMBs, which are often observed in more severe cases of TBI, to cases involving smaller lesions in which visual detection of injury is difficult. The hypointensity burden metric proposed here shows statistically significant changes over time in the male subjects. A smaller, nonsignificant increase in the burden metric was observed in the female subjects.	[Helmer, Karl G.] Massachusetts Gen Hosp Massachusetts Inst Technol, Charlestown, MA USA; [Preciado, Ronny I.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Pasternak, Ofer; Fredman, Eli; Koerte, Inga K.; Sasaki, Takeshi; Mayinger, Michael; Shenton, Martha E.; Echlin, Paul S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02115 USA; [Koerte, Inga K.; Mayinger, Michael] Univ Munich, Inst Clin Radiol, Munich, Germany; [Sasaki, Takeshi] Tokyo Med & Dent Univ, Grad Sch, Dept Psychiat & Behav Sci, Tokyo, Japan; [Johnson, Andrew M.] Univ Western Ontario, Sch Hlth Studies, London, ON, Canada; [Holmes, Jeffrey D.] Univ Western Ontario, Sch Occupat Therapy, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Fowler Kennedy Sport Med Clin, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Sch Phys Therapy, London, ON, Canada; [Skopelja, Elaine N.] Indiana Univ, Ruth Lilly Med Lib, Indianapolis, IN 46204 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton, MA USA; [Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Echlin, Paul S.] Elliott Sports Med Clin, Burlington, ON L7N 2G3, Canada	Echlin, PS (corresponding author), Elliott Sports Med Clin, 1100 Walkers Line,Ste 2, Burlington, ON L7N 2G3, Canada.	psechlin@gmail.com	Johnson, Andrew M/B-2048-2012; Holmes, Jeffrey/M-6484-2015; Shenton, Martha/V-8780-2019	Holmes, Jeffrey/0000-0002-5744-8338; Skopelja, Elaine/0000-0002-2847-8909; Johnson, Andrew M./0000-0002-7269-3016	Ontario Trillium Foundation; Dave Irwin Foundation for Brain Injury; Ontario Neurotrauma Foundation; Air Canada; The Ontario Ministry of Health and Long-Term Care; The Ontario Ministry of Tourism, Culture and Sport; The Ontario Ministry of Education; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [S2301]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41RR013218, P41EB015902, R01MH074794]; Department of DefenseUnited States Department of Defense [X81XWH-07-CC-CSDoD]; NARSAD (National Alliance for Research on Schizophrenia and Depression)NARSAD; Brain & Behavior Research FoundationNARSAD; Else Kroner-Fresenius Foundation, Germany; Petraeic Legate Foundation; Henry Jackson Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902] Funding Source: NIH RePORTER	Funding for this work was provided to the HCEP and Dr. Echlin by the Ontario Trillium Foundation, the Dave Irwin Foundation for Brain Injury, the Ontario Neurotrauma Foundation, Air Canada, The Ontario Ministry of Health and Long-Term Care, The Ontario Ministry of Tourism, Culture and Sport, and The Ontario Ministry of Education. Dr. Sasaki is supported by Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from the Japan Society for the Promotion of Science (S2301). This work was partially funded by grants from the NIH (Grant Nos. P41RR013218, P41EB015902, and R01MH074794), the Department of Defense (No. X81XWH-07-CC-CSDoD), and a VA merit grant. Dr. Pasternak was partially supported by a NARSAD (National Alliance for Research on Schizophrenia and Depression) Young Investigator grant from the Brain & Behavior Research Foundation. Dr. Koerte is supported by the Else Kroner-Fresenius Foundation, Germany. Mr. Mayinger is supported by the Petraeic Legate Foundation. This work was part of Mr. Mayinger's doctoral thesis. Dr. Shenton is a consultant on an NIH grant to the State University of New York on velocardiofascial syndrome and on a grant supported by the Henry Jackson Foundation.	Agel J, 2010, CAN J SURG, V53, P319; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chappell MH, 2008, MAGN RESON IMAGING, V26, P1398, DOI 10.1016/j.mri.2008.04.004; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12287; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pasternak O, 2014, J NEUROSURG, DOI [10.3171/2013.12.JNS132090, DOI 10.3171/2013.12.JNS132090]]; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	52	86	86	1	13	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					864	890		10.3171/2013.12.JNS132093			27	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800011	24490839	Bronze, Green Accepted			2021-06-18	
J	Zhang, ZQ; Zoltewicz, JS; Mondello, S; Newsom, KJ; Yang, ZH; Yang, BX; Kobeissy, F; Guingab, J; Glushakova, O; Robicsek, S; Heaton, S; Buki, A; Hannay, J; Gold, MS; Rubenstein, R; Lu, XCM; Dave, JR; Schmid, K; Tortella, F; Robertson, CS; Wang, KKW				Zhang, Zhiqun; Zoltewicz, J. Susie; Mondello, Stefania; Newsom, Kimberly J.; Yang, Zhihui; Yang, Boxuan; Kobeissy, Firas; Guingab, Joy; Glushakova, Olena; Robicsek, Steven; Heaton, Shelley; Buki, Andras; Hannay, Julia; Gold, Mark S.; Rubenstein, Richard; Lu, Xi-chun May; Dave, Jitendra R.; Schmid, Kara; Tortella, Frank; Robertson, Claudia S.; Wang, Kevin K. W.			Human Traumatic Brain Injury Induces Autoantibody Response against Glial Fibrillary Acidic Protein and Its Breakdown Products	PLOS ONE			English	Article							SPINAL-CORD-INJURY; ALPHA-II-SPECTRIN; CENTRAL-NERVOUS-SYSTEM; GLASGOW OUTCOME SCALE; MULTIPLE-SCLEROSIS; ANTIMYELIN ANTIBODIES; ALZHEIMERS-DISEASE; ANTIPITUITARY ANTIBODIES; CEREBROSPINAL-FLUID; HEAD-INJURY	The role of systemic autoimmunity in human traumatic brain injury (TBI) and other forms of brain injuries is recognized but not well understood. In this study, a systematic investigation was performed to identify serum autoantibody responses to brain-specific proteins after TBI in humans. TBI autoantibodies showed predominant immunoreactivity against a cluster of bands from 38-50 kDa on human brain immunoblots, which were identified as GFAP and GFAP breakdown products. GFAP autoantibody levels increased by 7 days after injury, and were of the IgG subtype predominantly. Results from in vitro tests and rat TBI experiments also indicated that calpain was responsible for removing the amino and carboxyl termini of GFAP to yield a 38 kDa fragment. Additionally, TBI autoantibody staining co-localized with GFAP in injured rat brain and in primary rat astrocytes. These results suggest that GFAP breakdown products persist within degenerating astrocytes in the brain. Anti-GFAP autoantibody also can enter living astroglia cells in culture and its presence appears to compromise glial cell health. TBI patients showed an average 3.77 fold increase in anti-GFAP autoantibody levels from early (0-1 days) to late (7-10 days) times post injury. Changes in autoantibody levels were negatively correlated with outcome as measured by GOS-E score at 6 months, suggesting that TBI patients with greater anti-GFAP immune-responses had worse outcomes. Due to the long lasting nature of IgG, a test to detect anti-GFAP autoantibodies is likely to prolong the temporal window for assessment of brain damage in human patients.	[Zoltewicz, J. Susie; Newsom, Kimberly J.; Yang, Boxuan; Guingab, Joy; Glushakova, Olena] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarker Res, Gainesville, FL 32611 USA; [Zhang, Zhiqun; Yang, Zhihui; Kobeissy, Firas; Wang, Kevin K. W.] Banyan Biomarkers Inc, Alachua, FL 32615 USA; [Mondello, Stefania; Gold, Mark S.] Univ Messina, Messina, Italy; [Robicsek, Steven] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Heaton, Shelley] Univ Florida, Gainesville, FL USA; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Buki, Andras] Hungarian Acad Sci, Clin Neurosci Image Ctr, Pecs, Hungary; [Hannay, Julia] Univ Houston, Dept Psychol, Houston, TX USA; [Rubenstein, Richard] Suny Downstate Med Ctr, Lab Neurodegenerat Dis & CNS Biomarkers, Dept Neurol, Brooklyn, NY 11203 USA; [Rubenstein, Richard] Suny Downstate Med Ctr, Lab Neurodegenerat Dis & CNS Biomarkers, Dept Physiol Pharmacol, Brooklyn, NY 11203 USA; [Lu, Xi-chun May; Dave, Jitendra R.; Schmid, Kara; Tortella, Frank] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Zhang, ZQ (corresponding author), Banyan Biomarkers Inc, Alachua, FL 32615 USA.	zizizhang2012@gmail.com; susiezolt@gmail.com; kwang@ufl.edu	Kobeissy, Firas/E-7042-2017; Mondello, Stefania/A-1813-2012	Kobeissy, Firas/0000-0002-5008-6944; Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473; Hannay, H. Julia/0000-0001-7023-912X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01-NS052831-01, R01 NS051431-01]; Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03-1-0066]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175, R01NS052831, R01NS051431] Funding Source: NIH RePORTER	This study was supported in part by the NIH (R01 NS049175-01, R01-NS052831-01 and R01 NS051431-01), and in part by the Department of Defense (DAMD17-03-1-0772 and DAMD17-03-1-0066). The funders provide financial support and infrastructure support to this work.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Ankeny DP, 2010, TRENDS IMMUNOL, V31, P332, DOI 10.1016/j.it.2010.06.006; Berger T, 2003, NEW ENGL J MED, V349, P139, DOI 10.1056/NEJMoa022328; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Colasanti T. T., 2010, AUTOIMMUN REV, V9, P5; Cox AL, 2006, J NEUROIMMUNOL, V174, P180, DOI 10.1016/j.jneuroim.2006.01.007; D'Andrea MR, 2005, MED HYPOTHESES, V64, P458, DOI 10.1016/j.mehy.2004.08.024; Dambinova SA, 1997, J NEUROL SCI, V152, P93, DOI 10.1016/S0022-510X(97)00150-0; Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752; Darrah E, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00428; Deng SX, 2000, INT IMMUNOL, V12, P415, DOI 10.1093/intimm/12.4.415; Fujita K, 1998, NEUROCHEM RES, V23, P169, DOI 10.1023/A:1022476724381; Gomez-Tourino I, 2010, DIABETIC MED, V27, P247, DOI 10.1111/j.1464-5491.2009.02911.x; Gorny M, 1990, Neurol Neurochir Pol, V24, P17; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; Guingab-Cagmat JD, 2012, ELECTROPHORESIS, V33, P3786, DOI 10.1002/elps.201200326; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Hedegaard CJ, 2009, IMMUNOLOGY, V128, pe451, DOI 10.1111/j.1365-2567.2008.02999.x; Kamchatnov PR, 2009, ZH NEVROL PSIKHIATR, V109, P69; Kuhle J, 2007, NEW ENGL J MED, V356, P371, DOI 10.1056/NEJMoa063602; Lang B, 2003, CURR OPIN NEUROL, V16, P351, DOI 10.1097/00019052-200306000-00016; Levin EC, 2010, BRAIN RES, V1345, P221, DOI 10.1016/j.brainres.2010.05.038; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Liu MC, 2011, ASN NEURO, V3, P25, DOI 10.1042/AN20100012; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martinez JA, 2010, APOPTOSIS, V15, P1480, DOI 10.1007/s10495-010-0526-4; MECOCCI P, 1995, J NEUROIMMUNOL, V57, P165, DOI 10.1016/0165-5728(94)00180-V; MECOCCI P, 1992, BRAIN BEHAV IMMUN, V6, P286, DOI 10.1016/0889-1591(92)90049-T; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Mondello S., 2011, TRANSLATIONAL STROKE, V3, P1, DOI DOI 10.3389/FNEUR.2012.00147/ABSTRACT; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Moneim I A, 1999, J Egypt Public Health Assoc, V74, P121; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelayo R, 2007, NEW ENGL J MED, V356, P426, DOI 10.1056/NEJMc062467; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Poletaev AB, 2000, AUTOIMMUNITY, V32, P33, DOI 10.3109/08916930008995985; Ponomarenko NA, 2006, IMMUNOL LETT, V103, P45, DOI 10.1016/j.imlet.2005.10.006; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Schwartz M, 2002, PROG BRAIN RES, V137, P401; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Singh VK, 1997, PEDIATR NEUROL, V17, P88, DOI 10.1016/S0887-8994(97)00045-3; Sorokina EG, 2010, ZH NEVROL PSIKHIATR, V110, P30; TANAKA J, 1989, ACTA NEUROL SCAND, V80, P554, DOI 10.1111/j.1600-0404.1989.tb03926.x; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomkins O, 2011, NEUROLOGY, P1; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wei P, 2013, TUMOR BIOL, V34, P2283, DOI 10.1007/s13277-013-0770-7; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	67	86	89	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2014	9	3							e92698	10.1371/journal.pone.0092698			16	Multidisciplinary Sciences	Science & Technology - Other Topics	AE0SD	WOS:000333675600065	24667434	DOAJ Gold, Green Published			2021-06-18	
J	Fortier, CB; Amick, MM; Grande, L; McGlynn, S; Kenna, A; Morra, L; Clark, A; Milberg, WP; McGlinchey, RE				Fortier, Catherine Brawn; Amick, Melissa M.; Grande, Laura; McGlynn, Susan; Kenna, Alexandra; Morra, Lindsay; Clark, Alexandra; Milberg, William P.; McGlinchey, Regina E.			The Boston Assessment of Traumatic Brain Injury-Lifetime (BAT-L) Semistructured Interview: Evidence of Research Utility and Validity	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; OEF/OIF; veterans; blast; traumatic brain injury (TBI)	BLAST; MECHANISMS; SEQUELAE; IRAQ	Objective: Report the prevalence of lifetime and military-related traumatic brain injuries (TBIs) in Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans and validate the Boston Assessment of TBI-Lifetime (BAT-L). Setting: The BAT-L is the first validated, postcombat, semistructured clinical interview to characterize head injuries and diagnose TBIs throughout the life span. Participants: Community-dwelling convenience sample of 131 OEF/OIF veterans. Design: TBI criteria (alteration of mental status, posttraumatic amnesia, and loss of consciousness) were evaluated for all possible TBIs, including a novel evaluation of blast exposure. Main Measures: BAT-L, Ohio State University TBI Identification Method (OSU-TBI-ID). Results: About 67% of veterans incurred a TBI in their lifetime. Almost 35% of veterans experienced at least 1 military-related TBI; all were mild in severity, 40% of them were due to blast, 50% were due to some other (ie, blunt) mechanism, and 10% were due to both types of injuries. Predeployment TBIs were frequent (45% of veterans). There was strong correspondence between the BAT-L and the OSU-TBI-ID (Cohen kappa = 0.89; Kendall tau-b = 0.95). Interrater reliability of the BAT-L was strong (kappa s >0.80). Conclusions: The BAT-L is a valid instrument with which to assess TBI across a service member's lifetime and captures the varied and complex nature of brain injuries across OEF/OIF veterans' life span.	[Fortier, Catherine Brawn; Amick, Melissa M.; Kenna, Alexandra; Morra, Lindsay; Clark, Alexandra; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders & Geriatr, Educ & Clin Ctr, Boston, MA 02130 USA; [Grande, Laura] VA Boston Healthcare Syst, Psychol Serv, Boston, MA 02130 USA; [McGlynn, Susan] VA Boston Healthcare Syst, Phys Med & Rehabil Serv, Boston, MA 02130 USA; [Fortier, Catherine Brawn; Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Amick, Melissa M.; Grande, Laura; McGlynn, Susan] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA	Fortier, CB (corresponding author), VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders & Geriatr, Educ & Clin Ctr 182, 150 S Huntington Ave, Boston, MA 02130 USA.	Catherine_Fortier@hms.harvard.edu	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders, a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIA K01AG024898]; VA Merit Review AwardUS Department of Veterans Affairs; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG034258, K01AG024898] Funding Source: NIH RePORTER	This research was support by the Translational Research Center for TBI and Stress Disorders, a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C), NIH NIA K01AG024898, and VA Merit Review Award to Regina McGlinchey. We thank Wally Musto for his championship of our work among military personnel and his tireless recruitment efforts on our behalf. We also acknowledge the contributions of Drs Heidi Terrio and Doug Katz for their guidance in the development and analysis of the BAT-L.	Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs Department of Defense, 2009, VA DOD CLIN PRACT GU; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Owens BD, 2007, J ORTHOP TRAUMA, V21, P254, DOI 10.1097/BOT.0b013e31802f78fb; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Vanderploeg RD, 2012, J REHABIL RES DEV, V49, P545, DOI 10.1682/JRRD.2011.04.0069; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461	20	86	86	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					89	98		10.1097/HTR.0b013e3182865859			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400014	23535389	Green Accepted			2021-06-18	
J	Urban, JE; Davenport, EM; Golman, AJ; Maldjian, JA; Whitlow, CT; Powers, AK; Stitzel, JD				Urban, Jillian E.; Davenport, Elizabeth M.; Golman, Adam J.; Maldjian, Joseph A.; Whitlow, Christopher T.; Powers, Alexander K.; Stitzel, Joel D.			Head Impact Exposure in Youth Football: High School Ages 14 to 18 Years and Cumulative Impact Analysis	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Biomechanics; Brain injury; Concussion; Football; Pediatric; Youth; Helmet; Risk; High school	STATES HIGH-SCHOOL; UNITED-STATES; COLLEGIATE; PLAYERS; CONCUSSION; INJURY; ACCELERATION; EPIDEMIOLOGY; MAGNITUDE; LOCATION	Sports-related concussion is the most common athletic head injury with football having the highest rate among high school athletes. Traditionally, research on the biomechanics of football-related head impact has been focused at the collegiate level. Less research has been performed at the high school level, despite the incidence of concussion among high school football players. The objective of this study is to twofold: to quantify the head impact exposure in high school football, and to develop a cumulative impact analysis method. Head impact exposure was measured by instrumenting the helmets of 40 high school football players with helmet mounted accelerometer arrays to measure linear and rotational acceleration. A total of 16,502 head impacts were collected over the course of the season. Biomechanical data were analyzed by team and by player. The median impact for each player ranged from 15.2 to 27.0 g with an average value of 21.7 (+/- 2.4) g. The 95th percentile impact for each player ranged from 38.8 to 72.9 g with an average value of 56.4 (+/- 10.5) g. Next, an impact exposure metric utilizing concussion injury risk curves was created to quantify cumulative exposure for each participating player over the course of the season. Impacts were weighted according to the associated risk due to linear acceleration and rotational acceleration alone, as well as the combined probability (CP) of injury associated with both. These risks were summed over the course of a season to generate risk weighted cumulative exposure. The impact frequency was found to be greater during games compared to practices with an average number of impacts per session of 15.5 and 9.4, respectively. However, the median cumulative risk weighted exposure based on combined probability was found to be greater for practices vs. games. These data will provide a metric that may be used to better understand the cumulative effects of repetitive head impacts, injury mechanisms, and head impact exposure of athletes in football.	[Urban, Jillian E.; Davenport, Elizabeth M.; Golman, Adam J.; Stitzel, Joel D.] Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, Winston Salem, NC 27157 USA; [Urban, Jillian E.; Davenport, Elizabeth M.; Golman, Adam J.; Maldjian, Joseph A.; Whitlow, Christopher T.; Powers, Alexander K.; Stitzel, Joel D.] Wake Forest Sch Med, Winston Salem, NC 27157 USA; [Maldjian, Joseph A.; Whitlow, Christopher T.] Wake Forest Sch Med, Dept Radiol Neuroradiol, Winston Salem, NC 27157 USA; [Powers, Alexander K.] Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC 27157 USA; [Whitlow, Christopher T.] Wake Forest Sch Med, Translat Sci Inst, Winston Salem, NC 27157 USA; [Powers, Alexander K.; Stitzel, Joel D.] Wake Forest Sch Med, Childress Inst Pediat Trauma, Winston Salem, NC 27157 USA	Stitzel, JD (corresponding author), Wake Forest Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	jdstitzel@gmail.com	Stitzel, Joel/B-4045-2012	Stitzel, Joel/0000-0001-9762-3033; Maldjian, Joseph/0000-0002-6384-1072	Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082453] Funding Source: NIH RePORTER	The authors would like to thank the Reagan High School, especially Ashley Lake, ATC (Reagan High School), Corbin Ratcliffe, Lauren Smith and the football program. Thank you to Elizabeth Lillie and all those who contributed to the study development. Special thanks to the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center for providing support for this study.	[Anonymous], 2012, 2011 2012 HIGH SCH A; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Dick R, 2009, J ATHL TRAINING, V42, P173; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hodgson V., 1983, P 27 STAPP CAR CRASH; Irick E., 2011, NCAA SPORTS SPONSORS; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0	35	86	86	0	35	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	DEC	2013	41	12					2474	2487		10.1007/s10439-013-0861-z			14	Engineering, Biomedical	Engineering	249UN	WOS:000326803700002	23864337	Green Accepted			2021-06-18	
J	Galetta, MS; Galetta, KM; McCrossin, J; Wilson, JA; Moster, S; Galetta, SL; Balcer, LJ; Dorshimer, GW; Master, CL				Galetta, Matthew S.; Galetta, Kristin M.; McCrossin, Jim; Wilson, James A.; Moster, Stephen; Galetta, Steven L.; Balcer, Laura J.; Dorshimer, Gary W.; Master, Christina L.			Saccades and memory: Baseline associations of the King-Devick and SCAT2 SAC tests in professional ice hockey players	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Concussion; Sports; SCAT2; King-Devick test; Saccades; Memory	VISUAL SCREENING TOOL; CEREBRAL-DYSFUNCTION; EYE-MOVEMENTS; CONCUSSION; SPORT	Objective: The Sports Concussion Assessment Tool 2 (SCAT2) and King-Devick (K-D) tests have both been proposed as sideline tools to detect sports-related concussion. We performed an exploratory analysis to determine the relation of SCAT2 components, particularly the Standardized Assessment of Concussion (SAC), to K-D test scores in a professional ice hockey team cohort during pre-season baseline testing. We also examined changes in scores for two athletes who developed concussion and had rinkside testing. Methods: A modified SCAT2 (no balance testing) and the K-D test, a brief measure of rapid number naming, were administered to 27 members of a professional ice hockey team during the 2011-2012 pre-season. Athletes with concussion also underwent rinkside testing. Results: Lower (worse) scores for the SCAT2 SAC Immediate Memory Score and the overall SAC score were associated with greater (worse) times required to complete the K-D test at baseline. On average, for every 1-point reduction in SAC Immediate Memory Score, we found a corresponding increase (worsening) of K-D time score of 7.3 s (95% CI 4.9, 9.7, p<0.001, R-2 = 0.62, linear regression, accounting for age). For the overall SAC score, 1-point reductions were associated with K-D score worsening of 2.2 s (95% CI 0.6, 3.8, p = 0.01, R-2 = 0.25, linear regression). In two players tested rinkside immediately following concussion, K-D test scores worsened from baseline by 4.2 and 6.4 s. These athletes had no differences found for SCAT2 SAC components, but reported symptoms of concussion. Conclusion: In this study of professional athletes, scores for the K-D test, a measure for which saccadic (fast) eye movements are required for the task of rapid number naming, were associated with reductions in Immediate Memory at a pre-season baseline. Both working memory and saccadic eye movements share closely related anatomical structures, including the dorsolateral prefrontal cortex (DLPFC). A composite of brief rapid sideline tests, including SAC and K-D (and balance testing for non-ice hockey sports), is likely to provide an effective clinical tool to assess the athlete with suspected concussion. (c) 2013 Elsevier B.V. All rights reserved.	[Galetta, Matthew S.; Galetta, Kristin M.; Wilson, James A.; Moster, Stephen; Galetta, Steven L.; Balcer, Laura J.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Galetta, Steven L.; Balcer, Laura J.] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Balcer, Laura J.] Univ Penn, Dept Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dorshimer, Gary W.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [McCrossin, Jim] Philadelphia Flyers, Philadelphia, PA USA; [Master, Christina L.] Univ Penn, Dept Pediat, Perelman Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Master, Christina L.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Sports Med, Philadelphia, PA 19104 USA	Balcer, LJ (corresponding author), NYU, Sch Med, Dept Neurol, 240 East 38th St,15th Floor, New York, NY 10016 USA.	msg8809@yahoo.com; kristingaletta@gmail.com; jmccrossin@comcast-spectator.com; jawilson@mail.med.upenn.edu; smoster@gmail.com; steven.galetta@nyumc.org; laura.balcer@nyumc.org; gary.dorshimer@uphs.upenn.edu; masterc@email.chop.edu		Master, Christina/0000-0002-6717-4270	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24 EY 018136]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [K24EY018136] Funding Source: NIH RePORTER	This study was supported in part by NIH K24 EY 018136 (Dr. Balcer, funding for trainee research activities).	Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V1-13; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2002, PROG BRAIN RES, V140, P433; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Pierrot-Deseilligny C, 2003, BRAIN, V126, P1460, DOI 10.1093/brain/awg148; White OB, 2012, J NEURO-OPHTHALMOL, V32, P266, DOI 10.1097/WNO.0b013e3182688230	12	86	86	0	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	MAY 15	2013	328	1-2					28	31		10.1016/j.jns.2013.02.008			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	137VY	WOS:000318467500005	23499425				2021-06-18	
J	Goodrich, GL; Flyg, HM; Kirby, JE; Chang, CY; Martinsen, GL				Goodrich, Gregory L.; Flyg, Heidi M.; Kirby, Jennine E.; Chang, Chea-Yo; Martinsen, Gary L.			Mechanisms of TBI and Visual Consequences in Military and Veteran Populations	OPTOMETRY AND VISION SCIENCE			English	Article						traumatic brain injury; blast injuries; binocular vision; light sensitivity; oculomotor system	TRAUMATIC BRAIN-INJURY; POLYTRAUMA NETWORK SITE; DYSFUNCTION; IMPAIRMENT	Purpose. Blast-related (BR) traumatic brain injuries (TBIs) occur secondary to explosive blasts. Blast-related TBIs can be caused by the blast wave itself or by direct head trauma caused by events surrounding the blast. Non-blast-related (NBR) TBIs are caused by direct head trauma. Recent evidence shows that TBIs are associated with vision problems, particularly binocular system problems. The purpose of this study was to determine if similar types and amounts of vision problems are present in patients with BR TBIs and NBR TBIs. Methods. A retrospective analysis of eye examination records of 50 NBR TBI and 50 BR TBI patients was conducted. Frequencies of visual symptoms and abnormal vision function measurements were computed and compared for the two patient groups. Results. More than 65% of NRB TBI and BR TBI patients reported vision problems. Reading complaints were found in approximately 50% of the patients. Light sensitivity was reported significantly more often in BR TBI patients (67%) than in NBR TBI patients (33%) (p < 0.01). Saccadic dysfunction was measured more often in NBR TBI patients (85%) than in BR TBI patients (58%) (p < 0.01). High rates of accommodative dysfunction and convergence insufficiency were also found, but the group differences were not significant. Strabismus, pursuit abnormalities, fixation defects, and visual field defects were also common in both groups. Conclusions. For most findings, the mechanism of injury (NBR vs. BR) did not result in different frequencies or types of visual dysfunction. The reasons for finding higher frequencies of light sensitivity in the BR TBI group and saccadic dysfunction in the NBR TBI group are unknown, and further research is needed. Overall, the rates of vision complaints and oculomotor defects were high in both groups, indicating a need for a thorough eye examination for any patient with a history of TBI. (Optom Vis Sci 2013;90:105-112)	[Goodrich, Gregory L.; Flyg, Heidi M.; Kirby, Jennine E.; Chang, Chea-Yo; Martinsen, Gary L.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Goodrich, GL (corresponding author), Palo Alto Hlth Care Syst 124, Dept Vet Affairs, 795 Willow Rd, Menlo Pk, CA 94025 USA.	gregory.goodrich@va.gov	Goodrich, Gregory L./AAF-7184-2019		Veterans Affairs Quality Enhancement Research Initiative (QUERI) grant [RRP 11-008]	This project was supported in part by Veterans Affairs Quality Enhancement Research Initiative (QUERI) grant RRP 11-008.	American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Defense and Veterans Brain Injury Center, 2012, DOD WORLDWIDE NUMB T; Doble JE, 2010, PM&R, V2, P244, DOI 10.1016/j.pmrj.2010.01.011; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Du T, 2005, BRAIN INJURY, V19, P1125, DOI 10.1080/02699050500149817; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hofstetter HW., 1944, AM J OPTOM ARCH AM A, V21, P345, DOI [10.1097/00006324-194409000-00001, DOI 10.1097/00006324-194409000-00001]; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Stuhmiller JH, 2008, BLAST INJURY TRANSLA; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; United States Department of Veterans Affairs, 2011, POL TBI SYST CAR UND; Veterans Affairs Office of Research and Development Health Services Research and Development Service, 2011, POL BLAST REL INJ; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	31	86	86	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1040-5488			OPTOMETRY VISION SCI	Optom. Vis. Sci.	FEB	2013	90	2					105	112		10.1097/OPX.0b013e31827f15a1			8	Ophthalmology	Ophthalmology	082CC	WOS:000314368300007	23314131				2021-06-18	
J	Wu, QH; Xuan, WJ; Ando, T; Xu, T; Huang, LY; Huang, YY; Dai, TH; Dhital, S; Sharma, SK; Whalen, MJ; Hamblin, MR				Wu, Qiuhe; Xuan, Weijun; Ando, Takahiro; Xu, Tao; Huang, Liyi; Huang, Ying-Ying; Dai, Tianghong; Dhital, Saphala; Sharma, Sulbha K.; Whalen, Michael J.; Hamblin, Michael R.			Low-Level Laser Therapy for Closed-Head Traumatic Brain Injury in Mice: Effect of Different Wavelengths	LASERS IN SURGERY AND MEDICINE			English	Article						photobiomodulation; low-level laser therapy; traumatic brain injury; mouse model; Neurological Severity Score	CEREBRAL-ISCHEMIA; TRANSCRANIAL LASER; UNITED-STATES; STROKE; PHOTOTHERAPY; MECHANISMS; LIGHT; RATS; PATHOPHYSIOLOGY; REGENERATION	Background and Objectives Traumatic brain injury (TBI) affects millions worldwide and is without effective treatment. One area that is attracting growing interest is the use of transcranial low-level laser therapy (LLLT) to treat TBI. The fact that near-infrared light can penetrate into the brain would allow non-invasive treatment to be carried out with a low likelihood of treatment-related adverse events. LLLT may treat TBI by increasing respiration in the mitochondria, causing activation of transcription factors, reducing inflammatory mediators and oxidative stress, and inhibiting apoptosis. Study Design/Materials and Methods: We tested LLLT in a mouse model of closed-head TBI produced by a controlled weight drop onto the skull. Mice received a single treatment with continuous-wave 665, 730, 810, or 980 nm lasers (36 J/cm(2) delivered at 150 mW/cm(2)) 4-hour post-TBI and were followed up by neurological performance testing for 4 weeks. Results: Mice with moderate-to-severe TBI treated with 665 and 810 nm laser (but not with 730 or 980 nm) had a significant improvement in Neurological Severity Score that increased over the course of the follow-up compared to sham-treated controls. Morphometry of brain sections showed a reduction in small deficits in 665 and 810 nm laser treated mouse brains at 28 days. Conclusions: The effectiveness of 810 nm agrees with previous publications, and together with the effectiveness of 660 nm and non-effectiveness of 730 and 980 nm can be explained by the absorption spectrum of cytochrome oxidase, the candidate mitochondrial chromophore in transcranial LLLT. Lasers Surg. Med. 44: 218-226, 2012. (C) 2012 Wiley Periodicals, Inc.	[Wu, Qiuhe; Xuan, Weijun; Ando, Takahiro; Xu, Tao; Huang, Liyi; Huang, Ying-Ying; Dai, Tianghong; Dhital, Saphala; Sharma, Sulbha K.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Wu, Qiuhe; Xuan, Weijun; Xu, Tao; Huang, Liyi; Huang, Ying-Ying; Dai, Tianghong; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Wu, Qiuhe] Shandong Univ, Dept Burns & Plast Surg, Jinan Cent Hosp, Jinan 250100, Peoples R China; [Xuan, Weijun] Tradit Chinese Med Univ Guangxi, Dept Otolaryngol, Nanning, Peoples R China; [Ando, Takahiro] Keio Univ, Dept Elect & Elect Engn, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; [Xu, Tao] Shanghai Jiao Tong Univ, Lab Anesthesiol, Shanghai, Peoples R China; [Huang, Liyi] Guangxi Med Univ, Dept Infect Dis, Affiliated Coll & Hosp 1, Nanning, Peoples R China; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Dhital, Saphala] Univ Tokyo, Dept Microbiol, Tokyo, Japan; [Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR414,40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Huang, yingying/J-7329-2012; Ando, Takahiro/R-8374-2019; Ando, Takahiro/H-5209-2019; Hamblin, Michael R/H-2758-2019; Huang, Ying-ying/G-3153-2011; Dai, Tianhong/P-5961-2018	Huang, yingying/0000-0002-4038-0277; Hamblin, Michael R/0000-0001-6431-4605; Huang, Ying-ying/0000-0003-3066-6981; Dai, Tianhong/0000-0001-8960-8896; Xu, Tao/0000-0001-5868-4079; Dhital, Saphala/0000-0001-5566-0733	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI050875, R01AI050875] Funding Source: Medline; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [10J04881] Funding Source: KAKEN		Al-Watban FAH, 2007, PHOTOMED LASER SURG, V25, P72, DOI 10.1089/pho.2006.1094; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Davis PJ, 2007, METHODS NUMERICAL IN, p[xii, 612]; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Demir O, 2009, ANAT REC, V292, P1953, DOI 10.1002/ar.20980; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Hamblin MR., 2006, P SPIE, V6140, P1, DOI DOI 10.1117/12.646294; Huang YY, 2010, SER MED PHYS BIOMED, P687; Huang YY, 2010, SER MED PHYS BIOMED, P717; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751-1097.2008.00394.x; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lampl Yair, 2007, Expert Rev Neurother, V7, P961, DOI 10.1586/14737175.7.8.961; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Leung MCP, 2002, LASER SURG MED, V31, P283, DOI 10.1002/lsm.10096; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P443, DOI 10.1089/pho.2011.9908; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Park JJ, 2012, LASER MED SCI, V27, P223, DOI 10.1007/s10103-011-0944-8; Protheroe RT, 2011, ANAESTHESIA, V66, P1035, DOI 10.1111/j.1365-2044.2011.06874.x; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P436, DOI 10.1089/pho.2007.2093; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P137, DOI 10.1089/pho.2007.2076; Rovegno M, 2012, MED INTENSIVA, V36, P37, DOI 10.1016/j.medin.2011.06.008; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Skopin MD, 2009, PHOTODERMATOL PHOTO, V25, P75, DOI 10.1111/j.1600-0781.2009.00406.x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Zhang H, 2012, CELL SIGNAL, V24, P224, DOI 10.1016/j.cellsig.2011.09.004; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	49	86	90	0	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0196-8092	1096-9101		LASER SURG MED	Lasers Surg. Med.	MAR	2012	44	3					218	226		10.1002/lsm.22003			9	Dermatology; Surgery	Dermatology; Surgery	909NZ	WOS:000301572700005	22275301	Green Accepted			2021-06-18	
J	Berger, RP; Hayes, RL; Richichi, R; Beers, SR; Wang, KKW				Berger, Rachel P.; Hayes, Ronald L.; Richichi, Rudolph; Beers, Sue R.; Wang, Kevin K. W.			Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and alpha II-Spectrin Breakdown Product 145 kDa Correlate with Outcome after Pediatric TBI	JOURNAL OF NEUROTRAUMA			English	Article						alpha II-spectrin breakdown product; outcome; pediatric; traumatic brain injury; ubiquitin C-terminal hydrolase	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; ABUSIVE HEAD TRAUMA; CEREBROSPINAL-FLUID; S100B LEVELS; BIOMARKER CONCENTRATIONS; YOUNG-CHILDREN; COMA-SCALE; IDENTIFICATION; PREDICTION	Predicting outcome after pediatric traumatic brain injury (TBI) is important for providing information to families and prescribing rehabilitation services. Previously published studies evaluating the ability of serum biomarkers to predict outcome after pediatric TBI have focused on three markers: neuron-specific enolase (NSE), S100B, and myelin-basic protein (MBP), all of which have important limitations. The study objectives were to measure serum concentrations of two novel serum biomarkers, ubiquitin C-terminal hydrolase (UCH-L1) and alpha II-spectrin breakdown product 145 kDa (SBDP145), in children with TBI and healthy controls and to assess the ability of these markers to predict outcome as assessed by a dichotomous Glasgow Outcome Scale (GOS) score. We also sought to compare the predictive ability of UCH-L1 and SBDP145 to that of the clinical gold standard, the Glasgow Coma Scale (GCS) score, and to that of the well-accepted biomarkers NSE, S100B, and MBP. Serum UCH-L1 and SBDP145 concentrations were significantly greater in subjects than in controls. The increase in UCH-L1 and SBDP145 was exclusively seen in subjects with moderate and severe TBI; there was no increase after mild TBI. Both markers had a significant negative partial correlation with the GCS after controlling for age. Both UCH-L1 and SBDP145 were correlated with GOS, and this correlation was stronger than the correlations with NSE, S100B, or MBP. These results suggest that these two markers may be useful in assessing outcome after moderate and severe pediatric TBI.	[Berger, Rachel P.] UPMC, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15224 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Richichi, Rudolph] Stat Anal & Measurement Consultants Inc, Lanexa, VA USA; [Beers, Sue R.] Western Psychiat Inst & Clin, Pittsburgh, PA USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA	Berger, RP (corresponding author), UPMC, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	rachel.berger@chp.edu		Wang, Kevin/0000-0002-9343-6473	U.S. Department of DefenseUnited States Department of Defense [W81XWH-06-1-0517]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS052831, K23HD43843]; PCTRC of the University of Pittsburgh; Banyan Biomarkers Inc.; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831] Funding Source: NIH RePORTER	This work is supported in part by U.S. Department of Defense Award #W81XWH-06-1-0517 (to R.L.H. and K.K.W.W.), National Institutes of Health R01NS052831 (to R.L.H. and K.K.W.W.), K23HD43843 (to R.P.B.), and the PCTRC of the University of Pittsburgh (to R.P.B.). We would like to thank Stefania Mondello for her assistance making the figure and Haley Stutz for her administrative assistance.; Kevin K.W. Wang and Ronald L. Hayes own stock, receive royalties from, and are officers of Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research or work reported in this publication. No competing financial interests exist for the other authors.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger R, 2009, PEDIATR CRIT CARE ME, V10, P260, DOI 10.1097/PCC.0b013e31819a376d; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Blyth B., 2011, J NEUROTRAU IN PRESS; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Douglas-Escobar M, 2010, PEDIATR RES, V68, P531, DOI 10.1203/PDR.0b013e3181f85a03; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lo TYM, 2009, J NEUROTRAUM, V26, P1479, DOI [10.1089/neu.2008.0753, 10.1089/neu.2008-0753]; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Portela LVC, 2002, CLIN CHEM, V48, P950; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	37	86	91	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					162	167		10.1089/neu.2011.1989			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300019	22022780	Green Published			2021-06-18	
J	Lester, P; Saltzman, WR; Woodward, K; Glover, D; Leskin, GA; Bursch, B; Pynoos, R; Beardslee, W				Lester, Patricia; Saltzman, William R.; Woodward, Kirsten; Glover, Dorie; Leskin, Gregory A.; Bursch, Brenda; Pynoos, Robert; Beardslee, William			Evaluation of a Family-Centered Prevention Intervention for Military Children and Families Facing Wartime Deployments	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH; SOLDIERS; IRAQ; MALTREATMENT; CHECKLIST; PARENTS; RISK; CARE; WAR	Objectives. We evaluated the Families Over Coming Under Stress program, which provides resiliency training designed to enhance family psychological health in US military families affected by combat- and deployment-related stress. Methods. We performed a secondary analysis of Families Over Coming Under Stress program evaluation data that was collected between July 2008 and February 2010 at 11 military installations in the United States and Japan. We present data at baseline for 488 unique families (742 parents and 873 children) and pre-post outcomes for 331 families. Results. Family members reported high levels of satisfaction with the program and positive impact on parent child indicators. Psychological distress levels were elevated for service members, civilian parents, and children at program entry compared with community norms. Change scores showed significant improvements across all measures for service member and civilian parents and their children (P<.001). Conclusions. Evaluation data provided preliminary support for a strength-based, trauma-informed military family prevention program to promote resiliency and mitigate the impact of wartime deployment stress. (Am J Public Health. 2012;102:S48-S54. doi:10.2105/AJPH.2010.300088)	[Lester, Patricia; Saltzman, William R.; Glover, Dorie; Leskin, Gregory A.; Bursch, Brenda; Pynoos, Robert] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA; [Woodward, Kirsten] US Bur Navy Med & Surg, Washington, DC USA; [Beardslee, William] Childrens Hosp, Boston, MA 02115 USA; [Beardslee, William] Harvard Univ, Sch Med, Boston, MA USA	Lester, P (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,A8-159, Los Angeles, CA 90024 USA.	plester@mednet.ucla.edu			US Department of the Navy, Bureau of Medicine and Surgery [N00189-09-C-Z057]; Frederick R. Weisman Philanthropic Foundation and Discretionary Trust	The US Department of the Navy, Bureau of Medicine and Surgery (contract No. N00189-09-C-Z057) and the Frederick R. Weisman Philanthropic Foundation and Discretionary Trust supported Families OverComing Under Stress.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Baker DG, 2009, MIL MED, V174, P773; Beardslee WR, 2003, PEDIATRICS, V112, pE119, DOI 10.1542/peds.112.2.e119; Beardslee WR, 2009, ZERO 3, V29, P34; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Chandra A., 2008, UNDERSTANDING IMPACT; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Chartrand MM, 2008, ARCH PEDIAT ADOL MED, V162, P1009, DOI 10.1001/archpedi.162.11.1009; Compas BE, 1989, PRIMARY PREVENTION P, P60; Cozza SJ, 2005, PSYCHIAT QUART, V76, P371, DOI 10.1007/s11126-005-4973-y; Department of Defence Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Derogatis L, 1993, BRIEF SYMPTOM INVENT; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Flake EM, 2009, J DEV BEHAV PEDIATR, V30, P271, DOI 10.1097/DBP.0b013e3181aac6e4; Gewirtz A, 2008, J MARITAL FAM THER, V34, P177, DOI 10.1111/j.1752-0606.2008.00063.x; Gibbs DA, 2007, JAMA-J AM MED ASSOC, V298, P528, DOI 10.1001/jama.298.5.528; Goodman R, 2000, BRIT J PSYCHIAT, V177, P534, DOI 10.1192/bjp.177.6.534; Greeno CG, 2002, PSYCHIATR SERV, V53, P624, DOI 10.1176/appi.ps.53.5.624; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huebner AJ, 2007, FAM RELAT, V56, P112, DOI 10.1111/j.1741-3729.2007.00445.x; *I MED NAT RES COU, 2009, DEPR PAR PAR CHILDR; Layne CM, 2008, J AM ACAD CHILD PSY, V47, P1048, DOI 10.1097/CHI.0b013e31817eecae; Lester P., 2008, EVIDENCE BASED TREAT, P170; Lester P, 2011, MIL MED, V176, P19, DOI 10.7205/MILMED-D-10-00122; Lester P, 2011, RISK AND RESILIENCE IN U S MILITARY FAMILIES, P149, DOI 10.1007/978-1-4419-7064-0_8; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lincoln A, 2008, J CLIN PSYCHOL, V64, P984, DOI 10.1002/jclp.20520; MacDermid S. M., 2008, UNDERSTANDING PROMOT; McCarroll JE, 2008, CHILD ABUSE REV, V17, P108, DOI 10.1002/car.986; Nash W, 2009, COMBAT OPERATIONAL S; Nash WP, 2011, COMBAT OPERATIONAL B, P107; National Research Council Institute of Medicine, 1994, PREV MENT EM BEH DIS; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Palmer C, 2008, MIL PSYCHOL, V20, P205, DOI 10.1080/08995600802118858; PATTERSON JM, 1987, J ADOLESCENCE, V10, P163, DOI 10.1016/S0140-1971(87)80086-6; Rentz ED, 2007, AM J EPIDEMIOL, V165, P1199, DOI 10.1093/aje/kwm008; ROSEN LN, 1993, MIL MED, V158, P465; Rotheram-Borus MJ, 2001, AM J PUBLIC HEALTH, V91, P1294, DOI 10.2105/AJPH.91.8.1294; RUTTER M, 1984, PSYCHOL MED, V14, P853, DOI 10.1017/S0033291700019838; Ryan C.E., 2005, EVALUATION TREATING; Saltzman WR, 2009, FOCUS MILITARY UNPUB; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; SPIRITO A, 1988, J PEDIATR PSYCHOL, V13, P555, DOI 10.1093/jpepsy/13.4.555; Spoth Richard L, 2002, Prev Sci, V3, P145, DOI 10.1023/A:1019924615322; Sroufe LA, 2005, ATTACH HUM DEV, V7, P349, DOI 10.1080/14616730500365928; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Waldrep DA, 2004, IRAQ WAR CLIN GUIDE, P83; Walker EA, 2002, GEN HOSP PSYCHIAT, V24, P375, DOI 10.1016/S0163-8343(02)00203-7; Walsh F, 2002, FAM RELAT, V51, P130, DOI 10.1111/j.1741-3729.2002.00130.x; Walsh F., 2006, STRENGTHENING FAMILY, V2nd ed.; Weathers FW, 1993, 9 ANN M ISTSS OCT SA	54	86	88	0	25	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health		2012	102			1			S48	S54		10.2105/AJPH.2010.300088			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	893EO	WOS:000300338600018	22033756	Green Published			2021-06-18	
J	[Anonymous]				[Anonymous]			Concussion (Mild Traumatic Brain Injury) and the Team Physician: A Consensus Statement-2011 Update	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article							COLLEGIATE FOOTBALL PLAYERS; SPORT; MANAGEMENT; RISK; RELIABILITY						Guskiewicz, Kevin/0000-0002-8682-2130			[Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; [Anonymous], NCAA REQ CONC MAN PL; [Anonymous], CLIN TEAM PHYS CONS; [Anonymous], 2009, BRIT J SPORT MED, V43, pi85; [Anonymous], 2009, 2009 NFHS CONC BROCH; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Broglio SP, 2007, J ATHL TRAINING, V42, P509; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; DiFiori JP, 2010, CURR SPORT MED REP, V9, P35, DOI 10.1249/JSR.0b013e3181caba67; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; Meeham WP, 2010, CONCUSSION SPORTS CL; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Randolph C, 2005, J ATHL TRAINING, V40, P139; Van Kampen D., 2006, AM J SPORTS MED, V34, P1	34	86	86	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2011	43	12					2412	2422		10.1249/MSS.0b013e3182342e64			11	Sport Sciences	Sport Sciences	851EL	WOS:000297251100024	22089299				2021-06-18	
J	Donnelly, KT; Donnelly, JP; Dunnam, M; Warner, GC; Kittleson, CJ; Constance, JE; Bradshaw, CB; Alt, M				Donnelly, Kerry T.; Donnelly, James P.; Dunnam, Mina; Warner, Gary C.; Kittleson, C. J.; Constance, Janet E.; Bradshaw, Charles B.; Alt, Michelle			Reliability, Sensitivity, and Specificity of the VA Traumatic Brain Injury Screening Tool	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; mass screening; posttraumatic; stress disorders; sensitivity and specificity; veterans		Objective: To provide item analyses, estimates of temporal reliability and internal consistency, and examination of the sensitivity and specificity of a traumatic brain injury-screening tool. Participants: Five hundred veterans of the wars in Iraq and Afghanistan enrolled in the study, approximately half of whom (248) volunteered. The remaining 252 participants were referred to Veteran Affairs (VA) neuropsychology or polytrauma clinics. Design: This psychometric study constitutes part of a larger 4-year, multisite prospective cohort study of veterans returning from Iraq and Afghanistan. Setting: Five VA medical centers and one VA outpatient clinic. Main Measures: Veteran traumatic brain injury screening tool (VATBIST), a structured diagnostic interview for traumatic brain injury; a military-oriented posttraumatic stress disorder checklist. Results: The VATBIST appeared to have high-internal consistency (0.77) and test-retest reliability (0.80), high sensitivity (0.94) and moderate specificity (0.59). Diagnostic odds ratios for the screening tool ranged from 12.6 for the total sample to 24, when veterans with probable posttraumatic stress disorder were excluded from analysis. Conclusions: The VATBIST appears to be a reliable and valid instrument. The presence of significant posttraumatic stress disorder symptoms, however, reduces the accuracy of the measure and highlights the need for careful clinical follow-up of persons who screen positive.	[Donnelly, Kerry T.] VA WNY Healthcare Syst, Buffalo, NY 14215 USA; [Donnelly, James P.] SUNY Buffalo, Dept Counseling, Sch & Educ Psychol, Albany, NY USA; [Warner, Gary C.] Canandaigua VA Med Ctr, Canandaigua, NY USA; [Kittleson, C. J.] Bath VA Med Ctr, Bath, NY USA; [Constance, Janet E.; Bradshaw, Charles B.] Syracuse VA Med Ctr, Syracuse, NY USA; [Alt, Michelle] VA Western New York Healthcare Syst Buffalo, Buffalo, NY USA	Donnelly, KT (corresponding author), VA WNY Healthcare Syst, 3495 BaileyAve 116B, Buffalo, NY 14215 USA.	Kerry.Donnelly@va.gov	Donnelly, James/AAI-4840-2020		Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Office of Research and Development, Health Services Research and Development	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cifu D., 2009, MANAGEMENT CONCUSSIO; Donnelly K, 2008, AM J ALZHEIMERS DIS, V23, P218, DOI 10.1177/1533317508315932; Flahault A, 2005, J CLIN EPIDEMIOL, V58, P859, DOI 10.1016/j.jclinepi.2004.12.009; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jablensky A, 2002, AUST NZ J PSYCHIAT, V36, P297, DOI 10.1046/j.1440-1614.2002.01035.x; Mackinnon A, 2000, COMPUT BIOL MED, V30, P127, DOI 10.1016/S0010-4825(00)00006-8; Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28; Pascrell W, 2007, REPORT C BRAIN INJUR; Pascrell WJ, 2009, CLIN NEUROPSYCHOL, V23, P1281, DOI 10.1080/13854040902939319; Petzel R, 2009, SCREENING EVALUATION; Rutherford G., 2010, RETURNING HOME IRAQ; Rutherford GB, 2008, LONG TERMCONSEQUENCE; Schwab KA, 2006, NEUROLOGY, V66, pA235; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI 10.1016/j.drugalcdep.2009.12.003	23	86	86	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2011	26	6					439	453		10.1097/HTR.0b013e3182005de3			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	859AC	WOS:000297845000001	21386716				2021-06-18	
J	Zanier, ER; Montinaro, M; Vigano, M; Villa, P; Fumagalli, S; Pischiutta, F; Longhi, L; Leoni, ML; Rebulla, P; Stocchetti, N; Lazzari, L; De Simoni, MG				Zanier, Elisa R.; Montinaro, Mery; Vigano, Mariele; Villa, Pia; Fumagalli, Stefano; Pischiutta, Francesca; Longhi, Luca; Leoni, Matteo L.; Rebulla, Paolo; Stocchetti, Nino; Lazzari, Lorenza; De Simoni, Maria-Grazia			Human umbilical cord blood mesenchymal stem cells protect mice brain after trauma	CRITICAL CARE MEDICINE			English	Article						human cord blood mesenchymal stem cells; traumatic brain injury; microglia; transplantation; functional recovery; brain protection	MARROW STROMAL CELLS; BONE-MARROW; GENE-EXPRESSION; IN-VITRO; INJURY; TRANSPLANTATION; NEUROPROTECTION; GROWTH; INHIBITION; CHALLENGES	Objective: To investigate whether human umbilical cord blood mesenchymal stem cells, a novel source of progenitors with multilineage potential: 1) decrease traumatic brain injury sequelae and restore brain function; 2) are able to survive and home to the lesioned region; and 3) induce relevant changes in the environment in which they are infused. Design: Prospective experimental study. Setting: Research laboratory. Subjects: Male C57BI/6 mice. Interventions: Mice were subjected to controlled cortical impact/sham brain injury. At 24 hrs postinjury, human umbilical cord blood mesenchymal stem cells (150,000/5 mu L) or phosphate-buffered saline (control group) were infused intracerebroventricularly contralateral to the injured side. Immunosuppression was achieved by cyclosporine A (10 mg/kg intraperitoneally). Measurements and Main Results: After controlled cortical impact, human umbilical cord blood mesenchymal stem cell transplantation induced an early and long-lasting improvement in sensorimotor functions assessed by neuroscore and beam walk tests. One month postinjury, human umbilical cord blood mesenchymal stem cell mice showed attenuated learning dysfunction at the Morris water maze and reduced contusion volume compared with controls. Hoechst positive human umbilical cord blood mesenchymal stem cells homed to lesioned tissue as early as 1 wk after injury in 67% of mice and survived in the injured brain up to 5 wks. By 3 days postinjury, cell infusion significantly increased brain-derived neurotrophic factor concentration into the lesioned tissue, restoring its expression close to the levels observed in sham operated mice. By 7 days postinjury, controlled cortical impact human umbilical cord blood mesenchymal stem cell mice showed a nonphagocytic activation of microglia/macrophages as shown by a selective rise (260%) in CD11b staining (a marker of microglia/macrophage activation/recruitment) associated with a decrease (58%) in CD68 (a marker of active phagocytosis). Thirty-five days postinjury, controlled cortical impact human umbilical cord blood mesenchymal stem cell mice showed a decrease of glial fibrillary acidic protein positivity in the scar region compared with control mice. Conclusions: These findings indicate that human umbilical cord blood mesenchymal stem cells stimulate the injured brain and evoke trophic events, microglia/macrophage phenotypical switch, and glial scar inhibitory effects that remodel the brain and lead to significant improvement of neurologic outcome. (Crit Care Med 2011; 39: 2501-2510)	[Zanier, Elisa R.; Montinaro, Mery; Villa, Pia; Pischiutta, Francesca; Longhi, Luca; De Simoni, Maria-Grazia] Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, Italy; [Vigano, Mariele; Rebulla, Paolo; Lazzari, Lorenza] Ctr Transfus Med Cellular Therapy & Cryobiol, Dept Regenerat Med, Milan, Italy; [Villa, Pia] CNR, Inst Neurosci, I-20133 Milan, Italy; [Longhi, Luca; Leoni, Matteo L.; Stocchetti, Nino] Univ Milan, Dept Anesthesia & Crit Care Med, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy	De Simoni, MG (corresponding author), Mario Negri Inst Pharmacol Res, Dept Neurosci, Via Eritrea 62, Milan, Italy.	desimoni@marionegri.it	Pischiutta, Francesca/AAA-7927-2020; De Simoni, Maria Grazia/I-6021-2012; Leoni, Matteo L.G./AAT-4422-2020; Fumagalli, Stefano/I-3097-2019; Stocchetti, Nino/O-7444-2017; Longhi, Luca/AAF-9903-2021; Lazzari, Lorenza/J-4279-2015; Zanier, Elisa/AAA-8095-2020; Rebulla, Paolo/I-7684-2015	Pischiutta, Francesca/0000-0002-7151-0812; De Simoni, Maria Grazia/0000-0001-6695-5297; Stocchetti, Nino/0000-0003-3250-6834; Longhi, Luca/0000-0001-9894-8788; Lazzari, Lorenza/0000-0002-9434-4538; Fumagalli, Stefano/0000-0003-3598-6263; Leoni, Matteo Luigi Giuseppe/0000-0001-5228-3733; Zanier, Elisa/0000-0002-3011-8718; Rebulla, Paolo/0000-0002-3875-5754	fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Italy; Fondazione Monzino	Partially supported by fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Italy. Mr. Fumagalli is recipient of a fellowship from Fondazione Monzino.	Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS45; Brock JH, 2010, J NEUROSCI, V30, P9728, DOI 10.1523/JNEUROSCI.1924-10.2010; Broxmeyer HE, 2005, CYTOTHERAPY, V7, P209, DOI 10.1080/14653240510027190; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; CHENG H, 2010, MOL BIOL REP    1229; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Gu WD, 2010, NEUROPATHOLOGY, V30, P205, DOI 10.1111/j.1440-1789.2009.01063.x; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Heile AMB, 2009, NEUROSCI LETT, V463, P176, DOI 10.1016/j.neulet.2009.07.071; Jager M, 2009, STEM CELL REV REP, V5, P266, DOI 10.1007/s12015-009-9083-z; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Ksiazek K, 2009, REJUV RES, V12, P105, DOI 10.1089/rej.2009.0830; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Liao WB, 2009, CELL PHYSIOL BIOCHEM, V24, P307, DOI 10.1159/000233255; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; LONGHI L, 2011, J CEREB BLOOD F 0406; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2003, NEUROSURGERY, V53, P702; Makri G, 2010, STEM CELLS, V28, P127, DOI 10.1002/stem.258; Morigi M, 2010, STEM CELLS, V28, P513, DOI 10.1002/stem.293; Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Panepucci RA, 2004, STEM CELLS, V22, P1263, DOI 10.1634/stemcells.2004-0024; Paxinos G., 2008, MOUSE BRAIN STEREOTA, V3rd; Reimann, 2009, DTSCH ARZTEBL INT, V106, P831, DOI 10.3238/arztebl.2009.0831; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Stocchetti N, 2008, MINERVA ANESTESIOL, V74, P199; Storini C, 2006, J PHARMACOL EXP THER, V318, P849, DOI 10.1124/jpet.106.105064; Valle-Prieto A, 2010, STEM CELLS DEV, V19, P1885, DOI 10.1089/scd.2010.0093; Vigneron A, 2010, AGING-US, V2, P471, DOI 10.18632/aging.100189; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wanner IB, 2008, GLIA, V56, P1691, DOI 10.1002/glia.20721; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Yamaguchi S, 2006, BRAIN RES, V1087, P15, DOI 10.1016/j.brainres.2006.02.127; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031	55	86	97	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2011	39	11					2501	2510		10.1097/CCM.0b013e31822629ba			10	Critical Care Medicine	General & Internal Medicine	841JV	WOS:000296509500017	21725237				2021-06-18	
J	Daneshvar, DH; Baugh, CM; Nowinski, CJ; McKee, AC; Stern, RA; Cantu, RC				Daneshvar, Daniel H.; Baugh, Christine M.; Nowinski, Christopher J.; McKee, Ann C.; Stern, Robert A.; Cantu, Robert C.			Helmets and Mouth Guards: The Role of Personal Equipment in Preventing Sport-Related Concussions	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Equipment; Helmet; Headgear; Mouth guard; Face shield; Sport	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; FOR-DISEASE-CONTROL; ICE HOCKEY; HEAD-INJURIES; PROFESSIONAL FOOTBALL; NECK INJURIES; PROTECTIVE EQUIPMENT; AMERICAN FOOTBALL; SPINE INJURIES	Millions of athletes in the United States experience concussions annually. Although helmets and mouth guards have decreased the risk of catastrophic head injuries, their protective effects on concussions are less clear. This article evaluates the current literature on the effect of equipment on concussions. Understanding the role that these equipment play in preventing concussions is complicated by many factors, such as selection bias in nonrandomized studies, variations in playing style, and risk compensation in sports with mandatory protective equipment. Improving coach and player education about proper concussion management, encouraging neck-strengthening exercises, and minimizing high-risk impacts may reduce concussions in sports.	[Daneshvar, Daniel H.; Baugh, Christine M.; Nowinski, Christopher J.; McKee, Ann C.; Stern, Robert A.; Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurol, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Boston, MA 02118 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Surg, Concord, MA 01742 USA; [Cantu, Robert C.] Brigham & Womens Hosp, Dept Neurosurg, Neurol Sports Injury Ctr, Boston, MA 02115 USA	Daneshvar, DH (corresponding author), Boston Univ, Sch Med, Dept Neurol, Ctr Study Traumat Encephalopathy, 72 E Concord St,B7800, Boston, MA 02118 USA.	ddanesh@bu.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513; Stern, Robert/0000-0002-5008-077X	Boston University Alzheimer's Disease Center [NIA P30 AG13846, 0572063345-5]; National Operating Committee on Standards; National Collegiate Athletic Association; National Federation of State High School Associations; American Football Coaches Association; Sports Legacy Institute; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This work was supported by the Boston University Alzheimer's Disease Center NIA P30 AG13846, supplement 0572063345-5, the National Operating Committee on Standards for Athletic Equipment, the National Collegiate Athletic Association, the National Federation of State High School Associations, the American Football Coaches Association, and the Sports Legacy Institute.	Abu-Zidan FM, 2007, EMERG MED AUSTRALAS, V19, P366, DOI 10.1111/j.1742-6723.2007.00967.x; ADA, 2006, J AM DENT ASSOC, V137, P1712; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Asplund C, 2009, BRIT J SPORT MED, V43, P993, DOI 10.1136/bjsm.2009.060152; Barbic D, 2005, CLIN J SPORT MED, V15, P294, DOI 10.1097/01.jsm.0000171883.74056.21; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barth JT, 2001, J ATHL TRAINING, V36, P253; BENNETT T, 1977, NFLS OFFICIAL ENCY H, P1; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Benson Brian W, 2005, Med Sport Sci, V49, P86, DOI 10.1159/000085393; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Berg P, 2007, HEALTH PROMOT INT, V22, P191, DOI 10.1093/heapro/dam020; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; BISHOP PJ, 1984, AM J SPORT MED, V12, P233, DOI 10.1177/036354658401200313; BROGLIO SP, 2010, MED SCI SPORTS EXERC, V14, P13; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Buller DB, 2003, J TRAUMA, V55, P939, DOI 10.1097/01.TA.0000078694.53320.CA; CANTU R, 2010, J NEUROTRAUM, V27, P50; Cantu RC, 2009, BRIT J SPORT MED, V43, P981, DOI 10.1136/bjsm.2009.067728; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Cantu RC, 1998, CLIN SPORT MED, V17, pXI, DOI 10.1016/S0278-5919(05)70055-7; CANTU RC, J PHYS MED IN PRESS; CLARKE KS, 1979, MED SCI SPORT EXER, V11, P138; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Crisco JJ, 1997, MED SCI SPORT EXER, V29, P26, DOI 10.1097/00005768-199701000-00005; Cusimano MD, 2010, BRIT J SPORT MED, V44, P781, DOI 10.1136/bjsm.2009.070573; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; Danis R P, 2000, Inj Prev, V6, P232, DOI 10.1136/ip.6.3.232; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dick R, 2007, J ATHL TRAINING, V42, P255; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; Durkin MS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e74; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finch C, 2003, J SCI MED SPORT, V6, pV, DOI 10.1016/S1440-2440(03)80001-4; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Haileyesus T, 2007, INJURY PREV, V13, P202, DOI 10.1136/ip.2006.014019; HEINTZ WD, 1975, PHYSICIAN SPORTSMED, V3, P61; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Janda DH, 2003, CLIN ORTHOP RELAT R, P20, DOI 10.1097/01.blo.0000057789.10364.e3; Kahanov Leamor, 2005, Res Sports Med, V13, P77, DOI 10.1080/15438620590956025; Kis M, 2004, CAN J NEUROL SCI, V31, P499, DOI 10.1017/S031716710000370X; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Levy ML, 2004, NEUROSURGERY, V55, P661; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Marshall SW, 2003, JAMA-J AM MED ASSOC, V289, P568, DOI 10.1001/jama.289.5.568; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Mueller FO, 1982, CATASTROPHIC SPORT I; Myers Thomas J., 1993, Bio-Medical Materials and Engineering, V3, P15; Naunheim R, 2002, J TRAUMA, V53, P691, DOI 10.1097/00005373-200210000-00012; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Nicholls RL, 2004, SPORTS MED, V34, P17, DOI 10.2165/00007256-200434010-00003; Norton K, 2001, BRIT J SPORT MED, V35, P418, DOI 10.1136/bjsm.35.6.418; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pettersen JA, 2002, BRIT J SPORT MED, V36, P19, DOI 10.1136/bjsm.36.1.19; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Rihn JA, 2009, SPORTS MED, V39, P697, DOI 10.2165/11315190-000000000-00000; ROBEY JM, 1971, J AMER MED ASSOC, V217, P184, DOI 10.1001/jama.217.2.184; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; Scheiman S, 2010, ACCIDENT ANAL PREV, V42, P758, DOI 10.1016/j.aap.2009.11.005; Singh GD, 2009, DENT TRAUMATOL, V25, P515, DOI 10.1111/j.1600-9657.2009.00808.x; STEPHENS K, 2004, STANDARD DROP TEST M; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Thompson DC, 2000, COCHRANE DB SYST REV, V2; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Torg J S, 1999, Am J Orthop (Belle Mead NJ), V28, P128; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; VIANO DC, 1993, CLIN J SPORT MED, V4, P217; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5; Winters JE, 2001, J ATHL TRAINING, V36, P339; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; *XEN, 2010, XEN INN; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; 2006, J AM DENT ASS, V137, P1731	112	86	90	0	69	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					145	+		10.1016/j.csm.2010.09.006			20	Sport Sciences	Sport Sciences	691XR	WOS:000285114800014	21074089	Green Accepted			2021-06-18	
J	Green, P; Montijo, J; Brockhaus, R				Green, Paul; Montijo, Jorge; Brockhaus, Robbi			High Specificity of the Word Memory Test and Medical Symptom Validity Test in Groups with Severe Verbal Memory Impairment	APPLIED NEUROPSYCHOLOGY			English	Article						dementia; effort; malingering; specificity; SVT	CLASSIFICATION ACCURACY; PERFORMANCE	By definition, false positives occur when an otherwise very easy symptom validity test (SVT) or effort test is failed because of cognitive impairment and not because of poor effort. Therefore, the highest rate of false positives will be found in those groups with the most severe cognitive impairment. For that reason, it is important to study people with severe impairment when evaluating the specificity of SVTs. Some people with various types of dementia, notably those with Alzheimer's disease, suffer from severe impairment of memory and other cognitive abilities. In this study, patients with possible or probable dementia were tested with the Word Memory Test (WMT; Green, 2003; Green Astner, 1995) and the Medical Symptom Validity Test (MSVT; Green, 2004). While some dementia patients failed the easy subtests of these instruments and had severe verbal memory impairment, they showed distinctive profiles of scores that have been reported to be characteristic of people with severe impairment. Using profile analysis, the WMT and MSVT achieved a specificity of 98.4% or higher in the patients of the current study. This suggests that there will be extremely low false positive rates using the same methods in people with relatively minor impairment of the type found in, for example, mild traumatic brain injury or depression.	[Brockhaus, Robbi] Alexianer Krankenhaus Krefeld Klin, Duisburg, Germany	Green, P (corresponding author), Suite 210,10701103 Ave, Edmonton, AB T5S 1K7, Canada.	drpgreen@telus.net					Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Green P., 2008, MANUAL NONVERBAL MED; Green P., 2003, MANUAL WORD MEMORY T; Green P., 2004, MANUAL MED SYMPTOM V; Green P., DETECTION M IN PRESS; Green P., 1995, MANUAL ORAL WORD MEM; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry M, 2010, J CLIN EXP NEUROPSYC, V32, P19, DOI 10.1080/13803390902791653; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Howe L, 2009, CLIN NEUROPSYCHOL, V23, P329, DOI 10.1080/13854040801945060; Iverson G. L., 1999, J COGNITIVE REHABILI, V17, P4; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Rienstra A, 2009, ARCH CLIN NEUROPSYCH, V24, P255, DOI 10.1093/arclin/acp035; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Tombaugh TN, 1996, TEST MEMORY MALINGER	27	86	86	0	21	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2011	18	2					86	94	PII 938328944	10.1080/09084282.2010.523389			9	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	775XX	WOS:000291497900002	21660760				2021-06-18	
J	Spain, A; Daumas, S; Lifshitz, J; Rhodes, J; Andrews, PJD; Horsburgh, K; Fowler, JH				Spain, Aisling; Daumas, Stephanie; Lifshitz, Jonathan; Rhodes, Jonathan; Andrews, Peter J. D.; Horsburgh, Karen; Fowler, Jill H.			Mild Fluid Percussion Injury in Mice Produces Evolving Selective Axonal Pathology and Cognitive Deficits Relevant to Human Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal damage; cognition; memory; mild traumatic brain injury; white matter	SPATIAL NAVIGATION; UNMYELINATED AXONS; FLUORO-JADE; CONCUSSION; RAT; IMPAIRMENT; MODEL; ABNORMALITIES; VULNERABILITY; HIPPOCAMPUS	Mild traumatic brain injury (TBI) accounts for up to 80% of clinical TBI and can result in cognitive impairment and white matter damage that may develop and persist over several years. Clinically relevant models of mild TBI for investigation of neurobiological changes and the development of therapeutic strategies are poorly developed. In this study we investigated the temporal profile of axonal and somal injury that may contribute to cognitive impairments in a mouse model of mild TBI. Neuronal perikaryal damage (hematoxylin and eosin and Fluoro-Jade C), myelin integrity (myelin basic protein and myelin-associated glycoprotein), and axonal damage (amyloid precursor protein), were evaluated by immunohistochemistry at 4 h, 24 h, 72 h, 4 weeks, and 6 weeks after mild lateral fluid percussion brain injury (0.9 atm; righting time 167 +/- 15 sec). At 3 weeks post-injury spatial reference learning and memory were tested in the Morris water maze (MWM). Levels of damage to neuronal cell bodies were comparable in the brain-injured and sham groups. Myelin integrity was minimally altered following injury. Clear alterations in axonal damage were observed at various time points after injury. Axonal damage was localized to the cingulum at 4 h post-injury. At 4 and 6 weeks post-injury, axonal damage was evident in the external capsule, and was seen at 6 weeks in the dorsal thalamic nuclei. At 3 weeks post-injury, injured mice showed an impaired ability to learn the water maze task, suggesting injury-induced alterations in search strategy learning. The evolving localization of axonal damage points to ongoing degeneration after injury that is concomitant with a deficit in learning.	[Spain, Aisling; Horsburgh, Karen; Fowler, Jill H.] Univ Edinburgh, Ctr Cognit & Neural Syst, Edinburgh EH8 9JZ, Midlothian, Scotland; [Daumas, Stephanie] Univ Paris 06, Physiopathol Malad SNC, Paris, France; [Lifshitz, Jonathan] Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, Dept Phys Med & Rehabil,Chandler Med Ctr, Lexington, KY 40536 USA; [Rhodes, Jonathan; Andrews, Peter J. D.] Univ Edinburgh, Dept Anaesthesia Crit Care & Pain Med, Intens Care Unit, Western Gen Hosp, Edinburgh EH8 9JZ, Midlothian, Scotland	Fowler, JH (corresponding author), Univ Edinburgh, Ctr Cognit & Neural Syst, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.	Jill.Fowler@ed.ac.uk	Messier, Claude/A-2322-2008; Spain, Aisling/E-5740-2012	Messier, Claude/0000-0002-4791-1763; Spain, Aisling/0000-0003-1292-967X; Daumas, Stephanie/0000-0001-7048-7617; Horsburgh, Karen/0000-0002-9620-3691; Fowler, Jill/0000-0003-3204-1221	Alzheimer's Society; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0700704B, G9200370] Funding Source: researchfish; Royal Osteoporosis Society [128] Funding Source: researchfish	The support of the Alzheimer's Society is gratefully acknowledged.	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Blanchet S, 2009, BRAIN INJURY, V23, P111, DOI 10.1080/02699050802649688; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cain DP, 2006, BEHAV BRAIN RES, V170, P241, DOI 10.1016/j.bbr.2006.02.023; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Conti AC, 1998, J NEUROSCI, V18, P5663; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; DOMESICK VB, 1970, BRAIN RES, V20, P19, DOI 10.1016/0006-8993(70)90150-2; FRANKLIN W, 1997, MOUSE BRAIN STEREOTA; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jortner BS, 2006, NEUROTOXICOLOGY, V27, P628, DOI 10.1016/j.neuro.2006.03.002; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Lin CH, 2003, MOL PHARMACOL, V63, P44, DOI 10.1124/mol.63.1.44; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEUNIER B, 1988, INORG CHEM, V27, P161, DOI 10.1021/ic00274a032; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; SAPER CB, 1984, J COMP NEUROL, V222, P313, DOI 10.1002/cne.902220302; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Warburton EC, 2001, J NEUROSCI, V21, P7323, DOI 10.1523/JNEUROSCI.21-18-07323.2001; Warburton EC, 1999, BEHAV NEUROSCI, V113, P956, DOI 10.1037/0735-7044.113.5.956; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	59	86	88	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1429	1438		10.1089/neu.2010.1288			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900007	20528171				2021-06-18	
J	Shahrokhi, N; Khaksari, M; Soltani, Z; Mahmoodi, M; Nakhaee, N				Shahrokhi, Nader; Khaksari, Mohammad; Soltani, Zahra; Mahmoodi, Mehdi; Nakhaee, Nouzar			Effect of sex steroid hormones on brain edema, intracranial pressure, and neurologic outcomes after traumatic brain injury	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article						estrogen; progesterone; neuroprotective; ICP; CPP; brain edema; neurologic outcomes	CEREBRAL-BLOOD-FLOW; CLOSED-HEAD INJURY; PERFUSION-PRESSURE; EXPERIMENTAL-MODEL; RATS; ESTROGEN; PROGESTERONE; ISCHEMIA; AUTOREGULATION; REPERFUSION	Recent studies have reported that estrogen and progesterone have a neuroprotective effect after traumatic brain injury (TBI): however, the mechanism(s) for this effect have not yet been elucidated. The aim of the present study was to investigate the role of sex steroid hormones on changes in brain edema, intracranial pressure (ICP), and cerebral perfusion pressure (CPP) after TBI in ovariectomized (OVX) rats. In this study, 50 female rats were divided into 5 groups: control (intact), sham, and 3 TBI groups consisting of vehicle, estrogen (1 mg/kg), and progesterone (8 mg/kg). TBI was induced by the Marmarou method, and the hormones were injected i.p. 30 min after TBI. ICP was measured in the spinal cord, and CPP was calculated by subtracting the mean arterial pressure (MAP) from ICP. The results revealed that brain water content after TBI was lower (p < 0.001) in the estrogen and progesterone groups than in the vehicle group. After trauma, ICP was significantly higher in TBI rats (p < 0.001). The ICP in the estrogen and progesterone groups decreased at 4 and 24 h after TBI compared with vehicle (p < 0.001 and p < 0.05, respectively). The CPP in the estrogen and progesterone groups increased after 24 h compared with vehicle (p < 0.001). Also after TBI, the neurological score (veterinary coma scale) was significantly higher than vehicle at 1 h (p < 0.01) and 24 h (p < 0.001) in the group treated with estrogen. In conclusion, pharmacological doses of estrogen and progesterone improved ICP, CPP, and neurological scores after TBI in OVX rats, which implies that these hormones play a neuroprotective role in TBI.	[Shahrokhi, Nader; Nakhaee, Nouzar] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran; [Soltani, Zahra] Kerman Univ Med Sci, Dept Physiol, Kerman, Iran; [Mahmoodi, Mehdi] Rafsanjan Univ Med Sci, Dept Biochem, Rafsanjan, Iran	Shahrokhi, N (corresponding author), Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran.	nshahrokhisa@yahoo.com	Nakhaee, Nouzar/AAZ-2677-2020; Mahmoodi, Mehdi/H-2754-2017; Haddad, Mohammad Khaksari/AAB-9025-2019; Soltani, Zahra/AAC-1350-2019; Shahrokhi, Nader/AAV-3747-2020	Nakhaee, Nouzar/0000-0001-5808-6503; Mahmoodi, Mehdi/0000-0002-8463-8364; Haddad, Mohammad Khaksari/0000-0003-0770-4281; Soltani, Zahra/0000-0002-8423-6189; Shahrokhi, Nader/0000-0002-0149-7819	Neuroscience and Physiology Research Centers in Kerman University of Medical Sciences	This research project was approved by the Neuroscience and Physiology Research Centers in Kerman University of Medical Sciences, and the authors thank the managers of these centers for their financial support. We also acknowledge our colleagues Mr. P. Ghotbi, Miss. N. Habibpoor, Mr. R. Bakhshi, and Mr. M. Gohargazi.	AHMADMOLAI L, 2008, J KERMAN U MED SCI, V15, P47; ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; Dethloff TJ, 2008, J CEREBR BLOOD F MET, V28, P916, DOI 10.1038/sj.jcbfm.9600589; Duckles SP, 2007, CLIN EXP PHARMACOL P, V34, P801, DOI 10.1111/j.1440-1681.2007.04683.x; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Gilkes C., 2007, SURGERY OXFORD, V25, P530, DOI DOI 10.1016/J.MPSUR.2007.10.005; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Koyama Y, 2004, EUR J PHARMACOL, V489, P193, DOI 10.1016/j.ejphar.2004.03.018; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Krause DN, 2006, J APPL PHYSIOL, V101, P1252, DOI 10.1152/japplphysiol.01095.2005; Krause DN, 2002, INT CONGR SER, V1235, P395, DOI 10.1016/S0531-5131(02)00211-X; Kusaka G, 2004, J NEUROSCI METH, V135, P121, DOI 10.1016/j.jneumeth.2003.12.013; Liu R, 2005, BRAIN RES, V1060, P55, DOI 10.1016/j.brainres.2005.08.048; Marik P, 1999, J EMERG MED, V17, P711, DOI 10.1016/S0736-4679(99)00055-4; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MILDE LN, 1985, ANESTHESIOLOGY, V63, P371, DOI 10.1097/00000542-198510000-00005; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Nakamura T, 2006, ACTA NEUROCHIR SUPPL, V96, P218; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Rogatsky GG, 2005, BRAIN RES, V1047, P131, DOI 10.1016/j.brainres.2005.02.049; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Salluh JIF, 2007, ACTA ANAESTH SCAND, V51, P505, DOI 10.1111/j.1399-6576.2006.01252.x; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sunday L, 2006, AM J PHYSIOL-ENDOC M, V291, pE261, DOI 10.1152/ajpendo.00550.2005; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Reempts J, 2000, NEUROSCI RES COMMUN, V26, P161, DOI 10.1002/1520-6769(200005/06)26:3<161::AID-NRC4>3.0.CO;2-N; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207; 1997, LANCET, V349, P1263, DOI DOI 10.1016/S0140-6736(97)21018-4	40	86	94	2	12	NATL RESEARCH COUNCIL CANADA-N R C RESEARCH PRESS	OTTAWA	BUILDING M 55, OTTAWA, ON K1A 0R6, CANADA	0008-4212			CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	APR	2010	88	4					414	421		10.1139/Y09-126			8	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	616XB	WOS:000279243700002	20555409				2021-06-18	
J	Hoffer, ME; Balaban, C; Gottshall, K; Balough, BJ; Maddox, MR; Penta, JR				Hoffer, Michael E.; Balaban, Carey; Gottshall, Kim; Balough, Ben J.; Maddox, Michael R.; Penta, Joseph R.			Blast Exposure: Vestibular Consequences and Associated Characteristics	OTOLOGY & NEUROTOLOGY			English	Article; Proceedings Paper	Spring Meeting of the American-Neurotology-Society	MAY 29-30, 2009	Phoenix, AZ	Amer Neurotol Soc		Headaches; Hearing loss; Mild traumatic brain injury; Posttraumatic stress disorders; Traumatic brain injury; Vestibular disorders; Vestibular function tests	TRAUMATIC BRAIN-INJURY; DIZZINESS; IMPAIRMENT; DISORDER; STRESS; IRAQ; WAR	Objective: To characterize vestibular and related symptoms seen after blast exposure. Study Design: Prospective single-subject design. Settings: Tertiary care facility and military field hospital. Patients: Active-duty US Military personnel exposed to blast(s) in Iraq and/or Afghanistan. Interventions: Vestibular function tests, auditory tests, and a structured history and physical examination. Results: Blast exposure induced vestibular disorders, and related symptoms are significantly different than those seen in blunt head trauma. The vestibular characteristics and objective tests of vestibular function significantly worsen in blast-exposed patients as a function of time between injury and presentation. Conclusion: Blast exposure produces a unique set of vestibular disorders and associated symptoms that progress over time. Understanding the characteristics of these symptoms as they vary over time may be critical in designing treatment strategies that modify long-term outcome.	[Hoffer, Michael E.; Balaban, Carey; Gottshall, Kim; Balough, Ben J.] USN, Spatial Orientat Ctr, Dept Otolaryngol, San Diego Med Ctr, San Diego, CA 92134 USA; [Maddox, Michael R.] 1st Marine Expeditionary Grp, Camp Pendleton, CA USA; [Penta, Joseph R.] 1st Marine Logist Grp, Camp Pendleton, CA USA; [Balaban, Carey] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA	Hoffer, ME (corresponding author), USN, Spatial Orientat Ctr, Dept Otolaryngol, San Diego Med Ctr, 34800 Bob Wilson Dive, San Diego, CA 92134 USA.	Michael.hoffer@med.navy.mil	Balaban, Carey/O-6586-2019; Balaban, Carey/I-3467-2017	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844			*ASS SECR DEF, 2007, MEM TRAUM BRAIN INJ; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Engelhard IM, 2007, BRIT J PSYCHIAT, V191, P140, DOI 10.1192/bjp.bp.106.034884; Furman JM, 2005, J NEUROL NEUROSUR PS, V76, P1, DOI 10.1136/jnnp.2004.048926; Gottshall KR, 2007, MIL MED, V172, P852, DOI 10.7205/MILMED.172.8.852; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Newman-Toker DE, 2008, ACTA OTO-LARYNGOL, V128, P601, DOI 10.1080/00016480701596096; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; Solomon Z, 2005, J CLIN PSYCHIAT, V66, P1031, DOI 10.4088/JCP.v66n0811; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980	12	86	89	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1531-7129			OTOL NEUROTOL	Otol. Neurotol.	FEB	2010	31	2					232	236		10.1097/MAO.0b013e3181c993c3			5	Clinical Neurology; Otorhinolaryngology	Neurosciences & Neurology; Otorhinolaryngology	581VX	WOS:000276554400010	20009782				2021-06-18	
J	Englander, J; Bushnik, T; Oggins, J; Katznelson, L				Englander, Jeffrey; Bushnik, Tamara; Oggins, Jean; Katznelson, Laurence			Fatigue after traumatic brain injury: Association with neuroendocrine, sleep, depression and other factors	BRAIN INJURY			English	Article						Brain injuries; rehabilitation; fatigue; neuroendocrine systems	ANEURYSMAL SUBARACHNOID HEMORRHAGE; DISABILITY RATING-SCALE; QUALITY-OF-LIFE; 1ST 2 YEARS; MULTIPLE-SCLEROSIS; SEVERITY SCALE; LONG-TERM; HYPOPITUITARISM; INVENTORY; REHABILITATION	Objective: Define associations between post-traumatic brain injury (TBI) fatigue and abnormalities in neuroendocrine axes, sleep, mood, cognition and physical functioning. Design: Survey. Setting: Large community hospital-based rehabilitation centre. Participants: Convenience sample of 119 individuals at least 1 year post-TBI. Outcome measures: Multidimensional Assessment of Fatigue (MAF); Fatigue Severity Scale (FSS); neuroendocrine assessments-growth hormone (GH) reserve, thyroid, cortisol and testosterone levels; visual analogue pain rating; Pittsburgh Sleep Quality Index; Beck Depression Inventory-II; Disability Rating Scale; Craig Handicap Assessment and Reporting Technique; Neurobehavioural Functioning Inventory. Results: Fifty-three per cent reported fatigue on the MAF and one-third on the FSS; 65% were found to have moderate/severe GH deficiency; 64% had adrenal insufficiency (low fasting cortisol); 12% had central hypothyroidism; and 15% of men had testosterone deficiency. Pituitary dysfunction did not correlate with fatigue or other symptoms. Predictors of MAF total scores were female gender, depression, pain and self-assessed memory deficits. Predictors of FSS scores were depression, self-assessed motor deficits and anti-depressant usage. Conclusions: Robust correlates of fatigue were gender, depression, pain and memory and motor dysfunction. Investigation of post-TBI fatigue should include screening for depression, pain and sleep disturbance. There was no correlation between pituitary dysfunction and fatigue; however, the relatively high prevalence of hypothyroidism and adrenal dysfunction suggests screening for these hormone deficiencies.	[Englander, Jeffrey] Santa Clara Valley Med Ctr, PM&R, San Jose, CA 95128 USA; [Bushnik, Tamara] Santa Clara Valley Med Ctr, Rehabil Res, San Jose, CA 95128 USA; [Oggins, Jean] Consulting & Res Evaluat Serv, San Francisco, CA USA; [Katznelson, Laurence] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Katznelson, Laurence] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA	Bushnik, T (corresponding author), NYU, Langone Med Ctr, Rusk Inst Rehabil Res, 400 E 34th St,RR115A, New York, NY 10010 USA.	tamara.bushnik@nyumc.org	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Bushnik, Tamara/0000-0003-3328-257X	U.S. Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation ResearchUS Department of Education [H133A020524]	This research was funded in part by a grant from the U.S. Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research (Grant # H133A020524) and by a supplement grant from Pfizer Pharmaceuticals Inc. for neuroendocrine testing.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Baum HBA, 1996, J CLIN ENDOCR METAB, V81, P84, DOI 10.1210/jc.81.1.84; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; BELZA BL, 1995, J RHEUMATOL, V22, P639; BOGARO SR, 2005, J HEAD TRAUMA REHAB, V5, P416; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P25, DOI 10.1097/01.HTR.0000308718.88214.bb; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Dijkers MPJM, 2008, J HEAD TRAUMA REHAB, V23, P3, DOI 10.1097/01.HTR.0000308716.80590.6b; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Grady C, 1998, NURS RES, V47, P227, DOI 10.1097/00006199-199807000-00008; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; JONES SL, 1994, CLIN ENDOCRINOL, V41, P123, DOI 10.1111/j.1365-2265.1994.tb03793.x; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kleinman L, 2000, QUAL LIFE RES, V9, P499, DOI 10.1023/A:1008960710415; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PACKER TL, 1994, ARCH PHYS MED REHAB, V75, P1122, DOI 10.1016/0003-9993(94)90088-4; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; Srinivasan L, 2009, BRAIN INJURY, V23, P639, DOI 10.1080/02699050902970778; Substance Abuse and Mental Health Services Administration, NAT HOUS SURV DRUG A; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Widmer IE, 2005, J CLIN ENDOCR METAB, V90, P4579, DOI 10.1210/jc.2005-0354; Winstead-Fry P, 1998, J Nurs Meas, V6, P111	42	86	89	0	22	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	12					1379	1388		10.3109/02699052.2010.523041			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667NR	WOS:000283200800001	20961172				2021-06-18	
J	Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, JV				Anderson, Vicki; Catroppa, Cathy; Morse, Sue; Haritou, Flora; Rosenfeld, Jeffrey V.			Intellectual Outcome from Preschool Traumatic Brain Injury: A 5-Year Prospective, Longitudinal Study	PEDIATRICS			English	Article						traumatic brain injury; children; recovery of function; intelligence	CLOSED HEAD-INJURY; NEUROBEHAVIORAL RECOVERY; CHILDREN; ADOLESCENTS; SEQUELAE; AGE; PLASTICITY; SEVERITY; COHORT	INTRODUCTION: Traumatic brain injury (TBI) is a common, acquired disability that may be used as a model to understand the impact of early brain injury on brain structure and function. To date, few studies have followed very young children over time after insult. OBJECTIVE: To plot recovery and outcome of intellectual ability after early TBI over the 5 years after injury, and to identify predictors of outcome including injury, sociodemographic and preinjury characteristics, and acute functional recovery. DESIGN: Children aged between 2 and 7 years who were diagnosed with TBI (N = 54) were consecutively recruited on admission to the Royal Children's Hospital, Victoria, Australia, to participate in a prospective, longitudinal study. Our study had a between-factor design that used injury severity as the independent variable. The participants were categorized into groups according to injury severity (mild, moderate, or severe), and were compared with healthy control participants (n = 16) at the acute time point, and at 12 months, 30 months, and 5 years after injury. Intellectual measures, including verbal and nonverbal skills, attention, and processing speed, were administered. RESULTS: Children with severe injuries demonstrated slower recovery and poorer cognitive outcomes up to 5 years after injury than did those who were observed for less severe injuries. Recovery trajectories were associated with injury severity over the first 30 months after injury, with the greatest deterioration in function observed for more severe injuries. From 30 months to 5 years after injury, progress was stable. Only injury severity (as determined by the Glasgow Coma Scale score) and acute cognitive performance were strong predictors of 5-year outcomes. CONCLUSIONS: This study has confirmed the high risk of persisting and global deficits associated with severe brain insult in early childhood. Contrary to previous speculation about "growing into deficits," children with severe brain insults have more protracted recovery periods but do not continue to lose ground compared with their peers. By 30 months after insult, recovery seems to stabilize and children begin to make appropriate developmental gains. Pediatrics 2009; 124: e1064-e1071	[Anderson, Vicki; Catroppa, Cathy] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy; Morse, Sue; Haritou, Flora] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Anderson, Vicki] Royal Childrens Hosp, Dept Speech Pathol, Melbourne, Vic, Australia; [Catroppa, Cathy] Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Rosenfeld, Jeffrey V/B-7249-2011		National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Royal Children's Hospital Research Foundation	This study was supported by grants from the National Health and Medical Research Council of Australia and the Royal Children's Hospital Research Foundation.	ANDERSON V, 1994, ARCH DIS CHILD, V70, P476, DOI 10.1136/adc.70.6.476; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Bayley N., 1969, BAYLEY SCALES INFANT; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COUSENS P, 1991, J PEDIATR PSYCHOL, V16, P475, DOI 10.1093/jpepsy/16.4.475; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kraus J., 1995, TRAUMATIC HEAD INJUR, P117; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LACHAR D, 1992, PERSONALITY INVENT S; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P5; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; VANZOMERON E, 1994, CLIN NEUROPSYCHOLOGY; Walsh K. W., 1985, UNDERSTANDING BRAIN; WECHSLER D, 1991, MANUAL WECHSLER SCAL, V3; Wechsler D, 1989, MANUAL PRESCHOOL PRI; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	43	86	87	0	18	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2009	124	6					E1064	E1071		10.1542/peds.2009-0365			8	Pediatrics	Pediatrics	524SE	WOS:000272162400031	19948612				2021-06-18	
J	Ashman, TA; Cantor, JB; Gordon, WA; Spielman, L; Flanagan, S; Ginsberg, A; Engmann, C; Egan, M; Ambrose, F; Greenwald, B				Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Spielman, Lisa; Flanagan, Steve; Ginsberg, Annika; Engmann, Clara; Egan, Matthew; Ambrose, Felicia; Greenwald, Brian			A Randomized Controlled Trial of Sertraline for the Treatment of Depression in Persons With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Anxiety; Brain injuries; Depression; Minority groups; Randomized controlled trials [publication type]; Rehabilitation; Sertraline	STRUCTURED CLINICAL INTERVIEW; NATIONAL COMORBIDITY SURVEY; DSM-III-R; INTEGRATED CARE PATHWAY; MAJOR DEPRESSION; RATING-SCALE; MENTAL-DISORDERS; AXIS-I; ANTIDEPRESSANT TREATMENT; PSYCHIATRIC-DISORDERS	Objective: To examine the efficacy of sertraline in the treatment of depression after traumatic brain injury (TBI). Design: Double-blind, randomized controlled trial. Setting: Research center at a major urban medical center. Participants: Subjects were a referred and volunteer sample of 52 participants with TBI, a diagnosis of major depression disorder (MDD), and a score on the Hamilton Rating Scale for Depression (HAM-D) of 18 or greater. The majority of the sample was male (58%), had less than 14 years of education (73%), had incomes below $20,000 (82%), and were from minority backgrounds (75%). Approximately one third of the sample had mild brain injuries, and two thirds had moderate to severe brain injuries. The mean age was 47 +/- 11, and the mean time since injury was 17 +/- 14 years. One participant withdrew from the study because of side effects. Intervention: Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg) or placebo for 10 weeks. Main Outcome Measures: The HAM-D, the Beek Anxiety Inventory, and the Life-3 quality of life (QOL). Results: No statistically significant differences were found at baseline between drug and placebo groups on baseline measures of depression (24.8 +/- 7.3 vs 27.7 +/- 7.0), anxiety (16.4 +/- 12.3 vs 24.0 +/- 14.9), or QOL (2.96 +/- 1.0 vs 2.9 +/- 0.9). The income level of those receiving placebo was significantly lower than those participants receiving medication. Analyses of covariance revealed significant changes from preintervention to posttreatment for all 3 Outcome measures (P<.001) but no group effects. Random-effects modeling did not find any significant difference in patterns of scores of the outcome measures between the placebo and medication groups. Conclusions: Both groups showed improvements in mood, anxiety, and QOL, with 59% of the experimental group and 32% of the placebo group responding to the treatment, defined as a reduction of a person's HAM-D score by 50%.	[Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Engmann, Clara; Egan, Matthew; Ambrose, Felicia; Greenwald, Brian] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Flanagan, Steve] NYU, Rusk Inst Reliabil Med, New York, NY USA; [Ginsberg, Annika] NYU, Sch Med, Inst Canc, New York, NY USA	Ashman, TA (corresponding author), Mt Sinai Sch Med, Dept Rehabil, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013	Flanagan, Steven/0000-0001-9005-5897			Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Almeida OP, 2006, J CLIN PSYCHIAT, V67, P1104, DOI 10.4088/JCP.v67n0713; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andrews F. M., 1976, SOCIAL INDICATORS WE; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BECH P, 1984, PSYCHOPHARMACOLOGY, V84, P276, DOI 10.1007/BF00427459; Beck A. T., 1996, BECK DEPRESSION INVE; Beck A.T., 1993; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Booth BM, 1998, J PSYCHIAT RES, V32, P353, DOI 10.1016/S0022-3956(98)00031-4; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bowman ES, 2000, B MENNINGER CLIN, V64, P164; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Burns A, 1999, INT J GERIATR PSYCH, V14, P681, DOI 10.1002/(SICI)1099-1166(199908)14:8<681::AID-GPS49>3.0.CO;2-Z; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Cipriani A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004185.pub2; Davidson JRT, 2006, J CLIN PSYCHIAT, V67, P34; Deb S, 1999, AM J PSYCHIAT, V156, P374; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; Diggle P., 2002, ANAL LONGITUDINAL DA; Dijkers M., 2002, QUAL LIFE RES, V11, P672; Fach M, 2007, GEN HOSP PSYCHIAT, V29, P257, DOI 10.1016/j.genhosppsych.2007.01.016; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faries D, 2000, J PSYCHIAT RES, V34, P3, DOI 10.1016/S0022-3956(99)00037-0; FARM JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M., 1997, USERS GUIDE STRUCTUR; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; GIBBONS RD, 1993, J PSYCHIAT RES, V27, P259, DOI 10.1016/0022-3956(93)90037-3; Givens JL, 2007, GEN HOSP PSYCHIAT, V29, P182, DOI 10.1016/j.genhosppsych.2006.11.002; Glenn MB, 2005, J HEAD TRAUMA REHAB, V20, P51, DOI 10.1097/00001199-200501000-00006; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Goodnick P J, 2000, Expert Opin Pharmacother, V1, P1367, DOI 10.1517/14656566.1.7.1367; Greenberg PE, 2003, J CLIN PSYCHIAT, V64, P1465, DOI 10.4088/JCP.v64n1211; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jones JE, 2005, EPILEPSIA, V46, P731, DOI 10.1111/j.1528-1167.2005.49704.x; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kamijima Kunitoshi, 2006, Expert Rev Neurother, V6, P945, DOI 10.1586/14737175.6.7.945; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Maier W, 1990, Psychopharmacol Ser, V9, P64; MAIER W, 1988, J PSYCHIAT RES, V22, P13, DOI 10.1016/0022-3956(88)90023-4; MAIER W, 1988, J PSYCHIAT RES, V22, P3, DOI 10.1016/0022-3956(88)90022-2; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Murray V, 2005, J CLIN PSYCHIAT, V66, P708, DOI 10.4088/JCP.v66n0606; *NIH, 1998, NIH CONSENSUS STATEM, V16; O'Shanick GJ, 2006, J HEAD TRAUMA REHAB, V21, P282, DOI 10.1097/00001199-200605000-00009; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rasmussen A, 2003, PSYCHOSOMATICS, V44, P216, DOI 10.1176/appi.psy.44.3.216; REHM LP, 1985, J PSYCHIAT RES, V19, P31, DOI 10.1016/0022-3956(85)90066-4; Robins L, 1991, PSYCHIAT DISORDERS A; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satcher D, 2001, MENTAL HLTH CULTURE; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SEGAL DL, 1994, COMPR PSYCHIAT, V35, P316, DOI 10.1016/0010-440X(94)90025-6; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; Spalletta G, 2006, AM J GERIAT PSYCHIAT, V14, P220, DOI 10.1097/01.JGP.0000194647.72654.a1; Spalletta G, 2003, FUNCT NEUROL, V18, P227; Spalletta G, 2003, J NEUROL, V250, P449, DOI 10.1007/s00415-003-1023-2; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Turner-Stokes L, 2002, CLIN REHABIL, V16, P248, DOI 10.1191/0269215502cr488oa; Turner-Stokes L, 2005, CLIN MED, V5, P268, DOI 10.7861/clinmedicine.5-3-268; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wang JL, 2007, CURR MED RES OPIN, V23, P853, DOI 10.1185/030079907X182220; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006	88	86	86	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2009	90	5					733	740		10.1016/j.apmr.2008.11.005			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	443ZS	WOS:000265949900004	19406291				2021-06-18	
J	Appelberg, KS; Hovda, DA; Prins, ML				Appelberg, K. Sofia; Hovda, David A.; Prins, Mayumi L.			The Effects of a Ketogenic Diet on Behavioral Outcome after Controlled Cortical Impact Injury in the Juvenile and Adult Rat	JOURNAL OF NEUROTRAUMA			English	Article						behavior; ketone metabolism; Morris water maze; traumatic brain injury	TRAUMATIC BRAIN-INJURY; KETONE-BODY UTILIZATION; OXYGEN SPECIES PRODUCTION; BETA-HYDROXYBUTYRATE; GLUCOSE-UTILIZATION; METABOLISM; BODIES; CORTEX; ENZYMES; MCT1	The ketogenic diet has been shown to have unique properties that make it a more suitable cerebral fuel under various neuropathological conditions (e.g., starvation, ischemia, and traumatic brain injury (TBI). Recently, age-dependent ketogenic neuroprotection was shown among postnatal day 35 (PND35) and PND45 rats after TBI, but not in PND17 and PND65 animals (Prins et al., 2005). The present study addresses the therapeutic potential of a ketogenic diet on motor and cognitive deficits after TBI. PND35 and PND75 rats received sham or controlled cortical impact (CCI) surgery and were placed on either standard (Std) or ketogenic (KG) diet for 7 days. Beam walking and the Morris water maze (MWM) were used to assess sensory motor function and cognition, respectively. PND35 CCI Std animals showed significantly longer traverse times than sham and CCI KG animals at the beginning of motor training. Footslip analysis revealed better performance among the sham and the CCI KG animals compared to the CCI Std group. In the MWM PND35 CCI KG animals showed significantly shorter escape latencies compared to CCI Std-fed animals. During the same time period there was no significant difference between sham animals and CCI KG animals. The therapeutic effect of the ketogenic diet on beam walking and cognitive performance was not observed in PND75 animals. This finding supports our theory about age-dependent utilization and effectiveness of ketones as an alternative fuel after TBI.	[Appelberg, K. Sofia; Hovda, David A.; Prins, Mayumi L.] Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA	Prins, ML (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Room NPI 18-228,Box 957039, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	UCLA Brain Injury Research Center;  [NS052406]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052406] Funding Source: NIH RePORTER	This work was supported by NS052406 and the UCLA Brain Injury Research Center.	Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; CREMER JE, 1976, BIOCHIM BIOPHYS ACTA, V448, P633, DOI 10.1016/0005-2736(76)90120-6; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gerhart DZ, 1997, AM J PHYSIOL-ENDOC M, V273, pE207; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hasselbalch SG, 1996, AM J PHYSIOL-ENDOC M, V270, pE746; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Leino RL, 2001, NEUROCHEM INT, V38, P519, DOI 10.1016/S0197-0186(00)00102-9; Leino RL, 1999, DEV BRAIN RES, V113, P47, DOI 10.1016/S0165-3806(98)00188-6; LOCKWOOD EA, 1971, BIOCHEM J, V124, P249, DOI 10.1042/bj1240249; Lust WD, 2003, METAB BRAIN DIS, V18, P195, DOI 10.1023/A:1025503115837; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; MARIE C, 1990, METAB BRAIN DIS, V5, P65, DOI 10.1007/BF01001047; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murphy P, 2006, EXP NEUROL, V201, P84, DOI 10.1016/j.expneurol.2006.03.024; NEHLIG A, 1991, NEUROSCIENCE, V40, P871, DOI 10.1016/0306-4522(91)90018-J; NEHLIG A, 1987, NEUROCHEM RES, V12, P641, DOI 10.1007/BF00971014; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; PAGE MA, 1971, BIOCHEM J, V121, P49, DOI 10.1042/bj1210049; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins M, 2007, J NEUROTRAUM, V24, P1267; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; ROBERTSON C, 1992, STROKE, V23, P564, DOI 10.1161/01.STR.23.4.564; SATO K, 1995, FASEB J, V9, P651; SAUDUBRAY JM, 1981, J PEDIATR-US, V98, P904, DOI 10.1016/S0022-3476(81)80583-5; SOKOLOFF L, 1973, ANNU REV MED, V24, P271, DOI 10.1146/annurev.me.24.020173.001415; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Vannucci RC, 2000, SEMIN PERINATOL, V24, P107, DOI 10.1053/sp.2000.6361; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; Veech RL, 2001, IUBMB LIFE, V51, P241; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhao Q, 2004, PEDIATR RES, V55, P498, DOI 10.1203/01.PDR.0000112032.47575.D1; Ziegler DR, 2005, PHYSIOL BEHAV, V84, P421, DOI 10.1016/j.physbeh.2005.01.003; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399	53	86	86	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					497	506		10.1089/neu.2008.0664			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300003	19231995	Green Published			2021-06-18	
J	Sayeed, I; Parvez, S; Wali, B; Siemen, D; Stein, DG				Sayeed, Iqbal; Parvez, Suhel; Wali, Bushra; Siemen, Detlef; Stein, Donald G.			Direct inhibition of the mitochondrial permeability transition pore: A possible mechanism for better neuroprotective effects of allopregnanolone over progesterone	BRAIN RESEARCH			English	Article						Progesterone; Allopregnanolone; Traumatic brain injury; Stroke; Patch clamp; Single channel; Cytochrome c release	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; METHYL-D-ASPARTATE; CYTOCHROME-C; CYCLOSPORINE-A; CELL-DEATH; APOPTOTIC PATHWAYS; REPERFUSION INJURY; DOSE-RESPONSE	We previously demonstrated that the progesterone (PROG) metabolite allopregnanolone (AP) is more potent than FROG in the treatment of traumatic brain injury (TBI) and stroke, but the mechanisms for this differential effect are little understood. The mitochondrial permeability transition pore (mtPTP) appears to be a key player in the intrinsic pathway of apoptosis-induced loss of neurons. Its activation is accompanied by the release of cytochrome c (cyt c) from the intermembrane gap and subsequent cell death. We investigated whether mtPTP is implicated in the mechanisms of PROG and AP neuroprotection following traumatic and ischemic brain injury. To assess the neurosteroids' direct effects on mtPTP activity at the single-channel level, recordings from the inner mitochondrial membrane were obtained by a patch-clamp approach in rat liver mitoplasts. AP but not PROG strongly inhibited mtPTP currents. Interaction of AP with the PTP was further supported by a swelling assay demonstrating that AP inhibited Ca2+-triggered swelling in functionally intact rat liver and brain mitochondria. If AP inhibits the mtPTP, it should prevent the mitochondrial cyt c release seen in stroke and TBI. To test this idea, we subjected one group of rats to cortical contusion injury (CCI) and another to transient middle cerebral artery occlusion (MCAO). AP-treated animals showed substantially decreased cyt c release and AP was more potent than PROG in inhibiting mitochondrial cyt c release at 24 h post-CCI and -MCAO. Our results demonstrate that AP inhibits the mtPTP current. This may help to explain its more potent anti-apoptotic and neuroprotective effects compared to FROG. (C) 2009 Elsevier B.V. All rights reserved.	[Sayeed, Iqbal; Wali, Bushra; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA; [Parvez, Suhel; Siemen, Detlef] Otto VonGuericke Univ Magdegurg, Dept Neurol, D-39120 Magdeburg, Germany; [Parvez, Suhel] Leibniz Inst Neurobiol, Dept Neurophysiol, D-39118 Magdeburg, Germany	Sayeed, I (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, 1365 B Clifton Rd,Suite 5100, Atlanta, GA 30322 USA.	isayeed@emory.edu	Parvez, Suhel/E-6778-2010; Stein, Donald/AAJ-5139-2020	Parvez, Suhel/0000-0002-6318-6506; 	National institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS04851]; Alexander von Humboldt FoundationAlexander von Humboldt Foundation	We acknowledge Leslie McCann for her help in manuscript preparation. This work was supported by National institutes of Health Grant R01 NS04851. S.P. was supported by a senior fellowship from Alexander von Humboldt Foundation.	Andersson S, 1997, STEROIDS, V62, P143, DOI 10.1016/S0039-128X(96)00173-0; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Andrabi SA, 2004, BRAIN RES, V1017, P98, DOI 10.1016/j.brainres.2004.05.038; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; COMPAGNONE NA, 1995, ENDOCRINOLOGY, V136, P2689, DOI 10.1210/en.136.6.2689; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Di Lisa F, 2003, BASIC RES CARDIOL, V98, P235, DOI 10.1007/s00395-003-0415-x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DJEBAILI MJ, 2002, J NEUROTRAUM, V19, P1287; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; GIESELER A, 2008, BIOCH PHARM; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Johansson IM, 2002, BRAIN RES, V934, P125, DOI 10.1016/S0006-8993(02)02414-9; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Liu W, 2001, BRAIN RES, V916, P239, DOI 10.1016/S0006-8993(01)03006-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Loupatatzis C, 2002, CELL PHYSIOL BIOCHEM, V12, P269, DOI 10.1159/000067897; Mahesh VB, 1996, J STEROID BIOCHEM, V56, P209, DOI 10.1016/0960-0760(95)00238-3; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Sayeed I, 2006, FASEB J, V20, P556, DOI 10.1096/fj.05-4748fje; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Tatton WG, 1998, ANN NEUROL, V44, pS134, DOI 10.1002/ana.410440720; Timby E, 2006, PSYCHOPHARMACOLOGY, V186, P414, DOI 10.1007/s00213-005-0148-7; Walf AA, 2006, NEUROBIOL LEARN MEM, V86, P35, DOI 10.1016/j.nlm.2006.01.004; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang XD, 2001, GENE DEV, V15, P2922; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Youdim MBH, 2005, J NEUROSCI RES, V79, P172, DOI 10.1002/jnr.20350; Zhu D, 2004, BRIT J ANAESTH, V93, P560, DOI 10.1093/bja/aeh233	75	86	96	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 31	2009	1263						165	173		10.1016/j.brainres.2009.01.045			9	Neurosciences	Neurosciences & Neurology	431CV	WOS:000265039800018	19368823				2021-06-18	
J	Hemphill, JC; White, DB				Hemphill, J. Claude, III; White, Douglas B.			Clinical Nihilism in Neuroemergencies	EMERGENCY MEDICINE CLINICS OF NORTH AMERICA			English	Article						Prognosis; Do-not-resuscitate; Withdrawal of support; Intracerebral hemorrhage; Traumatic brain injury	INTENSIVE-CARE-UNIT; NOT-RESUSCITATE ORDERS; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; SEVERE HEAD-INJURY; OF-LIFE CARE; COMATOSE SURVIVORS; AMERICAN-ACADEMY; CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; TREATMENT PREFERENCES	Mortality and morbidity remain high from neurologic emergencies, such as acute stroke, traumatic brain injury, and hypoxic-ischemic encephalopathy after cardiac arrest. Decisions regarding initial aggressiveness of care must be made at the time of presentation, and perceived prognosis is often used as part of this decision-making process. These decisions are predicated on the accuracy of early outcome prediction, however. Decisions to limit treatment early after neuroemergencies must be balanced with avoidance of self-fulfilling prophecies of poor outcome attributable to clinical nihilism. This article examines the role of prognostication early after neuroemergencies, the potential impact of early treatment limitations, and how these may relate to communication with patients and surrogate decision makers in the context of these acute neurologic events.	[Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Neurocrit Care Program, San Francisco Gen Hosp, San Francisco, CA 94110 USA; [White, Douglas B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; [White, Douglas B.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94110 USA; [White, Douglas B.] Univ Calif San Francisco, San Francisco, CA 94143 USA	Hemphill, JC (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco Gen Hosp, Room 4M62,1001 Potrero Ave, San Francisco, CA 94110 USA.	chemphill@sfgh.ucsf.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS41240, U10NS058931, KL2RR024130]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041240, U10NS058931] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) grants K23NS41240 and U10NS058931 (JCH) and grant KL2RR024130 from the National Center for Research Resources, a component of the NIH and NIH Roadmap for Medical Research (DBW).	Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Danis M, 1997, CRIT CARE MED, V25, P887; Danis M, 1998, NEW HORIZ-SCI PRACT, V6, P110; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Flibotte JJ, 2004, NEUROLOGY, V63, P1059, DOI 10.1212/01.WNL.0000138428.40673.83; Frick S, 2003, CRIT CARE MED, V31, P456, DOI 10.1097/01.CCM.0000049945.69373.7C; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; Gregson BA, 2003, STROKE, V34, P2593, DOI 10.1161/01.STR.0000097491.82104.F3; Hemphill JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5687; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Holzer M, 2002, NEW ENGL J MED, V346, P549; Johnston SC, 2000, MUSCLE NERVE, V23, P839, DOI 10.1002/(SICI)1097-4598(200006)23:6<839::AID-MUS1>3.0.CO;2-V; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; Levy MM, 2006, CRIT CARE MED, V34, pS306, DOI 10.1097/01.CCM.0000246096.18214.79; LISK DR, 1994, NEUROLOGY, V44, P133, DOI 10.1212/WNL.44.1.133; Lloyd CB, 2004, CRIT CARE MED, V32, P649, DOI 10.1097/01.CCM.0000115636.29294.2F; Luce JM, 2002, AM J RESP CRIT CARE, V165, P750, DOI 10.1164/ajrccm.165.6.2109045; Lyden PD, 2007, STROKE, V38, P2262, DOI 10.1161/STROKEAHA.106.472746; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mendelow AD, 2005, LANCET, V365, P387; Merton Robert K., 1968, SOCIAL THEORY SOCIAL, P477; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; Rocker G, 2004, CRIT CARE MED, V32, P1149, DOI 10.1097/01.CCM.0000126402.51524.52; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; Shepardson LB, 1999, J GEN INTERN MED, V14, P15, DOI 10.1046/j.1525-1497.1999.00275.x; Shepardson LB, 1997, ARCH INTERN MED, V157, P1841, DOI 10.1001/archinte.157.16.1841; TERES D, 1993, CRIT CARE MED, V21, P598, DOI 10.1097/00003246-199304000-00022; THOMAS W.I., 1928, CHILD AM, P572; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; TUHRIM S, 1995, CRIT CARE MED, V23, P950, DOI 10.1097/00003246-199505000-00026; Vetsch G, 2002, SWISS MED WKLY, V132, P190; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Zahuranec DB, 2007, NEUROLOGY, V68, P1651, DOI 10.1212/01.wnl.0000261906.93238.72; Zier LS, 2008, CRIT CARE MED, V36, P2341, DOI 10.1097/CCM.0b013e318180ddf9; Zurasky JA, 2005, NEUROLOGY, V64, P725, DOI 10.1212/01.WNL.0000152045.56837.58	50	86	87	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8627			EMERG MED CLIN N AM	Emerg. Med. Clin. N. Am.	FEB	2009	27	1					27	+		10.1016/j.emc.2008.08.009			13	Emergency Medicine	Emergency Medicine	420MC	WOS:000264292900005	19218017	Green Accepted			2021-06-18	
J	Sherer, M; Struchen, MA; Yablon, SA; Wang, Y; Nick, TG				Sherer, M.; Struchen, M. A.; Yablon, S. A.; Wang, Y.; Nick, T. G.			Comparison of indices of traumatic brain injury severity: Glasgow Coma Scale, length of coma and post-traumatic amnesia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; OUTCOMES; PROGRAM; PREDICTION; MANAGEMENT; VARIABLES; RECOVERY; MODERATE; MODEL; TREE	Background: Classification of traumatic brain injury (TBI) severity guides management and contributes to determination of prognosis. Common indicators of TBI severity include Glasgow Coma Scale (GCS) scores, length of coma (LOC) and duration of post-traumatic amnesia (PTA). Objective: To compare GCS, LOC and PTA by examining distributions and intercorrelations and develop multivariable linear regression models for estimating LOC and PTA duration. Methods: Prospective study of 519 of 614 consecutive patients with TBI. Indices of TBI severity studied were GCS, LOC, PTA and PTA-LOC (the interval from return of command-following to return of orientation). Candidate predictor variables for estimation of LOC, PTA and PTA LOC intervals were age, years of education, year of injury (before 1997 vs 1997 or later), GCS, LOC (for PTA and PTA-LOC), pupillary responsiveness, type of injury, CT pathology and intracranial operations. Results: Although there was a severity/response relationship between GCS and LOC, PTA and PTA-LOC intervals, there was overlap in these intervals between GCS severity categories. Age, year of injury, GCS, pupillary responsiveness and CT pathology were predictive of LOC. Age, years of education, year of injury, GCS, LOC, pupillary responsiveness and intracranial operations were predictive of PTA duration. Age, years of education, year of injury, GCS, LOC and pupillary responsiveness were predictive of PTA-LOC. GCS and LOC effects were influenced by age. Conclusions: Predictors for estimating LOC, PTA and PTA-LOC intervals were determined and simple equations were developed. These equations will be helpful to clinicians, researchers and those counselling family members of patients with TBI.	[Sherer, M.; Struchen, M. A.] Mem Hermann TIRR, Dept Res, Houston, TX 77030 USA; [Sherer, M.; Struchen, M. A.] Baylor Coll Med, Houston, TX 77030 USA; [Yablon, S. A.] Methodist Rehabil Ctr, Jackson, MS USA; [Yablon, S. A.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Wang, Y.; Nick, T. G.] Cincinnati Childrens Hosp, Ctr Med, Ctr Biostat & Epidemiol, Cincinnati, OH USA; [Nick, T. G.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Sherer, M (corresponding author), Mem Hermann TIRR, Dept Res, 1333 Moursund, Houston, TX 77030 USA.	Sherer@memorialhermann.org					ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; [Anonymous], 2000, J Neurotrauma, V17, P563; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Bland JM, 1998, BRIT MED J, V317, P1572, DOI 10.1136/bmj.317.7172.1572; BULLOCK R, 1995, GUIDELINES MANAGEMEN; Capruso D. X., 2000, HEAD INJURY, P525; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELANEY KA, 2000, HEAD INJURY, P41; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EISENBERG HM, 1987, NEUROBEHAVIORAL RECO, P13; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Huang L, 2007, COMPUT METH PROG BIO, V86, P45, DOI 10.1016/j.cmpb.2006.12.005; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LAWLESS JF, 1978, BIOMETRICS, V34, P318, DOI 10.2307/2530022; Lehr D, 1997, J TRAUMA, V42, pS71, DOI 10.1097/00005373-199705001-00015; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SMITH PJ, 2004, INT J RELIABILITY QU, V11, P163; Stare J, 2001, COMPUT METH PROG BIO, V64, P45, DOI 10.1016/S0169-2607(00)00083-3; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Valadka AB, 1996, NEUROTRAUMA, P119; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	40	86	86	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2008	79	6					678	685		10.1136/jnnp.2006.111187			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	302FS	WOS:000255954800016	17928328				2021-06-18	
J	Inaba, K; Teixeira, PG; David, JS; Chan, LS; Salim, A; Brown, C; Browder, T; Beale, E; Rhee, P; Demetriades, D				Inaba, Kenji; Teixeira, Pedro Gr; David, Jean-Stephane; Chan, Linda S.; Salim, Ali; Brown, Carlos; Browder, Timothy; Beale, Elizabeth; Rhee, Peter; Demetriades, Demetrios			Beta-blockers in isolated blunt head injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							TRAUMATIC BRAIN-INJURY; ADULT BURN PATIENTS; IMPROVED OUTCOMES; MYOCARDIAL DAMAGE; IMPROVED SURVIVAL; NERVOUS-SYSTEM; BLOCKADE; CATECHOLAMINES; HEMORRHAGE; PROPRANOLOL	BACKGROUND: The purpose of this study was to evaluate the effect of beta-blockers on patients sustaining acute traumatic brain injury. Our hypothesis was that beta-blocker exposure is associated with improved survival. STUDY DESIGN: The trauma registry and the surgical ICU databases of an academic Level I trauma center were used to identify all patients sustaining blunt head injury requiring ICU admission from July 1998 to December 2005. Patients sustaining major associated injuries (Abbreviated Injury Score >= 4 in any body region other than the head) were excluded. Patient demographics, injury profile, Injury Severity Score, and beta-blocker exposure were abstracted. The primary outcomes measure evaluated was in-hospital mortality. RESULTS: During the 90-month study period, 1, 156 patients with isolated head injury were admitted to the ICU. Of these, 203 (18%) received beta-blockers and 953 (82%) did not. Patients receiving beta-blockers were older (50 +/- 21 years versus 38 +/- 20 years, p < 0.001), had more frequent severe (Abbreviated Injury Score 4) head injury (54% versus 43%, p < 0.01), Glasgow Coma Scale <= 8 less often (37% versus 47%, P=0.01), more skull fractures (20% versus 12%, p < 0.01), and underwent craniectomy more frequently (23% versus 4%, p < 0.001). Stepwise logistic regression identified beta-blocker use as an independent protective factor for mortality (adjusted odds ratio: 0.54; 95% CI, 0.33 to 0.91; p=0.01). On subgroup analysis, elderly patients (55 years or older) with severe head injury (Abbreviated Injury Score >= 4) had a mortality of 28% on beta-blockers as compared with 60% when they did not receive them (odds ratio: 0.3; 96% CI, 0.1 to 0.6; p=0.001). CONCLUSIONS: Beta-blockade in patients with traumatic brain injury was independently associated with improved survival. Older patients with severe head injuries demonstrated the largest reduction in mortality with beta-blockade.	[Inaba, Kenji; Teixeira, Pedro Gr; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Dept Surg, Div Trauma Surg & Surg Crit Care, Los Angeles, CA 90033 USA; [Chan, Linda S.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033 USA; [Chan, Linda S.] Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90033 USA; [Chan, Linda S.] Univ So Calif, Keck Sch Med, Dept Emergency Med, Los Angeles, CA 90033 USA; [Beale, Elizabeth] Univ So Calif, Keck Sch Med, Div Endocrinol, Dept Med, Los Angeles, CA 90033 USA; [David, Jean-Stephane] Univ Lyon 1, Dept Anesthesia & Crit Care, F-69365 Lyon, France; [Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; [Brown, Carlos] Univ Texas Austin, Med Branch, Dept Surg, Brackenridge Hosp, Austin, TX USA; [Browder, Timothy] Univ Nevada, Sch Med, Div Trauma & Surg Crit Care, Las Vegas, NV 89154 USA; Univ Arizona, Div Trauma Surg Crit Care & Emergency Surg, Tucson, AZ USA	Inaba, K (corresponding author), Univ So Calif, Div Trauma Surg & Surg Crit Care, LAC Med Ctr, 1200 N State St,Room 10-750, Los Angeles, CA 90033 USA.		David, Jean Stephane/H-9399-2019; INABA, KENJI/AAC-8532-2020; Teixeira, Pedro/H-2239-2011	David, Jean Stephane/0000-0001-6274-7044; Teixeira, Pedro/0000-0002-7258-7977			ALEXANDER RW, 1975, NATURE, V258, P437, DOI 10.1038/258437a0; Amory DW, 2002, J CARDIOTHOR VASC AN, V16, P270, DOI 10.1053/jcan.2002.124132; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; *CDC, 2003, MMWR-MORBID MORTAL W, V56, P167; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Enderson BL, 2007, J TRAUMA, V62, P33; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P115, DOI 10.1007/BF00571658; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAWKINS WE, 1971, CARDIOVASC RES, V5, P524, DOI 10.1093/cvr/5.4.524; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P489; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Martin M, 2005, J TRAUMA, V59, P1086, DOI 10.1097/01.ta.0000190249.19668.37; MEYR JS, 1976, STROKE, V7, P145; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; Pryor JP, 2007, J TRAUMA, V62, P61; Simon RJ, 2004, J TRAUMA, V56, P269; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875	28	86	87	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	MAR	2008	206	3					432	438		10.1016/j.jamcollsurg.2007.10.005			7	Surgery	Surgery	271LR	WOS:000253790400005	18308212				2021-06-18	
J	Delaney, JS; Al-Kashmiri, A; Drummond, R; Correa, JA				Delaney, J. S.; Al-Kashmiri, A.; Drummond, R.; Correa, J. A.			The effect of protective headgear on head injuries and concussions in adolescent football (soccer) players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; UNIVERSITY FOOTBALL; ICE HOCKEY; PREVALENCE; MECHANISMS; COLLEGIATE; STATES; SPORT; RISK	Objective: To examine the effects of protective headgear in adolescent football (soccer) players. Design: Cross-sectional study. Setting: Oakville Soccer Club, Oakville, Canada. Participants: Football players aged 12-17 years. Intervention: A questionnaire examining the 2006 football season using self-reported symptoms. Main outcome measures: The number of concussions experienced during the current football season, the duration of symptoms, injuries to the head and face and any associated risk factors for these injuries. Results: In the population studied, 47.8% had experienced symptoms of a concussion during the current football year. 26.9% of athletes who wore headgear (HG) and 52.8% of those who did not wear headgear (No-HG) had concussions. Approximately 4 out of 5 athletes in each group did not realize they had suffered a concussion. More than one concussion was experienced by 50.0% of the concussed HG athletes and 69.3% of the concussed No-HG group. 23.9% of all concussed players experienced symptoms for at least 1 day or longer. Variables that increased the risk of suffering a concussion during the 2006 football year included being female and not wearing headgear. Being female and not wearing football headgear increased the risk of suffering an abrasion, laceration or contusion on areas of the head covered by football headgear. Conclusion: Adolescent football players experience a significant number of concussions. Being female may increase the risk of suffering a concussion and injuries on the head and face, while the use of football headgear may decrease the risk of sustaining these injuries.	[Delaney, J. S.] McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; [Delaney, J. S.; Drummond, R.] McGill Univ, Ctr Hlth, Dept Emergency Med, Montreal, PQ, Canada; [Correa, J. A.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada	Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.	j.delaney@mcgill.ca	Al-Kashmiri, Ammar/AAG-4008-2020				Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth J T, 2000, Dent Clin North Am, V44, P67; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney J Scott, 2005, Clin J Sport Med, V15, P216, DOI 10.1097/01.jsm.0000168077.74497.a4; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; JANDA DH, 1995, AM J SPORT MED, V23, P340, DOI 10.1177/036354659502300316; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; *PED AAO, 2000, PEDIATRICS, V105, P659; *PED TAAO, 1988, PHYSICIAN SPORTSMED, V16, P165; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; STENGER J M, 1987, Basal Facts, V9, P133; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; WITHNALL C, 2005, BR J SPORTS MED S1, V39, P48; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	44	86	86	0	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2008	42	2					110	115		10.1136/bjsm.2007.037689			6	Sport Sciences	Sport Sciences	259RU	WOS:000252957200006	17615173				2021-06-18	
J	Shichinohe, H; Kuroda, S; Yano, S; Hida, K; Iwasaki, Y				Shichinohe, Hideo; Kuroda, Satoshi; Yano, Shunsuke; Hida, Kazutoshi; Iwasaki, Yoshinobu			Role of SDF-1/CXCR4 system in survival and migration of bone marrow stromal cells after transplantation into mice cerebral infarct	BRAIN RESEARCH			English	Article						bone marrow stromal cell; cerebral infarct; stromal derived factor-1; CXCR4; migration; transplantation	TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; SDF-1 CXCL12; IN-VITRO; STROKE; RAT; EXPRESSION; ASTROCYTES; CXCR4	Recent studies have indicated that bone marrow stromal cells (BMSC) have the potential to improve neurological function when transplanted into animal models of cerebral infarction. However, it is still obscure how the transplanted BMSC restore the lost neurological function. in this study, therefore, we aimed to elucidate the role of stromal cell-derived factor-1 (SDF-1) and its specific receptor, CXCR4, in BMSC transplantation into the brain subjected to cerebral infarction. The BMSC were harvested from the wild type (WT) and CXCR4-knockout (CXCR4-KO) mice and were cultured. The mice were subjected to permanent middle cerebral artery occlusion. The WT or CXCR4-KO BMSC was injected into the ipsilateral striatum 7 days after the insult. Motor function of the animals was serially evaluated, using a rotarod treadmill. Using fluorescence immunohistochemistry, we evaluated the distribution and phenotype of the transplanted cells 4 weeks after transplantation. Recovery of motor function in the WT BMSC-transplanted mice was more pronounced than in the CXCR4-KO-transplanted mice and the vehicle-treated ones. SDF-1 was extensively expressed in peri-infarct area. In the WT BMSC-transplanted mice, the transplanted cells were extensively distributed in the ipsilateral hemisphere, and many of them migrated towards the peri-infarct area and expressed the proteins specific for neurons and astrocytes, although these findings were not observed in the CXCR4-KO-transplanted mice. The results suggest that the SDF-1/CXCR4 system may play a critical role in the survival, proliferation and migration of the transplanted BMSC and contribute to recovery of neurological function. (c) 2007 Elsevier B.V. All rights reserved.	[Shichinohe, Hideo; Kuroda, Satoshi; Yano, Shunsuke; Hida, Kazutoshi; Iwasaki, Yoshinobu] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Shichinohe, H (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, N 15 W 7, Sapporo, Hokkaido 0608638, Japan.	hshichi@stanford.edu	Shichinohe, Hideo/G-5367-2012		Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591572] Funding Source: KAKEN		Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Borlongan CV, 2004, BRAIN RES, V1010, P108, DOI 10.1016/j.brainres.2004.02.072; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Guillemin GJ, 2003, GLIA, V41, P371, DOI 10.1002/glia.10175; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012; Lazarini F, 2003, GLIA, V42, P139, DOI 10.1002/glia.10139; Lee JB, 2004, BRAIN RES PROTOC, V14, P37, DOI 10.1016/j.brainresprot.2004.09.004; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Miller JT, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-63; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Pujol F, 2005, J CELL SCI, V118, P1071, DOI 10.1242/jcs.01694; Shichinohe H, 2004, BRAIN RES PROTOC, V13, P166, DOI 10.1016/j.brainresprot.2004.04.004; Shichinohe H, 2004, BRAIN RES, V1001, P51, DOI 10.1016/j.brainres.2003.11.054; Shichinohe H, 2006, J NUCL MED, V47, P486; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Stumm RK, 2003, J NEUROSCI, V23, P5123; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Wang Lei, 2002, Hematology, V7, P113; Yamaguchi S, 2006, BRAIN RES, V1087, P15, DOI 10.1016/j.brainres.2006.02.127; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	35	86	98	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 5	2007	1183						138	147		10.1016/j.brainres.2007.08.091			10	Neurosciences	Neurosciences & Neurology	244NC	WOS:000251871600014	17976542				2021-06-18	
J	Ponsford, J; Whelan-Goodinson, R; Bahar-Fuchs, A				Ponsford, Jennie; Whelan-Goodinson, Rochelle; Bahar-Fuchs, Alex			Alcohol and drug use following traumatic brain injury: A prospective study	BRAIN INJURY			English	Article						alcohol; drug use; traumatic brain injury	SUBSTANCE-ABUSE; DISORDERS; REHABILITATION; VALIDITY; MISUSE; LEVEL	Primary objectives: To establish pre-morbid alcohol and drug use in persons with TBI, relative to controls, investigate how patterns of substance use change over time following TBI and identify factors associated with heavy post-injury substance use. Methods and procedures: The Alcohol Use Disorders Identification test (AUDIT) and Drug Abuse Screening Test (DAST) was completed by 121 hospital inpatients with TBI, documenting pre-injury alcohol and drug use, and 133 demographically similar controls. Participants with TBI completed these measures and the Hospital Anxiety and Depression Scale (HADS) again 1 and 2 years post-injury and 76 also completed them at 3 years. Results: Participants with TBI showed similar levels of drug and alcohol use to controls pre-injury, with 31.4% of the TBI group and 29.3% of controls drinking at hazardous levels. Alcohol and drug use declined in the first year post-injury, but increased by 2 years post-injury, with only 21.4% of participants with TBI reporting abstinence from alcohol and 25.4% drinking at hazardous levels. Only 9% showed a drug problem, but 24% had returned to some drug use. Those showing heavy alcohol use post-injury were young, male and heavy drinkers pre-injury. Drug and alcohol use was similar at 3 years post-injury. Conclusions: More active intervention is needed to reduce alcohol and drug use following TBI.	[Ponsford, Jennie; Whelan-Goodinson, Rochelle; Bahar-Fuchs, Alex] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Dept Psychol, Richmond, Vic 3121, Australia; [Ponsford, Jennie; Whelan-Goodinson, Rochelle; Bahar-Fuchs, Alex] Monash Univ, Clayton, Vic 3168, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Dept Psychol, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@med.monash.edu.au		Bahar-Fuchs, Alex/0000-0002-9248-6057			Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Drubach D A, 1993, Md Med J, V42, P989; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Skinner HA, 1982, DRUG ABUSE SCREENING; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336	30	86	86	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1385	1392		10.1080/02699050701796960			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200006	18066940				2021-06-18	
J	Soane, L; Kahraman, S; Kristian, T; Fiskum, G				Soane, Lucian; Kahraman, Sibel; Kristian, Tibor; Fiskum, Gary			Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neuro degenerative disorders	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article; Proceedings Paper	7th International Conference on Brain Energy Metabolism	AUG 15-18, 2006	Ecole Polytech Fed Lausanne, Lausanne, SWITZERLAND		Ecole Polytech Fed Lausanne	PARP-1; nitric oxide; calcium; apoptosis; mitochondrial permeability transition	PERMEABILITY TRANSITION PORE; MAGNETIC-RESONANCE-SPECTROSCOPY; TRANSIENT FOCAL ISCHEMIA; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; CELL-DEATH; CYCLOSPORINE-A; CYCLOPHILIN-D; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS	Altered mitochondrial energy metabolism contributes to the pathophysiology of acute brain injury caused by ischemia, trauma, and neurotoxins and by chronic neurodegenerative disorders such as Parkinson's and Huntington's diseases. Although much evidence supports that the electron transport chain dysfunction in these metabolic abnormalities has both genetic and intracellular environmental causes, alternative mechanisms are being explored. These include direct, reversible inhibition of cytochrome oxidase by nitric oxide, release of mitochondrial cytochrome c, oxidative inhibition of mitochondrial matrix dehydrogenases and adenine nucleotide transport, the availability of NAD for dehydrogenase reactions, respiratory uncoupling by activities such as that of the permeability transition pore, and altered mitochondrial structure and intracellular trafficking. This review focuses on the catabolism of neuronal NAD and the release of neuronal mitochondrial NAD as important contributors to metabolic dysfunction. In addition, the relationship between apoptotic signaling cascades and disruption of mitochondrial energy metabolism is considered in light of the fine balance between apoptotic and necrotic neural cell death. (c) 2007 Wiley-Liss, Inc.	Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA	Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 W Baltimore St,MSTF 5-34, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu	Kristian, Tibor/I-5697-2019; Kristian, Tibor/U-6497-2019		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD016596-240013, HD16596, P01 HD016596] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07375, R01 NS034152, R01 NS034152-12, R21 NS050653, NS34152, NS050653, T32 NS007375] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007375, R21NS050653, R01NS034152] Funding Source: NIH RePORTER		Aksoy P, 2006, BIOCHEM BIOPH RES CO, V345, P1386, DOI 10.1016/j.bbrc.2006.05.042; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Albrecht J, 2006, HEPATOLOGY, V44, P788, DOI 10.1002/hep.21357; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ALLEN KL, 1995, J NEUROCHEM, V64, P2222; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; Cereghetti GM, 2006, ONCOGENE, V25, P4717, DOI 10.1038/sj.onc.1209605; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; CHANG LH, 1992, J CEREBR BLOOD F MET, V12, P1030, DOI 10.1038/jcbfm.1992.140; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Delivani P, 2006, MOL CELL, V21, P761, DOI 10.1016/j.molcel.2006.01.034; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Dohm CP, 2006, J MOL NEUROSCI, V29, P1, DOI 10.1385/JMN:29:1:1; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Dubinsky JM, 1999, BIOCHEM SOC SYMP, V66, P75, DOI 10.1042/bss0660075; Feldkamp T, 2004, AM J PHYSIOL-RENAL, V286, pF749, DOI 10.1152/ajprenal.00276.2003; Feng ZC, 1998, RESUSCITATION, V37, P33, DOI 10.1016/S0300-9572(98)00031-8; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Jacobson J, 2005, J NEUROCHEM, V95, P388, DOI 10.1111/j.1471-4159.2005.03374.x; Kahraman S, 2007, NEUROCHEM RES, V32, P799, DOI 10.1007/s11064-006-9206-8; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kirkinezos IG, 2005, J NEUROSCI, V25, P164, DOI 10.1523/JNEUROSCI.3829-04.2005; Kosenko E, 2004, J NEUROCHEM, V89, P1101, DOI 10.1111/j.1471-4159.2004.02426.x; Kristal BS, 2004, J BIOENERG BIOMEMBR, V36, P309, DOI 10.1023/B:JOBB.0000041759.35731.70; Kristian T, 2004, CELL CALCIUM, V36, P221, DOI 10.1016/j.ceca.2004.02.016; Kuroda S, 1996, ACTA PHYSIOL SCAND, V156, P149, DOI 10.1046/j.1365-201X.1996.449170000.x; KURUP CKR, 1990, J BIOENERG BIOMEMBR, V22, P61; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lindholm D, 2004, BIOCHEM BIOPH RES CO, V321, P753, DOI 10.1016/j.bbrc.2004.06.138; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Mannella CA, 2006, BBA-MOL BASIS DIS, V1762, P140, DOI 10.1016/j.bbadis.2005.07.001; Marmarou A, 2005, ACT NEUR S, V95, P149; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; Muruganandham M, 2005, CLIN CANCER RES, V11, P3503, DOI 10.1158/1078-0432.CCR-04-1399; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Narasimhan P, 2003, MOL BRAIN RES, V113, P28, DOI 10.1016/S0169-328X(03)00062-7; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Ouyang YB, 1997, NEUROSCI RES COMMUN, V20, P167, DOI 10.1002/(SICI)1520-6769(199705)20:3<167::AID-NRC198>3.3.CO;2-V; Parone PA, 2006, BBA-MOL CELL RES, V1763, P522, DOI 10.1016/j.bbamcr.2006.04.005; Perez-Pinzon MA, 1998, J CEREBR BLOOD F MET, V18, P215, DOI 10.1097/00004647-199802000-00013; PerezPinzon MA, 1997, BRAIN RES, V754, P163, DOI 10.1016/S0006-8993(97)00066-8; Polster BM, 2001, J BIOL CHEM, V276, P37887; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rostovtseva TK, 2005, J BIOENERG BIOMEMBR, V37, P129, DOI 10.1007/s10863-005-6566-8; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sensi SL, 2004, CURR MOL MED, V4, P87, DOI 10.2174/1566524043479211; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Sharpley MS, 2006, J BIOL CHEM, V281, P34803, DOI 10.1074/jbc.M607389200; Shuttleworth CW, 2003, J NEUROSCI, V23, P3196; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Suh SW, 2003, J NEUROSCI, V23, P10681; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tanaka S, 2005, J NEUROCHEM, V95, P179, DOI 10.1111/j.1471-4159.2005.03353.x; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Tretter L, 2000, J NEUROSCI, V20, P8972; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vesce S, 2005, J BIOL CHEM, V280, P38720, DOI 10.1074/jbc.M506575200; Vishwasrao HD, 2005, J BIOL CHEM, V280, P25119, DOI 10.1074/jbc.M502475200; Wallace DC, 2005, GENE, V354, P169, DOI 10.1016/j.gene.2005.05.001; Walter L, 2005, J BIOENERG BIOMEMBR, V37, P191, DOI 10.1007/s10863-005-6600-x; WELSH FA, 1982, J CEREBR BLOOD F MET, V2, P221, DOI 10.1038/jcbfm.1982.22; WOODFIELD K, 1988, BIOCHEM J, V336, P287; Yasuda O, 2006, J BIOL CHEM, V281, P23899, DOI 10.1074/jbc.M512610200; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Ying WH, 2006, FRONT BIOSCI-LANDMRK, V11, P3129, DOI 10.2741/2038; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; YU T, 2006, FRONT BIOSCI, V103, P2653; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103; Yuan H, 2007, CELL DEATH DIFFER, V14, P462, DOI 10.1038/sj.cdd.4402046; Zaidan E, 1999, J NEUROCHEM, V73, P2214; Zaidan E, 1996, NEUROSCI LETT, V218, P75, DOI 10.1016/S0304-3940(96)13128-1; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zanelli SA, 2006, J NEUROCHEM, V97, P724, DOI 10.1111/j.1471-4159.2006.03767.x; Zeng JY, 2007, J CEREBR BLOOD F MET, V27, P304, DOI 10.1038/sj.jcbfm.9600335; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	105	86	95	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV 15	2007	85	15					3407	3415		10.1002/jnr.21498			9	Neurosciences	Neurosciences & Neurology	231SW	WOS:000250970300022	17847081	Bronze, Green Accepted			2021-06-18	
J	Cherian, L; Goodman, JC; Robertson, C				Cherian, Leela; Clay Goodman, J.; Robertson, Claudia			Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; CEREBRAL-ISCHEMIA; SUBARACHNOID HEMORRHAGE; ENHANCES NEUROGENESIS; FUNCTIONAL RECOVERY; NEURONAL APOPTOSIS; BRAIN-INJURY; EXPRESSION	This study was designed to determine the effect of erythropoietin (Epo) on cerebral blood flow (CBF), nitric oxide (NO) concentration, and neurological outcome after traumatic brain injury. In one experiment, the hemodynamic effects of Epo were determined after controlled cortical impact injury (CCII) by measuring mean arterial pressure, intracranial pressure, CBF using laser Doppler flowmetry, and brain tissue NO concentrations using an NO electrode. In total, 41 rats were given either Epo (5000 U/kg) or saline s.c. 3 days before injury. In animals pretreated with saline, L-arginine but not D-arginine administration resulted in a significant increase in tissue NO concentrations and an improvement in CBF at the impact site. Likewise, in animals pretreated with Epo, L-arginine but not D-arginine given postinjury increased brain tissue NO concentrations and increased CBF. In another experiment, 74 rats underwent CCII (3-mm deformation, velocity 5 m/s), and they were given saline or Epo 5000 U/kg s.c. at 5 min, 1 h, 3 h, 6 h, 9 h, or 12 h postinjury. The contusion volume and cell counts of viable neurons in the CA1 and CA3 regions of the hippocampus were assessed at 2 weeks postinjury. The contusion volume was significantly reduced at 5 min, 1 h, 3 h, and 6 h postinjury Epo administration. The neuron density in the CA1 and CA3 region of the hippocampus was increased at 1, 3, and 6 h after injury. These data demonstrate the neuroprotective effects of Epo in traumatic injury, and the effects are optimal when Epo is given within 6 h of injury.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Cherian, L (corresponding author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.	lcherian@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		Alafaci C, 2000, EUR J PHARMACOL, V406, P219, DOI 10.1016/S0014-2999(00)00691-9; Banerjee D, 2000, KIDNEY INT, V57, P1895, DOI 10.1046/j.1523-1755.2000.00039.x; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Chong ZZ, 2003, J CEREBR BLOOD F MET, V23, P320, DOI 10.1097/01.WCB.0000050061.57184.AE; DELCASTILLO D, 1995, NEPHROL DIAL TRANSPL, V10, P505, DOI 10.1093/ndt/10.4.505; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; EGRIE J C, 1988, Kidney International, V33, P262; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2001, J Neurosurg Sci, V45, P7; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Iwasaki Y, 2002, NEUROL RES, V24, P643, DOI 10.1179/016164102101200681; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kang JQ, 2003, MOL PHARMACOL, V64, P557, DOI 10.1124/mol.64.3.557; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Noguchi K, 2001, BRIT J PHARMACOL, V133, P395, DOI 10.1038/sj.bjp.0704083; Ongil SL, 1996, EXP NEPHROL, V4, P37; Schena F, 2002, J SPORT MED PHYS FIT, V42, P129; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Sun Y, 2005, STROKE, V36, P1672, DOI 10.1161/01.STR.0000173406.04891.8c; Tsukahara H, 1997, SCAND J CLIN LAB INV, V57, P487, DOI 10.3109/00365519709084598; Vaziri ND, 1995, AM J PHYSIOL-RENAL, V269, pF838; Wada Y, 1999, AM J HYPERTENS, V12, P980, DOI 10.1016/S0895-7061(99)00081-3; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang XQ, 1999, HYPERTENSION, V33, P894, DOI 10.1161/01.HYP.33.3.894; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wu XC, 1999, CLIN SCI, V97, P413, DOI 10.1042/CS19990055; Yamamoto M, 2000, NEUROSCI LETT, V292, P131, DOI 10.1016/S0304-3940(00)01441-5; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	40	86	93	0	6	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	AUG	2007	322	2					789	794		10.1124/jpet.107.119628			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	192IM	WOS:000248194600041	17470644				2021-06-18	
J	Bodnar, LE; Pralune, MC; Cutting, LE; Denckla, MB; Mahone, EM				Bodnar, L. Elizabeth; Pralune, M. Cristine; Cutting, Laurie E.; Denckla, Martha B.; Mahone, E. Mark			Construct validity of parent ratings of inhibitory control	CHILD NEUROPSYCHOLOGY			English	Article; Proceedings Paper	32nd Annual Meeting of the International-Neuropsychological-Society	FEB 04-07, 2004	Baltimore, MD	Int Neuropsychol Soc		BRIEF; continuous performance test; attention; executive functions; ADHD	CONTINUOUS PERFORMANCE-TEST; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTION; RESPONSE-INHIBITION; TOURETTE-SYNDROME; CHILDREN; ADHD; METHYLPHENIDATE	Recent literature has emphasized the need to examine executive functions (EF) in children using multiple sources, including both parent rating and performance-based measures. Computerized Go/No-Go tests, including commercially available continuous performance tests (CPTs), represent one of the most commonly used methods of assessing inhibitory control-a variable central to the executive function construct. We examined the relationship between parent ratings of inhibitory control and CPT performance in two mixed clinical samples. Experiment I examined 109 children ages 6-18 using the Behavior Rating Inventory of Executive Function (BRIEF; Gioia, Isquith, Guy, & Kenworthy, 2000) and the Conners' CPT-II (Conners, 2000). In this sample, ratings on the BRIEF Inhibit scale (mean T-score = 62.3) were significantly higher than the CPT-II commissions score (mean T-score = 50.7, p < .0001); and the BRIEF and CPT-II scores were not highly correlated (r = -.12). Experiment 2 examined a sample of 131 children ages 7-18 using the BRIEF and the Tests of Variables of Attention (TOVA; Greenberg, 1996). In this sample, parent ratings on the BRIEF Inhibit scale (mean T-score = 56.8) were similar to TOVA commissions scores (mean T-score = 58.6; p = .33), although still poorly correlated (r = -.02). Factor analyses exploring covariance between BRIEF scales CPT-II variables (Experiment 1) and between BRIEF and TOVA (Experiment 2) yielded similar findings. In both experiments, all eight BRIEF scales loaded on a single factor, with no overlap with either the CPT-II or the TOVA. In mixed outpatient clinical samples, the BRIEF appears to measure different elements of inhibitory control than those assessed by computerized continuous performance tests.	Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; American Univ, Washington, DC 20016 USA	Mahone, EM (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 1750 E Fairmt Ave, Baltimore, MD 21231 USA.	mahone@kennedykrieger.org		Mahone, E. Mark/0000-0002-5022-1499	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD024061] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS035359] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00052] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-24061] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS 35359] Funding Source: Medline		Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Anderson V, 1997, Pediatr Rehabil, V1, P63; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Barkley RA, 2000, J AM ACAD CHILD PSY, V39, P1064, DOI 10.1097/00004583-200008000-00025; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bedard AC, 2004, J AM ACAD CHILD PSY, V43, P260, DOI 10.1097/00004583-200403000-00006; Beebe DW, 2004, J INT NEUROPSYCH SOC, V10, P962, DOI 10.1017/S135561770410708X; BERNSTEIN J, 1990, NEUROMETHODS NEUROPS, P311, DOI DOI 10.1385/0-89603-133-0:311; Brewis A, 2002, SOC BIOL, V49, P99; Brocki KC, 2004, DEV NEUROPSYCHOL, V26, P571, DOI 10.1207/s15326942dn2602_3; Burmeister R, 2005, CHILD NEUROPSYCHOL, V11, P265, DOI 10.1080/092970490911324; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Christ SE, 2003, NEUROPSYCHOLOGY, V17, P171, DOI 10.1037/0894-4105.17.1.171; Conners CK, 2000, CONNERS CONTINOUS PE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Denckla MB, 1996, DEV NEUROPSYCHOL, V12, P5, DOI 10.1080/87565649609540637; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; Epstein JN, 2003, J ABNORM CHILD PSYCH, V31, P543, DOI 10.1023/A:1025405216339; Evans DW, 2004, BRAIN COGNITION, V55, P220, DOI 10.1016/s0278-2626(03)00274-4; Gassio R, 2005, DEV MED CHILD NEUROL, V47, P443, DOI 10.1017/S0012162205000861; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia G.A., 2000, BEHAV RATING INVENTO; Goldberg MC, 2005, J AUTISM DEV DISORD, V35, P279, DOI 10.1007/s10803-005-3291-4; GREEBERG LM, 1996, TEST VARIABLES ATTEN; GREENBERG LM, 1993, J CHILD PSYCHOL PSYC, V34, P1019, DOI 10.1111/j.1469-7610.1993.tb01105.x; Grodzinsky GM, 1999, CLIN NEUROPSYCHOL, V13, P12, DOI 10.1076/clin.13.1.12.1983; Harris E L, 1995, J Int Neuropsychol Soc, V1, P511; Hays W. L., 1988, STATISTICS; Losier BJ, 1996, J CHILD PSYCHOL PSYC, V37, P971, DOI 10.1111/j.1469-7610.1996.tb01494.x; Mahone EM, 2005, DEV NEUROPSYCHOL, V27, P11, DOI 10.1207/s15326942dn2701_2; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mahone EM, 2001, J INT NEUROPSYCH SOC, V7, P102, DOI 10.1017/S1355617701711101; Mariani MA, 1997, DEV NEUROPSYCHOL, V13, P111, DOI 10.1080/87565649709540671; Martinussen R, 2005, J AM ACAD CHILD PSY, V44, P377, DOI 10.1097/01.chi.0000153228.72591.73; McGee RA, 2000, J ABNORM CHILD PSYCH, V28, P415, DOI 10.1023/A:1005127504982; Mostofsky SH, 2003, PERCEPT MOTOR SKILL, V97, P1315, DOI 10.2466/PMS.97.7.1315-1331; Mostofsky SH, 2002, BIOL PSYCHIAT, V52, P785, DOI 10.1016/S0006-3223(02)01412-9; *NAT I HLTH CONS S, 1998, DIAGN TREAT ATT DEF; Nigg JT, 1996, J CLIN CHILD PSYCHOL, V25, P330, DOI 10.1207/s15374424jccp2503_9; Nyden A, 2000, EUR CHILD ADOLES PSY, V9, P180, DOI 10.1007/s007870070041; OToole K, 1997, J AM ACAD CHILD PSY, V36, P531, DOI 10.1097/00004583-199704000-00016; Ozonoff S, 1999, J AUTISM DEV DISORD, V29, P171, DOI 10.1023/A:1023052913110; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Pliszka SR, 1997, J DEV BEHAV PEDIATR, V18, P254; Rice J.A., 2000, ADHD REPORT, V8, P1; Riva D, 2005, NEUROL SCI, V26, P263, DOI 10.1007/s10072-005-0469-7; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; Scheres A, 2003, J ABNORM CHILD PSYCH, V31, P105, DOI 10.1023/A:1021729501230; Seidman LJ, 1997, J AM ACAD CHILD PSY, V36, P366, DOI 10.1097/00004583-199703000-00015; Shucard DW, 1997, NEUROPSYCHOLOGY, V11, P147, DOI 10.1037/0894-4105.11.1.147; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1991, WECHSLER INTELLIGENC; WHITE JL, 1994, J ABNORM PSYCHOL, V103, P192, DOI 10.1037/0021-843X.103.2.192; Willcutt EG, 2005, DEV NEUROPSYCHOL, V27, P35, DOI 10.1207/s15326942dn2701_3; WODKA EL, IN PRESS J CLIN EXPT	61	86	86	2	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	JUL	2007	13	4					345	362		10.1080/09297040600899867			18	Clinical Neurology	Neurosciences & Neurology	207ZU	WOS:000249290400004	17564851				2021-06-18	
J	van Baalen, B; Odding, E; van Woensel, MPC; van Kessel, MA; Roebroeck, ME; Stam, HJ				van Baalen, B.; Odding, E.; van Woensel, M. P. C.; van Kessel, M. A.; Roebroeck, M. E.; Stam, H. J.			Reliability and sensitivity to change of measurement instruments used in a traumatic brain injury population	CLINICAL REHABILITATION			English	Article							FUNCTIONAL ASSESSMENT SCALES; HEALTH SURVEY SF-36; RATING-SCALE; HEAD-INJURY; FOLLOW-UP; REHABILITATION; COMMUNITY; SEVERITY; RECOVERY; OUTCOMES	Objective: To compile a minimum data set for the follow-up of traumatic brain injury patients from discharge from hospital to one year post injury to assess functioning and participation in the physical, cognitive and psychosocial domains, and in quality of life. Design: Repeated questionnaire interviews by two observers to establish interobserver reliability of the measurement instruments at discharge and at one year post injury, as well as their sensitivity to change over time in traumatic brain injury patients. Setting: Department of neurosurgery of an academic hospital, department of a rehabilitation centre, and at the patients' homes in the Netherlands. Subjects: The study at discharge included 25 patients aged 18-50 years with a moderate to severe traumatic brain injury (Glasgow Coma Scale score 3-14), whereas the one year post injury study included 14 patients aged 19-51 years. Main (outcome) measures: Physical domain: Barthel Index (BI), Functional Independence Measurement (FIM), Glasgow Outcome Scale (GOS), GOS Extended (GOSE). Cognitive domain: Disability Rating Scale (DRS), Functional Assessment Measurement (FAM), Levels of Cognitive Functioning Scale (LCFS), Neurobehavioural Bating Scale (NRS). Psychosocial domain: Community Integration Questionnaire (CIQ), Employability Rating Scale (ERS), Frenchay Activity Index (FAI), Multi Health Locus of Control (MHLC), Rehabilitation Activities Profile (RAP), Social Support List (SSL), Supervision Rating Scale (SRS), Wimbledon Self Reporting Rating Scale (WSRS). Quality of life: Coop/Wonca Charts (Coop), Rand SF-36 (Rand-36), Sickness Impact Profile-68 (SIP-68). Results: At both discharge and at one year post injury, in the physical domain the FIM showed excellent squared weighted kappa (SWK ranging from 0.75 to 0.80), and intraclass correlation coefficient (ICC ranging from 0.75 to 0.92), and a relatively small standard error of measurement (SEM 3.22) and smallest detectable difference (SDD 8.92). In the cognitive domain the FAM and the NRS showed excellent SWK, and ICC, and a relatively small SEM and SDD. In the psychosocial domain the FAI showed excellent SWK (0.89), and ICC (0.87), and a relatively small SEM (2.64) and SDD (7.31). For quality of life, at both discharge and at one year post injury the SIP-68 and the Coop showed excellent SWK (0.87), and ICC (0.89), and a relatively small SEM (3.79) and SDD (10.51). At both time points SWK and ICC ranged from 0.80 to 0.89, SEM ranged from 1.47 to 1.98, and the SDD was 4.07. Conclusions: An example of a reliable minimum data set that is also able to detect changes over time is: the FIM, the FAM and the Coop for the early stages in recovery, extended with the NRS, the FAI, and the SIP-68 later in recovery, thereby covering all relevant domains after traumatic brain injury.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Rehabil Med, NL-3000 CA Rotterdam, Netherlands; Rijndam Rehabil Ctr, Rotterdam, Netherlands	van Baalen, B (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Rehabil Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	j.t.m.vanbaalen@erasmusmc.nl					Beckerman H, 2001, QUAL LIFE RES, V10, P571, DOI 10.1023/A:1013138911638; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Collin C, 1988, Int Disabil Stud, V10, P61; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Geertzen JHB, 1998, ACTA ORTHOP SCAND, V69, P4, DOI 10.1080/17453674.1998.11744780; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; JELLES F, 1995, J CLIN EPIDEMIOL, V48, P407, DOI 10.1016/0895-4356(94)00152-G; JENNETT B, 1975, LANCET, V1, P480; Johnston M V, 1994, Arch Phys Med Rehabil, V75, pSC1; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC27; JOHNSTON MV, 1996, MED REHABILITATION T, P197; KONIGZAHN C, 1997, CROSS CULTURAL HLTH, P48; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MacDermid Joy C, 2004, J Hand Ther, V17, P165, DOI 10.1197/j.jht.2004.02.005; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roebroeck ME, 1998, ARCH PHYS MED REHAB, V79, P442, DOI 10.1016/S0003-9993(98)90147-2; Sacket DL, 1991, CLIN EPIDEMIOLOGY BA; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; Schreuders TAR, 2003, PHYS THER, V83, P806, DOI 10.1093/ptj/83.9.806; Smidt N, 2002, ARCH PHYS MED REHAB, V83, P1145, DOI 10.1053/apmr.2002.33728; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Streiner D., 1995, HLTH MEASUREMENT SCA, V2; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397; Turner-Stokes L, 1999, CLIN REHABIL, V13, P273, DOI 10.1191/026921599670005973; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; VANBALEN HGG, 1996, CLIN REHABIL, V10, P259; VANSONDEREN E, 1997, SOCIALE STEUN LIJST; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 1993, SF 36 HLTH SURVEY MA; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	60	86	89	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	AUG	2006	20	8					686	700		10.1191/0269215506cre982oa			15	Rehabilitation	Rehabilitation	077DN	WOS:000240008000005	16944826				2021-06-18	
J	Bartnik, BL; Sutton, RL; Fukushima, M; Harris, NG; Hovda, DA; Lee, SM				Bartnik, BL; Sutton, RL; Fukushima, M; Harris, NG; Hovda, DA; Lee, SM			Upregulation of pentose phosphate pathway and preservation of tricarboxylic acid cycle flux after experimental brain injury	JOURNAL OF NEUROTRAUMA			English	Article						C-13 nuclear magnetic resonance spectroscopy; glucose metabolism; pentose phosphate pathway; traumatic brain injury; tricarboxylic acid cycle	NUCLEAR-MAGNETIC-RESONANCE; ALPHA-KETOGLUTARATE DEHYDROGENASE; GLIAL-NEURONAL INTERACTIONS; CORTICAL CONTUSION INJURY; CEREBRAL-ARTERY OCCLUSION; EXPERIMENTAL HEAD-INJURY; EXCITATORY AMINO-ACIDS; IN-VIVO; RAT-BRAIN; C-13 NMR	The metabolic fate of [1,2 C-13]-labeled glucose was determined in male control and unilateral controlled cortical impact (CCI) injured rats at 3.5 and 24 h after surgery. The concentration of 13 C-labeled glucose, lactate, glutamate and glutamine were measured in the injured and contralateral cortex. CCI animals showed a 145% increase in C-13 lactate in the injured cortex at 3.5 h, but not at 24 h after injury, indicating increased glycolysis in neurons and/or astrocytes ipsilateral to CCI. Total levels of C-13 glutamate in cortical tissue extracts did not differ between groups. However, C-13 glutamine increased by 40% in the left and 98% in the right cortex at 3.5 h after injury, most likely resulting from an increase in astrocytic metabolism of glutamate. Levels of C-13 incorporation into the glutamine isotopomers had returned to control levels by 24 h after CCI. The singlet to doublet ratio of the lactate C3 resonances was calculated to estimate the flux of glucose through the pentose phosphate pathway (PPP). CCI resulted in bilateral increases (9-12%) in the oxidation of glucose via the PPP, with the largest increase occurring at 24 h. Since an increase in PPP activity is associated with NADPH generation, the data suggest that there was an increasing need for reducing equivalents after CCI. Furthermore, C-13 was incorporated into glutamate and glutamine isotopomers associated with multiple turns of the tricarboxylic acid (TCA) cycle, indicating that oxidative phosphorylation of glucose was maintained in the injured cortex at 3.5 and 24 h after a moderate to severe CCI injury.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Bartnik, BL (corresponding author), Loma Linda Univ, Dept Radiol, 11234 Anderson St,Room B623, Loma Linda, CA 92354 USA.	bbartnik@ahs.llume.edu		Bartnik-Olson, Brenda/0000-0002-1137-9437; Harris, Neil/0000-0002-1965-6750	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36373, NS27544] Funding Source: Medline		Auer DP, 2000, BIOL PSYCHIAT, V47, P305, DOI 10.1016/S0006-3223(99)00159-6; Aureli T, 1997, BRAIN RES, V765, P218, DOI 10.1016/S0006-8993(97)00514-3; BACHELARD H, 1993, J NEUROCHEM, V61, P412; BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; BAQUER NZ, 1988, CURR TOP CELL REGUL, V29, P265; Bartnik BL, 2003, J NEUROTRAUM, V20, P1093; BenYoseph O, 1996, J NEUROCHEM, V66, P2329; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Brand A, 1999, J NEUROSCI RES, V58, P576, DOI 10.1002/(SICI)1097-4547(19991115)58:4<576::AID-JNR10>3.3.CO;2-4; Chapa F, 2000, NEUROCHEM INT, V37, P217, DOI 10.1016/S0197-0186(00)00025-5; CHATENEVER D, 2001, J MINIMALLY INVASIVE, V1, P2; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Cruz F, 1998, J NEUROCHEM, V70, P2613; Cruz F, 1999, NMR BIOMED, V12, P451, DOI 10.1002/(SICI)1099-1492(199911)12:7<451::AID-NBM571>3.3.CO;2-5; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Eloqayli H, 2003, J NEUROCHEM, V85, P1200, DOI 10.1046/j.1471-4159.2003.01781.x; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; Garcia-Nogales P, 2003, J BIOL CHEM, V278, P864, DOI 10.1074/jbc.M206835200; Gibson GE, 2000, NEUROCHEM INT, V36, P97, DOI 10.1016/S0197-0186(99)00114-X; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Gruetter R, 2002, NEUROCHEM INT, V41, P143, DOI 10.1016/S0197-0186(02)00034-7; Haberg A, 2001, J CEREBR BLOOD F MET, V21, P1451, DOI 10.1097/00004647-200112000-00010; Haberg A, 1998, J CEREBR BLOOD F MET, V18, P1223, DOI 10.1097/00004647-199811000-00008; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HASSEL B, 1995, J NEUROCHEM, V64, P2773; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; HOTHERSALL JS, 1982, J NEUROCHEM, V39, P1325, DOI 10.1111/j.1471-4159.1982.tb12574.x; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Kanamori K, 2002, J NEUROCHEM, V83, P682, DOI 10.1046/j.1471-4159.2002.01161.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kondrat RW, 2002, J NEUROSCI METH, V120, P179, DOI 10.1016/S0165-0270(02)00201-7; LEE JG, 1994, ANESTH ANALG, V79, P58; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McKenna MC, 1996, J NEUROCHEM, V66, P386; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; MURR R, 1993, ANESTH ANALG, V77, P898; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OPII WO, 2004, PROTEOMIC STUDY OXID; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pascual JM, 1998, STROKE, V29, P1048, DOI 10.1161/01.STR.29.5.1048; Patel AB, 2004, J CEREBR BLOOD F MET, V24, P972, DOI 10.1097/01.WCB.0000126234.16188.71; Preece NE, 1996, J NEUROCHEM, V67, P1718; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Qu H, 2003, NEUROCHEM INT, V42, P101, DOI 10.1016/S0197-0186(02)00051-7; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Ramonet D, 2004, HIPPOCAMPUS, V14, P586, DOI 10.1002/hipo.10188; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; SCHRADER MC, 1993, BIOCHIM BIOPHYS ACTA, V1182, P162, DOI 10.1016/0925-4439(93)90138-Q; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Serres S, 2003, NMR BIOMED, V16, P430, DOI 10.1002/nbm.838; SHANK RP, 1993, J NEUROCHEM, V61, P315, DOI 10.1111/j.1471-4159.1993.tb03570.x; Sibson NR, 1998, DEV NEUROSCI-BASEL, V20, P321, DOI 10.1159/000017327; Sibson NR, 1997, P NATL ACAD SCI USA, V94, P2699, DOI 10.1073/pnas.94.6.2699; Sibson NR, 2001, J NEUROCHEM, V76, P975, DOI 10.1046/j.1471-4159.2001.00074.x; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STANLEY JA, 1995, MAGNET RESON MED, V34, P17, DOI 10.1002/mrm.1910340105; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tretter L, 2000, J NEUROSCI, V20, P8972; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	91	86	87	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1052	1065		10.1089/neu.2005.22.1052			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600003	16238483				2021-06-18	
J	Pouthas, V; Perbal, S				Pouthas, V; Perbal, S			Time perception depends on accurate clock mechanisms as well as unimpaired attention and memory processes	ACTA NEUROBIOLOGIAE EXPERIMENTALIS			English	Article; Proceedings Paper	Symposium on Time, Cognition Thinking	JUL 19-23, 2003	Strezekecino, POLAND			aged people; brain damaged patients; clock speed; attention; memory; duration reproduction; duration production	TEMPORAL-ORDER; DURATION JUDGMENTS; DIVIDED ATTENTION; HEAD; SPEED; AGE; DEFICITS; AMNESIA; LESIONS	We report a series of studies aimed at characterizing the relationships between duration judgments and slowing down of the internal clock, attention and memory deficits'. Different groups of participants (elderly people, patients with Parkinson's disease, patients with severe traumatic brain injury, and patients with temporal lobe lesions) performed a duration reproduction task and a duration production task in two conditions: a control counting condition and a concurrent reading condition. Participants were also administered reaction time tasks, tapping tasks, and a battery of attention and memory tests. The results allow us to characterize the relationships between cognitive deficits and impaired duration reproductions and productions in each group. Moreover, results as a whole clarify the respective weight of processing speed, attention and memory in both tasks, and allow better insight into the theoretical models of psychological time.	Hop La Pitie Salpetriere, CNRS, UPR 640, LENA,Unit Cognit Neurosci & Cerebral Imagery, F-75651 Paris 13, France	Pouthas, V (corresponding author), Hop La Pitie Salpetriere, CNRS, UPR 640, LENA,Unit Cognit Neurosci & Cerebral Imagery, 47 Blvd Hop, F-75651 Paris 13, France.	viviane.pouthas@chups.jussieu.fr					ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5; Basso G, 1996, NEUROREPORT, V7, P2111, DOI 10.1097/00001756-199609020-00009; Block R.A., 1990, COGNITIVE MODELS PSY, P59; Block RA, 1998, PSYCHOL AGING, V13, P584, DOI 10.1037/0882-7974.13.4.584; BOLTZ MG, 1994, J EXP PSYCHOL LEARN, V20, P1154, DOI 10.1037/0278-7393.20.5.1154; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brown SW, 1997, PERCEPT PSYCHOPHYS, V59, P1118, DOI 10.3758/BF03205526; Casini L, 1999, BEHAV PROCESS, V45, P73, DOI 10.1016/S0376-6357(99)00010-8; Casini L, 1999, NEUROPSYCHOLOGY, V13, P10, DOI 10.1037/0894-4105.13.1.10; CERELLA J, 1990, HDB PSYCHOL AGING, P201, DOI DOI 10.1016/B978-0-12-101280-9.50018-8; CHURCH RM, 1984, ANN NY ACAD SCI, V423, P566, DOI 10.1111/j.1749-6632.1984.tb23459.x; COOKE DL, 1995, J CLIN EXP NEUROPSYC, V17, P90, DOI 10.1080/13803399508406585; CORKIN S, 1965, NEUROPSYCHOLOGIA, V3, P339, DOI 10.1016/0028-3932(65)90006-0; Craik FIM, 1999, PERCEPT PSYCHOPHYS, V61, P549, DOI 10.3758/BF03211972; DENNER B, 1964, PERCEPT MOTOR SKILL, V19, P723, DOI 10.2466/pms.1964.19.3.723; Deweer B, 2001, BEHAV BRAIN RES, V127, P209, DOI 10.1016/S0166-4328(01)00366-7; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; Fraisse P., 1957, PSYCHOL TIME; GIBSON JJ, 1975, STUDY TIME, V2, P295; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Harrington DL, 1998, J NEUROSCI, V18, P1085; Harrington DL, 1999, REV NEUROSCIENCE, V10, P91, DOI 10.1515/REVNEURO.1999.10.2.91; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; JonesGotman M, 1997, NEUROPSYCHOLOGIA, V35, P963, DOI 10.1016/S0028-3932(97)00024-9; Kinsbourne M, 1990, NEUROPSYCHOLOGICAL I, P319, DOI DOI 10.1017/CBO9780511665547.017; Lange KW, 1995, J NEURAL TRANSM-SUPP, P423; Lange KW, 1995, J NEURAL TRANSM-SUPP, P433; Lustig C, 2001, PSYCHOL SCI, V12, P478, DOI 10.1111/1467-9280.00389; Malapani C, 1998, J COGNITIVE NEUROSCI, V10, P316, DOI 10.1162/089892998562762; Malapani C, 2002, J COGNITIVE NEUROSCI, V14, P1; Mattis S, 1988, DEMENTIA RATING SCAL; MICHON JA, 1990, COGNITIVE MODELS PSY, P37; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Mimura M, 2000, J INT NEUROPSYCH SOC, V6, P517, DOI 10.1017/S1355617700655017; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Nichelli P, 1995, ANN NY ACAD SCI, V769, P183, DOI 10.1111/j.1749-6632.1995.tb38139.x; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; PASTOR MA, 1992, BRAIN, V115, P211, DOI 10.1093/brain/115.1.211; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Perbal S, 2002, AGING NEUROPSYCHOL C, V9, P201, DOI 10.1076/anec.9.3.201.9609; Perbal S, 2001, NEUROREPORT, V12, P939, DOI 10.1097/00001756-200104170-00015; Perbal S, 2000, NEUROCASE, V6, P347, DOI 10.1080/13554790008402782; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RICHARDS W, 1973, ACTA PSYCHOL, V37, P279, DOI 10.1016/0001-6918(73)90020-6; Rubia K, 1997, NEUROREPORT, V8, P1273, DOI 10.1097/00001756-199703240-00043; SALTHOUSE TA, 1994, DEV REV, V14, P413, DOI 10.1006/drev.1994.1016; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Schroots J.J.F., 1990, HDB PSYCHOL AGING, V3, P45; SHAW C, 1994, NEUROPSYCHOLOGIA, V32, P857, DOI 10.1016/0028-3932(94)90023-X; Shimamura AP, 2000, PSYCHOBIOLOGY, V28, P207; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Squire Larry R., 1995, P825; SURWILLO WW, 1968, HUMAN AGING BEHAV, P1; Vakil E, 1998, NEUROPSY NEUROPSY BE, V11, P212; VAKIL E, 1994, NEUROPSY NEUROPSY BE, V7, P281; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VanderLinden M, 1996, COGN NEUROPSYCHOL, V13, P391; VANDERLINDEN M, 1995, BROKEN MEMORIES NEUR, P54; Vanneste S, 1999, EXP AGING RES, V25, P49, DOI 10.1080/036107399244138; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vidalaki VN, 1999, NEUROPSYCHOLOGIA, V37, P1061, DOI 10.1016/S0028-3932(98)00155-9; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Wearden JH, 1997, J EXP PSYCHOL HUMAN, V23, P962; Wearden JH, 2004, ACTA NEUROBIOL EXP, V64, P303; Wechsler D., 1981, WAIS R MANUAL WECHSL; WILLIAMS JM, 1989, J CLIN EXP NEUROPSYC, V11, P713, DOI 10.1080/01688638908400927; Zakay D, 2004, ACTA NEUROBIOL EXP, V64, P319; ZAKAY D, 1993, PERCEPTION, V22, P91, DOI 10.1068/p220091; Zakay Dan, 1989, TIME HUMAN COGNITION, V59, P365, DOI [DOI 10.1016/S0166-4115(08)61047-X, 10.1016/S0166-4115(08)61047-X]	74	86	90	0	7	NENCKI INST EXPERIMENTAL BIOLOGY	WARSAW	UL PASTEURA 3, 02-093 WARSAW, POLAND	0065-1400	1689-0035		ACTA NEUROBIOL EXP	Acta Neurobiol. Exp.		2004	64	3					367	385					19	Neurosciences	Neurosciences & Neurology	837OQ	WOS:000222645400008	15283479				2021-06-18	
J	Ruf, B; Heckmann, M; Schroth, I; Hugens-Penzel, M; Reiss, I; Borkhardt, A; Gortner, L; Jodicke, A				Ruf, B; Heckmann, M; Schroth, I; Hugens-Penzel, M; Reiss, I; Borkhardt, A; Gortner, L; Jodicke, A			Early decompressive craniectomy and duraplasty for refractory intracranial hypertension in children: results of a pilot study	CRITICAL CARE			English	Article						craniectomy; intensive care; pediatric; severe head injury	SEVERE HEAD-INJURY; HYPERTONIC SALINE; BRAIN-INJURY; PRESSURE; MANAGEMENT; HYPEREMIA	Introduction Severe traumatic brain injury (TBI) in childhood is associated with a high mortality and morbidity. Decompressive craniectomy has regained therapeutic interest during past years; however, treatment guidelines consider it a last resort treatment strategy for use only after failure of conservative therapy. Patients We report on the clinical course of six children treated with decompressive craniectomy after TBI at a pediatric intensive care unit. The standard protocol of intensive care treatment included continuous intracranial pressure (ICP) monitoring, sedation and muscle relaxation, normothermia, mild hyperventilation and catecholamines to maintain an adequate cerebral perfusion pressure. Decompressive craniectomy including dura opening was initiated in cases of a sustained increase in ICP > 20 mmHg for > 30 min despite maximally intensified conservative therapy (optimized sedation and ventilation, barbiturates or mannitol). Results In all cases, the ICP normalized immediately after craniectomy. At discharge, three children were without disability, two children had a mild arm-focused hemiparesis ( one with a verbal impairment), and one child had a spastic hemiparesis and verbal impairment. This spastic hemiparesis improved within 6 months follow-up ( no motor deficit, increased muscle tone), and all others remained unchanged. Conclusion These observational pilot data indicate feasibility and efficacy of decompressive craniectomy in malignant ICP rise secondary to TBI. Further controlled trials are necessary to evaluate the indication and standardization of early decompressive craniectomy as a 'second tier' standard therapy in pediatric severe head injury.	Univ Giessen, Univ Med Ctr, Dept Pediat, Giessen, Germany; Univ Giessen, Univ Med Ctr, Dept Neurosurg, Giessen, Germany; Univ Giessen, Univ Med Ctr, Dept Neuroradiol, Giessen, Germany	Ruf, B (corresponding author), Univ Giessen, Univ Med Ctr, Dept Pediat, Giessen, Germany.	bettina.ruf@paediat.med.uni-giessen.de		Jodicke, Andreas/0000-0003-4584-4875			BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bruce DA, 2000, CHILD NERV SYST, V16, P755, DOI 10.1007/PL00013720; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Orliaguet GA, 1997, ANESTH ANALG, V85, P1218; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; REKATE HL, 2000, CHILD NERV SYST, V17, P632; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; Suzuki K., 1990, NAGOYA MED J, V34, P159; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	29	86	89	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	DEC	2003	7	6					R133	R138		10.1186/cc2361			6	Critical Care Medicine	General & Internal Medicine	751FL	WOS:000187042100002	14624687	DOAJ Gold, Green Published			2021-06-18	
J	Andersson, EH; Bjorklund, R; Emanuelson, I; Stalhammar, D				Andersson, EH; Bjorklund, R; Emanuelson, I; Stalhammar, D			Epidemiology of traumatic brain injury: a population based study in western Sweden	ACTA NEUROLOGICA SCANDINAVICA			English	Article						traumatic brain injury; epidemiology; incidence	HEAD-INJURY	Background - This study on traumatic brain injury (TBI) is based on prospective and retrospective population based data from a head injury register in Boras. Methods - Data was collected from the hospital emergency unit, the discharge register, the regional neurosurgical clinic and the coroner's records during 1 year. This district is mixed urban and rural with a population of 138 000. Results - The 753 cases identified represent an incidence of 546 per 100 000 which includes deaths (0.7%), hospital admissions (67%) and attendance at the emergency department in patients not admitted (32%). Males (644 per 100 000), had 1.46 higher overall rate than females (442 per 100 000). The external causes were dominated by fall from same level (31%) and fall from different level (27%) followed by traffic accidents (16%) and persons hit by objects (15%). Conclusions - The incidence of TBI found in this study is high but well in accordance with earlier published Swedish studies.	Cent Hosp Boras, Dept Rehabil Med, Boras, Sweden; Sahlgrenska Univ Hosp, Dept Hlth Women & Children, Gothenburg, Sweden; Sahlgrenska Univ Hosp, Inst Clin Neurosci, Gothenburg, Sweden	Andersson, EH (corresponding author), Boras Lasarett, Dept Rehabil Med, SE-50182 Boras, Sweden.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CARLSSON GS, 1986, THESIS GOTHENBURG U; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Eker C, 2000, BRAIN INJURY, V14, P605; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P581; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	17	86	92	0	4	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	APR	2003	107	4					256	259		10.1034/j.1600-0404.2003.00112.x			4	Clinical Neurology	Neurosciences & Neurology	663MB	WOS:000182008400003	12675698				2021-06-18	
J	Murphy, SJ; Littleton-Kearney, MT; Hurn, PD				Murphy, SJ; Littleton-Kearney, MT; Hurn, PD			Progesterone administration during reperfusion, but not preischemia alone, reduces injury in ovariectomized rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						experimental stroke; progesterone; hormone replacement therapy	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; GABA-A RECEPTOR; STROKE INJURY; BLOOD-FLOW; FEMALE; ESTROGEN; RECOVERY; DAMAGE; EDEMA	Although progesterone is neuroprotective in traumatic brain injury, its efficacy in stroke is unclear. The authors determined whether there are infarction differences after middle cerebral artery occlusion (MCAO) in ovariectomized rats treated acutely with progesterone before MCAO or both pre- and postischemia. Rats received vehicle, 5 (P5), 10 (P10), or 20 (P20) mg/kg progesterone intraperitoneally 30 minutes before MCAO. In another cohort, animals received vehicle or 5 (P5R) mg/kg progesterone intraperitoneally 30 minutes before MCAO, at reperfusion initiation, and at 6-hour reperfusion. Animals underwent 2-hour MCAO by the intraluminal filament technique, followed by 22-hour reperfusion. Cortical (CTX) and caudate-putamen (CP) infarctions were determined by 2,3,5-triphenyltetrazolium chloride staining and digital image analysis. End-ischemic and early reperfusion regional cerebral blood flow (CBF) was measured by [C-14]-iodoantipyrine quantitative autoradiography in vehicle- or progesterone (5 mg/kg)treated rats. Cortical infarction (% contralateral CTX) was 31 30% (vehicle), 39 +/- 23% (P5), 41 +/- 14% (P10), and 28 +/- 20% (P20). Caudate-putamen infarction (% contralateral CP) was 45 +/- 37% (vehicle), 62 +/- 34% (P5), 75 +/- 17% (P10), and 52 30% (P20). In vehicle and P5R groups, CTX infarction was 37 +/- 20% and *20 +/- 17%, respectively (*P < 0.05 from vehicle). In vehicle and P5R groups, CP infarction was 63 +/- 26% and 43 +/- 29%, respectively. End-ischemic regional CBF and CBF recovery during initial reperfusion was unaffected by progesterone treatment. These data suggest that progesterone administration both before MCAO and during reperfusion decreases ischemic brain injury.	Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA	Murphy, SJ (corresponding author), Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St,Blalock 1408, Baltimore, MD 21287 USA.	sjmurphy@jhmi.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR00163] Funding Source: Medline		Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; BETZ AL, 1990, ACT NEUR S, V51, P256; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gillum LA, 2000, JAMA-J AM MED ASSOC, V284, P72, DOI 10.1001/jama.284.1.72; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Grattan DR, 1996, BRAIN RES, V733, P46, DOI 10.1016/0006-8993(96)00532-X; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; HURN PD, 1998, PHARM CEREBRAL ISCHE, P379; JIANG CW, 1992, EUR J PHARMACOL, V211, P163, DOI 10.1016/0014-2999(92)90524-8; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; JUPTNER M, 1991, J STEROID BIOCHEM, V38, P141, DOI 10.1016/0960-0760(91)90119-P; JUSSOFIE A, 1995, EXP CLIN ENDOCR DIAB, V103, P196, DOI 10.1055/s-0029-1211350; KAGSTROM E, 1983, J CEREBR BLOOD F MET, V3, P170, DOI 10.1038/jcbfm.1983.24; Karas RH, 2001, J CLIN INVEST, V108, P611; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Lee WS, 1997, NAT MED, V3, P1005, DOI 10.1038/nm0997-1005; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lu GP, 1996, MICROVASC RES, V51, P393, DOI 10.1006/mvre.1996.0035; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MCCARTHY MM, 1995, HORM BEHAV, V29, P131, DOI 10.1006/hbeh.1995.1010; Moffat CA, 1998, J NEUROSCI, V18, P9556; Moran MH, 1998, BRAIN RES, V807, P84, DOI 10.1016/S0006-8993(98)00782-3; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; NEQUIN LG, 1979, BIOL REPROD, V20, P659, DOI 10.1095/biolreprod20.3.659; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Smith SS, 1998, NATURE, V392, P926, DOI 10.1038/31948; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; SMITH SS, 1991, NEUROSCIENCE, V42, P309, DOI 10.1016/0306-4522(91)90377-Z; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; STEIN DG, 1999, COGNITIVE NEUROREHAB, P73; SUTTERDUB MT, 1974, HORM METAB RES, V6, P297, DOI 10.1055/s-0028-1093852; TISCHKAU SA, 1993, P NATL ACAD SCI USA, V90, P1285, DOI 10.1073/pnas.90.4.1285; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; WEILAND NG, 1992, ENDOCRINOLOGY, V131, P2697, DOI 10.1210/en.131.6.2697; WEILAND NG, 1995, MOL BRAIN RES, V32, P271, DOI 10.1016/0169-328X(95)00087-9; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WIEST WG, 1970, ENDOCRINOLOGY, V87, P43, DOI 10.1210/endo-87-1-43; World Hlth Org, 1998, CONTRACEPTION, V57, P315; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	57	86	89	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2002	22	10					1181	1188					8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	600PF	WOS:000178399200005	12368656				2021-06-18	
J	Labombarda, F; Gonzalez, SL; Deniselle, MCG; Guennoun, R; Schumacher, M; de Nicola, AF				Labombarda, F; Gonzalez, SL; Deniselle, MCG; Guennoun, R; Schumacher, M; de Nicola, AF			Cellular basis for progesterone neuroprotection in the injured spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						choline acetyltransferase; GAP-43; Na,K-ATPase; neuroprotection; progesterone; spinal cord injury	CENTRAL-NERVOUS-SYSTEM; GAP-43 MESSENGER-RNA; TRAUMATIC BRAIN INJURY; GROWTH-FACTOR RECEPTOR; ADULT-RAT; GLUCOCORTICOID RECEPTORS; CHOLINE-ACETYLTRANSFERASE; AXONAL REGENERATION; NEUROTROPHIC FACTOR; DOWN-REGULATION	Progesterone (PROG) exerts beneficial and neuroprotective effects in the injured central and peripheral nervous system. In the present! work, we examine PROG effects on three measures of neuronal function under negative regulation (choline acetyltransferase [ChAT] and Na,K-ATPase) or stimulated (growth-associated protein [GAP-43]) after acute spinal cord transection injury in rats. As expected, spinal cord injury reduced ChAT immunostaining intensity of ventral horn neurons. A 3-day course of intensive PROG treatment of transected rats restored ChAT immunoreactivity, as assessed by frequency histograms that recorded shifts from predominantly light neuronal staining to medium, dark or intense staining typical of control rats. Transection also reduced the expression of the mRNA for the alpha3 catalytic and beta1 regulatory subunits of neuronal Na,K-ATPase, whereas PROG treatment restored both subunit mRNA to normal levels. Additionally, the upregulation observed for GAP-43 mRNA in ventral horn neurons in spinal cord-transected rats, was further enhanced by PROG administration. In no case did PROG modify ChAT immunoreactivity, Na,K-ATPase subunit mRNA or GAP-43 mRNA in control, sham-operated rats. Further, the PROG-mediated effects on these three markers were observed in large, presumably Lamina IX motoneurons, as well as in smaller neurons measuring approximately <500 mu(2). Overall, the stimulatory effects of PROG on ChAT appears to replenish acetylcholine, with its stimulatory effects on Na,K-ATPase seems capable of restoring membrane potential, ion transport and nutrient uptake. PROG effects on GAP-43 also appear to accelerate reparative responses to injury. As the cellular basis for PROG neuroprotection becomes better understood it may prove of therapeutic benefit to spinal cord injury patients.	Univ Buenos Aires, Fac Med, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Human Biochem, RA-1428 Buenos Aires, DF, Argentina; INSERM U488 Steroids & Syst Nerveux, Le Kremlin Bicetre, France; Univ Buenos Aires, Inst Ciencias Salud, Fdn Barcelo, Buenos Aires, DF, Argentina	de Nicola, AF (corresponding author), Univ Buenos Aires, Fac Med, Inst Biol & Med Expt, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Guennoun, Rachida/F-2420-2011; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371			BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Burke RE, 1977, HDB PHYSL NERVOUS SY, VI, P877; CHAO HM, 1992, MOL CELL NEUROSCI, V3, P529, DOI 10.1016/1044-7431(92)90065-A; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; CURTIS R, 1993, J NEUROCYTOL, V22, P51, DOI 10.1007/BF01183975; CURTIS R, 1993, J NEUROCYTOL, V22, P39, DOI 10.1007/BF01183974; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Deniselle MCG, 1999, BRAIN RES, V841, P78, DOI 10.1016/S0006-8993(99)01783-7; Derfoul A, 1998, J BIOL CHEM, V273, P20702, DOI 10.1074/jbc.273.33.20702; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; DUNCAN GE, 1984, BRAIN RES, V307, P321, DOI 10.1016/0006-8993(84)90486-4; EIDELBERG E, 1989, BRAIN RES BULL, V22, P39, DOI 10.1016/0361-9230(89)90125-1; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; Elliott EJ, 1997, BRAIN RES, V755, P221, DOI 10.1016/S0006-8993(97)00100-5; FARMAN N, 1994, AM J PHYSIOL, V266, pC423; FERRINI M, 1995, LIFE SCI, V57, P2403, DOI 10.1016/0024-3205(95)02236-3; FERRINI M, 1993, CELL MOL NEUROBIOL, V13, P387, DOI 10.1007/BF00711579; Forger NG, 1998, J NEUROSCI, V18, P8720; Gonzalez S, 1996, NEUROREPORT, V7, P1041, DOI 10.1097/00001756-199604100-00017; Gonzalez SL, 1999, CELL MOL NEUROBIOL, V19, P597, DOI 10.1023/A:1006980301382; Grillo C, 1997, BRAIN RES, V767, P120, DOI 10.1016/S0006-8993(97)00541-6; GUTH L, 1994, P NATL ACAD SCI USA, V91, P12308, DOI 10.1073/pnas.91.25.12308; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; JOHNSON H, 1995, J COMP NEUROL, V359, P69, DOI 10.1002/cne.903590106; JONES KJ, 1993, BRAIN RES BULL, V30, P491, DOI 10.1016/0361-9230(93)90283-H; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; KOU SY, 1995, J NEUROBIOL, V27, P561, DOI 10.1002/neu.480270410; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; MCKINNEY M, 1994, MOL BRAIN RES, V23, P213, DOI 10.1016/0169-328X(94)90228-3; MEIRI H, 1986, BRAIN RES, V385, P193, DOI 10.1016/0006-8993(86)91566-0; Nacimiento W, 1996, BRAIN RES, V714, P177, DOI 10.1016/0006-8993(95)01534-5; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; ORTH DN, 1998, WILLIAMS TXB ENDOCRI, P605; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Peluso JJ, 1999, BIOL REPROD, V60, P290, DOI 10.1095/biolreprod60.2.290; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; RENDE M, 1995, J COMP NEUROL, V363, P249, DOI 10.1002/cne.903630207; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SANNE JL, 1995, J NEUROCHEM, V65, P528; Schmitt AB, 1999, NEUROBIOL DIS, V6, P122, DOI 10.1006/nbdi.1998.0231; Siegel S., 1989, NONPARAMETRIC STAT B; STAHL WL, 1986, NEUROCHEM INT, V8, P449, DOI 10.1016/0197-0186(86)90179-8; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; STEINER T J, 1972, Journal of Physiology (Cambridge), V222, P123; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; VEDECKIS WV, 1992, P SOC EXP BIOL MED, V199, P1; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425; WOOLE NJ, 1989, NEUROSCIENCE, V30, P143, DOI 10.1016/0306-4522(89)90360-6; YAN Q, 1994, J NEUROSCI, V14, P5281; YU WH, 1989, BRAIN RES, V49, P379; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	61	86	93	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					343	355		10.1089/089771502753594918			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900006	11939502				2021-06-18	
J	Castriotta, RJ; Lai, JM				Castriotta, RJ; Lai, JM			Sleep disorders associated with traumatic brain injury.	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 12-13, 1999	WASHINGTON, D.C.	Amer Acad Phys Med & Rehabil		craniocerebral trauma; hypersomnia; rehabilitation; sleep apnea; obstructive; sleep-disordered breathing	POSTTRAUMATIC NARCOLEPSY; DAYTIME SLEEPINESS; APNEA; ACCIDENTS	Objectives: To investigate the frequency of sleep disorders in traumatic brain injury (TBI) patients with hypersomnia and to discern the relationship between posttraumatic sleep disorders and pretraumatic sleep symptoms. Design: Prospective cohort study using the criterion standard to diagnose sleep disorders in a consecutive sample of TBI patients. Setting: Academic medical center with level I trauma center, rehabilitative medicine services, and accredited sleep disorders center. Patients: Ten TBI patients with subjective excessive sleepiness. Intervention: Nocturnal polysomnography followed by Multiple Sleep Latency Test. Subjects who had overt sleep apnea on the first nocturnal polysomnography had a second nocturnal polysomnography with titration of nasal continuous positive airway pressure. Main Outcome Measures: Diagnosis of sleep-disordered breathing, narcolepsy, and posttraumatic hypersomnia. Results: A diagnosis of treatable sleep disorder was made in all 10 subjects. Sleep-disordered breathing was found in 7 subjects: overt obstructive sleep apnea (OSA) was diagnosed in 5 subjects, rapid eye movement-related OSA in 1, and upper airway resistance syndrome (UARS) in 1. Narcolepsy was diagnosed in 2 subjects, and the diagnosis of posttraumatic hypersomnia was made in 1 subject. Three subjects had symptoms of hypersomnia before their injury (1 each with narcolepsy, OSA, UARS), and 2 of these were driving a car at the time of injury. Conclusion: Treatable sleep disorders appear to be common in the sleepy TBI population, but may be largely undiagnosed and untreated.	Univ Texas, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Mem Hermann Hosp, Sleep Disorders Ctr, Houston, TX USA	Castriotta, RJ (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, 6431 Fannin,Ste 1-266, Houston, TX 77030 USA.	Richard.J.Castriotta@uth.tmc.edu	Castriotta, Richard/B-1158-2009; Sanguansri, Luz/B-6630-2011; Lang, Steven/AAE-8102-2021	Sanguansri, Luz/0000-0003-1908-7604; Lang, Steven/0000-0003-1669-9146; Castriotta, Richard/0000-0003-3502-4558			CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; *CDCP, IN PRESS TRAUM INJ U; CHESNUT RM, 1999, AGENCY HLTH CARE HLT; DERDERIAN SS, 1988, CHEST, V94, P1023, DOI 10.1378/chest.94.5.1023; Engleman HM, 2000, SLEEP, V23, pS102; FINDLEY LJ, 1986, CHEST, V90, P686, DOI 10.1378/chest.90.5.686; Gill AW, 1941, LANCET, V1, P474; GOOD JL, 1989, J NEUROSURG, V71, P765, DOI 10.3171/jns.1989.71.5.0765; GREENBERG GD, 1987, SLEEP, V10, P254, DOI 10.1093/sleep/10.3.254; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Horstmann S, 2000, SLEEP, V23, P383; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MONTPLAISIR J, 1992, SLEEP S6, V15, pS517; RECHSTHAFFEN A, 1968, BRAIN INFORMATION SE; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705	22	86	88	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2001	82	10					1403	1406		10.1053/apmr.2001.26081			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	479NQ	WOS:000171410800009	11588744				2021-06-18	
J	Macciocchi, SN; Barth, JT; Littlefield, L; Cantu, RC				Macciocchi, SN; Barth, JT; Littlefield, L; Cantu, RC			Multiple concussions and neuropsychological functioning in collegiate football players	JOURNAL OF ATHLETIC TRAINING			English	Article						sports injuries; neuropsychological tests; symptoms	RECOVERY; SPORTS	Objective: To document neurocognitive and neurobehavioral consequences of 1 versus 2 concussions. Design and Setting: Nonequivalent, pretest-posttest cohort design with multiple dependent measures. Participants were selected from a large sample of athletes who participated in a comprehensive, multiuniversity study of football-related concussion. Subjects: College football players who sustained 1 and 2 grade 1 concussive injuries were matched for age, education, and duration of competitive football. Measurements: Neuropsychological tests and symptoms checklists. Results: Multivariate analysis of variance did not show a statistically significant difference in test performance between players with 1 or 2 concussions. Chi square analyses revealed that concussions significantly increased the number of symptom complaints, but symptoms returned to baseline by 10 days post-injury. The effects of 2 injuries did not appear to be significantly greater than that of a single injury. Differences in response to concussion were observed. Conclusions: Neurocognitive and neurobehavioral consequences of 2 concussions did not appear to be significantly different from those of 1 concussion, but methodologic issues place limitations on data interpretation. Additional studies are needed to clarify the neuropsychological consequences of multiple concussions.	Shepherd Ctr, Atlanta, GA 30309 USA; Emory Univ, Atlanta, GA 30322 USA; Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; Washington Coll, Chestertown, MD USA; Emerson Hosp, Concord, MA USA	Macciocchi, SN (corresponding author), Shepherd Ctr, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.						Barth JT, 1989, MILD HEAD INJURY; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; MACCIOCCHI SN, 2000, NEUROLOGIC ATHLETIC, P101; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Spreen O., 1998, COMPENDIUM NEUROPSYC; Wechsler D., 2008, WECHSLER ADULT INTEL	11	86	88	0	10	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					303	306					4	Sport Sciences	Sport Sciences	557NC	WOS:000175913800014					2021-06-18	
J	Couch, JR; Bearss, C				Couch, JR; Bearss, C			Chronic daily headache in the posttrauma syndrome: Relation to extent of head injury	HEADACHE			English	Article						head injury; posttraumatic headache; chronic daily headache	EPIDEMIOLOGY; POPULATION; CONCUSSION; TRAUMA; BRAIN	Objective.-To evaluate the occurrence of continued intermittent headache and chronic daily headache in patients with head injury and the relationship between severity of the headache problem and intensity of the head injury, Background.-In the majority of patients with posttraumatic headache, the condition is self-limited, but a minority of patients may develop persistent headaches. The features of posttraumatic headache may vary, but the most distressing type is the chronic daily headache. This study evaluates occurrence of chronic daily headache in relation to the intensity of head injury. Methods.-All patients with head injury who were seen by the senior author (J.R.C.) in the Southern Illinois University Medical School (SIUMS) Neurology Clinic between 1980 and 1991 were identified from the SIUMS headache registry. Data on headache status before and after head injury was obtained, and patients with more than one headache per week before head injury were excluded. Each patient's headache status at the time of the clinic visit was classified as chronic daily headache (headache occurring at least 5 of 7 days for 6 months), intermittent migraine, or no headache. Head injury severity was graded by duration of loss of consciousness or amnesia as minimal (less than 5 minutes), mild (5 to 60 minutes), moderate (1 to 24 hours), or severe (more than 24 hours). Results.-There was an inverse relation between extent of head injury and occurrence of chronic daily headache. For minimal head injury (n = 54), 80% had chronic daily headache, and 11% had no headache, while for moderate/severe head injury (n = 23), only 27% had chronic daily headache, and 68% had no headache (P<,001, <chi>(2)) Conclusion.-This study suggests that the risk of developing posttraumatic chronic daily headache is greater for less severe head injury compared with moderate/severe head injury. The reason for this relation is unclear.	Univ Oklahoma, Hlth Sci Ctr, Dept Neurol, Oklahoma City, OK 73190 USA; So Illinois Univ, Sch Med, Carbondale, IL 62901 USA	Couch, JR (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Neurol, 711 Stanton L Young Blvd, Oklahoma City, OK 73190 USA.						Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; Cartlidge NEF, 1981, HEAD INJURY, P95; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; COUCH JR, 1995, J NEUROL REHABIL, V9, P83; COUCH JR, 1998, HEADACHE, V38, P5; FRIEDMAN AP, 1969, LATE EFFECTS HEAD IN, V5, P55; GUTMAN E, 1943, LANCET, V1, P10; *HEAD CLASS COMM I, 1988, CEPHALALGIA S7, V8, P10; KAY DWK, 1971, LANCET, V2, P1052; KELLY R, 1981, J ROY SOC MED, V74, P242; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; RASKIN NH, 1987, HEADACHE, V27, P416, DOI 10.1111/j.1526-4610.1987.hed2708416.x; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1001/jama.279.5.381; SIMONS DJ, 1946, PSYCHOSOM MED, V8, P227, DOI 10.1097/00006842-194607000-00001; SPEED WG, 1989, HEADACHE, V29, P643, DOI 10.1111/j.1526-4610.1989.hed2910643.x; Symonds CP, 1943, LANCET, V1, P7; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67; WELCH KMA, 1990, NEUROL CLIN, V8, P817, DOI 10.1016/S0733-8619(18)30319-0	25	86	89	0	1	BLACKWELL SCIENCE INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0017-8748			HEADACHE	Headache	JUN	2001	41	6					559	564		10.1046/j.1526-4610.2001.041006559.x			6	Clinical Neurology	Neurosciences & Neurology	447TC	WOS:000169587700007	11437891				2021-06-18	
J	Kersel, DA; Marsh, NV; Havill, JH; Sleigh, JW				Kersel, DA; Marsh, NV; Havill, JH; Sleigh, JW			Neuropsychological functioning during the year following severe traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; RECOVERY; COMA	The neuropsychological functioning of a group of 65 adults with severe traumatic brain injury was assessed at 6 months and 1 year post-injury. The cognitive domains assessed were pre-morbid intellectual level, current level of general intellectual functioning, simple and complex attention, verbal memory, executive functioning, and perceptual functioning. At least 40%, and up to 74%, of the TBI patients displayed some degree of impairment on tests administered at 6 months. Improvement was found to occur in all areas of cognitive functioning over the first year following injury. Despite this improvement at least 31%, and up to 63%, of TBI patients displayed some degree of impairment on tests administered at 1 year post-injury. The various types of neuropsychological functioning were affected to different degrees, indicating that different aspects of cognition are more susceptible to injury, and that recovery takes place at a differential rate across functions. The implications of these findings for the appropriate planning and allocation of treatment and rehabilitation resources, and the development of effective rehabilitation interventions are outlined.	Univ Waikato, Dept Psychol, Hamilton, New Zealand; Waikato Hosp, Intens Care Unit, Hamilton, New Zealand	Marsh, NV (corresponding author), Univ Waikato, Dept Psychol, Private Bag 3105, Hamilton, New Zealand.	mvmarsh@waikato.ac.nz	Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432			Bond M R, 1975, Ciba Found Symp, P141; Brooks D N, 1979, Int Rehabil Med, V1, P166; Brooks D N, 1979, Int Rehabil Med, V1, P160; Brooks D. N, 1990, REHABILITATION ADULT, P163; CARADOCDAVIES TH, 1995, NEUROEPIDEMIOLOGY, V14, P199, DOI 10.1159/000109797; Conkey RC, 1938, ARCH PSYCHOL, P5; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; DYE OA, 1979, ACTA NEUROL SCAND, V59, P10; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Havill JH, 1998, NEW ZEAL MED J, V111, P161; JENNETT B, 1975, LANCET, V1, P480; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Reynell WR, 1944, J MENT SCI, V90, P710; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; Spreen O., 1998, COMPENDIUM NEUROPSYC; *SPSS INC, 1998, SPSS BASE 8 0 US GUI; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TOOTH G, 1947, J NEUROL NEUROSUR PS, V10, P1, DOI 10.1136/jnnp.10.1.1; Vogenthaler D R, 1987, Brain Inj, V1, P113	34	86	89	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2001	15	4					283	296		10.1080/02699050010005887			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	420ZK	WOS:000168035000001	11299130				2021-06-18	
J	Vanderploeg, RD; Crowell, TA; Curtiss, G				Vanderploeg, RD; Crowell, TA; Curtiss, G			Verbal learning and memory deficits in traumatic brain injury: Encoding, consolidation, and retrieval	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; PATTERNS; PERFORMANCE	The present study examined the nature of verbal memory deficits in individuals with traumatic brain injury (TBI) compared to healthy controls. The study was designed to control for methodological shortcomings of previous related research. Three groups of participants were used: (a) a head injured sample with moderate to severe traumatic brain injuries (N = 55), (b) a control sample matched on age and initial performance on CVLT Trial 5 and Sum of Trials 1 to 5 (N = 55), and (c) a control sample matched on age, education, and race, but not on initial CVLT learning performance (N = 55). Current findings indicate that: (a) rate of learning was comparable across groups, consistent with no encoding differences, (b) TBI patients have a significantly more rapid rate of forgetting of new information than either acquisition-matched or demographic-matched controls, consistent with consolidation problems in TBI, (c) TBI patients have less proactive interference than demographic-matched control participants, consistent with a consolidation problem in the TBI group, (d) TBI patients and acquisition-matched controls have comparably low rates of proactive interference, consistent with impaired acquisition in both of these groups, and (e) TBI patients and controls do not differ in the benefit experienced from semantic or recognition retrieval cues, consistent with no differences in retrieval processes. These data support an impaired consolidation hypothesis, rather than encoding or retrieval deficits, as the primary deficit underlying memory impairment in TBI.	Univ S Florida, James A Haley Vet Adm Med Ctr, Tampa, FL 33620 USA; Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA; Univ S Florida, Dept Neurol, Tampa, FL 33620 USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Def & Vet Head Injury Program, Washington, DC USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychiat Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				[Anonymous], 1988, JAMA, V259, P2701; Baum KM, 1996, CLIN NEUROPSYCHOL, V10, P340; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; Carlesimo GA, 1997, CORTEX, V33, P131, DOI 10.1016/S0010-9452(97)80009-3; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COOKE DL, 1995, J CLIN EXP NEUROPSYC, V17, P90, DOI 10.1080/13803399508406585; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; CURTIS G, IN PRESS J INT NEURO; Delis DC, 1987, CALIFORNIA VERBAL LE; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; ERICKSON RC, 1977, PSYCHOL BULL, V84, P1130, DOI 10.1037/0033-2909.84.6.1130; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; Hart R. P., 1994, NEUROPSYCHOLOGY, V8, P325, DOI [10.1037/0894-4105.8.3.325, DOI 10.1037/0894-4105.8.3.325]; Kirk R. E., 1995, EXPT DESIGN PROCEDUR; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kramer J. H., 1991, PSYCHOL ASSESSMENT J, V3, P299; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; NOVACK TA, 1995, CLIN NEUROPSYCHOL, V9, P38; Numan B, 2000, J CLIN PSYCHOL, V56, P553, DOI 10.1002/(SICI)1097-4679(200004)56:4<553::AID-JCLP8>3.0.CO;2-Q; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PANIAK CE, 1989, J CLIN EXP NEUROPSYC, V11, P631, DOI 10.1080/01688638908400921; Riggs, 1971, WOODWORTH SCHLOSBERG, P1019; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; Spencer J, 1998, CLIN NEUROPSYCHOL, V12, P296; Squire L. R., 1983, MEMORY CONSOLIDATION, P185; SQUIRE LR, 1987, MEMORY BRAIN; VANDERPLOEG RD, 1990, ANN M AM PSYCH ASS B; Wechsler D., 1981, WAIS R MANUAL WECHSL; Wilde MC, 1995, J CLIN EXP NEUROPSYC, V17, P849, DOI 10.1080/01688639508402434; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	35	86	87	2	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	2					185	195		10.1076/jcen.23.2.185.1210			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	412QZ	WOS:000167567000005	11309672				2021-06-18	
J	Gilad, GM; Gilad, VH				Gilad, GM; Gilad, VH			Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats	NEUROSCIENCE LETTERS			English	Article						decarboxylated arginine; motoneurons; neuroprotective treatment; neurotrauma; transient ischemia; rat model	CLONIDINE-DISPLACING SUBSTANCE; NITRIC-OXIDE SYNTHASE; NEURONAL DAMAGE; BRAIN; POLYAMINES; INHIBITION; ARGININE; RECEPTOR; DECARBOXYLATION; ACCUMULATION	Treatment with agmatine, decarboxylated arginine, proved to be non-toxic and to exert neuroprotective effects in several models of neurotoxic and ischemic brain and spinal cord injuries. Here we sought to find out whether agmatine treatment would also prove beneficial in a rat spinal cord ischemia model (balloon occlusion of the abdominal aorta bellow the branching point of the left subclavian artery for 5 min). Agmatine was injected (100 mg/kg, i.p.) 5 min after beginning of re-perfusion and again once daily for the next 3 post-operative days. Motor performance ('combined motor score') was recorded for up to 17 days post-operative and motoneuron cell counts (in representative spinal cord sections) performed on the 17th post-operative day. Agmatine treatment was found to accelerate recovery of motor deficits and to prevent the loss of motoneurons in the spinal cord after transient ischemia. Together, the present and previous findings demonstrate that agmatine is an efficacious neuroprotective agent and that this naturally occurring non-toxic compound should be tried for therapeutic use after neurotrauma and in neurodegenerative diseases. (C) 2000 Published by Elsevier Science Ireland Ltd.	Assaf Harofeh Med Ctr, Lab Neurosci Res & Dev, IL-70300 Zerifin, Israel	Gilad, GM (corresponding author), Assaf Harofeh Med Ctr, Lab Neurosci Res & Dev, PO Beer Yaakov, IL-70300 Zerifin, Israel.		Gilad, Gad M/E-7193-2010				AriciogluKartal F, 1997, LIFE SCI, V61, P1775, DOI 10.1016/S0024-3205(97)00801-1; AUGUET M, 1995, JPN J PHARMACOL, V69, P285, DOI 10.1254/jjp.69.285; BREWER KL, 1998, SOC NEUR ABSTR, V24, P577; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; Fairbanks CA, 2000, P NATL ACAD SCI USA, V97, P10584, DOI 10.1073/pnas.97.19.10584; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GILAD GM, 1991, EXP NEUROL, V111, P349, DOI 10.1016/0014-4886(91)90102-I; Gilad GM, 1996, NEUROREPORT, V7, P1730, DOI 10.1097/00001756-199607290-00007; GILAD GM, 1993, MOL CHEM NEUROPATHOL, V18, P197, DOI 10.1007/BF03160034; Gilad GM, 1996, NEUROSCI LETT, V216, P33; GILAD GM, 1995, LIFE SCI, V58; HARA H, 1993, PROG NEUROBIOL, V40, P645, DOI 10.1016/0301-0082(93)90009-H; Kolesnikov Y, 1996, EUR J PHARMACOL, V296, P17, DOI 10.1016/0014-2999(95)00669-9; KOMORI Y, 1994, ARCH BIOCHEM BIOPHYS, V315, P213, DOI 10.1006/abbi.1994.1492; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; LORING RH, 1990, BRIT J PHARMACOL, V99, P207, DOI 10.1111/j.1476-5381.1990.tb14680.x; MARSALA M, 1994, J CEREBR BLOOD F MET, V14, P526, DOI 10.1038/jcbfm.1994.65; MARX M, 1995, NEPHRON, V69, P155, DOI 10.1159/000188432; MURAYAMA T, 1993, BIOCHEMISTRY-US, V32, P561, DOI 10.1021/bi00053a022; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; PFEIFFER B, 1981, H-S Z PHYSIOL CHEM, V362, P1331, DOI 10.1515/bchm2.1981.362.2.1331; PILETZ JE, 1995, J PHARMACOL EXP THER, V272, P581; PINTHONG D, 1995, BRIT J PHARMACOL, V115, P689, DOI 10.1111/j.1476-5381.1995.tb14988.x; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; Sastre M., 1995, Society for Neuroscience Abstracts, V21, P2059; SENER A, 1989, BIOCHEM PHARMACOL, V38, P327, DOI 10.1016/0006-2952(89)90044-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; VLASSARA H, 1994, LAB INVEST, V70, P138; WEITZEL G, 1980, H-S Z PHYSIOL CHEM, V361, P51, DOI 10.1515/bchm2.1980.361.1.51; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544	32	86	88	0	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	DEC 22	2000	296	2-3					97	100		10.1016/S0304-3940(00)01625-6			4	Neurosciences	Neurosciences & Neurology	383AP	WOS:000165859800009	11108990				2021-06-18	
J	Sanders, MJ; Sick, TJ; Perez-Pinzon, MA; Dietrich, WD; Green, EJ				Sanders, MJ; Sick, TJ; Perez-Pinzon, MA; Dietrich, WD; Green, EJ			Chronic failure in the maintenance of long-term potentiation following fluid percussion injury in the rat	BRAIN RESEARCH			English	Article						brain injury; fluid percussion; hippocampus; LTP; rat	TRAUMATIC BRAIN INJURY; PROTEIN-KINASE-C; HIPPOCAMPAL SLICES; DENTATE GYRUS; CA1 REGION; GLUTAMATE; DEFICITS; IMPAIRMENT; RECEPTORS; INDUCTION	Traumatic brain injury (TBI) can produce chronic cognitive learning/memory deficits that are thought to be mediated, in part, by impaired hippocampal function. Experimentally induced TBI is associated with deficits in hippocampal synaptic plasticity (long-term potentiation, or LTP) at acute post-injury intervals but plasticity has not been examined at long-term survival periods. The present study was conducted to assess the temporal profile of LTP after injury and to evaluate the effects of injury severity on plasticity. Separate groups of rats were subjected to mild (1.1-1.4 atm), moderate (1.8-2.1 arm), or severe (2.2-2.7 atm) fluid percussion (FP) injury (or sham surgery) and processed for hippocampal electrophysiology in the first or eighth week after injury. LTP was defined as a lasting increase in field excitatory post-synaptic potential (fEPSP) slope in area CAI following tetanic stimulation of the Schaffer collaterals. The fEPSP slope was measured for 60 min after tetanus. Assessment of LTP at the acute interval (6 days) revealed modest peak slope potentiation Values (129-139%), which declined in each group (including sham) over the hour-long recording session and did not differ between groups. Eight weeks following injury, slices from all groups exhibited robust maximal potentiation (134-147%). Levels of potentiation among groups were similar at the 5-min test interval but differed significantly at the 30- and 60-min test intervals. Whereas sham slices showed stable potentiation for the entire 60-min assessment period, slices in all of the injury groups exhibited a significant decline in potentiation over this period. These experiments reveal a previously unknown effect of TBI whereby experimentally induced injury results in a chronic inability of the CA1 hippocampus to,maintain synaptic plasticity. They also provide evidence that sham surgical procedures can significantly influence hippocampal physiology at the acute post-TBI intervals. The results have implications for the mechanisms underlying the impaired synaptic plasticity following TBI. (C) 2000 Published by Elsevier Science B.V. All rights reserved.	Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA; Univ Miami, Dept Neurol Surg, Coral Gables, FL 33124 USA; Univ Miami, Dept Neurol, Coral Gables, FL USA; Univ Miami, Program Neurosci, Coral Gables, FL USA	Sanders, MJ (corresponding author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL036588] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL36588] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 3029] Funding Source: Medline		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEHNISCH T, 1993, NEUROSCIENCE, V54, P37, DOI 10.1016/0306-4522(93)90381-O; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HIROTSU I, 1989, BRAIN RES, V482, P194, DOI 10.1016/0006-8993(89)90561-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katsuki H, 1997, NEUROSCIENCE, V76, P1113, DOI 10.1016/S0306-4522(97)80003-6; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Matthies H, 1997, NEUROREPORT, V8, P3533, DOI 10.1097/00001756-199711100-00023; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STANTON PK, 1985, J NEUROSCI, V5, P2169; STELZER A, 1994, P NATL ACAD SCI USA, V91, P3058, DOI 10.1073/pnas.91.8.3058; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; WAGNER JJ, 1993, NATURE, V363, P451, DOI 10.1038/363451a0; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287	33	86	91	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 7	2000	861	1					69	76		10.1016/S0006-8993(00)01986-7			8	Neurosciences	Neurosciences & Neurology	302DJ	WOS:000086349900008	10751566				2021-06-18	
J	Oshiro, Y; Sakurai, Y; Sato, S; Kurahashi, N; Tanaka, T; Kikuchi, T; Tottori, K; Uwahodo, Y; Miwa, T; Nishi, T				Oshiro, Y; Sakurai, Y; Sato, S; Kurahashi, N; Tanaka, T; Kikuchi, T; Tottori, K; Uwahodo, Y; Miwa, T; Nishi, T			3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: Synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone and its derivatives	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; THYROTROPIN-RELEASING-HORMONE; ANTI-DEPRESSANT DRUGS; AFFECTIVE-DISORDERS; CEREBROPROTECTIVE AGENTS; STIMULATING ACTIVITY; BEHAVIORAL DESPAIR; SIGMA-RECEPTORS; CNS AGENTS; LIGANDS	To develop a novel antidepressant drug with central nervous system-stimulating activity, me prepared a series of 1-[w-(4-substituted phenyl-1-piperazinyl)alkyl]-3,4-dihydro-2(1H)-quinlinone derivatives and examined their activities by their effects at 30 and 100 mg/kg po on the sleeping time of mice anesthetized with halothane and on the time required for recovery from coma induced in mice by cerebral concussion. We examined their binding affinities for a receptors by evaluating their ability to inhibit [H-3]-1,3-di(o-tolyl)guanidine ([H-3]DTG) binding to the rat whole brain membrane in comparison with three putative a receptor agonists: 1,3-di(o-tolyl)guanidine (DTG, 66), (+)-1,2,3,4,5,6-hexahydro-6,11-dimethylmethano-3-benzazecin-8-ol (SKF10,047, 67), and (+)-1,2,3,4,5,6-hexahydro-6, 11-dimethyl-3(3 -methyl-2-butenyl)-2,6-methano-3-benzazecin-8-ol (pentazocine, 68). Among the series of derivatives, 1-3-[4-(3-chlorophenyl)-1-piperazinyl]-3p linone hydrochloride (34b) and its mesylate (34c), at a dose of 30 mg/kg po, reduced the sleeping time and the time for recovery from coma and they inhibited [H-3]DTG binding for a receptors. The putative a receptor agonists reduced the sleeping time and the time for recovery from coma whereas two a receptor antagonists, alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl) piperazinebutanol hydrochloride (BMY14802, 69) and cis-9-[3-(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride (rimcazole, 70), were inactive in the two tests. Preadministration of the putative a receptor antagonists 69 (3 mg/kg po) and 70 (30 mg/kg po) completely antagonized the actions of 34b and the a receptor agonists in the test for recovery from coma. These results suggested that 34b and 34c are a receptor agonists. Furthermore, a single administration of 1 and 10 mg/kg po 34b and 34c showed antidepressant-like activity by reducing the immobility time in the forced-swimming test with mice, while a tricyclic antidepressant, 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride (imipramine, 1) (10 and 30 mg/kg po), did not reduce the time after a single administration. 1 reduced the time after repeated administration of 30 mg/kg po once a day for 4 days. The structure-activity relationship of the series of compounds is also discussed.	Otsuka Pharmaceut Co Ltd, Tokushima Inst New Drug Res 3, Kawauchi, Tokushima 7710192, Japan	Oshiro, Y (corresponding author), Otsuka Pharmaceut Co Ltd, Tokushima Inst New Drug Res 3, 463-10 Kagasuno, Kawauchi, Tokushima 7710192, Japan.						ABOUGHARBIA M, 1993, ANNU REP MED CHEM, V28, P1; ALEY KO, 1989, N-S ARCH PHARMACOL, V339, P306; BANNO K, 1988, CHEM PHARM BULL, V36, P4377; BANNO K, Patent No. 8149359; BLACKWELL B, 1981, DRUGS, V21, P201, DOI 10.2165/00003495-198121030-00002; BLACKWELL B, 1981, DRUGS, V21, P273, DOI 10.2165/00003495-198121040-00003; BORSINI F, 1986, EUR J PHARMACOL, V121, P265, DOI 10.1016/0014-2999(86)90498-X; Callahan AM, 1997, BIOL PSYCHIAT, V41, P264, DOI 10.1016/S0006-3223(97)00372-7; FERNANDEZ M, 1994, HETEROCYCLES, V38, P2615; HAVERA HJ, 1969, J MED CHEM, V12, P580, DOI 10.1021/jm00304a004; HEALY D, 1987, PSYCHOPHARMACOLOGY, V93, P271; ISHIKAWA H, 1989, CHEM PHARM BULL, V37, P2103; ITOH K, 1984, CHEM PHARM BULL, V32, P130; ITZHAK Y, 1990, LIFE SCI, V47, P1073, DOI 10.1016/0024-3205(90)90165-N; JANOWSKY DS, 1994, AM J MED GENET, V54, P335, DOI 10.1002/ajmg.1320540412; KIKUCHI T, UNPUB; Lancel M, 1996, NEUROPSYCHOPHARMACOL, V15, P63, DOI 10.1016/0893-133X(95)00157-9; LONDON JD, 1955, J CHEM SOC, P739; LONGONI B, 1993, J PHARMACOL EXP THER, V266, P153; LYSER D, 1994, ANNU REP MED CHEM, V29, P1; Maj Jerzy, 1996, Polish Journal of Pharmacology, V48, P379; MANAKA S, 1977, IGAKU NO AYUMI, V102, P867; Matsuno K, 1996, EUR J PHARMACOL, V312, P267, DOI 10.1016/0014-2999(96)00497-9; MATSUYAMA T, Patent No. 8541670; MAYER F, 1927, CHEM BER, V60, P858; MISZTAL S, 1992, MED CHEM RES, V2, P82; MIYAMOTO M, 1981, LIFE SCI, V28, P861, DOI 10.1016/0024-3205(81)90047-3; MOKROSZ JL, 1994, ARCH PHARM, V327, P529, DOI 10.1002/ardp.19943270811; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OSHIRO Y, 1991, J MED CHEM, V34, P2014, DOI 10.1021/jm00111a014; OSHIRO Y, 1991, J MED CHEM, V34, P2004, DOI 10.1021/jm00111a013; OTSUBO J, Patent No. 8242679; PINDER RM, 1993, MED RES REV, V13, P259, DOI 10.1002/med.2610130304; POLLARD CB, 1954, J AM CHEM SOC, V76, P1853, DOI 10.1021/ja01636a034; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; SCATTON B, 1987, J PHARMACOL EXP THER, V241, P251; SCHOENWALD RD, 1995, LIFE SCI, V56, P1275, DOI 10.1016/0024-3205(95)00073-9; SHIGEMATSU N, 1961, CHEM PHARM BULL, V9, P970; Shimidzu T, 1997, EUR J PHARMACOL, V338, P225, DOI 10.1016/S0014-2999(97)81925-5; SHONO T, 1981, J ORG CHEM, V46, P3719, DOI 10.1021/jo00331a027; Soares JC, 1996, DRUGS, V52, P477, DOI 10.2165/00003495-199652040-00001; Stocca G, 1996, PEPTIDES, V17, P1197, DOI 10.1016/S0196-9781(96)00128-3; TAMURA Y, 1970, CHEM IND-LONDON, P1435; TAMURA Y, 1972, YAKUGA ZASSHI, V92, P772, DOI 10.1248/yakushi1947.92.6_772; TAMURA Y, 1975, CHEM IND-LONDON, P922; TURNBULL MJ, 1976, BRIT J PHARMACOL, V58, P27, DOI 10.1111/j.1476-5381.1976.tb07689.x; WALKER JM, 1990, PHARMACOL REV, V42, P355; WETTSTEIN JG, 1991, PSYCHOPHARMACOLOGY, V104, P157, DOI 10.1007/BF02244171	48	86	88	0	9	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623			J MED CHEM	J. Med. Chem.	JAN 27	2000	43	2					177	189		10.1021/jm980333v			13	Chemistry, Medicinal	Pharmacology & Pharmacy	279FP	WOS:000085034000006	10649973				2021-06-18	
J	Fasotti, L; Kovacs, F; Eling, PATM; Brouwer, WH				Fasotti, L; Kovacs, F; Eling, PATM; Brouwer, WH			Time pressure management as a compensatory strategy training after closed head injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							ANTICIPATORY BEHAVIOR DEFICITS; PERFORMANCE; ATTENTION; BRAIN	Following severe closed head injury, deficits in speed of information processing are common. As a result, many head-injured patients experience a feeling of "information overload" in daily tasks that once were relatively easy. Many remedial programmes have been designed that treat different aspects of attention (often including mental speed requirements) by repetitive exercises. In the present study, a different approach to slow information processing has been taken, namely Time Pressure Management (TPM). TPM consists of a set of alternative cognitive strategies that allow head-injured patients in real-life tasks to compensate for their mental slowness. In a randomised pre-training vs. post-training vs. follow-up group study, the effectiveness of TPM training was compared with concentration training in which verbal instruction was the key element. The results indicate that specific TPM strategies are learned by the experimental subjects but that both treatments improve task performance significantly for an information intake task. TPM, however, produces greater gains than concentration training and also appears to generalise to other measures of speed and memory function.	St Maartensklin Res, NL-6500 GM Nijmegen, Netherlands; Rijnlands Zeehospitium, Katwijk Aan Zee, Netherlands; Univ Nijmegen, Dept Comparat & Physiol Psychol, Nijmegen, Netherlands; Univ Groningen, Dept Neuropsychol & Gerontol, Groningen, Netherlands			Eling, Paul/D-5786-2012				BLEIBERG J, 1985, INT J CLIN NEUROPSYC, V7, P153; BROUWER WH, 1985, THESIS STATE U GRONI; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; FREEDMAN PE, 1987, J NEUROL NEUROSUR PS, V50, P398, DOI 10.1136/jnnp.50.4.398; GRONWALL DMA, 1981, J NEUROL NEUROSUR PS, V44, P880; Meichenbaum D., 1977, COGNITIVE BEHAV MODI; Meichenbaum D., 1980, HELPING PEOPLE CHANG; MELAMED S, 1985, SCAND J REHABIL MED, P16; MICHON JA, 1979, SUMM REP WORKSH TRAF; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; PONSFORD JL, 1990, COGNITIVE REHABILITA, P50; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; RUSSEL WR, 1971, TRAUMATIC AMNESIAS; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1992, NEUROPSYCHOL REHABIL, P183; VANZOOMEREN AH, 1981, THESIS STATE U GRONI; Ylvisaker M., 1987, COMMUNITY REENTRY HE, P137	23	86	87	0	20	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	2000	10	1					47	65		10.1080/096020100389291			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	290TT	WOS:000085694500004					2021-06-18	
J	Hicks, RR; Martin, VB; Zhang, L; Seroogy, KB				Hicks, RR; Martin, VB; Zhang, L; Seroogy, KB			Mild experimental brain injury differentially alters the expression of neurotrophin and neurotrophin receptor mRNAs in the hippocampus	EXPERIMENTAL NEUROLOGY			English	Article						BDNF; NT-3; trkB; trkC; hippocampus; traumatic brain injury	NERVE GROWTH-FACTOR; LONG-TERM POTENTIATION; TRKB MESSENGER-RNA; FOCAL CEREBRAL-ISCHEMIA; MOTOR-VEHICLE ACCIDENT; HEAD-INJURY; RAT FOREBRAIN; ADULT-RAT; SPREADING DEPRESSION; DOPAMINERGIC-NEURONS	The molecular events responsible for impairments in cognition following mild traumatic brain injury are poorly understood. Neurotrophins, such as brain-derived neurotrophic factor (BDNF), have been identified as having a role in learning and memory. We have previously demonstrated that following experimental brain trauma of moderate severity (2.0-2.1 atm), mRNA levels of BDNF and its high-affinity receptor, trkB, are increased bilaterally in the hippocampus for several hours, whereas NT-3 mRNA expression is decreased. In the present study, we used in situ hybridization to compare BDNF, trkB, NT-3, and trkC mRNA expression in rat hippocampus at 3 or 6 h after a lateral fluid percussion brain injury (FPI) of mild severity (1.0 atm) to sham-injured controls at equivalent time points. Mild FPI induced significant increases in hybridization levels for BDNF and trkB mRNAs, and a decrease in NT-3 mRNA in the hippocampus. However, in contrast to the bilateral effects of moderate experimental brain injury, the present changes with mild injury were restricted to the injured side. These findings demonstrate that even a mild traumatic brain injury differentially alters neurotrophin and neurotrophin receptor levels in the hippocampus. Such alterations may have important implications for neural plasticity and recovery of function in people who sustain a mild head injury. (C) 1999 Academic Press.	Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hicks, RR (corresponding author), Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035164] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35164] Funding Source: Medline		AKENYA Y, 1997, J NEUROSCI, V17, P6707; Albers KM, 1996, J CELL BIOL, V134, P487, DOI 10.1083/jcb.134.2.487; ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; Behrens MM, 1999, MICROSC RES TECHNIQ, V45, P276, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<276::AID-JEMT11>3.0.CO;2-4; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEKKER AJ, 1994, BRAIN RES, V639, P149, DOI 10.1016/0006-8993(94)91775-2; DIXON JE, 1994, DEV BRAIN RES, V77, P177, DOI 10.1016/0165-3806(94)90194-5; Dragunow M, 1997, MOL BRAIN RES, V46, P274, DOI 10.1016/S0169-328X(97)00021-1; Elmer E, 1997, EXP NEUROL, V145, P93, DOI 10.1006/exnr.1997.6478; EMFORS P, 1990, NEURON, V5, P511; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Fiumelli H, 1999, EUR J NEUROSCI, V11, P1639, DOI 10.1046/j.1460-9568.1999.00580.x; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; Goodness TP, 1997, EUR J NEUROSCI, V9, P1574, DOI 10.1111/j.1460-9568.1997.tb01515.x; Hagg T, 1998, EXP NEUROL, V149, P183, DOI 10.1006/exnr.1997.6684; Hallbook F, 1998, J NEUROSCI, V18, P8700; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Horger BA, 1999, J NEUROSCI, V19, P4110; Huber KM, 1998, NEUROPHARMACOLOGY, V37, P571, DOI 10.1016/S0028-3908(98)00050-1; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; KANG HJ, 1995, J PHYSIOLOGY-PARIS, V89, P11, DOI 10.1016/0928-4257(96)80547-X; Kariko K, 1998, J CEREBR BLOOD F MET, V18, P1308, DOI 10.1097/00004647-199812000-00005; KINDY MS, 1993, J CEREBR BLOOD F MET, V13, P372, DOI 10.1038/jcbfm.1993.50; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Kokaia M, 1998, J NEUROSCI, V18, P8730; KOKAIA Z, 1993, MOL BRAIN RES, V19, P277, DOI 10.1016/0169-328X(93)90126-A; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LAUTERBORN JC, 1994, MOL CELL NEUROSCI, V5, P46, DOI 10.1006/mcne.1994.1005; Lindsay RM, 1996, PHILOS T ROY SOC B, V351, P365, DOI 10.1098/rstb.1996.0030; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NAKAO N, 1995, EXP NEUROL, V131, P1, DOI 10.1016/0014-4886(95)90002-0; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Numan S, 1999, J COMP NEUROL, V403, P295, DOI 10.1002/(SICI)1096-9861(19990118)403:3<295::AID-CNE2>3.0.CO;2-L; Numan S, 1997, EUR J NEUROSCI, V9, P489, DOI 10.1111/j.1460-9568.1997.tb01626.x; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; ROCOMORA NE, 1996, J NEUROSCI, V16, P4411; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Seroogy K., 1997, NEUROCHEMISTRY PRACT, P121; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SINSON G, 1995, J NEUROCHEM, V65, P2209; SKAPER SD, 1993, J NEUROSCI RES, V34, P478, DOI 10.1002/jnr.490340413; Skaper SD, 1998, MOL CELL NEUROSCI, V12, P179, DOI 10.1006/mcne.1998.0714; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; Tokuyama W, 1998, MOL BRAIN RES, V62, P206, DOI 10.1016/S0169-328X(98)00261-7; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; von Meyenburg J, 1998, EXP NEUROL, V154, P583, DOI 10.1006/exnr.1998.6912; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	86	86	88	0	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	1999	160	2					469	478		10.1006/exnr.1999.7216			10	Neurosciences	Neurosciences & Neurology	264WE	WOS:000084205300016	10619564				2021-06-18	
J	Gosling, J; Oddy, M				Gosling, J; Oddy, M			Rearranged marriages: marital relationships after head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; SEXUAL DYSFUNCTION; FOLLOW-UP; UNEMPLOYMENT; DAMAGE	An in depth study of 18 heterosexual couples investigated the quality of the marital and sexual relationships 1-7 years after the male partner had suffered a severe head injury. Both quantitative and qualitative methods were employed and the focus was on the perspective of the uninjured female partner. The female partners reported both marital and sexual satisfaction as lower following injury. They rated their current marital satisfaction as significantly less than their brain injured partners. The quantitative part of the study revealed major role changes experienced by the women, with many comparing their new role to that of a parent with total decision making responsibility. The incompatibility of this role with that of sexual partner was mentioned by many. A tendency for the males to express gratitude but not to communicate their feelings was described by many women. Most women were resigned to the expectation that there would be little change in the future and, for most, the only positive aspect of the relationship was a sense of commitment and continuing companionship. The implications of the findings for rehabilitation and couple therapy an discussed.	Ticehurst House & Unsted Pk Hosp, Brain Injury Rehabil Unit, Tiechurst TN5 7HU, E Sussex, England; St Thomas Hosp, Pain Management Unit, London, England	Oddy, M (corresponding author), Ticehurst House & Unsted Pk Hosp, Brain Injury Rehabil Unit, Tiechurst TN5 7HU, E Sussex, England.						ANDERSONPARENTE JK, 1990, COGNITIVE REHABI JAN, P22; AUBRY T, 1990, J COMMUNITY PSYCHOL, V18, P99, DOI 10.1002/1520-6629(199004)18:2<99::AID-JCOP2290180202>3.0.CO;2-Y; CREWE NM, 1988, ARCH PHYS MED REHAB, V69, P435; Elliott ML, 1996, BRAIN INJURY, V10, P703, DOI 10.1080/026990596123972; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Goldberg D., 1992, GEN HLTH QUESTIONNAI; GRANT S, 1994, JOB STRESS CHANGING, P311, DOI DOI 10.1037/10165-020; HENWOOD K, 1995, PSYCHOLOGIST, V8, P115; JONES L, 1988, J DIVORCE, V12, P99; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P163; KRAVETZ S, 1995, BRAIN INJURY, V9, P131, DOI 10.3109/02699059509008186; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; LARSON JH, 1988, FAM RELAT, V33, P253; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Lobo F., 1995, J FAMILY STUDIES, V1, P103; MATZ EA, 1995, J HEAD TRAUMA REHAB, V10, P1; MAUSSCLUM N, 1981, J NEUROSURGICAL NURS, V16, P36; MAY JL, 1988, J SEX MARITAL THER, V14, P253; MCKEE L, 1985, NEW APPROACHES EC LI, P387; MOROKOFF PJ, 1993, J SEX RES, V30, P43, DOI 10.1080/00224499309551677; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Panting A., 1972, REHABILITATION, V38, P33; Price J R, 1985, Rehabil Nurs, V10, P12; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUST J, 1986, GOLOMBEK RUST INVENT; RUST J, 1988, GOLONBOK RUST INVENT; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Zencius A H, 1989, Brain Inj, V3, P199, DOI 10.3109/02699058909004553	35	86	87	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1999	13	10					785	796					12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	247TV	WOS:000083236800004	10576462				2021-06-18	
J	Quinn, SM; Walters, WM; Vescovi, AL; Whittemore, SR				Quinn, SM; Walters, WM; Vescovi, AL; Whittemore, SR			Lineage restriction of neuroepithelial precursor cells from fetal human spinal cord	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						stem cells; neurons; astrocytes; differentiation; human spinal cord	CENTRAL-NERVOUS-SYSTEM; NEURAL PROGENITOR CELLS; FIBROBLAST GROWTH-FACTOR; ADULT-MOUSE BRAIN; STEM-CELLS; NEURONAL DIFFERENTIATION; TRANSPLANTATION; RAT; SURVIVAL; CULTURE	In the presence of epidermal growth factor (EGF) and/or fibroblast growth factor 2 (FGF2), neuroepithelial precursor cells from dissociated fetal human spinal cord are mitotically active and form free-floating spheres of undifferentiated cells, Proliferating cells were obtained in approximately 40% of preparations with each mitogen, were immunoreactive for the intermediate filament nestin, and did not express neuronal- or glial-specific markers, Early passage neuroepithelial precursor cells were pluripotent and differentiated into neurons expressing MAP2a,b, NF-M, and Tall, and GFAP-positive astrocytes; however, oligodendrocytes were never seen. As the cells were passaged from PO to P4, the percentage of differentiating neurons significantly decreased and the prevalence of astrocytes significantly increased. While the majority of cell populations from individual preparations stopped proliferating between 3 and 6 passages, two expanding cell lines have been successfully expanded in EGF and FGF2 for over 25 passages and have been maintained in culture for over one year. These cells express nestin and not other cell-specific lineage markers. When differentiated, these neuroepithelial cell lines differentiate only into astrocytes, showing no expression of any neuronal marker. These data suggest that continued passage under these conditions preferentially selects for spinal cord neural precursors that are restricted to the astrocytic lineage. Despite the lineage restriction of later passage cell populations, these results provide a rationale for future investigation into the lineage potential of these cells in vivo following transplantation into the adult CNS, potentially as a therapeutic approach. for traumatic injury and neurodegenerative disease. J. Neurosci. Res. 57:590-602, 1999, (C) 1999 Wiley-Liss, Inc.	Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40202 USA; Univ Miami, Sch Med, Miami Project, Miami, FL USA; Univ Miami, Sch Med, Dept Biol, Miami, FL USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Natl Neurol Inst, Milan, Italy	Whittemore, SR (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, 210 E Gray St,Suite 1102, Louisville, KY 40202 USA.	swhittemore@louisville.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26887] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026887, R01NS026887] Funding Source: NIH RePORTER		BAYER SA, 1993, NEUROTOXICOLOGY, V14, P83; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DELOULME JC, 1991, J NEUROSCI RES, V29, P499, DOI 10.1002/jnr.490290410; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; Ghosh MM, 1995, BIOREMED SER, V3, P15; Gritti A, 1996, J NEUROSCI, V16, P1091; Hammang JP, 1997, EXP NEUROL, V147, P84, DOI 10.1006/exnr.1997.6592; HOFFER BJ, 1991, TRENDS NEUROSCI, V14, P384, DOI 10.1016/0166-2236(91)90168-T; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kalyani A, 1997, DEV BIOL, V186, P202, DOI 10.1006/dbio.1997.8592; KAWAMOTO JC, 1986, BRAIN RES, V384, P84, DOI 10.1016/0006-8993(86)91222-9; KILPATRICK TJ, 1994, NEUROSCI LETT, V181, P129, DOI 10.1016/0304-3940(94)90576-2; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; Kopyov OV, 1998, EXP NEUROL, V149, P97, DOI 10.1006/exnr.1997.6685; LIU RH, 1999, IN PRESS EXP NEUROL; Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Moyer MP, 1997, TRANSPLANT P, V29, P2040, DOI 10.1016/S0041-1345(97)00221-2; Onifer SM, 1997, CELL TRANSPLANT, V6, P327, DOI 10.1016/S0963-6897(97)00037-7; Onifer SM, 1997, TRANSPL P, V29, P2221, DOI 10.1016/S0041-1345(97)00308-4; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; RAY J, 1994, J NEUROSCI, V14, P3548; RAY J, 1994, ABSTS AM SOC NEUR, V20, P670; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; SABATE O, 1995, NAT GENET, V9, P256, DOI 10.1038/ng0395-256; Shihabuddin LS, 1997, EXP NEUROL, V148, P577, DOI 10.1006/exnr.1997.6697; Shihabuddin LS, 1996, EXP NEUROL, V139, P61, DOI 10.1006/exnr.1996.0081; STREILEIN JW, 1988, INT J DEV NEUROSCI, V6, P497; Studer L, 1998, NAT NEUROSCI, V1, P290; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Svendsen CN, 1996, EXP NEUROL, V137, P376, DOI 10.1006/exnr.1996.0039; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Weiss S, 1996, J NEUROSCI, V16, P7599; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; WHITE LA, 1994, J NEUROSCI, V14, P6744; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; WHITTEMORE SR, 1993, INT J DEV NEUROSCI, V11, P755, DOI 10.1016/0736-5748(93)90064-K; WIDNER H, 1988, BRAIN RES REV, V13, P287, DOI 10.1016/0165-0173(88)90010-0; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; WIRTH ED, 1998, ABST AM SOC NEUR, V24, P70	54	86	91	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP 1	1999	57	5					590	602		10.1002/(SICI)1097-4547(19990901)57:5<590::AID-JNR2>3.3.CO;2-O			13	Neurosciences	Neurosciences & Neurology	229WF	WOS:000082218200002	10462684				2021-06-18	
J	Hans, VHJ; Kossmann, T; Lenzlinger, PM; Probstmeier, R; Imhof, HG; Trentz, O; Morganti-Kossmann, MC				Hans, VHJ; Kossmann, T; Lenzlinger, PM; Probstmeier, R; Imhof, HG; Trentz, O; Morganti-Kossmann, MC			Experimental axonal injury triggers interleukin-6 mRNA, protein synthesis and release into cerebrospinal fluid	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						rat model; brain injury; interleukin-6; neuron; in situ hybridization; immunohistochemistry	TRAUMATIC BRAIN INJURY; GROWTH-FACTOR PRODUCTION; EXCITATORY AMINO-ACIDS; TUMOR NECROSIS FACTOR; CLOSED-HEAD INJURY; RAT-BRAIN; MONONUCLEAR PHAGOCYTES; CHOLINERGIC NEURONS; GENE-EXPRESSION; MESSENGER-RNA	Diffuse axonal injury is a frequent pathologic sequel of head trauma, which, despite its devastating consequences for the patients, remains to be fully elucidated. Here we studied the release of interleukin-6 (IL-6) into CSF and serum, as well as the expression of IL-6 messenger ribonucleic acid (mRNA) and protein in a weight drop model of axonal injury in the rat. The IL-6 activity was elevated in CSF within 1 hour and peaked between 2 and 4 hours, reaching maximal values of 82,108 pg/mL, and returned to control values after 24 hours. In serum, the levels of IL-6 remained below increased CSF levels and did not exceed 393 pg/mL. In sial hybridization demonstrated augmented IL-6 mRNA expression in several regions including cortical pyramidal cells, neurons in thalamic nuclei, and macrophages in the basal subarachnoid spaces. A weak constitutive expression of IL-6 protein was shown by immunohistochemical study in control brain. After injury, IL-6 increased at 1 hour and remained elevated through the first 24 hours, returning to normal afterward. Most cells producing IL-6 were cortical, thalamic, and hippocampal neurons as confirmed by staining for the neuronal marker NeuN. These results extend our previous studies showing IL-6 production in the cerebrospinal fluid of patients with severe head trauma and demonstrate that neurons are the main source of IL-6 after experimental axonal injury.	Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; Univ Bonn, Inst Anim Anat & Physiol, Dept Biochem, D-5300 Bonn, Germany; Univ Hosp, Inst Neuropathol, Bonn, Germany	Morganti-Kossmann, MC (corresponding author), Univ Zurich Hosp, Dept Surg, Div Res, Raemistr 100, CH-8091 Zurich, Switzerland.		Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; BENVENISTE EN, 1995, HUMAN CYTOKINES THEI, P195; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CSUKA E, 1997, SHOCK S, V8, P6; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiebich BL, 1995, J NEUROIMMUNOL, V63, P207, DOI 10.1016/0165-5728(95)00145-X; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; GADIENT RA, 1994, BRAIN RES, V637, P10, DOI 10.1016/0006-8993(94)91211-4; GADIENT RA, 1994, NEUROSCI LETT, V182, P243, DOI 10.1016/0304-3940(94)90807-9; GEHRMANN J, 1995, IMMUNE RESPONSES NER, P61; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Paxinos G, 1986, RAT BRAIN STEROTAXIC; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; QIU ZH, 1995, J NEUROSCI, V15, P6688; Ringheim GE, 1995, J NEUROIMMUNOL, V63, P113, DOI 10.1016/0165-5728(95)00134-4; RINK A, 1995, AM J PATHOL, V147, P1575; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Skowronski EW, 1996, CELL DEATH DIFFER, V3, P171; Soares HD, 1995, J NEUROSCI, V15, P8223; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEREBUH PD, 1992, AM J PATHOL, V140, P649; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; VANDAMME J, 1987, J IMMUNOL, V139, P1867; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.iy.08.040190.001345; VONCOELLN R, 1995, DEV BRAIN RES, V89, P150, DOI 10.1016/0165-3806(95)00123-U; Wagner JA, 1996, J EXP MED, V183, P2417, DOI 10.1084/jem.183.6.2417; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	57	86	90	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	1999	19	2					184	194					11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	185KZ	WOS:000079669300010	10027774				2021-06-18	
J	Hurt, CP; Rice, RR; McIntosh, GC; Thaut, MH				Hurt, CP; Rice, RR; McIntosh, GC; Thaut, MH			Rhythmic auditory stimulation in gait training for patients with traumatic brain injury	JOURNAL OF MUSIC THERAPY			English	Article								Rhythmic auditory stimulation (RAS) was studied in a frequency entrainment design and as a therapeutic stimulus to facilitate gait patterns in 8 traumatically brain injured individuals (5 male/3 female; mean age 30 +/- 5 years) with persisting gait disorder, 4-24 months postinjury. During entrainment, with RAS frequency matched to baseline cadence, velocity and stride symmetry both increased by an average of 18%. Increases contributing to the velocity improvement were seen in both stride length (7%) and cadence (8%). With RAS accelerated 5% over the fast walking step rate of the patients, 5 patients could entrain to a higher step frequency. The 2 patients with the slowest baseline gait velocity could not entrain to faster RAS frequencies. After 5 weeks of daily RAS training, 5 patients' mean velocity increased significantly (p <.05) by 51% (38.8 m/min to 57.6 m/min; p <.43). cadence (+16%) and stride length (+29%) also showed statistically significant improvement. Stride symmetry improved nonsignificantly by 12%.	Colorado State Univ, Ctr Biomed Res Music, Ft Collins, CO 80523 USA	Hurt, CP (corresponding author), Colorado State Univ, Ctr Biomed Res Music, Ft Collins, CO 80523 USA.						Ashley MJ, 1995, TRAUMATIC BRAIN INJU; OEBERG T, 1993, J REHABIL RES DEV, V30, P210; PALTSEV YI, 1967, BIOPHYS-USSR, V12, P1219; Perry J, 1992, GAIT ANAL NORMAL PAT; Prassas S, 1997, GAIT POSTURE, V6, P218, DOI 10.1016/S0966-6362(97)00010-6; ROSSIGNOL S, 1976, ELECTROEN CLIN NEURO, V41, P83, DOI 10.1016/0013-4694(76)90217-0; STAUM MJ, 1983, J MUSIC THER, V20, P69, DOI 10.1093/jmt/20.2.69; Thaut M. H., 1992, J NEUROL REHABIL, V6, P185; THAUT MH, 1996, MOVEMENT DISORD, V11, P1; THAUT MH, 1998, BIOL CYBERNETICS; Thaut MH, 1997, J NEUROL SCI, V151, P7	11	86	86	0	17	NATL ASSOC MUSIC THERAPY INC	SILVER SPRING	8455 COLESVILLE RD, STE 1000, SILVER SPRING, MD 20910 USA	0022-2917			J MUSIC THER	J. Music Ther.	WIN	1998	35	4					228	241		10.1093/jmt/35.4.228			14	Music; Rehabilitation	Music; Rehabilitation	158MR	WOS:000078119700001	10519837				2021-06-18	
J	Murdoch, I; Perry, EK; Court, JA; Graham, DI; Dewar, D				Murdoch, I; Perry, EK; Court, JA; Graham, DI; Dewar, D			Cortical cholinergic dysfunction after human head injury	JOURNAL OF NEUROTRAUMA			English	Article						head-injury; choline acetyltransferase; nicotine; synaptophysin	TRAUMATIC BRAIN INJURY; NUCLEUS BASALIS MAGNOCELLULARIS; TRANSIENT CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; ACETYLTRANSFERASE ACTIVITY; BINDING-SITES; NICOTINE BINDING; H-3 NICOTINE; RAT-BRAIN; NEURONS	Loss of cholinergic neurotransmission is implicated in memory impairment and cognitive dysfunction after head injury. The aim of the present study was to investigate presynaptic markers, particularly in relation to cholinergic neurotransmission in human postmortem brain from patients who died following a head injury and age-matched controls. Choline acetyltransferase activity and high-affinity nicotinic receptor binding sites were assayed in the inferior temporal gyrus, cingulate gyrus, and superior parietal cortex of 16 head-injured patients and 8 controls. Synaptophysin immunoreactivity was determined in the left cingulate gyrus from the same patient groups. In the head-injured group, choline acetyltransferase activity was consistently reduced in each cortical region compared to control subjects. The presence of a subdural haematoma and a prolonged survival period after head injury tended to be associated with lower choline acetyltransferase activity. In contrast to the marked reduction in choline acetyltransferase activity, nicotine receptor binding was unchanged in head-injured compared to control patients. Synaptophysin immunoreactivity in the cingulate gyrus was reduced by approximately 30% (p < 0.05) in the head-injured group compared to controls. Correlation of choline acetyltransferase activity with synaptophysin immunoreactivity indicated there is a deficit of cholinergic presynaptic terminals in postmortem human brain following head injury.	Univ Glasgow, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Hugh Fraser Neurosci Labs, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Neuropathol, Glasgow G61 1QH, Lanark, Scotland; Newcastle Gen Hosp, MRC, Neurochem Pathol Unit, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Murdoch, I (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.						ABDULLA FA, 1995, SYNAPSE, V21, P281, DOI 10.1002/syn.890210402; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; CARLSEN J, 1985, J COMP NEUROL, V234, P155, DOI 10.1002/cne.902340203; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; COURT JA, 1994, CNS DRUGS, V2, P216, DOI 10.2165/00023210-199402030-00006; COURT JA, 1992, NEUROSCI RES COMMUN, V10, P125; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dewar D., 1996, Society for Neuroscience Abstracts, V22, P1900; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; FLORES CM, 1992, MOL PHARMACOL, V41, P31; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; FRANCIS A, 1982, BRAIN RES, V243, P271, DOI 10.1016/0006-8993(82)90250-5; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GOTO S, 1993, ACTA NEUROPATHOL, V85, P515; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Henderson Z, 1996, PROG NEUROBIOL, V48, P219, DOI 10.1016/0301-0082(95)00041-0; ISHIMARU H, 1995, BRAIN RES, V673, P112, DOI 10.1016/0006-8993(94)01409-B; ISHIMARU H, 1995, NEUROREPORT, V6, P557, DOI 10.1097/00001756-199502000-00037; KELLER KJ, 1990, NICOTINE PHARM; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin H., 1987, HEAD INJURY, P442; Lindstrom J, 1996, PROG BRAIN RES, V109, P125; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marchi M, 1996, J NEUROCHEM, V67, P1974; MASLIAH E, 1991, AM J PATHOL, V138, P235; Masliah E, 1996, ANN NEUROL, V40, P759, DOI 10.1002/ana.410400512; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; Masliah E, 1996, AM J PATHOL, V148, P201; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MIYAI I, 1990, J NEURAL TRANSM-GEN, V82, P79, DOI 10.1007/BF01245165; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NYBERG P, 1989, STROKE, V20, P495, DOI 10.1161/01.STR.20.4.495; PERRY EK, 1987, J NEUROL NEUROSUR PS, V50, P806, DOI 10.1136/jnnp.50.6.806; PERRY EK, 1990, J NEURAL TRANSM-PARK, V2, P149, DOI 10.1007/BF02257646; PERRY RH, 1982, NEUROSCI LETT, V33, P311, DOI 10.1016/0304-3940(82)90391-3; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; WHITEHOUSE PJ, 1986, BRAIN RES, V371, P146, DOI 10.1016/0006-8993(86)90819-X	47	86	89	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1998	15	5					295	305		10.1089/neu.1998.15.295			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZL515	WOS:000073441300001	9605345				2021-06-18	
J	Hu, LY; Guo, JQ; Magar, SS; Fischer, JB; Burke-Howie, KJ; Durant, GJ				Hu, LY; Guo, JQ; Magar, SS; Fischer, JB; Burke-Howie, KJ; Durant, GJ			Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N '-(3-substituted phenyl)-N '-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							PHENCYCLIDINE BINDING-SITE; SIGMA; ANTAGONISTS; DERIVATIVES; AFFINITY; COMPLEX; PCP; KETAMINE; LIGANDS; AGENTS	In the mammalian central nervous system, the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may play an important role in brain diseases such as stroke, brain or spinal cord trauma, epilepsy, and certain neurodegenerative diseases. Compounds which specifically antagonize the actions of the neurotransmitter glutamate at the NMDA receptor ion-channel site offer a novel approach to treating these disorders. CERESTAT (4, aptiganel CNS 1102) is currently undergoing clinical trial for the treatment of traumatic brain injury and stroke. Previously, we reported that analogues of N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine (4) bound to the NMDA receptor ion-channel site with high potency and selectivity. Recently, molecules active at both a receptors and NMDA receptor sites were investigated. A series of substituted diphenylguanidines 6 which are structurally related to N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine was prepared. Compounds containing appropriate substitution pattern in one of the phenyl rings of diphenylguanidines displayed high affinity. For example, N-(2,5-dibromophenyl)-N'-(3-ethylphenyl)-N'-methylguanidine (27b, R-2 = R-5 = Br, R-3 = C2H5) exhibited potency at both a receptors and NMDA receptor sites; 27b also showed high efficacy in vivo in a neonatal rat excitotoxicity model. Further studies indicated that substituent effects were important in this compound series, and 2,5-disubstituted phenyl was the preferred substitution pattern for high-affinity binding at NMDA receptor sites. Bromo and methylthio were the optimal substituents for the R-2 and R-5 positions of the 2,5-disubstituted phenyl group, respectively. N-(2-Bromo-5-(methylthio)phenyl)-N'-(3-ethylphenyl)- N'-methylguanidine (34b, R-2 = Br, R-5 = SMe, R-3 = C2H5) was highly active at NMDA receptor sites. We found that the binding affinity of guanidines of type 6 could be further enhanced with the appropriate substitution at R-3. Optimal activity in this series are afforded by 43b and 44b (R-2 = Cl or Br, R-5 = R-3 = SCH3). Both 43b and 44b bound to NMDA receptor sites with high potency and selectivity (K-i vs [H-3]MK-801: 1.87 and 1.65 nM, respectively); these compounds are active in vivo in various animal models of neuroprotection. The structure-activity relationships for-these compounds at the NMDA receptor ion-channel site are discussed.	Cambridge Neurosci Inc, Cambridge, MA 02139 USA	Hu, LY (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.						BENAVIDES J, 1988, EUR J PHARMACOL, V149, P62; BIGGE CF, 1993, J MED CHEM, V36, P1977, DOI 10.1021/jm00066a007; BIGGE CF, 1992, MULTIPLE SIGMA PCP R, P1; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; GEE KR, 1993, J MED CHEM, V36, P1938, DOI 10.1021/jm00066a002; GREENAMYRE JT, 1986, ARCH NEUROL-CHICAGO, V43, P1058, DOI 10.1001/archneur.1986.00520100062016; HAYS SJ, 1993, J MED CHEM, V36, P654, DOI 10.1021/jm00058a002; HONEY CR, 1985, NEUROSCI LETT, V61, P135, DOI 10.1016/0304-3940(85)90414-8; HU LY, 1994, MED CHEM RES, V4, P146; INAMI Y, 1991, CHEM PHARM BULL, V39, P1426; ITZHAK Y, 1988, LIFE SCI, V42, P745, DOI 10.1016/0024-3205(88)90646-7; IVERSEN LL, 1994, NEUROTRANSMISSION, V10; KEANA, 1988, LIFE SCI, V3, P965; KEANA JFW, 1989, P NATL ACAD SCI USA, V86, P5631, DOI 10.1073/pnas.86.14.5631; KOZIKOWSKI AP, 1990, MOL PHARMACOL, V37, P352; KROGSGAARD P, 1991, TXB DRUG DESIGN DEV, P80; KUENZLE F, 1969, HELV CHIM ACTA, V52, P622; KUMAR V, 1995, J MED CHEM, V38, P1826, DOI 10.1021/jm00010a028; MERCHANT JR, 1978, INDIAN J CHEM B, V16, P385; PONTECORVO MJ, 1991, BRAIN RES BULL, V26, P461, DOI 10.1016/0361-9230(91)90025-F; RAO TS, 1990, NEUROPHARMACOLOGY, V29, P1199, DOI 10.1016/0028-3908(90)90045-S; REDDY NL, 1994, J MED CHEM, V37, P260, DOI 10.1021/jm00028a009; SCHERZ MW, 1990, J MED CHEM, V33, P2421, DOI 10.1021/jm00171a016; SHARP FR, 1992, J NEUROSCI RES, V33, P605, DOI 10.1002/jnr.490330413; THOMPSON WJ, 1990, J MED CHEM, V33, P789, DOI 10.1021/jm00164a052; TRUEDSSON LA, 1982, J CHROMATOGR, V234, P36; WATKINS JC, 1989, NMDA RECEPTOR, P227; WEBER E, 1986, P NATL ACAD SCI USA, V83, P8784, DOI 10.1073/pnas.83.22.8784; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; ZUKIN SR, 1979, P NATL ACAD SCI USA, V76, P5372, DOI 10.1073/pnas.76.10.5372	31	86	87	2	6	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623			J MED CHEM	J. Med. Chem.	DEC 19	1997	40	26					4281	4289		10.1021/jm970459c			9	Chemistry, Medicinal	Pharmacology & Pharmacy	YQ059	WOS:000071343300009	9435897				2021-06-18	
J	Bond, F; Godfrey, HPD				Bond, F; Godfrey, HPD			Conversation with traumatically brain-injured individuals: A controlled study of behavioural changes and their impact	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; SOCIAL-INTERACTION; ABILITY; SCHIZOPHRENIA; VALIDATION	The conversations of 62 traumatically brain-injured (TBI) patients, assessed between 6 months and 3 years post-injury, were compared with those of an orthopaedic control (OC) group (n = 25). Conversations involving TBI subjects were rated as significantly less interesting, less appropriate, less rewarding and more effortful than interactions involving OC subjects, and were characterized by differences in the frequency of prompt usage and turn duration. Furthermore, measures of turn duration and prompt frequency were significantly associated with the perceived quality of conversation. These findings provide a microbehavioural description of the social process through which TBI individuals fail to adequately reinforce others.	UNIV OTAGO,CLIN PSYCHOL RES & TRAINING CTR,DUNEDIN,NEW ZEALAND							BARCH D, 1994, J ABNORM PSYCHOL, V103, P371; BELLACK AS, 1994, J ABNORM PSYCHOL, V103, P371, DOI 10.1037/0021-843X.103.2.371; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; DERLEGA VJ, 1986, FRIENDSHIP SOCIAL IN; DOW MG, 1985, BEHAV THER, V16, P76, DOI 10.1016/S0005-7894(85)80057-5; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; GODFREY H P D, 1991, Brain Injury, V5, P207, DOI 10.3109/02699059109008091; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; Jennett B, 1981, MANAGEMENT HEAD INJU; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCFALL RM, 1982, BEHAV ASSESS, V4, P1; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Nelson H., 1982, NATIONAL ADULT READI; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; PENN DL, 1993, J NERV MENT DIS, V181, P13, DOI 10.1097/00005053-199301000-00003; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; ROMANO JM, 1980, J CONSULT CLIN PSYCH, V48, P478, DOI 10.1037/0022-006X.48.4.478; SMITH LM, 1985, FAMILY SUPPORT PROGR, P175; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P302; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; Trower P., 1978, SOCIAL SKILLS MENTAL; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY	28	86	86	0	15	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY	1997	11	5					319	329		10.1080/026990597123476			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WW455	WOS:A1997WW45500002	9146837				2021-06-18	
J	Fortune, JB; Feustel, PJ; Graca, L; Hasselbarth, J; Kuehler, DH				Fortune, JB; Feustel, PJ; Graca, L; Hasselbarth, J; Kuehler, DH			Effect of hyperventilation, mannitol, and ventriculostomy drainage on cerebral blood flow after head injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	8th Annual Scientific Session of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 14, 1995	SANIBEL, FL	E Assoc Surg Trauma			ACUTE BRAIN INJURY; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; PRESSURE; MANAGEMENT; ICP; OXYGENATION; METABOLISM; VISCOSITY; CHILDREN	Therapies to lower intracranial pressure (ICP) after traumatic brain injury (TBI) include hyperventilation (HV), intravenous mannitol (IM), and cerebrospinal fluid drainage from a ventriculostomy (DV), To determine the effects of these therapies on cerebral blood flow (CBF), fiberoptic oximetry was used to measure jugular venous O-2 saturation (SjvO2) as an index of the CBF to cerebral metabolic rate for O-2 (CMRO(2)) ratio after IM (25 g IV for more than 5 min), DV (3 min), or HV (increase respiratory rate by 4) therapy for elevated ICP, Assuming CMRO(2) is constant, changes in SjvO2 reflect changes in CBF, Continuous measurements of SjvO2, ICP, blood pressure, artery rial O-2 saturation, and end-tidal CO2 were obtained in 22 patients with a Glasgow Coma Scale score of 5.3 +/- 0.4 (mean +/- SD) in the first 5 days after TBI, Therapy was initiated a total of 196 times when ICP was > 15 mm Hg for > 5 minutes, and measurements made at 20 minutes after treatment were compared with those made just before, After DV, ICP fell in 90% of the observations by 8.6 +/- 0.7 mm Hg (mean +/- SEM, n = 119); after IM, ICP fell in 90% of the observations by 7.4 +/- 0.7 mm Hg (n = 43); and after HV, ICP fell in 88% of the observations by 6.3 +/- 1.2 mm Hg (n = 14), In patients where ICP fell, SjvO2 increased by 2.49 +/- 0.7% saturation (from 68.0 +/- 1.3%) with IM, but only by 0.39 +/- 0.4% saturation (from 67.2 +/- 0.9%) with DV, When HV resulted in a decrease in ICP, SjvO2 decreased by 7.7 +/- 1.0% saturation (from 63.4 +/- 2.5%), The magnitude of the effect was assessed by considering the change in SjvO2 resulting from a measured change in ICP (SjvO2/ICP). For each decrease in ICP of 1 mm Hg, SjvO2 increased 0.53 +/- 0.14% saturation with IM, 0.10 +/- 0.10 with DV, and decreased by 1.95 +/- 0.53 with HV, In this study DV, IM, and HV effectively reduced elevated ICP after cerebral injury, For a given change in ICP, however, LM increased the CBF to CMRO(2) ratio nearly five times as much as DV, whereas HV decreased this ratio in all cases, These data suggest that mannitol improves CBF while reducing ICP; HV, although effective at reducing ICP, results in marked lowering of CBF and should be used cautiously.	ALBANY MED COLL, DEPT SURG, SECT TRAUMA SURG, ALBANY, NY USA				Feustel, Paul/0000-0002-6963-4349	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030303] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30303] Funding Source: Medline		BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; DARBY JM, 1988, NEUROSURGERY, V23, P84, DOI 10.1227/00006123-198807000-00014; DURIVAND QJ, 1983, J NEUROSURG, V59, P803; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; FORTUNE JB, 1992, J TRAUMA, V32, P618, DOI 10.1097/00005373-199205000-00014; GAAB MR, 1990, ACT NEUR S, V51, P320; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Monro A., 1783, OBSERVATIONS STRUCTU; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NATH F, 1986, J NEUROSURG, V65, P41, DOI 10.3171/jns.1986.65.1.0041; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Procaccio F, 1991, Agressologie, V32, P381; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; SHALMON E, 1990, ACT NEUR S, V51, P116; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Tomei G, 1991, J Neurosurg Sci, V35, P61; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087; ZORNOW MH, 1990, ACT NEUR S, V51, P324	37	86	87	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1995	39	6					1091	1099		10.1097/00005373-199512000-00014			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	TL905	WOS:A1995TL90500014	7500400				2021-06-18	
J	WILLINGER, R; TALEB, L; KOPP, CM				WILLINGER, R; TALEB, L; KOPP, CM			MODAL AND TEMPORAL ANALYSIS OF HEAD MATHEMATICAL-MODELS	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		HEAD BIOMECHANICS; MODAL ANALYSIS; TEMPORAL ANALYSIS; LUMPED MODEL; FINITE ELEMENT MODELS; INJURY MECHANISMS		The basic hypotheses used during these investigations were based on the vibration analysis of the head, which demonstrated that the head is not a solid nondeformable body, but a complex structure including deformable elements. Laboratoire des Systemes Biomecanique (LSBM) has recently proposed three mathematical models: a lumped model, a finite element model of the head in its sagittal plane, and a three-dimensional finite element model. These models were validated by their modal behavior and enabled the lesion mechanisms to be distinguished as a function of the spectral characteristics of the shock. The objective of this study is to complete these modal results by temporal analysis of the models by calculating the evolution of the intracranian mechanical parameters under shock conditions. To describe the head's dynamic behavior in the temporal domain, constant energy shocks of variable duration were simulated to evaluate their influence on different quantities as the intracerebral stresses in terms of compression, tensile, and shearing stresses, the relative brain-skull displacement, and the skull deformation. The importance of modal behavior of the head is illustrated by analyzing its temporal response to variable duration impacts, thus exciting very different frequencies. For a triangular shock, the critical duration times are between 10 and 15 x 10(-3) s, which correspond to impacts that excite the first resonance frequency of the head. Taking modal behavior into consideration in developing the finite element model leads to a harmonization of the calculated intracerebral stresses, even for short duration shocks. So, when the head is considered as a complex structure made up of several deformable elements, risk limitation is conditioned by an impact energy reduction for frequencies close to the natural frequencies of the structure. In the time field, the objective will be to avoid a number of impact shapes and durations. Therefore, the aim will not be to dampen the impact at any cost, but to damper it in an ''intelligent'' manner. In the future, this will allow the reduction of an injury mechanism-related risk, without increasing the risk of an injury generated by another mechanism.		WILLINGER, R (corresponding author), UNIV STRASBOURG, LSBM, IMF, CNRS 854, 2 RUE BOUSSINGAULT, STRASBOURG, FRANCE.						ALEM NM, 1974, 18TH STAPP CAR CRASH, P579; BRINN J, 1970, 14TH STAPP CAR CRASH; DIMASI F, 1991, P INT TECHNICAL C EX; GADD CW, 1966, SAE660793; GADD CW, 1968, SAE680053; Harris C. M., 1988, SHOCK VIBRATION HDB; HODGSON VR, 1968, STAPP C, V12, P280; HODGSON VR, 1967, 11TH STRAPP CAR CRAS, P79; KALLIERIS D, 1980, BRAIN INJURIES HIGH, P229; McElhaney JH., 1976, HDB HUMAN TOLERANCE; PLUCHE R, 1985, ADV ANTHROPOMORPHIC; SHUGER TA, 1977, DOTHS2893550TA REP, V1; SIMPSON DA, 1991, P INT IRCOBI C BIOME, P89; SLATTENSCHEK A, 1968, 1970 INT AUT SAF C; STALNAKER RL, 1971, J BIOMECH, V4, P127, DOI 10.1016/0021-9290(71)90023-6; STALNAKER RL, 1991, P INT COUNCIL BIOKIN, P69; STALNAKER RL, 1985, C P INT RES COUNC BI, P191; THIBAULT LE, 1990, C P INT RES COUNCIL, P191; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; WARD CC, 1975, 19TH P STAPP CAR CRA; WILLINGER R, 1994, ACCIDENT ANAL PREV, V26, P767, DOI 10.1016/0001-4575(94)90053-1; WILLINGER R, 1991, P INT TECHNICAL C EX; WILLINGER R, 1995, 1995 IRCOBI C; Willinger R., 1990, C P INT RES COUNCIL, P203; WILLINGER R, 1993, SEP P INT IRCOBI C B, P229; WILLINGER R, 1992, SEP P INT RES COUNC, P283; WILLINGER R, 1992, MECANIQUE ELECTRICIT, V443, P36; WILLINGER R, 1990, MECANIQUE ELECTRICIT, V434, P45; WILLINGER RW, 1991, 35TH P ANN C DES PLA, P387; ZIENKIEWICZ OC, 1973, METHODE ELEMENTS FIN	30	86	96	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					743	754		10.1089/neu.1995.12.743			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000026	8683626				2021-06-18	
J	SCALEA, TM; MALTZ, S; YELON, J; TROOSKIN, SZ; DUNCAN, AO; SCLAFANI, SJA				SCALEA, TM; MALTZ, S; YELON, J; TROOSKIN, SZ; DUNCAN, AO; SCLAFANI, SJA			RESUSCITATION OF MULTIPLE TRAUMA AND HEAD-INJURY - ROLE OF CRYSTALLOID FLUIDS AND INOTROPES	CRITICAL CARE MEDICINE			English	Article						HEAD INJURY; BLUNT TRAUMA; LACTATE; INTRACRANIAL PRESSURE; HEMODYNAMICS; RESUSCITATION; OXYGENATION; CRYSTALLOIDS; HYPERTENSION, INTRACRANIAL; NEUROLOGIC EMERGENCIES	CEREBRAL BLOOD-FLOW; HEMORRHAGIC-SHOCK; BRAIN INJURY; PRESSURE; VOLUME; SURVIVAL; PATTERNS; EDEMA; MODEL; DEATH	Objectives: To determine the hemodynamic responses to blunt trauma with a closed-head injury and to investigate the effect that volume resuscitation has on intracranial pressure. Design: Prospective study with retrospective analysis of patient data and hemodynamic responses. Setting: Surgical intensive care unit at an inner-city, Level I trauma center. Patients: Consecutive patients (n = 30) who sustained multiple system injury, including a closed-head injury that was severe enough to require intracranial pressure monitoring but not a craniotomy. Interventions: All patients underwent invasive hemodynamic monitoring with percutaneous arterial and pulmonary arterial catheters. Serum lactate concentrations and hemodynamic and oxygen transport variables were measured every 4 hrs. Intracranial pressures and vital signs were recorded each hour. Attempts were made to achieve a state of nonflow-dependent oxygen consumption and a normal serum lactate concentration. Measurements and Main Results: Despite being normotensive and neither tachycardiac nor oliguric, 80% of patients had evidence of inadequate tissue perfusion. Only 50% of the remaining patients had an adequate response to volume. The other 50% received vasodilating inotropic agents. Despite volume loading and the administration of inotropic agents, intracranial pressure did not increase. This observation was found in patients who showed clinically important intracranial pathology on computed tomography scan, as well as in all other patients. Intracranial pressure did not correlate with the amount of fluid or blood infused or with hemodynamic performance, but intracranial pressures did correlate with serum lactate concentrations. Conclusions: Many patients with diffuse blunt trauma closed-head injuries, even when they are normotensive, have evidence of impaired peripheral perfusion. Volume infusion and vasodilating inotropic support improve oxygen transport without increasing intracranial pressure. The observed relationship between intracranial pressure and the serum lactate concentration requires further study.	SUNY HLTH SCI CTR,DEPT EMERGENCY MED,BROOKLYN,NY 11203	SCALEA, TM (corresponding author), SUNY HLTH SCI CTR,DEPT SURG,BOX 40,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.						ABOUKHALIL B, 1994, CRIT CARE MED, V22, P633, DOI 10.1097/00003246-199404000-00020; ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; ADAMS S L, 1986, Journal of Emergency Medicine, V4, P383, DOI 10.1016/0736-4679(86)90216-7; BROWN RS, 1973, ANN SURG, V177, P187, DOI 10.1097/00000658-197302000-00011; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; DAVIS DH, 1980, J NEUROSURG, V52, P745, DOI 10.3171/jns.1980.52.6.0745; HAUSDORFER J, 1975, RESUSCITATION, V2, P261; KAISER R, 1989, ANESTHESIOLOGY, V71, P554; MORSE ML, 1985, CRIT CARE MED, V13, P563, DOI 10.1097/00003246-198507000-00011; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; PETROPALI JA, 1992, J TRAUMA, V33, P403; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCALEA TM, 1990, J TRAUMA, V30, P129, DOI 10.1097/00005373-199002000-00001; SCALEA TM, 1988, J TRAUMA, V28, P725, DOI 10.1097/00005373-198806000-00001; SHACKFORD SR, 1990, J TRAUMA, V30, P768, DOI 10.1097/00005373-199007000-00002; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; SHOEMAKER WC, 1967, ARCH SURG-CHICAGO, V95, P492; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SMITH SD, 1982, J TRAUMA, V22, P588, DOI 10.1097/00005373-198207000-00011; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010; 1988, ADV TRAUMA LIFE SUPP	25	86	91	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	OCT	1994	22	10					1610	1615					6	Critical Care Medicine	General & Internal Medicine	PK865	WOS:A1994PK86500017	7924373				2021-06-18	
J	PALMER, AM; MARION, DW; BOTSCHELLER, ML; REDO, EE				PALMER, AM; MARION, DW; BOTSCHELLER, ML; REDO, EE			THERAPEUTIC HYPOTHERMIA IS CYTOPROTECTIVE WITHOUT ATTENUATING THE TRAUMATIC BRAIN INJURY-INDUCED ELEVATIONS IN INTERSTITIAL CONCENTRATIONS OF ASPARTATE AND GLUTAMATE	JOURNAL OF NEUROTRAUMA			English	Article							MILD HYPOTHERMIA; AMINO-ACIDS; ISCHEMIA; RAT; DAMAGE; TEMPERATURE; RECEPTORS; RELEASE	Moderate hypothermia has been shown to have therapeutic utility in the treatment of cerebral ischemia and to attenuate the rise in interstitial concentrations of the excitatory amino acid neurotransmitter L-glutamate. In this study, the influence of hypothermia on traumatic brain injury (TBI) was assessed using a controlled cortical impact model. Rats were cooled to 32.0-33.0 degrees C at least 30 min before injury and maintained at this temperature for 2 h after injury. The influence of hypothermia on the immediate increase in interstitial concentrations of aspartate and glutamate and the volume of the resultant lesion 14 days after TBI was then determined. The volume of the lesion (mean +/- SEM) in hypothermic animals (8.2 +/- 1.3 mm(3), n = 9) was significantly smaller than that of normothermic animals (13.2 +/- 1.7 mm(3), n = 8). By contrast, TBI-induced increases in dialysate concentrations of aspartate and glutamate were similar at the two temperatures. Thus, aspartate content (nmol/10 min) in animals maintained at 37.0-37.5 degrees C (n = 6) and 32.0-33.0 degrees C (n = 6) increased from respective mean preinjury values of 0.05 +/- 0.02 and 0.08 +/- 0.02 to much larger peak values (0.78 +/- 0.13 and 0.71 +/- 0.09, respectively). Similarly, under normothermic conditions glutamate content (nmol/10 min) increased from 0.13 +/- 0.03 to 3.08 +/- 0.52 and from 0.19 +/- 0.06 to a peak value of 3.09 +/- 0.26 under hypothermic conditions. These data clearly demonstrate the cytoprotective action of moderate hypothermia and further suggest that this action is not mediated by attenuation of the rise in interstitial concentrations of aspartate and glutamate.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT NEUROL SURG,PITTSBURGH,PA 15213	PALMER, AM (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,W1642 BIOMED SCI TOWER,3811 OHARA ST,PITTSBURGH,PA 15213, USA.		Marion, Donald/AAR-5749-2021; Palmer, Alan/AAP-8650-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BERNERT H, 1992, SOC NEUR ABSTR, V18, P457; BORISMOLLER F, 1989, NEUROSCI RES COMMUN, V5, P87; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COHADON F, 1991, J NEUROSCI S, V103, pS23; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; ONESTI ST, 1991, NEUROSURGERY, V29, P369, DOI 10.1227/00006123-199109000-00005; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Whittingham TS, 1990, CEREBRAL ISCHEMIA RE, P101	40	86	87	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	WIN	1993	10	4					363	372		10.1089/neu.1993.10.363			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	MQ818	WOS:A1993MQ81800001	7908337				2021-06-18	
J	CANTU, RC				CANTU, RC			CEREBRAL CONCUSSION IN SPORT - MANAGEMENT AND PREVENTION	SPORTS MEDICINE			English	Article								This article explains the various stresses (tensile, compressive, and shearing) that can affect the brain, and how they may produce the different types of brain injury. The biomechanical forces and dynamics that produce coup versus contra coup injury are covered, as are the common intracranial athletic head injuries, i.e. concussion and the various intracranial haematomas (epidural, subdural, subarachnoid and intracerebral). Though less common in occurrence, because their outcome is so catastrophic, space is also devoted to the recognition, the treatment and (especially in the latter case) the prevention of the malignant brain oedema syndrome of the adolescent and the second impact syndrome of the adult. A major emphasis of this paper is the recognition of the 3 grades of cerebral concussion and the delineation of clear guidelines as to when it is safe to return to collision sports after sustaining such injuries, for the first, second or third time during a given season. Clear guidelines are also presented as to when to discontinue collision sport competition for the remainder of the season after multiple concussions. Because of the concern for the second impact syndrome, the requirement to never allow an athlete with postconcussion syndrome symptoms to return to competition is emphasised. Also covered is the prevention of head injuries, which sports are at greatest risk, and the need for additional research on the cumulative effects of concussion.		CANTU, RC (corresponding author), EMERSON HOSP,NEUROSURG SERV,JOHN CUMING BLDG,SUITE 820,CONCORD,MA 01742, USA.							0	86	86	0	20	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.	JUL	1992	14	1					64	74		10.2165/00007256-199214010-00005			11	Sport Sciences	Sport Sciences	HZ813	WOS:A1992HZ81300005	1641543				2021-06-18	
J	BAKAY, L; LEE, JC; LEE, GC; PENG, JR				BAKAY, L; LEE, JC; LEE, GC; PENG, JR			EXPERIMENTAL CEREBRAL CONCUSSION .1. ELECTRON-MICROSCOPIC STUDY	JOURNAL OF NEUROSURGERY			English	Article									SUNY BUFFALO,CTR CLIN,DEPT NEUROSURG,BUFFALO,NY 14214; SUNY BUFFALO,DEPT ANAT SCI,BUFFALO,NY 14214; SUNY BUFFALO,DEPT CIVIL ENGN,BUFFALO,NY 14214							BAKAY L, 1968, BRAIN, V91, P697, DOI 10.1093/brain/91.4.697; BAKAY L, 1975, EXP BRAIN RES, V23, P241; BRODERSON P, 1975, BRAIN WORK, P269; CASSEN B, 1960, AM J PHYSIOL, V198, P1296; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; GRONWALL D, 1975, LANCET, V2, P995; Gurdjian E S, 1972, Clin Neurosurg, V19, P1; HAMBERGER A, 1966, J NEUROPATH EXP NEUR, V25, P68, DOI 10.1097/00005072-196601000-00004; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; QUADBECK G, 1955, Z NATURFORSCH PT B, V10, P168, DOI 10.1515/znb-1955-0310; RINDER L, 1968, ACTA NEUROPATHOL, V11, P201; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; ROIZIN L, 1975, J HISTOCHEM CYTOCHEM, V23, P402, DOI 10.1177/23.6.168247; WARD AA, 1966, CLIN NEUROSURG, V12, P95; YU MC, 1972, ACTA NEUROPATHOL, V22, P222, DOI 10.1007/BF00684525	17	86	89	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1977	47	4					525	531		10.3171/jns.1977.47.4.0525			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DW525	WOS:A1977DW52500004	903805				2021-06-18	
J	DENNYBROWN, D				DENNYBROWN, D			DISABILITY ARISING FROM CLOSED HEAD INJURY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																Abbott WD, 1943, J AMER MED ASSOC, V121, P739, DOI 10.1001/jama.1943.02840100025007; Abbott WD, 1943, J AMER MED ASSOC, V121, P664, DOI 10.1001/jama.1943.02840090034010; COLE EM, IN PRESS A RES NERV; Denny-Brown D., 1942, NEW ENGL J MED, V227, P771; DENNYBROWN D, 1942, NEW ENGL J MED, V227, P813; DENNYBROWN D, IN PRESS A RES NERV; GREENWOOD J, 1940, SO M J, V33, P1077; Lewis A. J., 1942, P ROY SOC MED, V35, P607; Moore BE, 1944, NEW ENGL J MED, V230, P445, DOI 10.1056/NEJM194404132301501; MUNRO D, 1938, CRANIOCEREBRAL INJUR; PILCHER C, 1942, WAR MED, V2, P114; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Russell W Ritchie, 1934, Edinb Med J, V41, P129; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Schaller WF, 1939, J AMER MED ASSOC, V113, P1779; Symonds C P, 1937, Proc R Soc Med, V30, P1081; Symonds CP, 1943, LANCET, V1, P7	18	86	86	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.		1945	127	8					429	436		10.1001/jama.1945.02860080001001			8	Medicine, General & Internal	General & Internal Medicine	YA929	WOS:A1945YA92900001					2021-06-18	
J	Harting, MT; Srivastava, AK; Zhaorigetu, S; Bair, H; Prabhakara, KS; Furman, NET; Vykoukal, JV; Ruppert, KA; Cox, CS; Olson, SD				Harting, Matthew T.; Srivastava, Amit K.; Zhaorigetu, Siqin; Bair, Henry; Prabhakara, Karthik S.; Furman, Naama E. Toledano; Vykoukal, Jody V.; Ruppert, Katherine A.; Cox, Charles S., Jr.; Olson, Scott D.			Inflammation-Stimulated Mesenchymal Stromal Cell-Derived Extracellular Vesicles Attenuate Inflammation	STEM CELLS			English	Article						Mesenchymal stromal cells; Mesenchymal stem cells; Extracellular vesicles; Exosomes; Microvesicles; Inflammation; Current good manufacturing practices	TRAUMATIC BRAIN-INJURY; LONG NONCODING RNAS; STEM-CELLS; EXOSOMES; MICROVESICLES; MICRORNAS; COMMUNICATION; MACROPHAGES; ACTIVATION; MECHANISM	Extracellular vesicles (EVs) secreted by mesenchymal stromal cells (MSCs) have been proposed to be a key mechanistic link in the therapeutic efficacy of cells in response to cellular injuries through paracrine effects. We hypothesize that inflammatory stimulation of MSCs results in the release of EVs that have greater anti-inflammatory effects. The present study evaluates the immunomodulatory abilities of EVs derived from inflammation-stimulated and naive MSCs (MSCEv(+) and MSCEv, respectively) isolated using a current Good Manufacturing Practice-compliant tangential flow filtration system. Detailed characterization of both EVs revealed differences in protein composition, cytokine profiles, and RNA content, despite similarities in size and expression of common surface markers. MSCEv(+) further attenuated release of pro-inflammatory cytokines in vitro when compared to MSCEv, with a distinctly different pattern of EV-uptake by activated primary leukocyte subpopulations. The efficacy of EVs was partially attributed to COX2/PGE(2) expression. The present study demonstrates that inflammatory stimulation of MSCs renders release of EVs that have enhanced anti-inflammatory properties partially due to COX2/PGE(2) pathway alteration.	[Harting, Matthew T.; Srivastava, Amit K.; Zhaorigetu, Siqin; Bair, Henry; Prabhakara, Karthik S.; Furman, Naama E. Toledano; Ruppert, Katherine A.; Cox, Charles S., Jr.; Olson, Scott D.] Univ Texas Houston, McGovern Med Sch, Dept Pediat Surg, 6431 Fannin St,MSB 5-233, Houston, TX 77030 USA; [Vykoukal, Jody V.] Univ Texas MD Anderson Canc Ctr, McCombs Inst Early Detect & Treatment Canc, Houston, TX 77030 USA	Harting, MT (corresponding author), Univ Texas Houston, McGovern Med Sch, Dept Pediat Surg, 6431 Fannin St,MSB 5-233, Houston, TX 77030 USA.	matthew.t.harting@uth.tmc.edu	Srivastava, Amit/L-7019-2019	Harting, Matthew/0000-0002-8929-8311; Bair, Henry/0000-0002-3422-0373; Olson, Scott/0000-0001-8032-3755; Srivastava, Amit/0000-0001-7554-7201	Center for Clinical and Translational Sciences Training Award, University of Texas McGovern Medical School [5KL2-TR000370-10]; Ladybug; Glassell Family Stem Cell Research Fund; Ansh Labs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000370] Funding Source: NIH RePORTER	This study was supported by grants Center for Clinical and Translational Sciences Training Award, University of Texas McGovern Medical School (5KL2-TR000370-10) (M.T.H.); Ladybug (C.S.C. and M.T.H.); Glassell Family Stem Cell Research Fund. We acknowledge Ansh Labs support with Activin-A, follistatin, and PAPP-A2 assays.	Baglio SR, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00359; Boomsma RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035685; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Butler J, 2017, CIRC RES, V120, P332, DOI 10.1161/CIRCRESAHA.116.309717; Camussi G, 2013, BIOCHEM SOC T, V41, P283, DOI 10.1042/BST20120192; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Clayton A, 2001, J IMMUNOL METHODS, V247, P163, DOI 10.1016/S0022-1759(00)00321-5; Cruz FF, 2015, STEM CELL TRANSL MED, V4, P1302, DOI 10.5966/sctm.2014-0280; Deng ZB, 2013, J IMMUNOL, V190, P3579, DOI 10.4049/jimmunol.1203170; Elling R, 2016, EUR J IMMUNOL, V46, P504, DOI 10.1002/eji.201444558; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Gamez-Valero A, 2016, SCI REP-UK, V6, DOI 10.1038/srep33641; Gardiner C, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.32945; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Heinemann ML, 2014, J CHROMATOGR A, V1371, P125, DOI 10.1016/j.chroma.2014.10.026; Heward JA, 2014, TRENDS IMMUNOL, V35, P408, DOI 10.1016/j.it.2014.07.005; Jones KL, 2007, P NATL ACAD SCI USA, V104, P16239, DOI 10.1073/pnas.0705971104; Katakowski M, 2016, CELL MOL NEUROBIOL, V36, P343, DOI 10.1007/s10571-015-0280-9; Katsuda T, 2013, PROTEOMICS, V13, P1637, DOI 10.1002/pmic.201200373; Kim CW, 2002, CANCER RES, V62, P6312; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Koniusz S, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00109; Kota DJ, 2017, STEM CELLS, V35, P1416, DOI 10.1002/stem.2603; Kota DJ, 2016, STEM CELL TRANSL MED, V5, P33, DOI 10.5966/sctm.2015-0065; Kota DJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04565; Lai Ruenn Chai, 2012, Int J Proteomics, V2012, P971907, DOI 10.1155/2012/971907; Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7; Lee HD, 2016, SCI REP-UK, V6, DOI 10.1038/srep35250; Lee RH, 2006, P NATL ACAD SCI USA, V103, P17438, DOI 10.1073/pnas.0608249103; Li TF, 2013, STEM CELLS DEV, V22, P845, DOI 10.1089/scd.2012.0395; Liu J, 2016, STEM CELLS, V34, P2943, DOI 10.1002/stem.2448; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Mao XH, 2017, IMMUNOLOGY, V150, P379, DOI 10.1111/imm.12698; Nakai W, 2016, SCI REP-UK, V6, DOI 10.1038/srep33935; Njock MS, 2015, BLOOD, V125, P3202, DOI 10.1182/blood-2014-11-611046; Olsen AB, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12121; Palanisamy V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008577; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Robbins PD, 2016, J CLIN INVEST, V126, P1173, DOI 10.1172/JCI81131; Ropper AE, 2017, P NATL ACAD SCI USA, V114, pE820, DOI 10.1073/pnas.1616340114; Schageman J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/253957; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Silva AM, 2017, EUR J PHARM SCI, V98, P86, DOI 10.1016/j.ejps.2016.09.017; Srivastava AK, 2016, EXP NEUROL, V275, P154, DOI 10.1016/j.expneurol.2015.10.008; Subra C, 2010, J LIPID RES, V51, P2105, DOI 10.1194/jlr.M003657; Taylor DD, 2015, METHODS, V87, P3, DOI 10.1016/j.ymeth.2015.02.019; Tetta C, 2013, ENDOCRINE, V44, P11, DOI 10.1007/s12020-012-9839-0; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Ti DD, 2016, SCI CHINA LIFE SCI, V59, P1305, DOI 10.1007/s11427-016-0240-4; Ti DD, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0642-6; van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Yang J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140551; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Zhou Y, 2016, AM J PHYSIOL-RENAL, V310, pF27, DOI 10.1152/ajprenal.00303.2015	56	85	90	4	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	JAN	2018	36	1					79	90		10.1002/stem.2730			12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	FR3CB	WOS:000418942500009	29076623	Bronze			2021-06-18	
J	Hiploylee, C; Dufort, PA; Davis, HS; Wennberg, RA; Tartaglia, MC; Mikulis, D; Hazrati, LN; Tator, CH				Hiploylee, Carmen; Dufort, Paul A.; Davis, Hannah S.; Wennberg, Richard A.; Tartaglia, Maria Carmela; Mikulis, David; Hazrati, Lili-Naz; Tator, Charles H.			Longitudinal Study of Postconcussion Syndrome: Not Everyone Recovers	JOURNAL OF NEUROTRAUMA			English	Article						definitions; eligibility; and exclusions; number of symptoms; postconcussion syndrome; recovery	POST-CONCUSSION SYMPTOMS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; GENE-EXPRESSION; MILD; PREDICTORS; QUESTIONNAIRE; VALIDATION; MANAGEMENT; AGE	We examined recovery from postconcussion syndrome (PCS) in a series of 285 patients diagnosed with concussion based on international sport concussion criteria who received a questionnaire regarding recovery. Of 141 respondents, those with postconcussion symptoms lasting less than 3 months, a positive computed tomography (CT) and/or magnetic resonance imaging (MRI), litigants, and known Test of Memory Malingering (TOMM)-positive cases were excluded, leaving 110 eligible respondents. We found that only 27% of our population eventually recovered and 67% of those who recovered did so within the first year. Notably, no eligible respondent recovered from PCS lasting 3 years or longer. Those who did not recover (n = 80) were more likely to be non-compliant with a do-not-return-to-play recommendation (p = 0.006) but did not differ from the recovered group (n = 30) in other demographic variables, including age and sex (p >= 0.05). Clustergram analysis revealed that symptoms tended to appear in a predictable order, such that symptoms later in the order were more likely to be present if those earlier in the order were already present. Cox proportional hazards model analysis showed that the more symptoms reported, the longer the time to recovery (p = 7.4 x 10(-6)), with each additional symptom reducing the recovery rate by approximately 20%. This is the first longitudinal PCS study to focus on PCS defined specifically as a minimum of 3 months of symptoms, negative CT and/or MRI, negative TOMM test, and no litigation. PCS may be permanent if recovery has not occurred by 3 years. Symptoms appear in a predictable order, and each additional PCS symptom reduces recovery rate by 20%. More long-term follow-up studies are needed to examine recovery from PCS.	[Hiploylee, Carmen; Davis, Hannah S.; Tator, Charles H.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Wennberg, Richard A.; Tartaglia, Maria Carmela] Univ Toronto, Div Neurol, Toronto, ON, Canada; [Mikulis, David] Univ Toronto, Div Neuroradiol, Toronto, ON, Canada; [Hiploylee, Carmen] Toronto Western Hosp, 399 Bathurst St,Room 4W-422, Toronto, ON M5T 2S8, Canada; [Hiploylee, Carmen; Dufort, Paul A.; Davis, Hannah S.; Wennberg, Richard A.; Tartaglia, Maria Carmela; Mikulis, David; Hazrati, Lili-Naz; Tator, Charles H.] Toronto Western Hosp, Canadian Concuss Ctr, Toronto, ON, Canada; [Hazrati, Lili-Naz] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Hiploylee, C (corresponding author), Toronto Western Hosp, 399 Bathurst St,Room 4W-422, Toronto, ON M5T 2S8, Canada.	charles.tator@uhn.ca	hazrati, lili-naz/AAE-7785-2020; Mikulis, David J/H-5167-2019	hazrati, lili-naz/0000-0003-2715-1485; Mikulis, David/0000-0003-3956-0892	Ontario Brain Institute; Toronto General and Western Hospital Foundation; SmartCentres Limited; Marion and Gerald Soloway Concussion Chair Fund	The authors thank Dr. Adrian Crawley for his helpful comments on the statistical analyses and manuscript. This study was funded by grants from the Ontario Brain Institute and the Toronto General and Western Hospital Foundation, including grants from SmartCentres Limited and the Marion and Gerald Soloway Concussion Chair Fund.	Bar-Joseph Z., 2001, BIOINFORMATICS, V17, pS22, DOI [10.1093/bioinformatics/17.suppl_1.S22., 10.1093/bioinformatics/17.suppl_1.S22, DOI 10.1093/BIOINFORMATICS/17.SUPPL_1.S22]; Baruch Y, 1999, HUM RELAT, V52, P421, DOI 10.1023/A:1016905407491; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; COX DR, 1984, ANAL SURVIVAL DATA; DAVIES DL, 1979, IEEE T PATTERN ANAL, V1, P224, DOI 10.1109/TPAMI.1979.4766909; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Harabasz, 1974, COMMUN STAT, V3, P1, DOI DOI 10.1080/03610927408827101; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Jolliffe I, 2002, PRINCIPAL COMPONENT; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Kaufman L., 1990, PARTITIONING MEDOIDS; King N, 2014, NEUROREHABILITATION, V34, P741, DOI 10.3233/NRE-141072; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koller D., 2009, PROBABILISTIC GRAPHI; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Pearl J., 2009, CAUSALITY MODELS REA; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spirtes P., 2001, CAUSATION PREDICTION; Tator CH, 2016, J NEUROSURG, V125, P1206, DOI 10.3171/2015.6.JNS15664; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wall PLH, 2012, J AM PSYCHIAT NURSES, V18, P278, DOI 10.1177/1078390312460578; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zhang HH, 2007, BIOMETRIKA, V94, P691, DOI 10.1093/biomet/asm037	38	85	85	1	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1511	1523		10.1089/neu.2016.4677			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500002	27784191	Bronze, Green Published			2021-06-18	
J	Kumar, A; Barrett, JP; Alvarez-Croda, DM; Stoica, BA; Faden, AI; Loane, DJ				Kumar, Alok; Barrett, James P.; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.; Faden, Alan I.; Loane, David J.			NOX2 drives M1-like microglial/macrophage activation and neurodegeneration following experimental traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						NADPH oxidase; NOX2; Traumatic brain injury; Microglia; Macrophage; Neuroinflammation; M1-/M2-like; Neurodegeneration	SPINAL-CORD-INJURY; NADPH OXIDASE; MICROGLIAL ACTIVATION; OXIDATIVE STRESS; WHITE-MATTER; ALTERNATIVE ACTIVATION; INFLAMMATORY RESPONSE; THERAPEUTIC TARGETS; REDOX REGULATION; MOUSE MODEL	Following traumatic brain injury (TBI), activation of microglia and peripherally derived inflammatory macrophages occurs in association with tissue damage. This neuroinflammatory response may have beneficial or detrimental effects on neuronal survival, depending on the functional polarization of these cells along a continuum from M1-like to M2-like activation states. The mechanisms that regulate M1-like and M2-like activation after TBI are not well understood, but appear in part to reflect the redox state of the lesion microenvironment. NADPH oxidase (NOX2) is a critical enzyme system that generates reactive oxygen species in microglia/macrophages. After TBI, NOX2 is strongly up-regulated in Ml-like, but not in M2-like polarized cells. Therefore, we hypothesized that NOX2 drives M1-like neuroinflammation and contributes to neurodegeneration and loss of neurological function after TBI. In the present studies we inhibited NOX2 activity using NOX2-knockout mice or the selective peptide inhibitor gp91ds-tat. We show that NOX2 is highly up-regulated in infiltrating macrophages after injury, and that NOX2 deficiency reduces markers of M1-like activation, limits tissue loss and neurodegeneration, and improves motor recovery after moderate-level control cortical injury (CCI). NOX2 deficiency also promotes M2-like activation after CCI, through increased IL-4R alpha signaling in infiltrating macrophages, suggesting that NOX2 acts as a critical switch between M1- and M2-like activation states after TBI. Administration of gp91ds-tat to wild-type CCI mice starting at 24 h post-injury reduces deficits in cognitive function and increased M2-like activation in the hippocampus. Collectively, our data indicate that increased NOX2 activity after TBI drives Ml-like activation that contributes to inflammatory-mediated neurodegeneration, and that inhibiting this pathway provides neuroprotection, in part by altering M1-/M2-like balance towards the M2-like neuroinflammatory response. (C) 2016 Elsevier Inc. All rights reserved.	[Kumar, Alok; Barrett, James P.; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; [Kumar, Alok; Barrett, James P.; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A.; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; [Alvarez-Croda, Dulce-Mariely] Univ Veracruzana, Posgrad Neuroetol, Xalapa, Veracruz, Mexico; [Alvarez-Croda, Dulce-Mariely] Univ Veracruzana, Ctr Invest Cerebrales, Xalapa, Veracruz, Mexico	Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.	dloane@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348; Barrett, James/0000-0002-0924-9449	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308, R01NS037313]; National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center [P30-AG028747]; CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [249772/389071]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R01NS082308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	We thank Ashley Singh for expert technical assistance. This work was supported by NIH grant R01NS082308 (D.J. Loane), R01NS037313 (A.I. Faden), The National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center P30-AG028747 (D.J. Loane), and a CONACYT Scholarship 249772/389071 (DM Alvarez-Croda).	Abais JM, 2013, ANTIOXID REDOX SIGN, V18, P1537, DOI 10.1089/ars.2012.4666; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Averaimo S, 2010, FEBS LETT, V584, P2076, DOI 10.1016/j.febslet.2010.02.073; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Brune B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Csanyi G, 2011, FREE RADICAL BIO MED, V51, P1116, DOI 10.1016/j.freeradbiomed.2011.04.025; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gao HM, 2003, J NEUROSCI, V23, P1228; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hsieh C. L., 2014, J NEUROTRAUMA; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Khayrullina G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0391-8; Kumar A., 2015, J NEUROTRAUMA; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Liu XR, 2016, STROKE, V47, P498, DOI 10.1161/STROKEAHA.115.012079; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Mander P, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-20; Matsubara K, 2015, J NEUROSCI, V35, P2452, DOI 10.1523/JNEUROSCI.4088-14.2015; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nolan Y, 2005, J BIOL CHEM, V280, P9354, DOI 10.1074/jbc.M412170200; Novak ML, 2013, AM J PATHOL, V183, P1352, DOI 10.1016/j.ajpath.2013.06.034; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Qin LY, 2013, GLIA, V61, P855, DOI 10.1002/glia.22479; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shimohama S, 2000, BIOCHEM BIOPH RES CO, V273, P5, DOI 10.1006/bbrc.2000.2897; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Taetzsch T, 2015, GLIA, V63, P423, DOI 10.1002/glia.22762; Tang XN, 2011, ANN NEUROL, V70, P606, DOI 10.1002/ana.22476; van Horssen J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-156; von Leden R. E, 2016, J NEUROTRAUMA; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Wu DC, 2006, P NATL ACAD SCI USA, V103, P12132, DOI 10.1073/pnas.0603670103; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	70	85	85	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2016	58						291	309		10.1016/j.bbi.2016.07.158			19	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	DZ5MG	WOS:000385905600034	27477920	Green Accepted			2021-06-18	
J	Olivera, A; Lejbman, N; Jeromin, A; French, LM; Kim, HS; Cashion, A; Mysliwiec, V; Diaz-Arrastia, R; Gill, J				Olivera, Anlys; Lejbman, Natasha; Jeromin, Andreas; French, Louis M.; Kim, Hyung-Suk; Cashion, Ann; Mysliwiec, Vincent; Diaz-Arrastia, Ramon; Gill, Jessica			Peripheral Total Tau in Military Personnel Who Sustain Traumatic Brain Injuries During Deployment	JAMA NEUROLOGY			English	Article							MILD COGNITIVE IMPAIRMENT; HEAD-INJURY; ALZHEIMERS-DISEASE; MOUSE MODEL; RISK; ENCEPHALOPATHY; BIOMARKERS; ASSOCIATION; CONCUSSION; ACTIVATION	IMPORTANCE Approximately one-third of military personnel who deploy for combat operations sustain 1 or more traumatic brain injuries (TBIs), which increases the risk for chronic symptoms of postconcussive disorder, posttraumatic stress disorder, and depression and for the development of chronic traumatic encephalopathy. Elevated concentrations of tau are observed in blood shortly following a TBI, but, to our knowledge, the role of tau elevations in blood in the onset and maintenance of chronic symptoms after TBI has not been investigated. OBJECTIVES To assess peripheral tau levels in military personnel exposed to TBI and to examine the relationship between chronic neurological symptoms and tau elevations. DESIGN, SETTING, AND PARTICIPANTS Observational assessment from September 2012 to August 2014 of US military personnel at the Madigan Army Medical Center who had been deployed within the previous 18 months. Plasma total tau concentrations were measured using a novel ultrasensitive single-molecule enzyme-linked immunosorbent assay. Classification of participants with and without self-reported TBI was made using the Warrior Administered Retrospective Casualty Assessment Tool. Self-reported symptoms of postconcussive disorder, posttraumatic stress disorder, and depression were determined by the Neurobehavioral Symptom Inventory, the Posttraumatic Stress Disorder Checklist Military Version, and the Quick Inventory of Depressive Symptomatology, respectively. Group differences in tau concentrations were determined through analysis of variance models, and area under the receiver operating characteristic curve determined the sensitivity and specificity of tau concentrations in predicting TBI and chronic symptoms. Seventy participants with self-reported TBI on theWarrior Administered Retrospective Casualty Assessment Tool and 28 control participants with no TBI exposure were included. MAIN OUTCOMES AND MEASURES Concentration of total tau in peripheral blood. RESULTS Concentrations of plasma tau were significantly elevated in the 70 participants with self-reported TBI compared with the 28 controls (mean [SD], 1.13 [0.78] vs 0.63 [0.48] pg/mL, respectively; F-1,F-97 = 4.97; P = .03). Within the self-reported TBI cases, plasma total tau concentrations were significantly associated with having a medical record of TBI compared with self-reported TBI only (mean [SD], 1.57 [0.92] vs 0.85 [0.52] pg/mL, respectively; F1,69 = 6.15; P = .02) as well as reporting the occurrence of 3 of more TBIs during deployment compared with fewer than 3 TBIs (mean [SD], 1.52 [0.82] vs 0.82 [0.60] pg/mL, respectively; F1,69 = 8.57; P = .008). The severity of total postconcussive symptoms correlated with total tau concentrations in the self-reported TBI group (r = 0.37; P = .003). CONCLUSIONS AND RELEVANCE Military personnel who report multiple TBIs have long-term elevations in total tau concentration. The total tau concentration relates to symptoms of postconcussive disorder.	[Olivera, Anlys; Lejbman, Natasha; Kim, Hyung-Suk; Cashion, Ann; Gill, Jessica] NINR, NIH, Bethesda, MD 20814 USA; [Jeromin, Andreas] Quantenx Corp, Lexington, MA USA; [French, Louis M.] Natl Intrepid Ctr Excellence, Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [French, Louis M.; Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Mysliwiec, Vincent] Madigan Army Med Ctr, Tacoma, WA 98431 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Gill, J (corresponding author), NINR, NIH, One Cloister Court,Room 256, Bethesda, MD 20814 USA.	gillj@mail.nih.gov	french, louis/AAB-2083-2020; Gill, Gill M/Q-2020-2017	Diaz-Arrastia, Ramon/0000-0001-6051-3594; french, louis/0000-0002-9451-0604	Intramural Research Program of the National Institutes of Nursing Research; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [60855]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000027, ZIANR000030, ZIANR000015] Funding Source: NIH RePORTER	This work was supported by the Intramural Research Program of the National Institutes of Nursing Research and in part by grant 60855 from the Center for Neuroscience and Regenerative Medicine.	Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brickell TA, 2014, MIL MED, V179, P827, DOI 10.7205/MILMED-D-13-00506; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Ghoshal N, 2002, EXP NEUROL, V177, P475, DOI 10.1006/exnr.2002.8014; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P437, DOI 10.1007/978-3-211-85578-2_85; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Han DH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6633; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morales I, 2013, J ALZHEIMERS DIS, V37, P849, DOI 10.3233/JAD-131843; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Quanterix, SIM SCI; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Small GW, 2006, NEW ENGL J MED, V355, P2652, DOI 10.1056/NEJMoa054625; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Vanderploeg RD, 2015, J HEAD TRAUMA REHAB, V30, P1, DOI 10.1097/HTR.0000000000000009; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	48	85	89	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	OCT	2015	72	10					1109	1116		10.1001/jamaneurol.2015.1383			8	Clinical Neurology	Neurosciences & Neurology	CT6ZQ	WOS:000362963000005	26237304	Bronze			2021-06-18	
J	Wang, S; Cheng, HB; Dai, GH; Wang, XD; Hua, RR; Liu, XB; Wang, PS; Chen, GM; Yue, W; An, YH				Wang, Sen; Cheng, Hongbin; Dai, Guanghui; Wang, Xiaodong; Hua, Rongrong; Liu, Xuebin; Wang, Peishen; Chen, Guangming; Yue, Wu; An, Yihua			Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury	BRAIN RESEARCH			English	Article						Umbilical cord mesenchymal stem cells; Traumatic brain injury; Stem cell transplantation; Rehabilitation	QUALITY-OF-LIFE; THERAPY; STROKE; OUTCOMES	The aim of this study was to investigate the effects of transplantation with umbilical cord mesenchymal stem cells in patients with sequelae of traumatic brain injury (TBI). The study hypothesis was that umbilical cord mesenchymal stem cell transplantation could safely and effectively improve neurological function in patients with sequelae of traumatic brain injury. Forty patients with sequelae of TBI were randomly assigned to the stem cell treatment group or the control group. The patients in the stem cell treatment group underwent 4 stem cell transplantations via lumbar puncture. All patients of the group were also evaluated using Fugl-Meyer Assessments (FMA) and Functional Independence Measures (FIM) before and at 6 months after the stem cell transplantation. The patients in the control group did not receive any medical treatment (i.e., neither surgery nor medical intervention), and their FMA and FIM scores were determined on the day of the visit to the clinic and at 6 months after that clinical observation. The FMA results demonstrated an improvement in upper extremity motor sub-score, lower extremity motor sub-score, sensation sub-score and balance sub-score in the stem cell transplantation group at 6 months after the transplantation (P<0.05). The FIM results also exhibited significant improvement (P<0.05) in the patient self-care sub-score, sphincter control sub-score, mobility sub-score, locomotion sub-score, communication sub-score and social cognition sub-score. The control group exhibited no improvements after 6 months (P>0.05). All in all, the study results confirmed that the umbilical cord mesenchymal stem cell transplantation improved the neurological function and self-care in patients with TBI sequels. Umbilical cord mesenchymal stem cell transplantation may be a potential treatment for patients with sequelae of TBI. Further research, including a multicenter and large sample size prospective randomized clinical trial, will be required to define definitively the role of umbilical cord mesenchymal stem cell transplantation on sequelae of TBI. (c) 2013 Elsevier B.V. All rights reserved.	[Wang, Sen; Dai, Guanghui; Wang, Xiaodong; Liu, Xuebin; Wang, Peishen; Chen, Guangming; An, Yihua] Gen Hosp Chinese Peoples Armed Police Forces, Dept Cell Transplantat, Beijing 100039, Peoples R China; [Cheng, Hongbin; Yue, Wu; An, Yihua] Harbin Med Univ, Affiliated Hosp 4, Dept Neurosurg, Harbin 150001, Peoples R China	Yue, W (corresponding author), Harbin Med Univ, Affiliated Hosp 4, Dept Neurosurg, Harbin 150001, Peoples R China.	yuewu@vip.163.com; riveran@163.com		Hua, Rongrong/0000-0001-5102-115X; An, Yihua/0000-0003-0033-2999	Department of Science and Technology, Guangdong Province, China [2011A08401003]	This research was supported by a Grant from the Department of Science and Technology, Guangdong Province, China (2011A08401003).	Al-Jarrah MD, 2009, NEUROSCIENCES, V14, P41; Ali H, 2012, STEM CELL REV REP, V8, P210, DOI 10.1007/s12015-011-9287-x; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Carrade DD, 2011, CYTOTHERAPY, V13, P1180, DOI 10.3109/14653249.2011.602338; Cheng JL, 2010, CHIN J TRAUMATOL, V13, P173, DOI 10.3760/cma.j.issn.1008-1275.2010.03.008; Chernykh ER, 2011, B EXP BIOL MED+, V151, P512, DOI 10.1007/s10517-011-1369-x; Chuang TJ, 2012, J TRAUMA ACUTE CARE, V73, P1161, DOI 10.1097/TA.0b013e318265d128; Connell LA, 2012, CLIN REHABIL, V26, P68, DOI 10.1177/0269215511412982; Cui YF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017126; Dasari VR, 2009, J NEUROTRAUM, V26, P2057, DOI [10.1089/neu.2008.0725, 10.1089/neu.2008-0725]; Deuse T, 2011, CELL TRANSPLANT, V20, P655, DOI 10.3727/096368910X536473; Fan CG, 2011, STEM CELL REV REP, V7, P195, DOI 10.1007/s12015-010-9168-8; Feng M, 2011, J NUCL MED, V52, P90, DOI 10.2967/jnumed.110.080325; Fugl-Meyer AR, 1975, Scand J Rehabil Med, V7, P13; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Granger C. V., 1984, FUNCTIONAL ASSESSMEN; Hsieh YW, 2009, STROKE, V40, P1386, DOI 10.1161/STROKEAHA.108.530584; Hu XB, 2012, BRAIN INJURY, V26, P183, DOI 10.3109/02699052.2011.648707; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Jackson EL, 2008, CELLS TISSUES ORGANS, V188, P212, DOI 10.1159/000114541; Jaracz K, 2008, NEUROL NEUROCHIR POL, V42, P525; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Li JM, 2010, BRAIN RES, V1334, P65, DOI 10.1016/j.brainres.2010.03.080; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; Lu LL, 2006, HAEMATOLOGICA, V91, P1017; Lu ZJ, 2012, CURR NEUROVASC RES, V9, P250, DOI 10.2174/156720212803530708; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Palmgren B, 2012, EXP NEUROL, V235, P599, DOI 10.1016/j.expneurol.2012.03.014; Pardal R, 2012, ADV EXP MED BIOL, V741, P206, DOI 10.1007/978-1-4614-2098-9_14; Park JH, 2012, DIABETES RES CLIN PR, V98, P465, DOI 10.1016/j.diabres.2012.09.034; Qiu J, 1998, CHINESE J REHABILITA, V13, P54; Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21-1-105; Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253; Secco M, 2008, STEM CELLS, V26, P146, DOI 10.1634/stemcells.2007-0381; Shi W, 2012, BIOMATERIALS, V33, P3119, DOI 10.1016/j.biomaterials.2012.01.009; Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439; Tu Y, 2012, J NEUROTRAUM, V29, P2393, DOI 10.1089/neu.2012.2374; Wang Y, 2011, STEM CELLS DEV, V21, P1401; Wu KH, 2007, J CELL BIOCHEM, V100, P608, DOI 10.1002/jcb.21078; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiong N, 2011, GENE THER, V18, P394, DOI 10.1038/gt.2010.152; Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang HT, 2010, DIFFERENTIATION, V79, P15, DOI 10.1016/j.diff.2009.09.002; Zhao YD, 2001, WORLD J SURG, V25, P1202	48	85	93	0	30	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 26	2013	1532						76	84		10.1016/j.brainres.2013.08.001			9	Neurosciences	Neurosciences & Neurology	228NS	WOS:000325194100008	23942181				2021-06-18	
J	Crupi, R; Marino, A; Cuzzocrea, S				Crupi, R.; Marino, A.; Cuzzocrea, S.			n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity	CURRENT MEDICINAL CHEMISTRY			English	Article						n-3 fatty acids; dentate gyrus; neurogenesis; synaptic plasticity	DIETARY DOCOSAHEXAENOIC ACID; DENDRITIC SPINE DENSITY; TRAUMATIC BRAIN-INJURY; AGE-RELATED-CHANGES; EICOSAPENTAENOIC ACID; DOUBLE-BLIND; AMYLOID-BETA; NEURODEGENERATIVE DISEASES; HIPPOCAMPAL NEUROGENESIS; ALZHEIMERS-DISEASE	Omega-3 polyunsaturated fatty acids (PUFA) are essential unsaturated fatty acids with a double bond (C=C) starting after the third carbon atom from the end of the carbon chain. They are important nutrients but, unfortunately, mammals cannot synthesize them, whereby they must be obtained from food sources or from supplements. Amongst nutritionally important polyunsaturated n-3 fatty acids, alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are highly concentrated in the brain and have anti-oxidative stress, anti-inflammatory and antiapoptotic effects. They are involved in many bodily processes and may reportedly lead to neuron protection in neurological diseases. aged or damaged neurons and in Alzheimer's disease. Their effect in cognitive and behavioral functions and in several neurological and psychiatric disorders has been also proven. The dentate gyrus (DG), a sub-region of hippocampus, is implicated in cognition and mood regulation. The hippocampus represents one of the two areas in the mammalian brain in which adult neurogenesis occurs. This process is associated with beneficial effects on cognition, mood and chronic pharmacological treatment. The exposure to n-3 fatty acids enhances adult hippocampal neurogenesis associated with cognitive and behavioral processes, promotes synaptic plasticity by increasing long-term potentiation and modulates synaptic protein expression to stimulate the dendritic arborization and new spines formation. On this basis we review the effect of n-3 fatty acids on adult hippocampal neurogenesis and neuroplasticity. Moreover their possible use as a new therapeutic approach for neurodegenerative diseases is pointed out.	[Crupi, R.; Cuzzocrea, S.] Univ Messina, Policlin Univ, Sch Med, Inst Pharmacol, I-98123 Messina, Italy; [Marino, A.] Univ Messina, Sect Gen Physiol & Pharmacol, Dept Life Sci M Malpighi, I-98166 Messina, Italy; [Cuzzocrea, S.] Univ Manchester, Manchester M13 9PL, Lancs, England	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Torre Biol Policlin Univ Via C Valeria Gazzi, I-98100 Messina, Italy.	salvator@unime.it	Crupi, Rosalia/U-4364-2019	Crupi, Rosalia/0000-0002-7629-3132; Cuzzocrea, Salvatore/0000-0001-6131-3690			Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804; Baldelli P, 2007, J NEUROSCI, V27, P13520, DOI 10.1523/JNEUROSCI.3151-07.2007; Bate C, 2008, NEUROPHARMACOLOGY, V54, P934, DOI 10.1016/j.neuropharm.2008.02.003; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Beltz BS, 2007, NEUROSCI LETT, V415, P154, DOI 10.1016/j.neulet.2007.01.010; Beltz BS, 2003, ARTHROPOD STRUCT DEV, V32, P39, DOI 10.1016/S1467-8039(03)00038-0; Bertrand PC, 2006, J NUTR, V136, P1570; Bhatia HS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028451; Blanpied TA, 2004, BIOL PSYCHIAT, V55, P1121, DOI 10.1016/j.biopsych.2003.10.006; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; Bourre JM, 2006, J NUTR HEALTH AGING, V10, P386; Bousquet M, 2008, FASEB J, V22, P1213, DOI 10.1096/fj.07-9677com; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Brenna JT, 2002, CURR OPIN CLIN NUTR, V5, P127, DOI 10.1097/00075197-200203000-00002; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Calon F, 2007, PROSTAG LEUKOTR ESS, V77, P287, DOI 10.1016/j.plefa.2007.10.019; Cansev M, 2008, ALZHEIMERS DEMENT, V4, pS153, DOI 10.1016/j.jalz.2007.10.005; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Chalon S, 2001, LIPIDS, V36, P937, DOI 10.1007/s11745-001-0804-7; Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x; Chen H, 2003, AM J EPIDEMIOL, V157, P1007, DOI 10.1093/aje/kwg073; Chiu CC, 2008, PROG NEURO-PSYCHOPH, V32, P1538, DOI 10.1016/j.pnpbp.2008.05.015; Cline HT, 2001, CURR OPIN NEUROBIOL, V11, P118, DOI 10.1016/S0959-4388(00)00182-3; Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S; CRAWFORD MA, 1968, P ROY SOC MED, V61, P159, DOI 10.1177/003591576806100217; Crupi R, 2012, PREV MED, V54, pS103, DOI 10.1016/j.ypmed.2011.12.019; de Lau LML, 2005, NEUROLOGY, V64, P2040, DOI 10.1212/01.WNL.0000166038.67153.9F; Deneris ES, 2011, NEUROSCIENCE, V197, P17, DOI 10.1016/j.neuroscience.2011.08.061; Dyall SC, 2007, NEUROBIOL AGING, V28, P424, DOI 10.1016/j.neurobiolaging.2006.01.002; EATON SB, 1985, NEW ENGL J MED, V312, P283, DOI 10.1056/NEJM198501313120505; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; Freeman M P, 2000, Ann Clin Psychiatry, V12, P159, DOI 10.3109/10401230009147106; Fujita S, 2001, BRIT J PHARMACOL, V132, P1417, DOI 10.1038/sj.bjp.0703970; Fukaya T, 2007, NEUROBIOL AGING, V28, P1179, DOI 10.1016/j.neurobiolaging.2006.05.023; Futerman AH, 1996, TRENDS NEUROSCI, V19, P144, DOI 10.1016/S0166-2236(96)80025-7; Candela CG, 2011, NUTR HOSP, V26, P323, DOI [10.3305/nh.2011.26.2.5117, 10.1590/S0212-16112011000200013]; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Green KN, 2007, J NEUROSCI, V27, P4385, DOI 10.1523/JNEUROSCI.0055-07.2007; Green P, 1999, J LIPID RES, V40, P960; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Haastrup E, 2012, J NEUROIMMUNOL, V243, P69, DOI 10.1016/j.jneuroim.2011.12.006; Harzsch S, 1999, J NEUROSCI, V19, P3472; Hashimoto M, 2011, FOOD FUNCT, V2, P386, DOI 10.1039/c1fo00002k; Hashimoto M, 2009, J NUTR BIOCHEM, V20, P965, DOI 10.1016/j.jnutbio.2008.08.009; He CW, 2009, P NATL ACAD SCI USA, V106, P11370, DOI 10.1073/pnas.0904835106; Hibbeln JR, 1998, LANCET, V351, P1213, DOI 10.1016/S0140-6736(05)79168-6; Hibbeln JR, 1998, BIOL PSYCHIAT, V44, P243, DOI 10.1016/S0006-3223(98)00143-7; Jacobs BL, 2002, BRAIN BEHAV IMMUN, V16, P602, DOI 10.1016/S0889-1591(02)00015-6; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; Kan I, 2007, J LIPID RES, V48, P513, DOI 10.1194/jlr.C600022-JLR200; Kashiyae Y, 2009, NEUROSCI RES, V64, P143, DOI 10.1016/j.neures.2009.02.008; Kawakita E, 2006, NEUROSCIENCE, V139, P991, DOI 10.1016/j.neuroscience.2006.01.021; KELLEY VE, 1985, J IMMUNOL, V134, P1914; Kerchner GA, 2008, NAT REV NEUROSCI, V9, P813, DOI 10.1038/nrn2501; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; KINSELLA JE, 1990, JPEN-PARENTER ENTER, V14, pS200, DOI 10.1177/014860719001400511; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lang-Lazdunski L, 2003, J VASC SURG, V38, P564, DOI 10.1016/S0741-5214(03)00473-7; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lim SN, 2010, PROSTAG LEUKOTR ESS, V83, P193, DOI 10.1016/j.plefa.2010.08.003; Lim SY, 2000, INT J VITAM NUTR RES, V70, P251, DOI 10.1024/0300-9831.70.5.251; Lukiw WJ, 2008, J NUTR, V138, P2510, DOI 10.3945/jn.108.096016; Maes M, 1996, J AFFECT DISORDERS, V38, P35, DOI 10.1016/0165-0327(95)00092-5; Matsuoka Y, 2011, BIOPSYCHOSOC MED, V5, DOI 10.1186/1751-0759-5-3; McGahon BM, 1999, NEUROBIOL AGING, V20, P655, DOI 10.1016/S0197-4580(99)00050-0; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Minogue AM, 2007, J NEUROCHEM, V103, P914, DOI 10.1111/j.1471-4159.2007.04848.x; Nakamura MT, 2003, PROSTAG LEUKOTR ESS, V68, P145, DOI 10.1016/S0952-3278(02)00264-8; Nemets H, 2006, AM J PSYCHIAT, V163, P1098, DOI 10.1176/appi.ajp.163.6.1098; Oertner TG, 2005, CELL CALCIUM, V37, P477, DOI 10.1016/j.ceca.2005.01.016; Orr SK., 2012, PROSTAGLANDINS LEUKO; Peet M, 1998, BIOL PSYCHIAT, V43, P315, DOI 10.1016/S0006-3223(97)00206-0; Peet M, 1996, PROSTAG LEUKOTR ESS, V55, P71, DOI 10.1016/S0952-3278(96)90148-9; Peet M, 2001, SCHIZOPHR RES, V49, P243, DOI 10.1016/S0920-9964(00)00083-9; Rapoport SI, 2001, J LIPID RES, V42, P678; Riedel M, 2011, J MOL NEUROSCI, V43, P290, DOI 10.1007/s12031-010-9439-5; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Sakamoto T, 2007, BRAIN RES, V1182, P50, DOI 10.1016/j.brainres.2007.08.089; Samadikuchaksaraei A, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-15; Shahbakhti H, 2004, PHOTOCHEM PHOTOBIOL, V80, P231, DOI 10.1562/2004-01-27-RA-066.1; Shrivastava R, 2005, NUTR NEUROSCI, V8, P317, DOI 10.1080/10284150500510242; Simopoulos AP, 2006, BIOMED PHARMACOTHER, V60, P502, DOI 10.1016/j.biopha.2006.07.080; Simopoulos A P, 1995, World Rev Nutr Diet, V77, P47; Simopoulos AP, 2000, POULTRY SCI, V79, P961, DOI 10.1093/ps/79.7.961; Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311; Song C, 1998, J AFFECT DISORDERS, V49, P211, DOI 10.1016/S0165-0327(98)00025-1; Song C, 2007, EXPERT OPIN INV DRUG, V16, P1627, DOI 10.1517/13543784.16.10.1627; Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9; Stoll AL, 1999, ARCH GEN PSYCHIAT, V56, P407, DOI 10.1001/archpsyc.56.5.407; Strokin M, 2006, NEUROSCIENCE, V140, P547, DOI 10.1016/j.neuroscience.2006.02.026; Su HM, 2010, J NUTR BIOCHEM, V21, P364, DOI 10.1016/j.jnutbio.2009.11.003; Tanabe Y, 2004, CLIN EXP PHARMACOL P, V31, P700, DOI 10.1111/j.1440-1681.2004.04068.x; Venna VR, 2009, PSYCHONEUROENDOCRINO, V34, P199, DOI 10.1016/j.psyneuen.2008.08.025; Wada T, 2006, BIOL PHARM BULL, V29, P49, DOI 10.1248/bpb.29.49; Wang PY, 2010, J NUTR BIOCHEM, V21, P345, DOI 10.1016/j.jnutbio.2009.01.012; Ward RE, 2010, J NEUROTRAUM, V27, P1769, DOI 10.1089/neu.2010.1348; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Yamashima T, 2008, PROG NEUROBIOL, V84, P105, DOI 10.1016/j.pneurobio.2007.11.002; YOREK M, 1989, INVEST OPHTH VIS SCI, V30, P2087; Youdim KA, 2000, INT J DEV NEUROSCI, V18, P383, DOI 10.1016/S0736-5748(00)00013-7	105	85	87	2	90	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	0929-8673	1875-533X		CURR MED CHEM	Curr. Med. Chem.	AUG	2013	20	24					2953	2963		10.2174/09298673113209990140			11	Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	179XU	WOS:000321556900002	23746276				2021-06-18	
J	Meffre, D; Labombarda, F; Delespierre, B; Chastre, A; De Nicola, AF; Stein, DG; Schumacher, M; Guennoun, R				Meffre, D.; Labombarda, F.; Delespierre, B.; Chastre, A.; De Nicola, A. F.; Stein, D. G.; Schumacher, M.; Guennoun, R.			DISTRIBUTION OF MEMBRANE PROGESTERONE RECEPTOR ALPHA IN THE MALE MOUSE AND RAT BRAIN AND ITS REGULATION AFTER TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						membrane progesterone receptor (mPR); neurons; astrocytes; oligodendrocytes; microglia; traumatic brain injury (TBI)	BINDING-PROTEIN 25-DX; NONCLASSICAL MECHANISMS; NEUROPROTECTIVE FACTOR; PLASMA-MEMBRANE; SEXUAL-BEHAVIOR; EXPRESSION; NEUROSTEROIDS; HYPOTHALAMUS; ESTRADIOL; HORMONE	Progesterone has been shown to exert pleiotropic actions in the brain of both male and females. In particular, after traumatic brain injury (TBI), progesterone has important neuroprotective effects. In addition to intracellular progesterone receptors, membrane receptors of the hormone such as membrane progesterone receptor (mPR) may also be involved in neuroprotection. Three mPR subtypes (mPR alpha, mPR beta and mPR gamma) have been described and mPR alpha is best characterized pharmacologically. In the present study we investigated the distribution, cellular localization and the regulation of mPR alpha in male mouse and rat brain. We showed by reverse transcription-PCR that mPR alpha is expressed at similar levels in the male and female mouse brain suggesting that its expression may not be influenced by steroid levels. Treatment of males by estradiol or progesterone did not modify the level of expression of mPR alpha as shown by Western blot analysis. In situ hybridization and immunohistochemistry analysis showed a wide expression of mPR alpha in particular in the olfactory bulb, striatum, cortex, thalamus, hypothalamus, septum, hippocampus and cerebellum. Double immunofluorescence and confocal microscopy analysis showed that mPR alpha is expressed by neurons but not by oligodendrocytes and astrocytes. In the rat brain, the distribution of mPR alpha was similar to that observed in mouse brain; and after TBI, mPR alpha expression was induced in oligodendrocytes, astrocytes and reactive microglia. The wide neuroanatomical distribution of mPR alpha suggests that this receptor may play a role beyond neuroendocrine and reproductive functions. However, in the absence of injury its role might be restricted to neurons. The induction of mPR alpha after TBI in microglia, astrocytes and oligodendrocytes, points to a potential role in mediating the modulatory effects of progesterone in inflammation, ion and water homeostasis and myelin repair in the injured brain. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Meffre, D.; Labombarda, F.; Delespierre, B.; Chastre, A.; Schumacher, M.; Guennoun, R.] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; [Meffre, D.; Labombarda, F.; Delespierre, B.; Chastre, A.; Schumacher, M.; Guennoun, R.] Univ Paris 11, F-94276 Le Kremlin Bicetre, France; [Labombarda, F.; De Nicola, A. F.] Univ Buenos Aires, Lab Neuroendocrine Biochem, Inst Biol & Med Expt, RA-1053 Buenos Aires, DF, Argentina; [Labombarda, F.; De Nicola, A. F.] Univ Buenos Aires, Dept Human Biochem, RA-1053 Buenos Aires, DF, Argentina; [Stein, D. G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA USA	Guennoun, R (corresponding author), INSERM, UMR 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	rachida.guennoun@inserm.fr	Labombarda, Fabien/AAE-7747-2020; Guennoun, Rachida/F-2420-2011; Stein, Donald/AAJ-5139-2020; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371; MEFFRE, Delphine/0000-0002-9204-2245	Government of France (INSERM/CONICET); Government of Argentina (INSERM/CONICET)	We thank Philippe Leclerc for confocal microscopy. This work was partly supported by a cooperative program between the Governments of France and Argentina (INSERM/CONICET).	Ashley RL, 2006, ENDOCRINOLOGY, V147, P4151, DOI 10.1210/en.2006-0002; Auger CJ, 2006, J NEUROENDOCRINOL, V18, P187, DOI 10.1111/j.1365-2826.2005.01400.x; Balasubramanian B, 2008, ENDOCRINOLOGY, V149, P5509, DOI 10.1210/en.2008-0712; Balasubramanian B, 2008, ENDOCRINOLOGY, V149, P5518, DOI 10.1210/en.2008-0713; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; BROWN TJ, 1987, J NEUROSCI, V7, P2529; Cekic M, 2010, NEUROTHERAPEUTICS, V7, P81, DOI 10.1016/j.nurt.2009.10.017; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; de Sousa FL, 2010, BEHAV BRAIN RES, V212, P84, DOI 10.1016/j.bbr.2010.03.050; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; Falkenstein E, 2000, EUR J CLIN INVEST, V30, P51, DOI 10.1046/j.1365-2362.2000.0300s3051.x; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Frye CA, 2001, HORM BEHAV, V40, P226, DOI 10.1006/hbeh.2001.1674; Garcia-Ovejero D, 2002, J COMP NEUROL, V450, P256, DOI 10.1002/cne.10325; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2009, NEUROSCIENTIST, V15, P324, DOI 10.1177/1073858409333069; Gomez C, 2002, PHARMACOL BIOCHEM BE, V72, P543, DOI 10.1016/S0091-3057(02)00722-0; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Greco B, 2001, ENDOCRINOLOGY, V142, P5172, DOI 10.1210/en.142.12.5172; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; GUENNOUN R, 1995, MOL BRAIN RES, V30, P287, DOI 10.1016/0169-328X(95)00016-L; Gunn BG, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00131; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Hwang JY, 2009, CELL CALCIUM, V45, P233, DOI 10.1016/j.ceca.2008.10.006; Intlekofer KA, 2011, NEUROSCIENCE, V176, P86, DOI 10.1016/j.neuroscience.2010.12.033; Intlekofer KA, 2011, NEUROSCIENCE, V172, P55, DOI 10.1016/j.neuroscience.2010.10.051; KE FC, 1990, J NEUROCHEM, V54, P467, DOI 10.1111/j.1471-4159.1990.tb01895.x; Krebs CJ, 2000, P NATL ACAD SCI USA, V97, P12816, DOI 10.1073/pnas.97.23.12816; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LAN NC, 1991, J NEUROCHEM, V57, P1818, DOI 10.1111/j.1471-4159.1991.tb06388.x; Liu B, 2009, J NEUROENDOCRINOL, V21, P993, DOI 10.1111/j.1365-2826.2009.01920.x; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; Meyer C, 1996, EUR J BIOCHEM, V239, P726, DOI 10.1111/j.1432-1033.1996.0726u.x; Mong JA, 2004, MOL PSYCHIATR, V9, P550, DOI 10.1038/sj.mp.4001493; Peluso JJ, 2005, BIOL REPROD, V73, P261, DOI 10.1095/biolreprod.105.041061; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pfaff Donald W., 1994, P107; Phelps SM, 1998, HORM BEHAV, V34, P294, DOI 10.1006/hbeh.1998.1485; ProTECT-III, 2011, PROTECT 3 PROGESTERO; RAMIREZ VD, 1987, J STEROID BIOCHEM, V27, P589, DOI 10.1016/0022-4731(87)90358-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Sakamoto H, 2001, J NEUROSCI, V21, P6221; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; Schneider JS, 2003, P NATL ACAD SCI USA, V100, P2951, DOI 10.1073/pnas.0130100100; Schumacher M, 2007, ENDOCR REV, V28, P387, DOI 10.1210/er.2006-0050; Selmin O, 1996, CARCINOGENESIS, V17, P2609, DOI 10.1093/carcin/17.12.2609; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sleiter N, 2009, ENDOCRINOLOGY, V150, P3833, DOI 10.1210/en.2008-0774; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stein DG, 2010, AM J ROENTGENOL, V194, P20, DOI 10.2214/AJR.09.3407; SyNAPSe, 2011, RAND DOUBL BLIND PLA; Tang YT, 2005, J MOL EVOL, V61, P372, DOI 10.1007/s00239-004-0375-2; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Thomas P, 2004, MED CHEM RES, V13, P202, DOI 10.1007/s00044-004-0026-6; Thomas P, 2007, ENDOCRINOLOGY, V148, P705, DOI 10.1210/en.2006-0974; TISCHKAU SA, 1993, P NATL ACAD SCI USA, V90, P1285, DOI 10.1073/pnas.90.4.1285; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; TOWLE AC, 1983, J STEROID BIOCHEM, V18, P135, DOI 10.1016/0022-4731(83)90079-1; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; WITT DM, 1995, PHYSIOL BEHAV, V57, P307, DOI 10.1016/0031-9384(94)00247-3; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100; Zuloaga DG, 2012, ENDOCRINOLOGY	87	85	87	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 12	2013	231						111	124		10.1016/j.neuroscience.2012.11.039			14	Neurosciences	Neurosciences & Neurology	087EN	WOS:000314744200011	23211561				2021-06-18	
J	Maegele, M				Maegele, Marc			Coagulopathy after traumatic brain injury: incidence, pathogenesis, and treatment options	TRANSFUSION			English	Article							RECOMBINANT FACTOR VIIA; HEAD-INJURY; INTRAVASCULAR COAGULATION; PLATELET TRANSFUSION; HYPERFIBRINOLYSIS; MICROPARTICLES; PROGRESSION; HEMORRHAGE; MORTALITY; RATIOS	Coagulopathy after traumatic brain injury (TBI) is frequent and represents a powerful predictor related to outcome and prognosis. The complex pathophysiological mechanisms of the coagulopathy of TBI are multifactorial and remain still undefined. The nature of the coagulation abnormalities differs between severe TBI and non-TBI with somatic injuries. The current hypothesis for the development of coagulopathy after TBI includes combinations of both hypo- and hypercoagulable states promoted by the magnitude and the extent of the injury resulting in a variable degree of secondary injury via subsequent ischemic and hemorrhagic lesioning. The proposed underlying mechanisms may comprise the release of tissue factor (TF), hyperfibrinolysis, shock, and hypoperfusion thus triggering the protein C pathway, disseminated intravascular coagulation, and platelet dysfunction. Hemocoagulative disorders after TBI may be amenable to treatment, and adequate and timely management may protect from secondary injury and poor outcomes. Functional assays such as viscoelastic tests may be supportive in early detection, diagnosis, and guidance of treatment. This review summarizes the current understanding with regard to frequency, pathogenesis, diagnosis, and treatment of the coagulopathy after TBI.	[Maegele, Marc] Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany; [Maegele, Marc] Univ Witten Herdecke, Cologne Merheim Med Ctr, Inst Res Operat Med IFOM, D-51109 Cologne, Germany	Maegele, M (corresponding author), Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de					Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Bartal C, 2007, J TRAUMA, V63, P725, DOI 10.1097/TA.0b013e318031ccca; Borgman MA, 2011, VOX SANG, V101, P44, DOI 10.1111/j.1423-0410.2011.01466.x; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Etemadrezaie H, 2007, CLIN NEUROL NEUROSUR, V109, P166, DOI 10.1016/j.clineuro.2006.09.001; Giesen PLA, 2000, SEMIN THROMB HEMOST, V26, P379, DOI 10.1055/s-2000-8456; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hoyt DB, 2004, SEMIN HEMATOL, V41, P40, DOI 10.1053/j.seminhematol.2003.11.009; Ives C, 2012, J AM COLL SURGEONS, V215, P496, DOI 10.1016/j.jamcollsurg.2012.06.005; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Letarte PB, 2008, J TRAUMA, V64, P627; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pathak A, 2005, Neurol India, V53, P178; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schochl H, 2012, HAMOSTASEOLOGIE, V32, P22, DOI 10.5482/ha-1178; Schochl H, 2011, J NEUROTRAUM, V28, P2033, DOI 10.1089/neu.2010.1744; Schochl H, 2009, J TRAUMA, V67, P125, DOI 10.1097/TA.0b013e31818b2483; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Stein DM, 2008, J TRAUMA, V64, P620, DOI 10.1097/TA.0b013e3181650fc7; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Swanson CA, 2010, J TRAUMA, V68, P1072, DOI 10.1097/TA.0b013e3181d7a6f2; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; VanWijk MJ, 2003, CARDIOVASC RES, V59, P277, DOI 10.1016/S0008-6363(03)00367-5; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929	43	85	92	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	JAN	2013	53			1	SI		28S	37S		10.1111/trf.12033			10	Hematology	Hematology	071SR	WOS:000313615000006	23301970				2021-06-18	
J	Dashnaw, ML; Petraglia, AL; Bailes, JE				Dashnaw, Matthew L.; Petraglia, Anthony L.; Bailes, Julian E.			An overview of the basic science of concussion and subconcussion: where we are and where we are going	NEUROSURGICAL FOCUS			English	Article						concussion; subconcussion; traumatic brain injury; chronic traumatic encephalopathy; pathophysiology	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; FLUID-PERCUSSION INJURY; CLOSED-HEAD INJURY; AXONAL INJURY; DIFFUSION TENSOR; MITOCHONDRIAL DYSFUNCTION; MOUSE MODEL; COGNITIVE IMPAIRMENT; NEUROLOGIC FUNCTION	There has been a growing interest in the diagnosis and management of mild traumatic brain injury (TBI), or concussion. Repetitive concussion and subconcussion have been linked to a spectrum of neurological sequelae, including postconcussion syndrome, chronic traumatic encephalopathy, mild cognitive impairment, and dementia pugilistica. A more common risk than chronic traumatic encephalopathy is the season-ending or career-ending effects of concussion or its mismanagement. To effectively prevent and treat the sequelae of concussion, it will be important to understand the basic processes involved. Reviewed in this paper are the forces behind the primary phase of injury in mild TBI, as well as the immediate and delayed cellular events responsible for the secondary phase of injury leading to neuronal dysfunction and possible cell death. Advanced neuroimaging sequences have recently been developed that have the potential to increase the sensitivity of standard MRI to detect both structural and functional abnormalities associated with concussion, and have provided further insight into the potential underlying pathophysiology. Also discussed are the potential long-term effects of repetitive mild TBI, particularly chronic traumatic encephalopathy. Much of the data regarding this syndrome is limited to postmortem analyses, and at present there is no animal model of chronic traumatic encephalopathy described in the literature. As this arena of TBI research continues to evolve, it will be imperative to appropriately model concussive and even subconcussive injuries in an attempt to understand, prevent, and treat the associated chronic neurodegenerative sequelae. (http://thejns.org/doi/abs/10.3171/2012.10.FOCUS12284)	[Dashnaw, Matthew L.; Petraglia, Anthony L.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Bailes, Julian E.] Univ Chicago, Pritzker Sch Med, Dept Neurosurg, NorthShore Univ Hlth Syst, Evanston, IL USA	Petraglia, AL (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, 601 Elmwood Ave,Box 670, Rochester, NY 14642 USA.	anthony_petraglia@urmc.rochester.edu					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; ANDREW RD, 1991, J NEUROL SCI, V101, P7, DOI 10.1016/0022-510X(91)90013-W; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Engel S, 1996, Acta Neurochir Suppl, V66, P89; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hootman JM, 2007, J ATHL TRAINING, V42, P311; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Kalimo H, 1981, Acta Neuropathol Suppl, V7, P20; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luther N, 2012, NEUROSURGERY, V71, pE558, DOI 10.1227/01.neu.0000417733.09300.04; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; MASUZAWA H, 1976, Neurologia Medico-Chirurgica, V16, P77, DOI 10.2176/nmc.16pt1.77; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCullough BJ, 2011, PHYS MED REH CLIN N, V22, P635, DOI 10.1016/j.pmr.2011.08.005; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; ROSEN AS, 1990, NEUROSCIENCE, V38, P579, DOI 10.1016/0306-4522(90)90052-6; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SALY V, 1993, J NEUROPHYSIOL, V69, P2200; SASS DJ, 1971, J BIOMECH, V4, P331, DOI 10.1016/0021-9290(71)90054-6; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schwartzkroin PA, 1998, EPILEPSY RES, V32, P275, DOI 10.1016/S0920-1211(98)00058-8; SEKINO H, 1980, Neurologia Medico-Chirurgica, V20, P127; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Talavage T. M., 2010, J NEUROTRAUMA; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YARNELL P, 1969, B NEW YORK ACAD MED, V45, P39; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	110	85	85	0	60	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E5	10.3171/2012.10.FOCUS12284			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500006	23199428	Bronze			2021-06-18	
J	Lin, AP; Liao, HJ; Merugumala, SK; Prabhu, SP; Meehan, WP; Ross, BD				Lin, A. P.; Liao, H. J.; Merugumala, S. K.; Prabhu, S. P.; Meehan, W. P., III; Ross, B. D.			Metabolic imaging of mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Spectroscopy; Single photon emissioncomputed tomography; Positron emission tomography; Mild traumatic brain injury; Metabolic imaging	MAGNETIC-RESONANCE-SPECTROSCOPY; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; PROTON MR SPECTROSCOPY; TECHNETIUM-99M-HMPAO SPECT; HEAD-INJURY; COMPUTED-TOMOGRAPHY; SUBSTANCE-ABUSE; AXONAL INJURY; CONCUSSION	Traumatic brain injury results in a metabolic cascade of changes that occur at the molecular level, invisible to conventional imaging methods such as computed tomography or magnetic resonance imaging. Non-invasive metabolic imaging tools such as single photon emission computed tomography (SPECT), positron emission tomography (PET), and magnetic resonance spectroscopy (MRS) are the ideal methods for providing insight to these changes by measuring regional cerebral blood flow, glucose metabolism, and brain metabolite concentrations, respectively, after mild traumatic brain injury (mTBI). The purpose of this review is to provide an overview of the different methodologies and provide an up-to-date summary of recent findings with SPECT, PET, and MRS technologies, specifically after mTBI, as defined by standardized criteria. Given that the different physiological and pathological responses are heterogeneous, efforts will be made to separate studies at different time points after injury (acute, subacute, and chronic stages) as well as to the different types of mTBI such sports-related head injury where repetitive head injuries are much more common and may present a unique signature.	[Lin, A. P.; Liao, H. J.; Merugumala, S. K.; Ross, B. D.] Harvard Univ, Sch Med, Dept Radiol, Brigham & Womens Hosp, Boston, MA 02115 USA; [Prabhu, S. P.] Harvard Univ, Sch Med, Adv Image Anal Lab, Dept Radiol,Childrens Hosp Boston, Boston, MA 02115 USA; [Meehan, W. P., III] Harvard Univ, Sch Med, Sports Concuss Clin, Dept Med,Childrens Hosp Boston, Boston, MA 02115 USA; [Ross, B. D.] Huntington Med Res Inst, Pasadena, CA USA	Lin, AP (corresponding author), Harvard Univ, Sch Med, Dept Radiol, Brigham & Womens Hosp, Boston, MA 02115 USA.	aplin@partners.org	PRABHU, SANJAY/A-9947-2013	PRABHU, SANJAY/0000-0003-0871-115X	Department of Defense Psychological Health/Traumatic Brain Injury Research Program of the Office of the Congressionally Directed Medical Research Programs [W81XWH-10-1-0835]; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [(R01 NS 078337)]; Center for Integration of Medicine (CIMIT) Innovation Grants; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER	This work was supported in part by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program of the Office of the Congressionally Directed Medical Research Programs (W81XWH-10-1-0835; APL, HL), by an National Institutes of Health/National Institute of Neurological Disorders and Stroke funded R01 (R01 NS 078337; APL), by the Center for Integration of Medicine (CIMIT) Innovation Grants (APL), and by an NIH training grant (T32 HD040128-06A1; WPM)	Abu-Judeh HH, 1998, J NUCL MED, V39, P1357; Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Audenaert Kurt, 2003, Med Sci Monit, V9, pMT112; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bluml S, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P197, DOI 10.1007/0-387-32565-4_9; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Catafau AM, 2001, J NUCL MED, V42, P259; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; GRAY BG, 1992, J NUCL MED, V33, P52; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Hashimoto K, 2009, J REHABIL MED, V41, P661, DOI 10.2340/16501977-0388; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V35, P217; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jacobs A, 1996, J NUCL MED, V37, P1605; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEONARD JP, 1986, J NUCL MED, V27, P1819; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lin A. P., 2010, 96 SCI ASS ANN M RAD; Lin Alexander, 2005, NeuroRx, V2, P197, DOI 10.1602/neurorx.2.2.197; Lin AP, 2003, MAGN RESON MATER PHY, V16, P29, DOI 10.1007/s10334-003-0004-x; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McDonald B. C., 2012, BRAIN IMAGING BEHAV; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Rushdie Salman., 2012, NEUROIMAGING FORENSI, P1; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Slobounov S. M., 2012, BRAIN IMAGING BEHAV; Umile EM, 1998, BRAIN INJURY, V12, P577; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; WOODS SW, 1992, J CLIN PSYCHIAT, V53, P20; Wortzel HS, 2008, J AM ACAD PSYCHIATRY, V36, P310; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	64	85	88	0	41	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		208	223		10.1007/s11682-012-9181-4			16	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900005	22684770				2021-06-18	
J	Tobinick, E; Kim, NM; Reyzin, G; Rodriguez-Romanacce, H; DePuy, V				Tobinick, Edward; Kim, Nancy M.; Reyzin, Gary; Rodriguez-Romanacce, Helen; DePuy, Venita			Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept	CNS DRUGS			English	Article							TUMOR-NECROSIS-FACTOR; MONTREAL COGNITIVE ASSESSMENT; MENTAL-STATE-EXAMINATION; TRIALS COMPARING PLACEBO; FACTOR-ALPHA INHIBITOR; LONG-TERM SAFETY; ALZHEIMERS-DISEASE; TARGETED ETANERCEPT; RAPID IMPROVEMENT; NATURAL-HISTORY	Background Brain injury from stroke and traumatic brain injury (TBI) may result in a persistent neuroinflammatory response in the injury penumbra. This response may include microglial activation and excess levels of tumour necrosis factor (TNF). Previous experimental data suggest that etanercept, a selective TNF inhibitor, has the ability to ameliorate microglial activation and modulate the adverse synaptic effects of excess TNF. Perispinal administration may enhance etanercept delivery across the blood-CSF barrier. Objective The objective of this study was to systematically examine the clinical response following perispinal administration of etanercept in a cohort of patients with chronic neurological dysfunction after stroke and TBI. Methods After approval by an independent external institutional review board (IRB), a chart review of all patients with chronic neurological dysfunction following stroke or TBI who were treated open-label with perispinal etanercept (PSE) from November 1, 2010 to July 14, 2012 at a group medical practice was performed. Results The treated cohort included 629 consecutive patients. Charts of 617 patients following stroke and 12 patients following TBI were reviewed. The mean age of the stroke patients was 65.8 years +/- 13.15 (range 13-97). The mean interval between treatment with PSE and stroke was 42.0 +/- 57.84 months (range 0.5-419); for TBI the mean interval was 115.2 +/- 160.22 months (range 4-537). Statistically significant improvements in motor impairment, spasticity, sensory impairment, cognition, psychological/behavioural function, aphasia and pain were noted in the stroke group, with a wide variety of additional clinical improvements noted in individuals, such as reductions in pseudobulbar affect and urinary incontinence. Improvements in multiple domains were typical. Significant improvement was noted irrespective of the length of time before treatment was initiated; there was evidence of a strong treatment effect even in the subgroup of patients treated more than 10 years after stroke and TBI. In the TBI cohort, motor impairment and spasticity were statistically significantly reduced. Discussion Irrespective of the methodological limitations, the present results provide clinical evidence that stroke and TBI may lead to a persistent and ongoing neuroinflammatory response in the brain that is amenable to therapeutic intervention by selective inhibition of TNF, even years after the acute injury. Conclusion Excess TNF contributes to chronic neurological, neuropsychiatric and clinical impairment after stroke and TBI. Perispinal administration of etanercept produces clinical improvement in patients with chronic neurological dysfunction following stroke and TBI. The therapeutic window extends beyond a decade after stroke and TBI. Randomized clinical trials will be necessary to further quantify and characterize the clinical response.	[Tobinick, Edward; Kim, Nancy M.; Reyzin, Gary] Inst Neurol Recovery, Los Angeles, CA 90095 USA; [Tobinick, Edward; Kim, Nancy M.; Reyzin, Gary] Inst Neurol Recovery, Newport Beach, CA USA; [Tobinick, Edward; Rodriguez-Romanacce, Helen] Inst Neurol Recovery, Boca Raton, FL USA; [DePuy, Venita] Bowden Analyt, Apex, NC USA	Tobinick, E (corresponding author), Inst Neurol Recovery, 100 UCLA Med Plaza,Suites 205-210, Los Angeles, CA 90095 USA.	nrimed@gmail.com		Tobinick, Edward/0000-0001-7614-499X	Institute of Neurological Recovery(R) (INR(R))	Funding for the study was provided by the Institute of Neurological Recovery (R) (INR (R)). Edward Tobinick, Nancy M. Kim, Gary Reyzin, Helen Rodriguez-Romanacce and Venita DePuy played an important role in the acquisition, analysis and interpretation of the data, wrote the manuscript, made substantive suggestions for revision and approved the final submitted version. Venita DePuy performed the statistical analyses. Edward Tobinick was responsible for the conception and planning of the work that led to the manuscript. The authors acknowledge the general assistance of Lynna Sim, Daniel Gendler, Shea Sullivan and Young Hee Jennifer Kim. Edward Tobinick is the named inventor and receives royalties from multiple issued and pending US and international patents assigned to TACT IP LLC that describe perispinal administration of etanercept for the treatment of stroke and other methods of use of etanercept and other biologics for the treatment of neurological disorders. These patents include, but are not limited to, US patents 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306 and Australian patent 758,523. The INR (R) is a private medical practice that has licensed the TACT IP LLC patents. Nancy Kim, Helen Rodriguez-Romanacce and Gary Reyzin are INR (R) employees. Venita DePuy received payment for her authorship contributions.	Antoniou C, 2011, J EUR ACAD DERMATOL, V25, P1113, DOI 10.1111/j.1468-3083.2010.03820.x; Arnason BGW, 1999, NEUROLOGY, V53, P457, DOI 10.1212/wnl.53.3.457; Atkinson HH, 2007, J GERONTOL A-BIOL, V62, P844, DOI 10.1093/gerona/62.8.844; Bains JS, 2007, TRENDS NEUROSCI, V30, P417, DOI 10.1016/j.tins.2007.06.007; Balakrishnan Preethi, 2008, Curr Treat Options Cardiovasc Med, V10, P216, DOI 10.1007/s11936-008-0023-z; BANKS WA, 1995, NEUROIMMUNOMODULAT, V2, P161, DOI 10.1159/000096887; BATSON OV, 1957, AMER J ROENTGENOL RA, V78, P195; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Benucci Maurizio, 2012, Acta Biomed, V83, P72; Buchhave P, 2010, NEUROBIOL AGING, V31, P1877, DOI 10.1016/j.neurobiolaging.2008.10.012; Butchart J, 2012, CNS NEUROSCI THER, V18, P64, DOI 10.1111/j.1755-5949.2011.00245.x; Cavanagh C, 2011, FUTUR NEUROL, V6, P757, DOI 10.2217/FNL.11.50; Cheng X, 2010, J ALZHEIMERS DIS, V19, P621, DOI 10.3233/JAD-2010-1253; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chou SHY, 2012, J INVEST MED, V60, P1054, DOI 10.2310/JIM.0b013e3182686932; Christensen MC, NEUROCRIT CARE; CLARK IA, 1994, PARASITOL TODAY, V10, P410, DOI 10.1016/0169-4758(94)90237-2; CLARK IA, 1993, Q J MED, V86, P217; Clark I, 2012, PHARMACOL REV, V64, P1004, DOI 10.1124/pr.112.005850; Clark IA, 2007, CYTOKINE GROWTH F R, V18, P335, DOI 10.1016/j.cytogfr.2007.04.002; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Cohen SP, 2009, ANESTHESIOLOGY, V110, P1116, DOI 10.1097/ALN.0b013e3181a05aa0; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Creutzfeldt CJ, 2012, J GEN INTERN MED, V27, P853, DOI 10.1007/s11606-011-1966-4; Cumming TB, 2011, STROKE, V42, P2642, DOI 10.1161/STROKEAHA.111.619486; DeMonaco HJ, 2006, PHARMACOTHERAPY, V26, P323, DOI 10.1592/phco.26.3.323; Dong YH, 2010, J NEUROL SCI, V299, P15, DOI 10.1016/j.jns.2010.08.051; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; Esposito E, 2011, TRENDS PHARMACOL SCI, V32, P107, DOI 10.1016/j.tips.2010.11.009; Felger JC, FRONT NEUROENDOCRINO; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Furrer E, 2009, J NEUROIMMUNOL, V215, P65, DOI 10.1016/j.jneuroim.2009.08.005; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Giuliani F, 2009, BRAIN RES BULL, V80, P302, DOI 10.1016/j.brainresbull.2009.07.009; Gladman DD, 2011, J RHEUMATOL, V38, P1355, DOI 10.3899/jrheum.100698; Glasziou P, 2007, BMJ-BRIT MED J, V334, P349, DOI 10.1136/bmj.39070.527986.68; Gottlieb AB, 2011, J DRUGS DERMATOL, V10, P289; Griffin WST, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-3; Halassa MM, 2007, TRENDS MOL MED, V13, P54, DOI 10.1016/j.molmed.2006.12.005; Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Hrobjartsson A, 2004, J INTERN MED, V256, P91, DOI 10.1111/j.1365-2796.2004.01355.x; Hrobjartsson A, 2011, J CLIN EPIDEMIOL, V64, P1223, DOI 10.1016/j.jclinepi.2011.01.008; Hrobjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jiang H, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-69; Johanson CE, 2005, PHARM RES-DORDR, V22, P1011, DOI 10.1007/s11095-005-6039-0; Kato K, 2009, NEUROSCIENCE, V160, P492, DOI 10.1016/j.neuroscience.2009.02.038; Kato K, 2010, J NEUROSCI RES, V88, P360, DOI 10.1002/jnr.22202; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Kerensky TA, 2012, EXPERT OPIN DRUG SAF, V11, P121, DOI 10.1517/14740338.2012.633509; Klareskog L, 2011, CLIN EXP RHEUMATOL, V29, P238; Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; Kuhn T., 1962, STRUCTURE SCI REVOLU; Lang L, 2005, GASTROENTEROLOGY, V129, P1813, DOI 10.1053/j.gastro.2005.10.046; Langdon PC, 2007, J CLIN NEUROSCI, V14, P630, DOI 10.1016/j.jocn.2006.04.009; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Linde K, 2011, PHILOS T R SOC B, V366, P1905, DOI 10.1098/rstb.2010.0383; Macrez R, 2011, LANCET NEUROL, V10, P471, DOI 10.1016/S1474-4422(11)70066-7; Marchand F, 2009, EUR J PAIN, V13, P673, DOI 10.1016/j.ejpain.2008.08.001; McNaull BBA, 2010, GERONTOLOGY, V56, P3, DOI 10.1159/000237873; Miller A, 2011, EXPERT REV NEUROTHER, V11, P1077, DOI [10.1586/ERN.11.68, 10.1586/ern.11.68]; Nadeau S, 1999, NEUROSCIENCE, V93, P1449, DOI 10.1016/S0306-4522(99)00225-0; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nathoo N, 2011, NEUROSURGERY, V69, P1007, DOI 10.1227/NEU.0b013e3182274865; Neurex, 2012, M ROL TNF BRAIN DYSF; Ohtori S, 2012, SPINE, V37, P439, DOI 10.1097/BRS.0b013e318238af83; Pardridge William M, 2005, NeuroRx, V2, P3; Pariser DM, 2012, J AM ACAD DERMATOL, V67, P245, DOI 10.1016/j.jaad.2011.07.040; Patel M, 2003, CLIN REHABIL, V17, P158, DOI 10.1191/0269215503cr596oa; Patel M, 2001, STROKE, V32, P122, DOI 10.1161/01.STR.32.1.122; Patel MD, 2002, J AM GERIATR SOC, V50, P700, DOI 10.1046/j.1532-5415.2002.50165.x; Paty DW, 1998, CAN J NEUROL SCI, V25; Pearce JMS, 2006, EUR NEUROL, V56, P136, DOI 10.1159/000095706; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Pilcher Maria, 2012, Nurs Stand, V26, P39; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; Rossi D, 2011, CNS DRUGS, V25, P641, DOI 10.2165/11593090-000000000-00000; Rotar M, 2011, NEUROUROL URODYNAM, V30, P1315, DOI 10.1002/nau.21013; Schweizer TA, 2012, J NEUROL SCI, V316, P137, DOI 10.1016/j.jns.2012.01.003; Shen CH, 2011, ANESTH ANALG, V113, P184, DOI 10.1213/ANE.0b013e318217f7eb; Shen CH, 2011, ANESTH ANALG, V112, P454, DOI 10.1213/ANE.0b013e3182025b15; Shi JQ, 2011, BRAIN RES, V1368, P239, DOI 10.1016/j.brainres.2010.10.053; Shichita T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00132; SKILBECK CE, 1983, J NEUROL NEUROSUR PS, V46, P5, DOI 10.1136/jnnp.46.1.5; Smith Mark, 2012, Nurs Stand, V26, P35; Smith T, 2007, CAN J PSYCHIAT, V52, P329, DOI 10.1177/070674370705200508; Sobel R K, 2001, US News World Rep, V131, P59; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Sumbria RK, 2012, J CEREBR BLOOD F MET, V32, P1933, DOI 10.1038/jcbfm.2012.97; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Tarkowski E, 1999, J CLIN IMMUNOL, V19, P223, DOI 10.1023/A:1020568013953; Tarkowski E, 2003, J NEUROL NEUROSUR PS, V74, P1200, DOI 10.1136/jnnp.74.9.1200; Tobinick E, 2004, CURR MED RES OPIN, V20, P1075, DOI 10.1185/030079903125004286; Tobinick E, 2007, CURR ALZHEIMER RES, V4, P550, DOI 10.2174/156720507783018217; Tobinick Edward, 2006, MedGenMed, V8, P25; Tobinick Edward, 2006, MedGenMed, V8, P53; Tobinick E, 2012, CURR ALZHEIMER RES, V9, P99, DOI 10.2174/156720512799015073; Tobinick E, 2011, CNS DRUGS, V25, P145, DOI 10.2165/11588400-000000000-00000; Tobinick E, 2010, EXPERT REV NEUROTHER, V10, P985, DOI 10.1586/ERN.10.52; Tobinick E, 2009, CNS DRUGS, V23, P713, DOI 10.2165/11310810-000000000-00000; Tobinick Edward, 2008, Medscape J Med, V10, P135; Tobinick E, 2009, DRUG DISCOV TODAY, V14, P168, DOI 10.1016/j.drudis.2008.10.005; Tobinick EL, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-27; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Tobinick Edward L, 2009, BMC Res Notes, V2, P28; Tobinick EL, 2009, DRUG NEWS PERSPECT, V22, P119, DOI 10.1358/dnp.2009.22.2.1303818; Tobinick EL, 2003, CLIN THER, V25, P2279, DOI 10.1016/S0149-2918(03)80219-9; Tobinick EL, 2003, SWISS MED WKLY, V133, P170; Tobinick EL, 2003, CLIN THER, V25, P1211, DOI 10.1016/S0149-2918(03)80077-2; Toglia J, 2011, ARCH PHYS MED REHAB, V92, P792, DOI 10.1016/j.apmr.2010.12.034; Toole James F, 2004, J Stroke Cerebrovasc Dis, V13, P99, DOI 10.1016/j.jstrokecerebrovasdis.2004.03.005; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106; Vakhnina N V, 2009, Neurosci Behav Physiol, V39, P719, DOI 10.1007/s11055-009-9198-3; Vandenbroucke JP, 2001, ANN INTERN MED, V134, P330, DOI 10.7326/0003-4819-134-4-200102200-00017; vanOosten BW, 1996, NEUROLOGY, V47, P1531, DOI 10.1212/WNL.47.6.1531; Vender R, 2011, J DRUGS DERMATOL, V10, P396; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; Wang G, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/825364; Watanabe K, 2011, EUR SPINE J, V20, P1877, DOI 10.1007/s00586-011-1854-y; Wolinsky H, 2008, EMBO REP, V9, P416, DOI 10.1038/embor.2008.65; Wong GK, J NEUROL NEUROSURG P; Zanella JM, 2008, SPINE, V33, P227, DOI 10.1097/BRS.0b013e318162340a; Zhou QH, 2011, J PHARMACOL EXP THER, V339, P618, DOI 10.1124/jpet.111.185876; Zivin JA, 2010, TPA STROKE STORY CON	131	85	86	0	22	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs		2012	26	12					1051	1070		10.1007/s40263-012-0013-2			20	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	057PT	WOS:000312576200003	23100196				2021-06-18	
J	Nilsson, AL; Tennant, A				Nilsson, Asa Lundgren; Tennant, Alan			PAST AND PRESENT ISSUES IN RASCH ANALYSIS: THE FUNCTIONAL INDEPENDENCE MEASURE (FIM (TM)) REVISITED	JOURNAL OF REHABILITATION MEDICINE			English	Article						outcome assessment; patient; physiopathology; psychometrics; Rasch; Functional Independence Measure	TRAUMATIC BRAIN-INJURY; MEASUREMENT MODEL; DEPRESSION SCALE; STROKE PATIENTS; CEREBRAL-PALSY; REHABILITATION; IMPAIRMENT; DISABILITY; CATEGORIES; INTERVAL	Objective: To review the development of Rasch analysis by examining the history of its application to the Functional Independence Measure (FIM (TM)), and highlighting current issues in the approach. Methods: All Rasch-based papers concerning the FIM (TM) were reviewed for their analytical strategy and results. Four analytical pathways were identified that accommodated the majority of these strategies. Data derived from secondary analysis of 340 in-patients undergoing rehabilitation following stroke, measured on the FIM (TM) Motor Scale, were fitted to the Rasch measurement model according to these 4 pathways, with 2 additional pathways to accommodate recent developments. Results: In the analytical pathway, where items are not re-scored, the fit to the Partial Credit parameterization was better than the Rating Scale version. Fit improved following re-scoring of disordered thresholds. When local dependency was accommodated by 4 testlets, the Partial Credit, re-scored testlet version achieved adequate summary fit with no misfit among items, and unidimensionality. All other pathways required item deletion. Conclusion: The current study has shown that the FIM (TM) Motor Scale, as applied to a stroke rehabilitation sample, satisfies Rasch model expectations and the unidimensionality assumptions, having accommodated local dependency issues, and by using the partial credit parameterization with re-scored categories. Other analytical pathways gave less ideal solutions, and are consistent with the wide range of solutions found for the scale over the years. Consequently, the development of the Rasch approach in health outcomes can be traced in the history of analysis of the FIM (TM), and that development continues to this day.	[Nilsson, Asa Lundgren] Univ Gothenburg, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, S-41345 Gothenburg, Sweden; [Tennant, Alan] Univ Leeds, Dept Rehabil Med, Fac Med & Hlth, Leeds, W Yorkshire, England	Nilsson, AL (corresponding author), Univ Gothenburg, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Per Dubbsgatan 14, S-41345 Gothenburg, Sweden.						ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814; Andrich D, 1985, TEST DESIGN DEV PSYC; Andrich D., 2010, RUMM 2030; Andrich D, 1988, RASCH MODELS MEASURE; BECH P, 1981, ACTA PSYCHIAT SCAND, V63, P290, DOI 10.1111/j.1600-0447.1981.tb00676.x; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Cantagallo A, 2006, BRAIN INJURY, V20, P913, DOI 10.1080/02699050600832742; Chira-Adisai W, 2001, Electromyogr Clin Neurophysiol, V41, P79; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P355, DOI 10.1016/S0003-9993(95)80661-X; Dallmeijer AJ, 2005, J REHABIL MED, V37, P346, DOI 10.1080/16501970510038284; Dorans NJ, 1993, DIFFERENTIAL ITEM FU, P36; Elhan A, 2010, RES ISSUES PHYS REHA, P89; Glass CA, 2009, J REHABIL MED, V41, P723, DOI 10.2340/16501977-0398; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Grimby G, 1996, ARCH PHYS MED REHAB, V77, P1109, DOI 10.1016/S0003-9993(96)90131-8; Guttman L. A., 1950, MEASUREMENT PREDICTI, P60; Hagquist C, 2009, INT J NURS STUD, V46, P380, DOI 10.1016/j.ijnurstu.2008.10.007; HALEY SM, 1994, J CLIN EPIDEMIOL, V47, P671, DOI 10.1016/0895-4356(94)90215-1; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; Holland P. W., 1993, DIFFERENTIAL ITEM FU; Itzkovich M, 2002, SPINAL CORD, V40, P396, DOI 10.1038/sj.sc.3101315; Johnston MV, 2006, BRAIN INJURY, V20, P391, DOI 10.1080/02699050500487795; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Lange R, 2002, PERS INDIV DIFFER, V33, P937, DOI 10.1016/S0191-8869(01)00203-3; Leonard C T, 1998, J Stroke Cerebrovasc Dis, V7, P145, DOI 10.1016/S1052-3057(98)80142-0; LEWINE RRJ, 1983, SCHIZOPHRENIA BULL, V9, P368, DOI 10.1093/schbul/9.3.368; Linacre J.M., 1994, RASCH MEASUREMENT T, V7, P328; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LUCE RD, 1964, J MATH PSYCHOL, V1, P1, DOI 10.1016/0022-2496(64)90015-X; Lundgren-Nilsson A, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-55; Marais Ida, 2008, J Appl Meas, V9, P200; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; NANDAKUMAR R, 1993, J EDUC MEAS, V30, P293, DOI 10.1111/j.1745-3984.1993.tb00428.x; New PW, 2007, J SPINAL CORD MED, V30, P225, DOI 10.1080/10790268.2007.11753930; Newby Van A, 2009, J Appl Meas, V10, P348; Nilsson AL, 2005, ACTA NEUROL SCAND, V111, P264, DOI 10.1111/j.1600-0404.2005.00404.x; Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348/014466506X96931; Rasch G., 1960, PROBABILISTIC MODELS; Rosenberg R, 1979, Ugeskr Laeger, V141, P3232; SILVERSTEIN B, 1992, ARCH PHYS MED REHAB, V73, P507; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith R M, 1998, J Outcome Meas, V2, P66; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Tennant A, 1996, BRIT J RHEUMATOL, V35, P574; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; Tennant A, 2006, RASCH MEASUREMENT T, V20, P1048; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Teresi JA, 2007, QUAL LIFE RES, V16, P43, DOI 10.1007/s11136-007-9186-4; Teresi JA, 2006, MED CARE, V44, pS152, DOI 10.1097/01.mlr.0000245142.74628.ab; Tesio L, 2008, EUR J PHYS REHAB MED, V44, P365; Thurstone LL, 1928, AM J SOCIOL, V33, P529, DOI 10.1086/214483; Tsuji T, 1995, AM J PHYS MED REHAB, V74, P432, DOI 10.1097/00002060-199511000-00007; Tur BS, 2009, DEV MED CHILD NEUROL, V51, P732, DOI 10.1111/j.1469-8749.2008.03255.x; Velozo CA, 2007, J REHABIL RES DEV, V44, P467, DOI 10.1682/JRRD.2006.06.0068; WAINER H, 1987, J EDUC MEAS, V24, P185, DOI 10.1111/j.1745-3984.1987.tb00274.x; Wang Wen-Chung, 2008, J Appl Meas, V9, P387; Werner RA, 1996, AM J PHYS MED REHAB, V75, P114, DOI 10.1097/00002060-199603000-00006; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857	59	85	85	0	13	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	OCT	2011	43	10					884	891		10.2340/16501977-0871			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	844KF	WOS:000296745400003	21947180	DOAJ Gold			2021-06-18	
J	Krueger, F; Pardini, M; Huey, ED; Raymont, V; Solomon, J; Lipsky, RH; Hodgkinson, CA; Goldman, D; Grafman, J				Krueger, Frank; Pardini, Matteo; Huey, Edward D.; Raymont, Vanessa; Solomon, Jeffrey; Lipsky, Robert H.; Hodgkinson, Colin A.; Goldman, David; Grafman, Jordan			The Role of the Met66 Brain-Derived Neurotrophic Factor Allele in the Recovery of Executive Functioning after Combat-Related Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							BDNF VAL66MET POLYMORPHISM; ACTIVITY-DEPENDENT SECRETION; FAMILY-BASED ASSOCIATION; PENETRATING HEAD-INJURY; CARD SORTING TEST; FACTOR GENE; ALZHEIMERS-DISEASE; NEURONAL DEVELOPMENT; MEMORY PERFORMANCE; RECEPTOR SORTILIN	Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, promotes survival and synaptic plasticity in the human brain. The Val66Met polymorphism of the BDNF gene interferes with intracellular trafficking, packaging, and regulated secretion of this neurotrophin. The human prefrontal cortex (PFC) shows lifelong neuroplastic adaption implicating the Val66Met BDNF polymorphism in the recovery of higher-order executive functions after traumatic brain injury (TBI). In this study, we examined the effect of this BDNF polymorphism on the recovery of executive functioning after TBI. We genotyped a sample of male Vietnam combat veterans consisting of a frontal lobe lesion group with focal penetrating head injuries and a non-head-injured control group for the Val66Met BDNF polymorphism. The Delis-Kaplan Executive Function System as a standardized psychometric battery was administrated to examine key domains of executive functions. The results revealed that the Met allele but not the hypothesized Val allele promotes recovery of executive functioning. Overall, the Met66 carriers in the lesion group performed as well as the Met66 carriers in the control group. The Met66 allele accounted for 6.2% of variance for executive functioning independently of other significant predictors including preinjury intelligence, left hemisphere volume loss, and dorsolateral PFC volume loss. The findings point to different mechanisms of the Val66Met BDNF gene in complex phenotypes under normal and pathological conditions. Abetter understanding of these mechanisms could be instrumental in the development and application of effective therapeutic strategies to facilitate recovery from TBI.	[Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Krueger, Frank; Raymont, Vanessa; Grafman, Jordan] Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Hodgkinson, Colin A.; Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; [Pardini, Matteo] Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy; [Huey, Edward D.] Study Alzheimers Dis & Memory Disorders, Litwin Zucker Res Ctr, Manhasset, NY 11030 USA; [Raymont, Vanessa] Johns Hopkins Univ, Dept Radiol, Baltimore, MD 21287 USA; [Lipsky, Robert H.] Inova Fairfax Hosp, Dept Neurosci, Falls Church, VA 22042 USA	Krueger, F (corresponding author), George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA.	fkrueger@gmu.edu; grafmanj@ninds.nih.gov	Pardini, Matteo/F-8414-2010; Majid, Salma/AAT-2616-2020; Goldman, David/F-9772-2010	Pardini, Matteo/0000-0002-4740-1982; Majid, Salma/0000-0002-1724-5405; Goldman, David/0000-0002-1724-5405; Lipsky, Robert/0000-0001-7753-1473; Grafman, Jordan H./0000-0001-8645-4457	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000301] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the U.S. Army Medical Research and Material Command administrated by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30 year postinjury follow-up study). We are grateful to all the Vietnam veterans who participated in this study. Without their long-term commitment to improving the health care of veterans, this study could not have been completed. We thank the National Naval Medical Center for their support and provision of their facilities. We are grateful to S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding, and G. Tasick for their invaluable help with the testing of participants and organization of this study. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U. S. Government.	Al-Shawi R, 2008, EUR J NEUROSCI, V27, P2103, DOI 10.1111/j.1460-9568.2008.06152.x; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Beste C, 2010, NEUROSCIENCE, V166, P178, DOI 10.1016/j.neuroscience.2009.12.022; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; CATHOMAS F, 2010, INT J NEUROPSYCHOPH, V19, P1; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; Delis DC, 2001, DELISKAPLAN EXECUTIV; Dempster E, 2005, AM J MED GENET B, V134B, P73, DOI 10.1002/ajmg.b.30150; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Erickson KI, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.011.2008; Frustaci A, 2008, NEUROPSYCHOBIOLOGY, V58, P163, DOI 10.1159/000182892; Gao BL, 2000, J NEUROPSYCH CLIN N, V12, P385, DOI 10.1176/appi.neuropsych.12.3.385; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Gratacos M, 2007, BIOL PSYCHIAT, V61, P911, DOI 10.1016/j.biopsych.2006.08.025; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Harris SE, 2006, MOL PSYCHIATR, V11, P505, DOI 10.1038/sj.mp.4001799; Ho BC, 2007, AM J PSYCHIAT, V164, P1890, DOI 10.1176/appi.ajp.2007.05111903; Ho BC, 2006, ARCH GEN PSYCHIAT, V63, P731, DOI 10.1001/archpsyc.63.7.731; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huey ED, 2009, NEUROLOGY, V72, P453, DOI 10.1212/01.wnl.0000341781.39164.26; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662; Karnik MS, 2010, PSYCHIAT RES, V178, P425, DOI 10.1016/j.psychres.2009.09.008; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kunugi H, 2001, MOL PSYCHIATR, V6, P83, DOI 10.1038/sj.mp.4000792; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LING G, 2008, EXPLOSION BLAST RELA, P91; Lu B, 2003, NEURON, V39, P735, DOI 10.1016/S0896-6273(03)00538-5; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Montag C, 2009, PSYCHOL MED, V39, P1831, DOI 10.1017/S0033291709005509; Neves-Pereira M, 2002, AM J HUM GENET, V71, P651, DOI 10.1086/342288; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Oroszi G, 2006, ANN RHEUM DIS, V65, P1330, DOI 10.1136/ard.2006.051623; Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Riemenschneider M, 2002, MOL PSYCHIATR, V7, P782, DOI 10.1038/sj.mp.4001073; Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x; Rybakowski JK, 2003, BIPOLAR DISORD, V5, P468, DOI 10.1046/j.1399-5618.2003.00071.x; Rybakowski JK, 2006, MOL PSYCHIATR, V11, P122, DOI 10.1038/sj.mp.4001765; Sambataro F, 2010, MOL PSYCHIATR, V15, P116, DOI 10.1038/mp.2009.64; Sen S, 2003, NEUROPSYCHOPHARMACOL, V28, P397, DOI 10.1038/sj.npp.1300053; Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Strauss J, 2004, NEUROMOL MED, V5, P181, DOI 10.1385/NMM:5:3:181; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Tan YL, 2005, SCHIZOPHR RES, V77, P355, DOI 10.1016/j.schres.2005.03.012; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; Tettamanti G, 2010, GENE, V450, P85, DOI 10.1016/j.gene.2009.07.023; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; *US DEP DEF, 1960, AFQT7A US DEP DEF; Ventriglia M, 2002, MOL PSYCHIATR, V7, P136, DOI 10.1038/sj.mp.4000952; Volosin M, 2006, J NEUROSCI, V26, P7756, DOI 10.1523/JNEUROSCI.1560-06.2006; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; Zivadinov R, 2007, HUM MOL GENET, V16, P2659, DOI 10.1093/hmg/ddm189	70	85	88	0	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 12	2011	31	2					598	606		10.1523/JNEUROSCI.1399-10.2011			9	Neurosciences	Neurosciences & Neurology	705MR	WOS:000286139100021	21228168	Green Published, Bronze, Green Accepted			2021-06-18	
J	Fischer, M; Ruegg, S; Czaplinski, A; Strohmeier, M; Lehmann, A; Tschan, F; Hunziker, PR; Marsch, SC				Fischer, Michael; Rueegg, Stephan; Czaplinski, Adam; Strohmeier, Monika; Lehmann, Angelika; Tschan, Franziska; Hunziker, Patrick R.; Marsch, Stephan C.			Inter-rater reliability of the Full Outline of UnResponsiveness score and the Glasgow Coma Scale in critically ill patients: a prospective observational study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; CONSCIOUSNESS; PREDICTION; VALIDATION; VALIDITY; LEVEL	Introduction: The Glasgow Coma Scale (GCS) is the most widely used scoring system for comatose patients in intensive care. Limitations of the GCS include the impossibility to assess the verbal score in intubated or aphasic patients, and an inconsistent inter-rater reliability. The FOUR (Full Outline of UnResponsiveness) score, a new coma scale not reliant on verbal response, was recently proposed. The aim of the present study was to compare the inter-rater reliability of the GCS and the FOUR score among unselected patients in general critical care. A further aim was to compare the inter-rater reliability of neurologists with that of intensive care unit (ICU) staff. Methods: In this prospective observational study, scoring of GCS and FOUR score was performed by neurologists and ICU staff on 267 consecutive patients admitted to intensive care. Results: In a total of 437 pair wise ratings the exact inter-rater agreement for the GCS was 71%, and for the FOUR score 82% (P = 0.0016); the inter-rater agreement within a range of +/- 1 score point for the GCS was 90%, and for the FOUR score 92% (P = ns.). The exact inter-rater agreement among neurologists was superior to that among ICU staff for the FOUR score (87% vs. 79%, P = 0.04) but not for the GCS (73% vs. 73%). Neurologists and ICU staff did not significantly differ in the inter-rater agreement within a range of +/- 1 score point for both GCS (88% vs. 93%) and the FOUR score (91% vs. 88%). Conclusions: The FOUR score performed better than the GCS for exact inter-rater agreement, but not for the clinically more relevant agreement within the range of +/- 1 score point. Though neurologists outperformed ICU staff with regard to exact inter-rater agreement, the inter-rater agreement of ICU staff within the clinically more relevant range of +/- 1 score point equalled that of the neurologists. The small advantage in inter-rater reliability of the FOUR score is most likely insufficient to replace the GCS, a score with a long tradition in intensive care.	[Fischer, Michael; Strohmeier, Monika; Lehmann, Angelika; Hunziker, Patrick R.; Marsch, Stephan C.] Univ Basel Hosp, Dept Med Intens Care, CH-4031 Basel, Switzerland; [Rueegg, Stephan; Czaplinski, Adam] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Tschan, Franziska] Univ Neuchatel, Dept Psychol, CH-2000 Neuchatel, Switzerland	Marsch, SC (corresponding author), Univ Basel Hosp, Dept Med Intens Care, Spitalstr, CH-4031 Basel, Switzerland.	smarsch@uhbs.ch					Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572; Eken C, 2009, EUR J EMERG MED, V16, P29, DOI 10.1097/MEJ.0b013e32830346ab; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Kho ME, 2007, AM J CRIT CARE, V16, P378; LANDIS JR, 1977, BIOMETRICS, V33, P174; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; TEASDALE G, 1974, LANCET, V2, P81; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435	16	85	86	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2010	14	2							R64	10.1186/cc8963			9	Critical Care Medicine	General & Internal Medicine	611LO	WOS:000278816800039	20398274	DOAJ Gold, Green Published			2021-06-18	
J	Monetta, L; Grindrod, CM; Pell, MD				Monetta, Laura; Grindrod, Christopher M.; Pell, Marc D.			Irony comprehension and theory of mind deficits in patients with Parkinson's disease	CORTEX			English	Article						Fronto-striatal mechanisms; Nonliteral language; Neurogenic language impairment; Parkinson's disease; Pragmatics; Theory of mind	WORKING-MEMORY DEFICITS; TRAUMATIC BRAIN-INJURY; SENTENCE COMPREHENSION; METAPHOR COMPREHENSION; EXECUTIVE DYSFUNCTION; DAMAGED INDIVIDUALS; PROCESSING SPEED; VERBAL FLUENCY; ADULTS; COMMUNICATION	Many individuals with Parkinson's disease (PD) are known to have difficulties in understanding pragmatic aspects of language. In the present study, a group of eleven non-demented PD patients and eleven healthy control (HC) participants were tested on their ability to interpret communicative intentions underlying verbal irony and lies, as well as on their ability to infer first- and second-order mental states (i.e., theory of mind). Following Winner et al. (1998), participants answered different types of questions about the events which unfolded in stories which ended in either an ironic statement or a lie. Results showed that PD patients were significantly less accurate than HC participants in assigning second-order beliefs during the story comprehension task, suggesting that the ability to make a second-order mental state attribution declines in PD. The PD patients were also less able to distinguish whether the final statement of a story should be interpreted as a joke or a lie, suggesting a failure in pragmatic interpretation abilities. The implications of frontal lobe dysfunction in PD as a source of difficulties with working memory, mental state attributions, and pragmatic language deficits are discussed in the context of these findings. (C) 2009 Elsevier Srl. All rights reserved.	[Monetta, Laura] Univ Laval, Dept Readaptat, Ctr Rech Robert Giffard, Quebec City, PQ G1V 0A6, Canada; [Grindrod, Christopher M.] Univ Illinois, Dept Speech & Hearing Sci, Champaign, IL USA; [Monetta, Laura; Pell, Marc D.] McGill Univ, Sch Commun Sci & Disorders, Montreal, PQ, Canada	Monetta, L (corresponding author), Univ Laval, Dept Readaptat, Ctr Rech Robert Giffard, Pavillon F Vandry,1050 Ave Med, Quebec City, PQ G1V 0A6, Canada.	laura.monetta@rea.ulaval.ca	Monetta, Laura/AAK-7657-2020; Pell, Marc D./AAL-3121-2021	Pell, Marc D./0000-0002-9947-1552	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); CIHR Institute of AgingCanadian Institutes of Health Research (CIHR); Fonds de la recherche en sante du QuebecFonds de la Recherche en Sante du Quebec; McGill University	This research was financed by an operating grant from the Canadian Institutes of Health Research (to MDP) and by a CIHR Institute of Aging postdoctoral fellowship (to LK. The senior author is grateful for support from the Fonds de la recherche en sante du Quebec (Chercheur-boursier junior 2 award) and McGill University (William Dawson Chair). We are particularly indebted to Marie Desmarteau for her help in running the study.	Angwin AJ, 2005, COGNITIVE BRAIN RES, V25, P78, DOI 10.1016/j.cogbrainres.2005.04.008; Barkley RA, 2001, NEUROPSYCHOL REV, V11, P1, DOI 10.1023/A:1009085417776; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Berg E, 2003, CLIN LINGUIST PHONET, V17, P63, DOI 10.1080/0269920021000055540; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Brown P, 1998, LANCET, V351, P1801, DOI 10.1016/S0140-6736(97)11225-9; BROWN RG, 1991, BRAIN, V114, P215; Brownell H, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P309; CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721; Champagne M, 2004, BRAIN LANG, V91, P172, DOI 10.1016/j.bandl.2004.06.089; Channon S, 2007, NEUROPSYCHOLOGIA, V45, P1725, DOI 10.1016/j.neuropsychologia.2006.12.021; Cheang HS, 2008, SPEECH COMMUN, V50, P366, DOI 10.1016/j.specom.2007.11.003; Collins P, 2000, BEHAV NEUROSCI, V114, P3, DOI 10.1037/0735-7044.114.1.3; Culbertson W. C., 2001, TOWER LONDON DX TOL; D'Elia L., 1996, COLOR TRAILS TEST PR; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Dara C, 2008, BRAIN RES, V1188, P100, DOI 10.1016/j.brainres.2007.10.034; Demakis George J, 2007, Dis Mon, V53, P152, DOI 10.1016/j.disamonth.2007.04.005; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Dubois B, 1997, J NEUROL, V244, P2, DOI 10.1007/pl00007725; Eviatar Z, 2006, NEUROPSYCHOLOGIA, V44, P2348, DOI 10.1016/j.neuropsychologia.2006.05.007; Friederici AD, 2003, NEUROPSYCHOLOGY, V17, P133, DOI 10.1037/0894-4105.17.1.133; Gabrieli JDE, 1996, NEUROPSYCHOLOGY, V10, P322, DOI 10.1037/0894-4105.10.3.321; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gernsbacher MA, 2001, J MEM LANG, V45, P433, DOI 10.1006/jmla.2000.2782; Gibbs Jr R.W., 2000, METAPHOR SYMBOL, V15, P5, DOI DOI 10.1080/10926488.2000.9678862; Grossman M, 2003, NEUROLOGY, V60, P775, DOI 10.1212/01.WNL.0000044398.73241.13; Grossman M, 2002, NEUROPSYCHOLOGY, V16, P174, DOI 10.1037//0894-4105.16.2.174; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Henry JD, 2004, J INT NEUROPSYCH SOC, V10, P608, DOI 10.1017/S1355617704104141; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Lee C, 2003, BRAIN LANG, V85, P347, DOI 10.1016/S0093-934X(03)00063-4; LESLIE AM, 1994, COGNITION, V50, P211, DOI 10.1016/0010-0277(94)90029-9; Lewis SJG, 2003, NEUROPSYCHOLOGIA, V41, P645, DOI 10.1016/S0028-3932(02)00257-9; LIEBERMAN P, 1990, J NERV MENT DIS, V178, P360, DOI 10.1097/00005053-199006000-00003; Martin I, 2004, J AUTISM DEV DISORD, V34, P311, DOI 10.1023/B:JADD.0000029553.52889.15; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; Mattis S, 1988, DEMENTIA RATING SCAL; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McNamara P, 2003, BRAIN LANG, V84, P414, DOI 10.1016/S0093-934X(02)00558-8; Monetta L, 2008, J NEUROLINGUIST, V21, P400, DOI 10.1016/j.jneuroling.2007.11.002; Monetta L, 2007, BRAIN LANG, V101, P80, DOI 10.1016/j.bandl.2006.06.007; Monetta L, 2008, J NEUROPSYCHOL, V2, P415, DOI 10.1348/174866407X216675; Mutter SA, 2006, Q J EXP PSYCHOL, V59, P1556, DOI 10.1080/17470210500343546; Natsopoulos D, 1997, CORTEX, V33, P463, DOI 10.1016/S0010-9452(08)70230-2; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; Pell MD, 2003, COGN AFFECT BEHAV NE, V3, P275, DOI 10.3758/CABN.3.4.275; Pell MD, 2006, BRAIN LANG, V97, P123, DOI 10.1016/j.bandl.2005.08.010; PITCAIRN TK, 1990, BRIT J DISORD COMMUN, V25, P85; Reynolds WM, 1995, HAMILTON DEPRESSION; Saltzman J, 2000, J INT NEUROPSYCH SOC, V6, P781, DOI 10.1017/S1355617700677056; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; TOMPKINS CA, 1994, J SPEECH HEAR RES, V37, P896, DOI 10.1044/jshr.3704.896; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Walsh K. W., 1985, UNDERSTANDING BRAIN; Warrington EK., 1984, RECOGNITION MEMORY T; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889	60	85	89	0	33	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	SEP	2009	45	8			SI		972	981		10.1016/j.cortex.2009.02.021			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	473LD	WOS:000268206700009	19371867				2021-06-18	
J	Livingston, DH; Tripp, T; Biggs, C; Lavery, RF				Livingston, David H.; Tripp, Tovah; Biggs, Carina; Lavery, Robert F.			A Fate Worse Than Death? Long-Term Outcome of Trauma Patients Admitted to the Surgical Intensive Care Unit	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma		Trauma; Outcomes; Critical care; Quality of life	QUALITY-OF-LIFE; MULTIPLE ORGAN FAILURE; 5-YEAR FOLLOW-UP; MAJOR TRAUMA; FUNCTIONAL OUTCOMES; BRAIN-INJURY; INPATIENT REHABILITATION; PHYSICAL IMPAIRMENT; RECOVERY PROJECT; ELDERLY-PATIENTS	Introduction: Trauma centers successfully save lives of severely injured patients who would have formerly died. However, survivors often have multiple complications and morbidities associated with prolonged intensive care unit (ICU) stays. Because the reintegration of patients into the society to lead an active and a productive life is the ultimate goal of trauma center care, we questioned whether our "success" may condemn these patients to a fate worse than death? Methods: Charts on all patients >= 18 years with ICU stay >= 10 days, discharged alive between June 1, 2002, and May 3 1, 2005, were reviewed. Patients with complete spinal cord injuries were excluded. Demographics, Injury Severity Score (ISS), presence of severe traumatic brain injury (TBI; Head Abbreviated Injury Scale [AIS] score = 4 or 5), presence of extremity fractures, need for operative procedures, ventilator days, complications, and discharge disposition were collected. Glasgow Outcome Scale score was calculated on discharge. Patients were contacted by phone to determine general health, work status, and using this data, Glasgow Outcome Scale score and a modified Functional Independence Measure (FIM) score were calculated. Results: Two hundred and forty-one patients met inclusion criteria. Thirty-three patients died postdischarge from the hospital and 39 were known to be alive from the electronic medical records but were unable to be contacted. Sixty-nine patients could not be tracked down and were ultimately considered as lost to follow-up. The remaining 100 patients who were successfully contacted participated in the study. Eighty-one percent were men with a mean age of 42 years, mean and median ISS of 28. Severe TBI was present in 50 (50%) patients. Mean and median follow-up was 3.3 years from discharge. At the time of follow-up, 92 (92%) patients were living at home, 5 in nursing homes, and 3 in assisted living, a shelter, or halfway house. FIM scores ranged from 6 to 12 with 55% reached a maximal FIM score of 12. One quarter of patients had FIM scores <= 10 and 10% had locomotion scores of <= 2 (very dependent). Seventy percent considered themselves to be less active. Seventy-six patients were either working or in full-time school before their trauma. Of the 24 patients not working preinjury, 12 were >= 55 years of age. At the time of follow-up, 37 patients (49%) were back to work or school. Severe TBI patients (57%, 21 of 37) were less likely to return to work when compared with 38% (12 of 38; p = 0.03) without severe TBI. There was no relationship with age, ISS, presence of any TBI, head AIS, presence of any extremity fracture, extremity AIS, or ventilator days in patients who did or did not return to work. Conclusions: These data demonstrate that ICU survivors >3 years after severe injury have significant impairments including inability to return to work or regain previous levels of activity and that the goal of reintegrating patients back into the society is not being met. Further studies better defining the limitations and barriers to improved quality of life are necessary. Survival, although important, is no longer a sufficient outcome to measure trauma center success.	[Livingston, David H.; Tripp, Tovah; Biggs, Carina; Lavery, Robert F.] Univ Med & Dent New Jersey, New Jersey Med Sch, Div Trauma, Dept Surg, Newark, NJ 07103 USA	Livingston, DH (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Div Trauma, Univ Hosp M234, 185 S Orange Ave, Newark, NJ 07103 USA.	livingst@umdnj.edu					Abelha Fernando J, 2007, BMC Surg, V7, P23, DOI 10.1186/1471-2482-7-23; Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; Braithwaite IJ, 1998, INJURY, V29, P55; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Delle Karth G, 2006, WIEN KLIN WOCHENSCHR, V118, P390, DOI 10.1007/s00508-006-0616-z; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dimopoulou I, 2004, AM J PHYS MED REHAB, V83, P171, DOI 10.1097/01.PHM.0000107497.77487.C1; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Frick S, 2002, INTENS CARE MED, V28, P1405, DOI 10.1007/s00134-002-1434-z; FRUTIGER A, 1991, J TRAUMA, V31, P1216, DOI 10.1097/00005373-199109000-00004; FRUTIGER A, 1991, J TRAUMA, V31, P1225; Gabbe BJ, 2008, ANN SURG, V247, P854, DOI 10.1097/SLA.0b013e3181656d1e; Girotto JA, 2001, PLAST RECONSTR SURG, V108, P312, DOI 10.1097/00006534-200108000-00005; Grotz M, 1997, J TRAUMA, V42, P919, DOI 10.1097/00005373-199705000-00024; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holtslag HR, 2007, INJURY, V38, P280, DOI 10.1016/j.injury.2006.10.026; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Huang ME, 2000, AM J PHYS MED REHAB, V79, P327, DOI 10.1097/00002060-200007000-00003; Kaarlola A, 2006, CRIT CARE MED, V34, P2120, DOI 10.1097/01.CCM.0000227656.31911.2E; KING S, 2000, NEW YORKER      0619, P78; KONOPAD E, 1995, CRIT CARE MED, V23, P1653, DOI 10.1097/00003246-199510000-00008; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MACKENZIE EJ, 1993, J TRAUMA, V34, P538; Mata GV, 1996, J TRAUMA, V41, P326, DOI 10.1097/00005373-199608000-00022; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Monneuse OJY, 2008, J AM COLL SURGEONS, V207, P179, DOI 10.1016/j.jamcollsurg.2008.01.021; Montuclard L, 2000, CRIT CARE MED, V28, P3389, DOI 10.1097/00003246-200010000-00002; Morris JA, 1999, J TRAUMA, V46, P771; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; MORRIS JA, 1991, J TRAUMA, V31, P833; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Niskanen M, 1999, CRIT CARE MED, V27, P1132, DOI 10.1097/00003246-199906000-00035; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PARKS J, 2007, J TRAUMA, V62, P267; Pirente N, 2007, LANGENBECK ARCH SURG, V392, P739, DOI 10.1007/s00423-007-0171-8; Redmill DA, 2006, INJURY, V37, P243, DOI 10.1016/j.injury.2005.11.014; Rivara FP, 2008, ARCH SURG-CHICAGO, V143, P282, DOI 10.1001/archsurg.2007.61; Sampalis JS, 2006, J TRAUMA, V60, P806, DOI 10.1097/01.ta.0000215103.62783.4d; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; Ulvik A, 2007, CRIT CARE, V11, DOI 10.1186/cc6111; Ulvik A, 2008, INTENS CARE MED, V34, P447, DOI 10.1007/s00134-007-0936-0; van der Sluis CK, 1998, INJURY, V29, P281, DOI 10.1016/S0020-1383(97)00199-X; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watson WL, 2007, INJURY PREV, V13, P45, DOI 10.1136/ip.2005.010157; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	53	85	85	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2009	67	2					341	348		10.1097/TA.0b013e3181a5cc34			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	482OL	WOS:000268898500026	19667888				2021-06-18	
J	Piermartiri, TCB; Vandresen, S; Herculano, BD; Martins, WC; Dal'Agnolo, D; Stroeh, E; Carqueja, CL; Boeck, CR; Tasca, CI				Piermartiri, Tetsade C. B.; Vandresen-Filho, Samuel; Herculano, Bruno de Araujo; Martins, Wagner C.; Dal'Agnolo, Denis; Stroeh, Ellen; Carqueja, Cristiane Lima; Boeck, Carina R.; Tasca, Carla I.			Atorvastatin Prevents Hippocampal Cell Death due to Quinolinic Acid-Induced Seizures in Mice by Increasing Akt Phosphorylation and Glutamate Uptake	NEUROTOXICITY RESEARCH			English	Article						Atorvastatin; Quinolinic acid; Seizures; Neuroprotection; Hippocampus	TRAUMATIC BRAIN-INJURY; NMDA PRECONDITIONING PROTECTS; NITRIC-OXIDE SYNTHASE; CEREBROSPINAL-FLUID; SYNAPTIC VESICLES; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; LIPID RAFTS; YOUNG-RATS; SIMVASTATIN	Statins are cholesterol-lowering agents due to the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Recent studies have shown statins possess pleiotropic effects, which appear to be independent from its cholesterol-lowering action. In this study, we investigated whether atorvastatin would have protective effects against hippocampal cell death promoted by quinolinic acid (QA)-induced seizures in mice. Mice were pretreated with Atorvastatin (1 or 10 mg/kg) or vehicle (saline, 0.9%), orally, once a day for 7 days before the intracerebroventricular (i.c.v.) QA infusion (36.8 nmol/site). Atorvastatin treatment with 1 mg/kg/day did not significantly prevent QA-induced seizures (13.34%). However, administration of atorvastatin 10 mg/kg/day prevented the clonic and/or tonic seizures induced by QA in 29.41% of the mice. Additionally, administration of atorvastatin 10 mg/kg/day significantly prevented QA-induced cell death in the hippocampus. Atorvastatin treatment promoted an increased Akt phosphorylation, which was sustained after QA infusion in both convulsed and non-convulsed mice. Moreover, atorvastatin pretreatment prevented the reduction in glutamate uptake into hippocampal slices induced by QA i.c.v. infusion. These results show that atorvastatin attenuated QA-induced hippocampal cellular death involving the Akt pathway and glutamate transport modulation. Therefore, atorvastatin treatment might be a useful strategy in the prevention of brain injury caused by the exacerbation of glutamatergic toxicity in neurological diseases such as epilepsy.	[Piermartiri, Tetsade C. B.; Vandresen-Filho, Samuel; Herculano, Bruno de Araujo; Martins, Wagner C.; Dal'Agnolo, Denis; Stroeh, Ellen; Carqueja, Cristiane Lima; Tasca, Carla I.] Univ Fed Santa Catarina, Dept Bioquim, Ctr Ciencias Biol, BR-88040900 Florianopolis, SC, Brazil; [Boeck, Carina R.] Univ Extremo Catarinense, Lab Neurociencias, Programa Posgrad Ciencias Saude, BR-88806000 Criciuma, SC, Brazil	Tasca, CI (corresponding author), Univ Fed Santa Catarina, Dept Bioquim, Ctr Ciencias Biol, BR-88040900 Florianopolis, SC, Brazil.	tasca@ccb.ufsc.br	Vandresen-Filho, Samuel/A-1239-2013; Boeck, Carina Rodrigues/E-9472-2011; Tasca, Carla Ines/AAB-8287-2019; Herculano, Bruno/F-8917-2018; Herculano, Bruno/N-4587-2019	Vandresen-Filho, Samuel/0000-0002-4718-2900; Boeck, Carina Rodrigues/0000-0002-6828-5634; Tasca, Carla Ines/0000-0002-3414-6150; Herculano, Bruno/0000-0003-0095-3381; Herculano, Bruno/0000-0003-0095-3381; Piermartiri, Tetsade/0000-0002-9773-6983	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); FAPESCFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC); FINEP-IBN(Net)Financiadora de Inovacao e Pesquisa (Finep) [01.06.0842-00]	This work was supported by grants from CNPq, FAPESC, and FINEP-IBN(Net)#01.06.0842-00 to C. I. Tasca. C. I. T. is recipient of CNPq productivity fellowship.	Boeck CR, 2005, J NEUROCHEM, V94, P48; Boeck CR, 2004, EPILEPSIA, V45, P745, DOI 10.1111/j.0013-9580.2004.65203.x; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cheng Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-156; CLARKE RM, 1942, NEUROPHARMACOLOGY, V1, P136; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; de Oliveira DL, 2004, BRAIN RES, V1018, P48, DOI 10.1016/j.brainres.2004.05.033; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Ferrer I, 2001, MOL BRAIN RES, V94, P48, DOI 10.1016/S0169-328X(01)00198-X; FOSTER AC, 1983, NEUROPHARMACOLOGY, V22, P1331, DOI 10.1016/0028-3908(83)90221-6; Ganzella M, 2006, NEUROSCI RES, V55, P397, DOI 10.1016/j.neures.2006.05.003; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Hayashi T, 2005, BRAIN RES, V1037, P52, DOI 10.1016/j.brainres.2004.12.051; Hering H, 2003, J NEUROSCI, V23, P3262; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1990, EPILEPSIA, V31, P172, DOI 10.1111/j.1528-1167.1990.tb06302.x; Kim D, 2002, J BIOCHEM MOL BIOL, V35, P106; Kretz A, 2006, NEUROBIOL DIS, V21, P421, DOI 10.1016/j.nbd.2005.08.003; LAPIN IP, 1981, EPILEPSIA, V22, P257, DOI 10.1111/j.1528-1157.1981.tb04108.x; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Lee JK, 2008, NEUROSCI LETT, V440, P260, DOI 10.1016/j.neulet.2008.05.112; Lee ST, 2008, J NEUROCHEM, V104, P1190, DOI 10.1111/j.1471-4159.2007.05044.x; Leipnitz G, 2005, INT J DEV NEUROSCI, V23, P695, DOI 10.1016/j.ijdevneu.2005.08.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Miida Takashi, 2004, J Atheroscler Thromb, V11, P253; Molz S, 2005, NEUROCHEM RES, V30, P83, DOI 10.1007/s11064-004-9689-0; Molz S, 2008, NEUROCHEM RES, V33, P27, DOI 10.1007/s11064-007-9402-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakao T, 2007, J PHARMACOL SCI, V105, P334, DOI 10.1254/jphs.FP0070682; Nieoullon A, 2006, J NEUROCHEM, V98, P1007, DOI 10.1111/j.1471-4159.2006.03978.x; Patassini S, 2008, NEUROSCI LETT, V448, P166, DOI 10.1016/j.neulet.2008.10.023; PERKINS MN, 1983, J PHARMACOL EXP THER, V226, P551; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Piamsomboon Chumpol, 2002, Journal of the Medical Association of Thailand, V85, P297; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23; Schmidt AP, 2000, BRAIN RES, V864, P40, DOI 10.1016/S0006-8993(00)02106-5; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Stepien K, 2005, PHARMACOL REP, V57, P561; STONE TW, 1993, PHARMACOL REV, V45, P309; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; Tavares RG, 2008, NEUROCHEM RES, V33, P97, DOI 10.1007/s11064-007-9421-y; Tavares RG, 2000, NEUROREPORT, V11, P249, DOI 10.1097/00001756-200002070-00005; Tavares RG, 2002, NEUROCHEM INT, V40, P621, DOI 10.1016/S0197-0186(01)00133-4; Torres GE, 2007, CURR OPIN NEUROBIOL, V17, P304, DOI 10.1016/j.conb.2007.05.002; Wallis RA, 2005, EPILEPSIA, V46, P128; Waters DD, 2005, AM J CARDIOL, V96, p69F, DOI 10.1016/j.amjcard.2005.06.028; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Yoshida Masayuki, 2003, J Atheroscler Thromb, V10, P140; Yrjanheikki J, 2005, BRAIN RES, V1052, P174, DOI 10.1016/j.brainres.2005.06.004; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhang L, 2007, ARTERIOSCL THROM VAS, V27, P2470, DOI 10.1161/ATVBAHA.107.150748	57	85	85	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	AUG	2009	16	2					106	115		10.1007/s12640-009-9057-6			10	Neurosciences	Neurosciences & Neurology	458AY	WOS:000266984000002	19526287				2021-06-18	
J	Lo, C; Shifteh, K; Gold, T; Bello, JA; Lipton, ML				Lo, Calvin; Shifteh, Keivan; Gold, Tamar; Bello, Jacqueline A.; Lipton, Michael L.			Diffusion Tensor Imaging Abnormalities in Patients With Mild Traumatic Brain Injury and Neurocognitive Impairment	JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY			English	Article						traumatic brain injury; diffusion tensor imaging; cognitive impairment	POST-CONCUSSION SYNDROME; WHITE-MATTER INJURY; AXONAL INJURY; HEAD-INJURY; REHABILITATION; PREVALENCE; SYMPTOMS	Objective: To determine if diffusion tensor imaging can differentiate patients with chronic cognitive impairment after mild traumatic brain injury (TBI) from normal controls. Methods: Ten patients with persistent cognitive impairment after mild TBI were evaluated at least 2 years after injury. Fractional anisotropy (FA) and apparent diffusion coefficient (ADC) were measured at white matter regions susceptible to axonal injury after TBI. Comparison was made to 10 normal controls. Results: Fractional anisotropy was significantly lower (4.5%; P = 0.01) and ADC higher (7.1%; P = 0.04) in patients at the left side of the genu of the corpus callosum. The mild TBI group also demonstrated a significant increase in FA within the posterior limb of the internal capsule bilaterally (left, 5.1%; P = 0.03; right, 1.9%; P = 0.04). Conclusions: These results demonstrate low FA and high ADC in the germ of the corpus callosum of mild TBI patients with persistent cognitive impairment, suggesting that permanent white matter ultrastructural damage occurs in mild TBI, and that such damage may be associated with persistent cognitive disability. Further longitudinal studies are warranted to elucidate the full importance of the findings.	[Lo, Calvin; Shifteh, Keivan; Gold, Tamar; Bello, Jacqueline A.; Lipton, Michael L.] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA; [Lipton, Michael L.] Montefiore Med Ctr, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; [Lipton, Michael L.] Nathan S Kline Inst Psychiat Res, Ctr Adv Brain Imaging, Orangeburg, NY 10962 USA	Lipton, ML (corresponding author), Montefiore Med Ctr, Dept Radiol, 111 E 210th St, Bronx, NY 10467 USA.	mlipton@aecom.yu.edu					Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Houenou J, 2007, MOL PSYCHIATR, V12, P1001, DOI 10.1038/sj.mp.4002010; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Palmese CA, 2000, BRAIN INJURY, V14, P535; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Yu CS, 2007, NEUROIMAGE, V36, P411, DOI 10.1016/j.neuroimage.2007.03.003; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	29	85	88	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0363-8715	1532-3145		J COMPUT ASSIST TOMO	J. Comput. Assist. Tomogr.	MAR-APR	2009	33	2					293	297		10.1097/RCT.0b013e31817579d1			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	427KB	WOS:000264777100025	19346863				2021-06-18	
J	Gallagher, S; Phillips, AC; Oliver, C; Carroll, D				Gallagher, Stephen; Phillips, Anna C.; Oliver, Christopher; Carroll, Douglas			Predictors of Psychological Morbidity in Parents of Children with Intellectual Disabilities	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						anxiety; caregiving; depression; parents of children with intellectual disability	ZARIT-BURDEN-INTERVIEW; TRAUMATIC BRAIN-INJURY; SCHOOL-AGE-CHILDREN; BEHAVIOR PROBLEMS; DIFFICULTIES QUESTIONNAIRE; FAMILY CAREGIVERS; HOSPITAL ANXIETY; SOCIAL SUPPORT; DOWNS-SYNDROME; STRESS	Objective This study examined predictors of excess psychological morbidity in parents of children with intellectual disabilities. Methods Thirty-two parents of children with intellectual disabilities and 29 parents of typically developing children completed the Hospital Depression and Anxiety Scale, and measures of social support, child problem behaviors, sleep quality, and perceived caregiver burden. Results Parents of children with intellectual disabilities registered high depression and anxiety scores, and the majority met the criteria for possible clinical depression and/or anxiety. The strongest predictor of psychological morbidity was caregiver burden. Analyses of its component dimensions indicated that feelings of guilt held the greatest consequence for depression and anxiety. Conclusions Caregiver burden, in general, and its guilt component, in particular, predicted symptoms of depression and anxiety in parents of children with intellectual disabilities. Assisting such parents to resolve their feelings of guilt should benefit their psychological status.	[Gallagher, Stephen; Phillips, Anna C.; Carroll, Douglas] Univ Birmingham, Sch Sport & Exercise Sci, Birmingham B15 2TT, W Midlands, England; [Oliver, Christopher] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England	Gallagher, S (corresponding author), Univ Birmingham, Sch Sport & Exercise Sci, Birmingham B15 2TT, W Midlands, England.	sxg598@bham.ac.uk	Whittaker, Anna C./A-3577-2013; Oliver, Christopher/A-7519-2008	Whittaker, Anna C./0000-0002-5461-0598; Oliver, Christopher/0000-0001-5217-6209; , Stephen/0000-0002-5471-7774			Achenbach T. M., 1991, MANUAL CHILD BEHAV C; AMAN MG, 1987, AM J MENT RETARD, V91, P570; Ankri J, 2005, INT J GERIATR PSYCH, V20, P254, DOI 10.1002/gps.1275; Bailey D., 1994, J SOCIOL SOC WELFARE, V21, P127; Baker BL, 2003, J INTELL DISABIL RES, V47, P217, DOI 10.1046/j.1365-2788.2003.00484.x; Benderix Y, 2006, AUTISM, V10, P629, DOI 10.1177/1362361307070902; Blacher J, 2006, J INTELL DISABIL RES, V50, P184, DOI 10.1111/j.1365-2788.2005.00768.x; BRAMLEY PN, 1988, ACTA PSYCHIAT SCAND, V77, P133, DOI 10.1111/j.1600-0447.1988.tb05089.x; Brummett BH, 2006, HEALTH PSYCHOL, V25, P220, DOI 10.1037/0278-6133.25.2.220; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carter PA, 2006, CANCER NURS, V29, P95, DOI 10.1097/00002820-200603000-00003; Clyburn LD, 2000, J GERONTOL B-PSYCHOL, V55, pS2, DOI 10.1093/geronb/55.1.s2; Dunn ME, 2001, COMMUNITY MENT HLT J, V37, P39, DOI 10.1023/A:1026592305436; Dunst C., 1988, ENABLING EMPOWERING; DYSON LL, 1993, AM J MENT RETARD, V98, P207; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Floyd FJ, 1997, FAM RELAT, V46, P359, DOI 10.2307/585096; GALLAGHER D, 1985, 38 ANN SCI M GER SOC; Glidden LM, 2003, J INTELL DISABIL RES, V47, P250, DOI 10.1046/j.1365-2788.2003.00487.x; Goodman R, 1998, EUR CHILD ADOLES PSY, V7, P125, DOI 10.1007/s007870050057; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Goodman R, 1999, J ABNORM CHILD PSYCH, V27, P17, DOI 10.1023/A:1022658222914; Grandner Michael A, 2006, Sleep Biol Rhythms, V4, P129, DOI 10.1111/j.1479-8425.2006.00207.x; Graungaard AH, 2007, CHILD CARE HLTH DEV, V33, P296, DOI 10.1111/j.1365-2214.2006.00666.x; GRAY DE, 1992, J INTELLECT DEV DIS, V18, P83, DOI DOI 10.1080/07263869200034841; Hastings RP, 2006, AM J MENT RETARD, V111, P48, DOI 10.1352/0895-8017(2006)111[48:MDAEEC]2.0.CO;2; Hastings RP, 2005, AUTISM, V9, P377, DOI 10.1177/1362361305056078; Hastings RP, 2002, AM J MENT RETARD, V107, P222, DOI 10.1352/0895-8017(2002)107<0222:BPOCWA>2.0.CO;2; Hebert R, 2000, CAN J AGING, V19, P494, DOI 10.1017/S0714980800012484; Hedov G, 2002, SCAND J CARING SCI, V16, P424, DOI 10.1046/j.1471-6712.2002.00109.x; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Lenhard W, 2005, AM J MED GENET A, V133A, P170, DOI 10.1002/ajmg.a.30571; Maes B, 2003, J INTELL DISABIL RES, V47, P447, DOI 10.1046/j.1365-2788.2003.00513.x; Magana SM, 2007, PSYCHIAT SERV, V58, P378, DOI 10.1176/appi.ps.58.3.378; MCCUBBIN HI, 1981, SYSTEMATIC ASSESSMEN, P67; McCurry SM, 2007, SLEEP MED REV, V11, P143, DOI 10.1016/j.smrv.2006.09.002; MCGUBBIN HI, 1983, SOCIAL STRESS FAMILY, P7; Meltzer LJ, 2008, J PEDIATR PSYCHOL, V33, P279, DOI 10.1093/jpepsy/jsm118; Meltzer LJ, 2006, ARCH INTERN MED, V166, P1749, DOI 10.1001/archinte.166.16.1749; Nikcevic AV, 2007, J PSYCHOSOM RES, V63, P283, DOI 10.1016/j.jpsychores.2007.04.004; Ostwald SK, 1999, GERONTOLOGIST, V39, P299, DOI 10.1093/geront/39.3.299; Phipps S, 2005, J PEDIATR PSYCHOL, V30, P139, DOI 10.1093/jpepsy/jsi002; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; Shearn J, 2000, J APPL RES INTELLECT, V13, P109, DOI 10.1046/j.1468-3148.2000.00021.x; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; Stores R, 1998, J INTELL DISABIL RES, V42, P228, DOI 10.1046/j.1365-2788.1998.00123.x; THOMPSON A, INT J GERIA IN PRESS; TRIVETTE C, 1985, PERSONAL WELL UNPUB; Vedhara K, 2002, J PSYCHOSOM RES, V53, P1153, DOI 10.1016/S0022-3999(02)00343-4; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Weiss MJ, 2002, AUTISM, V6, P115, DOI 10.1177/1362361302006001009; White N, 2004, J APPL RES INTELLECT, V17, P181, DOI 10.1111/j.1468-3148.2004.00197.x; Wilcox S, 1999, J GERONTOL B-PSYCHOL, V54, pP189, DOI 10.1093/geronb/54B.3.P189; Wright Marilyn, 2006, Phys Occup Ther Pediatr, V26, P55, DOI 10.1300/J006v26n03_05; Yirmiya N, 2005, J CHILD PSYCHOL PSYC, V46, P69, DOI 10.1111/j.1469-7610.2004.00334.x; Zammit GK, 1999, SLEEP, V22, pS379; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649; Zarit SH., 1990, MEMORY BEHAV PROBLEM; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	59	85	91	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	NOV-DEC	2008	33	10					1129	1136		10.1093/jpepsy/jsn040			8	Psychology, Developmental	Psychology	367NB	WOS:000260557600007	18430761	Bronze, Green Published			2021-06-18	
J	Lee, JK; Won, JS; Singh, AK; Singh, I				Lee, Jin-Koo; Won, Je-Seong; Singh, Avtar K.; Singh, Inderjit			Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death	NEUROSCIENCE LETTERS			English	Article						atorvastatin; excitotoxicity; inflammation; hippocampus; kainic acid; lovastatin and seizure	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; INDUCED STATUS-EPILEPTICUS; COA REDUCTASE INHIBITOR; TEMPORAL-LOBE EPILEPSY; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; LEWIS RATS; NEUROLOGIC DISEASES; ALZHEIMERS-DISEASE	Statins are inhibitors of HMG-CoA reductase that have been recently recognized as anti-inflammatory and neuroprotective drugs. Herein, we investigated anti-excitotoxic and anti-seizure effects of statins by using kainic acid (KA)-rat seizure model, an animal model for temporal lobe epilepsy and excitotoxic neurodegeneration. We observed that pre-treatment with Lipitor (atorvastatin) efficiently reduced KA-induced seizure activities, hippocampal neuron death, monocyte infiltration and proinflammatory gene expression. In addition, we also observed that lovastatin treatment attenuated KA- or glutamate-induced excitotoxicity of cultured hippocampal neurons. These observations suggest a potential for use of statin treatment in modulation of seizures and other neurological diseases associated with excitotoxicity. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Lee, Jin-Koo; Won, Je-Seong; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Won, Je-Seong; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA; [Lee, Jin-Koo] Hallym Univ, Inst Nat Med, Chunchon, South Korea	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave,505 Childrens Res Bldg, Charleston, SC 29425 USA.	singhi@musc.edu		Won, Jeseong/0000-0003-2408-0386	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS022576, R01 NS037766, R01 NS022576-17, R01 NS040144, NS-37766, R37 NS022576, NS-22576, R01 NS037766-10, R01 NS034741, NS-40144, NS-34741, R01 NS034741-12] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034741, R01NS040144, R01NS037766, R37NS022576, R01NS022576] Funding Source: NIH RePORTER		Ananth C, 2003, HIPPOCAMPUS, V13, P375, DOI 10.1002/hipo.10090; BEAL MF, 1992, FASEB J, V6, P3338; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Bittigau P, 1997, J CHILD NEUROL, V12, P471, DOI 10.1177/088307389701200802; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Diaz-Villoslada P, 1998, CURR OPIN NEUROL, V11, P235, DOI 10.1097/00019052-199806000-00008; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Hering H, 2003, J NEUROSCI, V23, P3262; Hong H, 2006, AM J PHYSIOL-HEART C, V291, pH2210, DOI 10.1152/ajpheart.01270.2005; Kirsch C, 2003, PHARMACOPSYCHIATRY, V36, pS113; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; Laufs U, 2002, BRAIN RES, V942, P23, DOI 10.1016/S0006-8993(02)02649-5; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lutjohann D, 2004, STEROIDS, V69, P431, DOI 10.1016/j.steroids.2004.03.012; Martinez-Palma L, 2003, NEUROTOX RES, V5, P399, DOI 10.1007/BF03033168; Molinuevo Jose L, 2005, Am J Alzheimers Dis Other Demen, V20, P77, DOI 10.1177/153331750502000206; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pai GS, 2000, MOL GENET METAB, V69, P312; Paintlia AS, 2005, FASEB J, V19, P1407, DOI 10.1096/fj.05-3861com; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Prasad R, 2005, J NEUROCHEM, V94, P204, DOI 10.1111/j.1471-4159.2005.03182.x; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Rizzi M, 2003, NEUROBIOL DIS, V14, P494, DOI 10.1016/j.nbd.2003.08.001; Ruocco A, 2007, EUR J NEUROSCI, V26, P3261, DOI 10.1111/j.1460-9568.2007.05935.x; Semenova MM, 2007, NAT NEUROSCI, V10, P436, DOI 10.1038/nn1869; Singh I, 1998, FEBS LETT, V426, P342, DOI 10.1016/S0014-5793(98)00370-6; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; Stanislaus R, 2002, NEUROSCI LETT, V333, P167, DOI 10.1016/S0304-3940(02)00943-6; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang JQ, 2004, MOL NEUROBIOL, V29, P1, DOI 10.1385/MN:29:1:01; Won JS, 2003, J NEUROSCI, V23, P7470; WON JS, 2008, J NEUROCHEM; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zacco A, 2003, J NEUROSCI, V23, P11104	44	85	88	1	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	AUG 8	2008	440	3					260	264		10.1016/j.neulet.2008.05.112			5	Neurosciences	Neurosciences & Neurology	331MP	WOS:000258016600014	18583044	Green Accepted			2021-06-18	
J	Stiver, SI; Wintermark, M; Manley, GT				Stiver, Shirley I.; Wintermark, Max; Manley, Geoffrey T.			Reversible monoparesis following decompressive hemicraniectomy for traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebrospinal fluid; cerebrovascular circulation; cranioplasty; craniotomy; neurological deficit; trephine	ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURIES; COMMUNICATING HYDROCEPHALUS; BLOOD-FLOW; CRANIECTOMY; CRANIOPLASTY; MANAGEMENT; DEFECTS; METABOLISM; DYNAMICS	Object. The "syndrome of the trephined" is an uncommon and poorly understood disorder of delayed neurological deficit following craniectomy. From the authors' extensive experience with decompressive hemicraniectomy for traumatic brain injury (TBI), they have encountered a number of patients who developed delayed motor deficits, also called "motor trephine syndrome," and reversal of the weakness following cranioplasty repair. The authors set out to study motor function systematically in this patient population to define the incidence, contributing factors, and outcome of patients with motor trephine syndrome. Methods. The authors evaluated patient demographics, injury characteristics, detailed motor examinations, and CT scans in 38 patients with long-term follow-up after decompressive hemicraniectomy for TBI. Results. Ten patients (26%) experienced delayed contralateral upper-extremity weakness, beginning 4.9 +/- 0.4 months (mean standard error) after decompressive hemicraniectomy. Motor deficits improved markedly within 72 hours of cranioplasty repair, and all patients recovered full motor function. The CT perfusion scans, performed in 2 patients, demonstrated improvements in cerebral blood flow commensurate with resolution of cerebrospinal fluid flow disturbances on CT scanning and return of motor strength. Comparisons between 10 patients with and 20 patients (53%) without delayed motor deficits identified 3 factors - ipsilateral contusions, abnormal cerebrospinal fluid circulation, and longer intervals to cranioplasty repair-to be strongly associated with delayed, reversible monoparesis following decompressive hemicraniectomy. Conclusions. Delayed, reversible monoparesis, also called motor trephine syndrome, is common following decompressive hemicraniectomy for TBI. The results of this study suggest that close follow-up of motor strength with early cranioplasty repair may prevent delayed motor complications of decompressive hemicraniectomy.	[Stiver, Shirley I.; Manley, Geoffrey T.] Univ Calif San Francisco, Sch Med, Dept Neurosurg, San Francisco, CA 94110 USA; [Wintermark, Max] Univ Calif San Francisco, Sch Med, Dept Radiol, San Francisco, CA 94110 USA	Stiver, SI (corresponding author), Univ Calif San Francisco, Sch Med, Dept Neurosurg, 1001 Potrero Ave,Roomm 101, San Francisco, CA 94110 USA.	sstiver@neurosurg.ucsf.edu		Wintermark, Max/0000-0002-6726-3951			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Carmelo A, 2002, ACT NEUR S, V81, P109; Cohen JE, 2004, NEUROL RES, V26, P763, DOI 10.1179/016164104225015930; Colohan Austin R T, 2005, Clin Neurosurg, V52, P19; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; DUJOVNY M, 1998, CALVARIAL DURAL RECO, P77; Falconer MA, 1944, J NEUROSURG, V1, P182, DOI 10.3171/jns.1944.1.3.0182; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; GARDNER WJ, 1945, SURG GYNECOL OBSTET, V80, P303; GEORGE AE, 1974, RADIOLOGY, V111, P627; GOTTLOB L, 2002, STRABISMUS, V10, P271; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; JAMES AE, 1974, RADIOLOGY, V111, P143, DOI 10.1148/111.1.143; JAMES AE, 1975, J NEUROL SCI, V24, P151, DOI 10.1016/0022-510X(75)90231-2; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maeshima S, 2005, EUR NEUROL, V53, P164, DOI 10.1159/000086129; Makino H, 1979, Acta Neurochir Suppl (Wien), V28, P193; Marion DW, 2006, NEUROSURGERY, V58, P655; Matsuno A, 2003, SURG NEUROL, V60, P23, DOI 10.1016/S0090-3019(03)00023-5; Meier U, 2005, ACT NEUR S, V95, P55; MORI K, 1977, SURG NEUROL, V8, P337; NAU HE, 1981, NEUROCHIRURGIA, V24, P192; RICHAUD J, 1985, NEUROCHIRURGIE, V31, P183; RINALDI A, 1990, ACT NEUR S, V51, P394; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; STULA D, 1985, NEUROCHIRURGIA, V28, P164; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Winter CD, 2005, J CLIN NEUROSCI, V12, P619, DOI 10.1016/j.jocn.2005.02.002; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yamaura A, 1977, No Shinkei Geka, V5, P345; YOSHIDA K, 1994, AM J NEURORADIOL, V15, P1681	44	85	91	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2008	109	2					245	254		10.3171/JNS/2008/109/8/0245			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	330QR	WOS:000257958400012	18671636				2021-06-18	
J	Cloots, RJH; Gervaise, HMT; van Dommelen, JAW; Geers, MGD				Cloots, R. J. H.; Gervaise, H. M. T.; van Dommelen, J. A. W.; Geers, M. G. D.			Biomechanics of traumatic brain injury: Influences of the morphologic heterogeneities of the cerebral cortex	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						traumatic brain injury; brain tissue; cerebrum; cerebral cortex; inhomogeneities; finite element model	DIFFUSE AXONAL INJURY; MECHANICAL-BEHAVIOR; DYNAMIC-RESPONSE; WHITE-MATTER; HEAD; MODEL; STRETCH; TISSUE; ACCELERATION; DAMAGE	Traumatic brain injury (TBI) can be caused by accidents and often leads to permanent health issues or even death. Brain injury criteria are used for assessing the probability of TBI, if a certain mechanical load is applied. The currently used injury criteria in the automotive industry are based on global head kinematics. New methods, based on finite element modeling, use brain injury criteria at lower scale levels, e.g., tissue-based injury criteria. However, most current computational head models lack the anatomical details of the cerebrum. To investigate the influence of the morphologic heterogeneities of the cerebral cortex, a numerical model of a representative part of the cerebral cortex with a detailed geometry has been developed. Several different geometries containing gyri and sulci have been developed for this model. Also, a homogeneous geometry has been made to analyze the relative importance of the heterogeneities. The loading conditions are based on a computational head model simulation. The results of this model indicate that the heterogeneities have an influence on the equivalent stress. The maximum equivalent stress in the heterogeneous models is increased by a factor of about 1.3-1.9 with respect to the homogeneous model, whereas the mean equivalent stress is increased by at most 10%. This implies that tissue-based injury criteria may not be accurately applied to most computational head models used nowadays, which do not account for sulci and gyri.	[Cloots, R. J. H.; Gervaise, H. M. T.; van Dommelen, J. A. W.; Geers, M. G. D.] Eindhoven Univ Technol, Mat Technol Inst, NL-5600 MB Eindhoven, Netherlands	Cloots, RJH (corresponding author), Eindhoven Univ Technol, Mat Technol Inst, POB 513, NL-5600 MB Eindhoven, Netherlands.	r.j.h.cloots@tue.nl	Geers, Marc G.D./E-4385-2014	Geers, Marc G.D./0000-0002-0009-6351			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Al-Bsharat A. S., 1999, STAPP CAR CRASH J, V43, P321; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Brands Dave W A, 2002, Stapp Car Crash J, V46, P103; CLAESSENS M, 1997, STAPP CAR CRASH J, V41, P315; Cotter CS, 2002, INT J NUMER METH FL, V40, P303, DOI 10.1002/fld.287; DIMASI FP, 1995, STAPP CAR CRASH C P, V39; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183; Garo A, 2007, BIORHEOLOGY, V44, P51; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Goldsmith Werner, 2005, Critical Reviews in Biomedical Engineering, V33, P105, DOI 10.1615/CritRevBiomedEng.v33.i2.20; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Henn HW, 1998, TEACHING MATH ITS AP, V17, P162, DOI [10.1093/teamat/17.4.162, DOI 10.1093/teamat/17.4.162]; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Hrapko M, 2006, BIORHEOLOGY, V43, P623; HRAPKO M, 2007, P IRCOBI C ZUR SWITZ, P143; Jin Xin, 2006, Stapp Car Crash J, V50, P637; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kouznetsova V, 2001, COMPUT MECH, V27, P37, DOI 10.1007/s004660000212; LAURET C, EXPT SETUP OPT UNPUB; LEONOV AI, 1976, RHEOL ACTA, V15, P85, DOI 10.1007/BF01517499; Lind NM, 2007, NEUROSCI BIOBEHAV R, V31, P728, DOI 10.1016/j.neubiorev.2007.02.003; Mai J. K., 1997, ATLAS HUMAN BRAIN; MAO H, 2006, STAPP CAR CRASH C P, V50; Marieb E. N., 1998, HUMAN ANATOMY PHYSL; Miller R.T., 1998, STAPP CAR CRASH J, P155; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Nishimoto T, 2000, JSAE REV, V21, P117, DOI 10.1016/S0389-4304(99)00079-X; NOLTE J, 2002, HUMAN BRAIN INTRO IT; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; Peters GWM, 1997, J NON-NEWTON FLUID, V68, P205, DOI 10.1016/S0377-0257(96)01511-X; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; Shen F, 2006, J BIOMECH ENG-T ASME, V128, P797, DOI 10.1115/1.2264393; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; WELKER W, 2007, COMP MAMMALIAN BRAIN; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714	47	85	86	0	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JUL	2008	36	7					1203	1215		10.1007/s10439-008-9510-3			13	Engineering, Biomedical	Engineering	307KQ	WOS:000256318200011	18465248	Green Published, Other Gold			2021-06-18	
J	Hartl, R; Gerber, LM; Ni, QH; Ghajar, J				Haertl, Roger; Gerber, Linda M.; Ni, Quanhong; Ghajar, Jamshid			Effect of early nutrition on deaths due to severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						metabolism; nutrition; outcome; traumatic brain injury	SEVERE HEAD-INJURY; ENTERAL NUTRITION; METABOLIC RESPONSE; CONTROLLED-TRIAL; CARE; MANAGEMENT; MORTALITY; STATE	Object. Traumatic brain injury (TBI) remains a serious public health crisis requiring continuous improvement in pre-hospital and inhospital care. This condition results in a hypermetabolic state that increases systemic and cerebral energy requirements, but achieving adequate nutrition to meet this demand has not been a priority in reducing death due to TBI. The effect of timing and quantity of nutrition on death within the first 2 weeks of injury was analyzed in a large prospective database of adult patients with severe TBI in New York State. Methods. The study is based on 797 patients with severe TBI (Glasgow Coma Scale [GCS] score < 9) treated at 22 trauma centers enrolled in a New York State quality improvement program between 2000 and 2006. The inhospital section of the prospectively collected database includes information on age, initial GCS score, weight and height, results of CT scanning, and daily parameters such as pupillary status, arterial hypotension, GCS score, and number of calories fed per day. Results. Patients who were not fed within 5 and 7 days after TBI had a 2- and 4-fold increased likelihood of death, respectively. The amount of nutrition in the first 5 days was related to death; every 10-kcal/kg decrease in caloric intake was associated with a 30-40% increase in mortality rates. This held up even after controlling for factors known to affect mortality, including arterial hypotension, age, pupillary status, initial GCS score, and CT scan findings. Conclusions. Nutrition is a significant predictor of death due to TBI. Together with prevention of arterial hypotension, hypoxia, and intracranial hypertension it is one of the few therapeutic interventions that can directly affect TBI outcome.	[Haertl, Roger; Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Gerber, Linda M.; Ni, Quanhong] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA	Hartl, R (corresponding author), Weill Cornell Med Coll, Dept Neurol Surg, Starr Bldg,Room 651,525 E 68th St,Box 99, New York, NY USA.	roger@hartlmd.net					Bastian L, 1998, UNFALLCHIRURG, V101, P105, DOI 10.1007/s001130050242; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; EYER SD, 1993, J TRAUMA, V34, P639, DOI 10.1097/00005373-199305000-00005; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jolliet P, 1999, CLIN NUTR, V18, P47, DOI 10.1016/S0261-5614(99)80049-1; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PEREL P, 2006, COCHRANE DB SYST REV, V3; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Sampalis JS, 1999, J TRAUMA, V46, P565, DOI 10.1097/00005373-199904000-00004; SMITH JS, 1990, J TRAUMA, V30, P1533, DOI 10.1097/00005373-199012000-00017; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	28	85	97	0	15	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2008	109	1					50	56		10.3171/JNS/2008/109/7/0050			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	319YS	WOS:000257201500010	18590432				2021-06-18	
J	Parcell, DL; Ponsford, JL; Redman, JR; Rajarathnam, SM				Parcell, Diane L.; Ponsford, Jeitnie L.; Redman, Jenitifet R.; Rajarathnam, Shantha M.			Poor sleep quality and changes in objectively recorded sleep after traumatic brain injury: A preliminary study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						anxiety; brain injuries; depression; recovery of function; rehabilitation; sleep	DAYTIME SLEEPINESS; HOSPITAL ANXIETY; EEG; DEPRESSION; INSOMNIA; DISTURBANCES; MECHANISMS; COMPLAINTS; DISORDERS; PATTERNS	Objectives: To evaluate changes in sleep quality and objectively assessed sleep parameters after traumatic brain injury (TBI) and to investigate the relationship between such changes and mood State and injury characteristics. Design: Survey and laboratory-based nocturnal polysommography. Setting: Sleep laboratory. Participants: Ten community-based subjects with moderate to very severe TBI and 10 age- and sex-matched controls from the general community. Interventions: Not applicable. Main Outcome Measures: Pittsburgh Sleep Quality Index for self-report sleep quality, nocturnal polysommography for objective sleep recording, and Hospital Anxiety and Depression Scales. Results: Compared with controls, TBI patients reported significantly poorer sleep quality and higher levels of anxiety and depression. Objective sleep recording showed that TBI patients showed an increase in deep (slow wave) sleep, a reduction in rapid eye movement sleep, and more frequent nighttime awakenings. No significant relationship was observed between these changes in sleep and injury severity of time. since injury. Anxiety and depression covaried with the observed changes in sleep. Conclusions: The findings contribute to the growing body of evidence that sleep is involved in the physiologic processes Underlying neural recovery. The association between anxiety and depression and the observed changes in sleep in TBI patients warrants further examination to determine whether a causative relationship exists.	[Parcell, Diane L.; Ponsford, Jeitnie L.; Redman, Jenitifet R.; Rajarathnam, Shantha M.] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia; [Ponsford, Jeitnie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Rajarathnam, SM (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Bldg 17, Melbourne, Vic 3800, Australia.	shantha.rajarathnam@med.monash.edu.au	Sanguansri, Luz/B-6630-2011; Rajaratnam, Shantha/D-8144-2012	Sanguansri, Luz/0000-0003-1908-7604; Rajaratnam, Shantha/0000-0001-7527-8558	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [334002]	Supported in part by the National Health and Medical Research Council (project no. 334002).	Achermann P, 2001, BRAIN RES, V913, P220, DOI 10.1016/S0006-8993(01)02796-2; [Anonymous], 1992, SLEEP, V15, P173; Armitage R, 2001, SLEEP MED REV, V5, P237, DOI 10.1053/smrv.2000.0144; Barbe F, 1998, AM J RESP CRIT CARE, V158, P18, DOI 10.1164/ajrccm.158.1.9709135; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Benca R. M., 2000, PRINCIPLES PRACTICE, P1140; Benington JH, 2003, PROG NEUROBIOL, V69, P71, DOI 10.1016/S0301-0082(03)00018-2; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BLIWISE BL, 2000, PRINCIPLES PRACTICE, P26; BOURDET C, 1994, J PSYCHOSOM RES, V38, P93, DOI 10.1016/0022-3999(94)90140-6; Broughton R, 2000, PRINCIPLES PRACTICE, V3rd, P693; Busek P, 2000, Sb Lek, V101, P233; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cajochen C, 1999, Sleep Res Online, V2, P65; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Coenen AML, 1998, CONSCIOUS COGN, V7, P42, DOI 10.1006/ccog.1997.0324; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Dement, 2000, PRINCIPLES PRACTICE, P1123; Evans BM, 2002, J ROY SOC MED, V95, P591, DOI 10.1258/jrsm.95.12.591; FEINBERG I, 1974, J PSYCHIATR RES, V10, P283, DOI 10.1016/0022-3956(74)90011-9; Ferrara M, 1999, Sleep Res Online, V2, P15; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; GRAHAM DI, 1999, REHABILITATION ADULT, P19; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Harner P, 1974, REV INT 10 20 SYSTEM; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Huber R, 2000, J NEUROPHYSIOL, V84, P1888; Institute of Medicine; Committee on Sleep Medicine and Research, 2006, SLEEP DIS SLEEP DEPR; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kajimura N, 1998, PSYCHIAT CLIN NEUROS, V52, P317, DOI 10.1046/j.1440-1819.1998.00401.x; Kecklund G, 2004, BIOL PSYCHOL, V66, P169, DOI 10.1016/j.biopsycho.2003.10.004; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kolb B, 2004, SCI PRACT NEUROPSYCH, P30; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LAUER CJ, 1991, BIOL PSYCHIAT, V29, P979, DOI 10.1016/0006-3223(91)90355-P; Legros B, 2003, SLEEP MED, V4, P51, DOI 10.1016/S1389-9457(02)00217-4; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Porkka-Heiskanen T, 1997, SCIENCE, V276, P1265, DOI 10.1126/science.276.5316.1265; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Riemann D, 2001, BIOL PSYCHOL, V57, P67, DOI 10.1016/S0301-0511(01)00090-4; Roehrs T, 2001, SLEEP MED REV, V5, P287, DOI 10.1053/smrv.2001.0162; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Schabus M, 2004, SLEEP, V27, P1479, DOI 10.1093/sleep/27.7.1479; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; Van Cauter E, 2000, JAMA-J AM MED ASSOC, V284, P861, DOI 10.1001/jama.284.7.861; Voderholzer U, 2003, DEPRESS ANXIETY, V17, P162, DOI 10.1002/da.10101; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	61	85	87	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					843	850		10.1016/j.apmr.2007.09.057			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900007	18452730				2021-06-18	
J	Terrell, TR; Bostick, RM; Abramson, R; Xie, D; Barfield, W; Cantu, R; Stanek, M; Ewing, T				Terrell, Thomas Roland; Bostick, Roberd M.; Abramson, Ruth; Xie, Dawen; Barfield, William; Cantu, Robert; Stanek, Michele; Ewing, Trina			APOE, APOE promoter, and tau genotypes and risk for concussion in college athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; soccer; football; genetic polymorphism; APOE; APOE G-219T promoter polymophism	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E EPSILON-4; DEVELOPING ALZHEIMERS-DISEASE; HEAD-INJURY; REGULATORY REGION; FOOTBALL PLAYERS; SOCCER PLAYERS; GENE PROMOTER; POLYMORPHISMS; ASSOCIATION	Objective: To investigate associations of APOE, APOE promoter (G-219T), and tau protein exon 6 polymorphisms ((His)47(Tyr) and (Ser)53(Pro)) and a history of self-reported concussion in college athletes. Design: Multi-center cross-sectional study. Setting: Male football and male and female soccer programs at the University of South Carolina, Jacksonville University, Benedict College, and the College of Charleston. Participants: Active 18- to 30-year-old (n = 195) intercollegiate male football players and male and female soccer players during 2001 and 2002. Assessment of Risk Factors: Written questionnaires and blood or mouthwash samples for DNA for genotyping by RFLP/PCR. Main Outcome Measurement: Self-reported history of concussions over the previous 8 years. Results: A statistically significant, nearly 3-fold increase in risk of a history of concussion for those with the APOE promoter G-219T TT genotype relative to the GG genotype (OR, 2.8; 95% CI, 1.1 to 6.9) adjusted for age, sport, school, and years in their primary sport a finding that was stronger for Cantu grade 2 and 3 concussions. Conclusions: These results suggest that college athletes with an APOE promoter G-219T TT genotype may be at increased risk for having a history of concussions, especially more severe concussions. Although there was some support for the possibility that the tau (Ser)53(Pro) polymorphism may be associated with increased risk of prior concussion (OR, 2.1; 95% CI, 0.3 to 14.5), there was no support for an association with APOE genotypes. The results of this crosssectional study support the need for a prospective study of genetic factors, such as APOE promoter polymorphisms, and the incidence of and sequelae from concussions in college athletes.	[Terrell, Thomas Roland] E Carolina Univ, Brody Sch Med, Dept Family Med, Greenville, NC 27834 USA; [Bostick, Roberd M.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA; [Bostick, Roberd M.] Emory Univ, Rollins Sch Publ Hlth, Dept Hematol Oncol, Atlanta, GA USA; [Abramson, Ruth] Univ S Carolina, Sch Med, Dept Neuropsychiat, Columbia, SC USA; [Xie, Dawen] Univ S Carolina, Dept Epidemiol & Biostat, Mol Epidemiol Res Lab, Columbia, SC USA; [Barfield, William] Med Univ S Carolina, Dept Orthoped Surg, Charleston, SC 29425 USA; [Cantu, Robert] Emerson Hosp, Dept Surg, Concord, MA USA; [Stanek, Michele; Ewing, Trina] Univ S Carolina, Sch Med, Dept Family & Prevent Med, Columbia, SC USA	Terrell, TR (corresponding author), E Carolina Univ, Brody Sch Med, Dept Family Med, 600 Moye Blvd,Brody 4N-51, Greenville, NC 27834 USA.	tomterrell@earthlink.net					Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Berr C, 2001, NEUROBIOL AGING, V22, P227, DOI 10.1016/S0197-4580(00)00227-X; Beyer K, 2002, NEUROREPORT, V13, P1403, DOI 10.1097/00001756-200208070-00011; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Crawford F, 1999, NEUROSCI LETT, V266, P193, DOI 10.1016/S0304-3940(99)00303-1; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HAYNEY MS, 1995, MAYO CLIN PROC, V70, P951, DOI 10.4065/70.10.951; HECHT S, 2005, CLIN J SPORT MED, V15, P279; HUANG DY, 1995, NEUROSCI LETT, V192, P209, DOI 10.1016/0304-3940(95)11649-H; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kimura M, 2000, J NEURAL TRANSM, V107, P1449, DOI 10.1007/s007020070008; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Kwon JM, 2000, NEUROSCI LETT, V284, P77, DOI 10.1016/S0304-3940(00)00972-1; Lambert JC, 1997, HUM MOL GENET, V6, P2151, DOI 10.1093/hmg/6.12.2151; Lambert JC, 2000, HUM MOL GENET, V9, P57, DOI 10.1093/hmg/9.1.57; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lambert JC, 2002, NEUROLOGY, V59, P59, DOI 10.1212/WNL.59.1.59; Laws SM, 1999, NEUROREPORT, V10, P879, DOI 10.1097/00001756-199903170-00038; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lilius L, 1999, NEUROSCI LETT, V277, P29, DOI 10.1016/S0304-3940(99)00833-2; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SKENE JHP, 1983, P NATL ACAD SCI-BIOL, V80, P4169, DOI 10.1073/pnas.80.13.4169; STOLL G, 1989, GLIA, V2, P170, DOI 10.1002/glia.440020306; Sun YL, 1998, J NEUROSCI, V18, P3261; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	52	85	85	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2008	18	1					10	17		10.1097/JSM.0b013e31815c1d4c			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	249XK	WOS:000252263600004	18185033				2021-06-18	
J	VanLandingham, JW; Cekic, M; Cutler, S; Hoffman, SW; Stein, DG				VanLandingham, Jacob W.; Cekic, Milos; Cutler, Sarah; Hoffman, Stuart W.; Stein, Donald G.			Neurosteroids reduce inflammation after TBI through CD55 induction	NEUROSCIENCE LETTERS			English	Article						traumatic brain injury; progesterone; allopregnanolone CD55; inflammation	TRAUMATIC BRAIN-INJURY; PROGESTERONE TREATMENT; CORTICAL CONTUSION; RECEPTOR PXR; CELL-DEATH; COMPLEMENT; EXPRESSION; ALLOPREGNANOLONE; EDEMA; C3	The inflammatory cascade that follows traumatic brain injury may lead to secondary cell death and can impede recovery of function. Complement factors and their convertases are increased in glia after brain injury and lead to the production of inflammatory products that kill vulnerable neurons. Progesterone and its metabolite allopregnanolone (5 alpha-pregnan-3 beta-ol-20-one) have been shown to reduce the expression of inflammatory cytokines in the acute stages of brain injury, although how they do this is not completely understood. In this study we show that both progesterone and allopregnanolone treatments enhance the production of CD55 following contusion injuries of the cerebral cortex in rats. CD55, a single-chain type 1 cell surface protein, is a potent inhibitor of the complement convertases which are activators of the inflammatory cascade. The increased expression of CD55 could be an important mechanism by which steroids help to reduce the cerebral damage caused by inflammation. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Brain Res Lab, Suite 5100,1365-B Clifton Rd NE, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020; Cekic, Milos/AAR-8250-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048451] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008169] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS048451, R01 NS048451-01A2, R01 NS048451-03S1, R01 NS048451-02, R01 NS048451-03] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01N540825, R01N538664] Funding Source: Medline		Baufreton C, 2005, ANN THORAC SURG, V79, P1597, DOI 10.1016/j.athoracsur.2004.08.061; Birzniece V, 2006, BRAIN RES REV, V51, P212, DOI 10.1016/j.brainresrev.2005.11.001; Blatteis CM, 2004, FRONT BIOSCI-LANDMRK, V9, P915, DOI 10.2741/1297; Boos L, 2004, J IMMUNOL, V173, P4708, DOI 10.4049/jimmunol.173.7.4708; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Conti AC, 1998, J NEUROSCI, V18, P5663; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Emmerling MR, 1997, IMMUNOPHARMACOLOGY, V38, P101, DOI 10.1016/S0162-3109(97)00067-2; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; KAUL A, 1995, AM J REPROD IMMUNOL, V34, P236, DOI 10.1111/j.1600-0897.1995.tb00947.x; Kim DD, 2006, J IMMUNOL, V177, P5558, DOI 10.4049/jimmunol.177.8.5558; Kliewer SA, 1999, RECENT PROG HORM RES, V54, P345; KUTTNERKONDO L, 2007, J BIOL CHEM; Lang E W, 1995, New Horiz, V3, P400; Langmade SJ, 2006, P NATL ACAD SCI USA, V103, P13807, DOI 10.1073/pnas.0606218103; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Mocco J, 2006, CIRC RES, V99, P209, DOI 10.1161/01.RES.0000232544.90675.42; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Ogden CA, 2006, CURR DIRECT AUTOIMMU, V9, P120; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Ren K, 2000, BRAIN RES, V865, P272, DOI 10.1016/S0006-8993(00)02267-8; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Singh M, 2006, ENDOCRINE, V29, P271, DOI 10.1385/ENDO:29:2:271; Song WC, 2004, CURR DIRECT AUTOIMMU, V7, P181; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Weetman AP, 1999, THYROID, V9, P643, DOI 10.1089/thy.1999.9.643; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; YOU Z, 2007, J CEREB BLOOD FLOW M; Zucchini N, 2005, BBA-MOL CELL RES, V1745, P48, DOI 10.1016/j.bbamcr.2005.02.005	44	85	87	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 25	2007	425	2					94	98		10.1016/j.neulet.2007.08.045			5	Neurosciences	Neurosciences & Neurology	222IZ	WOS:000250291000006	17826908	Green Accepted			2021-06-18	
J	Ract, C; Le Moigno, S; Bruder, N; Vigue, B				Ract, Catherine; Le Moigno, Sophie; Bruder, Nicolas; Vigue, Bernard			Transcranial Doppler ultrasound goal-directed therapy for the early management of severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						brain injuries; hypoxia-ischemia; brain; transcranial Doppler ultrasonography; time management; critical care	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW-VELOCITY; SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; MODERATE; CARE	Objective: To evaluate the usefulness of early transcranial Doppler ultrasound (TCD) goal-directed therapy after severe traumatic brain injury initiated before invasive cerebral monitoring is available. Design: Prospective, observational clinical study. Setting: Surgical intensive care unit, university hospital. Patients and participants: Twenty-four severely brain-injured patients. Interventions: All patients had TCD measurements immediately on admission (T0) and when invasive cerebral monitoring was available (T1). TCD was considered abnormal when two out of three measured values were outside the following limits: Vm < 30 cm/s, Vd < 20 cm/s, PI > 1.4. When admission TCD was abnormal, attending physicians modified treatment to increase cerebral perfusion pressure. Measurements and results: Admission TCD was performed 18 +/- 11 min (T0) after admission, whereas cerebral inasive monitoring was available 242 +/- 116 min (T1) after admission. At T0, 11 (46%) patients had abnormal TCD values (group 1) and 13 had normal TCD values (group 2); mean arterial pressure was comparable between groups. All group 1 patients received mannitol and/or norepinephrine. At T1, mean arterial pressure was increased compared to admission in group 1 (105 +/- 17 mmHg vs. 89 +/- 15 mmHg, p < 0.05) and only two patients had still an abnormal TCD. Although group 1 patients had higher intracranial pressure than those of group 2 (32 +/- 13 mmHg vs. 22 +/- 10 mmHg, p < 0.01), both cerebral perfusion pressure and jugular venous oxygen saturation were comparable between the groups. Conclusions: The use of TCD at hospital admission allows identification of severely brain-injured patients with brain hypoperfusion. In such high-risk patients, early TCD goal-directed therapy can restore normal cerebral perfusion and might then potentially help in reducing the extent of secondary brain injury.	Ctr Hosp Univ Bicetre, AP HP, F-94275 Le Kremlin Bicetre, France; Ctr Hosp Bretagne Atlantique, Dept Anesthesie Reanimat, Vannes, France; Ctr Hosp Univ Timone, Dept Anesthesie Reanimat, Marseille, France	Vigue, B (corresponding author), Ctr Hosp Univ Bicetre, AP HP, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	bernard.vigue@bct.aphp.fr					AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; CZOSNYKA M, 1994, NEUROSURGERY, V35, P287, DOI 10.1227/00006123-199408000-00015; DeWitt D S, 1995, New Horiz, V3, P376; Ducrocq X, 1998, J NEUROL SCI, V159, P145, DOI 10.1016/S0022-510X(98)00158-0; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Hlatky R, 2001, SEMIN RESP CRIT CARE, V22, P3, DOI 10.1055/s-2001-13835; Jaffres P, 2005, INTENS CARE MED, V31, P785, DOI 10.1007/s00134-005-2630-4; Jennett B., 1997, HEAD INJURY, P439; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kirkpatrick PJ, 1997, HEAD INJURY, P243; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Revell M, 2002, EMERG MED J, V19, P494, DOI 10.1136/emj.19.6.494; Rouxel JPM, 2004, ANN FR ANESTH, V23, P6, DOI 10.1016/j.annfar.2003.09.021; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; TUOR UI, 1986, AM J PHYSIOL, V251, pH824; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; 1999, ANN FR ANESTH REANIM, V18, P36	31	85	90	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	APR	2007	33	4					645	651		10.1007/s00134-007-0558-6			7	Critical Care Medicine	General & Internal Medicine	149TS	WOS:000245170300011	17325830				2021-06-18	
J	Zhu, XL; Poon, WS; Chan, CCH; Chan, SSH				Zhu, X. L.; Poon, W. S.; Chan, Chetwyn C. H.; Chan, Susanna S. H.			Does intensive rehabilitation improve the functional outcome of patients with traumatic brain injury (TBI)? A randomized controlled trial	BRAIN INJURY			English	Article						traumatic brain injury; rehabilitation; intensity; functional independence measure (FIM); Glasgow outcome scale (GOS); Neurobehavioural Cognitive Status Examination (NCSE)	COGNITIVE STATUS EXAMINATION; HEAD-INJURY; INPATIENT REHABILITATION; MULTICENTER ANALYSIS; ACUTE STROKE; THERAPY; MANAGEMENT; SCALE	Objective: To evaluate the effects of an increase in the intensity of rehabilitation on the functional outcome of patients with traumatic brain injury ( TBI). Design and methods: Sixty- eight patients ( age 12 - 65 years) with moderate- to- severe TBI were included. They were randomized into high ( 4- hour/ day) or control ( 2- hour/ day) intensity rehabilitation programmes at an average of 20 days after the injury. The programmes ended when the patients achieved independence in daily activities or when 6 months had passed. Outcome and results: No significant differences were found in the Functional Independence Measure ( FIM) ( primary outcome) and Neurobehavioural Cognitive Status Examination ( NCSE) total scores between the two groups. There were significantly more patients in the high intensity group than in the control group who achieved a maximum FIM total score at the third month ( 47% vs. 19%, p = 0.015) and a maximum Glasgow Outcome Scale ( GOS) score at the second ( 28% vs. 8%, p = 0.034) and third months ( 34% vs. 14%, p = 0.044). Conclusions: Early intensive rehabilitation may improve the functional outcome of patients with TBI in the early months post- injury and hence increase the chance of their returning to work early. Intensive rehabilitation in this study speeded up recovery rather than changed the final outcome.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Rehabil Sci, Appl Cognit Neurosci Lab, Hong Kong, Hong Kong, Peoples R China; Shatin Cheshire Home, Hong Kong, Hong Kong, Peoples R China	Poon, WS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China.	wpoon@cuhk.edu.hk	Poon, Wai Sang/F-1558-2011	Chan, Chetwyn C. H./0000-0003-0307-6337			ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BARNES M, 1998, REHABILITATION TRAUM; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Chan CCH, 2002, BRAIN INJURY, V16, P873, DOI 10.1080/02699050210131975; Chan CHC, 1999, ARCH CLIN NEUROPSYCH, V14, P71, DOI 10.1093/arclin/14.1.71; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Doninger NA, 2000, J HEAD TRAUMA REHAB, V15, P683, DOI 10.1097/00001199-200002000-00007; EVANS CD, 1994, NEUROLOGICAL REHABIL; Fong KNK, 2001, BRAIN INJURY, V15, P443, DOI 10.1080/02699050010005940; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GARRAWAY WM, 1980, BRIT MED J, V280, P1040, DOI 10.1136/bmj.280.6220.1040; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; HALL KM, 1994, ARCH PHYSICAL MED RE, V75, P10; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HETHERINGTON H, 1994, INJURY, V25, P527, DOI 10.1016/0020-1383(94)90095-7; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Kunishio Katsuzo, 1993, Neurologia Medico-Chirurgica, V33, P824, DOI 10.2176/nmc.33.824; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; LAU AEC, 1998, HONG KONG J OCCUPATI, V9, P52; LEE CMS, 1998, HONG KONG J OCCUPATI, V9, P52; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MITRUSHINA M, 1994, HOSP COMMUNITY PSYCH, V45, P252; MOONEY GF, 1988, COGNITIVE REHABILITA, V6, P14; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; *NO CAL NEUR GROUP, 1995, MAN COGN NEUR COGN S; Oehlert ME, 1997, J CLIN PSYCHOL, V53, P733, DOI 10.1002/(SICI)1097-4679(199711)53:7<733::AID-JCLP11>3.0.CO;2-M; PRIGATANO GP, 1988, BNI Q, V4, P30; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rice-Oxley M, 1999, CLIN REHABIL, V13, P7, DOI 10.1191/026921599668051623; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; Slade A, 2002, J REHABIL MED, V34, P260, DOI 10.1080/165019702760390347; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Turner-Stokes L, 2005, COCHRANE DB SYST REV, V20; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; WILLIAM HB, 1988, BRAIN INJURY, V2, P313; Zhu XL, 2001, BRIT J NEUROSURG, V15, P464, DOI 10.1080/02688690120097688	45	85	86	0	25	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	7					681	690		10.1080/02699050701468941			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	192LX	WOS:000248204400004	17653942				2021-06-18	
J	Iverson, GL				Iverson, Grant L.			Complicated vs uncomplicated mild traumatic brain injury: Acute neuropsychological outcome	BRAIN INJURY			English	Article						mild traumatic brain injury; complicated; outcome; neurocognitive	WORD-ASSOCIATION TEST; HEAD-INJURY; COMPUTED-TOMOGRAPHY; RISK-FACTORS; CONCUSSION; MODERATE; CT; RECOVERY; PERFORMANCE; DEPRESSION	Primary objective: The purpose of this study was to carefully examine the effects of a complicated vs uncomplicated mild traumatic brain injury (MTBI) on acute neuropsychological outcome. Research design: Participants were derived from an archival trauma database. This is a retrospective matched groups design. Methods and procedures: All patients were seen through a Head Injury Trauma Service clinical pathway. To be included, all patients must have undergone a day-of-injury CT scan and completed a small battery of neuropsychological tests within 2 weeks of injury. Patients were sorted into two groups on the basis of having a normal or abnormal CT scan. Patients were then carefully matched on age, education, gender and mode of injury (e.g. car accident, fall or assault). The final sample consisted of 100 patients, with 50 in each group. Main outcomes and results: The patients with complicated MTBIs performed significantly more poorly on some of the neuropsychological tests. However, the effect sizes were small or medium and the two groups could not be differentiated using logistic regression analysis. Conclusions: The reasons why people recover slowly or fail to recover fully from MTBIs remain poorly understood. Visible structural brain damage carries increased risk for slow and incomplete recovery, but certainly does not provide an explanation for good or poor outcome in the majority of patients.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC V6T 2A1, Canada	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton A., 1994, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; de Rotrou J, 2005, EUR J NEUROL, V12, P879, DOI 10.1111/j.1468-1331.2005.01100.x; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FRENCH BN, 1977, SURG NEUROL, V7, P171; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton RK, 2004, REVISED COMPREHENSIV; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson G L, 2000, Appl Neuropsychol, V7, P247, DOI 10.1207/S15324826AN0704_7; Iverson G.L., 2006, BRAIN INJURY MED PRI, P333; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; IVERSON GL, 2006, CANADIAN PSYCHOL, V47, P110; IVERSON GL, 1998, J INT NEUROPSYCH SOC, V4, P75; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kongs SK, 2000, WISCONSIN CARD SORTI; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Palmer BW, 1998, ARCH CLIN NEUROPSYCH, V13, P503, DOI 10.1016/S0887-6177(97)00037-1; Paolo AM, 1996, J CLIN EXP NEUROPSYC, V18, P892, DOI 10.1080/01688639608408310; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reitan R. M., 1992, TRAIL MAKING TEST MA; Robinson L J, 1991, Arch Clin Neuropsychol, V6, P27, DOI 10.1016/0887-6177(91)90019-6; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Tellier A, 1999, BRAIN INJURY, V13, P463; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wechsler D., 1987, WECHSLER MEMORY SCAL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29	64	85	85	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2006	20	13-14					1335	1344		10.1080/02699050601082156			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	130GF	WOS:000243787100003	17378225				2021-06-18	
J	Tian, DS; Yu, ZY; Xie, MJ; Bu, BT; Witte, OW; Wang, W				Tian, Dai-Shi; Yu, Zhi-Yuan; Xie, Min-Jie; Bu, Bi-Tao; Witte, Otto W.; Wang, Wei			Suppression of astroglial scar formation and enhanced axonal regeneration associated with functional recovery in a spinal cord injury rat model by the cell cycle inhibitor olomoucine	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						cell cycle; olomoucine; spinal cord injury; glial scar; CSPGs; GAP-43	CENTRAL-NERVOUS-SYSTEM; DEPENDENT KINASES; ALZHEIMERS-DISEASE; PROTEIN EXPRESSION; CORTICAL-NEURONS; WHITE-MATTER; GLIAL-CELLS; BRAIN; DEATH; INDUCTION	It is well established that axons of the adult mammalian CNS are capable of regrowing only a limited amount after injury. Astrocytes are believed to play a crucial role in the failure to regenerate, producing multiple inhibitory proteoglycans, such as chondroitin sulphate proteoglycans (CSPGs). After spinal cord injury (SCI), astrocytes become hypertrophic and proliferative and form a dense network of astroglial processes at the site of lesion constituting a physical and biochemical barrier. Downregulations of astroglial proliferation and inhibitory CSPG production might facilitate axonal regeneration. Recent reports indicated that aberrant activation of cell cycle machinery contributed to overproliferation and apoptosis of cells in various insults. In the present study, we sought to determine whether a cell cycle inhibitior, olomoucine, would decrease neuronal cell death, limit astroglial proliferation and production of inhibitory CSPGs, and eventually enhance the functional compensation after SCI in rats. Our results showed that up-regulations of cell cycle components were closely associated with neuronal cell death and astroglial proliferation as well as the production of CSPGs after SCI. Meanwhile, administration of olomoucine, a selective cell cycle kinase (CDK) inhibitor, has remarkably reduced the up-regulated cell cycle proteins and then decreased neuronal cell death, astroglial proliferation, and accumulation of CSPGs. More importantly, the treatment with olomoucine has also increased expression of growth-associated proteins-43, reduced cavity formation, and improved functional deficits. We consider that suppressing astroglial cell cycle in acute SCIs is beneficial to axonal growth. In the future, therapeutic strategies can be.-designed to achieve efficient axonal regeneration and functional compensation after traumatic CNS injury. (c) 2006 Wiley-Liss, Inc.	Huazhong Univ Sci & Technol, Dept Neurol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; Univ Jena, Dept Neurol, D-6900 Jena, Germany	Wang, W (corresponding author), Huazhong Univ Sci & Technol, Dept Neurol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	wwang_tjh@yaboo.com.cn	Witte, Otto/P-4127-2018; TIAN, DAISHI/A-8744-2018	Witte, Otto/0000-0003-2101-4105; 			AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies JE, 2004, EUR J NEUROSCI, V19, P1226, DOI 10.1111/j.1460-9568.2004.03184.x; Davies SJA, 1997, NATURE, V390, P680; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Eclancher F, 1996, BRAIN RES, V737, P201, DOI 10.1016/0006-8993(96)00732-9; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gallo V, 2001, SCIENCE, V292, P872, DOI 10.1126/science.1060854; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Hayashi T, 2000, NEUROPATH APPL NEURO, V26, P390, DOI 10.1046/j.1365-2990.2000.00264.x; HERRUP K, 1995, DEVELOPMENT, V121, P2385; Irwin N, 1997, PEDIATR NEUROSURG, V27, P113, DOI 10.1159/000121238; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Kalderon N, 2005, CURR PHARM DESIGN, V11, P1237, DOI 10.2174/1381612053507477; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; Kerr BJ, 2004, EXP NEUROL, V188, P391, DOI 10.1016/j.expneurol.2004.04.012; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; McShea A, 1999, MED HYPOTHESES, V52, P525, DOI 10.1054/mehy.1997.0680; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Nagy Z, 1998, NEUROSCIENCE, V87, P731; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Rideout HJ, 2003, J NEUROSCI, V23, P1237; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Silver IA, 1997, NEUROSCIENCE, V78, P589, DOI 10.1016/S0306-4522(96)00600-8; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith DS, 2000, CELL GROWTH DIFFER, V11, P625; Smith MZ, 1999, NEUROSCI LETT, V271, P45, DOI 10.1016/S0304-3940(99)00509-1; Stefanis L, 1999, J NEUROSCI, V19, P6235; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176	43	85	90	0	6	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	OCT	2006	84	5					1053	1063		10.1002/jnr.20999			11	Neurosciences	Neurosciences & Neurology	092VG	WOS:000241124800015	16862564				2021-06-18	
J	Broglio, SP; Ferrara, MS; Piland, SG; Anderson, RB				Broglio, S. P.; Ferrara, M. S.; Piland, S. G.; Anderson, R. B.			Concussion history is not a predictor of computerised neurocognitive performance	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							NEUROPSYCHOLOGICAL TEST PROTOCOL; SPORT-RELATED CONCUSSION; FOOTBALL PLAYERS; STABILITY; RECOVERY	Background: The long term effects of self reported concussion on neurocognitive functioning have been found to be variable. Objectives: To evaluate cognitive performance on the Headminder concussion resolution index (CRI) and ImPACT assessment tests of subjects with and without a history of self reported concussion. Methods: A retrospective analysis was completed on 235 Headminder CRI baseline assessments and 264 ImPACT baseline assessments. Participants were divided into four groups on the basis of reported number of concussions (zero, one, two, or three). Multivariate analysis of variance was used to evaluate differences between the concussion history groups on the two computer based concussion assessment programs. Results: Multivariate analysis of variance indicated no significant difference between those with and without a history of concussion on the CRI (Lambda = 0.963, F-(15,F- 627.05) = 0.57, p = 0.898). It also revealed no significant differences between groups on the ImPACT test (Lambda = 0.951, F-(12,F- (672.31)) = 1.07, p = 0.381). Conclusions: The results suggest that either long term cognitive decrements may not be associated with a history of concussion or the decrements may be subtle and undetectable by these computer programs.	Univ Georgia, Dept Kinesiol, St Marys Res Lab, Athens, GA 30602 USA; Univ Illinois, Dept Kinesiol & Community Hlth, Champaign, IL 61820 USA; Univ So Mississippi, Sch Human Performance & Recreat, Hattiesburg, MS 39406 USA; Florida Atlantic Univ, Boca Raton, FL 33431 USA	Ferrara, MS (corresponding author), Univ Georgia, Dept Kinesiol, St Marys Res Lab, 330 River Rd, Athens, GA 30602 USA.	mferrara@uga.edu		Collie, Alex/0000-0003-2617-9339			Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Keselman HJ, 1998, PSYCHOPHYSIOLOGY, V35, P470, DOI 10.1111/1469-8986.3540470; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044	23	85	85	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2006	40	9					802	805		10.1136/bjsm.2006.028019			4	Sport Sciences	Sport Sciences	076ZS	WOS:000239998100013	16929049	Green Published			2021-06-18	
J	Leblanc, J; De Guise, E; Gosselin, N; Feyz, M				Leblanc, Joanne; De Guise, Elaine; Gosselin, Nadia; Feyz, Mitra			Comparison of functional outcome following acute care in young, middle-aged and elderly patients with traumatic brain injury	BRAIN INJURY			English	Article						elderly; traumatic brain injury; acute care; outcome	CLOSED-HEAD INJURY; OLDER-ADULTS; NEUROBEHAVIORAL CONSEQUENCES; PRACTICAL SCALE; MORTALITY; COMA; DISCHARGE; SEVERITY; RECOVERY; SEQUELAE	Primary objective: To compare functional physical and cognitive outcome of patients in three age groups with mild, moderate and severe traumatic brain injury (TBI) at discharge from acute care. Research design: Retrospective database review. Methods and procedures: Scores on the Extended Glasgow Outcome Scale (GOSE) and on the FIM (TM) instrument,(1) discharge destination and length-of-stay (LOS) were gathered and compared for 2327 patients with TBI admitted to a level 1 trauma hospital from 1997-2003 divided into three age groups; 971 patients between 18-39 years, 672 between 40-59 years and 684 aged 60-99 years. Main outcomes and results: Relative to younger adults with similar TBI severity, elderly patients showed worse outcome on the GOSE and FIM (TM) instrument (physical and cognitive ratings) and longer LOS. No difference was observed between the young and middle-aged groups except for cognitive FIM (TM) ratings and LOS for severe TBI. A higher percentage of elderly patients went to in-patient rehabilitation, to long-term care facilities or died compared to young and middle-aged patients. A higher number of young and middle-aged patients were discharged home. Conclusions: Further development of services in early rehabilitation as well as post-rehabilitation geared to the specific needs of the elderly patient with TBI is required as the population ages.	McGill Univ, Montreal Gen Hosp, Ctr Hlth, Traumat Brain Injury Program, Montreal, PQ H3G 1A4, Canada; Univ Montreal, Montreal, PQ, Canada	Leblanc, J (corresponding author), McGill Univ, Montreal Gen Hosp, Ctr Hlth, Traumat Brain Injury Program, Local D13-124,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	joanne.leblanc@mcgill.ca					ADEKOYA N, 2002, SURVEILLANCE SUMMARI, V51, P1; AharonPeretz J, 1997, BRAIN INJURY, V11, P871; AMACHER AL, 1987, NEUROSURGERY, V20, P954; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; *COMM MED ASP AUT, 1971, JAMA-J AM MED ASSOC, V215, P277; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x; ENGLANDER J, 1999, REHABILITATION ADULT, P453; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hawkins ML, 2003, AM SURGEON, V69, P497; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MALKMUS D, 1979, REHABILITATION HEAD; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; RAKIER A, 1995, BRAIN INJURY, V9, P187, DOI 10.3109/02699059509008191; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	49	85	89	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					779	790		10.1080/02699050600831835			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300001	17060145				2021-06-18	
J	Ariza, M; Serra-Grabulosa, JM; Junque, C; Ramirez, B; Mataro, M; Poca, A; Bargallo, N; Sahuquillo, J				Ariza, Mar; Serra-Grabulosa, Josep M.; Junque, Carme; Ramirez, Blanca; Mataro, Maria; Poca, Antonia; Bargallo, Nuria; Sahuquillo, Juan			Hippocampal head atrophy after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						TBI; hippocampus; memory	HIGH INTRACRANIAL-PRESSURE; VERBAL MEMORY; VOLUME; AMYGDALA; DAMAGE; MRI; MORPHOLOGY; ANTERIOR; DEFICITS; FORNIX	Traumatic brain injury (TBI) causes hippocampal damage. The hippocampus can be macroscopically divided into the head, body and tail, which differ in terms of their sensitivity to excitability and also in terms of their cortical connections. We investigated whether damage also varies according to the hippocampal area involved, and studied the relationship of hippocampal reductions with memory performance. Twenty TBI patients and matched controls were examined. MRI measurements were performed separately for the hippocampal head, body and tail. Memory outcome was measured by Rey's auditory verbal learning test, Rey's complex figure test and a modified version of Warrington's facial recognition memory test. Group comparison showed that patients had bilateral hippocampal atrophy, mainly involving the hippocampal head. Moreover, TBI subjects showed verbal memory deficits which presented slight correlations with left hippocampal head atrophy. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, IDIBAPS, Dept Psychiat & Clin Psychol, Barcelona, Spain; Univ Autonoma Barcelona, Dept Neurosurg, Vall Hebron Univ Hosp, E-08193 Barcelona, Spain; Hosp Clin Barcelona, CDI, Dept Radiol, Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, IDIBAPS, Dept Psychiat & Clin Psychol, C Casanova,143, Barcelona, Spain.	cjunque@ub.edu	Serra-Grabulosa, Josep M/B-4655-2011; Ariza, Mar/F-2754-2019; Mataro, Maria/B-4524-2011; Junque, Carme/B-4400-2011; Serra-Grabulosa, Josep M/S-8371-2019; Sahuquillo, Juan/B-3577-2008; Bargallo, Nuria/G-6854-2016; Poca, Maria A./B-8475-2008	Mataro, Maria/0000-0002-9946-2656; Junque, Carme/0000-0002-6381-3063; Serra-Grabulosa, Josep M/0000-0002-4291-9432; Sahuquillo, Juan/0000-0003-0713-5875; Bargallo, Nuria/0000-0001-6284-5402; Poca, Maria A./0000-0002-3831-0536; Ariza, Mar/0000-0003-1020-6945			Baxendale SA, 1997, NEUROPSYCHOLOGIA, V35, P591, DOI 10.1016/S0028-3932(96)00123-6; Bernal F, 2000, EXP NEUROL, V161, P686, DOI 10.1006/exnr.1999.7293; Bernasconi N, 2003, BRAIN, V126, P462, DOI 10.1093/brain/awg034; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BULLOCK MR, 2000, J NEUROTRAUM, V17, P1; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; Duvernoy HM, 1988, HUMAN HIPPOCAMPUS; FREE SL, 1995, AM J NEURORADIOL, V16, P37; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gimenez M, 2004, NEUROIMAGE, V23, P869, DOI 10.1016/j.neuroimage.2004.07.029; Hackert VH, 2002, NEUROIMAGE, V17, P1365, DOI 10.1006/nimg.2002.1248; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; JACK CR, 1989, RADIOLOGY, V172, P549, DOI 10.1148/radiology.172.2.2748838; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mishkin M, 1997, PHILOS T R SOC B, V352, P1461, DOI 10.1098/rstb.1997.0132; Mitrushina M., 1999, HDB NORMATIVE DATA N; O'Driscoll GA, 2001, PSYCHIAT RES-NEUROIM, V107, P75, DOI 10.1016/S0925-4927(01)00095-6; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Pruessner JC, 2001, J NEUROSCI, V21, P194, DOI 10.1523/JNEUROSCI.21-01-00194.2001; Rey A., 1959, TEST COPIE REPROD ME; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; SQUIRE LR, 1992, NEUROPSYCHOLOGY MEMO; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wang L, 2003, NEUROIMAGE, V20, P667, DOI 10.1016/S1053-8119(03)00361-6; WARRINGTON EK, 1984, WARRINGTON RECOGNITI	37	85	88	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	10					1956	1961		10.1016/j.neuropsychologia.2005.11.007			6	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	068VS	WOS:000239403200033	16352320				2021-06-18	
J	Livingston, DH; Lavery, RF; Mosenthal, AC; Knudson, MM; Lee, S; Morabito, D; Manley, GT; Nathens, A; Jurkovich, G; Hoyt, DB; Coimbra, R				Livingston, DH; Lavery, RF; Mosenthal, AC; Knudson, MM; Lee, S; Morabito, D; Manley, GT; Nathens, A; Jurkovich, G; Hoyt, DB; Coimbra, R			Recovery at one year following isolated traumatic brain injury: A Western Trauma Association prospective multicenter trial	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	35th Annnual Meeting of the Western-Trauma-Association	FEB 27-MAR 05, 2005	Jackson Hole, WY	Western Trauma Assoc		traumatic brain injury; multicenter trial; FIM score; outcomes	INPATIENT REHABILITATION; FUNCTIONAL OUTCOMES; HEAD-INJURY; AGE; MORTALITY; SEVERITY; HOSPITALIZATION; INDEPENDENCE; EPIDEMIOLOGY; MORBIDITY	Background: Age has been shown to be a primary determinant of survival following isolated traumatic brain injury (TBI). We have previously reported that patients >= 65 years who survived mild TBI have decreased functional outcome at 6 months compared with younger patients. The purpose of this study was to further investigate the effect of age on outcome at 1 year in all patients surviving isolated TBI. Methods: The Western Trauma Association multicenter prospective study included all patients sustaining isolated TBI defined as Abbreviated Injury Scale score for Head >= 3 with an Abbreviated Injury Scale score in any other body area <= 1. Outcome data included discharge disposition, Glasgow Outcome Scale score (1 = dead to 5 = full recovery) and modified Functional Independence Measure (FIM) score measuring feeding, expression, and locomotion (1 = total dependence to 4 = total independence) for each component at discharge and 1 year. Results: In all, 295 patients were enrolled with a follow-up of 82%, resulting in 241 study patients. An additional five patients died from non-TBI causes and were excluded. The mean and median times for the last follow-up in the 236 remaining patients were 307 and 357 days, respectively. Patients were divided into four age ranges: 18 to 29 years (n = 66),30 to 44 years (n = 54),45 to 59 years (n = 50), and >= 60 years (n = 65). More severe TBIs, as measured by admitting Glasgow Coma Scale (GCS), were observed in the youngest group compared with all others but there were no differences in mean GCS between the remaining three groups. There were no differences in neurosurgical intervention between the groups. Age was a major determinant in the outcome at discharge and last follow-up. Patients over 60 years discharged with a GOS <= 4 were less likely to improve at 1 year than all other groups (37% versus 63 to 85%; p <= 0.05). Patients between 18 and 29 years of age had the lowest mean Glasgow Outcome Scale and discharge FIM scores, which correlated with the low admission GCS. Despite the increased severity of TBI, this group had the best FIM score at 1 year. In contrast, patients older than 60 years had the least improvement and had a significantly lower final FIM score at 1 year compared with all other groups. Conclusion: Older patients following isolated TBI have poorer functional status at discharge and make less improvement at 1 year compared with all other patients. These worse outcomes occur despite what appears to be less severe TBI as measured by a higher GCS upon admission. Differences in outcome begin to appear even in patients between 45 and 59 years. Further investigations with more detailed outcome instruments are required to better understand the qualitative limitations of a patient's recovery and to devise strategies to maximize functional improvement following TBI. Age is an exceedingly important parameter affecting recovery from isolated TBI.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, New Jersey Trauma Ctr, Newark, NJ 07103 USA; Univ Calif San Francisco, Dept Surg, San Francisco Gen Med Ctr, San Francisco, CA 94143 USA; Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Injury Prevent & Res Inst, Seattle, WA 98104 USA; Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA	Livingston, DH (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, New Jersey Trauma Ctr, 185 S Orange Ave, Newark, NJ 07103 USA.		Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			*AG HEALTHC RES PO, 1998, REH TRAUM BRAIN INJ; ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; Arrich J, 2005, STROKE, V36, P310, DOI 10.1161/01.STR.0000152962.92621.b5; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Holcomb JB, 2003, J AM COLL SURGEONS, V196, P549, DOI 10.1016/S1072-7515(02)01894-X; Huang ME, 2000, AM J PHYS MED REHAB, V79, P327, DOI 10.1097/00002060-200007000-00003; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; *NAT BUR HLTH STAT, 2004, US INT PROJ AG RAC H; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SAYWELL RM, 1989, J AM GERIATR SOC, V37, P625, DOI 10.1111/j.1532-5415.1989.tb01253.x; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; VANAALST JA, 1991, J TRAUMA, V31, P1096; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	32	85	86	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2005	59	6					1298	1304		10.1097/01.ta.0000196002.03681.18			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	001DP	WOS:000234514100004	16394900				2021-06-18	
J	Stalnacke, BM; Bjornstig, U; Karlsson, K; Sojka, P				Stalnacke, BM; Bjornstig, U; Karlsson, K; Sojka, P			One-year follow-up of mild traumatic brain injury: Post-concussion symptoms, disabilities and life satisfaction in relation to serum levels of S-100B and neurone-specific enolase in acute phase	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; head trauma; brain concussion; biochemical marker; S-100 proteins; life satisfaction; post-concussion symptoms	MINOR HEAD-INJURY; NEUROBIOCHEMICAL MARKERS; ELITE PLAYERS; DAMAGE; QUESTIONNAIRE; EPIDEMIOLOGY; POPULATION; PREDICTORS; SWEDEN; TRIAL	Objective: To investigate, in patients with mild traumatic brain injury, serum concentrations of S-100B and neurone-specific enolase in acute phase and post-concussion symptoms, disabilities and life satisfaction 1 year after the trauma. Design: Prospective study. Patients: Eighty-eight patients (age range 18-87 years). Methods: Blood samples were taken on admission and about 7 hours later. At follow-up 15 4 months later, the patients filled in questionnaires about symptoms (Rivermead Post Concussion Symptoms), disability (Rivermead Head Injury Follow-up) and life satisfaction (LiSat-11). Results: Concentrations of S-100B and neurone-specific enolase were regularly increased in the first blood sample. Of the 69 patients participating in the follow-up, 45% reported post-concussion symptom, 48% exhibited disability and 55% were satisfied with "life as a whole". In comparison with the "sick-leave" situation on admission to hospital, 3 patients were on sick-leave at the time of follow-up because of the head trauma. Stepwise forward logistic regression analysis revealed a statistically significant association (p<0.05) between disability and S-100B and dizziness. Conclusion: In spite of frequent persistent symptoms, disabilities and low levels of life satisfaction, the sick-leave frequency was low at follow-up. The association between S-100B and disability supports the notion that long-term consequences of a mild brain injury may partly be a result of brain tissue injury.	Umea Univ, Univ Umea Hosp, Dept Community Med & Rehabil, SE-90185 Umea, Sweden; Univ Umea Hosp, Dept Surg & Perioperat Sci, SE-90185 Umea, Sweden; Univ Umea Hosp, Sect Surg, SE-90185 Umea, Sweden; Univ Umea Hosp, Dept Med Biosci Clin Chem, SE-90185 Umea, Sweden	Stalnacke, BM (corresponding author), Umea Univ, Univ Umea Hosp, Dept Community Med & Rehabil, Bldg 9A, SE-90185 Umea, Sweden.	brittmarie.stalnacke@rehabmed.umu.se					*AB SANGT MED B, 2001, LIAIS SANGT 100 INST, P3; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Paniak C, 2000, BRAIN INJURY, V14, P219; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	29	85	85	0	7	TAYLOR & FRANCIS AS	OSLO	PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY	1650-1977			J REHABIL MED	J. Rehabil. Med.	SEP	2005	37	5					300	305		10.1080/16501970510032910			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	969HN	WOS:000232225300005	16208863	DOAJ Gold			2021-06-18	
J	Lefebvre, H; Pelchat, D; Swaine, B; Gelinas, I; Levert, MJ				Lefebvre, H; Pelchat, D; Swaine, B; Gelinas, I; Levert, MJ			The experiences of individuals with a traumatic brain injury, families, physicians and health professionals regarding care provided throughout the continuum	BRAIN INJURY			English	Article						traumatic brain injuries; adaptation; relationships; uncertainty; continuity of care; care continuum; empowerment; social integration	SERVICE DELIVERY; EMPOWERMENT; REHABILITATION; MORTALITY; PARADOX; IMPACT; NEWS; BAD	Primary objective: To investigate the experiences of individuals who had sustained a traumatic brain injury, their families and the physicians and health professionals involved, from the critical care episodes and subsequent rehabilitation. Research design: Semi-structured interviews were conducted with individuals who had sustained a TBI (n=8) and their families (n=8) as well as with the health professionals (or service providers) (n=22) and physicians (n=9) who provided them care. Main outcomes and results: Results revealed the difficulties encountered by the different people involved, from the standpoint of the readjustment of the individual with the TBI and their family, the relationships among the various actors and the continuity of care. Conclusions: This study brings to light the importance of including the family and the person with a TBI in the care process by calling for their participation and by setting up suitable structures that prioritize a meaningful partnership among the key individuals.	Univ Montreal, ERIFAM, Montreal, PQ H3C 3J7, Canada; Montreal Ctr Interdisciplinary Res Rehabil, Montreal, PQ, Canada; Sacre Coeur Hosp, Res Ctr, Montreal, PQ, Canada; Montreal Rehabil Inst, Montreal, PQ, Canada; McGill Univ, Montreal, PQ, Canada; Jewish Rehabil Hosp, Montreal, PQ, Canada	Lefebvre, H (corresponding author), Univ Montreal, ERIFAM, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	helene.lefebvre@umontreal.ca					BARIBEAU C, 1996, REV SCI ED, V22, P3; Bouchard J., 1988, ED FAMILIALE, P157; Bouchard J., 1999, APPRENTISSAGE SOCIAL, V19, P47; BOURQUE C, 1999, CADRE REFERENCE CLIN; BURY JA, 1988, ED SANTE CONCEPT ENJ; Carson P, 1993, J Neurosci Nurs, V25, P165; Cohen M H, 1993, West J Nurs Res, V15, P77, DOI 10.1177/019394599301500106; DELLORTO AE, 1997, HEAD INJURY FAMILY L; DEMERS C, 2001, UNPUB A GIR C; DEPOMPEI R, 1994, TOP LANG DISORD, V15, P68, DOI 10.1097/00011363-199411000-00007; DUMONT C, 2003, THESIS LAVAL U; Dunst C., 1988, ENABLING EMPOWERING; DUNST CJ, 1987, SCHOOL PSYCHOL REV, V16, P443; DUNST CJ, 1991, COLLABORATION PARENT, P25; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Fallowfield L, 2004, LANCET, V363, P312, DOI 10.1016/S0140-6736(03)15392-5; Gadoury M, 2001, CADRE REFERENCE CLIN; GELINAS I, 1998, INNOVATIONS APPRENTI, P105; GENDRON S, 2002, THESIS U MONTREAL; Gervais M, 1999, ETUDE EXPLORATOIRE B; Glaser B. G., 1967, DISCOVERY GROUNDED T; Gregory RJ, 2001, DISABIL REHABIL, V23, P22, DOI 10.1080/09638280150211257; Guba E., 1985, NATURALISTIC INQUIRY; Habermas Jurgen, 1987, THEORIE AGIR COMMUNI; HOBBES N, 1984, STRENGTHENING FAMILI; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kendall E, 2000, DISABIL REHABIL, V22, P435, DOI 10.1080/09638280050045901; Kosco M, 2000, Crit Care Nurs Q, V23, P60; Lawlor MC, 1998, AM J OCCUP THER, V52, P259, DOI 10.5014/ajot.52.4.259; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lefebvre H., 2002, FAMILLE SITUATION HA, P27; Marquis R, 1996, Am J Hosp Palliat Care, V13, P38, DOI 10.1177/104990919601300408; Merton R.K., 1990, FOCUSED INTERVIEW MA; Ministere de la Sante et des Services Sociaux, 1999, CONT SERV PERS AYANT; Mishel M H, 1997, Annu Rev Nurs Res, V15, P57; Mucchielli A, 1996, DICT METHODES QUALIT; MURRELL KL, 1992, ORG DEV J, V10, P47; NOLTE ML, 2000, DISS ABSTR INT B, V60, P4000; PELCHAT D, 2003, RS3004 CQRS U MONTR; PELCHAT D, 2001, REV INFIRMIERE QUEBE, V9, P26; PELCHAT D, 1998, REV CANADIENNE RECHE, V30, P99; PELCHAT D, 2003, SR3537 CQRS U MONTR; PIRES A, 1997, RECHERCHE QUALITATIV, P173; Poupart J., 1997, RECHERCHE QUALITATIV; POUPART J., 1997, RECHERCHE QUALITATIV, P173; POURTOIS JP, 1999, ED POSTMODERNE; Ptacek J T, 2000, Crit Care Nurs Q, V23, P51; Ptacek JT, 1996, JAMA-J AM MED ASSOC, V276, P496; RANDOLPH WA, 1995, ORGAN DYN, V23, P19, DOI 10.1016/0090-2616(95)90014-4; RAPPAPORT J, 1981, AM J COMMUN PSYCHOL, V9, P1, DOI 10.1007/BF00896357; RISSEL C, 1994, HEALTH PROMOT INT, V9, P39, DOI 10.1093/heapro/9.1.39; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SAMPALIS JS, 1995, J TRAUMA, V39, P232, DOI 10.1097/00005373-199508000-00008; SANDRINEBERTHON.B, 2000, ED PATIENT SECOURS M; SCHERZER BP, 1995, EVEIL, V1, P3; SCHUMACHER KL, 1994, J NURS SCHOLARSHIP, V26, P72; *STAT CAN, 1999, CAN INJ DAT MORT 199; STCHARLES D, 1998, INNOVATIONS APPRENTI, P97; STONGE M, 1998, COLLABORATION ENTRE; TOCHON FV, 1996, REV SCI ED, V22, P467, DOI DOI 10.7202/031889AR; Van der Maren J.-M, 1995, METHODES RECHERCHE E	61	85	85	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2005	19	8					585	597		10.1080/02699050400025026			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	933IS	WOS:000229622700003	16175812				2021-06-18	
J	Spinella, M				Spinella, M			Self-rated executive function: Development of the executive function index	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						executive; Executive Function Index; prefrontal; psychometric; self-rating	TRAUMATIC BRAIN-INJURY; EVENT-RELATED FMRI; RESPONSE-INHIBITION; PREFRONTAL CORTEX; PARKINSONS-DISEASE; WORKING-MEMORY; HEAD-INJURY; LONDON TASK; IMPULSIVITY; ATTENTION	There are several self-rating executive function (SREF) measures in existence that were developed solely in clinical populations or which sample a limited range of executive functions. The Executive Function Index (EFI) was developed here in a normal population with five subscales derived through factor analysis: Motivational Drive, Strategic Planning, Organization, Impulse Control, and Empathy. The content of three second order factors is consistent with the functions mediated by dorsolateral, orbitofrontal, and medial prefrontal circuits. Intrascale reliability and demographic relationships are reported as well as strong correlations with other SREF measures validated in clinical and neuroimaging studies. This brief measure provides a quick and efficient means of collecting data in large samples in order to test hypotheses regarding the role of prefrontal systems in various aspects of behavior and to corroborate findings of other methods, such as objective tests and functional neuroimaging.	Richard Stockton Coll New Jersey, Div Social & Behav Sci, Pomona, NJ 08240 USA	Spinella, M (corresponding author), Richard Stockton Coll New Jersey, Div Social & Behav Sci, POB 195, Pomona, NJ 08240 USA.	marcello.spinella@stockton.edu	Brennan, Kathy/D-6118-2011				Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; Bartzokis G, 2001, ARCH GEN PSYCHIAT, V58, P461, DOI 10.1001/archpsyc.58.5.461; Beauchamp MH, 2003, NEUROIMAGE, V20, P1649, DOI 10.1016/j.neuroimage.2003.07.003; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bolla KI, 2003, NEUROIMAGE, V19, P1085, DOI 10.1016/S1053-8119(03)00113-7; BOONE KB, 1993, J CLIN PSYCHOL, V49, P54, DOI 10.1002/1097-4679(199301)49:1<54::AID-JCLP2270490108>3.0.CO;2-6; Booth JR, 2003, NEUROIMAGE, V20, P737, DOI 10.1016/S1053-8119(03)00404-X; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Cahn-Weiner DA, 2002, NEUROPSY NEUROPSY BE, V15, P79, DOI 10.1097/01.WNN.0000012908.05122.F4; CARRILLODELAPENA MT, 1993, PERCEPT MOTOR SKILL, V77, P567, DOI 10.2466/pms.1993.77.2.567; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Chow T W, 2000, Curr Psychiatry Rep, V2, P446, DOI 10.1007/s11920-000-0031-5; Colvin MK, 2001, J COGNITIVE NEUROSCI, V13, P1129, DOI 10.1162/089892901753294419; Courtney SM, 1998, PHILOS T R SOC B, V353, P1819, DOI 10.1098/rstb.1998.0334; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Curwen Tracey, 2003, Sex Abuse, V15, P347, DOI 10.1023/A:1025056312935; Davis M.H, 1980, J PERS SOC PSYCHOL, V10, P85; Decety J, 2003, NEUROPSYCHOLOGIA, V41, P127, DOI 10.1016/S0028-3932(02)00143-4; Dougherty DM, 1999, PSYCHIAT RES, V85, P315, DOI 10.1016/S0165-1781(99)00011-6; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Farrow TFD, 2001, NEUROREPORT, V12, P2433, DOI 10.1097/00001756-200108080-00029; Faw B, 2003, CONSCIOUS COGN, V12, P83, DOI 10.1016/S1053-8100(02)00030-2; Fincham JM, 2002, P NATL ACAD SCI USA, V99, P3346, DOI 10.1073/pnas.052703399; Fuster JM, 2000, EXP BRAIN RES, V133, P66, DOI 10.1007/s002210000401; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Govern JM, 2001, CONSCIOUS COGN, V10, P366, DOI 10.1006/ccog.2001.0506; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; GRACE J, 2001, FORMAL SYSTEMS BEHAV; GUR RC, 2000, CEREB CORTEX, V12, P998; Heaton R., 1993, WISCONSIN CARD SORTI; Hoptman MJ, 2002, BIOL PSYCHIAT, V52, P9, DOI 10.1016/S0006-3223(02)01311-2; Horn NR, 2003, NEUROPSYCHOLOGIA, V41, P1959, DOI 10.1016/S0028-3932(03)00077-0; Jentsch JD, 2003, BEHAV NEUROSCI, V117, P76, DOI 10.1037/0735-7044.117.1.76; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Kertesz A, 1997, CAN J NEUROL SCI, V24, P29, DOI 10.1017/S0317167100021053; Kircher TTJ, 2002, NEUROPSYCHOLOGIA, V40, P683, DOI 10.1016/S0028-3932(01)00138-5; KLINTEBERG B. A., 1987, PERCEPT MOTOR SKILL, V65, P683; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; Lyke JA, 2004, INT J EAT DISORDER, V36, P229, DOI 10.1002/eat.20025; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; Martel SJ, 1999, ENVIRON ENG GEOSCI, V5, P213; Matsumoto K, 2004, CURR OPIN NEUROBIOL, V14, P178, DOI 10.1016/j.conb.2004.03.005; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MEADE ER, 1981, MERRILL PALMER QUART, V27, P271; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; MENDEZ MF, 1989, NEUROLOGY, V39, P349, DOI 10.1212/WNL.39.3.349; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miyakawa L, 2001, JAPANESE J PSYCHOL, V72, P435; Murphy KR, 2004, J CLIN PSYCHIAT, V65, P12; Newman SD, 2003, NEUROPSYCHOLOGIA, V41, P1668, DOI 10.1016/S0028-3932(03)00091-5; Oswald PA, 2003, PERCEPT MOTOR SKILL, V97, P1184, DOI 10.2466/PMS.97.7.1184-1186; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Paul T, 2002, AM J PSYCHIAT, V159, P408, DOI 10.1176/appi.ajp.159.3.408; Paulsen JS, 2000, J INT NEUROPSYCH SOC, V6, P815, DOI 10.1017/S1355617700677081; Perez-Albeniz A, 2003, CHILD ABUSE NEGLECT, V27, P769, DOI 10.1016/S0145-2134(03)00111-X; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Rubia K, 2000, NEUROSCI BIOBEHAV R, V24, P13, DOI 10.1016/S0149-7634(99)00055-X; Sarazin M, 2003, J NEUROL, V250, P827, DOI 10.1007/s00415-003-1087-z; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Speer NK, 2003, COGN AFFECT BEHAV NE, V3, P155, DOI 10.3758/CABN.3.3.155; Spinella M, 2004, INT J NEUROSCI, V114, P95, DOI 10.1080/00207450490249347; Spinella M, 2003, ADDICT BIOL, V8, P67, DOI 10.1080/1355621031000069909; SPINELLA M, 2005, IN PRESS COLL STUDEN; Spinella M., 2003, COLL STUDENT J, V37, P545; SPINELLA M, 2005, IN PRESS ROLE PREFRO; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Swann AC, 2001, PSYCHIAT RES, V101, P195, DOI 10.1016/S0165-1781(00)00249-3; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; van den Heuvel OA, 2003, NEUROIMAGE, V18, P367, DOI 10.1016/S1053-8119(02)00010-1; Varney NR, 1998, J HEAD TRAUMA REHAB, V13, P63; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zilberman ML, 2003, BMC PSYCHIATRY, V3, DOI 10.1186/1471-244X-3-1; ZWICK WR, 1986, PSYCHOL BULL, V99, P432, DOI 10.1037/0033-2909.99.3.432	82	85	88	2	27	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0020-7454			INT J NEUROSCI	Int. J. Neurosci.	MAY	2005	115	5					649	667		10.1080/00207450590524304			19	Neurosciences	Neurosciences & Neurology	923PI	WOS:000228921400004	15823930				2021-06-18	
J	Hang, CH; Shi, JX; Tian, J; Li, JS; Wu, W; Yin, HX				Hang, CH; Shi, JX; Tian, J; Li, JS; Wu, W; Yin, HX			Effect of systemic LPS injection on cortical NF-kappa B activity and inflammatory response following traumatic brain injury in rats	BRAIN RESEARCH			English	Article						traumatic brain injury; NF-kappa B; proinflammatory cytokine; ICAM-1; apoptosis; inflammation; lipopolysaccharide	TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; ALPHA MESSENGER-RNA; CLOSED-HEAD INJURY; IMPACT INJURY; TNF-ALPHA; CEREBROSPINAL-FLUID; AXONAL INJURY; UP-REGULATION; CELL-DEATH	The aim of current study is to investigate the effect of systemic administration of lipopolysaccharide (LPS) on the temporal pattern of cortical nuclear factor kappa B (NF-kappaB) binding activity, inflammatory response and secondary damage in the injured brain following traumatic brain injury (TBI). Right parietal cortical contusion in rats was made by using weight-dropping method. The rats were randomly divided into sham, LPS, TBI and TBI-LPS groups, with LPS injected intraperitoneally. NF-kappaB binding activity, cytokines, intercellular adhesion molecule-1 (ICAM-1) and brain damage were detected by electrophoretic mobility shift assay (EMSA), enzyme-linked immunosorbent assay (ELISA), immunohistochemistry and terminal deoxynucleotidyl-transferase-mediated biotin-dUTP nick end labeling (TUNEL) apoptosis, respectively. The results showed that systemic administration of LPS following TBI could induce an immediate, strong and persistent upregulation of NF-kappaB, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and ICAM-1 in the area surrounding the injured brain. As compared with rats of sham, LPS and TBI groups, NF-kappaB binding activity, TNF-alpha and IL-6 were significantly upregulated in the surrounding cortex of injured site as early as 3 h postinjury when challenged with LPS, kept at high level up to 7-days postinjury. ICAM-1 positive vessels and apoptotic TUNEL-positive cells in the injured brain were also significantly increased in TBI LPS rats. It was concluded that inflammatory response and secondary brain damage occurred in the injured brain could be highly exacerbated by endotoxemia. (C) 2004 Elsevier B.V. All rights reserved.	Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; Nanjing Univ, Sch Life Sci, Nanjing 210093, Peoples R China; Nanjing Univ, Sch Clin Med, Jinling Hosp, Res Inst Gen Surg, Nanjing 210002, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China.	hang1965@163.com					ANDERSSON J, 1992, IMMUNOL REV, V127, P69, DOI 10.1111/j.1600-065X.1992.tb01409.x; ARDITI M, 1995, J IMMUNOL, V155, P3994; Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bohatschek M, 2001, EXP NEUROL, V172, P137, DOI 10.1006/exnr.2001.7764; BREDER CD, 1994, P NATL ACAD SCI USA, V91, P11393, DOI 10.1073/pnas.91.24.11393; Cai ZW, 2003, BRAIN RES, V975, P37, DOI 10.1016/S0006-8993(03)02545-9; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; GATTI S, 1993, BRAIN RES, V624, P291, DOI 10.1016/0006-8993(93)90090-A; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; HERY C, 1995, J NEUROIMMUNOL, V57, P101, DOI 10.1016/0165-5728(94)00168-N; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; RINK A, 1995, AM J PATHOL, V147, P1575; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Zhang J, 2001, J NEUROCHEM, V76, P855, DOI 10.1046/j.1471-4159.2001.00080.x; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438	45	85	94	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 5	2004	1026	1					23	32		10.1016/j.brainres.2004.07.090			10	Neurosciences	Neurosciences & Neurology	865OU	WOS:000224713200003	15476694				2021-06-18	
J	Bigler, ED				Bigler, ED			Neuropsychological results and neuropathological findings at autopsy in a case of mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						mild traumatic brain injury; neuropathology; neuroimaging	DIFFUSE AXONAL INJURY; HEAD-INJURY; ALZHEIMERS-DISEASE; WHITE-MATTER; EARLY ADULTHOOD; TIME-COURSE; RISK; DAMAGE; DEGENERATION; RAT	Autopsy studies were undertaken in a 47-year-old college-educated male patient who, 7 months prior to an unexpected death, had sustained a mild traumatic brain injury (TBI) as manifested by brief loss of consciousness and an initial Glasgow Coma Scale score of 14. The patient died from cardiac arrest secondary to an undiagnosed and unknown arteriosclerotic cardiovascular disease as assessed by the coroner's office at the time of autopsy. Gross inspection of the brain at autopsy was normal; however, microscopic analysis demonstrated what were considered trauma findings of hemosiderin-laden macrophages in the perivascular space and macrophages in the white matter, particularly the section taken from the frontal lobe. The patient had partially returned to work at the time of death, but had encountered problems with diminished cognitive performance in his work as an appraiser. Neuropsychological studies were generally within normal limits although several tests of either speed of processing or short-term memory showed lower than expected performance. This case demonstrates the presence of subtle neuropathological changes in the brain of a patient who sustained a mild TBI and was still symptomatic for the residual effects of the injury 7 months post injury when he unexpectedly died.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT USA; LDS Hosp, Salt Lake City, UT USA; Univ Utah, Dept Psychiat & Radiol, Salt Lake City, UT USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu					Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Albert CM, 2000, NEW ENGL J MED, V343, P1355, DOI 10.1056/NEJM200011093431902; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BECK AT, 1978, BECK DEPRESSION INVE; Beck AT., 1990, BECK ANXIETY INVENTO; Benton A. L., 1992, BENTON VISUAL RETENT; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; DAVIS RL, 1985, TXB NEUROPATHOLOGY; DEROGATIS LR, 1996, SYMPTOM CHECKLIST 90; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FASCHINGBAUER TR, 1974, J CONSULT CLIN PSYCH, V42, P645, DOI 10.1037/h0037049; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; GOODGLASS H, 1987, ASSESSMENT APHASIA R; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; GREENBERG GD, 1994, ADULT NEUROPSYCHOLOG; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hooper H.E., 1958, HOOPER VISUAL ORG TE; Imaizumi T, 2004, J NEUROIMAGING, V14, P251, DOI 10.1177/1051228404265714; Jastak S., 1993, WIDE RANGE ACHIEVEME; Johnston KC, 2003, NEUROLOGY, V60, P518, DOI 10.1212/01.WNL.0000050462.52753.B2; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kumar R, 2003, AM J NEURORADIOL, V24, P218; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malamud N., 1973, ATLAS NEUROPATHOLOGY; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Preul C, 2003, EUR J RADIOL, V48, P244, DOI 10.1016/S0720-048X(03)00050-0; PRITCHARD DA, 1998, TESTS NEUROPSYCHOLOG; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; RAVEN JA, 1947, COLORED PROGRESSIVE; Rey A, 1964, EXAMEN CLIN PSYCHOL; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Soares HD, 1995, J NEUROSCI, V15, P8223; STOLL G, 1989, J NEUROSCI, V9, P2327; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Tartaglia MC, 2004, ARCH NEUROL-CHICAGO, V61, P201, DOI 10.1001/archneur.61.2.201; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Varney NR, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P115; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; WARRINGTON EK, 1984, WARRINGTON RECOGNITI; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wong KS, 2003, NEUROLOGY, V60, P511, DOI 10.1212/01.WNL.0000046583.40125.20; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	82	85	85	2	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2004	10	5					794	806		10.1017/S1355617704105146			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	848XZ	WOS:000223502700014	15327725				2021-06-18	
J	Stalnacke, BM; Tegner, Y; Sojka, P				Stalnacke, BM; Tegner, Y; Sojka, P			Playing soccer increases serum concentrations of the biochemical markers of brain damage S-100B and neuron-specific enolase in elite players: a pilot study	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; PROTEIN MEASUREMENTS; NEUROPSYCHOLOGICAL IMPAIRMENT; NEUROBIOCHEMICAL MARKERS; ICE HOCKEY; SPORTS; FOOTBALL; RELEASE; HISTORY	Primary objective: To analyse serum concentrations of two biochemical markers of brain tissue damage, S-100B and NSE (neurone-specific enolase), in male soccer players in connection to the game. Methods: Blood samples were taken in players before and after a competitive game and the numbers of headers and of trauma events during soccer play were assessed. Results: Both S-100B and NSE were significantly raised in serum samples obtained after the game in comparison with the pre-game values (S-100B: 0.118 +/- 0.040 mug L-1 vs 0.066 +/- 0.025 mug L-1 , p < 0.001; NSE: 10.29 +/- 2.16 mug L-1 vs 8.57 +/- 2.31 mug L-1 , p < 0.001). Only changes in S-100B concentrations (post-game minus pre-game values) were statistically significantly correlated to the number of headers (r = 0.428, p = 0.02) and to the number of other trauma events (r = 0.453, p = 0.02). Conclusion: Playing competitive elite soccer was found to cause increase in serum concentrations of S-100B and NSE. Increases in S-100B were significantly correlated to the number of headers, and heading may accordingly have contributed to these increases.	Umea Univ, Dept Community Med & Rehabil, Umea, Sweden; Umea Univ, Dept Surg & Perioperat Sci, Umea, Sweden; Lulea Univ Technol, Inst Hlth Sci, Boden, Sweden	Sojka, P (corresponding author), Umea Univ Hosp, Dept Community Med & Rehabil, Bldg 9A, S-90185 Umea, Sweden.	peter.sojka@clinphys.umu.se		Tegner, Yelverton/0000-0003-3628-0705			Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Biberthaler P, 2002, EUR J MED RES, V7, P164; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Ergun R, 1998, NEUROL RES, V20, P418; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; INGEBRIGTSEN T, 2003, 3 INT C BIOCH MARK B; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; *NAT COLL ATHL ASS, INJ SURV SYST; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; TOWNEND WJ, 2000, J NEUROL NEUROSUR PS, V73, P542; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wills SM, 2001, BRAIN INJURY, V15, P645, DOI 10.1080/02699050010010502; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	62	85	86	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2004	18	9					899	909		10.1080/02699050410001671865			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	831FG	WOS:000222178700005	15223742				2021-06-18	
J	Zinn, S; Stein, R; Swartzwelder, HS				Zinn, S; Stein, R; Swartzwelder, HS			Executive functioning early in abstinence from alcohol	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						alcoholism; cognition disorders; memory disorders; abstinence; alcohol-induced disorders	ADDICTION SEVERITY INDEX; TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE; NEUROPSYCHOLOGICAL PERFORMANCE; COGNITIVE IMPAIRMENT; MEMORY PERFORMANCE; FIGURAL FLUENCY; TEST-RETEST; RECOVERY; DEFICITS	Background: Executive dysfunction is among the cognitive impairments that may persist after abstinence in alcohol-dependent persons. The type(s) and extent of executive dysfunction early in abstinence have not been well characterized, but they may have important implications for the evolution of behavioral treatment strategies. Methods: To determine which aspects of executive functioning were impaired in early abstinence, we administered memory and executive function tests to veterans who successively presented for treatment at an outpatient substance abuse clinic. We then compared the neuropsychological performance of these recovering alcoholics (n = 27) with that of age-matched primary care outpatients (n = 18). We also examined group differences in self-evaluation of cognitive decline and evaluated associations between drinking history and cognitive impairment in the index group. Results: We found that the normal and alcohol-dependent groups differed on abstract reasoning, memory discrimination, and effectiveness on timed tasks. Patients in the alcohol-dependent sample were also more likely to perceive themselves as cognitively impaired. It is interesting to note that the duration of alcohol use did not relate to neuropsychological test performance, but recent quantity consumed and days of sobriety were associated with nonverbal abstract reasoning ability. Conclusions: Executive functions are impaired early in abstinence and should, therefore, be taken into account when early behavioral treatments are being developed.	Durham Vet Affairs MEd Ctr, Res & Dev, Durham, NC 27705 USA; Durham Vet Affairs MEd Ctr, Hlth Serv Res & Dev, Durham, NC 27705 USA; Durham Vet Affairs MEd Ctr, Mental Hlth Serv, Durham, NC 27705 USA; Duke Univ, Ctr Med, Dept Psychiat & Behav Sci, Durham, NC 27706 USA	Swartzwelder, HS (corresponding author), VA Med Ctr, 508 Fulton St,Bldg 16,Room 24, Durham, NC 27705 USA.	hss@duke.edu					ADAMS KM, 1993, ALCOHOL CLIN EXP RES, V17, P205, DOI 10.1111/j.1530-0277.1993.tb00750.x; ADAMS KM, 1986, J CLIN EXP NEUROPSYC, V8, P362, DOI 10.1080/01688638608401327; ALTERMAN AI, 1994, DRUG ALCOHOL DEPEN, V34, P201, DOI 10.1016/0376-8716(94)90157-0; Armitage SG, 1946, PSYCHOL MONOGR, V60, P1; BARONA A, 1986, INT J CLIN NEUROPSYC, V8, P169; Beatty WW, 2000, ALCOHOL CLIN EXP RES, V24, P149, DOI 10.1097/00000374-200002000-00003; BECKER JT, 1984, J STUD ALCOHOL, V45, P339, DOI 10.15288/jsa.1984.45.339; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BLENNERHASSETT R, 1993, J PSYCHOL MED, V10, P6; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; CARLEN PL, 1984, CAN J NEUROL SCI, V11, P441, DOI 10.1017/S0317167100045972; CLIFFORD JS, 1986, J COUNS DEV, V65, P31, DOI 10.1002/j.1556-6676.1986.tb01225.x; COCCHI R, 1995, ITAL J INTELLECTIVE, V8, P197; Dao-Castellana MH, 1998, PSYCHOL MED, V28, P1039, DOI 10.1017/S0033291798006849; Dawson LK, 2000, J INT NEUROPSYCH SOC, V6, P12, DOI 10.1017/S1355617700611025; Demir B, 2002, PSYCHIAT RES-NEUROIM, V115, P115, DOI 10.1016/S0925-4927(02)00071-9; DESOTO CB, 1985, ALCOHOL CLIN EXP RES, V9, P505; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DONOVAN DM, 1984, ALCOHOL CLIN EXP RES, V8, P470, DOI 10.1111/j.1530-0277.1984.tb05704.x; ECKARDT MJ, 1979, BIOL PSYCHIAT, V14, P943; ECKARDT MJ, 1995, AM J PSYCHIAT, V152, P53; Edwin D, 1999, HEPATOLOGY, V30, P1363, DOI 10.1002/hep.510300605; Gaffan D, 2002, J NEUROSCI, V22, P7288; Giancola PR, 1998, RECENT DEV ALCOHOL, V14, P227, DOI 10.1007/0-306-47148-5_10; Godding P., 1992, PSYCHOL ADDICTIVE BE, V6, P34, DOI [10.1037/h0080602, DOI 10.1037/h0080602]; GRANT I, 1987, J CLIN PSYCHIAT, V48, P319; GRANT I, 1987, J CONSULT CLIN PSYCH, V55, P310, DOI 10.1037/0022-006X.55.3.310; HODGINS DC, 1992, J NERV MENT DIS, V180, P197; Ihara H, 2000, J NEUROL NEUROSUR PS, V68, P731, DOI 10.1136/jnnp.68.6.731; Jin H, 1998, J STUD ALCOHOL, V59, P640, DOI 10.15288/jsa.1998.59.640; KISH GB, 1980, J CLIN PSYCHOL, V36, P584, DOI 10.1002/jclp.6120360234; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Kril JJ, 1997, NEUROSCIENCE, V79, P983, DOI 10.1016/S0306-4522(97)00083-3; Kubota M, 2001, J NEUROL NEUROSUR PS, V71, P104, DOI 10.1136/jnnp.71.1.104; Lange G, 2000, ARCH PHYS MED REHAB, V81, P89, DOI 10.1016/S0003-9993(00)90227-2; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LOTFI J, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P2; Macciocchi S N, 1989, Arch Clin Neuropsychol, V4, P365, DOI 10.1016/0887-6177(89)90026-7; Mangels JA, 1996, NEUROPSYCHOLOGY, V10, P32, DOI 10.1037/0894-4105.10.1.32; Mann K, 1999, ALCOHOL ALCOHOLISM, V34, P567, DOI 10.1093/alcalc/34.4.567; MCCRADY BS, 1986, ALCOHOL CLIN EXP RES, V10, P145, DOI 10.1111/j.1530-0277.1986.tb05061.x; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MILLER L, 1991, J SUBST ABUSE TREAT, V8, P277, DOI 10.1016/0740-5472(91)90051-B; Moriyama Y, 2002, ALCOHOL CLIN EXP RES, V26, P1239, DOI 10.1097/01.ALC.0000026103.08053.86; Moscovitch M, 1997, NEUROPSYCHOLOGIA, V35, P1017, DOI 10.1016/S0028-3932(97)00028-6; Moselhy HF, 2001, ALCOHOL ALCOHOLISM, V36, P357, DOI 10.1093/alcalc/36.5.357; Munro CA, 2000, ALCOHOL CLIN EXP RES, V24, P1510, DOI 10.1097/00000374-200010000-00008; Noel X, 2001, ARCH GEN PSYCHIAT, V58, P1152, DOI 10.1001/archpsyc.58.12.1152; PARSONS O A, 1983, Substance and Alcohol Actions-Misuse, V4, P175; PARSONS O A, 1986, Annals of Behavioral Medicine, V8, P13, DOI 10.1207/s15324796abm0802&3_3; Ratti MT, 2002, ACTA NEUROL SCAND, V105, P276, DOI 10.1034/j.1600-0404.2002.0o315.x; REED RJ, 1992, ALCOHOL CLIN EXP RES, V16, P677, DOI 10.1111/j.1530-0277.1992.tb00660.x; Rey A, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI DOI 10.1080/13854049308401883; Rourke SB, 1999, J INT NEUROPSYCH SOC, V5, P234, DOI 10.1017/S1355617799533067; ROURKE SB, 1996, NEUROPSYCHOLOGICAL A, P423; RUFF RM, 1994, ARCH CLIN NEUROPSYCH, V9, P41, DOI 10.1016/0887-6177(94)90013-2; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; SKINNER FK, 1989, ALCOHOL ALCOHOLISM, V24, P129, DOI 10.1093/oxfordjournals.alcalc.a044876; SMITH DE, 1991, ADDICT BEHAV, V16, P265, DOI 10.1016/0306-4603(91)90019-E; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; STOFFELMAYR BE, 1994, J SUBST ABUSE TREAT, V11, P373, DOI 10.1016/0740-5472(94)90048-5; Sullivan EV, 2000, ALCOHOL CLIN EXP RES, V24, P611, DOI 10.1097/00000374-200005000-00005; TUCK RR, 1991, MED J AUSTRALIA, V155, P225, DOI 10.5694/j.1326-5377.1991.tb142226.x; Unkenstein A.E., 1991, CLIN NEUROPSYCHOL, V5, P24; VOLKOW ND, 1994, AM J PSYCHIAT, V151, P178; Wechsler D., 1997, WAIS 3 ADM SCORING M; YOHMAN JR, 1985, ALCOHOL CLIN EXP RES, V9, P114, DOI 10.1111/j.1530-0277.1985.tb05530.x; ZINN S, 2002, J INT NEUROPSYCH SOC, V8, P205	69	85	89	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0145-6008	1530-0277		ALCOHOL CLIN EXP RES	Alcoholism (NY)	SEP	2004	28	9					1338	1346		10.1097/01.ALC.0000139814.81811.62			9	Substance Abuse	Substance Abuse	856VV	WOS:000224074300009	15365304	Green Published			2021-06-18	
J	Hawley, CA; Ward, AB; Magnay, AR; Long, J				Hawley, CA; Ward, AB; Magnay, AR; Long, J			Outcomes following childhood head injury: a population study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; CHILDREN; ADOLESCENTS; REHABILITATION; PERFORMANCE; SEQUELAE; INFANTS	Objectives: To identify outcomes following head injury (HI) among a population of children admitted to one hospital centre and to compare outcomes between different severity groups. Methods: A postal follow up of children admitted with HI to one National Health Service Trust, between 1992 and 1998, was carried out. Children were aged 5-15 years at injury (mean 9.8), followed up at a mean of 2.2 years post-injury. Parents of 526 injured children (419 mild, 58 moderate, 49 severe) and 45 controls completed questionnaires. Outcomes were assessed using the King's Outcome Scale for Childhood Head Injury (KOSCHI). Results: Frequent behavioural, emotional, memory, and attention problems were reported by one third of the severe group, one quarter of the moderate, and 10-18% of the mild. Personality change since HI was reported for 148 children (28%; 21% mild HI, 46% moderate, 69% severe). There was a significant relationship between injury severity and KOSCHI outcomes. Following the HI, 252 (48%) had moderate disability (43% mild HI, 64% moderate, 69% severe), while 270 (51%) made a good recovery (57% mild HI, 36% moderate, 22% severe). There was a significant association between social deprivation and poor outcome (p = 0.002). Only 30% (158) of children received hospital follow up after the HI. All children with severe disability received appropriate follow up, but 64% of children with moderate disability received none. No evidence was found to suggest a threshold of injury severity below which the risk of late sequelae could be safely discounted. Conclusions: Children admitted with mild HI may be at risk of poor outcomes, but often do not receive routine hospital follow up. A postal questionnaire combined with the KOSCHI to assess outcomes after HI may be used to identify children who would benefit from clinical assessment. Further research is needed to identify factors that place children with mild HI at risk of late morbidity.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent ST6 7AG, Staffs, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England	Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				Audit Commission, 2002, STAT ASS STAT SEN NE; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; *HC SEL COMM HLTH, 2001, 3 REP HEAD INJ REH; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; JENNETT B, 1975, LANCET, V1, P480; JOHNSON DA, 1998, ED NEEDS HEAD INJURY; JONES A, 1994, BR J SPEC ED, V21, P113; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; Nash J, 1998, OX MED PUBL, P43; Parmelee D X, 1989, Psychiatr Med, V7, P11; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1993, ARCH PHYSICAL MED RE, V74, P1947; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; Sharples PM, 1998, INJURY YOUNG, P151; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; TEASDALE G, 1974, LANCET, V2, P81; Tellier A, 1999, BRAIN INJURY, V13, P463; Townsend P, 1986, INEQUALITIES HLTH NO	35	85	87	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2004	75	5					737	742		10.1136/jnnp.2003.020651			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	813DB	WOS:000220886700017	15090570	Green Published, Bronze			2021-06-18	
J	Natale, JE; Ahmed, F; Cernak, I; Stoica, B; Faden, AI				Natale, JE; Ahmed, F; Cernak, I; Stoica, B; Faden, AI			Gene expression profile changes are commonly modulated across models and species after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; fluid percussion; gene expression; mRNA	TISSUE-PLASMINOGEN ACTIVATOR; SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; CALCIUM-BINDING PROTEINS; RAT-BRAIN; CORTICAL IMPACT; NEURONAL DEATH; MESSENGER-RNA; HEAT-SHOCK; PERIPHERAL BENZODIAZEPINE	Brain trauma is a major cause of morbidity and mortality, both in adult and pediatric populations. Much of the functional deficit derives from delayed cell death resulting from induction of neurotoxic factors that overwhelm endogenous neuroprotective responses. To identify the potential molecular mechanisms underlying such delayed responses, we compared gene expression patterns using high-density oligonucleotide arrays at 4, 8, 24, and 72 h after moderate levels of lateral fluid percussion-induced brain injury in rats and lateral controlled cortical impact injury in mice (a total of 47 profiles). Expression of 82 genes in 12 functional categories was significantly changed in both species after trauma. The largest number of gene expression changes were found in the functional groups related to inflammation (17%), transcription regulation (16%), and cell adhesion/extracellular matrix (15%). Fifty percent of genes similarly altered across models had not been previously implicated in traumatic brain injury. Of particular interest were expression changes in genes linked to neurodegeneration, such as ATF3 and lysosomal membrane glycoprotein 2, and to neuroprotection including lipocortin 1, calponin 3, gelsolin, Id-1, and p45 NF-E2. Gene expression profiling across species and models may help identify candidate molecular pathways induced by brain injury, some of which may provide novel targets for therapeutic intervention.	Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; Childrens Natl Med Ctr, Neurosci Res Ctr, Washington, DC 20010 USA; Georgetown Univ, Sch Med, Dept Neurosci, Washington, DC USA	Natale, JE (corresponding author), Childrens Natl Med Ctr, Med Genet Res Ctr, 111 Michigan Ave NW, Washington, DC 20010 USA.		Cernak, Ibolja/A-6399-2008; STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Ibolja, Cernak/0000-0003-3214-698X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS041273, R01NS036537] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1P30HD40677-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36537, 1K08 NS41273] Funding Source: Medline		Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BRASSARD M, 1996, CONTROL CHART MEMORY, P288; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; CARRI NG, 1992, INT J DEV NEUROSCI, V10, P393, DOI 10.1016/0736-5748(92)90029-Y; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Fujino I, 1997, NEUROSCI RES, V28, P243, DOI 10.1016/S0168-0102(97)00050-3; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Gong PF, 2002, ANTIOXID REDOX SIGN, V4, P249, DOI 10.1089/152308602753666307; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Hill IE, 1997, BRAIN RES, V751, P206, DOI 10.1016/S0006-8993(96)01403-5; Hussain S, 1996, NEUROCHEM INT, V29, P145, DOI 10.1016/0197-0186(95)00114-X; Iadecola C, 1999, J EXP MED, V189, P719, DOI 10.1084/jem.189.4.719; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKANNA JA, 1993, J NEUROSCI RES, V36, P491, DOI 10.1002/jnr.490360415; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Miyachi T, 2001, NEUROSCI RES, V40, P53, DOI 10.1016/S0168-0102(01)00208-5; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nicole O, 2001, NAT MED, V7, P59; O'Keefe GM, 2001, J IMMUNOL, V166, P2260, DOI 10.4049/jimmunol.166.4.2260; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Plantier M, 1999, EUR J NEUROSCI, V11, P2801, DOI 10.1046/j.1460-9568.1999.00702.x; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rammes A, 1997, J BIOL CHEM, V272, P9496; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rhodes DR, 2002, CANCER RES, V62, P4427; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Tang Y, 2003, J CEREBR BLOOD F MET, V23, P310, DOI 10.1097/01.WCB.0000048518.34839.DE; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3; Young W, 1992, J NEUROTRAUMA S1, V9, P9	74	85	86	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					907	927		10.1089/089771503770195777			21	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300001	14588109				2021-06-18	
J	Suo, ZM; Wu, M; Citron, BA; Gao, CH; Festoff, BW				Suo, ZM; Wu, M; Citron, BA; Gao, CH; Festoff, BW			Persistent protease-activated receptor 4 signaling mediates thrombin-induced microglial activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; MOLECULAR-CLONING; NERVOUS-SYSTEM; BRAIN; INJURY; RAT; THROMBOMODULIN; INFLAMMATION; MECHANISMS; CELLS	We have previously reported that thrombin, the ultimate serine protease in the coagulation cascades, is a proinflammatory agent that causes proliferation and activation of brain microglial cells. However, participation of its principal receptor, the protease-activated receptor 1 (PAR1) appears to be limited to promoting microglial proliferation and not induction of inflammatory mediators. In the present study, we now report that thrombin action in promoting inflammatory mediators from brain microglia is mediated through another thrombin receptor, PAR4. Here we show that the PAR4 agonist peptide (PAR4AP, GYPGKF), but not the PAR1AP (TRAP, SFLLRN), induced tumor necrosis factor-alpha (TNF-alpha) production not only in cultured murine microglial cells in vitro but also in rat cortex in vivo. Down-regulation of PAR4 expression in microglial cultures by a specific antisense, but not a sense, oligonucleotide reduced PAR4AP- induced TNF-alpha. Mechanistic studies indicated that, in comparison with PAR1 signaling, prolonged increase of [Ca2+](i) and phosphorylation of p44/42 mitogen-activated protein kinases, as well as NFkappaB activation may be responsible for PAR4AP-induced TNF-alpha production in microglia. Taken together, these results demonstrate that PAR4 activation mediates the potentially detrimental effects of thrombin on microglia, implying that perspectives of exploiting PAR1 as a potential anti-inflammatory target should be shifted toward PAR4 as a much more specific therapeutic target in brain inflammatory conditions associated with neurotrauma and neurodegenerations.	Vet Affairs Med Ctr, Lab Alzheimers Dis & Aging Res, Kansas City, MO 64128 USA; Vet Affairs Med Ctr, Mol Biol Res Lab, Kansas City, MO 64128 USA; Vet Affairs Med Ctr, Neurobiol Res Lab, Kansas City, MO 64128 USA; Univ Kansas, Dept Neurol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Pharmacol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Toxicol, Sch Med, Kansas City, KS 66170 USA; Univ Kansas, Dept Therapeut, Sch Med, Kansas City, KS 66170 USA	Suo, ZM (corresponding author), Vet Affairs Med Ctr, Lab Alzheimers Dis & Aging Res, 4801 Linwood Blvd, Kansas City, MO 64128 USA.	zsuo@kumc.edu					AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; DESCHEPPER CF, 1991, MOL BRAIN RES, V11, P355, DOI 10.1016/0169-328X(91)90045-Y; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FESTOFF BW, 1997, NEUROPROTECTIVE SIGN, P221; FESTOFF BW, 1992, HDB AMYOTROPHIC LATE, V12, P661; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; HO GJ, 1994, BIOMED PHARMACOTHER, V48, P296, DOI 10.1016/0753-3322(94)90175-9; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Mollison J, 2002, J FAM PLAN REPROD H, V28, P101, DOI 10.1783/147118902101196072; Nakanishi-Matsui M, 2000, NATURE, V404, P609; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Pindon A, 1997, GLIA, V19, P259, DOI 10.1002/(SICI)1098-1136(199703)19:3<259::AID-GLIA8>3.3.CO;2-L; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Ruscher K, 2000, J BIOTECHNOL, V78, P163, DOI 10.1016/S0168-1656(00)00207-8; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Sarker KP, 1999, THROMB HAEMOSTASIS, V82, P1071; Shapiro MJ, 2000, J BIOL CHEM, V275, P25216, DOI 10.1074/jbc.M004589200; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Strukova SM, 2001, BIOCHEMISTRY-MOSCOW+, V66, P8, DOI 10.1023/A:1002869310180; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Suo ZM, 2002, J NEUROCHEM, V80, P655, DOI 10.1046/j.0022-3042.2001.00745.x; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	36	85	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					31177	31183		10.1074/jbc.M302137200			7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	710AN	WOS:000184658800095	12775717	Other Gold			2021-06-18	
J	Alderman, N				Alderman, N			Contemporary approaches to the management of irritability and aggression following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; NEUROPSYCHIATRIC SEQUELAE; COGNITIVE THERAPY; OVERT AGGRESSION; CLINICAL-USE; OAS-MNR; BEHAVIOR; REHABILITATION; REDUCTION; MILD	In this paper, the principal means of managing irritability and aggression following traumatic brain injury (TBI) will be briefly reviewed. The paper will initially consider the prevalence of irritability, what it is and some of the likely causes that drive the condition. Aggression will then be similarly contemplated. Prior to a discussion regarding those methods most regularly employed in their management, the attention of the reader will be directed to a range of methodological issues that need to be considered in relation to reporting treatment efficacy, including lack of homogeneity and the need to use standardised assessment tools. Three principal management approaches will then be described and appraised, these being pharmacology, psychotherapy, and behaviour therapy. Within the discussion of psychotherapeutic methods, special mention will be made with regard to use of cognitive behaviour therapy, and two detailed case studies will be employed to illustrate issues relating to both cognitive behaviour therapy and behaviour therapy.	St Andrews Hosp, Kemsley Div, Northampton NN1 5DG, England	Alderman, N (corresponding author), St Andrews Hosp, Kemsley Div, Northampton NN1 5DG, England.			Alderman, Nick/0000-0002-8523-4142			ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Alderman N, 2001, BRAIN DAM B, P175; ALDERMAN N, 1991, Brain Injury, V5, P77, DOI 10.3109/02699059108998516; Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Alderman N, 1999, NEUROPSYCHOL REHABIL, V9, P385, DOI 10.1080/096020199389455; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Alderman N, 1997, BRAIN INJURY, V11, P79, DOI 10.1080/026990597123683; Alderman N., 2002, EVIDENCE MENTAL HLTH; ALDERMAN N, 1992, PHYSIOTHERAPY, V78, P335; ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; ALDERMAN N, 2002, NEUROLOGICAL REHABIL; Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; Beck A., 1979, COGNITIVE THERAPY EM; Beck A. T., 1979, COGNITIVE THERAPY DE; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; BURGESS PW, 1990, COGNITIVE REHABILITA; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQ; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; CLARK DM, 1986, BEHAV PSYCHOTHER, V14, P283, DOI 10.1017/S0141347300014907; CLARK DM, 1994, BRIT J PSYCHIAT, V164, P759, DOI 10.1192/bjp.164.6.759; CLARK DM, 1989, COGNITIVE BEHAV THER; DAVIS JR, 1994, BRAIN INJURY, V8, P589, DOI 10.3109/02699059409151011; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; Demark J, 2002, BRAIN INJURY, V16, P91, DOI 10.1080/02699050110102059; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Eames P, 1985, Int Rehabil Med, V7, P130; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; Eames P. G., 1990, NEUROBEHAVIOURAL SEQ; Eames PG, 2001, BRAIN DAM B, P29; FOSTER HG, 1989, PROG NEURO-PSYCHOPH, V13, P865, DOI 10.1016/0278-5846(89)90038-9; GIAKAS WJ, 1990, J CLIN PSYCHIAT, V51, P525; Gibbs JC, 1996, AGGRESS VIOLENT BEH, V1, P283, DOI 10.1016/1359-1789(95)00018-6; GILES GM, 1988, REHABILITATION SEVER; GOLL S, 1988, MODELS BRAIN INJURY; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; HAAGA DA, 1986, HELPING PEOPLE CHANG; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hawton K.E., 1989, COGNITIVE BEHAV THER; Hayes N, 1997, ARCH CLIN NEUROPSYCH, V12, P333; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; HIRSCH J, 1993, HEADLINES        MAR, P10; JACKSON WT, 1992, HDB HEAD TRAUMA ACUT; Jahoda A, 2001, BRIT J MED PSYCHOL, V74, P305, DOI 10.1348/000711201161000; JOHNSTON S, 1991, J NEUROL NEUROSUR PS, V54, P272, DOI 10.1136/jnnp.54.3.272; JONES RSP, 1993, PEOPLE SEVERE LEARNI; Kanfer F.H, 1986, HELPING PEOPLE CHANG; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Kinney A., 2001, J CONTEMP PSYCHOTHER, V31, P89, DOI DOI 10.1023/A:1010261422373; LEWIN J, 1992, BRIT J PSYCHIAT, V161, P261, DOI 10.1192/bjp.161.2.261; LONG CJ, 1995, NEUROPSYCHOLOGICAL A; Manchester D, 2001, BRAIN DAM B, P157; MATEER CA, 1990, NEUROBEHAVIOURAL SEQ; Mattes J A, 1990, J Neuropsychiatry Clin Neurosci, V2, P159; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCMILLAN T M, 1990, Brain Injury, V4, P399, DOI 10.3109/02699059009026193; McMillan TM, 2001, NEUROBEHAVIOURAL DIS; MEICHENBAUM D, 1986, HELPING PEOPLE CHANG; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; MONROE RR, 1989, COMPR PSYCHIAT, V30, P489, DOI 10.1016/0010-440X(89)90078-3; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; PATTERSON CH, 1986, THEORIES COUNSELLING; POWELL GE, 1981, BRAIN FUNCTION THERA; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1987, BNI Q, V3, P2; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Reeder D M, 1991, Arch Psychiatr Nurs, V5, P147, DOI 10.1016/0883-9417(91)90015-W; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; ROHRBAUGH RM, 1988, J AM GERIATR SOC, V36, P736, DOI 10.1111/j.1532-5415.1988.tb07177.x; Sartorius N, 1974, MEASUREMENT CLASSIFI; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; Scott J, 1997, CURR OPIN PSYCHIATR, V10, P256, DOI 10.1097/00001504-199705000-00016; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; Starkstein S. E., 1991, FRONTAL LOBE FUNCTIO; STEIN G, 1992, BRIT J PSYCHIAT, V161, P167, DOI 10.1192/bjp.161.2.167; SUKHODOLSKY DG, 2000, J CHILD ADOLESC GROU, V10, P159, DOI DOI 10.1023/A:1009488701736; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLIAMS WH, 1997, COGNITIVE BEHAV THER; Wilson B., 1989, PRACTICE BEHAV MED; WOOD R, 1988, J HEAD TRAUMA REHAB, V3, P53; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood R. L. L., 1981, APPL CONDITIONING TH; Wood R. L1., 1990, NEUROBEHAVIOURAL SEQ; Wood RL, 2001, NEUROBEHAVIOURAL DIS; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	96	85	87	0	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		211	240		10.1080/09602010244000327			30	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500012	21854335				2021-06-18	
J	Shirvan, A; Kimron, M; Holdengreber, V; Ziv, I; Ben-Shaul, Y; Melamed, S; Melamed, E; Barzilai, A; Solomon, AS				Shirvan, A; Kimron, M; Holdengreber, V; Ziv, I; Ben-Shaul, Y; Melamed, S; Melamed, E; Barzilai, A; Solomon, AS			Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE COLLAPSE; IN-VIVO; AXON GUIDANCE; ADULT-RATS; NEURONAL APOPTOSIS; MOLECULAR-BIOLOGY; TRANSGENIC MICE; III COLLAPSIN-1; HUMAN BRAIN; EXPRESSION	Damage to the optic nerve in mammals induces retrograde degeneration and apoptosis of the retinal ganglion cell (RGC) bodies. The mechanisms that mediate the response of the neuronal cells to the axonal injury are still unknown. We have previously shown that semaphorins, axon guidance molecules with repulsive cues, are capable of mediating apoptosis in cultured neuronal cells (Shirvan, A., Ziv, I., Fleminger, G., Shina, R., He, Z., Brudo, I., Melamed, E., and Brazilai, A. (1999) J. Neurochem. 73, 961-971). In this study, we examined the involvement of semaphorins in an in vivo experimental animal model of complete axotomy of the rat optic nerve. We demonstrate that a marked induction of type III semaphorin proteins takes place in ipsilateral retinas at early stages following axotomy, well before any morphological signs of RGC apoptosis can be detected. Time course analysis revealed that a peak of expression occurred after 2-3 days and then declined. A small conserved peptide derived from semaphorin 3A that was previously shown to induce neuronal death in culture was capable of inducing RGC loss upon its intravitreous injection into the rat eye. Moreover, we demonstrate a marked inhibition of RGC loss when axotomized eyes were co-treated by intravitreous injection of function-blocking antibodies against the semaphorin 3A-derived peptide. Marked neuronal protection from degeneration was also observed when the antibodies were applied 24 h post-injury. We therefore suggest that semaphorins are key proteins that modulate the cell fate of axotomized RGC. Neutralization of the semaphorin repulsive function may serve as a promising new approach for treatment of traumatic injury in the adult mammalian central nervous system or of opthalmologic diseases such as glaucoma and ischemic optic neuropathy that induce apoptotic RGC death.	Rabin Med Ctr, Dept Neurol, IL-49100 Petah Tiqwa, Israel; Rabin Med Ctr, Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel; Sackler Sch Med, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, San Rothberg Glaucoma Ctr, Goldschleger Eye Res Inst, IL-69978 Tel Aviv, Israel	Shirvan, A (corresponding author), NST Ltd, 5 Odem St, IL-49170 Petah Tiqwa, Israel.		Solomon, Arieh/AAF-4361-2021				Adamus G, 1998, J AUTOIMMUN, V11, P523, DOI 10.1006/jaut.1998.0221; Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagnard D, 1998, DEVELOPMENT, V125, P5043; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bonfanti L, 1996, J NEUROSCI, V16, P4186; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Chierzi S, 1998, VISION RES, V38, P1537, DOI 10.1016/S0042-6989(97)00332-5; Cuevas P, 1998, NEUROSCI LETT, V255, P1, DOI 10.1016/S0304-3940(98)00672-7; Delaire S, 1998, CELL MOL LIFE SCI, V54, P1265, DOI 10.1007/s000180050252; Djamgoz MBA, 1996, J NEUROSCI METH, V64, P237, DOI 10.1016/0165-0270(95)00109-3; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; Fujita H, 2001, BRAIN RES, V914, P1, DOI 10.1016/S0006-8993(01)02765-2; Gagliardini V, 1999, MOL CELL NEUROSCI, V14, P301, DOI 10.1006/mcne.1999.0787; GARCIAVALENZUEL.E, 1994, EXP EYE RES, V61, P33; Giger RJ, 1998, J NEUROSCI RES, V52, P27, DOI 10.1002/(SICI)1097-4547(19980401)52:1<27::AID-JNR4>3.0.CO;2-M; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; HARLOW E, 1988, LAB MANUAL, P490; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hirsch E, 1999, BRAIN RES, V823, P67, DOI 10.1016/S0006-8993(99)01103-8; Isenmann S, 1999, CELL DEATH DIFFER, V6, P673, DOI 10.1038/sj.cdd.4400538; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Isenmann S, 1997, EXP NEUROL, V147, P28, DOI 10.1006/exnr.1997.6585; Jin Z, 1997, J NEUROSCI, V17, P6256; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kermer P, 1998, J NEUROSCI, V18, P4656; Koeberle PD, 1998, VISION RES, V38, P1505, DOI 10.1016/S0042-6989(97)00364-7; Kolodkin AL, 1998, PROG BRAIN RES, V117, P115; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Lafuente MP, 2001, INVEST OPHTH VIS SCI, V42, P2074; Lambiase A, 1997, GRAEF ARCH CLIN EXP, V235, P780, DOI 10.1007/BF02332863; Lazarov-Spiegler O, 1999, VISION RES, V39, P169, DOI 10.1016/S0042-6989(98)00089-3; Levin LA, 1999, SURV OPHTHALMOL, V43, pS98, DOI 10.1016/S0039-6257(99)00027-2; Lieberman A.R., 1974, ESSAYS NERVOUS SYSTE, P71; Lucius R, 1997, MOL BRAIN RES, V48, P181, DOI 10.1016/S0169-328X(97)00170-8; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Mark MD, 1997, CELL TISSUE RES, V290, P299, DOI 10.1007/s004410050934; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101; Nieto MA, 1996, NEURON, V17, P1039, DOI 10.1016/S0896-6273(00)80237-8; Ohguro H, 1999, INVEST OPHTH VIS SCI, V40, P3160; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 1998, EXP NEUROL, V153, P313, DOI 10.1006/exnr.1998.6886; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; RABACCHI SA, 1994, J NEUROSCI, V14, P5292; Schwartz M, 1996, J GLAUCOMA, V5, P427; Seigel G M, 1997, Mol Vis, V3, P14; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Shirvan A, 2000, MOL BRAIN RES, V83, P81, DOI 10.1016/S0169-328X(00)00198-4; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; So KF, 1998, VISION RES, V38, P1525, DOI 10.1016/S0042-6989(97)00226-5; Solomon AS, 1996, J NEUROSCI METH, V70, P21, DOI 10.1016/S0165-0270(96)00098-2; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Tanelian DL, 1997, NAT MED, V3, P1398, DOI 10.1038/nm1297-1398; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THANOS S, 1995, J NEUROSCI, V15, P1057, DOI 10.1523/jneurosci.15-02-01057.1995; THANOS S, 1993, J NEUROSCI, V13, P455; Van Vactor D, 1999, CURR BIOL, V9, pR201; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Verma MJ, 1999, INVEST OPHTH VIS SCI, V40, P2465; VILLEGASPEREZ MP, 1988, J NEUROSCI, V8, P265; Xu XM, 1998, J BIOL CHEM, V273, P22428, DOI 10.1074/jbc.273.35.22428; Yamada T, 1997, P NATL ACAD SCI USA, V94, P14713, DOI 10.1073/pnas.94.26.14713; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Yu HH, 1999, NEURON, V22, P11, DOI 10.1016/S0896-6273(00)80672-8	69	85	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49799	49807		10.1074/jbc.M204793200			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	629AU	WOS:000180028900093	12376549	Other Gold			2021-06-18	
J	Heinemann, AW; Sokol, K; Garvin, L; Bode, RK				Heinemann, AW; Sokol, K; Garvin, L; Bode, RK			Measuring unmet needs and services among persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference on TBI in the 21st Century	DEC 02, 1999	BETHESDA, MD			brain injuries; health services; health services needs and demand; psychometrics; rehabilitation	HEAD-INJURY; LIFE; QUALITY; STATE	Objectives: (1) To develop a comprehensive list of needs and services appropriate for persons with traumatic brain injury (TBI); (2) to determine whether these needs and services formed unidimensional hierarchies from least common to most common; (3) to describe the relationship between unmet needs and services received; and (4) to estimate the extent to which a variety of demographic, injury, and service characteristics predict unmet needs. Design: Statewide mailed survey. Setting: Illinois communities. Participants: A total of 895 persons who had had a TBI recruited from Brain Injury Association members and rehabilitation service recipients. The median time post-TBI was 7 years; the median age was 37 years. Interventions: Not applicable. Main Outcome Measures: A 27-item instrument assessing service needs and utilization of services, and equal-interval measures of needs and services derived with Rasch analysis. Results: The most prevalent unmet needs were improving memory or problem-solving skills (51.9%), increasing income (50.5%), and improving job skills (46.3%). The instrument defined unidimensional and reliable constructs of needs and services. Persons with greater unmet needs tended to receive fewer services; to report lower life satisfaction and worse medical health and psychologic well-being since injury; to be younger, single, black, dependent in 1 or more daily activities; and to have more recent injuries. Conclusions: The results show the common pattern of unmet needs and services and emphasize the importance of comprehensive, statewide assessment of services and needs in developing policies.	Rehabil Inst Chicago, Ctr Rehabil Outcome Res, Chicago, IL 60611 USA; Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Chicago, IL 60611 USA; US Govt Accounting Off, Chicago, IL USA; Loyola Univ, Chicago, IL 60611 USA	Heinemann, AW (corresponding author), Rehabil Inst Chicago, Ctr Rehabil Outcome Res, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326			Allen SM, 1997, MED CARE, V35, P1132, DOI 10.1097/00005650-199711000-00005; ALSTON RJ, 1992, J APPL REHABILITATIO, V23, P12; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FRIEMAN M, 1998, HLTH SERV RES 1, V33, P867; GORDON W, 1999, LIVING LIFE TBI PUBL; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; LINACRE JM, 2000, WINSTEPS PC COMPATIB; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PATRICK DL, 1989, DISABLEMENT COMMUNIT; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rasch G., 1980, PROBABILISTIC MODELS; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wright B. D., 1982, RATING SCALE ANAL RA	23	85	86	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2002	83	8					1052	1059		10.1053/apmr.2002.34283			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	580QG	WOS:000177244800003	12161825				2021-06-18	
J	Nesic, O; Svrakic, NM; Xu, GY; McAdoo, D; Westlund, KN; Hulsebosch, CE; Ye, ZM; Galante, A; Soteropoulos, P; Tolias, P; Young, W; Hart, RP; Perez-Polo, JR				Nesic, O; Svrakic, NM; Xu, GY; McAdoo, D; Westlund, KN; Hulsebosch, CE; Ye, ZM; Galante, A; Soteropoulos, P; Tolias, P; Young, W; Hart, RP; Perez-Polo, JR			DNA microarray analysis of the contused spinal cord: Effect of NMDA receptor inhibition	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						spinal cord injury; NMDA receptor; MK-801; DNA microarray; Affymetrix; expression profile	MESSENGER-RNA EXPRESSION; KAPPA-B ACTIVATION; FUNCTIONAL RECOVERY; GENE-EXPRESSION; CELLULAR-LOCALIZATION; TRANSCRIPTION FACTORS; IMPACT INJURY; BRAIN-INJURY; C-FOS; RAT	Spinal cord injury (SCI)-induced neurodegeneration leads to irreversible and devastating motor and sensory dysfunction. Post-traumatic outcomes are determined by events occurring during the first 24 hours after SCI. An increase in extracellular glutamate concentration to neurotoxic levels is one of the earliest events after SCI. We used Affymetrix DNA oligonucleotide microarrays (with 1,322 DNA probes) analysis to measure gene expression in order to test the hypothesis that SCI-induced N-methyl-D-aspartate (NMDA) receptor activation triggers significant postinjury transcriptional changes. Here we report that SCI, 1 hour after trauma, induced change in mRNA levels of 165 genes and expression sequence tags (ESTs). SCI affected mRNA levels of those genes that regulate predominantly transcription factors, inflammation, cell survival, and membrane excitability. We also report that NMDA receptor inhibition (with -(+)-5-methyl-10,11 -dihydro-5H-dibenzo[a,d]-cyclohepten-5, 10-imine hydrogen maleate [MK-801]) reversed the effect of SCI on about 50% of the SCI-affected mRNAs. Especially interesting is the finding that NMDA receptor activation participates in the up-regulation of inflammatory factors. Therefore, SCI-induced NMDA receptor activation is one of the dominant, early signals after trauma that leads to changes in mRNA levels of a number of genes relevant to recovery processes. The majority of MK-801 effects on the SCI-induced mRNA changes reported here are novel. Additionally, we found that the MK-801 treatment also changed the mRNA levels of 168 genes and ESTs that had not been affected by SCI alone, and that some of their gene products could have harmful effects on SCI outcome. (C) 2002 Wiley-Liss, Inc.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Inst Marine Biomed, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77550 USA; Washington Univ, St Louis, MO USA; Publ Hlth Res Inst, Ctr Appl Genomics, Newark, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA; UND, New Jersey Med Sch, Newark, NJ USA	Nesic, O (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 4 Floor,301 Univ Blvd, Galveston, TX 77555 USA.	olnesic@utmb.edu	Westlund, Karin/R-6960-2019; nesic, olivera/C-6456-2012; Perez-Polo, Jose R./B-6250-2009	Westlund High, Karin/0000-0002-7388-4834	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS011255] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS011255] Funding Source: NIH RePORTER		Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 2000, PROG BRAIN RES, V128, P33; Bethea JR, 1998, J NEUROSCI, V18, P3251; BUNGE RP, 1993, ADV NEUROL, V59, P75; Butte A J, 2001, Pac Symp Biocomput, P6; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; GADIENT RA, 1994, NEUROSCI LETT, V182, P243, DOI 10.1016/0304-3940(94)90807-9; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.0.CO;2-A; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Haghighi SS, 2000, SPINAL CORD, V38, P733, DOI 10.1038/sj.sc.3101074; Hamada Y, 1996, NEUROSCI LETT, V203, P97, DOI 10.1016/0304-3940(95)12271-0; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; HUMPEL C, 1994, EXP BRAIN RES, V98, P229; JACKSON GR, 1996, PARADIGMS NEURAL INJ, P1; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; Kent TA, 1999, J NEUROSCI RES, V55, P357, DOI 10.1002/(SICI)1097-4547(19990201)55:3<357::AID-JNR11>3.0.CO;2-W; Lai M, 1997, NEUROREPORT, V8, P2691, DOI 10.1097/00001756-199708180-00011; LI S, 1997, SPINAL CORD, V12, P820; Li SX, 2000, NEUROL RES, V22, P171, DOI 10.1080/01616412.2000.11758605; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; Luque JM, 2001, NEUROSCI LETT, V305, P87, DOI 10.1016/S0304-3940(01)01833-X; McAdoo DJ, 1999, EXP NEUROL, V159, P538, DOI 10.1006/exnr.1999.7166; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; McTigue DM, 2000, PROG BRAIN RES, V128, P3; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pulford BE, 1999, EXP NEUROL, V159, P114, DOI 10.1006/exnr.1999.7143; Qin ZH, 2000, MOL BRAIN RES, V80, P111, DOI 10.1016/S0169-328X(00)00147-9; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Ringheim GE, 1995, J NEUROIMMUNOL, V63, P113, DOI 10.1016/0165-5728(95)00134-4; Sallmann S, 2000, J NEUROSCI, V20, P8637; Sapolsky RM, 2001, J NEUROCHEM, V76, P1601, DOI 10.1046/j.1471-4159.2001.00203.x; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; Schulze A, 2001, NAT CELL BIOL, V3, pE190, DOI 10.1038/35087138; Segal JL, 1997, ARCH PHYS MED REHAB, V78, P44, DOI 10.1016/S0003-9993(97)90008-3; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tuna M, 2001, J NEUROSURG, V95, P64, DOI 10.3171/spi.2001.95.1.0064; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; VandeMeent H, 1996, J NEUROTRAUM, V13, P741; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Wong CS, 1998, ANESTH ANALG, V87, P605, DOI 10.1097/00000539-199809000-00021; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yan CH, 2000, J CEREBR BLOOD F MET, V20, P620, DOI 10.1097/00004647-200003000-00020; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257; J NEUROPATHOL EXP NE, V60, P422	67	85	89	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 15	2002	68	4					406	423		10.1002/jnr.10171			18	Neurosciences	Neurosciences & Neurology	550AN	WOS:000175481100004	11992467	Bronze			2021-06-18	
J	Wardlaw, JM; Easton, VJ; Statham, P				Wardlaw, JM; Easton, VJ; Statham, P			Which CT features help predict outcome after head injury?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							COMA DATA-BANK; COMPUTERIZED-TOMOGRAPHY; CLASSIFICATION; VARIABLES; LESION	Background: Information collected at baseline can be useful in predicting patient outcome after head injury. The appearance of the CT brain scan may add useful baseline information. The aim of this study was to evaluate which features on the admission CT scan might add significantly to other baseline clinical information for predicting survival in patients with head injury. Methods: Baseline CT scans were reviewed for patients with all grades of traumatic head injury in a head injury registry, in which baseline demographic and injury status and outcome at 1 year were recorded. Details from the CT scan on haemorrhage, brain swelling, and focal or diffuse damage were noted blind to clinical or outcome information and the scans classified according to the simple seven point grading (normal, mild, moderate, or severe focal injury, mild, moderate, or severe diffuse injury). An existing CT scoring system, the trauma coma databank (TCDB) classification, was also used. Logistic regression modelling was used to test the value of the CT appearance, in addition to the other baseline clinical characteristics, in predicting survival at 1 year. Results: 425 CT scans were read from patients with all severities of injury. Significant independent outcome predictors were age, Glasgow coma score (GCS), pupil reaction, presence of subarachnoid blood, and the simple grading of the overall appearance of the scan (all p<0.001). The TCDB classification was not a significant predictor of outcome. Conclusion: Age, GCS, and pupil reaction were all previously shown to be significant predictors of patient survival after head injury. A further two, easy to identify, CT scan variables are independent prognostic variables, and might help to identify patients at high risk of death at the time of admission.	Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Wardlaw, JM (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.						ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Hosmer D, 1989, APPL LOGISTIC REGRES; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Poca MA, 1998, ACT NEUR S, V71, P27; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TEASDALE E, 1996, NEURORADIOLOGY, V38, P192; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L	19	85	90	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2002	72	2					188	192		10.1136/jnnp.72.2.188			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	515AA	WOS:000173472200010	11796768	Green Published, Bronze			2021-06-18	
J	Borgens, RB; Shi, RY; Bohnert, D				Borgens, RB; Shi, RY; Bohnert, D			Behavioral recovery from spinal cord injury following delayed application of polyethylene glycol	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						spinal injury; neurotrauma; spinal cord; nerve injury; central nervous system injury; fusogen; polyethylene glycol; guinea pia	APPLIED ELECTRIC-FIELDS; GUINEA-PIG; MEMBRANE-FUSION; AXONS; 4-AMINOPYRIDINE; METHYLPREDNISOLONE; HEMISECTION; MECHANISM; GROWTH; REPAIR	Topical application of the hydrophilic polymer polyethylene glycol (PEG) to isolated adult guinea pig spinal cord injuries has been shown to lead to the recovery of both the anatomical integrity of the tissue and the conduction of nerve impulses through the lesion. Furthermore, a brief (2 min) application of the fusogen (M-r 1800, 50 % w/v aqueous solution) to the exposed spinal cord injury in vivo can also cause rapid recovery of nerve impulse conduction through the lesion in association with functional recovery. Behavioral recovery was demonstrated using a long-tract, spinal-cord-dependent behavior in rodents known as the cutaneus trunci muscle (CTM) reflex. This reflex is observed as a contraction of the skin of the back in response to tactile stimulation. Here, we confirm and extend these preliminary observations. A severe compression/contusion injury to the exposed thoracic spinal cord of the guinea pig was performed between thoracic vertebrae 10 and 11. Approximately 7 h later, a topical application of PEG was made to the injury (dura removed) for 2 min in 15 experimental animals, and levels of recovery were compared with those of 13 vehicle-treated control animals. In PEG-treated animals, 93 % recovered variable levels of CTM functioning and all recovered some level of conduction through the lesion, as measured by evoked potential techniques. The recovered reflex was relatively normal compared with the quantitative characteristics of the reflex prior to injury with respect to the direction, distance and velocity of skin contraction. Only 23 % of the control population showed any spontaneous CTM recovery (P=0.0003) and none recovered conduction through the lesion during the 1 month period of observation (P=0.0001). These results suggest that repair of nerve membranes by polymeric sealing can provide a novel means for the rapid restoration of function following spinal cord injury.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Inst Appl Neurol,Ctr Paralysis Res, W Lafayette, IN 47907 USA	Borgens, RB (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Inst Appl Neurol,Ctr Paralysis Res, W Lafayette, IN 47907 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039288] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39288-01] Funding Source: Medline		ASANO T, 1995, J NEUROTRAUM, V12, P993; Benowitz LI, 1999, P NATL ACAD SCI USA, V96, P13486, DOI 10.1073/pnas.96.23.13486; Blight A, 1988, J Am Paraplegia Soc, V11, P26; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1986, J COMP NEUROL, V250, P168, DOI 10.1002/cne.902500204; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 2001, IN PRESS NEUROSCI RE; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; BORGENS RB, 2001, IN PRESS J NEUROSURG; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bregman B. S., 1996, Society for Neuroscience Abstracts, V22, P764; COLLINS WF, 1979, NEURAL TRAUMA, P273; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; Duerstock BS, 2000, COMPUT MED IMAG GRAP, V24, P389, DOI 10.1016/S0895-6111(00)00034-3; Duerstock BS, 2002, J EXP BIOL, V205, P13; Griffin John W., 1995, P375; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; HANSEBOUT RR, 1993, J NEUROTRAUM, V10, P1, DOI 10.1089/neu.1993.10.1; HAYES KC, 1993, PARAPLEGIA, V31, P216, DOI 10.1038/sc.1993.40; Honmou Osamu, 1995, P480; KRAUSE TL, 1994, J NEUROSCI, V14, P6638; LazarovSpiegler O, 1996, FASEB J, V10, P1296; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; MALMGREN L, 1977, J HISTOCHEM CYTOCHEM, V25, P1280, DOI 10.1177/25.11.915248; MARKS JM, 2001, IN PRESS FASEB J; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; THIERAULT E, 1988, J NEUROPHYSIOL, V60, P446	46	85	88	0	10	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0022-0949			J EXP BIOL	J. Exp. Biol.	JAN	2002	205	1					1	12					12	Biology	Life Sciences & Biomedicine - Other Topics	516DH	WOS:000173536200001	11818407				2021-06-18	
J	Paniak, C; Reynolds, S; Toller-Lobe, G; Melnyk, A; Nagy, J; Schmidt, D				Paniak, C; Reynolds, S; Toller-Lobe, G; Melnyk, A; Nagy, J; Schmidt, D			A longitudinal study of the relationship between financial compensation and symptoms after treated mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; RANDOMIZED TRIAL; LITIGATION; MMPI-2	Demographic, injury-related, and symptom variables at intake, 3 months, and 12 months postinjury were compared between 50 treated adults with mild traumatic brain injury (MTBI) who were not seeking or receiving financial compensation at any time and 18 who were at each time. Compensation seekers/receivers reported symptom incidence and severity as approximately 1 SD higher at each time. The level of difference between the groups did not significantly differ across time. No demographic variables distinguished the groups. No injury-related variable other than more immediate postinjury prescription medication use was predictive of the greater symptom complaints for the patients seeking or receiving compensation. However, this medication effect did not explain away the compensation effect when medication use was co-varied in an analysis. Our study appears to be the first to examine the relationship between financial compensation and symptom report in an MTBI sample specifically treated for their condition. Our results indicate that even highly patient-rated treatment is not adequate to wash out the strong relationship between financial compensation status and symptom report after MTBI.	Glenrose Rehabil Hosp, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada	Paniak, C (corresponding author), Glenrose Rehabil Hosp, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM MED ASS, 1995, AMA DRUG EV; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER RL, 1991, AM J PSYCHIAT, V148, P1073; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Deb S, 1999, AM J PSYCHIAT, V156, P374; DUSH DM, 1994, J PERS ASSESS, V62, P299, DOI 10.1207/s15327752jpa6202_10; GREIFFENSTEIN MF, 2001, J INT NEUROPSYCH SOC, V7, P181; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; MENDELSON G, 1995, J PSYCHOSOM RES, V39, P695, DOI 10.1016/0022-3999(94)00154-W; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	21	85	85	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	2					187	193		10.1076/jcen.24.2.187.999			7	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	549MN	WOS:000175448100006	11992201				2021-06-18	
J	Raghupathi, R; Conti, AC; Graham, DI; Krajewski, S; Reed, JC; Grady, MS; Trojanowskii, JQ; McIntosh, TK				Raghupathi, R; Conti, AC; Graham, DI; Krajewski, S; Reed, JC; Grady, MS; Trojanowskii, JQ; McIntosh, TK			Mild traumatic brain injury induces apoptotic cell death in the cortex that is preceded by decreases in cellular Bcl-2 immunoreactivity	NEUROSCIENCE			English	Article						head injury; apoptosis; Bcl-2; Bax. white matter; hippocampus	CORTICAL IMPACT INJURY; SPINAL-CORD INJURY; HEAD-INJURY; TRANSGENIC MICE; NEURONAL APOPTOSIS; DNA FRAGMENTATION; CEREBRAL-ISCHEMIA; IN-VIVO; RAT; OVEREXPRESSION	Although mild traumatic brain injury is associated with behavioral dysfunction and histopathological alterations. few studies have assessed the temporal pattern of regional apoptosis following mild brain injury. Anesthetized rats were subjected to mild lateral fluid-percussion brain injury (1.1-1.3 atm), and brains were evaluated for the presence of in situ DNA fragmentation (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling, TUNEL) and morphologic characteristics of apoptotic cell death (nuclear and cytoplasmic condensation, presence of apoptotic bodies). Significant numbers of apoptotic TUNEL(+) cells were observed in the injured parietal cortex and underlying white matter up to 72 It post-injury (P < 0.05 compared to sham-injured-injured), with maximal numbers present at 24 h. Apoptosis was confirmed by the presence of 180-200 bp nuclear DNA fragments in tissue homogenates. The appearance of apoptotic TUNEL(+) cells in the injured cortex was preceded by a marked decrease in immunoreactivity for the anti-cell death protein, Bcl-2, as early as 2 h post-injury. This decrease in cellular Bcl-2 staining was not accompanied by a concomitant loss of staining for the pro-cell death Bax protein, suggesting that post-traumatic neuronal death in the cortex may be dependent on altered cellular ratios of Bcl-2:Bax. In the hippocampus, no significant increase in apoptotic TUNEL(+) cells was observed compared to sham-injured-injured animals. However, selective neuronal loss was evident in the CA3 region at 24 h post-injury, that was preceded by an overt loss of neuronal Bcl-2 immunoreactivity at 6 h. No changes in either cellular Bcl-2 or Bax expression were observed in the thalamus or white matter at any time post-injury. Taken together from these data, we suggest that apoptosis contributes to cell death in both gray and white matter, and that decreases in cellular Bcl-2 may, in part, be associated with both apoptotic and non-apoptotic cell death following mild brain trauma. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; So Gen Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland; Burnham Inst Canc Res, La Jolla, CA USA	Raghupathi, R (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Room 113,Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	rramesh@mail.med.upenn.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-10124, AG-09125] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36821, NS40978, P50-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS036821, R01NS040978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124] Funding Source: NIH RePORTER		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; FUNG KM, 1995, AM J PATHOL, V146, P1376; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Lawrence MS, 1996, J NEUROSCI, V16, P486; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERINI S, 1984, NEUROL CLIN, V2, P719, DOI 10.1016/S0733-8619(18)31071-5; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, pS494; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Regan RF, 1996, J NEUROTRAUM, V13, P223, DOI 10.1089/neu.1996.13.223; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tanaka M, 1997, CHIRALITY, V9, P17, DOI 10.1002/(SICI)1520-636X(1997)9:1<17::AID-CHIR4>3.0.CO;2-D; Tang SL, 1997, J CHART INST WATER E, V11, P14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Umile EM, 1998, BRAIN INJURY, V12, P577; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	63	85	87	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2002	110	4					605	616	PII S0306-4522(01)00461-4	10.1016/S0306-4522(01)00461-4			12	Neurosciences	Neurosciences & Neurology	545YN	WOS:000175245300002	11934469				2021-06-18	
J	Turkstra, LS; McDonald, S; DePompei, R				Turkstra, LS; McDonald, S; DePompei, R			Social information processing in adolescents: Data from normally developing adolescents and preliminary data from their peers with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescent brain injury; communication; pragmatic competence	CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; ABILITY; STUDENTS; BEHAVIOR; MODEL	Objective: To assess aspects of social information processing in naturalistic conversations, using online videotape tasks. Design and Participants: The tasks were administered to 60 normally developing (ND) subjects ages 13 to 21, and 10 adolescents with traumatic brain injury (TBT). Setting: University. Main Outcome Measure: Task accuracy scores and measures of reliability, and validity Results and Conclusions: ND group scores were generally high, without significant differences by race, sex or age, TBI group scores were significantly lower than ND group scores for both emotion recognition and detection of conversation skills, The results are discussed in light of the evaluation of pragmatic competence in adolescents with TBI.	Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH 44106 USA; Univ New S Wales, Sch Psychol, Kensington, NSW 2033, Australia; Univ Akron, Sch Speech Language Pathol & Audiol, Akron, OH 44325 USA	Turkstra, LS (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.	lst2@po.cwru.edu	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-00163] Funding Source: Medline		Achenbach T, 1980, CHILD BEHAV CHECKLIS; Anastasi A, 1997, PSYCHOL TESTING, V7th; ARGYLE M, 1986, INT J PSYCHOL, V21, P287, DOI 10.1080/00207598608247591; Belenky MF., 1986, WOMENS WAYS KNOWING; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Brice A, 1996, LANG SPEECH HEAR SER, V27, P68, DOI 10.1044/0161-1461.2701.68; BROWN L, 1992, MEETING CROSSROADS; BRYAN TH, 1977, J LEARN DISABIL, V10, P501, DOI 10.1177/002221947701000808; CAVELL TA, 1990, J CLIN CHILD PSYCHOL, V19, P111, DOI 10.1207/s15374424jccp1902_2; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; Cohen J., 1977, STAT POWER ANAL BEHA, P1; COHEN S, 1997, ACQUIRED BRAIN INJUR; CONDERMAN G, 1995, LEARN DISABILITY Q, V18, P13, DOI 10.2307/1511362; COOLEY EA, 1997, STUDENTS ACQUIRED BR; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DAMICO JS, 1993, LANG SPEECH HEAR SER, V24, P29; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DODGE KA, 1994, CHILD DEV, V65, P1385, DOI 10.2307/1131505; Flanagan S., 1998, AWARENESS SOCIAL INF; Gioia G.A., 2000, BEHAV RATING INVENTO; HARTLEY LL, 1995, NEUROGENIC COMMUNICA; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; KIM YY, 1985, INTERETHNIC COMMUNIC; Leffert JS, 1996, AM J MENT RETARD, V100, P441; Matthys W, 1999, J AM ACAD CHILD PSY, V38, P311, DOI 10.1097/00004583-199903000-00019; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCDONALD S, 1998, UNPUB FIELD TEST DAT; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Raven J. C., 1938, PROGR MATRICES PERCE; SABORNIE EJ, 1994, LEARN DISABILITY Q, V17, P268, DOI 10.2307/1511124; SCHUMAKER JB, 1984, J LEARN DISABIL, V17, P422, DOI 10.1177/002221948401700708; SCHUMAKER JB, 1982, LEARN DISABILITY Q, V5, P409, DOI 10.2307/1510924; Singer BD, 1999, LANG SPEECH HEAR SER, V30, P265, DOI 10.1044/0161-1461.3003.265; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; TRANEL D, 1989, NEUROPSYCHOLOGIA, V27, P381, DOI 10.1016/0028-3932(89)90046-8; TURKSTRA L, IN PRESS J COMMUN DI; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1991, WECHSLER INTELLIGENC; WIIG EH, 1974, PERCEPT MOTOR SKILL, V38, P239, DOI 10.2466/pms.1974.38.1.239; WINDSOR J, 1995, LANGUAGE INTERVENTIO; YEATES KO, 1989, DEV REV, V9, P64, DOI 10.1016/0273-2297(89)90024-5; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU	52	85	85	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2001	16	5					469	483		10.1097/00001199-200110000-00006			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	483JF	WOS:000171631700006	11574042				2021-06-18	
J	Lee, JH; Kelly, DF; Oertel, M; McArthur, DL; Glenn, TC; Vespa, P; Boscardin, WJ; Martin, NA				Lee, JH; Kelly, DF; Oertel, M; McArthur, DL; Glenn, TC; Vespa, P; Boscardin, WJ; Martin, NA			Carbon dioxide reactivity, pressure autoregulation, and metabolic suppression reactivity after head injury: a transcranial Doppler study	JOURNAL OF NEUROSURGERY			English	Article						cerebral vasoreactivity; carbon dioxide reactivity; hyperventilation; intracranial hypertension; autoregulation; propofol; transcranial Doppler ultrasonography; traumatic brain injury	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; INTRACRANIAL HYPERTENSION; AUTO-REGULATION; PROPOFOL; CIRCULATION; HUMANS; VASOREACTIVITY; VELOCITY; HYPERVENTILATION	Object. Contemporary management of head-injured patients is based on assumptions about CO., reactivity, pressure autoregulation (PA), and vascular reactivity to pharmacological metabolic suppression. In this study, serial assessments of vasoreactivity of the middle cerebral artery (MCA) were per-formed using bilateral transcranial Doppler (TCD) ultrasonography. Methods. Twenty-eight patients (mean age 33 +/- 13 years, median Glasgow Coma Scale score of 7) underwent a total of 61 testing sessions during postinjury Days 0 to 13. The CO, reactivity (58 studies in 28 patients), PA (51 studies in 23 patients), and metabolic suppression reactivity (35 studies in 16 patients) were quantified for each cerebral hemisphere by measuring changes in MCA velocity in response to transient hyperventilation, arterial blood pressure elevation, or propofol-induced burst suppression, respectively. One or both hemispheres registered below normal vasoreactivity scores in 40%, 69%, and 97% of study sessions for CO, reactivity, PA, and metabolic suppression reactivity (p < 0.0001), respectively. Intracranial hypertension, classified as intracranial pressure (ICP) greater than 20 mm Hg at the time of testing, was associated with global impairment of CO, reactivity, PA, and metabolic suppression reactivity (p < 0.05). A low baseline cerebral perfusion pressure (CPP) was also predictive of impaired CO, reactivity and PA (p < 0.01). Early postinjury hypotension or hypoxia was also associated with impaired CO, reactivity (p < 0.05), and hemorrhagic brain lesions in or overlying the MCA territory were predictive of impaired metabolic suppression reactivity (p < 0.01). The 6-month Glasgow Outcome Scale score correlated with the overall degree of impaired vasoreactivity (p < 0.05). Conclusions. During the first 2 weeks after moderate or severe head injury, CO, reactivity remains relatively intact, PA is variably impaired, and metabolic suppression reactivity remains severely impaired. Elevated ICP appears to affect all three components of vasoreactivity that were tested, whereas other clinical factors such as CPP, hypotensive and hypoxic insults, and hemorrhagic brain lesions have distinctly different impacts on the state of vasoreactivity. Incorporation of TCD ultrasonography-derived vasoreactivity data may facilitate more injury- and time-specific therapies for head-injured patients.	Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Div Neurosurg, Ctr Hlth Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Harbor Med Ctr, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Res & Educ Inst, Los Angeles, CA USA	Kelly, DF (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Room 18-218A NPI,Box 957039, Los Angeles, CA 90095 USA.	dfkelly@ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		AASLID R, 1987, STROKE, V18, P771, DOI 10.1161/01.STR.18.4.771; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BAILIE GR, 1992, BRIT J ANAESTH, V68, P486, DOI 10.1093/bja/68.5.486; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 1996, J NEUROTRAUM, V13, P711; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Gelb A. W., 1993, Canadian Journal of Anaesthesia, V40, pA68; GOMEZ SM, 1990, STROKE, V21, P1746, DOI 10.1161/01.STR.21.12.1746; ILLIEVICH UM, 1993, ANESTH ANALG, V77, P155; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KIRKHAM FJ, 1986, ULTRASOUND MED BIOL, V12, P15, DOI 10.1016/0301-5629(86)90139-0; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; Kochanek PM, 1997, ACT NEUR S, V70, P109; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LEE MW, 1994, J NEUROTRAUM, V11, P325, DOI 10.1089/neu.1994.11.325; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Littell R. C. G. A., 1996, SAS SYSTEM MIXED MOD; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Minassian AT, 1998, J NEUROSURG, V88, P996, DOI 10.3171/jns.1998.88.6.0996; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; Osborn A.G., 1994, DIAGNOSTIC NEURORADI, P117; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHAPIRO HM, 1974, J NEUROSURG, V40, P90, DOI 10.3171/jns.1974.40.1.0090; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; TEASDALE G, 1974, LANCET, V2, P81; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; VANHEMELRIJCK J, 1990, ANESTH ANALG, V71, P49; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383	61	85	87	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2001	95	2					222	232		10.3171/jns.2001.95.2.0222			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	459MP	WOS:000170254500007	11780891				2021-06-18	
J	Suh, DY; Davis, PC; Hopkins, KL; Fajman, NN; Mapstone, TB				Suh, DY; Davis, PC; Hopkins, KL; Fajman, NN; Mapstone, TB			Nonaccidental pediatric head injury: Diffusion-weighted imaging findings	NEUROSURGERY			English	Article						child abuse; diffusion-weighted imaging; magnetic resonance imaging; traumatic brain injury	TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; SHAKEN IMPACT SYNDROME; YOUNG-CHILDREN; T2-WEIGHTED MRI; INFANTS; RATS; HISTOPATHOLOGY; SPECTROSCOPY; DAMAGE	OBJECTIVE: Diffusion-weighted imaging (DWI) reveals nonhemorrhagic posttraumatic infarction hours to days before conventional computed tomographic scanning or magnetic resonance imaging (MRI). We evaluated the diagnostic utility of DWI in children with nonaccidental head trauma. METHODS: The medical records and imaging examinations obtained between January 1998 and May 2000 for all children less than 2 years of age with presumed or suspected nonaccidental head injury were reviewed retrospectively. Twenty children who had undergone DWI within 5 days of presentation were included in the study. Computed tomographic scans, conventional MRI sequences, and DWI combined with apparent diffusion coefficient (ADC) maps were evaluated. RESULTS: Eleven girls and nine boys (median age, 5 mo) were studied. Eighteen children had presumed nonaccidental head trauma, and two children had suspected nonaccidental head trauma. Of the 18 children with presumed nonaccidental trauma, 16 (89%) demonstrated abnormalities on DWI/ADC, as compared with neither of the two children with suspected nonaccidental trauma. In 13 (81%) of 16 positive cases, DWI revealed more extensive brain injury than was demonstrated on conventional MRI sequences or showed injuries not observed on conventional MRI. DWI combined with ADC maps allowed better delineation of the extent of white matter injury. DWI/ADC abnormalities in the nonaccidental head-injured children were likely to involve posterior aspects of the cerebral hemispheres, with relative sparing of the frontal and temporal poles. Severity on DWI correlated significantly with poor outcome (P < 0.005). CONCLUSION: DWI has broad applications in the early detection of infarction in children with nonaccidental head injury and enhances the sensitivity of conventional MRI. In the patients in this study, early DWI provided an indicator of severity that was more complete than any other imaging modality. The use of DWI may help to identify children at high risk for poor outcome and to guide management decisions.	Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA; Childrens Hosp Atlanta Egleston, Dept Pediat, Atlanta, GA USA; Childrens Hosp Atlanta Egleston, Dept Neurosurg, Atlanta, GA USA; Childrens Hosp Atlanta Egleston, Dept Radiol, Atlanta, GA USA	Suh, DY (corresponding author), Care Of Sherry A Ballenger, Emory Univ, Dept Neurosurg, 1365-B Clifton Rd,NE,Suite 6400, Atlanta, GA 30322 USA.						Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Barzo P, 1997, ACT NEUR S, V70, P115; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Bruce DA, 1996, NEUROSURGERY, P2709; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GILLILAND MG, 1996, FORENSIC SCI INT, V68, P117; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; KLEINMAN PK, 1987, DIAGNOSTIC IMAGING C, P159; KNIGHT RA, 1994, STROKE, V25, P1252, DOI 10.1161/01.STR.25.6.1252; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Li FH, 1999, ANN NEUROL, V46, P333, DOI 10.1002/1531-8249(199909)46:3<333::AID-ANA9>3.0.CO;2-X; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Lutsep HL, 1997, ANN NEUROL, V41, P574, DOI 10.1002/ana.410410505; MINEMATSU K, 1992, STROKE, V23, P1304, DOI 10.1161/01.STR.23.9.1304; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Ricci PE, 1999, AM J NEURORADIOL, V20, P1535; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Sane SM, 2000, PEDIATRICS, V105, P1345; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; WELCH KMA, 1995, STROKE, V26, P1983, DOI 10.1161/01.STR.26.11.1983; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349	43	85	89	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	AUG	2001	49	2					309	318		10.1097/00006123-200108000-00011			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	457MQ	WOS:000170141700035	11504106				2021-06-18	
J	Warrington, SA; Wright, CM				Warrington, SA; Wright, CM		ALSPAC Study Team	Accidents and resulting injuries in premobile infants: data from the ALSPAC study	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article						accident; burn; fall; injury	BURN INJURIES; CHILDREN FALL; BED; ABUSE; AGE	Background and aims-Little is known about injuries resulting from accidents in premobile infants. We aimed to describe the pattern of minor accidents in infants and their resulting injuries. Methods-The ALSPAC study collected data in successive postal questionnaires. At 6 months of age, parents were asked to describe any accident since birth. The type of fall, distance fallen, resulting injury, and help sought were independently coded. Burns were similarly coded. Results-A total of 11 466 responses were available. In 2554 children, 3357 falls were reported; 53% fell from beds or settees and 12% fell from arms or while being carried. Only 14% reported visible injury, of which 56% were bruises; 97% of injuries specified involved the head. Only 21 falls (<1%) resulted in concussion or fracture. A burn or scald occurred in 172 cases (1.5%). The main causes of scalds were hot drinks and water, with contact burns caused by radiators, cookers, and hot food. Conclusions-Falls in young infants are common while burns are rare. Injuries from falls are infrequent, predominantly trivial, and almost entirely confined to the head. Falls from beds and settees did not result in skull fractures. Serious injury was the result of complex accidents.	Univ Newcastle Upon Tyne, Dept Child Hlth, Community Child Hlth Unit, Newcastle Upon Tyne NE8 6ET, Tyne & Wear, England; Univ Bristol, ALSPAC Study Team, Bristol BS8 1TQ, Avon, England	Warrington, SA (corresponding author), 2 Beechfield Rd, Newcastle Upon Tyne NE3 4DR, Tyne & Wear, England.						BANCO L, 1994, PEDIATR EMERG CARE, V10, P98, DOI 10.1097/00006565-199404000-00010; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; CAFFEY J, 1974, PEDIATRICS, V54, P396; *CAPT CHILD ACC PR, 1992, NHS SOC COSTS CHILDR, P49; Carpenter RF, 1999, ARCH DIS CHILD, V80, P363, DOI 10.1136/adc.80.4.363; CARTER YH, 1993, BRIT J GEN PRACT, V43, P159; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Cronin KJ, 1996, BURNS, V22, P221, DOI 10.1016/0305-4179(95)00109-3; DATUBOBROWN DD, 1989, BURNS, V15, P285, DOI 10.1016/0305-4179(89)90002-8; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; HELFER RE, 1977, PEDIATRICS, V60, P533; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; JOFFE M, 1988, PEDIATRICS, V82, P457; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P105; KLEIN DM, 1981, CHILD ABUSE NEGLECT, P73; LINDBLAD BE, 1990, BURNS, V16, P254, DOI 10.1016/0305-4179(90)90134-I; LYONS TJ, 1993, PEDIATRICS, V92, P125; MADDOCKS GB, 1978, PUBLIC HEALTH, V92, P171, DOI 10.1016/S0033-3506(78)80120-6; MCCORMICK MC, 1981, AM J DIS CHILD, V135, P159, DOI 10.1001/archpedi.1981.02130260051015; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; PHILLIPS W, 1986, BURNS, V12, P343, DOI 10.1016/0305-4179(86)90105-1; RIVARA FP, 1988, PEDIATRICS, V81, P93; ROSSIGNOL AM, 1990, BURNS, V16, P41, DOI 10.1016/0305-4179(90)90204-A; SIMON PA, 1994, ARCH PEDIAT ADOL MED, V148, P394, DOI 10.1001/archpedi.1994.02170040060010; *STAT HLTH, 1992, HLTH NAT STRAT HLTH; STEWART G, 1993, PEDIATR EMERG CARE, V9, P199, DOI 10.1097/00006565-199308000-00004; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; *US DHEW PHS DIV P, 1970, 71R3 FY US DHEW PHS; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; 1995, HLTH SURVEY ENGLAND, V1, pCH5	30	85	87	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	AUG	2001	85	2					104	107		10.1136/adc.85.2.104			4	Pediatrics	Pediatrics	456WK	WOS:000170105600004	11466183	Green Published, Bronze			2021-06-18	
J	Platz, T; Winter, T; Muller, N; Pinkowski, C; Eickhof, C; Mauritz, KH				Platz, T; Winter, T; Muller, N; Pinkowski, C; Eickhof, C; Mauritz, KH			Arm ability training for stroke and traumatic brain injury patients with mild arm paresis: A single-blind, randomized, controlled trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	2nd World Congress in Neurological Rehabilitation	APR 14, 1999	TORONTO, CANADA			activities of daily living; arm; brain injuries; cerebrovascular accident; paresis; rehabilitation	INDUCED MOVEMENT THERAPY; MOTOR; REHABILITATION; PERFORMANCE; RECOVERY; VALIDITY; DEFICITS; HAND	Objective: To test the efficacy of the arm ability training (AAT) on a sample of patients with central arm paresis after traumatic brain injury (TBI) or stroke. Design: Single-blind, randomized, controlled trial. Setting: Inpatient rehabilitation center. Patients: Consecutive sample of 74 patients of whom 60 (45 with stroke, 15 with TBI) completed the study; 37 patients received a 1-year follow-up. Intervention: Daily AAT with (n = 20) or without (n = 20) knowledge of results, or no AAT (n = 20) during a 3-week intervention period. Main Outcome Measures: Summary time scores of the Test Evaluant les Membres superieurs des Personnes Agees (TEMPA)-a test of upper extremity function with daily function-like activities (focal disability)-and kinematic analysis of aimed movements, Results: Patients with AAT realized superior improvement as compared with controls. Mean improvement in the time needed to perform (1) all TEMPA tasks was 41.4 versus 12.8 seconds (p =.0012); (2) unilateral TEMPA tasks, 16.5 versus 4.2 seconds (p=.0036); and (3) the ballistic component of aimed movements, 96 versus 20ms (p =.0115). Knowledge of result did not substantially modify these effects. A functional benefit existed at 1-year follow-up. Conclusion: The AAT reduces focal disability among stroke and TBI patients with mild central arm paresis.	Free Univ Berlin, Abt Neurol Rehabil, Klin Berlin, Klinikum Benjamin Franklin, D-12200 Berlin, Germany	Platz, T (corresponding author), Klin Berlin, Kladower Damm 223, D-14089 Berlin, Germany.			Platz, Thomas/0000-0003-2629-9744; Eickhof, Christel/0000-0002-1312-5297			ASANUMA H, 1991, NEUROREPORT, V2, P217, DOI 10.1097/00001756-199105000-00001; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; BASMAJIAN JV, 1987, ARCH PHYS MED REHAB, V68, P267; BRAUS DF, 1994, ANN NEUROL, V36, P728, DOI 10.1002/ana.410360507; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; CARR J, 1998, NEUROLOGICAL REHABIL, P264; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; DESROSIERS J, 1994, OCCUP THER J RES, V14, P267, DOI 10.1177/153944929401400405; Desrosiers J, 1993, CAN J OCCUP THER, V60, P9, DOI DOI 10.1177/000841749306000104; DICKSTEIN R, 1986, PHYS THER, V66, P1233, DOI 10.1093/ptj/66.8.1233; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; Fleishman E. A., 1964, STRUCTURE MEASUREMEN; Fleishman EA, 1965, TRAINING RES ED, P37; Fleishman EA, 1967, LEARN INDIVID DIFFER, P165; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KARNI A, 1995, NATURE, V377, P155; Kleinbaum D, 1988, APPL REGRESSION ANAL; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; Kramer M.S., 1988, CLIN EPIDEMIOLOGY BI; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; LOGIGIAN MK, 1983, ARCH PHYS MED REHAB, V64, P364; LORD JP, 1986, ARCH PHYS MED REHAB, V67, P88, DOI 10.1016/0003-9993(86)90108-5; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PINKOWSKI C, 2000, 9 REH K VDR 2000 MAR, P188; PLATZ T, 1994, NEUROPSYCHOLOGIA, V32, P1209, DOI 10.1016/0028-3932(94)90103-1; Platz T, 1997, BEHAV NEUROL, V10, P15, DOI 10.3233/BEN-1997-10103; Platz T, 1999, ARCH PHYS MED REHAB, V80, P270, DOI 10.1016/S0003-9993(99)90137-5; PLATZ T, 1999, KRANKENGYMNASTIK Z P, V51, P251; ROY CW, 1994, CLIN REHABIL, V8, P334, DOI DOI 10.1177/026921559400800410; SALMONI AW, 1984, PSYCHOL BULL, V95, P355, DOI 10.1037/0033-2909.95.3.355; Schmidt R. A., 1988, MOTOR CONTROL LEARNI; STEM PH, 1970, ARCH PHYS MED REHAB, V51, P526; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Wade DT, 1992, MEASUREMENT NEUROLOG; WILSON R S, 1979, Journal of Clinical Neuropsychology, V1, P49, DOI 10.1080/01688637908401097	36	85	86	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2001	82	7					961	968		10.1053/apmr.2001.23982			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	450KV	WOS:000169742800017	11441386				2021-06-18	
J	Singleton, RH; Stone, JR; Okonkwo, DO; Pellicane, AJ; Povlishock, JT				Singleton, RH; Stone, JR; Okonkwo, DO; Pellicane, AJ; Povlishock, JT			The immunophilin ligand FK506 attenuates axonal injury in an impact-acceleration model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; cytoskeleton; immunocytochemistry; immunophilin; rat; traumatic axonal injury; traumatic brain injury	MICROTUBULE-ASSOCIATED PROTEIN-2; CYCLOSPORINE-A; NEUROFILAMENT PROTEINS; PHOSPHORYLATION STATE; HEAD-INJURY; TAU-FACTOR; IN-VIVO; DAMAGE; CALCINEURIN; PERMEABILITY	The immunophilin ligand, cyclosporin A (CsA), is effective in reducing the axonal damage associated with traumatic brain injury (TBI). Based upon extensive ultrastructural and immunohistochemical studies, the neuroprotection afforded by CsA appeared to be mediated via mitochondrial protection, specifically, the prevention of mitochondrial swelling and inhibition of mitochondrial permeability transition (MPT). However, the potential that CsA could also be neuroprotective via the immunophilin-mediated inhibition of the protein phosphatase, calcineurin (CN) has not been directly assessed. To address this issue, the current study assessed the ability of FK506, another immunophilin ligand that inhibits CN with no effect on MPT, to attenuate axonal damage in a rat impact-acceleration model of TBI. Traumatic axonal injury (TAI), detected via an antibody against beta -amyloid precursor protein (APP), a specific marker of axonal injury, was significantly reduced at 24 hr postinjury in Sprague-Dawley rats receiving intravenous FK506 (2 mg/kg; n = 5) 30 min prior to injury compared to vehicle controls (n = 3). While not rejecting the established efficacy of CsA in providing neuroprotection via its targeting of MPT, this study does underscore the potential importance of CN in the progressive pathobiology of TAI, suggesting that CN may constitute another important therapeutic target.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Univ Virginia, Dept Neurosurg, Charlottesville, VA USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, 1101 E Marshall St,Campus Virginia Commonwealth U, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS7288, NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007288, R01NS020193] Funding Source: NIH RePORTER		Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Butcher SP, 1997, J NEUROSCI, V17, P6939; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Drake M, 1996, ACTA PHYSIOL SCAND, V158, P155, DOI 10.1046/j.1365-201X.1996.535298000.x; EYER J, 1988, BIOCHEM J, V252, P655, DOI 10.1042/bj2520655; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; JOHNSON GVW, 1992, J NEUROCHEM, V59, P2056; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin R, 1999, NEUROSCIENCE, V88, P327, DOI 10.1016/S0306-4522(98)00244-9; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; OCHIAI T, 1989, TRANSPLANT P, V21, P829; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pijak DS, 1996, J COMP NEUROL, V368, P569; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; TOYOSHIMA I, 1988, NEUROCHEM RES, V13, P621, DOI 10.1007/BF00973278; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	36	85	85	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2001	18	6					607	614		10.1089/089771501750291846			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	445ZQ	WOS:000169488800004	11437083				2021-06-18	
J	Yu, CG; Jimenez, O; Marcillo, AE; Weider, B; Bangerter, K; Dietrich, WD; Castro, S; Yezierski, RP				Yu, CG; Jimenez, O; Marcillo, AE; Weider, B; Bangerter, K; Dietrich, WD; Castro, S; Yezierski, RP			Beneficial effects of modest systemic hypothermia on locomotor function and histopathological damage following contusion-induced spinal cord injury in rats	JOURNAL OF NEUROSURGERY			English	Article						spinal cord injury; spinal cord; locomotion; hypothermia; neuroprotection	TRAUMATIC BRAIN INJURY; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; TEMPERATURE; PROTECTION; METHYLPREDNISOLONE; ISCHEMIA; LACTATE; DEVICE; OXYGEN	Object. Local spinal cord cooling (LSCC) is associated with beneficial effects when applied following ischemic or traumatic spinal cord injury (SCI). However, the clinical application of LSCC is associated with many technical difficulties such as the requirement of special cooling devices, emergency surgery, and complicated postoperative management, if hypothermia is to be considered for future application in the treatment of SCI, alternative approaches must be developed. The objectives of the present study were to evaluate 1) the relationship between systemic and epidural temperature after SCI; 2) the effects of modest systemic hypothermia on histopathological damage at 7 and 44 days post-SCI; and 3) the effects of modest systemic hypothermia on locomotor outcome at 44 days post-SCI. Methods. A spinal cord contusion (12.5 mm at T-10) was produced in adult rats that had been randomly divided into two groups. Group 1 rats (seven in Experiment 1; 12 in Experiment 2) received hypothermic treatment (epidural temperature 32-33 degrees C) 30 minutes postinjury for 4 hours; Group 2 rats (nine in Experiment 1; eight in Experiment 2) received normothermic treatment (epidural temperature 37 degrees C) 30 minutes postinjury for 4 hours. Blood pressure, blood gas levels, and temperatures (epidural and rectal) were monitored throughout the 4-hour treatment period. Twice weekly assessment of locomotor function was performed over a 6-week survival period by using the Basso-Beattie-Bresnahan locomotor rating scale. Seven (Experiment 1) and 44 (Experiment 2) days after injury, animals were killed, perfused, and their spinal cords were serially sectioned. The area of tissue damage was quantitatively analyzed from 16 longitudinal sections selected from the central core of the spinal cord. Conclusions. The results showed that 1) modest changes in the epidural temperature of the spinal cord can be produced using systemic hypothermia; 2) modest systemic hypothermia (32-33(C degrees)) significantly protects against locomotor deficits following traumatic SCI; and 3) modest systemic hypothermia (32-33 degrees C) reduces the area of tissue damage at both 7 and 44 days postinjury. Although additional research is needed to study the therapeutic window and long-term benefits of systemic hypothermia, these data support the possible use of modest systemic hypothermia in the treatment of acute SCI.	Miami Project, Miami, FL 33136 USA; Univ Miami, Dept Neurol Surg, Miami, FL 33152 USA; Univ Miami, Dept Anat, Miami, FL 33152 USA; Univ Miami, Dept Cell Biol, Miami, FL 33152 USA; Univ Miami, Neurosci Program, Miami, FL 33152 USA	Yezierski, RP (corresponding author), Miami Project, 1600 NW 10th Ave,R-48, Miami, FL 33136 USA.	ryezierski@miami.edu	Yu, Chen Guang/C-6176-2011				ALBIN MS, 1967, ANESTH ANAL CURR RES, V46, P8; ARAKI N, 1991, J CEREB BLOOD FLO S2, V11, pS843; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BLACK P, 1971, Surgical Forum (Chicago), V22, P409; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAIMBRIDGE MV, 1986, CARDIOPULMONARY BYPA, P385; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COOLEY DA, 1981, ANN THORAC SURG, V32, P260, DOI 10.1016/S0003-4975(10)61048-X; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DUCKER TB, 1969, J NEUROSURG, V30, P270, DOI 10.3171/jns.1969.30.3part1.0270; Eidelberg E, 1976, Surg Neurol, V6, P243; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HAGERDAL M, 1978, ANESTHESIOLOGY, V49, P165, DOI 10.1097/00000542-197809000-00003; HAGERDAL M, 1975, J NEUROCHEM, V24, P311, DOI 10.1111/j.1471-4159.1975.tb11881.x; HANSEBOUT RR, 1992, SPINAL CORD DYSFUNCT, P59; KELLY DL, 1970, J NEUROSURG, V33, P554, DOI 10.3171/jns.1970.33.5.0554; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; NATALE JE, 1989, STROKE, V20, P770, DOI 10.1161/01.STR.20.6.770; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TATOR CH, 1973, J NEUROSURG, V39, P52, DOI 10.3171/jns.1973.39.1.0052; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; Westergren H, 1998, J NEUROTRAUM, V15, P943, DOI 10.1089/neu.1998.15.943; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yu C. G., 1999, Society for Neuroscience Abstracts, V25, P1443	52	85	89	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2000	93	1		S			85	93		10.3171/spi.2000.93.1.0085			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	328UD	WOS:000087867800013	10879763				2021-06-18	
J	Dikmen, SS; Machamer, JE; Winn, HR; Anderson, GD; Temkin, NR				Dikmen, SS; Machamer, JE; Winn, HR; Anderson, GD; Temkin, NR			Neuropsychological effects of valproate in traumatic brain injury - A randomized trial	NEUROLOGY			English	Article						traumatic brain injuries; valproate; phenytoin; neuropsychological side effects; double-blind method		Objectives: To examine the neuropsychological side effects of valproate (VPA) given to prevent posttraumatic seizures. Methods: In a randomized, double-masked, parallel group clinical trial, we compared the seizure prevention and neuropsychological effects of 1 or 6 months of VPA to 1 week of phenytoin. We studied 279 adult subjects who were randomized within 24 hours of injury and examined with a battery of neuropsychological measures at 1, 6, and 12 months after injury. We examined drug effects cross-sectionally at 1, 6, and 12 months and longitudinally by examining differential change from 1 to 6 months and from 6 to 12 months as a function of protocol-dictated changes in treatment. Results: No significant adverse or beneficial neuropsychological effects of VPA were detected. Conclusions: Valproate (VPA) appears to have a benign neuropsychological side effects profile, making it a cognitively safe antiepileptic drug to use for controlling established seizures or stabilizing mood. However, based on this study, VPA should not be used for prophylaxis of posttraumatic seizures because it does not prevent posttraumatic seizures, there was a trend toward more deaths in the VPA groups, and it did not have positive effects on cognition.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Dikmen, SS (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643] Funding Source: Medline		Armon C, 1996, NEUROLOGY, V47, P626, DOI 10.1212/WNL.47.3.626; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; DYER FN, 1973, MEM COGNITION, V1, P106, DOI 10.3758/BF03198078; Guerrini R, 1998, EPILEPSIA, V39, P27, DOI 10.1111/j.1528-1157.1998.tb01270.x; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P264, DOI 10.1001/archneur.1963.00460030048004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Prevey ML, 1996, ARCH NEUROL-CHICAGO, V53, P1008, DOI 10.1001/archneur.1996.00550100086018; Reitan R.M., 1993, HALSTEADREITAN NEURO; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; TONNBY B, 1994, EPILEPSY RES, V19, P141, DOI 10.1016/0920-1211(94)90024-8; Vermeulen J, 1995, EPILEPSY RES, V22, P65, DOI 10.1016/0920-1211(95)00047-X; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1955, MANUAL WECHSLER ADUL	15	85	85	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	FEB 22	2000	54	4					895	902		10.1212/WNL.54.4.895			8	Clinical Neurology	Neurosciences & Neurology	284ZL	WOS:000085362700024	10690983				2021-06-18	
J	Xiong, Y; Peterson, PL; Lee, CP				Xiong, Y; Peterson, PL; Lee, CP			Effect of N-acetylcysteine on mitochondrial function following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						N-acetylcysteine; neuroprotection; rat brain mitochondria; reduced glutathione; traumatic brain injury	TRANSIENT FOREBRAIN ISCHEMIA; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; HEAD-INJURY; GLUTATHIONE; ANTIOXIDANT; BARRIER; CALCIUM; REPERFUSION	Efficacy of N-acetylcysteine (NAC) in traumatic brain injury (TBI)-induced mitochondrial dysfunction was evaluated following controlled cortical impact injury in rats, Respiratory function and calcium transport of rat forebrain mitochondria from injured and uninjured hemispheres were examined, NAC significantly restored mitochondrial electron transfer, energy coupling capacity, calcium uptake activity and reduced calcium content absorbed to brain mitochondrial membranes when examined 12 h post-TBI if NAC was administered i.p. 5 min before injury or 30 min or 1 h postinjury, Glutathione (reduced form, GSH) levels in brain tissues were decreased at all time points examined over a 14-day observation period, while mitochondrial GSH levels significantly decreased only at 3 days and 14 days following TBI, NAC treatment given within 1 h greatly restored brain GSH levels from 1 h to 14 days and mitochondrial GSH levels from 12 h to 14 days post-TBI, NAC did not show protective effects when given 2 h postinjury, Our data indicate that NAC administered postinjury at an early stage can effectively restore TBI-induced mitochondrial dysfunction and the protective effect of NAC may be related to its restoration of GSH levels in the brain.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA	Lee, CP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield St, Detroit, MI 48201 USA.	cplee@med.wayne.edu		Xiong, Ye/0000-0001-9770-6031			ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Banaclocha MM, 1997, BRAIN RES, V762, P256, DOI 10.1016/S0006-8993(97)00493-9; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COOPER AJL, 1980, J NEUROCHEM, V35, P1242, DOI 10.1111/j.1471-4159.1980.tb07882.x; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORCORAN GB, 1986, J PHARMACOL EXP THER, V238, P54; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; COTGREAVE I, 1991, BIOCHEM PHARMACOL, V42, P13, DOI 10.1016/0006-2952(91)90674-T; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FUKUZAWA K, 1995, TRANSPLANTATION, V59, P6, DOI 10.1097/00007890-199501150-00002; GRAMMAS P, 1993, FREE RADICAL BIO MED, V14, P553, DOI 10.1016/0891-5849(93)90113-9; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; Hall ED, 1996, ACT NEUR S, V66, P107; Hall ED, 1996, J NEUROSCI RES, V44, P293, DOI 10.1002/(SICI)1097-4547(19960501)44:3<293::AID-JNR10>3.0.CO;2-6; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hartl R, 1997, ACT NEUR S, V70, P240; HOVDA DA, 1994, ACTA NEUROCHIR, P521; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; Kelly G S, 1998, Altern Med Rev, V3, P114; KNUCKEY NW, 1995, STROKE, V26, P305, DOI 10.1161/01.STR.26.2.305; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KOSOWER NS, 1983, FUNCTIONS GLUTATHION, P307; Lee C. P., 1993, V2, P41; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Martinez M, 1995, MECH AGEING DEV, V84, P77, DOI 10.1016/0047-6374(95)01644-F; MCINTOSH TK, 1995, J HEAD TRAUMA REHAB, V10, P1; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; MEISTER A, 1995, BIOCHIM BIOPHYS ACTA, V1271, P273; MEREDITH MJ, 1982, J BIOL CHEM, V257, P3747; MIQUEL J, 1995, EUR J PHARM-ENVIRON, V292, P333, DOI 10.1016/0926-6917(95)90041-1; MOLDEUS P, 1986, RESPIRATION, V50, P31; PHELPS DT, 1992, AM J RESP CELL MOL, V7, P293, DOI 10.1165/ajrcmb/7.3.293; REHNCRONA S, 1980, J NEUROCHEM, V34, P477, DOI 10.1111/j.1471-4159.1980.tb11170.x; SCHINETTI ML, 1989, CARDIOVASC RES, V23, P76, DOI 10.1093/cvr/23.1.76; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SIMS NR, 1991, J NEUROCHEM, V56, P1836, DOI 10.1111/j.1471-4159.1991.tb03438.x; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; TRABER J, 1992, BIOCHEM PHARMACOL, V43, P961, DOI 10.1016/0006-2952(92)90599-E; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	54	85	87	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	1999	16	11					1067	1082		10.1089/neu.1999.16.1067			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	260MM	WOS:000083954500005	10595823				2021-06-18	
J	Vagnozzi, R; Marmarou, A; Tavazzi, B; Signoretti, S; Di Pierro, D; Del Bolgia, F; Amorini, AM; Fazzina, G; Sherkat, S; Lazzarino, G				Vagnozzi, R; Marmarou, A; Tavazzi, B; Signoretti, S; Di Pierro, D; Del Bolgia, F; Amorini, AM; Fazzina, G; Sherkat, S; Lazzarino, G			Changes of cerebral energy metabolism and lipid peroxidation in rats leading to mitochondrial dysfunction after diffuse brain injury	JOURNAL OF NEUROTRAUMA			English	Article						diffuse brain injury; energy metabolism; lipid peroxidation; MDA; reactive oxygen species; secondary insult	FLUID-PERCUSSION MODEL; OXIDATIVE STRESS; HEAD-INJURY; ISCHEMIA; DISRUPTION; RECOVERY; RADICALS	The effect of mild closed head trauma, induced by the weight-drop method (450 g from a l-m height), on lipid peroxidation and energy metabolism of brain tissue was determined at various times after cerebral injury in spontaneously breathing rats (1, 10, 30 minutes and 2, 6, 15, 24, 48, and 120 hours). Animals were continuously monitored for the evaluation of blood pressure, blood gases, heart rate, and intracranial pressure. Analysis of malondialdehyde (MDA) as an index of lipid peroxidation, ascorbic acid, high-energy phosphates, nicotinic coenzymes, oxypurines, and nucleosides was performed by high-performance liquid chromatography (HPLC) on neutralized perchloric acid extract of the whole brain. Data showed that MDA, undetectable in control, sham-operated rats, was already present within 1 minute of trauma (1.77 nmol/g wet weight; SD = 0.29) and reached maximal values by 2 hours (72.26 nmol/l w.w.; SD = 11.26), showing a progressive slow decrease thereafter. In contrast, ATP, GTP, and nicotinic coenzyme (NAD and NADP) concentrations showed significant reduction only by the second hour postinjury. Maximal decrease of the ATP and GTP concentrations were sceen at 6 hours postinjury, whereas NAD and NADP concentrations showed maximum decline by 15 hours. Values recorded in mechanically ventilated rats did not differ significantly from those obtained in spontaneously breathing animals. These findings, supported by the absence of blood gas and blood pressure changes in the spontaneously breathing rats, strongly support the premise that biochemical changes (primarily lipid peroxidation) are not caused by secondary ischemic-hypoxic phenomena but rather are triggered by these forces acting on the brain at the time of impact. In addition, these results suggest that depression of energy metabolism might be caused by peroxidation of the mitochondrial membrane with a consequent alteration of the main mitochondrial function-that is, the energy supply.	Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; Univ Catania, Dept Chem Sci, Div Biochem Mol Biol & Pharmacol, Catania, Italy	Vagnozzi, R (corresponding author), Univ Roma Tor Vergata, Dept Neurosci, Via Tor Vergata 135, I-00133 Rome, Italy.		TAVAZZI, BARBARA/AAB-9830-2019; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Signoretti, stefano/0000-0002-8086-1622; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0I NS 19235] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235] Funding Source: NIH RePORTER		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; HUMPHREY SM, 1987, BASIC RES CARDIOL, V82, P304, DOI 10.1007/BF01906863; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; LAZZARINO G, 1992, FREE RADICAL BIO MED, V13, P489, DOI 10.1016/0891-5849(92)90143-5; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MONTASSER A, 1994, J NEUROSURG, V80, P301; MORGAN WA, 1995, BIOCHEM PHARMACOL, V49, P1179, DOI 10.1016/0006-2952(95)00034-W; OBRENOVITCH TP, 1988, J CEREBR BLOOD F MET, V8, P866, DOI 10.1038/jcbfm.1988.144; PALOZZA P, 1992, FREE RADICAL BIO MED, V13, P127, DOI 10.1016/0891-5849(92)90074-Q; Siragusa P, 1997, J Neurosurg Sci, V41, P249; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; Vagnozzi R, 1997, EXP BRAIN RES, V117, P411, DOI 10.1007/s002210050235	27	85	90	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1999	16	10					903	913		10.1089/neu.1999.16.903			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	246JD	WOS:000083159900005	10547099				2021-06-18	
J	Stuss, DT; Binns, MA; Carruth, FG; Levine, B; Brandys, CE; Moulton, RJ; Snow, WG; Schwartz, ML				Stuss, DT; Binns, MA; Carruth, FG; Levine, B; Brandys, CE; Moulton, RJ; Snow, WG; Schwartz, ML			The acute period of recovery from traumatic brain injury: posttraumatic amnesia or posttraumatic confusional state?	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; acute recovery; posttraumatic amnesia; posttraumatic confusional state; attention; memory	SEVERE HEAD-INJURY; COGNITIVE SEQUELAE; PRACTICAL SCALE; EARLY INDEXES; COMA; ORIENTATION; PREDICTORS; PTA	Object. The goal of this study was to characterize more fully the cognitive changes that occur during the period of acute recovery after traumatic brain injury (TBI). Methods. The pattern of performance recovery on attention and memory tests was compared with the results of the Galveston Orientation and Amnesia Test (GOAT). Tests of memory and attention were administered serially to a hospitalized group of patients with TBI of varying severity. The tests differed in their level of complexity and/or requirement for more effortful or strategic processing. The authors found a regular pattern to recovery. As expected, ability to perform on simpler tests was recovered before performance on more effortful ones. The ability to recall three words freely after a 24-hour delay (the operational definition in this study of return to continuous memory) was recovered last, later than normal performance on the GOAT. Ability to perform simple attentional tasks was recovered before the less demanding memory task (recognition); ability to perform more complex attentional tasks was recovered before the free recall of three words after a 24-hour delay. This recovery of attention before memory was most notable and distinct in the group with mild TBI. Conclusions. The period of recovery after TBI, which is currently termed posttraumatic amnesia, appears to be primarily a confusional state and should be labeled as such. The authors propose a new definition for this acute recovery period and argue that the term posttraumatic confusional state should be used, because it more appropriately and completely characterizes the early period of recovery after TBI.	Baycrest Ctr Geriatr Care, Rotman Res Inst, N York, ON M6A 2E1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON, Canada; Univ Toronto, Dept Surg Neurosurg, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; St Michaels Hosp, Toronto, ON, Canada	Stuss, DT (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, N York, ON M6A 2E1, Canada.		Binns, Malcolm/AAQ-9195-2020; Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019	Binns, Malcolm/0000-0001-9998-6612; Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BENSON DF, 1976, NEUROLOGY, V26, P147, DOI 10.1212/WNL.26.2.147; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BROOKS D N, 1974, Cortex, V10, P224; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; CROVITZ HF, 1983, CORTEX, V19, P407, DOI 10.1016/S0010-9452(83)80009-4; DANIEL WF, 1987, CORTEX, V23, P169, DOI 10.1016/S0010-9452(87)80030-8; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; GASQUOINE P G, 1991, Brain Injury, V5, P169, DOI 10.3109/02699059109008087; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; JACKSON RD, 1989, ARCH PHYS MED REHAB, V70, P33; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; KATZ DI, 1994, HDB NEUROREHABILITAT, P493; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIPOWSKI ZJ, 1990, DELIRIUM ACTURE CONF; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; O'Shanick G J, 1986, Adv Psychosom Med, V16, P173; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RICHARDSON JTE, 1984, COGN NEUROPSYCHOL, V3, P217; SAS Institute, 1990, SAS STAT US GUID VER; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; STUSS DT, 1995, NEUROLOGY, V45, P1251, DOI 10.1212/WNL.45.7.1251; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Symonds CP, 1943, LANCET, V1, P7; TEASDALE G, 1974, LANCET, V2, P81	44	85	86	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	APR	1999	90	4					635	643		10.3171/jns.1999.90.4.0635			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	180CD	WOS:000079366700003	10193606				2021-06-18	
J	Leathem, JM; Murphy, LJ; Flett, RA				Leathem, JM; Murphy, LJ; Flett, RA			Self- and informant-ratings on the patient competency rating scale in patients with traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; QUESTIONNAIRE; MEMORY; TESTS	The Patient Competency Rating Scale (PCRS) provides self- and informant-ratings of everyday memory and gives a guide to patients' awareness of their difficulties. Research using the PCRS has focussed on groups with severe TBI and little is known about ratings of functioning in other severity groups or in a non-TBI population. In the current study the TBI group (n = 53) overrated their pre-accident competency compared to controls (n = 131). Patients with severe TBI (n = 25) underestimated their difficulties, while ratings of those with moderate (n = 14) and mild (n = 14) TBI were consistent with their informants, that is, in areas of cognition and emotion. Controls reported difficulty in interpersonal functioning and emotional control that their informants were unaware of.	Massey Univ, Sch Psychol, Palmerston North, New Zealand	Leathem, JM (corresponding author), Massey Univ, Sch Psychol, Palmerston North, New Zealand.	J.M.Leathem@massey.ac.nz		Flett, Ross/0000-0002-3638-710X			*ACC REH COMP INS, 1994, 1994 ACC ACC COMP CO; Acker MB, 1990, NEUROPSYCHOLOGY EVER, P19; ACRIMONVIC ML, 1993, J COGNITIVE REHABILI, V4, P8; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; BOLLER K, 1991, ARCH NEUROL-CHICAGO, V48, P661; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; *DEP STAT NZ, 1994, 1991 CENS POP DWELL; GILEWSKI MJ, 1986, HDB CLIN MEMORY ASSE, P93, DOI DOI 10.1037/10057-008; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [DOI 10.1007/BF02214959, 10.1007/BF02214959]; Gronwall Dorothy, 1990, HEAD INJURY FACTS GU; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Lezak M., 1989, ASSESSMENT BEHAV CON; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Morse P, 1992, CLIN SYNDROMES ADULT, P85; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; PRIGATANO GP, 1991, BARROW NEUROLOGICAL, V7, P17; RUFF RM, 1987, SAN DIEGO NEUROPSYCH; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; SEIDENBERG M, 1994, J CLIN EXP NEUROPSYC, V16, P93, DOI 10.1080/01688639408402620; SEIDENBERG M, 1994, ARCH CLIN NEUROPSYCH, V9, P353, DOI 10.1016/0887-6177(94)90023-X; Sherer M., 1995, J INT NEUROPSYCH SOC, V1, P163; SHERER M, 1996, ANN C INT NEUR SOC C; Stuss D.T., 1986, FRONTAL LOBES; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SWARTZ AF, 1989, CORTEX, V25, P665; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002	31	85	87	1	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1998	20	5					694	705		10.1076/jcen.20.5.694.1122			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	170ZB	WOS:000078836300010	10079045				2021-06-18	
J	Max, JE; Arndt, S; Castillo, CS; Bokura, H; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ				Max, JE; Arndt, S; Castillo, CS; Bokura, H; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ			Attention-deficit hyperactivity symptomatology after traumatic brain injury: A prospective study	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; attention-deficit hyperactivity disorder	DISORDER; CHILDREN; RELIABILITY; DEPRESSION; SCALE	Objective: To study prospectively the course of attention-deficit hyperactivity (ADH) symptomatology in children and adolescents after traumatic brain injury (TBI). It was hypothesized that ADH symptomatology would be significantly related to severity of injury. Method: Subjects were children (n = 50) aged 6 to 14 years at the time they were hospitalized after TBI.The study used a prospective follow-up design. Assessments of preinjury psychiatric, behavioral, socioeconomic, family functioning, and family psychiatric history status were conducted. Severity of injury was assessed by standard clinical scales, and neuroimaging was analyzed. Results: The main finding of this study was that change in ADH symptomatology in the first 2 years after TBI in children and adolescents was significantly related to severity of injury. Overall ADH symptomatology during the study was significantly related to a measure of family dysfunction when family psychiatric history, socioeconomic status, and severity of injury were controlled. Conclusion: The presence of a positive "dose-response" relationship between severity of injury and change in ADH symptoms, present from the 3-month assessment, was consistent with an effect directly related to brain damage.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA; Univ Montana, Missoula, MT 59812 USA; Cedar Ctr Psychiat Grp, Cedar Rapids, IA USA	Max, JE (corresponding author), Univ Iowa, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Arndt, Stephan/A-6976-2013; Robin, Donald/F-2109-2010	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R37MH031593, R01MH040856, P30MH043271, R01MH031593, P50MH043271] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH40856, MHCRC43271, MH31593] Funding Source: Medline		ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464; BLACK P, 1971, HEAD INJURIES, P131; BOCK RD, 1975, MULTIVARIATE STAT ME, P148; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cantwell DP, 1996, J AM ACAD CHILD PSY, V35, P978, DOI 10.1097/00004583-199608000-00008; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Ebaugh FG, 1923, AM J DIS CHILD, V25, P89; FINN JD, 1974, GEN MODEL MULTIVARIA; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; Littell R. C., 1991, SAS SYSTEM LINEAR MO; LOU HC, 1989, ARCH NEUROL-CHICAGO, V46, P48, DOI 10.1001/archneur.1989.00520370050018; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; TEASDALE G, 1974, LANCET, V2, P81; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001; ZIMMERMAN M, 1985, ARCH GEN PSYCHIAT, V42, P300	28	85	88	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	AUG	1998	37	8					841	847		10.1097/00004583-199808000-00014			7	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	103ZY	WOS:000074988800014	9695446				2021-06-18	
J	Kampfl, A; Franz, G; Aichner, F; Pfausler, B; Haring, HP; Felber, S; Luz, G; Schocke, M; Schmutzhard, E				Kampfl, A; Franz, G; Aichner, F; Pfausler, B; Haring, HP; Felber, S; Luz, G; Schocke, M; Schmutzhard, E			The persistent vegetative state after closed head injury: clinical and magnetic resonance imaging findings in 42 patients	JOURNAL OF NEUROSURGERY			English	Article						closed head injury; persistent vegetative state; magnetic resonance imaging	DIFFUSE AXONAL INJURY; ISCHEMIC BRAIN-DAMAGE; COMA DATA-BANK; TRAUMATIC COMA; WALLERIAN DEGENERATION; CORPUS-CALLOSUM; MR; FEATURES; LESIONS; NEUROPATHOLOGY	Object. In this retrospective study, the authors analyzed the frequency, anatomical distribution, and appearance of traumatic brain lesions in 42 patients in a posttraumatic persistent vegetative state. Methods. Cerebral magnetic resonance (MR) imaging was used to detect the number of lesions, which ranged from as few as five to as many as 19. with a mean of 11 lesions. In all 42 cases there was evidence on MR imaging of diffuse axonal injury, and injury to the corpus callosum was detected in all patients. The second most common area of diffuse axonal injury involved the dorsolateral aspect of the rostral brainstem (74% of patients). In addition, 65% of these patients exhibited white matter injury in the corona radiata and the frontal and temporal lobes. Lesions to the basal ganglia or thalamus were seen in 52% and 40% of patients, respectively, Magnetic resonance imaging showed some evidence of cortical contusion in 48% of patients in this study: the frontal and temporal lobes were most frequently involved. Injury to the parahippocampal gyrus was detected in 45% of patients; in this subgroup there was an 80% incidence of contralateral peduncular lesions in the midbrain. The most common pattern of injury (74% in this series) was the combination of focal lesions of the corpus callosum and the dorsolateral brainstem. In patients with no evidence of diffuse axonal injury in the upper brainstem (26% in this series), callosal lesions were most often associated with basal ganglia lesions. Lesions of the corona radiata and lobar white matter were equally distributed in patients with or without dorsolateral brainstem injury. Moreover, cortical contusions and thalamic, parahippocampal, and cerebral peduncular lesions were also similarly distributed in both groups. Conclusions. The: data indicate that diffuse axonal injury may be the major form of primary brain damage in the posttraumatic persistent vegetative state. In addition, the authors demonstrated in this study that MR imaging, in conjunction with a precise clinical correlation, may provide useful supportive information for the accurate diagnosis of a persistent vegetative state after traumatic brain injury.	Univ Innsbruck Hosp, Dept Neurol, Intens Care Unit, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Magnet Resonance & Spect, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Anesthesiol, A-6020 Innsbruck, Austria	Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Intens Care Unit, Anichstr 35, A-6020 Innsbruck, Austria.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BIRBAMER G, 1993, J NEUROL, V240, P407, DOI 10.1007/BF00867352; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CELESIA GG, 1993, NEUROLOGY, V43, P1457, DOI 10.1212/WNL.43.8.1457; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; DOUGHTERY JH, 1998, NEUROLOGY, V31, P991; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FUJIOKA M, 1994, STROKE, V25, P2091, DOI 10.1161/01.STR.25.10.2091; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Grossman P, 1996, DISABIL REHABIL, V18, P1; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; JELLINGER K, 1977, APALLIC SYNDROME, P89; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; KENNARD C, 1995, J NEUROL NEUROSUR PS, V59, P347, DOI 10.1136/jnnp.59.4.347; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; LEE JP, 1991, J TRAUMA, V31, P376, DOI 10.1097/00005373-199103000-00011; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MATSUO F, 1979, ANN NEUROL, V5, P72, DOI 10.1002/ana.410050111; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; ORITA T, 1994, J COMPUT ASSIST TOMO, V18, P943, DOI 10.1097/00004728-199411000-00019; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; PETERS G, 1977, APALLIC SYNDROME, P78; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; WADE TD, 1996, BRIT MED J, V343, P943; WARAGAI M, 1994, NEURORADIOLOGY, V36, P402, DOI 10.1007/BF00612128; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; 1995, N ENGL J MED, V333, P130	55	85	88	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1998	88	5					809	816		10.3171/jns.1998.88.5.0809			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZJ709	WOS:000073244500003	9576247				2021-06-18	
J	Meredith, W; Rutledge, R; Fakhry, SM; Emery, S; Kromhout-Schiro, S				Meredith, W; Rutledge, R; Fakhry, SM; Emery, S; Kromhout-Schiro, S			The conundrum of the Glasgow Coma Scale in intubated patients: A linear regression prediction of the Glasgow Verbal Score from the Glasgow Eye and Motor Scores	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	57th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma and the Japanese-Society-for-Acute-Medicine	SEP 24-27, 1997	WAIKOLOA, HAWAII	Amer Assoc Surg Trauma, Japanese Soc Acute Med			HEAD-INJURED PATIENTS; TRAUMATIC BRAIN INJURY; INTENSIVE-CARE UNIT; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; ACUTE PHYSIOLOGY; RISK-FACTORS; APACHE-II; SEVERITY; MORTALITY	Background: The Glasgow Coma Scale (GCS), which is the foundation of the Trauma Score, Trauma and Injury Severity Score, and the Acute Physiology and Chronic Health Evaluation scoring systems, requires a verbal response. In some series, up to 50% of injured patients must be excluded from analysis because of lack of a verbal component for the GCS. The present study extends previous work evaluating derivation of the verbal score from the eye and motor components of the GCS. Methods: Data were obtained from a state trauma registry for 24,565 unintubated patients. The eye and motor scores were used in a previously published regression model to predict the verbal score: Derived Verbal Score = -0.3756 + Motor Score * (0.5713) + Eye Score * (0.4233). The correlation of the actual and derived verbal and GCS scales were assessed. In addition the ability of the actual and derived GCS to predict patient survival in a logistic regression model were analyzed using the PC SAS system for statistical analysis. The predictive power of the actual and the predicted GCS were compared using the area under the receiver operator characteristic curve and Hosmer-Lemeshow goodness-of-fit testing. Results: A total of 24,085 patients were available for analysis. The mean actual verbal score was 4.4 +/- 1.3 versus a predicted verbal score of 4.3 +/- 1.2 (r = 0.90, p = 0.0001). The actual GCS was 13.6 +/- 3.5 versus a predicted GCS of 13.7 +/- 3.4 (r = 0.97, p = 0.0001). The results of the comparison of the prediction of survival in patients based on the actual GCS and the derived GCS shaw that the mean actual GCS was 13.5 + 3.5 versus 13.7 + 3.4 in the regression predicted model. The area under the receiver operator characteristic curve for predicting survival of the two values was similar at 0.868 for the actual GCS compared with 0.850 for the predicted GCS. Conclusions: The previously derived method of calculating the verbal score from the eye and motor scores is an excellent predictor of the actual verbal score. Furthermore, the derived GCS performed better than the actual GCS by several measures. The present study confirms previous work that a very accurate GCS can be derived in the absence of the verbal component.	Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA; N Carolina Baptist Hosp, Chapel Hill, NC USA; N Carolina Trauma Registry, Chapel Hill, NC USA	Rutledge, R (corresponding author), Univ N Carolina, Dept Surg, Campus Box 7210,Burnett Womack, Chapel Hill, NC 27599 USA.	rrutledg@med.unc.edu					ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; BENESCH CG, 1993, ARCH NEUROL-CHICAGO, V50, P1309, DOI 10.1001/archneur.1993.00540120024008; BRATTON SL, 1994, ARCH PEDIAT ADOL MED, V148, P167, DOI 10.1001/archpedi.1994.02170020053008; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chan Betty, 1993, Journal of Emergency Medicine, V11, P579, DOI 10.1016/0736-4679(93)90312-U; Ellis A, 1992, Intensive Crit Care Nurs, V8, P94, DOI 10.1016/0964-3397(92)90037-K; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENSEMER IB, 1989, ANN EMERG MED, V18, P9, DOI 10.1016/S0196-0644(89)80303-8; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; Hill DA, 1997, J TRAUMA, V42, P62, DOI 10.1097/00005373-199701000-00011; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; KARKELA J, 1992, CRIT CARE MED, V20, P378; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LANZA DC, 1990, ANN OTO RHINOL LARYN, V99, P38, DOI 10.1177/000348949009900106; LEE H, 1992, CRIT CARE MED, V20, P1555, DOI 10.1097/00003246-199211000-00013; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MARGULIES DR, 1994, AM SURGEON, V60, P387; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; METZ CA, 1993, CRIT CARE MED, V21, P1844, DOI 10.1097/00003246-199312000-00010; NISKANEN M, 1991, CRIT CARE MED, V19, P1465, DOI 10.1097/00003246-199112000-00005; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROCCA B, J TRAUMA, V29, P299; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; SANO K, 1994, NEUROL RES, V16, P23; SCHWARTZ ML, 1991, J TRAUMA, V31, P962, DOI 10.1097/00005373-199107000-00013; SEGATORE M, 1992, HEART LUNG, V21, P548; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; TEASDALE G, 1974, LANCET, V2, P81; TERES D, 1982, CRIT CARE MED, V10, P86, DOI 10.1097/00003246-198202000-00004; TUHRIM S, 1991, ANN NEUROL, V29, P658, DOI 10.1002/ana.410290614; TURAZZI S, 1984, ACTA NEUROCHIR, V72, P167, DOI 10.1007/BF01406869; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WOLFGOULD C, 1991, J TROP PEDIATRICS, V38, P290; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; ZIMMERMAN JE, 1989, CRIT CARE MED S, V17, pS169	50	85	86	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1998	44	5					839	845		10.1097/00005373-199805000-00016			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	ZN299	WOS:000073632000015	9603086				2021-06-18	
J	Jupiter, JB; Ring, D				Jupiter, JB; Ring, D			Operative treatment of post-traumatic proximal radioulnar synostosis	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							BONE	The results of operative resection of a post-traumatic proximal radioulnar synostosis performed by one surgeon in eighteen limbs of seventeen consecutive patients during an eight-year period were reviewed retrospectively, The resection was performed an average of nineteen months after the injury; eight limbs had the resection less than twelve months after the injury, A free fat graft was used in the first eight patients, No adjuvant non-steroidal anti-inflammatory medication or low-dose radiation was used postoperatively as prophylaxis against heterotopic ossification, We classified the proximal radioulnar synostoses into three subgroups: A indicated a synostosis at or distal to the bicipital tuberosity (four limbs), B indicated a synostosis involving the radial head and the proximal radioulnar joint (seven limbs), and C indicated a synostosis that was contiguous with bone extending across the elbow to the distal aspect of the humerus (seven limbs), The patients were followed for an average of thirty-four months (range, twenty-four to sixty months), The synostosis recurred in one patient, the only patient in the series who had sustained a closed head injury at the time of the initial injury, Additional complications included a fracture of the ulna, a broken pin on a hinged elbow distracter, and dislodgment of a free nonvascularized fat graft in one patient each, The seventeen limbs that did not have a recurrence regained an average of 139 degrees of rotation of the forearm, With the number of patients available, we could not detect a significant relationship between subsequent rotation of the forearm and the size of the synostosis, the use of interpositional fat, or the concomitant use of a hinged elbow distracter, The eight limbs that had resection of the synostosis less than twelve months after the injury regained an average of 144 degrees of rotation compared with 134 degrees in the nine limbs that had resection at least twelve months after the injury, This difference could not be shown to be significant. In this series, operative resection of a post-traumatic proximal radioulnar synostosis led to good results despite the lack of adjuvant radiation therapy or antiinflammatory medication.	Massachusetts Gen Hosp, Orthopaed Hand Serv, Dept Orthopaed Surg, Boston, MA 02114 USA	Jupiter, JB (corresponding author), Massachusetts Gen Hosp, Orthopaed Hand Serv, Dept Orthopaed Surg, WAC-527, Boston, MA 02114 USA.						ABRAMS RA, 1993, J HAND SURG-AM, V18A, P703, DOI 10.1016/0363-5023(93)90322-T; AYERS DC, 1986, J BONE JOINT SURG AM, V68A, P1423, DOI 10.2106/00004623-198668090-00016; BENJAMIN A, 1982, WATSONJONES FRACTURE, V2, P650; BOTTING TDJ, 1970, J TRAUM, V10, P16, DOI 10.1097/00005373-197001000-00002; BRADY L P, 1960, South Med J, V53, P507; BRADY LW, 1979, SKELETAL RADIOL, V4, P72, DOI 10.1007/BF00349330; BREIT R, 1983, CLIN ORTHOP RELAT R, P149; CARSTAM N, 1971, Scandinavian Journal of Plastic and Reconstructive Surgery, V5, P57; CORLESS JR, 1977, J BONE JOINT SURG BR, V59, P510; CULLEN JP, 1994, J HAND SURG-AM, V19A, P394, DOI 10.1016/0363-5023(94)90051-5; FAILLA JM, 1989, J BONE JOINT SURG AM, V71A, P1208, DOI 10.2106/00004623-198971080-00014; FIELDING JW, 1964, J BONE JOINT SURG AM, V46, P1277, DOI 10.2106/00004623-196446060-00014; FREITAG P, 1981, Orthopaedic Transactions, V5, P42; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Jupiter JB, 1991, INSTRUCTIONAL COURSE, V40, P41; Kapandji I.A., 1982, PHYSL JOINTS, V2nd ed; KELIKIAN H, 1957, J BONE JOINT SURG AM, V39, P945, DOI 10.2106/00004623-195739040-00017; KIM JH, 1978, RADIOLOGY, V129, P501, DOI 10.1148/129.2.501; KONSKI A, 1990, INT J RADIAT ONCOL, V18, P1139, DOI 10.1016/0360-3016(90)90450-X; MAEMPEL EZ, 1984, CLIN ORTHOPAEDICS, V186, P182; MODABBER R, 1995, J BONE JOINT SURG AM, V77, P1431, DOI 10.2106/00004623-199509000-00021; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; ORZEL JA, 1985, J NUCL MED, V26, P1125; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018; SACHAR K, 1994, HAND CLIN, V10, P399; THURSTON AJ, 1993, AUST NZ J SURG, V63, P976, DOI 10.1111/j.1445-2197.1993.tb01728.x; TOOMS RE, 1986, COMPLICATIONS ORTHOP, V1, P325; VINCE KG, 1987, J BONE JOINT SURG AM, V69A, P640, DOI 10.2106/00004623-198769050-00002; WARREN SB, 1992, J BONE JOINT SURG AM, V74A, P201, DOI 10.2106/00004623-199274020-00006; WATSON FM, 1978, J TRAUMA, V18, P467, DOI 10.1097/00005373-197806000-00013; YONGHING K, 1983, J BONE JOINT SURG BR, V65, P435	31	85	86	0	5	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	FEB	1998	80A	2					248	257		10.2106/00004623-199802000-00012			10	Orthopedics; Surgery	Orthopedics; Surgery	YY436	WOS:000072146400012	9486731				2021-06-18	
J	Doppenberg, EMR; Bullock, R				Doppenberg, EMR; Bullock, R			Clinical neuro-protection trials in severe traumatic brain injury: Lessons from previous studies	JOURNAL OF NEUROTRAUMA			English	Article						clinical trials; end-points assessment; mechanism-driven; neuroprotection	SEVERE HEAD-INJURY; CONJUGATED SUPEROXIDE-DISMUTASE; KALLIKREIN-KININ SYSTEM; FLUID-PERCUSSION MODEL; THERAPEUTIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; AXONAL CHANGE; OXYGEN; MEDIATOR; MODERATE	Major advances have been made in understanding the pathophysiological events after severe human traumatic brain injury, and consequently, many compounds have been tested in clinical trials, Thus far, no Phase III trials have been clearly successful, in human neurotrauma, although several Phase II studies have shown apparent benefit, This review is an attempt to identify factors that could be responsible for some of these failures, Recommendations are made that attempt to avoid these pitfalls in the future, Five criteria for future conduct of clinical trials are proposed, The usefulness of animal models for traumatic brain injury and their ability are discussed, Clearly, it is now becoming accepted that mechanism-driven trials, in which individual pathophysiological mechanisms are targeted, may be preferable in this heterogeneous patient population, The degree of brain penetration, the safety and tolerability of the compound, and end points used for outcome assessment are major influences upon the success of these trials, New approaches in developing, conducting, and analyzing these clinical trials should be considered in the future, if the costly failures of the past are not to be repeated, with the advent of newer ''neuroprotective agents'' and techniques.		Doppenberg, EMR (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, POB 980631, RICHMOND, VA 23298 USA.						ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; ADAMS JH, 1983, ACTA NEUROCHIR, V32, pS15; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BROADDUS WC, 1996, 46 ANN M MONTR; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Drummond ME, 1987, METHODS EC EVALUATIO; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GROSSET DG, 1993, J NEUROSURG, V78, P183; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; KHANDELWAL SR, 1993, AM J PHYSIOL, V265, pH1450; LANDOLT H, 1994, ACTA NEUROCHIR, P475; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1996, CRIT CARE MED, V24, pS81; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1996, ACTA NEUROCHIR S, V66, P188; MARMAROU A, 1993, J NEUROTRAUM, V10, pS61; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1994, ADV EXP MED BIOL, V366, P389; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PEERLESS SJ, 1981, STROKE, V12, P558, DOI 10.1161/01.STR.12.5.558; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RANDAD RS, 1991, J MED CHEM, V34, P752, DOI 10.1021/jm00106a041; Sakas DE, 1996, CEREBROVAS BRAIN MET, V8, P209; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; STEIN SC, 1996, NEUROTRAUMA, P755; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WEI EP, 1993, AM J PHYSIOL, V265, pH1439; Whitehead J., 1983, DESIGN ANAL SEQUENTI; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; ZAUNER A, 1997, UNPUB CONTINUOUS MUL	47	85	86	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	1997	14	2					71	80		10.1089/neu.1997.14.71			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WN400	WOS:A1997WN40000001	9069438				2021-06-18	
J	Yang, K; PerezPolo, JR; Mu, XS; Yan, HQ; Xue, JJ; Iwamoto, Y; Liu, SJ; Dixon, CE; Hayes, RL				Yang, K; PerezPolo, JR; Mu, XS; Yan, HQ; Xue, JJ; Iwamoto, Y; Liu, SJ; Dixon, CE; Hayes, RL			Increased expression of brain-derived neurotrophic factor but not neurotrophin-3 mRNA in rat brain after cortical impact injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						gene expression; neurotrophin; BDNF; NT3; traumatic brain injury	NERVE GROWTH-FACTOR; BDNF MESSENGER-RNA; CULTURED HIPPOCAMPAL-NEURONS; TRANSIENT FOREBRAIN ISCHEMIA; LIMBIC SEIZURES; DIFFERENTIAL REGULATION; INSITU HYBRIDIZATION; CEREBRAL-ISCHEMIA; SENSORY NEURONS; RAPID INCREASE	Levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT3) mRNA expression were measured in a rodent model of traumatic brain injury (TBI) following unilateral injury to the cerebral cortex, To obtain reliable data on the co-expression of neurotrophin genes, adjacent coronal sections from the same rat brains were hybridized in situ with BDNF and NT3 cRNA probes, BDNF mRNA increased at 1, 3, and 5 hr after unilateral cortical injury in the cortex ipsilateral to the injury site and bilaterally in the dorsal hippocampus, NT3 mRNA did not change significantly following injury. Our results suggest that TBI produces rapid increases in BDNF mRNA expression in rat brain without changes in NT3 mRNA expression, a finding which differs from studies of ischemia and seizures, It is possible that increased levels of BDNF mRNA rather than NT3 are important components of pathophysiological responses to TBI. (C) 1996 Wiley-Liss, Inc.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOCHEM & GENET,GALVESTON,TX 77550			Perez-Polo, Jose R./B-6250-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 21458, P01 NS 31998] Funding Source: Medline		ANDERSON RF, 1990, NEURON, V5, P297; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; BESSHO Y, 1993, MOL BRAIN RES, V18, P201, DOI 10.1016/0169-328X(93)90190-Z; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FRIEDMAN WJ, 1991, J NEUROSCI, V11, P1577; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL C, 1992, EPILEPSY RES S, V7, P171; GALL C, 1991, EPILEPSY RES S, V4, P225; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, J NEUROSCI, V13, P3394; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KINDSAY RM, 1985, DEV BIOL, V112, P319; KNUSEL B, 1992, J NEUROCHEM, V59, P715, DOI 10.1111/j.1471-4159.1992.tb09427.x; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; KOKAIA Z, 1993, MOL BRAIN RES, V19, P277, DOI 10.1016/0169-328X(93)90126-A; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAISONPIERRE PC, 1990, SCIENCE, V247, P446; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; PRASAD MR, 1994, J NEUROCHEM, V63, P773; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMITH DH, 1993, J NEUROSCI, V13, P5383; SMITH MA, 1995, J NEUROSCI, V15, P1768; SPRINGER JE, 1994, MOL BRAIN RES, V23, P135, DOI 10.1016/0169-328X(94)90219-4; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAKEDA A, 1992, BRAIN RES, V569, P177, DOI 10.1016/0006-8993(92)90388-P; TAKEDA A, 1993, NEUROSCIENCE, V55, P23, DOI 10.1016/0306-4522(93)90451-K; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; ZAAL K, 1993, MOL BRAIN RES, V19, P277; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	55	85	88	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	APR 15	1996	44	2					157	164		10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C			8	Neurosciences	Neurosciences & Neurology	UG271	WOS:A1996UG27100008	8723224				2021-06-18	
J	Roberts, WO; Brust, JD; Leonard, B; Hebert, BJ				Roberts, WO; Brust, JD; Leonard, B; Hebert, BJ			Fair-play rules and injury reduction in ice hockey	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article								Objective: To determine the rate, type, and severity of injuries incurred and penalties assessed during the qualifying fair-play (points for playing without excessive penalties) and championship ''regular'' rules (winner advances) portions of a 1994 Junior Gold ice hockey tournament. Design: A prospective evaluation of injuries by certified athletic trainers at the tournament site. Setting: A community-organized, 3-day, 31-game tournament in Minnesota. Participants: Two hundred seventy-three male players, younger than 20 years and in high school. Measurements/Main Results: Injuries were recorded by an on-site certified athletic trainer, and the penalties were tallied from the score sheets. The injury rates for the total number of injuries were 26.4 injuries per 1000 athlete exposures and 273.8 injuries per 1000 player hours. When only notable injuries (concussion, facial laceration, or moderate level of severity and above) were considered, the injury rates were 10 per 1000 athlete exposures and 103.9 per 1000 player hours. The ratio of notable fair-play to notable regular-rules injuries was 1:4.8. The number of penalties assessed per game averaged 7.1 penalties during fair-play rules and 13 penalties during the regular-rules competition. Penalties related to rough play and injury occurred four times more frequently during games with regular rules than those with fair-play rules. Conclusions: The fair-play concept can reduce injury rates, penalty rates, and severity of penalties and should be considered for ice hockey at all levels of play. The fair-play concept could be applied to other contact sports to reduce injury rates and rules infractions.	UNIV MINNESOTA,SCH MED,DEPT FAMILY PRACTICE & COMMUNITY HLTH,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH NURSING,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; ALLINA HLTH SYST,PUBL AFFAIRS DEPT,MINNEAPOLIS,MN	Roberts, WO (corresponding author), MINNHLTH SPORTSCARE CONSULTANTS,4786 BANNING AVE,WHITE BEAR LAKE,MN 55110, USA.			Roberts, William O/0000-0003-4517-4330			BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; MARCHAND S, 1993, APS J, V2, P103; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Sutherland G W, 1976, Am J Sports Med, V4, P264, DOI 10.1177/036354657600400605; VAZ EW, 1982, PROFESSIONALIZATION; 1994, NCAA9824394 SPORTS S	10	85	86	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	FEB	1996	150	2					140	145		10.1001/archpedi.1996.02170270022003			6	Pediatrics	Pediatrics	TT878	WOS:A1996TT87800003	8556117				2021-06-18	
J	STEIN, SC; SPETTELL, C				STEIN, SC; SPETTELL, C			THE HEAD-INJURY SEVERITY SCALE (HISS) - A PRACTICAL CLASSIFICATION OF CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							GLASGOW COMA SCALE; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC VALUE; DATA-BANK; MANAGEMENT; PREDICTION; DISABILITY; TRAUMA; CONSCIOUSNESS; PRESSURE	The authors introduce a two-dimensional scale for rating closed-head injury, the Head Injury Severity Scale (HISS). This system is based on a five-interval severity classification (minimal through critical), determined primarily by the initial post-resuscitation Glasgow Coma Scale score. The second dimension is predicated on the presence or absence of complications, appropriate for each severity interval. The outcomes of almost 25 000 patients with head injury encountered at our institution over a 7-year period were evaluated. We discovered that adding a complication dimension to each seventy category resulted in significant outcome differences and effectively divided patients into groups with very different risks, prognosis and treatment requirements. The HISS is proposed as a framework on which further research can be done to guide care to predict outcome and to perform audits on head-injured patients.	UNIV MED & DENT NEW JERSEY, COOPER HOSP UNIV MED CTR, ROBERT WOOD JOHNSON MED SCH, DEPT SURG, CAMDEN, NJ 08103 USA; MEDIPLEX REHAB, CAMDEN, NJ 08103 USA							BARLOW P, 1986, NEUROSURGERY, V19, P989, DOI 10.1227/00006123-198612000-00014; BARROW DL, 1983, PHARMACOLOGICAL APPR, P76; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; BECKER DP, 1982, NEUROLOGICAL SURGERY, V4, P1938; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BRAAKMAN R, 1986, ACTA NEUROCHIRUR S36, P112; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CROSBY L, 1989, HEART LUNG, V18, P121; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIBSON RM, 1989, LANCET, V2, P369; HOLMGREN E, 1981, ACTA NEUROCHIR, V56, P141; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; KARNAZE DS, 1985, NEUROLOGY, V35, P1122, DOI 10.1212/WNL.35.8.1122; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KOZIOL JA, 1990, J NEUROL, V237, P461, DOI 10.1007/BF00314762; LANGFITT T, 1989, MILD MODERATE HEAD I, P235; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LINDGREN S, 1986, ACTA NEUROCHIRUR S36, P70; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MURRAY GD, 1986, STAT MED, V5, P403, DOI 10.1002/sim.4780050504; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; PRICE DJ, 1986, ACTA NEUROCHIRUR S36, P67; RANSOHOFF J, 1975, JAMA-J AM MED ASSOC, V234, P861, DOI 10.1001/jama.234.8.861; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Safar P., 1981, BRAIN FAILURE RESUSC, P155; SALCMAN M, 1981, NEUROSURGERY, V8, P15; SEGATORE M, 1992, HEART LUNG, V21, P548; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1989, MILD MODERATE HEAD I, P227; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; YEN JK, 1978, J NEUROL NEUROSUR PS, V41, P1125, DOI 10.1136/jnnp.41.12.1125; 1993, INT CLASSIFICATION D, P77; 1990, ABBERIVATED INJURY S, P15; 1993, INT CLASSIFICATION D, P213	53	85	85	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1995	9	5					437	444		10.3109/02699059509008203			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100002	7550215				2021-06-18	
J	HANSTOCK, CC; FADEN, AI; BENDALL, R; VINK, R				HANSTOCK, CC; FADEN, AI; BENDALL, R; VINK, R			DIFFUSION-WEIGHTED IMAGING DIFFERENTIATES ISCHEMIC TISSUE FROM TRAUMATIZED TISSUE	STROKE			English	Article						BRAIN EDEMA; BRAIN INJURIES; MAGNETIC RESONANCE IMAGING; RATS	MAGNETIC-RESONANCE SPECTROSCOPY; CEREBRAL BLOOD-FLOW; EXPERIMENTAL BRAIN INJURY; T2-WEIGHTED MRI; FLUID; EDEMA; P-31; RATS; PERFUSION; CLEARANCE	Background and Purpose Diffusion-weighted magnetic resonance imaging (MRI) has been shown to be particularly effective in detecting early (0 to 4 hours) pathophysiological changes in localized brain regions after cerebral ischemia. The present study sought to establish whether diffusion-weighted MRI would be similarly effective in predicting outcome after traumatic brain injury. Methods Diffusion-weighted MRI images and T2-weighted MRI images were obtained over 4 hours after either moderate fluid percussion-induced traumatic brain injury or unilateral carotid ligation in rats. Results Diffusion-weighted MRI images of traumatic brain injury demonstrated focal regions of image hypointensity as early as 1 hour after trauma. The relative diffusion coefficient in these hypointense regions was significantly increased (P<.005) by 4 hours after trauma compared with the noninjured hemisphere, but only in the transverse plane in the x direction. In contrast, induction of diffuse, nonfocal ischemia by unilateral carotid ligation resulted in scattered regions of hyperintensity with a significant (P<.001) decrease in relative diffusion coefficient as early as 1 hour after ligation compared with the noninjured hemisphere. This decrease exhibited no directionality. Conclusions We conclude that traumatic brain injury results in an increased water diffusion distance with the directionality indicative of bulk flow of extracellular fluid toward the lateral ventricles (vasogenic edema). In contrast, the decreased water diffusion distance with no apparent directionality observed in ischemia is most likely indicative of cytotoxic edema. Diffusion-weighted MRI therefore has the potential to differentiate cases of traumatic brain injury with no focal ischemia from those instances of traumatic brain injury in which focal ischemia is a complication.	JAMES COOK UNIV N QUEENSLAND, DEPT MOLEC SCI, TOWNSVILLE, QLD 4811, AUSTRALIA; UNIV ALBERTA, DEPT APPL SCI MED, EDMONTON T6G 2E1, ALBERTA, CANADA; GEORGETOWN UNIV, MED CTR, DEPT NEUROL, WASHINGTON, DC 20007 USA			AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		BOUMA GJ, 1992, 1991 MA LIEB INC CEN, P333; BRAUGHLER JM, 1992, 1991 MA LIEB INC CEN, P1; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROCKARD HA, 1987, J CEREBR BLOOD F MET, V7, P394, DOI 10.1038/jcbfm.1987.82; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FADEN AI, 1989, SCIENCE, V244, P7988; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUCHARCZYK J, 1991, MAGNET RESON MED, V19, P311, DOI 10.1002/mrm.1910190220; Kulkarni M V, 1988, Radiographics, V8, P1059; KUWASHIMA J, 1978, JPN J PHARMACOL, V28, P277, DOI 10.1254/jjp.28.277; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1991, MAGNET RESON MED, V19, P221, DOI 10.1002/mrm.1910190206; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; NARITOMI H, 1988, J CEREBR BLOOD F MET, V8, P16, DOI 10.1038/jcbfm.1988.3; REULEN HJ, 1978, J NEUROSURG, V48, P754, DOI 10.3171/jns.1978.48.5.0754; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; SCHUIER FJ, 1980, STROKE, V11, P593, DOI 10.1161/01.STR.11.6.593; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; TAYLOR DG, 1985, PHYS MED BIOL, V30, P341; TORNHEIM PA, 1985, CENTRAL NERVOUS SYST, P431; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; VINK R, 1991, MAGNESIUM EXCITABLE, P695; WEINSTEIN PR, 1990, PROTECTION BRAIN ISC, P111; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOUNG W, 1992, CENTRAL NERVOUS SYST, P9; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	36	85	86	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	1994	25	4					843	848		10.1161/01.STR.25.4.843			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	ND342	WOS:A1994ND34200016	8160231	Bronze			2021-06-18	
J	LYETH, BG; JIANG, JY; LIU, S				LYETH, BG; JIANG, JY; LIU, S			BEHAVIORAL PROTECTION BY MODERATE HYPOTHERMIA INITIATED AFTER EXPERIMENTAL TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							ISCHEMIC NEURONAL INJURY; CEREBRAL-ISCHEMIA; RAT; TEMPERATURE; ACIDS; DEATH	The effects of postinjury hypothermia on behavioral outcome following moderate fluid percussion traumatic brain injury (TBI) were examined. In Experiment 1, three groups of rats were examined. The first group was normothermic (37.5-degrees-C); and hypothermia (30-degrees-C) was initiated 15 min and 30 min postinjury in the second and third groups, respectively. Whole body cooling was achieved by ventral ice pack. Cooling of the brain to 30-degrees-C was achieved in 25 min and maintained for 60 min. Brain temperature was measured indirectly by a probe in the temporalis muscle. Behavioral outcome was assessed by beam-balance performance, beam-walking performance, and body weight loss measured daily for 5 days after TBI. Both the normothermic group and the 30-min postinjury hypothermic group exhibited significant (p < 0.05) beam-balance and beam-walking deficits on days 1 through 5 after TBI. In contrast, the 15-min postinjury hypothermic group exhibited significant (p < 0.05) beam-walking deficits only on day 1 after TBI and significant (p < 0.05) beam-balance deficits on days 1, 3, and 4 after TBI. In Experiment II, subcortical brain temperature was compared to temporalis muscle temperature in normothermic (37.5-degrees-C) and hypothermic (30-degrees-C) rats subjected to TBI. In both groups brain temperature tracked within 0.4-degrees-C of temporalis muscle temperature. These results are similar to post-TBI excitatory receptor antagonist studies and indicate a therapeutic window for moderate hypothermia of less than 30 min after moderate fluid percussion TBI in the rat.	CHANG ZHENG HOSP,DEPT NEUROSURG,SHANGHAI,PEOPLES R CHINA	LYETH, BG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,BOX 693,MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 29995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, R01NS029995, P01NS012587] Funding Source: NIH RePORTER		BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BAKER AJ, 1991, STROKE, V22, P673; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOFFMAN WE, 1991, J NEUROSURG ANESTH, V3, P34, DOI 10.1097/00008506-199103000-00006; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V	20	85	86	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SPR	1993	10	1					57	64		10.1089/neu.1993.10.57			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LC106	WOS:A1993LC10600006	8320732				2021-06-18	
J	OKIYAMA, K; SMITH, DH; THOMAS, MJ; MCINTOSH, TK				OKIYAMA, K; SMITH, DH; THOMAS, MJ; MCINTOSH, TK			EVALUATION OF A NOVEL CALCIUM-CHANNEL BLOCKER, (S)-EMOPAMIL, ON REGIONAL CEREBRAL EDEMA AND NEUROBEHAVIORAL FUNCTION AFTER EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						(S)-EMOPAMIL; CALCIUM CHANNEL BLOCKER; FLUID-PERCUSSION INJURY; CEREBRAL EDEMA; MEMORY; RAT	FLUID-PERCUSSION MODEL; SUBARACHNOID HEMORRHAGE; NMDA RECEPTORS; HEAD-INJURY; BLOOD-FLOW; CELL-DEATH; ISCHEMIA; RAT; NIMODIPINE; CATS	The authors investigated the effects of a novel calcium channel blocker, (S)-emopamil, on cerebral edema and neurobehavioral and memory function following experimental fluid-percussion brain injury in the rat. Two independent experiments were performed to evaluate the effects of this compound on cardiovascular variables and postinjury cerebral edema (increases in tissue water content), and on cognitive deficits and neurological motor function following brain injury. Treatment with (S)-emopamil significantly reduced focal brain edema at 48 hours after brain injury. Profound memory dysfunction induced by brain injury was significantly attenuated following (S)-emopamil treatment. In addition, (S)-emopamil also attenuated the deficits in motor function that were observed over a 2-week period following brain injury. These results suggest that changes in calcium homeostasis may play an important role in the pathogenesis of trauma to the central nervous system and that the calcium channel blocker (S)-emopamil might be a useful compound for the treatment of traumatic brain injury.	UNIV CONNECTICUT, CTR HLTH,DEPT SURG,SURG RES CTR, CENT NERVOUS SYST INJURY LAB, FARMINGTON, CT 06032 USA			smith, douglas/A-1321-2007		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026818, R01NS026818] Funding Source: NIH RePORTER		ALKON DL, 1989, SCI AM, V261, P42, DOI 10.1038/scientificamerican0789-42; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BETZ AL, 1989, STROKE, V20, P1253, DOI 10.1161/01.STR.20.9.1253; BIELENBERG GW, 1989, CEREBRAL ISCHEMIA CA, P274; BLISS T V P, 1988, P3; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHAN PH, 1985, PROG BRAIN RES, V63, P227; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DECOURTENMYERS GM, 1985, STROKE, V16, P1016, DOI 10.1161/01.STR.16.6.1016; DEFEUDIS FV, 1989, TRENDS PHARMACOL SCI, V10, P215, DOI 10.1016/0165-6147(89)90262-9; DIETRICH WD, 1989, J CEREBR BLOOD F MET, V9, P812, DOI 10.1038/jcbfm.1989.115; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GREENBERG DA, 1987, ANN NEUROL, V21, P317, DOI 10.1002/ana.410210402; HOFFMEISTER F, 1985, NIMODIPINE PHARM CLI, P77; HOFMANN HP, 1989, ARZNEIMITTEL-FORSCH, V39-1, P304; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; Kostron H, 1985, Neurochirurgia (Stuttg), V28 Suppl 1, P103; KUCHARCZYK J, 1989, STROKE, V20, P268, DOI 10.1161/01.STR.20.2.268; LEVERE TE, 1989, BEHAV NEUROSCI, V103, P561, DOI 10.1037/0735-7044.103.3.561; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LIU D, 1990, Journal of Neurotrauma, V7, P219, DOI 10.1089/neu.1990.7.219; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MATZEL LD, 1990, J NEUROSCI, V10, P2300; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER JR, 1989, SOC NEUR ABSTR, V15, P534; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NAKAYAMA H, 1988, NEUROLOGY, V38, P1667, DOI 10.1212/WNL.38.11.1667; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PALMER GC, 1988, J NEUROSCI RES, V19, P252, DOI 10.1002/jnr.490190211; ROBINSON MJ, 1990, CEREBROVAS BRAIN MET, V2, P205; ROSS DT, 1989, BRAIN RES, V501, P129, DOI 10.1016/0006-8993(89)91034-2; SATO M, 1984, J CEREBR BLOOD F MET, V4, P173, DOI 10.1038/jcbfm.1984.25; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHIGENO T, 1989, STROKE, V20, P1260, DOI 10.1161/01.STR.20.9.1260; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SQUIRE LR, 1987, MEMORY BRAIN; SZABO L, 1989, ARZNEIMITTEL-FORSCH, V39-1, P309; SZABO L, 1989, ARZNEIMITTELFORSCH, V39-1, P314; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YASUDA SU, 1989, DICP ANN PHARMAC, V23, P451, DOI 10.1177/106002808902300602; Young W, 1985, Cent Nerv Syst Trauma, V2, P109; Young W, 1986, Cent Nerv Syst Trauma, V3, P235; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	63	85	85	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	1992	77	4					607	615		10.3171/jns.1992.77.4.0607			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JP648	WOS:A1992JP64800019	1527621				2021-06-18	
J	HSIEH, AHH; BISHOP, MJ; KUBILIS, PS; NEWELL, DW; PIERSON, DJ				HSIEH, AHH; BISHOP, MJ; KUBILIS, PS; NEWELL, DW; PIERSON, DJ			PNEUMONIA FOLLOWING CLOSED HEAD-INJURY	AMERICAN REVIEW OF RESPIRATORY DISEASE			English	Article							CONTINUOUS MECHANICAL VENTILATION; QUANTITATIVE CULTURE TECHNIQUES; PROTECTED SPECIMEN BRUSH; GRAM-NEGATIVE BACILLI; NOSOCOMIAL PNEUMONIA; RESPIRATORY-TRACT; CARE; RISK; INFECTION; DIAGNOSIS	Pneumonia is common among patients with artificial airways in place. Most prior studies of such pneumonia involve a heterogeneous group of patients, usually with major medical or surgical illnesses. We studied the incidence of pneumonia in a group of patients with isolated closed head injury (CHI) in an effort to determine the pattern of the problem in the absence of other injuries and to determine whether the pattern of development of pneumonia in these patients was comparable to that in more heterogeneous groups of mechanically ventilated patients. We studied 109 initially comatose patients with isolated CHI who were ventilated 24 h or more. The mean age was 30.3 +/- 20.2 yr, 72% were male, and the admission Glasgow coma score was 4.9T +/- 1.4. Overall, 45 patients (41%) developed pneumonia, with the majority (29/45) occurring during the first 3 days of hospitalization. No patient developed pneumonia after the first week despite the fact that many were still ventilated, others remained intubated, and yet others were extubated but comatose. Patients who developed pneumonia experienced a longer ICU stay (10.5 +/- 5.4 days versus 7.2 +/- 4.3 days, p = 0.001) and hospital stay (34.8 +/- 27.6 versus 22.5 +/- 20.2 days, p = 0.01). We concluded that (1) CHI is associated with a high incidence of pneumonia; (2) pneumonia occurs earlier in CHI than in other patient groups, suggesting that the etiology may be different; (3) pneumonia does not tend to occur after the first week of hospitalization in CHI; (4) extubation of CHI patients did not tend to lead to pneumonia; and (5) pneumonia prolongs ICU and hospital stay in CHI patients.	UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT MED PULM & CRIT CARE,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT NEUROSURG,SEATTLE,WA 98104			Pierson, David/AAJ-9872-2021		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30543] Funding Source: Medline		ANDREWS CP, 1981, CHEST, V80, P254, DOI 10.1378/chest.80.3.254; ATHERTON ST, 1978, LANCET, V2, P968; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; BRYAN CS, 1984, AM REV RESPIR DIS, V129, P668, DOI 10.1164/arrd.1984.129.5.668; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; COX DR, 1984, ANAL SURVIVAL DATA; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; CROSS AS, 1981, AM J MED, V70, P681, DOI 10.1016/0002-9343(81)90596-9; DRICKS MR, 1987, NEW ENGL J MED, V317, P1376; ESPERSEN F, 1981, J INFECT DIS, V144, P19, DOI 10.1093/infdis/144.1.19; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; Fleiss JL, 1981, STATISTICAL METHODS; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JIMENEZ P, 1989, CRIT CARE MED, V17, P882, DOI 10.1097/00003246-198909000-00007; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; LAFORCE FM, 1981, AM J MED, V70, P664, DOI 10.1016/0002-9343(81)90593-3; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; LANGER M, 1987, INTENS CARE MED, V13, P342; MANDELLI M, 1986, LANCET, V2, P1094; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; SCHWARTZ SN, 1978, J INFECT DIS, V138, P227, DOI 10.1093/infdis/138.2.227; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523	26	85	86	0	0	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019	0003-0805			AM REV RESPIR DIS	Am. Rev. Respir. Dis.	AUG	1992	146	2					290	294		10.1164/ajrccm/146.2.290			5	Respiratory System	Respiratory System	JP348	WOS:A1992JP34800004	1489114				2021-06-18	
J	LEVIN, HS; GOLDSTEIN, FC				LEVIN, HS; GOLDSTEIN, FC			ORGANIZATION OF VERBAL MEMORY AFTER SEVERE CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article										LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07377, NS 21889] Funding Source: Medline		BADDELEY AD, 1984, CLIN MANAGEMENT MEMO, P5; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BATTIG WF, 1969, J EXP PSYCHOL, V80, P1, DOI 10.1037/h0027577; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; Buschke H., 1984, NEUROPSYCHOLOGY MEMO, P33; BUTTERS N, 1973, NEUROPSYCHOLOGIA, V11, P291, DOI 10.1016/0028-3932(73)90040-7; CERMAK LS, 1973, NEUROPSYCHOLOGIA, V11, P85, DOI 10.1016/0028-3932(73)90068-7; COHEN BH, 1954, 10 U CONN TECH REP; CROVITZ HF, 1979, CORTEX, V15, P225, DOI 10.1016/S0010-9452(79)80027-1; Donaldson W., 1972, ORG MEMORY, P381, DOI [DOI 10.1016/B978-0-12-809324-5.21037-7, DOI 10.1017/S0140525X00047257]; FRANKEL MT, 1985, J EXP CHILD PSYCHOL, V40, P304, DOI 10.1016/0022-0965(85)90092-X; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Jenkins J.J., 1970, NORMS WORD ASS, P1; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWINSOHN PM, 1977, J CONSULT CLIN PSYCH, V45, P717, DOI 10.1037/0022-006X.45.5.717; MARSHALL GR, 1970, NORMS WORD ASS, P321; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; SCHACTER DL, 1986, J CLIN EXP NEUROPSYC, V8, P727, DOI 10.1080/01688638608405192; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; Squire LR, MEMORY BRAIN; STERNBERG RJ, 1977, PSYCHOL BULL, V84, P539, DOI 10.1037/0033-2909.84.3.539; TEASDALE G, 1974, LANCET, V2, P81; Thorndike EL., 1944, TEACHERS WORD BOOK 3; Wechsler, 1981, WAIS R MANUAL; WEINGARTNER H, 1983, SCIENCE, V221, P380, DOI 10.1126/science.6867715; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; Wilson BA, 1984, CLIN MANAGEMENT MEMO; ZATORRE RJ, 1983, BRAIN COGNITION, V2, P331, DOI 10.1016/0278-2626(83)90017-9	34	85	85	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1986	8	6					643	656		10.1080/01688638608405185			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	F0782	WOS:A1986F078200003	3782445				2021-06-18	
J	LEVIN, HS; EISENBERG, HM				LEVIN, HS; EISENBERG, HM			NEUROPSYCHOLOGICAL OUTCOME OF CLOSED HEAD-INJURY IN CHILDREN AND ADOLESCENTS	CHILDS BRAIN			English	Article										LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DEPT SURG,DIV NEUROSURG,GALVESTON,TX 77550, USA.						Benton A., 1968, CORTEX, V4, P344, DOI DOI 10.1016/S0010-9452(68)80018-8; Benton A., 1959, RIGHT LEFT DISCRIMIN; BENTON AL, 1962, ARCH NEUROL-CHICAGO, V7, P347, DOI 10.1001/archneur.1962.04210040099011; Benton AL, 1967, CORTEX, V3, P32, DOI [10.1016/S0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; BENTON AL, 1969, STEREOGNOSIS TEST; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; CRAFT AW, 1972, HDB CLIN NEUROLOGY, V23, P445; DENCKLA MB, 1973, DEV MED CHILD NEUROL, V15, P635; Flach J, 1972, Scand J Rehabil Med, V4, P9; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1969, BRIT J PSYCHIAT; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Koppitz EM, 1964, BENDER GESTALT TEST; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; LEVIN HS, 1977, CORTEX, V13, P119, DOI 10.1016/S0010-9452(77)80003-8; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1976, J PEDIATR PSYCHOL, V1, P38; LEVIN HS, ARCH NEUROL; SCHAFFER D, 1975, CIBA F S, V34; Spreen O., 1969, CORTEX, V5, P171; Spreen O, 1969, NEUROSENSORY CTR COM; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; TEASDALE G, 1974, LANCET, V2, P81; WARRINGT.EK, 1970, NATURE, V228, P628, DOI 10.1038/228628a0	26	85	85	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0302-2803			CHILD BRAIN			1979	5	3					281	292					12	Clinical Neurology; Neurosciences; Pediatrics	Neurosciences & Neurology; Pediatrics	GS718	WOS:A1979GS71800011	456104				2021-06-18	
J	LEECH, PJ; PATERSON, A				LEECH, PJ; PATERSON, A			CONSERVATIVE AND OPERATIVE MANAGEMENT FOR CEREBROSPINAL-FLUID LEAKAGE AFTER CLOSED HEAD-INJURY	LANCET			English	Article									SO GEN HOSP,INST NEUROL SCI,DIV NEUROSURG,GLASGOW G51 4TF,SCOTLAND							ADSON AW, 1948, ARCHS SURG CHICAGO, V58, P623; APPELBAUM A, 1960, J AM MED ASS, V173, P1818; BRAWLEY BW, 1967, J NEUROSURG, V26, P57, DOI 10.3171/jns.1967.26.1part1.0057; CALVERT CA, 1942, P ROY SOC MED, V35, P865; Chiari H, 1884, Z HEILK, V5, P383; CHOROBSKI J, 1950, J NEUROL NEUROSUR PS, V13, P280, DOI 10.1136/jnnp.13.4.280; Dandy WE, 1926, ARCH SURG-CHICAGO, V12, P949, DOI 10.1001/archsurg.1926.01130050003001; Dandy WE, 1944, ARCH SURG-CHICAGO, V49, P75, DOI 10.1001/archsurg.1944.01230020080001; Gissane W, 1940, BRIT J SURG, V27, P717, DOI 10.1002/bjs.18002710811; JEFFERSON A, 1972, BRIT J SURG, V59, P585, DOI 10.1002/bjs.1800590802; JENNETT WB, 1970, INTRO NEUROSURGERY; Lewin W, 1964, Clin Neurosurg, V12, P237; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; LEWIN W, 1951, BRIT MED J, V1, P1, DOI 10.1136/bmj.1.4696.1; LIST C, 1944, J NEUROSURG, V1, P348; MACGEE EE, 1970, J NEUROSURG, V33, P312, DOI 10.3171/jns.1970.33.3.0312; MCKENZIE P, 1967, POSTGRAD MED J, VS 43, P142; MINCY JE, 1966, J TRAUM, V6, P618, DOI 10.1097/00005373-196609000-00007; MORLEY TP, 1957, SURG GYNECOL OBSTET, V104, P88; NORTH JB, 1971, BRIT J SURG, V58, P826, DOI 10.1002/bjs.1800581106; NORTH JB, 1972, LANCET, V1, P598; POTTER JM, 1964, PRACTICAL MANAGEMENT; RASKIND R, 1965, J Int Coll Surg, V43, P141; Raskind R, 1966, Int Surg, V46, P223; TAYLOR J, 1934, T OPHTHAL SOC UK, V54, P312; 1972, LANCET, V1, P134	26	85	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet		1973	1	7811					1013	1015					3	Medicine, General & Internal	General & Internal Medicine	P6495	WOS:A1973P649500001	4122107				2021-06-18	
J	Theadom, A; Parag, V; Dowell, T; McPherson, K; Starkey, N; Barker-Collo, S; Jones, K; Ameratunga, S; Feigin, VL				Theadom, Alice; Parag, Varsha; Dowell, Tony; McPherson, Kathryn; Starkey, Nicola; Barker-Collo, Suzanne; Jones, Kelly; Ameratunga, Shanthi; Feigin, Valery L.		BIONIC Res Grp	Persistent problems 1 year after mild traumatic brain injury: a longitudinal population study in New Zealand	BRITISH JOURNAL OF GENERAL PRACTICE			English	Article						epidemiology; head injury; mild traumatic brain injury; outcome; prediction	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; RELIABILITY; QUESTIONNAIRE; GUIDELINES; VALIDITY; ADULTS; SCALE	Background Mild traumatic brain injury (mTBI) is a common problem in general practice settings, yet previous research does not take into account those who do not attend hospital after injury. This is important as there is evidence that effects may be far from mild. Aim To determine whether people sustain any persistent effects 1 year after mTBI, and to identify the predictors of health outcomes. Design and setting A community-based, longitudinal population study of an mTBI incidence cohort (n = 341) from a mixed urban and rural region (Hamilton and Waikato Districts) of the North Island of New Zealand (NZ). Method Adults (>16 years) completed assessments of cognitive functioning, global functioning, post-concussion symptoms, mood, and quality of life over the year after injury. Results Nearly half of participants (47.9%) reported experiencing four or more post-concussion symptoms 1 year post-injury. Additionally, 10.9% of participants revealed very low cognitive functioning. Levels of anxiety, depression, or reduced quality of life were comparable with the general population. Having at least one comorbidity, history of brain injury, living alone, non-white ethnic group, alcohol and medication use, and being female were significant predictors of poorer outcomes at 12 months. Conclusion Although some people make a spontaneous recovery after mTBI, nearly half continue to experience persistent symptoms linked to their injury. Monitoring of recovery from mTBI may be needed and interventions provided for those experiencing persistent difficulties. Demographic factors and medical history should be taken into account in treatment planning.	[Theadom, Alice; Jones, Kelly] Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Feigin, Valery L.] Natl Inst Stroke & Appl Neurosci, Neurol & Epidemiol, Auckland, New Zealand; [McPherson, Kathryn] Auckland Univ Technol, Hlth & Rehabil Inst, Person Centred Res Ctr, Rehabil, Auckland, New Zealand; [Parag, Varsha] Natl Inst Hlth Innovat, Auckland, New Zealand; [Barker-Collo, Suzanne] Univ Auckland, Sch Psychol, Psychol, Auckland 1, New Zealand; [Ameratunga, Shanthi] Univ Auckland, Sch Populat Hlth, Epidemiol, Auckland 1, New Zealand; [Dowell, Tony] Univ Otago, Primary Hlth Care & Gen Practice, Primary Hlth Care, Wellington, New Zealand; [Starkey, Nicola] Univ Waikato, Sch Psychol, Psychol, Hamilton, New Zealand	Theadom, A (corresponding author), Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, 90 Akoranga Dr, Auckland 1142, New Zealand.	alice.theadom@aut.ac.nz	Jones, Kelly/I-5199-2019; Starkey, Nicola/AAJ-3795-2020; Feigin, Valery/AAF-2313-2019	Starkey, Nicola/0000-0002-4370-8186; Feigin, Valery L./0000-0002-6372-1740; McPherson, Kathryn/0000-0003-1240-8882; Ameratunga, Shanthi/0000-0001-8042-2251; McPherson, Kath/0000-0003-0487-8497	Health Research Council of New ZealandHealth Research Council of New Zealand [09/063A, 11/192]; ABI Management Rehabilitation	This work was funded by the Health Research Council of New Zealand (09/063A, 11/192), although the research was conducted independently from the sponsor. Alice Theadom was co-funded by ABI Management Rehabilitation and Kathryn McPherson holds the Laura Fergusson Trust Chair.	Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P429, DOI 10.1348/014466501163904; Cunningham J, 2011, J EMERG MED, V40, P262, DOI 10.1016/j.jemermed.2008.08.017; Dischinger P, 2003, Annu Proc Assoc Adv Automot Med, V47, P577; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri C Thomas, 2008, Medscape J Med, V10, P90; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; JENNETT B, 1975, LANCET, V1, P480; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; MaGPIe Research Group, 2003, NZ MED J, V116, pU379; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Ontario Neurotrauma Foundation, 2013, GUID CONC MILD TRAUM; Petrie KJ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005374; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; SANCHEZCRAIG M, 1995, AM J PUBLIC HEALTH, V85, P823, DOI 10.2105/AJPH.85.6.823; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	35	84	84	0	9	ROYAL COLL GENERAL PRACTITIONERS	LONDON	14 PRINCES GATE, HYDE PARK, LONDON SW7 1PU, ENGLAND	0960-1643	1478-5242		BRIT J GEN PRACT	Br. J. Gen. Pract.	JAN	2016	66	642					E16	E23		10.3399/bjgp16X683161			8	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	DC3UW	WOS:000369145400003	26719482	Bronze, Green Published			2021-06-18	
J	Sweet, JJ; Benson, LM; Nelson, NW; Moberg, PJ				Sweet, Jerry J.; Benson, Laura M.; Nelson, Nathaniel W.; Moberg, Paul J.			The American Academy of Clinical Neuropsychology, National Academy of Neuropsychology, and Society for Clinical Neuropsychology (APA Division 40) 2015 TCN Professional Practice and 'Salary Survey': Professional Practices, Beliefs, and Incomes of U.S. Neuropsychologists	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neuropsychology.; Salary; Professional Practice; Survey; Income	FOLLOW-UP SURVEY; CAREER SATISFACTION; PSYCHOLOGY; LIFE	Objective: The current survey updated professional practice and income information pertaining to clinical neuropsychology. Methods: Doctoral-level members of the American Academy of Clinical Neuropsychology, Division 40 (Clinical Neuropsychology) of the American Psychological Association, and the National Academy of Neuropsychology and other neuropsychologists, as well as postdoctoral trainees in the Association of Postdoctoral Programs in Clinical Neuropsychology and at other training sites were invited to participate in a web-based survey in early 2015. The sample of 1777 respondents, of whom 1579 were doctoral-level practitioners and 198 were postdoctoral trainees, was larger than the prior 2010 income and practice survey. Results: The substantial proportional change in gender has continued, with women now a clear majority in the postdoctoral trainee sample as well as in the practitioner sample. Dissimilar from the median age trajectory of American Psychological Association members, the median age of clinical neuropsychologists remains essentially unchanged since 1989, indicating a substantial annual influx of young neuropsychologists. The question of whether the Houston Conference training model has become an important influence in the specialty can now be considered settled in the affirmative among postdoctoral trainees and practitioners. Testing assistant usage remains commonplace, and continues to be more common in institutions. The vast majority of clinical neuropsychologists work full-time and very few are unemployed and seeking employment. The numbers of neuropsychologists planning to retire in the coming 5-10years do not suggest a "baby boomer" effect or an unexpected bolus of planned retirements in the next 10 years that would be large enough to be worrisome. Average length of time reported for evaluations appears to be increasing across time. The most common factors affecting evaluation length were identified, with the top three being: (1) goal of evaluation, (2) stamina/health of examinee, and (3) age of examinee. Pediatric specialists remain more likely than others to work part-time, more likely to work in institutions, report lower incomes than respondents with a lifespan professional identity, and are far more likely to be women. Incomes continue to vary considerably by years of clinical practice, work setting, amount of forensic practice, state, and region of country. Neurologists are the number one referral source in institutions and in private practice, as well as for pediatric, adult, and lifespan practitioners. Learning disability is no longer among the top five conditions seen by pediatric neuropsychologists; traumatic brain injury and seizure disorder are common reasons for clinical evaluations at all age ranges. There is a continued increase in forensic practice and a clear consensus on the use of validity testing. There is a substantial interest in subspecialization board certification, with the greatest interest evident among postdoctoral trainees. Income satisfaction, job satisfaction, and work-life balance satisfaction are higher for men. Job satisfaction varies across general work setting and across age range of practice. Work-life balance satisfaction is moderately correlated with income satisfaction and job satisfaction. Again in this five-year interval survey, a substantial majority of respondents reported increased incomes, despite experiencing substantial negative practice effects related to changes in the US health care system. Numerous breakdowns related to income and professional activities are provided. Conclusions: Professional practice survey information continues to provide valuable perspectives regarding consistency and change in the activities, beliefs, and incomes of US clinical neuropsychologists.	[Sweet, Jerry J.; Benson, Laura M.] NorthShore Univ HealthSyst, Evanston, IL USA; [Sweet, Jerry J.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Nelson, Nathaniel W.] Univ St Thomas, Minneapolis, MN USA; [Moberg, Paul J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	Sweet, JJ (corresponding author), NorthShore Univ HealthSyst, Pritzker Sch Med, 909 Davis St,Suite 160, Evanston, IL 60201 USA.; Sweet, JJ (corresponding author), Univ Chicago, Evanston, IL 60201 USA.	jerrysweet@uchicago.edu					American Psychological Association, 2005, APA MEMB PROF DEM CH; American Psychological Association, 2000, APA MEMB PROF DEM CH; American Psychological Association, 2014, APA MEMB PROF DEM CH; American Psychological Association, 2010, APA MEMB PROF DEM CH; Baron IS, 2011, CLIN NEUROPSYCHOL, V25, P1075, DOI 10.1080/13854046.2011.594455; Cox DR, 2010, CLIN NEUROPSYCHOL, V24, P493, DOI 10.1080/13854040902802947; Cummins R.A., 2000, J HAPPINESS STUD, V1, P133, DOI DOI 10.1023/A:1010079728426; Diener E, 2009, SOC INDIC RES SER, V37, P201, DOI [10.1111/j.0963-7214.2004.00501001.x, 10.1007/978-90-481-2350-6_9]; Hannay HJ, 1998, ARCH CLIN NEUROPSYCH, V13, P157, DOI 10.1016/S0887-6177(98)00003-1; HOWARD A, 1986, AM PSYCHOL, V41, P1311, DOI 10.1037/0003-066X.41.12.1311; Judge TA, 2010, J VOCAT BEHAV, V77, P157, DOI 10.1016/j.jvb.2010.04.002; Kahneman D, 2010, P NATL ACAD SCI USA, V107, P16489, DOI 10.1073/pnas.1011492107; Khanna C., 2010, IND ORG PSYCHOL, V48, P23; Khanna C., 2013, IND ORG PSYCHOL, V51, P18; Leigh JP, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-166; Lin L., 2015, MONITOR PSYCHOL  JUL, P17; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Mindt MR, 2010, CLIN NEUROPSYCHOL, V24, P429, DOI 10.1080/13854040903058960; OSTERTAG PA, 1991, PSYCHOL WOMEN QUART, V15, P349, DOI 10.1111/j.1471-6402.1991.tb00413.x; Putnam S., 1989, CLIN NEUROPSYCHOL, V3, P97; Romero HR, 2009, CLIN NEUROPSYCHOL, V23, P761, DOI 10.1080/13854040902881958; Rupert PA, 2012, PROF PSYCHOL-RES PR, V43, P495, DOI 10.1037/a0029420; Shanafelt TD, 2015, MAYO CLIN PROC, V90, P1600, DOI 10.1016/j.mayocp.2015.08.023; Sweet J., 1990, CLIN NEUROPSYCHOL, V4, P101, DOI DOI 10.1080/13854049008401504; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P325, DOI 10.1080/13854040600760488; Sweet JJ, 2011, CLIN NEUROPSYCHOL, V25, P12, DOI 10.1080/13854046.2010.544165; Sweet JJ, 2000, CLIN NEUROPSYCHOL, V14, P18, DOI 10.1076/1385-4046(200002)14:1;1-8;FT018; Sweet JJ, 2000, CLIN NEUROPSYCHOL, V14, P479, DOI 10.1076/clin.14.4.479.7201; The Physicians Foundation, 2014, 2014 SURV AM PHYS PR	29	84	84	1	18	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 17	2015	29	8					1069	1162		10.1080/13854046.2016.1140228			94	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	DF0DC	WOS:000371008200001	26878229	Bronze			2021-06-18	
J	Arciniegas, DB; Wortzel, HS				Arciniegas, David B.; Wortzel, Hal S.			Emotional and Behavioral Dyscontrol After Traumatic Brain Injury	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Pathological laughing and crying; Affective lability; Irritability; Management; Aggression; Traumatic brain injury; Assessment; Disinhibition	CLOSED-HEAD-INJURY; SOCIAL COMMUNICATION-SKILLS; RANDOMIZED CONTROLLED-TRIAL; OF-THE-LITERATURE; AFFECTIVE INSTABILITY; COGNITIVE REHABILITATION; BORDERLINE PERSONALITY; AGGRESSIVE-BEHAVIOR; NEUROPSYCHIATRIC INVENTORY; POSTCONCUSSIVE SYMPTOMS	Emotional and behavioral dyscontrol are relatively common neuropsychiatric sequelae of traumatic brain injury and present substantial challenges to recovery and community participation. Among the most problematic and functionally disruptive of these types of behaviors are pathologic laughing and crying, affective lability, irritability, disinhibition, and aggression. Managing these problems effectively requires an understanding of their phenomenology, epidemiology, and clinical evaluation. This article reviews these issues and provides clinicians with brief and practical suggestions for the management of emotional and behavioral dyscontrol.	[Arciniegas, David B.; Wortzel, Hal S.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Beth K & Stuart C Yudofsky Div Neuropsychiat, Houston, TX 77030 USA; [Arciniegas, David B.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA; [Arciniegas, David B.; Wortzel, Hal S.] Univ Colorado, Sch Med, Dept Psychiat, Neuropsychiat Serv, Aurora, CO USA; [Wortzel, Hal S.] VISN 19 MIRECC, Denver Vet Med Ctr, Denver, CO USA	Arciniegas, DB (corresponding author), TIRR Mem Hermann Res Ctr, 1333 Moursund St,Room 202, Houston, TX 77030 USA.	david.arciniegas@bcm.edu					Aboulafia-Brakha T, 2013, NEUROPSYCHOL REHABIL, V23, P216, DOI 10.1080/09602011.2012.747443; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Allen MH, 2005, J PSYCHIAT PRACT S1, V11, p[5, 110]; Allen Michael H, 2005, J Psychiatr Pract, V11 Suppl 1, P5, DOI 10.1097/00131746-200511001-00002; Alpert JE, 1997, PSYCHIAT CLIN N AM, V20, P453, DOI 10.1016/S0193-953X(05)70322-1; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, P624; American Psychiatric Association, 2006, QUICK REF AM PSYCH A; American Psychiatric Association & DSM-5 Task Force, 2013, DIAGN STAT MAN MENT; Arciniegas, 2000, Curr Treat Options Neurol, V2, P169; Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554; Arciniegas D. B., 2013, MANAGEMENT ADULTS TR; Arciniegas DB, 2008, CRIT CARE CLIN, V24, P737, DOI 10.1016/j.ccc.2008.06.001; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Arciniegas David B, 2011, Dialogues Clin Neurosci, V13, P325; Arciniegas DB, 2013, BEHAV NEUROLOGY NEUR; Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BARRATT E. S., 1959, PERCEPT MOTOR SKILLS, V9, P191; Beresford TP, 2005, BRAIN INJURY, V19, P309, DOI 10.1080/02699050410001720121; Bickett AK, 2013, J HEAD TRAUMA REHABI; Block S H, 1987, Brain Inj, V1, P203, DOI 10.3109/02699058709034459; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Braden C, 2010, BRAIN INJURY, V24, P1298, DOI 10.3109/02699052.2010.506859; Brooks D. N., 1987, J HEAD TRAUMA REHAB, V2, P1; Bryant FB, 2001, J RES PERS, V35, P138, DOI 10.1006/jrpe.2000.2302; CANTAGALLO A, 2002, EURA MEDICOPHYS, V38, P167; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Caracuel A, 2012, NEUROREHABILITATION, V30, P43, DOI 10.3233/NRE-2011-0726; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Monsalve BC, 2012, REV PSIQUIATR SALUD, V5, P160, DOI 10.1016/j.rpsm.2012.02.004; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Chahine LM, 2006, EPILEPSY BEHAV, V8, P610, DOI 10.1016/j.yebeh.2006.01.017; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Chow Tiffany W, 2005, Curr Psychiatry Rep, V7, P376, DOI 10.1007/s11920-005-0040-5; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Corrigan JD, 2005, PSYCHOL ADDICT BEHAV, V19, P131, DOI 10.1037/0893-164X.19.2.131; Craig KJ, 2008, PSYCHIAT RES, V159, P367, DOI 10.1016/j.psychres.2007.03.002; Cummings JL, 2006, CNS SPECTRUMS, V11, P1; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; de Medeiros K, 2010, INT PSYCHOGERIATR, V22, P984, DOI 10.1017/S1041610210000876; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Eames P, 2003, NEUROPSYCHOL REHABIL, V13, P241, DOI 10.1080/09602010244000435; Eames PG, 2001, BRAIN DAM B, P29; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fava M, 1997, PSYCHIAT CLIN N AM, V20, P427, DOI 10.1016/S0193-953X(05)70321-X; Ferguson SD, 2009, J PERS DISORD, V23, P230, DOI 10.1521/pedi.2009.23.3.230; Flanagan SR, 2009, PM&R, V1, P76, DOI 10.1016/j.pmrj.2008.10.013; Flashman LA, 2013, BEHAV NEUROLOGY NEUR, P604; GREEN RL, 1987, AM J PSYCHIAT, V144, P442; Gualtieri CT, 1991, J HEAD TRAUMA REHAB, V6, P90; Guay DRP, 2009, CLIN THER, V31, P1, DOI 10.1016/j.clinthera.2009.01.009; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hankin CS, 2011, J PSYCHIATR PRACT, V17, P170, DOI 10.1097/01.pra.0000398410.21374.7d; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hart T, 2012, J HEAD TRAUMA REHAB, V27, P113, DOI 10.1097/HTR.0b013e31820e686c; HARVEY PD, 1989, J CLIN PSYCHOL, V45, P786, DOI 10.1002/1097-4679(198909)45:5<786::AID-JCLP2270450515>3.0.CO;2-P; Henry C, 2001, J PSYCHIATR RES, V35, P307, DOI 10.1016/S0022-3956(01)00038-3; Henry C, 2008, PSYCHIAT RES, V159, P1, DOI 10.1016/j.psychres.2005.11.016; Herrmann N, 2012, AM J GERIAT PSYCHIAT, V20, P789, DOI 10.1097/JGP.0b013e31823033f3; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jamora CW, 2013, BRAIN INJURY, V27, P1134, DOI 10.3109/02699052.2013.804196; Johansson SH, 2008, BRAIN INJURY, V22, P999, DOI 10.1080/02699050802530573; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kant R, 1998, BRAIN INJURY, V12, P661, DOI 10.1080/026990598122223; Karol RL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1053; Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/jnp.12.2.233; Kilmer RP, 2006, REHABIL PSYCHOL, V51, P232, DOI 10.1037/0090-5550.51.3.232; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kim E, 2006, J NEUROPSYCH CLIN N, V18, P547, DOI 10.1176/appi.neuropsych.18.4.547; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koenigsberg HW, 2002, AM J PSYCHIAT, V159, P784, DOI 10.1176/appi.ajp.159.5.784; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lauterbach EC, 2013, NEUROSCI BIOBEHAV R, V37, P1893, DOI 10.1016/j.neubiorev.2013.03.002; Leon-Carrion J, 2001, REV NEUROLOGIA, V33, P377, DOI 10.33588/rn.3304.2000196; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; LEWIN J, 1992, BRIT J PSYCHIAT, V161, P261, DOI 10.1192/bjp.161.2.261; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Look AE, 2010, PERS INDIV DIFFER, V49, P187, DOI 10.1016/j.paid.2010.03.030; MacKinnon DF, 2006, BIPOLAR DISORD, V8, P1, DOI 10.1111/j.1399-5618.2006.00283.x; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McGrath J, 2000, BEHAV NEUROL, V12, P201, DOI 10.1155/2000/612185; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mendez Mario F., 2009, V24, P168, DOI 10.1159/000197896; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; MICHALS ML, 1993, J CLIN PSYCHOPHARM, V13, P198; Moore SR, 1997, J NEUROL NEUROSUR PS, V63, P89, DOI 10.1136/jnnp.63.1.89; Morey L. C., 1991, PERSONALITY ASSESSME; Muller U, 1999, BRAIN INJURY, V13, P805, DOI 10.1080/026990599121197; Mysiw WJ, 2006, BRAIN INJURY, V20, P905, DOI 10.1080/02699050600743972; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; *NAT CTR HLTH STAT, 2009, INT CLASS DIS; National Institute of Neurological Disorders and Stroke Common Data Elements Team, 2013, TRAUM BRAIN INJ COMM; Olney NT, 2011, BRAIN, V134, P3455, DOI 10.1093/brain/awr297; Pabis DJ, 1996, ANN PHARMACOTHER, V30, P278, DOI 10.1177/106002809603000312; Parmentier C, 2012, EUR PSYCHIAT, V27, P570, DOI 10.1016/j.eurpsy.2011.05.005; Pelegrin-Valero C, 2001, REV NEUROLOGIA, V32, P681, DOI 10.33588/rn.3207.2000180; Poeck K., 1969, HDB CLIN NEUROLOGY, P343; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rabins PV, 2007, CNS SPECTRUMS, V12, P17, DOI 10.1017/S1092852900025979; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rees RJ, 2007, NEUROREHABILITATION, V22, P229; Reich DB, 2009, INT CLIN PSYCHOPHARM, V24, P270, DOI 10.1097/YIC.0b013e32832d6c2f; Ripoll LH, 2012, CURR OPIN PSYCHIATR, V25, P52, DOI 10.1097/YCO.0b013e32834c3f19; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; Scherer KR, 2004, SOC SCI INFORM, V43, P499, DOI 10.1177/0539018404047701; Scott LK, 2009, J NEUROS-PEDIATR, V3, P484, DOI 10.3171/2009.2.PEDS08292; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; SIEVER LJ, 1991, AM J PSYCHIAT, V148, P1647; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Simon RI, 2008, TXB VIOLENCE ASSESSM, P161; Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596; SLOAN R L, 1992, Brain Injury, V6, P315, DOI 10.3109/02699059209034945; Solhan MB, 2009, PSYCHOL ASSESSMENT, V21, P425, DOI 10.1037/a0016869; Sorgi P, 1991, J Neuropsychiatry Clin Neurosci, V3, pS52; Spinella M, 2007, INT J NEUROSCI, V117, P359, DOI 10.1080/00207450600588881; Swartz JR, 1997, J CLIN PSYCHIAT, V58, P212, DOI 10.4088/JCP.v58n0506; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Teichner G, 1999, Rehabil Nurs, V24, P207; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; UDAKA F, 1984, ARCH NEUROL-CHICAGO, V41, P1095, DOI 10.1001/archneur.1984.04050210093023; Umene-Nakano W, 2013, GEN HOSP PSYCHIAT, V35, DOI 10.1016/j.genhosppsych.2012.05.002; van der Naalt J, 2000, BRAIN INJURY, V14, P781; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Votruba KL, 2008, J HEAD TRAUMA REHAB, V23, P65, DOI 10.1097/01.HTR.0000314525.93381.69; Walker AJ, 2010, BRAIN INJURY, V24, P517, DOI 10.3109/02699051003601721; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Willner P, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17210; Willner P, 2013, BRIT J PSYCHIAT, V203, P288, DOI 10.1192/bjp.bp.112.124529; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Wood RLL, 2013, BRAIN INJURY, V27, P253, DOI 10.3109/02699052.2012.743181; Wood RL, 2011, J HEAD TRAUMA REHAB, V26, P202, DOI 10.1097/HTR.0b013e318217b46d; Wood S, 2000, AM J GERIAT PSYCHIAT, V8, P75, DOI 10.1097/00019442-200002000-00010; Wortzel HS, 2008, CNS DRUGS, V22, P531, DOI 10.2165/00023210-200822070-00001; Wortzel HS, 2013, J AM ACAD PSYCHIATRY, V41, P274; Woyshville MJ, 1999, BIOL PSYCHIAT, V45, P261, DOI 10.1016/S0006-3223(98)00152-8; Wroblewski BA, 1997, BRAIN INJURY, V11, P37, DOI 10.1080/026990597123791; Yang CC, 2013, BRAIN INJURY, V27, P1008, DOI 10.3109/02699052.2013.794975; Yang CC, 2012, BRAIN INJURY, V26, P1185, DOI 10.3109/02699052.2012.666374; Yang CC, 2011, BRAIN IMPAIR, V12, P200; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Yudofsky SC, 1985, PSYCHIATRY UPDATE, V4, P142; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160	188	84	88	0	44	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	MAR	2014	37	1					31	+		10.1016/j.psc.2013.12.001			24	Psychiatry	Psychiatry	AD8UM	WOS:000333541200004	24529422				2021-06-18	
J	Davis, PK; Musunuru, H; Walsh, M; Cassady, R; Yount, R; Losiniecki, A; Moore, EE; Wohlauer, MV; Howard, J; Ploplis, VA; Castellino, FJ; Thomas, SG				Davis, Patrick K.; Musunuru, Harsha; Walsh, Mark; Cassady, Robert; Yount, Robert; Losiniecki, Andrew; Moore, Ernest E.; Wohlauer, Max V.; Howard, Janet; Ploplis, Victoria A.; Castellino, Francis J.; Thomas, Scott G.			Platelet Dysfunction is an Early Marker for Traumatic Brain Injury-Induced Coagulopathy	NEUROCRITICAL CARE			English	Article						Traumatic Brain Injury (TBI); Platelet function in TBI; Thromboelastography (TEG); Thromboelastography modified platelet mapping (TEG/PM); Coagulation; Coagulopathy of trauma	SEVERE HEAD-INJURY; INTRAVASCULAR COAGULATION; INTRACEREBRAL HEMORRHAGE; CARE; THROMBELASTOGRAPHY; CONSEQUENCES; ASSOCIATION; MANAGEMENT; SEVERITY; PATIENT	The goal of this study is to determine the presence of platelet dysfunction in patients with traumatic brain injury (TBI). The mechanisms underlying the coagulopathy associated with TBI remain elusive. The question of platelet dysfunction in TBI is unclear. This was a prospective observational study conducted at Memorial Hospital of South Bend, IN, and Denver Health Medical Center, CO. A total of 50 patients sustaining TBI, and not under treatment with anticoagulants or platelet inhibitors, were analyzed utilizing modified thromboelastography (TEG) with platelet mapping (TEG/PM), along with standard coagulation tests. Compared to normal controls, patients with severe TBI had a significantly increased percentage of platelet ADP and arachidonic acid (AA) receptor inhibition. Furthermore, the percentage of ADP inhibition distinguished between survivors and non-survivors in patients with TBI (Mann-Whitney test, P = 0.035). ADP inhibition correlates strongly with severity of TBI (Mann-Whitney test, P = 0.014), while AA inhibition did not. These data indicate that early platelet dysfunction is prevalent after severe TBI, can be measured in a point-of-care setting using TEG/PM, and correlates with mortality. The mechanism responsible for this platelet dysfunction and associated implications for TBI management remains to be defined.	[Davis, Patrick K.; Musunuru, Harsha; Walsh, Mark; Cassady, Robert; Ploplis, Victoria A.; Castellino, Francis J.] Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; [Walsh, Mark; Cassady, Robert; Yount, Robert; Losiniecki, Andrew; Howard, Janet; Thomas, Scott G.] Mem Hosp South Bend, Emergency Trauma Ctr, South Bend, IN 46601 USA; [Walsh, Mark] Indiana Univ Sch Med, South Bend, IN 46617 USA; [Moore, Ernest E.] Univ Colorado, Denver, CO 80045 USA; [Wohlauer, Max V.] Denver Hlth Med Ctr, Dept Surg, Denver, CO USA	Walsh, M (corresponding author), Mem Hosp South Bend, Emergency Trauma Ctr, South Bend, IN 46601 USA.	markwalshmd@gmail.com		Walsh, Mark/0000-0002-5795-1144	CSL Behring; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL013423] Funding Source: NIH RePORTER	Dr. Walsh received consulting fees from CSL Behring.	Akins PT, 2010, NEUROCRIT CARE, V12, P375, DOI 10.1007/s12028-010-9336-3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bartal C, 2009, CURR OPIN ANESTHESIO, V22, P281, DOI 10.1097/ACO.0b013e328325a6be; Bochsen Louise, 2007, Thromb J, V5, P3, DOI 10.1186/1477-9560-5-3; Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Carroll RC, 2009, TRANSL RES, V154, P34, DOI 10.1016/j.trsl.2009.04.001; Chen LQ, 2004, J THORAC CARDIOV SUR, V128, P425, DOI 10.1016/j.jtcvs.2004.02.019; CIAVARELLA D, 1987, BRIT J HAEMATOL, V67, P365, DOI 10.1111/j.1365-2141.1987.tb02359.x; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Creutzfeldt CJ, 2009, STROKE, V40, pE645, DOI 10.1161/STROKEAHA.109.561191; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Enriquez LJ, 2009, BRIT J ANAESTHESI S1, V103, pi14, DOI 10.1093/bja/aep318; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Gonzalez E, 2010, SEMIN THROMB HEMOST, V36, P723, DOI 10.1055/s-0030-1265289; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Inaba K, 2010, J AM COLL SURGEONS, V210, P957, DOI 10.1016/j.jamcollsurg.2010.01.031; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; Kashuk JL, 2010, ANN SURG, V251, P604, DOI 10.1097/SLA.0b013e3181d3599c; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maeda T, 1997, ACT NEUR S, V70, P102; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; SCHOCHL H, 2011, NEUROTRAUMA, V28, P2033, DOI DOI 10.1089/NEU.2010.1744; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P1; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Ziai Wendy C, 2003, J Stroke Cerebrovasc Dis, V12, P201, DOI 10.1016/S1052-3057(03)00075-2	47	84	92	1	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2013	18	2					201	208		10.1007/s12028-012-9745-6			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	105PR	WOS:000316084700007	22847397				2021-06-18	
J	Kerr, ZY; Casa, DJ; Marshall, SW; Comstock, RD				Kerr, Zachary Y.; Casa, Douglas J.; Marshall, Stephen W.; Comstock, R. Dawn			Epidemiology of Exertional Heat Illness Among U.S. High School Athletes	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							CONCUSSION; INJURIES	Background: It is estimated that more than 9000 high school athletes are treated for exertional heat illness annually. Risk factors include being obese and beginning practice during hot and humid weather, when athletes are not yet acclimated to physical exertion in heat. Purpose: To describe the epidemiology of exertional heat illness in high school athletes. Methods: National High School Sports-Related Injury Surveillance System data (2005/2006-2010/2011) were analyzed in 2012 to calculate rates and describe circumstances of exertional heat illness. Results: Exertional heat illness occurred at a rate of 1.20 per 100,000 athlete exposures (95% CI = 1.12, 1.28). Exertional heat illnesses were widely distributed geographically, and most occurred in August (60.3%). Of the exertional heat illnesses reported during practice, almost one third (32.0%) occurred more than 2 hours into the practice session. The exertional heat illness rate in football (4.42 per 100,000 athlete exposures) was 11.4 times that in all other sports combined (95% CI = 8.3, 15.5, p < 0.001). In addition, approximately one third (33.6%) of exertional heat illnesses occurred when a medical professional was not onsite at the time of onset. Conclusions: Although most exertional heat illnesses occurred in football, athletes in all sports and all geographic areas are at risk. Because exertional heat illness frequently occurs when medical professionals are not present, it is imperative that high school athletes, coaches, administrators, and parents are trained to identify and respond to it. Implementing effective preventive measures depends on increasing awareness of exertional heat illness and relevant preventive and therapeutic countermeasures. (Am J Prev Med 2013;44(1):8-14) (C) 2013 American Journal of Preventive Medicine	[Kerr, Zachary Y.; Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Casa, Douglas J.] Univ Connecticut, Korey Stringer Inst, Dept Kinesiol, Storrs, CT USA; [Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA	Comstock, RD (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	dawn.comstock@nationwidechildrens.org		Marshall, Stephen/0000-0002-2664-9233; Kerr, Zachary/0000-0003-1423-1259	Society for Public Health Education (SOPHE)/CDC Student Fellowship in Injury/Violence Prevention and Control; CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; DonJoy Orthotics; EyeBlack; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172, R49CE000674] Funding Source: NIH RePORTER	ZYK was funded by The Society for Public Health Education (SOPHE)/CDC Student 2012 Fellowship in Injury/Violence Prevention and Control.; The content of this report was also funded in part by the CDC Grant Nos. R49/CE000674-01 and R49/CE001172-01. The authors also acknowledge the generous research funding contributions of the National Federation of State High School Associations, DonJoy Orthotics, and EyeBlack.	Anderson SJ, 2000, PEDIATRICS, V106, P158; Armstrong L. E., 1996, MED SCI SPORTS EXERC, V28, P139; Armstrong LE, 2007, MED SCI SPORT EXER, V39, P556, DOI 10.1249/MSS.0b013e31802fa199; Binkley HM, 2002, J ATHL TRAINING, V37, P329; Brady Erik, 2011, US TODAY; Casa D., 2003, NATA NEWS, V6, P24; Casa Douglas J, 2005, Curr Sports Med Rep, V4, P309; Casa DJ, 2012, CURR SPORT MED REP, V11, P115, DOI 10.1249/JSR.0b013e31825615cc; Casa DJ, 2009, J ATHL TRAINING, V44, P332, DOI 10.4085/1062-6050-44.3.332; CDC, 2012, YOUTH RISK BEH SURV; *CDC, 2000, CDC GROWTH CHARTS US; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Council Sports Med, 2011, PEDIATRICS, V128, pE741, DOI 10.1542/peds.2011-1664; Howe AS, 2007, AM J SPORT MED, V35, P1384, DOI 10.1177/0363546507305013; Huffman EA, 2008, J ATHL TRAINING, V43, P624, DOI 10.4085/1062-6050-43.6.624; Kerr ZY, 2013, AM J LIFESTYLE MED, V7, P138, DOI 10.1177/1559827612450683; Luke AC, 2007, CLIN J SPORT MED, V17, P488, DOI 10.1097/JSM.0b013e31815889f2; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Mueller FO, 2009, ANN SURVEY FOOTBALL; Mueller FO, 2010, 28 U N CAR CHAP HILL; Mueller FO, 2011, ANN SURVEY FOOTBALL; National Athletic Trainers' Association, 2009, ATHL TRAIN FILL NEC; National High School Federation, 2011, HIGH SCH SPORTS PART; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Sports Medicine Advisory Committee, 2012, HEAT ACCL HEAT ILLN; United States Census Bureau, 2009, CENS REG US; Yard EE, 2010, J SAFETY RES, V41, P471, DOI 10.1016/j.jsr.2010.09.001; Youth Football Coaches Associaton, 2012, HYDR	29	84	85	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	JAN	2013	44	1					8	14		10.1016/j.amepre.2012.09.058			7	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	071FQ	WOS:000313574700002	23253644				2021-06-18	
J	Juhra, C; Wieskotter, B; Chu, K; Trost, L; Weiss, U; Messerschmidt, M; Malczyk, A; Heckwolf, M; Raschke, M				Juhra, C.; Wieskoetter, B.; Chu, K.; Trost, L.; Weiss, U.; Messerschmidt, M.; Malczyk, A.; Heckwolf, M.; Raschke, M.			Bicycle accidents - Do we only see the tip of the iceberg? A prospective multi-centre study in a large German city combining medical and police data	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Bicycle accidents; Traumatic brain injury; Helmet; Economic impact; Fracture	HELMET LEGISLATION; ROAD	Introduction: Bicycles are becoming increasingly popular. In Munster, a German town with a population of 273,000, bicycles were the main method of transportation in 2009, used more often (37.8%) than cars (36.4%). Each day in Munster, bicycles are used around 450,000 times. In 1982, they were only used around 270,000 times a day. However, the increased use of bicycles has also led to an increased number of bicycle accidents. Methods: Between February 2009 and January 2010, data on bicycle-accidents leading to injuries were collected by the Police of Munster and in all emergency units of the six hospitals in Munster. A systematic acquisition of technical data from the police and the medical data from the hospitals were combined anonymously. None of the forms contained personal data of patients involved, except for patient age and sex as well as time and place of bicycle accidents to match the questionnaires. The data were entered into a central database (MS Access for input/MySQL for data retrieval). Results: 2250 patients were included in this study. For each of these patients either a patient record or a hospital record or a police record or a combination of any of these different records existed in our database. In total, 1767 patients received medical treatment at a hospital and 484 people included in the study did not go to a hospital. Three fatalities occurred as a result of bicycle accidents. Considering reasons for hospital admission, traumatic brain injuries were the leading cause (25.7%). However, the largest resource consumption was attributed to fractures of the upper extremities (36.8%) and lower extremities (29.9%) with major surgery. Discussion: Bicycle accidents occur more frequently than indicated by police records. The results of the Munster Bicycle Study have shown that the actual number of bicycle accidents exceeds the officially reported number by nearly two times. Since bicycle helmets cannot prevent accidents it is recommended not only to focus on helmet use as the only injury prevention method. Other factors, such as weather, pavement and default of traffic, roadworthiness of the bicycles or alcohol/drug abuse also affect the accident rates. (C) 2011 Elsevier Ltd. All rights reserved.	[Juhra, C.; Wieskoetter, B.; Chu, K.; Trost, L.; Raschke, M.] Univ Hosp Munster, Dept Trauma Hand & Reconstruct Surg, D-48149 Munster, Germany; [Weiss, U.; Messerschmidt, M.] Police Munster, Munster, Germany	Juhra, C (corresponding author), Univ Hosp Munster, Dept Trauma Hand & Reconstruct Surg, Waldeyerstr 1, D-48149 Munster, Germany.	juhra@ukmuenster.de	Juhra, Christian/W-4888-2019		German Insurance Association/German Insurers Accident Research; German Insurers Accident Research	This study was funded by the German Insurance Association/German Insurers Accident Research. The German Insurers Accident Research supported the scientific study design, analysis and interpretation of data from a technical perspective. The funding source was not involved in the collection and analysis of the data or in the interpretation of the data from a medical perspective. The joint authors' decision to submit this paper was supported by the funding source.	Andersen LB, 2000, ARCH INTERNAL MED, V160; [Anonymous], 70 MILL DRAHT WERD D; [Anonymous], BAU STADT FAHRR; ECMT, 2000, SAF TRAFF VULN US; Guttler Martina, 2009, FAKTEN FAHRRADHAUPTS; Haileyesus T, 2007, INJURY PREV, V13, P202, DOI 10.1136/ip.2006.014019; Hautzinger H, 1993, DUNKELZIFFER UNFALLE; Karkhaneh M, 2006, INJURY PREV, V12, P76, DOI 10.1136/ip.2005.010942; Macpherson A, 2009, BICYCLE HELMET LEGIS; Naci H, 2009, INJURY PREV, V15, P55, DOI 10.1136/ip.2008.018721; Osberg J.S., 1998, TRANSPORT Q, V52, P61; Richter M, 2001, UNFALLCHIRURG, V104, P733, DOI 10.1007/s001130170075; Richter M, 2005, Z ORTHOPADIE, V146, P604, DOI [10.1055/s-2005-923493, DOI 10.1055/S-2005-923493]; Rivara F P, 1997, Inj Prev, V3, P110, DOI 10.1136/ip.3.2.110; Robinson DL, 2007, ACCIDENT ANAL PREV, V39, P86, DOI 10.1016/j.aap.2006.06.007; Thompson DC, 2005, COCHRANE DATABASE SY, V4; Towner E, 2002, 30 ROAD SAF DFT; Wardlaw MJ, 2000, BRIT MED J, V321, P1582, DOI 10.1136/bmj.321.7276.1582; World Health Organization, TRANSP HLTH HLTH EC	19	84	84	1	33	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	DEC	2012	43	12					2026	2034		10.1016/j.injury.2011.10.016			9	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	028XM	WOS:000310458600011	22105099				2021-06-18	
J	Bossu, P; Cutuli, D; Palladino, I; Caporali, P; Angelucci, F; Laricchiuta, D; Gelfo, F; De Bartolo, P; Caltagirone, C; Petrosini, L				Bossu, Paola; Cutuli, Debora; Palladino, Ilaria; Caporali, Paola; Angelucci, Francesco; Laricchiuta, Daniela; Gelfo, Francesca; De Bartolo, Paola; Caltagirone, Carlo; Petrosini, Laura			A single intraperitoneal injection of endotoxin in rats induces long-lasting modifications in behavior and brain protein levels of TNF-alpha and IL-18	JOURNAL OF NEUROINFLAMMATION			English	Article						Neuroinflammation; Lipopolysaccharide (LPS); Behavioral impairment; Cytokines; Hippocampus; Frontal cortex; Cerebellum	NECROSIS-FACTOR-ALPHA; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; MICROGLIAL ACTIVATION; CYTOKINE TRANSCRIPTS; OBJECT RECOGNITION; INTERLEUKIN-18; LIPOPOLYSACCHARIDE	Background: Systemic inflammation might cause neuronal damage and sustain neurodegenerative diseases and behavior impairment, with the participation of pro-inflammatory cytokines, like tumor necrosis factor (TNF)-alpha and interleukin (IL)-18. However, the potential contribution of these cytokines to behavioral impairment in the long-term period has not been fully investigated. Methods: Wistar rats were treated with a single intraperitoneal injection of LPS (5 mg/ kg) or vehicle. After 7 days and 10 months, the animal behavior was evaluated by testing specific cognitive functions, as mnesic, discriminative, and attentional functions, as well as anxiety levels. Contextually, TNF-alpha and IL-18 protein levels were measured by ELISA in defined brain regions (that is, frontal cortex, hippocampus, striatum, cerebellum, and hypothalamus). Results: Behavioral testing demonstrated a specific and persistent cognitive impairment characterized by marked deficits in reacting to environment modifications, possibly linked to reduced motivational or attentional deficits. Concomitantly, LPS induced a TNF-a increase in the hippocampus and frontal cortex (from 7 days onward) and cerebellum (only at 10 months). Interestingly, LPS treatment enhanced IL-18 expression in these same areas only at 10 months after injection. Conclusions: Overall, these results indicate that the chronic neuroinflammatory network elicited by systemic inflammation involves a persistent participation of TNF-a accompanied by a differently regulated contribution of IL-18. This leads to speculation that, though with still unclear mechanisms, both cytokines might take part in long-lasting modifications of brain functions, including behavioral alteration.	[Bossu, Paola; Palladino, Ilaria; Angelucci, Francesco; Gelfo, Francesca; Caltagirone, Carlo] IRCCS, Fdn Santa Lucia, Rome, Italy; [Cutuli, Debora; Caporali, Paola; Laricchiuta, Daniela; De Bartolo, Paola; Petrosini, Laura] Fdn Santa Lucia, CERC, Rome, Italy; [Cutuli, Debora; Caporali, Paola; Laricchiuta, Daniela; De Bartolo, Paola; Petrosini, Laura] Univ Roma La Sapienza, Dipartimento Psicol, Rome, Italy	Bossu, P (corresponding author), IRCCS, Fdn Santa Lucia, Via Ardeatina 30600179, Rome, Italy.	p.bossu@hsantalucia.it	Cutuli, Debora/K-1081-2016; Laricchiuta, Daniela/K-1080-2016; Bosso, Paola/E-4832-2014; Caltagirone, Carlo/B-4930-2013; De Bartolo, Paola/AAI-2695-2020; CAPORALI, PAOLA/K-8486-2016; NACMIAS, Benedetta/J-5084-2018	Laricchiuta, Daniela/0000-0003-2237-2086; Bosso, Paola/0000-0002-1432-0078; De Bartolo, Paola/0000-0002-0557-3620; CAPORALI, PAOLA/0000-0002-0112-3497; NACMIAS, Benedetta/0000-0001-9338-9040; CUTULI, Debora/0000-0003-4788-2461	Italian Ministry of HealthMinistry of Health, Italy [RF07.96B]	Authors gratefully acknowledge the kind help of F. Foti and D. Saraulli in the various experimental procedures. This study received financial support from Italian Ministry of Health, Grant RF07.96B (PB).	Alboni S, 2011, BRAIN BEHAV IMMUN, V25, P483, DOI 10.1016/j.bbi.2010.11.011; Alboni S, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-9; Alkam T, 2008, BEHAV BRAIN RES, V189, P100, DOI 10.1016/j.bbr.2007.12.014; Barrientos RM, 2006, NEUROBIOL AGING, V27, P723, DOI 10.1016/j.neurobiolaging.2005.03.010; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P450, DOI 10.1016/j.bbi.2009.01.016; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; BLUTHE RM, 1992, BRAIN RES, V573, P318, DOI 10.1016/0006-8993(92)90779-9; Bossu P, 2008, BRAIN BEHAV IMMUN, V22, P487, DOI 10.1016/j.bbi.2007.10.001; Bossu P, 2010, CURR PHARM DESIGN, V16, P4213, DOI 10.2174/138161210794519147; BREDER CD, 1994, P NATL ACAD SCI USA, V91, P11393, DOI 10.1073/pnas.91.24.11393; Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014; Carvey PM, 2003, FRONT BIOSCI S8, P26; Conti B, 1999, MOL BRAIN RES, V67, P46, DOI 10.1016/S0169-328X(99)00034-0; Culhane AC, 1998, MOL PSYCHIATR, V3, P362, DOI 10.1038/sj.mp.4000389; Cunningham C, 2008, BRAIN BEHAV IMMUN, V22, P1117, DOI 10.1016/j.bbi.2008.05.007; Cunningham C, 2009, BIOL PSYCHIAT, V65, P304, DOI 10.1016/j.biopsych.2008.07.024; Curran B, 2001, NEUROSCIENCE, V108, P83, DOI 10.1016/S0306-4522(01)00405-5; Dantzer R, 2001, BRAIN BEHAV IMMUN, V15, P7, DOI 10.1006/brbi.2000.0613; Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Felderhoff-Mueser U, 2005, TRENDS NEUROSCI, V28, P487, DOI 10.1016/j.tins.2005.06.008; Foti F, 2011, CEREBELLUM, V10, P104, DOI 10.1007/s12311-010-0236-z; Frayling TM, 2007, J GERONTOL A-BIOL, V62, P73, DOI 10.1093/gerona/62.1.73; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; GATTI S, 1993, BRAIN RES, V624, P291, DOI 10.1016/0006-8993(93)90090-A; Girault JA, 2004, ARCH NEUROL-CHICAGO, V61, P641, DOI 10.1001/archneur.61.5.641; Giuliani F, 2009, BRAIN RES BULL, V80, P302, DOI 10.1016/j.brainresbull.2009.07.009; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Graybiel AM, 1997, SCHIZOPHRENIA BULL, V23, P459, DOI 10.1093/schbul/23.3.459; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Holmes C, 2003, J NEUROL NEUROSUR PS, V74, P788, DOI 10.1136/jnnp.74.6.788; Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95; Jacewicz M, 2009, FOLIA NEUROPATHOL, V47, P321; Jander S, 2002, J CEREBR BLOOD F MET, V22, P62, DOI 10.1097/00004647-200201000-00008; Janelsins MC, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-23; Jenkins TA, 2009, BEHAV BRAIN RES, V205, P355, DOI 10.1016/j.bbr.2009.07.014; Kakizaki Y, 1999, ENDOCR J, V46, P487, DOI 10.1507/endocrj.46.487; LAYE S, 1994, MOL BRAIN RES, V27, P157, DOI 10.1016/0169-328X(94)90197-X; Medeiros R, 2010, BEHAV BRAIN RES, V209, P165, DOI 10.1016/j.bbr.2010.01.040; Mrak RE, 2009, J ALZHEIMERS DIS, V18, P473, DOI 10.3233/JAD-2009-1158; Nguyen MD, 2004, J NEUROSCI, V24, P1340, DOI 10.1523/JNEUROSCI.4786-03.2004; Pepeu G, 2004, LEARN MEMORY, V11, P21, DOI 10.1101/lm.68104; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Pitossi F, 1997, J NEUROSCI RES, V48, P287, DOI 10.1002/(SICI)1097-4547(19970515)48:4<287::AID-JNR1>3.0.CO;2-7; Pitychoutis PM, 2009, NEUROSCIENCE, V159, P1216, DOI 10.1016/j.neuroscience.2009.01.072; Prinz M, 1999, J NEUROCHEM, V72, P2215, DOI 10.1046/j.1471-4159.1999.0722215.x; Puren AJ, 1998, J INFECT DIS, V178, P1830, DOI 10.1086/314481; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Ricceri L, 2003, NEUROSCI BIOBEHAV R, V27, P377, DOI 10.1016/S0149-7634(03)00068-X; Rothwell NJ, 1996, PHARMACOL THERAPEUT, V69, P85, DOI 10.1016/0163-7258(95)02033-0; Sarter M, 2001, BRAIN RES REV, V35, P146, DOI 10.1016/S0165-0173(01)00044-3; Schmidt OI, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-13; Semmler A, 2007, EXP NEUROL, V204, P733, DOI 10.1016/j.expneurol.2007.01.003; Sifringer M, 2007, NEUROBIOL DIS, V25, P614, DOI 10.1016/j.nbd.2006.11.003; Sugama S, 2004, NEUROSCIENCE, V128, P451, DOI 10.1016/j.neuroscience.2004.07.020; Sugama S, 2002, BRAIN RES, V958, P1, DOI 10.1016/S0006-8993(02)03363-2; Sy HN, 2010, PHARMACOL BIOCHEM BE, V95, P158, DOI 10.1016/j.pbb.2009.12.020; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Weberpals M, 2009, J NEUROSCI, V29, P14177, DOI 10.1523/JNEUROSCI.3238-09.2009; Wheeler RD, 2000, MOL BRAIN RES, V77, P290, DOI 10.1016/S0169-328X(00)00069-3; Yaguchi T, 2010, BEHAV BRAIN RES, V206, P47, DOI 10.1016/j.bbr.2009.08.033; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	62	84	85	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 29	2012	9								101	10.1186/1742-2094-9-101			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	013GB	WOS:000309292800001	22642744	DOAJ Gold, Green Published			2021-06-18	
J	Kim, S; Endres, NK; Johnson, RJ; Ettlinger, CF; Shealy, JE				Kim, Suezie; Endres, Nathan K.; Johnson, Robert J.; Ettlinger, Carl F.; Shealy, Jasper E.			Snowboarding Injuries Trends Over Time and Comparisons With Alpine Skiing Injuries	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						snowboard; skiing; injuries	UPPER-EXTREMITY INJURIES; SPINAL-INJURIES; WRIST; SKIERS; RISK; SEVERITY	Background: Participation in snowboarding as a winter sport is comparable to alpine skiing concerning the demographics of the participants, risk of injury, and variation in types of injuries sustained. Purpose: To examine the types of snowboarding injuries and changes in injury patterns over time. We also sought to highlight important differences in injury patterns between snowboarders and alpine skiers as affected by age, experience, and sex. Study Design: Case control; Level of evidence, 3. Methods: Data were collected on injured snowboarders and skiers in a base-lodge clinic of a ski resort in Vermont over 18 seasons (1988-2006) and included extensive information about injury patterns, demographics, and experience. Control data were also obtained during this time period to provide information about the population at risk. Results: The injury rates were assessed as mean days between injuries (MDBI). The average MDBI for all injuries among snowboarders was 345 as compared with 400 for skiers (the lower the number, the higher the injury rate). The most common type of injury for snowboarders was a wrist injury (MDBI, 1258), while for skiers, it was an anterior cruciate ligament (ACL) sprain (MDBI, 2332). Wrist injuries accounted for 27.6% of all snowboard injuries and 2.8% of skiing injuries, and ACL injuries composed 1.7% of all snowboard injuries and 17.2% of skiing injuries. Among snowboarders, more wrist injuries, shoulder soft tissue injuries, ankle injuries, concussions, and clavicle fractures were seen, while skiers had more ACL sprains, medial collateral ligament (MCL) sprains of the knee, lateral collateral ligament (LCL) sprains of the knee, lower extremity contusions, and tibia fractures. The trend analysis revealed an increased incidence of clavicle fractures (P < .01) and a decrease in MCL injuries (P < .01) and ankle injuries (P < .025) among snowboarders over time. Skiers had a decrease in thumb metacarpophalangeal-ulnar collateral ligament (MCP-UCL) injuries (P < .001) and MCL injuries of the knee (P < .001) over time. We found the highest rate of injury among young, inexperienced, female snowboarders. When examining the location of injury, 21.8% of snowboard injuries occurred in the terrain park compared with 6.5% of ski injuries. Conclusion: Injury rates in snowboarders have fluctuated over time but currently remain higher than in skiers. Wrist, shoulder, and ankle injuries are more common among snowboarders, while knee ligament injuries are more common in skiers. Injured snowboarders were significantly younger, less experienced, and more likely to be female than injured skiers or snowboard control participants. We did not find any evidence that those who spend time in terrain parks are overrepresented in the injury population.	[Kim, Suezie; Endres, Nathan K.; Johnson, Robert J.] Univ Vermont, Coll Med, Dept Orthopaed & Rehabil, Burlington, VT USA; [Ettlinger, Carl F.] Vermont Ski Safety Equipment Corp, Underhill, VT USA	Kim, S (corresponding author), NYU, Hosp Joint Dis, Dept Orthopaed Surg, 301 E 17th St,Room 1402, New York, NY 10003 USA.	suezie.kim@nyumc.org					ABULABAN RB, 1991, CAN MED ASSOC J, V145, P1097; Ackery A, 2007, INJURY PREV, V13, P368, DOI 10.1136/ip.2007.017285; Bissell BT, 2008, AM J SPORT MED, V36, P1880, DOI 10.1177/0363546508318195; Chow TK, 1996, J TRAUMA, V41, P321, DOI 10.1097/00005373-199608000-00021; Davidson TM, 1996, WESTERN J MED, V164, P231; Davies H, 2009, KNEE SURG SPORT TR A, V17, P1048, DOI 10.1007/s00167-008-0695-7; DeMorat G, 2004, AM J SPORT MED, V32, P477, DOI 10.1177/0363546503258928; Dohjima T, 2001, ACTA ORTHOP SCAND, V72, P657, DOI 10.1080/000164701317269111; Domire ZJ, 2011, J BIOMECH, V44, P1630, DOI 10.1016/j.jbiomech.2011.03.001; Franz T, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.038166; Greenwald RM, 1998, AM J SPORT MED, V26, P825, DOI 10.1177/03635465980260061501; Hagel B, 2005, ACCIDENT ANAL PREV, V37, P103, DOI 10.1016/j.aap.2004.04.003; Hagel B, 2005, AM J EPIDEMIOL, V162, P149, DOI 10.1093/aje/kwi181; Hagel BE, 2004, EPIDEMIOLOGY, V15, P279, DOI 10.1097/01.ede.0000120044.62029.b4; Hagel BE, 1999, CLIN J SPORT MED, V9, P9, DOI 10.1097/00042752-199901000-00003; Hayes JR, 2008, J PEDIATR SURG, V43, P928, DOI 10.1016/j.jpedsurg.2007.12.041; Idzikowski JR, 2000, AM J SPORT MED, V28, P825, DOI 10.1177/03635465000280061001; Janes PC, 1999, AM SOC TEST MATER, V1345, P141, DOI 10.1520/STP12364S; Johnson RJ, 1989, ASTM STP, P25; Johnson RJ, 2009, AM SOC TEST MATER, V1510, P11, DOI 10.1520/STP47461S; Kary JM, 2008, CURR SPORT MED REP, V7, P35, DOI 10.1097/01.CSMR.0000308670.07441.4f; Kirkpatrick DP, 1998, AM J SPORT MED, V26, P271, DOI 10.1177/03635465980260021901; Langran M, 2004, AM J SPORT MED, V32, P96, DOI 10.1177/0095399703258684; Langran M, 2002, BRIT J SPORT MED, V36, P135, DOI 10.1136/bjsm.36.2.135; Machold W, 2002, J TRAUMA, V52, P517, DOI 10.1097/00005373-200203000-00016; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; Matsumoto K, 2002, CLIN J SPORT MED, V12, P354, DOI 10.1097/00042752-200211000-00006; O'Neill DF, 1999, AM J SPORT MED, V27, P94; O'Neill DF, 2003, CLIN ORTHOP RELAT R, P91, DOI 10.1097/01.blo.0000057785.10364.dc; Ogawa H, 2010, AM J SPORT MED, V38, P532, DOI 10.1177/0363546509348763; Ronning R, 2000, AM J SPORT MED, V28, P506, DOI 10.1177/03635465000280041001; Ronning R, 2001, AM J SPORT MED, V29, P581, DOI 10.1177/03635465010290051001; Russell K, 2007, CLIN J SPORT MED, V17, P145, DOI 10.1097/JSM.0b013e31803f901b; Sakamoto Y, 2008, AM J SPORT MED, V36, P943, DOI 10.1177/0363546507313573; Sasaki K, 1999, J TRAUMA, V46, P1059, DOI 10.1097/00005373-199906000-00015; Shealy JE, 1989, SKIING TRAUMA SAFETY, P75; Snowsports Industries America, SNOW SPORTS FACT SHE; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5; Wasden CC, 2009, J TRAUMA, V67, P1022, DOI 10.1097/TA.0b013e3181b0d559; Yamakawa H, 2001, J TRAUMA, V50, P1101, DOI 10.1097/00005373-200106000-00020; Yamauchi K, 2010, AM J SPORT MED, V38, P1468, DOI 10.1177/0363546509361190	41	84	86	1	30	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2012	40	4					770	776		10.1177/0363546511433279			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	918XO	WOS:000302285100005	22268231				2021-06-18	
J	Feng, JF; Liu, J; Zhang, XZ; Zhang, L; Jiang, JY; Nolta, J; Zhao, M				Feng, Jun-Feng; Liu, Jing; Zhang, Xiu-Zhen; Zhang, Lei; Jiang, Ji-Yao; Nolta, Jan; Zhao, Min			Guided Migration of Neural Stem Cells Derived from Human Embryonic Stem Cells by an Electric Field	STEM CELLS			English	Article						Human neural stem cells; Directional cell migration; Electric field; Electrotaxis; Rho-kinase; C-X-C chemokine receptor type 4	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; IN-VITRO; PROGENITOR CELLS; HIPPOCAMPAL-NEURONS; DIRECTED MIGRATION; PRECURSOR CELLS; SPINAL-CORD; RAT MODEL; TRANSPLANTATION	Small direct current (DC) electric fields (EFs) guide neurite growth and migration of rodent neural stem cells (NSCs). However, this could be species dependent. Therefore, it is critical to investigate how human NSCs (hNSCs) respond to EF before any possible clinical attempt. Aiming to characterize the EF-stimulated and guided migration of hNSCs, we derived hNSCs from a well-established human embryonic stem cell line H9. Small applied DC EFs, as low as 16 mV/mm, induced significant directional migration toward the cathode. Reversal of the field polarity reversed migration of hNSCs. The galvanotactic/electrotactic response was both time and voltage dependent. The migration directedness and distance to the cathode increased with the increase of field strength. (Rho-kinase) inhibitor Y27632 is used to enhance viability of stem cells and has previously been reported to inhibit EF-guided directional migration in induced pluripotent stem cells and neurons. However, its presence did not significantly affect the directionality of hNSC migration in an EF. Cytokine receptor [C-X-C chemokine receptor type 4 (CXCR4)] is important for chemotaxis of NSCs in the brain. The blockage of CXCR4 did not affect the electrotaxis of hNSCs. We conclude that hNSCs respond to a small EF by directional migration. Applied EFs could potentially be further exploited to guide hNSCs to injured sites in the central nervous system to improve the outcome of various diseases. STEM CELLS 2012; 30:349355.	[Feng, Jun-Feng; Liu, Jing; Zhang, Xiu-Zhen; Zhang, Lei; Nolta, Jan; Zhao, Min] Univ Calif Davis, Inst Regenerat Cures, Sch Med, Sacramento, CA 95817 USA; [Feng, Jun-Feng; Zhang, Xiu-Zhen; Zhang, Lei; Zhao, Min] Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA; [Liu, Jing; Nolta, Jan] Univ Calif Davis, Sch Med, Dept Internal Med, Stem Cells Program, Sacramento, CA 95817 USA; [Zhao, Min] Univ Calif Davis, Sch Med, Dept Ophthalmol, Sacramento, CA 95817 USA; [Feng, Jun-Feng; Jiang, Ji-Yao] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200030, Peoples R China	Zhao, M (corresponding author), Univ Calif Davis, Inst Regenerat Cures, Sch Med, 2921 Stockton Blvd, Sacramento, CA 95817 USA.	minzhao@ucdavis.edu		Nolta, Jan/0000-0003-4576-8542	California Institute of Regenerative MedicineCalifornia Institute for Regenerative Medicine [RB1-01417, TR1-01257]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01EY019101, 5P30AG010129, 5RC1AG036022-02, 2P51RR000169-49]; NSFNational Science Foundation (NSF) [MCB-0951199]; UC Davis; Research to Prevent Blindness, Inc.Research to Prevent Blindness (RPB); NSFCNational Natural Science Foundation of China (NSFC) [30901543]; Shriners of Northern California; CIRMCalifornia Institute for Regenerative Medicine; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000169] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY019101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010129, RC1AG036022] Funding Source: NIH RePORTER	We thank Dr. Lin Cao and other members from the Zhao and Nolta laboratories for assistance. This work was supported by grants from the California Institute of Regenerative Medicine RB1-01417 (to M.Z.) and TR1-01257 (to J.N.). M.Z. is also supported by NIH 1R01EY019101, NSF MCB-0951199, and UC Davis Dermatology Developmental Fund, and in part by the Research to Prevent Blindness, Inc. J.N. is also supported by the NIH (5P30AG010129, 5RC1AG036022-02, and 2P51RR000169-49). J.F.F. is supported by NSFC (30901543). J.L. is supported by a fellowship from the Shriners of Northern California.; M.Z. has research funding/contracted research with CIRM.	Aguirre A, 2005, J NEUROSCI, V25, P11092, DOI 10.1523/JNEUROSCI.2981-05.2005; Arocena M, 2010, J NEUROSCI RES, V88, P3267, DOI 10.1002/jnr.22502; CASSEL JC, 1993, NEUROSCI LETT, V150, P89, DOI 10.1016/0304-3940(93)90115-2; Chang TC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009187; Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374; CORK RJ, 1994, J NEUROBIOL, V25, P1509, DOI 10.1002/neu.480251204; Cormie P, 2007, NEUROSCI LETT, V411, P128, DOI 10.1016/j.neulet.2006.10.030; Cummings BJ, 2006, NEUROL RES, V28, P474, DOI 10.1179/016164106X115116; Darsalia V, 2011, J CEREBR BLOOD F MET, V31, P235, DOI 10.1038/jcbfm.2010.81; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Hartman NW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015856; Hatami M, 2009, CYTOTHERAPY, V11, P618, DOI 10.1080/14653240903005802; Heng BC, 2009, TISSUE CELL, V41, P376, DOI 10.1016/j.tice.2009.01.004; HINKLE L, 1981, J PHYSIOL-LONDON, V314, P121, DOI 10.1113/jphysiol.1981.sp013695; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jin KL, 2010, AGING CELL, V9, P1076, DOI 10.1111/j.1474-9726.2010.00638.x; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Joo KM, 2009, MOL THER, V17, P570, DOI 10.1038/mt.2008.290; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Khaidoyanidi S, 2008, CELL STEM CELL, V2, P198, DOI 10.1016/j.stem.2008.02.012; Kim SK, 2006, CLIN CANCER RES, V12, P5550, DOI 10.1158/1078-0432.CCR-05-2508; Koyanagi M, 2008, J NEUROSCI RES, V86, P270, DOI 10.1002/jnr.21502; Lee SH, 2009, NEUROL RES, V31, P996, DOI 10.1179/174313209X385626; Li L, 2008, STEM CELLS, V26, P2193, DOI 10.1634/stemcells.2007-1022; Li QA, 2011, J SURG RES, V166, P162, DOI 10.1016/j.jss.2009.08.031; Li XY, 2008, STEM CELLS DEV, V17, P1079, DOI 10.1089/scd.2007.0247; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; McCaig CD, 2005, PHYSIOL REV, V85, P943, DOI 10.1152/physrev.00020.2004; Meng XT, 2011, EXP NEUROL, V227, P210, DOI 10.1016/j.expneurol.2010.11.002; Miller RJ, 2008, J NEUROIMMUNOL, V198, P31, DOI 10.1016/j.jneuroim.2008.04.008; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; PATEL N, 1982, J NEUROSCI, V2, P483; Rajasekharan S, 2010, J NEUROCHEM, V113, P1589, DOI 10.1111/j.1471-4159.2010.06717.x; RAJNICEK AM, 1992, EXP PHYSIOL, V77, P229, DOI 10.1113/expphysiol.1992.sp003580; Rajnicek AM, 2006, J CELL SCI, V119, P1723, DOI 10.1242/jcs.02896; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Robinson KR, 2008, DEV NEUROBIOL, V68, P274, DOI 10.1002/dneu.20570; Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272; Shih CC, 2007, STEM CELLS DEV, V16, P893, DOI 10.1089/scd.2007.0070; Song B, 2007, NAT PROTOC, V2, P1479, DOI 10.1038/nprot.2007.205; Srivastava AS, 2006, STEM CELLS, V24, P1689, DOI 10.1634/stemcells.2005-0531; Suzuki T, 2006, STEM CELLS, V24, P2406, DOI 10.1634/stemcells.2005-0587; Tai GP, 2009, METHODS MOL BIOL, V571, P77, DOI 10.1007/978-1-60761-198-1_5; van der Meulen AAE, 2009, NEUROPATH APPL NEURO, V35, P579, DOI 10.1111/j.1365-2990.2009.01036.x; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Yao L, 2008, J CELL PHYSIOL, V216, P527, DOI 10.1002/jcp.21431; Yao L, 2009, HIPPOCAMPUS, V19, P855, DOI 10.1002/hipo.20569; Yasuhara T, 2006, J NEUROSCI, V26, P12497, DOI 10.1523/JNEUROSCI.3719-06.2006; Zhang J., 2011, STEM CELL REV; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 2009, SEMIN CELL DEV BIOL, V20, P674, DOI 10.1016/j.semcdb.2008.12.009	56	84	90	0	54	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	FEB	2012	30	2					349	355		10.1002/stem.779			7	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	877UW	WOS:000299209200026	22076946	Bronze, Green Accepted			2021-06-18	
J	Yu, FS; Wang, ZF; Tchantchou, F; Chiu, CT; Zhang, YM; Chuang, DM				Yu, Fengshan; Wang, Zhifei; Tchantchou, Flaubert; Chiu, Chi-Tso; Zhang, Yumin; Chuang, De-Maw			Lithium Ameliorates Neurodegeneration, Suppresses Neuroinflammation, and Improves Behavioral Performance in a Mouse Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						GSK-3/beta; lithium; neuroinflammation; neuroprotection; traumatic brain injury	GLYCOGEN-SYNTHASE KINASE-3; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; BARRIER BREAKDOWN; NEURONAL SURVIVAL; BIPOLAR DISORDER; RAT MODEL; CYCLOOXYGENASE-2; MICE; INHIBITION	Although traumatic brain injury (TBI) is recognized as one of the leading causes of death from trauma to the central nervous system (CNS), no known treatment effectively mitigates its effects. Lithium, a primary drug for the treatment of bipolar disorder, has been known to have neuroprotective effects in various neurodegenerative conditions such as stroke. Until this study, however, it has not been investigated as a post-insult treatment for TBI. To evaluate whether lithium could have beneficial effects following TBI, lithium at a dose of 1.5 mEq/kg was administered after injury. Assessed at 3 days and 3 weeks post-injury using hematoxylin and eosin staining, lithium treatment was found to reduce lesion volume. Lithium at doses of 2.0 and 3.0 mEq/kg also significantly reduced lesion volume at 3 days after injury, and the therapeutic window was at least 3 h post-injury. TBI-induced neuronal death, microglial activation, and cyclooxygenase-2 induction were all attenuated by lithium at 3 days after injury. In addition, lithium treatment reduced TBI-induced matrix metalloproteinase-9 expression and preserved the integrity of the blood brain barrier. As for behavioral outcomes, lithium treatment reduced anxiety-like behavior in an open-field test, and improved short- and long-term motor coordination in rotarod and beam-walk tests. Lithium robustly increased serine phosphorylation of glycogen synthase kinase-3 beta (GSK-3 beta), suggesting that the underlying mechanisms responsible for lithium's protective effects are triggered by increasing phosphorylation of this kinase and thereby inhibiting its activity. Our results support the notion that lithium has heretofore unrecognized capacity to mitigate the neurodegenerative effects and improve functional outcomes in TBI.	[Yu, Fengshan; Wang, Zhifei; Chiu, Chi-Tso; Chuang, De-Maw] NIMH, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA; [Yu, Fengshan; Zhang, Yumin; Chuang, De-Maw] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Yu, Fengshan; Tchantchou, Flaubert; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, NIH, 10 Ctr Dr,MSC 1363, Bethesda, MD 20892 USA.	yzhang@usuhs.mil; chuang@mail.nih.gov	Wang, Zhifei/I-2787-2013	Yu, Fengshan/0000-0001-8620-3084	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Blast Lethality Injury and Research Program; National Institute of Mental Health, National Institutes of Health (NIMH-NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002468] Funding Source: NIH RePORTER	Support for this work included funding from the Department of Defense in the Center for Neuroscience and Regenerative Medicine, the Blast Lethality Injury and Research Program, and the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (NIMH-NIH). The authors wish to gratefully acknowledge the editorial assistance of Dr. Elizabeth Sherman, Ioline Henter, and Peter Leeds of the NIMH. We are also grateful to Dr. Oz Malkesman, Laura Tucker, and Dr. Amanda Fu from the Center for Neuroscience and Regenerative Medicine for help with behavioral tests and CCI surgery.	Adachi M, 2008, BIOL PSYCHIAT, V63, P642, DOI 10.1016/j.biopsych.2007.09.019; Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Andreasson K, 2010, PROSTAG OTH LIPID M, V91, P104, DOI 10.1016/j.prostaglandins.2009.04.003; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Beurel E, 2010, TRENDS IMMUNOL, V31, P24, DOI 10.1016/j.it.2009.09.007; Bijur GN, 2000, J NEUROCHEM, V75, P2401, DOI 10.1046/j.1471-4159.2000.0752401.x; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Cheng T, 2006, NAT MED, V12, P1278, DOI 10.1038/nm1498; Chiu CT, 2010, PHARMACOL THERAPEUT, V128, P281, DOI 10.1016/j.pharmthera.2010.07.006; Chuang DM, 2007, BIOL PSYCHIAT, V62, P4, DOI 10.1016/j.biopsych.2007.04.008; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Kirshenboim N, 2004, J MOL NEUROSCI, V24, P237, DOI 10.1385/JMN:24:2:237; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Koh SH, 2008, BIOCHEM BIOPH RES CO, V371, P894, DOI 10.1016/j.bbrc.2008.05.006; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Li XH, 2010, NEUROPSYCHOPHARMACOL, V35, P2143, DOI 10.1038/npp.2010.105; Liang MH, 2007, J BIOL CHEM, V282, P3904, DOI 10.1074/jbc.M605178200; Liang MH, 2006, J BIOL CHEM, V281, P30479, DOI 10.1074/jbc.M607468200; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Niwa K, 2000, J NEUROSCI, V20, P763, DOI 10.1523/JNEUROSCI.20-02-00763.2000; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; Omata N, 2011, INT J NEUROPSYCHOPH, V14, P711, DOI 10.1017/S1461145710000726; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Quiroz JA, 2010, NEUROPSYCHOBIOLOGY, V62, P50, DOI 10.1159/000314310; Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100; Rosell A, 2008, STROKE, V39, P1121, DOI 10.1161/STROKEAHA.107.500868; Rowe MK, 2007, NEUROSCI BIOBEHAV R, V31, P920, DOI 10.1016/j.neubiorev.2007.03.002; Sassi RB, 2002, NEUROSCI LETT, V329, P243, DOI 10.1016/S0304-3940(02)00615-8; Senatorov VV, 2004, MOL PSYCHIATR, V9, P371, DOI 10.1038/sj.mp.4001463; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Walker CT, 2010, BRAIN RES, V1347, P125, DOI 10.1016/j.brainres.2010.05.075; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Yasuda S, 2009, MOL PSYCHIATR, V14, P51, DOI 10.1038/sj.mp.4002099; Yu F, 2008, J NEUROTRAUM, V25, P184, DOI 10.1089/neu.2007.0438; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196; Yuskaitis CJ, 2009, CELL SIGNAL, V21, P264, DOI 10.1016/j.cellsig.2008.10.014; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	59	84	86	1	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					362	374		10.1089/neu.2011.1942			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300015	21895523	Green Published			2021-06-18	
J	Barha, CK; Ishrat, T; Epp, JR; Galea, LAM; Stein, DG				Barha, Cindy K.; Ishrat, Tauheed; Epp, Jonathan R.; Galea, Liisa A. M.; Stein, Donald G.			Progesterone treatment normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Progesterone; Hippocampal neurogenesis	18 KDA TSPO; ESTRADIOL ENHANCES NEUROGENESIS; FOCAL CEREBRAL-ISCHEMIA; DENDRITIC SPINE DENSITY; BINDING PROTEIN 25-DX; ADULT MALE-MICE; FLUORO-JADE-B; PROGENITOR CELLS; NEURONAL DIFFERENTIATION; FUNCTIONAL DEFICITS	Traumatic brain injury (TB!) increases cell death in the hippocampus and impairs hippocampus-dependent cognition. The hippocampus is also the site of ongoing neurogenesis throughout the lifespan. Progesterone treatment improves behavioral recovery and reduces inflammation, apoptosis, lesion volume, and edema, when given after TBI. The aim of the present study was to determine whether progesterone altered cell proliferation and short-term survival in the dentate gyrus after TBI. Male Sprague-Dawley rats with bilateral contusions of the frontal cortex or sham operations received progesterone or vehicle at 1 and 6 h post-surgery and daily through post-surgery Day 7, and a single injection of bromodeoxyuridine (BrdU) 48 h after injury. Brains were then processed for Ki67 (endogenous marker of cell proliferation), BrdU (short-term cell survival), doublecortin (endogenous marker of immature neurons), and Fluoro-jade B (marker of degenerating neurons). TBI increased cell proliferation compared to shams and progesterone normalized cell proliferation in injured rats. Progesterone alone increased cell proliferation in intact rats. Interestingly, injury and/or progesterone treatment did not influence short-term cell survival of BrdU-ir cells. All treatments increased the percentage of BrdU-ir cells that were co-labeled with doublecortin (an immature neuronal marker in this case labeling new neurons that survived 5 days), indicating that cell fate is influenced independently by TBI and progesterone treatment. The number of immature neurons that survived 5 days was increased following TBI, but progesterone treatment reduced this effect. Furthermore, TBI increased cell death and progesterone treatment reduced cell death to levels seen in intact rats. Together these findings suggest that progesterone treatment after TBI normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus. (C) 2011 Elsevier Inc. All rights reserved.	[Barha, Cindy K.; Galea, Liisa A. M.] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada; [Epp, Jonathan R.; Galea, Liisa A. M.] Univ British Columbia, Grad Program Neurosci, Vancouver, BC V6T 1Z4, Canada; [Galea, Liisa A. M.] Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z4, Canada; [Ishrat, Tauheed; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA USA	Galea, LAM (corresponding author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	lgalea@psych.ubc.ca	Stein, Donald/AAJ-5139-2020	Barha, Cindy/0000-0003-3149-5539; Galea, Liisa/0000-0003-2874-9972	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for Medical Research; BHR Pharma; LLC; Allen Company;  [U01-NSO-62676-02A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS062676] Funding Source: NIH RePORTER	We would like to thank Stephanie Lieblich for assistance with this work. Financial support for this research was provided by the Canadian Institutes of Health Research (LAMG) and U01-NSO-62676-02A2 (DGS). CKB and JRE are funded by Michael Smith Foundation for Medical Research senior trainee awards. LAMG is a Michael Smith Senior Scholar. DGS receives research support from BHR Pharma, LLC and Allen & Company.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Barha CK, 2009, HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION, P2165; Barha CK, 2009, J NEUROENDOCRINOL, V21, P155, DOI 10.1111/j.1365-2826.2008.01809.x; Barha CK, 2011, HIPPOCAMPUS, V21, P1216, DOI 10.1002/hipo.20829; BARHA CK, NEUROBIOL AGING; Batarseh A, 2010, MOL CELL ENDOCRINOL, V327, P1, DOI 10.1016/j.mce.2010.06.013; Baulieu EE, 2000, HUM REPROD, V15, P1; Bimonte-Nelson HA, 2004, BEHAV NEUROSCI, V118, P707, DOI 10.1037/0735-7044.118.4.707; Birzniece V, 2006, BRAIN RES REV, V51, P212, DOI 10.1016/j.brainresrev.2005.11.001; Boonyaratanakornkit V, 2008, STEROIDS, V73, P922, DOI 10.1016/j.steroids.2008.01.010; Brandt MD, 2010, EUR J NEUROSCI, V32, P1256, DOI 10.1111/j.1460-9568.2010.07410.x; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Brown RC, 2001, INT REV NEUROBIOL, V46, P117; Butz M, 2008, HIPPOCAMPUS, V18, P879, DOI 10.1002/hipo.20445; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Bottino MC, 2011, BREAST CANCER RES TR, V126, P621, DOI 10.1007/s10549-010-0971-3; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Choi JM, 2003, ENDOCRINOLOGY, V144, P4734, DOI 10.1210/en.2003-0216; Chrousos GP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3143pe36; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Dalla C, 2009, P NATL ACAD SCI USA, V106, P2927, DOI 10.1073/pnas.0809650106; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Eadie BD, 2005, J COMP NEUROL, V486, P39, DOI 10.1002/cne.20493; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Epp JR, 2011, NEUROSCIENCE, V172, P342, DOI 10.1016/j.neuroscience.2010.10.025; Epp JR, 2010, HIPPOCAMPUS, V20, P866, DOI 10.1002/hipo.20692; Epp JR, 2009, NEUROBIOL LEARN MEM, V91, P437, DOI 10.1016/j.nlm.2009.01.001; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Falkenstein E, 2000, PHARMACOL REV, V52, P513; FARR SA, 1995, PHYSIOL BEHAV, V58, P715, DOI 10.1016/0031-9384(95)00124-2; Foy MR, 2010, VITAM HORM, V82, P219, DOI 10.1016/S0083-6729(10)82012-6; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2009, NEUROSCIENTIST, V15, P324, DOI 10.1177/1073858409333069; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; GOULD E, 1990, J NEUROSCI, V10, P1286; Gould E, 2001, P NATL ACAD SCI USA, V98, P10910, DOI 10.1073/pnas.181354698; Gould E, 1997, J NEUROSCI, V17, P2492; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Harburger LL, 2008, BEHAV BRAIN RES, V194, P174, DOI 10.1016/j.bbr.2008.07.014; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Huang S, 1998, MECH DEVELOP, V71, P23, DOI 10.1016/S0925-4773(97)00199-8; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jessberger S, 2007, J NEUROSCI, V27, P5967, DOI 10.1523/JNEUROSCI.0110-07.2007; Johansson IM, 2002, BRAIN RES, V934, P125, DOI 10.1016/S0006-8993(02)02414-9; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Kronenberg G, 2003, J COMP NEUROL, V467, P455, DOI 10.1002/cne.10945; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Lavenex P, 2000, EUR J NEUROSCI, V12, P643, DOI 10.1046/j.1460-9568.2000.00949.x; Leclerc N, 1996, MOL BIOL CELL, V7, P443; Leuner B, 2009, J COMP NEUROL, V517, P123, DOI 10.1002/cne.22107; Liu LF, 2009, ENDOCRINOLOGY, V150, P3186, DOI 10.1210/en.2008-1447; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Ormerod BK, 2004, NEUROSCIENCE, V128, P645, DOI 10.1016/j.neuroscience.2004.06.039; Ormerod BK, 2001, NEUROSCIENCE, V102, P369, DOI 10.1016/S0306-4522(00)00474-7; Orr PI, 2009, PHARMACOL BIOCHEM BE, V93, P177, DOI 10.1016/j.pbb.2009.05.012; Packard D S Jr, 1973, Differentiation, V1, P397, DOI 10.1111/j.1432-0436.1973.tb00137.x; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Ramirez-Rodriguez G, 2009, NEUROPSYCHOPHARMACOL, V34, P2180, DOI 10.1038/npp.2009.46; Reyna-Neyra A, 2002, BRAIN RES BULL, V58, P607, DOI 10.1016/S0361-9230(02)00829-8; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sliwowska JH, 2010, STRESS, V13, P302, DOI 10.3109/10253890903531582; Smith Sheryl S, 2004, Cleve Clin J Med, V71 Suppl 2, pS4; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; Stein DG, 2007, PROG BRAIN RES, V161, P339, DOI 10.1016/S0079-6123(06)61024-8; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stein DG, 2010, AM J ROENTGENOL, V194, P20, DOI 10.2214/AJR.09.3407; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Tsutsui K, 2004, NEUROSCI RES, V49, P273, DOI 10.1016/j.neures.2004.03.006; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wang JP, 2009, BRAIN RES BULL, V79, P426, DOI 10.1016/j.brainresbull.2009.05.018; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zhang Z, 2010, NEUROPHARMACOLOGY, V58, P930, DOI 10.1016/j.neuropharm.2010.01.002; Zhang Z, 2010, HIPPOCAMPUS, V20, P402, DOI 10.1002/hipo.20642; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	130	84	87	0	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2011	231	1					72	81		10.1016/j.expneurol.2011.05.016			10	Neurosciences	Neurosciences & Neurology	810DX	WOS:000294106700009	21684276	Green Accepted			2021-06-18	
J	Sink, EL; Beaule, PE; Sucato, D; Kim, YJ; Millis, MB; Dayton, M; Trousdale, RT; Sierra, RJ; Zaltz, I; Schoenecker, P; Monreal, A; Clohisy, J				Sink, Ernest L.; Beaule, Paul E.; Sucato, Daniel; Kim, Young-Jo; Millis, Michael B.; Dayton, Michael; Trousdale, Robert T.; Sierra, Rafael J.; Zaltz, Ira; Schoenecker, Perry; Monreal, Amy; Clohisy, John			Multicenter Study of Complications Following Surgical Dislocation of the Hip	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							ANTERIOR FEMOROACETABULAR IMPINGEMENT; FEMORO-ACETABULAR IMPINGEMENT; OSTEOCHONDROPLASTY; CLASSIFICATION; ARTHROSCOPY; HEAD	Background: Surgical hip dislocation enables complete exposure of the hip joint for treatment of various hip disorders. There is limited information regarding the complications associated with this procedure. Our purpose is to report the incidence of complications associated with surgical dislocation of the hip in a large, multicenter patient cohort. Methods: A retrospective, multicenter analysis of patients who had undergone surgical hip dislocation was performed. Patients who had undergone a simultaneous osteotomy were excluded. Complications were recorded, with specific assessment for osteonecrosis, trochanteric nonunion, femoral neck fracture, nerve injury, heterotopic ossification, and thromboembolic disease. We graded complications with a validated classification scheme that includes five grades based on the treatment required to manage the complication and any long-term morbidity. With this classification, a Grade-I complication is one that requires no change in the routine postoperative course, Grade II requires a change in outpatient management, Grade III requires invasive surgical or radiologic management, Grade IV is associated with long-term morbidity or is life-threatening, and Grade V results in death. Results: The study included 334 hips in 302 patients seen at eight different North American centers. There were eighteen complications (5.4%) that were classified as Grade I (not clinically relevant and required no deviation from routine postoperative care). There were six complications (1.8%) classified as Grade II (treated on an outpatient basis or with close observation and resolved). There were nine complications (2.7%) classified as Grade III (treatable and resolved with surgery or inpatient management). There was one complication (0.3%) classified as Grade IV (resulting in a long-term deficit). A total of thirty hips had one or more complications, for an overall incidence of 9%. Excluding heterotopic ossification, the complication rate was sixteen (4.8%) of 334. Conclusions: Surgical hip dislocation is a safe procedure with a low complication rate. Many of the complications were clinically unimportant heterotopic ossification. There were no cases of femoral head osteonecrosis or femoral neck fracture, and, with the exception of one sciatic neurapraxia that partially resolved, no other complication resulted in long-term morbidity.	[Sink, Ernest L.; Monreal, Amy] Childrens Hosp, Aurora, CO 80045 USA	Sink, EL (corresponding author), Childrens Hosp, 13123 E 16th Ave, Aurora, CO 80045 USA.	sinke@hss.edu		Beaule, Paul E./0000-0001-7667-9994			Beaule PE, 2007, J BONE JOINT SURG BR, V89B, P9, DOI 10.1302/0301-620X.89B1.18011; Beaule PE, 2007, J BONE JOINT SURG AM, V89A, P773, DOI 10.2106/JBJS.F.00681; Beck M, 2004, CLIN ORTHOP RELAT R, P67; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; Byrd JWT, 2010, CLIN ORTHOP RELAT R, V468, P741, DOI 10.1007/s11999-009-0841-7; Clavien PA, 2009, ANN SURG, V250, P197, DOI 10.1097/SLA.0b013e3181b6dcab; Clohisy JC, 2010, J BONE JOINT SURG AM, V92A, P1697, DOI 10.2106/JBJS.I.00326; Clohisy JC, 2010, CLIN ORTHOP RELAT R, V468, P555, DOI 10.1007/s11999-009-1138-6; Davey JP, 1999, CLIN ORTHOP RELAT R, P33; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Espinosa N, 2006, J BONE JOINT SURG AM, V88A, P925, DOI 10.2106/JBJS.E.00290; Espinosa Norman, 2007, J Bone Joint Surg Am, V89 Suppl 2 Pt.1, P36, DOI 10.2106/JBJS.F.01123; Ganz R, 2001, J BONE JOINT SURG BR, V83B, P1119, DOI 10.1302/0301-620X.83B8.11964; Goldhahn S, 2009, J BONE JOINT SURG AM, V91A, P1847, DOI 10.2106/JBJS.H.01455; Larson CM, 2008, ARTHROSCOPY, V24, P540, DOI 10.1016/j.arthro.2007.11.007; Peters CL, 2006, J BONE JOINT SURG AM, V88A, P1735, DOI 10.2106/JBJS.E.00514; Philippon MJ, 2009, J BONE JOINT SURG BR, V91B, P16, DOI 10.1302/0301-620X.91B1.21329; Tannast M, 2010, OPER ORTHOPADE TRAUM, V22, P3, DOI 10.1007/s00064-010-3001-7	18	84	89	0	2	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	JUN 15	2011	93A	12					1132	1136		10.2106/JBJSJ.00794			5	Orthopedics; Surgery	Orthopedics; Surgery	777LX	WOS:000291623400006	21571987				2021-06-18	
J	Beauchamp, MH; Ditchfield, M; Babl, FE; Kean, M; Catroppa, C; Yeates, KO; Anderson, V				Beauchamp, Miriam H.; Ditchfield, Michael; Babl, Franz E.; Kean, Michael; Catroppa, Cathy; Yeates, Keith O.; Anderson, Vicki			Detecting Traumatic Brain Lesions in Children: CT versus MRI versus Susceptibility Weighted Imaging (SWI)	JOURNAL OF NEUROTRAUMA			English	Article						child; CT; MRI; SWI; TBI	DIFFUSE AXONAL INJURY; HEAD-INJURY; MILD; PREDICTION; MODERATE; CLASSIFICATION; ADOLESCENTS; CHILDHOOD; SYMPTOMS; RULE	Cranial CT scans are at the center of decision making in brain injuries in children because of their speed and ability to detect surgically relevant lesions. However, alternative techniques, such as conventional MRI may have advantages in terms of radiation exposure and sensitivity to detect brain injury. Susceptibility-weighted imaging (SWI), a relatively novel MRI sequence, shows promise in terms of its sensitivity in detecting hemorrhagic lesions; however, its clinical potential remains uncertain. In this observational study of children (5-16 years of age) with traumatic brain injury (TBI) at a tertiary pediatric emergency department (ED) we compared the ability of detecting traumatic brain lesions on acute CT and MRI/SWI similar to 5 weeks post-injury based on detecting the presence or absence, extent, and type of traumatic brain lesions. We analyzed the results of 76 patients (53 male) after TBI (mean age 10.24 +/- 2.50 years, range 5.75-14.67 years). Glasgow Coma Score was 13-15 in 54 patients (71%), 9-12 in 13 patients (17%) and <8 in 9 patients (12%). CTs were completed in the ED; MRI and SWI were completed at a mean of 36.11 +/- 15.75 days post-injury. Detection of any lesions occurred on CT scan in 68%, on MRI in 54%, and on SWI in 86% of cases, and SWI detected additional lesions 30% of the time compared to CT and MRI. SWI may be more sensitive in detecting traumatic lesions than CT or MRI. This may be important for the ongoing management of TBIs and their prognosis.	[Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Ditchfield, Michael] Monash Med Ctr, Melbourne, Vic, Australia; [Babl, Franz E.; Kean, Michael; Catroppa, Cathy; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia; [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	Victoria Neurotrauma Initiative [CO6E1]	We gratefully acknowledge the financial support of the Victoria Neurotrauma Initiative (No. CO6E1) and the research assistance of Ms. Louise Crossley.	Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; COFFEY CE, 1991, AM PSYCHOP, P243; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Conners GP, 1999, PEDIATR EMERG CARE, V15, P241; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Gazelle GS, 2005, RADIOLOGY, V235, P361, DOI 10.1148/radiol.2352040330; Giza CC, 2001, J ATHL TRAINING, V36, P228; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; VADE A, 1995, AM J ROENTGENOL, V165, P905, DOI 10.2214/ajr.165.4.7676990; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Woischneck D, 2003, CHILD NERV SYST, V19, P174, DOI 10.1007/s00381-002-0703-z; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Zhu GW, 2009, J INT MED RES, V37, P983, DOI 10.1177/147323000903700402	39	84	86	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					915	927		10.1089/neu.2010.1712			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600006	21501069				2021-06-18	
J	Chard, KM; Schumm, JA; McIlvain, SM; Bailey, GW; Parkinson, RB				Chard, Kathleen M.; Schumm, Jeremiah A.; McIlvain, Susan M.; Bailey, Gregory W.; Parkinson, R. Bruce			Exploring the Efficacy of a Residential Treatment Program Incorporating Cognitive Processing Therapy-Cognitive for Veterans With PTSD and Traumatic Brain Injury	JOURNAL OF TRAUMATIC STRESS			English	Article							POSTTRAUMATIC-STRESS-DISORDER	As the numbers of military personnel participating in the wars in Afghanistan and Iraq continue to grow, the percentage of individuals who return with both a traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) also increases. Although there appears to be significant overlap in the symptoms resulting from PTSD and TBI, the best course of treatment remains an area of controversy. The authors present initial findings from a Veterans Administration residential program for comorbid PTSD and TBI. Forty-two participants completed a program comprising psychoeducational groups and cognitive skill building that was augmented with a modification of standard cognitive processing therapy. The results suggest that residential programs that incorporate this form of cognitive therapy can anticipate meaningful participation from patients, and that it may be an effective approach to treat PTSD in individuals with a history of TBI.	[Chard, Kathleen M.; Schumm, Jeremiah A.; McIlvain, Susan M.; Bailey, Gregory W.; Parkinson, R. Bruce] Cincinnati VA Med Ctr, PTSD & Anxiety Disorders Div, Cincinnati, OH 45220 USA; [Chard, Kathleen M.; Schumm, Jeremiah A.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA	Chard, KM (corresponding author), Cincinnati VA Med Ctr, PTSD & Anxiety Disorders Div, 3200 Vine St, Cincinnati, OH 45220 USA.	Kathleen.Chard@va.gov	Schumm, Jeremiah/I-9634-2019				Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Chard KM, 2005, J CONSULT CLIN PSYCH, V73, P965, DOI 10.1037/0022-006X.73.5.965; Chard KM, 2008, COGNITIVE PROCESSING; Department of Veterans Affairs Department of Defense, 2009, VA DOD CLIN PRACT GU; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; First MB., 2002, STRUCTURED CLIN INTE; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; RESICK PA, 1992, J CONSULT CLIN PSYCH, V60, P748, DOI 10.1037/0022-006X.60.5.748; Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Twamley E. W., 2008, COGNITIVE SYMP UNPUB; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Weathers FW, 1993, P ANN C INT SOC TRAU	24	84	84	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	JUN	2011	24	3					347	351		10.1002/jts.20644			5	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	773ZF	WOS:000291350300014	21626573				2021-06-18	
J	Martini, DN; Sabin, MJ; DePesa, SA; Leal, EW; Negrete, TN; Sosnoff, JJ; Broglio, SP				Martini, Douglas N.; Sabin, Matthew J.; DePesa, Sarah A.; Leal, Elisa W.; Negrete, Tabitha N.; Sosnoff, Jacob J.; Broglio, Steven P.			The Chronic Effects of Concussion on Gait	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Cognitive function; Dual task; Motor control; Rehabilitation; Traumatic brain injuries (TBIs)	POSTURAL-CONTROL; INTERNATIONAL-CONFERENCE; RECURRENT CONCUSSION; MOTOR FUNCTION; SPORT; STABILITY; STATEMENT	Martini DN, Sabin MJ, DePesa SA, Leal EW, Negrete TN, Sosnoff JJ, Broglio SP. The chronic effects of concussion on gait. Arch Phys Med Rehabil 2011;92:585-9. Objective: To examine the effects of concussion on gait patterns of young adults with and without a history of concussion during single- and dual-task paradigms. Design: Cross-sectional evaluation. Setting: A research laboratory. Participants: Persons with (n=28; mean, 6.32y postinjury) and without (n=40) a concussion history. Intervention: Not applicable. Main Outcome Measures: A battery of gait analyses during single- and dual-task conditions. Normalized velocity, step length, stride width, number correct from cognitive task, time in single-leg stance, and time in double-leg stance were the variables of interest. Gait was analyzed using an electronic walkway system, and the Brooks visuospatial cognitive task was used to index cognition. Results: Data analyses using multiple 2-way repeated-measures analyses of variance and correlations indicated that participants with a history of concussion spent significantly more time in a double-leg stance and significantly decreased time in a single-leg stance and had slower gait velocity. There also was a significant negative correlation between number of concussions and time in single-leg stance and positive correlations between number of concussions and time in double-leg stance and double-stance percent. Conclusion: These findings suggest that persons with a history of concussion adopt a more conservative gait strategy.	[Broglio, Steven P.] Univ Illinois, Dept Kinesiol & Community Hlth, Neurotrauma Res Lab, Urbana, IL 61801 USA; [Sosnoff, Jacob J.] Univ Illinois, Motor Control Lab, Urbana, IL 61801 USA	Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, Neurotrauma Res Lab, 906 Goodwin Ave, Urbana, IL 61801 USA.	broglio@illinois.edu	Sosnoff, Jacob/P-3397-2019	Sosnoff, Jacob/0000-0002-0286-9207			Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; BROOKS LR, 1967, Q J EXP PSYCHOL, V19, P289, DOI 10.1080/14640746708400105; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; EBERSBACH G, 1995, PERCEPT MOTOR SKILL, V81, P107, DOI 10.2466/pms.1995.81.1.107; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; *GAITRITE I, 2006, GAITRITE EL WALKW ME, P9; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Montero-Odasso M, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-35; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Paterson KL, 2008, ARCH PHYS MED REHAB, V89, P2360, DOI 10.1016/j.apmr.2008.06.018; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Siu KC, 2007, GAIT POSTURE, V25, P121, DOI 10.1016/j.gaitpost.2006.02.002; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Voisin T, 2009, DRUG AGING, V26, P135, DOI 10.2165/0002512-200926020-00005; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Webster KE, 2005, GAIT POSTURE, V22, P317, DOI 10.1016/j.gaitpost.2004.10.005	31	84	84	0	28	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2011	92	4					585	589		10.1016/j.apmr.2010.11.029			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	743VT	WOS:000289047500009	21440703				2021-06-18	
J	Carroll, E; Coetzer, R				Carroll, Emma; Coetzer, Rudi			Identity, grief and self-awareness after traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Identity; Traumatic brain injury; Psychotherapy	HOSPITAL ANXIETY; HEAD-INJURY; DEPRESSION; DISORDERS; ESTEEM; NARRATIVES; DISTRESS; DEFICITS; THERAPY	The objective of this study was to investigate perceived identity change in adults with traumatic brain injury (TBI) and explore associations between identity change, grief, depression, self-esteem and self-awareness. The participants were 29 adults with TBI who were being followed up by a community brain injury rehabilitation service. Participants were longer post-injury than those more commonly studied. Time since injury ranged from 2.25 to 40 years (mean = 11.17 years, SD = 11.4 years). Participants completed a battery of questionnaires. Significant others and clinicians completed a parallel version of one of these measures. Questionnaires included the Head Injury Semantic Differential Scale (HISDS-III), Brain Injury Grief Inventory (BIGI), Hospital Anxiety and Depression Scale - Depression, Rosenberg Self-Esteem Scale (RSES) and the Awareness Questionnaire (Self/Significant other/Clinician versions). The main findings were that participants reported significant changes in self-concept with current self being viewed negatively in comparison to pre-injury self. Perceived identity change was positively associated with depression and grief and negatively associated with self-esteem and awareness. Awareness was negatively associated with self-esteem and positively associated with depression. These findings were consistent with previous research, revealing changes in identity following TBI. Further research is needed to increase our understanding of the psychological factors involved in emotional adjustment after TBI and to inform brain injury rehabilitation interventions, including psychotherapy approaches.	[Carroll, Emma] Belfast Hlth & Social Care Trust, Royal Victoria Hosp, Belfast, Antrim, North Ireland	Coetzer, R (corresponding author), Betsi Cadwaladr Univ, N Wales Brain Injury Serv, Hlth Board NHS Wales, Colwyn Bay Hosp, Hesketh Rd, Colwyn Bay LL29 8AY, England.	Rudi.Coetzer@wales.nhs.uk		Coetzer, Rudi/0000-0003-4505-7230			ALOIA MS, 1995, BRAIN INJURY, V9, P575, DOI 10.3109/02699059509008216; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Cloute K, 2008, NEUROPSYCHOL REHABIL, V18, P651, DOI 10.1080/09602010701306989; Coetzer B. R., 2003, J COGNITIVE REHABILI, V21, P4; Coetzer B. R., 2003, BRAIN INJURY G UNPUB; Coetzer BR, 2001, J COGN REHABIL, V19, P8; Coetzer R., 2010, ANXIETY MOOD DISORDE; Coetzer R, 2008, NEUROPSYCHOL REHABIL, V18, P766, DOI 10.1080/09602010701860266; Cooper-Evans S, 2008, NEUROPSYCHOL REHABIL, V18, P607, DOI 10.1080/09602010801948516; Ellis-Hill CS, 2000, CLIN REHABIL, V14, P279, DOI 10.1191/026921500671231410; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; FLEMING JS, 1980, J PERS SOC PSYCHOL, V39, P921, DOI 10.1037/0022-3514.39.5.921; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Gracey F, 2007, NEUROPSYCHOL REHABIL, V17, P106, DOI 10.1080/09602010500505260; Guindon MH, 2002, J COUNS DEV, V80, P204, DOI 10.1002/j.1556-6678.2002.tb00184.x; HAYNES SD, 1994, ARCH CLIN NEUROPSYCH, V9, P323, DOI 10.1016/0887-6177(94)90020-5; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Judd D. P., 1999, COUNS PSYCHOL, V14, P4; Keppel CC, 2000, NEUROPSYCHOL REHABIL, V10, P15, DOI 10.1080/096020100389273; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Man DWK, 2003, BRAIN INJURY, V17, P775, DOI 10.1080/0269905031000088577; McBrinn J, 2008, BRAIN INJURY, V22, P765, DOI 10.1080/02699050802372208; Meredith K., 1999, J COGNITIVE REHABILI, V17, P10; Myles SM, 2004, INT J PSYCHOL PSYCHO, V4, P487; Naylor E, 2008, NEUROPSYCHOL REHABIL, V18, P590, DOI 10.1080/09602010701608681; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; Prigatano G. P., 1997, NEUROPSYCHOL REHABIL, P301; Roberts CB, 2006, BRAIN INJURY, V20, P485, DOI 10.1080/02699050600664665; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Ruddle JA., 2005, ILLNESS, V13, P235; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Stonnington CM, 2001, BRAIN INJURY, V15, P561, DOI 10.1080/02699050110034316; STREIN W, 1993, SCHOOL PSYCHOL REV, V22, P273; TASKER SL, 2003, ILLNESS CRISIS LOSS, V11, P337, DOI DOI 10.1177/1054137303256585; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x; Yeates GN, 2008, NEUROPSYCHOL REHABIL, V18, P566, DOI 10.1080/09602010802151532; Ylvisaker M, 2008, NEUROPSYCHOL REHABIL, V18, P713, DOI 10.1080/09602010802201832; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	54	84	84	0	42	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	3					289	305	PII 934339402	10.1080/09602011.2011.555972			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	761ND	WOS:000290403800001	21391119				2021-06-18	
J	Warner, MA; de la Plata, CM; Spence, J; Wang, JY; Harper, C; Moore, C; Devous, M; Diaz-Arrastia, R				Warner, Matthew A.; de la Plata, Carlos Marquez; Spence, Jeffrey; Wang, Jun Yi; Harper, Caryn; Moore, Carol; Devous, Michael; Diaz-Arrastia, Ramon			Assessing Spatial Relationships between Axonal Integrity, Regional Brain Volumes, and Neuropsychological Outcomes after Traumatic Axonal Injury	JOURNAL OF NEUROTRAUMA			English	Article						atrophy; diffuse axonal injury; diffusion tensor imaging; traumatic brain injury; volumetric magnetic resonance imaging	MAGNETIC-RESONANCE IMAGES; SURFACE-BASED ANALYSIS; WHITE-MATTER INJURY; NEURONS IN-VIVO; HEAD-INJURY; CEREBRAL ATROPHY; MILD; AXOTOMY; SEGMENTATION; DISABILITY	Diffuse traumatic axonal injury (TAI) is a type of traumatic brain injury (TBI) characterized predominantly by white matter damage. While TAI is associated with cerebral atrophy, the relationship between gray matter volumes and TAI of afferent or efferent axonal pathways remains unknown. Moreover, it is unclear if deficits in cognition are associated with post-traumatic brain volumes in particular regions. The goal of this study was to determine the relationship between markers of TAI and volumes of cortical and subcortical structures, while also assessing the relationship between cognitive outcomes and regional brain volumes. High-resolution magnetic resonance imaging scans were performed in 24 patients with TAI within 1 week of injury and were repeated 8 months later. Diffusion tensor imaging (DTI) tractography was used to reconstruct prominent white matter tracts and calculate their fractional anisotropy (FA) and mean diffusivity (MD) values. Regional brain volumes were computed using semi-automated morphometric analysis. Pearson's correlation coefficients were used to assess associations between brain volumes, white matter integrity (i.e., FA and MD), and neuropsychological outcomes. Post-traumatic volumes of many gray matter structures were associated with chronic damage to related white matter tracts, and less strongly associated with measures of white matter integrity in the acute scans. For example, left and right hippocampal volumes correlated with FA in the fornix body (r = 0.600, p = 0.001; r = 0.714, p<0.001, respectively). In addition, regional brain volumes were associated with deficits in corresponding neuropsychological domains. Our results suggest that TAI may be a primary mechanism of post-traumatic atrophy, and provide support for regional morphometry as a biomarker for cognitive outcome after injury.	[Warner, Matthew A.; Harper, Caryn; Moore, Carol; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Spence, Jeffrey] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Devous, Michael] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [de la Plata, Carlos Marquez] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75230 USA; [Wang, Jun Yi] Univ Calif Davis, Ctr Mind & Brain, Davis, CA 95616 USA	Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF); National Institutes of Health-National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652]; United States Department of EducationUS Department of Education [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	This work was supported by the Doris Duke Charitable Foundation (Clinical Research Fellowship to M.W.); the National Institutes of Health-National Institute of Child Health and Human Development (R01 HD48179 to R.D.-A and, U01 HD42652 to R.D.-A.); and the United States Department of Education Grant (H133 A020526 to R.D.-A.).	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benton AL, 1983, MULTILINGUAL APHASIA; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Delis DC, 2000, CALIFORNIA VERBAL LE; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McAllister TW, 2002, NEUROREHABILITATION, V17, P263; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reitan R. M., 1992, TRAIL MAKING TEST MA; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schiff ND, 2006, J HEAD TRAUMA REHAB, V21, P388, DOI 10.1097/00001199-200609000-00003; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; WARNER MA, 2010, ARCH NEUROL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	49	84	88	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2121	2130		10.1089/neu.2010.1429			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400001	20874032	Green Published			2021-06-18	
J	Pham, N; Fazio, V; Cucullo, L; Teng, QS; Biberthaler, P; Bazarian, JJ; Janigro, D				Pham, Nancy; Fazio, Vincent; Cucullo, Luca; Teng, Qingshan; Biberthaler, Peter; Bazarian, Jeffrey J.; Janigro, Damir			Extracranial Sources of S100B Do Not Affect Serum Levels	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; MINOR HEAD TRAUMA; ACUTE ISCHEMIC-STROKE; S-100B PROTEIN; BARRIER DISRUPTION; CARDIAC-SURGERY; PERIPHERAL MARKERS; BLOOD; DAMAGE	S100B, established as prevalent protein of the central nervous system, is a peripheral biomarker for blood-brain barrier disruption and often also a marker of brain injury. However, reports of extracranial sources of S100B, especially from adipose tissue, may confound its interpretation in the clinical setting. The objective of this study was to characterize the tissue specificity of S100B and assess how extracranial sources of S100B affect serum levels. The extracranial sources of S100B were determined by analyzing nine different types of human tissues by ELISA and Western blot. In addition, brain and adipose tissue were further analyzed by mass spectrometry. A study of 200 subjects was undertaken to determine the relationship between body mass index (BMI) and S100B serum levels. We also measured the levels of S100B homo- and heterodimers in serum quantitatively after blood-brain barrier disruption. Analysis of human tissues by ELISA and Western blot revealed variable levels of S100B expression. By ELISA, brain tissue expressed the highest S100B levels. Similarly, Western blot measurements revealed that brain tissue expressed high levels of S100B but comparable levels were found in skeletal muscle. Mass spectrometry of brain and adipose tissue confirmed the presence of S100B but also revealed the presence of S100A1. The analysis of 200 subjects revealed no statistically significant relationship between BMI and S100B levels. The main species of S100B released from the brain was the B-B homodimer. Our results show that extracranial sources of S100B do not affect serum levels. Thus, the diagnostic value of S100B and its negative predictive value in neurological diseases in intact subjects (without traumatic brain or bodily injury from accident or surgery) are not compromised in the clinical setting.	[Pham, Nancy; Janigro, Damir] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland Clin Fdn, Cleveland, OH 44106 USA; [Fazio, Vincent; Cucullo, Luca] Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; [Biberthaler, Peter] Univ Munich, Surg Dept Munich Cent, Munich, Germany; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA	Pham, N (corresponding author), Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland Clin Fdn, Cleveland, OH 44106 USA.	janigrd@ccf.org	Cucullo, Luca/X-2765-2019	Cucullo, Luca/0000-0002-2827-7162; Janigro, Damir/0000-0003-2165-5826	Roche Diagnostics [RO1 NS43284, RO1 NS38195, R21 HD057256]; Cleveland Clinic- Swedish Satellite Laboratory Feasibility Project, Federal Appropriation Washington State; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043284, R01NS038195] Funding Source: NIH RePORTER	This study was supported by RO1 NS43284, RO1 NS38195, R21 HD057256 to Damir Janigro. It was also supported by "A Prospective Pilot Study on S100B in TBI" funded by Roche Diagnostics and by the Cleveland Clinic- Swedish Satellite Laboratory Feasibility Project, Federal Appropriation Washington State. None of the funding agencies had role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdul-Khaliq H, 2000, CLIN CHEM LAB MED, V38, P1173, DOI 10.1515/CCLM.2000.181; Abdul-Khaliq H, 2000, CLIN CHEM LAB MED, V38, P1169, DOI 10.1515/CCLM.2000.180; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; BAUDIER J, 1986, J BIOL CHEM, V261, P8204; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2000, ACT NEUR S, V76, P177; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Dassan P, 2009, CEREBROVASC DIS, V27, P295, DOI 10.1159/000199468; DONATO R, 2001, INT J BIOCHEM CELL B, V637, P668; Fazio V, 2004, ANN THORAC SURG, V78, P46, DOI 10.1016/j.athoracsur.2003.11.042; Foerch C, 2007, STROKE, V38, P2491, DOI 10.1161/STROKEAHA.106.480111; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Korfias S, 2006, CURR MED CHEM, V13, P3719, DOI 10.2174/092986706779026129; Mann M, 2008, J PROTEOME RES, V7, P3065, DOI 10.1021/pr800463v; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2003, J NEUROSCI, V23, P1949; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Mazzone PJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007242; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2000, ACT NEUR S, V76, P393; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pineau JC, 2007, ANN NUTR METAB, V51, P421, DOI 10.1159/000111161; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rothermundt M, 2004, INT REV NEUROBIOL, V59, P445; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI [10.1089/neu.2009.0928, 10.1089/neu.2009-0928]; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Steiner J, 2010, PSYCHONEUROENDOCRINO, V35, P321, DOI 10.1016/j.psyneuen.2009.07.012; Vogelbaum MA, 2005, CANCER-AM CANCER SOC, V104, P817, DOI 10.1002/cncr.21220; Watson P, 2005, AM J PHYSIOL-REG I, V288, pR1689, DOI 10.1152/ajpregu.00676.2004	48	84	88	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2010	5	9							e12691	10.1371/journal.pone.0012691			9	Multidisciplinary Sciences	Science & Technology - Other Topics	648IX	WOS:000281687300022	20844757	DOAJ Gold, Green Published			2021-06-18	
J	Kabadi, SV; Hilton, GD; Stoica, BA; Zapple, DN; Faden, AI				Kabadi, Shruti V.; Hilton, Genell D.; Stoica, Bogdan A.; Zapple, David N.; Faden, Alan I.			Fluid-percussion-induced traumatic brain injury model in rats	NATURE PROTOCOLS			English	Article							MORRIS WATER MAZE; DIFFUSE AXONAL INJURY; HEAD-INJURY; COGNITIVE DEFICITS; INTRACRANIAL-PRESSURE; NEUROLOGIC DEFICITS; NEURONAL APOPTOSIS; BLAST INJURY; ADULT-RAT; MOTOR	Traumatic brain injury (TBI) is a major cause of mortality and morbidity. Various attempts have been made to replicate clinical TBI using animal models. The fluid-percussion model (FP) is one of the oldest and most commonly used models of experimentally induced TBI. Both central (CFP) and lateral (LFP) variations of the model have been used. Developed initially for use in larger species, the standard FP device was adapted more than 20 years ago to induce consistent degrees of brain injury in rodents. Recently, we developed a microprocessor-controlled, pneumatically driven instrument, micro-FP (MFP), to address operational concerns associated with the use of the standard FP device in rodents. We have characterized the MFP model with regard to injury severity according to behavioral and histological outcomes. In this protocol, we review the FP models and detail surgical procedures for LFP. The surgery involves tracheal intubation, craniotomy and fixation of Luer fittings, and induction of injury. The surgical procedure can be performed within 45-50 min.	[Kabadi, Shruti V.; Stoica, Bogdan A.; Faden, Alan I.] Sch Med, Dept Anesthesiol, Baltimore, MD USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Faden, Alan I.] Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD USA; [Kabadi, Shruti V.; Hilton, Genell D.; Stoica, Bogdan A.; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Hilton, Genell D.] San Francisco Gen Hosp, Dept Surg, Trauma Serv, San Francisco, CA 94110 USA; [Zapple, David N.] Georgetown Univ, Off Informat Serv, Washington, DC USA	Faden, AI (corresponding author), Sch Med, Dept Anesthesiol, Baltimore, MD USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health Grant no. NS052568. We would like to thank D.J. Loane for his helpful comments on the paper.; The project was conceived by A.I.F and was supported by the National Institutes of Health Grant no. NS052568 to A.I.F. The study was designed by A.I.F., B.A.S. and G.D.H. D.N.Z. originally developed the model. G.D.H. and S.V.K. equally contributed to the paper in terms of conducting the study, compiling the results and writing the paper.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANDREWS JS, 1995, PHYSIOL BEHAV, V57, P785, DOI 10.1016/0031-9384(94)00336-X; Avila MA, 2008, J CEREBR BLOOD F MET, V28, P1733, DOI 10.1038/jcbfm.2008.66; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; CAREY ME, 1995, NEUROSURG CLIN N AM, V6, P629; *CDCP, 2010, GET STATS TRAUM BRAI; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAVID S, 1985, J NEUROCYTOL, V14, P1, DOI 10.1007/BF01150259; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Finnie J, 1999, J CLIN NEUROSCI, V6, P38, DOI 10.1016/S0967-5868(99)90601-X; FINNIE JW, 1993, J COMP PATHOL, V108, P93, DOI 10.1016/S0021-9975(08)80231-9; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HILTON DL, 1993, J NEUROTRAUM, V10, P121, DOI 10.1089/neu.1993.10.121; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Hoh T, 1999, J Neurosci, V19, pRC2; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; LIU S, 2009, J NEUROTRAUM, V11, P73; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; Marmarou A, 1990, Adv Neurol, V52, P233; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; PARK HJ, 1995, ACTA OTO-LARYNGOL, V115, P273, DOI 10.3109/00016489509139307; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Stalhammar D, 1987, Brain Inj, V1, P73, DOI 10.3109/02699058709034448; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	84	84	88	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1754-2189	1750-2799		NAT PROTOC	Nat. Protoc.	SEP	2010	5	9					1552	1563		10.1038/nprot.2010.112			12	Biochemical Research Methods	Biochemistry & Molecular Biology	646US	WOS:000281569200006	20725070	Green Accepted			2021-06-18	
J	Hollis, SJ; Stevenson, MR; McIntosh, AS; Shores, EA; Collins, MW; Taylor, CB				Hollis, Stephanie J.; Stevenson, Mark R.; McIntosh, Andrew S.; Shores, E. Arthur; Collins, Michael W.; Taylor, Colman B.			Incidence, Risk, and Protective Factors of Mild Traumatic Brain Injury in a Cohort of Australian Nonprofessional Male Rugby Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						brain concussion; incidence; risk factors; football; head injuries; athletic injuries	UNION FOOTBALL; PERFORMANCE PROJECT; NEUROCOGNITIVE PERFORMANCE; PROFESSIONAL FOOTBALL; CONCUSSION HISTORY; HEAD-INJURY; EPIDEMIOLOGY; MOUTHGUARDS; IMPACT	Background: Mild traumatic brain injury (mTBI) is an emerging public health issue in high-contact sports. Understanding the incidence along with the risk and protective factors of mTBI in high-contact sports such as rugby is paramount if appropriate preventive strategies are to be developed. Purpose: To estimate the incidence and identify the risk and protective factors of mTBI in Australian nonprofessional rugby players. Study Design: Cohort study; Level of evidence, 2. Methods: A cohort of 3207 male nonprofessional rugby players from Sydney, Australia, was recruited and followed over 1 or more playing seasons. Demographic information, history of recent concussion, and information on risk and protective factors were collected. The incidence of mTBI was estimated and the putative risk and protective factors were modeled in relation to mTBI. Results: The incidence of mTBI was 7.97 per 1000 player game hours, with 313 players (9.8%) sustaining 1 or more mTBIs during the study. Players who reported always wearing protective headgear during games were at a reduced risk (incident rate ratio [IRR], 0.57; 95% confidence interval [CI], 0.40-0.82) of sustaining an mTBI. In contrast, the likelihood of mTBI was almost 2 times higher among players who reported having sustained either 1 (IRR, 1.75; 95% CI, 1.11-2.76) or more mTBIs (IRR, 1.65; 95% CI, 1.11-2.45) within the 12 months before recruitment. Conclusion: Nonprofessional rugby has a high incidence of mTBI, with the absence of headgear and a recent history of mTBI associated with an increased risk of subsequent mTBI. These findings highlight that both use of headgear and the management of prior concussion would likely be beneficial in reducing the likelihood of mTBI among nonprofessional rugby players, who compose more than 99% of rugby union players in Australia.	[Hollis, Stephanie J.; Stevenson, Mark R.; Taylor, Colman B.] Univ Sydney, George Inst Int Hlth, Sydney, NSW 2050, Australia; [McIntosh, Andrew S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW, Australia; [Shores, E. Arthur] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Collins, Michael W.] Univ Pittsburgh, UPMC Ctr Sports Med, Pittsburgh, PA USA	Hollis, SJ (corresponding author), Univ Sydney, George Inst, POB M201,Missenden Rd, Sydney, NSW 2050, Australia.	shollis@george.org.au	stevenson, mark/AAE-9706-2019; Hollis, Stephanie J/B-5977-2011	stevenson, mark/0000-0003-3166-5876; Shores, Edwin A/0000-0003-1553-5131	U. S. Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [5R49CE323155]; Australian Government's National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER	One or more authors has declared a potential conflict of interest: This study was supported by the U. S. Centers for Disease Control and Prevention grant 5R49CE323155 to the University of Pittsburgh Center for Injury Research and Control. Mark Stevenson is supported by funding from the Australian Government's National Health and Medical Research Council. Stephanie Hollis is supported by postgraduate scholarship funding from the Australian Government's National Health and Medical Research Council.	*AUSTR I HLTH WELF, 2003, AUSTR WELF, P65; BECKER DP, 1987, PHYSL BASIS MODERN S, P763; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Blignaut J B, 1987, Br J Sports Med, V21, P5; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chapman P, 1985, AUST J SCI MED SPORT, V17, P23; CLARK DR, 1990, S AFR MED J, V77, P559; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; GARRAWAY M, 1995, LANCET, V345, P1485; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kerr HA, 2008, BRIT J SPORT MED, V42, P595, DOI 10.1136/bjsm.2007.035881; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2003, J SCI MED SPORT, V6, P355, DOI 10.1016/S1440-2440(03)80030-0; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; MCINTOSH AS, 2008, BR J SPORTS MED 0402; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Woodward M., 1999, EPIDEMIOLOGY STUDY D; ZUCKERMAN M, 1983, BIOL BASES SENSATION, P37	44	84	87	0	30	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2009	37	12					2328	2333		10.1177/0363546509341032			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	524YO	WOS:000272180500005	19789332				2021-06-18	
J	Pontifex, MB; O'Connor, PM; Broglio, SP; Hillman, CH				Pontifex, Matthew B.; O'Connor, Phillip M.; Broglio, Steven P.; Hillman, Charles H.			The association between mild traumatic brain injury history and cognitive control	NEUROPSYCHOLOGIA			English	Article						Executive control; ERP; ERN; P-e; mTBI; Concussion	ANTERIOR CINGULATE CORTEX; ERROR-RELATED ERPS; PROFESSIONAL FOOTBALL; PHYSICAL-ACTIVITY; NEURAL SYSTEM; CONCUSSION; COMPONENTS; SYMPTOMS; ENCEPHALOPATHY; LOCALIZATION	The influence of multiple mild traumatic brain injuries (mTBIs) on neuroelectric and task performance indices of the cognitive control of action monitoring was assessed in individuals with and without a history of concussion. Participants completed a standard clinical neurocognitive assessment and the error-related negativity of the response-locked event-related brain potential and task performance were measured during a modified flanker task. The findings suggested that those individuals with a history of mTBI demonstrate certain failures in cognitive control, and indicated that a greater number of mTBIs may relate to poorer integrity in the evaluation or signaling for control during instances of conflict. Given that these neuroelectric and behavioral differences exist in the absence of disparities in standard clinical assessment, the findings suggest that measures of cognitive control may be more sensitive to signs of chronic cognitive dysfunction resulting from mTBI. (C) 2009 Elsevier Ltd. All rights reserved.	[Pontifex, Matthew B.; O'Connor, Phillip M.; Broglio, Steven P.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA	Hillman, CH (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 317 Louise Freer Hall,906 S Goodwin Ave, Urbana, IL 61801 USA.	chhilima@illinois.edu	Hillman, Charles/AAD-4828-2019; Hillman, Charles/A-4479-2009; Pontifex, Matthew B/A-4474-2009	Pontifex, Matthew B/0000-0001-9819-9625; Hillman, Charles/0000-0002-3722-5612	Disability Research and the Research Board at the University of Illinois	This work was supported by the Mary Jane Neer Fund for Disability Research and the Research Board at the University of Illinois.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; BROGLIO SP, 2009, J NEUROTRAUMA; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Coles MGH, 2001, BIOL PSYCHOL, V56, P173, DOI 10.1016/S0301-0511(01)00076-X; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Compumedics Neuroscan, 2003, OFFL AN ACQ DAT SCAN, VII; Davies PL, 2001, BIOL PSYCHOL, V56, P191, DOI 10.1016/S0301-0511(01)00080-1; DEBEAUMONT L, 2009, BRAIN; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Diamond A., 2006, LIFESPAN COGNITION M, P70, DOI DOI 10.1093/ACPROF:OSO/9780195169539.003.0006; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Falkenstein M, 2001, EXP BRAIN RES, V138, P258, DOI 10.1007/s002210100712; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Hillman CH, 2006, HEALTH PSYCHOL, V25, P678, DOI 10.1037/0278-6133.25.6.678; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kaufman A.S., 1990, KAUFMAN BRIEF INTELL; Kelly JP, 1997, NEUROLOGY, V48, P581; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Mathewson KJ, 2005, BIOL PSYCHOL, V70, P88, DOI 10.1016/j.biopsycho.2004.12.005; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Miltner WHR, 2003, BIOL PSYCHOL, V64, P157, DOI 10.1016/S0301-0511(03)00107-8; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P747, DOI 10.1111/j.1469-8986.1996.tb02371.x; Pontifex MB, 2007, CLIN NEUROPHYSIOL, V118, P570, DOI 10.1016/j.clinph.2006.09.029; Rabbitt P, 2002, Q J EXP PSYCHOL-A, V55, P1081, DOI 10.1080/02724980244000080; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Spencer KM, 1999, PSYCHOPHYSIOLOGY, V36, P364, DOI 10.1017/S0048577299970749; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Themanson JR, 2006, NEUROBIOL AGING, V27, P1335, DOI 10.1016/j.neurobiolaging.2005.07.002; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837	55	84	85	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	DEC	2009	47	14					3210	3216		10.1016/j.neuropsychologia.2009.07.021			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	529SQ	WOS:000272537900021	19664646				2021-06-18	
J	Helmy, A; Carpenter, KLH; Skepper, JN; Kirkpatrick, PJ; Pickard, JD; Hutchinson, PJ				Helmy, Adel; Carpenter, Keri L. H.; Skepper, Jeremy N.; Kirkpatrick, Peter J.; Pickard, John D.; Hutchinson, Peter J.			Microdialysis of Cytokines: Methodological Considerations, Scanning Electron Microscopy, and Determination of Relative Recovery	JOURNAL OF NEUROTRAUMA			English	Article						albumin; cytokine; electron microscopy; microdialysis; relative recovery	BRAIN	Cerebral microdialysis is a monitoring technique with expanding clinical and research utility following traumatic brain injury. This study's aim was to determine the relative recovery for 12 cytokines using both crystalloid (CNS perfusion fluid) and colloid (CNS perfusion fluid supplemented with 3.5% human serum albumin) perfusate. Six CMA71 microdialysis catheters (nominal molecular weight cut-off 100 kDa) were perfused in vitro with either crystalloid or colloid and the relative recovery (%) determined for the cytokines as follows (crystalloid/colloid perfusate): IL-1 alpha (50.6/48), IL-1 beta (34.6/38.4), IL-1ra (21.9/38.4), IL-2 (17.1/52.8), IL-4 (26/56.7), IL-6 (9.8/25.5), IL-8 (47.7/73.4), IL-10 (2.9/8.7), IL-17 (14.4/43.7), TNF-alpha (4.4/31.2), MIP-1 alpha (31.8/55.6), and MIP-1 beta (31.9/50.1). The colloid perfusate significantly improved relative recovery for nine of these cytokines (p < 0.05), but not for IL-1 alpha, IL-1 beta, and IL-8. Relative recovery was related to apparent molecular weight of cytokine and to isoelectric point (pI), a surrogate marker of hydrophilicity. The mean fluid recovery for crystalloid and colloid perfusate was 92% and 145%, respectively. Scanning electron microscopy was utilized to investigate the ultrastructure of microdialysis membranes: (1) 20-kDa membrane, (2) 100-kDa membrane, and (3) ex vivo 100-kDa membrane. The 100-kDa membranes possessed multiple large cavities and the catheter examined after use in human brain clearly demonstrated cellular debris within the pores of the membrane. While colloid perfusate improves relative recovery, it causes a net influx of fluid into the microdialysis catheter, potentially dehydrating the extracellular space. This study is the first to systematically determine relative recovery in vitro for a wide range of cytokines. The two forms of perfusion fluid require direct comparison in vivo.	[Helmy, Adel] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Addenbrookes Hosp, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Addenbrookes Hosp, Cambridge CB2 0QQ, England; [Skepper, Jeremy N.] Univ Cambridge, Multi Imaging Ctr, Dept Physiol Dev & Neurosci, Cambridge CB2 0QQ, England	Helmy, A (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Addenbrookes Hosp, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	adelhelmy@cantab.net	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carpenter, Keri/0000-0001-8236-7727	National Institute for Health; Royal College of Surgeons of England; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research Council (Acute Brain Injury Programme Grant)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883]; Academy of Medical Sciences/Health Foundation; University of Manchester; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390, G0802251] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004] Funding Source: researchfish	We thank R. Doffinger, L. Ceron-Gutierrez, and L. Maskell for technical assistance. A. H. is supported by the National Institute for Health Research as an Academic Clinical Fellow, and by the Royal College of Surgeons of England as a Research Fellow. P.J.H. is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. K. L. H. C. is supported by the Medical Research Council (Acute Brain Injury Programme Grant) and the National Institute for Health Research Biomedical Research Centre, Cambridge. This study was supported by the Medical Research Council (grant no. G9439390 ID 65883), and the Academy of Medical Sciences/Health Foundation. We acknowledge our on-going collaboration with the University of Manchester on cytokine studies following acute brain injury (N. Rothwell, P. Tyrell, S. Hopkins, J. Galea, S. Hume).	Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BUNGAY PM, 1990, LIFE SCI, V46, P105, DOI 10.1016/0024-3205(90)90043-Q; Clough GF, 2005, AAPS J, V7, pE686, DOI 10.1208/aapsj070369; Hamrin K, 2002, J APPL PHYSIOL, V92, P385; Helmy A, 2007, CURR MED CHEM, V14, P1525, DOI 10.2174/092986707780831113; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Maurer Martin H, 2003, Proteome Sci, V1, P7, DOI 10.1186/1477-5956-1-7; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Rosenbloom AJ, 2005, J NEUROSCI METH, V148, P147, DOI 10.1016/j.jneumeth.2005.04.018; Stahl M., 2002, Current Pharmaceutical Biotechnology, V3, P165, DOI 10.2174/1389201023378373; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; Wang XD, 2007, ANAL CHEM, V79, P1816, DOI 10.1021/ac061503b; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; Wisniewski N, 2001, J BIOMED MATER RES, V57, P513, DOI 10.1002/1097-4636(20011215)57:4<513::AID-JBM1197>3.0.CO;2-E	18	84	84	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					549	561		10.1089/neu.2008.0719			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300007	19196175				2021-06-18	
J	Bayir, H; Adelson, PD; Wisniewski, SR; Shore, P; Lai, YC; Brown, D; Janesko-Feldman, KL; Kagan, VE; Kochanek, PM				Bayir, Huelya; Adelson, P. David; Wisniewski, Stephen R.; Shore, Paul; Lai, YiChen; Brown, Danielle; Janesko-Feldman, Keri L.; Kagan, Valerian E.; Kochanek, Patrick M.			Therapeutic hypothermia preserves antioxidant defenses after severe traumatic brain injury in infants and children	CRITICAL CARE MEDICINE			English	Article						pediatric head injury; biomarkers of oxidative stress; chemiluminescence; fluorescence	MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; MILD HYPOTHERMIA; CARDIAC-ARREST; LIPID-PEROXIDATION; OXIDATIVE STRESS; POSTTRAUMATIC HYPOTHERMIA; EXTRACELLULAR LEVELS; IN-SITU; TEMPERATURE	Objective: Oxidative stress contributes to secondary damage after traumatic brain injury (TBI). Hypothermia decreases endogenous antioxidant consumption and lipid peroxidation after experimental cerebral injury. Our objective was to determine the effect of therapeutic hypothermia on oxidative damage after severe TBI in infants and children randomized to moderate hypothermia vs. normothermia. Design: Prospective randomized controlled study. Setting: Pediatric intensive care unit of Pittsburgh Children's Hospital. Patients: The study included 28 patients. Measurements and Main Results: We compared the effects of hypothermia (32 degrees C-33 degrees C) vs. normothermia in patients treated in a single center Involved in a multicentered randomized controlled trial of hypothermia in severe pediatric TBI (Glasgow Coma Scale score <= 8). The patients randomized to hypothermia (n = 13) were cooled to target temperature within -6 to 24 hours for 48 hours and then rewarmed. Antioxidant status was assessed by measurements of total antioxidant reserve and glutathione. Protein oxidation and lipid peroxidation were assessed by measurements of protein thiols and F2-isoprostane, respectively, in ventricular cerebrospinal fluid (CSF) samples (n = 76) obtained on day 1-3 after injury. The association between Glasgow Coma Scale score, age, gender, treatment, temperature, time after injury, and CSF antioxidant reserve, glutathi one, protein-thiol, F2-isoprostane levels were assessed by bivariate and multiple regression models. Demographic and clinical characteristics were similar between the two treatment groups. Mechanism of injury included both accidental injury and nonaccidental injury. Multiple regression models revealed preservation of CSF antioxidant reserve by hypothermia (p = 0.001). Similarly, a multiple regression model showed that glutathione levels were inversely associated with patient temperature at the time of sampling (p = 0.002). F2-isoprostane levels peaked on day 1 after injury and were progressively decreased thereafter. Although F2-isoprostane levels were approximately threefold lower in patients randomized to hypothermia vs. normothermia, this difference was not statistically significant. Conclusion: To our knowledge, this is the first study demonstrating that hypothermia attenuates oxidative stress after severe TBI in infants and children. Our data also support the concept that CSF represents a valuable tool for monitoring treatment effects on oxidative stress after TBI. (Crit Care Med 2009; 37:689-695)	[Bayir, Huelya; Janesko-Feldman, Keri L.; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Bayir, Huelya; Adelson, P. David; Brown, Danielle; Kochanek, Patrick M.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Ctr Free Radical & Anfioxidant Hlth, Pittsburgh, PA 15213 USA; [Bayir, Huelya; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; [Adelson, P. David; Brown, Danielle] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol & Publ Hlth, Pittsburgh, PA 15213 USA; [Shore, Paul] Univ Texas SW Med Ctr Dallas, Childrens Med Ctr Dallas, Div Crit Care Serv, Dept Pediat, Dallas, TX 75390 USA; [Lai, YiChen] Baylor Coll Med, Div Crit Care, Dept Pediat, Houston, TX 77030 USA	Bayir, H (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	bayihx@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Kagan, Valerian E./0000-0002-7245-1885	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS30318, NS38087, NS34884, NS052478, NS061817, HD057587, T32-HD40686]; Laerdal Foundation; CDC (University of Pittsburgh Centers for Injury Research and Control [CIRCL])United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; American Heart AssociationAmerican Heart Association [0535365N]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087, P01NS030318, R01NS061817, P20NS030318, U01NS052478, P50NS030318] Funding Source: NIH RePORTER	Supported, in part, by grants NS30318, NS38087, NS34884, NS052478, NSO61817, HD057587, and T32-HD40686 (to PS and YCL) from NIH, Laerdal Foundation, CDC (University of Pittsburgh Centers for Injury Research and Control [CIRCL]) and 0535365N by American Heart Association.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Behringer W, 2002, J CEREBR BLOOD F MET, V22, P105, DOI 10.1097/00004647-200201000-00013; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; DeKosky ST, 2004, J NEUROCHEM, V90, P998, DOI 10.1111/j.1471-4159.2004.02575.x; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Holzer M, 2002, NEW ENGL J MED, V346, P549; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; KARIBE H, 1994, BRAIN RES, V649, P12, DOI 10.1016/0006-8993(94)91043-X; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Lee King-Teh, 1998, Kaohsiung Journal of Medical Sciences, V14, P6; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Maeda T, 1998, J NEUROTRAUM, V15, P655, DOI 10.1089/neu.1998.15.655; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; McAnulty JF, 1997, CRYOBIOLOGY, V34, P406, DOI 10.1006/cryo.1997.2011; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; OCONNOR F, 1975, J CARDIOVASC SURG, V16, P493; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Quinones-Hinojosa A, 2003, NEUROSURGERY, V52, P1178, DOI 10.1227/01.NEU.0000057836.64972.A0; Rainio P, 1998, SCAND CARDIOVASC J, V32, P353, DOI 10.1080/14017439850139807; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SELDEN PD, 2003, PEDIATR CRIT CARE ME, V4, pS53; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Simkhovich BZ, 2004, J CARDIOVASC PHARM T, V9, P83, DOI 10.1177/107424840400900203; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Takata T, 1997, NEUROSCI LETT, V227, P41, DOI 10.1016/S0304-3940(97)00296-6; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; YAGER J, 1993, PEDIATR RES, V34, P525, DOI 10.1203/00006450-199310000-00029; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	63	84	84	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2009	37	2					689	695		10.1097/CCM.0b013e318194abf2			7	Critical Care Medicine	General & Internal Medicine	402LI	WOS:000263014800039	19114918	Green Accepted			2021-06-18	
J	Sumowski, JF; Chiaravalloti, N; DeLuca, J				Sumowski, James F.; Chiaravalloti, Nancy; DeLuca, John			Cognitive reserve protects against cognitive dysfunction in multiple sclerosis	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Multiple sclerosis; Cognitive reserve; Intelligence; Processing speed; Memory; Cognition	RELAPSING-REMITTING MS; INFORMATION-PROCESSING EFFICIENCY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL IMPAIRMENT; MEMORY; EDUCATION; ATROPHY; RISK; PERFORMANCE	Cognitive reserve theory helps to explain the neuropsychological expression of neurologic disease (e. g., Alzheimer's disease; Stern, 2006). Multiple sclerosis (MS) is a neurologic disease characterized by information processing inefficiency and verbal learning and memory deficits. The current study is the first to investigate whether higher cognitive reserve moderates the relationship between MS and cognitive functioning. A word-reading proxy of premorbid intelligence was used to estimate cognitive reserve for 58 persons with MS and 43 healthy controls. Dependent measures of simple processing efficiency, complex information processing efficiency, and verbal learning and memory were administered. There were significant Group x Cognitive Reserve interactions for complex information processing efficiency and verbal learning and memory, such that persons with MS demonstrated deficits relative to controls at lower, but not higher, levels of reserve. No such interaction was found for simple processing efficiency. The protective influence of higher cognitive reserve against disease-related cognitive deficits is discussed.	[Sumowski, James F.; Chiaravalloti, Nancy; DeLuca, John] Neuropsychol & Neurosci Lab, Kessler Fdn Res Ctr, W Orange, NJ 07052 USA; [Sumowski, James F.; Chiaravalloti, Nancy; DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; [DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA	Sumowski, JF (corresponding author), Neuropsychol & Neurosci Lab, Kessler Fdn Res Ctr, 300 Execut Dr,Suite 010, W Orange, NJ 07052 USA.	jsumowski@kesslerfoundation.net		Chiaravalloti, Nancy/0000-0003-2943-7567	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 HD07522 and RO1 HD38249]; Sclerosis Society [MB0003]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD038249] Funding Source: NIH RePORTER	This project was supported by National Institutes of Health (NIH) Grants RO1 HD07522 and RO1 HD38249, as well as a MB0003 fellowship training grant from the National Multiple Sclerosis Society.	Alexander GE, 1997, AM J PSYCHIAT, V154, P165; Archibald CJ, 2000, J CLIN EXP NEUROPSYC, V22, P686, DOI 10.1076/1380-3395(200010)22:5;1-9;FT686; Ball JD, 2007, CLIN NEUROPSYCHOL, V21, P422, DOI 10.1080/13854040600582577; Basso MR, 2000, J CLIN EXP NEUROPSYC, V22, P208, DOI 10.1076/1380-3395(200004)22:2;1-1;FT208; Beatty WW, 1995, J NEUROL REHABIL, V9, P167; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benedict RHB, 2007, MULT SCLER, V13, P722, DOI 10.1177/1352458507075592; Benedict RHB, 2007, SEMIN NEUROL, V27, P78, DOI 10.1055/s-2006-956758; Benedict RHB, 2006, ARCH NEUROL-CHICAGO, V63, P1301, DOI 10.1001/archneur.63.9.1301; Benedict RHB, 2004, ARCH NEUROL-CHICAGO, V61, P226, DOI 10.1001/archneur.61.2.226; Benedict RHB, 2002, CLIN NEUROPSYCHOL, V16, P381, DOI 10.1076/clin.16.3.381.13859; Bennett DA, 2003, NEUROLOGY, V60, P1909, DOI 10.1212/01.WNL.0000069923.64550.9F; Bermel RA, 2006, LANCET NEUROL, V5, P158, DOI 10.1016/S1474-4422(06)70349-0; Bleecker ML, 2007, NEUROLOGY, V69, P470, DOI 10.1212/01.wnl.0000266628.43760.8c; Bobholz JA, 2006, NEUROLOGY, V67, P1640, DOI 10.1212/01.wnl.0000242885.71725.76; Bobholz JA, 2003, CURR OPIN NEUROL, V16, P283, DOI 10.1097/00019052-200306000-00006; Bonnet MC, 2006, J NEUROL SCI, V251, P23, DOI 10.1016/j.jns.2006.08.002; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; CRYSTAL H, 1988, NEUROLOGY, V38, P1682, DOI 10.1212/WNL.38.11.1682; Cutter GR, 1999, BRAIN, V122, P871, DOI 10.1093/brain/122.5.871; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DELUCA J, 1993, ARCH NEUROL-CHICAGO, V50, P301, DOI 10.1001/archneur.1993.00540030065016; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Dufouil C, 2003, NEUROLOGY, V60, P831, DOI 10.1212/01.WNL.0000049456.33231.96; Elkins JS, 2006, NEUROLOGY, V67, P435, DOI 10.1212/01.wnl.0000228246.89109.98; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Feinstein A, 2006, J NEUROL SCI, V245, P63, DOI 10.1016/j.jns.2005.08.020; GOLDSTEIN FC, 1992, ARCH NEUROL-CHICAGO, V49, P1060, DOI 10.1001/archneur.1992.00530340080021; Goverover Y, 2007, MULT SCLER, V13, P636, DOI 10.1177/1352458506072984; Grabner RH, 2006, BRAIN RES BULL, V69, P422, DOI 10.1016/j.brainresbull.2006.02.009; Grabner RH, 2007, NEUROIMAGE, V38, P346, DOI 10.1016/j.neuroimage.2007.07.041; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; Hohol MJ, 1997, ARCH NEUROL-CHICAGO, V54, P1018, DOI 10.1001/archneur.1997.00550200074013; Iezzoni LI, 2007, MULT SCLER J, V13, P534, DOI 10.1177/1352458506071356; Kalmar J. H., 2008, INFORM PROCESSING SP; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; KESSLER HR, 1992, INT J NEUROSCI, V62, P17, DOI 10.3109/00207459108999754; Korneck B, 2003, BRAIN RES BULL, V61, P321, DOI 10.1016/S0361-9230(03)00095-9; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lazeron RHC, 2005, MULT SCLER J, V11, P524, DOI 10.1191/1352458505ms1201oa; Lengenfelder J, 2006, ARCH CLIN NEUROPSYCH, V21, P229, DOI 10.1016/j.acn.2005.12.001; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1394, DOI 10.1001/archneur.60.10.1394; Nyenhuis D L, 1995, J Int Neuropsychol Soc, V1, P291; O'Brien A, 2007, ARCH CLIN NEUROPSYCH, V22, P933, DOI 10.1016/j.acn.2007.07.002; Parmenter BA, 2007, MULT SCLER J, V13, P52, DOI 10.1177/1352458506070750; PEYSER JM, 1990, ARCH NEUROL-CHICAGO, V47, P94, DOI 10.1001/archneur.1990.00530010120030; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rao S.M., 1993, NEUROPSYCHOLOGY, V7, P364, DOI [10.1037/0894-4105.7.3.364, DOI 10.1037/0894-4105.7.3.364]; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; Rosti E, 2007, J INT NEUROPSYCH SOC, V13, P791, DOI 10.1017/S1355617707071019; Rosti E, 2007, APPL NEUROPSYCHOL, V14, P101, DOI 10.1080/09084280701319938; Sanfilipo MP, 2006, NEUROLOGY, V66, P685, DOI 10.1212/01.wnl.0000201238.93586.d9; SATZ P, 1993, J ACQ IMMUN DEF SYND, V6, P503; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Sepulcre J, 2006, MULT SCLER J, V12, P187, DOI 10.1191/1352458506ms1258oa; Siegert RJ, 2005, J NEUROL NEUROSUR PS, V76, P469, DOI 10.1136/jnnp.2004.054635; Simon JH, 1999, NEUROLOGY, V53, P139, DOI 10.1212/WNL.53.1.139; Smith A., 1982, SYMBOL DIGIT MODALIT; STERN Y, 1992, ANN NEUROL, V32, P371, DOI 10.1002/ana.410320311; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, pS69, DOI 10.1097/00002093-200607001-00010; Stevens J.P, 2009, APPL MULTIVARIATE ST; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037/0894-4105.11.3.357; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; US Census Bureau, 2006, AM COMM SURV PERC PE; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742	77	84	84	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	8					913	926		10.1080/13803390902740643			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	520GT	WOS:000271830800002	19330566				2021-06-18	
J	Post, MWM; de Witte, LP; Reichrath, E; Verdonschot, MM; Wijlhuizen, GJ; Perenboom, RJM				Post, Marcel W. M.; de Witte, Luc P.; Reichrath, Enid; Verdonschot, Manon M.; Wijlhuizen, Gert Jan; Perenboom, Rom J. M.			Development and validation of IMPACT-S, an ICF-based questionnaire to measure activities and participation	JOURNAL OF REHABILITATION MEDICINE			English	Article						validation studies; disabled persons; questionnaires; reproducibility of results; outcome assessment	INTERNATIONAL CLASSIFICATION; HEALTH ICF; DISABILITY; CONSEQUENCES; AGREEMENT; HANDICAP; CARE	Objective: IMPACT-S is the screener part of the ICF Measure of Participation and ACTivities questionnaire. IMPACT-S consists of 33 items in 9 scales, reflecting the 9 activity and participation chapters of the International Classification of Functioning, Disability and Health (ICF). The reliability and validity of IMPACT-S as an independent brief measure of activities and participation was examined. Design: Repeated administration of a postal questionnaire. Patients: Road accident victims were recruited through several Dutch hospitals and rehabilitation centres. A total of 276 patients participated and 197 took part in both measurements. Methods: Examination of test-retest reliability, reproducibility and construct validity. The World Health Organization Disability Assessment Schedule II (WHODAS-II) was included as criterion measure for concurrent validity. Results: Types of main injury were fractures (38%), traumatic brain injury (37%), spinal cord injury (13%), whiplash (9%) and other (3%). Mean time after injury was 2.2 years. Internal consistency of IMPACT-S was satisfying for all 9 domains (0.75-0.89) and excellent for the total score (0.96). Test-retest reliability was good at item level (0.44-0.72), domain level (0.72-0.92) and total score (0.94). Strong correlations (0.61-0.88) between IMPACT-S and corresponding WHODAS-II scores were found. Conclusion: IMPACT-S is a reliable and valid generic measure of activity limitations and participation restrictions that fits the ICF.	[Post, Marcel W. M.] Rehabil Ctr De Hoogstr, NL-3583 TM Utrecht, Netherlands; [Post, Marcel W. M.] Rudolf Magnus Inst Neurosci, NL-3508 TA Utrecht, Netherlands; [Post, Marcel W. M.; de Witte, Luc P.; Reichrath, Enid; Verdonschot, Manon M.] iRv Inst Rehabil Res, Hoensbroek, Netherlands; [Wijlhuizen, Gert Jan; Perenboom, Rom J. M.] TNO Qual Life, Leiden, Netherlands	Post, MWM (corresponding author), Rehabil Ctr De Hoogstr, Rembrandtkade 10, NL-3583 TM Utrecht, Netherlands.	m.post@dehoogstraat.nl		de Witte, Luc/0000-0002-3013-2640			*AIHW, 2003, ICF AUSTR US GUID VE; Biering-Sorensen F, 2006, SPINAL CORD, V44, P541, DOI 10.1038/sj.sc.3101918; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Cieza A, 2005, QUAL LIFE RES, V14, P1225, DOI 10.1007/s11136-004-4773-0; Cieza A, 2004, J REHABIL MED, V36, P9, DOI 10.1080/16501960410015353; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; de Vet HCW, 2006, J CLIN EPIDEMIOL, V59, P1033, DOI 10.1016/j.jclinepi.2005.10.015; Epping-Jordan J. E., 2000, WHO MENTAL HLTH B, V6, P5; Farin E, 2007, J REHABIL MED, V39, P537, DOI 10.2340/16501977-0083; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Gandek B, 2007, AM J PHYS MED REHAB, V86, P57, DOI 10.1097/01.PHM.0000233200.43822.21; Geyh S, 2007, QUAL LIFE RES, V16, P833, DOI 10.1007/s11136-007-9174-8; Haley SM, 2004, ARCH PHYS MED REHAB, V85, P649, DOI 10.1016/j.apmr.2003.08.098; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; Jette AM, 2003, J REHABIL MED, V35, P145, DOI 10.1080/16501970310010501; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; Nunnally J.C., 1967, PSYCHOMETRIC THEORY, V226; Perenboom R, 2006, NEWSLETTER WHO FAMIL, V4, P8; Perenboom RJM, 2003, DISABIL REHABIL, V25, P577, DOI 10.1080/0963828031000137081; Posl M, 2007, QUAL LIFE RES, V16, P1521, DOI 10.1007/s11136-007-9259-4; Reichrath E, 2005, KWALITEIT DOELMATIGH; Schepers VPM, 2007, DISABIL REHABIL, V29, P221, DOI 10.1080/09638280600756257; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Stucki G, 2005, AM J PHYS MED REHAB, V84, P733, DOI 10.1097/01.phm.0000179521.70639.83; Stucki G, 2002, DISABIL REHABIL, V24, P281, DOI 10.1080/09638280110105222; Stucki G, 2007, J REHABIL MED, V39, P279, DOI 10.2340/16501977-0041; Van Brakel WH, 2006, DISABIL REHABIL, V28, P193, DOI 10.1080/09638280500192785; VANDERHOEKEN D, 2000, NEDERLANDSE WHODAS 2; Visser-Meily JMA, 2004, CLIN REHABIL, V18, P601, DOI 10.1191/0269215504cr776oa; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 1999, ICIDH 2 INT CLASS FU; *WHO, 1980, INT CLASS PAIRM DIS; *WHO, 2001, WHO DIS ASS SCH WHOD; World Health Organization, 2001, INT CLASS FUNCT DIS	36	84	86	0	15	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2008	40	8					620	627		10.2340/16501977-0223			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	351FF	WOS:000259409200007	19020695	DOAJ Gold			2021-06-18	
J	Ruff, RL; Ruff, SS; Wang, XF				Ruff, Robert L.; Ruff, Suzanne S.; Wang, Xiao-Feng			Headaches among Operation Iraqi Freedom/Operation Enduring Freedom veterans with mild traumatic brain injury associated with exposures to explosions	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast; combat; explosion; headache; migraine; OEF; OIF; pain; sleep; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; EDITION CVLT-II; OLFACTORY DYSFUNCTION; COGNITIVE IMPAIRMENT; SCREENING TOOL; MEMORY; PERFORMANCE; CLASSIFICATION; AFGHANISTAN; DEFICITS	Traumatic brain injury (TBI) is a common injury type among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) veterans, and headaches are a frequent consequence of TBI. We examined the hypothesis that among veterans who reported mild TBI caused by exposure to an explosion during deployment in OIF/OEF, those with residual neurocognitive deficits would have a higher frequency of headaches and more severe headaches. We evaluated 155 consecutive veterans with neurological examination and neuropsychological testing. We excluded 29 veterans because they did not have mild TBI or they did not complete the evaluation. We analyzed headache pattern, intensity, and frequency. Among the 126 veterans studied, 80 had impairments on neurological examination or neuropsychological testing that were best attributed to TBI. Veterans with impairments had been exposed to more explosions and were more likely to have headache, features of migraine, more severe pain, more frequent headaches, posttraumatic stress disorder, and impaired sleep with nightmares.	[Ruff, Robert L.] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Neurol Serv & Polytrauma Syst Care, Cleveland, OH USA; [Ruff, Robert L.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Ruff, Suzanne S.] Louis Stokes Cleveland VAMC, Psychol Serv & Polytrauma Syst Care, Cleveland, OH 44106 USA; [Wang, Xiao-Feng] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA	Ruff, RL (corresponding author), Louis Stokes Cleveland VAMC, Neurol Serv W127, 10701 E Blvd, Cleveland, OH 44106 USA.	Robert.Ruff1@va.gov			Patient Care Services of the LSCVAMC, Cleveland, Ohio	This material is the result of work supported by Patient Care Services of the LSCVAMC, Cleveland, Ohio.	Agresti A, 1996, INTRO CATEGORICAL DA, P16; AGRESTI A, 1996, INTRO CATEGORICAL DA, P71; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1996, BECK DEPRESSION INVE, P128; Benge JF, 2007, BRAIN INJURY, V21, P395, DOI 10.1080/02699050701311091; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Bowden SC, 1998, NEUROPSYCHOL REHABIL, V8, P243, DOI 10.1080/713755573; Breslau N, 2001, BIOL PSYCHIAT, V50, P699, DOI 10.1016/S0006-3223(01)01167-2; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Donders J, 2008, ASSESSMENT, V15, P123, DOI 10.1177/1073191107310926; Doty RL, 2007, AM J RHINOL, V21, P460, DOI 10.2500/ajr.2007.21.3043; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; DOTY RL, 1989, PERCEPT PSYCHOPHYS, V45, P381, DOI 10.3758/BF03210709; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; GRAHAM JR, 1999, MMPI 2 ASSESSING PER, P256; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HOCHBERG Y, 1987, MULTIPLE COMPARISON; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Jacobs ML, 2008, ARCH CLIN NEUROPSYCH, V23, P113, DOI 10.1016/j.acn.2007.09.003; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kern RC, 2000, LARYNGOSCOPE, V110, P2106, DOI 10.1097/00005537-200012000-00025; KERR C, 1995, BRAIN INJURY, V9, P777, DOI 10.3109/02699059509008234; Khasnis A, 2003, J Postgrad Med, V49, P169; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KREMER E, 1981, PAIN, V10, P241, DOI 10.1016/0304-3959(81)90199-8; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; LICHTENBERGER EO, 2001, ESSENTIALS WMS 3 ASS, P288; Linder Steven L, 2007, Curr Pain Headache Rep, V11, P396, DOI 10.1007/s11916-007-0223-3; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; London B, 2008, ANN NEUROL, V63, P159, DOI 10.1002/ana.21293; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Maujean A., 2003, BRAIN IMPAIR, V4, P135, DOI DOI 10.1375/BRIM.4.2.135.27024; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Meyers J E, 1996, Appl Neuropsychol, V3, P89, DOI 10.1207/s15324826an0302_8; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Ozakbas S, 2004, MULT SCLER, V10, P686, DOI 10.1191/1352458504ms1111oa; Pickett TC, 2007, J REHABIL RES DEV, V44, P983, DOI 10.1682/JRRD.2007.01.0001; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ryan JJ, 2003, ASSESSMENT, V10, P151, DOI 10.1177/1073191103010002006; SAMUELS MA, 2003, OFFICE PRACTICE NEUR, P1661; SAWYER RN, 1993, NEUROLOGY, V43, P1596, DOI 10.1212/WNL.43.8.1596; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Suchy Y, 2003, CLIN NEUROPSYCHOL, V17, P492, DOI 10.1076/clin.17.4.492.27949; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P753, DOI 10.1016/j.acn.2006.08.009; VANBELLE G, 2004, BIOSTATISTICS METHOD, P345; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F.W., 1991, PCL M DSM 4; Western SL, 1997, ARCH CLIN NEUROPSYCH, V12, P426; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; ZADIKOFF C, 2007, MOVEMENT DISORD, V23, P297, DOI DOI 10.1002/MDS.21837	85	84	84	0	9	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2008	45	7					941	952		10.1682/JRRD.2008.02.0028			12	Rehabilitation	Rehabilitation	387WI	WOS:000261981900001	19165684	Bronze			2021-06-18	
J	Ofek, H; Defrin, R				Ofek, Hadas; Defrin, Ruth			The characteristics of chronic central pain after traumatic brain injury	PAIN			English	Article						traumatic brain injury; chronic pain; central pain; quantitative somatosensory testing	SPINAL-CORD-INJURY; CENTRAL NEUROPATHIC PAIN; SENSORY FUNCTION; PHARMACOLOGICAL-TREATMENT; MULTIPLE-SCLEROSIS; THRESHOLDS; MECHANISMS; RELIABILITY; THALAMUS; PATIENT	Central pain following traumatic brain injury (TBI) has not been studied in depth. Our purpose was to conduct a systematic study of patients with TBI suffering from chronic central pain, and to describe the characteristics of the central pain. Groups were TBI patients with (TBIP) and without central pain (TBINP) and healthy controls. TBI patients with other pain mechanisms were excluded from the study. Participants underwent quantitative somatosensory testing in the painful and pain-free body regions. Thresholds for warmth, cold, heat-pain, touch and graphesthesia were measured and pathologically evoked pain (allodynia, hyperpathia and wind-up pain) evaluated. Chronic pain was mapped and characterized. Chronic pain developed at a relatively late onset (6.6 +/- 9 months) was almost exclusively unilateral and reported as pricking, throbbing and burning. Although both TBIP and TBINP exhibited a significant reduction in thermal and tactile sensations compared to controls, thermal sensations in the painful regions of TBIP were significantly more impaired than pain-free regions in the same patients (p < 0.01) and in TBINP (p < 0.01). Painful regions also exhibited very high rates of allodynia, hyperpathia and exaggerated wind-up. The characteristics of the chronic pain resembled those of other central pain patients although TBIP displayed several unique features. The sensory profile indicated that damage to the pain and temperature systems is a necessary but not sufficient condition for the development of chronic central pain following TBI. Neuronal hyperexcitability may be a contributing factor to the chronic pain. (C) 2007 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Dept Phys Therapy, IL-69978 Ramat Aviv, Israel; Loewenstein Hosp Rehabil Ctr, Raanana, Israel	Defrin, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Dept Phys Therapy, IL-69978 Ramat Aviv, Israel.	rutidef@post.tau.ac.il	ofek, hadas/AAM-7017-2020				Alfano DP, 2000, ARCH CLIN NEUROPSYCH, V15, P831, DOI 10.1016/S0887-6177(00)80329-7; Barraquer-Bordas L, 1993, Neurologia, V8, P147; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BELLKROTOSKI J, 1987, J HAND SURG-AM, V12A, P155, DOI 10.1016/S0363-5023(87)80189-2; Beniczky S, 2005, J NEURAL TRANSM, V112, P735, DOI 10.1007/s00702-005-0300-x; BERIC A, 1988, PAIN, V34, P109, DOI 10.1016/0304-3959(88)90155-8; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; BOIVIE J, 1999, TXB PAIN, P871; Bowsher D, 1996, J NEUROL NEUROSUR PS, V61, P62, DOI 10.1136/jnnp.61.1.62; Bowsher D, 1998, NEUROLOGY, V51, P1352, DOI 10.1212/WNL.51.5.1352; CASEY KL, 1999, 9 WORLD C PAIN SEATT, P435; COOPER PR, 1993, HEAD INJURY, P1; COSGROVE JL, 1989, AM J PHYS MED REHAB, V68, P15, DOI 10.1097/00002060-198902000-00005; Defrin R, 2002, BRAIN, V125, P501, DOI 10.1093/brain/awf055; Defrin R, 2001, PAIN, V89, P253, DOI 10.1016/S0304-3959(00)00369-9; Defrin R, 1999, PAIN, V83, P275, DOI 10.1016/S0304-3959(99)00115-3; Ducreux D, 2006, BRAIN, V129, P963, DOI 10.1093/brain/awl016; Eide PK, 1996, J NEUROL NEUROSUR PS, V60, P411, DOI 10.1136/jnnp.60.4.411; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Finnerup NB, 2003, BRAIN, V126, P57, DOI 10.1093/brain/awg007; Frese A, 2006, CLIN J PAIN, V22, P252, DOI 10.1097/01.ajp.0000173020.10483.13; FRUHSTORFER H, 1976, J NEUROL NEUROSUR PS, V39, P1071, DOI 10.1136/jnnp.39.11.1071; Gellman H, 1996, J HEAD TRAUMA REHAB, V11, P23, DOI 10.1097/00001199-199608000-00005; Greenspan JD, 2004, PAIN, V109, P357, DOI 10.1016/S0304-3959(04)00068-5; Hansson P, 2004, EUR J NEUROL, V11, P22, DOI 10.1111/j.1471-0552.2004.00793.x; Hulsebosch CE, 2005, CURR PHARM DESIGN, V11, P1411, DOI 10.2174/1381612053507864; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; JOHANSSON RS, 1980, BRAIN RES, V184, P343, DOI 10.1016/0006-8993(80)90803-3; KATZ N, 1989, AM J OCCUP THER, V43, P184, DOI 10.5014/ajot.43.3.184; Khoshyomn S, 2004, J TRAUMA, V56, P1131, DOI 10.1097/01.TA.0000071299.31349.D6; LAHUERTA J, 1990, PAIN, V42, P23, DOI 10.1016/0304-3959(90)91087-Y; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LENZ FA, 1994, J NEUROPHYSIOL, V72, P1570; LENZ FA, 1987, PAIN, V31, P225, DOI 10.1016/0304-3959(87)90038-8; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Merskey H, 1994, CLASSIFICATION CHRON; Ness TJ, 1998, PAIN, V78, P139, DOI 10.1016/S0304-3959(98)00153-5; OCHOA JL, 1993, ANN NEUROL, V33, P465, DOI 10.1002/ana.410330509; Osterberg A, 2005, EUR J PAIN, V9, P531, DOI 10.1016/j.ejpain.2004.11.005; Pattany PM, 2002, AM J NEURORADIOL, V23, P901; Peyron R, 2000, PAIN, V84, P77, DOI 10.1016/S0304-3959(99)00190-6; PRICE DD, 1992, PAIN, V49, P163, DOI 10.1016/0304-3959(92)90139-3; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Son BC, 2006, PAIN, V123, P210, DOI 10.1016/j.pain.2006.02.028; Svendsen KB, 2005, PAIN, V114, P473, DOI 10.1016/j.pain.2005.01.015; TASKER RR, 1992, J NEUROSURG, V77, P373, DOI 10.3171/jns.1992.77.3.0373; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VERDUGO R, 1992, BRAIN, V115, P893, DOI 10.1093/brain/115.3.893; VESTERGAARD K, 1995, PAIN, V61, P177, DOI 10.1016/0304-3959(94)00140-A; VOGELBAUM MA, 1998, CLIN NEUROL, V3, P1; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; WILCOX GL, 1984, BRAIN RES BULL, V12, P143, DOI 10.1016/0361-9230(84)90227-2; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; YARNITSKY D, 1990, PAIN, V40, P85, DOI 10.1016/0304-3959(90)91055-N	58	84	85	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	OCT	2007	131	3					330	340		10.1016/j.pain.2007.06.015			11	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	220SU	WOS:000250178400015	17689190				2021-06-18	
J	Schachtrup, C; Lu, P; Jones, LL; Lee, JK; Lu, J; Sachs, BD; Zhengt, B; Akassoglou, K				Schachtrup, Christian; Lu, Paul; Jones, Leonard L.; Lee, Jae K.; Lu, Jerry; Sachs, Ben D.; Zhengt, Binhai; Akassoglou, Katerina			Fibrinogen inhibits neurite outgrowth via beta 3 integrin-mediated phosphorylation of the EGF receptor	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						blood-brain barrier; regeneration; spinal cord injury; transactivation; scar	ACUTE INFLAMMATORY RESPONSES; AXONAL REGENERATION; SPINAL-CORD; CNS MYELIN; GROWTH; BRAIN; ACTIVATION; NERVE; BARRIER; ABNORMALITIES	Changes in the molecular and cellular composition of the CNS after injury or disease result in the formation of an inhibitory environment that inhibits the regeneration of adult mammalian CNS neurons. Although a dramatic change in the CNS environment after traumatic injury or disease is hemorrhage because of vascular rupture or leakage of the blood-brain barrier, the potential role for blood proteins in repair processes remains unknown. Here we show that the blood protein fibrinogen is an inhibitor of neurite outgrowth that is massively deposited in the spinal cord after injury. We show that fibrinogen acts as a ligand for beta 3 integrin and induces the transactivation of EGF receptor (EGFR) in neurons. Fibrinogen-mediated inhibition of neurite outgrowth is reversed by blocking either beta 3 integrin or phoshorylation of EGFR. Inhibition of Src family kinases that mediate the cross-talk between integrin and growth factor receptors rescue the fibrinogen-induced phosphorylation of EGFR. These results identify fibrinogen as the first blood-derived inhibitor of neurite outgrowth and suggest fibrinogen-induced EGFR transactivation on neuronal cells as a molecular link between vascular and neuronal damage in the CNS after injury.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Akassoglou, K (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	akass@ucsd.edu		Akassoglou, Katerina/0000-0002-2632-1465	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054734, P30NS047101, R01NS052189, R01NS051470] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS047101, R01 NS054734, R01 NS052189, R01 NS051470, R01NS052189, R01NS051470] Funding Source: Medline		Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adams RA, 2004, MOL INTERV, V4, P163; Adams RA, 2007, J EXP MED, V204, P571, DOI 10.1084/jem.20061931; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Akassoglou K, 2000, J CELL BIOL, V149, P1157, DOI 10.1083/jcb.149.5.1157; Akassoglou K, 2004, P NATL ACAD SCI USA, V101, P6698, DOI 10.1073/pnas.0303859101; Akassoglou K, 2002, NEURON, V33, P861, DOI 10.1016/S0896-6273(02)00617-7; Akassoglou K, 2002, BIOL CHEM, V383, P37, DOI 10.1515/BC.2002.004; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Busso N, 1998, J CLIN INVEST, V102, P41, DOI 10.1172/JCI2312; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Case LC, 2005, CURR BIOL, V15, pR749, DOI 10.1016/j.cub.2005.09.008; Chavis P, 2001, NATURE, V411, P317, DOI 10.1038/35077101; CLAUDIO L, 1995, ACTA NEUROPATHOL, V90, P228; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; Degen JL, 2001, ANN NY ACAD SCI, V936, P276; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Flick MJ, 2004, J CLIN INVEST, V113, P1596, DOI 10.1172/JCI200420741; Gay FW, 1997, BRAIN, V120, P1461, DOI 10.1093/brain/120.8.1461; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gveric D, 2003, BRAIN, V126, P1590, DOI 10.1093/brain/awg167; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hardy J, 2006, NAT MED, V12, P756, DOI 10.1038/nm0706-756; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Jo M, 2007, ONCOGENE, V26, P2585, DOI 10.1038/sj.onc.1210066; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Leyton L, 2001, CURR BIOL, V11, P1028, DOI 10.1016/S0960-9822(01)00262-7; Lipinski B, 2006, ALZ DIS ASSOC DIS, V20, P323, DOI 10.1097/01.wad.0000213844.21001.a2; Lluis F, 2001, BLOOD, V97, P1703, DOI 10.1182/blood.V97.6.1703; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; Petzelbauer P, 2005, NAT MED, V11, P298, DOI 10.1038/nm1198; Pinkstaff JK, 1999, J NEUROSCI, V19, P1541; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; Selnes OA, 2006, NAT CLIN PRACT NEURO, V2, P538, DOI 10.1038/ncpneuro0294; TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147; Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549; Thompson RD, 2000, J IMMUNOL, V165, P426, DOI 10.4049/jimmunol.165.1.426; TOMA JG, 1992, J NEUROSCI, V12, P2504; Ugarova TP, 2001, ANN NY ACAD SCI, V936, P368; Vos CMP, 2005, NEUROBIOL DIS, V20, P953, DOI 10.1016/j.nbd.2005.06.012; Wang H, 2003, BIOL CHEM, V384, P193, DOI 10.1515/BC.2003.021; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	56	84	87	0	7	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUL 10	2007	104	28					11814	11819		10.1073/pnas.0704045104			6	Multidisciplinary Sciences	Science & Technology - Other Topics	190MQ	WOS:000248063400054	17606926	Green Published, Bronze			2021-06-18	
J	Ohman, L; Nordin, S; Bergdahl, J; Birgander, LS; Neely, AS				Ohman, Lena; Nordin, Steven; Bergdahl, Jan; Birgander, Lisbeth Slunga; Neely, Anna Stigsdotter			Cognitive function in outpatients with perceived chronic stress	SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH			English	Article						burnout; executive functioning; memory; work stress	TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; PROSPECTIVE MEMORY; PREFRONTAL CORTEX; EPISODIC MEMORY; CHRONIC BURNOUT; PERFORMANCE; DYSFUNCTION; ATTENTION; VALIDITY	Objectives The number of employees on sick leave due to stress-related syndromes has increased drastically in many industrialized countries. Cognitive dysfunction is a common complaint among patients suffering from chronic stress. Previous research on chronic stress has mainly focused on its interpersonal, attitudinal, psychological, organizational, and physical effects. Less attention has been allocated to effects of chronic stress on cognitive functioning. Hence the aim of the present study was to investigate the relationship between chronic stress and cognition. Methods The cognitive performance of 19 chronic stress outpatients and 19 matched controls was studied. A battery of standard and experimental cognitive tests assessing processing speed, attention, working memory, and episodic and semantic memory were administered. Results Performance deficits of the chronic stress patients relative to the performance of the controls were found for some but not all cognitive tasks, indicating a selective deficit. Deficits were found for episodic memory, particularly for learning across repeated trials and for tasks requiring divided attention during either the encoding or retrieval of words. Performance differences were also found for aspects of working memory, mental tempo, semantic access, and prospective memory, but not for basic perceptual speed measures. Conclusions These findings may suggest suboptimal executive functioning (eg, strategic or attentional control) among chronic stress patients. Particularly, poor performance in letter fluency and prospective memory were significantly associated with chronic stress, the finding suggesting the usefulness of these tests as clinical tools in evaluations of chronic stress states.	Umea Univ, Dept Psychol, S-90187 Umea, Sweden; Orebro Univ Hosp, Dept Occupat & Environm Med, Orebro, Sweden; Univ Tromso, Fac Med, Inst Clin Dent, Tromso, Norway; Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden	Neely, AS (corresponding author), Umea Univ, Dept Psychol, S-90187 Umea, Sweden.	anna.neely@psy.umu.se	Stigsdotter Neely, Anna/H-4140-2012				Alderson AL, 2002, J CLIN EXP NEUROPSYC, V24, P335, DOI 10.1076/jcen.24.3.335.987; Benton A, 1989, MULTILINGUAL APHASIA; Bergdahl J, 2005, SCAND J PSYCHOL, V46, P395, DOI 10.1111/j.1467-9450.2005.00470.x; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Braver TS, 2002, NEUROSCI BIOBEHAV R, V26, P809, DOI 10.1016/S0149-7634(02)00067-2; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Capuron L, 2006, NEUROPSYCHOPHARMACOL, V31, P1777, DOI 10.1038/sj.npp.1301005; DUREMAN I, 1971, MANUAL DS BATTERIET; Grossi G, 2003, J PSYCHOSOM RES, V55, P309, DOI 10.1016/S0022-3999(02)00633-5; Henry JD, 2004, NEUROPSYCHOLOGIA, V42, P1212, DOI 10.1016/j.neuropsychologia.2004.02.001; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lupien SJ, 2001, BEHAV BRAIN RES, V127, P137, DOI 10.1016/S0166-4328(01)00361-8; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mantyla T, 2003, MEM COGNITION, V31, P15, DOI 10.3758/BF03196078; Mantyla T, 1997, AGING NEUROPSYCHOL C, V4, P81, DOI 10.1080/13825589708256638; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MEIER ST, 1984, J OCCUP PSYCHOL, V57, P211, DOI 10.1111/j.2044-8325.1984.tb00163.x; Melamed S, 1999, J PSYCHOSOM RES, V46, P591, DOI 10.1016/S0022-3999(99)00007-0; MELAMED S, 1992, BEHAV MED, V18, P53, DOI 10.1080/08964289.1992.9935172; Melamed S, 2006, PSYCHOL BULL, V132, P327, DOI 10.1037/0033-2909.132.3.327; Meyers J., 1995, REY COMPLEX FIGURE T; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moscovitch M., 2002, PRINCIPLES FRONTAL L, P188, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0012; Mungas D, 2001, NEUROLOGY, V57, P2229, DOI 10.1212/WNL.57.12.2229; MURDOCK BB, 1965, BRIT J PSYCHOL, V56, P413, DOI 10.1111/j.2044-8295.1965.tb00983.x; Nilsson LG, 1997, AGING NEUROPSYCHOL C, V4, P1, DOI 10.1080/13825589708256633; Nyberg L, 2003, P NATL ACAD SCI USA, V100, P13728, DOI 10.1073/pnas.1735487100; Nyberg L, 1997, EXP AGING RES, V23, P137, DOI 10.1080/03610739708254029; Paulesu E, 1997, NEUROREPORT, V8, P2011, DOI 10.1097/00001756-199705260-00042; Prins JB, 2006, LANCET, V367, P346, DOI 10.1016/S0140-6736(06)68073-2; Pruessner JC, 1999, PSYCHOSOM MED, V61, P197, DOI 10.1097/00006842-199903000-00012; Quintner JL, 1999, LANCET, V353, P1092, DOI 10.1016/S0140-6736(98)06468-X; Radley JJ, 2004, NEUROSCIENCE, V125, P1, DOI 10.1016/j.neuroscience.2004.01.006; REITAN RM, 1992, TRAIL MAKING TEST TU; Rey A., 1993, CLIN NEUROPSYCHOL, V7, P4; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; SALTHOUSE TA, 1993, DEV PSYCHOL, V29, P722, DOI 10.1037/0012-1649.29.4.722; Sandstrom A, 2005, BIOL PSYCHOL, V69, P271, DOI 10.1016/j.biopsycho.2004.08.003; Schaufeli W., 1998, BURNOUT COMPANION ST; Shirom A, 2003, ANXIETY STRESS COPIN, V16, P83, DOI 10.1080/1061580021000057059; Spiegel K, 1999, LANCET, V354, P1435, DOI 10.1016/S0140-6736(99)01376-8; Ursin H, 2001, ANN NY ACAD SCI, V933, P119; Van der Linden D, 2005, WORK STRESS, V19, P23, DOI 10.1080/02678370500065275; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2	51	84	86	0	28	SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH	HELSINKI	TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND	0355-3140	1795-990X		SCAND J WORK ENV HEA	Scand. J. Work Environ. Health	JUN	2007	33	3					223	232					10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	184UF	WOS:000247667400007	17572832				2021-06-18	
J	Leinhase, I; Rozanski, M; Harhausen, D; Thurman, JM; Schmidt, OI; Hossini, AM; Taha, ME; Rittirsch, D; Ward, PA; Holers, VM; Ertel, W; Stahel, PF				Leinhase, Iris; Rozanski, Michal; Harhausen, Denise; Thurman, Joshua M.; Schmidt, Oliver I.; Hossini, Amir M.; Taha, Mohy E.; Rittirsch, Daniel; Ward, Peter A.; Holers, V. Michael; Ertel, Wolfgang; Stahel, Philip F.			Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice	JOURNAL OF NEUROINFLAMMATION			English	Article; Proceedings Paper	21st International Complement Workshop	OCT 20-27, 2006	Beijing, PEOPLES R CHINA				CLOSED-HEAD INJURY; CENTRAL-NERVOUS-SYSTEM; NEURONAL CELL-DEATH; CLINICAL-TRIALS; FUNCTIONAL RECOVERY; NEUROPROTECTION; INFLAMMATION; DISEASE; MODEL; PROTEIN	Background: The posttraumatic response to traumatic brain injury (TBI) is characterized, in part, by activation of the innate immune response, including the complement system. We have recently shown that mice devoid of a functional alternative pathway of complement activation ( factor B-/-mice) are protected from complement-mediated neuroinflammation and neuropathology after TBI. In the present study, we extrapolated this knowledge from studies in genetically engineered mice to a pharmacological approach using a monoclonal anti-factor B antibody. This neutralizing antibody represents a specific and potent inhibitor of the alternative complement pathway in mice. Methods: A focal trauma was applied to the left hemisphere of C57BL/ 6 mice (n = 89) using a standardized electric weight-drop model. Animals were randomly assigned to two treatment groups: ( 1) Systemic injection of 1 mg monoclonal anti-factor B antibody (mAb 1379) in 400 mu l phosphate-buffered saline (PBS) at 1 hour and 24 hours after trauma; ( 2) Systemic injection of vehicle only (400 mu l PBS), as placebo control, at identical time-points after trauma. Sham-operated and untreated mice served as additional negative controls. Evaluation of neurological scores and analysis of brain tissue specimens and serum samples was performed at defined time-points for up to 1 week. Complement activation in serum was assessed by zymosan assay and by murine C5a ELISA. Brain samples were analyzed by immunohistochemistry, terminal deoxynucleotidyl transferase dUTP nick-end labeling ( TUNEL) histochemistry, and real-time RT-PCR. Results: The mAb 1379 leads to a significant inhibition of alternative pathway complement activity and to significantly attenuated C5a levels in serum, as compared to head-injured placebo-treated control mice. TBI induced histomorphological signs of neuroinflammation and neuronal apoptosis in the injured brain hemisphere of placebo-treated control mice for up to 7 days. In contrast, the systemic administration of an inhibitory anti-factor B antibody led to a substantial attenuation of cerebral tissue damage and neuronal cell death. In addition, the posttraumatic administration of the mAb 1379 induced a neuroprotective pattern of intracerebral gene expression. Conclusion: Inhibition of the alternative complement pathway by posttraumatic administration of a neutralizing anti-factor B antibody appears to represent a new promising avenue for pharmacological attenuation of the complement-mediated neuroinflammatory response after head injury.	Charite Univ Med Berlin, Sch Med, Dept Trauma & Reconstruct Surg, D-12200 Berlin, Germany; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Colorado, Sch Med, Dept Orthoped Surg, Denver, CO 80204 USA	Stahel, PF (corresponding author), Charite Univ Med Berlin, Sch Med, Dept Trauma & Reconstruct Surg, Campus Benjamin Franklin, D-12200 Berlin, Germany.	iris.leinhase@charite.de; michalr@gazeta.pl; denise.harhausen@charite.de; joshua.thurman@uchsc.edu; olischmidt@web.de; amir.hossini@charite.de; mohy_kom@yahoo.com; drittirs@med.umich.edu; pward@umich.edu; michael.holers@uchsc.edu; wolfgang.ertel@charite.de; philip.stahel@dhha.org		Rittirsch, Daniel/0000-0002-1185-2431	NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI31105, R01 AI031105] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK064790] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 61656, R01 GM061656, GM 029507, R37 GM029507, R01 GM029507] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI031105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R37GM029507, R01GM029507, R01GM061656] Funding Source: NIH RePORTER		Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208; Banda NK, 2006, J IMMUNOL, V177, P1904, DOI 10.4049/jimmunol.177.3.1904; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Felderhoff-Mueser U, 2005, TRENDS NEUROSCI, V28, P487, DOI 10.1016/j.tins.2005.06.008; FRANCIS K, 2003, EXPERT REV MOL MED, P1; Harris CL, 2002, BIOCHEM SOC T, V30, P1019, DOI 10.1042/bst0301019; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kulkarni AP, 2005, ANN NY ACAD SCI, V1056, P413, DOI 10.1196/annals.1352.020; Kulkarni AP, 2004, ANN NY ACAD SCI, V1035, P147, DOI 10.1196/annals.1332.010; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Morgan BP, 1997, IMMUNOPHARMACOLOGY, V38, P43; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pillay NS, 2005, ANN NY ACAD SCI, V1056, P450, DOI 10.1196/annals.1352.021; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sauerland S, 2004, LANCET, V364, P1291, DOI 10.1016/S0140-6736(04)17202-4; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Taube C, 2006, P NATL ACAD SCI USA, V103, P8084, DOI 10.1073/pnas.0602357103; Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305; Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043; Thurman JM, 2006, J AM SOC NEPHROL, V17, P707, DOI 10.1681/ASN.2005070698; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wong A K, 1999, IDrugs, V2, P686; Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	49	84	84	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 2	2007	4								13	10.1186/1742-2094-4-13			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	213RX	WOS:000249685900002	17474994	DOAJ Gold, Green Published			2021-06-18	
J	Dawson, DR; Schwartz, ML; Winocur, G; Stuss, DT				Dawson, Deirdre R.; Schwartz, Michael L.; Winocur, Gordon; Stuss, Donald T.			Return to productivity following traumatic brain injury: Cognitive, psychological, physical, spiritual, and environmental correlates	DISABILITY AND REHABILITATION			English	Article						traumatic brain injury; productivity; coping	SEVERE HEAD-INJURY; CHRONIC PAIN; POSTTRAUMATIC AMNESIA; COPING STRATEGIES; EMPLOYMENT; RECOVERY; DEPRESSION; PREDICTORS; MODERATE; ADULTS	Purpose. The purpose of this study was to investigate the determinants and correlates of return to productivity (RTP) defined here as return to paid employment and/or school four years following traumatic brain injury (TBI). Method. Participants included 46 people with TBI, part of a prospective, cohort study, and 14 friend/family member controls all employed and/or in school at time of injury or inception into the study. Variables were selected for investigation based on two models of recovery. Demographic and injury severity data including time to recover free recall were collected at time of injury, on admission to a trauma unit. Data on other variables (neuropsychological, psychological, physical, spiritual, environmental) were collected concurrent with productivity status at a mean of 4.3 years post-TBI. Results. Time to recover free recall (measured acutely), neuropsychological status, pain severity, depression, and the use of maladaptive coping behaviours were all related to productivity status (p < 0.05). When these variables were entered into exploratory, planned hierarchical logistic regression models time to free recall, pain, and maladaptive coping remained in the models with depression only dropping out because of the high correlation with pain (r > 0.80). Conclusions. Injury severity (time to free recall), physical status (pain), and psychological status (depression, coping) are important to understanding differences in productivity outcomes. Addressing pain, depression and coping in rehabilitation programs may have a positive impact on outcomes.	Baycrest, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Occupat Sci, Toronto, ON, Canada; Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada; Baycrest, Rotman Res Inst, Toronto, ON, Canada	Dawson, DR (corresponding author), Baycrest, Kunin Lunenfeld Appl Res Unit, 2560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121			ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BECK AT, 1978, BECK DEPRESSION INVE; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOSCHEN KA, 1995, VARIABLES AFFECTING; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CODY RP, 1997, APPL STAT SAS PPROGR; Coughlin AM, 2000, ARCH PHYS MED REHAB, V81, P739, DOI 10.1016/S0003-9993(00)90103-5; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2006, BRAIN COGNITION, V60, P214; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Folkman S., 1998, MANUAL WAYS COPING Q; Frankl V.E, 1963, MANS SEARCH MEANING; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Judge TA, 2001, J APPL PSYCHOL, V86, P80, DOI 10.1037/0021-9010.86.1.80; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kennedy P, 2003, BRIT J CLIN PSYCHOL, V42, P41, DOI 10.1348/014466503762842002; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Logan M., 2000, DISS ABSTR INT, V61, P881; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; McColl MA, 2000, ARCH PHYS MED REHAB, V81, P817, DOI 10.1053/apmr.2000.5567; MCCOLL MA, 1995, INT J REHABIL RES, V18, P325, DOI 10.1097/00004356-199512000-00004; MCCOLL MA, 1995, DISABIL REHABIL, V17, P24, DOI 10.3109/09638289509166624; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MOORE AD, 1994, BRAIN INJURY, V7, P193; NOMAN GR, 2000, BIOSTATISTICS BARE E; NOSEK MA, 1992, REHABIL COUNS BULL, V36, P21; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Oppermann JD, 2004, BRAIN INJURY, V18, P941, DOI 10.1080/02699050410001671919; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; Reker GT., 1992, MANUAL LIFE ATTITUDE; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sarason, 1985, SOCIAL SUPPORT THEOR, P73, DOI DOI 10.1007/978-94-009-5115-0_5; *SAS I INC, 1999, SAS VERS 8 2; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spreen O., 1998, COMPENDIUM NEUROPSYC; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STROUP ES, 2000, DISS ABSTR INT, V60, P4913; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; THOMPSON JL, 1986, METHODS OBSERVATIONA; Turner GR, 2004, SCI PRACT NEUROPSYCH, P224; TYRER S, 2003, NEUROPSYCHOL REHABIL, P189; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Wechsler D, 1981, WECSLER ADULT INTELL; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; WHO, 1976, INT CLASS IMP DIS HA; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; WINOCUR G, J INT NEUROPSYCHOLOG; World Health Organization, 2001, INT CLASS FUNCT DIS	83	84	86	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	FEB 28	2007	29	4					301	313		10.1080/09638280600756687			13	Rehabilitation	Rehabilitation	140SJ	WOS:000244526700004	17364780				2021-06-18	
J	Hanks, RA; Rapport, LJ; Vangel, S				Hanks, Robin A.; Rapport, Lisa J.; Vangel, Stephen			Caregiving appraisal after traumatic brain injury: The effects of functional status, coping style, social support and family functioning	NEUROREHABILITATION			English	Article						caregiving; traumatic brain injury; TBI; burden of care; satisfaction with caregiving; mastery of caregiving; family functioning; social support; coping style	ASSESSMENT DEVICE; HEAD-INJURY; DISTRESS; SCALE; PREDICTORS; IMPACT; COMA	Perception of caregiving after traumatic brain injury (TBI) has been shown to be an important part of both survivor and family adjustment. The roles of coping style, family functioning, perceived social support and the TBI survivor's functional status have not been fully examined with respect to appraisal of caregiving. This study examined these factors with respect to both positive and negative appraisals of caregiving in four main areas: perceived burden, caregiving relationship satisfaction, beliefs about caregiving, and mastery with caregiving. Sixty primary caregivers of individuals who sustained a TBI within the last 6 months to 15 years were administered the Caregiver Appraisal Scale, as well as the Coping Inventory for Stressful Situations, a 21-item version of the Family Assessment Device, and the Social Provision Scale. These findings were examined in relation to the TBI survivor's scores on the Disability Rating Scale and the Functional Independence Measure at the same time points post-injury. Results revealed that the majority of caregivers in those with moderate to severe brain injuries experienced dissatisfaction with many aspects of caregiving, especially with respect to feelings of burden and mastery. Additionally, emotionally-focused coping, behavioral control issues with respect to family functioning, and perceived social support appear to be most highly related to perceptions of burden, whereas perceived social support alone was the strongest factor in one's perception of caregiving mastery and satisfaction with the caregiving relationship. Interestingly, caregiving ideology was most closely related to avoidance-oriented coping. These results have direct implications for the development of interventions for caregivers of persons with TBI, especially with respect for the need to assess coping style and the development of social support networks.	Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Wayne State Univ, Dept Psychol, Detroit, MI USA	Hanks, RA (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, 261 Mack Blvd, Detroit, MI 48201 USA.	rhanks@dmc.org					BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; ENDLER NS, 1990, J PERS SOC PSYCHOL, V58, P844, DOI 10.1037/0022-3514.58.5.844; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Jones TG, 2003, CLIN NEUROPSYCHOL, V17, P3, DOI 10.1076/clin.17.1.3.15626; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KINNEY JM, 1989, PSYCHOL AGING, V4, P402, DOI 10.1037/0882-7974.4.4.402; Kosciulek J.F., 1998, J APPL REHABILITATIO, V29, P8; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lawton M., 1989, J GERONTOL, V44, P61, DOI [DOI 10.1093/GER0NJ/44.3.P61, 10.1093/geronj/44.3.P61]; Lazarus R.S., 1984, STRESS APPRAISAL COP; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; MAITZ EA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199504000-00003; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PEARLIN LI, 1978, J HLTH SOCIAL BEHAV, V19, P12; PELLETIER PM, 2000, ROTTM I ABSTR, P45; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ridenour TA, 1999, FAM PROCESS, V38, P497, DOI 10.1111/j.1545-5300.1999.00497.x; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; Smith L.M., 1995, FAMILY SUPPORT PROGR; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; Stebbins P, 2001, REHABIL PSYCHOL, V46, P178, DOI 10.1037/0090-5550.46.2.178; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Tabachnick B., 2001, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406	34	84	88	2	16	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2007	22	1					43	52					10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	150TE	WOS:000245240600005	17379947				2021-06-18	
J	Skoglund, TS; Eriksson-Ritzen, C; Jensen, C; Rydenhag, B				Skoglund, Thomas S.; Eriksson-Ritzen, Catherine; Jensen, Christer; Rydenhag, Bertil			Aspects on decompressive craniectomy in patients with traumatic head injuries	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; decompressive craniectomy; intracranial pressure; outcome; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; BRAIN VOLUME REGULATION; INTRACRANIAL HYPERTENSION; MANAGEMENT; CHILDREN; THERAPY; EDEMA; GUIDELINES; SCALE; CRANIOTOMY	In patients with traumatic brain injury (TBI), intracranial hypertension secondary to cerebral edema is a major problem. A last-tier treatment in these cases is decompressive craniectomy. The aim of the present retrospective investigation was to (1) study the long-time outcome in patients with traumatic head injuries with intracranial hypertension treated with decompressive craniectomy; (2) examine the effects on intracranial pressure (ICP) by the craniectomy; and (3) investigate the possible relationship between the size of the removed bone-flap and the effects on ICP. Among the about 150 patients with severe TBI treated at our neurointensive care unit during 1997-2002, 19 patients were treated with decompressive craniectomy. All patients were young (mean 22 +/- 11 years, range 7-46 years), and 68% were male. The mean ICP was reduced from 29.2 +/- 3.5 before to 11.1 +/- 6.0 mm Hg immediately after the craniectomy; at 24 h after the craniectomy, the mean ICP was 13.9 +/- 9.7 mm Hg. Paired-samples t-test revealed a statistically significant decrease, both when comparing the preoperative values to the values immediately postoperative as well as to the values after 24 h (p < 0.01). A significant correlation between the size of the craniectomy and the decrease in ICP was found using Pearson regression analysis. The outcome of all patients could be assessed. The survival rate was 89%. Two patients died (both day 4 after the trauma); 68% of the patients had a favorable outcome (Glasgow Outcome Scale [GOS] score of 4 or 5); 16% were severely disabled (GOS score of 3); and one patient (5%) was left in a vegetative state.	Gothenburg Univ, Sahlgrens Hosp, Dept Neurosurg, S-41345 Gothenburg, Sweden; Gothenburg Univ, Sahlgrens Hosp, Dept Anesthesia & Intens Care Med, S-41345 Gothenburg, Sweden; Gothenburg Univ, Sahlgrens Hosp, Dept Radiol, S-41345 Gothenburg, Sweden	Skoglund, TS (corresponding author), Gothenburg Univ, Sahlgrens Hosp, Dept Neurosurg, S-41345 Gothenburg, Sweden.	thomas.skoglund@.vgregion.se					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Hutchinson PJ, 2005, ACTA NEUROCHIR, V147, P1, DOI 10.1007/s00701-004-0400-7; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Meier U, 2003, ACTA NEUROCHIR SUPPL, V86, P367; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Munch E, 2000, NEUROSURGERY, V47, P315; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Polin RS, 2003, CRIT CARE, V7, P409, DOI 10.1186/cc2370; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Prat R, 1998, ACTA NEUROCHIR, V140, P1257, DOI 10.1007/s007010050247; RANSOHOFF J, 1971, J NEUROL NEUROSUR PS, V34, P106, DOI 10.1136/jnnp.34.1.106-a; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, P1; Schneider GH, 2002, ACT NEUR S, V81, P77; Simma B, 2002, INTENS CARE MED, V28, P1000, DOI 10.1007/s00134-002-1333-3; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; WIRTZ CR, 1997, NEUROSURG FOCUS, V15, pE3; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	41	84	91	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1502	1509		10.1089/neu.2006.23.1502			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500009	17020484				2021-06-18	
J	Greve, KW; Bianchini, KJ; Love, JM; Brennan, A; Heinly, MT				Greve, Kevin W.; Bianchini, Kevin J.; Love, Jeffrey M.; Brennan, Adrianne; Heinly, Matthew T.			Sensitivity and specificity of MMPI-2 validity scales and indicators to malingered neurocognitive dysfunction in traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							FAKE-BAD SCALE; ADULT INTELLIGENCE SCALE; CARD SORTING TEST; MILD HEAD-INJURY; SYMPTOM EXAGGERATION; INCOMPLETE EFFORT; RESPONSE BIAS; LITIGANTS; PERFORMANCE; TESTS	The present study used a known-groups design to determine the classification accuracy of 10 MMPI-2 validity scales and indicators in the detection of cognitive malingering in traumatic brain injury. Participants were 259 traumatic brain injury and 133 general clinical patients seen for neuropsychological evaluation. The TBI patients were subdivided into groups based on a comprehensive examination of effort following Slick, Sherman, and Iverson's (1999) criteria. More extreme scores demonstrated excellent specificity; often impressive sensitivity was seen even while maintaining a low false positive error rate. Specificity was good even in stroke, memory disorder, and psychiatric patients without incentive. The results of this study are presented in frequency tables that can be easily referenced in clinical practice.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAND DIGIT RECOG; BUTCHER JN, 1989, MMPI2 MANUAL ADM SCO; Daubert V., 1993, MERRELL DOW PHARM, V113; Gouvier WD, 1998, CRIT ISS NE, P55; GRAHAM JR, 1990, MMPI2 ASSESSING PERS; GREENE RL, 2000, MMPI2 INTERPRETIVE M; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Hennekens CH, 1987, EPIDEMIOLOGY MED; Iverson GL, 2002, PSYCHOL REP, V90, P131, DOI 10.2466/PR0.90.1.131-136; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 2003, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCusker PJ, 2003, INT J OFFENDER THER, V47, P585, DOI 10.1177/0306624X03254013; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Tombaugh TN, 1996, TEST MEMORY MALINGER; Webb, 2001, PSYCHOL ASSESSMENT M	37	84	84	1	10	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	SEP	2006	20	3					491	512		10.1080/13854040590967144			22	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	071MT	WOS:000239607000010	16895861				2021-06-18	
J	Swartz, BE; Houser, CR; Tomiyasu, U; Walsh, GO; DeSalles, A; Rich, JR; Delgado-Escueta, A				Swartz, Barbara E.; Houser, Carolyn R.; Tomiyasu, Uwami; Walsh, Gregory O.; DeSalles, Antonio; Rich, J. Ronald; Delgado-Escueta, Antonio			Hippocampal cell loss in posttraumatic human epilepsy	EPILEPSIA			English	Article						temporal lobe epilepsy; traumatic brain injury; hippocampal sclerosis; dentate gyrus	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; DENTATE GYRUS; HEAD TRAUMA; SURGICAL OUTCOMES; DUAL PATHOLOGY; NEURON LOSS; REORGANIZATION; RAT; PATHOGENESIS	Purpose: We performed this study to determine whether significant head trauma in human adults can result in hippocampal cell loss, particularly in hilar (polymorph) and CA3 neurons, similar to that observed in animal models of traumatic brain injury. We examined the incidence of hippocampal pathology and its relation to temporal neocortical pathology, neuronal reorganization, and other variables. Methods: Twenty-one of 200 sequential temporal lobectomies had only trauma as a risk factor for epilepsy. Tissue specimens from temporal neocortex and hippocampus were stained with glial fibrillary acidic protein (GFAP) and hematoxylin and eosin (H&E). Eleven hippocampal specimens had additional analysis of neuronal distributions by using cresyl violet and immunolabeling of a neuron-specific nuclear protein. Results: The median age at onset of trauma was 19 years, the median time between trauma and onset of seizures was 2 years, and the median epilepsy duration was 16 years. The length of the latent period was inversely related to the age at the time of trauma (r = 0.75; Spearman). The neocortex showed gliosis in all specimens, with hemosiderosis (n = 8) or heterotopias (n = 6) in some, a distribution differing from chance (p = 0.02; Fisher). Hippocampal neuronal loss was found in 94% of specimens, and all of these had cell loss in the polymorph (hilar) region of the dentate gyrus. Hilar cell loss ranged from mild, when cell loss was confined to the hilus, to severe, when cell loss extended into CA3 and CA1. Some degree of mossy fiber sprouting was found in the dentate gyrus of all 10 specimens in which it was evaluated. Granule cell dispersion (n = 4) was seen only in specimens with moderate to severe neuronal loss. Conclusions: Neocortical pathology was universally present after trauma. Neuronal loss in the hilar region was the most consistent finding in the hippocampal formation, similar to that found in the fluid-percussion model of traumatic head injury. These findings support the idea that head trauma can induce hippocampal epilepsy in humans in the absence of other known risk factors.	Hoag Mem Hosp, Epilepsy Ctr, Newport Beach, CA 92658 USA; VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA; VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA USA; VA Greater Los Angeles Healthcare Syst, Pathol Serv, Los Angeles, CA USA; Univ Calif Los Angeles, Calif Comprehens Epilepsy Program, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA USA	Swartz, BE (corresponding author), Hoag Mem Hosp, Epilepsy Ctr, 1 Hoag Dr,POB 6100, Newport Beach, CA 92658 USA.	BSwartz@Hoaghospital.org		Delgado-Escueta, Antonio V./0000-0002-1581-6999	Veterans AffairsUS Department of Veterans Affairs [I01BX000404] Funding Source: NIH RePORTER; BLRD VA [I01 BX000404] Funding Source: Medline		Annegers J.F., 1996, TREATMENT EPILEPSY P, P165; BABB T, 1996, TREATMENT EPILEPSY P, P106; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bratz E, 1899, ARCH PSYCHIAT NERVEN, V32, P820; BRUTON CJ, 1988, MAUDSLEY MONOGRAPHS, V31; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CENDES F, 1995, NEUROLOGY, V45, P2058, DOI 10.1212/WNL.45.11.2058; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; COURVILLE CB, 1958, TEMPORAL LOBE EPILEP, P220; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; EVANS JH, 1962, NEUROLOGY, V12, P665, DOI 10.1212/WNL.12.10.665; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Fuerst D, 2003, ANN NEUROL, V53, P413, DOI 10.1002/ana.10509; GILMORE LF, 1979, ANN NEUROL, V4, P329; Golarai G, 2001, J NEUROSCI, V21, P8523; HARDIMAN O, 1988, NEUROLOGY, V38, P1041, DOI 10.1212/WNL.38.7.1041; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HOUSER CR, 1990, BRAIN RES, V535, P195, DOI 10.1016/0006-8993(90)91601-C; HOUSER CR, 1990, J NEUROSCI, V10, P267; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JOHANSEN FF, 1993, ACTA NEUROL SCAND, V88, P1; LEVESQUE MF, 1991, J NEUROSURG, V75, P364, DOI 10.3171/jns.1991.75.3.0364; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MANAKA S, 1981, FOLIA PSYCHIAT NEU J, V35, P301; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; Mathern G.W., 1997, EPILEPSY COMPREHENSI, V1, P133; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MEENCKE HJ, 1984, EPILEPSIA, V25, P8, DOI 10.1111/j.1528-1157.1984.tb04149.x; OBENAUS A, 1993, J NEUROSCI, V13, P4470; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; ROBBINS RJ, 1991, ANN NEUROL, V29, P325, DOI 10.1002/ana.410290316; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schottler F, 1998, J COMP NEUROL, V395, P29; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; SWARTZ BE, 1990, EPILEPSY RES, V5, P146, DOI 10.1016/0920-1211(90)90031-P; SWARTZ BE, 1992, EPILEPSIA, V33, P624, DOI 10.1111/j.1528-1157.1992.tb02338.x; SWARTZ BE, 1990, EPILEPSY RES, V5, P61, DOI 10.1016/0920-1211(90)90066-5; Swartz BE, 1998, EPILEPSY RES, V29, P97, DOI 10.1016/S0920-1211(97)00070-3; Toth Z, 1997, J NEUROSCI, V17, P8106; WILLMORE LJ, 1992, NEUROL CLIN, V10, P869; Wolf P, 2001, EPILEPSIA, V42, P573	53	84	93	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	AUG	2006	47	8					1373	1382		10.1111/j.1528-1167.2006.00602.x			10	Clinical Neurology	Neurosciences & Neurology	071XB	WOS:000239636100015	16922884	Bronze			2021-06-18	
J	Rahman, S; Robbins, TW; Hodges, JR; Mehta, MA; Nestor, PJ; Clark, L; Sahakian, BJ				Rahman, S; Robbins, TW; Hodges, JR; Mehta, MA; Nestor, PJ; Clark, L; Sahakian, BJ			Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia	NEUROPSYCHOPHARMACOLOGY			English	Article						orbitofrontal cortex; methylphenidate; risk-taking; decision-making; frontal variant frontotemporal dementia	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; DECISION-MAKING; PREFRONTAL CORTEX; PARKINSONS-DISEASE; COGNITIVE INFLEXIBILITY; METABOLIC IMPAIRMENT; ALZHEIMERS-DISEASE; NORMAL VOLUNTEERS; CONTROLLED-TRIAL	The frontal variant of frontotemporal dementia is a significant neurological condition worldwide. There exist few treatments available for the cognitive and behavioural sequelae of fvFTD. Previous research has shown that these patients display risky decision-making, and numerous studies have now demonstrated pathology affecting the orbitofrontal cortex. The present study uses a within-subjects, double-blind, placebo-controlled procedure to investigate the effects of a single dose of methylphenidate (40 mg) upon a range of different cognitive processes including those assessing prefrontal cortex integrity. Methylphenidate was effective in 'normalizing' the decision-making behavior of patients, such that they became less risk taking on medication, although there were no significant effects on other aspects of cognitive function, including working memory, attentional set shifting, and reversal learning. Moreover, there was an absence of the normal subjective and autonomic responses to methylphenidate seen in elderly subjects. The results are discussed in terms of the 'somatic marker' hypothesis of impaired decision-making following orbitofrontal dysfunction.	Univ Cambridge, Sch Clin Med, Dept Psychiat, Cambridge, England; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurol, Cambridge CB2 2QQ, England; Univ London, Inst Psychiat, London, England; MRC, Cognit & Brain Sci Unit, Cambridge, England	Sahakian, BJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Psychiat, Cambridge CB2 2QQ, England.		Nestor, Peter/Y-6106-2018; Mehta, Mitul/F-3960-2010; Sahakian, Barbara/AAW-1198-2020	Nestor, Peter/0000-0002-5860-5921; Sahakian, Barbara/0000-0001-7352-1745; Robbins, Trevor/0000-0003-0642-5977; Clark, Luke/0000-0003-1103-2422	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354, MC_U105559861, G108/653] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission [019407] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B] Funding Source: researchfish		ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Aron AR, 2003, BIOL PSYCHIAT, V54, P1465, DOI 10.1016/S0006-3223(03)00609-7; Bartzokis G, 2000, NEUROPSYCHOPHARMACOL, V22, P102, DOI 10.1016/S0893-133X(99)00077-9; Bechara A, 2003, ANN NY ACAD SCI, V985, P356, DOI 10.1111/j.1749-6632.2003.tb07094.x; BECHARA A, 2001, SOC NEUR ABSTR, V27; Bechara Antoine, 2003, J Gambl Stud, V19, P23, DOI 10.1023/A:1021223113233; Bettendorff L, 1997, J NEUROCHEM, V69, P2005; BOND A, 1974, BRIT J MED PSYCHOL, V47, P211, DOI 10.1111/j.2044-8341.1974.tb02285.x; BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416; Chatterjee A, 2002, J NEUROPSYCH CLIN N, V14, P461, DOI 10.1176/appi.neuropsych.14.4.461; Clark L, 2004, BRAIN COGNITION, V55, P41, DOI 10.1016/s0278-2626(03)00284-7; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Clarke HF, 2004, SCIENCE, V304, P878, DOI 10.1126/science.1094987; CONNERS CK, 1963, AM J PSYCHIAT, V120, P458, DOI 10.1176/ajp.120.5.458; Cools R, 2003, NEUROPSYCHOLOGIA, V41, P1431, DOI 10.1016/S0028-3932(03)00117-9; Coull JT, 1996, PSYCHOPHARMACOLOGY, V123, P239, DOI 10.1007/BF02246578; Crofts HS, 2001, CEREB CORTEX, V11, P1015, DOI 10.1093/cercor/11.11.1015; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; Deakin J, 2004, J INT NEUROPSYCH SOC, V10, P590, DOI 10.1017/S1355617704104104; Deakin JB, 2004, PSYCHOPHARMACOLOGY, V172, P400, DOI 10.1007/s00213-003-1686-5; Diehl J, 2004, NEUROBIOL AGING, V25, P1051, DOI 10.1016/j.neurobiolaging.2003.10.007; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; ELLSBERG D, 1961, Q J ECON, V75, P643, DOI 10.2307/1884324; FALLON JH, 1978, J COMP NEUROL, V180, P501; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; FRANCIS PT, 1993, DEMENTIA, V4, P172, DOI 10.1159/000107319; GILBERT JJ, 1988, ANN NEUROL, V24, P688, DOI 10.1002/ana.410240518; GILMAN AG, 1980, PHARM BASIS THERAPEU; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HEISHMAN SJ, 1991, PSYCHOPHARMACOLOGY, V103, P436, DOI 10.1007/BF02244241; Hollerman JR, 1998, NAT NEUROSCI, V1, P304; Howell D. C., 1997, STAT METHODS PSYCHOL; Ibach B, 2004, NEUROIMAGE, V23, P739, DOI 10.1016/j.neuroimage.2004.06.041; Kobayashi K, 1999, CLIN NEUROPATHOL, V18, P240; LACOCO D, 2004, J NEUROPSYCHIATRY CL, V16, P117; Lee ACH, 2003, EUR J NEUROSCI, V18, P1660, DOI 10.1046/j.1460-9568.2003.02883.x; Liu W, 2004, NEUROLOGY, V62, P742, DOI 10.1212/01.WNL.0000113729.77161.C9; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; Mavaddat N, 2000, BRAIN, V123, P2109, DOI 10.1093/brain/123.10.2109; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Mehta MA, 2000, J PSYCHOPHARMACOL, V14, P299, DOI 10.1177/026988110001400314; MENDEZ MF, 2003, DEMENTIA CLIN APPROA, P179; MULLER U, 2005, PSYCHOPHARMACOL 0414; Nagaoka S, 1995, PROG NEURO-PSYCHOPH, V19, P1251, DOI 10.1016/0278-5846(95)00264-2; OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; OWEN AM, 1995, NEUROPSYCHOLOGY, V9, P126, DOI 10.1037/0894-4105.9.1.126; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rahman S, 1999, BRAIN, V122, P1469, DOI 10.1093/brain/122.8.1469; RAHMAN S, 2000, EARLY ONSET DEMENTIA; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Salmon E, 2003, NEUROIMAGE, V20, P435, DOI 10.1016/S1053-8119(03)00346-X; SCHEELKRUGER J, 1971, EUR J PHARMACOL, V14, P47, DOI 10.1016/0014-2999(71)90121-X; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Sjogren M, 1998, NEUROBIOL AGING, V19, P379, DOI 10.1016/S0197-4580(98)00086-4; Smith K, 2002, MANAGE SCI, V48, P711, DOI 10.1287/mnsc.48.6.711.194; SPARKS DL, 1991, ARCH NEUROL-CHICAGO, V48, P796, DOI 10.1001/archneur.1991.00530200032014; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; TANNOCK R, 1989, J ABNORM CHILD PSYCH, V17, P473, DOI 10.1007/BF00916508; Turner DC, 2003, PSYCHOPHARMACOLOGY, V168, P455, DOI 10.1007/s00213-003-1457-3; Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005; Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007	65	84	87	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X			NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	MAR	2006	31	3					651	658		10.1038/sj.npp.1300886			8	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	023QP	WOS:000236141600018	16160709	Green Accepted, Bronze			2021-06-18	
J	Buse, GJ				Buse, GJ			No holds barred sport fighting: a 10 year review of mixed martial arts competition	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INJURIES; JUDO; CONCUSSION; KARATE	Objective: To identify the most salient medical issues that may be associated with mixed martial arts competition by determining the types and proportions of match stoppages. Methods: Publicly available video footage of 1284 men competing in 642 consecutive televised matches from November 1993 to November 2003 was reviewed to determine the reasons for which matches were stopped. Matches were sanctioned by either a United States or Japan based mixed martial arts organisation. Results: Of the 642 matches, 182 (28.3 +/- 3.4%) were stopped because of head impact, 106 (16.5 +/- 2.9%) because of musculoskeletal stress, 91 (14.1 +/- 2.7%) because of neck choke, 83 (12.9 +/- 2.6%) because of miscellaneous trauma, 173 (27.0 +/- 3.4%) because of expiration of match time, and seven ( 1.0 +/- 0.8%) because of disqualification, where the values in parentheses are percentages +/- 95% confidence interval. Conclusions: Blunt force to the head resulted in the highest proportion of match stoppages. Further research is warranted to delineate the morbidity associated with participation in mixed martial arts.	Cannon USAF Clin, Clovis, NM 88103 USA	Buse, GJ (corresponding author), Cannon USAF Clin, Clovis, NM 88103 USA.	george.buse@cannon.af.mil					Aotsuka A, 1990, Rinsho Shinkeigaku, V30, P1243; ARVANITIS J, 2003, PANKRATION TRADITION, P1; Birrer RB, 1996, AM J SPORT MED, V24, pS72, DOI 10.1177/036354659602406S21; Buckwalter JA, 2004, CLIN ORTHOP RELAT R, P7, DOI 10.1097/01.blo.0000131638.81519.de; Chang Eli L., 2002, International Ophthalmology Clinics, V42, P187; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; ESTWANIK J J, 1984, Physician and Sportsmedicine, V12, P123; Gartland S, 2005, CLIN J SPORT MED, V15, P34, DOI 10.1097/00042752-200501000-00007; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; GENTRY C, 2001, NO HOLDS BARRED EVOL, P1; Hainsworth R, 2004, CLIN AUTON RES, V14, P18, DOI 10.1007/s10286-004-1004-2; HEARN W, 1996, AM MED NEWS, V39, P11; Kelly JP, 1997, NEUROLOGY, V48, P581; Kochhar T, 2005, BRIT J SPORT MED, V39, P444, DOI 10.1136/bjsm.2004.011270; KOIWAI EK, 1987, J FORENSIC SCI, V32, P419; KUJALA UM, 1995, BRIT MED J, V311, P1465, DOI 10.1136/bmj.311.7018.1465; KURILOFF DB, 1989, ANN OTO RHINOL LARYN, V98, P824, DOI 10.1177/000348948909801014; Lundberg GD, 1996, JAMA-J AM MED ASSOC, V275, P1684, DOI 10.1001/jama.275.21.1684; McCarron MA, 1997, BRIT J SPORT MED, V31, P346, DOI 10.1136/bjsm.31.4.346; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; OWENS RG, 1991, J SPORT MED PHYS FIT, V31, P627; POLIAKOFF MB, 1995, COMBAT SPORTS ANCIEN, P54; PORTER K, 1998, CHIPLEY MAN DIES INJ; RABADI MH, 2000, NEUROLOGIC ATHLETIC, P297; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448	29	84	85	0	31	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2006	40	2					169	172		10.1136/bjsm.2005.021295			4	Sport Sciences	Sport Sciences	005NP	WOS:000234831400017	16432006	Green Published			2021-06-18	
J	Chambers, IR; Jones, PA; Lo, TYM; Forsyth, RJ; Fulton, B; Andrews, PJD; Mendelow, AD; Minns, RA				Chambers, IR; Jones, PA; Lo, TYM; Forsyth, RJ; Fulton, B; Andrews, PJD; Mendelow, AD; Minns, RA			Critical thresholds of intracranial pressure and cerebral perfusion pressure related to age in paediatric head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE; SECONDARY INSULTS; YOUNG-CHILDREN; ADULTS; MANAGEMENT; INFANTS; SCALE; COMA	Background: The principal strategy for managing head injury is to reduce the frequency and severity of secondary brain insults from intracranial pressure (ICP) and cerebral perfusion pressure (CPP), and hence improve outcome. Precise critical threshold levels have not been determined in head injured children. Objective: To create a novel pressure-time index (PTI) measuring both duration and amplitude of insult, and then employ it to determine critical insult thresholds of ICP and CPP in children. Methods: Prospective, observational, physiologically based study from Edinburgh and Newcastle, using patient monitored blood pressure, ICP, and CPP time series data. The PTI for ICP and CPP for 81 children, using theoretical values derived from physiological norms, was varied systematically to derive critical insult thresholds which delineate Glasgow outcome scale categories. Results: The PTI for CPP had a very high predictive value for outcome (receiver operating characteristic analyses: area under curve=0.957 and 0.890 for mortality and favourable outcome, respectively) and was more predictive than for ICP. Initial physiological values most accurately predicted favourable outcome. The CPP critical threshold values determined for children aged 2-6, 7-10, and 11-15 years were 48, 54, and 58 mm Hg. respectively. Conclusions: The PTI is the first substantive paediatric index of total ICP and CPP following head injury. The insult thresholds generated are identical to age related physiological values. Management guidelines for paediatric head injuries should take account of these CPP thresholds to titrate appropriate pressor therapy.	Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Gen Hosp, Dept Paediat, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Gen Hosp, Dept Anaesthet, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Edinburgh, Royal Hosp Sick Children, Edinburgh, Midlothian, Scotland; Western Gen Hosp, Dept Anaesthet, Edinburgh EH4 2XU, Midlothian, Scotland	Chambers, IR (corresponding author), Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	i.r.chambers@ncl.ac.uk	Forsyth, Rob J/I-9226-2012; Forsyth, Rob/H-9193-2019	Forsyth, Rob J/0000-0002-5657-4180; Forsyth, Rob/0000-0002-5657-4180			Abbate B, 2000, Minerva Pediatr, V52, P623; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; BROOKES M, 1990, J EPIDEMIOL COMMUN H, V44, P147, DOI 10.1136/jech.44.2.147; *BTF AANS, 2000, MAN PROGN SEV TRAUM; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; EMAUELSON I, 1997, ACTA PAEDIATR, V86, P730; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOWELLS TP, 1994, EDINBURGH MONITOR BR; JACKSON S, 1999, BRIT J NEUROSURG, V13, P104; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MINNS RA, 2005, PAEDIAT FORENSIC MED; *NHLBI, 1987, REP 2 TASK FORC BLOO; REILLY PL, 1988, CHILD NERV SYST, V4, P30; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; *SIGN, 2000, 46 SIGN; TEASDALE G, 1974, LANCET, V2, P81	26	84	89	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2006	77	2					234	240		10.1136/jnnp.2005.072215			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	011QY	WOS:000235284400025	16103043	Green Published			2021-06-18	
J	Lepore, AC; Bakshi, A; Swanger, SA; Rao, MS; Fischer, I				Lepore, AC; Bakshi, A; Swanger, SA; Rao, MS; Fischer, I			Neural precursor cells can be delivered into the injured cervical spinal cord by intrathecal injection at the lumbar cord	BRAIN RESEARCH			English	Article						neural stem cell; spinal cord injury; neuron; glial cell; transplantation; neural progenitor	NEUROEPITHELIAL STEM-CELLS; PROGENITOR CELLS; CEREBROSPINAL-FLUID; ADULT BRAIN; RESTRICTED PRECURSORS; CHEMOKINE RECEPTORS; FUNCTIONAL RECOVERY; WHITE-MATTER; RAT MODEL; TRANSPLANTATION	Neural precursor cells (NPCs) are promising grafts for treatment of traumatic CNS injury and neurodegenerative disorders because of their potential to differentiate into neurons and glial cells. When designing clinical protocols for NPC transplantation, it is important to develop alternatives to direct parenchymal injection, particularly at the injury site. We reasoned that since it is minimally invasive, intrathecal delivery of NPCs at lumbar spinal cord (lumbar puncture) represents an important and clinically applicable strategy. We tested this proposition by examining whether NPCs can be delivered to the injured cervical spinal cord via lumbar puncture using a mixed population of neuronal-restricted precursors (NRPs) and glial-restricted precursors (GRPs). For reliable tracking, the NPCs were derived from the embryonic spinal cord of transgenic donor rats that express the marker gene, human placental alkaline phosphatase, under the control of the ubiquitous Rosa 26 promoter. We found that mixed NRP/GRP grafts can be efficiently delivered to a cervical hemisection injury site by intrathecal delivery at the lumbar cord. Similar to direct parenchymal injections, transplanted NRP/GRP cells survive at the injury cavity for at least 5 weeks post-engraftment, migrate into intact spinal cord along white matter tracts and differentiate into all three mature CNS cell types, neurons, astrocytes, and oligodendrocytes. Furthermore, very few graft-derived cells localize to areas outside the injury site, including intact spinal cord and brain. These results demonstrate the potential of delivering lineage-restricted NPCs using the minimally invasive lumbar puncture method for the treatment of spinal cord injury. (C) 2005 Elsevier B.V. All rights reserved.	Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; NIA, Neurosci Lab, Baltimore, MD 21224 USA	Fischer, I (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	Itzhak.fischer@drexel.edu	Fischer, Itzhak/D-1080-2012	Fischer, Itzhak/0000-0003-3187-8740; Swanger, Sharon/0000-0003-0615-6244	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 37515, NS24707] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS024707, P01NS024707, R01NS037515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [Z01AG000324, ZIAAG000324] Funding Source: NIH RePORTER		Aarum J, 2003, P NATL ACAD SCI USA, V100, P15983, DOI 10.1073/pnas.2237050100; Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bai HL, 2003, J NEUROSCI METH, V124, P181, DOI 10.1016/S0165-0270(03)00007-4; Bakshi A, 2004, J NEUROSURG-SPINE, V1, P330, DOI 10.3171/spi.2004.1.3.0330; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Ben-Hur T, 2003, MOL CELL NEUROSCI, V24, P623, DOI 10.1016/S1044-7431(03)00218-5; Ben-Hur T, 2003, GLIA, V41, P73, DOI 10.1002/glia.10159; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; De la Calle JL, 2002, BRAIN RES BULL, V59, P245, DOI 10.1016/S0361-9230(02)00866-3; De la Calle JL, 2002, BRAIN RES BULL, V59, P205, DOI 10.1016/S0361-9230(02)00867-5; Ehtesham M, 2004, NEOPLASIA, V6, P287, DOI 10.1593/neo.03427; Einstein O, 2003, MOL CELL NEUROSCI, V24, P1074, DOI 10.1016/j.mcn.2003.08.009; Fischer I, 2000, PROG BRAIN RES, V128, P253; Forsberg-Nilsson K, 1998, J NEUROSCI RES, V53, P521, DOI 10.1002/(SICI)1097-4547(19980901)53:5<521::AID-JNR2>3.0.CO;2-B; Han SSW, 2004, GLIA, V45, P1, DOI 10.1002/glia.10282; Han SSW, 2002, EXP NEUROL, V177, P360, DOI 10.1006/exnr.2002.7995; Herrera J, 2001, EXP NEUROL, V171, P11, DOI 10.1006/exnr.2001.7729; Ishii K, 2001, J NEUROSCI RES, V65, P500, DOI 10.1002/jnr.1180; Ji JF, 2004, NEUROSCI LETT, V355, P236, DOI 10.1016/j.neulet.2003.11.024; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Lepore AC, 2004, NEURON GLIA BIOL, V1, P113, DOI 10.1017/S1740925X04000213; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mujtaba T, 2002, EXP NEUROL, V174, P48, DOI 10.1006/exnr.2001.7847; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Ohta M, 2004, NEUROREPORT, V15, P1249, DOI 10.1097/01.wnr.0000129998.72184.e1; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Parent JM, 2002, PROG BRAIN RES, V135, P121; Parent JM, 1997, J NEUROSCI, V17, P3727; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Rao MS, 2000, PROG BRAIN RES, V128, P273; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Tran PB, 2004, J NEUROSCI RES, V76, P20, DOI 10.1002/jnr.20001; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wu SF, 2002, J NEUROSCI RES, V69, P940, DOI 10.1002/jnr.10346; Yamamoto S, 2001, EXP NEUROL, V172, P115, DOI 10.1006/exnr.2001.7798; Yang H, 2000, P NATL ACAD SCI USA, V97, P13366, DOI 10.1073/pnas.97.24.13366	43	84	94	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 31	2005	1045	1-2					206	216		10.1016/j.brainres.2005.03.050			11	Neurosciences	Neurosciences & Neurology	932BX	WOS:000229530300024	15910779				2021-06-18	
J	Shinoda, S; Schindler, CK; Meller, R; So, NK; Araki, T; Yamamoto, A; Lan, JQ; Taki, W; Simon, RP; Henshall, DC				Shinoda, S; Schindler, CK; Meller, R; So, NK; Araki, T; Yamamoto, A; Lan, JQ; Taki, W; Simon, RP; Henshall, DC			Bim regulation may determine hippocampal vulnerability after injurious seizures and in temporal lobe epilepsy	JOURNAL OF CLINICAL INVESTIGATION			English	Article							FORKHEAD TRANSCRIPTION FACTOR; INDUCED NEURONAL DEATH; BCL-2 FAMILY-MEMBER; TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN-INJURY; CELL-DEATH; STATUS EPILEPTICUS; NERVOUS-SYSTEM; CYTOCHROME-C; AKT	Programmed cell. death pathways have been implicated in the mechanism by which neurons die following brief and prolonged seizures, but the significance of proapoptotic Bcl-2 family proteins in the process remains poorly defined. Expression of the death agonist Bcl-2-interacting mediator of cell death (Bim) is under the control of the forkhead in rhabdomyosarcoma (FKHR) transcription factors. This prompted us to examine the response of this pathway to experimental seizures and in hippocampi from patients with intractable temporal lobe epilepsy. A short period of status epilepticus in rats that damaged the hippocampus activated FKHR/FKHRL-1 and induced a significant increase in expression of Bim. Blocking of FKHR/FKHRL-1 dephosphorylation after seizures improved hippocampal neuronal survival in vivo, and Bim antisense oligonucleotides were neuroprotective against seizures in vitro. Inhibition of Akt increased the FKHR/Bim response and DNA fragmentation within the normally resistant cortex. Analysis of hippocampi from patients with intractable epilepsy revealed that Bim levels were significantly lower than in controls and FKHR was inhibited; we were able to reproduce these results experimentally in rats by evoking multiple brief, noninjurious electroshock seizures. We conclude that Bim. expression maybe a critical determinant of whether seizures damage the brain, and that its control may be neuroprotective in status epilepticus and epilepsy.	Ctr Neurol Sci, Oregon Comprehens Epilepsy Program, Portland, OR USA; Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 514, Japan; Legacy Res, Robert S Dow Neurobiol Labs, Portland, OR USA	Henshall, DC (corresponding author), Legacy Clin Res & Technol Ctr, Robert S Dow Neurol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	dhenshall@DowNeurobiolog.org	Henshall, David/C-3364-2012	Henshall, David/0000-0001-6237-9632	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41935, NS39016, R01 NS039016, R01 NS041935] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039016, R01NS041935] Funding Source: NIH RePORTER		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aminoff MJ, 1998, ARCH NEUROL-CHICAGO, V55, P119, DOI 10.1001/archneur.55.1.119; Bengzon J, 2002, PROG BRAIN RES, V135, P111; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Duncan JS, 2002, PROG BRAIN RES, V135, P253; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; Gary DS, 2002, NEUROMOL MED, V2, P261, DOI 10.1385/NMM:2:3:261; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jokeit H, 1999, J NEUROL, V246, P926, DOI 10.1007/s004150050484; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kawano T, 2001, J CEREBR BLOOD F MET, V21, P1268, DOI 10.1097/00004647-200111000-00003; Kawano T, 2002, J CEREBR BLOOD F MET, V22, P926, DOI 10.1097/00004647-200208000-00004; KELLY ME, 1994, BRAIN RES, V634, P245, DOI 10.1016/0006-8993(94)91927-5; KHAN A, 1995, CONVULSIVE THER, V11, P114; Kondratyev A, 2001, MOL BRAIN RES, V91, P1, DOI 10.1016/S0169-328X(01)00099-7; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kotloski R, 2002, PROG BRAIN RES, V135, P95; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Meldrum BS, 2002, PROG BRAIN RES, V135, P487; Meller R, 2003, CELL DEATH DIFFER, V10, P539, DOI 10.1038/sj.cdd.4401206; Mikati MA, 2003, EPILEPSIA, V44, P282, DOI 10.1046/j.1528-1157.2003.22502.x; Moriwaki A, 1998, NEUROSCIENCE, V86, P855, DOI 10.1016/S0306-4522(98)00071-2; Murphy JV, 2003, CNS DRUGS, V17, P101, DOI 10.2165/00023210-200317020-00003; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Narkilahti S, 2003, NEUROPHARMACOLOGY, V44, P1068, DOI 10.1016/S0028-3908(03)00115-1; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Paxinos P., 1997, RAT BRAIN STEREOTAXI; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Roy M, 2002, GENE THER, V9, P214, DOI 10.1038/sj.gt.3301642; Sayin U, 2003, J NEUROSCI, V23, P2759; Shibata M, 2002, J CEREBR BLOOD F MET, V22, P810, DOI 10.1097/00004647-200207000-00006; Shinoda S, 2003, J NEUROCHEM, V86, P460, DOI 10.1046/j.1471-4159.2003.01860.x; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Sutula TP, 2001, NEUROLOGY, V57, P169, DOI 10.1212/WNL.57.2.169; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; WOODBURY LA, 1952, ARCH INT PHARMACOD T, V92, P97; Zhang X, 2002, J NEUROSCI, V22, P6052	56	84	88	0	6	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA	0021-9738	1558-8238		J CLIN INVEST	J. Clin. Invest.	APR	2004	113	7					1059	1068		10.1172/JCI200419971			10	Medicine, Research & Experimental	Research & Experimental Medicine	809QR	WOS:000220651700019	15057313	Bronze, Green Published			2021-06-18	
J	Larrabee, GJ				Larrabee, GJ			Exaggerated MMPI-2 symptom report in personal injury litigants with malingered neurocognitive deficit	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	28th Annual Meeting of the International-Neuropsychological-Society	FEB 09-12, 2000	DENVER, COLORADO	Int Neuropsychol Soc		FBS; MND; MMPI-2	FAKE BAD SCALE; HEAD-INJURY; VALIDITY SCALES; PERFORMANCE; LITIGATION; VALIDATION; CLAIMANTS; SEVERITY; PROFILES; SAMPLES	Traditional MMPI-2 validity scales, the Lees-Haley Fake Bad Scale (FBS), and the Arbisi and Ben Porath Infrequency Psychopathology Scale (F(p)) were evaluated in 33 personal injury litigants who had failed forced-choice symptom validity testing and other measures of effort in patterns consistent with the Slick, Sherman, and Iverson (1999) criteria for definite and probable malingered neurocognitive deficit (MND). The FBS was more sensitive to symptom exaggeration than F, Fb, and F(p). The definite and probable MND litigants also produced mean elevations on MMPI-2 scales 1, 3 and 7 that were significantly higher than those produced by various clinical groups including non-litigating severe closed head injury, multiple sclerosis, spinal cord injury, chronic pain, and depression. These data suggest that MMPI-2 profiles characteristic of malingered injury differ from those associated with malingered psychopathology. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.		Larrabee, GJ (corresponding author), Suite 202,630 S Orange Ave, Sarasota, FL 34236 USA.						Arbisi P. A., 1995, PSYCHOL ASSESSMENT, V7, P425; Berry DTR, 1995, PSYCHOL ASSESSMENT, V7, P517; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Butcher JN, 1989, MANUAL ADM SCORING M; BUTCHER JN, IN PRESS ARCH CLIN N; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Connor B, 1998, ARCH CLIN NEUROPSYCH, V13, P109; Fruchter B., 1973, FUNDAMENTAL STAT PSY; GRAHAM JR, 1991, J PERS ASSESS, V57, P264, DOI 10.1207/s15327752jpa5702_6; GRAHAM JR, 2000, ASSESSING PERSONALIT; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; HARTMAN DE, 1995, NEUROPSYCHOLOGICAL T; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Keller L. S., 1991, ASSESSMENT CHRONIC P; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2000, CLIN GUIDE NEUROPSYC, P301; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; MILLER JS, 1995, CHEM ENG NEWS, V73, P30, DOI 10.1021/cen-v073n040.p030; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Nelson L, 1998, ARCH CLIN NEUROPSYCH, V13, P92; PUTNAM SH, 1998, ANN M AM PSYCH ASS S; RODEVICH MA, 1995, REHABIL PSYCHOL, V40, P181; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	41	84	85	1	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2003	18	6					673	686	PII S0887-6177(02)00157-9	10.1016/S0887-6177(02)00157-9			14	Psychology, Clinical; Psychology	Psychology	715FU	WOS:000184961000010	14591440				2021-06-18	
J	Grandmaison, E; Simard, M				Grandmaison, E; Simard, M			A critical review of memory stimulation programs in Alzheimer's disease	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN INJURY; COGNITIVE REHABILITATION; EARLY DEMENTIA; ENCODING SPECIFICITY; PROCEDURAL MEMORY; IMPAIRED PATIENTS; EVERYDAY MEMORY; SENILE DEMENTIA; MENTAL-IMAGERY; AMNESIA	The authors describe the memory stimulation programs used in the treatment of Alzheimer's disease (AD) and review their efficacy. Visual imagery, errorless learning, dyadic approaches, spaced retrieval techniques, encoding specificity with cognitive support at retrieval, and external memory aids were the memory stimulation programs used alone or in combination in AD. Preliminary evidence suggests that the errorless learning, spaced retrieval, and vanishing cues techniques and the dyadic approach, used alone or in combination are efficacious in stimulating memory in patients with AD.	Univ Moncton, Sch Psychol, Geriatr Neuropsychol Lab, Moncton, NB E1A 3E9, Canada; Ctr Addict & Mental Hlth, Neuropsychiat Program, Toronto, ON, Canada	Grandmaison, E (corresponding author), Univ Moncton, Sch Psychol, Geriatr Neuropsychol Lab, Moncton, NB E1A 3E9, Canada.	eric.grandmaison@gnb.ca	Simard/Q-9675-2019	Simard/0000-0003-1257-8275			Alivisatos B, 1997, NEUROPSYCHOLOGIA, V35, P111, DOI 10.1016/S0028-3932(96)00083-8; Andrewes D, 1999, NEUROPSYCHOL REHABIL, V9, P77, DOI 10.1080/713755591; Arkin S, 2000, AM J ALZHEIMERS DIS, V15, P152; ARKIN SM, 1991, AM J ALZHEIMERS CARE, V6, P17; BACKMAN L, 1991, PSYCHOL AGING, V6, P489; BACKMAN L, 1992, ACTA NEUROL SCAND, V85, P84; Backman L, 1998, SCAND J PSYCHOL, V39, P131, DOI 10.1111/1467-9450.393067; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; BADDELEY AD, 1992, CLIN MANAGEMENT MEMO, P1; Beck C, 1988, J Geriatr Psychiatry, V21, P73; BOWERS D, 1991, BRAIN, V114, P2593, DOI 10.1093/brain/114.6.2593; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BREUIL V, 1994, INT J GERIATR PSYCH, V9, P211, DOI 10.1002/gps.930090306; Buschke H, 1997, NEUROLOGY, V48, P989, DOI 10.1212/WNL.48.4.989; Buschke H, 1995, J Int Neuropsychol Soc, V1, P483; BUSCHKE H, 1994, J CLIN NEUROPSYCH, V6, P433; CALVANIO R, 1993, NEUROL CLIN, V11, P25; Camp CJ, 1996, APPL COGNITIVE PSYCH, V10, P193, DOI 10.1002/(SICI)1099-0720(199606)10:3<193::AID-ACP374>3.0.CO;2-4; Camp CJ, 1992, EVERYDAY MEMORY AGIN, P155; Camp CJ, 1989, MEMORY AGING THEORY, P212; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Clare L, 2001, NEUROPSYCHOL REHABIL, V11, P477, DOI 10.1080/09602010042000213; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; Clare L, 1999, NEUROCASE, V5, P37, DOI 10.1080/13554799908404063; DAMASIO AR, 1990, MOL DEFICITS ALZHEIM; Davis RN, 2001, ALZ DIS ASSOC DIS, V15, P1, DOI 10.1097/00002093-200101000-00001; De Vreese LP, 2001, INT J GERIATR PSYCH, V16, P794, DOI 10.1002/gps.428; DEWEER B, 1995, J NEUROL NEUROSUR PS, V58, P590, DOI 10.1136/jnnp.58.5.590; DIESFELDT HFA, 1984, ARCH GERONTOL GERIAT, V3, P51, DOI 10.1016/0167-4943(84)90014-1; FARAH MJ, 1984, COGNITION, V18, P245, DOI 10.1016/0010-0277(84)90026-X; FARAH MJ, 1988, PSYCHOL REV, V95, P307, DOI 10.1037/0033-295X.95.3.307; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; HAXBY JV, 1990, ARCH NEUROL-CHICAGO, V47, P753, DOI 10.1001/archneur.1990.00530070043010; HERLITZ A, 1991, BRAIN COGNITION, V15, P119, DOI 10.1016/0278-2626(91)90020-9; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; HODGES JR, 1995, NEUROPSYCHOLOGIA, V33, P441, DOI 10.1016/0028-3932(94)00127-B; Iyo M, 1997, LANCET, V349, P1805, DOI 10.1016/S0140-6736(96)09124-6; Jobst K A, 1998, Int Psychogeriatr, V10, P271, DOI 10.1017/S1041610298005389; KARLSSON T, 1989, NEUROPSYCHOLOGIA, V27, P737, DOI 10.1016/0028-3932(89)90119-X; Kasl-Godley J, 2000, CLIN PSYCHOL REV, V20, P755, DOI 10.1016/S0272-7358(99)00062-8; Kesslak JP, 1997, BEHAV NEUROL, V10, P137, DOI 10.3233/BEN-1997-10407; Kime SK, 1996, BRAIN INJURY, V10, P17; Kixmiller JS, 2002, BRAIN COGNITION, V49, P237, DOI 10.1006/brcg.2001.1476; Kuzis G, 1999, NEUROPSY NEUROPSY BE, V12, P265; Landauer T.K., 1978, PRACTICAL ASPECTS ME, P625; LEVINE DN, 1985, NEUROLOGY, V35, P1010, DOI 10.1212/WNL.35.7.1010; LINTON M, 1988, PRACTICAL ASPECTS ME, P378; Lipinska B, 1997, BRAIN COGNITION, V34, P274, DOI 10.1006/brcg.1997.0916; LIPINSKA B, 1994, J CLIN EXP NEUROPSYC, V16, P809, DOI 10.1080/01688639408402695; MARTIN A, 1985, BRAIN LANG, V25, P323, DOI 10.1016/0093-934X(85)90088-4; MCKITRICK LA, 1992, J GERONTOL, V47, pP337, DOI 10.1093/geronj/47.5.P337; MOFFAT N, 1992, CLIN MANAGEMENT MEMO, P87; MONTALDI D, 1990, J NEUROL NEUROSUR PS, V53, P33, DOI 10.1136/jnnp.53.1.33; MORRIS RG, 1988, J CLIN EXP NEUROPSYC, V10, P279, DOI 10.1080/01688638808408242; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Postle BR, 1996, LEARN MEMORY, V3, P305, DOI 10.1101/lm.3.4.305; QUAYHAGEN MP, 1995, NURS RES, V44, P153; QUAYHAGEN MP, 1989, GERONTOLOGIST, V29, P150, DOI 10.1093/geront/29.2.150; Quayhagen MP, 2000, INT PSYCHOGERIATR, V12, P249, DOI 10.1017/S1041610200006360; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; ROBERTSON IH, 1993, CURR OPIN NEUROL, V6, P756, DOI 10.1097/00019052-199310000-00013; Sandman Curt A., 1993, Clinical Gerontologist, V13, P19, DOI 10.1300/J018v13n04_03; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; Simard M, 1999, DRUG AGING, V14, P197, DOI 10.2165/00002512-199914030-00004; SIMARD M, 2000, CLIN GERIATR MED, V8, P32; SQUIRE LR, 1987, MEMORY BRAIN; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; Sykes R.N, 1988, PRACTICAL ASPECTS ME, V1, P396; TERI L, 1991, GERONTOLOGIST, V31, P413, DOI 10.1093/geront/31.3.413; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; Verfaellie M, 2000, NEUROPSYCHOLOGIA, V38, P1581, DOI 10.1016/S0028-3932(00)00073-7; WECHSLER D, 1987, WECHLSER MEMORY SCAL; WILSON B, 1988, BRAIN COGNITION, V8, P31, DOI 10.1016/0278-2626(88)90037-1; Wilson B. A, 1999, CASE STUDIES NEUROPS; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; WOLFE N, 1995, ARCH NEUROL-CHICAGO, V52, P257, DOI 10.1001/archneur.1995.00540270049018; Zanetti O, 2001, NEUROPSYCHOL REHABIL, V11, P263, DOI 10.1080/09602010042000088; ZARIT SH, 1982, GERONTOLOGIST, V22, P373, DOI 10.1093/geront/22.4.373	85	84	89	0	16	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2003	15	2					130	144		10.1176/appi.neuropsych.15.2.130			15	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	672VQ	WOS:000182544000002	12724453				2021-06-18	
J	Paterson, B; Scott-Findlay, S				Paterson, B; Scott-Findlay, S			Critical issues in interviewing people with traumatic brain injury	QUALITATIVE HEALTH RESEARCH			English	Article								People with cognitive impairments often cannot effectively recall and articulate experiences, feelings, and perceptions, Therefore, interviewing them can be fraught with pragmatic and methodological difficulties. Given this situation, the authors' experience in a study oil the allocation of rehabilitative services to survivors of traumatic brain injury is discussed. Participants had physiological impairments affecting their ability to focus on interview questions. The authors discuss the unique challenges, including participants' recall of events, intolerance to stimuli, and image management and offer strategies for mitigating these concerns. The traditional view that reality is captured only in the subjective accounts of articulate people who can remember events in a precise and reflective manner is challenged.	Univ British Columbia, Sch Nursing, Vancouver, BC V5Z 1M9, Canada	Paterson, B (corresponding author), Univ British Columbia, Sch Nursing, Vancouver, BC V5Z 1M9, Canada.						Acton G J, 1999, J Gerontol Nurs, V25, P6; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BOWERS LJ, 1995, TOPICS CLIN CHIROPRA, V2, P94; BOWERS LJ, 1995, TOPICS CLIN CHIROPRA, V2, P86; Crowe M, 1998, J ADV NURS, V28, P339, DOI 10.1046/j.1365-2648.1998.00780.x; Docherty S, 1999, RES NURS HEALTH, V22, P177, DOI 10.1002/(SICI)1098-240X(199904)22:2<177::AID-NUR9>3.0.CO;2-H; GORDON N, 1997, NURSE RES, V5, P72; GRANT NK, 1993, J ADV NURS, V18, P2020, DOI 10.1046/j.1365-2648.1993.18122020.x; Gregory R J, 1998, J Psychosoc Nurs Ment Health Serv, V36, P28; Hertz R., 1995, QUAL INQ, V1, P429; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Holstein J. A., 1995, ACTIVE INTERVIEW; HUTCHINSON S, 1992, NURS RES, V41, P117; Lynch RT, 1995, J SPECIALISTS GROUP, V20, P108, DOI DOI 10.1080/01933929508411333; Meyer P. H., 1998, CLIN APPL BOWEN FAMI, P69; NELSON K, 1993, MINN SYM CHILD PSYCH, V26, P1; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Paterson B, 1992, QUALITATIVE HLTH RES, V2, P99; RAMOS MC, 1989, RES NURS HEALTH, V12, P57, DOI 10.1002/nur.4770120109; Rolls C, 1997, Contemp Nurse, V6, P152; SARGEANT R, 2000, J COGNIT REHABIL, V18, P20; SCOTTFINDLAY S, 1998, THESIS U MANITOBA WI; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Thorne S, 1998, Image J Nurs Sch, V30, P173, DOI 10.1111/j.1547-5069.1998.tb01275.x; Thorne S E, 2000, Annu Rev Nurs Res, V18, P3; Williams CC, 1999, PSYCHIATRY, V62, P61, DOI 10.1080/00332747.1999.11024853; WORTH A, 1993, J ADV NURS, V18, P1077, DOI 10.1046/j.1365-2648.1993.18071077.x	27	84	85	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323	1552-7557		QUAL HEALTH RES	Qual. Health Res.	MAR	2002	12	3					399	409		10.1177/104973202129119973			11	Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	523KM	WOS:000173952900009	11918104				2021-06-18	
J	Bullinger, M				Bullinger, M		TBI Consensus Grp	Quality of life in patients with traumatic brain injury - basic issues, assessment and recommendations - Results of a consensus meeting	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	Consensus Conference on Quality of Life after Multiple Trauma	SEP 29-OCT 02, 1999	WERMELSKIRCHEN, GERMANY	German Minist Educ & Res		traumatic brain injury; quality of life; consensus conference	GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; OF-LIFE; COMMUNITY; INTEGRATION; PERSPECTIVE; EMPLOYMENT; DISABILITY	Introduction: Traumatic brain injuries (TBI) are one of the most common consequences of traffic accidents. Patients with mild, moderate or severe brain injuries suffer from physical, cognitive, behavioral, emotional and social problems. Most of these problems have been a long standing focus amongst practitioners and researchers. Only recently a development has started that took interest in the quality of life outcome of TBI patients. The international members of this consensus meeting reviewed the literature on Quality of Life assessment after TBI and discussed the applicability of different measurements to this specific patient group. Time Points: During the acute phase (T1; < 3 month after trauma) QoL it is difficult to assess due to the reduced conciousness of TBI patients. In the phase of rehabilitation (T2; < one year after trauma) and in the post-rehabilitation phase (T3) repeated assessment of QoL is recommended. Instruments: Several generic and disease-specific instruments possibly relevant to TBI patients or specifically developed for this group were assessed according to the existing evidence in the literature. Criteria for the evaluation of these intruments were: feasibility, specificity, validity, comprehensiveness, international availability, existence of norms, and psychometric quality. The cognitive impairment and the existential dimension were not sufficiently considered in most of the reviewed instruments. Group Consensus: The familiy's and relatives' view of the patient's QoL should not be used as a proxy but provides an additional source of information in the acute phase. At T2 and T3, assessment of the patient's quality of life should include a generic as well as a disease specific instrument. Among the generic instruments the SF-36, the EuroQol and the WHO-QoL should be considered. The literature about specific instruments for patients with TBI like the EBIC is scarce. Therefore, the group could hardly give an empiracally based recommendation. The need for further investigation on QoL instruments in TBI patients is strongly emphasized.	Univ Hamburg, Dept Med Psychol, D-20246 Hamburg, Germany	Bullinger, M (corresponding author), Univ Hamburg, Dept Med Psychol, Martinistr 52, D-20246 Hamburg, Germany.						Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bergner M, 1991, MED CARE, V19, P780; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; DELOCHE G, 1994, INT HDB NEUROPSYCHOL, P81; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; DIKMEN S, 1993, BRAIN INJURY, V7; DIKMEN S, 1995, NEUROPSYCHOLOGY, V4, P80; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; HUNT SM, 1981, SOC SCI MED-MED SOC, V15, P221, DOI 10.1016/0271-7123(81)90005-5; HUTTER BO, 1998, ZENTRALBL NEUROCHIR, V59, P63; HUTTER BO, 1997, QUAL LIFE RES, V6, P662; HUTTER BO, 1999, Z NEUROPSYCHOL, V10, P38; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; JENNETT B, 1994, REAN URG, V3, P153; Jennett B., 1997, HEAD INJURY, P439; KAPLAN RM, 1996, QUALITY LIFE PHARMAC, P309; Kind P, 1996, QUALITY LIFE PHARMAC, V2, P191; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Lang DA, 1999, J NEUROSURG, V91, P359, DOI 10.3171/jns.1999.91.3.0359; MOORE A D, 1990, Brain Injury, V4, P379, DOI 10.3109/02699059009026191; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Ware DL, 1996, QUALITY LIFE PHARMAC, P337; *WHO QOL GROUP, 1993, QUAL LIF ASS INT PER; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	37	84	87	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2002	20	3-4					111	124					14	Neurosciences	Neurosciences & Neurology	633MR	WOS:000180287500006	12454360				2021-06-18	
J	McCullers, D; Sullivan, PG; Scheff, SW; Herman, JP				McCullers, D; Sullivan, PG; Scheff, SW; Herman, JP			Mifepristone protects CA1 hippocampal neurons following traumatic brain injury in rat	NEUROSCIENCE			English	Article						glucocorticoid receptor; mineralocorticoid receptor; spironolactone; bcl-2; bax; cortical impact	MESSENGER-RNA EXPRESSION; SEVERE HEAD-INJURY; CELL-DEATH; KAINIC ACID; GLUCOCORTICOID TOXICITY; GENE-EXPRESSION; IN-VIVO; MINERALOCORTICOID RECEPTOR; SELECTIVE VULNERABILITY; SUPPRESSOR GENE	The present study addresses mincralocorticoid receptor and glucocorticoid receptor effects on hippocampal neuron viability after experimental traumatic brain injury. Rats were pretreated for 48 h with vehicle, the mineralocorticoid receptor antagonist spironolactone, or the glucocorticoid receptor antagonist mifepristone (RU486) and subsequently subjected to sham operation or unilateral controlled cortical impact injury. To determine the effects of receptor antagonist pretreatments on cell survival, neurons in regions CA1, CA3, and dentate gyrus of the hippocampal formation were counted 24 h post-injury using the optical fractionator method. Injury decreased the number of viable neurons in CA1 and CA3 of vehicle-pretreated animals. Notably, this cell loss was prevented in CA1 by RU486 pretreatment. Neuronal loss was also observed in dentate gyros. The effects of receptor blockade and injury on the expression of viability-related genes were also assessed by comparing relative bel-2, bax, and p53 messenger RNA levels using in situ hybridization analysis. Spironolactone and RU486 decreased basal bel-2 messenger RNA levels in CA1 and dentate gyrus but did not affect basal bax or p53 levels. Injury decreased bel-2 messenger RNA levels in dentate gyrus but did not affect bax or p53 levels in vehicle-pretreated animals. These data demonstrate that RU486 pretreatment prevents the loss of CA1 pyramidal neurons 24 It after traumatic brain injury. RU486 modulation of bel-2, bux, or p53 messenger RNA expression does not predict neuronal viability at this time point, suggesting that RU486-mediated preservation of CA1 neurons does not involve transcriptional regulation of those cell death-related genes. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	McCullers, D (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, POB 670559,231 Albert Sabin Way, Cincinnati, OH 45267 USA.		Herman, James P/D-4960-2015	Herman, James P/0000-0003-3571-2406	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836, R01AG012962] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00242, AG10836, AG12962] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline		Antonawich FJ, 1999, NEUROSCIENCE, V88, P319, DOI 10.1016/S0306-4522(98)00213-9; ARONSSON M, 1988, P NATL ACAD SCI USA, V85, P9331, DOI 10.1073/pnas.85.23.9331; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Bullock MR, 1996, J NEUROTRAUM, V13, P715; Cadepond F, 1997, ANNU REV MED, V48, P129; Carpenter SEK, 1996, FERTIL STERIL, V66, P90, DOI 10.1016/S0015-0282(16)58392-7; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clark RSB, 1997, J NEUROSCI, V17, P9172; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; ELLIOTT EM, 1992, J NEUROCHEM, V59, P1033, DOI 10.1111/j.1471-4159.1992.tb08345.x; ELLIOTT EM, 1993, BRAIN RES, V602, P84, DOI 10.1016/0006-8993(93)90245-I; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GREENAMYRE JT, 1985, J PHARMACOL EXP THER, V233, P254; HALL ED, 1992, J NEUROTRAUMA, V9, P425; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HERMAN JP, 1993, CELL MOL NEUROBIOL, V13, P349, DOI 10.1007/BF00711577; Herman JP, 1998, J NEUROSCI, V18, P7462; HERMAN JP, 1989, MOL ENDOCRINOL, V3, P1886, DOI 10.1210/mend-3-11-1886; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HORNER HC, 1990, NEUROENDOCRINOLOGY, V52, P57; JOELS M, 1989, SCIENCE, V245, P1502, DOI 10.1126/science.2781292; Joels M, 1998, MOL NEUROBIOL, V17, P87, DOI 10.1007/BF02802026; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KARST H, 1994, BRAIN RES, V649, P234, DOI 10.1016/0006-8993(94)91069-3; KATO J, 1994, HORM BEHAV, V28, P454, DOI 10.1006/hbeh.1994.1043; KERR DS, 1989, SCIENCE, V245, P1505, DOI 10.1126/science.2781293; KERR DS, 1992, P NATL ACAD SCI USA, V89, P8527, DOI 10.1073/pnas.89.18.8527; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KOHLER C, 1983, NEUROSCIENCE, V8, P819, DOI 10.1016/0306-4522(83)90013-1; McCullers DL, 1998, NEUROREPORT, V9, P3085, DOI 10.1097/00001756-199809140-00031; McCullers DL, 2001, J NEUROSCI RES, V64, P277; MCCULLERS DL, 2000, SOC NEUR ABSTR, V26, P419; MCEWEN BS, 1986, PHYSIOL REV, V66, P1121; McIntosh LJ, 1996, EXP NEUROL, V141, P201, DOI 10.1006/exnr.1996.0154; McIntosh LJ, 1996, NEUROTOXICOLOGY, V17, P873; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; MORSE JK, 1990, EXP NEUROL, V110, P86, DOI 10.1016/0014-4886(90)90053-U; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; Nair SM, 1998, J NEUROSCI, V18, P2685; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; NORDEEN SK, 1995, STEROIDS, V60, P97, DOI 10.1016/0039-128X(94)00001-S; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARTHASARATHY S, 1994, J CLIN INVEST, V94, P1990, DOI 10.1172/JCI117551; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RATKA A, 1989, NEUROENDOCRINOLOGY, V50, P117, DOI 10.1159/000125210; Reagan LP, 1997, J CHEM NEUROANAT, V13, P149, DOI 10.1016/S0891-0618(97)00031-8; REUL JMHM, 1987, J ENDOCRINOL, V115, P459, DOI 10.1677/joe.0.1150459; REUL JMHM, 1989, MOL ENDOCRINOL, V3, P1674, DOI 10.1210/mend-3-10-1674; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; SAPOLSKY RM, 1988, BRAIN RES, V453, P367, DOI 10.1016/0006-8993(88)90180-1; SAPOLSKY RM, 1986, NEUROENDOCRINOLOGY, V43, P440, DOI 10.1159/000124561; SAPOLSKY RM, 1986, J NEUROSCI, V6, P2240; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1228; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SEROOGY KB, 1996, NEUROCHEMISTRY PRACT, P121; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; STEIN BA, 1988, BRAIN RES, V473, P175, DOI 10.1016/0006-8993(88)90332-0; STEINBEHRENS BA, 1994, J NEUROCHEM, V63, P596; STEINBEHRENS BA, 1992, J NEUROCHEM, V58, P1730, DOI 10.1111/j.1471-4159.1992.tb10047.x; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Tarazi FI, 1996, PSYCHOPHARMACOLOGY, V128, P371, DOI 10.1007/s002130050147; TORNHEIM PA, 1978, J NEUROSURG, V48, P220, DOI 10.3171/jns.1978.48.2.0220; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Young W, 1992, J NEUROTRAUMA S1, V9, P9	85	84	86	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	109	2					219	230	PII S0306-4522(01)00477-8	10.1016/S0306-4522(01)00477-8			12	Neurosciences	Neurosciences & Neurology	525NV	WOS:000174078600002	11801359				2021-06-18	
J	Goodman, D; Gaetz, M; Meichenbaum, D				Goodman, D; Gaetz, M; Meichenbaum, D			Concussions in hockey: there is cause for concern	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						demographics; treatment; prevention	ICE-HOCKEY; INJURIES; PLAYERS; CANADA; HEAD	Purpose: The purpose of the study A Lis to document various aspects of concussion in Canadian Amateur hockey including demographics, causes. treatment, and prevention in order to guide future recommendation,,, on how to reduce injury. Methods: A detailed prospective and retrospective concussion history was obtained from British Columbia Junior Hockey League players over the course of two seasons (1998-2000). Results: Higher rates of concussions occur in games versus practice, and there was an overrepresentation of forwards injured versus defensemen or goaltenders. There Aas between 4.63 and 5.95 concussions per 1000 player/game hours with the average age of the First hockey-related concussion in the 15th year. The greatest cause of Concussion was contact with the ice and/or the boards. Fighting was not a major cause of concussion, although other illegal actions such as elbowing were, Conclusions: The primary recommendation to reduce the number and severity of concussions is to eliminate plays where there is a demonstrable intent to injure another player. Concussions in hockey are of considerable concern: however, there is now encouraging information with respect to the treatment of these injuries.	Simon Fraser Univ, Sch Kinesiol, Human Motor Syst Lab, Burnaby, BC V5A 1S6, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada	Goodman, D (corresponding author), Simon Fraser Univ, Sch Kinesiol, Human Motor Syst Lab, Burnaby, BC V5A 1S6, Canada.	goodman@sfu.ca					Barth J T, 2000, Dent Clin North Am, V44, P67; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Jorgensen U, 1986, Br J Sports Med, V20, P7; Kelly JP, 1997, NEUROLOGY, V48, P581; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Molsa J, 1997, AM J SPORT MED, V25, P495, DOI 10.1177/036354659702500412; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; Pinto M, 1999, CLIN J SPORT MED, V9, P70, DOI 10.1097/00042752-199904000-00005; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; SIM FH, 1987, AM J SPORTS MED, V15, pS86; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Tator CH, 2000, CAN MED ASSOC J, V162, P787; Tegner Y, 1991, Br J Sports Med, V25, P87; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251	19	84	84	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2001	33	12					2004	2009		10.1097/00005768-200112000-00005			6	Sport Sciences	Sport Sciences	500CA	WOS:000172607300005	11740291				2021-06-18	
J	McIntosh, AS; McCrory, P				McIntosh, AS; McCrory, P			Effectiveness of headgear in a pilot study of under 15 rugby union football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						rugby union; headgear; helmets; concussion; adolescents	ICE-HOCKEY; INJURIES; CHILDREN; IMPACT	Objective-To determine whether protective headgear reduced the incidence of concussion in a pilot study of under 15 rugby union. Methods-Sixteen under 15 rugby union teams were recruited from three interschool competitions in metropolitan Sydney and the adjacent country region. A prospective study was undertaken over a single competitive season. The study had two arms: a headgear arm and a control arm. Headgear wearing rates and injury data were reported to the investigators and verified using spot checks. Results-A total of 294 players participated in the study. There were 1179 player exposures with headgear and 357 without headgear. In the study time frame, there were nine incidences of concussion; seven of the players involved wore headgear and two did not. There was no significant difference between concussion rates between the two study arms. Conclusions-Although there is some controversy about the desirability of wearing protective headgear in football, this pilot study strongly suggests that current headgear does not provide significant protection against concussion in rugby union at a junior level.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Univ Melbourne, Ctr Sports Med Res, Parkville, Vic 3052, Australia; Univ Melbourne, Brain Res Inst, Parkville, Vic 3052, Australia	McIntosh, AS (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.		McCrory, Paul/Q-8688-2019				BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; CLARKE KS, 1979, MED SCI SPORT EXER, V11, P138; EDGAR M, 1995, LANCET, V345, P1452, DOI 10.1016/S0140-6736(95)91031-X; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; Finch C, 1993, 51 MON U ACC RES CTR; GARRAWAY M, 1995, LANCET, V345, P1485; Gissane C, 1997, Aust J Sci Med Sport, V29, P91; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; *IRB, 1996, LAWS GAM RUGB FOOTB; McCrory P, 1998, SPORTS NEUROLOGY, P441; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Mills N J, 1990, Br J Sports Med, V24, P55; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; VIRGIN H, 1980, AM J SPORT MED, V8, P310, DOI 10.1177/036354658000800503; Wekesa M, 1996, BRIT J SPORT MED, V30, P61, DOI 10.1136/bjsm.30.1.61; Wilson BD, 1998, SPORTS MED, V25, P333, DOI 10.2165/00007256-199825050-00005	19	84	85	0	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	JUN	2001	35	3					167	169		10.1136/bjsm.35.3.167			3	Sport Sciences	Sport Sciences	440UV	WOS:000169193700009	11375874	Green Published, Bronze			2021-06-18	
J	Philips, MF; Mattiasson, G; Wieloch, T; Bjorklund, A; Johansson, BB; Tomasevic, G; Martinez-Serrano, A; Lenzlinger, PM; Sinson, G; Grady, MS; McIntosh, TK				Philips, MF; Mattiasson, G; Wieloch, T; Bjorklund, A; Johansson, BB; Tomasevic, G; Martinez-Serrano, A; Lenzlinger, PM; Sinson, G; Grady, MS; McIntosh, TK			Neuroprotective and behavioral efficacy of nerve growth factor-transfected hippocampal progenitor cell transplants after experimental traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						stem cell; growth factor; traumatic brain injury; transplantation; neuroprotection; gene therapy; rat	FETAL MESENCEPHALIC TISSUE; CHOLINERGIC NEURON ATROPHY; FLUID-PERCUSSION INJURY; FACTOR GENE-TRANSFER; RAT BASAL FOREBRAIN; LONG-TERM SURVIVAL; ADULT-RAT; PARKINSONS-DISEASE; ASTROCYTES PROMOTE; NEURITE OUTGROWTH	Object. Immortalized neural progenitor cells derived from embryonic rat hippocampus (HiB5), were transduced ex vivo with the gene for mouse nerve growth factor (NGF) to secrete NGF (NGF-HiB5) at 2 ng/hr/10(5) cells in culture. Methods. Fifty-nine male Wistar rats weighing 300 to 370 g each were anesthetized with 60 mg/kg sodium pentobarbital and subjected to lateral fluid-percussion brain injury of moderate severity (2.3-2.4 atm, 34 rats) or sham injury (25 rats). At 24 hours postinjury, 2 mul (150,000 cells/mul) of [H-3]thymidine-labeled NGF-HiB5 cells were transplanted stereotactically into three individual sites in the cerebral cortex adjacent to the injury site (14 rats). Separate groups of brain-injured rats received nontransfected (naive [n])-HiB5 cells (12 animals) or cell suspension vehicle (eight animals). One week postinjury, animals underwent neurological evaluation for motor function and cognition (Morris water maze) and were killed for histological, autoradiographic, and immunocytochemical analysis. Viable HiB5 cell grafts were identified in all animals, together with reactive microglia and macrophages located throughout the periinjured parenchyma and grafts (OX-42 immunohistochemistry). Brain-injured animals transplanted with either NGF-HiB5 or n-HiB5 cells displayed significantly improved neuromotor function (p < 0.05) and spatial learning behavior (p < 0.005) compared with brain-injured animals receiving microinjections of vehicle alone. A significant reduction in hippocampal CA3 cell death was observed in brain-injured animals receiving transplants of NGF-HiB5 cells compared with those receiving n-HiB5 cells or vehicle (p < 0.025). Conclusions. This study demonstrates that immortalized neural stem cells that have been retrovirally transduced to produce NGF can markedly improve cognitive and neuromotor function and rescue hippocampal CA3 neurons when transplanted into the injured brain during the acute posttraumatic period.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19144 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Lund, Dept Physiol & Neurosci, Lund, Sweden; Univ Lund Hosp, Div Expt Brain Res, S-22185 Lund, Sweden; Autonomous Univ Madrid, Ctr Mol Biol Severo Ochoa, Madrid, Spain	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19144 USA.		Bjorklund, Geir/B-7319-2014; Martinez-Serrano, Alberto/J-8146-2014; Bjorklund, Anders/ABA-1326-2020; Lenzlinger, Philipp/A-3822-2008	Bjorklund, Geir/0000-0003-2632-3935; Martinez Serrano, Alberto/0000-0003-3927-6699; Wieloch, Tadeusz/0000-0002-7669-2520; Bjorklund, Anders/0000-0002-5676-6203	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM74690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803] Funding Source: Medline		Andsberg G, 1998, EUR J NEUROSCI, V10, P2026, DOI 10.1046/j.1460-9568.1998.00214.x; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; BRADBURY EJ, 1995, NEUROSCIENCE, V65, P955, DOI 10.1016/0306-4522(94)00540-L; BRUCKNER MK, 1992, NEUROSCI LETT, V141, P251, DOI 10.1016/0304-3940(92)90906-N; CONNER JM, 1992, J COMP NEUROL, V319, P454, DOI 10.1002/cne.903190310; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; FRODL EM, 1994, BRAIN RES, V647, P286, DOI 10.1016/0006-8993(94)91328-5; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GRABOWSKI M, 1993, ANN NEUROL, V34, P362, DOI 10.1002/ana.410340310; HADANI M, 1992, J NEUROTRAUM, V9, P107, DOI 10.1089/neu.1992.9.107; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; KESSLAK JP, 1988, BRAIN RES, V454, P347, DOI 10.1016/0006-8993(88)90836-0; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Krobert K, 1997, EXP NEUROL, V145, P511, DOI 10.1006/exnr.1997.6483; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; LINDVALL O, 1997, NEUROREPORT, V8, P3; Lundberg C, 1996, NEUROREPORT, V7, P847, DOI 10.1097/00001756-199603220-00002; Lundberg C, 1997, EXP NEUROL, V145, P342, DOI 10.1006/exnr.1997.6503; Martinez-Serrano A, 1998, P NATL ACAD SCI USA, V95, P1858, DOI 10.1073/pnas.95.4.1858; MartinezSerrano A, 1996, P NATL ACAD SCI USA, V93, P6355, DOI 10.1073/pnas.93.13.6355; MARTINEZSERRANO A, 1995, NEURON, V15, P473, DOI 10.1016/0896-6273(95)90051-9; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Olby NJ, 1996, J NEUROCYTOL, V25, P481, DOI 10.1007/BF02284817; Onizuka K, 1996, EXP NEUROL, V137, P324, DOI 10.1006/exnr.1996.0033; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Peschanski M, 1996, NEUROSCIENCE, V71, P899, DOI 10.1016/0306-4522(95)00575-7; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; RUDGE JS, 1990, J NEUROSCI, V10, P3594; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinson G, 1996, Clin Neurosurg, V43, P219; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMITH GM, 1990, DEV BIOL, V138, P377, DOI 10.1016/0012-1606(90)90204-V; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; Snyder Evan Y., 1994, Current Opinion in Neurobiology, V4, P742, DOI 10.1016/0959-4388(94)90018-3; Snyder EY, 1998, NEUROSCIENTIST, V4, P408, DOI 10.1177/107385849800400613; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Soares HD, 1995, J NEUROSCI, V15, P8223; Sorensen JC, 1996, EXP NEUROL, V138, P227, DOI 10.1006/exnr.1996.0061; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; Spenger C, 1996, EXP BRAIN RES, V112, P47; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; VICARIOABEJON C, 1995, J NEUROSCI, V15, P6351; WANG JJ, 1995, NEUROSCIENCE, V65, P973, DOI 10.1016/0306-4522(94)00519-B; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; WUNDERLICH G, 1994, GLIA, V10, P49, DOI 10.1002/glia.440100107; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415	74	84	106	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2001	94	5					765	774		10.3171/jns.2001.94.5.0765			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	429NV	WOS:000168524600011	11354408				2021-06-18	
J	Cvek, M; Andreasen, JO; Borum, MK				Cvek, M; Andreasen, JO; Borum, MK			Healing of 208 intraalveolar root fractures in patients aged 7-17 years	DENTAL TRAUMATOLOGY			English	Article						root fractures; pulp heating; splinting	PERMANENT INCISORS; PROGNOSIS; REPLANTATION; MONKEYS; REPAIR; TEETH	This retrospective study consisted of 208 root-fractured, 168 splinted and 40 not splinted incisors in young individuals ja,oed 7-17 years) created in the period 1959-1973 at the Pedodontic Department. Eastman Institute, Stockholm. Clinical and radiographic analyses showed that 69 teeth (33%) had developed hard tissue (fusion) healing of, fragments. Interposition of periodontal ligament (PDL) and bone between the fragments was found in 17 teeth (8%). Interposition of PBL, alone was found in 74 teeth (36%). Finally non-healing with pulp necrosis and inflammatory: changes between fragments was seen in 48 teeth (23%), Various clinical factors were analyzed for their relationship to the healing outcome with respect to healing/no healing and type of healing (hard tissue versus interposition of bone and/or PDL). Immature root and positive pulp sensitivity at time of injury was found to be significantly related to both pulp healing and hard tissue repair of the fracture. The same applied to concussion or subluxation of the coronal fragment compared to luxation with displacement (extrusive or lateral luxation). This relation was also represented by the variable millimeter diastasis between fragments before and after repositioning. Repositioning appeared to enhance the likelihood of both pulp healing and hard tissue repair. A positive effect of splinting, splinting methods (cap splints or orthodontic bands with an arch wire) or splinting periods could not be demonstrated on either pulp healing or type of healing (hard tissue versus interposition of bone and/or PDL). In conclusion, the findings from this retrospective study have cast doubts an the efficacy of long-term splinting and the types of splint used for root fracture healing. It is suggested that the role of splinting and splinting methods be examined in further studies.	Eastman Inst, Dept Pedodont, Stockholm, Sweden; Rigshosp, Dept Oral & Maxillofacial Surg, Taastrup, Denmark; Municipal Dent Serv, Taastrup, Denmark	Cvek, M (corresponding author), Eastman Inst, Dept Pedodont, Stockholm, Sweden.						ANDREASEN FM, 1988, ENDOD DENT TRAUMATOL, V4, P202; ANDREASEN FM, 1989, ENDOD DENT TRAUMATOL, V5, P11; ANDREASEN FM, 1989, ENDOD DENT TRAUMATOL, V5, P111; ANDREASEN FM, 1994, TXB COLOR ATLAS TRAU, P279; ANDREASEN JO, 1967, J ORAL SURG, V25, P414; ANDREASEN JO, 1981, INT J ORAL MAXILLOF, V10, P54, DOI 10.1016/S0300-9785(81)80008-7; ANDREASEN JO, 1975, ACTA ODONTOL SCAND, V33, P313, DOI 10.3109/00016357509004636; Andreasen JO., 1972, TRAUMATIC INJURIES T, P111; Armitage P., 1987, STAT METHODS MED RES; BENATI FW, 1994, OKLA DENT ASS J, V65, P30; Caliskan MK, 1996, ENDOD DENT TRAUMATOL, V12, P129; CHANG SP, 1988, ENDOD DENT TRAUMATOL, V4, P186; Feiglin B, 1995, Dent Clin North Am, V39, P53; FOUNTAIN SB, 1984, PATHWAYS PULP, P502; KRISTERSON L, 1983, INT J ORAL SURG, V10, P54; MANDEL U, 1989, ARCH ORAL BIOL, V34, P209, DOI 10.1016/0003-9969(89)90010-1; MICHANOWICZ AE, 1971, J AM DENT ASSOC, V82, P569, DOI 10.14219/jada.archive.1971.0101; RABIE G, 1988, ENDOD DENT TRAUMATOL, V4, P99; TZIAFAS D, 1993, ENDOD DENT TRAUMATOL, V9, P40; YATES JA, 1992, INT ENDOD J, V25, P150, DOI 10.1111/j.1365-2591.1992.tb00778.x; ZACHRISSON BU, 1975, SCAND J DENT RES, V83, P345	21	84	88	1	11	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	1600-4469			DENT TRAUMATOL	Dent. Traumatol.	APR	2001	17	2					53	62		10.1034/j.1600-9657.2001.017002053.x			10	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	424TN	WOS:000168248700002	11475947				2021-06-18	
J	Ruppel, RA; Kochanek, PM; Adelson, PD; Rose, ME; Wisniewski, SR; Bell, MJ; Clark, RSB; Marion, DW; Graham, SH				Ruppel, RA; Kochanek, PM; Adelson, PD; Rose, ME; Wisniewski, SR; Bell, MJ; Clark, RSB; Marion, DW; Graham, SH			Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: The role of child abuse	JOURNAL OF PEDIATRICS			English	Article; Proceedings Paper	Annual Congress of the American-Academy-of-Pediatrics	OCT 16-19, 1998	SAN FRANCISCO, CA	Amer Acad Pediat			SHAKEN-BABY SYNDROME; NONACCIDENTAL HEAD-INJURY; CENTRAL-NERVOUS-SYSTEM; DEVELOPING RAT-BRAIN; METHYL-D-ASPARTATE; YOUNG-CHILDREN; NEUROTOXICITY; BLOCKADE; RELEASE; CSF	Background: Excitotoxicity is an important mechanism in secondary neuronal injury after traumatic brain injury (TBI). Excitatory amino acids (EAAs) are increased in cerebrospinal fluid (CSF) in adults after TBI; however, studies in pediatric head trauma are lacking. We hypothesized that CSF glutamate, aspartate, and glycine would be increased after TBI in children and that these increases would be associated with age, child abuse, poor outcome, and cerebral ischemia. Methods: EAAs were measured in 66 CSF samples from 18 children after severe TBI. Control samples were obtained from 19 children who received lumbar punctures to rule out meningitis. Results: Peak and mean CSF glycine and peak CSF glutamate levels were increased versus control values. Subgroups of patients with TBI were compared by using univariate regression analysis. Massive increases in CSF glutamate were found in children <4 years old and in child abuse victims. Increased CSF glutamate and glycine were associated with poor outcome. A trend toward an association between high glutamate concentration and ischemic blood flow was observed. Conclusions: CSF EAAs are increased in infants and children with severe TBI. Young age and child abuse were associated with extremely high CSF glutamate concentrations after TBI. A possible role for excitotoxicity after pediatric TBI is supported.	Univ Pittsburgh, Sch Med,Childrens Hosp Pittsburgh, Dept Anesthesiol & Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res,Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res,Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res,Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med,Childrens Hosp Pittsburgh, Dept Epidemiol & Publ Hlth, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med,Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.		Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860			Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; ARAKI K, 1988, ACTA NEUROL SCAND, V78, P473, DOI 10.1111/j.1600-0404.1988.tb03690.x; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CAMPAGNE MV, 1994, J CEREBR BLOOD F MET, V14, P1011, DOI 10.1038/jcbfm.1994.133; CHOI DW, 1987, J NEUROSCI, V7, P357; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; FADEN AI, 1989, SCIENCE, V244, P789; Gilliland MGF, 1998, J FORENSIC SCI, V43, P723; GUR D, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P68; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HU B, 1991, J NEUROCHEM, V56, P933, DOI 10.1111/j.1471-4159.1991.tb02011.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Zauner A, 1996, ACT NEUR S, V67, P40	34	84	85	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JAN	2001	138	1					18	25		10.1067/mpd.2001.110979			8	Pediatrics	Pediatrics	393PK	WOS:000166478700005	11148507				2021-06-18	
J	Lane, PL; Skoretz, TG; Doig, G; Girotti, MJ				Lane, PL; Skoretz, TG; Doig, G; Girotti, MJ			Intracranial pressure monitoring and outcomes after traumatic brain injury	CANADIAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	Joint Meeting of the Trauma-Association-of-Canada / Royal-College-of-Physicians-and-Surgeons-of-Canada	SEP 24-28, 1997	VANCOUVER, CANADA	Trauma Assoc Canada, Royal Coll Physicians & Surgeons Canada			GLASGOW-COMA-SCALE; SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; SEVERITY SCORE; MANAGEMENT; HEMATOMAS; CARE	OBJECTIVE: Uncontrolled intracranial hypertension after traumatic brain injury (TBI) contributes significantly to the death rate and to poor functional outcome. There is no evidence that intracranial pressure (ICP) monitoring alters the outcome of TBI. The objective of this study was to test the hypothesis that insertion of ICP monitors in patients who have TBI is not associated with a decrease in the death rate. DESIGN: Study of case records. METHODS: The data files from the Ontario Trauma Registry from 1989 to 1995 were examined. Included were all cases with an Injury Severity Score (ISS) greater than 12 from the 14 trauma centres in Ontario. Cases identifying a Maximum Abbreviated Injury Scale score in the head region (MAIS head) greater than 3 were selected for further analysis. Logistic regression analyses mere conducted to investigate the relationship between ICP and death. RESULTS: Of 9001 registered cases of TBI, an MAIS head greater than 3 was recorded in 5507. Of these patients, 541 (66.8% male, mean age 34.1 years) had an ICP monitor inserted. Their average ISS was 33.4 and 71.7% survived. There was wide variation among the institutions in the rate of insertion of ICP monitors in these patients (ranging from 0.4% to over 20%). Univariate logistic regression indicated that increased MAIS head, ISS, penetrating trauma and the insertion of an ICP monitor were each associated with an increased death rate. However, multivariate analyses controlling for MAIS head, ISS and injury mechanism indicated that ICP monitoring was associated with significantly improved survival (P < 0.015). CONCLUSIONS: ICP monitor insertion rates vary widely in Ontario's trauma hospitals. The insertion of an ICP monitor is associated with a statistically significant decrease in death rate among patients with severe TBI. This finding strongly supports the need for a prospective randomized trial of management protocols, including ICP monitoring, in patients with severe TBI.	Albert Einstein Med Ctr, Dept Emergency Med, Philadelphia, PA 19141 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA; Univ Western Ontario, Fac Med, Div Crit Care Med, London, ON, Canada; London Hlth Sci Ctr, Trauma Program, London, ON, Canada; Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada	Lane, PL (corresponding author), Albert Einstein Med Ctr, Dept Emergency Med, 5501 Old York Rd, Philadelphia, PA 19141 USA.	lanep@aehn2.einstein.edu		Doig, Gordon/0000-0003-2141-7000			*AM ASS AUT MED, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brain Trauma Foundation, 1995, GUID MAN SEV HEAD IN; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; BULLOCK R, 1995, GUIDELINES MANAGEMEN; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; EDDY VA, 1995, AM SURGEON, V61, P24; Fleischer A S, 1976, Surg Neurol, V6, P31; GUILLAUME J, 1951, REV NEUROL, V84, P131; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; Hosmer D, 1989, APPL LOGISTIC REGRES; JOHNSTON IH, 1973, ACTA NEUROCHIR, V29, P53, DOI 10.1007/BF01414616; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; KUDAY C, 1994, ACTA NEUROCHIR, V131, P203, DOI 10.1007/BF01808613; Lane PL, 1997, ACCIDENT ANAL PREV, V29, P53, DOI 10.1016/S0001-4575(96)00061-9; Lane PL, 1996, J TRAUMA, V41, P731, DOI 10.1097/00005373-199610000-00023; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; MIKROGIANAKIS A, 1995, UWO MED J, V64, P97; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; PUCKETT DC, 1990, ED ANNOTATION ICD 9; Rating the severity of tissue damage. I, 1971, JAMA-J AM MED ASSOC, V215, P277; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSS SE, 1992, ACCIDENT ANAL PREV, V24, P181, DOI 10.1016/0001-4575(92)90035-H; Rossi S, 1998, ACT NEUR S, V71, P91; *SAS I INC, 1990, SAS US GUID STAT VER; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Stewart TC, 1995, J TRAUMA, V39, P1036, DOI 10.1097/00005373-199512000-00003; STUART GG, 1983, J NEUROSURG, V59, P601, DOI 10.3171/jns.1983.59.4.0601; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; TEASDALE G, 1974, LANCET, V2, P81; *TRIAN INC, 1991, TRICODE 5 0 PERS COM; *TRIAN INC, 1991, COLLECTOR TRAUM REG; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049	41	84	90	0	3	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0008-428X	1488-2310		CAN J SURG	Can. J. Surg.	DEC	2000	43	6					442	448					7	Surgery	Surgery	381GD	WOS:000165753200011	11129833				2021-06-18	
J	Spell, LA; Frank, E				Spell, LA; Frank, E			Recognition of nonverbal communication of affect following traumatic brain injury	JOURNAL OF NONVERBAL BEHAVIOR			English	Article						nonverbal communication; facial expression; vocal prosody; traumatic brain injury; affect	HEMISPHERE; DISCRIMINATION; LESIONS	Recognition of facial expressions and vocal prosody was examined using the Diagnostic Assessment of Nonverbal Accuracy 2 (DANVA-2) and the Carolina Older Adult Test of Nonverbal Communication (COAT-NC) for 24 individuals with traumatic brain injury (TBI) and 24 matched controls. Results demonstrated that participants without TBI scored significantly higher than participants with TBI when presented with adult photo and voice stimuli. No significant group difference was noted with child photo and voice stimuli. Both groups scored significantly higher on photo subtests than on voice subtests for child and younger adult stimuli. For older adult stimuli, both groups scored significantly higher on the voice subtest than on the photo subtest. For the subjects with TBI, a significant relationship was found between scores on the voice subtests and a functional measure of cognition and communication.	Univ S Carolina, Dept Speech Language Pathol & Audiol, Columbia, SC 29208 USA	Spell, LA (corresponding author), Columbia Coll, Dept Educ, 1301 Columbia Coll Dr, Columbia, SC 29203 USA.						BENOWITZ LI, 1983, CORTEX, V19, P5, DOI 10.1016/S0010-9452(83)80046-X; BLONDER LX, 1991, BRAIN, V114, P1115, DOI 10.1093/brain/114.3.1115; BOWERS D, 1991, BRAIN, V114, P2593, DOI 10.1093/brain/114.6.2593; DEKOSKY ST, 1980, BRAIN LANG, V9, P206, DOI 10.1016/0093-934X(80)90141-8; Dixon WJ, 1988, BMDP STAT SOFTWARE M; Feldman R.S., 1991, FUNDAMENTALS NONVERB, P329, DOI DOI 10.1037/A0036052; Frattali C. M., 1995, FUNCTIONAL ASSESSMEN; HAGAN C, 1979, REHAB HEAD INJURED A; Helm-Estabrooks N., 1990, BRIEF TEST HEAD INJU; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JENNETT B, 1974, LANCET, V1, P81; Kertesz A., 1982, W APHASIA BATTERY; Kowner R, 1996, J EXP PSYCHOL HUMAN, V22, P662, DOI 10.1037/0096-1523.22.3.662; LALANDE S, 1992, BRAIN LANG, V42, P165, DOI 10.1016/0093-934X(92)90123-V; Lehiste Ilse, 1970, SUPRASEGMENTALS; MCCUTCHEON EP, 1992, HEAD SPINAL CORD INJ; Meredith W. H., 1967, BASIC MATH STAT TABL; NOWICKI S, 1993, J SOC PSYCHOL, V133, P749, DOI 10.1080/00224545.1993.9713934; NOWICKI S, 1994, J NONVERBAL BEHAV, V18, P9, DOI 10.1007/BF02169077; PAZGAN A, 1996, THESIS U S CAROLINA; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; SHAVER M, 1996, THESIS U S CAROLINA; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; *SUNY RES FDN, 1993, GUID US UN DAT SET M; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEATHERS M, 1996, THESIS U S CAROLINA; YLVISAKER M, 1987, COMMUNITY REENTRY HE	27	84	85	0	15	KLUWER ACADEMIC-HUMAN SCIENCES PRESS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013-1578 USA	0191-5886			J NONVERBAL BEHAV	J. Nonverbal Behav.	WIN	2000	24	4					285	300		10.1023/A:1006675230193			16	Psychology, Social	Psychology	368VC	WOS:000090137300003					2021-06-18	
J	Buchanan, KM; Elias, LJ; Goplen, GB				Buchanan, KM; Elias, LJ; Goplen, GB			Differing perspectives on outcome after subarachnoid hemorrhage: The patient, the relative, the neurosurgeon	NEUROSURGERY			English	Article						family burden; neurobehavioral changes; psychological distress; subarachnoid hemorrhage outcome; surgical outcome	TRAUMATIC BRAIN INJURY; BLUNT HEAD-INJURY; ARTERIOVENOUS-MALFORMATIONS; NEUROPSYCHOLOGICAL DEFICITS; COGNITIVE PERFORMANCE; INTRACRANIAL ANEURYSM; CAREGIVER BURDEN; FAMILY; RECOVERY; REHABILITATION	OBJECTIVE: To better understand patients' and relatives' views of outcome after surgery for subarachnoid hemorrhage (SAH), we evaluated neurobehavioral changes, psychological distress, and family burden of patients who had been considered by their neurosurgeon as having a "good recovery" or a "moderate disability," as rated on the Glasgow Outcome Scale. METHODS: A heterogeneous sample of 28 patients treated surgically for SAH from an aneurysm or an arteriovenous malformation and their relatives separately underwent a semistructured interview. They also completed a revised version of the Adjective Checklist to assess their perceptions of the patient's neurobehavioral changes and the Brief Symptom Inventory as a measure of their own psychological distress. Levels of family burden on the relatives were evaluated with a Likert strain scale and the Zarit Burden Interview. RESULTS: Approximately 19 months after surgery for SAH, the majority of the patients reported significant negative neurobehavioral changes and negative changes in employment, energy levels, tolerance to mild stressors, leisure activities, and social and sexual relationships. Patients and relatives both reported elevated levels of psychological distress, and the relatives reported elevated levels of family burden. Patients' acid relatives' perceptions differed, with the relatives reporting more problems; both viewed the patient's outcome more negatively than did the operating neurosurgeon. CONCLUSION: Despite the neurosurgeon's classification of patients as having a "good recovery" or "moderate disability," the majority of patients surgically treated for SAH reported psychosocial and neurobehavioral changes that were disabling for them and burdensome to their family. Patients and relatives who are interviewed separately by an experienced clinician may provide differing perspectives on SAH outcome that are not necessarily good.	Univ Saskatchewan, Royal Univ Hosp, Div Neurosurg, Saskatoon, SK S7N 0W8, Canada; Univ Saskatchewan, Dept Psychol, Saskatoon, SK S7N 0W8, Canada	Buchanan, KM (corresponding author), Univ Saskatchewan, Royal Univ Hosp, Div Neurosurg, 103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.						BORNSTEIN RA, 1987, NEUROSURGERY, V21, P651, DOI 10.1227/00006123-198711000-00008; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; CLINCHOT DM, 1994, ARCH PHYS MED REHAB, V75, P1342; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1982, BRIEF SYMPTOM INVENT, V1; DERUTY R, 1988, Neurological Research, V10, P217; Dombovy ML, 1998, BRAIN INJURY, V12, P887; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; FRISS LR, 1991, AM J ALZHEIMERS  SEP; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; GOLD DP, 1995, J AM GERIATR SOC, V43, P10, DOI 10.1111/j.1532-5415.1995.tb06235.x; HADJISTAVROPOULOS T, 1994, J AM GERIATR SOC, V42, P308, DOI 10.1111/j.1532-5415.1994.tb01757.x; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; HUTTER BO, 1995, BRIT J NEUROSURG, V9, P465, DOI 10.1080/02688699550041106; HUTTER BO, 1993, NEUROSURGERY, V33, P999; JENNETT B, 1975, LANCET, V1, P480; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LINDBERG M, 1992, BRIT J NEUROSURG, V6, P297, DOI 10.3109/02688699209023787; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; MAHALICK DM, 1991, NEUROSURGERY, V29, P351, DOI 10.1227/00006123-199109000-00003; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; MAURICEWILLIAMS RS, 1991, J NEUROL NEUROSUR PS, V54, P335, DOI 10.1136/jnnp.54.4.335; MCKENNA P, 1989, NEUROSURGERY, V24, P361, DOI 10.1227/00006123-198903000-00009; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; Ogden J. A., 1990, NEUROPSY NEUROPSY BE, V3, P260; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; Ogden JA, 1997, NEUROSURGERY, V41, P25, DOI 10.1097/00006123-199707000-00008; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RICHARDSON JTE, 1991, ACTA NEUROL SCAND, V83, P110, DOI 10.1111/j.1600-0404.1991.tb04659.x; SAVELAND H, 1992, J NEUROSURG, V76, P729, DOI 10.3171/jns.1992.76.5.0729; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; STOREY PB, 1967, BRIT MED J, V3, P261, DOI 10.1136/bmj.3.5560.261; TIDSWELL P, 1995, NEUROLOGY, V45, P875; VILKKI J, 1990, NEUROSURGERY, V26, P579, DOI 10.1227/00006123-199004000-00004; WHITLATCH CJ, 1991, GERONTOLOGIST, V31, P9, DOI 10.1093/geront/31.1.9; ZARIT RH, 1985, HIDDEN VICTIMS ALZHE	42	84	87	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	APR	2000	46	4					831	838		10.1097/00006123-200004000-00012			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	302HR	WOS:000086360100029	10764256				2021-06-18	
J	Gordon, WA; Haddad, L; Brown, M; Hibbard, MR; Sliwinski, M				Gordon, WA; Haddad, L; Brown, M; Hibbard, MR; Sliwinski, M			The sensitivity and specificity of self-reported symptoms in individuals with traumatic brain injury	BRAIN INJURY			English	Article							MILD HEAD-INJURY; BASE RATES; ETIOLOGY	In this study, self-reported symptoms (cognitive, physical, behavioural/affective) from the TIRR Symptom Checklist are compared across six panels: 135 individuals with mild TBI, 275 with moderate/severe TBI, 287 with no disability, 104 with spinal cord injury:, 197 who are HIV positive and 107 who had undergone liver transplantation. Participants with TBI and SCI were at least 1 year post injury. Individuals with TBI reported significantly more symptoms than other panels. Symptom repot ts in the: TBI panels were independent of demographic variables (gender, education, income, ethnicity, age), as well as time since injury and depression Five of the 67 symptoms were found to be sensitive/specific to TBI in general; 25 symptoms were sensitive/specific to mild TBI (23 were cognitive, one physical and one behavioural/affective). Implications of these results in terms of current debates about the 'reality' of symptom reports in individuals with mild TBI are discussed, as well as implications for using symptom checklists for TBI screening.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Albert Einstein Coll Med, New York, NY USA	Gordon, WA (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.		Carneiro D'Albuquerque, Luiz Augusto/A-8812-2013	Carneiro D'Albuquerque, Luiz Augusto/0000-0001-7607-7168			Beck A.T., 1987, BECK DEPRESSION INVE; BINDER LM, 1997, J CLIN EXPT NEUROPSY, V5, P361; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GORDON W A, 1991, Archives of Physical Medicine and Rehabilitation, V72, P798; GORDON WA, 1998, J HEAD TRAUMA REHAB, V13, P17; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; *NEW YORK RES TRAI, 1994, QUAL LIF INT HLTH IN; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; VONZOMEREN AH, 1984, CLOSED HEAD INJURY P, P74; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; 1997, SPSS WINDOWS VERSION	21	84	84	2	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2000	14	1					21	33		10.1080/026990500120907			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	274CY	WOS:000084747200004	10670659				2021-06-18	
J	Munar, F; Ferrer, AM; de Nadal, M; Poca, MA; Pedraza, S; Sahuquillo, J; Garnacho, A				Munar, F; Ferrer, AM; de Nadal, M; Poca, MA; Pedraza, S; Sahuquillo, J; Garnacho, A			Cerebral hemodynamic effects of 7.2% hypertonic saline in patients with head injury and raised intracranial pressure	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	1998 Annual Meeting of the European-Society-of-Anesthesiology	MAY, 1998	BARCELONA, SPAIN	European Soc Anesthesiol		cerebral blood flow; cerebral perfusion pressure; head injury; hemodynamics; hypertonic saline; intracranial pressure; osmolality	LACTATED RINGERS SOLUTION; SEVERE HEMORRHAGIC-SHOCK; TRAUMATIC BRAIN INJURY; ORGAN BLOOD-FLOW; PORCINE MODEL; WATER-CONTENT; RESUSCITATION; FLUID; HYPERTENSION; MANNITOL	The aim of the present study was to investigate the acute effects of 7.2% hypertonic saline (HS) on intracranial pressure (ICP), cerebral and systemic hemodynamics, serum sodium, and osmolality in 14 patients with moderate and severe traumatic brain injury (Glasgow Coma Scale less than or equal to 13) and raised ICP (>15 mm Hg) within the first 72 h postinjury. After CO2 reactivity and autoregulation were tested, each patient received a 15-min infusion of 7.2% HS (1,232 mEq/L, volume 1.5 mL/kg). ICP, serial hemodynamics, cerebral blood flow (CBF) estimated from cerebral arteriovenous oxygen content difference (AVDO(2)), and laboratory variables, including serum osmolality, electrolytes, urea, and creatinine were collected before infusion (T-0) and at 5, 30, 60, and 120 min after (T-5, T-30, T-60, T-120). Urine output was measured 2 h before infusion and at T-120. While CO2 reactivity was preserved in all patients, autoregulation was preserved in only four. ICP decreased to about 30% of base line (p = 0.0001) during the whole study period. During the first hour after infusion, cerebral perfusion pressure (p less than or equal to 0.04) and cardiac index (CI; p less than or equal to 0.01) increased, while systemic vascular resistance index fell (p less than or equal to 0.05). Heart rate increased (p less than or equal to 0.04) during the first 30 min. Pulmonary artery occlusion pressure (PAOP) increased (p = 0.004) at T-5. There were no significant changes in mean arterial blood pressure (MABP), urine output, and estimated CBF. A significant positive correlation (r = 0.75; p = 0.02) between ICP and serum osmolality was found at T-5. The administration of 7.2% HS in patients with traumatic brain injury significantly reduces ICP without significant changes in relative global CBF (expressed as 1/AVDO(2)), increases CI and transiently increases PAOP, without changing MABP and urine output. The correlation between changes in osmolality and ICP supports the hypothesis that HSS may in part decrease ICP by means of an osmotic mechanism.	Univ Barcelona, Hosp Gen Valle Hebron, Dept Anesthesiol, E-08035 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Dept Neurosurg, E-08035 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Dept Neuroradiol, E-08035 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Neurotraumatol Res Unit, E-08035 Barcelona, Spain	Munar, F (corresponding author), Hosp Gen Valle Hebron, Unidad Neurotraumatol, Hosp Traumatol, Paseo Vall Hebron 119-129, E-08035 Barcelona, Spain.	davaz@i3d.es	Sahuquillo, Juan/B-3577-2008; Bauza, Francisca Munar/AAB-6682-2019; Poca, Maria A./B-8475-2008; de Nadal, Miriam/J-8127-2017; Garnacho, Angel/A-9309-2013; pedraza, salvador/AAC-1728-2019	Sahuquillo, Juan/0000-0003-0713-5875; Bauza, Francisca Munar/0000-0003-4579-3027; Poca, Maria A./0000-0002-3831-0536; de Nadal, Miriam/0000-0002-4559-2463; pedraza, salvador/0000-0003-2517-4413			BAKAY L, 1952, SURG GYNECOL OBSTET, V95, P67; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BINET L, 1949, CR SOC BIOL, V143, P1416; DEFELIPPE J, 1980, LANCET, V2, P1002; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GUNNAR W, 1988, SURGERY, V103, P398; Hartl R, 1997, ACT NEUR S, V70, P126; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; JENNETT B, 1975, LANCET, V1, P480; KIEN ND, 1991, ANESTH ANALG, V73, P597; KOCH T, 1994, ACTA ANAESTH SCAND, V38, P104, DOI 10.1111/j.1399-6576.1994.tb03849.x; KREIMEIER U, 1990, J SURG RES, V49, P493, DOI 10.1016/0022-4804(90)90174-Z; LASSEN NA, 1959, PHYSIOL REV, V39, P183; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; OLSEN KS, 1993, ANESTHESIOLOGY, V79, P666, DOI 10.1097/00000542-199310000-00006; OMAHONY JB, 1984, J TRAUMA, V24, P869, DOI 10.1097/00005373-198410000-00001; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; READ RC, 1960, CIRC RES, V8, P538, DOI 10.1161/01.RES.8.3.538; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; Sahuquillo J, 1998, ACT NEUR S, V71, P233; SAHUQUILLO J, 1994, NEUROCHEMICAL MONITO, P180; Schatzmann C, 1998, ACT NEUR S, V71, P31; SCHMIDT JF, 1990, J CARDIOVASC PHARM, V15, P983, DOI 10.1097/00005344-199006000-00017; SCHMOKER JD, 1992, J TRAUMA, V33, P476, DOI 10.1097/00005373-199209000-00024; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SILVA MRF, 1987, AM J PHYSIOL, V253, pH751; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; STANFORD GG, 1989, ARCH SURG-CHICAGO, V124, P733; STIFF JL, 1979, ANESTH ANALG, V58, P42; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Sztark F, 1997, ANN FR ANESTH, V16, P282, DOI 10.1016/S0750-7658(97)86412-X; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; TRAVERSO LW, 1987, J TRAUMA, V27, P32, DOI 10.1097/00005373-198701000-00006; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WEINSTABL C, 1991, ANESTHESIOLOGY, V75, pA201; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	55	84	87	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2000	17	1					41	51		10.1089/neu.2000.17.41			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	278WR	WOS:000085012400004	10674757				2021-06-18	
J	Neumann-Haefelin, T; Witte, OW				Neumann-Haefelin, T; Witte, OW			Periinfarct and remote excitability changes after transient middle cerebral artery occlusion	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						focal cerebral ischemia; middle cerebral artery occlusion; reperfusion; penumbra; diaschisis; electrophysiology	INDUCED CORTICAL INFARCTS; LONG-TERM POTENTIATION; TRAUMATIC BRAIN INJURY; ACUTE STROKE; NEURONAL HYPEREXCITABILITY; INTRAVENOUS THROMBOLYSIS; RAT-BRAIN; IN-VITRO; ISCHEMIA; RECOVERY	Transient middle cerebral artery (MCA) occlusion results in substantially smaller cortical infarcts than permanent MCA occlusion if reperfusion is initiated within the first few hours. Only little information is available on the long-term functional outcome of the cortical regions "salvaged" by early reperfusion. To address this issue we examined basic electrophysiologic parameters in vitro using standard extracellular recording techniques at 7 and 28 days after transient MCA occlusion (1- and 2-hour ischemia) in rats. Both neocortical areas ipsi- and contralateral to MCA occlusion were systematically mapped to delineate the extent of periinfarct and remote alterations. In the periinfarct region we found a significant reduction of field potential amplitudes up to 3 mm when measuring from the infarct border at 7 days and up to 7 mm at 28 days. Paired-pulse inhibition, an indicator of GABAergic transmission, was only moderately impaired in this region at 7 days and not significantly different from control at 28 days. Remote effects were observed both ipsi- and contralaterally. Ipsilaterally they were restricted to a region close to the midline (presumably motor cortex) and were most likely attributable to the degeneration of corticostriatal connections. The extent of the contra lateral excitability changes was clearly related to the size of the neocortical infarcts with large infarcts resulting in the widespread reduction of field potential amplitudes and an impairment of paired-pulse inhibition. The results show that there is a relatively large periinfarct region with decreased overall excitability after transient MCA occlusion which is Likely to have a profound effect on perilesional processes involved in functional recovery. Remote excitability changes may contribute to the functional deficit and are probably related to deafferentation.	Univ Dusseldorf, Neurol Klin, D-40225 Dusseldorf, Germany	Witte, OW (corresponding author), Univ Dusseldorf, Neurol Klin, Moorenstr 5, D-40225 Dusseldorf, Germany.		Witte, Otto/P-4127-2018; Neumann-Haefelin, Tobias/AAC-3915-2020	Witte, Otto/0000-0003-2101-4105; 			ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Becker KJ, 1998, CURR OPIN NEUROL, V11, P45, DOI 10.1097/00019052-199802000-00008; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bolay H, 1998, STROKE, V29, P1988, DOI 10.1161/01.STR.29.9.1988; BuchkremerRatzmann I, 1996, STROKE, V27, P1105, DOI 10.1161/01.STR.27.6.1105; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Chollet Francois, 1994, Current Opinion in Neurobiology, V4, P226, DOI 10.1016/0959-4388(94)90077-9; del Zoppo GJ, 1998, J NEUROL NEUROSUR PS, V65, P1, DOI 10.1136/jnnp.65.1.1; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DOMANN R, 1993, NEUROSCI LETT, V155, P69, DOI 10.1016/0304-3940(93)90675-B; Eysel UT, 1997, ADV NEUROL, V73, P195; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Garcia JH, 1996, STROKE, V27, P761, DOI 10.1161/01.STR.27.4.761; Garcia JH, 1997, NEUROLOGY, V49, pS27, DOI 10.1212/WNL.49.5_Suppl_4.S27; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hagemann G, 1998, ANN NEUROL, V44, P255, DOI 10.1002/ana.410440217; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; Koizumi J., 1986, NOSOTCHU, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LUHMANN HJ, 1995, EUR J NEUROSCI, V7, P180, DOI 10.1111/j.1460-9568.1995.tb01054.x; Luhmann HJ, 1996, PROG NEUROBIOL, V48, P131, DOI 10.1016/0301-0082(95)00042-9; Lyden PD, 1997, NEUROLOGY, V49, P14, DOI 10.1212/WNL.49.1.14; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MIES G, 1983, STROKE, V14, P22, DOI 10.1161/01.STR.14.1.22; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; Mittmann T, 1998, NEUROSCIENCE, V85, P15, DOI 10.1016/S0306-4522(97)00638-6; MITTMANN T, 1994, NEUROSCIENCE, V60, P891, DOI 10.1016/0306-4522(94)90270-4; MIYAZAKI S, 1993, NEUROL RES, V15, P249; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; NEDERGAARD M, 1988, ACTA NEUROL SCAND, V77, P81, DOI 10.1111/j.1600-0404.1988.tb05878.x; Neumann-Haefelin T, 1998, NEUROSCIENCE, V87, P871, DOI 10.1016/S0306-4522(98)00124-9; NEUMANNHAEFELIN T, 1995, NEUROSCI LETT, V193, P101, DOI 10.1016/0304-3940(95)11677-O; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; Qu M, 1998, NEUROSCIENCE, V85, P29, DOI 10.1016/S0306-4522(97)00656-8; Qu MS, 1998, BRAIN RES, V813, P374, DOI 10.1016/S0006-8993(98)01063-4; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reinecke S, 1999, NEUROSCI LETT, V261, P85, DOI 10.1016/S0304-3940(99)00014-2; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; URBAN L, 1989, J NEUROSCI, V9, P3966; VONMONAKOW C, 1914, LOKALISATION GROSSHI, P26; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Witte OW, 1997, ADV NEUROL, V73, P207; Witte OW, 1997, TRENDS NEUROSCI, V20, P348	50	84	84	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2000	20	1					45	52		10.1097/00004647-200001000-00008			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	281PJ	WOS:000085169600008	10616792	Bronze			2021-06-18	
J	Carbonnel, WS; Grady, MS				Carbonnel, WS; Grady, MS			Regional and temporal characterization of neuronal, glial, and axonal response after traumatic brain injury in the mouse	ACTA NEUROPATHOLOGICA			English	Article						axonal degeneration; gliosis; mice; neuronal death; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; FLUID-PERCUSSION INJURY; CORTICAL IMPACT INJURY; MEMORY DEFICITS; SPATIAL MEMORY; HEAD-INJURY; CELL-DEATH; DAMAGE; MODEL; RATS	Fluid percussion injury (FPI) is a commonly used and clinically relevant model of traumatic brain injury (TBI) in the rat. Recently, our lab successfully adapted FPI to mice. To account for differences in response to injury between mice and rats and provide a foundation for further use of FPI in gene-targeting studies, we sought to characterize the temporal and regional response to FPI in male C57BL/6 mice. Animals were killed at 10 min, 24 h, and 4, 7, 14, and 35 days (n = 3 for each group) after a very severe parasagittal FPI (> 4.0 atm) or sham injury (n = 3). Extensive numbers of damaged neurons were consistently found in the ipsilateral cortex, thalamus, and hippocampus by 10 min. This damage was nearly identical at 24 h, but quickly declined at subsequent time points. Activated microglia were found only in regions of neuronal injury at the earliest time points. Glial fibrillary acidic protein immunoreactivity reached significantly higher levels compared with controls at 7 days (P < 0.05) in the cortex, thalamus, and hippocampus and remained elevated for 35 days. White matter degeneration was present in all regions examined. This damage did not appear until at least day 4, but progressed up to day 35. The spatial pattern of damage we observed in mice after FPI is similar to that seen in rats. However, the temporal progression of neuronal injury in mice is comparatively abbreviated in the hippocampus and thalamus. In conclusion, these results suggest that FPI in mice may be a particularly useful tool for studying mechanisms of TBI in gene-targeting studies.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19096 USA	Grady, MS (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 5th Floor Silverstein Bldg,3400 Spruce St, Philadelphia, PA 19096 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030305, R01NS033107] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30305, NS33107] Funding Source: Medline		ADAMS JH, 1988, INTRO NEUROPATHOLOGY; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; FADEN AI, 1989, SCIENCE, V244, P789; FLOYD CL, 1997, NAT NEUR SOC ABS, V15, P34; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McNamara RK, 1996, MOL BRAIN RES, V40, P177, DOI 10.1016/0169-328X(96)00048-4; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; NADLER JV, 1983, METHOD ENZYMOL, V103, P393; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROSCI, V15, P8223; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	36	84	88	1	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	OCT	1999	98	4					396	406		10.1007/s004010051100			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	236NQ	WOS:000082605800013	10502046				2021-06-18	
J	Raby, CA; Morganti-Kossmann, MC; Kossmann, T; Stahel, PF; Watson, MD; Evans, LM; Mehta, PD; Spiegel, K; Kuo, YM; Roher, AE; Emmerling, MR				Raby, CA; Morganti-Kossmann, MC; Kossmann, T; Stahel, PF; Watson, MD; Evans, LM; Mehta, PD; Spiegel, K; Kuo, YM; Roher, AE; Emmerling, MR			Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's disease; beta-amyloid precursor protein; risk factors; brain; CSF; head trauma; injury	GROWTH-FACTOR PRODUCTION; ALZHEIMERS-DISEASE; HEAD-INJURY; PRECURSOR PROTEIN; BLOOD; INTERLEUKIN-6; ACCUMULATION; NEURONS; APP	The p-amyloid peptides, A beta 1-42 and A beta 1-40, were quantified in ventricular CSF taken daily for up to 3 weeks from six individuals with severe traumatic brain injury (TBI). There was considerable interindividual variability in the levels of A beta peptides, but in general A beta 1-42 levels equalled or exceeded those of A beta 1-40. Averaging the daily totals of our trauma cohort revealed that the levels of A beta 1-42 and A beta 1-40 rose after injury, peaking in the first week and then declining toward control levels over the next 2 weeks. A beta 1-42 levels were on average two to three times higher in the trauma cohort than in CSF from nontrauma samples. Compared with nontrauma samples, the A beta 1-40/A beta 1-42 ratio decreased about fivefold in the trauma patients, further indicative of increased A beta 1-42 levels. The ratio remained low at all time points studied. No change was measured in the levels of beta-amyloid precursor protein during the same interval, These results suggest that A beta 1-42 becomes elevated in the CSF after severe brain trauma.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Neurosci Therapeut, Ann Arbor, MI 48105 USA; New york Inst Basic Res, Staten Isl, NY USA; Sun Hlth Res Inst, Haldeman Lab Alzheimers Dis Res, Sun City, AZ USA; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland	Emmerling, MR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Neurosci Therapeut, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482; Morganti-Kossmann, Cristina/0000-0002-0807-2063			CARROLL RT, 1995, BIOCHEM BIOPH RES CO, V210, P345, DOI 10.1006/bbrc.1995.1667; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; JENNETT B, 1975, LANCET, V1, P480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martel CL, 1997, J NEUROCHEM, V69, P1995; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Mehta PD, 1998, NEUROSCI LETT, V241, P13, DOI 10.1016/S0304-3940(97)00966-X; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; STOCKER R, 1995, INTEGRATED APPROACH, P197; Tamaoka A, 1997, J NEUROL SCI, V148, P41, DOI 10.1016/S0022-510X(96)00314-0; TEASDALE G, 1974, LANCET, V2, P81; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085	33	84	84	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	1998	71	6					2505	2509					5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	139QH	WOS:000077040400030	9832149				2021-06-18	
J	Buxbaum, LJ; Schwartz, MF; Montgomery, MW				Buxbaum, LJ; Schwartz, MF; Montgomery, MW			Ideational apraxia and naturalistic action	COGNITIVE NEUROPSYCHOLOGY			English	Article							ALZHEIMERS-DISEASE; LEFT-HEMISPHERE; NEGLECT; DAMAGE	It is frequently claimed that ideational apraxia, an impairment of the performance of complex actions with objects, is a left-hemisphere syndrome. We assessed the consequences of left-hemisphere damage for naturalistic action performance in two studies. In Study 1, we compared the action errors of left-hemisphere stroke patients (LCVA) to previously reported patients with right-hemisphere stroke (RCVA) and closed head injury (CHI), and found that LCVA were no more vulnerable to errors of action than the other patient groups once differences in severity were controlled. In Study 2, we compared the naturalistic action performance of a patient with severe ideational apraxia and left-hemisphere damage to that of two RCVA patients of equal clinical severity. There was considerable quantitative and qualitative similarity in the errors of the three patients. From these-and other findings, we argue that deficits in left-hemisphere systems do not compromise complex action in a unique or transparent manner. We offer an alternative account based on nonspecific resource limitations that accommodates the data from all patient groups.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Temple Univ, Philadelphia, PA 19122 USA	Buxbaum, LJ (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.						ALLPORT A, 1993, ATTENTION PERFORMANC, V14; Baddeley A. D., 1994, Neuropsychology, V8, P485, DOI [10.1037/0894-4105.8.4.485., 10.1037/0894-4105.8.4.485]; Baddeley A. D., 1986, WORKING MEMORY; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; BROWN JW, 1988, AGNOSIA APRAXIA SELE; Buxbaum LJ, 1997, COGNITIVE NEUROPSYCH, V14, P219, DOI 10.1080/026432997381565; Buxbaum LJ, 1996, NEUROPSYCHOLOGIA, V34, P113, DOI 10.1016/0028-3932(95)00088-7; COSLETT HB, 1987, NEUROLOGY, V37, P957, DOI 10.1212/WNL.37.6.957; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DERENZI E, 1968, NEUROPSYCHOLOGIA, V6, P41, DOI 10.1016/0028-3932(68)90037-7; *FIM, 1993, FIM GUID US UN DAT S; HAALAND KY, 1984, BRAIN COGNITION, V3, P370, DOI 10.1016/0278-2626(84)90029-0; HARRINGTON DL, 1991, NEUROPSYCHOLOGIA, V29, P147, DOI 10.1016/0028-3932(91)90017-3; HECAEN H, 1981, HDB CLIN NEUROPSYCHO; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; Howard D., 1992, PYRAMIDS PALM TREES; Kertesz A., 1982, W APHASIA BATTERY; KIMURA D, 1982, PHILOS T ROY SOC B, V298, P135, DOI 10.1098/rstb.1982.0077; KIMURA D, 1974, BRAIN, V97, P337, DOI 10.1093/brain/97.1.337; Kleinbaum D.G., 1978, APPL REGRESSION ANAL; LEHMKUHL G, 1981, CORTEX, V17, P153, DOI 10.1016/S0010-9452(81)80017-2; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Liepmann H., 1920, ERGEBNISSE GESELLSCH, V1, P516; LUCCHELLI F, 1993, INT J GERIATR PSYCH, V8, P413, DOI 10.1002/gps.930080508; Luria A. R., 1966, HIGHER CORTICAL FUNC; MORLAAS J, 1928, CONTRIBUTION ETUDE A; Norman D, 1986, CONSCIOUSNESS SELF R, VIV; OCHIPA C, 1989, ANN NEUROL, V25, P190, DOI 10.1002/ana.410250214; Pocock SJ, 1983, CLIN TRIALS PRACTICA; POECK K, 1983, J NEUROL, V230, P1, DOI 10.1007/BF00313591; RAPCSAK SZ, 1989, NEUROLOGY, V39, P664, DOI 10.1212/WNL.39.5.664; Reason J., 1990, HUMAN ERROR; ROBERTSON I, 1992, INT J NEUROSCI, V62, P45; Robertson I.H., 1993, UNILATERAL NEGLECT C, P257; Schwartz M. F., 1997, APRAXIA NEUROPSYCHOL, P269; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; SCHWARTZ MF, 1998, NATURALISTIC ACTION; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Warrington E., 1991, VISUAL OBJECT SPACE; Wilson B., 1987, BEHAV INATTENTION TE	42	84	84	0	4	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.	SEP-DEC	1998	15	6-8					617	643		10.1080/026432998381032			27	Psychology; Psychology, Experimental	Psychology	156VL	WOS:000078022700006	22448839				2021-06-18	
J	Henker, RA; Brown, SD; Marion, DW				Henker, RA; Brown, SD; Marion, DW			Comparison of brain temperature with bladder and rectal temperatures in adults with severe head injury	NEUROSURGERY			English	Article						brain injury; hyperthermia; hypothermia	NEUROSURGICAL PATIENTS	OBJECTIVE: The purpose of this study was to compare brain temperature (Tbr) with conventional indicators of core body temperature (i.e., rectal temperature [Tre] and bladder temperature [Tbl]), in adults with severe head injury. METHODS: The relationships between Tbr and Tbl and between Tbr and Tre are described in terms of differences in temperature in eight patients with severe head injury. INSTRUMENTATION: Brain tissue temperature was measured every minute, with a thermocouple embedded 2 cm from the tip of a ventriculostomy catheter used to measure intracranial pressure. Tbl was measured with a thermistor embedded in a bladder catheter, and Tre was measured with a thermistor in a rectal probe. RESULTS: Tbr was usually greater than Tbl and Tre. The average difference between Tbr and Tbl for each patient ranged from 0.32 to 1.9 degrees C, with standard deviations of the difference ranging from 0.30 to 0.80 degrees C. The average difference between Tbr and Tre for each patient ranged from 0.1 to 2.0 degrees C, with, standard deviations of the difference ranging from 0.32 to 1.08 degrees C. In the majority of patients, the differences (Tbr - Tbl and Tbr - Tre) were greater at temperatures outside of the normal temperature range (Tbr less than or equal to 36 degrees C and >38 degrees C). CONCLUSION: Tbl and Tre often underrepresent Tbr after traumatic brain injury, particularly when the patient is hypo- or hyperthermic.	Univ Pittsburgh, Sch Nursing, Dept Acute Tertiary Care, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA	Henker, RA (corresponding author), Univ Pittsburgh, Sch Nursing, Dept Acute Tertiary Care, Pittsburgh, PA 15261 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [3 P50 NS30318-05S1] Funding Source: Medline		Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BRENGELMANN GL, 1989, TXB PHYSL, P1584; Brengelmann GL, 1987, MAN STRESSFUL ENV TH, V1, P5; Crowder CM, 1996, J NEUROSURG, V85, P98, DOI 10.3171/jns.1996.85.1.0098; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HAYWARD JN, 1968, AM J PHYSIOL, V215, P389; HAYWARD JN, 1969, BRAIN RES, V16, P417, DOI 10.1016/0006-8993(69)90236-4; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MELLERGARD P, 1991, NEUROSURGERY, V28, P709, DOI 10.1227/00006123-199105000-00012; SHIRAKI K, 1988, J APPL PHYSIOL, V65, P482; WHITBY JD, 1971, BRIT J ANAESTH, V43, P673, DOI 10.1093/bja/43.7.673	13	84	90	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1998	42	5					1071	1075		10.1097/00006123-199805000-00071			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZK454	WOS:000073322500062	9588552				2021-06-18	
J	Awasthi, D; Church, DF; Torbati, D; Carey, ME; Pryor, WA				Awasthi, D; Church, DF; Torbati, D; Carey, ME; Pryor, WA			Oxidative stress following traumatic brain injury in rats	SURGICAL NEUROLOGY			English	Article						ascorbic acid; ascorbyl radical; brain injury; ESR spectroscopy; free radicals; oxidative stress; spin trapping; trauma	CENTRAL NERVOUS-SYSTEM; HYDROXYL RADICAL GENERATION; LIPID-PEROXIDATION; ASCORBIC-ACID; METABOLIC-ACTIVATION; CARBON-TETRACHLORIDE; CEREBRAL-ISCHEMIA; ARACHIDONIC-ACID; SPINAL-CORD; OXYGEN	BACKGROUND Free radicals may be involved in the pathophysiology of traumatic brain injury (TBI) through oxidative damage of neurovascular structures. Endogenous antioxidants, such as ascorbate and alpha-tocopherol, may play a critical role in combating these oxidative reactions and their oxidized products can serve as an important index of oxidative stress. METHODS We used electron spin resonance (ESR) spectroscopy and in vivo spin trapping (reaction of an organic compound with free radical species) to detect the possible generation of free radicals after TBI. Injury was inflicted by a weight drop technique over the head (5.1 kg-cm). Rats were intravenously infused with either 1 mL, 0.1 M of the spin trap, alpha-phenyl-N-tert-butyl nitrone (PBN), or an equivalent volume of saline immediately before TBI or sham-injury. Animals were divided into four groups: (1) Group I: PBN-infused sham-injured, (2) Group II: PBN-infused injured, (3) Group III: saline-infused sham-injured, and (4) Group IV: saline-infused injured. Additional groups of saline-infused uninjured, salin-infused, and PBN-infused injured animals were used for histopathology. Sixty minutes after TBI or sham-injury, rats were again anesthetized and decapitated. The brains were removed within 1 minute, homogenized, and extracted for lipids. The extracts were analyzed by ESR spectroscopy. Brain ascorbic acid (AA) concentration was determined spectrophotometrically, using the ascorbate oxidase assay. RESULTS No PBN spin adduct signals (indicating trapped free radical species) were visible 60 minutes after TBI. All groups of rats showed an ascorbyl free radical signal. The ascorbyl signal intensity (AI) was, however, significantly higher in the injured rats, while the brain (AA) was significantly reduced. In addition, the ratio of AI/AA, which eliminates the effect of variable ascorbate concentrations in the brain, was also significantly higher in the injured animals. CONCLUSIONS We conclude that 60 minutes following TBI there was a significantly increased level of oxidative stress in the brain. This may reflect formation of free radical species with subsequent interaction with ascorbate (antioxidant) during the 60 minute period. The lack of PEN spin adduct signals 1 hour after TBI may indicate that free radical generation is time dependent and might be detectable earlier or later than the 60 minute period. (C) 1997 by Elsevier Science Inc.	UNIV MINNESOTA, MINNEAPOLIS, MN USA; LOUISIANA STATE UNIV, INST BIODYNAM, BATON ROUGE, LA 70803 USA	Awasthi, D (corresponding author), LOUISIANA STATE UNIV, MED CTR, DEPT NEUROSURG, 1542 TULANE AVE, NEW ORLEANS, LA 70112 USA.						ALBANO E, 1982, BIOCHEM J, V204, P593, DOI 10.1042/bj2040593; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; BENDICH A, 1986, ADV FREE RADICAL BIO, V2, P419, DOI 10.1016/S8755-9668(86)80021-7; BODANNES RS, 1979, FEBS LETT, V105, P195, DOI 10.1016/0014-5793(79)80609-2; BRAY TM, 1985, ENVIRON HEALTH PERSP, V64, P61, DOI 10.2307/3429999; BUETTNER GR, 1993, FREE RADICAL BIO MED, V14, P49, DOI 10.1016/0891-5849(93)90508-R; CADET JL, 1988, INT J NEUROSCI, V40, P13, DOI 10.3109/00207458808985722; CHIUEH CC, 1992, FREE RADICAL BIO MED, V13, P581, DOI 10.1016/0891-5849(92)90151-6; CLOUGHHELFMAN C, 1991, FREE RADICAL RES COM, V15, P177, DOI 10.3109/10715769109049138; COHEN G, 1984, NEUROTOXICOLOGY, V5, P77; CONNOR HD, 1986, J BIOL CHEM, V261, P4542; DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FLOYD RA, 1984, J BIOCHEM BIOPH METH, V10, P221, DOI 10.1016/0165-022X(84)90042-3; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1987, FASEB J, V1, P358; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; IKEDA Y, 1990, NEUROSURGERY, V27, P1; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V280, P33, DOI 10.1016/0003-9861(90)90514-Y; KINUTA Y, 1989, J NEUROSURG, V71, P421, DOI 10.3171/jns.1989.71.3.0421; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; LAL EK, 1986, ARCH BIOCHEM BIOPHYS, V244, P156; LIEBLER DC, 1986, J BIOL CHEM, V261, P2114; MACHLIN LJ, 1987, FASEB J, V1, P441; MCCAY PB, 1984, J BIOL CHEM, V259, P2135; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Michael C., 1988, Nuclear Physics B, Proceedings Supplements, V4, P209, DOI 10.1016/0920-5632(88)90104-1; ORTEGA BD, 1972, STEROIDS BRAIN EDEMA, P167; PAPPIUS HM, 1983, NEUROCHEM RES, V8, P63, DOI 10.1007/BF00965654; PIETRI S, 1994, FREE RADICAL BIO MED, V16, P523, DOI 10.1016/0891-5849(94)90131-7; PIETRI S, 1989, EUR J BIOCHEM, V186, P163, DOI 10.1111/j.1432-1033.1989.tb15191.x; Pryor W., 1976, FREE RADICALS BIOLOG, P1; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; REHNCRONA S, 1980, J NEUROCHEM, V34, P1630, DOI 10.1111/j.1471-4159.1980.tb11254.x; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Sen S., 1993, Society for Neuroscience Abstracts, V19, P636; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P253, DOI 10.1038/jcbfm.1985.32; SPECTOR R, 1977, NEW ENGL J MED, V296, P1393, DOI 10.1056/NEJM197706162962409; TAUBER AI, 1985, ADV FREE RADICAL BIO, V1, P265; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; Yavorsky M, 1934, J BIOL CHEM, V106, P525; ZINI I, 1992, NEUROSCI LETT, V138, P279, DOI 10.1016/0304-3940(92)90933-X	54	84	86	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	1997	47	6					575	581		10.1016/S0090-3019(96)00461-2			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XA470	WOS:A1997XA47000020	9167783				2021-06-18	
J	Goodman, JC; Valadka, AB; Gopinath, SP; Cormio, M; Robertson, CS				Goodman, JC; Valadka, AB; Gopinath, SP; Cormio, M; Robertson, CS			Lactate and excitatory amino acids measured by microdialysis are decreased by pentobarbital coma in head-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						intracranial pressure; barbiturate coma; pentobarbital; microdialysis; lactic acid; amino acids; glutamate; aspartate; excitotoxicity	IN-VIVO MICRODIALYSIS; CEREBRAL-ARTERY OCCLUSION; CONCUSSIVE BRAIN INJURY; BARBITURATE THERAPY; BLOOD-FLOW; NEURONAL ENVIRONMENT; ISCHEMIA; DAMAGE; TEMPERATURE; PATHOPHYSIOLOGY	Primary traumatic brain injury and secondary ischemic/hypoxic injury are being increasingly characterized at the neurochemical level. Neurochemical monitoring using microdialysis has shown that these forms of tissue damage share many common features. In particular, anaerobic glycolysis with increased lactate production and release of excitatory amino acids into the extracellular space are seen in both conditions. Clinical microdialysis studies have heretofore focused on methodological issues, establishment of basal analyte values, and clinico-neurochemical correlation. Here we report the neurochemical consequences of therapeutic intervention in head injury. Specifically, induction of thiopental coma to manage severe increased intracranial pressure in seven patients was associated with a 37% reduction of lactate, 59% reduction of glutamate, and 66% reduction in aspartate in the extracellular space of the brain.	BAYLOR COLL MED, DEPT NEUROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT NEUROSURG, HOUSTON, TX 77030 USA	Goodman, JC (corresponding author), BAYLOR COLL MED, DEPT PATHOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		Bellec C, 1991, Agressologie, V32, P396; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; BULLOCK R, 1992, NEUROCHEMICAL MONITO, V9, P443; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOI DW, 1993, CALCIUM GLUTAMATE IN; CROUGHWELL N, 1992, J THORAC CARDIOV SUR, V103, P549; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DURING MJ, 1991, MICRODIALYSIS NEUROS, V7, P450; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GINSBERG MD, 1990, PROTECTION BRAIN ISC, P37; GOODMAN JC, 1995, NEUROCHEMICAL MONITO, P78; HAMBERGER A, 1991, J INTERN MED, V230, P375, DOI 10.1111/j.1365-2796.1991.tb00460.x; HAMBERGER A, 1995, NEUROL RES, V17, P97, DOI 10.1080/01616412.1995.11740295; HAMBERGER A, 1991, MICRODIALYSIS NEUROS, V7, P450; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p695A; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; HILLERED L, 1991, RES EXP MED, V191, P219, DOI 10.1007/BF02576677; HILLERED L, 1995, NEUROCHEMICAL MONITO, P59; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; KATAYAMA Y, 1992, BRAIN RES, V584, P329, DOI 10.1016/0006-8993(92)90916-W; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, NEUROCHEMICAL MONITO, P72; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; KRAIG RP, 1988, J CEREB BLOOD FLOW M, V10, P1; LANDOLT H, 1994, ACTA NEUROCHIR, P475; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; McIntosh TK, 1996, LAB INVEST, V74, P315; MELDRUM BS, 1994, NEUROLOGY, V44, P14; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; MICHENFELDER JD, 1976, ARCH NEUROL-CHICAGO, V33, P345, DOI 10.1001/archneur.1976.00500050031006; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; PARSONS LH, 1994, CRIT REV NEUROBIOL, V8, P189; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; REA GL, 1995, NEUROSURGERY, V3, P410; Robertson C S, 1995, New Horiz, V3, P410; Robertson CS, 1990, J NEUROTRAUM, V7, P1, DOI 10.1089/neu.1990.7.1; Robinson TE, 1991, MICRODIALYSIS NEUROS; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHEYER RD, 1994, NEUROLOGY, V44, P1469, DOI 10.1212/WNL.44.8.1469; SCHEYER RD, 1994, EPILEPSY RES, V18, P227, DOI 10.1016/0920-1211(94)90043-4; SHAPIRO HM, 1985, BRIT J ANAESTH, V57, P82, DOI 10.1093/bja/57.1.82; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SMITH AL, 1972, ANESTHESIOLOGY, V36, P378, DOI 10.1097/00000542-197204000-00015; SMITH DS, 1980, ACTA PHYSIOL SCAND, P129; SMITH ML, 1986, J CEREBR BLOOD F MET, V6, P574, DOI 10.1038/jcbfm.1986.104; STEEN PA, 1980, ANESTHESIOLOGY, V53, P183; STEEN PA, 1978, J NEUROCHEM, V31, P1317, DOI 10.1111/j.1471-4159.1978.tb06257.x; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; UNGERSTEDT U, 1987, LIFE SCI, V41, P861, DOI 10.1016/0024-3205(87)90181-0; UNGERSTEDT U, 1991, MICRODIALYSIS NEUROS, V7, P450; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120	59	84	84	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1996	13	10					549	556		10.1089/neu.1996.13.549			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VQ834	WOS:A1996VQ83400001	8915906				2021-06-18	
J	BROWN, SJ; FANN, JR; GRANT, I				BROWN, SJ; FANN, JR; GRANT, I			POSTCONCUSSIONAL DISORDER - TIME TO ACKNOWLEDGE A COMMON SOURCE OF NEUROBEHAVIORAL MORBIDITY	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MINOR HEAD-INJURY; MILD; SYMPTOMS; SEQUELAE; POPULATION; TRAUMA; CONCUSSION; DEFICITS		UNIV CALIF SAN DIEGO,SCH MED,DEPT PSYCHIAT,SAN DIEGO,CA 92093; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; VET AFFAIRS MED CTR,PSYCHIAT SERV,SAN DIEGO,CA					NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH45294] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH045294] Funding Source: NIH RePORTER		Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BORNSTEIN RA, 1988, NEUROSURGERY, V23, P622, DOI 10.1227/00006123-198811000-00013; BROOKS N, 1984, NEUROBEHAVIORAL CONS; CARTLIDGE NEF, 1981, MAJOR PROBLEMS NEURO, V10, P95; DACEY RG, 1993, HEAD INJURY, P159; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN S, 1987, NEUROBEHAVIORAL RECO; Edna T H, 1987, J Oslo City Hosp, V37, P41; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; ENOMOTO T, 1986, CHILD NERV SYST, V2, P72; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; JACOME DE, 1984, CLIN ELECTROENCEPHAL, V15, P214, DOI 10.1177/155005948401500406; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jennett B, 1981, MANAGEMENT HEAD INJU; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay Thomas E., 1992, Archives of Physical Medicine and Rehabilitation, V73, P955; KELLY JP, 1991, JAMA-J AM MED ASSOC, V226, P2867; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1989, MILD HEAT INJURY; LIDVALL H F, 1974, Acta Neurologica Scandinavica Supplementum, V50, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P160; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Mahon D, 1989, J Neurosci Nurs, V21, P382; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MIDDELBOE T, 1992, J PERS DISORD, V6, P246, DOI 10.1521/pedi.1992.6.3.246; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; OMAYA AK, 1985, BIOMECHANICS TRAUMA, P245; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARKER N, 1977, MED J AUSTRALIA, V2, P318, DOI 10.5694/j.1326-5377.1977.tb99164.x; POVLISHOCK J, 1983, J NEUROPATHOL EXP NE, V22, P225; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; UOMOTO JM, IN PRESS ARCH PHYS M; VERDUYN W H, 1992, Brain Injury, V6, P245, DOI 10.3109/02699059209029666; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	66	84	84	0	1	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1994	6	1					15	22					8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	MV318	WOS:A1994MV31800003	8148632				2021-06-18	
J	BRUNO, VMG; GOLDBERG, MP; DUGAN, LL; GIFFARD, RG; CHOI, DW				BRUNO, VMG; GOLDBERG, MP; DUGAN, LL; GIFFARD, RG; CHOI, DW			NEUROPROTECTIVE EFFECT OF HYPOTHERMIA IN CORTICAL CULTURES EXPOSED TO OXYGEN-GLUCOSE DEPRIVATION OR EXCITATORY AMINO-ACIDS	JOURNAL OF NEUROCHEMISTRY			English	Article						GLUTAMATE; NMDA; KAINATE; S-ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID (AMPA); STROKE; HYPOXIA; ISCHEMIA; EXCITOTOXICITY	NMDA-RECEPTOR ACTIVATION; TRAUMATIC BRAIN INJURY; D-ASPARTATE RECEPTORS; NEURONAL INJURY; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA; CELL-CULTURE; SPINAL-CORD; NEUROTRANSMITTER RELEASE; MODERATE HYPOTHERMIA	We examined the effect of moderate hypothermia (30 degrees C) on neuronal injury in murine cortical cell cultures. Lowering the temperature during and after a period of oxygen-glucose deprivation reduced both the release of glutamate to the bathing medium and accompanying neuronal degeneration. Hypothermia immediately after brief exposure to high concentrations of NMDA or glutamate also reduced the resulting neuronal degeneration. This protective effect was not eliminated when MK-801 and 6-cyano-7-nitroquinoxaline-2,3-dione were added immediately after washout of the exogenously added excitotoxin, suggesting that it was mediated by actions additional to reduction of endogenous late glutamate release. Hypothermia applied only during exposure to NMDA or glutamate, whether brief or prolonged, did not reduce subsequent cytosolic calcium accumulation or neuronal degeneration, suggesting that the postsynaptic induction of NMDA receptor-mediated excitotoxicity is not sensitive to temperature reduction. However, hypothermia during prolonged S-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid or kainate exposure did reduce neuronal degeneration.	WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA; STANFORD UNIV, SCH MED, DEPT ANESTHESIA, STANFORD, CA 94305 USA; WASHINGTON UNIV, SCH MED, CTR STUDIES NERVOUS SYST INJURY, ST LOUIS, MO USA			bruno, Valeria/F-3146-2012	bruno, Valeria/0000-0003-4231-0739; Goldberg, Mark/0000-0003-3534-6979; Giffard, Rona/0000-0003-2173-4436	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01425, NS 01543, NS 26907] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001543, R01NS026907, K08NS001425] Funding Source: NIH RePORTER		ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; AMARA SG, 1992, NATURE, V360, P420, DOI 10.1038/360420d0; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BUCHAN A, 1992, NEUROL CLIN, V10, P49; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARDELL M, 1991, J NEUROCHEM, V57, P1814, DOI 10.1111/j.1471-4159.1991.tb06387.x; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLORY JC, 1976, BIOCHIM BIOPHYS ACTA, V443, P301, DOI 10.1016/0005-2736(76)90512-5; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; GINSBERG MD, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P499; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GOLDBERG MP, 1991, J CEREB BLOOD FLOW M, V11, pS422; GRODEN DL, 1991, CELL CALCIUM, V12, P279, DOI 10.1016/0143-4160(91)90002-V; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAIKALA H, 1986, BRAIN RES, V375, P313, DOI 10.1016/0006-8993(86)90751-1; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; IKONOMIDOU C, 1989, BRAIN RES, V487, P184, DOI 10.1016/0006-8993(89)90956-6; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; KOH JY, 1990, J NEUROSCI, V10, P693; KOONS D D, 1972, Cleveland Clinic Quarterly, V39, P109; KRANTIS A, 1983, ACTA NEUROPATHOL, V60, P61, DOI 10.1007/BF00685348; LANTOS J, 1986, ACTA PHYSIOL HUNG, V67, P141; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LUST WD, 1981, ANAL BIOCHEM, V110, P258, DOI 10.1016/0003-2697(81)90144-5; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; MCDONALD JW, 1991, NEUROSCI LETT, V126, P83, DOI 10.1016/0304-3940(91)90377-6; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; MONYER H, 1992, NEURON, V8, P967, DOI 10.1016/0896-6273(92)90211-U; NASLUND TC, 1992, ANN SURG, V215, P409, DOI 10.1097/00000658-199205000-00002; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NICHOLS RA, 1987, J NEUROCHEM, V48, P615, DOI 10.1111/j.1471-4159.1987.tb04137.x; NORWOOD WI, 1982, AM J PHYSIOL, V243, pC62; OKADA Y, 1988, NEUROSCI LETT, V84, P277, DOI 10.1016/0304-3940(88)90520-4; PONTIUS RG, 1954, SURG FORUM, V5, P224; ROKKAS CK, 1991, SURG FORUM, V50, P265; RONG H, 1993, BRAIN RES, V618, P346, DOI 10.1016/0006-8993(93)91289-5; ROSE K, 1993, METHODS TOXICOLOGY, V1, P46; ROSOMOFF HL, 1957, ARCH NEURO PSYCHIATR, V78, P454, DOI 10.1001/archneurpsyc.1957.02330410018002; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SHUAIB A, 1993, NEUROCHEM RES, V18, P663, DOI 10.1007/BF00966779; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SIMPSON RE, 1991, NEUROSCI LETT, V124, P83, DOI 10.1016/0304-3940(91)90827-G; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; WEISS J, 1986, BRAIN RES, V380, P186, DOI 10.1016/0006-8993(86)91447-2; WELLS JD, 1978, SURG NEUROL, V10, P200; ZEEVALK GD, 1993, J NEUROCHEM, V61, P1445, DOI 10.1111/j.1471-4159.1993.tb13639.x	65	84	89	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	1994	63	4					1398	1406					9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	PH202	WOS:A1994PH20200026	7523591				2021-06-18	
J	TRUEBLOOD, W				TRUEBLOOD, W			QUALITATIVE AND QUANTITATIVE CHARACTERISTICS OF MALINGERED AND OTHER INVALID WAIS-R AND CLINICAL MEMORY DATA	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Meeting of the National-Academy-of-Neuropsychology	NOV, 1992	PITTSBURGH, PA	NATL ACAD NEUROPSYCHOL			FORCED-CHOICE METHOD; CLOSED-HEAD-INJURY; PERFORMANCE; IMPAIRMENT; DEFICITS; TRAUMA; TESTS	To further the understanding of malingering and other compromises to data validity on standard neuropsychological tasks, the present study evaluated WAIS-R and clinical memory data produced by two groups from a mildly head-injured sample: Malingerers (MPs; n = 12) were identified via below chance forced-choice testing; ''QVs'' (n = 10) provided implausible neuropsychological performances but were not clearly malingering. A low level of performance characterized the data of the MPs and QVs: Full Scale IQ and Performance IQ were significantly lower for MPs and QVs than for matched controls, and obtained IQ for MPs and QVs averaged 18 points below estimated IQ. On the California Verbal Learning Test, total words recalled and recognition memory were significantly lower for MPs and QVs than for controls. In contrast, qualitative analyses, such as approximate answers, bizarre responses, ''scatter'' on the WAIS-R, inconsistency in performance across similar tasks, clustering, and intrusions on memory measures, generally yielded negative findings.								ANDERSON EW, 1956, P ROY SOC MED, V49, P513; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BASH IY, 1980, ANN NY ACAD SCI, V347, P86, DOI 10.1111/j.1749-6632.1980.tb21257.x; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BIGLER ED, 1989, J CLIN PSYCHOL, V45, P277, DOI 10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M; Binder L. M., 1992, HDB NEUROPSYCHOLOGIC, P353; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Bradley JV, 1968, DISTRIBUTION FREE ST; BRANDT J, 1988, CLIN ASSESSMENT MALI, P65; BROWN LM, 1990, EFFECTS SEVERITY CLO; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1991, HDB NEUROPSYCHOLOGY, V3, P3; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; Franzen M. D., 1989, RELIABILITY VALIDITY; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Hathaway S. R., 1989, MINNESOTA MULTIPHASI; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Hunt W., 1943, NAVAL MED B, V41, P1318; Jastak S, 1984, WIDE RANGE ACHIEVEME; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; Levin H. S., 1989, J CLIN EXP NEUROPSYC, V12, P129; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Macartney-Filgate M S, 1988, Arch Clin Neuropsychol, V3, P121, DOI 10.1016/0887-6177(88)90057-1; Martin R., 1991, NEUROPSYCHOLOGY, V5, P3, DOI DOI 10.1037/0894-4105.5.1.3; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Norusis M., 1990, SPSS PC; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Schear J.M., 1989, CLIN NEUROPSYCHOL, V3, P162; SCHRETLEN DJ, 1988, CLIN PSYCHOL REV, V8, P451, DOI 10.1016/0272-7358(88)90074-8; SQUIRE LR, 1986, NEUROPSYCHOLOGICAL A, P268; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wachspress M, 1953, PSYCHIAT QUART, V27, P463, DOI 10.1007/BF01562502; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; WIRSEN A, 1991, NEUROPSYCHOLOGY, V5, P151; ZAPPALA G, 1992, ARCH CLIN NEUROPSYCH, V7, P145, DOI 10.1016/0887-6177(92)90008-B	48	84	85	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1994	16	4					597	607		10.1080/01688639408402671			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	NW682	WOS:A1994NW68200012	7962361				2021-06-18	
J	ROSS, DT; MEANEY, DF; SABOL, MK; SMITH, DH; GENNARELLI, TA				ROSS, DT; MEANEY, DF; SABOL, MK; SMITH, DH; GENNARELLI, TA			DISTRIBUTION OF FOREBRAIN DIFFUSE AXONAL INJURY FOLLOWING INERTIAL CLOSED HEAD INJURY IN MINIATURE SWINE	EXPERIMENTAL NEUROLOGY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ABERRANT NEUROFILAMENT PHOSPHORYLATION; MONOCLONAL-ANTIBODIES DISTINGUISH; ALPHA-B-CRYSTALLIN; NEURONAL PERIKARYA; BALLOONED NEURONS; SCIATIC-NERVE; TRANSECTION; EPITOPES; PRIMATE	Diffuse axonal injury (DAI) is one of the most frequently encountered types of brain damage resulting from closed head injury. This study was designed to verify whether DAI could be produced in miniature swine by rapid acceleration and deceleration of the head in the coronal plane. Hanford miniature swine (16-19 kg) were anesthetized with 3% isoflurane and their heads accelerated rapidly once through a 60-105 degrees arc in the coronal plane, producing only transient post-traumatic unconsciousness without prolonged coma. All animals made a good recovery and were sacrificed between 6 h and 10 days after injury. The response of forebrain projection systems to this injury was studied using neurofilament immunohistochemistry with antisera to nonphosphorylated (SMI-32) and phosphorylated (SMI-31) epitopes common to heavy (200 kDa) and medium (160 kDa) neurofilament proteins. In 9 of 12 animals, lesions characterized by foci of SMI-32 positive axonal retraction balls were present at the white matter/gray matter junction at the crests of gyri in the dorsolateral regions of the frontal, parietal, and temporal cortices and along margins of the lateral ventricles. A high density of pyramidal neuron perikarya in layers III and V within cortical gyri associated with subcortical DAI were intensely positive for SMI-31 immunohistochemistry. These results validate the use of miniature swine in studies of axonal injury and demonstrate that axonal injury analogous to that seen in the mildest form of DAI (grade I) can be produced in these animals without producing prolonged coma. (C) 1994 Academic Press, Inc.	UNIV PENN, DEPT BIOENGN, PHILADELPHIA, PA 19104 USA; UNIV PENN, ANIM RESOURCES LAB, PHILADELPHIA, PA 19104 USA	ROSS, DT (corresponding author), UNIV PENN, CTR HEAD INJURY, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA.		smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803-21-22] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Brasko J., 1993, Society for Neuroscience Abstracts, V19, P1659; CAJAL SRY, 1928, DEGENERATION REGENER, V1; DRAGER UC, 1984, NATURE, V309, P624, DOI 10.1038/309624a0; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GENNARELLI TA, 1987, STAPP CAR CRASH C, P49; GOLD BG, 1991, BRAIN RES, V563, P151, DOI 10.1016/0006-8993(91)91528-9; GOLD BG, 1991, J NEUROPATH EXP NEUR, V50, P615, DOI 10.1097/00005072-199109000-00007; GOLDSTEIN ME, 1987, J NEUROSCI, V7, P1586; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GRCEVIC N, 1988, SCAND J REHABIL MED, P25; GRCEVIC N, 1982, RAD JUGOSL AKAD ZNAN, V402, P265; ITOH T, 1992, ACTA NEUROPATHOL, V83, P240, DOI 10.1007/BF00296785; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KATO S, 1992, ACTA NEUROPATHOL, V84, P443; KATO S, 1990, ACTA NEUROPATHOL, V80, P334, DOI 10.1007/BF00294653; KLOSEN P, 1990, BRAIN RES, V526, P259, DOI 10.1016/0006-8993(90)91230-E; KOLIATSOS VE, 1989, BRAIN RES, V482, P205, DOI 10.1016/0006-8993(89)91183-9; LEE VMY, 1987, J NEUROSCI, V7, P3474; LOWE J, 1992, NEUROPATH APPL NEURO, V18, P341, DOI 10.1111/j.1365-2990.1992.tb00796.x; MANSOUR H, 1989, J COMP NEUROL, V283, P481, DOI 10.1002/cne.902830404; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P78, DOI 10.1007/BF00427218; MEANEY DF, 1990, P IRCOBI C, V11, P215; MEANEY DF, 1993, P AM SOC MECH ENG, V169, P169; MIZUSAWA H, 1989, ACTA NEUROPATHOL, V79, P37, DOI 10.1007/BF00308955; MUNOZ DG, 1988, J NEUROPATH EXP NEUR, V47, P9, DOI 10.1097/00005072-198801000-00002; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PREISEGGER KH, 1992, LAB INVEST, V66, P193; ROSENFELD J, 1987, J NEUROPATH EXP NEUR, V46, P269, DOI 10.1097/00005072-198705000-00004; Ross D. T., 1992, Society for Neuroscience Abstracts, V18, P1088; ROSS D T, 1991, Society for Neuroscience Abstracts, V17, P1081; ROSS DT, 1994, UNPUB DISPARITY EXTE; ROSS DT, 1994, UNPUB INFLUENCE INDE; ROSS DT, 1994, UNPUB OPTIC NERVE ST; ROSS DT, 1994, UNPUB INFLUENCE IMPA; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SHANKAR SK, 1989, ANN NEUROL, V25, P146, DOI 10.1002/ana.410250207; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STRICH SJ, 1961, LANCET, V2, P443; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; THIBAULT LE, 1982, ADV BIOENG, V7, P85; WANG LN, 1991, CHINESE MED J-PEKING, V104, P1011; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	59	84	87	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	1994	126	2					291	299		10.1006/exnr.1994.1067			9	Neurosciences	Neurosciences & Neurology	NM716	WOS:A1994NM71600015	7925827				2021-06-18	
J	HAYES, RL; PECHURA, CM; KATAYAMA, Y; POVLISHOCK, JT; GIEBEL, ML; BECKER, DP				HAYES, RL; PECHURA, CM; KATAYAMA, Y; POVLISHOCK, JT; GIEBEL, ML; BECKER, DP			ACTIVATION OF PONTINE CHOLINERGIC SITES IMPLICATED IN UNCONSCIOUSNESS FOLLOWING CEREBRAL CONCUSSION IN THE CAT	SCIENCE			English	Article										HAYES, RL (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		AMATRUDA TT, 1975, BRAIN RES, V98, P501, DOI 10.1016/0006-8993(75)90369-8; BAXTER BL, 1969, EXP NEUROL, V23, P220, DOI 10.1016/0014-4886(69)90059-4; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; BRIGGS TL, 1971, BRAIN RES, V29, P17, DOI 10.1016/0006-8993(71)90414-8; CARLTON S, 1982, SOC NEUR ABSTR, V8, P167; CHATRIAN GE, 1963, ELECTROEN CLIN NEURO, V15, P272, DOI 10.1016/0013-4694(63)90096-8; DEWITT DS, 1981, J CEREB BLOOD FLO S1, V1, pS579; GEORGE R, 1964, INT J NEUROPHARMACOL, V3, P541; GOOCHEE C, 1980, ANN NEUROL, V7, P359, DOI 10.1002/ana.410070414; HOSHINO K, 1976, ARCH ITAL BIOL, V114, P244; KATAYAMA Y, UNPUB; KIMURA H, 1981, J COMP NEUROL, V200, P151, DOI 10.1002/cne.902000202; MITLER MM, 1974, BRAIN RES, V68, P335, DOI 10.1016/0006-8993(74)90402-8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PEON H, 1965, PROG BRAIN RES, V18, P96; PLUM F, 1980, DIAGNOSIS STUPOR COM, P11; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; PROUDFIT HK, 1980, BRAIN RES, V201, P459, DOI 10.1016/0006-8993(80)91053-7; RATCHESON RA, 1977, J NEUROCHEM, V28, P223, DOI 10.1111/j.1471-4159.1977.tb07730.x; ROSENBLUM W, 1980, NEUROSURGERY, V9, P613; RUGE D, 1948, J NEUROSURG, V11, P77; SHINOHARA M, 1979, SCIENCE, V203, P188, DOI 10.1126/science.758688; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SOKOLOFF L, 1978, CIBA F S, V56, P171, DOI DOI 10.1002/9780470720370.CH10; STOCKARD JJ, 1975, HDB CLIN NEUROLOGY, V23, P317; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TARLOV IM, 1957, SPINAL CORD COMPRESS; TOWER DB, 1948, J CLIN INVEST, V27, P558; VANDONGEN PAM, 1980, EXP NEUROL, V67, P52, DOI 10.1016/0014-4886(80)90161-2; VANDONGEN PAM, 1977, PHARM BIOCH BEHAV, V8, P527; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398	31	84	84	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science		1984	223	4633					301	303		10.1126/science.6701514			3	Multidisciplinary Sciences	Science & Technology - Other Topics	RY262	WOS:A1984RY26200040	6701514				2021-06-18	
J	BROOKS, DN				BROOKS, DN			WECHSLER MEMORY SCALE PERFORMANCE AND ITS RELATIONSHIP TO BRAIN-DAMAGE AFTER SEVERE CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV GLASGOW SO GEN HOSP,DEPT PSYCHOL MED,GLASGOW,SCOTLAND							BADDELEY AD, 1970, J VERB LEARN VERB BE, V9, P176, DOI 10.1016/S0022-5371(70)80048-2; BOND MR, 1975, OUTCOME SEVERE CNS D; BROOKS D N, 1974, Cortex, V10, P224; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; FAHY TJ, 1967, LANCET, V2, P476; HPAY H, 1971, HEAD INJURIES; KIRK RE, 1968, EXPT DESIGN PROCEDUR, P279; Klove H, 1972, Scand J Rehabil Med, V4, P55; LEVIN HS, IN PRESS; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Talland G.A., 1965, DERANGED MEMORY; TOOTH G, 1947, J NEUROL NEUROSUR PS, V10, P1, DOI 10.1136/jnnp.10.1.1; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WILLIAMS M, 1952, J NEUROL NEUROSUR PS, V15, P54, DOI 10.1136/jnnp.15.1.54	19	84	84	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1976	39	6					593	601		10.1136/jnnp.39.6.593			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	BV904	WOS:A1976BV90400013	950571	Green Published, Bronze			2021-06-18	
J	Alosco, ML; Kasimis, AB; Stamm, JM; Chua, AS; Baugh, CM; Daneshvar, DH; Robbins, CA; Mariani, M; Hayden, J; Conneely, S; Au, R; Torres, A; McClean, MD; McKee, AC; Cantu, RC; Mez, J; Nowinski, CJ; Martin, BM; Chaisson, CE; Tripodis, Y; Stern, RA				Alosco, M. L.; Kasimis, A. B.; Stamm, J. M.; Chua, A. S.; Baugh, C. M.; Daneshvar, D. H.; Robbins, C. A.; Mariani, M.; Hayden, J.; Conneely, S.; Au, R.; Torres, A.; McClean, M. D.; McKee, A. C.; Cantu, R. C.; Mez, J.; Nowinski, C. J.; Martin, B. M.; Chaisson, C. E.; Tripodis, Y.; Stern, R. A.			Age of first exposure to American football and long-term neuropsychiatric and cognitive outcomes	TRANSLATIONAL PSYCHIATRY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; HEAD IMPACT EXPOSURE; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL FOOTBALL; RETIRED NFL PLAYERS; LEAGUE PLAYERS; ADULT COGNITION; YOUTH FOOTBALL; BRAIN-INJURY; RECURRENT CONCUSSION	Previous research suggests that age of first exposure (AFE) to football before age 12 may have long-term clinical implications; however, this relationship has only been examined in small samples of former professional football players. We examined the association between AFE to football and behavior, mood and cognition in a large cohort of former amateur and professional football players. The sample included 214 former football players without other contact sport history. Participants completed the Brief Test of Adult Cognition by Telephone (BTACT), and self-reported measures of executive function and behavioral regulation (Behavior Rating Inventory of Executive Function-Adult Version Metacognition Index (MI), Behavioral Regulation Index (BRI)), depression (Center for Epidemiologic Studies Depression Scale (CES-D)) and apathy (Apathy Evaluation Scale (AES)). Outcomes were continuous and dichotomized as clinically impaired. AFE was dichotomized into <12 and >= 12, and examined continuously. Multivariate mixed-effect regressions controlling for age, education and duration of play showed AFE to football before age 12 corresponded with >2 x increased odds for clinically impaired scores on all measures but BTACT: (odds ratio (OR), 95% confidence interval (CI): BRI, 2.16,1.19-3.91; MI, 2.10,1.17-3.76; CES-D, 3.08,1.65-5.76; AES, 2.39,1.32-4.32). Younger AFE predicted increased odds for clinical impairment on the AES (OR, 95% CI: 0.86, 0.76-0.97) and CES-D (OR, 95% CI: 0.85,0.74-0.97). There was no interaction between AFE and highest level of play. Younger AFE to football, before age 12 in particular, was associated with increased odds for impairment in self-reported neuropsychiatric and executive function in 214 former American football players. Longitudinal studies will inform youth football policy and safety decisions.	[Alosco, M. L.; Kasimis, A. B.; Stamm, J. M.; Baugh, C. M.; Daneshvar, D. H.; Robbins, C. A.; Mariani, M.; Hayden, J.; Conneely, S.; McKee, A. C.; Cantu, R. C.; Mez, J.; Nowinski, C. J.; Martin, B. M.; Chaisson, C. E.; Tripodis, Y.; Stern, R. A.] Boston Univ, Alzheimers Dis & CTE Ctr, Sch Med, 72 East Concord St,B7800, Boston, MA 02118 USA; [Alosco, M. L.; Baugh, C. M.; Au, R.; McKee, A. C.; Cantu, R. C.; Mez, J.; Stern, R. A.] Boston Univ, Dept Neurol, Sch Med, Boston, MA USA; [Stamm, J. M.] Univ Wisconsin Madison, Dept Kinesiol, Madison, WI USA; [Chua, A. S.; Tripodis, Y.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Baugh, C. M.] Harvard Univ, Interfac Initiat Hlth Policy, Boston, MA USA; [Robbins, C. A.; Cantu, R. C.; Nowinski, C. J.] Concuss Legacy Fdn, Boston, MA USA; [Au, R.] Boston Univ, Sch Med, Boston, MA USA; [Au, R.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Au, R.; Stern, R. A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA USA; [Torres, A.] Boston Univ, Sch Med, Pediat Neurol, Boston, MA USA; [Torres, A.] Boston Med Ctr, Pediat Neurol, Boston, MA USA; [McClean, M. D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [McKee, A. C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Boston, MA USA; [McKee, A. C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA USA; [McKee, A. C.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Cantu, R. C.; Stern, R. A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA USA; [Cantu, R. C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Martin, B. M.; Chaisson, C. E.] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA	Stern, RA (corresponding author), Boston Univ, Alzheimers Dis & CTE Ctr, Sch Med, 72 East Concord St,B7800, Boston, MA 02118 USA.	bobstern@bu.edu	Baugh, Christine/AAG-2324-2020; Chua, Alicia/AAA-3628-2019; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Tripodis, Yorghos/0000-0003-2190-7608; Chua, Alicia/0000-0001-6908-8539; Daneshvar, Daniel/0000-0003-3691-9513	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 078337, R56 9500304025, U01 NS093334, U01NS086659-01, K23AG046377]; National Center for Advancing Translational Sciences, NIH, through BU-CTSI [1UL1TR001430]; Concussion Legacy Foundation; Pilot Grant from the Boston University Alzheimer's Disease Center [AG013846]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803, U01NS086659, R01NS078337, U01NS093334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG046377, P30AG013846] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (NIH; R01 NS 078337; R56 9500304025; U01 NS093334; U01NS086659-01; and K23AG046377). This publication was also supported by the National Center for Advancing Translational Sciences, NIH, through BU-CTSI Grant Number 1UL1TR001430, as well as the Concussion Legacy Foundation. Michael L Alosco and research reported in this publication are supported by a Pilot Grant from the Boston University Alzheimer's Disease Center (AG013846), and NIH/NINDS under grant number F32NS096803. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. There is no sponsor.	Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Adler CM, 2016, CLIN J SPORT MED; Alosco ML, 2017, BRAIN INJURY, V31, P1116, DOI 10.1080/02699052.2017.1294709; Alosco ML, 2017, J NEUROTRAUM, V34, P772, DOI 10.1089/neu.2016.4536; Alosco ML, 2016, J NEUROPSYCHIATRY CL, V29, P6; Amen DG, 2016, J ALZHEIMERS DIS, V53, P237, DOI 10.3233/JAD-160207; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Borna Merchant-, 2017, BRAIN IMAGING BEHAV; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Caviness VS, 1996, CEREB CORTEX, V6, P726, DOI 10.1093/cercor/6.5.726; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Ducharme S, 2014, CEREB CORTEX, V24, P2941, DOI 10.1093/cercor/bht151; Epstein HT, 1999, BRAIN DEV-JPN, V21, P535, DOI 10.1016/S0387-7604(99)00066-2; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; Gallagher M, 1996, CURR OPIN NEUROBIOL, V6, P221, DOI 10.1016/S0959-4388(96)80076-6; Gardner Raquel C, 2015, Neurol Clin Pract, V5, P285; Gardner RC, 2016, J NEUROTRAUM, V33, P157, DOI 10.1089/neu.2014.3805; Gavett BE, 2013, NEUROREHABILITATION, V32, P253, DOI 10.3233/NRE-130842; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gurnani AS, 2015, ARCH CLIN NEUROPSYCH, V30, P280, DOI 10.1093/arclin/acv005; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lewinsohn PM, 1997, PSYCHOL AGING, V12, P277, DOI 10.1037/0882-7974.12.2.277; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Rasia-Filho AA, 2000, J PSYCHIATR NEUROSCI, V25, P14; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roth R., 2005, BRIEF A BEHAV RATING; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain JF, 2017, J NEUROTRAUM, V34, P372, DOI 10.1089/neu.2016.4446; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Tun PA, 2006, AGE AGEING, V35, P629, DOI 10.1093/ageing/afl095; Uematsu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046970; Wilson RS, 2005, NEUROEPIDEMIOLOGY, V25, P19, DOI 10.1159/000085309; Wright MJ, 2016, J CLIN EXP NEUROPSYC, V38, P561, DOI 10.1080/13803395.2016.1139057; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	82	83	83	6	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	SEP 19	2017	7								e1236	10.1038/tp.2017.197			8	Psychiatry	Psychiatry	FH9KJ	WOS:000411529100004	28926003	DOAJ Gold, Green Published			2021-06-18	
J	Edlow, BL; Chatelle, C; Spencer, CA; Chu, CJ; Bodien, YG; O'Connor, KL; Hirschberg, RE; Hochberg, LR; Giacino, JT; Rosenthal, ES; Wu, O				Edlow, Brian L.; Chatelle, Camille; Spencer, Camille A.; Chu, Catherine J.; Bodien, Yelena G.; O'Connor, Kathryn L.; Hirschberg, Ronald E.; Hochberg, Leigh R.; Giacino, Joseph T.; Rosenthal, Eric S.; Wu, Ona			Early detection of consciousness in patients with acute severe traumatic brain injury	BRAIN			English	Article						traumatic brain injury; consciousness; functional MRI; EEG; intensive care unit	INTENSIVE-CARE-UNIT; VEGETATIVE STATE; CEREBRAL RESPONSE; FUNCTIONAL OUTCOMES; COVERT COGNITION; OWN NAME; DISORDERS; EEG; SCALE; RECOMMENDATIONS	Patients with acute severe traumatic brain injury may recover consciousness before self-expression. Without behavioural evidence of consciousness at the bedside, clinicians may render an inaccurate prognosis, increasing the likelihood of withholding life-sustaining therapies or denying rehabilitative services. Task-based functional magnetic resonance imaging and electroencephalography techniques have revealed covert consciousness in the chronic setting, but these techniques have not been tested in the intensive care unit. We prospectively enrolled 16 patients admitted to the intensive care unit for acute severe traumatic brain injury to test two hypotheses: (i) in patients who lack behavioural evidence of language expression and comprehension, functional magnetic resonance imaging and electroencephalography detect command-following during a motor imagery task (i. e. cognitive motor dissociation) and association cortex responses during language and music stimuli (i. e. higher-order cortex motor dissociation); and (ii) early responses to these paradigms are associated with better 6-month outcomes on the Glasgow Outcome Scale-Extended. Patients underwent functional magnetic resonance imaging on post-injury Day 9.2 +/- 5.0 and electroencephalography on Day 9.8 +/- 4.6. At the time of imaging, behavioural evaluation with the Coma Recovery Scale-Revised indicated coma (n = 2), vegetative state (n = 3), minimally conscious state without language (n = 3), minimally conscious state with language (n = 4) or post-traumatic confusional state (n = 4). Cognitive motor dissociation was identified in four patients, including three whose behavioural diagnosis suggested a vegetative state. Higher-order cortex motor dissociation was identified in two additional patients. Complete absence of responses to language, music and motor imagery was only observed in coma patients. In patients with behavioural evidence of language function, responses to language and music were more frequently observed than responses to motor imagery (62.5-80% versus 33.3-42.9%). Similarly, in 16 matched healthy subjects, responses to language and music were more frequently observed than responses to motor imagery (87.5-100% versus 68.8-75.0%). Except for one patient who died in the intensive care unit, all patients with cognitive motor dissociation and higher-order cortex motor dissociation recovered beyond a confusional state by 6 months. However, 6-month outcomes were not associated with early functional magnetic resonance imaging and electroencephalography responses for the entire cohort. These observations suggest that functional magnetic resonance imaging and electroencephalography can detect command-following and higher-order cortical function in patients with acute severe traumatic brain injury. Early detection of covert consciousness and cortical responses in the intensive care unit could alter time-sensitive decisions about withholding life-sustaining therapies.	[Edlow, Brian L.; Chatelle, Camille; Bodien, Yelena G.; Hochberg, Leigh R.] Massachusetts Gen Hosp, Ctr Neurotechnol & Neurorecovery, 175 Cambridge St,Suite 300, Boston, MA 02114 USA; [Edlow, Brian L.; Chatelle, Camille; Spencer, Camille A.; Chu, Catherine J.; Bodien, Yelena G.; O'Connor, Kathryn L.; Hochberg, Leigh R.; Rosenthal, Eric S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, 175 Cambridge St, Boston, MA 02114 USA; [Edlow, Brian L.; Wu, Ona] Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, 149 13th St, Charlestown, MA 02129 USA; [Chatelle, Camille] Univ Liege, GIGA Consciousness, Coma Sci Grp, Liege, Belgium; [Bodien, Yelena G.; Hirschberg, Ronald E.; Giacino, Joseph T.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 300 First Ave, Charlestown, MA 02129 USA; [Hirschberg, Ronald E.; Giacino, Joseph T.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Phys Med & Rehabil, 55 Fruit St, Boston, MA 02114 USA; [Hochberg, Leigh R.] Brown Univ, Dept Engn, 184 Hope St, Providence, RI 02912 USA	Edlow, BL (corresponding author), Massachusetts Gen Hosp, Ctr Neurotechnol & Neurorecovery, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.	bedlow@mgh.harvard.edu	Hochberg, Leigh/R-6872-2019; Giacino, Joseph/AAF-1952-2021; Rosenthal, Eric Scott/A-2085-2017	Hochberg, Leigh/0000-0003-0261-2273; Giacino, Joseph/0000-0002-7916-9698; Rosenthal, Eric Scott/0000-0003-3900-356X; Wu, Ona/0000-0002-5509-9461; Bodien, Yelena/0000-0003-4858-2903; Chatelle, Camille/0000-0002-7526-2107; Van Pelt, Kathryn/0000-0002-5494-2357	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS094538]; Center for Integration of Medicine & Innovative Technology (Boston, MA, USA); American Academy of Neurology/American Brain Foundation; James S. McDonnell Foundation; Massachusetts General Hospital Department of Neurology; Division of Neurocritical Care and Emergency Neurology; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS092923, K23NS094538] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (K23NS094538), the Center for Integration of Medicine & Innovative Technology (Boston, MA, USA), the American Academy of Neurology/American Brain Foundation, the James S. McDonnell Foundation, and the Massachusetts General Hospital Department of Neurology and Division of Neurocritical Care and Emergency Neurology.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Brattico E, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00308; Bruno M.-A., 2012, COMA DISORD CONSCIOU, P11, DOI [10.1007/978-1-4471-2440-5_2, DOI 10.1007/978-1-4471-2440-5_2]; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Cruse D, 2012, NEUROLOGY, V78, P816, DOI 10.1212/WNL.0b013e318249f764; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Danielsen A, 2014, NEUROSCIENCE, V275, P469, DOI 10.1016/j.neuroscience.2014.06.029; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Di HB, 2008, CLIN MED, V8, P502, DOI 10.7861/clinmedicine.8-5-502; Edlow BL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0375-y; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Faugeras F, 2011, NEUROLOGY, V77, P264, DOI 10.1212/WNL.0b013e3182217ee8; Fernandez-Espejo D, 2008, BRAIN INJURY, V22, P882, DOI 10.1080/02699050802403573; Fins JJ., 2015, RIGHTS COME MIND BRA; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fischer DB, 2015, NEUROLOGY, V85, P543, DOI 10.1212/WNL.0000000000001748; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2006, BRAIN INJURY, V20, P1321, DOI 10.1080/02699050601081802; Good P.I., 2004, PERMUTATION PARAMETR; Gosseries O, 2014, BRAIN INJURY, V28, P1141, DOI 10.3109/02699052.2014.920522; Hauger SL, 2017, J HEAD TRAUMA REHAB, V32, P185, DOI 10.1097/HTR.0000000000000267; Hauger SL, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/145913; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; King JR, 2013, NEUROIMAGE, V83, P726, DOI 10.1016/j.neuroimage.2013.07.013; Kovacs S, 2006, INVEST RADIOL, V41, P87, DOI 10.1097/01.rli.0000189637.42344.09; Lepage KQ, 2014, J NEUROSCI METH, V235, P101, DOI 10.1016/j.jneumeth.2014.05.008; Liu XL, 2012, HUM BRAIN MAPP, V33, P2487, DOI 10.1002/hbm.21385; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Lule D, 2013, CLIN NEUROPHYSIOL, V124, P101, DOI 10.1016/j.clinph.2012.04.030; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Majerus S, 2009, PROG BRAIN RES, V177, P49, DOI 10.1016/S0079-6123(09)17705-1; Makris N, 2006, SCHIZOPHR RES, V83, P155, DOI 10.1016/j.schres.2005.11.020; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Noirhomme Q, 2014, NEUROIMAGE-CLIN, V4, P687, DOI 10.1016/j.nicl.2014.04.004; O'Kelly J, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00884; Ojala M, 2010, J MACH LEARN RES, V11, P1833; Okumura Y, 2014, BRAIN INJURY, V28, P944, DOI 10.3109/02699052.2014.888477; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Piarulli A, 2016, J NEUROL, V263, P1746, DOI 10.1007/s00415-016-8196-y; Portas CM, 2000, NEURON, V28, P991, DOI 10.1016/S0896-6273(00)00169-0; Posner J., 2007, PLUM POSNERS DIAGNOS, V4; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Ropper AH, 2010, NEW ENGL J MED, V362, P648, DOI 10.1056/NEJMe0909667; Schiff N, 1999, J COGNITIVE NEUROSCI, V11, P650, DOI 10.1162/089892999563715; Schiff ND, 2015, JAMA NEUROL, V72, P1413, DOI 10.1001/jamaneurol.2015.2899; Schnakers C, 2015, NEUROLOGY CONSCIOUSN; Schnakers C, 2015, NEUROREHAB NEURAL RE, V29, P308, DOI 10.1177/1545968314547767; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; Wang FY, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0330-7; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1855, DOI 10.1016/j.apmr.2012.10.041; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woolrich MW, 2004, NEUROIMAGE, V21, P1732, DOI 10.1016/j.neuroimage.2003.12.023; Wu J, 2013, NEUROSCIENCE, V250, P49, DOI 10.1016/j.neuroscience.2013.06.021	80	83	86	1	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP	2017	140		9				2399	2414		10.1093/brain/awx176			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FF0PB	WOS:000408602500021	29050383	Green Published, Bronze			2021-06-18	
J	Bogoslovsky, T; Wilson, D; Chen, Y; Hanlon, D; Gill, J; Jeromin, A; Song, LN; Moore, C; Gong, YH; Kenney, K; Diaz-Arrastia, R				Bogoslovsky, Tanya; Wilson, David; Chen, Yao; Hanlon, David; Gill, Jessica; Jeromin, Andreas; Song, Linan; Moore, Carol; Gong, Yunhua; Kenney, Kimbra; Diaz-Arrastia, Ramon			Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid beta up to 90 Days after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						diagnostic and prognostic biomarkers; GFAP; highly sensitive immunoassays; TBI; total tau	C-TERMINAL HYDROLASE-L1; GLASGOW COMA SCALE; CEREBROSPINAL-FLUID; ELEVATED LEVELS; CLEAVED-TAU; SERUM; BIOMARKERS; CSF; MILD; PREDICTORS	Glial fibrillary acidic protein (GFAP), microtubule-associated protein tau, and amyloid beta peptide (A beta 42) have been proposed as diagnostic and prognostic biomarkers in traumatic brain injury (TBI). Single molecule array (Simoa) is a novel technology that employs highly sensitive immunoassays for accurate measurements of candidate biomarkers found at low concentration in biological fluids. Our objective was to trace the trajectory of tau, GFAP, and A beta 42 levels in plasma from the acute through subacute stages after TBI, compared with controls. Samples from 34 TBI subjects enrolled in the Citicoline Brain Injury Treatment Trial (COBRIT) were studied. Injury severity was assessed by Glasgow Coma Scale (GCS) and admission CT. Glasgow Outcome Scale Extended (GOSE) was assessed 6 months after injury. Plasma was collected within 24 h (Day 0), and 30 and 90 days after the TBI. Plasma collected from 69 healthy volunteers was used for comparison. At every time point, increases were noted in plasma GFAP (p < 0.0001 for all comparisons), tau (p < 0.0001, p < 0.0001, and p = 0.0044, at Days 0, 30, and 90, respectively), and A beta 42 (p < 0.001, p < 0.0001, and p = 0.0203, respectively) in TBI cases compared with controls. The levels were maximal at Day 0 for GFAP and tau and at Day 30 for A beta 42. Area under curve (AUC) analyses for Day 0 GFAP and tau were excellent for discrimination of complicated mild TBI (cmTBI) from controls (0.936 and 0.901, correspondingly). Discriminant component analysis (DCA) for all three biomarkers at Days 0 and 30 differentiated controls from cmTBI (91.1% and 89.7% correctly classified, at each time point). Duration of post-traumatic amnesia (PTA) correlated weakly with tau levels at 30 days (Spearman's r = 0.40; 95% CI 0.0003-0.60, p = 0.044). The Marshall CT Grade on admission correlated weakly with Day 30 tau levels (Spearman's r = 0.41; 95% CI 0.04-0.68, p = 0.027). Day 30A beta 42 correlated with GOSE (standardized beta-0.486, p = 0.042). GFAP, tau and A beta 42 were increased up to 90 days after TBI compared with controls. Total tau levels correlated with clinical and radiological variables of TBI severity. Plasma A beta 42 correlated with clinical outcome. Combination of all three biomarkers at Days 0 and 30 can be used to differentiate controls from cmTBI populations, and may be useful as biomarkers of TBI in both acute and subacute phases.	[Bogoslovsky, Tanya; Gill, Jessica; Moore, Carol; Gong, Yunhua; Kenney, Kimbra; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 12725 Twinbrook Pkwy, Rockville, MD 20852 USA; [Wilson, David; Chen, Yao; Hanlon, David; Jeromin, Andreas; Song, Linan] Quanterix Inc, Lexington, MA USA; [Gill, Jessica] NINR, NIH, Bethesda, MD 20892 USA	Bogoslovsky, T (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 12725 Twinbrook Pkwy, Rockville, MD 20852 USA.	tanya.bogoslovsky.ctr@usuhs.edu	Gill, Gill M/Q-2020-2017	Diaz-Arrastia, Ramon/0000-0001-6051-3594	Center for Neuroscience and Regenerative Medicine (CNRM), GE/NFL TBI Award [U01 HD 42652]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000033] Funding Source: NIH RePORTER	This work was supported by the Center for Neuroscience and Regenerative Medicine (CNRM), GE/NFL TBI Award, U01 HD 42652.	Anderson JM, 2008, BRAIN, V131, P1736, DOI 10.1093/brain/awn119; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Irizarry Michael C, 2004, NeuroRx, V1, P226; Izumi K, 2014, J CANCER RES CLIN, V140, P1413, DOI 10.1007/s00432-014-1681-8; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Lawrence DW, 2015, BRAIN INJURY, V29, P1018, DOI 10.3109/02699052.2015.1005131; Lesko LJ, 2001, ANNU REV PHARMACOL, V41, P347, DOI 10.1146/annurev.pharmtox.41.1.347; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mehta PD, 2001, NEUROSCI LETT, V304, P102, DOI 10.1016/S0304-3940(01)01754-2; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Quiroz YT, 2015, JAMA NEUROL, V72, P912, DOI 10.1001/jamaneurol.2015.1099; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang TJ, 2006, NEW ENGL J MED, V355, P2631, DOI 10.1056/NEJMoa055373; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Wilson D. H., 2015, J LAB AUTOM; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263	45	83	84	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					66	73		10.1089/neu.2015.4333			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100009	27312416	Green Published			2021-06-18	
J	Ellis, MJ; Cordingley, D; Vis, S; Reimer, K; Leiter, J; Russell, K				Ellis, Michael J.; Cordingley, Dean; Vis, Sara; Reimer, Karen; Leiter, Jeff; Russell, Kelly			Vestibulo-ocular dysfunction in pediatric sports-related concussion	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						vestibulo-ocular dysfunction; sports-related concussion; postconcussion syndrome; pediatric; vestibular therapy; trauma	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; VESTIBULAR REHABILITATION; POSTCONCUSSION SYNDROME; SYMPTOM SEVERITY; NCAA CONCUSSION; MANAGEMENT; RECOVERY; SYSTEM; CONVERGENCE	OBJECT The objective of this study was 2-fold: 1) to examine the prevalence of vestibulo-ocular dysfunction (VOD) among children-and adolescents with acute sports-related concussion (SRC) and postconcussion syndrome (PCS) who were referred to a multidisciplinary pediatric concussion program; and 2) to determine if VOD is associated with the development of PCS in this cohort. METHODS The authors conducted a retrospective review of all patients with acute SRC (presenting 30 days or less postinjury) and PCS (3 or more symptoms for at least 1 month) referred to a multidisciplinary pediatric concussion program between September 2013 and July 2014. Initial assessment included clinical history, physical examination, and Post-Concussion Symptom Scale assessment. Patients were also assessed for VOD, which was defined as more than one subjective vestibular and oculomotor complaint (dizziness, blurred vision, and so on) and more than one objective physical examination finding (abnormal smooth pursuits, saccades, vestibulo-ocular reflex, and so on). This study was approved by the local institutional ethics review board. RESULTS A total of 101 patients (mean age 14.2 years, SD 2.3 years; 63 male and 38 female patients) participated, including 77 (76.2%) with acute SRC and 24(23.8%) with PCS. Twenty-two of the 77 patients (28.6%) with acute SRC and 15 of the 24 (62.5%) with PCS met the clinical criteria for VOD. The median duration of symptoms was 40 days (interquartile range [IQR] 28.5-54 days) for patients with acute SRC who had VOD compared with 21 days (IQR 13-32 days) for those without VOD (p = 0.0001). There was a statistically significant increase in the adjusted odds of developing PCS among patients with acute SRC who had VOD compared with those without VOD (adjusted OR 4.10; 95% CI 1.04-16.16). CONCLUSIONS Evidence of VOD was detected in a significant proportion of children and adolescents with acute SRC and PCS who were referred to a multidisciplinary pediatric concussion program. This clinical feature was a significant risk factor for the subsequent development of PCS in this pediatric acute SRC cohort.	[Ellis, Michael J.; Leiter, Jeff] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.; Russell, Kelly] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.] Univ Manitoba, Neurosurg Sect, Winnipeg, MB, Canada; [Ellis, Michael J.; Cordingley, Dean; Vis, Sara; Reimer, Karen; Leiter, Jeff] Pan Am Clin, Winnipeg, MB R3M 3E4, Canada; [Ellis, Michael J.; Russell, Kelly] Canada North Concuss Network, Childrens Hosp Res Inst Manitoba, Winnipeg, MB, Canada	Ellis, MJ (corresponding author), Pan Am Clin, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada.	mellis3@panamclinic.com		Russell, Kelly/0000-0002-9159-9201	Pan Am Clinic Foundation	We thank the Pan Am Clinic Foundation for their financial support of this study.	Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Brandt T, 2005, CLIN NEUROPHYSIOL, V116, P406, DOI 10.1016/j.clinph.2004.08.009; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Eggers SDZ, 2003, SEMIN NEUROL, V23, P47; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Khan S, 2013, NEUROREHABILITATION, V32, P437, DOI 10.3233/NRE-130866; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Leddy JJ, 2014, CLIN J SPORT MED; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAbee GN, 2014, J CHILD NEUROL; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Reneker JC, 2014, J SCI MED SPORT; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Slattery EL, 2011, NEUROREHABILITATION, V29, P143, DOI 10.3233/NRE-2011-0688; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	48	83	84	0	41	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	SEP	2015	16	3					248	255		10.3171/2015.1.PEDS14524			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CP6VY	WOS:000360027500002	26031619	Bronze			2021-06-18	
J	Guiza, F; Depreitere, B; Piper, I; Citerio, G; Chambers, I; Jones, PA; Lo, TYM; Enblad, P; Nillson, P; Feyen, B; Jorens, P; Maas, A; Schuhmann, MU; Donald, R; Moss, L; Van den Berghe, G; Meyfroidt, G				Guiza, Fabian; Depreitere, Bart; Piper, Ian; Citerio, Giuseppe; Chambers, Iain; Jones, Patricia A.; Lo, Tsz-Yan Milly; Enblad, Per; Nillson, Pelle; Feyen, Bart; Jorens, Philippe; Maas, Andrew; Schuhmann, Martin U.; Donald, Rob; Moss, Laura; Van den Berghe, Greet; Meyfroidt, Geert			Visualizing the pressure and time burden of intracranial hypertension in adult and paediatric traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Traumatic brain injury; Adults; Children; Intracranial pressure; Cerebral perfusion pressure; Cerebrovascular autoregulation	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; CENTERS YEAR 2001; AGGRESSIVE TREATMENT; EUROPEAN BRAIN; INTENSIVE-CARE; MANAGEMENT; AUTOREGULATION; THRESHOLDS; REACTIVITY	To assess the impact of the duration and intensity of episodes of increased intracranial pressure on 6-month neurological outcome in adult and paediatric traumatic brain injury. Analysis of prospectively collected minute-by-minute intracranial pressure and mean arterial blood pressure data of 261 adult and 99 paediatric traumatic brain injury patients from multiple European centres. The relationship of episodes of elevated intracranial pressure (defined as a pressure above a certain threshold during a certain time) with 6-month Glasgow Outcome Scale was visualized in a colour-coded plot. The colour-coded plot illustrates the intuitive concept that episodes of higher intracranial pressure can only be tolerated for shorter durations: the curve that delineates the duration and intensity of those intracranial pressure episodes associated with worse outcome is an approximately exponential decay curve. In children, the curve resembles that of adults, but the delineation between episodes associated with worse outcome occurs at lower intracranial pressure thresholds. Intracranial pressures above 20 mmHg lasting longer than 37 min in adults, and longer than 8 min in children, are associated with worse outcomes. In a multivariate model, together with known baseline risk factors for outcome in severe traumatic brain injury, the cumulative intracranial pressure-time burden is independently associated with mortality. When cerebrovascular autoregulation, assessed with the low-frequency autoregulation index, is impaired, the ability to tolerate elevated intracranial pressures is reduced. When the cerebral perfusion pressure is below 50 mmHg, all intracranial pressure insults, regardless of duration, are associated with worse outcome. The intracranial pressure-time burden associated with worse outcome is visualised in a colour-coded plot. In children, secondary injury occurs at lower intracranial pressure thresholds as compared to adults. Impaired cerebrovascular autoregulation reduces the ability to tolerate intracranial pressure insults. Thus, 50 mmHg might be the lower acceptable threshold for cerebral perfusion pressure.	[Guiza, Fabian; Van den Berghe, Greet; Meyfroidt, Geert] Univ Hosp Leuven, Dept Intens Care Med, B-3000 Leuven, Belgium; [Depreitere, Bart] Univ Hosp Leuven, Dept Neurosurg, B-3000 Leuven, Belgium; [Piper, Ian] So Gen Hosp, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland; [Citerio, Giuseppe] San Gerardo Hosp, Monza, Italy; [Chambers, Iain] James Cook Univ Hosp, Med Phys, Middlesbrough, England; [Jones, Patricia A.] Royal Hosp Sick Children, Dept Paediat Neurol, Edinburgh EH9 1LF, Midlothian, Scotland; [Lo, Tsz-Yan Milly] Royal Hosp Sick Children, Dept Paediat Intens Care, Edinburgh EH9 1LF, Midlothian, Scotland; [Enblad, Per; Nillson, Pelle] Dept Neurosurg, Neurosurg, Uppsala, Sweden; [Feyen, Bart; Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Jorens, Philippe] Univ Antwerp Hosp, Dept Intens Care Med, Edegem, Belgium; [Schuhmann, Martin U.] Univ Klinikum Tubingen, Klin Neurochirurg, Tubingen, Germany; [Donald, Rob] Univ Glasgow, Sch Math & Stat, Glasgow, Lanark, Scotland; [Moss, Laura] NHS Greater Glasgow & Clyde, Dept Clin Phys & Bioengn, Glasgow, Lanark, Scotland	Meyfroidt, G (corresponding author), Univ Hosp Leuven, Dept Intens Care Med, Herestr 49, B-3000 Leuven, Belgium.	geert.meyfroidt@uzleuven.be	Citerio, Giuseppe/B-1839-2015; Depreitere, Bart/AAA-9846-2020; Van den Berghe, Greet/J-6788-2018	Citerio, Giuseppe/0000-0002-5374-3161; Depreitere, Bart/0000-0002-7458-0648; Van den Berghe, Greet/0000-0002-5320-1362; Moss, Laura/0000-0003-4968-0900; Guiza, Fabian/0000-0001-7026-0957	Foundation for Scientific Research Flanders (FWO)FWO [G. 0904.11]; FWOFWO [1846113N]; Methusalem program by Flemish Government [METH/08/07]; European Framework Programme [FP5-QLRI-2000-00454, QLGT-2002-00160, FP7-IST-2007-217049]; Flemish Government Agency for Innovation by Science and Technology (IWT)-Applied Biomedical Research (TBM) program	We wish to acknowledge the non-co-author members of the BrainIT steering group: Barbara Gregson, Tim Howells, Karl Kiening, Julia Mattern, Arminas Ragauskas and Juan Sahuquillo, for collecting data and granting permission through the steering group to use them for this project. Similarly, we would also like to acknowledge the contributors to the original study resulting in the paediatric database used here: R.J. Forsyth, B. Fulton, P.J.D. Andrews, A.D. Mendelow and R.A. Minns. The present study was supported by the Foundation for Scientific Research Flanders (FWO) (Research project G. 0904.11). Geert Meyfroidt receives funding from FWO as senior clinical investigator (1846113N). Greet Van den Berghe receives long-term structural research financing via the Methusalem program funded by the Flemish Government (METH/08/07). BrainIT was funded by the European Framework Programme (FP5-QLRI-2000-00454, QLGT-2002-00160 AND FP7-IST-2007-217049). The NEMO project in the University Hospital Edegem (Antwerp), Belgium was funded by the Flemish Government Agency for Innovation by Science and Technology (IWT)-Applied Biomedical Research (TBM) program.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; [Anonymous], 2015, INT MISS PROGN AN CL; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chesnut RM, 2015, WHAT BEST TRIP STUDY; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Feyen BFE, 2012, MINERVA ANESTESIOL, V78, P949; Guiza F, 2014, INTENS CARE MED, V40, pS18; GUILLAUME J, 1951, REV NEUROL, V84, P131; Guiza F, 2014, CRIT CARE S1, V18, pP458; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Le Roux P, 2014, CURR OPIN CRIT CARE, V20, P141, DOI 10.1097/MCC.0000000000000078; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Nilsson P, 2005, ACTA NEUROCHIR SUPPL, V95, P51; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; Rosenfeld JV, 2005, LANCET, V366, P1509, DOI 10.1016/S0140-6736(05)67609-X; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Sigurta A, 2013, INTENS CARE MED, V39, P129, DOI 10.1007/s00134-012-2748-0; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	38	83	84	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2015	41	6					1067	1076		10.1007/s00134-015-3806-1			10	Critical Care Medicine	General & Internal Medicine	CL2UO	WOS:000356801200011	25894624				2021-06-18	
J	Fazel, S; Wolf, A; Pillas, D; Lichtenstein, P; Langstrom, N				Fazel, Seena; Wolf, Achim; Pillas, Demetris; Lichtenstein, Paul; Langstrom, Niklas			Suicide, Fatal Injuries, and Other Causes of Premature Mortality in Patients With Traumatic Brain Injury A 41-Year Swedish Population Study	JAMA PSYCHIATRY			English	Article							UNITED-STATES; HEAD-INJURY; RISK; SCHIZOPHRENIA; DIAGNOSES; DISCHARGE; REGISTER; HEALTH; DISORDERS; VALIDITY	IMPORTANCE Longer-term mortality in individuals who have survived a traumatic brain injury (TBI) is not known. OBJECTIVES To examine the relationship between TBI and premature mortality, particularly by external causes, and determine the role of psychiatric comorbidity. DESIGN, SETTING, AND PATIENTS We studied all persons born in 1954 or later in Sweden who received inpatient and outpatient International Classification of Diseases-based diagnoses of TBI from 1969 to 2009 (n = 218 300). We compared mortality rates 6 months or more after TBI to general population controls matched on age and sex (n = 2 163 190) and to unaffected siblings of patients with TBI (n = 150 513). Furthermore, we specifically examined external causes of death (suicide, injury, or assault). We conducted sensitivity analyses to investigate whether mortality rates differed by sex, age at death, severity (including concussion), and different follow-up times after diagnosis. MAIN OUTCOMES AND MEASURES Adjusted odds ratios (AORs) of premature death by external causes in patients with TBI compared with general population controls. RESULTS Among those who survived 6 months after TBI, we found a 3-fold increased odds of mortality (AOR, 3.2; 95% CI, 3.0-3.4) compared with general population controls and an adjusted increased odds of mortality of 2.6 (95% CI, 2.3-2.8) compared with unaffected siblings. Risks of mortality from external causes were elevated, including for suicide (AOR, 3.3; 95% CI, 2.9-3.7), injuries (AOR, 4.3; 95% CI, 3.8-4.8), and assault (AOR, 3.9; 95% CI, 2.7-5.7). Among those with TBI, absolute rates of death were high in those with any psychiatric or substance abuse comorbidity (3.8% died prematurely) and those with solely substance abuse (6.2%) compared with those without comorbidity (0.5%). CONCLUSIONS AND RELEVANCE Traumatic brain injury is associated with substantially elevated risks of premature mortality, particularly for suicide, injuries, and assaults, even after adjustment for sociodemographic and familial factors. Current clinical guidelines may need revision to reduce mortality risks beyond the first few months after injury and address high rates of psychiatric comorbidity and substance abuse.	[Fazel, Seena; Wolf, Achim] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; [Pillas, Demetris] UCL, Dept Epidemiol & Publ Hlth, London, England; [Lichtenstein, Paul; Langstrom, Niklas] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	seena.fazel@psych.ox.ac.uk	Langstrom, Niklas/C-5615-2009; Fazel, Seena/B-5307-2008	Langstrom, Niklas/0000-0002-2686-6799; Fazel, Seena/0000-0002-5383-5365; lichtenstein, paul/0000-0003-3037-5287	Wellcome TrustWellcome TrustEuropean Commission [095806]; Swedish Prison and Probation Service; Swedish Research CouncilSwedish Research CouncilEuropean Commission	This study was funded by grant 095806 from the Wellcome Trust (Dr Fazel and Mr Wolf), the Swedish Prison and Probation Service (Dr Langstrom), and the Swedish Research Council (Drs Lichtenstein and Langstrom).	ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; Ameratunga S, 2006, LANCET, V367, P1533, DOI 10.1016/S0140-6736(06)68654-6; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brown AW, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318280d3e6; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Coronado V. G., 2011, SURVEILLANCE FOR TRA; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dalman C, 2002, SOC PSYCH PSYCH EPID, V37, P527, DOI 10.1007/s00127-002-0582-3; Ekholm B, 2005, NORD J PSYCHIAT, V59, P457, DOI 10.1080/08039480500360906; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fazel S, 2013, LANCET, V382, P1646, DOI 10.1016/S0140-6736(13)60899-5; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Fazel S, 2009, JAMA-J AM MED ASSOC, V301, P2016, DOI 10.1001/jama.2009.675; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horton R, 2013, LANCET, V381, P509, DOI 10.1016/S0140-6736(13)60100-2; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JIANG GX, 1995, ACTA NEUROL SCAND, V91, P109; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Klein-Geltink JE, 2007, J CLIN EPIDEMIOL, V60, P766, DOI 10.1016/j.jclinepi.2006.11.008; LINDBLAD U, 1993, SCAND J SOC MED, V21, P3, DOI 10.1177/140349489302100102; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mathers CD, 2008, THE GLOBAL BURDEN OF; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; National Board of Health and Welfare, CAUSE OF DEATH REGIS; National Institute for Health and Clinical Excellence, 2004, SELF HARM THE SHORT; Neeleman J, 1997, PSYCHOL MED, V27, P467, DOI 10.1017/S0033291796004631; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Redelmeier DA, 2003, LANCET, V361, P2177, DOI 10.1016/S0140-6736(03)13770-1; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Runeson B, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3222; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Sellgren C, 2011, ACTA PSYCHIAT SCAND, V124, P447, DOI 10.1111/j.1600-0447.2011.01747.x; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; Statistics Sweden, 2005, FLERGENERATIONSREGIS; Swedish National Board of Health and Welfare, PATIENTREGISTRET; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Volavka J, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001148; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	50	83	84	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	MAR	2014	71	3					326	333		10.1001/jamapsychiatry.2013.3935			8	Psychiatry	Psychiatry	AC8FU	WOS:000332769700015	24430827	Green Accepted, Bronze			2021-06-18	
J	Zheng, WM; Zhuge, QC; Zhong, M; Chen, GR; Shao, B; Wang, H; Mao, XO; Xie, L; Jin, KL				Zheng, WeiMing; ZhuGe, Qichuan; Zhong, Ming; Chen, Gourong; Shao, Bei; Wang, Hong; Mao, XiaoOu; Xie, Lin; Jin, Kunlin			Neurogenesis in Adult Human Brain after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; human; injury; neurogenesis; stem cells	NEURAL STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; HIPPOCAMPAL CA3 REGION; ENHANCED NEUROGENESIS; SUBVENTRICULAR ZONE; DENTATE GYRUS; NEURONAL DIFFERENTIATION; DIRECTED MIGRATION; PROLIFERATION; DOUBLECORTIN	While much work has been conducted regarding the neurogenesis response to traumatic brain injury (TBI) in rodents, it remains largely unknown whether neurogenesis in adult human brain also responds to TBI in a similar manner. Here, we performed immunocytochemistry on 11 brain specimens from patients with traumatic brain injury, who underwent surgical intervention. We found that expression of neural stem/progenitor cell (NSC) protein markers, including DCX, TUC4, PSA-NCAM, SOX2 and NeuroD, was increased in the perilesional cortex of human brain after TBI compared to that of normal brain. Confocal images showed that these NSC proteins were expressed in one single cell. We also found that proliferative markers were expressed in NSC protein-positive cells after TBI, and the number of proliferative NSCs was significantly increased after TBI. Our data suggest that TBI may also induce neurogenesis in human brain.	[Zheng, WeiMing; ZhuGe, Qichuan; Zhong, Ming; Jin, Kunlin] First Affiliated Hosp, Wenzhou Med Coll, Dept Neurosurg, Wenzhou, Peoples R China; [Chen, Gourong] First Affiliated Hosp, Wenzhou Med Coll, Dept Pathol, Wenzhou, Peoples R China; [Shao, Bei; Wang, Hong] First Affiliated Hosp, Wenzhou Med Coll, Dept Neurol, Wenzhou, Peoples R China; [Mao, XiaoOu; Xie, Lin; Jin, Kunlin] Buck Inst Age Res, Novato, CA 94945 USA	Jin, KL (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	kjin@buckinstitute.org			Wenzhou Medical College; National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21980, NS62414]; Foundation of Zhejiang Provincial Top Key Discipline of Surgery; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RL1NS062414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021980] Funding Source: NIH RePORTER	This work was partially supported by a Wenzhou Medical College 5010 grant, a National Institute of Health (NIH) grant (AG21980 and NS62414, to K. J.), and funds from the Foundation of Zhejiang Provincial Top Key Discipline of Surgery. Some of the human tissue were obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland (Baltimore, MD). The role of the NICHD Brain and Tissue Bank is to distribute tissue, and, therefore, it does not endorse the studies performed or the interpretation of results.	Anderson VA, 2000, BRAIN INJURY, V14, P679; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Crespel A, 2005, NEUROBIOL DIS, V19, P436, DOI 10.1016/j.nbd.2005.01.020; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Doetsch F, 1997, J NEUROSCI, V17, P5046; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Fanarraga ML, 1999, EUR J NEUROSCI, V11, P517; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; GERDES J, 1984, J IMMUNOL, V133, P1710; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Komitova M, 2004, NEUROSCI LETT, V369, P24, DOI 10.1016/j.neulet.2004.07.035; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee JE, 1997, DEV NEUROSCI-BASEL, V19, P27, DOI 10.1159/000111182; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; MCDERMOTT KW, 1991, J ANAT, V178, P45; MINTURN JE, 1995, J NEUROSCI, V15, P6757; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Sgubin D, 2007, J NEUROSCI RES, V85, P1647, DOI 10.1002/jnr.21303; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Teramoto T, 2003, J CLIN INVEST, V111, P1125, DOI 10.1172/JCI200317170; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562	54	83	89	1	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2013	30	22					1872	1880		10.1089/neu.2010.1579			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	243PH	WOS:000326328400005	21275797	Green Published			2021-06-18	
J	Bowers, CA; Riva-Cambrin, J; Hertzler, DA; Walker, ML				Bowers, Christian A.; Riva-Cambrin, Jay; Hertzler, Dean A., II; Walker, Marion L.			Risk factors and rates of bone flap resorption in pediatric patients after decompressive craniectomy for traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						decompressive craniectomy; traumatic brain injury; autologous cranioplasty; bone flap resorption	DURA-MATER; CHILDREN; CRANIOPLASTY; OUTCOMES	Object. Decompressive craniectomy with subsequent autologous cranioplasty, or the replacement of the native bone flap, is often used for pediatric patients with traumatic brain injury (TBI) who have a mass lesion and intractable intracranial hypertension. Bone flap resorption is common after bone flap replacement, necessitating additional surgery. The authors reviewed their large database of pediatric patients with TBI who underwent decompressive craniectomy followed by bone flap replacement to determine the rate of bone flap resorption and identify associated risk factors. Methods. A retrospective cohort chart review was performed to identify long-term survivors who underwent decompressive craniectomy for severe TBI with bone flap replacement from January 1, 1996, to December 31, 2011. The risk factors investigated in a univariate statistical analysis were age, sex, underlying parenchymal contusion, Glasgow Coma Scale score on arrival, comminuted skull fracture, posttraumatic hydrocephalus, bone flap wound infection, and freezer time (the amount of time the bone flap was stored in the freezer before replacement). A multivariate logistic regression model was then used to determine which of these were independent risk factors for bone flap resorption. Results. Bone flap replacement was performed at an average of 2.1 months after decompressive craniectomy. Of the 54 patients identified (35 boys, 19 girls; mean age 6.2 years), 27 (50.0%) experienced bone flap resorption after an average of 4.8 months. Underlying parenchymal contusion, comminuted skull fracture, age <= 2.5 years, and posttraumatic hydrocephalus were significant, or nearly significant, on univariate analysis. Multivariate analysis identified underlying contusion (p = 0.004, OR 34.4, 95% CI 3.0-392.7), comminuted skull fractures (p = 0.046, OR 8.5, 95% CI 1.0-69.6), posttraumatic hydrocephalus (p = 0.005, OR 35.9, 95% CI 2.9-436.6), and age <= 2.5 years old (p = 0.01, OR 23.1, 95% CI 2.1-257.7) as independent risk factors for bone flap resorption. Conclusions. After decompressive craniectomy for pediatric TBI, half of the patients (50%) who underwent bone flap replacement experienced resorption. Multivariate analysis indicated young age (<= 2.5 years), hydrocephalus, underlying contusion as opposed to a hemispheric acute subdural hematoma, and a comminuted skull fracture were all independent risk factors for bone flap resorption. Freezer time was not found to be associated with bone flap resorption. (http://thejns.org/doi/abs/10.3171/2013.1.PEDS12483)	[Bowers, Christian A.; Riva-Cambrin, Jay; Hertzler, Dean A., II; Walker, Marion L.] Univ Utah, Primary Childrens Med Ctr, Dept Neurosurg, Salt Lake City, UT 84113 USA	Walker, ML (corresponding author), Univ Utah, Div Pediat Neurosurg, Dept Neurosurg, Primary Childrens Med Ctr, 100 North Med Dr, Salt Lake City, UT 84113 USA.	marion.walker@hsc.utah.edu					Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Bhaskar IP, 2011, ANZ J SURG, V81, P137, DOI 10.1111/j.1445-2197.2010.05584.x; Fong KD, 2003, PLAST RECONSTR SURG, V112, P1312, DOI 10.1097/01.PRS.0000079860.14734.D6; Gagan Jeffrey R., 2007, Birth Defects Research, V81, P297, DOI 10.1002/bdrc.20104; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; GRUBER R, 1988, Z KINDERCHIR, V43, P375; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; POCHON JP, 1991, EUR J PEDIATR SURG, V1, P199, DOI 10.1055/s-2008-1042487; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965	13	83	89	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	MAY	2013	11	5					526	532		10.3171/2013.1.PEDS12483			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	131LR	WOS:000317995700012	23473303				2021-06-18	
J	Zonfrillo, MR; Master, CL; Grady, MF; Winston, FK; Callahan, JM; Arbogast, KB				Zonfrillo, Mark R.; Master, Christina L.; Grady, Matthew F.; Winston, Flaura K.; Callahan, James M.; Arbogast, Kristy B.			Pediatric Providers' Self-Reported Knowledge, Practices, and Attitudes About Concussion	PEDIATRICS			English	Article						concussion; mild traumatic brain injury; primary care; emergency medicine	TRAUMATIC BRAIN-INJURY; PRIMARY-CARE; SPORT; EDUCATION; SUPPORT; SCHOOL; PLAY; POPULATION; MANAGEMENT; COACHES	OBJECTIVE: To determine the self-reported practices and attitudes surrounding concussion diagnosis and management in a single, large pediatric care network. METHODS: A cross-sectional survey was distributed to pediatric primary care and emergency medicine providers in a single, large pediatric care network. For all survey participants, practices and attitudes about concussion diagnosis and treatment were queried. RESULTS: There were 145 responses from 276 eligible providers, resulting in a 53% response rate, of which 91% (95% confidence interval [CI]: 86%-95%) had cared for at least 1 concussion patient in the previous 3 months. A Likert scale from 1 "not a barrier" to 5 "significant barrier" was used to assess providers' barriers to educating families about the diagnosis of concussion. Providers selected 4 or 5 on the scale for the following barriers and frequencies: inadequate training to educate 16% (95% CI: 11%-23%), inadequate time to educate 15% (95% CI: 12%-24%), and not my role to educate 1% (95% CI: 0.4%-5%). Ninety-six percent (95% CI: 91%-98%) of providers without a provider decision support tool (such as a clinical pathway or protocol) specific to concussion, and 100% (95% CI: 94%-100%) of providers without discharge instructions specific to concussion believed these resources would be helpful. CONCLUSIONS: Although pediatric primary care and emergency medicine providers regularly care for concussion patients, they may not have adequate training or infrastructure to systematically diagnose and manage these patients. Specific provider education, decision support tools, and patient information could help enhance and standardize concussion management. Pediatrics 2012;130:1120-1125	[Zonfrillo, Mark R.; Winston, Flaura K.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Callahan, James M.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Master, Christina L.; Grady, Matthew F.; Winston, Flaura K.; Callahan, James M.; Arbogast, Kristy B.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Winston, Flaura K.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	Zonfrillo, MR (corresponding author), Childrens Hosp Philadelphia, Div Emergency Med, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	zonfrillo@email.chop.edu	Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563; Arbogast, Kristy/0000-0002-1694-4562; Master, Christina/0000-0002-6717-4270	Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative	This study was supported by The Children's Hospital of Philadelphia Department of Pediatrics Chair's Initiative.	Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; *CDCP, HEADS CONC YOUTH SPO; Centers for Disease Control and Prevention, CONC MILD TBI; Creighton DW, 2010, CLIN J SPORT MED, V20, P379, DOI 10.1097/JSM.0b013e3181f3c0fe; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; Fiks AG, 2011, CURR PROB PEDIATR AD, V41, P60, DOI 10.1016/j.cppeds.2010.10.006; Fishbein M, 2006, J COMMUN, V56, pS1, DOI 10.1111/j.1460-2466.2006.00280.x; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kaye AJ, 2010, J TRAUMA, V68, P1396, DOI 10.1097/TA.0b013e3181cf7d1b; Langberg JM, 2009, EXPERT REV NEUROTHER, V9, P477, DOI 10.1586/ERN.09.5; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Power TJ, 2008, PEDIATRICS, V121, pE65, DOI 10.1542/peds.2007-0383; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Stevens PK, 2010, J TRAUMA NURS, V17, P183; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; The National Football League, HLTH SAF CONC LEG ST; Walkinshaw E, 2011, CAN MED ASSOC J, V183, pE1047, DOI 10.1503/cmaj.109-3942	31	83	85	0	26	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2012	130	6					1120	1125		10.1542/peds.2012-1431			6	Pediatrics	Pediatrics	087YZ	WOS:000314802000063	23147981				2021-06-18	
J	Ziebell, JM; Taylor, SE; Cao, TX; Harrison, JL; Lifshitz, J				Ziebell, Jenna M.; Taylor, Samuel E.; Cao, Tuoxin; Harrison, Jordan L.; Lifshitz, Jonathan			Rod microglia: elongation, alignment, and coupling to form trains across the somatosensory cortex after experimental diffuse brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Brain injury; Microglial rod cells; Rod microglia; Inflammation	RADIAL GLIAL-CELLS; INFLAMMATORY RESPONSE; IFN-GAMMA; ACTIVATION; EXPRESSION; MOUSE; NEUROPROTECTION; MORPHOLOGY; DYNAMICS; REVEALS	Background: Since their discovery, the morphology of microglia has been interpreted to mirror their function, with ramified microglia constantly surveying the micro-environment and rapidly activating when changes occur. In 1899, Franz Nissl discovered what we now recognize as a distinct microglial activation state, microglial rod cells (Stabchenzellen), which he observed adjacent to neurons. These rod-shaped microglia are typically found in human autopsy cases of paralysis of the insane, a disease of the pre-penicillin era, and best known today from HIV-1-infected brains. Microglial rod cells have been implicated in cortical 'synaptic stripping' but their exact role has remained unclear. This is due at least in part to a scarcity of experimental models. Now we have noted these rod microglia after experimental diffuse brain injury in brain regions that have an associated sensory sensitivity. Here, we describe the time course, location, and surrounding architecture associated with rod microglia following experimental diffuse traumatic brain injury (TBI). Methods: Rats were subjected to a moderate midline fluid percussion injury (mFPI), which resulted in transient suppression of their righting reflex (6 to 10 min). Multiple immunohistochemistry protocols targeting microglia with Iba1 and other known microglia markers were undertaken to identify the morphological activation of microglia. Additionally, labeling with Iba1 and cell markers for neurons and astrocytes identified the architecture that surrounds these rod cells. Results: We identified an abundance of Iba1-positive microglia with rod morphology in the primary sensory barrel fields (S1BF). Although present for at least 4 weeks post mFPI, they developed over the first week, peaking at 7 days post-injury. In the absence of contusion, Iba1-positive microglia appear to elongate with their processes extending from the apical and basal ends. These cells then abut one another and lay adjacent to cytoarchitecture of dendrites and axons, with no alignment with astrocytes and oligodendrocytes. Iba1-positive rod microglial cells differentially express other known markers for reactive microglia including OX-6 and CD68. Conclusion: Diffuse traumatic brain injury induces a distinct rod microglia morphology, unique phenotype, and novel association between cells; these observations entice further investigation for impact on neurological outcome.	[Ziebell, Jenna M.; Taylor, Samuel E.; Harrison, Jordan L.; Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA; [Ziebell, Jenna M.; Taylor, Samuel E.; Harrison, Jordan L.; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Ziebell, Jenna M.; Cao, Tuoxin; Harrison, Jordan L.; Lifshitz, Jonathan] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Dept Phys Med & Rehabil,Dept Anat & Neurobiol, Lexington, KY USA; [Harrison, Jordan L.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; [Harrison, Jordan L.; Lifshitz, Jonathan] Arizona State Univ, Neurosci Program, Tempe, AZ USA; [Lifshitz, Jonathan] Phoenix VA Healthcare Syst, Phoenix, AZ USA	Lifshitz, J (corresponding author), Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA.	jlifshitz@email.arizona.edu	Ziebell, Jenna/Y-4496-2019	Ziebell, Jenna/0000-0003-2497-4347	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065052]; Mission Support Fund at Phoenix Children's Hospital; University of Arizona; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER	The authors wish to thank to Amanda M. Lisembee for preparing the diffuse brain-injured rats. Supported by NIH NINDS R01 NS065052 and the Mission Support Fund at Phoenix Children's Hospital and University of Arizona.	ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gotz M, 2005, NEURON, V46, P369, DOI 10.1016/j.neuron.2005.04.012; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; GRAEBER MB, 1994, NEUROPATH APPL NEURO, V20, P178; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Gregg C, 2003, J NEUROSCI, V23, P11587; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hartfuss E, 2003, DEVELOPMENT, V130, P4597, DOI 10.1242/dev.00654; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Jones EG, 1991, HIST NEUROSCIENCE; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lambertsen KL, 2011, J NEUROPATH EXP NEUR, V70, P481, DOI 10.1097/NEN.0b013e31821db3aa; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Malatesta P, 2000, DEVELOPMENT, V127, P5253; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Navascues Julio, 2002, P15; Nissl F., 1899, ARCH PSYCHIAT NERVEN, V32, P656; OHNO M, 1992, DEV BRAIN RES, V67, P37, DOI 10.1016/0165-3806(92)90023-P; Perry VH, 2010, ASN NEURO, V2, P281, DOI 10.1042/AN20100024; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Reneer DV, 2012, BLAST INDUCED BRAIN; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Taylor SE, 2012, CURRENT PRO IN PRESS; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wierzba-Bobrowicz T, 2002, FOLIA NEUROPATHOL, V40, P125; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Wolf SA, 2002, J NEUROIMMUNOL, V133, P72, DOI 10.1016/S0165-5728(02)00367-3; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	46	83	84	0	18	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	OCT 30	2012	9								247	10.1186/1742-2094-9-247			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	060NU	WOS:000312785900001	23111107	DOAJ Gold, Green Published			2021-06-18	
J	Czeiter, E; Mondello, S; Kovacs, N; Sandor, J; Gabrielli, A; Schmid, K; Tortella, F; Wang, KKW; Hayes, RL; Barzo, P; Ezer, E; Doczi, T; Buki, A				Czeiter, Endre; Mondello, Stefania; Kovacs, Noemi; Sandor, Janos; Gabrielli, Andrea; Schmid, Kara; Tortella, Frank; Wang, Kevin K. W.; Hayes, Ronald L.; Barzo, Pal; Ezer, Erzsebet; Doczi, Tamas; Buki, Andras			Brain Injury Biomarkers May Improve the Predictive Power of the IMPACT Outcome Calculator	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; IMPACT calculator; outcome; prognostic models; traumatic brain injury	SPECTRIN BREAKDOWN PRODUCTS; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE; CEREBROSPINAL-FLUID; PROGNOSTIC MODELS; HEAD-INJURY; DIAGNOSIS; CLASSIFICATION; DESIGN; SERUM	Outcome prediction following severe traumatic brain injury (sTBI) is a widely investigated field of research. A major breakthrough is represented by the IMPACT prognostic calculator based on admission data of more than 8500 patients. A growing body of scientific evidence has shown that clinically meaningful biomarkers, including glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCH-L1), and alpha II-spectrin breakdown product (SBDP145), could also contribute to outcome prediction. The present study was initiated to assess whether the addition of biomarkers to the IMPACT prognostic calculator could improve its predictive power. Forty-five sTBI patients (GCS score <= 8) from four different sites were investigated. We utilized the core model of the IMPACT calculator (age, GCS motor score, and reaction of pupils), and measured the level of GFAP, UCH-L1, and SBDP145 in serum and cerebrospinal fluid (CSF). The forecast and actual 6-month outcomes were compared by logistic regression analysis. The results of the core model itself, as well as serum values of GFAP and CSF levels of SBDP145, showed a significant correlation with the 6-month mortality using a univariate analysis. In the core model, the Nagelkerke R-2 value was 0.214. With multivariate analysis we were able to increase this predictive power with one additional biomarker (GFAP in CSF) to R-2 = 0.476, while the application of three biomarker levels (GFAP in CSF, GFAP in serum, and SBDP145 in CSF) increased the Nagelkerke R-2 to 0.700. Our preliminary results underline the importance of biomarkers in outcome prediction, and encourage further investigation to expand the predictive power of contemporary outcome calculators and prognostic models in TBI.	[Czeiter, Endre; Kovacs, Noemi; Ezer, Erzsebet; Doczi, Tamas; Buki, Andras] Univ Pecs, Dept Neurosurg, Sch Med, H-7623 Pecs, Hungary; [Czeiter, Endre] Univ Pecs, Dept Anat, Sch Med, H-7623 Pecs, Hungary; [Mondello, Stefania; Gabrielli, Andrea; Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Wang, Kevin K. W.] Univ Florida, Ctr Neuroprote & Biomarkers Res, Dept Psychiat, McKnight Brain Inst, Gainesville, FL USA; [Mondello, Stefania; Hayes, Ronald L.] Banyan Biomarkers Inc, Dept Clin Programs, Ctr Innovat Res, Alachua, FL USA; [Wang, Kevin K. W.] Banyan Biomarkers Inc, Dept Diagnost Res & Dev, Ctr Innovat Res, Alachua, FL USA; [Sandor, Janos] Univ Debrecen, Div Biostat & Epidemiol, Fac Publ Hlth, H-4012 Debrecen, Hungary; [Schmid, Kara; Tortella, Frank] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD USA; [Barzo, Pal] Univ Szeged, Dept Neurosurg, Fac Med, Szeged, Hungary	Czeiter, E (corresponding author), Univ Pecs, Dept Neurosurg, Sch Med, 2 Ret St, H-7623 Pecs, Hungary.	endre.czeiter@gmail.com	Mondello, Stefania/A-1813-2012; Doczi, Tamas/C-5750-2009; Czeiter, Endre/B-1404-2009	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03-1-0066]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS049175-01, R01-NS052831-01, R01-NS051431-01]; University of FloridaUniversity of Florida [N00014-06-1-1029]; Developing Competitiveness of Universities in the South Transdanubian Region [SROP-4.2.1.B-10/2/KONV-2010-0002]; MTA-PTE Clinical Neuroscience MR Research Group; ETT [269/2009]; Banyan Biomarkers, Inc.; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175, R01NS051431, R01NS052831] Funding Source: NIH RePORTER	This study was primarily sponsored by Department of Defense Award numbers DAMD17-03-1-0772 and DAMD17-03-1-0066; we also acknowledge additional funding support from the National Institutes of Health (R01-NS049175-01, R01-NS052831-01, and R01-NS051431-01), Navy grant no. N00014-06-1-1029 (University of Florida), and Developing Competitiveness of Universities in the South Transdanubian Region (SROP-4.2.1.B-10/2/KONV-2010-0002), as well as the MTA-PTE Clinical Neuroscience MR Research Group and ETT grant no. 269/2009.; Drs. Czeiter, Mondello, Kovacs, Gabrielli, Barzo, Ezer, and Buki are consultants for Banyan Biomarkers, Inc., and received consulting fees. Drs. Wang and Hayes own stock, receive royalties from, and are officers of Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research. No competing financial interests exist for Drs. Sandor, Schmid, Tortella, and Doczi.	Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Gong B, 2007, DRUG NEWS PERSPECT, V20, P365, DOI 10.1358/dnp.2007.20.6.1138160; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schulz JB, 2008, J NEUROL, V255, P3, DOI 10.1007/s00415-008-5011-4; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2	39	83	89	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2012	29	9					1770	1778		10.1089/neu.2011.2127			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	954CN	WOS:000304924000006	22435839	Green Published			2021-06-18	
J	McLeod, TCV; Bay, RC; Lam, KC; Chhabra, A				McLeod, Tamara C. Valovich; Bay, R. Curtis; Lam, Kenneth C.; Chhabra, Anikar			Representative Baseline Values on the Sport Concussion Assessment Tool 2 (SCAT2) in Adolescent Athletes Vary by Gender, Grade, and Concussion History	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	37th Annual Meeting of the American-Orthopaedic-Society-for-Sports-Medicine (AOSSM)	JUL, 2011	San Diego, CA	Amer Orthopaed Soc Sports Med (AOSSM)		mild traumatic brain injury; balance; cognition; symptoms	POSTURAL STABILITY; HEAD-INJURY; HIGH-SCHOOL; SYMPTOMS; YOUTH; IDENTIFICATION; SENSITIVITY; RECOVERY; PLAYERS; SCALE	Background: To improve and standardize the sideline evaluation of sports-related concussion, the Sport Concussion Assessment Tool 2 (SCAT2) was developed. This tool assesses concussion-related signs and symptoms, cognition, balance, and coordination. This newly published assessment tool has not established representative baseline data on adolescent athletes. Hypothesis: Representative baseline SCAT2 scores in adolescent athletes will differ by gender, grade in school, and self-reported concussion history. Study Design: Descriptive epidemiology study. Methods: Interscholastic athletes were administered the SCAT2 during a preseason concussion baseline testing session. The SCAT2 total score ranges from 0 to 100 points, with lower scores indicating poorer performance. Overall, representative values were calculated using descriptive statistics. Separate independent-samples t tests, with gender and concussion history as the independent variables, and a 1-way analysis of variance, with grade as the independent variable, were conducted to assess differences in SCAT2 total score (P<.05). Results: There were 1134 high school athletes (872 male and 262 female) who participated. The SCAT2 total score across all participants was 88.3 +/- 6.8 (range, 58-100); skewness was -0.86 +/- 0.07, and kurtosis was 0.73 +/- 0.14. Male athletes scored significantly lower on the SCAT2 total score (P=.03; 87.7 +/- 6.8 vs 88.7 +/- 6.8), and 9th graders (86.9 +/- 6.8) scored significantly lower than 11th (88.7 +/- 7.0) and 12th (89.0 +/- 6.6) graders (P<.001). Athletes with a self-reported concussion history scored significantly lower on the SCAT2 total score than those with no concussion history (P<.001; 87.0 +/- 6.8 vs 88.7 +/- 6.5). Conclusion: These data provide representative scores on the SCAT2 in adolescent athletes and show that male athletes, 9th graders, and those with a self-reported concussion history scored significantly lower than their female, upperclassmen, or non-concussed peers. Clinical Relevance: These results suggest that healthy adolescent athletes display variability on the SCAT2 at baseline. Therefore, clinicians should administer baseline assessments of the SCAT2 because assuming a perfect baseline score of 100 points is not appropriate in an adolescent athlete population.	[McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ 85206 USA	McLeod, TCV (corresponding author), AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	McLeod, Tamara/AAU-9435-2020; Lam, Kenny/ABB-9733-2020	Bay, Ralph/0000-0003-3525-9269; Lam, Kenneth/0000-0002-2185-0990			Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; LaBotz M, 2005, CLIN J SPORT MED, V15, P73, DOI 10.1097/01.jsm.0000157649.99867.fc; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Rhee Hyekyun, 2005, Pediatr Nurs, V31, P314; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	29	83	83	0	24	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2012	40	4					927	933		10.1177/0363546511431573			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	918XO	WOS:000302285100027	22238056				2021-06-18	
J	Ganesalingam, K; Yeates, KO; Taylor, HG; Walz, NC; Stancin, T; Wade, S				Ganesalingam, Kalaichelvi; Yeates, Keith Owen; Taylor, H. Gerry; Walz, Nicolay Chertkoff; Stancin, Terry; Wade, Shari			Executive Functions and Social Competence in Young Children 6 Months Following Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; young children; executive functions; social competence	CLOSED-HEAD-INJURY; BEHAVIOR RATING INVENTORY; PRESCHOOL-CHILDREN; EARLY-CHILDHOOD; EXTERNALIZING PROBLEMS; ECOLOGICAL VALIDITY; CONSTRUCT-VALIDITY; SELF-REGULATION; SHAPE SCHOOL; SKILLS	Objective: This study examined the impact of traumatic brain injury (TBI) in young children on executive functions and social competence, and particularly on the role of executive functions as a predictor of social competence. Method: Data were drawn from a prospective, longitudinal study. Participants were children between the ages of 3 years 0 months and 6 years 11 months at time of injury. The initial sample included 23 with severe TBI, 64 with moderate TBI, and 119 with orthopedic injuries (OI). All participants were assessed at 3 and 6 months postinjury. Executive functions were assessed using neuropsychological tests (Delayed Alternation task and Shape School) and parent ratings on the Behavior Rating Inventory of Executive Function and Child Behavior Questionnaire. Parents rated children's social competence on the Adaptive Behavior Assessment System, Preschool and Kindergarten Behavior Scales, and Home and Community Social Behavior Scales. Results: Children with severe TBI displayed more negative outcomes than children with OI on neuropsychological tests, ratings of executive functions, and ratings of social competence (eta(2) ranged from .03 to .11). Neuropsychological tests of executive functions had significant but weak relationships with behavioral ratings of executive functions (Delta R-2 ranged from .06 to .08). Behavioral ratings of executive functions were strongly related to social competence (Delta R-2 ranged from .32 to .42), although shared rater and method variance likely contributed to these associations. Conclusions: Severe TBI in young children negatively impacts executive functions and social competence. Executive functions may be an important determinant of social competence following TBI.	[Ganesalingam, Kalaichelvi; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA; [Ganesalingam, Kalaichelvi; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Walz, Nicolay Chertkoff; Wade, Shari] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; [Walz, Nicolay Chertkoff; Wade, Shari] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Psychiat, Cleveland, OH USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	Keith.Yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729-01, R01 HD042729] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER		Ahadi S. A., 1994, DEV STRUCTURE TEMPER, P189; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Barkley R. A., 1997, ADHD NATURE SELF CON; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BEAUCHAMP MH, 2009, J NEUROTRAUM, V10, P9; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Canivez GL, 2002, PSYCHOL SCHOOLS, V39, P621, DOI 10.1002/pits.10063; CASPI A, 1995, DEV PSYCHOPATHOL, V2, P472; CICCHETTI D, 1994, DEV PSYCHOPATHOL, V6, P533, DOI 10.1017/S0954579400004673; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Dodge K. A., 1998, HDB CHILD PSYCHOL, V3, P779, DOI DOI 10.1002/9780470147658; Eisenberg N, 2000, CHILD DEV, V71, P1367, DOI 10.1111/1467-8624.00233; Eisenberg N, 1997, CHILD DEV, V68, P642, DOI 10.2307/1132116; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 1999, BRAIN COGNITION, V41, P178, DOI 10.1006/brcg.1999.1117; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; Espy KA, 2006, PSYCHOL ASSESSMENT, V18, P373, DOI 10.1037/1040-3590.18.4.373; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; GERSTADT CL, 1994, COGNITION, V53, P129, DOI 10.1016/0010-0277(94)90068-X; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hughes C, 1998, BRIT J DEV PSYCHOL, V16, P233, DOI 10.1111/j.2044-835X.1998.tb00921.x; Hughes C, 2000, J CHILD PSYCHOL PSYC, V41, P169, DOI 10.1111/1469-7610.00558; Isquith PK, 2005, MENT RETARD DEV D R, V11, P209, DOI 10.1002/mrdd.20075; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; MCEVOY RE, 1993, J CHILD PSYCHOL PSYC, V34, P563, DOI 10.1111/j.1469-7610.1993.tb01036.x; MERRELL KW, 1995, J PSYCHOEDUC ASSESS, V13, P230, DOI 10.1177/073428299501300302; Merrell KW, 2000, HOME COMMUNITY SOCIA; Moffitt TE, 2003, CAUSES OF CONDUCT DISORDER AND JUVENILE DELINQUENCY, P49; Morse S, 1999, Pediatr Rehabil, V3, P139; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nigg JT, 2000, PSYCHOL BULL, V126, P220, DOI 10.1037/0033-2909.126.2.220; Olson SL, 1999, J ABNORM CHILD PSYCH, V27, P151, DOI 10.1023/A:1021915615677; Olson SL, 2005, DEV PSYCHOPATHOL, V17, P25, DOI 10.1017/S0954579405050029; Posner MI, 2000, DEV PSYCHOPATHOL, V12, P427, DOI 10.1017/S0954579400003096; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; RICCIO CA, 1994, DEV NEUROPSYCHOL, V10, P215, DOI 10.1080/87565649409540580; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rothbart M.K., 2006, HDB CHILD PSYCHOL, P99, DOI DOI 10.1002/9780470147658.CHPSY0303; Rothbart M. K., 1989, TEMPERAMENT CHILDHOO, P59; RUBIN KH, 1986, MINN SYM CHILD PSYCH, V18, P1; Rubin KH, 1992, HDB SOCIAL DEV LIFES, P283, DOI DOI 10.1007/978-1-4899-0694-6; Senn TE, 2004, DEV NEUROPSYCHOL, V26, P445, DOI 10.1207/s15326942dn2601_5; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Smidts DP, 2004, DEV NEUROPSYCHOL, V26, P385, DOI 10.1207/s15326942dn2601_2; Speltz ML, 1999, J ABNORM PSYCHOL, V108, P315, DOI 10.1037/0021-843X.108.2.315; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; Verger K, 2000, BRAIN INJURY, V14, P495; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Vriezen ER, 2001, BRAIN COGNITION, V47, P222; Warschausky S, 2003, REHABIL PSYCHOL, V48, P250, DOI 10.1037/0090-5550.48.4.250; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WETHERINGTON CE, 2006, EXCEPTIONALITY, V12, P155; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Willmott C, 2000, DEV NEUROPSYCHOL, V17, P361, DOI 10.1207/S15326942DN1703_5; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Zahn-Waxler C., 2002, HDB PARENTING, V4, P295, DOI 10.4324/9780429398995-17; Zelazo PD, 1996, COGNITIVE DEV, V11, P37, DOI 10.1016/S0885-2014(96)90027-1	83	83	83	0	41	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2011	25	4					466	476		10.1037/a0022768			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	787WQ	WOS:000292407800005	21463038	Green Accepted			2021-06-18	
J	Kim, Y; Kent, RD; Weismer, G				Kim, Yunjung; Kent, Raymond D.; Weismer, Gary			An Acoustic Study of the Relationships Among Neurologic Disease, Dysarthria Type, and Severity of Dysarthria	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						acoustic measures; dysarthria; classification	VOICE ONSET TIME; SPEECH-INTELLIGIBILITY; SPEAKING RATE; BRAIN-INJURY; PARKINSONS; IDENTIFICATION; SLOPE	Purpose: This study examined acoustic predictors of speech intelligibility in speakers with several types of dysarthria secondary to different diseases and conducted classification analysis solely by acoustic measures according to 3 variables (disease, speech severity, and dysarthria type). Method: Speech recordings from 107 speakers with dysarthria due to Parkinson's disease, stroke, traumatic brain injury, and multiple system atrophy were used for acoustic analysis and for perceptual judgment of speech intelligibility. Acoustic analysis included 8 segmental/suprasegmental features: 2nd formant frequency slope, articulation rate, voiceless interval duration, 1st moment analysis for fricatives, vowel space, F0, intensity range, and Pairwise Variability Index. Results: The results showed that (a) acoustic predictors of speech intelligibility differed slightly across diseases and (b) classification accuracy by dysarthria type was typically worse than by disease type or severity. Conclusions: These findings were discussed with respect to (a) the relationship between acoustic characteristics and speech intelligibility and (b) dysarthria classification.	[Kim, Yunjung] Louisiana State Univ, Baton Rouge, LA 70803 USA; [Kent, Raymond D.; Weismer, Gary] Univ Wisconsin, Madison, WI 53706 USA	Kim, Y (corresponding author), Louisiana State Univ, Baton Rouge, LA 70803 USA.	ykim6@lsu.edu	Kent, Raymond D/AAI-1928-2020		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000319] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC00319] Funding Source: Medline		ACKERMANN H, 1995, FOLIA PHONIATR LOGO, V47, P15, DOI 10.1159/000266338; Ackermann H, 1997, BRAIN LANG, V56, P321, DOI 10.1006/brln.1997.1740; ANSEL BM, 1992, J SPEECH HEAR RES, V35, P296, DOI 10.1044/jshr.3502.296; Auzou P, 2000, CLIN LINGUIST PHONET, V14, P131; CANTER GJ, 1963, J SPEECH HEAR DISORD, V28, P221, DOI 10.1044/jshd.2803.221; CARMICHAEL JN, 2007, THESIS U SHEFFIELD U; *CDCP, 2003, TRAUM BRAIN INJ; CHIU MJ, 1996, EUR NEUROL, V46, P310; Darley F., 1975, MOTOR SPEECH DISORDE; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; De Bodt MS, 2002, J COMMUN DISORD, V35, P283, DOI 10.1016/S0021-9924(02)00065-5; Duffy J. R., 2006, MOTOR SPEECH DISORDE, P7; Duffy JR, 2019, MOTOR SPEECH DISORDE; ENGEN T, 1971, WOODWORTH SCHLOSBERG, P47; Fonville S, 2008, J NEUROL, V255, P1545, DOI 10.1007/s00415-008-0978-4; FORREST K, 1989, J ACOUST SOC AM, V85, P2608, DOI 10.1121/1.397755; Gescheider GA., 1976, PSYCHOPHYSICS METHOD; Goberman AM, 2005, J MED SPEECH-LANG PA, V13, P51; GOBERMAN AM, 2005, COMMUN SCI DISORD, V32, P22; Guerra EC, 2003, LECT NOTES COMPUT SC, V2905, P314; HERTRICH I, 1994, BRAIN LANG, V47, P182, DOI 10.1006/brln.1994.1048; KENT JF, 1992, J SPEECH HEAR RES, V35, P723, DOI 10.1044/jshr.3504.723; Kent RD, 2000, J SPEECH LANG HEAR R, V43, P1275, DOI 10.1044/jslhr.4305.1275; KENT RD, 1989, CLIN LINGUIST PHONET, V3, P347, DOI 10.3109/02699208908985295; Kent RD., 2008, HDB CLIN LINGUISTICS, P360; Kim Y, 2009, FOLIA PHONIATR LOGO, V61, P329, DOI 10.1159/000252849; Liss JM, 2009, J SPEECH LANG HEAR R, V52, P1334, DOI 10.1044/1092-4388(2009/08-0208); Liu HM, 2000, CLIN LINGUIST PHONET, V14, P447; Low E., 2000, LANG SPEECH, V43, P377, DOI DOI 10.1177/00238309000430040301; LUDLOW CL, 1987, BRAIN LANG, V32, P195, DOI 10.1016/0093-934X(87)90124-6; McRae PA, 2002, J SPEECH LANG HEAR R, V45, P35, DOI 10.1044/1092-4388(2002/003); MILENKOVIC P, 2001, TF 32 COMPUTER PROGR; MONSEN RB, 1983, J SPEECH HEAR DISORD, V48, P286, DOI 10.1044/jshd.4803.286; MORRIS RJ, 1989, J COMMUN DISORD, V22, P23, DOI 10.1016/0021-9924(89)90004-X; MULLIGAN M, 1994, J SPEECH HEAR RES, V37, P496, DOI 10.1044/jshr.3703.496; *NAT I NEUR DIS ST, 2001, HUNT DIS HOP RES; *NAT STROK ASS, 2002, ALL STROK; Nishio M, 2001, CLIN LINGUIST PHONET, V15, P309; Ozawa Y, 2001, FOLIA PHONIATR LOGO, V53, P67, DOI 10.1159/000052656; Ozsancak C, 2001, FOLIA PHONIATR LOGO, V53, P48, DOI 10.1159/000052653; SOLOMON NP, 1993, J SPEECH HEAR RES, V36, P294, DOI 10.1044/jshr.3602.294; STUNTEBECK S, 2002, THESIS U WISCONSIN M; Tjaden K, 2004, J SPEECH LANG HEAR R, V47, P766, DOI 10.1044/1092-4388(2004/058); TURNER GS, 1993, J SPEECH HEAR RES, V36, P1134, DOI 10.1044/jshr.3606.1134; Van der Graaff M, 2009, EUR NEUROL, V61, P295, DOI 10.1159/000206855; Van Nuffelen G, 2010, FOLIA PHONIATR LOGO, V62, P110, DOI 10.1159/000287209; Wang YT, 2005, J COMMUN DISORD, V38, P231, DOI 10.1016/j.jcomdis.2004.12.001; WEISMER G, 1992, J ACOUST SOC AM, V91, P1085, DOI 10.1121/1.402635; WEISMER G, 1988, J ACOUST SOC AM, V84, P1281, DOI 10.1121/1.396627; Weismer G, 2001, FOLIA PHONIATR LOGO, V53, P1, DOI 10.1159/000052649; Weismer G., 2010, SPEECH MOTOR CONTROL, P229; WEISMER G, 1991, NIDCD MONOGRAPH, V1, P83; WEISMER G, 1983, VOCAL FOLD PHYSL CON, P317; Weismer G., 1984, DYSARTHRIAS PHYSL AC, P101; WEISMER G, 1997, HDB PHONETIC SCI, P191; Weismer G, 2006, CLIN LINGUIST PHONET, V20, P315, DOI 10.1080/02699200400024806; White L, 2007, J PHONETICS, V35, P501, DOI 10.1016/j.wocn.2007.02.003; Zeplin J., 1996, DISORDERS MOTOR SPEE, P145; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZYSKI BJ, 1987, J COMMUN DISORD, V20, P367, DOI 10.1016/0021-9924(87)90025-6	61	83	85	2	30	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1092-4388	1558-9102		J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	APR 1	2011	54	2					417	429		10.1044/1092-4388(2010/10-0020)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	744BM	WOS:000289067600001	20884780				2021-06-18	
J	Struchen, MA; Davis, LC; Bogaards, JA; Hudler-Hull, T; Clark, AN; Mazzei, DM; Sander, AM; Caroselli, JS				Struchen, Margaret A.; Davis, Lynne Cole; Bogaards, Jay A.; Hudler-Hull, Terri; Clark, Allison N.; Mazzei, Diana M.; Sander, Angelle M.; Caroselli, Jerome S.			Making Connections After Brain Injury: Development and Evaluation of a Social Peer-Mentoring Program for Persons With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; peer mentoring; social integration; traumatic brain injury	CLOSED-HEAD-INJURY; QUALITY-OF-LIFE; UCLA LONELINESS SCALE; FOLLOW-UP; INITIAL FINDINGS; PARENT PROGRAMS; DEPRESSION; SUPPORT; INDIVIDUALS; INTEGRATION	Objective: To describe the development and implementation of a social peer-mentoring program for persons with traumatic brain injury (TBI) and to explore whether this program yielded increased social functioning outcomes compared with wait-list (WL) controls. Design: Pilot randomized controlled study. Participants: Community-dwelling individuals with TBI (12 matched with social peer mentors and 18 completing the WL condition). Intervention: Trained social peer mentors (SPMs) were matched to partners with TBI (peer partners [PP]) to foster skill-building in planning of social activities and improving social communication abilities through phone contacts and joint participation in social events within the community over a 3-month period. Measures: Social Activity Interview, Center for Epidemiological Studies Depression Scale, UCLA Loneliness Scale, Satisfaction with Life Scale, 6-Item Interpersonal Support Evaluation List (baseline and postmentoring); weekly social activity data (1-month baseline, continuously collected during 3-month mentoring or WL period); satisfaction survey. Results: Both SPM and PP participants reported high satisfaction with the mentoring program. Statistically significant improvements in perceived social support after mentoring were observed for the mentored group than for WL participants; however, an increase in depressive symptoms was also observed. While significant improvements in social activity level and social network size were not found, a trend toward increased satisfaction with social life was present for mentored participants. Conclusions: Satisfaction ratings for the SPM program were uniformly high and selected positive findings encourage further investigation of social mentoring as an intervention to effect improvements in social integration. Small sample size and reduced "dosage" of mentor interactions were limitations of this pilot study. Benefits of and challenges to implementation of an SPM program are outlined.	[Struchen, Margaret A.; Davis, Lynne Cole; Hudler-Hull, Terri; Clark, Allison N.; Sander, Angelle M.; Caroselli, Jerome S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Struchen, Margaret A.; Davis, Lynne Cole; Bogaards, Jay A.; Hudler-Hull, Terri; Clark, Allison N.; Mazzei, Diana M.; Sander, Angelle M.] Brain Injury Res Ctr, Houston, TX USA; [Caroselli, Jerome S.] TIRR Mem Hermann, Dept Neuropsychol, Houston, TX USA; [Clark, Allison N.; Sander, Angelle M.] Harris Cty Hosp Dist, Dept Phys & Rehabil, Quentin Mease Community Hosp, Houston, TX USA	Struchen, MA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1 Baylor Plaza, Houston, TX 77030 USA.	struchen@bcm.edu			National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133B031117, H133B090023]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grant H133B031117, Rehabilitation Research and Training Center on Community Integration of Persons with Traumatic Brain Injury, and H133B090023, Rehabilitation Research and Training Center on Developing Strategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury). The authors thank members of the Social Peer Mentor Working Committee for contributing to the development of measures, screening procedures, and training of peer mentors: DeLisa West, PhD, Niki Cannon, LaTricia Eckenrode, Patricia Backus, CCC-SLP, Shawn Jaffrey, CTRS, Melissa Gautreau, BS, and Lisa Keenan, PhD; Big Brothers Big Sisters of Greater Houston for assistance with developing mentor screening procedures, Sunil Kothari, MD, for his inspiration in designing this project, and Jason Ferguson for assistance with peer mentor training.	Akridge RL, 1991, P NAT FOR NAT I DIS; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Barrett W, 2004, EDUC PSYCHOL PRACT, V20, DOI [10.1080/0266736042000314286, DOI 10.1080/0266736042000314286]; Bay E, 2007, ARCH PSYCHIAT NURS, V21, P2, DOI 10.1016/j.apnu.2006.07.005; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Cornwall A, 1995, SOC SCI MED, V41, P1667, DOI 10.1016/0277-9536(95)00127-S; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; *CRAIG HOSP RES DE, 1999, CRAIG HAND ASS REP T; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Devins C. M., 1985, TEST CRITIQUES, V2; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fleming J., 1995, BRIT J OCCUP THER, V58, P55, DOI DOI 10.1177/030802269505800204; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Gee P, 2010, HONOLULU STAR B, V6; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HARING TG, 1992, J APPL BEHAV ANAL, V25, P319, DOI 10.1901/jaba.1992.25-319; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hoofien D, 2001, BRAIN INJURY, V15, P189; Izaute M, 2008, BRAIN INJURY, V22, P758, DOI 10.1080/02699050802366002; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Johnson K, 1998, BEHAV MODIF, V22, P502, DOI 10.1177/01454455980224004; KARPMAN T, 1985, J APPL REHABILITATIO, V17, P28; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Lazarus R.S., 1984, STRESS APPRAISAL COP; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Newsom JT, 1996, PSYCHOL AGING, V11, P34, DOI 10.1037/0882-7974.11.1.34; O'Brien J, 2006, MAKING DIFFERENCE GU; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODOM SL, 1986, J APPL BEHAV ANAL, V19, P59, DOI 10.1901/jaba.1986.19-59; ODOM SL, 1985, J APPL BEHAV ANAL, V18, P3, DOI 10.1901/jaba.1985.18-3; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Radloff L, 1977, APPL PSYCH MEAS, V1, P283; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUSSELL D, 1980, J PERS SOC PSYCHOL, V39, P472, DOI 10.1037/0022-3514.39.3.472; Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Santelli B, 1996, INFANT YOUNG CHILD, V9, P53, DOI 10.1097/00001163-199607000-00007; SANTELLI B, 1995, INFANT YOUNG CHILD, V8, P48, DOI 10.1097/00001163-199510000-00007; Sarason, 1985, SOCIAL SUPPORT THEOR, P73, DOI DOI 10.1007/978-94-009-5115-0_5; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; SPSS Inc, 2006, SPSS 15 0 WIND; Struchen MA, 2006, MAKING CONNECTIONS B; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Wallace CA, 2000, BRAIN INJURY, V14, P549; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P1187; Whiteneck GG, 1992, GUIDE USE CHART CRAI; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMSON GM, 1992, PSYCHOL AGING, V7, P343, DOI 10.1037/0882-7974.7.3.343; Williamson GM, 2000, HEALTH PSYCHOL, V19, P339, DOI 10.1037//0278-6133.19.4.339	67	83	83	1	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2011	26	1					4	19		10.1097/HTR.0b013e3182048e98			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	703GA	WOS:000285965200002	21209559				2021-06-18	
J	Hellewell, SC; Yan, EB; Agyapomaa, DA; Bye, N; Morganti-Kossmann, MC				Hellewell, Sarah C.; Yan, Edwin B.; Agyapomaa, Doreen A.; Bye, Nicole; Morganti-Kossmann, M. Cristina			Post-Traumatic Hypoxia Exacerbates Brain Tissue Damage: Analysis of Axonal Injury and Glial Responses	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; hypoxia; inflammation; macrophages; microglia; traumatic axonal injury	AMYLOID PRECURSOR PROTEIN; INTRAAXONAL NEUROFILAMENT COMPACTION; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; ULTRASTRUCTURAL-CHANGES; AXOLEMMAL PERMEABILITY; MICROGLIAL ACTIVATION; REACTIVE ASTROCYTES; SECONDARY INSULTS	Traumatic brain injury (TBI) resulting in poor neurological outcome is predominantly associated with diffuse brain damage and secondary hypoxic insults. Post-traumatic hypoxia is known to exacerbate primary brain injury; however, the underlying pathological mechanisms require further elucidation. Using a rat model of diffuse traumatic axonal injury (TAI) followed by a post-traumatic hypoxic insult, we characterized axonal pathology, macrophage/microglia accumulation, and astrocyte responses over 14 days. Rats underwent TAI alone, TAI followed by 30 min of hypoxia (TAI+Hx), hypoxia alone, or sham-operation (n=6/group). Systemic hypoxia was induced by ventilating rats with 12% oxygen in nitrogen, resulting in a similar to 50% reduction in arterial blood oxygen saturation. Brains were assessed for axonal damage, macrophage/microglia accumulation, and astrocyte activation at 1,7, and 14 days post-treatment. Immunohistochemistry with axonal damage markers (beta-amyloid precursor protein [beta-APP] and neurofilament) showed strong positive staining in TAI+Hx rats, which was most prominent in the corpus callosum (retraction bulbs 69.8 +/- 18.67; swollen axons 14.2 +/- 5.25), and brainstem (retraction bulbs 294 +/- 118.3; swollen axons 50.3 +/- 20.45) at 1 day post-injury. Extensive microglia/macrophage accumulation detected with the CD68 antibody was maximal at 14 days post-injury in the corpus callosum (macrophages 157.5 +/- 55.48; microglia 72.71 +/- 20.75), and coincided with regions of axonal damage. Astrocytosis assessed with glial fibrillary acidic protein (GFAP) antibody was also abundant in the corpus callosum and maximal at 14 days, with a trend toward an increase in TAI+Hx animals (18.99 +/- 2.45 versus 13.56 +/- 0.81; p=0.0617). This study demonstrates for the first time that a hypoxic insult following TAI perpetuates axonal pathology and cellular inflammation, which may account for the poor neurological outcomes seen in TBI patients who experience post-traumatic hypoxia.	[Hellewell, Sarah C.; Yan, Edwin B.; Agyapomaa, Doreen A.; Bye, Nicole; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Hellewell, Sarah C.; Yan, Edwin B.; Agyapomaa, Doreen A.; Bye, Nicole; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia	Morganti-Kossmann, MC (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu		Morganti-Kossmann, Cristina/0000-0002-0807-2063	Victorian Neurotrauma Initiative; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	We acknowledge the generous support of the Victorian Neurotrauma Initiative and the National Health and Medical Research Council in funding this project.	Adamides AA, 2009, ACTA NEUROCHIR, V151, P1399, DOI 10.1007/s00701-009-0398-y; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; ALLEN A, 1989, ACTA NEUROPATHOL, V78, P637, DOI 10.1007/BF00691291; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut R M, 1995, New Horiz, V3, P366; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; GUO G, 2010, J CEREB BLOOD FLOW M, V30, P628; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Iwadate Kimiharu, 2005, Legal Medicine, V7, P117, DOI 10.1016/j.legalmed.2004.10.003; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koob AO, 2006, J NEUROSCI RES, V83, P1558, DOI 10.1002/jnr.20837; Kuchta J, 2009, CENT EUR NEUROSURG, V70, P125, DOI 10.1055/s-0029-1214384; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li BY, 2009, ACTA CRYSTALLOGR E, V65, pM1, DOI 10.1107/S1600536808039846; LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637; Lovasik D, 2001, Crit Care Nurs Q, V23, P24; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mahmutyazicioglu Kamran, 2005, Diagn Interv Radiol, V11, P19; Maiti P, 2006, NEUROCHEM INT, V49, P709, DOI 10.1016/j.neuint.2006.06.002; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; Okonkwo DO, 2003, CLIN SPORT MED, V22, P467, DOI 10.1016/S0278-5919(02)00107-2; Perunovic B, 2001, J NEUROL SCI, V185, P55, DOI 10.1016/S0022-510X(01)00463-4; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P31, DOI 10.1016/S0165-3806(00)00110-3; Ramanathan L, 2005, J NEUROCHEM, V93, P47, DOI 10.1111/j.1471-4159.2004.02988.x; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; Rosenzweig HL, 2004, STROKE, V35, P2576, DOI 10.1161/01.STR.0000143450.04438.ae; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SABATES NR, 1991, J CLIN NEURO-OPHTHAL, V11, P273; Satoh JI, 2002, NEUROPATH APPL NEURO, V28, P95, DOI 10.1046/j.1365-2990.2002.00375.x; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; STOLL G, 2002, DETRIMENTAL BENEFICI; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	101	83	88	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1997	2010		10.1089/neu.2009.1245			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500007	20822466				2021-06-18	
J	Kemp, K; Hares, K; Mallam, E; Heesom, KJ; Scolding, N; Wilkins, A				Kemp, Kevin; Hares, Kelly; Mallam, Elizabeth; Heesom, Kate J.; Scolding, Neil; Wilkins, Alastair			Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival	JOURNAL OF NEUROCHEMISTRY			English	Article						bone marrow; mesenchymal stem cell; neurons; stem cell transplantation; superoxide dismutase; Purkinje cell	MARROW STROMAL CELLS; ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; P38 MAP KINASE; NITRIC-OXIDE; IN-VIVO; NEUROTROPHIC FACTOR; CORTICAL-NEURONS; C-JUN	P>It has been postulated that bone marrow-derived mesenchymal stem cells (MSCs) might be effective treatments for neurodegenerative disorders either by replacement of lost cells by differentiation into functional neural tissue; modulation of the immune system to prevent further neurodegeneration; and/or provision of trophic support for the diseased nervous system. Here we have performed a series of experiments showing that human bone marrow-derived MSCs are able to protect cultured rodent cerebellar neurons, and specifically cells expressing Purkinje cell markers, against either nitric oxide exposure or withdrawal of trophic support via cell-cell contact and/or secretion of soluble factors, or through secretion of soluble factors alone. We have demonstrated that MSCs protect cerebellar neurons against toxic insults via modulation of both the phosphatidylinositol 3-kinase/Akt and MAPK pathways and defined superoxide dismutase 3 as a secreted active antioxidant biomolecule by which MSCs modulate, at least in part, their neuroprotective effect on cerebellar cells in vitro. Together, the results demonstrate new and specific mechanisms by which MSCs promote cerebellar neuronal survival and add further evidence to the concept that MSCs may be potential therapeutic agents for neurological disorders involving the cerebellum.	[Kemp, Kevin; Hares, Kelly; Mallam, Elizabeth; Heesom, Kate J.; Scolding, Neil; Wilkins, Alastair] Univ Bristol, Inst Clin Neurosci, Multiple Sclerosis & Stem Cell Grp, Bristol, Avon, England	Kemp, K (corresponding author), Frenchay Hosp, MS Labs, Burden Ctr, 1st Floor, Bristol BS16 1JB, Avon, England.	kevin.kemp@bristol.ac.uk	Kemp, Kevin/B-9755-2017	Kemp, Kevin/0000-0003-1465-1309; Scolding, Neil/0000-0001-9177-1043	Ataxia UK; Ataxia UK [7160] Funding Source: researchfish	This work was carried out using a project grant from Ataxia UK.	Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Arnhold S, 2006, EUR J CELL BIOL, V85, P551, DOI 10.1016/j.ejcb.2006.01.015; Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; Chen RW, 2007, NEUROSCI LETT, V422, P64, DOI 10.1016/j.neulet.2007.06.004; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Christofidou-Solomidou Melpo, 2006, Treat Respir Med, V5, P47, DOI 10.2165/00151829-200605010-00004; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Devine SM, 2000, CURR OPIN HEMATOL, V7, P358, DOI 10.1097/00062752-200011000-00007; Diem R, 2001, J NEUROSCI, V21, P2058, DOI 10.1523/JNEUROSCI.21-06-02058.2001; Du YL, 2008, EXP BIOL MED, V233, P881, DOI 10.3181/0712-RM-329; Eilers A, 1998, J NEUROSCI, V18, P1713; Encinas M, 2001, J NEUROSCI, V21, P1464; Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818; Estevez AG, 1998, J NEUROSCI, V18, P923; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; HARRIS CA, 1991, J IMMUNOL, V147, P149; He F, 2008, COLLOID SURFACE B, V61, P290, DOI 10.1016/j.colsurfb.2007.09.009; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Isele NB, 2007, NEUROCHEM INT, V50, P243, DOI 10.1016/j.neuint.2006.08.007; Ishikawa Y, 2003, MOL CELL NEUROSCI, V24, P451, DOI 10.1016/S1044-7431(03)00203-3; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Klesse LJ, 1998, J NEUROSCI, V18, P10420; Lanza C, 2009, J NEUROCHEM, V110, P1674, DOI 10.1111/j.1471-4159.2009.06268.x; Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301-472X(03)00110-3; Lin SZ, 2001, NEUROSCI LETT, V315, P61, DOI 10.1016/S0304-3940(01)02324-2; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; Nozik-Grayck E, 2005, INT J BIOCHEM CELL B, V37, P2466, DOI 10.1016/j.biocel.2005.06.012; Park SY, 2002, MOL BRAIN RES, V107, P9, DOI 10.1016/S0169-328X(02)00421-7; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ratnam DV, 2006, J CONTROL RELEASE, V113, P189, DOI 10.1016/j.jconrel.2006.04.015; Sayre LM, 2008, CHEM RES TOXICOL, V21, P172, DOI 10.1021/tx700210j; Sun XM, 2008, INT J DEV NEUROSCI, V26, P363, DOI 10.1016/j.ijdevneu.2007.11.005; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Wijesekera LC, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-3; Wilkins A, 2001, GLIA, V36, P48, DOI 10.1002/glia.1094; Wilkins A, 2005, J NEUROCHEM, V92, P1487, DOI 10.1111/j.1471-4159.2004.02981.x; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamagishi S, 2003, MOL BRAIN RES, V119, P184, DOI 10.1016/j.molbrainres.2003.09.009; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhang J, 2006, J NEUROSCI RES, V84, P587, DOI 10.1002/jnr.20962; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005	57	83	90	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2010	114	6					1569	1580		10.1111/j.1471-4159.2009.06553.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	646NQ	WOS:000281549600004	20028455	Bronze			2021-06-18	
J	Morganti-Kossmann, MC; Yan, E; Bye, N				Morganti-Kossmann, M. C.; Yan, E.; Bye, N.			Animal models of traumatic brain injury: Is there an optimal model to reproduce human brain injury in the laboratory?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article; Proceedings Paper	Annual Trauma Research Methods Workshop	NOV 19, 2009	Monash Univ, Melbourne, AUSTRALIA	Australian Natl Trauma Res Inst	Monash Univ	Model of brain injury; Diffuse injury; Focal injury; Rodents; In vitro models	CLOSED-HEAD INJURY; PATHOPHYSIOLOGY; MICE; NEUROPROTECTION; RATS; COMA	Compared to other neurological diseases, the research surrounding traumatic brain injury (TBI) has a more recent history. The establishment and use of animal models of TBI remains vital to understand the pathophysiology of this highly complex disease. Such models share the ultimate goals of reproducing patterns of tissue damage observed in humans (thus rendering them clinically relevant), reproducible and highly standardised to allow for the manipulation of individual variables, and to finally explore novel therapeutics for clinical translation. There is no doubt that the similarity of cellular and molecular events observed in human and rodent TBI has reinforced the use of small animals for research. When confronted with the choice of the experimental model it becomes clear that the ideal animal model does not exist. This limitation derives from the fact that most models mimic either focal or diffuse brain injury, whereas the clinical reality suggests that each patient has an individual form of TBI characterised by various combinations of focal and diffuse patterns of tissue damage. This is additionally complicated by the occurrence of secondary insults such as hypotension, hypoxia, ischaemia, extracranial injuries, modalities of traumatic events, age, gender and heterogeneity of medical treatments and pre-existing conditions. This brief review will describe the variety of TBI models available for laboratory research beginning from the most widely used rodent models of focal brain trauma, to complex large species such as the pig. In addition, the models mimicking diffuse brain damage will be discussed in relation to the early primate studies until the use of most common rodent models to elucidate the intriguing and less understood pathology of axonal dysfunction. The most recent establishment of in vitro paradigms has complemented the in vivo modelling studies offering a further cellular and molecular insight of this pathology. (C) 2010 Elsevier Ltd. All rights reserved.	[Morganti-Kossmann, M. C.; Yan, E.; Bye, N.] Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Morganti-Kossmann, M. C.; Yan, E.; Bye, N.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia	Morganti-Kossmann, MC (corresponding author), Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@med.monash.edu.au		Morganti-Kossmann, Cristina/0000-0002-0807-2063			Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Centers for Disease Control and Prevention, 2001, TRAUM BRAIN INJ US R; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1996, LAB INVEST, V74, P315; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42	30	83	87	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JUL	2010	41			1			10	13		10.1016/j.injury.2010.03.032			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	617ZV	WOS:000279321600004	20416875				2021-06-18	
J	Chaput, G; Giguere, JF; Chauny, JM; Denis, R; Lavigne, G				Chaput, Genevieve; Giguere, Jean-Francois; Chauny, Jean-Marc; Denis, Ronald; Lavigne, Gilles			Relationship among subjective sleep complaints, headaches, and mood alterations following a mild traumatic brain injury	SLEEP MEDICINE			English	Article						Mild traumatic brain injury; Sleep complaints; Headaches; Mood alterations; Symptoms; Risk factor; Irritability; Depression	CLOSED-HEAD-INJURY; POSTCONCUSSION SYMPTOMS; RECOVERY; SCALE	Background: Sleep complaints (e.g., frequent awakenings, nightmares), headaches and mood alterations (e.g., feeling depressed, irritable) can appear following a mild traumatic brain injury (MTBI). The objective of this retrospective study was to assess the relationships between the above symptoms. Our hypothesis was that sleep complaints might be among the risk factors for the development of headaches and mood alterations. Methods: The consecutive charts of 443 patients (68.2% males vs. 31.8% female; mean age of 46.9 years) diagnosed with MTBI were reviewed for past medical history and above symptoms using the Rivermead post-concussion symptom assessment questionnaire and self-report. Data were retrieved in 2 time courses: 10 days and 6 weeks. Results: For the 2 time Courses, the prevalence of subjective sleep complaints were 13.3% and 33.5%; headaches 46.8% and 39.3%; feeling depressed 9.5% and 20.4%; and feeling irritable 5.6% and 20.2%, respectively. Reports of sleep complaints at 6 weeks were 2.9 times (p = 0.004) more likely if such a symptom was reported at 10 days. Moreover, the presence of sleep complaints at 10 days is associated with concomitant headaches, depressive symptoms, and feeling irritable by 2.3, 9.9, and 12.2 times (p = 0.0001 and 0.014): and by 2.9, 6.3, and 4.8 times (p = 0.0001) at 6 weeks, respectively. Conclusions: Our results suggest that patients afflicted with sleep complaints are more likely to suffer from concomitant headaches, depressive symptoms, and irritability. (C) 2008 Elsevier B.V. All rights reserved.	[Chaput, Genevieve; Giguere, Jean-Francois; Chauny, Jean-Marc; Denis, Ronald; Lavigne, Gilles] Univ Montreal, Hop Sacre Coeur, Dept Surg, Div Trauma Res, Montreal, PQ H4J 1C5, Canada; [Chaput, Genevieve; Lavigne, Gilles] Univ Montreal, Fac Med Dent, Montreal, PQ H3C 3J7, Canada; [Chaput, Genevieve; Lavigne, Gilles] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada	Lavigne, G (corresponding author), Univ Montreal, Hop Sacre Coeur, Dept Surg, Div Trauma Res, 5400 Blvd Gouin W, Montreal, PQ H4J 1C5, Canada.	gilles.lavigne@umontreal.ca	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604	CIHR/Pain M2CCanadian Institutes of Health Research (CIHR); Hopital du Sacre-Coeur de Montreal (Canada); FRSQFonds de la Recherche en Sante du Quebec	This study was supported by a CIHR/Pain M2C Training grant, as well as trauma hospital funds from Hopital du Sacre-Coeur de Montreal (Canada) and FRSQ to the Research Center. Our sincere thanks to Ariane Demers of the Trauma team for her valuable help in accessing MTBI patient charts, and to jean Paquet for statistics.	ALVES WM, 1993, PHYS MED REHABIL, V6, P21; Bay Esther, 2007, J Neurosci Nurs, V39, P43; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Chervin RD, 1999, NEUROLOGY, V52, P125, DOI 10.1212/WNL.52.1.125; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; KING N, 1995, J NEUROL, V242, P1432; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus JCL, 2005, TXB TRAUMATIC BRAIN; LINDSAY JT, 1998, J NEUROTRAUM, V15, P573; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; McHugh T, 2006, BRAIN COGNITION, V60, P209; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Olson LG, 1998, J SLEEP RES, V7, P248, DOI 10.1046/j.1365-2869.1998.00123.x; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	29	83	85	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	AUG	2009	10	7					713	716		10.1016/j.sleep.2008.07.015			4	Clinical Neurology	Neurosciences & Neurology	487UI	WOS:000269301700004	19147402				2021-06-18	
J	Knox, L; Douglas, J				Knox, Lucy; Douglas, Jacinta			Long-term ability to interpret facial expression after traumatic brain injury and its relation to social integration	BRAIN AND COGNITION			English	Article						Traumatic brain injury; Facial expression; Pragmatics; Social integration	QUALITY-OF-LIFE; NEURAL SYSTEMS; COMMUNICATION; RECOGNITION; EMOTION; PERCEPTION; FACES; COMPETENCE; HANDICAP; BEHAVIOR	There is considerable evidence that individuals with traumatic brain injury (TBI) experience problems interpreting the emotional state of others. However, the functional implications of these changes have not been fully investigated. A study of 13 individuals with severe TBI and an equal number of matched controls found that TBI participants had significantly more difficulty interpreting facial expression and matching emotions to social situations. A significant relationship was also established between social integration and ability to interpret facial expression for TBI participants. These results support the inclusion of therapy targeting this area within rehabilitation programs for individuals with TBI. Crown Copyright (C) 2008 Published by Elsevier Inc. All rights reserved.	[Knox, Lucy; Douglas, Jacinta] La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia	Douglas, J (corresponding author), La Trobe Univ, Sch Human Commun Sci, Kingsbury Dr, Bundoora, Vic 3086, Australia.	j.douglas@latrobe.edu.au	Knox, Lucy/E-8642-2013; Douglas, Jacinta M/C-2380-2009	Knox, Lucy/0000-0001-8331-6032; Douglas, Jacinta/0000-0003-0940-6624			Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Adolphs R, 1996, J NEUROSCI, V16, P7678; ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; BASSILI JN, 1978, J EXP PSYCHOL HUMAN, V4, P373, DOI 10.1037/0096-1523.4.3.373; BAYLES K, 1990, ARIZONA BATTERY COMM; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Birdwhistell R.L., 1970, KINESICS CONTEXT ESS; Borgaro SR, 2004, BRAIN INJURY, V18, P33, DOI 10.1080/0269905031000110562; BOROD JC, 1986, NEUROPSYCHOLOGIA, V24, P169; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; BURLEIGH SA, 1997, AM J OCCUPATIONAL TH, V52, P42; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DEKOSKY ST, 1980, BRAIN LANG, V9, P206, DOI 10.1016/0093-934X(80)90141-8; Douglas J., 2004, EVIDENCE BASED PRACT, P59; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; KAROW CM, 2003, SEMINARS SPEECH LANG, V242, P69; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Mandal MK, 1996, INT J NEUROSCI, V84, P87, DOI 10.3109/00207459608987253; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; Matsumoto D, 2004, JAPANESE CAUCASIAN F; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; MCDONALD S, 1999, BRAIN DAM B, P19; MCDONALD S, 2003, BRAIN IMPAIR, V4, P36, DOI DOI 10.1375/brim.4.1.36.27032; McDonald S., 2002, AWARENESS SOCIAL INF; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Morris JS, 1998, NATURE, V393, P467, DOI 10.1038/30976; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perry RJ, 2001, NEUROCASE, V7, P145, DOI 10.1093/neucas/7.2.145; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	48	83	83	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	MAR	2009	69	2					442	449		10.1016/j.bandc.2008.09.009			8	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	410MP	WOS:000263581900026	18951674				2021-06-18	
J	Le, TH; Gean, AD				Le, Tuong H.; Gean, Ahsa D.			Neuroimaging of Traumatic Brain Injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						brain herniation; cerebral edema; diffuse axonal injury; epidural hematoma; intracerebral hematoma; intraventricular hemorrhage; subarachnoid hemorrhage; subdural hematoma; traumatic brain injury	DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CT; MR; SPECT; RULE; METHODOLOGY; FLAIR; TIME	In this article, the neuroradiological evaluation of traumatic brain injury is reviewed. Different imaging strategies in the assessment of traumatic brain injury are initially discussed, and this is followed by a review of the imaging characteristics of both primary and secondary brain injuries. Computed tomography remains the modality of choice for the initial assessment of acute head injury because it is fast, widely available, and highly accurate in the detection of skull fractures and acute intracranial hemorrhage. Magnetic resonance imaging is recommended for patients with acute traumatic brain injury when the neurological findings are unexplained by computed tomography. Magnetic resonance imaging also the modality of choice for the evaluation of subacute or chronic traumatic brain injury. Mild traumatic brain injury continues to be difficult to diagnose with current imaging technology. Advanced magnetic resonance techniques, such as diffusion-weighted imaging, magnetic resonance spectroscopy, and magnetization transfer imging, can improve the identification of traumatic brain injury, especially in the case of mild traumatic brain injury. Further research is needed for other advanced imaging method such as magnetic source imaging, single photon emission tomography, and positron emission tomography. Mt. Sinai J Med 76:145-162, 2009 (C) 2009 Mount Sinai School of Medicine	[Le, Tuong H.; Gean, Ahsa D.] San Francisco Gen Hosp, Brain & Spinal Cord Injury Ctr, Dept Radiol, San Francisco, CA 94110 USA	Gean, AD (corresponding author), San Francisco Gen Hosp, Brain & Spinal Cord Injury Ctr, Dept Radiol, San Francisco, CA 94110 USA.	alisa.gean@radiology.ucsf.edu					ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Adams JH, 1991, NEUROIMAG CLIN N AM, V1, P397; Al-Nakshabandi NA, 2001, RADIOLOGY, V218, P433, DOI 10.1148/radiology.218.2.r01fe09433; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Frigon C, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790791; Gean A D, 1995, New Horiz, V3, P549; GEAN AD, 1994, IMAGING HEAD TRAUMA, P76; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Gentry LR., 1996, MAGNETIC RESONANCE I, P611; GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HACKNEY DB, 1991, RADIOLOGY, V181, P711, DOI 10.1148/radiology.181.3.1947086; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Le TH, 2006, SEMIN ROENTGENOL, V41, P177, DOI 10.1053/j.ro.2006.04.003; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; MASTERS SJ, 1980, AM J ROENTGENOL, V135, P539, DOI 10.2214/ajr.135.3.539; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Noguchi K, 1997, RADIOLOGY, V203, P257, DOI 10.1148/radiology.203.1.9122404; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Sodickson DK, 1997, MAGNET RESON MED, V38, P591, DOI 10.1002/mrm.1910380414; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Woodcock RJ, 2001, AM J NEURORADIOL, V22, P1698; Zee CS, 1998, NEUROIMAG CLIN N AM, V8, P525	45	83	90	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					145	162		10.1002/msj.20102			18	Medicine, General & Internal	General & Internal Medicine	427OE	WOS:000264787800008	19306377				2021-06-18	
J	Snell, D; Surgenor, L; Hay-Smith, EJ; Siegert, R				Snell, Deborah L.; Surgenor, Lois J.; Hay-Smith, E. Jean C.; Siegert, Richard J.			A systematic review of psychological treatments for mild traumatic brain injury: An update on the evidence	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Rehabilitation outcomes; Psychological interventions; Systematic review; Neuropsychological interventions	POST-CONCUSSION SYNDROME; ROUTINE FOLLOW-UP; HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; EARLY INTERVENTION; RANDOMIZED-TRIAL; INDIVIDUALS; ATTENTION; RECOVERY; IMPACT	Mild traumatic brain injury (MTBI) is common and results in persisting disability for a minority of cases. Evidence guiding clinical management of this more complex group is lacking. This study systematically reviews psychological/neuropsychological treatments for adults with MTBI, with an emphasis on external validity. A total of 8 further studies were found adding to 10 from previous reviews. Although the methodological quality remains poor, mild supportive evidence was found for educational interventions provided early following injury. However, the routine provision of interventions for all MTBI cases may not be effective. Continuing and novel research efforts are needed to identify factors associated with poor outcomes to enable efficient targeting of healthcare resources.	[Snell, Deborah L.; Hay-Smith, E. Jean C.] Univ Otago, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Surgenor, Lois J.] Univ Otago, Dept Psychol Med, Christchurch, New Zealand; [Siegert, Richard J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Sch Med Guys, London WC2R 2LS, England; [Siegert, Richard J.] Kings Coll London, St Thomas Hosp, London WC2R 2LS, England	Snell, D (corresponding author), Burwood Hosp, Brain Injury Rehabil Serv, Private Bag 4708, Christchurch, New Zealand.	deborah.snell@cdhb.govt.nz	Siegert, Richard J./K-2030-2019	Siegert, Richard/0000-0002-3074-0929			Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; DeJong G, 2005, NZ J DISABILITY STUD, V11, P120; Egger M, 2002, INT J EPIDEMIOL, V31, P1, DOI 10.1093/ije/31.1.1; Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P58; Hinkle J L, 1986, J Neurosci Nurs, V18, P268; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Hopewell S, 2002, STAT MED, V21, P1625, DOI 10.1002/sim.1191; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEONARD KN, 2004, THESIS U TEXAS AUSTI; Leventhal H, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P19; Leventhal H, 2008, ANNU REV PSYCHOL, V59, P477, DOI 10.1146/annurev.psych.59.103006.093643; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Onghena P, 2005, CLIN J PAIN, V21, P56, DOI 10.1097/00002508-200501000-00007; Pachankis JE, 2007, CLIN PSYCHOL REV, V27, P760, DOI 10.1016/j.cpr.2007.01.009; Palmese CA, 2000, BRAIN INJURY, V14, P535; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Peer JE, 2007, CLIN PSYCHOL REV, V27, P696, DOI 10.1016/j.cpr.2007.01.004; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rief W, 2007, CLIN PSYCHOL REV, V27, P821, DOI 10.1016/j.cpr.2007.07.005; Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILSON B, 1997, REHABILITATION STUDI, P161; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	57	83	84	0	20	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	1					20	38	PII 792843407	10.1080/13803390801978849			19	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	384IT	WOS:000261739200003	18608646				2021-06-18	
J	Gao, X; Deng-Bryant, Y; Cho, W; Carrico, KM; Hall, ED; Chen, JH				Gao, Xiang; Deng-Bryant, Ying; Cho, Wongil; Carrico, Kimberly M.; Hall, Edward D.; Chen, Jinhui			Selective death of newborn neurons in hippocampal dentate gyrus following moderate experimental traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; controlled cortical impact; cell death; dentate gyrus; Fluoro-Jade B	CONTROLLED CORTICAL IMPACT; GENERATED GRANULE CELLS; FLUORO-JADE-B; ADULT NEUROGENESIS; IN-VITRO; STEM-CELLS; SUBUNIT COMPOSITION; EXCITATORY ACTIONS; MOUSE MODEL; RAT	Memory impairment is one of the most significant residual deficits following traumatic brain injury (TBI) and is among the most frequent complaints heard from patients and their relatives. It has been reported that the hippocampus is particularly vulnerable to TBI, which results in hippocampus-dependent cognitive impairment. There are different regions in the hippocampus, and each region is composed of different cell types, which might respond differently to TBI. However, regional and cell type-specific neuronal death following TBI is not well described. Here, we examined the distribution of degenerating neurons in the hippocampus of the mouse brain following controlled cortical impact (CCI) and found that the majority of degenerating neurons observed were in the dentate gyrus after moderate (0.5 mm cortical deformation) CCI-TBI. In contrast, there were only a few degenerating neurons observed in the hilus, and we did not observe any degenerating neurons in the CA3 or CA1 regions. Among those degenerating cells in the dentate gyrus, about 80% of them were found in the inner granular neuron layer. Analysis with cell type-specific markers showed that most of the degenerating neurons in the inner granular neuron layer are newborn immature neurons. Further quantitative analysis shows that the number of newborn immature neurons in the dentate gyrus is dramatically decreased in the ipsilateral hemisphere compared with the contralateral side. Collectively, our data demonstrate the selective death of newborn immature neurons in the hippocampal dentate gyrus following moderate injury with CCI in mice. This selective vulnerability of newborn immature dentate neurons may contribute to the persistent impairment of learning and memory post-TBI and provide an innovative target for neuroprotective treatment strategies. (c) 2008 Wiley-Liss, Inc.	[Deng-Bryant, Ying; Hall, Edward D.; Chen, Jinhui] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Gao, Xiang; Deng-Bryant, Ying; Cho, Wongil; Carrico, Kimberly M.; Hall, Edward D.; Chen, Jinhui] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Chen, JH (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, 741 S Limestone St, Lexington, KY 40536 USA.	jchen@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566, R21NS072631, R21NS075733] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS046566, R21 NS075733, R01 NS046566, R21 NS072631] Funding Source: Medline		ALTMAN J, 1990, J COMP NEUROL, V301, P343, DOI 10.1002/cne.903010303; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; ALTMAN J, 1990, J COMP NEUROL, V301, P325, DOI 10.1002/cne.903010302; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chen G, 1996, J PHYSIOL-LONDON, V494, P451, DOI 10.1113/jphysiol.1996.sp021505; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Flint AC, 1997, J NEUROSCI, V17, P2469; Forster E, 2006, NAT REV NEUROSCI, V7, P259, DOI 10.1038/nrn1882; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Gupta Y K, 2006, Indian J Physiol Pharmacol, V50, P7; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Jagasia R, 2006, TRENDS MOL MED, V12, P400, DOI 10.1016/j.molmed.2006.07.006; Jiang Taipeng, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P392; Kelly Kevin M, 2004, Epilepsy Curr, V4, P160, DOI 10.1111/j.1535-7597.2004.44015.x; Kempermann G, 2006, P NATL ACAD SCI USA, V103, P780, DOI 10.1073/pnas.0510291103; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kim JH, 2003, METHOD ENZYMOL, V365, P303; Koizumi H, 2006, NEURON, V49, P55, DOI 10.1016/j.neuron.2005.10.040; Korzhevskii D E, 2006, Neurosci Behav Physiol, V36, P857, DOI 10.1007/s11055-006-0098-5; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu YB, 1996, J NEUROPHYSIOL, V76, P1074; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Mehrholz J, 2005, CLIN REHABIL, V19, P63, DOI 10.1191/0269215505cr824oa; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; Mizumori SJY, 2001, REV NEUROSCIENCE, V12, P347; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Overstreet-Wadiche LS, 2006, HIPPOCAMPUS, V16, P208, DOI 10.1002/hipo.20152; Overstreet-Wadiche LS, 2006, J NEUROSCI, V26, P2326, DOI 10.1523/JNEUROSCI.4111-05.2006; Owens DF, 2002, NEURON, V36, P989, DOI 10.1016/S0896-6273(02)01136-4; Pandis C, 2006, NEUROSCIENCE, V140, P163, DOI 10.1016/j.neuroscience.2006.02.003; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Prigatano GP, 2005, ACT NEUR S, V93, P39; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Represa A, 2005, TRENDS NEUROSCI, V28, P278, DOI 10.1016/j.tins.2005.03.010; Rivera C, 2005, J PHYSIOL-LONDON, V562, P27, DOI 10.1113/jphysiol.2004.077495; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sipila ST, 2005, J NEUROSCI, V25, P5280, DOI 10.1523/JNEUROSCI.0378-05.2005; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423; Somogyi P, 2005, J PHYSIOL-LONDON, V562, P9, DOI 10.1113/jphysiol.2004.078915; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Thomas CG, 2006, J NEUROPHYSIOL, V95, P1727, DOI 10.1152/jn.00771.2005; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Toni N, 2007, NAT NEUROSCI, V10, P727, DOI 10.1038/nn1908; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Traub RD, 2004, ANNU REV NEUROSCI, V27, P247, DOI 10.1146/annurev.neuro.27.070203.144303; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Ye GL, 2005, DEV BRAIN RES, V155, P26, DOI 10.1016/j.devbrainres.2004.12.002; Ye GL, 2000, DEV BRAIN RES, V124, P33, DOI 10.1016/S0165-3806(00)00103-6; ZHANG TY, 2006, PSYCHOPHARM IN PRESS; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	94	83	86	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 1	2008	86	10					2258	2270		10.1002/jnr.21677			13	Neurosciences	Neurosciences & Neurology	331MB	WOS:000258015200013	18381764	Green Accepted			2021-06-18	
J	Schirmer-Mikalsen, K; Vik, A; Gisvold, SE; Skandsen, T; Hynne, H; Klepstad, P				Schirmer-Mikalsen, K.; Vik, A.; Gisvold, S. E.; Skandsen, T.; Hynne, H.; Klepstad, P.			Severe head injury: control of physiological variables, organ failure and complications in the intensive care unit	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						severe head injury; secondary brain injury; control of physiological variables; intensive care; outcome; pneumonia	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; MARKED NEUROPROTECTIVE EFFICACY; SECONDARY ISCHEMIC INSULTS; COLLOID ONCOTIC PRESSURE; INTRACRANIAL-PRESSURE; VOLUME REGULATION; ALBUMIN THERAPY; LUND CONCEPT; BLOOD-FLOW	Background: In patients with severe head injury, control of physiological variables is important to avoid intracranial hypertension and secondary injury to the brain. The aims of this retrospective study were to evaluate deviations of physiological variables and the incidence of extracranial complications in patients with severe head injury. We also studied if these deviations could be related to outcome. Patients and methods: One hundred and thirty-three patients were included during a 5-year period (1998-2002). Deviations from treatment goals for the following physiological variables were studied: blood pressure, haemoglobin, blood sugar, serum sodium, serum albumin and temperature. Extra cerebral organ complications were also recorded as well as outcome at 6 months. Results: The median age was 32 years (range; 1-88 years). Median Glasgow Coma Scale (GCS) before intubation was 6 (range; 3-14). The frequencies of severe deviations from the desired values of the physiological variables for at least one treatment day were: hypotensive episodes (systolic BP < 90 mmHg) - 20%, anaemia (hgb < 8 g/dL) - 22%, blood glucose > 10 mmol/1 - 26%, serum sodium concentration < 130 mmol/1 - 10%, serum albumin < 25 g/l(-1) - 31% and hyperthermia > 39 degrees C - 24%. Pneumonia was diagnosed in 71% and Acute Lung Injury (ALI)/Adult Respiratory Distress Syndrome (ARDS) in 26% of the patients. Other complications such as severe sepsis (6%), renal failure (1.5%), a coagulation disorder (6%) and liver failure (one patient) were infrequent. Age, GCS, hypotension during the first day of treatment, elevated blood sugar and low albumin predicted an unfavourable outcome. Conclusions: Deviations of key physiological variables and pulmonary complications were frequent in patients suffering from severe head injury. During intensive care treatment, hypotension, elevated blood sugar and hypoalbuminemia are possible independent predictors of an unfavourable outcome.	St Olav Uni Hosp, Dept Anaesthesia & Acute Med, Trondheim, Norway; St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway; St Olavs Univ Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; Norwegian Univ Sci & Technol, Fac Med, Dept Circulat & Med Imaging, Trondheim, Norway; Norwegian Univ Sci & Technol, Fac Med, Dept Neurosci, Trondheim, Norway	Schirmer-Mikalsen, K (corresponding author), St Olav Uni Hosp, Dept Anaesthesia & Acute Med, Trondheim, Norway.	kari.schirmer@stolav.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Drummond JC, 1998, ANESTHESIOLOGY, V88, P993, DOI 10.1097/00000542-199804000-00020; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Gisvold SE, 2001, ACTA ANAESTH SCAND, V45, P399, DOI 10.1034/j.1399-6576.2001.045004399.x; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; HAKAMATA Y, 1995, STROKE, V26, P2149, DOI 10.1161/01.STR.26.11.2149; HARRISON MJG, 1981, LANCET, V2, P114, DOI 10.1016/S0140-6736(81)90298-1; Haynes GR, 2003, EUR J ANAESTH, V20, P771, DOI 10.1097/00003643-200310000-00003; Janssens U, 2000, INTENS CARE MED, V26, P1037, DOI 10.1007/s001340051316; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P554, DOI 10.1097/00000542-198910000-00013; Kongstad L, 1999, ACTA ANAESTH SCAND, V43, P501, DOI 10.1034/j.1399-6576.1999.430503.x; LANIER WL, 1987, ANESTHESIOLOGY, V66, P39, DOI 10.1097/00000542-198701000-00008; Leonard K, 2006, SOC SCI MED, V63, P2330, DOI 10.1016/j.socscimed.2006.06.003; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Portella G, 2005, ACTA NEUROCHIR, V147, P707, DOI 10.1007/s00701-005-0537-z; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schoon P, 2002, ACT NEUR S, V81, P285; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; THOMAS DJ, 1977, LANCET, V2, P941, DOI 10.1016/S0140-6736(77)90885-6; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	40	83	91	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2007	51	9					1194	1201		10.1111/j.1399-6576.2007.01372.x			8	Anesthesiology	Anesthesiology	209GE	WOS:000249376200012	17711565				2021-06-18	
J	Dusick, JR; Glenn, TC; Lee, WP; Vespa, PM; Kelly, DF; Lee, SM; Hovda, DA; Martin, NA				Dusick, Joshua R.; Glenn, Thomas C.; Lee, Wn Paul; Vespa, Paul M.; Kelly, Daniel F.; Lee, Stefan M.; Hovda, David A.; Martin, Neil A.			Increased pentose phosphate pathway flux after clinical traumatic brain injury: a [1,2-C-13(2)]glucose labeling study in humans	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						glucose; hyperglycolysis; lactate; metabolism; pentose phosphate cycle; traumatic brain injury	ACID CYCLE FLUX; MASS ISOTOPOMER ANALYSIS; CEREBRAL-BLOOD-FLOW; HEAD-INJURY; GLUCOSE-METABOLISM; IN-VIVO; RAT-BRAIN; LIPID-PEROXIDATION; OXIDATIVE STRESS; UP-REGULATION	Patients with traumatic brain injury (TBI) routinely exhibit cerebral glucose uptake in excess of that expected by the low levels of oxygen consumption and lactate production. This brings into question the metabolic fate of glucose. Prior studies have shown increased flux through the pentose phosphate cycle (PPC) during cellular stress. This study assessed the PPC after TBI in humans. [1,2-C-13(2)]glucose was infused for 60 mins in six consented, severe-TBI patients (GCS<9) and six control subjects. Arterial and jugular bulb blood sampled during infusion was analyzed for C-13-labeled isotoporners of lactate by gas chromatography/mass spectroscopy. The product of lactate concentration and fractional abundance of isotoporners was used to determine blood concentration of each isotopomer. The difference of jugular and arterial concentrations determined cerebral contribution. The formula PPC=(m1/m2)/(3+(m1/m2)) was used to calculate PPC flux relative to glycolysis. There was enrichment of [1,2-C-13(2)]glucose in arterial-venous blood (enrichment averaged 16.6% in TBI subjects and 28.2% in controls) and incorporation of C-13- label into lactate, showing metabolism of labeled substrate. The PPC was increased in TBI patients relative to controls (19.6 versus 6.9%, respectively; P= 0.002) and was excellent for distinguishing the groups (AUC=0.944, P<0.0001). No correlations were found between PPC and other clinical parameters, although PPC was highest in patients studied within 48 of injury (averaging 33% versus 13% in others; P= 0.0006). This elevation in the PPC in the acute period after severe TBI likely represents a shunting of substrate into alternative biochemical pathways that may be critical for preventing secondary injury and initiating recovery.	Univ Calif Los Angeles, Med Ctr, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Med Ctr, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; Harbor UCLA Med Ctr, Div Endocrinol, Torrance, CA 90509 USA; Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA USA	Glenn, TC (corresponding author), Univ Calif Los Angeles, Med Ctr, Div Neurosurg, 10833 Le Conte Ave,Room 18-265 NPI,Mail Code 7039, Los Angeles, CA 90095 USA.	t-lenn@mednet.ucla.edu		Glenn, Thomas/0000-0003-4273-3408; Martin, Neil/0000-0002-6565-4131	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NINDS 30308] Funding Source: Medline		Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; BAQUER NZ, 1988, CURR TOP CELL REGUL, V29, P265; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; BEACONSFIELD PETER, 1963, LIFE SCI, V7, P459; BENYOSEPH O, 1995, J NEUROCHEM, V64, P1336; BenYoseph O, 1996, J NEUROCHEM, V66, P2329; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Boros LG, 2002, DRUG DISCOV TODAY, V7, P364, DOI 10.1016/S1359-6446(02)02179-7; DIPIETRO DAVID, 1959, ARCH BIOCHEM AND BIOPHYS, V80, P268, DOI 10.1016/0003-9861(59)90251-6; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gruetter R, 2002, NEUROCHEM INT, V41, P143, DOI 10.1016/S0197-0186(02)00034-7; GUERRA RM, 1967, BIOCHIM BIOPHYS ACTA, V148, P356, DOI 10.1016/0304-4165(67)90131-6; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HARKONEN MH, 1974, BRAIN RES, V65, P141, DOI 10.1016/0006-8993(74)90341-2; HOSTETLE.KY, 1970, J NEUROCHEM, V17, P33, DOI 10.1111/j.1471-4159.1970.tb00499.x; HOSTETLE.KY, 1967, BIOCHEMISTRY-US, V6, P2961, DOI 10.1021/bi00862a001; HOTHERSALL JS, 1982, J NEUROCHEM, V39, P1325, DOI 10.1111/j.1471-4159.1982.tb12574.x; HOVDA DA, 1996, NEUROTRAUMA, P1459; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; KATZ J, 1989, J BIOL CHEM, V264, P12994; KATZ J, 1960, J BIOL CHEM, V235, P2165; KRASS ME, 1967, IOCH BIOPHYS ACTA, V148, P384; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Lee WNP, 1996, DEV NEUROSCI-BASEL, V18, P469, DOI 10.1159/000111442; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843; LEHNINGER AL, 2005, LEHNINGER PRINCIPLES, P549; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; Ross B, 2003, NMR BIOMED, V16, P358, DOI 10.1002/nbm.852; Rothman DL, 2003, ANNU REV PHYSIOL, V65, P401, DOI 10.1146/annurev.physiol.65.092101.142131; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF	42	83	84	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2007	27	9					1593	1602		10.1038/sj.jcbfm.9600458			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	202ZY	WOS:000248946100007	17293841	Bronze			2021-06-18	
J	O'Connor, CA; Cernak, I; Johnson, F; Vink, R				O'Connor, Christine A.; Cernak, Ibolja; Johnson, Felicity; Vink, Robert			Effects of progesterone on neurologic and morphologic outcome following diffuse traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						hormone; neurotrauma; progesterone; traumatic brain injury; gender	AMYLOID PRECURSOR PROTEIN; NEUROTROPHIC FACTOR; SPINAL-CORD; GENDER-DIFFERENCES; SEX-HORMONES; BLOOD-FLOW; ESTROGEN; EDEMA; EPIDEMIOLOGY; CONTUSION	Previous studies have identified that progesterone may be neuroprotective following traumatic brain injury (TBI). However, most of these have utilized models of TBI that produce a focal lesion or a significant ischemic component, neither of which is necessarily present in diffuse TBI. The current study uses a model of diffuse TBI in rats to examine the effects of progesterone on morphological changes and functional outcome following TBI. Male and ovariectomized female rats were subject to severe impact-acceleration injury under halothane anesthesia. After injury, animals were given a physiological, subcutaneous dose of progesterone (1.67 mg/kg) or equal volume of vehicle (sesame oil) daily throughout a 9-day neurologic assessment period where functional outcome was assessed using the rotarod and Barnes maze tests. There was a similar postinjury performance of male and ovariectomized female animals. Post-injury administration of progesterone improved the motor and cognitive performance of ovariectomized and male animals compared to vehicle-treated controls. Morphological differences between these animals, such as dark cell change, caspase-3 and APP immunoreactivity, were also investigated. Progesterone-treated males showed comparatively less dead or dying neurons, and marked attenuation of caspase-3 immunoreactivity. Both ovariectomized female and male animals treated with progesterone showed a profound reduction in axonal injury (seen via diminished APP immunoreactivity) when compared to controls. We conclude that physiological concentrations of progesterone administered after diffuse TBI confers beneficial effects on morphologic and functional outcome in both ovariectomized female and male animals. (C) 2007 Elsevier Inc. All rights reserved.	Univ Adelaide, Discipline Pathol, Adelaide, SA 5005, Australia; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20732 USA	Vink, R (corresponding author), Univ Adelaide, Discipline Pathol, Adelaide, SA 5005, Australia.	christine.o'connor@adelaide.edu.au; ibolja.cernak@hjhuapl.edu; felicity.johnson@adelaide.edu.au; Robert.Vink@adelaide.edu.au	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Duval P, 1998, J NEUROENDOCRINOL, V10, P823; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Franklin TB, 2006, PSYCHONEUROENDOCRINO, V31, P38, DOI 10.1016/j.psyneuen.2005.05.008; Gibbs RB, 1999, BRAIN RES, V844, P20, DOI 10.1016/S0006-8993(99)01880-6; Gibbs RB, 1998, BRAIN RES, V810, P294; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hillier SL, 1997, BRAIN INJURY, V11, P649; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Muneyyirci-Delale O, 1999, FERTIL STERIL, V72, P817, DOI 10.1016/S0015-0282(99)00386-6; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; PEDAZAR J, 1997, MULTIPLE REGRESSION; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 1999, PHYSIOL BEHAV, V68, P81, DOI 10.1016/S0031-9384(99)00162-6; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	44	83	85	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2007	205	1					145	153		10.1016/j.expneurol.2007.01.034			9	Neurosciences	Neurosciences & Neurology	166TO	WOS:000246403400017	17362936				2021-06-18	
J	Butcher, I; Maas, AIR; Lu, J; Marmarou, A; Murray, GD; Mushkudiani, NA; McHugh, GS; Steyerberg, EW				Butcher, Isabella; Maas, Andrew I. R.; Lu, Juan; Marmarou, Anthony; Murray, Gordon D.; Mushkudiani, Nino A.; McHugh, Gillian S.; Steyerberg, Ewout W.			Prognostic value of admission blood pressure in traumatic brain injury: Results from the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						blood pressure; outcome; predictors; prognosis; traumatic brain injury	SEVERE HEAD-INJURY	Hypotension following traumatic brain injury (TBI) is recognized as an important secondary insult that is associated with adverse outcome. We aimed to describe the relationship between actual levels of admission blood pressure and Glasgow Outcome Scale (GOS) at 6 months. Individual patient data from the IMPACT database were available on systolic (N = 6801) and mean arterial (N = 6647) blood pressure. Regression models with restricted cubic spline functions were used to explore the shape of the relationships between blood pressure and outcome in unadjusted and adjusted analyses. Proportional odds methodology was applied to quantify the strength of the associations across the full range of the GOS. Analyses were performed to search for threshold values. A smooth U-shaped relationship was observed between systolic (SBP) and mean arterial (MABP) blood pressures and outcome, without any evidence of an abrupt threshold effect. Best outcomes were observed for values of SBP of the order of 135 mm Hg and for values of MABP of the order of 90 mm Hg. Both lower (OR 1.53; 95% CI: 1.31-1.80) and higher levels (OR 1.42; CI: 1.20-1.68) of SBP and lower (OR 1.30; CI 1.12-1.51) and higher levels of MABP (OR 1.45; CI 1.19-1.76) were associated with poorer outcome. These findings were consistent across studies. The relationship between high blood pressure level and poorer outcome largely disappeared on adjusted analysis. Current guidelines for the management of blood pressure in TBI focus on the avoidance of hypotension as defined by SBP < 90 mm, Hg. Our finding of a smooth relationship with improving outcome as SBP increases up to 135 nun Hg, while not supporting a strong causal inference, does suggest that current guidelines need to be reconsidered.	Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA	Butcher, I (corresponding author), Univ Edinburgh, Sch Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Izzy.Butcher@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734; Lu, Juan/0000-0002-5389-7603	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dutton RP, 2002, J TRAUMA, V52, P1141, DOI 10.1097/00005373-200206000-00020; Fowler R, 2002, EMERG MED CLIN N AM, V20, P953, DOI 10.1016/S0733-8627(02)00038-X; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; PRYSROBERTS C, 1984, MONITORING ANESTHESI, P79; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0	11	83	83	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					294	302		10.1089/neu.2006.0032			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900009	17375994				2021-06-18	
J	Kurca, E; Sivak, S; Kucera, P				Kurca, E.; Sivak, S.; Kucera, P.			Impaired cognitive functions in mild traumatic brain injury patients with normal and pathologic magnetic resonance imaging	NEURORADIOLOGY			English	Article						mild traumatic brain injury; cognitive impairment; magnetic resonance imaging; postconcussion syndrome	DIFFUSE AXONAL INJURY; SPORT-RELATED CONCUSSION; COMA SCALE SCORE; HEAD-INJURY; MRI; CT	Introduction: Mild traumatic brain injury (MTBI) is a common neurological (neurotraumatological) diagnosis. As well as different subjective symptoms, many patients develop neuropsychological dysfunction with objective impairment of attention, memory and certain executive functions. Magnetic resonance imaging (MRI) is not routinely used in MTBI patients despite its proven greater sensitivity and specificity in comparison with computed tomography (CT). Methods: The patient group consisted of 30 persons with MTBI and the control group consisted of 30 sex- and age-matched healthy volunteers. Both groups underwent neurological examination, neuropsychological testing (including the Postconcussion Symptoms Scale questionnaire, PCSS) and brain MRI (the patient group within 96 h after injury). Results: The analyzed groups did not differ significantly in terms of sex, age, or level or duration of education. MRI pathological findings (traumatic and nonspecific) were present in nine patients. Traumatic lesions were found in seven patients. Nonspecific white matter lesions were found in five healthy controls. There were significant differences between MTBI patients and controls in terms of subjective symptoms (PCSS) and selected neuropsychological tests. Statistically significant neuropsychological differences were found between MTBI patients with true traumatic lesions and MTBI patients with nonspecific lesions. Conclusion: There is evidence that MTBI patients with true traumatic MRI lesions are neuropsychologically different from MTBI patients with nonspecific MRI lesions or normal brain MRI. These results support the hypothesis that some acute MTBI signs and symptoms have a real organic basis which can be detected by selected new MRI modalities.	Comenius Univ, Jessenius Fac Med, Neurol Clin, Martin, Slovakia; Comenius Univ, Fac Med, Clin Neurol 1, Bratislava, Slovakia	Kurca, E (corresponding author), Comenius Univ, Jessenius Fac Med, Neurol Clin, Martin, Slovakia.	kurca@mfn.sk	Sivak, Stefan/O-4237-2018	Sivak, Stefan/0000-0002-0348-3082			Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GODERSKY JC, 1990, ACT NEUR S, V51, P311; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; KUEERA M, 1980, TEST KONCENTRACE POZ; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MORITANI T, 2004, DIFFUSION WEIGHTED M; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sternberg R. J., 2002, KOGNITIVNI PSYCHOL; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Uchino Y, 2001, ACTA NEUROCHIR, V143, P1031, DOI 10.1007/s007010170008; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; VONKOMER J, 1992, DISJUNKENY REAKENY E; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wahlund LO, 2001, STROKE, V32, P1318, DOI 10.1161/01.STR.32.6.1318; WECHSLER D, 1999, WECHSLER MEMORY SCAL; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	26	83	84	0	11	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	SEP	2006	48	9					661	669		10.1007/s00234-006-0109-9			9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	082IF	WOS:000240379200009	16786351				2021-06-18	
J	Thomas, KE; Annest, JL; Gilchrist, J; Bixby-Hammett, DM				Thomas, K. E.; Annest, J. L.; Gilchrist, J.; Bixby-Hammett, D. M.			Non-fatal horse related injuries treated in emergency departments in the United States, 2001-2003	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							EQUESTRIAN INJURIES; RIDING INJURIES; CHILDREN; HELMETS; PATTERN; TRAUMA	Objective: To characterise and provide nationally representative estimates of persons with non-fatal horse related injuries treated in American emergency departments. Methods: The National Electronic Injury Surveillance System All Injury Program (NEISS-AIP) is a stratified probability sample comprising 66 hospitals. Data on injuries treated in these emergency departments are collected and reported. NEISS-AIP data on all types (horseback riding and otherwise) of non-fatal horse related injuries from 2001 to 2003 were analysed. Results: An estimated 102 904 persons with non-fatal horse related injuries (35.7 per 100 000 population) were treated in American emergency departments each year from 2001 to 2003 inclusive. Non-fatal injury rates were higher for females (41.5 per 100 000) than for males (29.8 per 100 000). Most patients were injured while mounted on a horse (66.1%), commonly from falling or being thrown by the horse; while not mounted, injuries most often resulted from being kicked by the horse. The body parts most often injured were the head/neck region (23.2%), lower extremity (22.2%), and upper extremity (21.5%). The most common principal diagnoses were contusions/abrasions (31.4%) and fractures (25.2%). For each year that was studied, an estimated 11 502 people sustained traumatic brain injuries from horse related incidents. Overall, more than 11% of those injured were admitted to hospital. Conclusions: Horse related injuries are a public health concern not just for riders but for anyone in close contact with horses. Prevention programmes should target horseback riders and horse caregivers to promote helmet use and educate participants about horse behaviour, proper handling of horses, and safe riding practices.	CDC, OSP, NCIPC, Atlanta, GA 30341 USA; CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Amer Med Equestrian Assoc Safe Riders Fdn, Albuquerque, NM USA	Thomas, KE (corresponding author), CDC, OSP, NCIPC, 4770 Buford Highway NE,Mailstop K-59, Atlanta, GA 30341 USA.	KEThomas@cdc.gov					*AM HORS COUNC, HORS IND STAT NAT EC; BIXBYHAMMETT D, 2002, AM EQUESTRIAN MED AS, V13, P8; BIXBYHAMMETT DM, 1992, PEDIATRICS, V89, P1173; BIXBYHAMMETT DM, 1987, AM FAM PHYSICIAN, V36, P209; BOND GR, 1995, PEDIATRICS, V95, P487; BYRD JWT, 1996, PLANNING EVENT COVER; Campbell-Hewson G L, 1999, Eur J Emerg Med, V6, P37; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P329; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P335; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P341; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; CONDIE C, 1993, PUBLIC HEALTH REP, V108, P121; CORDELL K, 2004, RECREATION STAT UPDA; FIRTH JL, 1994, SPORTS INJURIES MECH, P315; Frankel HL, 1998, AM SURGEON, V64, P151; Ghosh A, 2000, J PEDIATR SURG, V35, P1766, DOI 10.1053/jpsu.2000.19247; GIERUP J, 1976, ACTA CHIR SCAND, V142, P57; Grandin T, 1999, OCCUP MED-STATE ART, V14, P195; Griffen M, 2002, SOUTHERN MED J, V95, P441, DOI 10.1097/00007611-200204000-00013; HAMILTON MG, 1993, J TRAUMA, V34, P227, DOI 10.1097/00005373-199302000-00008; HUGHES KM, 1995, AM J EMERG MED, V13, P485, DOI 10.1016/0735-6757(95)90148-5; Jagodzinski Tanya, 2005, WMJ, V104, P50; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Lim J, 2003, ANZ J SURG, V73, P567, DOI 10.1046/j.1445-2197.2003.02707.x; McCrory P, 2005, MED SPORT SCI, V48, P8, DOI 10.1159/000084280; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McGhee C N, 1987, Br J Neurosurg, V1, P131, DOI 10.3109/02688698709034348; Moss PS, 2002, EMERG MED J, V19, P412, DOI 10.1136/emj.19.5.412; National Center for Health Statistics, US CENS POP BRIDG RA; NELSON DE, 1992, AM J DIS CHILD, V146, P611, DOI 10.1001/archpedi.1992.02160170091022; NELSON DE, 1994, AM J PREV MED, V10, P15; NELSON MA, 1992, PEDIATRICS, V89, P512; NISKANEN R, 1994, ANN CHIR GYNAECOL, V83, P225; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; Robson S E, 1979, Br J Sports Med, V13, P33; Sacks J J, 1996, Inj Prev, V2, P258, DOI 10.1136/ip.2.4.258; SCHROEDER T, 2001, NEISS SAMPLE DESIGN, P1; *SPEC VEH I AM, 2005, STAT ALL TERR VEH RE; Thompson JM, 1996, CAN FAM PHYSICIAN, V42, P1103; Thompson NJ, 2002, PATIENT EDUC COUNS, V46, P191, DOI 10.1016/S0738-3991(01)00212-9; VYROSTEK SB, 2004, MMWR-MORBID MORTAL W, V53, pSS1; Watt GM, 1996, SPORTS MED, V22, P187, DOI 10.2165/00007256-199622030-00005; 1997, AM MED EQUESTRIAN AS, V7	44	83	88	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUL	2006	40	7					619	626		10.1136/bjsm.2006.025858			8	Sport Sciences	Sport Sciences	056OH	WOS:000238533800011	16611723	Green Published			2021-06-18	
J	Suh, M; Kolster, R; Sarkar, R; McCandliss, B; Ghajar, J				Suh, Minah; Kolster, Rachel; Sarkar, Ranjeeta; McCandliss, Bruce; Ghajar, Jamshid		Cognitive Neurobiological Res Cons	Deficits in predictive smooth pursuit after mild traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						mild TBI; smooth pursuit eye movement; shearing injury; attention; executive function; variability; diffuse axonal injury (DAI)	HEAD-INJURY; EYE-MOVEMENTS; ATTENTION; MEMORY; INTEGRATION; MODULATION; SACCADES; MONKEY	Given that even mild traumatic brain injury (TBI) may produce extensive diffuse axonal injury (DAI), we hypothesized that mild TBI patients would show deficits in predictive smooth pursuit eye movements (SPEM), associated with impaired cognitive functions, as these processes are dependent on common white matter connectivity between multiple cerebral and cerebellar regions. The ability to predict target trajectories during SPEM was investigated in 21 mild TBI patients using a periodic sinusoidal paradigm. Compared to 26 control subjects, TBI patients demonstrated decreased target prediction. TBI patients also showed increased eye position error and variability of eye position, which correlated with decreased target prediction. In all subjects, average target prediction, eye position error and eye position variability correlated with scores related to attention and executive function on the California Verbal Learning Test (CVLT-II). However, there were no differences between TBI and control groups in average eye gain or intra-individual eye gain variability, or in performance on the Wechsler Abbreviated Scale of Intelligence (WASI), suggesting that the observed deficits did not result from general oculomotor impairment or reduced IQ. The correlation between SPEM performance and CVLT-II scores suggests that predictive SPEM may be a sensitive assay of cognitive functioning, including attention and executive function. This is the first report to our knowledge that TBI patients show impaired predictive SPEM and eye position variability, and that these impairments correlate with cognitive deficits. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA; Weill Cornell Med Coll, Brain Trauma Fdn, New York, NY 10021 USA; Weill Cornell Med Coll, Sackler Inst, Dept Psychiat, New York, NY 10021 USA	Suh, M (corresponding author), Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA.	minah@med.cornell.edu					Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barnes GR, 2005, EXP BRAIN RES, V160, P10, DOI 10.1007/s00221-004-1981-3; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; CANNON SC, 1987, J NEUROPHYSIOL, V57, P1383; Courchesne E, 1997, LEARN MEMORY, V4, P1, DOI 10.1101/lm.4.1.1; de Brouwer S, 2002, J NEUROPHYSIOL, V87, P1646, DOI 10.1152/jn.00432.2001; Delis DC, 2000, CALIFORNIA VERBAL LE; Fukushima K, 2002, NATURE, V419, P157, DOI 10.1038/nature00953; FUKUSHIMA K, 1995, NEUROSCI RES, V22, P249, DOI 10.1016/0168-0102(95)00904-8; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V33, P1305, DOI 10.1016/0028-3932(95)00103-A; Gottwald B, 2004, J NEUROL NEUROSUR PS, V75, P1524, DOI 10.1136/jnnp.2003.018093; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hutton SB, 2005, EXP BRAIN RES, V163, P306, DOI 10.1007/s00221-004-2171-z; Kalashnikova L A, 2005, Neurosci Behav Physiol, V35, P773, DOI 10.1007/s11055-005-0123-0; Kettner RE, 1996, EXP BRAIN RES, V108, P221; KHURANA B, 1987, VISION RES, V27, P1603, DOI 10.1016/0042-6989(87)90168-4; KOWLER E, 1989, VISION RES, V29, P1049, DOI 10.1016/0042-6989(89)90052-7; LANGER T, 1985, J COMP NEUROL, V235, P1, DOI 10.1002/cne.902350102; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; Machner B, 2005, NEUROREPORT, V16, P1507, DOI 10.1097/01.wnr.0000177015.75096.b6; Madelain L, 2003, J NEUROPHYSIOL, V90, P972, DOI 10.1152/jn.00869.2002; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; Missal M, 2004, J NEUROPHYSIOL, V92, P1257, DOI 10.1152/jn.01255.2003; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nagel M, 2006, NEUROIMAGE, V29, P1319, DOI 10.1016/j.neuroimage.2005.08.050; Nakamagoe K, 2000, SCIENCE, V288, P857, DOI 10.1126/science.288.5467.857; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reynolds JH, 2004, ANNU REV NEUROSCI, V27, P611, DOI 10.1146/annurev.neuro.26.041002.131039; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schmid A, 2001, NEUROREPORT, V12, P1409, DOI 10.1097/00001756-200105250-00023; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stone LS, 2000, PERCEPTION, V29, P771, DOI 10.1068/p2979; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; WAESPE W, 1992, EXP BRAIN RES, V89, P311; Wechsler D., 2011, WECHLSER ABBREVIATED; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Williams IM, 1997, J CLIN NEUROSCI, V4, P186, DOI 10.1016/S0967-5868(97)90072-2	47	83	83	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 19	2006	401	1-2					108	113		10.1016/j.neulet.2006.02.074			6	Neurosciences	Neurosciences & Neurology	050JB	WOS:000238082400022	16554121				2021-06-18	
J	Cummings, JL; Arciniegas, DB; Brooks, BR; Herndon, RM; Lauterbach, EC; Pioro, EP; Robinson, RG; Scharre, DW; Schiffer, RB; Weintraub, D				Cummings, Jeffrey L.; Arciniegas, David B.; Brooks, Benjamin R.; Herndon, Robert M.; Lauterbach, Edward C.; Pioro, Erik P.; Robinson, Robert G.; Scharre, Douglas W.; Schiffer, Randolph B.; Weintraub, Daniel			DEFINING AND DIAGNOSING INVOLUNTARY EMOTIONAL EXPRESSION DISORDER	CNS SPECTRUMS			English	Article								Uncontrollable episodes of emotional expression occur in a variety of neurological conditions. This emotional disinhibition syndrome is characterized by episodes of crying or laughing that are. unrelated to or out of proportion to the eliciting stimulus. This syndrome is common among patients with amyotrophic lateral sclerosis, multiple sclerosis, stroke, and traumatic brain injury and a variety of terms and definitions have been used to describe it. The confusing nomenclature has been a barrier to understanding, diagnosis, and treatment of this disorder. The authors propose a unifying term, involuntary emotional expression disorder (IEED), and provide diagnostic criteria for this disorder.	[Cummings, Jeffrey L.] Univ Calif Los Angeles, Rush Alzheimers Dis Ctr, Los Angeles, CA 90095 USA; [Cummings, Jeffrey L.] Univ Calif Los Angeles, Deanne F Johnson Ctr Neurotherapeut, Los Angeles, CA USA; [Cummings, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Cummings, Jeffrey L.] Eli Lilly & Co, Indianapolis, IN USA; [Scharre, Douglas W.] Pfizer, New York, NY USA; [Arciniegas, David B.] Univ Colorado, Sch Med, Neurobehav Disorders Program, Boulder, CO 80309 USA; [Arciniegas, David B.] HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Denver, CO USA; [Brooks, Benjamin R.] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA; [Herndon, Robert M.] Univ Mississippi, Dept Neurol, Jackson, MS USA; [Lauterbach, Edward C.] Mercer Univ, Div Adult & Geriatr Psychiat, Macon, GA 31207 USA; [Pioro, Erik P.] Cleveland Clin, Ctr ALS & Related Disorders, Cleveland, OH 44106 USA; [Pioro, Erik P.] Cleveland Clin, Dept Neurol, Cleveland, OH 44106 USA; [Robinson, Robert G.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; [Scharre, Douglas W.] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; [Scharre, Douglas W.] Ohio State Univ, Div Cognit Neurol, Columbus, OH 43210 USA; [Scharre, Douglas W.] Abbott, Abbott Pk, IL USA; [Schiffer, Randolph B.] Texas Tech Univ, Dept Psychiat & Behav Sci, Lubbock, TX 79409 USA; [Weintraub, Daniel] Univ Penn, Sch Med, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA; [Weintraub, Daniel] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany	Cummings, JL (corresponding author), Univ Calif Los Angeles, Rush Alzheimers Dis Ctr, Los Angeles, CA 90095 USA.		Weintraub, Daniel/AAD-8309-2020; Pioro, Erik P/AAZ-5318-2020; Weintraub, Daniel/AAC-5232-2020	Pioro, Erik P/0000-0002-0737-6065; Weintraub, Daniel/0000-0003-0633-7168			ACHARI A N, 1976, Journal of the American Medical Association, V235, P1469, DOI 10.1001/jama.235.14.1469; *AM MED ASS, 2005, INT CLASS DIS, P162; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSEN G, 1994, STROKE, V25, P1050, DOI 10.1161/01.STR.25.5.1050; ANGST J, 1986, PSYCHOPATHOLOGY, V19, P47, DOI 10.1159/000285131; Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554; Arciniegas DB, 2005, CNS SPECTRUMS, V10, P1, DOI 10.1017/S1092852900026602; ARROYO S, 1993, BRAIN, V116, P757, DOI 10.1093/brain/116.4.757; ASFORA WT, 1989, J NEUROL NEUROSUR PS, V52, P523, DOI 10.1136/jnnp.52.4.523; BLACK DW, 1982, J NERV MENT DIS, V170, P67, DOI 10.1097/00005053-198202000-00001; Brooks BR, 2004, NEUROLOGY, V63, P1364; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; CASCINO GD, 1993, NEUROLOGY, V43, P747, DOI 10.1212/WNL.43.4.747; Dark FL, 1996, AUST NZ J PSYCHIAT, V30, P472, DOI 10.3109/00048679609065020; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; Feinstein A, 1999, MULT SCLER, V5, P69, DOI 10.1177/135245859900500201; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; GhikaSchmid F, 1997, EUR NEUROL, V38, P75, DOI 10.1159/000113164; Green RL, 1998, SEMIN CLIN NEUROPSYC, V3, P195; HARVEY PD, 1989, J CLIN PSYCHOL, V45, P786, DOI 10.1002/1097-4679(198909)45:5<786::AID-JCLP2270450515>3.0.CO;2-P; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; IRONSIDE R, 1956, BRAIN, V79, P589, DOI 10.1093/brain/79.4.589; Kaschka WP, 2001, PHARMACOPSYCHIATRY, V34, P254, DOI 10.1055/s-2001-18031; Keller R, 1999, ITAL J NEUROL SCI, V20, P49, DOI 10.1007/s100720050010; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; Kim JS, 2002, J NEUROL, V249, P805, DOI 10.1007/s00415-002-0714-4; Kim JS, 1997, STROKE, V28, P2321; LAKE CR, 1982, AM J PSYCHIAT, V139, P1315; Langworthy OR, 1940, ARCH INTERN MED, V65, P106, DOI 10.1001/archinte.1940.00190070116008; Langworthy OR, 1941, AM J PSYCHIAT, V98, P243, DOI 10.1176/ajp.98.2.243; LAUTERBACH EC, 1994, NEUROLOGY, V44, P983, DOI 10.1212/WNL.44.5.983; LAUTERBACH EC, 1991, J CLIN PSYCHOPHARM, V11, P392, DOI 10.1097/00004714-199112000-00021; LAUTERBACH EC, 1994, BIOL PSYCHIAT, V35, P488, DOI 10.1016/0006-3223(94)90048-5; Lopez OL, 1996, NEUROPSY NEUROPSY BE, V9, P154; LUCIANO D, 1993, NEUROLOGY, V43, P2113, DOI 10.1212/WNL.43.10.2113; McGrath J, 2000, BEHAV NEUROL, V12, P201, DOI 10.1155/2000/612185; Moore SR, 1997, J NEUROL NEUROSUR PS, V63, P89, DOI 10.1136/jnnp.63.1.89; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; Newsom-Davis IC, 1999, J NEUROL SCI, V169, P22, DOI 10.1016/S0022-510X(99)00211-7; Okuda DT, 2005, MOVEMENT DISORD, V20, P1389, DOI 10.1002/mds.20607; Okun MS, 2001, ARCH NEUROL-CHICAGO, V58, P1682, DOI 10.1001/archneur.58.10.1682; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; Poeck K., 1969, HDB CLIN NEUROLOGY, P343; Robert D, 1999, ACTA OTO-LARYNGOL, V119, P724; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; SCHUCKIT MA, 1982, AM J PSYCHIAT, V139, P1431; Smi CK, 2006, STROKE, V37, P156, DOI 10.1161/01.STR.0000190892.93663.e2; Smith RA, 2004, MULT SCLER, V10, P1; STARKSTEIN SE, 1995, J NEUROL NEUROSUR PS, V59, P55, DOI 10.1136/jnnp.59.1.55; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160; 2005, 57 ANN M AM AC NEUR	55	83	86	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1092-8529	2165-6509		CNS SPECTRUMS	CNS Spectr.	JUN	2006	11	6		6			1	7					7	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	V04RU	WOS:000207076300001	16816786				2021-06-18	
J	Newman, MB; Willing, AE; Manresa, JJ; Sanberg, CD; Sanberg, PR				Newman, Mary B.; Willing, Alison E.; Manresa, John J.; Sanberg, Cyndy Davis; Sanberg, Paul R.			Cytokines produced by cultured human umbilical cord blood (HUCB) cells: Implications for brain repair	EXPERIMENTAL NEUROLOGY			English	Article						human umbilical cord blood; chemokines; cytokines; MCP-1; migration; IL-8; IL-6; IL-1 alpha; IL-10	MESSENGER-RNA EXPRESSION; C-KIT LIGAND; MAST-CELLS; TNF-ALPHA; PERIPHERAL-BLOOD; PROGENITOR CELLS; BONE-MARROW; STEM-CELLS; MIGRATION; IL-8	The potential therapeutic benefits from human umbilical cord blood (HUCB) cells for the treatment of injuries, diseases, and neurodegencration are becoming increasingly recognized. The transplantation or infusion of cord blood cells in various animal models, such as ischemia/stroke, traumatic brain injury, myocardial infarction, Parkinson's disease, and amyotropic lateral sclerosis, has resulted in amelioration of behavioral deficits, and with some diseases, a prolonged lifespan decreased neuropathology. Previously, we reported the migration of HUCB cells to ischemic brain supernatant (tissue extracts) is time-dependent, and the expression of specific chemokines responds to this migration pattern. The mechanism(s) responsible for these effects are unknown. The expression of cytokines and chemokines produced by HUCB cells (under various culturing conditions) was investigated in this study. IL-8, MCP-1, and IL-1 alpha were consistently expressed by the HUCB mononuclear cells regardless of the culture condition. These results provide insights to factors that may be partially responsible for the functional improvements seen in the animal models of injury investigating the therapeutic use of HUCB cells. (c) 2006 Elsevier Inc. All rights reserved.	Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA; Coll Arts & Sci, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Neurosurg, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Psychol, Tampa, FL 33612 USA; Saneron CCEL Therapeut Inc, Temple Terrace, FL 33617 USA	Newman, MB (corresponding author), Rush Univ, Med Ctr, Dept Pharmacol, Cohn Res Bldg,Suite 406,1735 W Harrison St,Room 4, Chicago, IL 60612 USA.	mnewman@rush.edu	Willing, Alison/AAP-7759-2021; Willing, Alison/I-4946-2012				Berner R, 2000, EUR J PEDIATR, V159, P205, DOI 10.1007/s004310050051; Brass LM, 2006, EXP NEUROL, V199, P16, DOI 10.1016/j.expneurol.2006.03.009; Broxmeyer HE, 1999, ANN NY ACAD SCI, V872, P142, DOI 10.1111/j.1749-6632.1999.tb08460.x; Chen S, 2001, METALL MATER TRANS B, V32, P11, DOI 10.1007/s11663-001-0002-1; Chen SH, 2006, EXP NEUROL, V199, P67, DOI 10.1016/j.expneurol.2005.11.015; COHEN SB, 2000, CORD BLOOD CHARACTER; Dollner H, 2001, BIOL NEONATE, V80, P41, DOI 10.1159/000047118; DVORAK AM, 1993, J LEUKOCYTE BIOL, V54, P465; DVORAK AM, 1993, EUR J CELL BIOL, V62, P422; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Ha Y, 2001, NEUROREPORT, V12, P3523, DOI 10.1097/00001756-200111160-00030; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; Kostulas N, 1999, STROKE, V30, P2174, DOI 10.1161/01.STR.30.10.2174; Krueger M, 2001, BIOL NEONATE, V80, P118, DOI 10.1159/000047130; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Lin TJ, 2000, J IMMUNOL, V165, P211, DOI 10.4049/jimmunol.165.1.211; Lin TJ, 2001, INT ARCH ALLERGY IMM, V124, P142, DOI 10.1159/000053693; Lu L, 1996, CRIT REV ONCOL HEMAT, V22, P61, DOI 10.1016/1040-8428(96)88370-3; Lund BT, 2004, J NEUROIMMUNOL, V155, P161, DOI 10.1016/j.jneuroim.2004.06.008; Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9; Newman MB, 2005, STEM CELLS DEV, V14, P576, DOI 10.1089/scd.2005.14.576; Qi XY, 2003, JPN HEART J, V44, P451, DOI 10.1536/jhj.44.451; Ramos CDL, 2003, CYTOKINE, V21, P214, DOI 10.1016/S1043-4666(03)00050-4; Salvucci O, 2004, J LEUKOCYTE BIOL, V76, P217, DOI 10.1189/jlb.1203609; Sanchez-Ramos JR, 2001, EXP NEUROL, V171, P109, DOI 10.1006/exnr.2001.7748; Senaris R, 1997, ENDOCRINOLOGY, V138, P4501, DOI 10.1210/en.138.10.4501; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Vendrame M, 2005, STEM CELLS DEV, V14, P595, DOI 10.1089/scd.2005.14.595; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Wang Ji Ming, 1996, Methods (Orlando), V10, P135, DOI 10.1006/meth.1996.0087; Widera D, 2004, EUR J CELL BIOL, V83, P381, DOI 10.1078/0171-9335-00403; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Yang YY, 2004, ATHEROSCLEROSIS, V174, P207, DOI 10.1016/j.atherosclerosis.2004.01.024; Yong K, 1999, BRIT J HAEMATOL, V107, P441, DOI 10.1046/j.1365-2141.1999.01714.x; Yoshimura T, 1996, HUMAN CYTOKINES HDB, VII, P198; Zigova T, 2002, CELL TRANSPLANT, V11, P265	41	83	92	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2006	199	1					201	208		10.1016/j.expneurol.2006.04.001			8	Neurosciences	Neurosciences & Neurology	060KI	WOS:000238800700022	16730351				2021-06-18	
J	Ziino, C; Ponsford, J				Ziino, C; Ponsford, J			Measurement and prediction of subjective fatigue following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						fatigue; closed head injuries; brain injuries; depression; anxiety	OUTCOME FOLLOWING MODERATE; HEAD-INJURY; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; CANCER-PATIENTS; DEPRESSION; SLEEP; SCALE; PREVALENCE; SEVERITY	Numerous outcome studies have found fatigue to be a common problem following traumatic brain injury (TBI). This study examined the magnitude, causes and impact of fatigue following TBI using three subjective fatigue scales, and investigated its relationship with demographic and injury-related factors, and mood. Forty-nine controls and 49 TBI participants (36.2% with GCS score of 13-15, 29.8% with GCS score of 9-12, and 34% with GCS score of 3-8) were seen at a mean of approximately 8 months post injury. All participants completed three subjective fatigue measures, including the Fatigue Severity Scale (FSS), Visual Analogue Scale-Fatigue (VAS-F) and Causes of Fatigue Questionnaire (COF). TBI participants reported a significantly greater impact of fatigue on their lifestyle on the FSS relative to controls, and reported activities requiring physical and mental effort as more frequent causes of fatigue on the COF. There were, however, no significant group differences on subscales of the VAS-F. Greater time since injury and higher education levels were associated with higher fatigue levels, independent of the effects of mood. Injury severity and age were not found to be significant predictors of subjective fatigue severity in TBI participants.	Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia; Monash Epworth Rehabil Res Ctr, Clayton, Vic 3800, Australia	Ziino, C (corresponding author), Monash Univ, Dept Psychol, POB 17, Clayton, Vic 3800, Australia.	Carlo.Ziino@med.monash.edu.au					Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Aaronson LS, 2003, WESTERN J NURS RES, V25, P419, DOI 10.1177/0193945903025004007; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beenen LFM, 1999, J NEUROL NEUROSUR PS, V67, P474, DOI 10.1136/jnnp.67.4.474; BELZA BL, 1993, NURS RES, V42, P93; Bensing JM, 1999, MED CARE, V37, P1078, DOI 10.1097/00005650-199910000-00011; Bruce IN, 1999, ANN RHEUM DIS, V58, P379, DOI 10.1136/ard.58.6.379; Caci H, 2003, PSYCHIAT RES, V118, P89, DOI 10.1016/S0165-1781(03)00044-1; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Cooke KM, 1998, J BEHAV MED, V21, P103, DOI 10.1023/A:1018719722614; De Vries J, 2003, OCCUP ENVIRON MED, V60, P10; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Ettinger AB, 1998, J EPILEPSY, V11, P105, DOI 10.1016/S0896-6974(97)00139-4; EVANS RW, 1992, NEUROL CLIN, V10, P815; Ferraccioli G, 1996, J RHEUMATOL, V23, P1539; Fishbain DA, 2003, PAIN MED, V4, P51, DOI 10.1046/j.1526-4637.2003.03008.x; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; Fleming J, 1999, BRAIN INJURY, V13, P417; FUHRER R, 1995, PSYCHOL MED, V25, P895, DOI 10.1017/S0033291700037387; Gaudino EA, 1997, ARCH NEUROL-CHICAGO, V54, P1372, DOI 10.1001/archneur.1997.00550230045015; GIBSON H, 1985, SPORTS MED, V2, P120, DOI 10.2165/00007256-198502020-00004; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1024929829627; Harter M, 2001, DISABIL REHABIL, V23, P737; Hayashi M, 1999, CLIN NEUROPHYSIOL, V110, P272, DOI 10.1016/S1388-2457(98)00003-0; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herlofson K, 2002, EUR J NEUROL, V9, P595, DOI 10.1046/j.1468-1331.2002.00444.x; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HILL B, 2001, INN REH C MELB AUSTR; JONES RK, 1974, SURG NEUROL, V2, P101; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; KRUPP LB, 1995, NEUROLOGY, V45, P1956, DOI 10.1212/WNL.45.11.1956; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lavidor M, 2003, BRIT J HEALTH PSYCH, V8, P95, DOI 10.1348/135910703762879237; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; Lichstein KL, 1997, BEHAV RES THER, V35, P733, DOI 10.1016/S0005-7967(97)00029-6; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McNair D. M., 1981, EDITS MANUAL PROFILE; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; *MIMS AUSTR, 2004, 2004 MIMS ANN; Morriss RK, 1997, J PSYCHOSOM RES, V42, P597, DOI 10.1016/S0022-3999(97)89895-9; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; PIPER BF, 1989, KEY ASPECTS COMFORT, P197; Piper BF, 1989, KEY ASPECTS COMFORT, DOI 10.1007/978-1-349-13397-0_25; Pollina DA, 1998, J NEUROPSYCH CLIN N, V10, P338, DOI 10.1176/jnp.10.3.338; Ponsford J., 1995, TRAUMATIC BRAIN INJU, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; Ream E, 1996, INT J NURS STUD, V33, P519, DOI 10.1016/0020-7489(96)00004-1; Reyes-Gibby CC, 2003, PAIN MED, V4, P231, DOI 10.1046/j.1526-4637.2003.03033.x; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; Salinsky MC, 1996, EPILEPSIA, V37, P181, DOI 10.1111/j.1528-1157.1996.tb00010.x; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; Schwartz TL, 2004, J CLIN PSYCHIAT, V65, P1223, DOI 10.4088/JCP.v65n0910; Schwarz R, 2003, ONKOLOGIE, V26, P140, DOI 10.1159/000069834; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SMETS EMA, 1993, BRIT J CANCER, V68, P220, DOI 10.1038/bjc.1993.319; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Spigset O, 1999, DRUG SAFETY, V20, P277, DOI 10.2165/00002018-199920030-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tench CM, 2000, RHEUMATOLOGY, V39, P1249, DOI 10.1093/rheumatology/39.11.1249; Tench CM, 2003, RHEUMATOLOGY, V42, P1050, DOI 10.1093/rheumatology/keg289; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Wade A, 2003, INT CLIN PSYCHOPHARM, V18, P133, DOI 10.1097/01.yic.0000068045.82050.00; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; WESSELY S, 1995, LANCET, V345, P1333, DOI 10.1016/S0140-6736(95)92537-6; Wilson, 1991, NATL ADULT READING T; Winstead-Fry P, 1998, J Nurs Meas, V6, P111	82	83	84	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2005	11	4					416	425		10.1017/S1355617705050472			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	948UY	WOS:000230742400009	16209422				2021-06-18	
J	Gabbita, SP; Scheff, SW; Menard, RM; Roberts, K; Fugaccia, I; Zemlan, FP				Gabbita, SP; Scheff, SW; Menard, RM; Roberts, K; Fugaccia, I; Zemlan, FP			Cleaved-tau: A biomarker of neuronal damage after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						axon; controlled cortical impact (CCI); cleaved-tau (C-tau); cyclosporin A; microtubule associated protein-tau (MAP-tau); neuron; traumatic brain injury (TBI)	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; CYCLOSPORINE-A; PROTEIN-TAU; S-100B PROTEIN; AXONAL DAMAGE; SERUM-LEVELS; HEAD-INJURY; C-TAU; RAT	Previous studies from our laboratory indicate that traumatic brain injury TBI) in humans results in proteolysis of neuronally-localized, intracellular microtubule associated protein (MAP)-tau to produce cleaved tau (C-tau). The present study evaluated the utility of C-tau to function as a biomarker of neuronal injury and as a biomarker for evaluating neuroprotectant drug efficacy in a controlled cortical impact model of rat TBI. Brain C-tau was determined in rats subjected to controlled cortical impact-induced mild, moderate or severe levels of TBI. A significant severity-dependent increase in C-tau levels was observed in the cortex and hippocampus (1.5-8-fold) of TBI rats compared to shams 72 h after impact. C-tau rat brain and serum time course was determined by measuring levels at 0.25, 6, 24, 48, 72 and 168 h after TBI. A significant time-dependent increase in C-tau levels was observed in ipsilateral cortex (5-16-fold) and hippocampus (2-40-fold) compared to sham animals. C-tau levels increased as early as 6 h after TBI with peak C-tau levels observed 168 h after injury. Elevated brain C-tau levels were associated with TBI-induced tissue loss, which was histologically determined. The effect of cyclosporin-A (CsA), previously demonstrated to be neuroprotective in rat TBI, on brain C-tau levels was examined. CsA (20 mg/kg i.p., 15 min and 24 h after TBI) significantly attenuated the TBI-induced increase in hippocampal C-tau levels observed in vehicle-treated animals confirming CsA's neuroprotectant effect. CsA treatment also lowered ipsilateral cortical C-tau levels, although it did not reach statistical significance. CsA's neuroprotectant effect was confirmed utilizing histologic measures of TBI-induced tissue loss. In addition, serum C-tau levels were significantly increased 6 h after TBI but not at later time points. These results suggest that C-tau is a reliable, quantitative biomarker for evaluating TBI-induced neuronal injury and a potential biomarker of neuroprotectant drug efficacy in the rat TBI model. Serum data suggests that C-tau levels are dependent both on a compromised blood-brain barrier as well as release of TBI biomarkers from the brain, which has implications for the study of human serum TBI biomarkers.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Gabbita, SP (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	prasad.gabbita@psychiatry.uc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43NS043837, R01NS039828] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828, NS43837] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Irazuzta JE, 2001, BRAIN RES, V913, P95, DOI 10.1016/S0006-8993(01)02764-0; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KOSIK KS, 1987, J NEUROSCI, V7, P3142; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Marsan MA, 2000, J SYST ARCHITECT, V46, P105, DOI 10.1016/S1383-7621(98)00064-2; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCMAHAN BT, 1986, BUS HEALTH, V3, P47; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Scallet AC, 1995, ANN NY ACAD SCI, V765, P47, DOI 10.1111/j.1749-6632.1995.tb16559.x; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Towbin H, 1992, Biotechnology, V24, P145; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Woertgen C, 2002, ACT NEUR S, V81, P205; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2003, NEUROSCIENCE, V121, P399, DOI 10.1016/S0306-4522(03)00459-7; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	42	83	88	1	18	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2005	22	1					83	94		10.1089/neu.2005.22.83			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	889OF	WOS:000226451600005	15665604				2021-06-18	
J	D'Ambrosio, R; Perucca, E				D'Ambrosio, R; Perucca, E			Epilepsy after head injury	CURRENT OPINION IN NEUROLOGY			English	Article						posttraumatic epilepsy; partial seizures; head trauma; epileptogenesis; antiepileptic drugs; microdialysis	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC EPILEPSY; ANTIEPILEPTIC DRUGS; MECHANICAL INJURY; ANIMAL-MODELS; RISK-FACTORS; SEIZURES; PREVENTION; EPILEPTOGENESIS; MODERATE	Purpose of review The purpose of this short review is to provide an update on the epidemiology of posttraumatic epilepsy, associated risk factors, data from prevention studies, and recent breakthroughs in experimental research. Recent findings There is increasing evidence that neuroimaging findings, stratification by neurosurgical procedures performed, and genomic information (e.g. apolipoprotein E and haptoglobin genotypes) may provide useful predictors of the individual risk of developing posttraumatic epilepsy. While antiepileptic drug prophylaxis can be effective in protecting against acute (provoked) seizures occurring within 7 days after injury, no antiepileptic drug treatment has been found to protect against the development of posttraumatic epilepsy and therefore long-term anticonvulsant prophylaxis is not recommended. Glucocorticoid administration early after head injury also has not been found to reduce the risk of posttraurnatic epilepsy. At the basic research level, there have been advances in the understanding of pathophysiological changes in posttraumatic excitatory and inhibitory synapses, and the critical period for epileptogenesis after head injury has been better defined. Finally, the development of a novel animal model, which mimicks more closely human posttraurnatic epilepsy, may facilitate efforts to characterize relevant epileptogenic mechanisms and to identify clinically effective antiepileptogenic treatments. Summary Despite the continuing lack of clinically effective agents for posttraurnatic epilepsy prophylaxis, recent advances in basic and clinical research offer new hope for success in the development of new strategies for prevention and treatment.	Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Reg Epilepsy Ctr, Seattle, WA 98104 USA; IRCCS, Mondino Fdn, Neurol Inst, Pavia, Italy	D'Ambrosio, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, 325 9Th Ave,Box 359915, Seattle, WA 98104 USA.	raid@u.washington.edu	Perucca, Emilio/Q-7308-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040823-03, NS040823, R01 NS040823] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040823] Funding Source: NIH RePORTER		Alves OL, 2003, ANN NY ACAD SCI, V993, P25, DOI 10.1111/j.1749-6632.2003.tb07508.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2003, J NEUROTRAUM, V20, P1059; DAMBROSIO R, 2004, IN PRESS J NEUROTRAU; DIAZARRASTIA R, 2003, ARCH NEUROL-CHICAGO, V60, P318; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Kumar R, 2003, AM J NEURORADIOL, V24, P218; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Loscher W, 2002, EPILEPSY RES, V50, P3, DOI 10.1016/S0920-1211(02)00063-3; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Nissinen Jari P. T., 2003, Epilepsia, V44, P175; PANTER SS, 1985, J EXP MED, V161, P748, DOI 10.1084/jem.161.4.748; Sadrzadeh SMH, 2004, CLIN CHEM, V50, P1095, DOI 10.1373/clinchem.2003.028001; Schmidt D, 2002, EPILEPSY RES, V50, P71, DOI 10.1016/S0920-1211(02)00070-0; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Watson NF, 2004, EPILEPSIA, V45, P690, DOI 10.1111/j.0013-9580.2004.59403.x; White HS, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s7.10.x; White HS, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.9_suppl_5.S7; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	37	83	86	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2004	17	6					731	735		10.1097/00019052-200412000-00014			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	878XY	WOS:000225682000013	15542983	Green Accepted			2021-06-18	
J	Suehiro, E; Fujisawa, H; Akimura, T; Ishihara, H; Kajiwara, K; Kato, S; Fujii, M; Yamashita, S; Maekawa, T; Suzuki, M				Suehiro, E; Fujisawa, H; Akimura, T; Ishihara, H; Kajiwara, K; Kato, S; Fujii, M; Yamashita, S; Maekawa, T; Suzuki, M			Increased matrix metalloproteinase-9 in blood in association with activation of interleukin-6 after traumatic brain injury: Influence of hypothermic therapy	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; hypothermia; interleukin-6; matrix metalloproteinase-9; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; MATRIX METALLOPROTEINASES; CYCLOSPORINE-A; RAT; EXPRESSION; BARRIER; TRANSCRIPTION; INHIBITION; ASTROCYTES; MICROGLIA	Recent experimental data have shown that levels of matrix metalloproteinase-9 (MMP-9) increase after traumatic brain injury (TBI), degrading components of the basal lamina disrupting the blood-brain barrier. However, the post-traumatic secretion patterns of MMP-9 in humans are unknown. We measured the concentration of MMP-9 in plasma after TBI at the same time as the concentration of interleukin-6 (IL-6) in serum. Levels of MMP-9 and IL-6 in systemic arterial and jugular venous blood from seven patients with TBI were measured on days 0 and 1 post-injury. All patients underwent hypothermia at 32-35 degreesC as soon as possible after admission. Before induction of hypothermia, levels of MMP-9 in arterial and internal jugular venous blood exceeded the normal range. Higher MMP-9 levels were detected in internal jugular venous blood than in arterial blood. After hypothermia had been induced, MMP-9 levels in arterial blood and internal jugular venous blood decreased significantly, to within the normal range. In addition to these changes, a significant correlation was seen between levels of MMP-9 and IL-6 in internal jugular venous blood during the investigation period. These results indicate that MMP-9 is elevated in patients with acute TBI, and may play an important role in traumatic brain damage. The elevation of MMP-9 is associated with inflammatory events following TBI. Hypothermic intervention may suppress the elevation of MMP-9 with suppression of the inflammatory response, affording neuroprotection in TBI.	Yamaguchi Univ, Sch Med, Dept Neurosurg, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Adv Med Emergency & Crit Care Ctr, Ube, Yamaguchi 7558505, Japan	Suehiro, E (corresponding author), Yamaguchi Univ, Sch Med, Dept Neurosurg, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan.	suehiro-nsu@umin.ac.jp	Suehiro, Eiichi/I-5852-2019				Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; GOTTSCHALL PE, 1995, J NEUROSCI RES, V42, P335, DOI 10.1002/jnr.490420307; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Petty MA, 2002, PROG NEUROBIOL, V68, P311, DOI 10.1016/S0301-0082(02)00128-4; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Schumann G, 1999, J NEUROCHEM, V73, P2009; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yamamoto T, 2002, NEUROL RES, V24, P789, DOI 10.1179/016164102101200906; Zawadzka M, 2003, MOL CELL NEUROSCI, V22, P202, DOI 10.1016/S1044-7431(03)00036-8; Zhang ZG, 2001, BRAIN RES, V912, P181, DOI 10.1016/S0006-8993(01)02735-4	25	83	90	0	3	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1706	1711		10.1089/0897715042664957			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400002	15684762				2021-06-18	
J	Kliegel, M; Eschen, A; Thone-Otto, AIT				Kliegel, M; Eschen, A; Thone-Otto, AIT			Planning and realization of complex intentions in traumatic brain injury and normal aging	BRAIN AND COGNITION			English	Article							PROSPECTIVE MEMORY IMPAIRMENT; EXECUTIVE FUNCTIONS; ELECTRONIC MEMORY; PREFRONTAL CORTEX; EVENT; PERFORMANCE; DEFICITS; AGE; TASK; TIME	I. The realization of delayed intentions (i.e., prospective memory) is a highly complex process composed of four phases: intention formation, retention, re-instantiation, and execution. The aim of this study was to investigate if executive functioning impairments are related to problems in the formation, re-instantiation, and execution of a delayed complex intention. In this context, it was another aim of the study to investigate the executive functioning hypothesis of cognitive aging in prospective memory performance. It, was, therefore, explored if age-related prospective memory decline leads to similar decrements in the process of prospective remembering as executive functioning-related decline in young patients with traumatic brain injury. A group of patients with traumatic brain injury with retrospective memory within normal limits but impaired executive functions, a group of healthy older and a group of healthy younger adults completed a complex prospective memory task that allows for the separate assessment of the four phases of the prospective memory process. All groups showed a similarly high performance in the intention retention phase, whereas the patients with deficits in executive functioning and the older participants performed worse than the healthy young participants in the intention formation, re-instantiation and execution phases. The importance of executive functioning for prospective remembering in traumatic brain injury and normal aging is discussed. (C) 2004 Elsevier Inc. All rights reserved.	Univ Zurich, Dept Gerontopsychol, CH-8006 Zurich, Switzerland; Univ Zurich Hosp, CH-8091 Zurich, Switzerland; Univ Leipzig, Day Care Clin Cognit Neurol, Leipzig, Germany	Kliegel, M (corresponding author), Univ Zurich, Dept Gerontopsychol, CH-8006 Zurich, Switzerland.	m.kliegel@psychologic.unizh.ch		Kliegel, Matthias/0000-0002-2001-2522			Bisiacchi PS, 1996, PROSPECTIVE MEMORY T, P297; BISIACCHI PS, 2000, 1 INT C PROSP MEM HA; Brunfaut E, 2000, NEUROPSYCHOLOGIA, V38, P975, DOI 10.1016/S0028-3932(00)00016-6; Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; Burgess P. W., 1997, METHODOLOGY FRONTAL, P81, DOI DOI 10.1024//1016-264X.10.2.123; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; CRAMON GM, 2000, LEHRBUCH KLIN NEUROP, P392; Crawford JR, 2000, AGING NEUROPSYCHOL C, V7, P9, DOI 10.1076/anec.7.1.9.806; DAIGNEAULT S, 1992, DEV NEUROPSYCHOL, V8, P99, DOI 10.1080/87565649209540518; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DOBBS AR, 1987, CAN J PSYCHOL, V41, P209, DOI 10.1037/h0084152; Einstein G., 1996, PROSPECTIVE MEMORY T, P115; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; FUNKE J, 1993, PLAN DAY; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; HARTING C, 2000, DTSCH ADAPTATION REV; HEATON RK, 1993, WISCONSIN SORTING TE; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; Huppert FA, 2000, APPL COGNITIVE PSYCH, V14, pS63, DOI 10.1002/acp.771; KEIDEL M, 1998, THERAPIE VERLAUF NEU, P569; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2000, MEM COGNITION, V28, P1041, DOI 10.3758/BF03209352; Kliegel M, 2001, MEMORY, V9, P1, DOI 10.1080/09658210042000003; Kliegel M, 2003, Z GERONTOL GERIATR, V36, P35, DOI 10.1007/s00391-003-0081-5; Kliegel M, 2003, INT J PSYCHOL, V38, P207, DOI 10.1080/00207590344000132; Kliegel M, 2003, INT J PSYCHOL, V38, P193, DOI 10.1080/00207590344000114; KLIEGEL M, 2003, Z NEUROPSYCHOL, V14, P293; KLIEGEL M, IN PRESS MEMORY; Kliegel M, 2002, PSYCHOL BEITR, V44, P303, DOI DOI 10.1037/0012-1649.44.2.612; Knight R.G., 1998, MEMORY NEURODEGENERA, P172; Kopp UA, 2003, INT J PSYCHOL, V38, P229, DOI 10.1080/00207590344000150; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Lehrl S., 1977, MEHRFACHWAHLWORTSCHA; Levin H. S., 1991, FRONTAL LOBE FUNCTIO; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mantyla T, 1997, AGING NEUROPSYCHOL C, V4, P81, DOI 10.1080/13825589708256638; Martin M, 2003, INT J PSYCHOL, V38, P195, DOI 10.1080/00207590344000123; Maylor EA, 2002, MEM COGNITION, V30, P871, DOI 10.3758/BF03195773; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; Meissner F, 2001, PSYCHIAT PRAX, V28, P180, DOI 10.1055/s-2001-13266; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; OURIACHE S, 2000, 1 INT C PROSP MEM HA; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Rude SS, 1999, COGNITION EMOTION, V13, P267, DOI 10.1080/026999399379276; Salat DH, 2001, ARCH NEUROL-CHICAGO, V58, P1403, DOI 10.1001/archneur.58.9.1403; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Sgaramella TM, 2000, BRAIN COGNITION, V43, P388; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shapiro JK, 1998, BRAIN COGNITION, V37, P175; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Thone-Otto AIT, 2003, INT J PSYCHOL, V38, P236, DOI 10.1080/00207590344000169; THONEOTTO AIT, 2001, Z NEUROPSYCHOL, V12, P102; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Ward G, 1997, Q J EXP PSYCHOL-A, V50, P49, DOI 10.1080/027249897392224; West R, 2001, NEUROREPORT, V12, P2855, DOI 10.1097/00001756-200109170-00020; West R, 2001, COGNITIVE BRAIN RES, V12, P1, DOI 10.1016/S0926-6410(01)00014-3; West R, 2001, PSYCHOL AGING, V16, P682, DOI 10.1037//0882-7974.16.4.682; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Wilson BA, 1996, BEHAV ASSESSMENT DYS	67	83	89	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	OCT	2004	56	1					43	54		10.1016/j.bandc.2004.05.005			12	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	860BU	WOS:000224313600007	15380875				2021-06-18	
J	Moore, BA; Donders, J				Moore, BA; Donders, J			Predictors of invalid neuropsychological test performance after traumatic brain injury	BRAIN INJURY			English	Article							MEMORY MALINGERING TOMM; VERBAL-LEARNING TEST; MILD HEAD-INJURY; VALIDITY; COMPENSATION; INDICATOR; RECOVERY; SCORES	Objective: To investigate the usefulness of the Test of Memory Malingering (TOMM) and the California Verbal Learning Test-Second Edition (CVLT-II) in assessing invalid test performance after traumatic brain injury (TBI). Design: Consecutive 3-year series of rehabilitation referrals (n = 132). Methods and procedures: Percentage of participants who failed validity criteria was determined. Hierarchical logistic regression analysis and odds ratios were used to identify predictors of invalid test performance. Results: Twenty patients (15%) performed in the invalid range when held to a priori specified criteria for invalid test performance (i.e. TOMM <45/50 on Trial 2 or CVLT-II <15/16 on Forced-Choice recognition trial). Both psychiatric history and financial compensation seeking were associated with an almost 4-fold increase in likelihood of invalid responding. Conclusions: The TOMM and CVLT-II are sensitive to the potential impact of current financial compensation seeking and prior psychiatric history on neuropsychological test performance after TBI.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALLEN LM, 1997, MANUAL COMPUTERISED; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Evans R. W., 1994, AM J FORENSIC PSYCH, V4, P19; Frederick RI, 2000, ARCH CLIN NEUROPSYCH, V15, P281, DOI 10.1016/S0887-6177(99)00002-5; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GERVAIS RO, IN PRESS ARCH CLIN N; Green P, 2001, CLIN NEUROPSYCHOL, V15, P492, DOI 10.1076/clin.15.4.492.1887; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 1996, MANUAL COMPUTERISED; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Hoffman R. G., 1999, J FORENSIC NEUROPSYC, V1, P3, DOI DOI 10.1300/J151V01N02_02; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Larrabee GJ, 2000, CLIN GUIDE NEUROPSYC, P301; LEMMON J, 1995, J COGNITIVE REHABILT, V13, P4; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2000, BRAIN INJURY, V14, P219; PUTMAN SH, 1994, ADV MED PSYCHOTHERAP, V7, P1; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; Sherman EMS, 2000, BRAIN INJURY, V14, P621; Slick D., 1997, VICTORIA SYMPTOM VAL; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; SWEET JJ, 1999, J FORENSIC NEUROPSYC, V1, P73; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; vanGorp WG, 1997, CLIN NEUROPSYCHOL, V11, P180, DOI 10.1080/13854049708407048; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]; YOUNGQUIST RC, 1984, OPT LETT, V9, P177, DOI 10.1364/OL.9.000177	49	83	84	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2004	18	10					975	984		10.1080/02699050410001672350			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	845LQ	WOS:000223244600002	15370897				2021-06-18	
J	Van Loo, MA; Moseley, AM; Bosman, JM; De Bie, RA; Hassett, L				Van Loo, MA; Moseley, AM; Bosman, JM; De Bie, RA; Hassett, L			Test-re-test reliability of walking speed, step length and step width measurement after traumatic brain injury: a pilot study	BRAIN INJURY			English	Article							INTERRATER RELIABILITY; CONCURRENT VALIDITY; PERFORMANCE; ADULTS; GAIT	Primary objective: Assess the test-re-test reliability of walking speed, step length and step width measurement in people with traumatic brain injury (TBI). Research design: Repeated measures (two test occasions). Methods: Thirteen people with TBI completed four comfortable and four fast-paced walking trials of the 10 m walk test and two trials of the 6-minute walk test (6MWT). Walking speed, step length and step width were measured during the 10 m walk test and walking distance and average speed were measured during the 6MWT. The tests were repeated 1-week later. Main results: Walking speed and distance showed excellent test-re-test reliability, with an intra-class correlation coefficient (ICC) of 0.95-0.96. Reliability was also high for step length and width measurement (ICC 0.91-0.98). Conclusions: This test-re-test reliability means that walking speed and distance and step length and width can be used by physiotherapists to monitor improvements in walking after TBI.	Univ Sydney, Fac Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Maastricht Univ, Maastricht, Netherlands; Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Moseley, AM (corresponding author), Univ Sydney, Fac Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	amoseley@mail.usyd.edu.au		Hassett, Leanne/0000-0002-3546-1822			Bohannon R W, 1992, Int J Rehabil Res, V15, P246, DOI 10.1097/00004356-199209000-00009; Bohannon RW, 1997, AGE AGEING, V26, P15, DOI 10.1093/ageing/26.1.15; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dean CM, 2001, CLIN REHABIL, V15, P415, DOI 10.1191/026921501678310216; Evans MD, 1997, ARCH PHYS MED REHAB, V78, P725, DOI 10.1016/S0003-9993(97)90080-0; Fleiss J. L., 1986, DESIGN ANAL CLIN EXP, P7; Fransen M, 1997, PHYS THER, V77, P944, DOI 10.1093/ptj/77.9.944; Harada ND, 1999, ARCH PHYS MED REHAB, V80, P837, DOI 10.1016/S0003-9993(99)90236-8; King MB, 2000, PHYS THER, V80, P8, DOI 10.1093/ptj/80.1.8; King S, 1999, J RHEUMATOL, V26, P2233; MAYERSON NH, 1984, ARCH PHYS MED REHAB, V65, P92; MCGAVIN CR, 1976, BMJ-BRIT MED J, V1, P822, DOI 10.1136/bmj.1.6013.822; Montgomery PS, 1998, J AM GERIATR SOC, V46, P706, DOI 10.1111/j.1532-5415.1998.tb03804.x; Stevens D, 1999, AM J RESP CRIT CARE, V160, P1540, DOI 10.1164/ajrccm.160.5.9808139; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; van Loo MA, 2003, DISABIL REHABIL, V25, P1195, DOI 10.1080/09638280310001599989; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wall JC, 2000, J ORTHOP SPORT PHYS, V30, P410, DOI 10.2519/jospt.2000.30.7.410; Watson M.J., 2002, PHYSIOTHERAPY, P386, DOI DOI 10.1016/S0031-9406(05)61264-3	19	83	85	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2004	18	10					1041	1048		10.1080/02699050410001672314			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	845LQ	WOS:000223244600007	15370902				2021-06-18	
J	Coles, JP; Fryer, TD; Smielewski, P; Rice, K; Clark, JC; Pickard, JD; Menon, DK				Coles, JP; Fryer, TD; Smielewski, P; Rice, K; Clark, JC; Pickard, JD; Menon, DK			Defining ischemic burden after traumatic brain injury using O-15 PET imaging if cerebral physiology	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						trauma; head injury; positron emission tomography; cerebral ischemia; ischemic penumbra	STEADY-STATE TECHNIQUE; BLOOD-FLOW; OXYGEN UTILIZATION; ENERGY-METABOLISM; ACUTE STROKE; HYPERVENTILATION; TOMOGRAPHY; TISSUE; PENUMBRA; VOLUME	Whereas postmortem ischemic damage is common in head injury, antemortern demonstration of ischemia has proven to be elusive. Although O-15 positron emission tomography may be useful in this area, the technique has traditionally analyzed data within regions of interest (ROIs) to improve statistical accuracy. In head injury, such techniques are limited because of the lack of a priori knowledge regarding the location of ischemia, coexistence of hyperaemia, and difficulty in defining ischemic cerebral blood flow (CBF) and cerebral oxygen metabolism (CMRO2) levels. We report a novel method for defining disease pathophysiology following head injury. Voxel-based approaches are used to define the distribution of oxygen extraction fraction (OEF) across the entire brain; the standard deviation of this distribution provides a measure of the variability of OEF. These data are also used to integrate voxels above a threshold OEF value to produce an ROI based upon coherent physiology rather than spatial contiguity (the ischemic brain volume; IBV). However, such approaches may suffer from poor statistical accuracy, particularly in regions with low blood flow. The magnitude of these errors has been assessed in modeling experiments using the Hoffman brain phantom and modified control datasets. We conclude that this technique is a valid and useful tool for quantifying ischemic burden after traumatic brain injury.	Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England	Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Rice, Kenneth M/A-4150-2013	Rice, Kenneth M/0000-0001-5779-4495; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237] Funding Source: Medline		ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; COLES JP, 2002, CLIN SCI, V103, P62; CORREIA JA, 1985, J CEREBR BLOOD F MET, V5, P591, DOI 10.1038/jcbfm.1985.88; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HERSCOVITCH P, 1983, J CEREBR BLOOD F MET, V3, P407, DOI 10.1038/jcbfm.1983.66; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOFFMAN EJ, 1990, IEEE T NUCL SCI, V37, P616, DOI 10.1109/23.106686; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; LAMMERTSMA AA, 1982, J COMPUT ASSIST TOMO, V6, P566, DOI 10.1097/00004728-198206000-00022; LAMMERTSMA AA, 1981, J COMPUT ASSIST TOMO, V5, P544, DOI 10.1097/00004728-198108000-00016; LAMMERTSMA AA, 1992, J CEREBR BLOOD F MET, V12, P291, DOI 10.1038/jcbfm.1992.39; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; LEBRUNGRANDIE P, 1983, ARCH NEUROL-CHICAGO, V40, P230, DOI 10.1001/archneur.1983.04050040060010; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; Marchal G, 1996, STROKE, V27, P599, DOI 10.1161/01.STR.27.4.599; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; PHELPS ME, 1979, J NUCL MED, V20, P328; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; SMIELEWSKI P, 2003, IN PRESS J CLIN MONI; STEINER LA, 2003, IN PRESS J CEREB BLO; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	34	83	85	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2004	24	2					191	201		10.1097/01.WCB.0000100045.07481.DE			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	772CG	WOS:000188822600007	14747746	Bronze			2021-06-18	
J	Pickett, W; Simpson, K; Walker, J; Brison, RJ				Pickett, W; Simpson, K; Walker, J; Brison, RJ			Traumatic spinal cord injury in Ontario, Canada	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						spinal cord injury; neurotrauma; blunt trauma; hospital admissions; injury surveillance; prevention; Canada	NATIONWIDE EPIDEMIOLOGIC SURVEY; UNITED-STATES; LIFE SATISFACTION; REGION; HEALTH; COUNTY; JAPAN; HEAD	Background. Few population-based analyses of spinal cord injuries exist from which to base Canadian prevention initiatives. This study aimed to calculate rates of traumatic spinal cord injury for the province of Ontario and describe these injuries by several epidemiologic parameters. Methods. Two thousand three hundred eighty-five hospital admissions were studied for April 1, 1994, through March 319 1999. Results. Annual age-standardized rates declined from a maximum of 46.2 hospitalizations per 1 million population (95% confidence interval, 42.1-50.3) to 37.2 per 1 million (95% confidence interval, 33.8-41.0). Male rates declined over the study period, whereas female rates remained stable. Leading external causes included unintentional falls (1,030 of 2,385 [43.2%]), especially among the elderly, and transport injuries (1,021 of 2,385 [42.8%]), especially among those aged less than 40 years. Intentional injuries were most commonly seen among those aged 20 to 39 years (48 of 86 [55.8%]). Misclassification of some elder fall cases as spinal cord injuries is a methodologic concern. Conclusion. The results indicate the relative importance of several external causes of injury and are useful in establishing rational priorities for prevention.	Queens Univ, Dept Emergency Med, Kingston, ON, Canada; Queens Univ, Dept Community Hlth & Epidemiol, Kingston, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; W Pk Healthcare Ctr, Clin Evaluat & Res Unit, Toronto, ON, Canada	Pickett, W (corresponding author), Kingston Gen Hosp, Dept Emergency Med, Angada 3,76 Stuart St, Kingston, ON K7L 2V7, Canada.	pickettW@post.queensu.ca					ACTON PA, 1993, ARCH PHYS MED REHAB, V74, P1035, DOI 10.1016/0003-9993(93)90058-I; Anderson GM, 1997, MED CARE, V35, pOS93, DOI 10.1097/00005650-199710001-00012; ANDREWS LG, 1979, PARAPLEGIA, V17, P442, DOI 10.1038/sc.1979.87; AO JDY, 1993, PARAPLEGIA, V31, P759; BO BK, 1995, SPINAL CORD INJURY C, P21; Botterell E H, 1975, Can J Neurol Sci, V2, P361; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; BRESLOW NE, 1987, IARC SCI PUBL, V82, P52; Burke DA, 2001, SPINAL CORD, V39, P274, DOI 10.1038/sj.sc.3101158; BURNEY RE, 1993, ARCH SURG-CHICAGO, V128, P596; *CAN I HLTH INF, 2001, ONT TRAUM REG 2001 R; *CAN I HLTH INF, 1999, SPIN CORD INJ ADM ON; *CAND I HLTH INF, 2001, NEUR HOSP ONT 1998 9; *CAND PAR ASS, 2000, CPA 2000 ANN REP; Cantella D, 1999, Crit Care Nurs Q, V22, P14; Carriere KC, 2000, HEALTH SERV RES, V35, P467; DANESH JN, 1991, NEW ZEAL MED J, V104, P295; DeVivo M, 1995, SPINAL CORD INJURY C, P234; DeVivo MJ, 1997, SPINAL CORD, V35, P809, DOI 10.1038/sj.sc.3100501; Dunnum L, 1990, J Neurosci Nurs, V22, P43; FINE PR, 1979, PARAPLEGIA, V17, P237, DOI 10.1038/sc.1979.47; GRIFFIN MR, 1985, AM J EPIDEMIOL, V121, P884, DOI 10.1093/oxfordjournals.aje.a114058; Hartkopp A, 1997, SPINAL CORD, V35, P76, DOI 10.1038/sj.sc.3100351; Hoque MF, 1999, SPINAL CORD, V37, P858, DOI 10.1038/sj.sc.3100938; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Karamehmetoglu SS, 1997, SPINAL CORD, V35, P531, DOI 10.1038/sj.sc.3100404; KRAMER CF, 1995, J TRAUMA, V39, P935, DOI 10.1097/00005373-199511000-00019; KRAUS JF, 1980, J NEUROSURG, V53, pS3; Krause JS, 2000, SPINAL CORD, V38, P77, DOI 10.1038/sj.sc.3100961; LAN C, 1993, PARAPLEGIA, V31, P398, DOI 10.1038/sc.1993.66; LASFARGUES JE, 1995, PARAPLEGIA, V33, P62, DOI 10.1038/sc.1995.16; Maharaj JC, 1996, SPINAL CORD, V34, P549, DOI 10.1038/sc.1996.99; Martins F, 1998, SPINAL CORD, V36, P574, DOI 10.1038/sj.sc.3100657; McColl MA, 1997, SPINAL CORD, V35, P818, DOI 10.1038/sj.sc.3100546; Miller T.R., 1995, DATABOOK NONFATAL IN; MINAIRE P, 1978, PARAPLEGIA, V16, P76, DOI 10.1038/sc.1978.13; NOBUNGA AI, 2002, ARCH PHYS MED REHAB, V80, P1372; Otom AS, 1997, SPINAL CORD, V35, P253, DOI 10.1038/sj.sc.3100402; Pajareya K, 1996, SPINAL CORD, V34, P608, DOI 10.1038/sc.1996.108; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; SHINGU H, 1995, PARAPLEGIA, V33, P183, DOI 10.1038/sc.1995.42; SHINGU H, 1994, PARAPLEGIA, V32, P3, DOI 10.1038/sc.1994.2; SILBERSTEIN B, 1995, PARAPLEGIA, V33, P322, DOI 10.1038/sc.1995.72; *SMARTR, 1999, EC BURD UN INJ ONT; SOOPRAMANIEN A, 1994, PARAPLEGIA, V32, P715, DOI 10.1038/sc.1994.116; *STAT CAN, 2000, 91213 STAT CAN; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Sullivan J, 1999, Crit Care Nurs Q, V22, P80; Surkin J, 2000, SPINE, V25, P716, DOI 10.1097/00007632-200003150-00011; Tarazi F, 1999, AM J SPORT MED, V27, P177, DOI 10.1177/03635465990270021101; TATOR CH, 1993, SURG NEUROL, V40, P207, DOI 10.1016/0090-3019(93)90069-D; Tator CH, 2000, CAN MED ASSOC J, V162, P787; THURMAN DJ, 1994, PARAPLEGIA, V32, P665, DOI 10.1038/sc.1994.107; Tyroch AH, 1997, ARCH SURG-CHICAGO, V132, P778; van Asbeck FWA, 2000, SPINAL CORD, V38, P420, DOI 10.1038/sj.sc.3101003; World Health Organization, 1985, INT CLASS DIS; Yeo JD, 1998, SPINAL CORD, V36, P329, DOI 10.1038/sj.sc.3100628	59	83	87	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1070	1076		10.1097/01.TA.0000034228.18541.D1			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	758TL	WOS:000187666200012	14676653				2021-06-18	
J	Geddes, DM; LaPlaca, MC; Cargill, RS				Geddes, DM; LaPlaca, MC; Cargill, RS			Susceptibility of hippocampal neurons to mechanically induced injury	EXPERIMENTAL NEUROLOGY			English	Article						neuron; selective vulnerability; TBI; stretch; cortex; hippocampus	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; GLUTAMATE-RECEPTOR; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; CALCIUM RESPONSE; NEURAL TRAUMA; CA1 NEURONS	Experimental models of traumatic cortical brain injury in rodents reveal that specific regions of the hippocampus (e.g., CA3 and hilar subfields) are severely injured despite their distance from the initial insult. Hippocampal neurons may be intrinsically more vulnerable to mechanical insult than cortical neurons due to increased NMDA receptor densities and lower energy capacities, as evidenced by increased susceptibility to ischemic insults. The selective vulnerability of hippocampal neurons was evaluated using an in vitro model of TBI in which either primary rat cortical or hippocampal neurons (E17) seeded onto silicone substrates were subjected to graded levels of mechanical stretch. Although cortical neurons exhibited significantly longer increases in stretch-induced membrane permeability, injury of hippocampal neurons resulted in larger increases in intracellular free calcium concentration [Ca2+](i) and cell death. [ATP](i) deficits due to stretch were apparent by 60 min after injury in cortical neurons but recovered by 24 h, whereas significant deficits in [ATP](i) were not observed in hippocampal neurons until 24 It after injury. MK801 pretreatment decreased the stretch-induced [Ca2+](i) transients in both hippocampal and cortical cultures, thereby negating the regional specificity. However, MK801 pretreatment did not improve hippocampal viability and paradoxically, significantly increased cell death among cortical neurons. As the hippocampus is the primary brain region responsible for the memory deficits and epileptic seizures associated with TBI, understanding why this region is selectively damaged could lead to the development of more accurate mechanical tolerances as well as effective pharmaceutical agents. (C) 2003 Elsevier Science (USA). All rights reserved.	Exponent Failure Anal Associates Inc, Philadelphia, PA 19104 USA; Georgia Inst Technol, Sch Biomed Engn, Atlanta, GA 30332 USA	Cargill, RS (corresponding author), Exponent Failure Anal Associates Inc, 3401 Market St,Suite 300, Philadelphia, PA 19104 USA.	rcargill@exponent.com					Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; ARAKI T, 1989, ACTA NEUROL SCAND, V80, P548, DOI 10.1111/j.1600-0404.1989.tb03925.x; BENSON DL, 1994, J NEUROCYTOL, V23, P279, DOI 10.1007/BF01188497; Bernaudin M, 1998, EXP NEUROL, V150, P30, DOI 10.1006/exnr.1997.6728; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cochran SA, 2001, ULTRASOUND MED BIOL, V27, P841, DOI 10.1016/S0301-5629(01)00382-9; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DeLima AD, 1997, J COMP NEUROL, V388, P526; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Golarai G, 2001, J NEUROSCI, V21, P8523; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guzman HR, 2001, J ACOUST SOC AM, V110, P597, DOI 10.1121/1.1376130; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Kovacs AD, 2001, EXP NEUROL, V168, P47, DOI 10.1006/exnr.2000.7576; Kuroiwa T, 2000, ACTA NEUROPATHOL, V100, P587, DOI 10.1007/s004010000235; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Ohmori T, 1996, BRAIN RES, V743, P109, DOI 10.1016/S0006-8993(96)01034-7; Peng TI, 1998, MOL PHARMACOL, V53, P974; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PYLOVA SI, 1989, BRAIN RES, V490, P170, DOI 10.1016/0006-8993(89)90446-0; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STOJANOVIC T, 1988, METAB BRAIN DIS, V3, P265, DOI 10.1007/BF00999536; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tang SL, 1997, J CHART INST WATER E, V11, P14; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Togo T, 1999, J CELL SCI, V112, P719; Toth Z, 1997, J NEUROSCI, V17, P8106; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wenzel A, 1997, J NEUROCHEM, V68, P469; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1985, J NEUROSCI, V5, P1626	52	83	85	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2003	184	1					420	427		10.1016/S0014-4886(03)00254-1			8	Neurosciences	Neurosciences & Neurology	747KZ	WOS:000186804800043	14637111				2021-06-18	
J	Logi, F; Fischer, C; Murri, L; Mauguiere, F				Logi, F; Fischer, C; Murri, L; Mauguiere, F			The prognostic value of evoked responses from primary somatosensory and auditory cortex in comatose patients	CLINICAL NEUROPHYSIOLOGY			English	Article						somatosensory evoked potentials; middle latency auditory evoked potentials; coma; post-anoxic coma; traumatic brain injury; outcome prediction	SEVERE HEAD-INJURY; EVENT-RELATED POTENTIALS; ANOXIC-ISCHEMIC COMA; SEVERE BRAIN-DAMAGE; OUTCOME PREDICTION; MIDDLE-LATENCY; CARDIAC-ARREST; BILATERAL LOSS; PARIETAL COMPONENTS; STEM	Objective: To evaluate somatosensory and auditory primary cortices using somatosensory evoked potentials (SEPs) and middle latency auditory evoked potentials (MLAEPs) in the prognosis of return to consciousness in comatose patients. Methods: SEPs and MLAEPs were recorded in 131 severe comatose patients. Latencies and amplitudes were measured. Coma had been caused by transient cardiac arrest (n = 49), traumatic brain injury (n = 22), stroke (n = 45), complications of neurosurgery (n = 12) and encephalitis (n = 3). One month after the onset of coma patients were classified as awake, still comatose or dead. Three months after (W), they were classified into one of the 5 categories of the Glasgow outcome scale (GOS). Results: At M3, 41.2% were dead, 47.3% were conscious (GOS 3-5) and 11.5% had not recovered consciousness. None of the patients in whom somatosensory N20 and auditory Pa were absent did return to consciousness and in the post-anoxic group, reduced cortical amplitude too was always associated with bad outcome. Conversely, N20 and Pa were present, respectively, in 33/69 and 34/69 patients who did not recover. Conclusions: The prognostic value of SEPs and MLAEPs in comatose patients depends on the cause of coma. Measurement of response amplitudes is informative. Abolition of cortical SEPs and/or cortical MLAEPs precludes post-anoxic comatose patients from returning to consciousness (100% specificity). In any case, the presence of short latency cortical somatosensory or auditory components is not a guarantee for return to consciousness. Late components should then be recorded. (C) 2003 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Hop Neurol, EA1880, F-69003 Lyon, France; Univ Pisa, Inst Neurol, Dept Neurosci, I-56100 Pisa, Italy	Fischer, C (corresponding author), Hop Neurol, EA1880, 59 Blvd Pinel, F-69003 Lyon, France.	catherine.fischer@univ-lyon1.fr		MAUGUIERE, Francois/0000-0003-4291-4727			ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; BARELLI A, 1991, CRIT CARE MED, V19, P1374, DOI 10.1097/00003246-199111000-00013; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; BEREK K, 1995, STROKE, V26, P543, DOI 10.1161/01.STR.26.4.543; Berkhoff M, 2000, CLIN NEUROPHYSIOL, V111, P297, DOI 10.1016/S1388-2457(99)00246-1; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Cheliou-Heraut F., 1992, Neurophysiologie Clinique, V22, P269, DOI 10.1016/S0987-7053(05)80259-X; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; DEGIORGIO CM, 1993, ACTA NEUROL SCAND, V87, P423; DESMEDT JE, 1987, ELECTROEN CLIN NEURO, V68, P1, DOI 10.1016/0168-5597(87)90065-7; DRUMMOND JC, 1987, NEUROSURGERY, V20, P830, DOI 10.1227/00006123-198706000-00002; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Facco E, 1998, ELECTROEN CLIN NEURO, V107, P332, DOI 10.1016/S0013-4694(98)00080-7; Facco E., 1993, Neurophysiologie Clinique, V23, P237, DOI 10.1016/S0987-7053(05)80233-3; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; FISCHER C, 1994, NEUROSURGERY, V35, P45, DOI 10.1227/00006123-199407000-00007; GANES T, 1988, ELECTROEN CLIN NEURO, V69, P6, DOI 10.1016/0013-4694(88)90030-2; Garcia-Larrea L., 1993, Neurophysiologie Clinique, V23, P141; Gendo A, 2001, INTENS CARE MED, V27, P1305, DOI 10.1007/s001340101008; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; Haupt WF, 2000, J CLIN NEUROPHYSIOL, V17, P326, DOI 10.1097/00004691-200005000-00010; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; LARREA LG, 1992, ELECTROEN CLIN NEURO, V84, P71, DOI 10.1016/0168-5597(92)90069-N; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; Litscher G, 1995, INT J NEUROSCI, V83, P253, DOI 10.3109/00207459508986342; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; Madl C, 1996, ARCH NEUROL-CHICAGO, V53, P512, DOI 10.1001/archneur.1996.00550060054017; MAUGUIERE F, 1983, BRAIN, V106, P271, DOI 10.1093/brain/106.2.271; Mauguiere F, 1999, EEG CL N SU, V50, P31; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; Morlet D, 1997, EVOKED POTENTIAL, V104, P437, DOI 10.1016/S0168-5597(97)00044-0; MORLET D, 2000, AUDIOL NEURO-OTOL, V5, P190; Nakabayashi M, 2001, INTENS CARE MED, V27, P1210, DOI 10.1007/s001340100984; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEWLON PG, 1983, NEUROSURGERY, V12, P613, DOI 10.1227/00006123-198306000-00003; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; ROSENBERG C, 1984, ARCH NEUROL-CHICAGO, V41, P835, DOI 10.1001/archneur.1984.04050190041012; ROSSINI PM, 1987, ELECTROEN CLIN NEURO, V68, P88, DOI 10.1016/0168-5597(87)90036-0; Rothstein TL, 2000, J CLIN NEUROPHYSIOL, V17, P486, DOI 10.1097/00004691-200009000-00007; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; Schwarz S, 1999, CRIT CARE MED, V27, P182, DOI 10.1097/00003246-199901000-00049; Sherman AL, 2000, NEUROLOGY, V54, P889, DOI 10.1212/WNL.54.4.889; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; SNYDER BD, 1981, NEUROLOGY, V31, P1092, DOI 10.1212/WNL.31.9.1092; SYNEK VM, 1990, CLIN ELECTROENCEPHAL, V21, P25, DOI 10.1177/155005949002100111; WALSER H, 1985, ARCH NEUROL-CHICAGO, V42, P32, DOI 10.1001/archneur.1985.04060010038013; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010; Wijdicks EFM, 2001, AM J NEURORADIOL, V22, P1561; Wohlrab G, 2001, NEUROPEDIATRICS, V32, P271, DOI 10.1055/s-2001-19123; YING Z, 1992, J NEUROL NEUROSUR PS, V55, P470, DOI 10.1136/jnnp.55.6.470; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; YOUNG B, 1993, NEUROLOGY S2, V43, pA229; Yvert B, 2001, CEREB CORTEX, V11, P411, DOI 10.1093/cercor/11.5.411; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076; ZENTNER J, 1992, NEUROSURGERY, V31, P429, DOI 10.1227/00006123-199209000-00007	76	83	99	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	SEP	2003	114	9					1615	1627		10.1016/S1388-2457(03)00086-5			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	722XJ	WOS:000185403100005	12948790				2021-06-18	
J	Slomine, BS; Gerring, JP; Grados, MA; Vasa, R; Brady, KD; Christensen, JR; Denckla, MB				Slomine, BS; Gerring, JP; Grados, MA; Vasa, R; Brady, KD; Christensen, JR; Denckla, MB			Performance on measures of 'executive function' following pediatric traumatic brain injury	BRAIN INJURY			English	Article							FRONTAL-LOBE LESIONS; HEAD-INJURY; CHILDREN; ADOLESCENTS; TESTS; COGNITION; AMNESIA; DAMAGE; SCALE; COMA	Objective: To investigate the relationships among age at injury, neuroanatomic lesion location, and measures of executive function (EF) following paediatric traumatic brain injury (TBI). Methods: EF was assessed in 68 children (aged 7-15) with moderate-to-severe TBI 1 year post-injury. EF tests included: (1) Tower of Hanoi (TOH), a measure of problem solving ability, (2) Wisconsin Card Sorting Test (WCST), a measure of categorization and ability to shift cognitive strategies, (3) Letter Fluency (LF), a measure of novel lexical search and rule-governed word generation. EF variables included number of moves needed to achieve a 3-ring solution on the TOH, number of perseverative and non-perseverative errors on the WCST, and number of words generated on LF. Intellectual functioning was also assessed using the Verbal Intellectual Quotient (VIQ) from the Wechsler Intelligence Scale from Children-3rd edn (WISC-III). Data from standardized MRIs, performed at 3-months post-injury, were available for all subjects and were used to determine lesion location, lesion volumes, and total number of lesions. The relationships among EF, lesion variables (frontal lesion volume, extrafrontal lesion volume, total number of lesions) and age at injury were examined. Pre-injury special education services and attention deficit hyperactivity disorder (ADHD) were controlled for. Results: Younger age at injury was associated with more perseverative errors on the WCST and worse performance on LF. Frontal lesion volume was not predictive of performance on any measures of EF. Greater extrafrontal lesion volume and total number of lesions were predictive of worse performance on LF. When controlling for pre-injury special education placement and pre-injury ADHD, there was little change in the results. Conclusions: Younger age at injury places children at greater risk of impairment on measures of EF. Performance on measures of EF depends on brain variables other than frontal lobes including extrafrontal cortical brain areas and total number of lesions. The relationship between extrafrontal brain regions and EF suggests that domain-specific cognitive content (i.e. language or visuospatial analysis), mediated by the parietal or temporal lobes, may disrupt underlying cognitive processes necessary for successful performance on measures of EF. In addition, the association between total number of lesions and EF may be related to disconnections and disruption of frontal/subcortical systems.	Kennedy Inst, Dept Neuropsychol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Slomine, BS (corresponding author), Kennedy Inst, Dept Neuropsychol, 707 N Broadway, Baltimore, MD 21205 USA.	slomine@kennedykrieger.org		Grados, Marco/0000-0002-6189-6264	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD 24061] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD024061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Archibald SJ, 1999, CHILD NEUROPSYCHOL, V5, P115, DOI 10.1076/chin.5.2.115.3167; Basso MR, 1999, CLIN NEUROPSYCHOL, V13, P283, DOI 10.1076/clin.13.3.283.1743; Benton AL, 1983, MULTILINGUAL APHASIA; BLASTER DD, 1997, AM J NEURORADIOL, V18, P1; Cripe L., 1996, ECOLOGICAL VALIDITY, P171; Cummings JL, 1992, DEMENTIA CLIN APPROA; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Denckla M.B., 1994, FRAMES REFERENCE ASS, P117; DENCKLA MB, 1997, DEV PREFRONTAL CORTE, P283; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; Filley CM, 1999, NEUROPSY NEUROPSY BE, V12, P156; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; GARTH J, 1997, PEDIAT REHABILITATIO, V2, P99; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R., 1993, WISCONSIN CARD SORTI; HOLLINGSHEAD AB, 1975, UNPUB 4 FACTOR INDEX; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Milner B, 1964, FRONTAL GRANULAR COR, P313; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; STUSS DT, 1991, SELF INTERDISCIPLINA; Talairach TM, 1988, COPLANAR STEREOTAXIC; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TAYLOR HG, 1984, EARLY BRAIN DAMAGE R, P325; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1991, WECHSLER INTELLIGENC; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILSON J T L, 1990, Brain Injury, V4, P349; YLIVASKER M, 1998, TRAUMATIC BRAIN INJU, P159; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	45	83	84	1	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2002	16	9					759	772		10.1080/02699050210127286			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	585PD	WOS:000177532800002	12217202				2021-06-18	
J	de Kruijk, JR; Leffers, P; Meerhoff, S; Rutten, J; Twijnstra, A				de Kruijk, JR; Leffers, P; Meerhoff, S; Rutten, J; Twijnstra, A			Effectiveness of bed rest after mild traumatic brain injury: a randomised trial of no versus six days of bed rest	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							MODERATE HEAD-INJURY; HEALTH SURVEY; DOUBLE-BLIND; FOLLOW-UP; SENSITIVITY; MANAGEMENT; SYMPTOMS; SF-36	Background: Outcome after mild traumatic brain injury (MTBI) is determined largely by the appearance of post-traumatic complaints (PTC). The prevalence of PTC after six months is estimated to be between 20 and 80%. Bed rest has been advocated to prevent PTC but its effectiveness has never been established. Objective: To evaluate the effect of bed rest on the severity of PTC after MTBI. Methods: Patients presenting with MTBI to the emergency room were randomly assigned to two intervention strategies. One group was advised not to take bed rest (NO) and the other to take full bed rest (FULL) for six days after the trauma. The primary outcome measures were severity of PTC on a visual analogue scale and physical and mental health on the medical outcomes study 36 item short form health survey (SF-36) at two weeks and three and six months after the trauma. Results: Between October 1996 and July 1999, 107 (54 NO, 53 FULL) patients were enrolled. Outcome variables in both groups clearly improved between two weeks and six months. After adjustment for differences in baseline variables, most PTC tended to be somewhat more severe in the FULL group six months after the trauma, but no significant differences were found. Neither were there any significant differences in the outcome parameters between the two groups after three months. Two weeks after the trauma, most PTC in the FULL group were slightly less severe than those in the NO group, and physical subscores of the SF-36 in the FULL group were slightly better. These differences were not significant. Patients in the FULL group reported significantly less dizziness during the intervention period. Conclusions: As a means of speeding up recovery of patients with PTC after MTBI, bed rest is no more effective than no bed rest at all. Bed rest probably has some palliative effect within the first two weeks after the trauma.	Univ Hosp Maastricht, Dept Neurol, NL-6229 HX Maastricht, Netherlands; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands; Maastricht Univ, Fac Med, Maastricht, Netherlands	de Kruijk, JR (corresponding author), Univ Hosp Maastricht, Dept Neurol, P Debeylaan 25, NL-6229 HX Maastricht, Netherlands.	jdk@sneu.azm.nl	Rutten, Joost/L-4618-2015; Leffers, Pieter/B-8642-2009	Rutten, Joost/0000-0002-5259-9794; 			Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; BOHNEN NI, 1993, NEUROLOGY, V43, P103, DOI 10.1212/WNL.43.1_Part_1.103; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; COLLINS MW, 1999, JAMA-J AM MED ASSOC, V282, P974; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Haase J, 1992, Acta Neurochir Suppl (Wien), V55, P75; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KRAUS JF, 1996, NEUROTRAUMA, P13; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MEERHOFF S, 2000, NED TIJDSCHR GENEES, V144, P915; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2000, BRAIN INJURY, V14, P219; Ruff RM, 1999, BRAIN INJURY, V13, P943; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANTHOOFT F, 1973, COMMOTIO CEREBRI AND; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	28	83	83	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2002	73	2					167	172		10.1136/jnnp.73.2.167			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	577KK	WOS:000177059900016	12122176	Green Published, Bronze			2021-06-18	
J	Iverson, GL; Lange, RT; Green, P; Franzen, MD				Iverson, GL; Lange, RT; Green, P; Franzen, MD			Detecting exaggeration and malingering with the Trail Making Test	CLINICAL NEUROPSYCHOLOGIST			English	Article							RECOGNITION MEMORY TEST; VERBAL-LEARNING TEST; MILD HEAD-INJURY; ADULT INTELLIGENCE SCALE; NEUROPSYCHOLOGICAL EVALUATION; INCOMPLETE EFFORT; CROSS-VALIDATION; PERFORMANCE; IMPAIRMENT; DEMENTIA	The purpose of this study was to examine whether unusual performance on the Trail Making Test could be indicative of deliberate exaggeration. Participants were 571 patients seen as part of a hospital trauma service who had acute traumatic brain injuries, and 228 patients involved in head injury litigation. As expected, the hospital patients with more severe traumatic brain injuries performed more poorly than the patients with less severe brain injuries on Trails A and Trails B. Cutoff score tables were developed for the patients with acute traumatic brain injuries for the total sample and by injury severity groups. Scores falling at or below the 5th percentile were considered suspicious for possible exaggeration. The performances of the head injury litigants who exaggerated on at least one well-validated symptom validity test were compared to these cutoffs. Very high positive predictive values for individuals with very mild head injuries on Trails A and B were identified (i.e., both 100%); lower positive predictive values were obtained for individuals with more severe head injuries (55.6-60%). The negative predictive values were only moderate (range = 66.4-78.2%), and the sensitivity was very low (range = 7.1-18.5%) for all groups. Scores that fall in the range of possible biased responding should be considered "red flags" for the clinician because they likely do not make biological or psychometric sense. However, the sensitivity of the test for deliberate exaggeration is very low, so clinicians who rely on this test in isolation to identify deliberately poor performance will fail to identify the vast majority of cases.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; Allegheny Gen Hosp, Dept Psychiat, Pittsburgh, PA 15212 USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Allen L.M., 1997, CARB 97 MANUAL COMPU; Amieva H, 1998, J CLIN EXP NEUROPSYC, V20, P280, DOI 10.1076/jcen.20.2.280.1161; Axelrod B N, 2000, Appl Neuropsychol, V7, P186; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; CONDER R, 1992, COMPUTERIZED ASSESSM; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; Gfeller JD, 1998, J CLIN PSYCHOL, V54, P431, DOI 10.1002/(SICI)1097-4679(199806)54:4<431::AID-JCLP5>3.0.CO;2-Q; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Golden C. J., 1981, INTERPRETATION HALST; Green P, 2001, CLIN NEUROPSYCHOL, V15, P492, DOI 10.1076/clin.15.4.492.1887; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 1996, WORD MEMORY TEST USE; GREEN P, 1997, NAT AC NEUR LAS VEG; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Iverson GL, 2000, J CLIN EXP NEUROPSYC, V22, P191, DOI 10.1076/1380-3395(200004)22:2;1-1;FT191; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; IVERSON GL, 1999, J COGNITIVE REHABILI, V17, P48; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Nilson L, 1999, CLIN NEUROPSYCHOL, V13, P314, DOI 10.1076/clin.13.3.314.1737; Rasmusson DX, 1998, CLIN NEUROPSYCHOL, V12, P169, DOI 10.1076/clin.12.2.169.2005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; REITAN RM, 1992, TRAIT MAKING TEST MA; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580	38	83	83	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2002	16	3					398	406		10.1076/clin.16.3.398.13861			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	664UZ	WOS:000182081500017	12607151				2021-06-18	
J	Girotto, JA; MacKenzie, E; Fowler, C; Redett, R; Robertson, B; Manson, PN				Girotto, JA; MacKenzie, E; Fowler, C; Redett, R; Robertson, B; Manson, PN			Long-term physical impairment and functional outcomes after complex facial fractures	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							TRAUMATIC BRAIN INJURY; HEALTH SURVEY SF-36; MIDFACIAL FRACTURES; HEAD-INJURY; RECOVERY; REHABILITATION; SEVERITY; TESTS	To develop an understanding of the expected functional outcomes after facial trauma, a retrospective cohort study of patients with complex facial fractures was conducted. A cohort of adults aged 18 to 55 years who were admitted to the R. Adams Cowley Shock Trauma Center between July of 1986 and July of 1994 for treatment of a Le Fort midface fracture (resulting from blunt force) was retrospectively identified. Outcomes of interest included measures of general health status and psychosocial well being in addition to self-reported somatic symptoms. General health status was ascertained using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). The Body Satisfaction Scale was used to define patient concerns about altered body image and shape. To determine whether complex maxillofacial trauma and facial fractures contributed to altered social interactions, the Social Avoidance and Distress scale was used. In addition, information about a patient, his or her injury, and its treatment were ascertained from the medical records. Using the methods described above, 265 patients with Le Fort fractures were identified. These individuals were matched to a similar group of 242 general injury patients. A total of 190 of the Le Fort patients (72 percent of those eligible for the study) and 144 (60 percent) general injury patients were successfully located, and long-term interview data were acquired. Le Fort fracture patients as a group had similar health status outcomes when compared with the group of general injury patients. However, when outcomes were examined by the complexity of the Le Fort fracture, the authors found that study subjects with severe, comminuted Le Fort injuries (group D) had significantly lower SF-36 scores (worse outcomes) for the two dimensions related to role limitations: role limitations due to physical problems and role limitations due to emotional problems (p < 0.05). SF-36 scores for all other dimensions except physical function were also lower for comminuted versus less complex Le Fort fractures, although differences were not statistically significant. Specifically, there was a direct relationship between severity of facial injury and patients reporting work disability. Of group C and D Le Fort patients (severely comminuted fractures) only 55 and 58 percent, respectively, had returned to work at the time of follow-up interview. These figures are significantly lower than the back-to-work percentage of patients with less severe facial injury (70 percent). When study participants were asked if they were experiencing specific somatic symptoms at the time of the interview that they had not experienced before the injury, a significantly larger percent of the Le Fort fracture patients (compared with the general injury patients) responded in the affirmative. Differences between the Le Fort fracture and general injury groups were statistically significant (p < 0.05) for all 11 symptoms. The percentage of patients reporting complaints increased with increasing complexity of facial fracture in the areas of visual problems, alterations in smell, difficulty with mastication, difficulty with breathing, and epiphora, and these differences reached statistical significance. Patients sustaining comminuted Le Fort facial fractures report poorer health outcomes than patients with less severe facial injury and substantially worse outcomes than population norms. It is also this severely injured population that reports the greatest percentage of injury-related disability, preventing employment at long-term follow-up. The long-term goal of centralized tertiary trauma treatment centers must be to return the patient to a productive, active lifestyle.	Johns Hopkins Univ, Sch Med, Dept Surg, Div Plast & Reconstruct Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA; Univ Maryland, Ctr Shock Trauma, Dept Surg, Div Plast & Reconstruct Surg, Baltimore, MD 21201 USA	Girotto, JA (corresponding author), Johns Hopkins Univ Hosp, Div Plast & Reconstruct Surg, JHOC Room 8152,601 N Carolina St, Baltimore, MD 21287 USA.	Girotto@Home.com					AFZELIUS LF, 1980, INT J ORAL MAXILLOF, V9, P25, DOI 10.1016/S0300-9785(80)80003-2; ALQURAINY IA, 1991, BRIT J ORAL MAX SURG, V29, P291; ALQURAINY IA, 1991, BRIT J ORAL MAX SURG, V29, P302; ALQURAINY IA, 1991, BRIT J ORAL MAX SURG, V29, P368, DOI 10.1016/0266-4356(91)90002-M; ASHBURN MA, 1989, MIL MED, V154, P86; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BRAMLEY P, 1972, P ROY SOC MED, V65, P916, DOI 10.1177/003591577206501063; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; CONVERSE JM, 1967, PLAST RECONSTR SURG, V39, P20, DOI 10.1097/00006534-196701000-00002; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; DUTTON GN, 1992, EYE, V6, P86, DOI 10.1038/eye.1992.17; Fingerhut LA., 1997, INJURY CHARTBOOK HLT; GENSEMER IB, 1988, J TRAUMA, V28, P44, DOI 10.1097/00005373-198801000-00006; GLANCY KE, 1992, J TRAUMA, V33, P602, DOI 10.1097/00005373-199210000-00017; Habal M B, 1992, J Craniofac Surg, V3, P175, DOI 10.1097/00001665-199211000-00011; Hakelius L, 1973, J Maxillofac Surg, V1, P150, DOI 10.1016/S0301-0503(73)80031-1; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HOLT JE, 1983, OPHTHALMOLOGY, V90, P14; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEIBSOHN R, 1976, ANN OPHTHALMOL, V8, P1057; LOVIUS BBJ, 1990, J CRANIO MAXILL SURG, V18, P339, DOI 10.1016/S1010-5182(05)80052-6; LUND K, 1971, J ORAL SURG, V29, P557; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MACKENZIE EJ, 1993, J ORTHOP TRAUMA, V7, P393, DOI 10.1097/00005131-199310000-00001; MCCOY FJ, 1980, LONG TERM RESULTS PL, P485; MCCOY FJ, 1962, PLAST RECONSTR SURG, V29, P381; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MORGAN B D G, 1972, British Journal of Plastic Surgery, V25, P147, DOI 10.1016/S0007-1226(72)80037-7; PATTERSON R, 1991, CAN J SURG, V34, P183; REYNOLDS JR, 1978, PLAST RECONSTR SURG, V61, P871, DOI 10.1097/00006534-197861060-00007; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; Secord PF., 1953, J CONSULT PSYCHOL, V17, P343; Slade P.D., 1990, PSYCHOL HLTH, V4, P213, DOI [10.1080/08870449008400391, DOI 10.1080/08870449008400391]; SPIESSL B, 1971, THER UMSCH, V28, P881; STEIDLER NE, 1980, J ORAL SURG, V9, P259; Tajima S, 1974, J Maxillofac Surg, V2, P201, DOI 10.1016/S0301-0503(74)80041-X; TESSIER P, 1972, PLAST RECONSTR SURG, V40, P497; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WATSON D, 1969, J CONSULT CLIN PSYCH, V33, P448, DOI 10.1037/h0027806; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581	45	83	90	2	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	AUG	2001	108	2					312	327		10.1097/00006534-200108000-00005			16	Surgery	Surgery	456RW	WOS:000170096900005	11496168				2021-06-18	
J	Greve, KW; Sherwin, E; Stanford, MS; Mathias, C; Love, J; Ramzinski, P				Greve, KW; Sherwin, E; Stanford, MS; Mathias, C; Love, J; Ramzinski, P			Personality and neurocognitive correlates of impulsive aggression in long-term survivors of severe traumatic brain injury	BRAIN INJURY			English	Article							DISTURBANCE; COGNITION; BEHAVIOR; LESIONS; DAMAGE; SCALE	This study addresses a common outcome of severe traumatic brain injury (TBI), disinhibited aggressive behaviour. This behaviour has been classified in aggression literature as `impulsive aggression' (IA). The purpose was to: (1) characterize those TBI patients who are likely to be an aggression risk, and (2) determine if TBI patients with IA demonstrate personality style and neurocognitive performance similar to that seen in other IA groups. Participants were 45 survivors of severe TBI (26 of whom had persisting problems with IA), who were clients of a residential brain injury treatment facility. IA participants had a higher incidence of pre- morbid aggressive behaviour, were younger, had a shorter tenure in the programme, and were more impulsive, irritable, and antisocial than the non- aggressive control participants. Unlike past research, no neurocognitive differences were found. The results are discussed in terms of the conceptualization, identification, and treatment of persisting IA in severe TBI.	Univ New Orleans, Dept Psychol, UNO Lakefront, New Orleans, LA 70148 USA; Georgia So Univ, Statesboro, GA 30460 USA; Tangram Premier, San Marcos, TX USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, UNO Lakefront, New Orleans, LA 70148 USA.			Mathias, Charles/0000-0003-1902-673X			Barratt ES, 1997, BIOL PSYCHIAT, V41, P1045, DOI 10.1016/S0006-3223(96)00175-8; Barratt ES, 1997, J CLIN PSYCHOPHARM, V17, P341, DOI 10.1097/00004714-199710000-00002; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BONTON AL, 1983, CONTRIBUTIONS NEUROP; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; COCCARO EF, 1989, ARCH GEN PSYCHIAT, V46, P587; Coccaro EF, 1997, PSYCHIAT RES, V73, P147, DOI 10.1016/S0165-1781(97)00119-4; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; ESLINGER PJ, 1995, NEUROREHABILITATION, V5, P161, DOI 10.3233/NRE-1995-5206; Eysenck H.J., 1975, EYSENCK PERSONALITY; FOSTER HG, 1989, PROG NEURO-PSYCHOPH, V13, P865, DOI 10.1016/0278-5846(89)90038-9; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Grafman J., 1994, HDB PERCEPTION COGNI, P159, DOI 10.1016/b978-0-08-092668-1.50014-4; Grafman J, 1994, HDB NEUROPSYCHOLOGY, P187; Grafman J., 1989, INTEGRATING THEORY P, P93; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton SK, 1993, WISCONSIN CARD SORTI; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mathias CW, 1999, PROG NEURO-PSYCHOPH, V23, P1037, DOI 10.1016/S0278-5846(99)00053-6; MUNGAS D, 1988, BRIT J PSYCHIAT, V152, P180, DOI 10.1192/bjp.152.2.180; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; *PSYCH ASS RES, 1990, WISC CARD SORT TEST; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stanford MS, 1996, PERS INDIV DIFFER, V21, P1073, DOI 10.1016/S0191-8869(96)00151-1; STANFORD MS, 1995, PERS INDIV DIFFER, V19, P757, DOI 10.1016/0191-8869(95)00144-U; Stanford MS, 1997, PERS INDIV DIFFER, V23, P961, DOI 10.1016/S0191-8869(97)00120-7; *WAR DEP ADJ GEN O, 1944, ARM IND TEST BATTR M	32	83	84	0	8	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2001	15	3					255	262					8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	407ZM	WOS:000167302100005	11260773				2021-06-18	
J	Puurunen, K; Jolkkonen, J; Sirvio, J; Haapalinna, A; Sivenius, J				Puurunen, K; Jolkkonen, J; Sirvio, J; Haapalinna, A; Sivenius, J			An alpha(2)-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats	NEUROPHARMACOLOGY			English	Article						alpha(2)-adrenoceptor antagonist; behavior; cerebral ischemia, focal; rats; recovery	SENSORIMOTOR CORTEX INJURY; TRAUMATIC BRAIN INJURY; RELEASE IN-VIVO; MOTOR RECOVERY; ARTERY OCCLUSION; ALPHA-2-ADRENOCEPTOR ANTAGONIST; FUNCTIONAL RECOVERY; 5-HT1A RECEPTORS; CONTROLLED TRIAL; LOCUS-COERULEUS	Previous studies suggest that enhanced noradrenergic neurotransmission promotes functional recovery following cerebral lesions. The present study investigated whether systemic administration of an alpha (2)-adrenergic antagonist, atipamezole, facilitates recovery following transient focal cerebral ischemia in rats. The effect of atipamezole therapy on recovery from ischemia was compared with the effect of enriched-environment housing in rats. Ischemia was induced by occlusion of the right middle cerebral artery (MCA) for 120 min using the intraluminal filament model. Daily atipamezole treatment (1 mg/kg, subcutaneously) was started on day 2 after ischemia induction and drug administration stopped after 10 days. Another group of rats was housed in an enriched environment from day 2 following ischemia induction until the end of the experiment. Several different behavioral tests were used to measure functional recovery during the 26 days following the induction of focal cerebral ischemia. Thew was improved performance in the limb-placing test from the beginning of atipamezole treatment to day 8, and in wheel-running in the foot-slip test on days 2 and 4. Enriched-environment housing facilitated recovery in the foot-slip test in a later phase of the test period (days 8 to 10). Discovery of a hidden platform in a water-maze task was also facilitated in rats housed in the enriched environment, but this was probably due to the increased swimming speed of these rats. The present data suggest that, the alpha (2)-adrenergic antagonist, atipamezole, facilitates sensorimotor recovery after focal ischemia, but has no effect on subsequent water-maze tests assessing spatial learning and memory, when assessed 11 days after the cessation of drug administration. (C) 2001 Elsevier Science Ltd. All rights reserved.	Univ Kuopio, Dept Neurosci & Neurol, SF-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland; Or Corp, Or Pharma, Turku, Finland; Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; Brain Res & Rehabil Ctr Neuron, Kuopio, Finland	Puurunen, K (corresponding author), Univ Kuopio, Dept Neurosci & Neurol, POB 1627, SF-70211 Kuopio, Finland.	kirsi.puurunen@uku.fi					BIEGON A, 1992, EUR J PHARMACOL, V224, P27, DOI 10.1016/0014-2999(92)94814-C; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Dombovy M L, 1988, Adv Neurol, V47, P265; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; DunnMeynell AA, 1997, J NEUROTRAUM, V14, P43, DOI 10.1089/neu.1997.14.43; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GARCIA JH, 1993, AM J PATHOL, V142, P623; Gobert A, 1997, J NEUROCHEM, V69, P2616; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; GRABOWSKI M, 1993, STROKE, V24, P889, DOI 10.1161/01.STR.24.6.889; GULATMARNAY C, 1989, J NEUROCHEM, V53, P519, DOI 10.1111/j.1471-4159.1989.tb07364.x; Haapalinna A, 1997, N-S ARCH PHARMACOL, V356, P570, DOI 10.1007/PL00005092; Haapalinna A, 1998, EUR J PHARMACOL, V347, P29, DOI 10.1016/S0014-2999(98)00077-6; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; KARNI A, 1995, NATURE, V377, P155; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; KOTILA M, 1984, STROKE, V15, P1039, DOI 10.1161/01.STR.15.6.1039; LAITINEN KSM, 1995, EUR J PHARMACOL, V285, P255, DOI 10.1016/0014-2999(95)00410-M; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MALING HM, 1946, J NEUROPHYSIOL, V9, P379; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; Mateo Y, 1999, EUR J PHARMACOL, V379, P53, DOI 10.1016/S0014-2999(99)00488-4; McCulloch J, 1996, J HYPERTENS, V14, pS131; Meana JJ, 1996, EUR J PHARMACOL, V312, P385, DOI 10.1016/0014-2999(96)00598-5; MINTZ M, 1986, PHARMACOL BIOCHEM BE, V25, P1307, DOI 10.1016/0091-3057(86)90127-9; NACHLAS MM, 1957, J HISTOCHEM CYTOCHEM, V5, P420, DOI 10.1177/5.4.420; Newman-Tancredi A, 1998, N-S ARCH PHARMACOL, V358, P197, DOI 10.1007/PL00005243; Nudo RJ, 1997, MOL PSYCHIATR, V2, P188, DOI 10.1038/sj.mp.4000188; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Puurunen K, 1997, STROKE, V28, P623, DOI 10.1161/01.STR.28.3.623; RAITERI M, 1990, N-S ARCH PHARMACOL, V356, P570; RIEKKINEN P, 1990, BEHAV BRAIN RES, V37, P81, DOI 10.1016/0166-4328(90)90073-N; Ronning OM, 1998, STROKE, V29, P779, DOI 10.1161/01.STR.29.4.779; ROSE F D, 1988, Medical Science Research, V16, P257; SAVONTAUS E, 1997, EUROPEAN J PHARM, V28, P207; SCHEININ H, 1988, EUR J PHARMACOL, V151, P35, DOI 10.1016/0014-2999(88)90689-9; SIMSON PE, 1987, J NEUROSCI, V7, P1732; SIRVIO J, 1992, J NEURAL TRANSM-PARK, V4, P99, DOI 10.1007/BF02251473; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TRENDELENBURG AU, 1994, N-S ARCH PHARMACOL, V350, P473; VIRTANEN R, 1989, ARCH INT PHARMACOD T, V297, P190; WADE DT, 1992, SCAND J REHABIL MED, P97; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; WINTER JC, 1998, J PHARM EXPT THERAPE, V263, P682; WOLF PA, 1998, CEREBROVASC DIS, P834; Xerri C, 1996, J PHYSIOLOGY-PARIS, V90, P277, DOI 10.1016/S0928-4257(97)81438-6; Yonemori F, 1999, J CEREBR BLOOD F MET, V19, P483, DOI 10.1097/00004647-199905000-00002	59	83	89	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	MAR	2001	40	4					597	606		10.1016/S0028-3908(00)00182-9			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	411ZQ	WOS:000167529900015	11249969				2021-06-18	
J	Faden, AI; O'Leary, DM; Fan, L; Bao, WL; Mullins, PGM; Movsesyan, VA				Faden, AI; O'Leary, DM; Fan, L; Bao, WL; Mullins, PGM; Movsesyan, VA			Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improves outcome after brain trauma	EXPERIMENTAL NEUROLOGY			English	Article						mGluR1 antagonists; brain trauma; neuronal death	METABOTROPIC GLUTAMATE RECEPTORS; IN-VITRO; NMDA-RECEPTORS; 1-AMINOINDAN-1,5-DICARBOXYLIC ACID; PHARMACOLOGICAL CHARACTERIZATION; AMINO-ACIDS; CELL-DEATH; ACTIVATION; RAT; ANTAGONIST	The effects of selective blockade of group I metabotropic glutamate receptor subtype 1 (mGluR1) on neuronal cell survival and post-traumatic recovery was examined using rat in vitro and in vivo trauma models. The selective mGluR1 antagonists (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA), 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester (CPCCOEt), and (S)-(+)-alpha -amino-4-carboxy-2-methylbezeneacetic acid (LY367385) provided significant neuroprotection in rat cortical neuronal cultures subjected to mechanical injury, in both pretreatment or posttreatment paradigms. Administration of the antagonists also attenuated glutamate-induced neuronal cell death in the cultures. Coapplication of these antagonists with the N-methyl-D-aspartate (NMDA) receptor antagonist (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10- imine (MK-801) had additive neuroprotective effects in glutamate injured cultures. Intracerebroventricular administration of AIDA to rats markedly improved recovery from motor dysfunction after lateral fluid percussion induced traumatic brain injury (TBI), Treatment with mGluR1 antagonists also significantly reduced lesion volumes in rats after TBI, as evaluated by MRI. It appears that these compounds mediate their neuroprotective effect through an mGluR1 antagonist action, as demonstrated by inhibition of agonist induced phosphoinositide hydrolysis in our in vitro system. Moreover, AIDA, CPCCOEt, and LY367385, at concentrations shown to be neuroprotective, had no significant effects on the steady state NMDA evoked whole cell current. Taken together, these data suggest that modulation of mGluR1 activity may have substantial therapeutic potential in brain injury. (C) 2001 Academic Press.	Georgetown Univ, Med Ctr, Dept Neurosci, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA.			Mullins, Paul/0000-0002-1339-6361	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS37313] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; Clark BP, 1997, BIOORG MED CHEM LETT, V7, P2777, DOI 10.1016/S0960-894X(97)10071-3; COPANI A, 1995, J NEUROCHEM, V64, P101; COPANI A, 1995, MOL PHARMACOL, V47, P890; Faden A. I., 1999, Society for Neuroscience Abstracts, V25, P282; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HOCKINGS PD, 1995, JMRI-J MAGN RESON IM, V5, P437, DOI 10.1002/jmri.1880050412; JOLY C, 1995, J NEUROSCI, V15, P3970; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Litschig S, 1999, MOL PHARMACOL, V55, P453; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Maiese K, 1999, NEUROSCI LETT, V264, P17, DOI 10.1016/S0304-3940(99)00199-8; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; SINENSKY MC, 1995, TOXICOL LETT, V75, P101; Strasser U, 1998, EUR J NEUROSCI, V10, P2848, DOI 10.1111/j.1460-9568.1998.00291.x; Vincent AM, 1999, EXP NEUROL, V155, P79, DOI 10.1006/exnr.1998.6966; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	41	83	96	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	2001	167	2					435	444		10.1006/exnr.2000.7577			10	Neurosciences	Neurosciences & Neurology	400BG	WOS:000166848300024	11161632				2021-06-18	
J	Levin, HS; Song, J; Ewing-Cobbs, L; Chapman, SB; Mendelsohn, D				Levin, HS; Song, J; Ewing-Cobbs, L; Chapman, SB; Mendelsohn, D			Word fluency in relation to severity of closed head injury, associated frontal brain lesions, and age at injury in children	NEUROPSYCHOLOGIA			English	Article						word fluency; closed head injury; children; frontal lesions; neuroplasticity	VERBAL FLUENCY; PREFRONTAL CORTEX; LOBE; RECOVERY; SEQUELAE; APHASIA; PERFORMANCE; MATURATION; DISCOURSE; TESTS	Effects of closed head injury (CHI) severity, focal brain lesions, and age at injury on word fluency (WF) were studied longitudinally in 122 children (78 severe, 44 mild); 112 CHI patients (68 severe, 44 mild CHI) and 104 uninjured normal controls participated in a cross-sectional study. WF was measured by asking the child to generate as many words as possible beginning with a designated letter within 60 s, repeated for three letters. Intellectual ability, receptive vocabulary, narrative discourse,and word list recall were also measured. Results of the cross-sectional study showed a significant group effect with poorer WF in severe CHI than mild CHI and control groups. Growth curve analysts of longitudinal data revealed an interaction of age, follow-up interval, and CHI severity as WF recovery was slower after severe CHI in younger children as compared to seven CHI in older children or mild CHI in younger children. An interaction of left frontal lesion with age and interval indicated a more adverse effect on WF in older children. Right frontal lesion effect was nonsignificant and did not interact with age. Correlations of WF with receptive vocabulary, word list recall, and narrative discourse were moderate and weak with estimated intellectual ability. Differences in focal lesion effects after traumatic versus nontraumatic brain injury in children, the contribution of diffuse white matter injury, reduced opportunity for language development, and functional commitment of left frontal region at time of CHI were discussed. (C) 2000 Elsevier Science Ltd. All rights reserved.	Baylor Coll Med, Dept Phys Med & Rehabil, MSC, Houston, TX 77003 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77003 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77003 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Texas, Callier Ctr Commun Disorders, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Dept Radiol, Div Neuroradiol, Dallas, TX 75235 USA	Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, MSC, 1 Baylor Plaza,ST1144, Houston, TX 77003 USA.	hlevin@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Bates E, 1997, DEV NEUROPSYCHOL, V13, P275, DOI 10.1080/87565649709540682; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BENTON AL, 1993, MANUAL MULTILINGUAL; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BRYK AS, 1987, PSYCHOL BULL, V101, P147, DOI 10.1037/0033-2909.101.1.147; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Crowe SF, 1998, J CLIN EXP NEUROPSYC, V20, P391, DOI 10.1076/jcen.20.3.391.810; CUENOD CA, 1995, NEUROLOGY, V45, P1821, DOI 10.1212/WNL.45.10.1821; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; Delis D, 1994, MANUAL CALIFORNIA VE; DIGGLE P, 1994, J R STAT SOC C-APPL, V43, P49; Dunn L., 1981, PEABODY PICTURE VOCA; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FELDMAN HM, 1992, BRAIN LANG, V42, P89, DOI 10.1016/0093-934X(92)90058-M; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin HS, 1996, ARCH NEUROL-CHICAGO, V53, P88, DOI 10.1001/archneur.1996.00550010108024; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Little RC, 1996, SAS SYSTEM MIXED MOD; McIntosh TK, 1996, LAB INVEST, V74, P315; MICELI G, 1981, Journal of Clinical Neuropsychology, V3, P53, DOI 10.1080/01688638108403113; MILNER B, 1964, FRONTAL GRANULAR COR, P65; Mitrushina M., 1999, HDB NORMATIVE DATA N; PAPANICOLAOU AC, 1988, ARCH NEUROL-CHICAGO, V45, P1025, DOI 10.1001/archneur.1988.00520330117020; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Phelps EA, 1997, NEUROREPORT, V8, P561, DOI 10.1097/00001756-199701200-00036; RAMIER AM, 1970, REV NEUROL, V123, P17; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Rueckert L, 1994, J Neuroimaging, V4, P67; RUTTER CM, 1994, STAT MED, V13, P1211, DOI 10.1002/sim.4780131204; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Spreen O., 1998, COMPENDIUM NEUROPSYC; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Troxel AB, 1998, STAT MED, V17, P653, DOI 10.1002/(SICI)1097-0258(19980315/15)17:5/7<653::AID-SIM812>3.0.CO;2-M; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Warburton E, 1999, J NEUROL NEUROSUR PS, V66, P155, DOI 10.1136/jnnp.66.2.155; Wechsler D., 1974, WISCR MANUAL WECHSLE; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3	57	83	84	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2001	39	2					122	131		10.1016/S0028-3932(00)00111-1			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	386HK	WOS:000166054800003	11163370				2021-06-18	
J	Satake, K; Matsuyama, Y; Kamiya, M; Kawakami, H; Iwata, H; Adachi, K; Kiuchi, K				Satake, K; Matsuyama, Y; Kamiya, M; Kawakami, H; Iwata, H; Adachi, K; Kiuchi, K			Up-regulation of glial cell line-derived neurotrophic factor (GDNF) following traumatic spinal cord injury	NEUROREPORT			English	Article						glial cell line-derived neurotrophic factor; macrophage; microglia; rat; spinal cord injury; weight drop technique	FACTOR EXPRESSION; RAT; BRAIN; LOCALIZATION; ASTROCYTES; STRIATUM; CNS	We investigated the temporal and spatial expression patterns of the GDNF gene after subjecting rats to an acute contusion injury of the spinal cord using the weight drop technique. Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed that GDNF transcription in the spinal cord began to increase within 30 min after injury and peaked within 3 h. Immunohistochemical analysis showed GDNF immunoreactivity to be present mainly in microglia and macrophages 1 day after injury,but not in neurons or astrocytes. This immediate upregulation of GDNF gene expression may be a component of an inflammatory process and probably exerts a protective effect on neurons following spinal cord injury (SCI). NeuroReport 11:3877-3881 (C) 2000 Lippincott Williams & Wilkins.	Nagoya Univ, Sch Med, Dept Orthopaed Surg, Nagoya, Aichi 4668550, Japan; RIKEN, Biomimet Control Res Program, Lab Genes Motor Syst, Moriyama Ku, Nagoya, Aichi 4630003, Japan; Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan	Kiuchi, K (corresponding author), Nagoya Univ, Sch Med, Dept Orthopaed Surg, Nagoya, Aichi 4668550, Japan.						Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Appel E, 1997, NEUROREPORT, V8, P3309, DOI 10.1097/00001756-199710200-00023; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bizon JL, 1999, J COMP NEUROL, V408, P283; DOHRMANN GJ, 1971, J NEUROSURG, V35, P263, DOI 10.3171/jns.1971.35.3.0263; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Holstege JC, 1998, NEUROREPORT, V9, P2893, DOI 10.1097/00001756-199808240-00039; Ikeda T, 1999, INT J DEV NEUROSCI, V17, P681, DOI 10.1016/S0736-5748(99)00057-X; Lazarov-Spiegler O, 1998, MOL MED TODAY, V4, P337, DOI 10.1016/S1357-4310(98)01298-2; Lee MY, 1998, NEUROSCI LETT, V255, P79, DOI 10.1016/S0304-3940(98)00710-1; Liberatore GT, 1997, NEUROREPORT, V8, P3097, DOI 10.1097/00001756-199709290-00018; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LIN LFH, 1996, NEURAL NOTES, V11, P3; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; Pan WH, 1997, EXP NEUROL, V146, P367, DOI 10.1006/exnr.1997.6533; Pochon NAM, 1997, EUR J NEUROSCI, V9, P463, DOI 10.1111/j.1460-9568.1997.tb01623.x; POPOVICH PG, 1993, J NEUROTRAUM, V10, P37, DOI 10.1089/neu.1993.10.37; Sakurai M, 1999, NEUROSCI LETT, V276, P123, DOI 10.1016/S0304-3940(99)00804-6; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Trupp M, 1997, J NEUROSCI, V17, P3554; Verity AN, 1999, J NEUROSCI RES, V55, P187, DOI 10.1002/(SICI)1097-4547(19990115)55:2<187::AID-JNR6>3.0.CO;2-T	23	83	96	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	NOV 27	2000	11	17					3877	3881		10.1097/00001756-200011270-00054			5	Neurosciences	Neurosciences & Neurology	378DM	WOS:000165569800049	11117507				2021-06-18	
J	Diaz-Arrastia, R; Agostini, MA; Frol, AB; Mickey, B; Fleckenstein, J; Van Ness, PC				Diaz-Arrastia, R; Agostini, MA; Frol, AB; Mickey, B; Fleckenstein, J; Van Ness, PC			Neurophysiologic and neuroradiologic features of intractable epilepsy after traumatic brain injury in adults	ARCHIVES OF NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; HEAD-INJURY; POSTTRAUMATIC SEIZURES; RANDOMIZED TRIAL; PATHOLOGY; NEUROPROTECTION; LOCALIZATION; PREVENTION; LOBECTOMY; DAMAGE	Background: There is controversy regarding the precise mechanism by which epilepsy results after traumatic brain injury (TBI). Previous reports have suggested that mesial temporal lobe epilepsy may result from TBI only in young children, while neocortical epilepsy arises from TBI in later life. These conclusions were based on surgical series and may be biased because of patient selection. Objective: To determine the frequency of mesial temporal lobe as opposed to neocortical epilepsy in patients with intractable epilepsy resulting from TBI after the age of 10 years. Patients and Methods: We identified 23 patients with intractable epilepsy who had TBI after the age of 10 years, preceding the onset of epilepsy. Patients were studied by simultaneous videotape and scalp electroencephalographic recording of typical seizures; magnetic resonance imaging; neuropsychologic studies; and, when appropriate, intracarotid amobarbital testing. Two patients underwent anterior temporal lobectomies. Results: Of the 23 patients, 8 (35%) had mesial temporal lobe epilepsy, based on the finding of hippocampal sclerosis on a magnetic resonance imaging scan, consistent interictal and ictal electroencephalographic recordings, evidence of temporal lobe dysfunction on neuropsychologic testing, and characteristic seizure semiology. Two of these patients underwent anterior temporal lobectomies with clinical benefit, and hippocampal sclerosis was confirmed pathologically. In 2 cases, patients were not treated surgically because of bilateral temporal lobe dysfunction noted on intracarotid amobarbital testing. Eleven patients had neocortical epilepsy; 1 had primary generalized epilepsy; and, in 3, the site of seizure onset was not localized. Conclusions: Mesial temporal lobe epilepsy can result from TBI in adolescents and adults as well as in children, and can often be bilateral and associated with multifocal injury. This information may be useful in developing prophylactic therapy for posttraumatic epilepsy.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurosurg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neuroradiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neuropathol, Dallas, TX 75235 USA	Diaz-Arrastia, R (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Diaz-Arrastia, Ramon/0000-0001-6051-3594	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG16450, R01AG12297] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO8NS01763] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012297, R03AG016450] Funding Source: NIH RePORTER		Ajmone-Marsan Cosimo, 1993, P313; Annegers J.F., 1996, TREATMENT EPILEPSY P, P165; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arrowsmith JE, 1998, STROKE, V29, P2357, DOI 10.1161/01.STR.29.11.2357; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; CASCINO GD, 1992, EPILEPSY RES, V11, P51, DOI 10.1016/0920-1211(92)90021-K; CAVENESS WF, 1963, J NEUROSURG, V20, P570, DOI 10.3171/jns.1963.20.7.0570; COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; COURVILLE CB, 1958, TEMPORAL LOBE EPILEP, P220; DUNCAN JS, 1987, NEUROLOGY, V37, P405, DOI 10.1212/WNL.37.3.405; EVANS JH, 1962, NEUROLOGY, V12, P665, DOI 10.1212/WNL.12.10.665; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; GRAHAM DI, 1996, NEUROLOGY TRAUMA, P53; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; KUZNIECKY J, 1995, MAGNETIC RESONANCE I, P107; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MCNAMARA JO, 1989, EPILEPSIA, V30, pS13, DOI 10.1111/j.1528-1157.1989.tb05809.x; Pitkanen A, 1999, EPILEPSY RES, V33, P67, DOI 10.1016/S0920-1211(98)00074-6; Prince D A, 1999, Adv Neurol, V79, P665; RISINGER MW, 1989, NEUROLOGY, V39, P1288, DOI 10.1212/WNL.39.10.1288; Rushing EJ, 1997, AM J FOREN MED PATH, V18, P335, DOI 10.1097/00000433-199712000-00004; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; WILLMORE LJ, 1990, EPILEPSIA, V31, P67; Yang Y, 1998, BRAIN RES, V804, P169, DOI 10.1016/S0006-8993(98)00410-7	35	83	86	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	NOV	2000	57	11					1611	1616		10.1001/archneur.57.11.1611			6	Clinical Neurology	Neurosciences & Neurology	370NM	WOS:000165129200007	11074793	Bronze			2021-06-18	
J	Ownsworth, TL; McFarland, K; Young, RMD				Ownsworth, TL; McFarland, K; Young, RMD			Self-awareness and psychosocial functioning following acquired brain injury: An evaluation of a group support programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; REHABILITATION; PSYCHOTHERAPY; ADULTS	This study investigated a group support programme designed to improve self-awareness deficits and psychosocial functioning in a group of chronic patients (N = 21) with acquired brain injury (ABI). The participants were on average 8.6 years (range: 1-36 years) post-injury and were seen at the Brain Injury Association of Queensland, Australia. The assessment of participants involved two standardised measures of intellectual self-awareness with collateral reports from relatives. The present study introduced a new measure called the Self-Regulation Skills Interview (SRSI) which assessed higher levels of self awareness and self-regulation skills. Psychosocial functioning was assessed using a standardised self-report measure. At baseline the group had a relatively high level of intellectual self-awareness regarding their deficits, a low to moderate level of self-regulation skills, and significant psychosocial impairment. The participants were involved in a 16-week group programme which involved components of cognitive rehabilitation, cognitive-behavioural therapy, and social skills training. A post-intervention assessment indicated that participants had significantly improved levels of self-regulation skills and psychosocial functioning. A 6-month follow-up assessment indicated that overall, participants had maintained the gains made during the programme. The important role of self-regulation skills is emphasised as the principle factor contributing to the maintenance of the gains observed.	Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Psychiat, St Lucia, Qld, Australia	Ownsworth, TL (corresponding author), Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia.		Young, Ross/AAF-2082-2021	Young, Ross/0000-0002-6806-6503; Ownsworth, Tamara/0000-0003-1835-7094			Armengol CG, 1999, J HEAD TRAUMA REHAB, V14, P233, DOI 10.1097/00001199-199906000-00004; Barco P.P., 1991, COGNITIVE REHABILITA, P129; Bennett T L, 1997, Appl Neuropsychol, V4, P55, DOI 10.1207/s15324826an0401_7; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERQUIST TF, 1993, BRAIN INJURY, V7, P275; BOAKE C, 1991, COGNITIVE REHABILITA, P181; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; CARBERRY H, 1983, COGNITIVE REHABILITA, V1, P5; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; DEATON AV, 1991, COGNITIVE REHABILITA, P191; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; FLEMING JM, 1996, THESIS U QUEENSLAND; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; Geffen L., 1998, OXFORD HDB SPORTS ME, P152; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lishman WA, 1998, ORGANIC PSYCHIAT; LONG DF, 1993, NEUROPSYCHOLOGICAL T, P3; McAllister TW, 1997, COMMUNITY MENT HLT J, V33, P341, DOI 10.1023/A:1025055426260; MILLER L, 1992, J COGNITIVE REHABILI, V10, P14; Morse P, 1992, CLIN SYNDROMES ADULT, P85; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; OWNSWORTH TL, IN PRESS CLIN NEUROP; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; Pollens RD, 1988, COGNITIVE REHABILITA, V6, P26; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Schefft BK, 1997, CLIN NEUROPSYCHOLOGY, P237; Smith H.E., 1992, CLIN REHABIL, V6, P31; Stuss D.T., 1986, FRONTAL LOBES; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; YLVISAKER M, 1990, REHABILITATION ADULT, P558	39	83	84	0	18	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	OCT	2000	10	5					465	484		10.1080/09602010050143559			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	358XX	WOS:000089583400001					2021-06-18	
J	Anderson, VA; Catroppa, C; Rosenfeld, J; Haritou, F; Morse, SA				Anderson, VA; Catroppa, C; Rosenfeld, J; Haritou, F; Morse, SA			Recovery of memory function following traumatic brain injury in pre-school children	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; CHILDHOOD; SKILLS; AGE; ADOLESCENTS; DISCOURSE; DEFICITS; SEQUELAE; MOTOR	Traumatic brain injury (TBI) may have a profound impact on a child's ongoing development. Various risk factors have been found to predict outcome, but considerable variability remains unexplained. This study used a prospective, longitudinal design to examine recovery of memory function following TBI within the pre-school period. Ninety-six children with TBI were divided according to injury severity (mild, moderate, severe), and compared to age and SES matched healthy controls (n = 35). Children were evaluated acutely and at 6,12 and 18 months post-injury using intellectual and memory measures. Results showed a relationship between greater injury severity and poorer intellectual ability. This dose-response relationship was not clearly evident for memory function within the acute phase of recovery, but developed over time, with greater memory impairments evident for children with more severe TBI by 12 months post-injury. Children with mild TBI exhibited few memory problems. Findings are discussed in the context of theories of plasticity and recovery of function.	Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Res Inst, Melbourne, Vic, Australia	Anderson, VA (corresponding author), Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia.	anderson@psych.unimelb.edu.au					Alloway TP., 1997, DEV MEMORY CHILDHOOD, P163; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, 1988, P 13 ANN BRAIN IMP C, P223; Anderson V., 1995, NEUROPSYCHOLOGICAL A; ANDERSON V, UNPUB PEDIAT NEUROSU; ANDERSON V, IN PRESS BRIT J CANC; Anderson V A, 1996, Appl Neuropsychol, V3, P128, DOI 10.1207/s15324826an0303&4_5; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; CATROPPA C, IN PRESS CHILD NEURO; CATROPPA C, UNPUB NEUROPSYCHOLOG; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Chapman S.B, 1995, TRAUMATIC HEAD INJUR, P95; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Dennis M, 1996, J NEURO-ONCOL, V29, P91, DOI 10.1007/BF00165522; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1985, J CLIN EXP NEUROPSYC, V7, P526, DOI 10.1080/01688638508401283; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Garth J, 1997, Pediatr Rehabil, V1, P99; GRONWALL D, J INT NEUROPSYCHOLOG, V3, P592; HUDPETH W, 1990, J EDUC PSYCHOL, V82, P881; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kennard MA, 1936, AM J PHYSIOL, V115, P138; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kraus J., 1995, TRAUMATIC HEAD INJUR, P117; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LANGECASSOCK H, NEUROPEDIATRIE, V19, P105; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; McCarthy D., 1972, MANUAL MCCARTHY SCAL; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; SMITH A, 1983, J CONSULT CLIN PSYCH, V51, P768, DOI 10.1037/0022-006X.51.5.768; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Todd JA, 1996, NEUROPSYCHOL REHABIL, V6, P81, DOI 10.1080/713755500; TOMPKINS C, 1990, BRAIN LANG, V40, P86; WALSH K, 1978, NEUROPSYCHOLOGY CLIN; Wechsler D, 1989, MANUAL PRESCHOOL PRI; Wechsler D., 1991, MANUAL WECHSLER INTE; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	53	83	83	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2000	14	8					679	692					14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	342XT	WOS:000088672000001	10969886				2021-06-18	
J	Schnuelle, P; Lorenz, D; Mueller, A; Trede, M; van der Woude, FJ				Schnuelle, P; Lorenz, D; Mueller, A; Trede, M; van der Woude, FJ			Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation	KIDNEY INTERNATIONAL			English	Article						kidney transplantation; acute rejection; brain death; catecholamines; graft survival	ENDOTHELIAL ADHESION MOLECULES; TUMOR-NECROSIS-FACTOR; BRAIN-DEAD PATIENTS; KIDNEY-TRANSPLANTS; LIVER GRAFT; DOPAMINE; EXPRESSION; CYTOKINES; INJURY; INFLAMMATION	Background Epidemiological data implicate that renal transplants from living unrelated donors result in superior survival rates as compared with cadaveric grafts, despite a higher degree of human lymphocyte antigen (HLA) mismatching. We undertook a center-based case control study to identify donor-specific determinants affecting early outcome in cadaveric transplantation. Methods. The study database consisted of 152 consecutive cadaveric renal transplants performed at our center between June 1989 and September 1998. Of these, 24 patients received a retransplant. Donor kidneys were allocated on the basis of prospective HLA matching according to the Eurotransplant rules of organ sharing. Immunosuppressive therapy consisted of a cyclosporine-based triple-drug regimen. In 67 recipients, at least one acute rejection episode occurred during the first month after transplantation. They were taken as cases, and the remaining 85 patients were the controls. Stepwise logistic regression was done on donor-specific explanatory variables obtained from standardized Eurotransplant Necrokidney reports. In a secondary evaluation, the impact on graft survival in long-term follow-up was further measured by applying a Cox regression model. The mean follow-up of all transplant recipients was 3.8 years (SD 2.7 years). Results. Donor age [odds ratio (OR) 1.05; 95% CI, 1.02 to 1.08], traumatic brain injury as cause of death (OR 2.75; 95% CI, 1.16 to 6.52), and mismatch on HLA-DR (OR 3.0; 95% CI, 1.47 to 6.12) were associated with an increased risk of acute rejection, whereas donor use of dopamine (OR 0.22; 95% CI, 0.09 to 0.51) and/or noradrenaline (OR 0.24; 95% CI, 0.10 to 0.60) independently resulted in a significant beneficial effect. In the multivariate Cox regression analysis, both donor treatment with dopamine (HR 0.44; 95% CI, 0.22 to 0.84) and noradrenaline (HR 0.30; 95% CI, 0.10 to 0.87) remained a significant predictor of superior graft survival in long-term follow-up. Conclusions. Our data strongly suggest that the use of catecholamines in postmortal organ donors during intensive care results in immunomodulating effects and improves graft survival in long-term follow-up. These findings may at least partially be explained by down-regulating effects of adrenergic substances on the expression of adhesion molecules (VCAM, E-selectin) in the vessel walls of the graft.	Univ Hosp Mannheim, Med Clin Nephrol Endocrinol 5, D-68167 Mannheim, Germany; Univ Hosp Mannheim, Surg Clin, D-68167 Mannheim, Germany; Heidelberg Univ, Fac Med, D-6800 Mannheim, Germany	Schnuelle, P (corresponding author), Univ Hosp Mannheim, Med Clin Nephrol Endocrinol 5, Thedor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	schnuell@rumms.uni-mannheim.de					AGODOA LY, 1995, AM J KIDNEY DIS, V25, P119, DOI 10.1016/0272-6386(95)90638-X; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Betz A. Lorris, 1996, Keio Journal of Medicine, V45, P230; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CARMELLINI M, 1994, TRANSPLANT P, V26, P2626; CECKA JM, 1992, TRANSPLANTATION, V53, P59, DOI 10.1097/00007890-199201000-00011; CECKA JM, 1994, CLIN TRANSPLANT, V8, P324; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FERGUSON CJ, 1990, NEPHROL DIAL TRANSPL, V5, P816, DOI 10.1093/ndt/5.9.816; FERGUSON R, 1994, CLIN TRANSPLANT, V8, P328; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fortenberry JD, 1997, CRIT CARE MED, V25, P303, DOI 10.1097/00003246-199702000-00019; GRUNDMANN R, 1982, KLIN WOCHENSCHR, V60, P193, DOI 10.1007/BF01715586; HALLORAN PF, 1988, TRANSPLANTATION, V46, P223, DOI 10.1097/00007890-198808000-00007; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; Hourmant M, 1996, TRANSPLANTATION, V62, P1565, DOI 10.1097/00007890-199612150-00006; KADIEVA VS, 1993, ANESTH ANALG, V76, P362; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; Lehtonen SRK, 1997, TRANSPLANTATION, V64, P103, DOI 10.1097/00007890-199707150-00019; MALLICK NP, 1995, AM J KIDNEY DIS, V25, P176, DOI 10.1016/0272-6386(95)90642-8; MANAKA D, 1992, TRANSPLANTATION, V53, P545, DOI 10.1097/00007890-199203000-00010; Marcen R, 1998, TRANSPLANTATION, V66, P461, DOI 10.1097/00007890-199808270-00008; Marshall R, 1996, SURGERY, V120, P663, DOI 10.1016/S0039-6060(96)80014-6; MASSY ZA, 1995, KIDNEY INT, V48, pS85; NAKATANI T, 1991, INTENS CARE MED, V17, P103, DOI 10.1007/BF01691432; O'Brien E A, 1996, J Transpl Coord, V6, P215; Ojo AO, 1997, TRANSPLANTATION, V63, P968, DOI 10.1097/00007890-199704150-00011; OPELZ G, 1992, TRANSPLANT P, V24, P2342; PIENAAR H, 1990, TRANSPLANTATION, V50, P580, DOI 10.1097/00007890-199010000-00010; POBER JS, 1993, J IMMUNOL, V150, P5114; POBER JS, 1986, J IMMUNOL, V136, P1680; SANDBERG J, 1992, TRANSPLANT P, V24, P357; Shoskes DA, 1998, TRANSPLANTATION, V66, P1697, DOI 10.1097/00007890-199812270-00022; Stanimirovic DB, 1997, ACT NEUR S, V70, P12; SUTHERLAND FR, 1993, CAN J SURG, V36, P141; TAKEMOTO S, 1992, NEW ENGL J MED, V327, P834, DOI 10.1056/NEJM199209173271202; Terasaki PI, 1997, CLIN TRANSPLANT, V11, P366; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; VANSAASE JLCM, 1995, TRANSPLANTATION, V59, P1280, DOI 10.1097/00007890-199505000-00010; WALASZEWSKI J, 1988, TRANSPLANT P, V20, P913; YAMAOKA Y, 1990, TRANSPLANT INT, V3, P78, DOI 10.1007/BF00336208	42	83	90	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0085-2538	1523-1755		KIDNEY INT	Kidney Int.	AUG	1999	56	2					738	746		10.1046/j.1523-1755.1999.00567.x			9	Urology & Nephrology	Urology & Nephrology	219HE	WOS:000081601200041	10432416				2021-06-18	
J	Feickert, HJ; Drommer, S; Heyer, R				Feickert, HJ; Drommer, S; Heyer, R			Severe head injury in children: Impact of risk factors on outcome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; brain damage; trauma; child; seizure; intracranial pressure; brain swelling edema; skull fracture	TRAUMATIC BRAIN INJURY; COMA-DATA-BANK; ACUTE SUBDURAL-HEMATOMA; COMPUTERIZED-TOMOGRAPHY; PEDIATRIC TRAUMA; BLUNT TRAUMA; ADULTS; ADOLESCENTS; LESION; SCALE	Background: Outcome after severe head injury has been shown in some studies to be more favorable in children than in adults. Mortality rates reported range between 20% and 40% for children. Only contradicting data are available regarding the impact of trauma modalities on long-term outcome, or the relative influence of head fractures, intracranial hemorrhages, and brain edema on survival or neurologic sequelae in children. Methods: A retrospective study in a tertiary care facility of long-term outcome of children after severe head injury, and analysis of risk factors for poor outcome. All children up to 16 years of age with severe head injury (Glasgow Coma Scale [GCS] score less than or equal to 8), which have been treated in the pediatric intensive care unit from 1977 until 1994 in a single institution. Results: A total of 150 children with severe head injury (GCS score less than or equal to 8) were treated, 92 of them (61.3%) had traffic-related injuries, The median age was 6.6 years (SD +/- 3.6), There were 96 boys (64%) and 54 girls (36%), Sixty-five children (43.3%) had skull fractures, 87 patients (58.0%) developed an intracranial hemorrhage, and 79 patients (52.7%) developed a diffuse brain swelling/edema visible in computed tomographic scans within 72 hours after trauma. Of 150 children treated, 33 died (22%), In most cases, death was related to the development of secondary brain edema. Fifty-nine children (39.3%) had severe neurologic impairments at the time of discharge, The most significant risk factors for adverse outcome, shown by multivariate analysis, were primary areflexia and secondary brain edema. The risk for development of brain edema and poor prognosis was well predicted by the GCS score. Conclusion: The overall death rate in this study of children with severe head injury was low (22%) compared with other studies, However, the incidence of severe neurologic impairment at discharge remained high. The major risks for death or neurologic impairment were primary areflexia and the development of secondary brain swelling/edema, indicated by a low GCS score.	MHH, Kinderklin, D-30623 Hannover, Germany	Feickert, HJ (corresponding author), MHH, Kinderklin, D-30623 Hannover, Germany.						ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BULLOCK R, 1993, SCHWEIZ MED WSCHR, V123, P449; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; EICHELBERGER MR, 1988, J TRAUMA, V28, P430, DOI 10.1097/00005373-198804000-00002; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gjerris F, 1986, Acta Neurochir Suppl (Wien), V36, P155; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; JACOBI G, 1982, PADIAT FORTBILD PRAX, V55, P76; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAIMOVICH DG, 1991, J TRAUMA, V31, P196; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; Kazan S, 1997, ACTA NEUROCHIR, V139, P295, DOI 10.1007/BF01808824; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KRAUS JF, 1987, PEDIATRICS, V79, P501; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1992, NEUROSURGERY, V31, P1117, DOI 10.1227/00006123-199212000-00021; Lieb L, 1991, Anaesthesiol Reanim, V16, P118; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAZUREK AJ, 1994, J ACCID EMERG MED, V11, P9; MAZZA C, 1982, ACTA NEUROCHIR, V65, P67, DOI 10.1007/BF01405443; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; MILLER JD, 1994, LANCET, V344, P421; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Pospiech J, 1993, Aktuelle Traumatol, V23, P1; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RIVARA FP, 1993, PEDIATRICS, V92, P61; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1993, SURG NEUROL, V39, P269, DOI 10.1016/0090-3019(93)90003-J; SNYDER CL, 1990, J TRAUMA, V30, P1239, DOI 10.1097/00005373-199010000-00008; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008; Zukiel R, 1994, Neurol Neurochir Pol, V28, P201	55	83	87	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	1999	47	1					33	38		10.1097/00005373-199907000-00008			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	216ZQ	WOS:000081474700006	10421183				2021-06-18	
J	Lewine, JD; Davis, JT; Sloan, JH; Kodituwakku, PW; Orrison, WW				Lewine, JD; Davis, JT; Sloan, JH; Kodituwakku, PW; Orrison, WW			Neuromagnetic assessment of pathophysiologic brain activity induced by minor head trauma	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CONCUSSION; MR	BACKGROUND AND PURPOSE: Patients with mild traumatic brain injury (TBI) often show significant neuropsychological dysfunction despite the absence of abnormalities on traditional neuroradiologic examinations or EEG, Our objective was to determine if magnetic source imaging (MSI), using a combination of MR imaging and magnetoencephalography (MEG), is more sensitive than EEG and MR imaging in providing objective evidence of minor brain injury. METHODS: Four subject groups were evaluated with MR, MSI, and EEG, Group A consisted of 20 neurologically normal control subjects without histories of head trauma, Group B consisted of 10 subjects with histories of mild head trauma but complete recovery, Group C consisted of 20 subjects with histories of mild head injury and persistent postconcussive symptoms. The 15 subjects included in group D underwent repeat examinations at an interval of 2 to 4 months. RESULTS: No MR abnormalities were seen in the normal control group or the asymptomatic group, but five (20%) of the patients with persistent postconcussive symptoms had abnormal MR findings. EEG was abnormal for one subject (5%) from the normal control group, one (10%) from the asymptomatic group, and five (20%) from the group with persistent postconcussive symptoms, MSI was abnormal for one subject (5%) from the normal control group, one (10%) from the asymptomatic group, and 13 (65%) from the group with persistent postconcussive symptoms, There was a direct correlation between symptom resolution and MSI findings for the symptomatic head trauma group, CONCLUSION: MSI indicated brain dysfunction in significantly more patients with postconcussive symptoms than either EEG or MR imaging (P <.01). The presence of excessive abnormal low-frequency magnetic activity provides objective evidence of brain injury in patients with postconcussive syndromes and correlates well with the degree of symptomatic recovery.	New Mexico Reg Fed Med Ctr, Albuquerque, NM USA; Univ New Mexico, Sch Med, Dept Radiol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Psychol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA; St Josephs Med Ctr, St Josephs Rehabil Ctr, Albuquerque, NM USA	Lewine, JD (corresponding author), Univ Utah, Sch Med, Dept Radiol, Med Ctr 1A71, 50 N Med Dr, Salt Lake City, UT 84132 USA.						BAKER SP, 1989, JAMA-J AM MED ASSOC, V262, P2248; BENZEL EC, 1993, NEUROSURGERY, V33, P252, DOI 10.1227/00006123-199308000-00011; COURJON J, 1972, HDB ELECTROENCEPHA B, V14; Gallen CC, 1997, EPILEPSIA, V38, P452, DOI 10.1111/j.1528-1157.1997.tb01735.x; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; HARI R, 1986, CRIT REV BIOMED ENG, V14, P93; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HUGHES JR, 1977, J NEUROL, V217, P79, DOI 10.1007/BF00312921; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lewine JD, 1995, STUD APPL ELECTROMAG, V7, P55; LEWINE JD, 1995, FUNCTIONAL BRAIN IMA, P369; LEWINE JD, 1997, J NEUROSURG; Lewine JD, 1990, NONINVASIVE TECHNIQU; LEWINE JD, 1996, NEUROIMAGING EPILEPS, P193; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RUTHERFORD WH, 1977, LANCET, V1, P1; Schwartz BJ, 1995, STUD APPL ELECTROMAG, V7, P66; SHOENHUBER R, 1982, NEUROBEHAVIORAL CONS, P142; *US OFF SCI TECHN, 1991, MAX HUM POT DEC BRAI; Vieth J B, 1990, Adv Neurol, V54, P261; WILLIAMSON SI, 1987, HDB ELECTROENCEPHALO, V1	25	83	83	0	7	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAY	1999	20	5					857	866					10	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	198RY	WOS:000080439000021	10369357				2021-06-18	
J	Yablon, SA; Agana, BT; Ivanhoe, CB; Boake, C				Yablon, SA; Agana, BT; Ivanhoe, CB; Boake, C			Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: Am open-labeled trial	NEUROLOGY			English	Article							DOUBLE-BLIND	We studied the effect of botulinum toxin A (BTXA) among patients with traumatic brain injury (TBI) and severe spasticity unresponsive to conservative management. Twenty-one consecutive adult patients with severe spasticity involving the wrist and finger flexor musculature were treated with BTXA injection (20 to 40 units per muscle) under EMG guidance. After injection, patients received passive range of motion (ROM) exercise, with modalities and casting as clinically indicated. Outcome measures, including wrist ROM and the modified Ashworth Scale (MAS), were assessed 2 to 4 weeks after injection. Among the respective acute and chronic groups, mean ROM improved 42.9 (p = 0.001) and 36.2 degrees (p < 0.001). Mean MAS rating improved 1.5 (p = 0.01) and 1.47 (p = 0.002) points. There were no significant adverse effects. BTXA, in conjunction with conventional modalities, significantly improves spasticity and ROM in the distal upper extremity musculature of patients with TBI.	INST REHABIL & RES,BRAIN INJURY PROGRAM,HOUSTON,TX; UNIV TEXAS,HLTH SCI CTR HOUSTON,DEPT PHYS MED & REHABIL,HOUSTON,TX; BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030							AGANA BT, 1994, ARCH PHYS MED REHAB, V75, P1063; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; BARBIERI S, 1994, MOVEMENT DISORDER S1, V9, P128; BIEDERMANN RE, 1993, ARCH PHYSICAL MED RE, V74, P1282; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BORGSTEIN J, 1993, AM J PHYS MED REHAB, V72, P364; BOWERS D N, 1991, Archives of Physical Medicine and Rehabilitation, V72, P816; BURGAR CG, 1994, ARCH PHYSICAL MED RE, V75, P1031; CHAN CH, 1990, NEUROLOGY, V40, P1427, DOI 10.1212/WNL.40.9.1427; DAS TK, 1989, BRIT J CLIN PRACT, V43, P401; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; Delagi E.F., 1980, ANATOMIC GUIDE ELECT; DENGLER R, 1992, J NEUROL, V239, P375; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; GANS BM, 1990, PRACTICAL MANAGEMENT, P1; GLENN MB, 1990, PRACTICAL MANAGEMENT, P227; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; Hesse S, 1992, J REHABIL SCI, V5, P98; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; KASDON KL, 1990, PRACTICAL MANAGEMENT, P259; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; KOMAN LA, 1993, J PEDIATR ORTHOPED, V13, P489, DOI 10.1097/01241398-199307000-00013; KOMAN LA, 1992, DEV MED CHILD NE S66, V34, P23; KOSTANZER A, 1992, MOVEMENT DISORDER S1, V7, P137; LEHMKUHL LD, 1990, J HEAD TRAUMA REHAB, V5, P23, DOI DOI 10.1097/00001199-199012000-00005; Lux Warren E., 1992, Archives of Physical Medicine and Rehabilitation, V73, P1008; MAYER NH, 1991, J NEURO REHAB, V5, pS1; MEMIN B, 1992, REV NEUROL, V148, P212; MEYTHALER JM, 1994, ARCH PHYSICAL MED RE, V75, P1036; OBRIEN CF, 1995, NEUROLOGY, V45, pA329; PIERSON SH, 1994, NEUROLOGY, V44, pA184; REEVES KD, 1992, AJPM, V2, P205; Robinson K. M., 1990, PRACTICAL MANAGEMENT, P201; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; YARKONY GM, 1987, CLIN ORTHOP RELAT R, P93; YOUNG RR, 1987, CLIN ORTHOP RELAT R, V219, P50; 1990, NEUROLOGY, V40, P1332	38	83	85	0	2	LITTLE BROWN CO	BOSTON	34 BEACON STREET, BOSTON, MA 02108-1493	0028-3878			NEUROLOGY	Neurology	OCT	1996	47	4					939	944		10.1212/WNL.47.4.939			6	Clinical Neurology	Neurosciences & Neurology	VN295	WOS:A1996VN29500015	8857723				2021-06-18	
J	Ellenberg, JH; Levin, HS; Saydjari, C				Ellenberg, JH; Levin, HS; Saydjari, C			Posttraumatic amnesia as a predictor of outcome after severe closed head injury - Prospective assessment	ARCHIVES OF NEUROLOGY			English	Article							COMA DATA-BANK; PRACTICAL SCALE; SEQUELAE	Objectives: To identify the demographic and clinical variables related to the duration of posttraumatic amnesia after severe closed head injury; to evaluate the usefulness of posttraumatic amnesia duration in predicting outcome at the time of hospital discharge and at 6 months after injury. Setting: Four clinical centers located in primary care hospitals. Patients: Three hundred fourteen severely injured subjects aged 16 years or older who did not have trauma as a result of a penetrating injury and came out of coma before hospital discharge. Interventions: Approximately half of the subjects were administered phenytoin sodium for some period after termination of coma; 17% were administered dexamethasone and 41% morphine sulfate. Main Outcome Measures: Galveston Orientation and Amnesia Test scores defined the duration of posttraumatic amnesia. The Glasgow Outcome Scale was used to grade outcome at the time of hospital discharge and at 6 months. Results: Older age, low initial Glasgow Coma Scale score, nonreactive pupil(s), coma duration, and use of phenytoin were associated with a longer duration of posttraumatic amnesia. Poor pupillary response, time in coma, and duration of posttraumatic amnesia and use of phenytoin was predictive of the 6-month outcome. Conclusions:. The results support the prognostic usefulness of prospectively measuring duration of posttraumatic amnesia after termination of coma. Pending replication, our findings suggest that posttraumatic amnesia duration may be a useful surrogate outcome measure for clinical trials involving interventions for acute head injury.	WESTAT CORP,ROCKVILLE,MD; UNIV MARYLAND,DIV NEUROSURG,BALTIMORE,MD					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-NS-3-2339, N01-NS-3-2340, N01-NS-3-2341] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032339, N01NS032340, N01NS032341] Funding Source: NIH RePORTER		BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Cox D.R., 2018, ANAL BINARY DATA; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Levin H. S., 1992, NEUROPSYCHOLOGY MEMO, P290; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MANTEL N, 1959, J NATL CANCER I, V22, P719; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NATELSON BH, 1979, ARCH NEUROL-CHICAGO, V36, P444, DOI 10.1001/archneur.1979.00500430074014; NEWCOMER JW, 1994, J NEUROSCI, V14, P2047; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1932, TRAUMATIC AMNESIAS; *SAS I INC, 1988, SAS STAT US GUID LIF; *SAS I INC, 1990, SAS STAT US GUID LOG; *SAS I INC, 1991, P217 SAS; SHORES A, 1990, AUST NZ J PSYCHIAT, V24, P133, DOI 10.3109/00048679009062895; TEASDALE G, 1974, LANCET, V2, P81; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; WOLKOWITZ OM, 1992, AM J PSYCHIAT, V124, P1125	31	83	85	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	AUG	1996	53	8					782	791		10.1001/archneur.1996.00550080104018			10	Clinical Neurology	Neurosciences & Neurology	VB471	WOS:A1996VB47100014	8759985				2021-06-18	
J	Clark, RSB; Kochanek, PM; Obrist, WD; Wong, HR; Billiar, TR; Wisniewski, SR; Marion, DW				Clark, RSB; Kochanek, PM; Obrist, WD; Wong, HR; Billiar, TR; Wisniewski, SR; Marion, DW			Cerebrospinal fluid and plasma nitrite and nitrate concentrations after head injury in humans	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	24th Educational and Scientific Symposium of the Society-of-Critical-Care-Medicine	JAN 31-FEB 04, 1995	SAN FRANCISCO, CA	Soc Crit Care Med		cerebrospinal fluid; head injury; nitrate; nitrite; nitric oxide; hypothermia; critical illness; Glasgow Coma Scale; brain; neurologic emergencies	OXIDE SYNTHESIS; BRAIN INJURY; PERITONEAL-MACROPHAGES; MONONUCLEAR PHAGOCYTES; SPINAL-CORD; L-ARGININE; HYPOTHERMIA; INHIBITION; MECHANISM; CYTOKINES	Objectives: To measure cerebrospinal fluid and plasma nitrite and nitrate concentrations as indicators of nitric oxide production in adults after severe closed head injury. To determine if there is an association between cerebrospinal fluid and plasma nitrite and nitrate concentrations, and cerebral blood flow, arterio-jugular oxygen content difference, injury severity, and outcome after severe closed head injury. Design: A prospective, clinical study. Setting: Multidisciplinary intensive care unit. Patients: Fifteen comatose (Glasgow Coma Scale score of less than or equal to 7) adult patients with severe closed-head injury were studied during the prospective, randomized evaluation of the effect of moderate hypothermia (32 degrees C for 24 hrs) on neurologic outcome after closed-head injury. Seven patients were in the hypothermic group and eight patients were in the normothermic treatment group. Interventions: None. Measurements and Main Results: Patients were examined sequentially, every 12 hrs for 2 days. Intraventricular cerebrospinal fluid was assayed for nitrite and nitrate concentrations. Cerebral blood flow was measured by the (133)xenon intravenous method. Simultaneous blood samples were obtained for measurements of arterio-jugular oxygen content difference and plasma nitrite and nitrate concentrations. Cerebral metabolic rate for oxygen was calculated. Cerebrospinal fluid nitrite and nitrate concentrations were highest at 30 to 42 hrs vs. 6 to 18, 18 to 30, and 42 to 54 hrs (26.4 +/- 3.3 vs. 17.3 +/- 2.1, 20.0 +/- 2.2, and 18.8 +/- 2.4 mu M, respectively, p < .05). There was no difference over time in plasma nitrite and nitrate concentrations. Cerebral blood flow was increased and arterio-jugular oxygen content difference was reduced at 18 to 30, 30 to 42, and 42 to 54 hrs vs. 6 to 18 hrs (p < .05). At 30 to 42 hrs, cerebrospinal fluid nitrite and nitrate concentrations were 80% higher in patients who died vs. survivors (36.4 +/- 3.2 vs. 20.2 +/- 3.6, p < .05). Using a generalized, multivariate, linear regression model, both plasma nitrite and nitrate concentrations and Injury Severity Score independently predicted cerebrospinal fluid nitrite and nitrate concentrations (p < .00001 and p = .0053, respectively). Cerebral blood flow and arterio-jugular oxygen content difference were not associated with cerebrospinal fluid or plasma nitrite and nitrate concentrations using this model. Cerebrospinal fluid nitrite and nitrate concentrations were in creased over time in hypothermic vs. normothermic patients. But, where this difference occurred could not be determined by multiple comparisons (p = .03). The hypothermic patients had lower admission Glasgow Coma Scale scores than normothermic patients (p = .04) and tended to have higher Injury Severity Scores (p = .09). Conclusions: Increases in cerebrospinal fluid nitrite and nitrate concentrations peaked at 30 to 42 hrs after severe closed-head injury. This increase in cerebrospinal fluid nitrite and nitrate concentrations was greater in nonsurvivors. Also, cerebrospinal fluid and plasma nitrite and nitrate concentrations were associated with Injury Severity Score, suggesting that increased nitric oxide production in the brain is associated with injury severity and death. Hypothermia did not prevent the increase in cerebrospinal fluid nitrite and nitrate concentrations. Further study is required to determine the source of this increase in cerebrospinal fluid nitrite and nitrate concentrations and to further define the relationship to outcome and the effect of hypothermia on this process.	UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT NEUROSURG, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT SURG, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15260 USA	Clark, RSB (corresponding author), UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT ANESTHESIOL & CRIT CARE MED, 3434 5TH AVE, PITTSBURGH, PA 15260 USA.		Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wong, Hector/0000-0001-7989-1173; Wisniewski, Stephen/0000-0002-3877-9860	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318, 2P50 NS30318-04A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318] Funding Source: NIH RePORTER		ALBINA JE, 1993, J IMMUNOL, V150, P5080; ARCHER S, 1993, FASEB J, V7, P349; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BERNARD C, 1994, EUR J PHARM-ENVIRON, V270, P115, DOI 10.1016/0926-6917(94)90087-6; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DING AH, 1988, J IMMUNOL, V141, P2407; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GOODMAN JC, 1995, J NEUROTRAUM, V12, P971; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hewett S. J., 1995, Journal of Neurotrauma, V12, P350; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; JACOB TD, 1993, J TRAUMA, V35, P590, DOI 10.1097/00005373-199310000-00015; JENNETT B, 1975, LANCET, V1, P480; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KUIPER MA, 1994, J NEUROL SCI, V121, P46, DOI 10.1016/0022-510X(94)90155-4; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MASS AIR, 1977, CEREBROSPINAL FLUID, P17; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MILSTIEN S, 1994, J NEUROCHEM, V63, P1178; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; STOCLET JC, 1993, CIRCULATION, V87, P77; TEASDALE G, 1974, LANCET, V2, P81; VISSER JJ, 1994, ANN INTERN MED, V120, P345, DOI 10.7326/0003-4819-120-4-199402150-00023; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WONG HR, 1995, CRIT CARE MED, V23, P835, DOI 10.1097/00003246-199505000-00010; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x	50	83	86	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	1996	24	7					1243	1251		10.1097/00003246-199607000-00030			9	Critical Care Medicine	General & Internal Medicine	UX035	WOS:A1996UX03500030	8674343				2021-06-18	
J	McKinney, JS; Willoughby, KA; Liang, S; Ellis, EF				McKinney, JS; Willoughby, KA; Liang, S; Ellis, EF			Stretch-induced injury of cultured neuronal, glial, and endothelial cells - Effect of Polyethylene glycol-conjugated superoxide dismutase	STROKE			English	Article						brain injuries; cerebral blood flow; free radicals	CEREBRAL BLOOD-FLOW; INDUCED BRAIN EDEMA; ACUTE HYPERTENSION; ARTERIOLAR ABNORMALITIES; RADICAL FORMATION; ARACHIDONIC-ACID; RATS; PERMEABILITY; GENERATION; MECHANISM	Background nod Purpose There is abundant evidence that after in vivo traumatic brain injury, oxygen radicals contribute to changes in cerebrovascular structure and function; however, the cellular source of these oxygen radicals is not clear. The purpose of these experiments was to use a newly developed in vitro tissue culture model to elucidate the effect of strain, or stretch, on neuronal, glial, and endothelial cells and to determine the effect of the free radical scavenger polyethylene glycol-conjugated superoxide dismutase (PEG-SOD; pegorgotein, Dismutec) on the response of each cell type to trauma. Methods Rat brain astrocytes, neuronal plus glial cells, and aortic endothelial cells were grown in cell culture wells with 2-mm-thick silastic membrane bottoms. A controllable, 50-millisecond pressure pulse was used Co transiently deform the silastic membrane and thus stretch the cells. injury was assessed by quantifying the number of cells that took up the normally cell-impermeable dye propidium iodide. Some cultures were pretreated with 100 to 300 U/mL PEG-SOD. Results increasing degrees of deformation produced increased cell injury in astrocytes, neuronal plus glial cultures, and aortic endothelial cells. By 24 hours after injury, all cultures showed evidence of repair as demonstrated by cells regaining their capacity to exclude propidium iodide. Compared with astrocytes or neuronal plus glial cultures, endothelial cells were much more resistant to stretch-induced injury and more quickly regained their capacity to exclude propidium iodide. PEG-SOD had no effect on the neuronal or glial response to injury but reduced immediate posttraumatic endothelial cell dye uptake by 51%. Conclusions These studies further document the utility of the model for studying cell injury and repair and further support the vascular endothelial cell as a site of free radical generation and radical-mediated injury. On the assumption that like aortic endothelial cells, stretch-injured cerebral endothelial cells also produce oxygen radicals, our results further suggest the endothelial cell as a site of therapeutic action of fl ee radical scavengers after traumatic brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23284					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline		AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CHAN PH, 1988, J NEUROCHEM, V50, P1185, DOI 10.1111/j.1471-4159.1988.tb10591.x; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Hall ED, 1993, IRON CENTRAL NERVOUS, P173; HE YY, 1993, AM J PHYSIOL, V265, pH252; KAMITANI T, 1985, CIRC RES, V57, P545, DOI 10.1161/01.RES.57.4.545; KIRSCH JR, 1993, PEDIATR RES, V34, P530, DOI 10.1203/00006450-199310000-00030; KONTOS HA, 1981, AM J PHYSIOL, V240, pH511; LAMB RG, 1995, J NEUROTRAUM, V12, P969; LAURINDO FRM, 1994, CIRC RES, V74, P700, DOI 10.1161/01.RES.74.4.700; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; OURY TD, 1993, J BIOL CHEM, V268, P15394; RAYTCH RE, 1987, SURGERY, V102, P122; ROSEN GM, 1984, P NATL ACAD SCI-BIOL, V81, P7269, DOI 10.1073/pnas.81.23.7269; ROSENBLUM WI, 1995, AM J PHYSIOL-HEART C, V268, pH512; Santilli S M, 1991, Ann Vasc Surg, V5, P429, DOI 10.1007/BF02133047; SCHLEIEN CL, 1994, STROKE, V25, P1830, DOI 10.1161/01.STR.25.9.1830; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; TRUELOVE D, 1994, FREE RADICAL BIO MED, V17, P445, DOI 10.1016/0891-5849(94)90171-6; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHIDA K, 1992, J NEUROTRAUM, V9, P85, DOI 10.1089/neu.1992.9.85; ZHANG XM, 1991, STROKE, V22, P489, DOI 10.1161/01.STR.22.4.489; ZHANG XM, 1990, AM J PHYSIOL, V259, pH497; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	31	83	84	0	8	AMER HEART ASSOC	DALLAS	7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596	0039-2499			STROKE	Stroke	MAY	1996	27	5					934	940		10.1161/01.STR.27.5.934			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	UJ685	WOS:A1996UJ68500025	8623116				2021-06-18	
J	DeKosky, ST; Styren, SD; OMalley, ME; Goss, JR; Kochanek, P; Marion, D; Evans, CH; Robbins, PD				DeKosky, ST; Styren, SD; OMalley, ME; Goss, JR; Kochanek, P; Marion, D; Evans, CH; Robbins, PD			Interleukin-1 receptor antagonist suppresses neurotrophin response in injured rat brain	ANNALS OF NEUROLOGY			English	Article							NERVE GROWTH-FACTOR; SEVERE HEAD-INJURIES; AMINO-ACIDS; EXPRESSION; INCREASES; PROTEIN; IL-1; STIMULATION; FIBROBLASTS; ASTROCYTES	Traumatic brain injury (TBI) induces astrocytic and microglial activation and proliferation and augmented production of the cytokine interleukin-1 beta (IL-1 beta) and nerve growth factor (NGF). The increase in NGF temporally follows the increase in IL-1 beta, suggesting that the IL-1 beta up-regulation after trauma directly induces the increase in NGF. We examined the effect of IL-1 receptor antagonist protein (IL-1ra) on microglial proliferation and NGF production in rat cortex, following two different models of TBI. Rabbit fibroblasts infected with a retroviral vector containing the human IL-1ra gene were implanted into the wound cavity immediately following a cortical stab wound or 6 hours after a weight drop-induced trauma. Both microglial proliferation and NGF up-regulation were decreased significantly in animals receiving IL-1ra-expressing cells compared with animals receiving naive (untransfected) fibroblasts. These data demonstrate that the increase in NGF after central nervous system trauma is directly mediated through IL-1 beta and that blocking IL-1 beta following brain injury leads to suppression of an NGF-mediated reparative response. Such blockade of inflammation, however, may prove to be of significant therapeutic benefit in human brain injury and other inflammatory states.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT NEUROL,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT NEUROBIOL,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT NEUROSURG,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT ORTHOPED SURG,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; SAFAR CTR RESUSCITAT RES,PITTSBURGH,PA	DeKosky, ST (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,WESTERN PSYCHIAT INST & CLIN,3811 OHARA ST,PITTSBURGH,PA 15213, USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P01DK044935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK44935] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		BANDARA G, 1993, P NATL ACAD SCI USA, V90, P10764, DOI 10.1073/pnas.90.22.10764; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CASTELLANO B, 1991, J HISTOCHEM CYTOCHEM, V39, P561, DOI 10.1177/39.5.1707903; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEKOSKY ST, 1994, J NEUROTRAUMA, V11, P106; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOCH AE, 1992, CLIN IMMUNOL IMMUNOP, V65, P23, DOI 10.1016/0090-1229(92)90243-H; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; KRZESICKI RF, 1993, J IMMUNOL, V150, P4008; LEE SC, 1993, J IMMUNOL, V150, P2659; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; Lindholm D, 1990, Neuroreport, V1, P9; LOREZ H, 1989, NEUROSCI LETT, V98, P339, DOI 10.1016/0304-3940(89)90425-4; MANEV H, 1990, FASEB J, V4, P2789; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MERRILL JE, 1991, DEV NEUROSCI, V14, P1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Roitt I. M., 1993, IMMUNOLOGY; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; STOCKMAN BJ, 1992, BIOCHEMISTRY-US, V31, P5237, DOI 10.1021/bi00138a001; STYREN SD, 1995, EXP NEUROL, V131, P165, DOI 10.1016/0014-4886(95)90038-1; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Tuszynski M H, 1994, Neurobiol Dis, V1, P67, DOI 10.1006/nbdi.1994.0009	38	83	87	0	3	LITTLE BROWN CO	BOSTON	34 BEACON STREET, BOSTON, MA 02108-1493	0364-5134			ANN NEUROL	Ann. Neurol.	JAN	1996	39	1					123	127		10.1002/ana.410390118			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	TT880	WOS:A1996TT88000017	8572657				2021-06-18	
J	SBORDONE, RJ; LITER, JC; PETTLERJENNINGS, P				SBORDONE, RJ; LITER, JC; PETTLERJENNINGS, P			RECOVERY OF FUNCTION FOLLOWING SEVERE TRAUMATIC BRAIN INJURY - A RETROSPECTIVE 10-YEAR FOLLOW-UP	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY	It has been widely assumed that most of the recovery following severe traumatic brain injury (TBI) occurs within the first 6 months, and that virtually all of the recovery occurs within the first 1-2 years post-injury. In an effort to evaluate the long-term recovery of patients who had sustained severe TBI, we interviewed the relatives and significant others of 20 patients who had sustained TBI at least 5 years earlier, using a modified version of the Portland Adaptability Inventory. Retrospective ratings were collected to evaluate the patients' psychosocial, cognitive, physical, and emotional status prior to their injury, and at 1, 2, 5, and an average of 10.3 years post-injury. The results indicated that TBI patients exhibit significant improvements in their social, cognitive, physical, and emotional functioning after 2 years post-injury regardless of the severity of their initial brain trauma. These data suggest that patients who sustain severe TBI continue to make gradual improvements in their functioning for at least 10 years post-injury. Our findings contradict the widely held assumption that the recovery process ends after 1 or 2 years post-injury.	UNIV CALIF IRVINE,COLL MED,DEPT NEUROSURG,IRVINE,CA; UNIV CALIF IRVINE,COLL MED,DEPT MED PHYS,IRVINE,CA; UNIV CALIF IRVINE,COLL MED,DEPT REHABIL,IRVINE,CA; UNIV CALIF IRVINE,DEPT COGNIT SCI,IRVINE,CA 92717; UNIV SO CALIF,DEPT PSYCHOL,LOS ANGELES,CA 90089							Bond M R, 1979, Int Rehabil Med, V1, P155; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; COOPER PR, 1982, HEAD INJURY, P1; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; Kinsella G, 1989, Int Disabil Stud, V11, P9; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MILLER H, 1965, LANCET, V1, P225; Miller JD., 1983, REHABILITATION HEAD, P37; MILTON SB, 1991, J HEAD TRAUMA REHAB, V6, P35; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; SBORDONE RJ, 1984, PROF PSYCHOL-RES PR, V15, P165; SBORDONE RJ, IN PRESS EC VALIDITY; SBORDONE RJ, 1988, J HEAD TRAUMA REHAB, V3, P55; SBORDONE RJ, 1987, REHABILITATION COGNI, P3; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; TERAYAMA Y, 1993, SURG NEUROL, V39, P177, DOI 10.1016/0090-3019(93)90179-5; TERAYAMA Y, 1991, SURG NEUROL, V36, P335, DOI 10.1016/0090-3019(91)90021-Z; THOMSEN I V, 1981, Journal of Clinical Neuropsychology, V3, P43, DOI 10.1080/01688638108403112; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; WIRKINGER MS, 1992, BRAIN INJURY, V6, P183	30	83	83	0	3	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	APR	1995	9	3					285	299		10.3109/02699059509008199			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QR499	WOS:A1995QR49900006	7541681				2021-06-18	
J	LEACH, LR; FRANK, RG; BOUMAN, DE; FARMER, J				LEACH, LR; FRANK, RG; BOUMAN, DE; FARMER, J			FAMILY FUNCTIONING, SOCIAL SUPPORT AND DEPRESSION AFTER TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							RATING-SCALE; HEAD-INJURY; PERSONALITY	Functional outcome after traumatic brain injury (TBI) is thought to be dependent upon effective social support and avoidance of depressive episodes. Research indicates that post-injury changes often occur in the family's functioning, hence impacting the family's ability to provide the needed social support. Social support, in turn, has been hypothesized to work as a buffer between significant life event and levels of depressive symptoms. Thus poor social support after a TBI, due to changes in family functioning, could result in depressive episodes for the person with a TBI. This paper empirically examines this question by investigating whether social support is predictive of depression in persons who have sustained a TBI. Thirty-nine persons who had sustained TBI were interviewed to assess their family functioning, perceived social support, and current depressive symptomatology. The results showed that the effective use of problem-solving and behavioural coping strategies by the family in response to TBI was significantly related to lower levels of depression in the person who sustained the TBI. However, perceived social support was not predictive of depression.	UNIV MISSOURI,DEPT PHYS MED & REHABIL,2R01 RUSK REHABILITAT CTR,COLUMBIA,MO 65212; UNIV MISSOURI,DEPT PSYCHOL,COLUMBIA,MO 65201							BARRERA M, 1990, J SOCIAL PERSONAL RE, V71, P541; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CASSEL J, 1974, INT J HEALTH SERV, V4, P471, DOI 10.2190/WF7X-Y1L0-BFKH-9QU2; CLEARY PD, 1982, J HEALTH SOC BEHAV, V23, P159, DOI 10.2307/2136512; COYNE JC, 1976, PSYCHIATRY, V39, P28, DOI 10.1080/00332747.1976.11023874; ELLIOTT TR, 1990, REHABIL PSYCHOL, V35, P111; ENDICOTT J, 1981, ARCH GEN PSYCHIAT, V38, P98; FLORIAN V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; FRANK R G, 1990, Brain Injury, V4, P289, DOI 10.3109/02699059009026179; HOLAHAN CJ, 1986, J PERS SOC PSYCHOL, V51, P389, DOI 10.1037/0022-3514.51.2.389; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; MCCUBBIN HI, 1985, FAMILY INVENTORIES I, P143; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PIERCE GR, 1986, MAY W PSYCHOL ASS CO; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; STRACK S, 1983, J PERS SOC PSYCHOL, V44, P798, DOI 10.1037/0022-3514.44.4.798; THOMSEN IV, 1974, SCANDINAVIAN J REHAB, V6, P189; WHYBROW PC, 1984, MOOD DISORDERS NEW P; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; WORTMAN CB, 1989, J CONSULT CLIN PSYCH, V57, P349, DOI 10.1037/0022-006X.57.3.349	25	83	83	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1994	8	7					599	606		10.3109/02699059409151012			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PH426	WOS:A1994PH42600003	7804296				2021-06-18	
J	DHILLON, HS; DONALDSON, D; DEMPSEY, RJ; PRASAD, MR				DHILLON, HS; DONALDSON, D; DEMPSEY, RJ; PRASAD, MR			REGIONAL LEVELS OF FREE FATTY-ACIDS AND EVANS BLUE EXTRAVASATION AFTER EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							INCREASED PROSTAGLANDIN SYNTHESIS; CONTROLLED CORTICAL IMPACT; EXPERIMENTAL HEAD-INJURY; ARACHIDONIC-ACID; CEREBRAL-ISCHEMIA; VASCULAR-PERMEABILITY; AMINO-ACIDS; RAT; METABOLISM; LEUKOTRIENE-C4	The recently developed controlled cortical-impact (CCI) model of brain injury in rats serves as an excellent tool to understand some of the neurochemical mechanisms mediating the pathophysiology of traumatic brain injury. In this study, rats were subjected to lateral CCI brain injury of low-grade severity. Their brains were frozen in situ at various times after injury to measure regional levels of free fatty acids. Tissue total free fatty acids at the injury site within the left cortex were increased at 30 min, 2.5 h, and 24 h postinjury. In injured animals, increases in stearic and arachidonic acids were slightly greater than those in palmitic and oleic acids. The levels of total free fatty acids in the cortex adjacent to the injury site were also increased in injured animals at 2.5 h and 24 h after injury (p < 0.05). Only stearic and arachidonic acids were observed to be significantly increased (p < 0.05) in the adjacent cortex of injured animals at all times after injury. Although no significant increases in total free fatty acids were observed in the left hippocampus adjacent to the injury site, stearate and arachidonate concentrations were increased at 30 min and 2.5 h after injury (p < 0.05). Extravasation of Evans blue was found to be significantly increased in the ipsilateral cortex of injured animals at 30 min and 10 h after brain injury. These results indicate the degradation of membrane phospholipids and blood-brain barrier breakdown in the ipsilateral cortex after lateral CCI brain injury. These results also suggest that arachidonic acid and its metabolites may play a role as a mediator in the blood-brain barrier breakdown associated with cortical impact brain injury in rats.	UNIV KENTUCKY, MED CTR, DEPT SURG, DIV NEUROSURG, LEXINGTON, KY 40536 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 31816] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS031816, R01NS031816] Funding Source: NIH RePORTER		ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CHAN PH, 1984, FED PROC, V43, P210; COMBS DJ, 1990, STROKE, V21, P936, DOI 10.1161/01.STR.21.6.936; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 1983, Am J Emerg Med, V1, P147, DOI 10.1016/0735-6757(83)90082-7; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; IKEDA M, 1986, J NEUROCHEM, V47, P123; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; MARCOUX FW, 1988, BRAIN RES, V452, P329, DOI 10.1016/0006-8993(88)90037-6; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MONCADA S, 1978, PHARMACOL REV, V30, P293; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; PRASAD MR, 1988, CAN J PHYSIOL PHARM, V66, P1518, DOI 10.1139/y88-248; PRASAD MR, 1994, J NEUROCHEM, V63, P1089; PRASAD MR, 1994, J NEUROTRAUMA, V11, P123; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TZIGARET C, 1993, J NEUROCHEM, V60, P827, DOI 10.1111/j.1471-4159.1993.tb03226.x; UNTERBERG A, 1987, ACTA NEUROPATHOL, V73, P209, DOI 10.1007/BF00686613; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; VINK R, 1988, J BIOL CHEM, V263, P757; VISOLI F, 1993, J NEUROCHEM, V61, P1835; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	52	83	88	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1994	11	4					405	415		10.1089/neu.1994.11.405			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PG289	WOS:A1994PG28900006	7837281				2021-06-18	
J	ANDERSEN, BJ; MARMAROU, A				ANDERSEN, BJ; MARMAROU, A			POSTTRAUMATIC SELECTIVE STIMULATION OF GLYCOLYSIS	BRAIN RESEARCH			English	Article						TRAUMA; ACIDOSIS; GLYCOLYSIS; P-13 MRS; BLOOD FLOW	CEREBRAL ENERGY-METABOLISM; NUCLEAR MAGNETIC-RESONANCE; PERCUSSION BRAIN INJURY; HEAD-INJURY; BLOOD-FLOW; FLUID; CAT; POTASSIUM; RAT; PH	Ventilated, chloralose anesthetized cats were subjected to 3.2 atmosphere fluid percussion injury and compared with sham operated controls. In both groups, global cerebral blood flow (CBF), cerebral metabolic rate of oxygen utilization (CMRO2), cerebral metabolic rate of glucose utilization (CMRGl), and P-31 magnetic resonance spectroscopy (MRS) determinations of tissue pH (pH(i)) phosphocreatine (PCr), and inorganic phosphate (Pi) were measured before and 5, 15, 30, and 60 min post-trauma. Following trauma, pH decreased slightly 30 min following trauma and gradually returned to normal. CMRO2, CBF, and arterial pO2 remained at control values throughout the experiment while CMRGl increased 243% at 5 min post-injury then rapidly returned to control values. This combination of acidosis and increased glucose utilization indicates that trauma causes a transient isolated increase in cerebral glycolysis and may be important to consider when investigating the etiology of post traumatic acidosis.	VIRGINIA COMMONWEALTH UNIV,DIV NEUROSURG,RICHMOND,VA 23284	ANDERSEN, BJ (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT NEUROSURG,SLOT 507,4301 W MARKHAM ST,LITTLE ROCK,AR 72205, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, R56NS019235, P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587, NS19235] Funding Source: Medline		ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; CHAPMAN AG, 1977, J NEUROCHEM, V28, P1025, DOI 10.1111/j.1471-4159.1977.tb10665.x; CISBA L, 1985, BRAIN RES, V336, P167; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; GROOTEGOED JA, 1986, J REPROD FERTIL, V77, P109, DOI 10.1530/jrf.0.0770109; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOWSE DC, 1975, J NEUROCHEM, V24, P935, DOI 10.1111/j.1471-4159.1975.tb03658.x; HOWSE DC, 1974, AM J PHYSIOL, V227, P1444; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; JENKINS L, 1981, ANAT REC, V199, pA127; JULIAN FJ, 1962, J GEN PHYSIOL, V46, P297, DOI 10.1085/jgp.46.2.297; KING LJ, 1967, J NEUROCHEM, V14, P613, DOI 10.1111/j.1471-4159.1967.tb09564.x; KRIVANEK J, 1961, J NEUROCHEM, V6, P183, DOI 10.1111/j.1471-4159.1961.tb13463.x; LAURITZEN M, 1987, J CEREB BLOOD FLOW M, V7, pS125; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LEWIS DV, 1975, BRAIN RES, V99, P175, DOI 10.1016/0006-8993(75)90623-X; LOTHMAN E, 1975, BRAIN RES, V88, P15, DOI 10.1016/0006-8993(75)90943-9; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; SACKTOR B, 1966, J BIOL CHEM, V241, P5071; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	32	83	83	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 10	1992	585	1-2					184	189		10.1016/0006-8993(92)91205-S			6	Neurosciences	Neurosciences & Neurology	JH130	WOS:A1992JH13000022	1511300				2021-06-18	
J	WROBLEWSKI, BA; LEARY, JM; PHELAN, AM; WHYTE, J; MANNING, K				WROBLEWSKI, BA; LEARY, JM; PHELAN, AM; WHYTE, J; MANNING, K			METHYLPHENIDATE AND SEIZURE FREQUENCY IN BRAIN INJURED PATIENTS WITH SEIZURE DISORDERS	JOURNAL OF CLINICAL PSYCHIATRY			English	Article								Background: Psychostimulant drugs such as methylphenidate are increasingly being used in patients with traumatic brain injury or other brain injuries for a variety of cognitive and behavioral problems. However, there is some reluctance among clinicians and family members to use methylphenidate in brain injured patients because of warnings of seizure occurrence, which are prominently reported by the product labeling included in the Physicians' Desk Reference. Method: We retrospectively studied the use of methylphenidate in 30 consecutive patients with active seizure disorders. We compared the seizure frequency in the 3 months before and after methylphenidate with the seizure frequency during methylphenidate treatment, using the Wilcoxon signed-rank test. Results: Overall, the findings demonstrated a trend toward a lesser incidence of seizures in patients during methylphenidate treatment. Only 4 patients had greater seizure frequency during methylphenidate treatment, and 3 of these 4 were receiving tricyclic antidepressants. Conclusion: Methylphenidate can be safely used in brain injured patients, even those at high risk for seizures, as it was associated with a trend toward reduction (rather than increase) in seizure frequency in this population.	TUFTS UNIV,SCH MED,DEPT REHABIL MED,BOSTON,MA 02111; MASSACHUSETTS COLL PHARM & ALLIED HLTH SCI,BOSTON,MA; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PHYS MED & REHABIL,PHILADELPHIA,PA 19140; MOSS REHABIL HOSP,DRUCKER BRAIN INJURY CTR,PHILADELPHIA,PA 19141	WROBLEWSKI, BA (corresponding author), GREENERY REHABIL CTR,99 CHESTNUT HILL AVE,BOSTON,MA 02135, USA.			Whyte, John/0000-0002-4381-1474			APPLEBY JG, 1985, J S C MED ASS, V5, P281; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Evans R. W., 1987, J HEAD TRAUMA REHAB, V2, P29; EVANS RW, 1986, J NERV MENT DIS, V175, P106; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FELDMAN H, 1989, AM J DIS CHILD, V143, P1081, DOI 10.1001/archpedi.1989.02150210117030; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LIVINGSTON S, 1975, JAMA-J AM MED ASSOC, V233, P278, DOI 10.1001/jama.233.3.278; LIVINGSTON S, 1948, J PEDIATR, V32, P490, DOI 10.1016/S0022-3476(48)80169-1; MALKMUS D, 1980, REHABILITATION HEAD; Parmelee D X, 1987, Brain Inj, V1, P41, DOI 10.3109/02699058709034443; Weinberg R M, 1987, Brain Inj, V1, P57, DOI 10.3109/02699058709034445; WROBLEWSKI BA, 1990, J CLIN PSYCHOPHARM, V10, P124, DOI 10.1097/00004714-199004000-00009; 1991, MED EC	16	83	84	0	3	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 240008, MEMPHIS, TN 38124	0160-6689			J CLIN PSYCHIAT	J. Clin. Psychiatry	MAR	1992	53	3					86	89					4	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	HM911	WOS:A1992HM91100003	1548250				2021-06-18	
J	GOWER, DJ; LEE, KS; MCWHORTER, JM				GOWER, DJ; LEE, KS; MCWHORTER, JM			ROLE OF SUBTEMPORAL DECOMPRESSION IN SEVERE CLOSED HEAD-INJURY	NEUROSURGERY			English	Article									WAKE FOREST UNIV, MED CTR,BOWMAN GRAY SCH MED,DEPT SURG, NEUROSURG SECT,300 S HAWTHORNE RD, WINSTON SALEM, NC 27103 USA							ALEXANDER E, 1987, BRIT J NEUROSURG, V1, P421; ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRUCE DA, 1986, ANESTHESIA NEUROSURG, P150; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CRONE KR, 1985, NEUROSURGERY, V16, P726; FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; YAMAURA A, 1979, Neurologia Medico-Chirurgica, V19, P717, DOI 10.2176/nmc.19.717; YOUNG PH, 1982, SOUTHERN MED J, V75, P473, DOI 10.1097/00007611-198204000-00025	17	83	85	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	1988	23	4					417	422		10.1227/00006123-198810000-00002			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	Q5611	WOS:A1988Q561100002	3200370				2021-06-18	
J	OMMAYA, AK; ROCKOFF, SD; BALDWIN, M				OMMAYA, AK; ROCKOFF, SD; BALDWIN, M			EXPERIMENTAL CONCUSSION - FIRST REPORT	JOURNAL OF NEUROSURGERY			English	Article																Cannon WB, 1901, AM J PHYSIOL, V6, P91; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DOW RS, 1945, J NEUROPHYSIOL, V8, P161; EVANS FG, 1961, BIOMECHANICAL STUDIE, V9, P192; FOLTZ EL, 1953, J NEUROSURG, V10, P342, DOI 10.3171/jns.1953.10.4.0342; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; GROAT R, 1950, J NEUROPATH EXP NEUR, V9, P150, DOI 10.1097/00005072-195004000-00003; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; Gurdjian ES, 1944, J NEUROSURG, V1, P393, DOI 10.3171/jns.1944.1.6.0393; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; GURDJIAN ES, 1961, BIOMECHANICAL STUDIE, V9, P192; HADDAD B. F., 1955, NEUROLOGY, V5, P798; Holbourn AHS, 1943, LANCET, V2, P438; HOLLISTER NR, 1958, 58 WADC TECH REP WRI; Jakob A., 1912, HISTOL HISTOPATH ARB, V5, P182; JOHNSON T, WORKS FAMOUS CHIRURG, P350; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KRUEGER TP, 1963, AMER J ROENTGENOL RA, V90, P506; LITTRE, 1905, HIST ACAD SCI PARIS, P54; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; Miller GG, 1927, ARCH SURG-CHICAGO, V14, P891, DOI 10.1001/archsurg.1927.01130160100005; MOORE GE, 1953, DIAGNOSIS LOCALIZATI, V23, P221; OMMAYA A K, 1963, Med Ann Dist Columbia, V32, P18; OMMAYA AK, 1963, MED ANN DC, V32, P38; ROCKOFF SD, IN PRESS; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P326; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P470; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; STRICH SJ, 1961, LANCET, V2, P443; SYMONDS C, 1962, LANCET, V1, P1; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; TEDESCHI CG, 1945, ARCH NEURO PSYCHIATR, V53, P333, DOI 10.1001/archneurpsyc.1945.02300050007002; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WARD JW, 1948, SCIENCE, V107, P349, DOI 10.1126/science.107.2779.349; White JC, 1943, ANN SURG, V119, P619, DOI 10.1097/00000658-194310000-00010; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210; WINDLE WF, 1948, ANAT REC, V100, P725; WITKOWSKI L, 1877, VIRCHOWS ARCH, V69, P498; ZIMMERMAN FT, 1947, ARCH NEURO PSYCHIATR, V57, P521, DOI 10.1001/archneurpsyc.1947.02300280015001	44	83	83	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.		1964	21	4					249	+		10.3171/jns.1964.21.4.0249			1	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	6091B	WOS:A19646091B00011	14152540				2021-06-18	
J	GROSS, AG				GROSS, AG			A NEW THEORY ON THE DYNAMICS OF BRAIN CONCUSSION AND BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article																BERGMANN L, 1954, ULTRASCHALL SEINE AN, V16; Courville CB, 1942, ARCH SURG-CHICAGO, V45, P19, DOI 10.1001/archsurg.1942.01220010022002; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; Duret H, 1920, REV NEUROL-FRANCE, V36, P888; GAMA JP, 1835, TRAITE PLAIES TETE E, V24; Goggio AF, 1941, J NEUROL PSYCHIATRY, V4, P11, DOI 10.1136/jnnp.4.1.11; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; Holbourn AHS, 1943, LANCET, V2, P438; MILES A, 1892, BRAIN, V15, P153; MUNRO D, 1938, CRANIO CEREBRAL INJU, V28; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WARD JW, 1948, SCIENCE, V107, P349, DOI 10.1126/science.107.2779.349	14	83	84	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1958	15	5					548	561		10.3171/jns.1958.15.5.0548			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WG964	WOS:A1958WG96400009	13576198				2021-06-18	
J	Collins, MW; Kontos, AP; Okonkwo, DO; Almquist, J; Bailes, J; Barisa, M; Bazarian, J; Bloom, OJ; Brody, DL; Cantu, R; Cardenas, J; Clugston, J; Cohen, R; Echemendia, R; Elbin, RJ; Ellenbogen, R; Fonseca, J; Gioia, G; Guskiewicz, K; Heyer, R; Hotz, G; Iverson, GL; Jordan, B; Manley, G; Maroon, J; McAllister, T; McCrea, M; Mucha, A; Pieroth, E; Podell, K; Pombo, M; Shetty, T; Sills, A; Solomon, G; Thomas, DG; McLeod, TCV; Yates, T; Zafonte, R				Collins, Michael W.; Kontos, Anthony P.; Okonkwo, David O.; Almquist, Jon; Bailes, Julian; Barisa, Mark; Bazarian, Jeffrey; Bloom, O. Josh; Brody, David L.; Cantu, Robert; Cardenas, Javier; Clugston, Jay; Cohen, Randall; Echemendia, Ruben; Elbin, R. J.; Ellenbogen, Richard; Fonseca, Janna; Gioia, Gerard; Guskiewicz, Kevin; Heyer, Robert; Hotz, Gillian; Iverson, Grant L.; Jordan, Barry; Manley, Geoffrey; Maroon, Joseph; McAllister, Thomas; McCrea, Michael; Mucha, Anne; Pieroth, Elizabeth; Podell, Kenneth; Pombo, Matthew; Shetty, Teena; Sills, Allen; Solomon, Gary; Thomas, Danny G.; McLeod, Tamara C. Valovich; Yates, Tony; Zafonte, Ross			Statements of Agreement From the Targeted Evaluation and Active Management (TEAM) Approaches to Treating Concussion Meeting Held in Pittsburgh, October 15-16, 2015	NEUROSURGERY			English	Article						Concussion; mTBI; Rehabilitation; Treatment	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC MIGRAINE CHARACTERISTICS; PREDICT PROTRACTED RECOVERY; COLLEGIATE FOOTBALL PLAYERS; FEMALE HIGH-SCHOOL; LOW-BACK-PAIN; NEUROCOGNITIVE PERFORMANCE; COGNITIVE IMPAIRMENT; SEX-DIFFERENCES	BACKGROUND: Conventional management for concussion involves prescribed rest and progressive return to activity. Recent evidence challenges this notion and suggests that active approaches may be effective for some patients. Previous concussion consensus statements provide limited guidance regarding active treatment. OBJECTIVE: To describe the current landscape of treatment for concussion and to provide summary agreements related to treatment to assist clinicians in the treatment of concussion. METHODS: On October 14 to 16, 2015, the Targeted Evaluation and Active Management (TEAM) Approaches to Treating Concussion meeting was convened in Pittsburgh, Pennsylvania. Thirty-seven concussion experts from neuropsychology, neurology, neurosurgery, sports medicine, physical medicine and rehabilitation, physical therapy, athletic training, and research and 12 individuals representing sport, military, and public health organizations attended the meeting. The 37 experts indicated their agreement on a series of statements using an audience response system clicker device. RESULTS: A total of 16 statements of agreement were supported covering (1) Summary of the Current Approach to Treating Concussion, (2) Heterogeneity and Evolving Clinical Profiles of Concussion, (3) TEAM Approach to Concussion Treatment: Specific Strategies, and (4) Future Directions: A Call to Research. Support (ie, response of agree or somewhat agree) for the statements ranged from to 97% to 100%. CONCLUSION: Concussions are characterized by diverse symptoms and impairments and evolving clinical profiles; recovery varies on the basis of modifying factors, injury severity, and treatments. Active and targeted treatments may enhance recovery after concussion. Research is needed on concussion clinical profiles, biomarkers, and the effectiveness and timing of treatments.	[Collins, Michael W.; Kontos, Anthony P.; Thomas, Danny G.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA USA; [Okonkwo, David O.; Maroon, Joseph] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Almquist, Jon] Fairfax Family Practice Comprehens Concuss Ctr, Fairfax, VA USA; [Bailes, Julian] NorthShore Univ Hlth Syst, Dept Neurosurg, Chicago, IL USA; [Barisa, Mark] Baylor Inst Rehabil, Frisco, TX USA; [Bazarian, Jeffrey] Univ Rochester, Dept Emergency Med, Rochester, NY USA; [Bloom, O. Josh; Fonseca, Janna] Carolina Sports Concuss Clin, Cary, NC USA; [Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO USA; [Cantu, Robert] Boston Univ, Emerson Hosp, Robert C Cantu Concuss Ctr, Concord, MA USA; [Cardenas, Javier] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA; [Clugston, Jay] Univ Florida, Community Hlth & Family Med, Gainesville, FL USA; [Cohen, Randall] Univ Arizona, Athlet Dept, Tucson, AZ USA; [Echemendia, Ruben] Psychol & Neurobehav Associates, State Coll, PA USA; [Elbin, R. J.] Univ Arkansas, Off Sports Concuss Res, Fayetteville, AR 72701 USA; [Ellenbogen, Richard] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Gioia, Gerard] Childrens Natl Hlth Syst, Div Neuropsychol, Washington, DC USA; [Guskiewicz, Kevin] Univ N Carolina, Coll Arts & Sci, Chapel Hill, NC USA; [Heyer, Robert] Carolinas Med Ctr, Charlotte, NC 28203 USA; [Hotz, Gillian] Univ Miami, Miller Sch Med, Neurosci Ctr, Miami, FL 33136 USA; [Iverson, Grant L.] Harvard Med Sch, Brigham & Womens Hosp, Massachusetts Gen Hosp, Dept Phys Med & Rehabil,Spaulding Rehabil Hosp, Boston, MA USA; [Jordan, Barry] Burke Rehabil & Res, Neurorehabilitat, White Plains, NY USA; [Manley, Geoffrey] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [McAllister, Thomas] Indiana Univ, Dept Psychiat, Bloomington, IN USA; [McCrea, Michael; Thomas, Danny G.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Mucha, Anne] Univ Pittsburgh, Med Ctr, Ctr Rehabil Serv, Pittsburgh, PA USA; [Pieroth, Elizabeth] NorthShore Univ Hlth Syst, Neurol Inst, Chicago, IL USA; [Podell, Kenneth] Houston Methodist Hosp, Houston Methodist Concuss Ctr, Houston, TX USA; [Pombo, Matthew] Emory Univ Healthcare, Dept Orthoped, Atlanta, GA USA; [Shetty, Teena] Weill Cornell Med Coll, Hosp Special Surg, Dept Neurol, New York, NY USA; [Solomon, Gary] Vanderbilt Univ, Dept Neurosurg, Vanderbilt Sports Concuss Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA; [Thomas, Danny G.] Childrens Hosp Wisconsin, Pediat Emergency Med, Wauwatosa, WI USA; [McLeod, Tamara C. Valovich] AT Still Univ, Dept Athlet Training, Kirksville, MO USA; [Yates, Tony] Pittsburgh Steelers, Pittsburgh, PA USA	Collins, MW (corresponding author), UPMC Rooney Sports Complex,3200 S Water St, Pittsburgh, PA 15203 USA.	collinsmw@upmc.edu	McLeod, Tamara/AAU-9435-2020; Echemendia, Ruben/R-6939-2019; Solomon, Gary/K-9011-2019	Clugston, James/0000-0002-2103-1039; Thomas, Danny/0000-0002-7470-9835; Kontos, Anthony/0000-0002-3749-4310; Iverson, Grant/0000-0001-7348-9570	National Football League; University of Pittsburgh Medical Center; DoDUnited States Department of Defense; NCAA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; GE-NFL; Banyan Biomarkers; Brainscope; Health South; PfizerPfizer; Arizona Super Bowl Host Committee grant; Banyan Biomarkers, Inc; NCAA-DoD CARE Consortium; Brainscope Co, Inc.; MCI; Neuro-Health Research and Rehabilitation, Inc; NeuroHealth LLC; AbbottAbbott Laboratories; Pittsburgh Steelers; GE-NFL Head Health Challenge I; CE Speakers' Bureau-American Physical Therapy Association; Medbridge Education; ImPACT Applications, Inc; Brainsteps; Inova; GE-NFL Head Initiative and Brainscope; Chembio; National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services; NFL Players Association; National Operating Committee on Standards for Athletic Equipment; American Medical Society for Sports Medicine; New Jersey Commission on Brain Injury Research; NFL; USA Hockey; National Athletic Trainers' Association; NFL Benefits Association for Neurocognitive Disability Benefit; Innovative CEUs; NCAA-DoD; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	The TEAM Approaches to Treating Concussion Meeting was supported by grants from the National Football League and University of Pittsburgh Medical Center. Dr Collins is a consultant for the Pittsburgh Steelers and Pittsburgh Penguins and a developer and shareholder in ImPACT (Immediate Post Concussion Assessment and Cognitive Testing) Applications Inc. He receives research funding from the DoD, NCAA, NIH, and GE-NFL. Dr Okonkwo receives research funding from the NIH, DoD, and GE-NFL. He is a paid consultant for Lanx. J. Almquist receives an honorarium for presentations from ImPACT Applications, Inc and is owner of JLA Consulting LLC and codeveloper of BrainTrax. Dr Barisa is on the ImPACT speakers' bureau. Dr Bazarian receives grant/research support from Banyan Biomarkers and Brainscope; is a consultant for Banyan Biomarkers and a virtual shares stockholder in Black Biometrics; and is on the data safety and monitoring board for Neuren Pharmaceuticals. Dr Brody receives grant/research support from Health South and Pfizer and is a consultant for Pfizer Inc, Intellectual Ventures, Signum Nutralogix, Kypha Inc, Sage Therapeutics, iPerian Inc, and Avid Radiopharmaceuticals (Eli Lily & Co). Dr Cantu serves as vice president for the National Operating Committee on Standards for Athletic Equipment; is cofounder, chairman, and medical director for Sports Legacy (SLI, Waltham, MA); and is senior advisor to the NFL's Head, Neck and Spine Committee, providing expert witness testimony in trials. Dr Cardenas has an Arizona Super Bowl Host Committee grant for a domestic violence program, is a consultant in the NFL unaffiliated neurotrauma consultant program, and serves on the ImPACT application scientific advisory board. Dr Clugston receives grant/research support from Banyan Biomarkers, Inc and the NCAA-DoD CARE Consortium. Dr Elbin receives grant/research support from Brainscope Co, Inc. Dr Ellenbogen receives grant/research support from NIH and MCI; is an unpaid consultant for NFL-GE and a member of the NFL Head, Neck and Spine Committee; and is a scientific consultant for the VICIS helmet company. J. Fonseca is a consultant for ImPACT Applications, Inc. Dr Gioia is a test author for Psychological Assessment Resources, Inc and a consultant for the Washington Capitals and Baltimore Ravens. Dr Heyer is a consultant for the Carolina Panthers and is president of the NFL Physicians Society. Dr Hotz receives grant/research support from GE-NFL. Dr Iverson receives grant/research support from several organizations for mTBI. He is a salaried as an independent practitioner in neuropsychology, including giving expert testimony, for Neuro-Health Research and Rehabilitation, Inc, NeuroHealth LLC. He receives reimbursements from government, professional scientific bodies, and commercial organizations for discussing/presenting mTBI. Dr Manley receives grant/research support from NIH, DoD, and Abbott. Dr Maroon is employed by the University of Pittsburgh Medical Center, which has received grants from the National Football League and the Pittsburgh Steelers. He is an unpaid consultant for the Pittsburgh Steelers football club. He has been the team neurosurgeon for the Pittsburgh Steelers since 1981 and the medical director for World Wrestling Entertainment Corp since 2008 for the management of spine and brain-related injury. He also has served on the NFL's Head, Neck and Spine Committee since 2007 and is currently a consultant to the committee.; He is a founder and shareholder in ImPACT, and the World Wrestling Entertainment has partnered with ImPACT to provide concussion management. He has served as an expert witness in medical legal cases involving concussions. Dr McCrea receives grant/ research support from GE-NFL Head Health Challenge I. He is a GE Healthcare consultant and a member of the NFL Head, Neck and Spine Committee. Dr Mucha has received speaker's fees/honoraria from CE Speakers' Bureau-American Physical Therapy Association, Medbridge Education, ImPACT Applications, Inc, Brainsteps, Inova, and various healthcare and/or educational societies. Dr Podell receives grant/research support from GE-NFL Head Initiative and Brainscope. Dr Shetty receives grant/research support from GE-NFL, Chembio, and Abbott and is on the GE-NFL Medical Advisory Board. Dr Solomon receives DoD grant/research support; is a consultant for the University of Tennessee Athletics, Tennessee Tech Athletics, Tennessee Titans, and Nashville Predators; and is on the Advisory Board of ImPACT Applications, Inc. He has received speaking honoraria from the American Academy of Neurology, American Medical Society for Sports Medicine, and American Associations of Neurological Surgeons. Dr Zafonte receives grant/ research support from NIH, DoD, National Institute on Disability, Independent Living, and Rehabilitation Research, and NFL Players Association and is a consultant for Harvard football. He has relationships with Oakstone Publishing, Demos Publishing, Oxeia Biopharma, and Myomo Orthotic Devices.; The following authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. Dr Kontos receives research funding from the NIH, NCAA, DoD, and GE-NFL. Dr Bailes is chairman for the Pop Warner Football medical advisory board. Dr Bloom is a consultant for the Carolina Hurricanes. Dr Echemendia is a consultant to the NHL, Major League Soccer, the US Soccer Federation, and Princeton University. He is principal investigator or coprincipal investigator on grants funded by National Operating Committee on Standards for Athletic Equipment, American Medical Society for Sports Medicine, and the New Jersey Commission on Brain Injury Research. Dr Guskiewicz is a member of the NCAA Health and Safety Advisory Committee for Concussion, is a member of the NFL Head, Neck and Spine Committee, has given paid expert testimonials for TBI cases, and receives research funding from NIH, NCAA, NFL, USA Hockey, and National Athletic Trainers' Association. Dr Jordan is a paid consultant for NFL Benefits Association for Neurocognitive Disability Benefit. He receives compensation from Innovative CEUs for coaching their education program and is chief medical officer of the New York State Athletic Association. Dr McAllister receives research funding from the NCAA-DoD. Dr Pieroth is a consultant for the Chicago Bears, White Sox, and Blackhawks. Dr Sills is on the Medical Board of the Federation Equestrian Internationale; is an unpaid consultant for the US Equestrian Foundation, Southeastern Conference, and the Nashville Predators; and is an unaffiliated neurotrauma consultant for the NFL. Dr Yates is the team physician for the Pittsburgh Steelers and a member of the NFL Head, Neck and Spine Committee. Drs Cohen, Pombo, Thomas, and Valovich have no funding to disclose.	Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Andersen LL, 2011, SCAND J WORK ENV HEA, V37, P547, DOI 10.5271/sjweh.3170; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bandelow B, 2014, DTSCH ARZTEBL INT, V111, P473, DOI 10.3238/arztebl.2014.0473; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bloom J, SIDELINE EVALUATION; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown BE, 2014, BRAIN INJURY, V28, P838; Brown HE, 2013, SPORTS MED, V43, P195, DOI 10.1007/s40279-012-0015-8; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Buckley TA, 2016, J HEAD TRAUMA REHAB, V31, P233, DOI 10.1097/HTR.0000000000000165; Cacioppo JT, 2011, ANN NY ACAD SCI, V1231, P17, DOI 10.1111/j.1749-6632.2011.06028.x; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Casson IR, 2015, NEUROLOGY, V85, P110, DOI 10.1212/WNL.0000000000001700; Centers for Disease Control and Prevention, 2015, HEADS SCH SPORTS; Centers for Disease Control and Prevention, 2015, HEADS PROV; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colloca L, 2012, JAMA-J AM MED ASSOC, V307, P567, DOI 10.1001/jama.2012.115; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2014, J ATHL TRAINING, V49, P462, DOI 10.4085/1062-6059-49.2.03; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Custer A, 2016, J ATHL TRAINING, V51, P136, DOI 10.4085/1062-6050-51.2.12; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Dean PJ, 2015, BRAIN INJURY, P1; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DIAMOND MC, 1976, J NEUROBIOL, V7, P75, DOI 10.1002/neu.480070108; Dias M, 2014, ARQ NEURO-PSIQUIAT, V72, P851, DOI 10.1590/0004-282X20140148; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; DiFiori JP, 2010, CURR SPORT MED REP, V9, P35, DOI 10.1249/JSR.0b013e3181caba67; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Elbin R, 2015, PERSPECT NEUROPHYSIO, V25, P4, DOI DOI 10.1044/NNSLD25.1.4; Elbin RJ, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0320-7; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frasca Diana, 2013, Front Hum Neurosci, V7, P31, DOI 10.3389/fnhum.2013.00031; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gioia GA, 2016, J HEAD TRAUMA REHAB, V31, P397, DOI 10.1097/HTR.0000000000000205; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glang AE, 2015, J ADOLESCENT HEALTH, V56, P91, DOI 10.1016/j.jadohealth.2014.08.011; Graham R., 2014, SPORTS RELATED CONCU; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harris Poll, 2015, KNOWL AR AM CONC ASS; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Heyer GL, 2016, CEPHALALGIA, V36, P309, DOI 10.1177/0333102415590240; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kontos AP, 2016, BRIT J SPORT MED, V50, P139, DOI 10.1136/bjsports-2015-095564; Kontos Anthony P, 2015, J Trauma Acute Care Surg, V79, pS146, DOI 10.1097/TA.0000000000000667; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kostyun RO, 2015, AM J SPORT MED, V43, P633, DOI 10.1177/0363546514560727; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee Michael A, 2010, Conn Med, V74, P149; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lynall RC, 2013, J ATHL TRAINING, V48, P844, DOI 10.4085/1062-6050-48.6.04; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McAvoy K, 2009, CONCUSSION RMSMICF; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Morgan CD, 2015, CHILD NERV SYST, V31, P2305, DOI 10.1007/s00381-015-2916-y; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2015, BRAIN INJURY, V29, P58, DOI 10.3109/02699052.2014.964771; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; MURTHA S, 1990, BEHAV BRAIN RES, V39, P249, DOI 10.1016/0166-4328(90)90031-9; National Collegiate Athletic Association, 2013, CONC GUID; Nelson LD, 2016, CLIN J SPORT MED, V26, P120, DOI 10.1097/JSM.0000000000000207; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Poltavski DV, 2014, BRAIN INJURY, V28, P475, DOI 10.3109/02699052.2014.888771; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Quatman-Yates C, 2014, PHYSICIAN SPORTSMED, V42, P32, DOI 10.3810/psm.2014.09.2073; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Reddy CC, 2013, J HEAD TRAUMA REHAB, V28, P260, DOI 10.1097/HTR.0b013e318257fbc6; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Reynolds Erin, 2014, Neurosurgery, V75 Suppl 4, pS71, DOI 10.1227/NEU.0000000000000471; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Smith A, 2011, CLIN NEUROPSYCHOL, V25, P689, DOI 10.1080/13854046.2011.586561; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Stewart GW, 2012, INT J SPORTS PHYS TH, V7, P433; Sufrinko A, 2016, NEUROPSYCHOLOGY, V30, P484, DOI 10.1037/neu0000250; Thiagarajan P, 2014, BRAIN INJURY, V28, P930, DOI 10.3109/02699052.2014.888761; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Upchurch C, 2015, CLIN J SPORT MED, V25, P297, DOI 10.1097/JSM.0000000000000123; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Varkey E, 2011, CEPHALALGIA, V31, P1428, DOI 10.1177/0333102411419681; Wilkins SA, 2014, J NEUROSURG-PEDIATR, V13, P82, DOI 10.3171/2013.10.PEDS13241; Yang JZ, 2015, DEV NEUROPSYCHOL, V40, P18, DOI 10.1080/87565641.2014.973499; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zafonte R, 2011, JAMA-J AM MED ASSOC, V306, P79, DOI 10.1001/jama.2011.819; Zemek R., 2014, GUIDELINES DIAGNOSIN; Zemek R, 2011, GUIDELINES CONCUSSIO; Zemek R, 2013, GUIDELINES MILD TRAU; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413; Zuckerbraun NS, 2014, PEDIATRICS, V133, P635, DOI 10.1542/peds.2013-2600	175	82	83	0	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2016	79	6					912	929		10.1227/NEU.0000000000001447			18	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EI6OH	WOS:000392614700043	27741219	Green Accepted, Bronze			2021-06-18	
J	McGinn, MJ; Povlishock, JT				McGinn, Melissa J.; Povlishock, John T.			Pathophysiology of Traumatic Brain Injury	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Focal and diffuse damage; Diffuse axonal injury; Neuronal circuit disruption; Altered neuronal and vascular responses; Influence of comorbid factors	CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; EXCITATORY AMINO-ACIDS; DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; GLUTAMATE TRANSPORTER GLT-1; CENTRAL-NERVOUS-SYSTEM; SPREADING DEPOLARIZATIONS; INFLAMMATORY RESPONSE; CEREBROSPINAL-FLUID	This article provides a concise overview, at the structural and functional level, of those changes evoked by traumatic brain injury across the spectrum of the disease. Using data derived from animals and humans, the pathogenesis of focal versus diffuse brain damage is presented for consideration of its overall implications for morbidity. Emphasis is placed on contusion and its potential expansion in concert with diffuse changes primarily assessed at the axonal level. Concomitant involvement of neuroexcitation and its role in global and focal metabolic changes is considered. Lastly, the influence of premorbid factors including age, genetics, and socioeconomic background is discussed.	[McGinn, Melissa J.; Povlishock, John T.] Virginia Commonwealth Univ, Coll Med, Dept Anat & Neurobiol, Virginia Campus 1101 East Marshall St,Room 12-048, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Coll Med, Dept Anat & Neurobiol, Virginia Campus 1101 East Marshall St,Room 12-048, Richmond, VA 23298 USA.	john.povlishock@vcuhealth.org					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alessandri B, 1999, ACT NEUR S, V75, P21; Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Diamond ML, 2015, EPILEPSIA, V56, P1198, DOI 10.1111/epi.13044; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; FUJISAWA H, 1994, ACT NEUR S, V60, P193; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hinzman JM, 2015, EXP NEUROL, V267, P243, DOI 10.1016/j.expneurol.2015.03.014; Hinzman JM, 2016, J NEUROTRAUMA; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOVDA DA, 1990, ACT NEUR S, V51, P331; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1981, ANNU REV PHYSIOL, V43, P397, DOI 10.1146/annurev.ph.43.030181.002145; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Koura SS, 1998, ACT NEUR S, V71, P244; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Lobue C, 2016, J ALZHEIMERS DIS, V51, P727, DOI 10.3233/JAD-150895; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MATHEW P, 1994, ACTA NEUROCHIR, P428; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Povlishock J T, 1992, Hum Cell, V5, P345; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Rock KL, 2008, ANNU REV PATHOL-MECH, V3, P99, DOI 10.1146/annurev.pathmechdis.3.121806.151456; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sanchez Jose J, 2013, Acta Neurochir Suppl, V118, P223, DOI 10.1007/978-3-7091-1434-6_42; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Smith CJ, 2015, FRONT NEUROL, V6, DOI [10.3389/fneur.2015.00240, 10.3389/fneur.2015.00073]; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2004, BRAIN PATHOL, V14, P210, DOI 10.1111/j.1750-3639.2004.tb00055.x; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171	114	82	87	2	28	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					397	+		10.1016/j.nec.2016.06.002			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800004	27637392				2021-06-18	
J	Wang, W; Nguyen, LTT; Burlak, C; Chegini, F; Guo, F; Chataway, T; Ju, SL; Fisher, OS; Miller, DW; Datta, D; Wu, F; Wu, CX; Landeru, A; Wells, JA; Cookson, MR; Boxer, MB; Thomas, CJ; Gai, WP; Ringe, D; Petsko, GA; Hoang, QQ				Wang, Wei; Nguyen, Linh T. T.; Burlak, Christopher; Chegini, Fariba; Guo, Feng; Chataway, Tim; Ju, Shulin; Fisher, Oriana S.; Miller, David W.; Datta, Debajyoti; Wu, Fang; Wu, Chun-Xiang; Landeru, Anuradha; Wells, James A.; Cookson, Mark R.; Boxer, Matthew B.; Thomas, Craig J.; Gai, Wei Ping; Ringe, Dagmar; Petsko, Gregory A.; Hoang, Quyen Q.			Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein alpha-synuclein	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						synuclein; Parkinson's disease; caspase; inflammasome; aggregation	TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR-ALPHA; CEREBROSPINAL-FLUID; MOUSE MODEL; IN-VIVO; NEURODEGENERATION; INTERLEUKIN-1-BETA; NEUROINFLAMMATION; INFLAMMATION; PATHOGENESIS	The aggregation of alpha-synuclein (aSyn) leading to the formation of Lewy bodies is the defining pathological hallmark of Parkinson's disease (PD). Rare familial PD-associated mutations in aSyn render it aggregation-prone; however, PD patients carrying wild type (WT) aSyn also have aggregated aSyn in Lewy bodies. The mechanisms by which WT aSyn aggregates are unclear. Here, we report that inflammation can play a role in causing the aggregation of WT aSyn. We show that activation of the inflammasome with known stimuli results in the aggregation of aSyn in a neuronal cell model of PD. The insoluble aggregates are enriched with truncated aSyn as found in Lewy bodies of the PD brain. Inhibition of the inflammasome enzyme caspase-1 by chemical inhibition or genetic knockdown with shRNA abated aSyn truncation. In vitro characterization confirmed that caspase-1 directly cleaves aSyn, generating a highly aggregation-prone species. The truncation-induced aggregation of aSyn is toxic to neuronal culture, and inhibition of caspase-1 by shRNA or a specific chemical inhibitor improved the survival of a neuronal PD cell model. This study provides a molecular link for the role of inflammation in aSyn aggregation, and perhaps in the pathogenesis of sporadic PD as well.	[Wang, Wei; Nguyen, Linh T. T.; Wu, Chun-Xiang; Landeru, Anuradha; Hoang, Quyen Q.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Wang, Wei; Nguyen, Linh T. T.; Wu, Chun-Xiang; Landeru, Anuradha; Hoang, Quyen Q.] Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Burlak, Christopher] Univ Minnesota, Dept Surg, Schulze Diabet Inst, Box 242 UMHC, Minneapolis, MN 55455 USA; [Chegini, Fariba; Guo, Feng; Chataway, Tim; Gai, Wei Ping] Flinders Univ S Australia, Dept Human Physiol, Ctr Neurosci, Adelaide, SA 5001, Australia; [Ju, Shulin; Fisher, Oriana S.; Wu, Fang; Ringe, Dagmar; Petsko, Gregory A.] Brandeis Univ, Dept Chem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; [Ju, Shulin; Fisher, Oriana S.; Wu, Fang; Ringe, Dagmar; Petsko, Gregory A.] Brandeis Univ, Dept Biochem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; [Miller, David W.; Cookson, Mark R.] NIH, Neurogenet Lab, Bldg 10, Bethesda, MD 20892 USA; [Datta, Debajyoti; Wells, James A.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; [Wells, James A.] Univ Calif San Francisco, Dept Cellular & Mol Physiol, San Francisco, CA 94143 USA; [Boxer, Matthew B.; Thomas, Craig J.] NIH, Natl Ctr Adv Translat Sci, Chem Genom Ctr, Bldg 10, Bethesda, MD 20892 USA; [Ringe, Dagmar; Petsko, Gregory A.] Harvard Med Sch, Dept Neurol, Cambridge, MA 02139 USA; [Ringe, Dagmar; Petsko, Gregory A.] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02116 USA; [Hoang, Quyen Q.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; [Ju, Shulin] Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA; [Fisher, Oriana S.] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA; [Wu, Fang; Petsko, Gregory A.] Univ Calif Berkeley, Dept Mol & Cell Biol, Calif Inst Quantitat Biol, 229 Stanley Hall, Berkeley, CA 94720 USA; [Petsko, Gregory A.; Hoang, Quyen Q.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA	Hoang, QQ (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Hoang, QQ (corresponding author), Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA.; Petsko, GA (corresponding author), Brandeis Univ, Dept Chem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.; Petsko, GA (corresponding author), Brandeis Univ, Dept Biochem, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.; Petsko, GA (corresponding author), Harvard Med Sch, Dept Neurol, Cambridge, MA 02139 USA.; Petsko, GA (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02116 USA.; Hoang, QQ (corresponding author), Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA.; Petsko, GA (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Calif Inst Quantitat Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.; Petsko, GA; Hoang, QQ (corresponding author), Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA.	gpetsko@med.cornell.edu; qqhoang@iu.edu	Petsko, Gregory/AAO-7962-2020; Wells, Jim A/O-9854-2016	Thomas, Craig/0000-0001-9386-9001; Chataway, Tim/0000-0003-0254-8099; Fisher, Oriana/0000-0003-3215-0831	Community Fast Track grant from Michael J. Fox Foundation; National Institutes of Health GrantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21NS079881-01, 5R01GM111639]; Indiana University School of Medicine Biomedical Research Grant; Indiana University-Purdue University Indianapolis Research Support Funds Grant; Fidelity Biosciences Research Initiative; Ellison Medical FoundationLawrence Ellison Foundation; McKnight Endowment for Neuroscience; Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Intramural Research Program of the National Human Genome Research Institute, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI); Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM111639, R01GM115844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS079881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000939] Funding Source: NIH RePORTER	We thank S. Lindquist for the yeast expression vectors of aSyn, and Z. Y. Z. Zhang and L. Chen for their generous support and access to the Chemical Genomics Core Facility at Indiana University. Q.Q.H., D.R., and G.A.P. were supported through a Community Fast Track grant from the Michael J. Fox Foundation. Q.Q.H. was also supported by National Institutes of Health Grants 1R21NS079881-01 and 5R01GM111639, an Indiana University School of Medicine Biomedical Research Grant, and an Indiana University-Purdue University Indianapolis Research Support Funds Grant. D.R. and G.A.P. also acknowledge support from the Fidelity Biosciences Research Initiative (with much useful discussion from Dr. S. Weninger) and early support from the Ellison Medical Foundation and the McKnight Endowment for Neuroscience. M.B.B. and C.J.T. acknowledge support from the Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research and the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. This research was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health.	Arai H, 2006, HISTOL HISTOPATHOL, V21, P673, DOI 10.14670/HH-21.673; Bartels AL, 2007, MOVEMENT DISORD, V22, P1852, DOI 10.1002/mds.21552; Bassil F, 2016, P NATL ACAD SCI USA, V113, P9593, DOI 10.1073/pnas.1609291113; Ben-Shlomo Y, 1997, BAILLIERE CLIN NEUR, V6, P55; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; Boxer MB, 2010, CHEMMEDCHEM, V5, P730, DOI 10.1002/cmdc.200900531; Cullen V, 2011, ANN NEUROL, V69, P940, DOI 10.1002/ana.22400; Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Furuya T, 2004, J NEUROSCI, V24, P1865, DOI 10.1523/JNEUROSCI.3309-03.2004; Gao HM, 2011, ENVIRON HEALTH PERSP, V119, P807, DOI 10.1289/ehp.1003013; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Harris MA, 2012, MOVEMENT DISORD, V27, P1111, DOI 10.1002/mds.25077; Henry J, 2010, PARKINSONISM RELAT D, V16, P566, DOI 10.1016/j.parkreldis.2010.06.012; Iwata A, 2003, HUM MOL GENET, V12, P2625, DOI 10.1093/hmg/ddg283; Jang HM, 2009, P NATL ACAD SCI USA, V106, P14063, DOI 10.1073/pnas.0900096106; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lewis KA, 2010, AM J PATHOL, V177, P3037, DOI 10.2353/ajpath.2010.100552; Lewis KA, 2010, J BIOENERG BIOMEMBR, V42, P85, DOI 10.1007/s10863-009-9258-y; Li WX, 2005, P NATL ACAD SCI USA, V102, P2162, DOI 10.1073/pnas.0406976102; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liu B, 2003, ENVIRON HEALTH PERSP, V111, P1065, DOI 10.1289/ehp.6361; Liu CW, 2005, J BIOL CHEM, V280, P22670, DOI 10.1074/jbc.M501508200; MAURIZI CP, 1985, MED HYPOTHESES, V16, P1, DOI 10.1016/0306-9877(85)90034-9; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; MCGEER PL, 1988, ACTA NEUROPATHOL, V76, P550, DOI 10.1007/BF00689592; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Michell AW, 2007, CELL TRANSPLANT, V16, P461, DOI 10.3727/000000007783464911; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Oh M, 2014, P NATL ACAD SCI USA, V111, P11007, DOI 10.1073/pnas.1320556111; Oueslati A, 2010, PROG BRAIN RES, V183, P115, DOI 10.1016/S0079-6123(10)83007-9; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Periquet M, 2007, J NEUROSCI, V27, P3338, DOI 10.1523/JNEUROSCI.0285-07.2007; Prasad K, 2012, BRAIN PATHOL, V22, P811, DOI 10.1111/j.1750-3639.2012.00597.x; RAIL D, 1981, J NEUROL NEUROSUR PS, V44, P670, DOI 10.1136/jnnp.44.8.670; Scheer JM, 2005, PROTEIN EXPRES PURIF, V41, P148, DOI 10.1016/j.pep.2005.01.008; Schwartz M, 2006, J NEUROIMMUNE PHARM, V1, P4, DOI 10.1007/s11481-005-9010-2; Sevlever D, 2008, BIOCHEMISTRY-US, V47, P9678, DOI 10.1021/bi800699v; Sung JY, 2005, J BIOL CHEM, V280, P25216, DOI 10.1074/jbc.M503341200; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Ulusoy A, 2010, EUR J NEUROSCI, V32, P409, DOI 10.1111/j.1460-9568.2010.07284.x; Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009; Villoslada P, 2008, CLIN IMMUNOL, V128, P294, DOI 10.1016/j.clim.2008.04.003; Wakamatsu M, 2008, NEUROBIOL AGING, V29, P574, DOI 10.1016/j.neurobiolaging.2006.11.017; Wang W, 2011, P NATL ACAD SCI USA, V108, P17797, DOI 10.1073/pnas.1113260108	50	82	87	1	23	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 23	2016	113	34					9587	9592		10.1073/pnas.1610099113			6	Multidisciplinary Sciences	Science & Technology - Other Topics	DT9ZK	WOS:000381860800060	27482083	Green Published, Bronze			2021-06-18	
J	Nielson, JL; Paquette, J; Liu, AW; Guandique, CF; Tovar, CA; Inoue, T; Irvine, KA; Gensel, JC; Kloke, J; Petrossian, TC; Lum, PY; Carlsson, GE; Manley, GT; Young, W; Beattie, MS; Bresnahan, JC; Ferguson, AR				Nielson, Jessica L.; Paquette, Jesse; Liu, Aiwen W.; Guandique, Cristian F.; Tovar, C. Amy; Inoue, Tomoo; Irvine, Karen-Amanda; Gensel, John C.; Kloke, Jennifer; Petrossian, Tanya C.; Lum, Pek Y.; Carlsson, Gunnar E.; Manley, Geoffrey T.; Young, Wise; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.			Topological data analysis for discovery in preclinical spinal cord injury and traumatic brain injury	NATURE COMMUNICATIONS			English	Article							BIG DATA; RATING-SCALE; CELL-DEATH; RECOVERY; CONSEQUENCES; TRANSLATION; MECHANISMS; MANAGEMENT; LOCOMOTOR; SEVERITY	Data-driven discovery in complex neurological disorders has potential to extract meaningful syndromic knowledge from large, heterogeneous data sets to enhance potential for precision medicine. Here we describe the application of topological data analysis (TDA) for data-driven discovery in preclinical traumatic brain injury (TBI) and spinal cord injury (SCI) data sets mined from the Visualized Syndromic Information and Outcomes for Neurotrauma-SCI (VISION-SCI) repository. Through direct visualization of inter-related histopathological, functional and health outcomes, TDA detected novel patterns across the syndromic network, uncovering interactions between SCI and co-occurring TBI, as well as detrimental drug effects in unpublished multicentre preclinical drug trial data in SCI. TDA also revealed that perioperative hypertension predicted long-term recovery better than any tested drug after thoracic SCI in rats. TDA-based data-driven discovery has great potential application for decision-support for basic research and clinical problems such as outcome assessment, neurocritical care, treatment planning and rapid, precision-diagnosis.	[Nielson, Jessica L.; Liu, Aiwen W.; Guandique, Cristian F.; Manley, Geoffrey T.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Ferguson, Adam R.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurosurg, San Francisco, CA 94143 USA; [Paquette, Jesse] Tagb Io, San Francisco, CA 94131 USA; [Tovar, C. Amy] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Inoue, Tomoo] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 9800856, Japan; [Irvine, Karen-Amanda] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA 94110 USA; [Gensel, John C.] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Dept Physiol, Lexington, KY 40536 USA; [Kloke, Jennifer; Carlsson, Gunnar E.] Ayasdi Inc, Menlo Pk, CA 94025 USA; [Petrossian, Tanya C.] GenePeeks Inc, New York, NY 10001 USA; [Lum, Pek Y.] Capella Biosci, Palo Alto, CA 94301 USA; [Carlsson, Gunnar E.] Stanford Univ, Dept Math, Stanford, CA 94305 USA; [Young, Wise] Rutgers State Univ, Dept Cell Biol & Neurosci, WM Keck Ctr Collaborat Neurosci, Piscataway, NJ 08854 USA; [Ferguson, Adam R.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Neurosurg, San Francisco, CA 94110 USA	Ferguson, AR (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94143 USA.	adam.ferguson@ucsf.edu		Nielson, Jessica/0000-0002-3677-3959; Ferguson, Adam/0000-0001-7102-1608; Petrossian, Tanya/0000-0002-1205-9144	Craig H. Neilsen Foundation [224308]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS067092, NS069537, NS038079, NS031193, AG032518, NS079030, NS032000]; NYSCoRE [CO19772]; Department of Defense (DoD)United States Department of Defense [W81XWH-10-1-0910, W81XWH-13-1-0297]; Wings for Life Foundation [WFLUS008/12, WFLUS006/14]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069537, R01NS031193, R01NS032000, R01NS067092, F32NS079030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG032518] Funding Source: NIH RePORTER	This work was funded by the Craig H. Neilsen Foundation Grant 224308, the National Institutes of Health (NIH) NS067092 (A.R.F.), NS069537 (A.R.F), NS038079 (J.C.B. and M.S.B.), NS031193 and AG032518 (M.S.B. and J.C.B.), NS079030 (J.L.N.), NS032000 (W.Y.; M.S.B. site PI, multicentre study); NYSCoRE CO19772 (M.S.B. and J.C.B.), the Department of Defense (DoD) grants W81XWH-10-1-0910 (M.S.B.) and W81XWH-13-1-0297 (M.S.B.), and Wings for Life Foundation grants WFLUS008/12 and WFLUS006/14 (A.R.F.). We thank J.R. Huie and J. Haefeli for useful comments, and A. Lin and S. Visuthikraisee for technical support.	Akil H, 2011, SCIENCE, V331, P708, DOI 10.1126/science.1199305; Bacchetti P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001628; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Burke DA, 2013, J NEUROTRAUM, V30, P797, DOI 10.1089/neu.2012.2704; Carlsson G, 2009, B AM MATH SOC, V46, P255, DOI 10.1090/S0273-0979-09-01249-X; Celi LA, 2013, AM J RESP CRIT CARE, V187, P1157, DOI 10.1164/rccm.201212-2311ED; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen MJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8864; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Fasy B. T., 2014, TDA STAT TOOLS TOPOL; Ferguson AR, 2008, J NEUROSCI, V28, P11391, DOI 10.1523/JNEUROSCI.3708-08.2008; Ferguson AR, 2014, NAT NEUROSCI, V17, P1442, DOI 10.1038/nn.3838; Ferguson AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059712; Ferguson AR, 2004, J NEUROTRAUM, V21, P1601, DOI 10.1089/0897715042441747; Filli L, 2012, ANN NEUROL, V72, P491, DOI 10.1002/ana.23630; Fox P, 2011, SCIENCE, V331, P705, DOI 10.1126/science.1197654; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Gorelick PB, 2002, LANCET NEUROL, V1, P149, DOI 10.1016/S1474-4422(02)00070-4; Gough Nancy R, 2011, Sci Signal, V4, peg2, DOI 10.1126/scisignal.2001871; GUHA A, 1989, STROKE, V20, P372, DOI 10.1161/01.STR.20.3.372; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Hawryluk G, 2015, J NEUROTRAUM, V32, P1958, DOI 10.1089/neu.2014.3778; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Hou SP, 2014, COMPR PHYSIOL, V4, P1419, DOI 10.1002/cphy.c130045; Inoue T, 2014, J NEUROTRAUM, V31, P284, DOI 10.1089/neu.2013.3061; Inoue T, 2013, EXP NEUROL, V248, P136, DOI 10.1016/j.expneurol.2013.06.006; Irvine K.-A., 2010, JOVE-J VIS EXP, DOI [10.3791/2246, DOI 10.3791/2246]; Irvine KA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00116; Kong CY, 2013, SPINAL CORD, V51, P466, DOI 10.1038/sc.2013.32; Korthius, 2010, CAPILLARY FLUID EXCH; Larson EB, 2013, JAMA-J AM MED ASSOC, V309, P2443, DOI 10.1001/jama.2013.5914; Lee H, 2012, IEEE T MED IMAGING, V31, P2267, DOI 10.1109/TMI.2012.2219590; Lum PY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01236; MACCALLUM RC, 1992, PSYCHOL BULL, V111, P490, DOI 10.1037/0033-2909.111.3.490; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Martinez M, 2009, J NEUROTRAUM, V26, P1043, DOI 10.1089/neu.2008.0717; Nicolau M, 2011, P NATL ACAD SCI USA, V108, P7265, DOI 10.1073/pnas.1102826108; Nielson JL, 2014, J NEUROTRAUM, V31, P1789, DOI 10.1089/neu.2014.3399; Nout YS, 2012, J NEUROTRAUM, V29, P990, DOI 10.1089/neu.2011.1845; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Ramer LM, 2014, LANCET NEUROL, V13, P1241, DOI 10.1016/S1474-4422(14)70144-9; Rosenzweig ES, 2010, NAT NEUROSCI, V13, P1505, DOI 10.1038/nn.2691; Sarikonda G, 2014, J AUTOIMMUN, V50, P77, DOI 10.1016/j.jaut.2013.12.003; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Siddiqui AM, 2015, PROG BRAIN RES, V218, P15, DOI 10.1016/bs.pbr.2014.12.007; Singh G.M., 2007, EUR S POINT BAS GRAP; Singh G, 2008, J VISION, V8, DOI 10.1167/8.8.11; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Yao Y, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3103496; Young W, 2002, PROG BRAIN RES, V137, P231	55	82	83	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	OCT	2015	6								8581	10.1038/ncomms9581			12	Multidisciplinary Sciences	Science & Technology - Other Topics	CW4AD	WOS:000364932600028	26466022	DOAJ Gold, Green Published			2021-06-18	
J	Takeda, YS; Xu, QB				Takeda, Yuji S.; Xu, Qiaobing			Neuronal Differentiation of Human Mesenchymal Stem Cells Using Exosomes Derived from Differentiating Neuronal Cells	PLOS ONE			English	Article							SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; SCIATIC-NERVE INJURY; BONE-MARROW; MICRORNA EXPRESSION; MEDIATED TRANSFER; PROGENITOR CELLS; STROMAL CELLS; PROLIFERATION; REGENERATION	Exosomes deliver functional proteins and genetic materials to neighboring cells, and have potential applications for tissue regeneration. One possible mechanism of exosome-promoted tissue regeneration is through the delivery of microRNA (miRNA). In this study, we hypothesized that exosomes derived from neuronal progenitor cells contain miRNAs that promote neuronal differentiation. We treated mesenchymal stem cells (MSCs) daily with exosomes derived from PC12 cells, a neuronal cell line, for 1 week. After the treatment with PC12-derived exosomes, MSCs developed neuron-like morphology, and gene and protein expressions of neuronal markers were upregulated. Microarray analysis showed that the expression of miR-125b, which is known to play a role in neuronal differentiation of stem cells, was much higher in PC12-derived exosomes than in exosomes from B16-F10 melanoma cells. These results suggest that the delivery of miRNAs contained in PC12-derived exosomes is a possible mechanism explaining the neuronal differentiation of MSC.	[Takeda, Yuji S.; Xu, Qiaobing] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA	Xu, QB (corresponding author), Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.	qiaobing.xu@tufts.edu			Pew Charitable Trusts	QX received a grant from The Pew Charitable Trusts (http://www.pewtrusts.org/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberti KA, 2014, BIOMATERIALS, V35, P3551, DOI 10.1016/j.biomaterials.2013.12.082; Aldrich BT, 2009, NEUROSCIENCE, V164, P711, DOI 10.1016/j.neuroscience.2009.08.033; Lopez-Verrilli MA, 2013, GLIA, V61, P1795, DOI 10.1002/glia.22558; Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01-0656fje; Bell JHA, 2012, TISSUE ENG PART B-RE, V18, P116, DOI [10.1089/ten.teb.2011.0498, 10.1089/ten.TEB.2011.0498]; Cantaluppi V, 2012, CELL TRANSPLANT, V21, P1305, DOI 10.3727/096368911X627534; Chen XP, 2014, CANCER LETT, V353, P201, DOI 10.1016/j.canlet.2014.07.026; Cvjetkovic A, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.23111; Das KP, 2004, NEUROTOXICOL TERATOL, V26, P397, DOI 10.1016/j.ntt.2004.02.006; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Harrop JS, 2012, J NEUROSURG-SPINE, V17, P230, DOI 10.3171/2012.5.AOSPINE12115; Kennea NL, 2009, CELL CYCLE, V8, P1069, DOI 10.4161/cc.8.7.8121; Kim BM, 2012, BIOCHEM BIOPH RES CO, V426, P183, DOI 10.1016/j.bbrc.2012.08.058; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Kim SY, 2012, BIOCHEM BIOPH RES CO, V429, P173, DOI 10.1016/j.bbrc.2012.10.117; Krampera M, 2007, BONE, V40, P382, DOI 10.1016/j.bone.2006.09.006; Kumar AA, 2009, EXP CLIN TRANSPLANT, V7, P241; Lai CPK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00228; Lattanzi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067411; Le MTN, 2009, MOL CELL BIOL, V29, P5290, DOI 10.1128/MCB.01694-08; Li WG, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-55; Liu DZ, 2012, GENE, V495, P120, DOI 10.1016/j.gene.2011.12.041; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loohuis NFMO, 2012, CELL MOL LIFE SCI, V69, P89, DOI 10.1007/s00018-011-0788-1; Prabhakaran MP, 2009, BIOMATERIALS, V30, P4996, DOI 10.1016/j.biomaterials.2009.05.057; Rau CS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-181; Rehfeld F, 2015, CELL TISSUE RES, V359, P145, DOI 10.1007/s00441-014-1872-2; Saba R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003652; Scuteri A, 2011, CURR STEM CELL RES T, V6, P82, DOI 10.2174/157488811795495486; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sharma A, 2012, CELL TRANSPLANT, V21, pS79, DOI 10.3727/096368912X633798; Shelke GV, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24783; Straley KS, 2010, J NEUROTRAUM, V27, P1, DOI 10.1089/neu.2009.0948; Strickland IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023423; Sykova E, 2006, CELL MOL NEUROBIOL, V26, P1113, DOI 10.1007/s10571-006-9007-2; Tabesh H, 2009, NEUROCHEM INT, V54, P73, DOI 10.1016/j.neuint.2008.11.002; Takeda YS, 2015, NEURAL REGEN RES, V10, P689, DOI 10.4103/1673-5374.156946; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang R, 2012, CELL PHYSIOL BIOCHEM, V29, P381, DOI 10.1159/000338493; Willerth SM, 2007, ADV DRUG DELIVER REV, V59, P325, DOI 10.1016/j.addr.2007.03.014; Williams AH, 2009, SCIENCE, V326, P1549, DOI 10.1126/science.1181046; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Wu D, 2011, NEUROSCIENCE, V190, P386, DOI 10.1016/j.neuroscience.2011.06.017; Wu R, 2013, CELL BIOL INT, V37, P812, DOI 10.1002/cbin.10103; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xu JA, 2011, NUCLEIC ACIDS RES, V39, P825, DOI 10.1093/nar/gkq832; Xu WY, 2013, INT J ONCOL, V42, P757, DOI 10.3892/ijo.2012.1742; Yau WWY, 2012, BIOMATERIALS, V33, P2608, DOI 10.1016/j.biomaterials.2011.12.021; Yu B, 2012, NUCLEIC ACIDS RES, V40, P10356, DOI 10.1093/nar/gks750; Yu B, 2012, J CELL SCI, V125, P2675, DOI 10.1242/jcs.098996; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhou SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044768; Zhou SL, 2011, NEUROSCI LETT, V494, P89, DOI 10.1016/j.neulet.2011.02.064	56	82	90	3	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2015	10	8							e0135111	10.1371/journal.pone.0135111			15	Multidisciplinary Sciences	Science & Technology - Other Topics	CO3MQ	WOS:000359062300101	26248331	DOAJ Gold, Green Published			2021-06-18	
J	Hennessy, E; Griffin, EW; Cunningham, C				Hennessy, Edel; Griffin, Eadaoin W.; Cunningham, Colm			Astrocytes Are Primed by Chronic Neurodegeneration to Produce Exaggerated Chemokine and Cell Infiltration Responses to Acute Stimulation with the Cytokines IL-1 beta and TNF-alpha	JOURNAL OF NEUROSCIENCE			English	Article						astrocyte; chemokine; cytokine; microglia; neurodegeneration; neuroinflammation	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; SPINAL-CORD; INFLAMMATORY RESPONSE; BRAIN; EXPRESSION; INDUCTION; MODEL; RECRUITMENT; ACTIVATION	Microgliosis and astrogliosis are standard pathological features of neurodegenerative disease. Microglia are primed by chronic neurodegeneration such that toll-like receptor agonists, such as LPS, drive exaggerated cytokine responses on this background. However, sterile inflammatory insults are more common than direct CNS infection in the degenerating brain and these insults drive robust IL-1 beta and TNF-alpha responses. It is unclear whether these pro-inflammatory cytokines can directly induce exaggerated responses in the degenerating brain. We hypothesized that glial cells in the hippocampus of animals with chronic neurodegenerative disease (ME7 prion disease) would display exaggerated responses to central cytokine challenges. TNF-alpha or IL-1 beta were administered intrahippocampally to ME7-inoculated mice and normal brain homogenate-injected (NBH) controls. Both IL-1 beta and TNF-alpha produced much more robust IL-1 beta synthesis in ME7 than in NBH animals and this occurred exclusively in microglia. However, there was strong nuclear localization of the NF kappa B subunit p65 in the astrocyte population, associated with marked astrocytic synthesis of the chemokines CXCL1 and CCL2 in response to both cytokine challenges in ME7 animals. Conversely, very limited expression of these chemokines was apparent in NBH animals similarly challenged. Thus, astrocytes are primed in the degenerating brain to produce exaggerated chemokine responses to acute stimulation with pro-inflammatory cytokines. Furthermore, this results in markedly increased neutrophil, T-cell, and monocyte infiltration in the diseased brain. These data have significant implications for acute sterile inflammatory insults such as stroke and traumatic brain injury occurring on a background of aging or neurodegeneration.	[Hennessy, Edel; Griffin, Eadaoin W.; Cunningham, Colm] Univ Dublin Trinity Coll, Sch Biochem & Immunol, Inst Neurosci, Dublin 2, Ireland	Cunningham, C (corresponding author), Univ Dublin Trinity Coll, Sch Biochem & Immunol, Inst Neurosci, Dublin 2, Ireland.	colm.cunningham@tcd.ie	Hennessy, Edel/H-4438-2019; Cunningham, Colm/A-1743-2010	Hennessy, Edel/0000-0003-4024-0802; Cunningham, Colm/0000-0003-1423-5209; Griffin, Eadaoin/0000-0002-2017-453X	Wellcome TrustWellcome TrustEuropean Commission; Trinity College Dublin Research Studentship	This work was supported by The Wellcome Trust and E.H. was supported by a Trinity College Dublin Research Studentship. We acknowledge the gift of the Mc21 anti CCR2 antibody from Steffen Jung, Weizmann Institute of Science, Israel, and the MBS-1 neutrophil antibody from Daniel Anthony, Oxford, UK. We thank Hugh Perry and Diego Gomez-Nicola for helpful discussions and Gavin MacManus for technical assistance with confocal microscopy.	An Y, 2011, J INFLAMM RES, V4, P11, DOI 10.2147/JIR.S15357; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; Blond D, 2002, BRAIN RES, V958, P89, DOI 10.1016/S0006-8993(02)03473-X; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brambilla R, 2014, GLIA, V62, P452, DOI 10.1002/glia.22616; Bruhl H, 2007, ARTHRITIS RHEUM, V56, P2975, DOI 10.1002/art.22854; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Chen J, 2008, BRAIN BEHAV IMMUN, V22, P301, DOI 10.1016/j.bbi.2007.08.014; Choi K, 2011, J NEUROCHEM, V116, P438, DOI 10.1111/j.1471-4159.2010.07124.x; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005; Fouillet A, 2012, BRAIN RES, V1437, P115, DOI 10.1016/j.brainres.2011.11.049; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Gomez-Nicola D, 2013, J NEUROSCI, V33, P2481, DOI 10.1523/JNEUROSCI.4440-12.2013; Henn A, 2011, J IMMUNOL, V186, P3237, DOI 10.4049/jimmunol.1002787; Hughes MM, 2010, GLIA, V58, P2017, DOI 10.1002/glia.21070; Jing T, 2010, BIOCHEM BIOPH RES CO, V402, P241, DOI 10.1016/j.bbrc.2010.10.006; Khorooshi R, 2008, J IMMUNOL, V181, P7284, DOI 10.4049/jimmunol.181.10.7284; Kim JM, 2005, CLIN EXP IMMUNOL, V140, P450, DOI 10.1111/j.1365-2249.2005.02804.x; Lee YH, 2012, INT IMMUNOPHARMACOL, V12, P547, DOI 10.1016/j.intimp.2012.01.011; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; McKimmie CS, 2010, BIOCHEM BIOPH RES CO, V394, P1006, DOI 10.1016/j.bbrc.2010.03.111; Moreno M, 2014, J NEUROSCI, V34, P8175, DOI 10.1523/JNEUROSCI.1137-14.2014; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Murray C, 2012, NEUROBIOL AGING, V33, P603, DOI 10.1016/j.neurobiolaging.2010.04.002; PACE JL, 1983, J IMMUNOL, V130, P2011; Godoy MCP, 2008, BRAIN, V131, P1880, DOI 10.1093/brain/awn101; Ritter L, 2011, MICROCIRCULATION, V18, P552, DOI 10.1111/j.1549-8719.2011.00115.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Sly LM, 2001, BRAIN RES BULL, V56, P581, DOI 10.1016/S0361-9230(01)00730-4; Stamatovic SM, 2006, J BIOL CHEM, V281, P8379, DOI 10.1074/jbc.M513122200; Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081; Thornton P, 2010, BLOOD, V115, P3632, DOI 10.1182/blood-2009-11-252643; Wang YF, 2007, J NEUROCHEM, V103, P814, DOI 10.1111/j.1471-4159.2007.04803.x; Yao Y, 2011, J CELL SCI, V124, P1486, DOI 10.1242/jcs.082834; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang ZJ, 2013, PAIN, V154, P2185, DOI 10.1016/j.pain.2013.07.002	41	82	83	1	14	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 3	2015	35	22					8411	8422		10.1523/JNEUROSCI.2745-14.2015			12	Neurosciences	Neurosciences & Neurology	CN2JV	WOS:000358247900005	26041910	Other Gold, Green Published			2021-06-18	
J	Xuan, WJ; Agrawal, T; Huang, LY; Gupta, GK; Hamblin, MR				Xuan, Weijun; Agrawal, Tanupriya; Huang, Liyi; Gupta, Gaurav K.; Hamblin, Michael R.			Low-level laser therapy for traumatic brain injury in mice increases brain derived neurotrophic factor (BDNF) and synaptogenesis	JOURNAL OF BIOPHOTONICS			English	Article						traumatic brain injury; transcranial low level light therapy; synaptogenesis; neurogenesis; BDNF; Synapsin-1	LIGHT THERAPY; INDUCED NEUROGENESIS; ISCHEMIC-STROKE; TERM; EXERCISE; MODERATE	Transcranial low-level laser (light) therapy (LLLT) is a new non-invasive approach to treating a range of brain disorders including traumatic brain injury (TBI). We (and others) have shown that applying near-infrared light to the head of animals that have suffered TBI produces improvement in neurological functioning, lessens the size of the brain lesion, reduces neuroinflammation, and stimulates the formation of new neurons. In the present study we used a controlled cortical impact TBI in mice and treated the mice either once (4 h post-TBI, 1-laser), or three daily applications (3-laser) with 810 nm CW laser 36 J/cm(2) at 50 mW/cm(2). Similar to previous studies, the neurological severity score improved in laser-treated mice compared to untreated TBI mice at day 14 and continued to further improve at days 21 and 28 with 3-laser being better than 1-laser. Mice were sacrificed at days 7 and 28 and brains removed for immunofluorescence analysis. Brain-derived neurotrophic factor (BDNF) was significantly up-regulated by laser treatment in the dentate gyrus of the hippocampus (DG) and the subventricular zone (SVZ) but not in the perilesional cortex (lesion) at day 7 but not at day 28. Synapsin-1 (a marker for synaptogenesis, the formation of new connections between existing neurons) was significantly upregulated in lesion and SVZ but not DG, at 28 days but not 7 days. The data suggest that the benefit of LLLT to the brain is partly mediated by stimulation of BDNF production, which may in turn encourage synaptogenesis. Moreover the pleiotropic benefits of BDNF in the brain suggest LLLT may have wider applications to neurodegenerative and psychiatric disorders.	[Xuan, Weijun] Guangxi Univ Chinese Med, Affiliated Coll & Hosp 1, Dept Otolaryngol, Nanning, Peoples R China; [Xuan, Weijun; Agrawal, Tanupriya; Huang, Liyi; Gupta, Gaurav K.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Xuan, Weijun; Agrawal, Tanupriya; Huang, Liyi; Gupta, Gaurav K.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning 530021, Peoples R China; [Gupta, Gaurav K.] Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA 02111 USA; [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605; Agrawal, Tanupriya/0000-0002-7649-2828	US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9550-13-1-0068]; US Army Medical Research Acquisition Activity grant [W81XWH-09-1-0514]; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0067]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work was supported by US NIH grant R01AI050875, by Air Force Office of Scientific Research grant FA9550-13-1-0068, by US Army Medical Research Acquisition Activity grant W81XWH-09-1-0514 and by US Army Medical Research and Materiel Command grant W81XWH-13-2-0067.	Gomes LEA, 2012, PHOTOMED LASER SURG, V30, P642, DOI 10.1089/pho.2012.3242; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Ambrogini P, 2013, BRAIN RES, V1534, P1, DOI 10.1016/j.brainres.2013.08.023; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Avci P, 2014, LASER SURG MED, V46, P144, DOI 10.1002/lsm.22170; Avci P, 2013, LASER SURG MED, V45, P349, DOI 10.1002/lsm.22153; Barker JM, 2011, EUR J NEUROSCI, V34, P963, DOI 10.1111/j.1460-9568.2011.07823.x; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen A, 2013, BIOMED REP, V1, P167, DOI 10.3892/br.2012.48; Ferreira AFB, 2011, BRAIN RES, V1425, P111, DOI 10.1016/j.brainres.2011.10.004; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; Huang YY, 2014, J BIOPHOTONICS, V7, P656, DOI 10.1002/jbio.201300125; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huisa BN, 2013, INT J STROKE, V8, P315, DOI 10.1111/j.1747-4949.2011.00754.x; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kokaia Z, 2006, CEREB CORTEX, V16, pI162, DOI 10.1093/cercor/bhj174; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Leeds PR, 2014, ACS CHEM NEUROSCI, V5, P422, DOI 10.1021/cn500040g; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Meng CB, 2013, J NEUROSCI, V33, P13505, DOI 10.1523/JNEUROSCI.0918-13.2013; Migliario M, 2014, LASER MED SCI, V29, P1463, DOI 10.1007/s10103-014-1556-x; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Vaynman SS, 2006, BRAIN RES, V1070, P124, DOI 10.1016/j.brainres.2005.11.062; Waterhouse EG, 2009, MOL CELL NEUROSCI, V42, P81, DOI 10.1016/j.mcn.2009.06.009; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zivin J. A., 2012, INT J STROKE, DOI [10.1111/j.1747-4949, DOI 10.1111/J.1747-4949]	41	82	85	0	20	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1864-063X	1864-0648		J BIOPHOTONICS	J. Biophotonics	JUN	2015	8	6					502	511		10.1002/jbio.201400069			10	Biochemical Research Methods; Biophysics; Optics	Biochemistry & Molecular Biology; Biophysics; Optics	CK2VH	WOS:000356071500006	25196192	Green Accepted			2021-06-18	
J	Failli, V; Kopp, MA; Gericke, C; Martus, P; Klingbeil, S; Brommer, B; Laginha, I; Chen, YY; DeVivo, MJ; Dirnagl, U; Schwab, JM				Failli, Vieri; Kopp, Marcel A.; Gericke, Christine; Martus, Peter; Klingbeil, Susann; Brommer, Benedikt; Laginha, Ines; Chen, Yuying; DeVivo, Michael J.; Dirnagl, Ulrich; Schwab, Jan M.			Functional neurological recovery after spinal cord injury is impaired in patients with infections	BRAIN			English	Article						intrinsic/endogenous recovery potential; poor outcome; neurological recovery	CLINICAL-TRIALS; NEURODEGENERATIVE DISEASE; SYSTEMIC INFLAMMATION; EXPERIMENTAL STROKE; ISCHEMIC-STROKE; ICCP PANEL; BRAIN; MOTOR; REHABILITATION; PLASTICITY	Infections are a common threat to patients after spinal cord injury. Furthermore, infections might propagate neuronal death, and consequently contribute to the restriction of neurological recovery. We investigated the association of infections (i.e. pneumonia and/or postoperative wound infections) with functional neurological outcome after acute severe traumatic spinal cord injury. We screened data sets of 24 762 patients enrolled in a prospective cohort study (National Spinal Cord Injury Database, Birmingham, AL, USA). Patients were assessed according to the ASIA classification. ASIA impairment scale-classified A and B patients recruited within 24 h post-trauma (n = 1436) were selected as being a major recruitment population for interventional trials. Patients with documented pneumonia and/or postoperative wound infections (n = 581) were compared with control subjects (non-documented infections, n = 855). The functional neurological outcome parameters (i) upward ASIA impairment scale conversions; (ii) gain of ASIA motor scores; and (iii) gain of motor and sensory levels were consecutively analysed over time up to 1 year after spinal cord injury. The group with pneumonia and/or postoperative wound infections revealed less ASIA impairment scale upward conversions after 1 year than the control group (ASIA impairment scale A: 17.2 versus 23.9%, P = 0.03; ASIA impairment scale B: 57.1 versus 74.7%, P = 0.009). ASIA motor score gain [median (interquartile range)] was lower in patients with infections [ASIA impairment scale A: 8 (4-12) versus 10 (5-17), P = 0.01; ASIA impairment scale B: 19.5 (8-53.5) versus 42 (20.5-64), P = 0.03)]. Analysis of acquired motor/sensory levels supported these findings. In ASIA impairment scale A patients, the gain in motor levels (21.7 versus 33.3%, P = 0.04) and sensory levels (24.4 versus 38 of 102, 37.3%, P = 0.03) was significantly lower in the group with pneumonia and/or postoperative wound infections than in the control group. Multiple regression analysis identified pneumonia and/or postoperative wound infections as independent risk factors for impaired ASIA impairment scale upward conversion (odds ratio: 1.89, 95% confidence interval: 1.36-2.63, P < 0.0005) or lower gain in ASIA motor score (regression coefficient: -8.21, 95% confidence interval: -12.29 to -4.14, P < 0.0005). Infections associated with spinal cord injury, such as pneumonia and/or postoperative wound infections, qualify as independent risk factors for poor neurological outcome after motor complete spinal cord injury. Infections constitute a clinically relevant target for protecting the limited endogenous functional regeneration capacity. Upcoming interventional trials might gain in efficacy with improved patient stratification and might benefit from complementary protection of the intrinsic recovery potential after spinal cord injury.	[Dirnagl, Ulrich; Schwab, Jan M.] Charite, Dept Neurol & Expt Neurol, Ctr Stroke Res Berlin, D-10117 Berlin, Germany; [Gericke, Christine; Martus, Peter] Charite, Inst Biostat & Clin Epidemiol, D-12203 Berlin, Germany; [Martus, Peter] Univ Tubingen, Dept Clin Epidemiol & Appl Biostat, D-72070 Tubingen, Germany; [Klingbeil, Susann] Univ Hosp Cologne, Dept Neurol, D-50937 Cologne, Germany; [Chen, Yuying; DeVivo, Michael J.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Natl Spinal Cord Injury Stat Ctr, Birmingham, AL 35233 USA	Schwab, JM (corresponding author), Charite, Dept Neurol & Expt Neurol, Ctr Stroke Res Berlin, Charite Pl 1, D-10117 Berlin, Germany.	jan.schwab@charite.de	Kopp, Marcel/AAX-3960-2020	Dirnagl, Ulrich/0000-0003-0755-6119; Kopp, Marcel/0000-0001-6832-9599; Schwab, Jan/0000-0001-6784-4919	German Research Council (DFG, Research Training School, Neuroinflammation)German Research Foundation (DFG) [1258]; Berlin-Brandenburg Centre for Regenerative Therapies (BCRT) [81717034]; International Foundation for Research in Paraplegia, Switzerland (IFP) [P102]; Wings for Life Spinal Cord Research Foundation, Austria [WfL-DE-006/12]; National Institute on Disability and Rehabilitation Research (NIDRR), U.S. Department of Education, USA [H133A060039]	This work was supported by the German Research Council (DFG, Research Training School, Neuroinflammation, Grant number 1258); the Berlin-Brandenburg Centre for Regenerative Therapies (BCRT, Grant number 81717034); the International Foundation for Research in Paraplegia, Switzerland (IFP, Grant number P102); and Wings for Life Spinal Cord Research Foundation, Austria (Grant Number WfL-DE-006/12). The NSCID is funded by the National Institute on Disability and Rehabilitation Research (NIDRR, Grant number H133A060039), U.S. Department of Education, USA.	Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Burns AS, 2003, J NEUROTRAUM, V20, P477, DOI 10.1089/089771503765355540; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; DeVivo Michael J, 2002, J Spinal Cord Med, V25, P335; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Dobkin BH, 2007, DEV NEUROBIOL, V67, P1133, DOI 10.1002/dneu.20514; Dobkin BH, 2009, CURR OPIN NEUROL, V22, P563, DOI 10.1097/WCO.0b013e3283314b11; Dobkin BH, 2007, NEUROREHAB NEURAL RE, V21, P3, DOI 10.1177/1545968306297329; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Finlayson O, 2011, NEUROLOGY, V77, P1338, DOI 10.1212/WNL.0b013e31823152b1; Fouad K, 2011, BRAIN RES BULL, V84, P337, DOI 10.1016/j.brainresbull.2010.04.017; Furlan JC, 2006, SPINE, V31, P2674, DOI 10.1097/01.brs.0000244569.91204.01; Furlan JC, 2008, J NEUROTRAUM, V25, P1273, DOI 10.1089/neu.2008.0617; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Held KS, 2010, EXP NEUROL, V226, P242, DOI 10.1016/j.expneurol.2010.08.036; Koennecke HC, 2011, NEUROLOGY, V77, P965, DOI 10.1212/WNL.0b013e31822dc795; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; Marino RJ, 2002, J SPINAL CORD MED S1, V26, pS50; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C; Moreno B, 2011, ANN NEUROL, V70, P932, DOI 10.1002/ana.22550; Oropallo MA, 2012, J IMMUNOL, V188, P5257, DOI 10.4049/jimmunol.1101934; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Popovich P, 2009, NAT MED, V15, P736, DOI 10.1038/nm0709-736; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Richards J. Scott, 1995, P10; Riegger T, 2003, ACTA NEUROPATHOL, V106, P392; Riegger T, 2009, NEUROSCIENCE, V158, P1194, DOI 10.1016/j.neuroscience.2008.08.021; Riegger T, 2007, EUR J NEUROSCI, V25, P1743, DOI 10.1111/j.1460-9568.2007.05447.x; Schnell L, 1997, EUR J NEUROSCI, V9, P1000, DOI 10.1111/j.1460-9568.1997.tb01450.x; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Steeves JD, 2007, SPINAL CORD, V45, P206, DOI 10.1038/sj.sc.3102008; Steeves JD, 2011, SPINAL CORD, V49, P257, DOI 10.1038/sc.2010.99; Stover SL, 1999, ARCH PHYS MED REHAB, V80, P1365, DOI 10.1016/S0003-9993(99)90246-0; Urra X, 2009, J CEREBR BLOOD F MET, V29, P994, DOI 10.1038/jcbfm.2009.25; Vega JL, 2003, J NEUROPATH EXP NEUR, V62, P848, DOI 10.1093/jnen/62.8.848; Vermeij FH, 2009, CEREBROVASC DIS, V27, P465, DOI 10.1159/000210093; Westendorp WF, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-110; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; Zariffa J, 2011, SPINAL CORD, V49, P463, DOI 10.1038/sc.2010.140; Zorner B, 2010, J NEUROTRAUM, V27, P241, DOI 10.1089/neu.2009.0901	44	82	82	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	NOV	2012	135		11				3238	3250		10.1093/brain/aws267			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	044SV	WOS:000311644800012	23100450	Bronze			2021-06-18	
J	Dykiert, D; Der, G; Starr, JM; Deary, IJ				Dykiert, Dominika; Der, Geoff; Starr, John M.; Deary, Ian J.			Age Differences in Intra-Individual Variability in Simple and Choice Reaction Time: Systematic Review and Meta-Analysis	PLOS ONE			English	Article							LIFE-STYLE; PERFORMANCE VARIABILITY; COGNITIVE IMPAIRMENT; PUBLICATION BIAS; SEX-DIFFERENCES; HIGH-ALTITUDE; INCONSISTENCY; ATTENTION; HEALTH; SPEED	Background: Intra-individual variability in reaction time (RT IIV) is considered to be an index of central nervous system functioning. Such variability is elevated in neurodegenerative diseases or following traumatic brain injury. It has also been suggested to increase with age in healthy ageing. Objectives: To investigate and quantify age differences in RT IIV in healthy ageing; to examine the effect of different tasks and procedures; to compare raw and mean-adjusted measures of RT IIV. Data Sources: Four electronic databases: PsycINFO, Medline, Web of Science and EMBASE, and hand searching of reference lists of relevant studies. Study Eligibility: English language journal articles, books or book chapters, containing quantitative empirical data on simple and/or choice RT IIV. Samples had to include younger (under 60 years) and older (60 years and above) human adults. Study Appraisal and Synthesis: Studies were evaluated in terms of sample representativeness and data treatment. Relevant data were extracted, using a specially-designed form, from the published report or obtained directly from the study authors. Age-group differences in raw and RT-mean-adjusted measures of simple and choice RT IIV were quantified using random effects meta-analyses. Results: Older adults (60+ years) had greater RT IIV than younger (20-39) and middle-aged (40-59) adults. Age effects were larger in choice RT tasks than in simple RT tasks. For all measures of RT IIV, effect sizes were larger for the comparisons between older and younger adults than between older and middle-aged adults, indicating that the age-related increases in RT IIV are not limited to old age. Effect sizes were also larger for raw than for RT-mean-adjusted RT IIV measures. Conclusions: RT IIV is greater among older adults. Some (but not all) of the age-related increases in RT IIV are accounted for by the increased RT means.	[Dykiert, Dominika; Der, Geoff; Deary, Ian J.] Univ Edinburgh, Dept Psychol, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland; [Der, Geoff] MRC, Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; [Starr, John M.] Univ Edinburgh, Geriatr Med Unit, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland	Dykiert, D (corresponding author), Univ Edinburgh, Dept Psychol, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland.	ddykiert@staffmail.ed.ac.uk	Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X; Der, Geoff/0000-0002-8677-073X; Dykiert, Dominika/0000-0002-6050-8223	UK Medical Research Council PhD studentshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative [G0700704/84698]; Biotechnology and Biological Sciences Research Council (BBSRC)UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC); Engineering and Physical Sciences Research Council (EPSRC)UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC); Economic and Social Research Council (ESRC)UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC); Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_UP_A540_1021, MC_U130059823, G0700704B, G0700704] Funding Source: researchfish; Chief Scientist Office [SPHSU2] Funding Source: researchfish	Dominika Dykiert was supported by a UK Medical Research Council PhD studentship. The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (G0700704/84698). Funding from the Biotechnology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC) and Medical Research Council (MRC) is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam M, 2006, SLEEP, V29, P55, DOI 10.1093/sleep/29.1.55; Anstey KJ, 1999, AGING NEUROPSYCHOL C, V6, P84, DOI 10.1076/anec.6.2.84.786; Anstey KJ, 2005, Q J EXP PSYCHOL-A, V58, P5, DOI 10.1080/02724980443000232; Bherer L, 2006, ACTA PSYCHOL, V123, P261, DOI 10.1016/j.actpsy.2006.01.005; Borenstein M., 2009, INTRO METAANALYSIS; Brebner J. T., 1980, REACTION TIMES, P1; Bunce D, 2004, BRAIN COGNITION, V56, P320, DOI 10.1016/j.bandc.2004.08.006; Bunce D, 2008, J GERONTOL B-PSYCHOL, V63, pP67, DOI 10.1093/geronb/63.2.P67; Bunce D, 2012, ACCIDENT ANAL PREV, V49, P293, DOI 10.1016/j.aap.2012.01.001; Bunce D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013567; Bunce D, 2008, PSYCHOL AGING, V23, P848, DOI 10.1037/a0013678; Burton CL, 2006, J CLIN EXP NEUROPSYC, V28, P67, DOI 10.1080/13803390490918318; Cherbuin N, 2010, AM J GERIAT PSYCHIAT, V18, P723, DOI 10.1097/JGP.0b013e3181cdecf1; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Deary IJ, 2011, BEHAV RES METHODS, V43, P258, DOI 10.3758/s13428-010-0024-1; Deary IJ, 2005, AGING NEUROPSYCHOL C, V12, P187, DOI 10.1080/13825580590969235; Der G, 2006, PSYCHOL AGING, V21, P62, DOI 10.1037/0882-7974.21.1.62; Dixon RA, 2007, NEUROPSYCHOLOGY, V21, P381, DOI 10.1037/0894-4105.21.3.381; Duchek JM, 2009, NEUROPSYCHOLOGY, V23, P746, DOI 10.1037/a0016583; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Dykiert D, 2012, DEV PSYCHOL, V48, P1262, DOI 10.1037/a0027550; Finkel D, 2007, EXP AGING RES, V33, P13, DOI 10.1080/03610730601006222; Fontani G, 2004, EUR J APPL PHYSIOL, V92, P452, DOI 10.1007/s00421-004-1108-3; FOZARD JL, 1994, J GERONTOL, V49, pP179, DOI 10.1093/geronj/49.4.P179; FOZARD JL, 1976, J GERONTOL, V31, P556, DOI 10.1093/geronj/31.5.556; Gooch CM, 2009, AGING NEUROPSYCHOL C, V16, P285, DOI 10.1080/13825580802592771; Gorus E, 2006, AGING CLIN EXP RES, V18, P407, DOI 10.1007/BF03324837; Hendrickson AE, 1982, MODEL INTELLIGENCE, P151, DOI DOI 10.1007/978-3-642-68664-1_6; Hogan MJ, 2003, IRISH J PSYCHOL, V24, P161; Hultsch D. F., 2008, HDB AGING COGNITION, P491, DOI DOI 10.4324/9780203837665.CH10; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Jackson JD, 2012, NEUROPSYCHOLOGIA, V50, P357, DOI 10.1016/j.neuropsychologia.2011.11.024; LAHTELA K, 1985, SCAND J PSYCHOL, V26, P357, DOI 10.1111/j.1467-9450.1985.tb01175.x; Li SC, 2009, PSYCHOL RES-PSYCH FO, V73, P777, DOI 10.1007/s00426-008-0190-2; MacDonald SWS, 2012, J NEUROSCI, V32, P8186, DOI 10.1523/JNEUROSCI.5474-11.2012; MacDonald SWS, 2003, PSYCHOL AGING, V18, P510, DOI 10.1037/0882-7974.18.3.510; Martin DM, 2009, NEUROPSYCHOLOGY, V23, P158, DOI 10.1037/a0014182; Maruff P, 2005, J SLEEP RES, V14, P21, DOI 10.1111/j.1365-2869.2004.00438.x; McAuley T, 2006, DEV NEUROPSYCHOL, V29, P447, DOI 10.1207/s15326942dn2903_4; McFarland RA, 1937, J COMP PSYCHOL, V23, P227, DOI 10.1037/h0056332; McFarland RA, 1937, J COMP PSYCHOL, V23, P191, DOI 10.1037/h0058262; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Obrist WD, 1953, J PSYCHOL, V35, P259, DOI 10.1080/00223980.1953.9712860; PIERSON WR, 1958, J GERONTOL, V13, P418, DOI 10.1093/geronj/13.4.418; Rakitin BC, 2006, J COGNITIVE NEUROSCI, V18, P376, DOI 10.1162/jocn.2006.18.3.376; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Shammi P, 1998, AGING NEUROPSYCHOL C, V5, P1, DOI 10.1076/anec.5.1.1.23; Shipley BA, 2006, PSYCHOSOM MED, V68, P17, DOI 10.1097/01.psy.0000195867.66643.0f; Smulders FTY, 1997, BIOL PSYCHOL, V45, P217, DOI 10.1016/S0301-0511(96)05229-5; Sparrow WA, 2006, MOTOR CONTROL, V10, P201, DOI 10.1123/mcj.10.3.201; SPIRDUSO WW, 1978, J GERONTOL, V33, P26, DOI 10.1093/geronj/33.1.26; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; SURWILLO WW, 1963, ELECTROEN CLIN NEURO, V15, P1029, DOI 10.1016/0013-4694(63)90146-9; WAUGH NC, 1973, J GERONTOL, V28, P466, DOI 10.1093/geronj/28.4.466; West R, 2002, BRAIN COGNITION, V49, P402, DOI 10.1006/brcg.2001.1507; WILKINSON RT, 1989, J GERONTOL, V44, pP29, DOI 10.1093/geronj/44.2.P29; Williams BR, 2007, AGING NEUROPSYCHOL C, V14, P417, DOI 10.1080/13825580600584590; Williams BR, 2005, NEUROPSYCHOLOGY, V19, P88, DOI 10.1037/0894-4105.19.1.88; Wolf F. M., 1986, METAANALYSIS QUANTIT; Yan JH, 1998, EXP AGING RES, V24, P155	62	82	83	1	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2012	7	10							e45759	10.1371/journal.pone.0045759			23	Multidisciplinary Sciences	Science & Technology - Other Topics	020KP	WOS:000309807700013	23071524	DOAJ Gold, Green Published			2021-06-18	
J	Mondello, S; Jeromin, A; Buki, A; Bullock, R; Czeiter, E; Kovacs, N; Barzo, P; Schmid, K; Tortella, F; Wang, KK; Hayes, RL				Mondello, Stefania; Jeromin, Andreas; Buki, Andras; Bullock, Ross; Czeiter, Endre; Kovacs, Noemi; Barzo, Pal; Schmid, Kara; Tortella, Frank; Wang, Kevin K.; Hayes, Ronald L.			Glial Neuronal Ratio: A Novel Index for Differentiating Injury Type in Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; computed tomography; diagnostic; glial neuronal ratio; traumatic brain injury	COMPUTED-TOMOGRAPHY FINDINGS; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE; CEREBRAL-ISCHEMIA; AXONAL INJURY; MARKERS; BIOMARKERS; PROGNOSIS; DAMAGE; AREAS	Neurobiochemical marker levels in blood after traumatic brain injury (TBI) may reflect structural changes detected by neuroimaging. This study evaluates whether correlations between neuronal (ubiquitin carboxyterminal hydrolase-L1 [UCH-L1]) and glial (glial fibrillary acidic protein [GFAP]) biomarkers may be used as an indicator for differing intracranial pathologies after brain trauma. In 59 patients with severe TBI (Glasgow Coma Scale [GCS] score <= 8) serum samples were obtained at the time of hospital admission and analyzed for UCH-L1 and GFAP. Glial neuronal ratio (GNR) was evaluated as the ratio between GFAP and UCH-L1 concentrations. A logistic regression analysis was used to identify variables associated with type of injury. GNR had a median of 0.85 and was positively correlated with age (R = 0.45, p = 0.003). Twenty-nine patients presented with diffuse injury and 30 with focal mass lesions as assessed by CT scan at admission and classified according to the Marshall Classification. GNR was significantly higher in the focal mass lesion group compared with the diffuse injury group (1.77 versus 0.48, respectively; p = 0.003). Receiver operating characteristic curve analysis showed that GNR discriminated between types of injury (area under the curve [AUC] = 0.72; p = 0.003). GNR was more accurate earlier (<= 12 h after injury) than later (AUC = 0.80; p = 0.002). Increased GNR was independently associated with type of injury, but not age, gender, GCS score, or mechanism of injury. GNR was significantly higher in patients who died, but was not an independent predictor of death. The data from the present study indicate that GNR provides valuable information about different injury pathways, which may be of diagnostic significance. In addition, GNR may help to identify different pathophysiological mechanisms following different types of brain trauma, with implications for therapeutic interventions.	[Mondello, Stefania] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Dept Clin Programs, Alachua, FL 32615 USA; [Buki, Andras; Czeiter, Endre; Kovacs, Noemi] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Bullock, Ross] Univ Miami, Dept Neurosurg, Miami, FL USA; [Barzo, Pal] Univ Szeged, Dept Neurosurg, Szeged, Hungary; [Schmid, Kara; Tortella, Frank] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Dept Appl Neurobiol, Silver Spring, MD USA; [Wang, Kevin K.] Banyan Biomarkers Inc, Ctr Innovat Res, Diagnost Res & Dev Dept, Alachua, FL USA	Mondello, S (corresponding author), Univ Florida, Dept Anesthesiol, 12085 Res Dr, Alachua, FL 32615 USA.	smondello@banyanbio.com	Czeiter, Endre/B-1404-2009; Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03-1-0066]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01-NS052831-01, R01 NS051431-01]; University of FloridaUniversity of Florida [N00014-06-1-1029]; Developing Competitiveness of Universities in the South Transdanubian Region [SROP-4.2.1.B-10/2/KONV-2010-0002]; Banyan Biomarkers, Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831, R01NS049175, R01NS051431] Funding Source: NIH RePORTER	This study was primarily sponsored by Department of Defense Award numbers DAMD17-03-1-0772 and DAMD17-03-1-0066, but we also acknowledge additional fund support from National Institutes of Health grants R01 NS049175-01, R01-NS052831-01, and R01 NS051431-01, Navy grant N00014-06-1-1029 (University of Florida), and Developing Competitiveness of Universities in the South Transdanubian Region grant SROP-4.2.1.B-10/2/KONV-2010-0002.; Drs. Mondello, Buki, Bullock, Czeiter, and Barzo, are consultants of and received consulting fees from Banyan Biomarkers, Inc. Dr. Jeromin is an employee and received salary from Banyan Biomarkers, Inc. Drs. Wang and Hayes own stock and receive royalties and salaries from, and are officers of, Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research. Banyan Biomarkers, Inc. filed patent applications based upon the disclosure of this publication. Drs. Tortella, Kovacs, and Schmid report no disclosures.	Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; CHEN H, 1993, J NEUROL SCI, V118, P109, DOI 10.1016/0022-510X(93)90099-K; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; FOULKES MA, 1991, J NEUROSURG, V75, pS1, DOI 10.3171/sup.1991.75.1s.00s1; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gong B, 2007, DRUG NEWS PERSPECT, V20, P365, DOI 10.1358/dnp.2007.20.6.1138160; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Lee DR, 2003, BRAIN RES, V989, P221, DOI 10.1016/S0006-8993(03)03373-0; LI Y, 1995, J NEUROL SCI, V128, P134, DOI 10.1016/0022-510X(94)00228-G; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Servadei F, 2000, NEUROSURGERY, V46, P70; Setsuie R, 2007, NEUROCHEM INT, V51, P105, DOI 10.1016/j.neuint.2007.05.007; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2	32	82	83	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1096	1104		10.1089/neu.2011.2092			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100009	22165978	Green Published			2021-06-18	
J	Berger, TW; Song, D; Chan, RHM; Marmarelis, VZ; LaCoss, J; Wills, J; Hampson, RE; Deadwyler, SA; Granacki, JJ				Berger, Theodore W.; Song, Dong; Chan, Rosa H. M.; Marmarelis, Vasilis Z.; LaCoss, Jeff; Wills, Jack; Hampson, Robert E.; Deadwyler, Sam A.; Granacki, John J.			A Hippocampal Cognitive Prosthesis: Multi-Input, Multi-Output Nonlinear Modeling and VLSI Implementation	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Hippocampus; multi-input/multi-output (MIMO) nonlinear model; neural prosthesis; spatio-temporal coding	TRAUMATIC BRAIN-INJURY; IDENTIFICATION; EXCITATION; AFFERENTS; SYSTEMS; MEMORY	This paper describes the development of a cognitive prosthesis designed to restore the ability to form new long-term memories typically lost after damage to the hippocampus. The animal model used is delayed nonmatch-to-sample (DNMS) behavior in the rat, and the "core" of the prosthesis is a biomimetic multi-input/multi-output (MIMO) nonlinear model that provides the capability for predicting spatio-temporal spike train output of hippocampus (CA1) based on spatio-temporal spike train inputs recorded presynaptically to CA1 (e.g., CA3). We demonstrate the capability of the MIMO model for highly accurate predictions of CA1 coded memories that can be made on a single-trial basis and in real-time. When hippocampal CA1 function is blocked and long-term memory formation is lost, successful DNMS behavior also is abolished. However, when MIMO model predictions are used to reinstate CA1 memory-related activity by driving spatio-temporal electrical stimulation of hippocampal output to mimic the patterns of activity observed in control conditions, successful DNMS behavior is restored. We also outline the design in very-large-scale integration for a hardware implementation of a 16-input, 16-output MIMO model, along with spike sorting, amplification, and other functions necessary for a total system, when coupled together with electrode arrays to record extracellularly from populations of hippocampal neurons, that can serve as a cognitive prosthesis in behaving animals.	[Berger, Theodore W.; Song, Dong; Chan, Rosa H. M.; Marmarelis, Vasilis Z.] Univ So Calif, Dept Biomed Engn, Ctr Neural Engn, Viterbi Sch Engn, Los Angeles, CA 90089 USA; [Marmarelis, Vasilis Z.] Univ So Calif, Dept Elect Engn, Ctr Neural Engn, Viterbi Sch Engn, Los Angeles, CA 90089 USA; [Hampson, Robert E.; Deadwyler, Sam A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; [LaCoss, Jeff; Wills, Jack; Granacki, John J.] Univ So Calif, Informat Sci Inst ISI, Viterbi Sch Engn, Los Angeles, CA 90089 USA; [Granacki, John J.] Univ So Calif, Viterbi Sch Engn, Dept Elect Engn & Biomed Engn, Los Angeles, CA 90089 USA	Berger, TW (corresponding author), Univ So Calif, Dept Biomed Engn, Ctr Neural Engn, Viterbi Sch Engn, Los Angeles, CA 90089 USA.	berger@bmsr.usc.edu; dsong@usc.edu; homchan@usc.edu; vzm@bmsrs.usc.edu; jlacoss@isi.edu; jackw@isi.edu; rhampson@wfubmc.edu; sdeadwyl@wfubmc.edu; granacki@usc.edu	Song, Dong/A-8314-2010; Chan, Rosa/B-6662-2008	Song, Dong/0000-0002-6179-1120; CHAN, Rosa/0000-0003-4808-2490; Hampson, Robert/0000-0002-8648-9462	Defense Advanced research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66601-09-C-2080, N66601-09-C-2081]; NSFNational Science Foundation (NSF) [EEC-0310723]; NIH/NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41-EB001978]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DA07625]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB001978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA007625] Funding Source: NIH RePORTER	Manuscript received May 22, 2011; revised December 08, 2011; accepted February 21, 2012. Date of current version March 16, 2012. This work was supported in part by Defense Advanced research Projects Agency (DARPA) contracts to S. A. Deadwyler N66601-09-C-2080 and to T. W. Berger N66601-09-C-2081 (Prog. Dir: COL G. Ling), and grants NSF EEC-0310723 to USC (T. W. Berger), NIH/NIBIB Grant P41-EB001978 to the Biomedical Simulations Resource at USC (to V. Z. Marmarelis and NIH R01DA07625 (to S. A. Deadwyler).	Berger T., 2005, REPLACEMENT PARTS BR; Berger T. W., 2007, NEURONANOTECHNOLOGY, P309; Berger T. W., 2008, BRAIN COMPUTER INTER; Berger TW, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046017; Berger TW, 2010, P IEEE, V98, P356, DOI 10.1109/JPROC.2009.2038804; Berger TW, 2001, P IEEE, V89, P993, DOI 10.1109/5.939806; BERGER TW, 1983, BEHAV BRAIN RES, V8, P49, DOI 10.1016/0166-4328(83)90171-7; Berger TW, 2005, IEEE ENG MED BIOL, V24, P30, DOI 10.1109/MEMB.2005.1511498; Brown EN, 2002, NEURAL COMPUT, V14, P325, DOI 10.1162/08997660252741149; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Chiu-Hsien Chan, 2006, 2006 IEEE Biomedical Circuits and Systems Conference - Healthcare Technology (BioCas), P214, DOI 10.1109/BIOCAS.2006.4600346; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Deadwyler SA, 2007, BEHAV PHARMACOL, V18, P571, DOI 10.1097/FBP.0b013e3282ee2adb; EICHENBAUM H, 1988, BEHAV NEUROSCI, V102, P331, DOI 10.1037/0735-7044.102.3.331; Fang X, 2009, MIDWEST SYMP CIRCUIT, P180, DOI 10.1109/MWSCAS.2009.5236122; Fang X, 2008, MIDWEST SYMP CIRCUIT, P826, DOI 10.1109/MWSCAS.2008.4616927; Hampson R. E., 2012, IEEE T NEURAL SYST R, V20; Hsiao MC, 2008, IEEE ENG MED BIO, P5535, DOI 10.1109/IEMBS.2008.4650468; Kelper A., 2006, NEW ATLANTIS; Marmarelis VZ, 2005, MATH BIOSCI, V196, P1, DOI 10.1016/j.mbs.2005.04.002; MARMARELIS VZ, 1993, ANN BIOMED ENG, V21, P573, DOI 10.1007/BF02368639; McCullagh P., 1989, GEN LINEAR MODELS; Milner B., 1970, MEMORY MEDIAL TEMPOR, P29; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Song D., 2009, STAT SIGNAL PROCESSI; Song D, 2007, IEEE T BIO-MED ENG, V54, P1053, DOI 10.1109/TBME.2007.891948; Song D, 2009, IEEE ENG MED BIO, P4555, DOI 10.1109/IEMBS.2009.5332719; Song Dong, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P6129; Song D, 2009, NEURAL NETWORKS, V22, P1340, DOI 10.1016/j.neunet.2009.05.004; Song D, 2009, J COMPUT NEUROSCI, V26, P1, DOI 10.1007/s10827-008-0097-3; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Truccolo W, 2005, J NEUROPHYSIOL, V93, P1074, DOI 10.1152/jn.00697.2004; YECKEL MF, 1995, HIPPOCAMPUS, V5, P108, DOI 10.1002/hipo.450050204; YECKEL MF, 1990, P NATL ACAD SCI USA, V87, P5832, DOI 10.1073/pnas.87.15.5832	34	82	82	1	30	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	MAR	2012	20	2					198	211		10.1109/TNSRE.2012.2189133			14	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	917MU	WOS:000302182500009	22438335	Green Accepted			2021-06-18	
J	Hunter, JV; Wilde, EA; Tong, KA; Holshouser, BA				Hunter, Jill V.; Wilde, Elisabeth A.; Tong, Karen A.; Holshouser, Barbara A.			Emerging Imaging Tools for Use with Traumatic Brain Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						adults; children; CT; MRI; neuroimaging; TBI	DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; PROTON MR SPECTROSCOPY; COMMON DATA ELEMENTS; WHITE-MATTER INJURY; CENTRAL-NERVOUS-SYSTEM; WORKING-MEMORY LOAD; SEVERE HEAD TRAUMA	This article identifies emerging neuroimaging measures considered by the inter-agency Pediatric Traumatic Brain Injury (TBI) Neuroimaging Workgroup. This article attempts to address some of the potential uses of more advanced forms of imaging in TBI as well as highlight some of the current considerations and unresolved challenges of using them. We summarize emerging elements likely to gain more widespread use in the coming years, because of 1) their utility in diagnosis, prognosis, and understanding the natural course of degeneration or recovery following TBI, and potential for evaluating treatment strategies; 2) the ability of many centers to acquire these data with scanners and equipment that are readily available in existing clinical and research settings; and 3) advances in software that provide more automated, readily available, and cost-effective analysis methods for large scale data image analysis. These include multi-slice CT, volumetric MRI analysis, susceptibility-weighted imaging (SWI), diffusion tensor imaging (DTI), magnetization transfer imaging (MTI), arterial spin tag labeling (ASL), functional MRI (fMRI), including resting state and connectivity MRI, MR spectroscopy (MRS), and hyperpolarization scanning. However, we also include brief introductions to other specialized forms of advanced imaging that currently do require specialized equipment, for example, single photon emission computed tomography (SPECT), positron emission tomography (PET), encephalography (EEG), and magnetoencephalography (MEG)/magnetic source imaging (MSI). Finally, we identify some of the challenges that users of the emerging imaging CDEs may wish to consider, including quality control, performing multi-site and longitudinal imaging studies, and MR scanning in infants and children.	[Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Hunter, Jill V.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Hunter, Jill V.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med Rehabil & Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA; [Tong, Karen A.; Holshouser, Barbara A.] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA USA	Hunter, JV (corresponding author), Texas Childrens Hosp, Dept Pediat Radiol, 6621 Fannin St,W1120, Houston, TX 77030 USA.	jhunter@bcm.edu			National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR); Department of Veterans' AffairsUS Department of Veterans Affairs; United States Department of DefenseUnited States Department of Defense	This project was jointly supported by the National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS), the United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR), the Department of Veterans' Affairs, and the United States Department of Defense.	Aaen GS, 2010, PEDIATRICS, V125, P295, DOI 10.1542/peds.2008-3312; Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Alessandri B, 2000, J CLIN NEUROSCI, V7, P47, DOI 10.1054/jocn.1998.0139; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; Barker PB, 2010, CLIN MR SPECTROSCOPY, P39; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bonte FJ, 2006, CLIN NUCL MED, V31, P376, DOI 10.1097/01.rlu.0000222736.81365.63; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Buxton RB, 2005, J MAGN RESON IMAGING, V22, P723, DOI 10.1002/jmri.20462; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Calhoun VD, 2002, MAGNET RESON MED, V48, P180, DOI 10.1002/mrm.10202; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chou YY, 2010, NEUROBIOL AGING, V31, P1386, DOI 10.1016/j.neurobiolaging.2010.05.001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Coles JP, 2007, BRIT J ANAESTH, V99, P49, DOI 10.1093/bja/aem141; DANIELSEN ER, 1994, NMR BIOMED, V7, P311, DOI 10.1002/nbm.1940070704; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Detre JA, 1999, EUR J RADIOL, V30, P115, DOI 10.1016/S0720-048X(99)00050-9; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Duckworth JL, 2010, CURR OPIN CRIT CARE, V16, P92, DOI 10.1097/MCC.0b013e3283374900; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Duhaime A.C., 2011, J NEUROTRAU IN PRESS; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Forbes ML, 1997, ADV EXP MED BIOL, V411, P7; FRAHM J, 1989, MAGNET RESON MED, V11, P47, DOI 10.1002/mrm.1910110105; Friedman L, 2006, J MAGN RESON IMAGING, V23, P827, DOI 10.1002/jmri.20583; Friedman L, 2008, HUM BRAIN MAPP, V29, P958, DOI 10.1002/hbm.20440; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Groen WB, 2011, J PSYCHIATR NEUROSCI, V36, P32, DOI 10.1503/jpn.090100; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hattingen E, 2008, NEURORADIOLOGY, V50, P759, DOI 10.1007/s00234-008-0409-3; Hattori N, 2004, J NUCL MED, V45, P775; Hattori N, 2003, J NUCL MED, V44, P1709; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hua X, 2010, NEUROBIOL AGING, V31, P1463, DOI 10.1016/j.neurobiolaging.2010.04.033; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; HUPPI PS, 1991, PEDIATR RES, V30, P574; Hutchinson E, 2010, EPILEPSY RES, V88, P208, DOI 10.1016/j.eplepsyres.2009.11.011; Inglese M, 2003, MAGNET RESON MED, V50, P190, DOI 10.1002/mrm.10481; James GA, 2009, NEUROIMAGE, V45, P778, DOI 10.1016/j.neuroimage.2008.12.049; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kaushik SS, 2011, MAGN RESON MED, V65, P1155, DOI 10.1002/mrm.22697; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kochanek PM, 2005, J CEREBR BLOOD F MET, V25, P1596, DOI 10.1038/sj.jcbfm.9600154; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; Kumar R, 2003, MAGN RESON IMAGING, V21, P893, DOI 10.1016/S0730-725X(03)00189-9; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laatsch L, 2004, REHABIL PSYCHOL, V49, P262, DOI 10.1037/0090-5550.49.3.262; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Maniega SM, 2008, STROKE, V39, P2467, DOI 10.1161/STROKEAHA.107.507020; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Maudsley AA, 2006, NMR BIOMED, V19, P492, DOI 10.1002/nbm.1025; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer A.R., 2011, HUM BRAIN MAPP; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Metting Z, 2010, J NEUROTRAUM, V27, P2183, DOI 10.1089/neu.2010.1395; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mueller Susanne G, 2005, Alzheimers Dement, V1, P55, DOI 10.1016/j.jalz.2005.06.003; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2008, ACTA NEUROCHIR SUPPL, V102, P247, DOI 10.1007/978-3-211-85578-2_47; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pagani E, 2008, NEUROL SCI, V29, pS290, DOI 10.1007/s10072-008-1001-7; Panigrahy A, 2010, PEDIATR RADIOL, V40, P3, DOI 10.1007/s00247-009-1450-z; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Pouwels PJW, 1999, PEDIATR RES, V46, P474, DOI 10.1203/00006450-199910000-00019; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rademacher J, 1999, NEUROIMAGE, V9, P393, DOI 10.1006/nimg.1998.0416; Rasmussen IA, 2008, J NEUROTRAUM, V25, P1057, DOI 10.1089/neu.2008.0520; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Risacher SL, 2010, NEUROBIOL AGING, V31, P1401, DOI 10.1016/j.neurobiolaging.2010.04.029; Robertson CL, 2000, ACT NEUR S, V76, P187; Rocca MA, 2002, ANN NEUROL, V51, P330, DOI 10.1002/ana.10120; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Schuff N, 2001, MAGN RESON MED, V45, P899, DOI 10.1002/mrm.1119; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Simmons A, 2011, INT J GERIATR PSYCH, V26, P75, DOI 10.1002/gps.2491; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Soustiel JF, 2008, NEURORADIOLOGY, V50, P189, DOI 10.1007/s00234-007-0337-7; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Strangman GE, 2008, ARCH PHYS MED REHAB, V89, P974, DOI 10.1016/j.apmr.2008.02.011; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tomkins O, 2011, CARDIOVASC PSYCHIAT; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Tshibanda L, 2009, PROG BRAIN RES, V177, P215, DOI 10.1016/S0079-6123(09)17715-4; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Vannorsdall TD, 2010, J NEUROPSYCH CLIN N, V22, P173, DOI 10.1176/appi.neuropsych.22.2.173; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wintermark M, 2005, STROKE, V36, pE83, DOI 10.1161/01.STR.0000177884.72657.8b; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; Wong EC, 2006, MAGN RESON MED, V55, P1334, DOI 10.1002/mrm.20906; Wong SBC, 2006, PROG BRAIN RES, V157, P173, DOI 10.1016/S0079-6123(06)57011-6; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	195	82	85	0	49	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					654	671		10.1089/neu.2011.1906			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500005	21787167	Green Published			2021-06-18	
J	Kenne, E; Erlandsson, A; Lindbom, L; Hillered, L; Clausen, F				Kenne, Ellinor; Erlandsson, Anna; Lindbom, Lennart; Hillered, Lars; Clausen, Fredrik			Neutrophil depletion reduces edema formation and tissue loss following traumatic brain injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Neutrophil; traumatic brain injury; brain edema; controlled cortical impact; neuroprotection; blood-brain-barrier; cell death; microglia; neutrophil-depletion; mouse	CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; MIDDLE CEREBRAL-ARTERY; BARRIER PERMEABILITY; ISCHEMIC BRAIN; POLYMORPHONUCLEAR LEUKOCYTES; VASCULAR-PERMEABILITY; ADHESION MOLECULES; TNF-ALPHA; RATS	Background: Brain edema as a result of secondary injury following traumatic brain injury (TBI) is a major clinical concern. Neutrophils are known to cause increased vascular permeability leading to edema formation in peripheral tissue, but their role in the pathology following TBI remains unclear. Methods: In this study we used controlled cortical impact (CCI) as a model for TBI and investigated the role of neutrophils in the response to injury. The outcome of mice that were depleted of neutrophils using an anti-Gr-1 antibody was compared to that in mice with intact neutrophil count. The effect of neutrophil depletion on blood-brain barrier function was assessed by Evan's blue dye extravasation, and analysis of brain water content was used as a measurement of brain edema formation (24 and 48 hours after CCI). Lesion volume was measured 7 and 14 days after CCI. Immunohistochemistry was used to assess cell death, using a marker for cleaved caspase-3 at 24 hours after injury, and microglial/macrophage activation 7 days after CCI. Data were analyzed using Mann-Whitney test for non-parametric data. Results: Neutrophil depletion did not significantly affect Evan's blue extravasation at any time-point after CCI. However, neutrophil-depleted mice exhibited a decreased water content both at 24 and 48 hours after CCI indicating reduced edema formation. Furthermore, brain tissue loss was attenuated in neutropenic mice at 7 and 14 days after injury. Additionally, these mice had a significantly reduced number of activated microglia/macrophages 7 days after CCI, and of cleaved caspase-3 positive cells 24 h after injury. Conclusion: Our results suggest that neutrophils are involved in the edema formation, but not the extravasation of large proteins, as well as contributing to cell death and tissue loss following TBI in mice.	[Erlandsson, Anna; Hillered, Lars; Clausen, Fredrik] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Kenne, Ellinor; Lindbom, Lennart] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden	Clausen, F (corresponding author), Uppsala Univ, Dept Neurosci, Uppsala, Sweden.	fredrik.clausen@neuro.uu.se		Lindbom, Lennart/0000-0001-9243-257X; Hillered, Lars/0000-0002-2808-9292; Kenne, Ellinor/0000-0002-2784-5244; Clausen, Fredrik/0000-0003-3592-4417	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation; Lars Hierta Memorial Fund; Swedish Brain Foundation; Selander Foundation; Ahlen Foundation; Uppsala University Hospital	This work was funded by grants from the Swedish Research Council (EK, LL, LH), the Swedish Heart-Lung Foundation (EK, LL), the Lars Hierta Memorial Fund (EK, LL), the Swedish Brain Foundation (LH, FC), the Selander Foundation (LH), the Ahlen Foundation (LH) and Uppsala University Hospital (LH).	ARFORS KE, 1987, BLOOD, V69, P338; Biber N, 2009, BRAIN INJURY, V23, P577, DOI 10.1080/02699050902926317; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clausen F, 2011, EUR J NEUROSCI; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Engelhardt B, 2009, SEMIN IMMUNOPATHOL, V31, P497, DOI 10.1007/s00281-009-0177-0; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Ikegame Y, 2010, HYPERTENS RES, V33, P703, DOI 10.1038/hr.2010.58; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Justicia C, 2003, J CEREBR BLOOD F MET, V23, P1430, DOI 10.1097/01.WCB.0000090680.07515.C8; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lindbom L, 2003, CHEM IMMUNOL, V83, P146; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Morancho A, 2010, ANN NY ACAD SCI, V1207, P123, DOI 10.1111/j.1749-6632.2010.05734.x; Moxon-Emre I, 2011, J NEUROPATH EXP NEUR, V70, P218, DOI 10.1097/NEN.0b013e31820d94a5; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Soares HD, 1995, J NEUROSCI, V15, P8223; Soehnlein O, 2008, EUR RESP J; Soehnlein O, 2008, BLOOD, V112, P1461, DOI 10.1182/blood-2008-02-139634; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1998, ACT NEUR S, V71, P212; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	47	82	84	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 23	2012	9								17	10.1186/1742-2094-9-17			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	917HX	WOS:000302165200001	22269349	DOAJ Gold, Green Published			2021-06-18	
J	Papa, L; Stiell, IG; Clement, CM; Pawlowicz, A; Wolfram, A; Braga, C; Draviam, S; Wells, GA				Papa, Linda; Stiell, Ian G.; Clement, Catherine M.; Pawlowicz, Artur; Wolfram, Andrew; Braga, Carolina; Draviam, Sameer; Wells, George A.			Performance of the Canadian CT Head Rule and the New Orleans Criteria for Predicting Any Traumatic Intracranial Injury on Computed Tomography in a United States Level I Trauma Center	ACADEMIC EMERGENCY MEDICINE			English	Article							BRAIN-INJURY; RADIATION-EXPOSURE; CANCER-RISKS; MANAGEMENT	Objectives: This study compared the clinical performance of the Canadian CT Head Rule (CCHR) and the New Orleans Criteria (NOC) for detecting any traumatic intracranial lesion on computed tomography (CT) in patients with a Glasgow Coma Scale (GCS) score of 15. Also assessed were ability to detect patients with clinically important brain injury and patients requiring neurosurgical intervention. Additionally, the performance of the CCHR was assessed in a larger cohort of those presenting with GCS of 13 to 15. Methods: This prospective cohort study was conducted in a U.S. Level I trauma center and enrolled a consecutive sample of mildly head-injured adults who presented to the emergency department (ED) with witnessed loss of consciousness, disorientation or amnesia, and GCS 13 to 15. The rules were compared in the group of patients with GCS 15. The primary outcome was prediction of any traumatic intracranial injury on CT. Secondary outcomes included clinically important brain injury on CT and need for neurosurgical intervention. Results: Among the 431 enrolled patients, 314 patients (73%) had a GCS of 15, and 22 of the 314 (7%) had evidence of a traumatic intracranial lesion on CT. There were 11 of 314 (3.5%) who had clinically important brain injury, and 3 of 314 (1.0%) required neurosurgical intervention. The NOC and CCHR both had 100% sensitivity (95% confidence interval [CI] = 82% to 100%), but the CCHR was more specific for detecting any traumatic intracranial lesion on CT, with a specificity of 36.3% (95% CI = 31% to 42%) versus 10.2% (95% CI = 7% to 14%) for NOC. For clinically important brain lesions, the CCHR and the NOC had similar sensitivity (both 100%; 95% CI = 68% to 100%), but the specificity was 35% (95% CI = 30% to 41%) for CCHR and 9.9% (95% CI = 7% to 14%) for NOC. When the rules were compared for predicting need for neurosurgical intervention, the sensitivity was equivalent at 100% (95% CI = 31% to 100%) but the CCHR had a higher specificity at 80.7% (95% CI = 76% to 85%) versus 9.6% (95% CI = 7% to 14%) for NOC. Among all 431 patients with a GCS score 13 to 15, the CCHR had sensitivities of 100% (95% CI = 84% to 100%) for 27 patients with clinically important brain injury and 100% (95% CI = 46% to 100%) for five patients requiring neurosurgical intervention. Conclusions: In a U.S. sample of mildly head-injured patients, the CCHR and the NOC had equivalently high sensitivities for detecting any traumatic intracranial lesion on CT, clinically important brain injury, and neurosurgical intervention, but the CCHR was more specific. A larger cohort will be needed to validate these findings.	[Papa, Linda; Braga, Carolina; Draviam, Sameer] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA; [Stiell, Ian G.] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Wells, George A.] Ottawa Hlth Res Inst, Dept Epidemiol & Community Med, Ottawa, ON, Canada; [Pawlowicz, Artur] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA; [Wolfram, Andrew] Univ Penn, Philadelphia, PA 19104 USA	Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA.	lpstat@aol.com		Stiell, Ian/0000-0002-2583-6408	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS057676] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER		Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; de Gonzalez AB, 2009, ARCH INTERN MED, V169, P2071, DOI 10.1001/archinternmed.2009.440; Faul M, TRAUMATIC BRAIN INJU; Fayngersh V, 2009, LUNG, V187, P143, DOI 10.1007/s00408-009-9143-9; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Heilbrun Marta E, 2005, J Am Coll Radiol, V2, P889, DOI 10.1016/j.jacr.2005.06.013; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Mettler FA, 2008, HEALTH PHYS, V95, P502, DOI 10.1097/01.HP.0000326333.42287.a2; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Rosengren David, 2004, Emerg Med Australas, V16, P195, DOI 10.1111/j.1742-6723.2004.00563.x; Schwartz DT, 2008, WEST J EMERG MED, V9, P120; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell I.G., 2000, ACAD EMERG MED, V7, P572; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; WARDLAW JM, 2004, HEALTH TECHNOL ASSES, V8, pR9	29	82	82	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JAN	2012	19	1					2	10		10.1111/j.1553-2712.2011.01247.x			9	Emergency Medicine	Emergency Medicine	877CT	WOS:000299155200001	22251188	Green Accepted			2021-06-18	
J	Steinsapir, KD; Goldberg, RA				Steinsapir, Kenneth D.; Goldberg, Robert A.			Traumatic Optic Neuropathy: An Evolving Understanding	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							SPINAL-CORD-INJURY; NERVE TRAUMA; CONTROLLED-TRIAL; METHYLPREDNISOLONE; CORTICOSTEROIDS; DECOMPRESSION; MANAGEMENT	PURPOSE: To critically review the treatment of traumatic optic neuropathy. DESIGN: A perspective of clinical and basic science studies related to traumatic optic neuropathy and its treatment. METHODS: Published clinical and basic science studies on traumatic optic neuropathy were critically reviewed and interpreted. RESULTS: Clinical progress in the treatment of traumatic optic neuropathy is limited by small clinical studies lacking appropriate control groups. The Corticosteroid Randomization for Acute Head Trauma (CRASH) trial found an increased rate of death among patients with acute head trauma treated with high-dose corticosteroids compared to placebo-treated patients (21% vs 18%, P = .0001). Recent animal studies also suggest that high-dose corticosteroids are toxic to the injured optic nerve. CONCLUSIONS: The Corticosteroid Randomization for Acute Head Trauma study is immediately relevant to the treatment of traumatic optic neuropathy as individuals with traumatic optic neuropathy often have concomitant head trauma. High-dose corticosteroids for traumatic optic neuropathy will result in a measurable loss of life in patients who also have a brain injury. Death has never been an endpoint for traumatic optic neuropathy studies. Given human and animal data suggesting that treatment is harmful and the lack of demonstrated clinical efficacy, corticosteroids should not be used to treat traumatic optic neuropathy. The benefit of optic canal decompression is also unclear. There is a need to identify traumatic optic neuropathy soon after injury to further define the natural history of this injury. This information will provide a basis for assessing potential future treatments for traumatic optic neuropathy. (Am J Ophthalmol 2011;151: 928-933. (C) 2011 by Elsevier Inc. All rights reserved.)	[Steinsapir, Kenneth D.; Goldberg, Robert A.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Div Orbital & Ophthalm Plast Surg, Los Angeles, CA 90095 USA	Steinsapir, KD (corresponding author), 11645 Wilshire Blvd,Suite 750, Los Angeles, CA 90025 USA.	kenstein@ix.netcom.com	Goldberg, Robert/AAE-3046-2019				Alford MA, 2001, OPHTHAL PLAST RECONS, V17, P323, DOI 10.1097/00002341-200109000-00005; ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; Bracken MB, 2005, NEUROSURGERY, V57, P1300, DOI 10.1227/01.NEU.0000187320.71967.59; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Chou PI, 1996, NEURO-OPHTHALMOLOGY, V16, P325, DOI 10.3109/01658109609044636; Cirovic S, 2006, BRIT J OPHTHALMOL, V90, P778, DOI 10.1136/bjo.2005.086538; Cook MW, 1996, ARCH OTOLARYNGOL, V122, P389; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; Fukado Y, 1975, Mod Probl Ophthalmol, V14, P474; Holmes MD, 2004, OPHTHAL PLAST RECONS, V20, P342, DOI 10.1097/01.IOP.0000134272.55294.4C; HOOPER RS, 1951, BRIT J SURG, V39, P126, DOI 10.1002/bjs.18003915406; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jamal BT, 2009, J ORAL MAXIL SURG, V67, P986, DOI 10.1016/j.joms.2008.12.035; JOSEPH MP, 1990, ARCH OPHTHALMOL-CHIC, V108, P1091, DOI 10.1001/archopht.1990.01070100047032; Lee V, 2010, EYE, V24, P240, DOI 10.1038/eye.2009.79; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; Lubben B, 2001, LARYNGOSCOPE, V111, P320; MILLER NR, 1990, ARCH OPHTHALMOL-CHIC, V108, P1086, DOI 10.1001/archopht.1990.01070100042030; MILLESI W, 1988, ACTA NEUROCHIR, V93, P50, DOI 10.1007/BF01409902; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; NAU HE, 1987, ACTA NEUROCHIR, V89, P16, DOI 10.1007/BF01406662; Rajiniganth MG, 2003, ARCH OTOLARYNGOL, V129, P1203, DOI 10.1001/archotol.129.11.1203; Simon GJB, 2006, J NEUROTRAUM, V23, P1072, DOI 10.1089/neu.2006.23.1072; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; Steinsapir KD, 2006, J NEURO-OPHTHALMOL, V26, P65, DOI 10.1097/01.wno.0000204646.94991.68; STEINSAPIR KD, 1994, SURV OPHTHALMOL, V38, P487, DOI 10.1016/0039-6257(94)90145-7; Steinsapir KD, 2000, RESTOR NEUROL NEUROS, V17, P157; STEINSAPIR KD, 2005, COMP OPHTHALMOL UPDA, V6, P11; WALSH FRANK B., 1966, INVEST OPHTHALMOL, V5, P433; Wang BH, 2001, PLAST RECONSTR SURG, V107, P1655, DOI 10.1097/00006534-200106000-00003; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033	35	82	94	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	JUN	2011	151	6					928	933		10.1016/j.ajo.2011.02.007			6	Ophthalmology	Ophthalmology	773GQ	WOS:000291295400004	21529765				2021-06-18	
J	Creed, JA; DiLeonardi, AM; Fox, DP; Tessler, AR; Raghupathi, R				Creed, Jennifer A.; DiLeonardi, Ann Mae; Fox, Douglas P.; Tessler, Alan R.; Raghupathi, Ramesh			Concussive Brain Trauma in the Mouse Results in Acute Cognitive Deficits and Sustained Impairment of Axonal Function	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; axonal transport; compound action potential; concussion; spatial learning; traumatic brain injury; working memory	AMYLOID PRECURSOR PROTEIN; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; MINOR HEAD-INJURY; POSTCONCUSSION SYNDROME; NEURONAL DEGENERATION; CORPUS-CALLOSUM; WORKING-MEMORY; CORTEX LESIONS; ADULT-RAT	Concussive brain injury (CBI) accounts for approximately 75% of all brain-injured people in the United States each year and is particularly prevalent in contact sports. Concussion is the mildest form of diffuse traumatic brain injury (TBI) and results in transient cognitive dysfunction, the neuropathologic basis for which is traumatic axonal injury (TAI). To evaluate the structural and functional changes associated with concussion-induced cognitive deficits, adult mice were subjected to an impact on the intact skull over the midline suture that resulted in a brief apneic period and loss of the righting reflex. Closed head injury also resulted in an increase in the wet weight: dry weight ratio in the cortex suggestive of edema in the first 24 h, and the appearance of Fluoro-Jade-B-labeled degenerating neurons in the cortex and dentate gyrus of the hippocampus within the first 3 days post-injury. Compared to sham-injured mice, brain-injured mice exhibited significant deficits in spatial acquisition and working memory as measured using the Morris water maze over the first 3 days (p < 0.001), but not after the fourth day post-injury. At 1 and 3 days post-injury, intra-axonal accumulation of amyloid precursor protein in the corpus callosum and cingulum was accompanied by neurofilament dephosphorylation, impaired transport of Fluoro-Gold and synaptophysin, and deficits in axonal conductance. Importantly, deficits in retrograde transport and in action potential of myelinated axons continued to be observed until 14 days post-injury, at which time axonal degeneration was apparent. These data suggest that despite recovery from acute cognitive deficits, concussive brain trauma leads to axonal degeneration and a sustained perturbation of axonal function.	[Fox, Douglas P.; Tessler, Alan R.; Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; [Creed, Jennifer A.; DiLeonardi, Ann Mae; Raghupathi, Ramesh] Drexel Univ, Coll Med, Program Neurosci, Philadelphia, PA 19129 USA; [Tessler, Alan R.] Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane,Room 277, Philadelphia, PA 19129 USA.	RRamesh@drexelmed.edu		DiLeonardi, Ann Mae/0000-0002-1476-7726	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD41699, NS065017]; VA Merit Review grantUS Department of Veterans Affairs; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065017] Funding Source: NIH RePORTER	We would like acknowledge the efforts of Ms. Rachel Tang for the analysis of the electrophysiology data. These studies were supported in part by grants from the NIH (no. HD41699 and NS065017 to R. R.), and a VA Merit Review grant to R.R. and A.T.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; HOVDA DA, 1990, ACT NEUR S, V51, P331; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; Keene CS, 2009, NEUROBIOL LEARN MEM, V91, P408, DOI 10.1016/j.nlm.2008.10.009; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ohlsson M, 2004, RESTOR NEUROL NEUROS, V22, P1; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Papp H, 2002, NEUROCHEM INT, V41, P429, DOI 10.1016/S0197-0186(02)00014-1; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Pothuizen HHJ, 2010, BEHAV BRAIN RES, V208, P566, DOI 10.1016/j.bbr.2010.01.001; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SCHALOMON PM, 1995, PHYSIOL BEHAV, V57, P1199; SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Smits M., 2010, NEURORADIOLOGY; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	75	82	82	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					547	563		10.1089/neu.2010.1729			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200006	21299360	Green Published			2021-06-18	
J	Meyers, JE; Volbrecht, M; Axelrod, BN; Reinsch-Boothby, L				Meyers, John E.; Volbrecht, Marie; Axelrod, Bradley N.; Reinsch-Boothby, Lorrie			Embedded Symptom Validity Tests and Overall Neuropsychological Test Performance	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; symptom validity testing; Meyers Neuropsychological Battery; Overall Test Battery Mean	BRAIN-INJURY; VALIDATION	A sample of 314 consecutive clinical and forensic referrals with mild traumatic brain injury was evaluated using the Meyers Neuropsychological Battery (MNB). A comparison was made of the test performance and performance on the embedded Symptom Validity Tests (SVTs) with a control for multicolinearity utilized. Using the nine embedded SVTs in the MNB, the incidence of poor effort fell at 26% of the total sample. Involvement in litigation was related to more failures on the individual SVTs. The correlation between failed effort measures and the Overall Test Battery Mean (OTBM) was consistently negative, regardless of litigation status, in that more failures were associated with lower OTBM scores. The correlation between the number of SVTs failed and the OTBM was -.77. Our results are similar to those presented by Green, Rohling, Lees-Haley, and Allen (2001); who reported a .73 correlation with the failure on the Word Memory Test and performance on the OTBM. The results of the current study also indicate that 50% of the variance in neuropsychological testing can be accounted by failures on internal SVTs.	[Meyers, John E.; Reinsch-Boothby, Lorrie] Meyers Neuropsychol Serv, Mililani, HI USA; [Volbrecht, Marie] Neuropsychol Consultants, Sioux Falls, SD USA; [Axelrod, Bradley N.] Vet Affairs Med Ctr, John D Dingell Dept, Detroit, MI USA	Meyers, JE (corresponding author), Meyers Neuropsychol Serv, Mililani, HI USA.	jmeyersneuro@yahoo.com					ANDREWS FM, 1981, GUIDE SELECTING STAT; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Boone K., 2007, ASSESSMENT FEIGNED C; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Green, 2003, WORD MEMORY TEST; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2010, CLIN NEUROPSYCHOL, V24, P137, DOI 10.1080/13854040902927546; Halstead WC, 1985, HALSTEAD REITAN NEUR; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Kozel JJ, 1998, ARCH CLIN NEUROPSYCH, V13, P327, DOI 10.1016/S0887-6177(97)00036-X; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Meyers J., 1995, REY COMPLEX FIGURE T; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/S15324826AN0804_6; Meyers J E, 1996, Appl Neuropsychol, V3, P89, DOI 10.1207/s15324826an0302_8; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 2004, ARCH CLIN NEUROPSYCH, V19, P637, DOI 10.1016/j.acn.2003.08.007; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Wechsler D., 1997, WAIS 3 ADM SCORING M	28	82	82	1	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2011	26	1					8	15		10.1093/arclin/acq083			8	Psychology, Clinical; Psychology	Psychology	709SU	WOS:000286462500002	21242283	Bronze			2021-06-18	
J	Berry, JG; Bloom, S; Foley, S; Palfrey, JS				Berry, Jay G.; Bloom, Sheila; Foley, Susan; Palfrey, Judith S.			Health Inequity in Children and Youth With Chronic Health Conditions	PEDIATRICS			English	Article						children; chronic disease; disability; disparity; epidemiology; incidence; prevalence; survival; special needs	TRAUMATIC BRAIN-INJURY; NUTRITION EXAMINATION SURVEY; FOLIC-ACID FORTIFICATION; UNITED-STATES; CYSTIC-FIBROSIS; CEREBRAL-PALSY; MEDICAL HOME; ETHNIC DISPARITIES; CHILDHOOD ASTHMA; CARE UTILIZATION	BACKGROUND: Over the last decades, there have been great advances in health care delivered to children with chronic conditions, but not all children have benefitted equally from them. OBJECTIVES: To describe health inequities experienced by children with chronic health conditions. METHODS: We performed a literature review of English-language studies identified from the Medline, Centers for Disease Control and Prevention, National Cancer Institute, and Cystic Fibrosis Foundation Web sites that were published between January 1985 and May 2009, included children aged 0 to 18 years, and contained the key words "incidence," "prevalence," "survival," "mortality," or "disparity" in the title or abstract for the following health conditions: acute leukemia, asthma, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorders, cerebral palsy, cystic fibrosis, diabetes mellitus, Down syndrome, HIV/AIDS, major congenital heart defects, major depressive disorder, sickle cell anemia, spina bifida, and traumatic brain injury. RESULTS: Black children had higher rates of cerebral palsy and HIV/AIDS, were less likely to be diagnosed with ADHD, had more emergency department visits, hospitalizations, and had higher mortality rates associated with asthma; and survived less often with Down syndrome, type 1 diabetes, and traumatic brain injury when compared with white children. Hispanic children had higher rates of spina bifida from Mexico-born mothers, had higher rates of HIV/AIDS and depression, were less likely to be diagnosed with ADHD, had poorer glycemic control with type 1 diabetes, and survived less often with acute leukemia compared with white children. CONCLUSIONS: Serious racial and ethnic health and health care inequities persist for children with chronic health conditions. Pediatrics 2010; 126: S111-S119	[Berry, Jay G.] Harvard Univ, Program Patient Safety & Qual, Childrens Hosp Boston, Sch Med,Div Gen Pediat,Complex Care Serv, Boston, MA 02115 USA; [Bloom, Sheila] Harvard Univ, Sch Med, Ctr Child & Adolescent Hlth Policy, Mass Gen Hosp Children, Boston, MA 02115 USA; [Foley, Susan] Inst Community Inclus, Boston, MA USA; [Palfrey, Judith S.] Amer Acad Pediat, Elk Grove Village, IL USA	Berry, JG (corresponding author), Harvard Univ, Program Patient Safety & Qual, Childrens Hosp Boston, Sch Med,Div Gen Pediat,Complex Care Serv, Fegan 10,300 Longwood Ave, Boston, MA 02115 USA.	jay.berry@childrens.harvard.edu			National Institute on Disability and Rehabilitation Research [H133B060012]; HSC Foundation (Washington, DC)	This work was supported by National Institute on Disability and Rehabilitation Research grant H133B060012 and the HSC Foundation (Washington, DC). We thank James Perrin, MD, Naomi Sacks, MA, Veronica Palmer-Segal, BA, Berna Kahrama, MS, Amy Yang, and Morgan Crossman for help with the background analysis for this article.	Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; [Anonymous], 2000, TERATOLOGY, V61, P86; Barbaresi WJ, 2005, ARCH PEDIAT ADOL MED, V159, P37, DOI 10.1001/archpedi.159.1.37; Bertrand J, 2001, PEDIATRICS, V108, P1155, DOI 10.1542/peds.108.5.1155; Betancourt JR, 2009, KAOHSIUNG J MED SCI, V25, P471, DOI 10.1016/S1607-551X(09)70553-4; Bishop J, 1997, AM J EPIDEMIOL, V145, P134; Boneva RS, 2001, CIRCULATION, V103, P2376; Botto LD, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e32; Boudreaux ED, 2003, PEDIATRICS, V111, pE615, DOI 10.1542/peds.111.5.e615; Canfield MA, 2006, BIRTH DEFECTS RES A, V76, P747, DOI 10.1002/bdra.20294; *CDCP, AUT SPECTR DIS; *CDCP, HIV AIDS AM YOUTH; *CDCP, 2008, HIV SURV REP DIAGN H, V20; *CDCP, 2005 NAT DIAB FACT S; Centers for Disease Control and Prevention, 1999, MMWR-MORBID MORTAL W, V48, P892; Centers for Disease Control and Prevention, 2007, HIV AIDS SURV REP CA; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P849; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P362; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P463; Cobanoglu A, 2002, ANN THORAC SURG, V74, P133, DOI 10.1016/S0003-4975(02)03619-6; Coker TR, 2009, ACAD PEDIATR, V9, P89, DOI 10.1016/j.acap.2008.11.007; Dabelea D, 2007, JAMA-J AM MED ASSOC, V298, P627; Dabelea D, 2007, JAMA-J AM MED ASSOC, V297, P2716; Duncan GE, 2006, ARCH PEDIAT ADOL MED, V160, P523, DOI 10.1001/archpedi.160.5.523; Dynesen H, 1978, Ugeskr Laeger, V140, P463; Flores G, 2008, PEDIATRICS, V121, pE286, DOI 10.1542/peds.2007-1243; Flores G, 2010, PEDIATRICS, V125, pE979, DOI 10.1542/peds.2010-0188; Forrester MB, 2002, TERATOLOGY, V65, P207, DOI 10.1002/tera.10042; Froehlich TE, 2007, ARCH PEDIAT ADOL MED, V161, P857, DOI 10.1001/archpedi.161.9.857; Gallegos-Macias Angela R, 2003, Pediatr Diabetes, V4, P19, DOI 10.1034/j.1399-5448.2003.00020.x; Gatford A, 2001, Br J Nurs, V10, P1193; Gilman SE, 2003, PSYCHOL MED, V33, P1341, DOI 10.1017/S0033291703008377; GITHENS JH, 1990, AM J DIS CHILD, V144, P466, DOI 10.1001/archpedi.1990.02150280088018; GORTMAKER SL, 1984, PEDIATR CLIN N AM, V31, P3; Grijalva C. G., 2009, Morbidity and Mortality Weekly Report, V58, P1; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Guyer B, 2000, PEDIATRICS, V106, P1307, DOI 10.1542/peds.106.6.1307; Homer CJ, 2008, PEDIATRICS, V122, pE922, DOI 10.1542/peds.2007-3762; Honein MA, 2001, JAMA-J AM MED ASSOC, V285, P2981, DOI 10.1001/jama.285.23.2981; Horn IB, 2004, AMBUL PEDIATR, V4, P269, DOI 10.1367/1539-4409(2004)4<269:CHDFAR>2.0.CO;2; Hoyert DL, 2001, PEDIATRICS, V108, P1241, DOI 10.1542/peds.108.6.1241; Hutton JL, 2006, CLIN PERINATOL, V33, P545, DOI 10.1016/j.clp.2006.03.016; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361; Karapurkar-Bhasin T, 2006, MMWR SURVEILL SUMM, V55, P1; Kemper AR, 2006, AMBUL PEDIATR, V6, P178, DOI 10.1016/j.ambp.2006.01.001; Kessler R C, 1998, Depress Anxiety, V7, P3, DOI 10.1002/(SICI)1520-6394(1998)7:1<3::AID-DA2>3.0.CO;2-F; Kosorok MR, 1996, STAT MED, V15, P449, DOI 10.1002/(SICI)1097-0258(19960315)15:5<449::AID-SIM173>3.0.CO;2-X; Lai HCJ, 2005, J PEDIATR-US, V147, pS57, DOI 10.1016/j.jpeds.2005.08.014; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEWINSOHN PM, 1993, J ABNORM PSYCHOL, V102, P133, DOI 10.1037/0021-843X.102.4.517; Linabery AM, 2008, CANCER-AM CANCER SOC, V113, P2575, DOI 10.1002/cncr.23866; Liptak GS, 2008, J DEV BEHAV PEDIATR, V29, P152, DOI 10.1097/DBP.0b013e318165c7a0; Lipton R, 1999, PEDIATRICS, V103, P952, DOI 10.1542/peds.103.5.952; Liu SL, 2002, JAMA-J AM MED ASSOC, V287, P1561, DOI 10.1001/jama.287.12.1561; Mahle WT, 2000, CIRCULATION, V102, P136; Mandell DS, 2009, AM J PUBLIC HEALTH, V99, P493, DOI 10.2105/AJPH.2007.131243; Mandell DS, 2002, J AM ACAD CHILD PSY, V41, P1447, DOI 10.1097/00004583-200212000-00016; Mathews T J, 2002, MMWR Recomm Rep, V51, P9; Mikolajczyk RT, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-21; Milazzo AS, 2002, J NATL MED ASSOC, V94, P875; Miller TW, 2009, CLIN PSYCHOL REV, V29, P77, DOI 10.1016/j.cpr.2008.10.001; Mulvihill BA, 2007, PEDIATRICS, V119, pS107, DOI 10.1542/peds.2006-2089P; *NAT DOWN SYNDR SO, POS PAP RAC DISP; National Cancer Institute, SEER CANC STAT REV 1; Newacheck PW, 2003, ARCH PEDIAT ADOL MED, V157, P244, DOI 10.1001/archpedi.157.3.244; Newacheck PW, 2002, AMBUL PEDIATR, V2, P247, DOI 10.1367/1539-4409(2002)002<0247:RAEDIA>2.0.CO;2; Nicholas SW, 2005, AM J PUBLIC HEALTH, V95, P245, DOI 10.2105/AJPH.2004.042705; O'Connor GT, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e333; PALFREY JS, 1987, J PEDIATR-US, V111, P651, DOI 10.1016/S0022-3476(87)80238-X; PALFREY JS, 2006, CHILD HLTH AM; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Perrin JM, 2007, JAMA-J AM MED ASSOC, V297, P2755, DOI 10.1001/jama.297.24.2755; Powars DR, 2005, MEDICINE, V84, P363, DOI 10.1097/01.md.0000189089.45003.52; Prejean J., 2008, Morbidity and Mortality Weekly Report, V57, P985; PUESCHEL SM, 1995, ACTA PAEDIATR, V84, P823, DOI 10.1111/j.1651-2227.1995.tb13768.x; Raphael JL, 2009, ACAD PEDIATR, V9, P242, DOI 10.1016/j.acap.2009.05.002; Resta RG, 2005, AM J MED GENET A, V133A, P31, DOI 10.1002/ajmg.a.30553; Riolo SA, 2005, AM J PUBLIC HEALTH, V95, P998, DOI 10.2105/AJPH.2004.047225; Roberts RE, 1997, AM J COMMUN PSYCHOL, V25, P95, DOI 10.1023/A:1024649925737; ROBERTS RE, 1995, J AM ACAD CHILD PSY, V34, P1608, DOI 10.1097/00004583-199512000-00011; Rock MJ, 2005, J PEDIATR-US, V147, pS73, DOI 10.1016/j.jpeds.2005.08.004; Rodriguez MA, 2002, ARCH PEDIAT ADOL MED, V156, P269, DOI 10.1001/archpedi.156.3.269; Schechter MS, 1998, J PEDIATR-US, V132, P260, DOI 10.1016/S0022-3476(98)70442-1; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shafer FE, 1996, J PEDIAT HEMATOL ONC, V18, P36, DOI 10.1097/00043426-199602000-00007; Shonkoff JP., 2000, NEURONS NEIGHBORHOOD; Sia C, 2004, PEDIATRICS, V113, P1473; SIMON GE, 1995, J CLIN EPIDEMIOL, V48, P1109, DOI 10.1016/0895-4356(95)00010-2; Singh GK, 2008, ANN EPIDEMIOL, V18, P682, DOI 10.1016/j.annepidem.2008.05.001; SMEDLEY BD, 2003, UNEQUAL TREATMENT CO; Sontag MK, 2005, J PEDIATR-US, V147, pS83, DOI 10.1016/j.jpeds.2005.08.005; Strauss DJ, 1998, PEDIATR NEUROL, V18, P143, DOI 10.1016/S0887-8994(97)00172-0; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Szilagyi PG, 2007, AMBUL PEDIATR, V7, P10, DOI 10.1016/j.ambp.2006.09.006; Telfair J, 2003, PUBLIC HEALTH REP, V118, P27, DOI 10.1093/phr/118.1.27; *US DEP HLTH HUM R, AD YOUNG AD HIV AIDS; Velie EM, 2006, PAEDIATR PERINAT EP, V20, P219, DOI 10.1111/j.1365-3016.2006.00722.x; White House Task Force on Childhood Obesity, 2012, SOLV PROBL CHILDH OB; Williams LJ, 2002, TERATOLOGY, V66, P33, DOI 10.1002/tera.10060; Winter S, 2002, PEDIATRICS, V110, P1220, DOI 10.1542/peds.110.6.1220; Wise PH, 2007, J PEDIATR-US, V151, pS6, DOI 10.1016/j.jpeds.2007.08.013; Wong LYC, 2001, PAEDIATR PERINAT EP, V15, P374, DOI 10.1046/j.1365-3016.2001.00371.x; Wu YW, 2006, PEDIATRICS, V118, P690, DOI 10.1542/peds.2006-0278; Yeargin-Allsopp M, 2003, JAMA-J AM MED ASSOC, V289, P49, DOI 10.1001/jama.289.1.49; Yeargin-Allsopp M, 2008, PEDIATRICS, V121, P547, DOI 10.1542/peds.2007-1270	107	82	83	0	40	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2010	126			S			S111	S119		10.1542/peds.2010-1466D			9	Pediatrics	Pediatrics	734IV	WOS:000288328700002	21123473	Bronze			2021-06-18	
J	Kaiser, PR; Valko, PO; Werth, E; Thomann, J; Meier, J; Stocker, R; Bassetti, CL; Baumann, CR				Kaiser, P. R.; Valko, P. O.; Werth, E.; Thomann, J.; Meier, J.; Stocker, R.; Bassetti, C. L.; Baumann, C. R.			Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury	NEUROLOGY			English	Article							FATIGUE; PREVALENCE; VALIDATION; DISABILITY; DISEASE; TRIAL; SCALE	Background: Excessive daytime sleepiness (EDS) and fatigue are common symptoms after traumatic brain injury (TBI), but there is no specific treatment for affected patients. With this pilot study, we aimed at studying the effect of daily modafinil on posttraumatic EDS and fatigue. Methods: We conducted a prospective, double-blind, randomized, placebo-controlled pilot study in 20 patients with TBI who had fatigue or EDS or both. After baseline examinations (questionnaires including the Epworth Sleepiness Scale to assess EDS and the Fatigue Severity Scale to assess fatigue, actigraphy, polysomnography, maintenance of wakefulness test, and psychomotor vigilance test), 10 patients received 100 to 200 mg modafinil every morning, and 10 patients were treated with placebo. After a 6-week treatment period, all examinations were repeated. Results: EDS improved significantly in patients with TBI who were treated with modafinil, compared with the placebo group. Similarly, the ability to stay awake on the maintenance of wakefulness test improved only in the modafinil group. Modafinil, however, had no impact on posttraumatic fatigue. Clinically relevant side effects were not observed. Conclusion: This study indicates that modafinil is effective and well tolerated in the treatment of posttraumatic EDS but not of fatigue. Classification of evidence: This study provides Class I evidence that modafinil (100-200 mg daily) improves posttraumatic EDS compared with placebo. This study provides Class I evidence that modafinil (100-200 mg daily) does not improve posttraumatic fatigue compared with placebo. Neurology (R) 2010;75:1780-1785	[Kaiser, P. R.; Valko, P. O.; Werth, E.; Thomann, J.; Meier, J.; Bassetti, C. L.; Baumann, C. R.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Stocker, R.] Univ Zurich Hosp, Dept Surg Intens Care, CH-8091 Zurich, Switzerland; [Bassetti, C. L.] Osped Civ, Neuroctr So Switzerland, Dept Neurol, Lugano, Switzerland	Baumann, CR (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	christian.baumann@usz.ch	Werth, E/AAN-7955-2021	Baumann, Christian/0000-0003-3417-1978; Werth, Esther/0000-0002-5099-3122	Schweizerischer Versicherungsverband (SVV), Zurich, Switzerland; Cephalon GmbH, Martinsried, Germany; Fresenius Medical Care; Bio-Synthesis Inc.; Swiss National FoundationSwiss National Science Foundation (SNSF); SUVA Foundation; Swiss Academy for Medical Sciences; Swisstransplant; Lundbeck Inc.Lundbeck Corporation; Respironics, Inc.; ResMed Inc.; Vifor Pharma; UCBUCB Pharma SA; Zurich Center for Integrative Human Physiology; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Cephalon; NovartisNovartis	Supported by Schweizerischer Versicherungsverband (SVV), Zurich, Switzerland, and Cephalon GmbH, Martinsried, Germany.; Dr. Kaiser, Dr. Valko, Dr. Werth, Ms. Thomann, and Ms. Meier report no disclosures. Prof. Stocker has served on scientific advisory boards for KCI Europe Holding BV and Baxter International Inc.; has received funding for travel or speaker honoraria from Fresenius Medical Care and Bio-Synthesis Inc.; and receives research support from the Swiss National Foundation, SUVA Foundation, the Swiss Academy for Medical Sciences, and Swisstransplant. Prof. Bassetti serves as Chief Editor of the Swiss Archives of Neurology and Psychiatry and on the editorial boards of the Journal of Sleep Research, Sleep Medicine, Somnology, and the Belgian Neurological Journal; has served on scientific advisory boards for and received speaker honoraria from Boehringer Ingelheim, Lundbeck Inc., Novartis, Pfizer Inc, ResMed Inc., and UCB; receives research support from Lundbeck Inc., Respironics, Inc., ResMed Inc., Vifor Pharma, and UCB; and receives institutional research support from the Zurich Center for Integrative Human Physiology and the Swiss National Science Foundation. Dr. Baumann has served on scientific advisory boards for and received speaker honoraria from Boehringer Ingelheim, UCB, and GlaxoSmithKline; receives research support from UCB, Cephalon, and Novartis; and receives institutional research support from the Swiss National Foundation.	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Black JE, 2005, SLEEP, V28, P464, DOI 10.1093/sleep/28.4.464; Bloch KE, 1999, RESPIRATION, V66, P440, DOI 10.1159/000029408; Brioschi A, 2009, EUR NEUROL, V62, P243, DOI 10.1159/000232927; Broughton RJ, 1997, NEUROLOGY, V49, P444, DOI 10.1212/WNL.49.2.444; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; Czeisler CA, 2005, NEW ENGL J MED, V353, P476, DOI 10.1056/NEJMoa041292; Dorrian J, 2003, SLEEP, V26, pA182; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; King MA, 2005, SLEEP MED, V6, P507, DOI 10.1016/j.sleep.2004.12.010; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; *NAT CTR INJ PREV, 2006, TRAUM BRAIN INJ US E; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Teitelman E, 2001, AM J PSYCHIAT, V158, P1341, DOI 10.1176/ajp.158.8.1341; Tyne HL, 2010, J NEUROL, V257, P452, DOI 10.1007/s00415-009-5351-8; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	23	82	82	3	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 16	2010	75	20					1780	1785		10.1212/WNL.0b013e3181fd62a2			6	Clinical Neurology	Neurosciences & Neurology	680EO	WOS:000284215400007	21079179	Green Accepted			2021-06-18	
J	Semple, BD; Bye, N; Ziebell, JM; Morganti-Kossmann, MC				Semple, Bridgette D.; Bye, Nicole; Ziebell, Jenna M.; Morganti-Kossmann, M. Cristina			Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Chemokine; Inflammation; CXCR2; Neutrophils	TRAUMATIC BRAIN-INJURY; COLONY-STIMULATING FACTOR; BARRIER PERMEABILITY; LEUKOCYTE INFILTRATION; NEURONAL DEGENERATION; GROWTH-FACTOR; WEIGHT-DROP; CELL-DEATH; EXPRESSION; ISCHEMIA	The contribution of infiltrated neutrophils to secondary damage following traumatic brain injury remains controversial. Chemokines that regulate neutrophil migration by signaling through the CXCR2 receptor are markedly elevated by brain injury and are associated with the propagation of secondary damage. This study thus investigated the function of CXCR2 in posttraumatic inflammation and secondary degeneration by examining Cxcr2-deficient (Cxcr2(-/-)) mice over 14 days following closed head injury (CHI). We demonstrate a significant attenuation of neutrophil infiltration in Cxcr2(-/-) mice at 12 hours and 7 days after CHI, despite increased levels of CXC neutrophil-attracting chemokines in the lesioned cortex. This coincides with reduced tissue damage, neuronal loss, and cell death in Cxcr2(-/-) mice compared to wild-type controls, with heterozygotes showing intermediate responses. In contrast, blood-brain barrier permeability and functional recovery did not appear to be affected by Cxcr2 deletion. This study highlights the deleterious contribution of neutrophils to posttraumatic neurodegeneration and demonstrates the importance of CXC chemokine signaling in this process. Therefore, CXCR2 antagonistic therapeutics currently in development for other inflammatory conditions may also be of benefit in posttraumatic neuroinflammation. Crown Copyright (c) 2010 Published by Elsevier Inc. All rights reserved.	[Semple, Bridgette D.] Monash Univ, Natl Trauma Res Inst, Dept Med, Melbourne, Vic 3004, Australia; [Semple, Bridgette D.; Bye, Nicole; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia	Semple, BD (corresponding author), Monash Univ, Natl Trauma Res Inst, Dept Med, 4th Floor Burnet Tower,89 Commercial Rd, Melbourne, Vic 3004, Australia.	Bridgette.Semple@monash.edu; Nicole.Bye@monash.edu; Jenna.Ziebell@adelaide.edu.au; Cristina.Morganti-Kossmann@monash.edu	Ziebell, Jenna/Y-4496-2019	Morganti-Kossmann, Cristina/0000-0002-0807-2063; Ziebell, Jenna/0000-0003-2497-4347	Victorian Neurotrauma Initiative (VNI), Australian Government; Transport Accident Commission (TAC)	This study was supported by the Victorian Neurotrauma Initiative (VNI), Australian Government (Australian Postgraduate Award for B.D. Semple), and Transport Accident Commission (TAC). Technical assistance was provided by Ms. Nakisa Malakooti and Dr. Tom Woodcock.	Barsante MM, 2008, BRIT J PHARMACOL, V153, P992, DOI 10.1038/sj.bjp.0707462; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; Betsuyaku T, 1999, J CLIN INVEST, V103, P825, DOI 10.1172/JCI5191; Bhatia M, 2007, REGUL PEPTIDES, V138, P40, DOI 10.1016/j.regpep.2006.08.006; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Cardona AE, 2008, BLOOD, V112, P256, DOI 10.1182/blood-2007-10-118497; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CHAPMAN RW, 2008, PHARMACOL THERAPEUT, V121, P55; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Conti AC, 1998, J NEUROSCI, V18, P5663; Coughlan CM, 2000, NEUROSCIENCE, V97, P591, DOI 10.1016/S0306-4522(00)00024-5; Cowburn AS, 2008, CHEST, V134, P606, DOI 10.1378/chest.08-0422; Devalaraja RM, 2000, J INVEST DERMATOL, V115, P234, DOI 10.1046/j.1523-1747.2000.00034.x; Dinkel K, 2004, P NATL ACAD SCI USA, V101, P331, DOI 10.1073/pnas.0303510101; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Ertel W, 1999, J TRAUMA, V46, P784, DOI 10.1097/00005373-199905000-00005; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Garau A, 2005, CYTOKINE, V30, P125, DOI 10.1016/j.cyto.2004.12.014; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Harris AK, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-49; HEINEL LA, 1994, BRAIN RES BULL, V34, P137, DOI 10.1016/0361-9230(94)90010-8; Joice SL, 2009, BRAIN RES, V1298, P13, DOI 10.1016/j.brainres.2009.08.076; Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853; Koedel U, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000461; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lindner M, 2009, GLIA, V57, P465, DOI 10.1002/glia.20833; LLOYD AR, 1995, J BIOL CHEM, V270, P28188; LOPEZ AF, 1984, BRIT J HAEMATOL, V57, P489, DOI 10.1111/j.1365-2141.1984.tb02923.x; Luan J, 2001, CYTOKINE, V14, P253, DOI 10.1006/cyto.2001.0882; LUI L, 2010, NAT NEUROSCI, V13, P319; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matsumoto T, 1997, LAB INVEST, V77, P119; Mihara K, 2005, EUR J IMMUNOL, V35, P2573, DOI 10.1002/eji.200526021; Milatovic S, 2003, WOUND REPAIR REGEN, V11, P213, DOI 10.1046/j.1524-475X.2003.11310.x; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Omari KM, 2006, GLIA, V53, P24, DOI 10.1002/glia.20246; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Palmer C, 2004, PEDIATR RES, V55, P549, DOI 10.1203/01.PDR.0000113546.03897.FC; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Reutershan J, 2006, DRUG NEWS PERSPECT, V19, P615, DOI 10.1358/dnp.2006.19.10.1068009; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Rose JJ, 2004, J BIOL CHEM, V279, P24372, DOI 10.1074/jbc.M401364200; Ryu JK, 2007, GLIA, V55, P439, DOI 10.1002/glia.20479; Schmidt OI., 2004, EUR J TRAUMA, V30, P135, DOI [10.1007/s00068-004-1394-9, DOI 10.1007/S00068-004-1394-9]; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Shaftel SS, 2007, J NEUROSCI, V27, P9301, DOI 10.1523/JNEUROSCI.1418-07.2007; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Tanimoto N, 2007, BIOCHEM BIOPH RES CO, V361, P533, DOI 10.1016/j.bbrc.2007.07.060; Nguyen TT, 2008, J BIONIC ENG, V5, P1, DOI 10.1016/S1672-6529(08)60001-3; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Wengner AM, 2008, BLOOD, V111, P42, DOI 10.1182/blood-2007-07-099648; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; YAMASAKI Y, 1995, STROKE, V26, P318, DOI 10.1161/01.STR.26.2.318; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	69	82	83	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	NOV	2010	40	2					394	403		10.1016/j.nbd.2010.06.015			10	Neurosciences	Neurosciences & Neurology	652WJ	WOS:000282041300005	20621186				2021-06-18	
J	Le Brocque, RM; Hendrikz, J; Kenardy, JA				Le Brocque, Robyne M.; Hendrikz, Joan; Kenardy, Justin A.			The Course of Posttraumatic Stress in Children: Examination of Recovery Trajectories Following Traumatic Injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						children; posttraumatic stress; statistical applications	ROAD TRAFFIC ACCIDENTS; DEVELOPMENTAL TRAJECTORIES; PEDIATRIC INJURY; BRAIN-INJURY; EVENT SCALE; DISORDER; PTSD; SYMPTOMS; WAR; HOSPITALIZATION	Objective Group-based trajectory modeling was used to identify patterns of posttraumatic stress symptom (PTSS) in children 6-16 years following accidental injury. The aims were to: (a) identify probable groups of children following distinct trajectories, and (b) identify risk factors affecting the probability of group membership. Method Children's Impact of Events Scale (n = 190) was used to assess PTSS up to 2 years post injury. Age, gender, type of injury, and preinjury behavior were assessed as risk factors. Results Three distinct trajectory groups were identified: resilient (57%), elevated stress symptoms which recovered quickly (33%), and chronic (10%). Younger children were more likely to be in the recovery group. Those with serious injuries were more likely to be in the chronic group. Preinjury child behavior problems were predictive of recovery and high chronic symptoms. Conclusion Identification of distinct PTSS trajectory groups has implications for understanding the course and treatment of PTSS in children.	[Le Brocque, Robyne M.; Hendrikz, Joan; Kenardy, Justin A.] Univ Queensland, Ctr Natl Res Disabil & Rehabil Med, Mayne Med Sch, Herston, Qld 4006, Australia	Le Brocque, RM (corresponding author), Univ Queensland, Ctr Natl Res Disabil & Rehabil, Sch Med, Herston Rd, Herston, Qld 4006, Australia.	r.lebrocque@uq.edu.au	Kenardy, Justin/F-2085-2010; Le Brocque, Robyne/F-4848-2010; Kenardy, Justin A/H-6603-2014	Le Brocque, Robyne/0000-0002-4574-1254; Kenardy, Justin A/0000-0001-9475-8450			Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Bonanno GA, 2005, CURR DIR PSYCHOL SCI, V14, P135, DOI 10.1111/j.0963-7214.2005.00347.x; DALLOW N, 2007, QUEENSLAND TRAUMA RE; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; Dyregrov A, 1996, SCAND J PSYCHOL, V37, P339, DOI 10.1111/j.1467-9450.1996.tb00667.x; Gillies ML, 2003, J TRAUMA STRESS, V16, P523, DOI 10.1023/A:1025774915005; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kahana SY, 2006, TRAUMATOLOGY, V12, P148, DOI [10.77/1534765606294562, DOI 10.1177/1534765606294562]; Kassam-Adams N, 2004, J AM ACAD CHILD PSY, V43, P403, DOI 10.1097/00004583-200404000-00006; Kenardy JA, 2006, PEDIATRICS, V118, P1002, DOI 10.1542/peds.2006-0406; King LA, 2006, J TRAUMA STRESS, V19, P771, DOI 10.1002/jts.20188; Landolt MA, 2003, J CHILD PSYCHOL PSYC, V44, P1199, DOI 10.1111/1469-7610.00201; Langeland W, 2008, NEUROSCI BIOBEHAV R, V32, P161, DOI 10.1016/j.neubiorev.2007.07.002; Layne C. M., 2009, TREATING TRAUMATIZED, P13; Mather FJ, 2003, BRAIN INJURY, V17, P1077, DOI 10.1080/0269905031000114045; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Meiser-Stedman R, 2005, AM J PSYCHIAT, V162, P1381, DOI 10.1176/appi.ajp.162.7.1381; Nagin DS, 1999, PSYCHOL METHODS, V4, P139, DOI 10.1037/1082-989X.4.2.139; O'Donnell ML, 2007, BEHAV RES THER, V45, P601, DOI 10.1016/j.brat.2006.03.015; Olsson KA, 2008, J ANXIETY DISORD, V22, P1447, DOI 10.1016/j.janxdis.2008.02.007; Orcutt HK, 2004, J TRAUMA STRESS, V17, P195, DOI 10.1023/B:JOTS.0000029262.42865.c2; Perrin S, 2005, BEHAV COGN PSYCHOTH, V33, P487, DOI 10.1017/S1352465805002419; Pine DS, 2005, NEUROPSYCHOPHARMACOL, V30, P1781, DOI 10.1038/sj.npp.1300814; STALLARD P, 1999, INT HDB ROAD TRAFFIC, P117; Sturms LM, 2005, CLIN REHABIL, V19, P312, DOI 10.1191/0269215505cr867oa; Udwin O, 2000, J CHILD PSYCHOL PSYC, V41, P969, DOI 10.1111/1469-7610.00685; World Health Organization, 2006, CHILD AD INJ PREV WH; Yule W, 2000, J CHILD PSYCHOL PSYC, V41, P503, DOI 10.1111/1469-7610.00635; YULE W, 1997, NFER CHILD PORTFOLIO	31	82	82	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUL	2010	35	6					637	645		10.1093/jpepsy/jsp050			9	Psychology, Developmental	Psychology	616EN	WOS:000279191700007	19541598	Green Published, Bronze			2021-06-18	
J	Elkin, BS; Ilankovan, A; Morrison, B				Elkin, Benjamin S.; Ilankovan, Ashok; Morrison, Barclay, III			Age-Dependent Regional Mechanical Properties of the Rat Hippocampus and Cortex	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							TRAUMATIC BRAIN-INJURY; VISCOELASTIC PROPERTIES; ARTICULAR-CARTILAGE; IN-VIVO; CORTICAL CONTUSION; STRESS-RELAXATION; ELASTIC-MODULUS; TISSUE; DEFORMATION; MODEL	Age-dependent outcomes following traumatic brain injury motivate the study of brain injury biomechanics in experimental animal models at different stages of development. Finite element models of the rat brain are used to better understand the mechanical mechanisms behind these age-dependent outcomes; however, age- and region-specific rat brain tissue mechanical properties are required for biofidelity in modeling. Here, we have used the atomic force microscope (A FM) to measure region-dependent mechanical properties for subregions of the cortex and hippocampus in P10, P17, and adult rats. Apparent elastic modulus increased nonlinearly with indentation strain, and a nonlinear Ogden hyperelastic model was used to fit the force-deflection data. Subregional heterogeneous distributions of mechanical properties changed significantly with age. Apparent elastic modulus was also found to increase overall with age, increasing by >100% between P10 and adult rats. Unconfined compression tests (epsilon = -0.3) were performed on whole slices of the hippocampus and cortex of P10, P17, and adult rats to verify the mechanical properties measured with the AFM. Mean apparent elastic modulus at an indentation strain of 30% from A FM measurements for each region and age correlated well with the long-term elastic modulus measured from 30% unconfined compression tests (slope not significantly different from 1, p>0.05). Protein, lipid, and sulfated glycosaminoglycan content of the brain increased with age and were positively correlated with tissue stiffness, whereas water content decreased with age and was negatively correlated with tissue stiffness. These correlations can be used to hypothesize mechanistic models for describing the mechanical behavior of brain tissue as well as to predict relative differences between brain tissue mechanical properties of other species, at different ages, and for different regions based on differences in tissue composition. [DOI: 10.1115/1.4000164]	[Elkin, Benjamin S.; Ilankovan, Ashok; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA	Elkin, BS (corresponding author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.		Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864	National Highway Traffic Safety Administration (NHTSA); NSF Career Award of Kevin D. Costa [BES 0239138]	We would like to thank Evren U. Azeloglu and Kevin D. Costa for the enlightening discussions and help with AFM analysis, Van C. Mow for the use of the unconfined compression device, and Mohammed Shaik for the help with data collection. This work was supported by the National Highway Traffic Safety Administration (NHTSA) and funds for the AFM equipment came from the NSF Career Award of Kevin D. Costa (Grant No. BES 0239138).	ALVARADO MV, 1984, J NEUROSCI RES, V11, P13, DOI 10.1002/jnr.490110103; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Azeloglu EU, 2008, AM J PHYSIOL-HEART C, V294, pH1197, DOI 10.1152/ajpheart.01027.2007; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; BRANDS D. W. A., 2000, P STAPP CAR CRASH C, V44, P249; BRISCOE BJ, 1994, J PHYS D APPL PHYS, V27, P1156, DOI 10.1088/0022-3727/27/6/013; BRUCE DA, 1990, CURR PROBL PEDIATR, V20, P66; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Costa KD, 2003, DIS MARKERS, V19, P139, DOI 10.1155/2004/482680; Costa KD, 1999, J BIOMECH ENG-T ASME, V121, P462, DOI 10.1115/1.2835074; Couper Z, 2008, BIOMECH MODEL MECHAN, V7, P105, DOI 10.1007/s10237-007-0079-9; Darling EM, 2007, BIOPHYS J, V92, P1784, DOI 10.1529/biophysj.106.083097; Darvish K., 2003, STAPP CAR CRASH J, V47, P79; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Del Bigio MR, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-12; DESOUZA SW, 1971, EXP NEUROL, V32, P431, DOI 10.1016/0014-4886(71)90009-4; Dimitriadis EK, 2002, BIOPHYS J, V82, P2798, DOI 10.1016/S0006-3495(02)75620-8; DIRESTA GR, 1991, J NEUROSCI METH, V39, P245, DOI 10.1016/0165-0270(91)90103-7; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HARDY WN, 2001, STAPP CAR CRASH J, V45, P368; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Inouye LS, 2006, TALANTA, V70, P584, DOI 10.1016/j.talanta.2006.01.024; JOHNSON KL, 1970, J MECH PHYS SOLIDS, V18, P115, DOI 10.1016/0022-5096(70)90029-3; Katta J, 2008, P I MECH ENG H, V222, P1, DOI 10.1243/09544119JEIM325; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; LAI WM, 1991, J BIOMECH ENG-T ASME, V113, P245, DOI 10.1115/1.2894880; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lei FL, 2007, J BIOMECH, V40, P936, DOI 10.1016/j.jbiomech.2006.03.014; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; LIKHITPANICHKUL M, 2007, P ASME 2007 SUMM BIO; Lin DC, 2007, EXPRESS POLYM LETT, V1, P576, DOI 10.3144/expresspolymlett.2007.79; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; Lippert SA, 2004, BIORHEOLOGY, V41, P681; Lopez-Picon FR, 2003, HIPPOCAMPUS, V13, P767, DOI 10.1002/hipo.10122; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Mahaffy RE, 2000, PHYS REV LETT, V85, P880, DOI 10.1103/PhysRevLett.85.880; Mahaffy RE, 2004, BIOPHYS J, V86, P1777, DOI 10.1016/S0006-3495(04)74245-9; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; Martinez A, 2002, J CHEMOMETR, V16, P41, DOI 10.1002/cem.669; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Miller K, 2005, J BIOMECH, V38, P153, DOI 10.1016/j.jbiomech.2004.03.004; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; MOW VC, 1980, J BIOMECH ENG-T ASME, V102, P73, DOI 10.1115/1.3138202; Nicolle S, 2005, BIORHEOLOGY, V42, P209; OBRIEN JS, 1965, J LIPID RES, V6, P537; OOHIRA A, 1986, J NEUROCHEM, V47, P588; OVERBEEK JTG, 1953, J COLL SCI IMP U TOK, V8, P593, DOI 10.1016/0095-8522(53)90048-8; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; Pena A, 2005, ACT NEUR S, V95, P333; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Riu J, 1997, TRAC-TREND ANAL CHEM, V16, P211, DOI 10.1016/S0165-9936(97)00014-9; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Shreiber DI, 2009, BIOMECH MODEL MECHAN, V8, P311, DOI 10.1007/s10237-008-0137-y; Stolz M, 2004, BIOPHYS J, V86, P3269, DOI 10.1016/S0006-3495(04)74375-1; Sun DD, 2004, J BIOMECH ENG-T ASME, V126, P6, DOI 10.1115/1.1644562; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; WINICK M, 1968, PEDIATR RES, V2, P352, DOI 10.1203/00006450-196809000-00003; Xu G, 2009, BIOMECH MODEL MECHAN, V8, P253, DOI 10.1007/s10237-008-0131-4; YOFFE EH, 1984, PHILOS MAG A, V50, P813, DOI 10.1080/01418618408237539; ZENG K, 1992, J MATER SCI, V27, P3789, DOI 10.1007/BF00545457; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714	91	82	82	1	23	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JAN	2010	132	1							011010	10.1115/1.4000164			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	550CW	WOS:000274106900010	20524748				2021-06-18	
B	Patel, V; Lund, C; Hatherill, S; Plagerson, S; Corrigall, J; Funk, M; Flisher, AJ		Blas, E; Kurup, AS		Patel, Vikram; Lund, Crick; Hatherill, Sean; Plagerson, Sophie; Corrigall, Joanne; Funk, Michelle; Flisher, Alan J.			Mental disorders: equity and social determinants	EQUITY, SOCIAL DETERMINANTS AND PUBLIC HEALTH PROGRAMMES			English	Article; Book Chapter							DEFICIT-HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; MIDDLE-INCOME COUNTRIES; CHILD SEXUAL-ABUSE; MAJOR DEPRESSION; RISK-FACTORS; HEALTH SURVEYS; ANTIDEPRESSANT TREATMENT; PSYCHIATRIC-DISORDER; FAMILY-ENVIRONMENT	As with most nonconummicable diseases, the etiology of mental disorders is multifactorial, with risk determined by an interaction of genetic, other biological, psychological and social determinants. The large variation in the prevalence of most mental disorders between and within countries suggests that the social determinants have particular salience. This chapter focuses on social determinants with emphasis on evidence from low- and middle-income countries, and gives particular attention to two examples of mental disorders: depression and attention deficit hyperactivity disorder (ADHD). These disorders were selected because they are each associated with a considerable burden, and there is a substantive evidence base that interventions for these disorders are effective and feasible. There are significantly increased rates of depression among low socioeconomic groups, and exposure to risk factors is disproportionately high in contexts characterized by social disadvantage where vulnerable groups are over represented. There is convincing evidence of an association between depression and stressful life events; exposure to violence and other crimes; chronic physical ill-health; low levels of educational attainment; conflict; disasters; stressful working environments; and female gender. Additionally, reasonable evidence implicates discrimination, income inequality, food insecurity, hunger, unemployment, toxins, urbanization, lack of housing, overcrowding, low social capital, poor sanitation and built environment, and minority ethnicity. Overall rates of mental health service use are generally lower amongst the disadvantaged. Low mental health literacy and stigma may reduce the ability of people with depression to use treatment services effectively. Further, depression is associated with negative physical health outcomes, including cardiovascular disease, type 2 diabetes mellitus, injuries, HIV/AIDS and various perinatal and reproductive conditions; consequences of these comorbidities may also show social gradients. While increased risk of ADHD is associated with lower socioeconomic status and lower parental education in high-income countries, research on ADHD from low- and middle-income countries is scarce and inconclusive. The expression of genetic susceptibility to ADHD appears to be moderated by environmental exposures. Fetal or neonatal hypoxia, traumatic brain injury, epilepsy and antiepileptic medications, and HIV infection are all associated with ADHD, and these exposures all show social gradients. Also, male gender appears to confer additional risk. Children with ADHD experience adverse academic outcomes. Put simply, mental disorders are inequitably distributed, as people who are socially and economically disadvantaged bear a disproportionate burden of mental disorders and their adverse consequences. A vicious cycle of disadvantage and mental disorder is the result of the dynamic interrelationship between them. This chapter reviews a wealth of evidence on interventions that can break this cycle, by addressing both upstream social determinants and vulnerabilities, and downstream health outcomes and consequences through a combination of population- and individual-level actions. A key goal is for health care systems to be responsive to the mental health needs of the population. Efforts to increase coverage of cost-effective interventions must explicitly target disadvantaged populations and health impact assessments of macroeconomic policies must consider mental health outcomes. Evidence from low- and middle-income countries remains relatively scarce and more contextual research is required to inform mental health policy and practice. In particular, research is needed regarding the impacts of social and economic change on mental disorder, and the mechanisms through which protective factors strengthen resilience and promote mental health. Longitudinal monitoring of population mental health is crucial for this purpose.								Aaron R, 2004, LANCET, V363, P1117, DOI 10.1016/S0140-6736(04)15896-0; Achenbach TM, 1983, MANUAL CHILD BEHAV C; Ahmed SM, 2001, WORLD DEV, V29, P1957, DOI 10.1016/S0305-750X(01)00069-9; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andrade LH, 2008, SOC PSYCH PSYCH EPID, V43, P45, DOI 10.1007/s00127-007-0263-3; [Anonymous], 1992, JAMA, V268, P3098; Araya R, 2003, J EPIDEMIOL COMMUN H, V57, P501, DOI 10.1136/jech.57.7.501; Ashenafi Y, 2001, East Afr Med J, V78, P308; BEISER M, 1994, INT J METHOD PSYCH, V4, P157; BHATIA MS, 1991, J CHILD PSYCHOL PSYC, V32, P297, DOI 10.1111/j.1469-7610.1991.tb00308.x; Bhugra D, 2004, BRIT J PSYCHIAT, V184, P10, DOI 10.1192/bjp.184.1.10; Biederman J, 1996, J AM ACAD CHILD PSY, V35, P343, DOI 10.1097/00004583-199603000-00016; Biederman J, 2005, BIOL PSYCHIAT, V57, P1215, DOI 10.1016/j.biopsych.2004.10.020; BIEDERMAN J, 1995, ARCH GEN PSYCHIAT, V52, P464; Biederman J, 2002, AM J PSYCHIAT, V159, P1556, DOI 10.1176/appi.ajp.159.9.1556; Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2; Bodnar LM, 2005, BIOL PSYCHIAT, V58, P679, DOI 10.1016/j.biopsych.2005.05.009; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P161, DOI 10.1001/archpsyc.55.2.161; BROMET EJ, 2002, PSYCHIAT SOC, P241; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Buitelaar JK, 2006, EUR CHILD ADOLES PSY, V15, P177, DOI 10.1007/s00787-005-0523-2; Chakraborty A, 2002, BRIT J PSYCHIAT, V180, P475, DOI 10.1192/bjp.180.6.475; Chandola T, 2001, HEALTH PLACE, V7, P105, DOI 10.1016/S1353-8292(01)00002-8; Chatterjee S, 2008, WORLD PSYCHIATRY, V7, P39; Chisholm D, 2007, LANCET, V370, P1241, DOI 10.1016/S0140-6736(07)61242-2; Christakis DA, 2004, PEDIATRICS, V113, P708, DOI 10.1542/peds.113.4.708; Chronis AM, 2003, J AM ACAD CHILD PSY, V42, P1424, DOI 10.1097/00004583-200312000-00009; Cohen A, 2006, ARCH GEN PSYCHIAT, V63, P50, DOI 10.1001/archpsyc.63.1.50; Cohen A., 2002, WORLD MENTAL HLTH CA; Cooper PJ, 2002, BRIT J PSYCHIAT, V180, P76, DOI 10.1192/bjp.180.1.76; CORRIGALL J, 2007, DECREASING BURDEN ME; Covey LS, 1998, J ADDICT DIS, V17, P35, DOI 10.1300/J069v17n01_04; De Silva MJ, 2005, J EPIDEMIOL COMMUN H, V59, P619, DOI 10.1136/jech.2004.029678; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; DHADPHALE M, 1984, ACTA PSYCHIAT SCAND, V69, P151, DOI 10.1111/j.1600-0447.1984.tb02480.x; Dunn DW, 2003, DEV MED CHILD NEUROL, V45, P50, DOI 10.1017/S0012162203000094; Faraone Stephen V, 2003, World Psychiatry, V2, P104; FINKELHOR D, 1990, PROF PSYCHOL-RES PR, V21, P325, DOI 10.1037/0735-7028.21.5.325; FLAHERTY JA, 1988, J NERV MENT DIS, V176, P257; Flisher A. J, 2007, MONITORING CHILD WEL, P111; Flisher AJ, 1997, PSYCHOL MED, V27, P1145, DOI 10.1017/S0033291797005412; FLISHER AJ, 2007, J CHILD ADOLESCENT M, V19, P170; FRONEBERG B, 2003, AFRICAN NEWSLETTER O, V13, P32; Ghanizadeh A, 2005, J CHILD ADOLESC MENT, V17, P31, DOI 10.2989/17280580509486590; Goldberg D., 1978, MANUAL GEN HLTH QUES; Goodman R, 2000, BRIT J PSYCHIAT, V177, P534, DOI 10.1192/bjp.177.6.534; GUEVARA JP, 2007, EXPERT REV PHARM OUT, V3, P201; HARDING TW, 1980, PSYCHOL MED, V10, P231, DOI 10.1017/S0033291700043993; Heflin CM, 2005, SOC SCI MED, V61, P1971, DOI 10.1016/j.socscimed.2005.04.014; Heise L, 2002, INT J GYNECOL OBSTET, V78, pS5, DOI 10.1016/S0020-7292(02)00038-3; Herrman H, 2006, PROMOTING MENTAL HLT; HOSMAN CMH, 2005, EVIDENCE EFFECTIVE I; Hu TW, 2006, J MENT HEALTH POLICY, V9, P3; Hyman S, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P605; *I MED, 2001, NEUR PSYCH DEV MENT; JIN RL, 1995, CAN MED ASSOC J, V153, P529; Jorm AF, 1997, MED J AUSTRALIA, V166, P182, DOI 10.5694/j.1326-5377.1997.tb140071.x; Kaplan H. I., 1994, KAPLAN SADOCKS SYNOP; Kashala E, 2005, Afr Health Sci, V5, P172; Kashala E, 2006, EUR CHILD ADOLES PSY, V15, P292, DOI 10.1007/s00787-006-0536-5; Kendall J, 2002, ADV NURS SCI, V25, P22, DOI 10.1097/00012272-200212000-00003; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Kleinmann A., 2004, NEW ENGL J MED, V31, P10; Kurihara T, 2007, PSYCHIAT CLIN NEUROS, V61, P205, DOI 10.1111/j.1440-1819.2007.01642.x; LEIBSON CL, 2007, JAMA-J AM MED ASSOC, V285, P60; Linnet KM, 2003, AM J PSYCHIAT, V160, P1028, DOI 10.1176/appi.ajp.160.6.1028; London L, 2005, AM J IND MED, V47, P308, DOI 10.1002/ajim.20147; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Lorant V, 2003, AM J EPIDEMIOL, V157, P98, DOI 10.1093/aje/kwf182; Lovisi GM, 2003, SOC PSYCH PSYCH EPID, V38, P493, DOI 10.1007/s00127-003-0666-8; MANN EM, 1992, AM J PSYCHIAT, V149, P1539; Marsella AJ, 1998, AM PSYCHOL, V53, P624, DOI 10.1037/0003-066X.53.6.624; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; McKee-Ryan FM, 2005, J APPL PSYCHOL, V90, P53, DOI 10.1037/0021-9010.90.1.53; Melfi CA, 1999, J HEALTH CARE POOR U, V10, P201; Mick E, 2002, J AM ACAD CHILD PSY, V41, P378, DOI 10.1097/00004583-200204000-00009; Mick E, 2002, J DEV BEHAV PEDIATR, V23, P16, DOI 10.1097/00004703-200202000-00004; Mollica RF, 2004, LANCET, V364, P2058, DOI 10.1016/S0140-6736(04)17519-3; Moussavi S, 2007, LANCET, V370, P851, DOI 10.1016/S0140-6736(07)61415-9; Nigg J.T., 2006, WHAT CAUSES ADHD UND; Nozyce ML, 2006, PEDIATRICS, V117, P763, DOI 10.1542/peds.2005-0451; Olfson M, 2006, AM J PSYCHIAT, V163, P101, DOI 10.1176/appi.ajp.163.1.101; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; Paperwalla KN, 2004, MED CLIN N AM, V88, P1483, DOI 10.1016/j.mcna.2004.06.007; Patel V, 2004, BMJ-BRIT MED J, V328, P820, DOI 10.1136/bmj.328.7443.820; Patel V, 2003, LANCET, V361, P33, DOI 10.1016/S0140-6736(03)12119-8; Patel V, 2002, AM J PSYCHIAT, V159, P43, DOI 10.1176/appi.ajp.159.1.43; Patel V, 2001, BRIT MED BULL, V57, P33, DOI 10.1093/bmb/57.1.33; Patel V, 2006, ARCH GEN PSYCHIAT, V63, P404, DOI 10.1001/archpsyc.63.4.404; PATEL V, 2001, POVERTY INEQUALITY H, P247; PATEL V, 2005, PROMOTING MENTAL HLT; Patel V, 2007, LANCET, V370, P991, DOI 10.1016/S0140-6736(07)61240-9; Patel V, 2007, INT J EPIDEMIOL, V36, P703, DOI 10.1093/ije/dym147; Patel V, 2007, LANCET, V369, P1302, DOI 10.1016/S0140-6736(07)60368-7; Patel V, 2007, TROP MED INT HEALTH, V12, P130, DOI 10.1111/j.1365-3156.2006.01756.x; Patel V, 2007, BRIT J PSYCHIAT, V190, P77, DOI 10.1192/bjp.bp.106.025692; Patel V, 2006, BRIT J PSYCHIAT, V189, P547, DOI 10.1192/bjp.bp.106.022558; Paykel ES, 1998, BRIT J PSYCHIAT, V173, P519, DOI 10.1192/bjp.173.6.519; Phillips MR, 2002, LANCET, V359, P835, DOI 10.1016/S0140-6736(02)07954-0; Piccinelli M, 2000, BRIT J PSYCHIAT, V177, P486, DOI 10.1192/bjp.177.6.486; Pineda DA, 2003, INT J NEUROSCI, V113, P49, DOI 10.1080/00207450390161921; PRATINIDHI AK, 1999, INDIAN J PEDIATR, V59, P423; Pressman LJ, 2006, J AM ACAD CHILD PSY, V45, P346, DOI 10.1097/01.chi.0000192248.61271.c8; Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0; RAPPLEY MD, 2007, NEW ENGL J MED, V352, P165; Ritsher JB, 2004, PSYCHIAT RES, V129, P257, DOI 10.1016/j.psychres.2004.08.003; Rodriguez A, 2005, J CHILD PSYCHOL PSYC, V46, P246, DOI 10.1111/j.1469-7610.2004.00359.x; Rohde LA, 1999, J AM ACAD CHILD PSY, V38, P716, DOI 10.1097/00004583-199906000-00019; Rohde LA, 2005, BIOL PSYCHIAT, V57, P1436, DOI 10.1016/j.biopsych.2005.01.042; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Rusch N, 2005, EUR PSYCHIAT, V20, P529, DOI 10.1016/j.eurpsy.2005.04.004; RUTTER M, 1975, BRIT J PSYCHIAT, V126, P493, DOI 10.1192/bjp.126.6.493; RUTTER M, 1976, PSYCHOL MED, V6, P313, DOI 10.1017/S003329170001388X; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Samaan RA, 2000, J HEALTH CARE POOR U, V11, P100; Saraceno Benedetto, 2005, World Psychiatry, V4, P181; SARTORIUS N, 1996, BRIT J PSYCHIAT, pS38; Sartorius Norman, 2006, Psychol Health Med, V11, P383, DOI 10.1080/13548500600595418; Sartorius N, 2007, LANCET, V370, P810, DOI 10.1016/S0140-6736(07)61245-8; SAUGATA B, 1996, IND J CLIN PSYCHOL, V23, P184; Saxena S, 2006, BRIT J PSYCHIAT, V188, P81, DOI 10.1192/bjp.bp.105.011221; Saxena S, 2007, LANCET, V370, P878, DOI 10.1016/S0140-6736(07)61239-2; Scahill L, 1999, J AM ACAD CHILD PSY, V38, P976, DOI 10.1097/00004583-199908000-00013; Sirey JA, 2001, AM J PSYCHIAT, V158, P479, DOI 10.1176/appi.ajp.158.3.479; Spataro J, 2004, BRIT J PSYCHIAT, V184, P416, DOI 10.1192/bjp.184.5.416; STAVROULA L, 2004, WORK ORG STRESS; Stewart WF, 2003, JAMA-J AM MED ASSOC, V289, P3135, DOI 10.1001/jama.289.23.3135; Thomson H, 2003, J EPIDEMIOL COMMUN H, V57, P11, DOI 10.1136/jech.57.1.11; Tramontina S, 2001, CAN J PSYCHIAT, V46, P941; *US SUBST AB MENT, 1999, MENT HLTH REP SURG G; Vinokur A D, 2000, J Occup Health Psychol, V5, P32, DOI 10.1037/1076-8998.5.1.32; Wang PS, 2008, AM J PSYCHIAT, V165, P34, DOI 10.1176/appi.ajp.2007.07030502; Wang PS, 2007, LANCET, V370, P841, DOI 10.1016/S0140-6736(07)61414-7; Weich S, 2001, BRIT J PSYCHIAT, V178, P222, DOI 10.1192/bjp.178.3.222; Weich S, 1998, BMJ-BRIT MED J, V317, P115, DOI 10.1136/bmj.317.7151.115; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; *WHO W PAC REG OFF, 2005, INT POV GEND HLTH PR; Wilcox CE, 2007, SOC SCI MED, V64, P1600, DOI 10.1016/j.socscimed.2006.11.032; World Health Organisation (WHO), 2005, MENT HLTH INF SYST M; World Health Organization, 2001, WORLD HLTH REP 2001; World Health Organization, 2007, INT STAT CLASS DIS R; Wright A, 2005, MED J AUSTRALIA, V183, P18, DOI 10.5694/j.1326-5377.2005.tb06881.x; Wright A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-215; Zimmerman FJ, 2005, HEALTH ECON, V14, P1197, DOI 10.1002/hec.1011	144	82	86	1	43	WORLD HEALTH ORGANIZATION	GENEVA	DISTRIBUTION & SALES SERVICE, 1211 27 GENEVA, SWITZERLAND			978-92-4-156397-0				2010							115	134					20	Public, Environmental & Occupational Health; Sociology	Public, Environmental & Occupational Health; Sociology	BPH11	WOS:000278839000007					2021-06-18	
J	Fergenbaum, JH; Bruce, S; Lou, W; Hanley, AJG; Greenwood, C; Young, TK				Fergenbaum, Jennifer H.; Bruce, Sharon; Lou, Wendy; Hanley, Anthony J. G.; Greenwood, Carol; Young, T. Kue			Obesity and Lowered Cognitive Performance in a Canadian First Nations Population	OBESITY			English	Article							BODY-MASS INDEX; TRAUMATIC BRAIN-INJURY; RISK-FACTORS; EXECUTIVE DYSFUNCTION; INSULIN-RESISTANCE; INCIDENT DEMENTIA; TRAIL; IMPAIRMENT; ADIPOSITY; DECLINE	The association between obesity, other cardiovascular risk factors, and cognitive function in a Canadian First Nations population was investigated using a cross-sectional design. Eligible individuals were aged >= 18 years, without a history of stroke, nonpregnant, with First Nations status, and who had undergone cognitive function assessment by the Clock Drawing Test (CDT) and Trail Making Test Parts A and B. Parts A and B were combined into an Executive Function Score (TMT-exec). Hypertension, a previous history of cardiovascular disease, dyslipidemia, metabolic syndrome, insulin resistance, and the presence and duration of diabetes were examined in addition to obesity. In the case of TMT-exec only, obese individuals were at an approximately fourfold increased risk for lowered cognitive performance compared to those who were not obese in multivariable models (odds ratio (OR): 3.77, 95% confidence interval (CI): 1.46-9.72) whereas there was no effect for overweight individuals compared to those with a normal weight in unadjusted analysis. Those having an increased waist circumference also had 5 times the risk compared to those without an increased waist circumference (OR: 5.41, 95% CI: 1.83-15.99). Adjusted for age, sex, and insulin resistance, individuals having the metabolic syndrome were at an approximately fourfold increased risk compared to those without the metabolic syndrome (OR: 3.67, 95% CI: 1.34-10.07). No other cardiovascular risk factors were associated. Obesity and metabolic syndrome were associated with lowered cognitive performance. These results highlight the importance of studying the health effects of obesity beyond traditional disease endpoints, even in a relatively youthful population.	[Fergenbaum, Jennifer H.; Lou, Wendy; Hanley, Anthony J. G.; Young, T. Kue] Univ Toronto, Div Epidemiol, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Bruce, Sharon] Univ Manitoba, Dept Community Hlth Sci, Fac Med, Winnipeg, MB R3T 2N2, Canada; [Hanley, Anthony J. G.; Greenwood, Carol] Univ Toronto, Fac Med, Dept Nutr Sci, Toronto, ON, Canada	Fergenbaum, JH (corresponding author), Univ Toronto, Div Epidemiol, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.	jennifer.fergenbaum@utoronto.ca	Duran, Bonnie m/A-3029-2009	Salerno, Jennifer/0000-0001-7282-5579	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [CRT-43825]; Canadian Stroke Network	Funding for the study was provided by Canadian Institutes of Health Research (CIHR) (CRT-43825, PI: T. K. Y.) and the Canadian Stroke Network (PI: S. B.). J. H. F. is the recipient of a CIHR doctoral award.	Abbatecola AM, 2004, J AM GERIATR SOC, V52, P1713, DOI 10.1111/j.1532-5415.2004.52466.x; [Anonymous], 2000, OB PREV MAN GLOB EP; Beydoun MA, 2008, OBES REV, V9, P204, DOI 10.1111/j.1467-789X.2008.00473.x; Bowler JV, 2005, J NEUROL NEUROSUR PS, V76, pV35, DOI 10.1136/jnnp.2005.082313; Bruce SG, 2008, DIABETES CARE, V31, P1837, DOI 10.2337/dc08-0278; Cukierman T, 2005, DIABETOLOGIA, V48, P2460, DOI 10.1007/s00125-005-0023-4; Dufouil C, 2005, NEUROLOGY, V64, P1531, DOI 10.1212/01.WNL.0000160114.42643.31; Elias MF, 2005, NEUROBIOL AGING, V26, pS11, DOI 10.1016/j.neurobiolaging.2005.08.019; Greenwood CE, 2005, NEUROBIOL AGING, V26, pS42, DOI 10.1016/j.neurobiolaging.2005.08.017; Gunstad J, 2007, COMPR PSYCHIAT, V48, P57, DOI 10.1016/j.comppsych.2006.05.001; Gustafson D, 2008, EUR J PHARMACOL, V585, P163, DOI 10.1016/j.ejphar.2008.01.052; Gustafson D, 2006, LANCET NEUROL, V5, P713, DOI 10.1016/S1474-4422(06)70526-9; Hester RL, 2005, CLIN NEUROPSYCHOL, V19, P45, DOI 10.1080/13854040490524137; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; KALMIJN S, 1995, DIABETOLOGIA, V38, P1096, DOI 10.1007/s001250050397; Knecht S, 2008, PROG NEUROBIOL, V84, P85, DOI 10.1016/j.pneurobio.2007.09.003; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; Naismith SL, 2003, J CLIN EXP NEUROPSYC, V25, P866, DOI 10.1076/jcen.25.6.866.16472; *NIH, 2000, NIH PUBL; Ogden CL, 2007, GASTROENTEROLOGY, V132, P2087, DOI 10.1053/j.gastro.2007.03.052; Peila R, 2004, NEUROLOGY, V63, P228, DOI 10.1212/01.WNL.0000129989.28404.9B; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rosengren A, 2005, ARCH INTERN MED, V165, P321, DOI 10.1001/archinte.165.3.321; Russell D, 2002, J NEUROL SCI, V203, P211, DOI 10.1016/S0022-510X(02)00293-9; STUNKARD AJ, 1993, NEW ENGL J MED, V329, P1036, DOI 10.1056/NEJM199309303291411; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Turgeon JL, 2006, ENDOCR REV, V27, P575, DOI 10.1210/er.2005-0020; van Exel E, 2002, ANN NEUROL, V51, P716, DOI 10.1002/ana.10220; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; WATSON YI, 1993, J AM GERIATR SOC, V41, P1235, DOI 10.1111/j.1532-5415.1993.tb07308.x; Whitmer RA, 2008, NEUROLOGY, V71, P1057, DOI 10.1212/01.wnl.0000306313.89165.ef; Whitmer RA, 2005, BMJ-BRIT MED J, V330, P1360, DOI 10.1136/bmj.38446.466238.E0; Whitmer RA, 2007, CURR ALZHEIMER RES, V4, P103, DOI 10.2174/156720507780362047; Wolf PA, 2007, CURR ALZHEIMER RES, V4, P111, DOI 10.2174/156720507780362263; Yaffe K, 2002, ARCH NEUROL-CHICAGO, V59, P378, DOI 10.1001/archneur.59.3.378; Yaffe K, 2007, J AM GERIATR SOC, V55, P758, DOI 10.1111/j.1532-5415.2007.01139.x; Young SE, 2006, DIABETES CARE, V29, P2688, DOI 10.2337/dc06-0915; 2001, JAMA, V285, P2486	42	82	82	0	15	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1930-7381	1930-739X		OBESITY	Obesity	OCT	2009	17	10					1957	1963		10.1038/oby.2009.161			7	Endocrinology & Metabolism; Nutrition & Dietetics	Endocrinology & Metabolism; Nutrition & Dietetics	502UD	WOS:000270484800022	19478788				2021-06-18	
J	Pytel, P; Alexander, JJ				Pytel, Peter; Alexander, Jessy J.			Pathogenesis of septic encephalopathy	CURRENT OPINION IN NEUROLOGY			English	Article						brain; inflammation; sepsis	BLOOD-BRAIN-BARRIER; MAGNESIUM-SULFATE; NITRIC-OXIDE; COGNITIVE IMPAIRMENT; CRITICAL ILLNESS; TRAUMATIC BRAIN; SEPSIS SYNDROME; RAT MODEL; SHOCK; INJURY	Purpose of review Septic encephalopathy is a frequent complication in severe sepsis, the pathogenesis and mechanisms of which are not fully understood. Here, we review recent advances in our understanding of septic encephalopathy, from molecular mechanisms to behavioral alterations, from diagnostic tools to potential therapeutic agents. Recent findings Recent insights into septic encephalopathy include: microcirculatory failure precedes changes in evoked potential responses; blood-brain barrier alteration is prevented by reducing intercellular adhesion molecule expression and pericyte detachment; reducing infiltration of CD68 macrophages and inhibiting complement activation alleviates neuroinflammation in septic encephalopathy; and reducing mitochondrial dysfunction and inducible nitric oxide synthase expression can restore altered brain function. In addition, other factors such as the circulating levels of growth hormone are independent predictors for mortality and correlate with the severity of sepsis. Similar to humans, septic rats present recognition memory impairment and depressive-like symptoms but not anxiety-like behavior and will serve as efficient models to study the underlying mechanisms of septic encephalopathy. Summary Septic encephalopathy is a dynamic disease caused by a complex network of systems and pathways going awry. More insights into the pathogenesis of septic encephalopathy are expected to lead to new cellular and molecular targets, which in turn will permit design of specific septic encephalopathy-alleviating drugs and prevent its negative influence on survival.	[Alexander, Jessy J.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Pytel, Peter] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Alexander, JJ (corresponding author), Univ Chicago, Dept Med, Chicago, IL 60637 USA.	jalexand@medicine.bsd.uchicago.edu	Alexander, Jessy/ABA-7664-2020				Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Audoy-Remus J, 2008, J NEUROSCI, V28, P10187, DOI 10.1523/JNEUROSCI.3510-08.2008; Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96; Bartynski WS, 2006, AM J NEURORADIOL, V27, P2179; Baumgart K, 2009, INTENS CARE MED, V35, P344, DOI 10.1007/s00134-008-1319-x; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Dubin A, 2007, INTENS CARE MED, V33, P485, DOI 10.1007/s00134-006-0519-5; Ebersoldt M, 2007, INTENS CARE MED, V33, P941, DOI 10.1007/s00134-007-0622-2; Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470; Esen F, 2005, CRIT CARE, V9, pR18, DOI 10.1186/cc3004; Euser AG, 2008, EXP PHYSIOL, V93, P254, DOI 10.1113/expphysiol.2007.039966; Fioretto JR, 2008, CYTOKINE, V43, P160, DOI 10.1016/j.cyto.2008.05.005; Fischer MB, 1997, J IMMUNOL, V159, P976; Flierl MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002560; Flierl MA, 2008, FASEB J, V22, P3483, DOI 10.1096/fj.08-110595; Ghabriel MN, 2006, ACTA NEUROCHIR SUPPL, V96, P402; Gunther ML, 2007, MED HYPOTHESES, V69, P1179, DOI 10.1016/j.mehy.2007.03.039; Handa O, 2008, AM J PHYSIOL-HEART C, V295, pH1712, DOI 10.1152/ajpheart.00476.2008; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; Hofer S, 2008, J SURG RES, V146, P276, DOI 10.1016/j.jss.2007.07.021; Hopkins RO, 2006, CURR OPIN CRIT CARE, V12, P388, DOI 10.1097/01.ccx.0000244115.24000.f5; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2006, BRAIN INJURY, V20, P263, DOI 10.1080/02699050500488199; Hsu AA, 2008, PEDIATR CRIT CARE ME, V9, P245, DOI 10.1097/PCC.0b013e3181727b22; Huang YH, 2002, PROTEOMICS, V2, P1220, DOI 10.1002/1615-9861(200209)2:9<1220::AID-PROT1220>3.0.CO;2-3; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Jacob A, 2007, LAB INVEST, V87, P1186, DOI 10.1038/labinvest.3700686; Kadoi Y, 2004, ANESTH ANALG, V99, P212, DOI 10.1213/01.ANE.0000118111.94913.22; Kafa IM, 2007, NEUROPATHOLOGY, V27, P213, DOI 10.1111/j.1440-1789.2007.00757.x; Kunze K, 2002, J NEUROL, V249, P1150, DOI 10.1007/s00415-002-0869-z; Levy RJ, 2007, CRIT CARE MED, V35, pS468, DOI 10.1097/01.CCM.0000278604.93569.27; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Maeda Shigeru, 2008, Neuropsychiatr Dis Treat, V4, P663; NAKAE H, 1994, RES COMMUN CHEM PATH, V84, P189; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; NISHIOKU T, 2008, CELL MOL NEUROBIOL; Pan W, 2008, J NEUROCHEM, V106, P313, DOI 10.1111/j.1471-4159.2008.05390.x; Pan WH, 2008, AM J PHYSIOL-CELL PH, V294, pC1436, DOI 10.1152/ajpcell.00489.2007; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Piazza O, 2007, BRIT J ANAESTH, V99, P518, DOI 10.1093/bja/aem201; Prodeus AP, 1997, NATURE, V390, P172; Riedemann NC, 2003, FASEB J, V17, P370, DOI 10.1096/fj.03-0708fje; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Rosengarten B, 2008, INFLAMM RES, V57, P479, DOI 10.1007/s00011-008-8042-5; Rosengarten B, 2007, CEREBROVASC DIS, V23, P140, DOI 10.1159/000097051; Semmler A, 2007, EXP NEUROL, V204, P733, DOI 10.1016/j.expneurol.2007.01.003; Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x; Sharshar T, 2007, INTENS CARE MED, V33, P798, DOI 10.1007/s00134-007-0598-y; Siami S, 2008, CRIT CARE CLIN, V24, P67, DOI 10.1016/j.ccc.2007.10.001; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; Streck EL, 2008, NEUROCHEM RES, V33, P2171, DOI 10.1007/s11064-008-9671-3; Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013; Turkoglu OF, 2008, J CLIN NEUROSCI, V15, P60, DOI 10.1016/j.jocn.2007.03.005; Umgelter A, 2008, BLOOD PURIFICAT, V26, P333, DOI 10.1159/000132464; Vissers JLM, 2006, CLIN CHIM ACTA, V366, P336, DOI 10.1016/j.cca.2005.11.017; Wratten ML, 2008, EUR J ANAESTH, V25, P1, DOI 10.1017/S0265021507003444; YOUNG GB, 1990, CLIN INVEST MED, V13, P297; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016	61	82	93	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	JUN	2009	22	3					283	287		10.1097/WCO.0b013e32832b3101			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	447KA	WOS:000266188800013	19387342				2021-06-18	
J	Ding, K; de la Plata, CM; Wang, JY; Mumphrey, M; Moore, C; Harper, C; Madden, CJ; McColl, R; Whittemore, A; Devous, MD; Diaz-Arrastia, R				Ding, Kan; de la Plata, Carlos Marquez; Wang, Jun Yi; Mumphrey, Marysa; Moore, Carol; Harper, Caryn; Madden, Christopher J.; McColl, Roderick; Whittemore, Anthony; Devous, Michael D.; Diaz-Arrastia, Ramon			Cerebral Atrophy after Traumatic White Matter Injury: Correlation with Acute Neuroimaging and Outcome	JOURNAL OF NEUROTRAUMA			English	Article						MR imaging; post-traumatic atrophy; TBI	DIFFUSE AXONAL INJURY; BRAIN-INJURY; HEAD-INJURY; MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; MRI FINDINGS; RECOVERY; ROBUST; MILD; REGISTRATION	Traumatic brain injury (TBI) is a pathologically heterogeneous disease, including injury to both neuronal cell bodies and axonal processes. Global atrophy of both gray and white matter is common after TBI. This study was designed to determine the relationship between neuroimaging markers of acute diffuse axonal injury (DAI) and cerebral atrophy months later. We performed high-resolution magnetic resonance imaging (MRI) at 3 Tesla (T) in 20 patients who suffered non-penetrating TBI, during the acute (within 1 month after the injury) and chronic stage (at least 6 months after the injury). Volume of abnormal fluid-attenuated inversion-recovery (FLAIR) signal seen in white matter in both acute and follow-up scans was quantified. White and gray matter volumes were also quantified. Functional outcome was measured using the Functional Status Examination (FSE) at the time of the chronic scan. Change in brain volumes, including whole brain volume (WBV), white matter volume (WMV), and gray matter volume (GMV), correlates significantly with. acute DAI volume (r = -0.69, -0.59, -0.58, respectively; p < 0.01 for all). Volume of acute R-AIR hyperintensities correlates with volume of decreased FLAIR signal in the follow-up scans (r -0.86, p < 0.001). FSE performance correlates with acute hyperintensity volume and chronic cerebral atrophy (r = 0.53, p = 0.02; r = -0.45, p = 0.03, respectively). Acute axonal lesions measured by FLAIR imaging are strongly predictive of post-traumatic cerebral atrophy. Our findings suggest that axonal pathology measured as white matter lesions following TBI can be identified using MRI, and may be a useful measure for DAI-directed therapies.	[Ding, Kan; Mumphrey, Marysa; Moore, Carol; Harper, Caryn; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [de la Plata, Carlos Marquez] Univ Texas Dallas, Ctr Brain Hlth, Richardson, TX 75083 USA; [de la Plata, Carlos Marquez] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Wang, Jun Yi] Univ Texas Dallas, Dept Cognit & Neurosci, Richardson, TX 75083 USA; [Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA; [McColl, Roderick; Whittemore, Anthony; Devous, Michael D.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA	Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ramon.diaz-arrastia@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594; , Kan/0000-0003-3485-8200; McColl, Roderick/0000-0001-7022-100X	U.S. Department of EducationUS Department of Education [H133 A020526]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD48179, U01 HD42652]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	The present study was supported by the U.S. Department of Education (grant NIDRR H133 A020526) and the National Institutes of Health (grants NIH R01 HD48179 and NIH U01 HD42652).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Anderson VM, 2007, J NEUROIMAGING, V17, P61, DOI 10.1111/j.1552-6569.2006.00081.x; Anderson VM, 2006, J MAGN RESON IMAGING, V23, P605, DOI 10.1002/jmri.20550; Ayala RR, 2008, NEUROLOGY, V70, pA362; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Jasperse B, 2007, J MAGN RESON IMAGING, V26, P881, DOI 10.1002/jmri.21101; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Langlois JA., TRAUMATIC BRAIN INJU; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SK, 2004, POPUL RES POLICY REV, V23, P1, DOI 10.1023/B:POPU.0000019918.24143.c9; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2007, NEUROIMAGE, V36, P1200, DOI 10.1016/j.neuroimage.2007.04.035; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079	55	82	85	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1433	1440		10.1089/neu.2008.0683			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500004	19072588	Green Published			2021-06-18	
J	Faux, S; Sheedy, J				Faux, S.; Sheedy, J.			A Prospective Controlled Study in the Prevalence of Posttraumatic Headache Following Mild Traumatic Brain Injury	PAIN MEDICINE			English	Article						Mild Truamatic Brain Injury; Posttraumatic Headache; Epidemiology; Pain; Prevalence; Head Injury	POST-CONCUSSION SYNDROME; EPIDEMIOLOGY; SYMPTOMS; COMPLAINTS; SEVERITY; MODERATE; COHORT; SCALE; PAIN	To establish the prevalence of post traumatic headache, persisting at 3 months following minor traumatic brain injury. A prospective controlled study of patients admitted with a diagnosis of mild traumatic brain injury and matched orthopedic controls over 12 months during 2004. A level two inner city Emergency Department in Sydney, Australia. One hundred eligible sequential admissions with mild traumatic brain injury as defined by American Congress of Rehabilitation Medicine, 1993, and 100 matched minor injury controls with nondeceleration injuries. Subjects were part of a study on prediction of postconcussive syndrome and had neuropsychological tests, balance test and pain recordings taken at the time of injury, at 1 month and at 3 months post injury. Main measures were the reporting of headache "worse than prior to the injury" and concordant with the definition of Posttraumatic Headache according to International Headache Society Classification of Headache Disorders 2003. 15.34% of those with minor head injury continued to complain of perisistant posttraumatic headache at 3 months compared to 2.2% of the minor injury controls. To the authors' knowledge this is the first controlled prospective study in the prevalence of posttraumatic headache following mild traumatic brain injury.	[Faux, S.; Sheedy, J.] St Vincents Hosp, Darlinghurst, NSW 2010, Australia; [Faux, S.; Sheedy, J.] St Vincents Hosp, Sacred Heart Rehabil Unit, Sydney, NSW 2010, Australia	Faux, S (corresponding author), St Vincents Hosp, Sydney 170 Darlinghurst Rd, Darlinghurst, NSW 2010, Australia.	sfaux@optusnet.com.au	Faux, Steven/Y-3409-2019	Faux, Steven/0000-0001-8846-216X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; EVANS RW, 1992, NEUROL CLIN, V10, P815; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; *INT HEAD SOC, 2003, INT CLASS HEAD DIS, P56; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; PACKARD RC, 2005, CURR PAIN HEADACHE R, V9, P58; Packard Russell C, 2002, Curr Pain Headache Rep, V6, P301, DOI 10.1007/s11916-002-0051-4; Pons-Sanz SM, 2005, ANQ-Q J SHORT ART N, V18, P6; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Povlishock JT., 1996, NEUROTRAUMA, P1325; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Todd KH, 2005, EMERG MED CLIN N AM, V23, P285, DOI 10.1016/j.emc.2004.12.002; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; Williams RA, 1998, ARCH PHYS MED REHAB, V79, P366, DOI 10.1016/S0003-9993(98)90135-6	39	82	82	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	NOV-DEC	2008	9	8					1001	1011		10.1111/j.1526-4637.2007.00404.x			11	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	375HZ	WOS:000261106100007	18266807	Bronze			2021-06-18	
J	Harting, MT; Jimenez, F; Adams, SD; Mercer, DW; Cox, CS				Harting, Matthew T.; Jimenez, Fernando; Adams, Sasha D.; Mercer, David W.; Cox, Charles S., Jr.			Acute, regional inflammatory response after traumatic brain injury: Implications for cellular therapy	SURGERY			English	Article							MESENCHYMAL STEM-CELLS; NECROSIS-FACTOR-ALPHA; MARROW STROMAL CELLS; CLOSED-HEAD INJURY; INTERFERON-GAMMA; RAT-BRAIN; TNF-ALPHA; CYTOKINES; INTERLEUKIN-6; RELEASE	Background. Although cellular therapy has shown promise in the management of traumatic brain injury (TBI), microenvironment interactions between the intracerebral milieu and therapeutic stem cells are poorly understood. We sought to characterize the acute, regional inflammatory response after TBI. Methods. Rats underwent a controlled cortical impact (CCI) injury or sham injury, penumbral, 24, 48, and 72 hours, and intracerebral fluid (IF) was isolated from the direct injury, penumbral, ipsilateral frontal, and contralateral regions. Cortical and hippocampal areas were also isolated. Regional cytokine levels were measured. Polymorphonuclear cell (PMN) oxidative burst and marker expression were assessed after incubation with the IF. Immunohistochemistry was used to identify intracerebral CD68(+) cells (microglia/macrophages). Results. The proinflammatory cytokines interleukin (IL)-1 alpha, IL-1 beta, and tumor necrosis factor-alpha were significantly elevated after CCI in the injury and penumbral regions. Increases in the same cytokines were localized to the cortex and the hippocampus. Increased PMN expression of CD11b and L-selectin was identified after incubation with injury or penumbral area IF, without change in PMN oxidative burst. CD68(+) cells were noted in the direct injury and penumbral areas. Conclusion. The local cerebral milieu in the first 48 hours after TBI is highly proinflammatory. This response is most pronounced in areas at a proximal to the direct injury. The local acute proinflammatory response after TBI may serve as a therapeutic target of early cell therapy or, conversely, may create on unfavorable local milieu, limiting the efficacy of early cellular therapy. (Surgery 2008; 144:803-13).	[Harting, Matthew T.; Jimenez, Fernando; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Harting, Matthew T.; Jimenez, Fernando; Cox, Charles S., Jr.] Childrens Mem Hermann Hosp, Dept Pediat Surg, Houston, TX USA; [Harting, Matthew T.; Adams, Sasha D.; Mercer, David W.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Harting, Matthew T.; Adams, Sasha D.; Mercer, David W.] Univ Texas Med Sch Houston, Trauma Res Ctr, Houston, TX 77030 USA; [Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst, College Stn, TX USA	Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin Street,MSB 5-254, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Harting, Matthew/0000-0002-8929-8311	Children's Memorial Hermann Hospital Foundation [T32 GM008792-06, P50 GM38529, MO1 RR 02558, R21 HD 04 2659-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD042659] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792, P50GM038529] Funding Source: NIH RePORTER	Supported by grant T32 GM008792-06, P50 GM38529, MO1 RR 02558, and R21 HD 04 2659-01A1, Children's Memorial Hermann Hospital Foundation, Texas Higher Education Coordinating Board.	Adams SD, 2008, J TRAUMA, V65, P170, DOI 10.1097/TA.0b013e31805824ca; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Partrick DA, 1997, J TRAUMA, V43, P297, DOI 10.1097/00005373-199708000-00015; Penolazzi L, 2008, CELL BIOL INT, V32, P320, DOI 10.1016/j.cellbi.2007.08.030; Phinney DG, 2006, STEM CELLS DEV, V15, P437, DOI 10.1089/scd.2006.15.437; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Turrin NP, 2007, STEM CELLS, V25, P3165, DOI 10.1634/stemcells.2007-0508; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; WONG D, 1992, J NEUROIMMUNOL, V39, P11, DOI 10.1016/0165-5728(92)90170-P; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	28	82	96	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	NOV	2008	144	5					803	813		10.1016/j.surg.2008.05.017			11	Surgery	Surgery	372NK	WOS:000260908100013	19081024	Green Accepted			2021-06-18	
J	Shafi, S; de la Plata, CM; Diaz-Arrastia, R; Shipman, K; Carlile, M; Frankel, H; Parks, J; Gentilello, LM				Shafi, Shahid; de la Plata, Carlos Marquez; Diaz-Arrastia, Ramon; Shipman, Kristin; Carlile, Mao; Frankel, Heidi; Parks, Jennifer; Gentilello, Larry M.			Racial disparities in long-term functional outcome after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		ethnic disparities; TBI	ACUTE MYOCARDIAL-INFARCTION; IMPACT; RACE; TRANSPLANTATION; EPIDEMIOLOGY; CHILDREN; SCALE; CARE	Objectives: Ethnic disparities have been demonstrated in several diseases, but not in trauma. We hypothesized that access to acute rehabilitation and long-term functional outcomes among traumatic brain injury (TBI) patients are influenced by patient race and ethnicity. Methods: Patients with severe TBI (Abbreviated Injury Scale [AIS] score, 3-5) who were discharged alive from initial hospitalization were recruited from an urban Level I trauma center (1998-2005). Functional outcome was measured 6 to 12 months after injury using the Glasgow Outcome Scale-Extended (GOSE) score, and classified as good recovery (GOSE score, and 8) or moderate to severe disability (GOSE score, 1-6). Ethnic minorities (n = 114) were compared with non-Hispanic Whites (NHW, n = 230). Logistic regression was used to measure the association between ethnicity and functional outcome while controlling for age, gender, Injury Severity Score (ISS), head AIS score, Glasgow Coma Scale (GCS) score, discharge disposition, and insurance. Results: Minority and NHW groups had similar ISS, GCS score, and head AIS score. Ethnic minorities were less likely to be insured (uninsured, 66 % vs. 31 %, p < 0.001), but were equally likely to be placed in a rehabilitation facility upon trauma center discharge (47% vs. 42%, p = 0.417). Minority patients were more likely to have moderate to severe disability at follow-up (74% vs. 61%; adjusted odds ratio [OR], 2.17; 95% confidence interval [CI], 1.27-3.69). The relationship between ethnicity and functional outcome became insignificant when insurance was taken into account (OR, 1.52; 95% CI, 0.81-2.72). Conclusion: Despite equal access to acute rehabilitation, ethnic minorities have significantly worse long-term functional outcomes after TBI, which is related to lack of health insurance.	[Shafi, Shahid; Shipman, Kristin; Frankel, Heidi; Parks, Jennifer; Gentilello, Larry M.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [de la Plata, Carlos Marquez; Diaz-Arrastia, Ramon; Carlile, Mao] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA	Shafi, S (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	shahid.shafi@uthsouthwestern.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652] Funding Source: Medline		BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Barnato AE, 2005, MED CARE, V43, P308, DOI 10.1097/01.mlr.0000156848.62086.06; Barnhart JM, 2003, ARCH INTERN MED, V163, P461, DOI 10.1001/archinte.163.4.461; Bertoni AG, 2005, J NATL MED ASSOC, V97, P317; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293; Carrasquillo O, 1999, J GEN INTERN MED, V14, P82, DOI 10.1046/j.1525-1497.1999.00293.x; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Collins KS, 1999, US MINORITY HLTH CHA; Delano BG, 1997, ASAIO J, V43, pM861; Dubay LC, 1996, FUTURE CHILD, V6, P152, DOI 10.2307/1602499; Flattery Maureen P, 2004, J Cult Divers, V11, P25; FRANKOWSKI RAJ, 1985, DESCRIPTIVE EPIDEMIO; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; McAlearney JS, 2004, J HEALTH CARE POOR U, V15, P357, DOI 10.1353/hpu.2004.0044; Mochari Heidi, 2006, Prev Cardiol, V9, P8, DOI 10.1111/j.1520-037X.2005.3703.x; PERRY MJ, 1998, BARRIERS MED CAL ENR; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; Reid AE, 2004, LIVER TRANSPLANT, V10, P834, DOI 10.1002/lt.20174; SHAFI S, IN PRESS J TRAUMA; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Syed M, 2000, AM HEART J, V140, P643, DOI 10.1067/mhj.2000.109644; Thrall Terese Hudson, 2002, Hosp Health Netw, V76, P30; U.S Department of Health and Human Services, 2000, HLTH PEOPL 2010; *US DEP COMM EC ST, 2004, ADM INC POV HLTH INS; US Department of Health and Human Services, 2005, NAT HEALTHC DISP REP; Venkat A, 2003, ACAD EMERG MED, V10, P1199, DOI 10.1197/S1069-6563(03)00490-1; Werner RM, 2005, CIRCULATION, V111, P1257, DOI 10.1161/01.CIR.0000157729.59754.09; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; 1998, GAOHEHS9893	34	82	82	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2007	63	6					1263	1268		10.1097/TA.0b013e31815b8f00			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	243AU	WOS:000251768100013	18212648				2021-06-18	
J	Darwish, RS; Amiridze, N; Aarabi, B				Darwish, Ribal S.; Amiridze, Nana; Aarabi, Bizhan			Nitrotyrosine as an oxidative stress marker: Evidence for involvement in neurologic outcome in human traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 22-26, 2005	Atlanta, GA	Amer Soc Anesthesiologists		nitrotyrosine; activated caspase-3; traumatic brain injury; oxidative stress	NITRIC-OXIDE SYNTHASE; NEUROPROTECTION; DYSFUNCTION; APOPTOSIS; INDUCTION; CASPASE-3; CONTUSION; DAMAGE; RATS	Background. Oxidative stress has been indicated as a mechanism of secondary neuronal injury in traumatic brain injury (TBI). Nitrotyrosine in the cerebrospinal fluid (CSF) may be an in vivo marker of oxidative nitric oxide damage. We tested the hypothesis that increased levels of nitrotyrosine correlate with poor neurologic outcomes in patients with TBI and attempted to identify the source of increased CSF nitrotyrosine. Methods. This institutional-reviewboard-approved study included 10 adults with severe closed TBI (Glasgow Coma Scale score <8) and no documented hypoxic brain injury. These patients underwent routine evaluation and, when indicated, placement of an intraventricular catheter. CSF samples (n = 27) were collected 2 to 72 hours after TBI and were also obtained from four healthy individuals. Nitrotyrosine levels were measured, and immunohistochemistry was performed. Neurologic follow-up extended to 1 month after injury. Results. Nitrotyrosine was not detected in the control samples but was detected in 13 CSF samples from 7 TBI patients (range, 22.4-97.6 nM/mL). Seven patients had poor outcomes, and, in each, ni- trotyrosine was detected. Nitrotyrosine immunoreactivity was detected in neurons and glia and confirmed in brain homogenate. Conclusion. Oxidative stress contributes to secondary brain injury in patients with TBI. Poor neurologic outcome is associated with increased levels of nitrotyrosine in the CSF. Identifying patients or the stage at which oxidative stress is more active using CSF markers of oxidative injury may help in the development of more targeted treatments.	Univ Maryland, Sch Med, Med Ctr, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Diagnost Radiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA	Darwish, RS (corresponding author), Univ Maryland, Sch Med, Med Ctr, Dept Anesthesiol, 22 S Greene St, Baltimore, MD 21201 USA.	rdarwish@anes.umm.edu		Darwish, Ribal/0000-0003-0727-0401			Acarin L, 2005, J NEUROTRAUM, V22, P189, DOI 10.1089/neu.2005.22.189; Bayir H, 2003, J CEREBR BLOOD F MET, V23, P51, DOI 10.1097/01.WCB.0000040399.30600.E3; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Peluffo H, 2004, J NEUROCHEM, V89, P602, DOI 10.1046/j.1471-4159.2004.02363.x; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	14	82	85	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2007	63	2					439	442		10.1097/TA.0b013e318069178a			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	200AC	WOS:000248735300037	17693848				2021-06-18	
J	Plesnila, N; von Baumgarten, L; Retiounskaia, M; Engel, D; Ardeshiri, A; Zimmermann, R; Hoffmann, F; Landshamer, S; Wagner, E; Culmsee, C				Plesnila, N.; von Baumgarten, L.; Retiounskaia, M.; Engel, D.; Ardeshiri, A.; Zimmermann, R.; Hoffmann, F.; Landshamer, S.; Wagner, E.; Culmsee, C.			Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappa B transcriptional activity	CELL DEATH AND DIFFERENTIATION			English	Article						programmed cell death; apoptosis; pifithrin; XIAP; Bax; DNA damage	FOCAL CEREBRAL-ISCHEMIA; ANTI-APOPTOTIC ACTIVITY; CELL-DEATH; P53-INDUCED APOPTOSIS; TRANSGENIC MICE; NERVOUS-SYSTEM; RAT-BRAIN; P53; XIAP; PROTECTS	Acute and chronic neurodegeneration, for example, following brain injury or Alzheimer's disease, is characterized by programmed death of neuronal cells. The present study addresses the role and interaction of p53- and NF-kappa B- dependent mechanisms in delayed neurodegeneration following traumatic brain injury ( TBI). After experimental TBI in mice p53 rapidly accumulated in the injured brain tissue and translocated to the nucleus of damaged neurons, whereas NF-kappa B transcriptional activity simultaneously declined. Post- traumatic neurodegeneration correlated with the increase in p53 levels and was significantly reduced by the selective p53 inhibitor pifithrin-alpha ( PFT). Strikingly, this protective effect was observed even when PFT treatment was delayed up to 6 h after trauma. Inhibition of p53 activity resulted in the concomitant increase in NF-kappa B transcriptional activity and upregulation of NF-kappa B- target proteins, for example X- chromosomal- linked inhibitor of apoptosis (XIAP). It is interesting to note that inhibition of XIAP abolished the neuroprotective effects of PFT in cultured neurons exposed to camptothecin, glutamate, or oxygen glucose deprivation. In conclusion, delayed neuronal cell death after brain trauma is mediated by p53- dependent mechanisms that involve inhibition of NF-kappa B transcriptional activity. Hence, p53 inhibition provides a promising approach for the treatment of acute brain injury, since it blocks apoptotic pathways and concomitantly triggers survival signaling with a therapeutic window relevant for clinical applications.	Univ Munich, Ctr Med, Inst Surg Res, Dept Neurosurg, D-81377 Munich, Germany; Univ Munich, Dept Pharm, D-81377 Munich, Germany; Erasmus MC, Dept Neurosci, Rotterdam, Netherlands; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands	Culmsee, C (corresponding author), Univ Munich, Dept Pharm, Butenandtstr 5-13, D-81377 Munich, Germany.	carsten.culmsee@cup.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019; Wagner, Ernst/ABB-5976-2020; von Baumgarten, Louisa/A-4636-2016; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Culmsee, Carsten/0000-0002-5121-5015			Bhakar AL, 2002, J NEUROSCI, V22, P8466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Chopp M, 2006, ADV EXP MED BIOL, V585, P49; Cregan SP, 1999, J NEUROSCI, V19, P7860; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Culmsee C, 2003, J NEUROSCI, V23, P8586; Culmsee C, 2002, NEUROSCIENCE, V115, P1089, DOI 10.1016/S0306-4522(02)00539-0; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Deveraux Quinn L., 2001, Cardiology Clinics, V19, P57; Endo H, 2006, J NEUROSCI, V26, P7974, DOI 10.1523/JNEUROSCI.0897-06.2006; Guegan C, 2006, NEUROBIOL DIS, V22, P177, DOI 10.1016/j.nbd.2005.10.014; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Leker RR, 2004, EXP NEUROL, V187, P478, DOI 10.1016/j.expneurol.2004.01.030; Li TF, 2006, EXP NEUROL, V197, P301, DOI 10.1016/j.expneurol.2005.08.021; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; Mattson MP, 2005, NEUROCHEM RES, V30, P883, DOI 10.1007/s11064-005-6961-x; Millet I, 2000, J BIOL CHEM, V275, P15114, DOI 10.1074/jbc.275.20.15114; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Renwick J, 2006, GENE THER, V13, P339, DOI 10.1038/sj.gt.3302683; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Schneider A, 1999, NAT MED, V5, P554; Siegelin M, 2005, NEUROBIOL DIS, V20, P509, DOI 10.1016/j.nbd.2005.04.006; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wang XY, 2004, NEUROBIOL DIS, V16, P179, DOI 10.1016/j.nbd.2004.01.014; Webster GA, 1999, MOL CELL BIOL, V19, P3485; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang W, 2005, J CEREBR BLOOD F MET, V25, P30, DOI 10.1038/sj.jcbfm.9600004; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	39	82	85	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047	1476-5403		CELL DEATH DIFFER	Cell Death Differ.	AUG	2007	14	8					1529	1541		10.1038/sj.cdd.4402159			13	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	192OI	WOS:000248211000015	17464322	Bronze			2021-06-18	
J	Agel, J; Dick, R; Nelson, B; Marshall, SW; Dompier, TP				Agel, Julie; Dick, Randall; Nelson, Bradley; Marshall, Stephen W.; Dompier, Thomas P.			Descriptive epidemiology of collegiate women's ice hockey injuries: National Collegiate Athletic Association injury surveillance system, 2000-2001 through 2003-2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; concussions		Objective: To review 4 years of National Collegiate Athletic Association (NCAA) injury surveillance data for women's ice hockey and to identify potential areas for injury prevention initiatives. Background: The NCAA ISS prospectively collects data on injuries sustained during collegiate participation. Women's NCAA ice hockey began participation in the ISS during the 2000-2001 season. On average, over the 4 years, 15.6% of the eligible schools elected to send their injury data. Main Results: Over the 4 years of study, the rate of injury in games was more than 5 times higher than the injury rate in practices (12.6 versus 2.5 injuries per 1000 athlete-exposures, rate ratio = 5.0, 95% confidence interval = 4.2, 6.1, P <.01). Preseason practice injury rates were almost twice as high as in-season practice rates (4.2 versus 2.3 injuries per 1000 athlete-exposures, rate ratio = 1.8, 95% confidence interval = 1.7, 2.0, P <.01). Concussions were the most common injury in both games (21.6%) and practices (13.2%). The rate of concussions in games appeared to be trending upward over the study period. The greatest number of game injuries (approximately 50%) resulted from player contact, whereas practice injuries were from. either contact with another object or non-contact mechanisms. Recommendations: Women's ice hockey is an evolving NCAA sport. Only 4 years of ISS data are available and, therefore, data should be interpreted with caution. Women's ice hockey does not allow for formal body checking; however, approximately 50% of all game injuries were reported to result from contact with another player. Future researchers need to evaluate the effectiveness of the no-checking rule. Additional years of data collection will be required to allow the data to become more stable, and to increase attention to mechanism-of-injury issues. We anticipate that the hypothesized inconsistencies in skill level across and within the various women's teams also will be reduced as more consistently skilled players develop, allowing for more stability in the injury scenario.	Univ Minnesota, Minneapolis, MN 55455 USA; Natl Coll Athlet Assoc, Indianapolis, IN USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Univ No Iowa, Cedar Falls, IA USA	Agel, J (corresponding author), Univ Minnesota, 2450 Riverside Ave, Minneapolis, MN 55455 USA.	agelx001@umn.edu		Marshall, Stephen/0000-0002-2664-9233; Nelson, Bradley J/0000-0002-7931-5085			BUESCHER P, PROBLEMS RATES BASED; Dick R, 2007, J ATHL TRAINING, V42, P173; Dryden DM, 2006, MED SCI SPORT EXER, V38, P799, DOI 10.1249/01.mss.0000210152.83076.f1; Marchie A, 2003, CAN MED ASSOC J, V169, P124; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06	6	82	82	0	5	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					249	254					6	Sport Sciences	Sport Sciences	180RC	WOS:000247382300011	17710173				2021-06-18	
J	Tanriverdi, F; Unluhizarci, K; Coksevim, B; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Unluhizarci, Kursad; Coksevim, Bekir; Selcuklu, Ahmed; Casanueva, Felipe F.; Kelestimur, Fahrettin			Kickboxing sport as a new cause of traumatic brain injury-mediated hypopituitarism	CLINICAL ENDOCRINOLOGY			English	Article							GROWTH-HORMONE GH; REPLACEMENT THERAPY; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; DEFICIENT PATIENTS; SHEEHANS-SYNDROME; HIGH-RISK; ADULTS; CONCUSSION; EPIDEMIOLOGY	Objective Traumatic brain injury, which is a frequent and a worldwide important public health problem, may result in pituitary dysfunction. Concussion, a common type of lesion after traumatic brain injury, is an injury associated with sports including boxing and kickboxing. Kickboxing is one of the most popular martial arts and approximately 1-million people around the world participate in kickboxing sport. Head is the most common site of injury in amateur and professional kickboxers. Pituitary consequences of chronic repetitive head trauma in kickboxing have not been investigated until now. Therefore, the present study was designed to investigate the pituitary function in both retired and active amateur kickboxers. Patients and Design Twenty-two amateur kickboxers who have boxed in national and international championships (16 men, 6 women) with a mean age of 27.3 +/- 7.1 years, and 22 age- and sex-matched healthy controls were included in the study. Basal hormone levels were obtained from the participants. To assess GH-IGF-I axis, GHRH + GHRP-6 test and glucagon stimulation tests were used. Hypothalamo-pituitary-adrenal axis was assessed by glucagon stimulation test. Result When mean basal hormone levels were compared between kickboxers and the controls, IGF-I level was significantly lower in kickboxers (P < 0.05). Five (22.7%) and two (9.1%) of the 22 kickboxers had GH deficiency had ACTH deficiency, respectively. There were significant negative correlations between IGF-I levels and age, duration of sports and number of bouts (P < 0.05). Conclusions Present data clearly demonstrate for the first time that amateur kickboxing is a novel cause of hypopituitarism and kickboxers are at a risk for hypopituitarism especially isolated GH deficiency. Therefore, participants of the combative sports who were exposed to chronic repetitive head trauma need to be screened.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Physiol, Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Neurosurg, Kayseri, Turkey; Dept Med, Div Endocrine, Santiago De Compostela, Galicia, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr		Coksevim, Bekir/0000-0002-8637-071X			ABSTRACT R, 2005, GROWTH HORM IGF RES, V15, P349; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; AMATO G, 1993, J CLIN ENDOCR METAB, V77, P1671, DOI 10.1210/jc.77.6.1671; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BIRRER RB, 1996, AM J SPORTS MED, V24, P72; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; DEBOER H, 1994, METABOLISM, V43, P199, DOI 10.1016/0026-0495(94)90245-3; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dokmetas HS, 2000, J CLIN ENDOCR METAB, V85, P3713, DOI 10.1210/jc.85.10.3713; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; Golgeli A, 2004, EUR J ENDOCRINOL, V150, P153, DOI 10.1530/eje.0.1500153; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Hillier SL, 1997, BRAIN INJURY, V11, P649; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelestimur F, 2006, CLIN ENDOCRINOL, V64, P667, DOI 10.1111/j.1365-2265.2006.02525.x; Kelestimur Fahrettin, 2003, Pituitary, V6, P181, DOI 10.1023/B:PITU.0000023425.20854.8e; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Powell JW, 2001, J ATHL TRAINING, V36, P307; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; Sonksen PH, 2001, J ENDOCRINOL, V170, P13, DOI 10.1677/joe.0.1700013; Tanriverdi F, 2005, GROWTH HORM IGF RES, V15, P231, DOI 10.1016/j.ghir.2005.03.005; Tanriverdi F, 2005, CLIN ENDOCRINOL, V62, P706, DOI 10.1111/j.1365-2265.2005.02283.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	39	82	84	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	MAR	2007	66	3					360	366		10.1111/j.1365-2265.2006.02737.x			7	Endocrinology & Metabolism	Endocrinology & Metabolism	134UQ	WOS:000244110100008	17302869				2021-06-18	
J	Hilton, GD; Nunez, JL; Bambrick, L; Thompson, SM; McCarthy, MM				Hilton, Genell D.; Nunez, Joseph L.; Bambrick, Linda; Thompson, Scott M.; McCarthy, Margaret M.			Glutamate-mediated excitotoxicity in neonatal hippocampal neurons is mediated by mGluR-induced release of Ca++ from intracellular stores and is prevented by estradiol	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						excitatory amino acids; imaging; metabotropic receptors; neuroprotection; perinatal brain injury; steroids	ESTROGEN-RECEPTOR-ALPHA; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; GROUP-II; KAINIC ACID; CELL-DEATH; RAT-BRAIN; PERINATAL ASPHYXIA; SEX-DIFFERENCES; NERVOUS-SYSTEM	Hypoxic/ischernic (HI) brain injury in newborn full-term and premature infants is a common and pervasive source of life time disabilities in cognitive and locomotor function. In the adult, HI induces glutamate release and excitotoxic cell death dependent on NMDA receptor activation. In animal models of the premature human infant, glutamate is also released following HI, but neurons are largely insensitive to NMDA or AMPA/kainic acid (KA) receptor-mediated damage. Using primary cultured hippocampal neurons we have determined that glutamate increases intracellular calcium much more than kainic acid. Moreover, glutamate induces cell death by activating Type I metabotropic glutamate receptors (mGluRs). Pretreatment of neurons with the gonadal steroid estradiol reduces the level of the Type I metabotropic glutamate receptors and completely prevents cell death, suggesting a novel therapeutic approach to excitotoxic brain damage in the neonate.	Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Neurosci Program, Baltimore, MD 21201 USA; Univ Maryland, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA; Michigan State Univ, Neurosci Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA	Hilton, GD (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW,Room WG 03, Washington, DC 20057 USA.	Gdh4@georgetown.edu	McCarthy, Margaret/O-2059-2017; Thompson, Scott M/K-8921-2015	McCarthy, Margaret/0000-0003-2243-4726; 	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH52716, K01 MH068347-01A1, R01 MH052716] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040338, R01 NS40338] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH052716, K01MH068347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040338] Funding Source: NIH RePORTER		Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Amateau SK, 2004, ENDOCRINOLOGY, V145, P2906, DOI 10.1210/en.2003-1363; AMIELTISON C, 1986, DEV MED CHILD NEUROL, V28, P671; Azcoitia I, 1998, NEUROREPORT, V9, P3075, DOI 10.1097/00001756-199809140-00029; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Baskys A, 2005, NEUROPHARMACOLOGY, V49, P146, DOI 10.1016/j.neuropharm.2005.04.029; BENARI Y, 1984, DEV BRAIN RES, V14, P284, DOI 10.1016/0165-3806(84)90314-6; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; Biagas Katherine, 1999, Current Opinion in Pediatrics, V11, P223, DOI 10.1097/00008480-199906000-00009; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; Boulware MI, 2005, J NEUROSCI, V25, P5066, DOI 10.1523/JNEUROSCI.1427-05.2005; Brazel CY, 2005, NEUROSCIENCE, V131, P55, DOI 10.1016/j.neuroscience.2004.10.038; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; Chen T, 2004, J NEUROTRAUM, V21, P271, DOI 10.1089/089771504322972068; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; COOK TM, 1986, NEUROSCIENCE, V18, P79, DOI 10.1016/0306-4522(86)90180-6; Cozzi A, 2002, NEUROPHARMACOLOGY, V43, P119, DOI 10.1016/S0028-3908(02)00080-1; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Defagot MC, 2002, DEV NEUROSCI-BASEL, V24, P272, DOI 10.1159/000066741; Dobrev D, 1999, BRIT J PHARMACOL, V127, P576, DOI 10.1038/sj.bjp.0702574; Dubal DB, 1999, J NEUROSCI, V19, P6385; FAVIT A, 1991, BRAIN RES, V555, P65, DOI 10.1016/0006-8993(91)90860-X; Folbergrova J, 2005, EXP NEUROL, V192, P420, DOI 10.1016/j.expneurol.2004.12.019; Fotopoulos S, 2001, BIOL NEONATE, V79, P213; Gerevini VDD, 2004, DEV BRAIN RES, V150, P17, DOI 10.1016/j.devbrainres.2004.02.003; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Hilton GD, 2006, ENDOCRINOLOGY, V147, P1246, DOI 10.1210/en.2005-1258; Hilton GD, 2004, DEV BRAIN RES, V150, P191, DOI 10.1016/j.devbrainres.2004.03.006; Hilton GD, 2003, NEUROSCIENCE, V116, P383, DOI 10.1016/S0306-4522(02)00716-9; Kelly MJ, 1999, TRENDS ENDOCRIN MET, V10, P369, DOI 10.1016/S1043-2760(99)00190-3; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Kurata K, 2001, EUR J PHARMACOL, V416, P203, DOI 10.1016/S0014-2999(01)00880-9; Liu ZP, 2001, J COMP NEUROL, V441, P1, DOI 10.1002/cne.1393; Lopez-Bendito G, 2002, CEREB CORTEX, V12, P625, DOI 10.1093/cercor/12.6.625; Lou HC, 1996, ACTA PAEDIATR, V85, P1266, DOI 10.1111/j.1651-2227.1996.tb13909.x; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MATTSON MP, 1992, EXP GERONTOL, V27, P29, DOI 10.1016/0531-5565(92)90027-W; McGeer E G, 1981, Int Rev Neurobiol, V22, P173, DOI 10.1016/S0074-7742(08)60293-7; Mermelstein PG, 1996, J NEUROSCI, V16, P595; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Nunez JL, 2005, EUR J NEUROSCI, V21, P3251, DOI 10.1111/j.1460-9568.2005.04175.x; Nunez JL, 2003, ENDOCRINOLOGY, V144, P2350, DOI 10.1210/en.2002-220840; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; Prange-Kiel J, 2003, HIPPOCAMPUS, V13, P226, DOI 10.1002/hipo.10075; RHODA J, 1984, ENDOCRINOLOGY, V114, P1754, DOI 10.1210/endo-114-5-1754; Ritz MF, 2002, NEUROCHEM RES, V27, P1677, DOI 10.1023/A:1021695213099; ROBERTSON CMT, 1993, CLIN PERINATOL, V20, P483; Romano C, 1996, J COMP NEUROL, V367, P403, DOI 10.1002/(SICI)1096-9861(19960408)367:3<403::AID-CNE6>3.0.CO;2-9; Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738; Semyanov A, 2000, NEURON, V25, P663, DOI 10.1016/S0896-6273(00)81068-5; SIESJO BK, 1989, MAGNESIUM, V8, P223; Simon NP, 1999, CLIN PERINATOL, V26, P767; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x; Toh VC, 2000, ACTA PAEDIATR, V89, P343, DOI 10.1080/080352500750028500; Vannucci RC, 1997, ANN NY ACAD SCI, V835, P234, DOI 10.1111/j.1749-6632.1997.tb48634.x; Wade CNB, 2003, ENDOCRINOLOGY, V144, P832, DOI 10.1210/en.2002-220899; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; WEISZ J, 1980, ENDOCRINOLOGY, V106, P306, DOI 10.1210/endo-106-1-306; WOLF G, 1984, DEV BRAIN RES, V14, P15, DOI 10.1016/0165-3806(84)90004-X; Wu JQ, 2004, NEUROPHARMACOLOGY, V46, P311, DOI 10.1016/j.neuropharm.2003.09.014; Zhang YM, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-32; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	67	82	88	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2006	24	11					3008	3016		10.1111/j.1460-9568.2006.05189.x			9	Neurosciences	Neurosciences & Neurology	124IO	WOS:000243361700005	17156362	Green Accepted			2021-06-18	
J	Tien, HCN; Tremblay, LN; Rizoli, SB; Gelberg, J; Chughtai, T; Tikuisis, P; Shek, P; Brenneman, FD				Tien, Homer C. N.; Tremblay, Lorraine N.; Rizoli, Sandro B.; Gelberg, Jacob; Chughtai, Talat; Tikuisis, Peter; Shek, Pang; Brenneman, Frederick D.			Association between alcohol and mortality in patients with severe traumatic head injury	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	Joint Meeting of the Trauma-Association-of-Canada/Australasian-Trauma-Society	APR 06-09, 2005	Whistler, CANADA	Trauma Assoc Canada, Australasian Trauma Soc			ACUTE ETHANOL INTOXICATION; MOTOR-VEHICLE CRASHES; BRAIN-INJURY; HEMORRHAGIC-SHOCK; HOSPITAL COURSE; LEVEL; MODEL; RATS; HYPOTENSION; INGESTION	Hypothesis: Admission blood alcohol concentration (BAC) is associated with in-hospital death in patients with severe brain injury from blunt head trauma. Design: Retrospective cohort study. Setting: Academic level I trauma center in Toronto, Ontario. Patients: Using trauma registry data, between January 1, 1988, and December 31, 2003, we identified 1158 consecutive patients with severe brain injury from blunt head trauma. Intervention: There was no active intervention. The primary exposure of interest was the BAC at admission, stratified into the following 3 levels: 0, no BAC; 0 to less than 230 mg/dL, low to moderate BAC; and 230 mg/dL or greater, high BAC. Main Outcome Measure: in-hospital death. Results: In patients with severe brain injury, low to moderate BAC was associated with lower mortality than was no BAC (27.9% vs 36.3%; P=.008). High BAC was associated with higher mortality than was no BAC (44.7% vs 36.3%), although this was not statistically significant (P=.10). These associations were all statistically significant after adjusting for demographic data and injury factors using logistic regression analysis. The odds ratio for death was 0.76 (95% confidence interval, 0.52-0.98) for low to moderate BAC compared with no BAC. The odds ratio for death was 1.73 (95% confidence interval, 1.05-2.84) for high BAC compared with no BAC. Conclusions: Low to moderate BAC may be beneficial in patients with severe brain injury from blunt head trauma. In contrast, high BAC seems to have a deleterious effect on in-hospital death in these patients, which may be related to its detrimental hemodynamic and physiologic effects. Alcohol-based fluids may have a role in the management of patients with severe brain injury after they have been well resuscitated.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Trauma Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Surg, Toronto, ON, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada; Dept Natl Def, Canadian Forces Hlth Serv Grp, Ottawa, ON, Canada; Def Res & Dev, Toronto, ON, Canada	Tien, HCN (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Trauma Program, 2075 Bayview Ave,Suite H186, Toronto, ON M4N 3M5, Canada.	homer.tien@sw.ca					Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP D; ANDERSEN JA, 1990, J TRAUMA, V30, P415, DOI 10.1097/00005373-199030040-00007; Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Blondell RD, 2002, J STUD ALCOHOL, V63, P380, DOI 10.15288/jsa.2002.63.380; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; BULLOCK MR, BRAIN TRAUMA FDN GUI; Crews FT, 1998, PHARMACOL BIOCHEM BE, V59, P981, DOI 10.1016/S0091-3057(97)00538-8; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; Elder RW, 2004, AM J PREV MED, V27, P57, DOI 10.1016/j.amepre.2004.03.002; Fabbri A, 2002, EMERG MED J, V19, P210, DOI 10.1136/emj.19.3.210; Fabian MJ, 2002, J TRAUMA, V53, P864, DOI 10.1097/00005373-200211000-00010; FLETCHER F, 1996, CLIN EPIDEMIOLOGY ES; GABRIEL EJ, 2000, BRAIN TRAUMA FDN GUI; George RL, 2003, J TRAUMA, V54, P464, DOI 10.1097/01.TA.0000051939.95039.E6; GETTLER DT, 1963, ANN SURG, V158, P151, DOI 10.1097/00000658-196308000-00001; Goodnough LT, 1999, NEW ENGL J MED, V340, P525, DOI 10.1056/NEJM199902183400706; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KNOTT DH, 1963, NEW ENGL J MED, V269, P292, DOI 10.1056/NEJM196308082690604; KNOTT DH, 1967, JAMA-J AM MED ASSOC, V84, P178; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Li GH, 2001, JAMA-J AM MED ASSOC, V285, P893, DOI 10.1001/jama.285.7.893; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; LUCAS CE, 2000, TRAUMA, P1059; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MALT SH, 1971, J TRAUM, V11, P76, DOI 10.1097/00005373-197101000-00007; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Martin RCG, 2002, AM SURGEON, V68, P477; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; OSLER T, 1988, AM J SURG, V156, P537, DOI 10.1016/S0002-9610(88)80548-8; Piriyawat P, 2003, STROKE, V34, P1242, DOI 10.1161/01.STR.0000067706.23777.04; Poole GV, 1997, J TRAUMA, V42, P711, DOI 10.1097/00005373-199704000-00022; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schenker S, 1998, Adv Intern Med, V43, P27; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Strong R, 2000, NEUROPHARMACOLOGY, V39, P515, DOI 10.1016/S0028-3908(99)00156-2; Tate PS, 1999, BRAIN INJURY, V13, P767; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; VANNATTA TL, 2000, TRAUMA; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	59	82	88	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	DEC	2006	141	12					1185	1191		10.1001/archsurg.141.12.1185			7	Surgery	Surgery	114ME	WOS:000242669500006	17178960	Bronze			2021-06-18	
J	Bach, LJ; David, AS				Bach, Laura J.; David, Anthony S.			Self-awareness after acquired and traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							IMPAIRED AWARENESS; HEAD-INJURY; BEHAVIORAL LIMITATIONS; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; CLOSE RELATIVES; FRONTAL LOBES; RATING-SCALE; MIND; REHABILITATION	Self-awareness deficits are common after acquired and (traumatic) brain injury (ABI), particularly in social behaviour, yet the underlying cognitive and neuroanatomical structures supporting social self-awareness are not fully understood. This paper reviews the current literature on prevalence, type and severity of self-awareness deficits in ABI. Neuropsychological and neuroanatomical models are reviewed and theoretical frameworks are examined. We summarise results of a case-control comparison of 20 ABI patients with and 20 ABI patients without behavioural disturbance. Our research found that lack of social self-awareness predicts behavioural disturbance in acquired and traumatic brain injury independent of cognitive and executive function. Theory of mind ability was related to self-awareness and a possible role for metacognition and affective processes in self-awareness is discussed to account for social self-awareness deficits.	Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, London SE5 8AZ, England; Inst Psychiat, Dept Med Psychol, London, England	Bach, LJ (corresponding author), Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, Denmark Hill, London SE5 8AZ, England.	l.bach@iop.kcl.ac.uk	David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X			Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BARONCOHEN S, 1989, J CHILD PSYCHOL PSYC, V30, P285, DOI 10.1111/j.1469-7610.1989.tb00241.x; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BRAMHAM J, 2006, EMOTIONAL SOCIAL FUN; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Clare L, 2004, J CLIN EXP NEUROPSYC, V26, P215, DOI 10.1076/jcen.26.2.215.28088; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; DAVID A, 1992, BRIT J PSYCHIAT, V161, P599, DOI 10.1192/bjp.161.5.599; DAVID AS, 1990, BRIT J PSYCHIAT, V156, P798, DOI 10.1192/bjp.156.6.798; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FLEMING JM, 1999, P 21 ANN BRAIN IMP C; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Freeland J, 1996, MAGAZINE, V4, P32; Frith C, 1996, J PSYCHOPHARMACOL, V10, P9, DOI 10.1177/026988119601000103; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; HORNAK J, 1996, J COGNITIVE NEUROSCI, V16, P463; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1993, HEAD INJURY, P1; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MALIA K, 1997, J COGNITIVE REHA MAY, P10; Markova IS, 2000, MEMORY DISORDERS IN PSYCHIATRIC PRACTICE, P204, DOI 10.1017/CBO9780511530197.011; McCrae RR, 1998, J PERS, V66, P285, DOI 10.1111/1467-6494.00013; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Newman AC, 2000, BRAIN INJURY, V14, P333; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P162; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V9, P145; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; TYRER P, 1979, BRIT J PSYCHIAT, V135, P163, DOI 10.1192/bjp.135.2.163; VANREEKUM R, 1996, BRAIN INJURY, V10, P19; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO	68	82	83	0	22	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	AUG	2006	16	4					397	414		10.1080/09602010500412830			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	078YU	WOS:000240143500004	16864479				2021-06-18	
J	Nakayama, N; Okumura, A; Shinoda, J; Nakashima, T; Iwama, T				Nakayama, N.; Okumura, A.; Shinoda, J.; Nakashima, T.; Iwama, T.			Relationship between regional cerebral metabolism and consciousness disturbance in traumatic diffuse brain injury without large focal lesions: an FDG-PET study with statistical parametric mapping analysis	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							POSITRON EMISSION TOMOGRAPHY; ANTERIOR CINGULATE CORTEX; CLOSED HEAD-INJURY; AXONAL INJURY; ALZHEIMERS-DISEASE; COMA; GYRUS; MILD	Background: The cerebral metabolism of patients in the chronic stage of traumatic diffuse brain injury (TDBI) has not been fully investigated. Aim: To study the relationship between regional cerebral metabolism (rCM) and consciousness disturbance in patients with TDBI. Methods: 52 patients with TDBI in the chronic stage without large focal lesions were enrolled, and rCM was evaluated by fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) with statistical parametric mapping (SPM). All the patients were found to have disturbed consciousness or cognitive function and were divided into the following three groups: group A (n=22), patients in a state with higher brain dysfunction; group B (n=13), patients in a minimally conscious state; and group C (n=17), patients in a vegetative state. rCM patterns on FDG-PET among these groups were evaluated and compared with those of normal control subjects on statistical parametric maps. Results: Hypometabolism was consistently indicated bilaterally in the medial prefrontal regions, the medial frontobasal regions, the cingulate gyrus and the thalamus. Hypometabolism in these regions was the most widespread and prominent in group C, and that in group B was more widespread and prominent than that in group A. Conclusions: Bilateral hypometabolism in the medial prefrontal regions, the medial frontobasal regions, the cingulate gyrus and the thalamus may reflect the clinical deterioration of TDBI, which is due to functional and structural disconnections of neural networks rather than due to direct cerebral focal contusion.	Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Minokamo City, Gifu 5050034, Japan; Gifu Prefectural Gifu Hosp, Dept Neurosurg, Gifu, Japan; Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan	Nakayama, N (corresponding author), Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, 630 Shimokobi, Minokamo City, Gifu 5050034, Japan.	doctor.1@jasmine.ocn.ne.jp					Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Chatfield C., 1980, INTRO MULTIVARIATE A; Dehaene S, 2001, COGNITION, V79, P1, DOI 10.1016/S0010-0277(00)00123-2; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FRACKOWIAK RS, 1997, HUMAN BRAIN FUNCTION, V105; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Hirono N, 1998, J NEUROL NEUROSUR PS, V64, P552, DOI 10.1136/jnnp.64.4.552; Holmes A., 1997, HUMAN BRAIN FUNCTION, P67; Kjaer TW, 2001, CONSCIOUS COGN, V10, P356, DOI 10.1006/ccog.2001.0509; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; SRERIADE M, 1997, THALAMUS; Stamatakis EA, 2002, J NUCL MED, V43, P476; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Talairach J., 1988, COPLANAR STEREOTACTI; Thompson C. J., 1986, Proceedings of the SPIE - The International Society for Optical Engineering, V671, P244; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; Whalen PJ, 1998, BIOL PSYCHIAT, V44, P1219, DOI 10.1016/S0006-3223(98)00251-0; Willis MW, 2002, PSYCHIAT RES-NEUROIM, V114, P23, DOI 10.1016/S0925-4927(01)00126-3; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263; Zeman AZJ, 1997, J NEUROL NEUROSUR PS, V62, P549, DOI 10.1136/jnnp.62.6.549	35	82	86	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2006	77	7							856	10.1136/jnnp.2005.080523			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	054ZL	WOS:000238417900013	16549415	Green Published			2021-06-18	
J	Lu, J; Moochhala, S; Moore, XL; Ng, KC; Tan, MH; Lee, LKH; He, BP; Wong, MC; Ling, EA				Lu, J; Moochhala, S; Moore, XL; Ng, KC; Tan, MH; Lee, LKH; He, BP; Wong, MC; Ling, EA			Adult bone marrow cells differentiate into neural phenotypes and improve functional recovery in rats following traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						bone marrow cells; transplantation; neural differentiation; traumatic brain injury; functional recovery; rats	MESENCHYMAL STEM-CELLS; IN-VIVO; SYNAPTIC TRANSMISSION; HIPPOCAMPUS; DEFICITS; NEURONS	This study aims to investigate the therapeutic potential of adult bone marrow stromal cells (BMSCs). Exposed to a cocktail of induction medium, some BMSCs could differentiate into cell types with phenotypes of neural lineages in vitro. These cells expressed neural markers nestin, GFAP, 68-kDa neurofilament and beta-tubulin III as detected by immunohistochemistry and RT-PCR. Fluorescence-labeled cells were injected intravenously at 72 h after traumatic brain injury. Transplanted cells survived and migrated to the ipsilateral cerebral cortex at different time points after injection. They were immunopositive for neuronal marker MAP-2, oligodendrocyte marker CNPase, astrocytic maker GFAP or microglial marker OX-42 in vivo. In rats receiving BMSC transplants, there were significant improvements in motor and neurological functions when compared with the control groups. Hence, the therapeutic potential of BMSCs for traumatic brain injury is further amplified. (C) 2005 Elsevier Ireland Ltd. All fights reserved.	DSO Natl Labs, Def Med & Environm Res Inst, Singapore 117510, Singapore; Natl Canc Ctr, Brain Tumor Res Lab, Singapore, Singapore; Natl Univ Singapore, Dept Anat, Singapore 117548, Singapore	Lu, J (corresponding author), DSO Natl Labs, Def Med & Environm Res Inst, 27 Med Dr,09-01, Singapore 117510, Singapore.	ljia@dso.org.sg; mshabbir@dso.org.sg	Lee, Lionel/F-3394-2015	MOOCHHALA, SHABBIR/0000-0003-4521-3192			Arvanian VL, 2003, J NEUROSCI, V23, P8706; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Hess D, 2003, NAT BIOTECHNOL, V21, P763, DOI 10.1038/nbt841; Humpel Christian, 1995, Journal of Neural Transplantation and Plasticity, V5, P257; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; NETTO CA, 1993, BEHAV BRAIN RES, V58, P107, DOI 10.1016/0166-4328(93)90095-8; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; SANCHEZRAMOS J, 2000, EXP NEUROL, V2, P47; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1	21	82	101	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAY 1	2006	398	1-2					12	17		10.1016/j.neulet.2005.12.053			6	Neurosciences	Neurosciences & Neurology	034FN	WOS:000236914500003	16455199				2021-06-18	
J	Meffre, D; Delespierre, B; Gouezou, M; Leclerc, P; Vinson, GP; Schumacher, M; Stein, DG; Guennoun, R				Meffre, D; Delespierre, B; Gouezou, M; Leclerc, P; Vinson, GP; Schumacher, M; Stein, DG; Guennoun, R			The membrane-associated progesterone-binding protein 25-Dx is expressed in brain regions involved in water homeostasis and is up-regulated after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						circumventricular organs; 25-Dx; neuroprotection; progesterone; steroids; traumatic brain injury	INNER ZONE ANTIGEN; RAT-BRAIN; PRIMARY CULTURES; GLIAL-CELLS; RECEPTOR; VASOPRESSIN; ESTROGEN; DAMAGE; IDENTIFICATION; MODULATION	After traumatic brain injury, progesterone has important neuroprotective effects in the nervous system. There is better functional outcome and less oedema formation in pseudopregnant rat females (high levels of endogenous progesterone) than in males. In addition to intracellular progesterone receptors, membrane binding sites of the hormone such as 25-Dx may also be involved in neuroprotection. In the present study we investigated the distribution of the membrane-associated progesterone-binding protein 25-Dx in rat brain. Immunohistochemical analysis showed that 25-Dx is particularly abundant in the hypothalamic area, circumventricular organs, and ependymal cells of the lateral walls of the third and lateral ventricles. A strong signal was also detected in the meninges. Double immunofluorescence immunolabelling and confocal microscopy showed that 25-Dx is co-expressed with vasopressin in neurones of the paraventricular, supraoptic and retrochiasmatic nuclei. Levels of 25-Dx expression were higher in pseudopregnant females than in males. After traumatic brain injury, 25-Dx expression was up-regulated in neurones and induced in astrocytes, which play an important role in regulating water and ion homeostasis. The expression of 25-Dx in structures involved in CSF production (choroid plexus) and in osmoregulation (circumventricular organs, hypothalamus and meninges), and its up-regulation after brain damage, point to a novel and potentially important role of this progesterone-binding protein in the maintenance of water homeostasis after traumatic brain injury.	INSERM, U488, F-94276 Le Kremlin Bicetre, France; Queen Mary Univ London, Div Biomed Sci, London, England; Emory Univ, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA	Guennoun, R (corresponding author), INSERM, U488, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	guen-noun@kb.inserm.fr	Guennoun, Rachida/F-2420-2011; Stein, Donald/AAJ-5139-2020; Schumacher, Michael/G-3581-2013	Guennoun, Rachida/0000-0002-9219-7300; Schumacher, Michael/0000-0001-6117-5371; MEFFRE, Delphine/0000-0002-9204-2245			Auger CJ, 2002, J NEUROENDOCRINOL, V14, P561, DOI 10.1046/j.1365-2826.2002.00809.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUKUSOGLU C, 1994, J NEUROCHEM, V63, P1434; CALDWELL JD, 1995, BRAIN RES, V693, P225, DOI 10.1016/0006-8993(95)00727-8; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; CROFTON JT, 1985, ENDOCRINOLOGY, V117, P1195, DOI 10.1210/endo-117-3-1195; De Nicola AF, 2003, ANN NY ACAD SCI, V1007, P317, DOI 10.1196/annals.1286.030; de Vries GJ, 1998, PROG BRAIN RES, V119, P3; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Falkenstein E, 1999, ENDOCRINOLOGY, V140, P5999, DOI 10.1210/en.140.12.5999; Falkenstein E, 1996, BIOCHEM BIOPH RES CO, V229, P86, DOI 10.1006/bbrc.1996.1761; FORSLING ML, 1982, J ENDOCRINOL, V95, P147, DOI 10.1677/joe.0.0950147; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GarciaSegura LM, 1996, FRONT NEUROENDOCRIN, V17, P180, DOI 10.1006/frne.1996.0005; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Guennoun R, 2003, CONTRO ISSU CLIM MED, P57; Hertz L, 2000, J NEUROSCI RES, V62, P480, DOI 10.1002/1097-4547(20001115)62:4<480::AID-JNR2>3.0.CO;2-K; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; JUNGTESTAS I, 1991, EXP CELL RES, V193, P12, DOI 10.1016/0014-4827(91)90532-Y; JUNGTESTAS I, 1992, J STEROID BIOCHEM, V41, P621, DOI 10.1016/0960-0760(92)90394-X; JungTestas I, 1996, CELL MOL NEUROBIOL, V16, P439, DOI 10.1007/BF02088110; KE FC, 1990, J NEUROCHEM, V54, P467, DOI 10.1111/j.1471-4159.1990.tb01895.x; Krebs CJ, 2000, P NATL ACAD SCI USA, V97, P12816, DOI 10.1073/pnas.97.23.12816; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LAIRD SM, 1988, ACTA ENDOCRINOL-COP, V119, P420, DOI 10.1530/acta.0.1190420; MANI SK, 2002, HORMONES BRAIN BEHAV, P643; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; Meyer C, 1998, STEROIDS, V63, P111, DOI 10.1016/S0039-128X(97)00143-8; Meyer C, 1996, EUR J BIOCHEM, V239, P726, DOI 10.1111/j.1432-1033.1996.0726u.x; Micevych P, 2003, NEUROENDOCRINOLOGY, V78, P29, DOI 10.1159/000071703; Mifsud W, 2002, GENOME BIOL, V3; Min L, 2004, MOL CELL ENDOCRINOL, V215, P143, DOI 10.1016/j.mce.2003.11.025; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; RAINBOW TC, 1982, NATURE, V300, P648, DOI 10.1038/300648a0; Ramirez VD, 1996, CELL MOL NEUROBIOL, V16, P175, DOI 10.1007/BF02088175; Raza FS, 2001, EUR J BIOCHEM, V268, P2141, DOI 10.1046/j.1432-1327.2001.02096.x; Redzic ZB, 2004, ADV DRUG DELIVER REV, V56, P1695, DOI 10.1016/j.addr.2004.07.005; Sakamoto H, 2004, NEUROSCIENCE, V126, P325, DOI 10.1016/j.neuroscience.2004.04.003; Sakamoto H, 2001, J NEUROSCI, V21, P6221; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Schumacher M, 2002, HORMONES BRAIN BEHAV, P683; Selmin O, 1996, CARCINOGENESIS, V17, P2609, DOI 10.1093/carcin/17.12.2609; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; SUBRAHMANYAM CS, 1982, NUCLEIC ACIDS RES, V10, P3667, DOI 10.1093/nar/10.12.3667; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	57	82	84	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2005	93	5					1314	1326		10.1111/j.1471-4159.2005.03127.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	927DP	WOS:000229172900024	15934950				2021-06-18	
J	Fleming, JM; Shum, D; Strong, J; Lightbody, S				Fleming, JM; Shum, D; Strong, J; Lightbody, S			Prospective memory rehabilitation for adults with traumatic brain injury: A compensatory training programme	BRAIN INJURY			English	Article							EVERYDAY MEMORY; SELF-AWARENESS; REMEDIATION	Primary objective: To describe a prospective memory rehabilitation programme based on a compensatory training approach and report the results of three case studies. Research design: Programme evaluation using pre-and post-intervention assessments and telephone follow-up. Methods and procedures: Three participants with traumatic brain injury completed 8 weeks of training with 1 - 2 hour individual sessions. Assessments were formal prospective memory assessment, self-report and measures of diary use. Experimental interventions: Intervention aimed to identify potential barriers, establish self-awareness of memory deficits, introduce a customized compensatory tool, a cueing system and organizational strategies. A significant other was involved in training to assist generalization. Main outcomes and results: All three participants improved on formal prospective memory assessment and demonstrated successful diary use after the programme. Self-report of prospective memory failure fluctuated and may reflect increased self-awareness. Conclusion: A compensatory approach may be useful in improving prospective memory performance following TBI.	Univ Queensland, Sch Hlth & Rehab Sci, Dept Occupat Therapy, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; Griffith Univ, Brisbane, Qld 4111, Australia	Fleming, JM (corresponding author), Univ Queensland, Sch Hlth & Rehab Sci, Dept Occupat Therapy, Brisbane, Qld 4072, Australia.	j.fleming@mailbox.uq.edu.au	Shum, David/A-3914-2008; Fleming, Jennifer M/B-4436-2011; Strong, Jenny/F-1211-2010	Shum, David/0000-0002-4810-9262; Strong, Jenny/0000-0002-9367-8755			BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Camp C. J., 1990, AGING COGNITION MENT, P231; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; COCKBURN J, 1996, PROSPECTIVE MEMORY T, P327; EINSTEIN GO, 1996, PROSPECTIVE MEMORY T, P116; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; FLEMING J, IN PRESS CANADIAN J; Fleming JM, 1996, BRAIN INJURY, V10, P1; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Hutchinson J, 1997, TOP LANG DISORD, V18, P45, DOI 10.1097/00011363-199711000-00006; KAPUR N, 1995, HDB MEMORY DISORDERS, P533; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; LYNCH WJ, 1995, J HEAD TRAUMA REHAB, V10, P94, DOI 10.1097/00001199-199502000-00011; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; RASKIN SA, UNPUB MEMORY INTENTI; Raymond MJ, 1996, J COGNITIVE REHABILI, V14, P18; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SHUM D, 2002, P INT NEUR SOC 13 AN; Shum D., 2002, BRAIN IMPAIR, V3, DOI [https://doi.org/10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Toglia JP, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P5; van den Broek MD, 2000, BRAIN INJURY, V14, P455; WAUGH N, 1999, UNPUB SELF REPORT YO; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; WILSON BA, 1995, HDB MEMORY DISORDERS, P451; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348; ZENICUS A, 1991, BRAIN INJURY, V5, P369	41	82	90	1	40	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2005	19	1					1	10		10.1080/02699050410001720059			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	875AS	WOS:000225392600001	15762096				2021-06-18	
J	Bull, R; Espy, KA; Senn, TE				Bull, R; Espy, KA; Senn, TE			A comparison of performance on the Towers of London and Hanoi in young children	JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY			English	Article						executive functions; inhibition; shifting; short-term memory; tower tasks; children	LEARNING-DISABLED READERS; EXECUTIVE FUNCTION TASKS; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; FRONTAL-LOBE; PRESCHOOL-CHILDREN; INDIVIDUAL-DIFFERENCES; PORTEUS MAZE; SYSTEM; INTELLIGENCE	Background: The Towers of London (TOL) and Hanoi (TOH) have been viewed as equivalent measures of planning and/or problem solving, although recent evidence in adults suggests that the underlying measurement characteristics of these two tasks may differ. As tower tasks are one of the few instruments that can be used to assess executive functioning in young children, the cognitive demands for both tasks merit further examination. Methods: The relation among tower tasks and those of shortterm memory, inhibition, and shifting ability were examined in a sample of 118 typically developing young children (M age - 4 years, 9 months, SD = 6 months). Half the children completed TOL and half completed TOH, with groups matched with respect to age, sex, and child vocabulary. Results: Whilst performance on a shifting task uniquely predicted TOH performance, none of the executive function measures were related to TOL performance after statistically controlling for the influence of baseline naming speed. For both tower tasks, performance on a shifting task contributed more strongly on complex trials that required more moves in the counter-intuitive direction relative to the end-state goal, whereas inhibition task performance only predicted performance on complex TOL trials. Conclusions: Successful tower task performance may be determined, at least at higher levels of complexity, by mental flexibility in this age range. However, overall the findings suggest that TOL and TOH are not interchangeable tasks even in young children, and more generally, raise methodological issues regarding the complex nature of executive function tasks.	Univ Aberdeen, Sch Psychol, Dept Psychol, Aberdeen AB24 2UB, Scotland; So Illinois Univ, Sch Med, Dept Family & Community Med, Carbondale, IL 62901 USA	Bull, R (corresponding author), Univ Aberdeen, Sch Psychol, Dept Psychol, William Guild Bldg, Aberdeen AB24 2UB, Scotland.	r.bull@abdn.ac.uk	Bull, Rebecca/A-7895-2008; Bull, Rebecca/AAC-4344-2020	Bull, Rebecca/0000-0003-3273-7202			Anderson M, 2001, J CHILD PSYCHOL PSYC, V42, P287, DOI 10.1111/1469-7610.00722; Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Baddeley Alan, 1996, Quarterly Journal of Experimental Psychology Section A Human Experimental Psychology, V49, P5, DOI 10.1080/027249896392784; Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; Bishop DVM, 2001, J CHILD PSYCHOL PSYC, V42, P551, DOI 10.1111/1469-7610.00749; Bull R, 1999, DEV NEUROPSYCHOL, V15, P421, DOI 10.1080/87565649909540759; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; Carlin D, 2000, NEUROPSYCHOLOGIA, V38, P655, DOI 10.1016/S0028-3932(99)00102-5; Chase-Carmichael CA, 1999, CLIN NEUROPSYCHOL, V13, P405, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT405; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Espy KA, 2002, CHILD NEUROPSYCHOL, V8, P83, DOI 10.1076/chin.8.2.83.8723; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; ESPY KA, IN PRESS DEV NEUROPS; Flavell J., 1977, PERSPECTIVES DEV MEM, P3; Gathercole SE, 2000, BRIT J EDUC PSYCHOL, V70, P177, DOI 10.1348/000709900158047; GILHOOLY KJ, IN PRESS THINKING RE; GNYS JA, 1991, DEV NEUROPSYCHOL, V7, P487, DOI 10.1080/87565649109540507; GOEL V, 1995, NEUROPSYCHOLOGIA, V33, P623, DOI 10.1016/0028-3932(95)90866-P; Goel V, 2001, COGNITIVE SCI, V25, P287; Heaton R., 1993, WISCONSIN CARD SORTI; Humes GE, 1997, ASSESSMENT, V4, P249, DOI 10.1177/107319119700400305; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; KINNEY HC, 1988, J NEUROPATH EXP NEUR, V47, P217, DOI 10.1097/00005072-198805000-00003; KLAHR D, 1994, MAC FDN MEN, P177; KLAHR D, 1981, COGNITIVE PSYCHOL, V13, P113, DOI 10.1016/0010-0285(81)90006-2; Klahr D., 1978, CHILDRENS THINKING W, P181; Korkman M, 1998, NEPSY DEV NEUROPSYCH; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Levin HS, 2001, NEUROPSYCHOLOGY, V15, P557, DOI 10.1037//0894-4105.15.4.557; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LEZAK MD, 1993, NEUROPSYCHOLOGICAL A; Lyon G., 1996, ATTENTION MEMORY EXE; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MORRIS RG, 1993, NEUROPSYCHOLOGIA, V31, P1367, DOI 10.1016/0028-3932(93)90104-8; Numminen H, 2001, RES DEV DISABIL, V22, P373, DOI 10.1016/S0891-4222(01)00078-6; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Ozonoff S, 1999, J AUTISM DEV DISORD, V29, P171, DOI 10.1023/A:1023052913110; Pennington B.F., 1996, ATTENTION MEMORY EXE, P327; Pennington BF, 1997, AM J HUM GENET, V60, P13; Phillips LH, 1999, MEMORY, V7, P209, DOI 10.1080/741944066; Rabbitt P., 1997, METHODOLOGY FRONTAL; Rowe JB, 2001, NEUROPSYCHOLOGIA, V39, P315, DOI 10.1016/S0028-3932(00)00109-3; SENN TE, IN PRESS NEUROPSYCHO; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1990, NEUROPSYCHOLOGY MENT; Shum D, 2000, BRAIN COGNITION, V44, P59; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Swanson HL, 1996, J EXP CHILD PSYCHOL, V61, P242, DOI 10.1006/jecp.1996.0016; Swanson HL, 2000, INTELLIGENCE, V28, P1, DOI 10.1016/S0160-2896(99)00025-2; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; van den Heuvel OA, 2003, NEUROIMAGE, V18, P367, DOI 10.1016/S1053-8119(02)00010-1; Wechsler D., 1990, WECHSLER PRESCHOOL P; WELSH M, 1995, J GEN PSYCHOL, V122, P69, DOI 10.1080/00221309.1995.9921223; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Welsh MC, 1999, BRAIN COGNITION, V41, P231, DOI 10.1006/brcg.1999.1123; WOODCOCK RW, 1989, WOODCOCK JOHNSON COG	59	82	86	1	28	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9630	1469-7610		J CHILD PSYCHOL PSYC	J. Child Psychol. Psychiatry	MAY	2004	45	4					743	754		10.1111/j.1469-7610.2004.00268.x			12	Psychology, Developmental; Psychiatry; Psychology	Psychology; Psychiatry	826CB	WOS:000221805400009	15056306	Green Published			2021-06-18	
J	Pfister, BJ; Weihs, TP; Betenbaugh, M; Bao, G				Pfister, BJ; Weihs, TP; Betenbaugh, M; Bao, G			An in vitro uniaxial stretch model for axonal injury	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						diffuse axonal injury; uniaxial stretch; neural cell death; traumatic brain injury; biomechanics	BRAIN-INJURY; CORTICAL-NEURONS; DEFORMATION; CELLS	We have developed a unique uniaxial stretching device to study axonal injury and neural cell death resulting from brain tissue deformations common in traumatic head injuries. Using displacement control rather than force control, this device is capable of achieving strains >70% and strain rates up to 90 s(-1), well above those currently used for studying axonal injury. We have demonstrated that the deformation of the specimen was uniaxial, uniform and highly reproducible; the prespecified displacement profiles could be realized almost precisely; and adequate cell adhesion could be achieved readily. The entire device can fit into a biological safety cabinet to maintain sterility, and the specimens are convenient for cell culture. This device can be used to investigate a wide range of biomechanical issues involved in diffuse axonal injury. (C) 2003 Biomedical Engineering Society.	Emory Univ, Atlanta, GA 30322 USA; Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21287 USA	Bao, G (corresponding author), Georgia Inst Technol, Dept Biomed Engn, 315 Ferest Dr,Room 2306, Atlanta, GA 30332 USA.	gang.bao@bme.gatech.edu	Betenbaugh, Michael J./A-3252-2010; Weihs, Timothy P/A-3313-2010	Betenbaugh, Michael J./0000-0002-6336-4659; 			Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gallant PE, 1997, J NEUROTRAUM, V14, P811, DOI 10.1089/neu.1997.14.811; Gennarelli T, 1996, NEUROSURGERY, V2, P2611; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McIntosh TK, 1996, LAB INVEST, V74, P315; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MEANEY DF, 1993, CRASHWORTHINESS OCCU, V169, P169; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sengoku T., 2000, Journal of Neurotrauma, V17, P971; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; STRICH SJ, 1961, LANCET, V2, P443; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang S. X., 2000, Journal of Neurotrauma, V17, P979	36	82	85	1	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2003	31	5					589	598		10.1114/1.1566445			10	Engineering, Biomedical	Engineering	675NJ	WOS:000182701200009	12757202				2021-06-18	
J	WoldeMussie, E; Yoles, E; Schwartz, M; Ruiz, G; Wheeler, LA				WoldeMussie, E; Yoles, E; Schwartz, M; Ruiz, G; Wheeler, LA			Neuroprotective effect of memantine in different retinal injury models in rats	JOURNAL OF GLAUCOMA			English	Article						chronic ocular hypertension; ganglion cells; memantine; neuroprotection; optic nerve	NMDA-RECEPTOR ANTAGONIST; CHANNEL BLOCKER MEMANTINE; TRAUMATIC BRAIN INJURY; OPTIC-NERVE CRUSH; GANGLION-CELLS; GLUTAMATE NEUROTOXICITY; PARKINSONS-DISEASE; VITREOUS BODY; ISCHEMIA; GLAUCOMA	Purpose: To evaluate the neuroprotective effect of memantine, an NMDA receptor channel blocker, in two retinal ganglion cell (RGC) injury models in rats. Methods: Neuroprotective effect of memantine was tested in partial optic nerve injury and chronic ocular hypertensive models. In the optic nerve injury model, memantine (0.1 - 30 mg/kg) was injected intraperitoneally immediately after injury. Two weeks later, optic nerve function was determined by measuring compound action potential and surviving RGC was determined by retrograde labeling with dextran tetramethyl rhodamine. Chronic ocular hypertension was attained by laser photocoagulation of episcleral and limbal veins. Memantine (5 or 10 mg/kg) was administered continuously each day with an osmotic pump, either immediately after or 10 days after first laser photocoagulation, for 3 weeks, after which RGC survival was determined. Results: Two weeks after partial optic nerve injury, there was approximate to80% reduction in RGC number. Memantine (5 mg/kg) caused a twofold increase in compound action potential amplitude and a 1.7-fold increase in survival of RGCs, respectively. In the chronic ocular hypertension model there was 37% decrease in RGCS after 3 weeks of elevated intraocular pressure. Memantine (10 mg/kg daily) reduced ganglion cell loss to 12% when applied immediately after first laser photocoagulation, and prevented any further loss when applied 10 days after first laser photocoagulation. Conclusion: The protective effect of memantine suggests that excessive stimulation of NMDA receptors by glutamate is involved in causing cell damage in these RGC injury models.	Allergan Pharmaceut Inc, Dept Sci Biol, Irvine, CA USA; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	WoldeMussie, E (corresponding author), Allergan Pharmaceut Inc, Dept Sci Biol, 2525 Dupont Dr, Irvine, CA USA.	WoldeMussieLiz@allergan.com					ABUELASRAR AM, 1992, INVEST OPHTH VIS SCI, V33, P3463; Block F, 1996, NEUROSCI LETT, V208, P41, DOI 10.1016/0304-3940(96)12545-3; BORMANN J, 1989, EUR J PHARMACOL, V166, P591, DOI 10.1016/0014-2999(89)90385-3; Brooks DE, 1997, AM J VET RES, V58, P864; Chaudhary P, 1998, BRAIN RES, V792, P154, DOI 10.1016/S0006-8993(98)00212-1; Chen HSV, 1998, NEUROSCIENCE, V86, P1121, DOI 10.1016/S0306-4522(98)00163-8; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Danysz W, 2002, CURR PHARM DESIGN, V8, P835, DOI 10.2174/1381612024607117; Donello JE, 2001, J PHARMACOL EXP THER, V296, P216; Dresser R, 2000, SCIENCE, V289, P869; Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012; Dreyer EB, 1997, CLIN NEUROSCI, V4, P270; FREESE A, 1990, BRAIN RES, V521, P254, DOI 10.1016/0006-8993(90)91550-Z; GORTELMEYER R, 1992, ARZNEIMITTEL-FORSCH, V42-2, P904; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P1397, DOI 10.1517/13543784.9.6.1397; Jones MW, 2002, SEIZURE-EUR J EPILEP, V11, P104, DOI 10.1053/seiz.2002.0589; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; KORNHUBER J, 1995, NEUROSCI LETT, V195, P137, DOI 10.1016/0304-3940(95)11785-U; Kreutz MR, 1999, RESTOR NEUROL NEUROS, V14, P127; Lagreze WA, 1998, INVEST OPHTH VIS SCI, V39, P1063; Lam TT, 1997, J OCUL PHARMACOL TH, V13, P129, DOI 10.1089/jop.1997.13.129; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LOUZADAJUNIOR P, 1992, J NEUROCHEM, V59, P358, DOI 10.1111/j.1471-4159.1992.tb08912.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Melton ST, 1997, ANN PHARMACOTHER, V31, P457, DOI 10.1177/106002809703100413; Neufeld AH, 1999, SURV OPHTHALMOL, V43, pS129, DOI 10.1016/S0039-6257(99)00010-7; Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944; Nikolajsen L, 2000, ANESTH ANALG, V91, P960, DOI 10.1097/00000539-200010000-00036; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; Osborne NN, 1999, VISUAL NEUROSCI, V16, P45, DOI 10.1017/S0952523899161017; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; PARSONS CG, 1995, NEUROPHARMACOLOGY, V34, P1239, DOI 10.1016/0028-3908(95)00092-K; Pease ME, 2000, INVEST OPHTH VIS SCI, V41, P764; RABEY JM, 1992, J NEURAL TRANSM-PARK, V4, P277, DOI 10.1007/BF02260076; Rao VLR, 2001, BRAIN RES, V911, P96; RIEDERER P, 1991, LANCET, V338, P1022, DOI 10.1016/0140-6736(91)91888-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Schmitt U, 1996, J NEUROTRAUM, V13, P791, DOI 10.1089/neu.1996.13.791; Solberg Y, 1997, INVEST OPHTH VIS SCI, V38, P1380; Stieg PE, 1999, EUR J PHARMACOL, V375, P115, DOI 10.1016/S0014-2999(99)00214-9; Sucher N J, 1990, Neuroreport, V1, P29, DOI 10.1097/00001756-199009000-00009; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618; Wilkinson D, 2001, INT J CLIN PRACT, V55, P129; WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49; Yoles E, 1999, INVEST OPHTH VIS SCI, V40, P65; Yoles E, 1997, J NEUROTRAUM, V14, P665, DOI 10.1089/neu.1997.14.665; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906	51	82	86	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1057-0829	1536-481X		J GLAUCOMA	J. Glaucoma	DEC	2002	11	6					474	480		10.1097/00061198-200212000-00003			7	Ophthalmology	Ophthalmology	628UV	WOS:000180015700003	12483089				2021-06-18	
J	Levin, HS; Hanten, G; Chang, CC; Zhang, LF; Schachar, R; Ewing-Cobbs, L; Max, JE				Levin, HS; Hanten, G; Chang, CC; Zhang, LF; Schachar, R; Ewing-Cobbs, L; Max, JE			Working memory after traumatic brain injury in children	ANNALS OF NEUROLOGY			English	Article							CLOSED-HEAD INJURY; SHORT-TERM-MEMORY; PREFRONTAL CORTEX; INFORMATION; INVOLVEMENT; LESIONS	To investigate the effects of traumatic brain injury on working memory in children, we administered semantic (letter identity) and phonological (letter rhyme) N-back tasks to children who were on average 5 years post-mild (n = 54) or -severe (n = 26) traumatic brain injury and 44 typically developing children who were comparable in age. The correct detection of targets and false alarms were measured for each task. Memory load (which varied from 0 to 3 letters back) and age significantly affected the detection of targets and false alarms in both tasks. The severity of traumatic brain injury affected the correct detection of letters on the identity task and false alarms on the rhyme task. Traumatic brain injury severity also interacted with memory load in its effect on false alarms on the rhyme task. Traumatic brain injury results in impaired working memory and diminished inhibition in children. The N-back working memory task is feasible for administration to brain-injured children and potentially could be useful for studying brain activation associated with working memory and effects of drug therapy in this group of patients.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 6560 Fannin St,Suite 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu		Schachar, Russell/0000-0002-2015-4395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Callicott JH, 1999, CEREB CORTEX, V9, P20, DOI 10.1093/cercor/9.1.20; DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Gathercole SE, 1997, J EXP CHILD PSYCHOL, V67, P290, DOI 10.1006/jecp.1997.2391; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Hanten G, 2000, J MEM LANG, V43, P335, DOI 10.1006/jmla.2000.2731; Harnishfeger KK, 1996, J EXP CHILD PSYCHOL, V62, P292, DOI 10.1006/jecp.1996.0032; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Jansma JM, 2000, NEUROIMAGE, V12, P688, DOI 10.1006/nimg.2000.0645; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Martin R.C., 1994, NEUROPSYCHOLOGY, V8, P506, DOI [10.1037/0894-4105.8.4.506, DOI 10.1037/0894-4105.8.4.506]; MARTIN RC, 1993, MEM COGNITION, V21, P176, DOI 10.3758/BF03202730; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mehta MA, 2000, J NEUROSCI, V20; Nystrom LE, 2000, NEUROIMAGE, V11, P424, DOI 10.1006/nimg.2000.0572; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; Saykin AJ, 1999, BRAIN, V122, P1963, DOI 10.1093/brain/122.10.1963; Swanson HL, 2001, J EXP CHILD PSYCHOL, V79, P294, DOI 10.1006/jecp.2000.2587; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; TEASDALE G, 1974, LANCET, V2, P81; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494	32	82	82	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUL	2002	52	1					82	88		10.1002/ana.10252			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	566WT	WOS:000176451800013	12112051				2021-06-18	
J	Tong, W; Igarashi, T; Ferriero, DM; Noble, LJ				Tong, W; Igarashi, T; Ferriero, DM; Noble, LJ			Traumatic brain injury in the immature mouse brain: Characterization of regional vulnerability	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; controlled cortical impact; immature brain; delayed neuronal damage; Fluoro-Jade; axonal degeneration	CLOSED HEAD-INJURY; PERINATAL HYPOXIA-ISCHEMIA; DISMUTASE TRANSGENIC MICE; NEURONAL DEGENERATION; NEONATAL RAT; FLUORO-JADE; CHILDREN; ADOLESCENTS; DAMAGE; NEURODEGENERATION	We characterized the regional and temporal patterns of neuronal injury and axonal degeneration after controlled cortical impact of moderate severity in mice at postnatal day 21. Animals were euthanized at 1, 3, or 7 days after injury or sham operation. The brains were removed and prepared for immunolocalization of neurons and microglia/macrophages or subjected to Fluoro-Jade and silver stains, indicators of irreversible neuronal cell injury and axonal degeneration. There was significant neuronal loss in both the ipsi- and the contralateral cortices, ipsilateral hippocampus, and ipsilateral thalamus by 7 days post injury compared to sham-operated animals. Activated microglia/macrophages were most prominent in regions of neuronal loss including the ipsilateral cortex, hippocampus, and thalamus. Neuronal injury, as evidenced by Fluoro-Jade labeling, was not apparent in sham-operated animals. In injured animals, labeling was identified in the ipsilateral cortex and hippocampus at 1 and 3 days post injury. Silver- and Fluoro-Jade-labeled degenerating axons were observed in the ipsilateral subcortical white matter by 1 day post injury, in the ipsilateral external capsule, caudate putamen, and contralateral subcortical white matter by 3 days post injury, and in the internal capsule, pyramidal tracts, and cerebellar peduncles by 7 days post injury. Our findings demonstrate that controlled cortical impact in the developing brain generates neuronal loss in both the ipsilateral and the contralateral cortex, a temporally distinct pattern of subcortical. neuronal injury/death, and widespread white matter damage. These observations serve as an important baseline for studying human brain injury and optimizing therapies for the brain-injured child. (C) 2002 Elsevier Science (USA).	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Noble, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BIROS MH, 1991, RESUSCITATION, V22, P283, DOI 10.1016/0300-9572(91)90036-X; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAVISON AN, 1966, BRIT MED BULL, V22, P40, DOI 10.1093/oxfordjournals.bmb.a070434; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FIFE D, 1984, J NEUROSURG, V60, P697, DOI 10.3171/jns.1984.60.4.0697; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; Greenwald B M, 1995, Adv Pediatr, V42, P47; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HUMPHREYS R, 1984, CONCEPTS PEDIAT NEUR, V4, P230; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Joashi UC, 1999, EUR J NEUROSCI, V11, P91, DOI 10.1046/j.1460-9568.1999.00409.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KOLB B, 1986, BRAIN RES, V397, P315, DOI 10.1016/0006-8993(86)90633-5; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Li L, 1998, MOL CELL NEUROSCI, V12, P157, DOI 10.1006/mcne.1998.0709; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Northington FJ, 2001, NEUROBIOL DIS, V8, P207, DOI 10.1006/nbdi.2000.0371; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Soares HD, 1995, J NEUROSCI, V15, P8223; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Zuckerman GB, 1997, PEDIATR ANN, V26, P621, DOI 10.3928/0090-4481-19971001-09	56	82	83	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUL	2002	176	1					105	116		10.1006/exnr.2002.7941			12	Neurosciences	Neurosciences & Neurology	574VV	WOS:000176911000010	12093087				2021-06-18	
J	Felmingham, KL; Baguley, IJ; Crooks, J				Felmingham, KL; Baguley, IJ; Crooks, J			A comparison of acute and postdischarge predictors of employment 2 years after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; forecasting; rehabilitation	HEAD-INJURY; SCALE; RETURN; WORK; VALIDATION; ABUSE; COMA	Objective: To examine whether adding postdischarge psychosocial predictors to premorbid and injury-related variables improved the capacity to predict employment 2 years after rehabilitation for traumatic brain injury (TBI). Design: Data were collected prospectively at 6 and 24 months after discharge from rehabilitation. Logistic regression analyses examined predictors of employment status. Setting: Inpatient and community TBI rehabilitation service attached to a major Australian teaching hospital. Participants: Fifty-five patients with TBI, aged 16 or older, who were consecutively admitted to a brain injury unit with complete longitudinal data and who agreed to participate in the study. Intervention: Measured injury severity (Glasgow Coma Scale scores, posttraumatic amnesia): functional independence (Functional Assessment Measure cognitive subscale) at admission and discharge from rehabilitation; self-report of employment (premorbid, postdischarge): postdischarge psychosocial status at 6 months and 2 years (Community Integration Questionnaire, General Health Questionnaire, Trauma Complaints List, Overt Aggression Scale. Alcohol Use Disorders Inventory Test, Satisfaction with Life Scale). Main Outcome Measures: Employment status (employed, unemployed) was used to reflect vocational outcome. Predictor variables comprised premorbid work status, injury-related variables (age, injury severity). and postdischarge variables (employ ment, community integration, psychologic, cognitive status). Results: Adding postdischarge predictors to premorbid and acute variables significantly improved the ability to predict work status 2 years after rehabilitation. Age at the time of injury, premorbid employment status, work status, and psychologic distress 6 months postdischarge were significant predictors of employment. Conclusions: It is important to consider postdischarge psychologic well-being. in conjunction with premorbid and acute factors, in vocational interventions after TBI.	Westmead Hosp, Brain Injury Unit, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia	Felmingham, KL (corresponding author), Westmead Hosp, Brain Injury Unit, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia.		Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Goldberg D.P, 1972, DETECTION PSYCHIAT I; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	29	82	82	0	10	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2001	82	4					435	439		10.1053/apmr.2001.21985			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	419GC	WOS:000167940100002	11295001				2021-06-18	
J	Keep, M; Elmer, E; Fong, KSK; Csiszar, K				Keep, M; Elmer, E; Fong, KSK; Csiszar, K			Intrathecal cyclosporin prolongs survival of late-stage ALS mice	BRAIN RESEARCH			English	Article						amyotrophic lateral sclerosis; neurodegeneration; SOD1-G93A transgenic mice; mitochondrial permeability transition; intrathecal cyclosporin A; neuroprotection	TRAUMATIC BRAIN INJURY; TRANSGENIC-MOUSE MODEL; MITOCHONDRIAL PERMEABILITY TRANSITION; SUPEROXIDE-DISMUTASE; OXIDATIVE DAMAGE; AXONAL DAMAGE; ANIMAL-MODEL; CYTOCHROME-C; SCLEROSIS; PROTEIN	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by upper and lower motor neuron death with ascending paralysis leading to death. In a transgenic mouse model of ALS (SOD1-G93A) weakness appears at 3 months of age, and because of progressive paralysis leads to death by 5 months. Cyclosporin A (CsA) is well known, for its extracerebral effect, as an immunosuppressant in organ transplantation. When able to access the brain, CsA is an effective neuroprotective agent mainly due to its protection of mitochondria through inhibition of the mitochondrial permeability transition. CsA does not cross the intact blood-brain barrier and was in the present study delivered to the brain through an infusion into the lateral cerebral ventricle. Injections started at the onset of late disease when weakness of the hindlimbs was apparent. CsA treatment prolonged the survival of ALS transgenic mice as compared to vehicle-treated controls. This finding implicates mitochondrial function in ALS and may have significance for human disease. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, Honolulu, HI 96822 USA; Univ Lund Hosp, Wallenburg Neurosci Ctr, Expt Brain Res Lab, SE-22185 Lund, Sweden; Maas BiolAB LLC, Honolulu, HI 96817 USA	Keep, M (corresponding author), Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, 1960 East West Rd, Honolulu, HI 96822 USA.		Elmer, Eskil/F-9341-2014	Elmer, Eskil/0000-0001-7901-1826			Andrus PK, 1998, J NEUROCHEM, V71, P2041; APPEL SH, 1988, ARCH NEUROL-CHICAGO, V45, P381, DOI 10.1001/archneur.1988.00520280027011; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; DALCANTO MC, 1995, BRAIN RES, V676, P25, DOI 10.1016/0006-8993(95)00063-V; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Friberg H, 1998, J NEUROSCI, V18, P5151; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Gurney ME, 1997, J NEUROL, V244, pS15, DOI 10.1007/BF03160575; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; HIRANO A, 1967, ARCH NEUROL-CHICAGO, V16, P232, DOI 10.1001/archneur.1967.00470210008002; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kong JM, 1998, J NEUROSCI, V18, P3241; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; LAD RP, 1991, MOL BRAIN RES, V9, P239, DOI 10.1016/0169-328X(91)90007-K; Lee JP, 1999, P NATL ACAD SCI USA, V96, P3251, DOI 10.1073/pnas.96.6.3251; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1; LENSMEYER GL, 1991, J ANAL TOXICOL, V15, P110, DOI 10.1093/jat/15.3.110; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Liu DX, 1999, FASEB J, V13, P2318; Martin LJ, 2000, INT J MOL MED, V5, P3; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Miller RG, 1998, WESTERN J MED, V168, P262; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pedersen WA, 1999, BRAIN RES, V833, P117, DOI 10.1016/S0006-8993(99)01471-7; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; TINDALL RSA, 1992, J AUTOIMMUN, V5, P301, DOI 10.1016/0896-8411(92)90048-U; Tsuji A, 1998, THER DRUG MONIT, V20, P588, DOI 10.1097/00007691-199810000-00024; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; WILLIAMS DB, 1991, MAYO CLIN PROC, V66, P54, DOI 10.1016/S0025-6196(12)61175-6; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3	47	82	85	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 16	2001	894	2					327	331		10.1016/S0006-8993(01)02012-1			5	Neurosciences	Neurosciences & Neurology	411WA	WOS:000167521200022	11251210				2021-06-18	
J	Salim, A; Velmahos, GC; Jindal, A; Chan, L; Vassiliu, P; Belzberg, H; Asensio, J; Demetriades, D				Salim, A; Velmahos, GC; Jindal, A; Chan, L; Vassiliu, P; Belzberg, H; Asensio, J; Demetriades, D			Clinically significant blunt cardiac trauma: Role of serum troponin levels combined with electrocardiographic findings	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	60th Annual Meeting of the American-Association-for-the-Surgery-of Trauma	OCT 11-15, 2000	SAN ANTONIO, TEXAS	Amer Assoc Surg Trauma		blunt cardiac trauma; blunt myocardial injury; troponin; electrocardiography; echocardiography; cardiac complications	SUSPECTED MYOCARDIAL CONTUSION; CHEST TRAUMA; INJURY; DIAGNOSIS; ECHOCARDIOGRAPHY; INFARCTION	Background: The true importance of blunt cardiac trauma (BCT) Is related to the cardiac complications arising from it. Diagnostic tests that can predict accurately if such complications will develop or not may allow early and aggressive monitoring or early discharge. We investigated the role of two simple and convenient tests, serum cardiac troponin I (cTnI) and electrocardiogram (ECG), when used to identify patients at risk of cardiac complications after BCT. Methods: Over a 10-month period, 115 patients with evidence of significant blunt thoracic trauma were prospectively followed to identify the presence of clinically significant BCT (Sig-BCT), defined as cardiogenic shock, arrhythmias requiring treatment, or structural cardiac abnormalities directly related to the cardiac trauma. An ECG was obtained at admission and at 8 hours. Cardiac troponin I was measured at admission, at 4 hours, and at 8 hours. Transthoracic echocardiography was performed when clinically indicated, The sensitivity, specificity, and positive and negative predictive values of ECG and cTnI to identify Sig-BCT were calculated, Clinical risk factors for Sig-BCT were examined by univariate and multivariate analysis. Results: Nineteen patients (16.5%) were diagnosed with Sig-BCT and, in 18 of them, symptoms presented within 24 hours of admission. Abnormal electrocardiographic findings were detected in 58 patients (50%) and elevated cTnI levels in 27 (23.5%), Electrocardiography and cTnI had positive predictive values of 28% and 48% and negative predictive values of 95% and 93%, respectively. However, when both tests were abnormal (positive) or normal (negative), the positive and negative predictive values increased to 62% and 100%, respectively. Other independent risk factors for Sig-BCT were head injury, spinal injury, history of preexisting cardiac disease, and a chest Abbreviated Injury Score greater than 2. Conclusion: The combination of ECG and cTnI identifies reliably the presence or absence of Sig-BCT, Patients with an abnormal ECG and cTnI need close monitoring for at least 24 hours. Patients with a normal admission ECG and cTnI can be safely discharged in the absence of other injuries.	LAC & USC, Med Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Biostat, Los Angeles, CA USA	Salim, A (corresponding author), LAC & USC, Med Ctr, 1200 N State St,Room 9900, Los Angeles, CA 90033 USA.			Vassiliu, Panteleimon/0000-0002-5859-7917			ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; Adams JE, 1996, AM HEART J, V131, P308, DOI 10.1016/S0002-8703(96)90359-2; ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; BEDOR GS, 1992, CLIN CHEM, V11, P2203; Bertinchant JP, 2000, J TRAUMA, V48, P924, DOI 10.1097/00005373-200005000-00018; BIFFL WL, 1994, AM J SURG, V169, P523; Christensen M A, 1993, Am J Crit Care, V2, P28; DUBROW TJ, 1989, SURGERY, V106, P262; EISENACH JC, 1986, ANESTHESIOLOGY, V64, P364, DOI 10.1097/00000542-198603000-00011; FEGHALI NT, 1995, CHEST, V108, P1673, DOI 10.1378/chest.108.6.1673; Ferjani M, 1997, CHEST, V111, P427, DOI 10.1378/chest.111.2.427; FILDES JJ, 1995, AM SURGEON, V61, P832; FLISS JL, 1973, STAT METHODS RATES P; FOIL MB, 1990, AM J SURG, V160, P638, DOI 10.1016/S0002-9610(05)80764-0; FRAZEE RC, 1986, J TRAUMA, V26, P510, DOI 10.1097/00005373-198606000-00004; Fulda GJ, 1997, J TRAUMA, V43, P304, DOI 10.1097/00005373-199708000-00016; GODBE D, 1992, ARCH SURG-CHICAGO, V127, P888; HEALEY MA, 1990, J TRAUMA, V30, P137, DOI 10.1097/00005373-199002000-00002; HELM M, 1998, TRAUMA CARE A, V8, P50; ILLIG KA, 1991, AM J SURG, V162, P537, DOI 10.1016/0002-9610(91)90105-M; KARALIS DG, 1994, J TRAUMA, V36, P53, DOI 10.1097/00005373-199401000-00008; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KING RM, 1983, J TRAUMA, V23, P610, DOI 10.1097/00005373-198307000-00011; LARUE C, 1993, CLIN CHEM, V39, P972; Maenza RL, 1996, AM J EMERG MED, V14, P237, DOI 10.1016/S0735-6757(96)90165-5; Mair J, 1996, CLIN CHIM ACTA, V245, P19, DOI 10.1016/0009-8981(95)06168-1; MATTOX KL, 1992, J TRAUMA, V33, P649; MILLER FA, 1982, AM J CARDIOL, V50, P1022, DOI 10.1016/0002-9149(82)90412-X; Newman PG, 1999, NEW HORIZ-SCI PRACT, V7, P26; Ognibene A, 1998, CLIN CHEM, V44, P889; RuDusky BM, 1997, CHEST, V112, P858, DOI 10.1378/chest.112.3.858-a; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; Weiss RL, 1996, CHEST, V109, P73, DOI 10.1378/chest.109.1.73; WISNER DH, 1990, ANN SURG, V212, P82, DOI 10.1097/00000658-199007000-00011	34	82	93	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2001	50	2					237	242		10.1097/00005373-200102000-00008			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	404WL	WOS:000167125000014	11242287				2021-06-18	
J	Mauler, F; Fahrig, T; Horvath, E; Jork, R				Mauler, F; Fahrig, T; Horvath, E; Jork, R			Inhibition of evoked glutamate release by the neuroprotective 5-HT1A receptor agonist BAY x 3702 in vitro and in vivo	BRAIN RESEARCH			English	Article						BAY x 3702; glutamate release; ischemia; middle cerebral artery occlusion; microdialysis	BAY X 3702; CEREBRAL-ARTERY OCCLUSION; EXCITATORY AMINO-ACIDS; ISCHEMIC BRAIN-DAMAGE; EXTRACELLULAR GLUTAMATE; NMDA ANTAGONIST; RAT STRIATUM; SEROTONIN; HYPOTHERMIA; METABOLITES	Brain ischemia provoked by stroke or traumatic brain injury induces a massive increase in neurotransmitter release, in particular of the excitotoxin glutamate. Glutamate triggers a cascade of events finally leading to widespread neuronal cell damage and death. The aminomethylchroman derivative BAY x 3702 is a novel neuroprotectant which shows pronounced beneficial effects in various animal models of ischemic brain injury. As shown previously BAY x 3702 binds to 5-HT1A receptors of different species in subnanomolar range and is characterized as a full receptor agonist. In this study we investigated the influence of BAY x 3702 on potassium-evoked glutamate release in vitro and ischemia-induced glutamate release in vivo. In rat hippocampal slices BAY x 3702 inhibited evoked glutamate release in a dose-dependent manner (IC50 = 1 muM). This effect was blocked by the selective 5-HT1A receptor antagonist WAY 100635, indicating that BAY x 3702 specifically acts via 5-HT1A receptors. In vivo, release of endogenous aspartate and glutamate was measured in the cortex of rats by microdialysis before and after onset of permanent middle cerebral artery occlusion. Single dose administration of BAY x 3702 (1 mug/kg or 10 mug/kg i.v.) immediately after occlusion reduced the increase and total release of extracellular glutumate by about 50% compared to non-treated animals, whereas the extracellular aspartate levels were not significantly affected. Inhibition of glutamate release may therefore contribute to the pronounced neuroprotective efficacy of BAY x 3702 in various animal models of ischemic brain damage. (C) 2001 Elsevier Science B.V. All rights reserved.	Bayer AG, PHR CNS, D-42096 Wuppertal, Germany	Mauler, F (corresponding author), Bayer AG, PHR CNS, Aprather Weg 18a, D-42096 Wuppertal, Germany.	frank.mauler.fm@buyer-ag.de					Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Boxer PA, 1997, DRUG DISCOV TODAY, V2, P219, DOI 10.1016/S1359-6446(97)01045-3; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CHEN J, 1995, BRAIN RES, V699, P121, DOI 10.1016/0006-8993(95)00868-Q; COLINO A, 1987, NATURE, V328, P73, DOI 10.1038/328073a0; DAMSMA G, 1990, J NEUROCHEM, V54, P801, DOI 10.1111/j.1471-4159.1990.tb02322.x; DAVIES MF, 1987, BRAIN RES, V423, P347, DOI 10.1016/0006-8993(87)90861-4; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GRAHAM JL, 1994, BRIT J PHARMACOL, V112, pU141; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HARRINGTON CR, 1990, ANAL BIOCHEM, V186, P285, DOI 10.1016/0003-2697(90)90081-J; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; Horvath E., 1997, Society for Neuroscience Abstracts, V23, P1923; HORVATH E, 1998, J NEUROTRAUM, V14, P800; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Koyama T, 1999, NEUROSCI LETT, V265, P33, DOI 10.1016/S0304-3940(99)00200-1; Lees KR, 1997, NEUROLOGY, V49, pS66, DOI 10.1212/WNL.49.5_Suppl_4.S66; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PAXINOS G, 1982, RAT BRAIN STEREOTACT; PERUCHE B, 1994, J NEURAL TRANSM-PARK, V8, P73, DOI 10.1007/BF02250918; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Shimada F, 1999, EUR J PHARMACOL, V386, P263, DOI 10.1016/S0014-2999(99)00735-9; SHIMIZU H, 1993, BRAIN RES, V605, P33, DOI 10.1016/0006-8993(93)91353-T; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; WAHL F, 1994, J NEUROCHEM, V63, P1003; Whitaker-Azmitia PM, 1999, NEUROPSYCHOPHARMACOL, V21, pS2, DOI 10.1038/sj.npp.1395355; Yenari MA, 1998, CLIN NEUROPHARMACOL, V21, P28	45	82	84	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 5	2001	888	1					150	157		10.1016/S0006-8993(00)03074-2			8	Neurosciences	Neurosciences & Neurology	392TB	WOS:000166427700016	11146061				2021-06-18	
J	Wallesch, CW; Curio, N; Galazky, I; Jost, S; Synowitz, H				Wallesch, CW; Curio, N; Galazky, I; Jost, S; Synowitz, H			The neuropsychology of blunt head injury in the early postacute stage: Effects of focal lesions and diffuse axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						contusion; diffuse axonal injury; neuropsychology; traumatic brain injury	FRONTAL-LOBE; TRAUMA; TOMOGRAPHY; COMA	This investigation evaluated the neuropsychological symptoms in the early posttraumatic period following blunt head injury and their correlation to routine imaging data in a consecutive series of TBI patients (Magdeburg Neurotrauma Databank). Of 135 consecutive patients, 68 could be assessed neuropsychologically 8-21 days after trauma. In 61 patients, routine clinical CT data were sufficient for neuroradiological analysis focusing on the presence or absence of CT signs of diffuse axonal injury (DAI) or focal traumatic injury. In these patients, the initial GCS score was significantly correlated with the presence of DAI but not with focal pathology. The presence of DAI was correlated with behavioral and cognitive symptoms of frontal lobe dysfunction, especially in interference tasks (Go/NoGO and Stroop reaction times) and semantic fluency. The presence of local frontal or temporal traumatic lesions was associated with deficits in concept formation, fluency tasks and behavioral symptoms, but not with increased interference. Patients with frontal contusions were impaired in a task of visuomotor planning and performance (Block design). Our data indicate that both traumatic DAI and focal lesions result in frontal lobe symptoms. We conclude that, even in clinically "mild" TBI, brain imaging should be used to identify patients with substantial brain damage. These should be assessed neuropsychologically for possible posttraumatic cognitive or behavioral impairment. In consideration of its easy accessibility, the refined use of the CT is considered a promising and valid tool for patient stratification. The application of MRI and biochemical markers may further improve prognostic predictions.	Otto Von Guericke Univ, Dept Neurol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neuropsychol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurosurg, D-39120 Magdeburg, Germany	Wallesch, CW (corresponding author), Otto Von Guericke Univ, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	wallesch@medizin.uni-magdeburg.de					ETTLIN T, 1999, SCI PRACT NEUROPSYCH, P233; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1994, HEAD INJURY, P137; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KESSLER J, 1988, DEMENZTEST; KRAMER J, 1977, KURZE ANLEITUNG KRAM; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masdeu J C, 1994, J Neuroimaging, V4, P177; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OSWALD WD, 1995, NURNBERGER ALTERSINV; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; PETRIDES M, 1986, J NEUROSCI, V6, P2054; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; TEASDALE G, 1974, LANCET, V2, P81; WALLESCH CW, 1983, ARCH PSYCHIAT NERVEN, V233, P279, DOI 10.1007/BF00345798; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; ZIMMERMANN P, 1993, NEUROPSYCHOLOGISCHE	27	82	84	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2001	18	1					11	20		10.1089/089771501750055730			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	390EU	WOS:000166283400002	11200246				2021-06-18	
J	Graham, SH; Chen, J; Clark, RSB				Graham, SH; Chen, J; Clark, RSB			Bcl-2 family gene products in cerebral ischemia and traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; bax; bcl-2; bcl-w; bcl-x; bid; cerebral ischemia; programmed cell death; traumatic brain injury	PROGRAMMED CELL-DEATH; PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; PROTOONCOGENE BCL-2; TRANSGENIC MICE; RAT-BRAIN; ISOLATED-MITOCHONDRIA; SEQUENCE SIMILARITY; GLOBAL-ISCHEMIA; FOCAL ISCHEMIA	The proto-oncogene bcl-2 plays a key role in regulating programmed cell death in neurons, The present review discusses the mechanisms by which bcl-2 family genes regulate programmed cell death, and their role in controlling cell death in cerebral ischemia and traumatic brain, Expression of several bcl-2 family members is altered in brain tissues after ischemia and trauma, suggesting that bcl-2 family genes could play a role in determining the fate of injured neurons. Furthermore, alteration of expression of bcl-2 family genes using transgenic approaches, viral vectors, or anti-sense oligonucleotides modifies neuronal cell death and neurological outcome after injury, These data suggest that the activity of bcl-2 family gene products participates in determining cellular and neurologic outcomes in ischemia and trauma, Strategies that either mimic the death-suppressor effects or inhibit the death-promoter effects of bcl-2 family gene products may improve outcome after ischemia and trauma.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Vet Affairs Pittsburgh Hlth Ctr, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Graham, SH (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 526 S BST, Pittsburgh, PA 15213 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS01946, P01 NS35965, P50 NS3031] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035965, K08NS001946] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Asahi M, 1997, J CEREBR BLOOD F MET, V17, P11, DOI 10.1097/00004647-199701000-00003; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen J, 2000, J CEREBR BLOOD F MET, V20, P1033, DOI 10.1097/00004647-200007000-00002; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHENG TS, 1997, MRS INTERNET J N S R, V2, P1; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; D'Agata V, 1998, NEUROSCI LETT, V243, P137, DOI 10.1016/S0304-3940(98)00116-5; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Enari M, 1998, NATURE, V391, P43; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hamner S, 1999, NEUROSCIENCE, V91, P673, DOI 10.1016/S0306-4522(98)00642-3; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN EY, 1993, J IMMUNOL, V151, P1979; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MacManus JP, 2000, J NEUROTRAUM, V17, P899, DOI 10.1089/neu.2000.17.899; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Minami M, 2000, NEUROSCI LETT, V279, P193, DOI 10.1016/S0304-3940(99)00987-8; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rickman DW, 1999, DEV BRAIN RES, V115, P41, DOI 10.1016/S0165-3806(99)00046-2; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Urabe T, 1998, NEUROSCI LETT, V247, P159, DOI 10.1016/S0304-3940(98)00311-5; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White MJ, 1997, ANN NEUROL, V42, P580, DOI 10.1002/ana.410420408; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yan CH, 2000, J CEREBR BLOOD F MET, V20, P620, DOI 10.1097/00004647-200003000-00020; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yin XM, 1999, NATURE, V400, P886; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	93	82	116	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2000	17	10					831	841		10.1089/neu.2000.17.831			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	364LR	WOS:000089894300004	11063051				2021-06-18	
J	Albensi, BC; Sullivan, PG; Thompson, MB; Scheff, SW; Mattson, MP				Albensi, BC; Sullivan, PG; Thompson, MB; Scheff, SW; Mattson, MP			Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity	EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer's disease; apoptosis; learning and memory; long-term depression; long-term potentiation; mitochondrial permeability transition	LONG-TERM POTENTIATION; PERMEABILITY TRANSITION PORE; EXCITATORY AMINO-ACIDS; MITOCHONDRIAL DYSFUNCTION; RAT HIPPOCAMPUS; COGNITIVE DEFICITS; LIPID-PEROXIDATION; CORTICAL IMPACT; CYTOCHROME-C; CELL-DEATH	Although traumatic brain injury (TBI) often results in impaired learning and memory functions, the underlying mechanisms are unknown and there are currently no treatments that can preserve such functions. We studied plasticity at CA3-CA1 synapses in hippocampal slices from rats subjected to controlled cortical impact TBI. Long-term potentiation (LTP) of synaptic transmission was markedly impaired, whereas long-term depression (LTD) was enhanced, 48 h following TBI when compared to unoperated and sham control rats. Post-TBI administration of cyclosporin A, a compound that stabilizes mitochondrial function, resulted in a highly significant amelioration of the impairment of LTP and completely prevented the enhancement of LTD. Our data suggest that alterations in hippocampal synaptic plasticity may be responsible for learning and memory deficits resulting from TBI and that agents such as cyclosporin A that stabilize mitochondrial function may be effective treatments for TBI. (C) 2000 Academic Press.	Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; NIA, Neurosci Lab, Baltimore, MD 21224 USA	Albensi, BC (corresponding author), Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA.		Albensi, Benedict/AAJ-2359-2021; Mattson, Mark P/F-6038-2012; Albensi, Benedict C/F-7304-2010	Albensi, Benedict/0000-0002-7884-9261; 	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000317, Z01AG000317, ZIAAG000312, ZIAAG000313, Z01AG000313, Z01AG000312] Funding Source: NIH RePORTER		Albensi BC, 2000, SYNAPSE, V35, P151; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Baldwin SA, 1996, GLIA, V16, P266; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1016/S0005-2728(98)00114-5; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS1; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Duan WZ, 1999, J NEUROCHEM, V72, P2312, DOI 10.1046/j.1471-4159.1999.0722312.x; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Frei U, 1999, TRANSPLANT P, V31, P1669, DOI 10.1016/S0041-1345(99)00090-1; Friberg H, 1998, J NEUROSCI, V18, P5151; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; Holtsberg FW, 1998, J NEUROCHEM, V70, P66; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keller JN, 1998, J NEUROSCI, V18, P687; Lu YF, 1996, BRAIN RES, V729, P142, DOI 10.1016/0006-8993(96)00568-9; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mattson MP, 1996, RESTOR NEUROL NEUROS, V9, P191, DOI 10.3233/RNN-1996-9401; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Montal M, 1998, BBA-BIOENERGETICS, V1366, P113, DOI 10.1016/S0005-2728(98)00124-8; NATHAN T, 1990, BRAIN RES, V531, P55, DOI 10.1016/0006-8993(90)90757-3; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; REEVES TM, 1995, EXP BRAIN RES, V106, P248; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stanton PK, 1996, HIPPOCAMPUS, V6, P35, DOI 10.1002/(SICI)1098-1063(1996)6:1<35::AID-HIPO7>3.3.CO;2-Z; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; TAKADA K, 1991, J PHARMACOBIO-DYNAM, V14, P34, DOI 10.1248/bpb1978.14.34; Tatton WG, 1998, ANN NEUROL, V44, pS134, DOI 10.1002/ana.410440720; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	56	82	84	0	3	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	APR	2000	162	2					385	389		10.1006/exnr.1999.7338			5	Neurosciences	Neurosciences & Neurology	305EH	WOS:000086526100014	10739643				2021-06-18	
J	Lundqvist, A; Gerdle, B; Ronnberg, J				Lundqvist, A; Gerdle, B; Ronnberg, J			Neuropsychological aspects of driving after a stroke - in the simulator and on the road	APPLIED COGNITIVE PSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; CEREBRAL-DAMAGE; AGE-DIFFERENCES; BRAIN-DAMAGE; PERFORMANCE; OPERATIONS; CONCUSSION; BEHAVIOR; DRIVERS; SPEED	Thirty patients with stroke and 30 matched controls participated in the study (mean age 68 years, mean interval since stroke onset 8.6 months). The patients performed significantly worse on cognitive and attentional processing measured by a neuropsychological test battery. The patients had significantly greater difficulty in allocating processing resources to a secondary information processing task during driving in an advanced simulator. The patients performed worse driving in real traffic, and had less driving skill; fifty per cent did not pass the driving test. The neuropsychological test battery showed a pattern with three factors: (1) attentional processing (2) executive capacity, and (3) cognitive processing. Regression models based on simulator driving variables and neuropsychological test variables respectively, overall classified correctly in 85% and 83% of the cases with respect to driving skill. Decreased cognitive and attentional processing were suggested + to be associated with an overall speed impairment. Copyright (C) 2000 John Wiley & Sons, Ltd.	Linkoping Univ, Fac Hlth Sci, Dept Rehabil Med, S-58185 Linkoping, Sweden; Pain & Rehabil Ctr, Linkoping, Sweden; Linkoping Univ, Dept Educ & Psychol, S-58185 Linkoping, Sweden	Lundqvist, A (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Rehabil Med, S-58185 Linkoping, Sweden.			Ronnberg, Jerker/0000-0001-7311-9959; Gerdle, Bjorn/0000-0002-4316-1264			ALM H, 1995, ACCIDENT ANAL PREV, V27, P707, DOI 10.1016/0001-4575(95)00026-V; ALM H, 1989, V1017; BADDELEY A, 1985, J MEM LANG, V24, P119, DOI 10.1016/0749-596X(85)90019-1; Baddeley A. D., 1990, HUMAN MEMORY THEORY, P67; BINDER LM, 1978, REHABIL PSYCHOL, P65; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brouwer W H, 1994, Disabil Rehabil, V16, P149; CHRISTIE N, 1996, 207 TRL TRANSP ROAD; CRAIK FIM, 1987, J EXP PSYCHOL LEARN, V13, P474, DOI 10.1037/0278-7393.13.3.474; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; ENGUM SG, 1989, COGNITIVE REHABILITA, V7, P22; Filley C. M., 1995, NEUROPSYCHIATRY COMP, P913; Fox G K, 1992, Disabil Rehabil, V14, P140; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Galski T, 1997, AM J OCCUP THER, V51, P352, DOI 10.5014/ajot.51.5.352; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; GREENWOOD P, 1991, DEV NEUROPSYCHOL, V7, P421, DOI 10.1080/87565649109540502; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRUBERBALDINI AL, 1991, HDB PSYCHOL AGING, P276; HAKAMIESBLOMQVI.L, 1996, J INT ASS TRAFFIC SA, V20, P91; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JOHANSSON K, 1997, THESIS KAROLINSKA I; KNAPP TR, 1989, WESTERN J NURS RES, V11, P635; LEVANDER S, 1988, 11 U TRONDH DEP PSYC; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Loong J., 1990, WISCONSIN CARD SORTI; Lundberg C, 1998, ACCIDENT ANAL PREV, V30, P371, DOI 10.1016/S0001-4575(97)00111-5; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McDowd JM, 1990, HDB PSYCHOL AGING, P222, DOI [10.1016/b978-0-12-101280-9.50019-x, DOI 10.1016/B978-0-12-101280-9.50019-X]; Michon J.A., 1985, HUMAN BEHAV TRAFFIC, P485; MICHON JA, 1979, WORKSH TRAFF RES CTR; NESTOR PG, 1989, DEV NEUROPSYCHOL, V5, P141, DOI 10.1080/87565648909540429; NILSSON L, 1995, V2006 DRIVE EMMIS; Nordmark S., 1988, VTI DRIVING SIMULATO; NORUSIS MJ, 1993, SPSS WIND; NOURI EM, 1987, INT DISABILITY STUDI, V9, P110; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; RONNBERG J, 1989, J SPEECH HEAR RES, V32, P725, DOI 10.1044/jshr.3204.725; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; SMITH GJ, 1986, MANUAL CWT SERIALT F; *SPSS INC, 1986, SPSS STAT PACK SOC S; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SUNDET K, 1995, SCAND J PSYCHOL, V36, P47, DOI 10.1111/j.1467-9450.1995.tb00967.x; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; van Zomeren AH, 1992, HDB NEUROPSYCHOLOGIC, P241; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; *VVFS, 1996, VAGV FOR MED KRAV IN; WELFORD AT, 1989, DEV NEUROPSYCHOL, V5, P261, DOI 10.1080/87565648909540436; WIEBERS DO, 1997, HDB STROKE, P43; Wilson T, 1983, Int Rehabil Med, V5, P170	60	82	83	0	4	JOHN WILEY & SONS LTD	W SUSSEX	BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND	0888-4080			APPL COGNITIVE PSYCH	Appl. Cogn. Psychol.	MAR-APR	2000	14	2					135	150		10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S			16	Psychology, Experimental	Psychology	301FQ	WOS:000086299900003					2021-06-18	
J	Murakami, N; Yamaki, T; Iwamoto, Y; Sakakibara, T; Kobori, N; Fushiki, S; Ueda, S				Murakami, N; Yamaki, T; Iwamoto, Y; Sakakibara, T; Kobori, N; Fushiki, S; Ueda, S			Experimental brain injury induces expression of amyloid precursor protein, which may be related to neuronal loss in the hippocampus	JOURNAL OF NEUROTRAUMA			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; ALZHEIMERS-DISEASE; BETA-PROTEIN; HEAD-INJURY; NEUROFIBRILLARY TANGLES; DEMENTIA-PUGILISTICA; LEVELS DECREASE; MESSENGER-RNA; RAT; DEPOSITION	Previous reports have demonstrated that some focal brain injuries increase amyloid precursor protein (APP) immunoreactivity in the region surrounding the injury where it was localized, in damaged axons and in pre-alpha 2 cells of the entorhinal cortex. However, to date, APP expession in the hippocampus remote from the impact site has not been comprehensively studied. Therefore, we have evaluated APP expression not only in the locally injured cerebral cortex but also in the hippocampus remote from the impact site, In the present paper, diffuse axonal injury was induced in rats in midline fluid percussion injury, APE expression was examined post injury using Western blot analysis and immunohistochemistry. Western blot analysis demonstrated that the expression of 100-kd APP was increased in both the cerebral cortex and hippocampus 24 h after injury. It then decreased in the hippocampus, but did not change in the cerebral cortex, 7 days after injury, Immunohistochemical studies showed increased immunoreactivity of APP in the neuronal perikarya and reactive astrocytes near the region of injury in the cerebral cortex 24 h to 7 days after injury, In the hippocampus, APP accumulated in the CA3 neurons 24 h and 3 days after injury, although no hemorrhagic lesions were seen at that site, The APP positive neurons in CA3 showed shrunken cell bodies and pyknotic nuclei 3 days after injury, and some of the neurons in CA3 had disappeared by 7 days postinjury, The results of present study suggest that traumatic brain injury induces overexpression and accumulation of APP in neuronal perikarya and that these events are followed by degeneration of CA3 neurons, Further, the decline in APP expression in the hippocampus is thought to be due to neuronal loss in CA3 subsector.	Kyoto Prefectural Univ Med, Dept Neurosurg, Kamigyo Ku, Kyoto 602, Japan; Kyoto Prefectural Univ Med, Dept Dynam Pathol, Res Inst Neurol Dis & Geriatr, Kyoto 602, Japan	Murakami, N (corresponding author), Kyoto Prefectural Univ Med, Dept Neurosurg, Kamigyo Ku, Kawaramachi Hirokoji, Kyoto 602, Japan.						ALLSOP D, 1990, AM J PATHOL, V136, P255; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DOYLE E, 1990, NEUROSCI LETT, V115, P97, DOI 10.1016/0304-3940(90)90524-D; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HILBICH C, 1993, J BIOL CHEM, V268, P26571; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; Lee RKK, 1996, ANN NY ACAD SCI, V777, P338, DOI 10.1111/j.1749-6632.1996.tb34443.x; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; MURAKAMI N, 1993, ADV NEUROTRAUMA RES, V5, P42; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pierce JES, 1996, J NEUROSCI, V16, P1083; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; RINK A, 1995, AM J PATHOL, V147, P1575; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROBERTS GW, 1988, LANCET, V2, P1456; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SHINVERS BD, 1988, EMBO J, V7, P1365; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; WALLACE WC, 1995, J NEUROSCI, V15, P4896; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WILLIAM E, 1992, P NATL ACAD SCI USA, V89, P2551; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	69	82	85	1	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1998	15	11					993	1003		10.1089/neu.1998.15.993			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	139RN	WOS:000077043400008	9840772				2021-06-18	
J	Hart, T; Giovannetti, T; Montgomery, MW; Schwartz, MF				Hart, T; Giovannetti, T; Montgomery, MW; Schwartz, MF			Awareness of errors in naturalistic action after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						deficit awareness; error detection; traumatic brain injury	HEAD-INJURY; DEFICITS	A prospective study was performed to develop a method for assessing "on-line" error detection and correction during performance of naturalistic action, to determine whether traumatic brain injury (TBI) affects error detection and correction, and to compare actual task performance with verbal self-ratings of performance. Participants included 18 persons who had sustained severe TBI from 34 to 186 days prior to study and who were comparable to controls in their rate of naturalistic action error, along with 18 control subjects chosen to be demographically comparable to subjects with TDI. Subjects performed two different tests of naturalistic action in which they completed everyday activities leg, wrapping a gift, making toast) at different levels of complexity, as manipulated by the addition of distractor objects, the number of tasks that had to be completed per trial, and other demands on planning and working memory. Using a specially developed coding system, each error on these tasks was scored as to whether the subject corrected it and whether the subject otherwise demonstrated awareness of the error. Error scores were also compared to subjects' responses to a questionnaire in which the) rated their own performance on the most challenging level of the naturalistic action test. In general, subjects with TDI corrected and showed awareness of proportionally fewer of their errors when compared to controls. Qualitative patterns for some error types also differed between groups. Despite making more errors than control subjects on the most challenging task, subjects with TBI did not rate themselves as performing more poorly with respect to its cognitive demands. However, for subjects with TBI, the number of errors was correlated with performance ratings on certain questionnaire items. This study showed that error detection and correction can be reliably measured during naturalistic action and appear to be impaired in severe TBI even when the base rate of error is controlled. TBI may affect error detection and correction by reducing, or impairing the allocation of, attentional resources needed for the simultaneous execution and monitoring of routine action.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; MossRehab Hosp, Drucker Brain Injury Ctr, Philadelphia, PA USA; Drexel Univ, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.		Giovannetti, Tania/H-3491-2019	Giovannetti, Tania/0000-0001-5661-152X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS31824] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031824] Funding Source: NIH RePORTER		ADAMS JA, 1973, J MOTOR BEHAV, V5, P217, DOI 10.1080/00222895.1973.10734968; ALLWOOD CM, 1984, COGNITIVE SCI, V8, P413, DOI 10.1016/S0364-0213(84)80009-9; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; [Anonymous], 1993, GUID UN DAT SET MED; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Buxbaum LJ, 1997, COGNITIVE NEUROPSYCH, V14, P219, DOI 10.1080/026432997381565; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Crisp R, 1992, Aust Occup Ther J, V39, P15, DOI 10.1111/j.1440-1630.1992.tb01730.x; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; Frith C. D., 1992, Journal of Psychopharmacology, V6, P436, DOI 10.1177/026988119200600314; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1986, CLIN NEUROPSYCHOLOGY; RABBITT, 1967, ACTA PSYCHOL, V27, P131; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; SALTHOUSE TA, 1986, PSYCHOL BULL, V99, P303, DOI 10.1037/0033-2909.99.3.303; Schmidt R., 1987, PERSPECTIVES PERCEPT; SCHMIDT RA, 1972, J MOTOR BEHAV, V4, P143, DOI 10.1080/00222895.1972.10734930; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; SCHWARTZ MF, IN PRESS NEUROPSYCHO; SELLEN AJ, 1992, EXPT SLIPS HUMAN ERR; SHAFFER LH, 1969, Q J EXP PSYCHOL, V21, P209, DOI 10.1080/14640746908400215; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Woods D.D., 1984, I CHEM ENG S SERIES, P21	32	82	82	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					16	28		10.1097/00001199-199810000-00004			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600004	9753532				2021-06-18	
J	Okonkwo, DO; Pettus, EH; Moroi, J; Povlishock, JT				Okonkwo, DO; Pettus, EH; Moroi, J; Povlishock, JT			Alteration of the neurofilament side arm and its relation to neurofilament compaction occurring with traumatic axonal injury	BRAIN RESEARCH			English	Article						traumatic brain injury; cat; cytoskeleton; neurofilament; phosphorylation; calcium	BRAIN INJURY; AXOLEMMAL PERMEABILITY; PHOSPHORYLATION; CALIBER	Traumatic injury evokes two characteristic forms of focal axonal injury, one of which involves focal perturbation of axolemmal permeability associated with rapid compaction of the underlying axonal neurofilament lattice and microtubular loss. In this process, the neurofilament sidearms have been the subject of intense scrutiny in relation to their role in this NF compaction, with the suggestion that the sidearms, thought to maintain interfilament distance, are proteolytically cleaved and degraded at the time of injury. The current communication addresses the fate of the NF sidearms in such injured axons. Adult cats were subjected to moderate/severe fluid percussion brain injury after intrathecal administration of horseradish peroxidase (HRP). This tracer, excluded by the intact axolemma of uninjured axons, was used to recognize injured axons via HRP intra-axonal uptake/flooding with HRP. Animals were perfused and processed for light microscopic and electron microscopic study of both HRP-containing and non-HRP containing axons from the same field. HRP-containing axons consistently displayed evidence of traumatically-induced (NF) cytoskeletal collapse. Electron micrographs of HRP-containing axons as well as uninjured, non-HRP-containing axons from the same fields were videographically captured, digitized, enlarged and analysed for NF sidearm length and NF density. HRP-containing axons were found to have increased NF density. Surprisingly, this increased NF density occurred despite the retention of the NF sidearms, which now, however, were reduced in height in comparison to the non-HRP-containing uninjured axons. These observations are not consistent with previously published reports suggesting that overt proteolytic degradation of sidearms was responsible for NF compaction. Based on our findings, we suggest that the NF compaction associated with traumatically-induced axolemmal permeability changes may have its genesis in more subtle sidearm modification, perhaps involving a change in phosphorylation state. (C) 1998 Elsevier Science B.V.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Box 980 709, Richmond, VA 23298 USA.						BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; Balentine JD, 1985, CENTRAL NERVOUS SYST, P455; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; HALL GF, 1996, J COMP NEUROL, V353, P39; ISHIZAKI Y, 1994, J NEUROSCI, V14, P3934; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Kampfl A, 1996, J NEUROCHEM, V67, P1575; MCHALE MK, 1995, J COMP NEUROL, V353, P25, DOI 10.1002/cne.903530105; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520	17	82	82	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 16	1998	784	1-2					1	6		10.1016/S0006-8993(97)01075-5			6	Neurosciences	Neurosciences & Neurology	ZC505	WOS:000072586800001	9518527				2021-06-18	
J	Sherer, M; Meyers, CA; Bergloff, P				Sherer, M; Meyers, CA; Bergloff, P			Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors	CANCER			English	Article; Proceedings Paper	3rd World Congress on Psycho-Oncology	OCT 04-06, 1996	NEW YORK, NY			brain tumor; rehabilitation; independence; productivity; cognitive deficits		BACKGROUND. Patients with primary malignant brain tumors (PMBT) often have neurobehavioral deficits due to the tumor, subsequent surgery, and therapies that interfere with their ability to live independently or work. Previous studies have shown that such patients generally have a progressive decline in functioning from diagnosis to death. Consequently, PMBT patients have not been considered good candidates for rehabilitation services. The current study is a preliminary, retrospective investigation of the effectiveness of postacute brain injury rehabilitation methods, originally developed for traumatic brain injury survivors, in a sample of patients with PMBT. METHODS. The subjects were 13 patients with a history of surgical resection of PMBT and subsequent radiation and chemotherapy. There were 8 males and 5 females with a mean age of 34.3 +/- 10.0 years and a mean educational level of 15.1 +/- 1.7 years. Mean time from tumor diagnosis to the commencement of rehabilitation was 75.4 +/- 87.9 months. All patients had cognitive deficits documented with neuropsychologic tests. Patients received an average of 2.6 +/- 1.9 months of postacute brain injury rehabilitation. RESULTS. Six patients had increased independence during the time from the start of rehabilitation to discharge, six were unchanged, and one patient had decreased independence. Eight patients had increased productivity during the same time period, four were unchanged, and one had decreased productivity. Treatment gains were maintained at follow-up 8.0 +/- 7.6 months after discharge. CONCLUSIONS. The results of the current study offer preliminary support for the effectiveness of postacute brain injury rehabilitation in the management of PMBT patients. Although additional investigation is needed, such treatment appears to be an attractive, relatively low cost option for these patients. (C) 1997 American Cancer Society.	BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX	Sherer, M (corresponding author), TIRR,CHALLENGE PROGRAM,DEPT NEUROPSYCHOL,4007 EE BELLAIRE BLVD,HOUSTON,TX 77025, USA.						AIKEN RD, 1994, SEMIN ONCOL, V21, P273; ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BERGLOFF P, IN PRESS ARCH CLIN N; *CENTR BRAIN TUM R, 1995, 1 CENTR BRAIN TURM B; DESMEULES M, 1992, J NATL CANCER I, V84, P442, DOI 10.1093/jnci/84.6.442; FOBAIR P, 1990, BRAIN TUM C LIV RES; HIGH WM, 1997, J INT NEUROPSYCHOL S, V3, P5; HOCHBERG FH, 1980, NEUROLOGY, V30, P172, DOI 10.1212/WNL.30.2.172; KREUTZER J, 1991, COGNITIVE REHABILITA; LEVIN VA, 1993, CANC PRINCIPLES PRAC, P1679; LIEBERMAN AN, 1982, NEUROSURGERY, V10, P50; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Meyers CA, 1996, CANC NERVOUS SYSTEM, P449; Meyers Christina A., 1993, Cancer Bulletin (Houston), V45, P362; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Radhakrishnan K, 1994, BRAIN TUMORS COMPREH, P1; SACHSENHEIMER W, 1992, J NEURO-ONCOL, V13, P177; Scheibel RS, 1996, J NEURO-ONCOL, V30, P61; SHERER M, 1997, J INT NEUROPSYCH SOC, V3, P75; Weitzner MA, 1996, BAILLIERE CLIN NEUR, V5, P425	21	82	82	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012	0008-543X			CANCER	Cancer	JUL 15	1997	80	2					250	257		10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T			8	Oncology	Oncology	XJ016	WOS:A1997XJ01600013	9217038	Bronze			2021-06-18	
J	Lee, KR; Drury, I; Vitarbo, E; Hoff, JT				Lee, KR; Drury, I; Vitarbo, E; Hoff, JT			Seizures induced by intracerebral injection of thrombin: A model of intracerebral hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						intracerebral hemorrhage; seizure; brain edema; coagulation cascade; thrombin; rat	POST-TRAUMATIC EPILEPSY; BRAIN EDEMA; INHIBITORS; ACTIVATION; IRON	The coagulation cascade plays an important role in brain edema formation caused by intracerebral blood. In particular, thrombin produces brain injury via direct brain cell toxicity. Seizures and increased cerebral electrical activity are commonly associated with intracerebral blood and are possible effects of thrombin leading to cell injury in the brain. In this study, artificial clots containing concentrations of thrombin found in hematomas were infused intracerebrally in rats. The animals were observed clinically for seizure activity, behavior, and neurological deficits. Several animals underwent video electroencephalographic (EEG) monitoring during intracerebral infusion and for 30 minutes postinfusion. All animals were killed 24 hours after injection, and brain water and ion contents were measured to determine the amount of brain edema. Clinically, thrombin produced focal motor seizures in all animals. None of the control animals or those receiving N alpha-(2-Naphthalenesulfonyl-glycyl)-4-amidino-DL-phenylalanine-piperidide (alpha-NAPAP), a thrombin inhibitor added to the thrombin, showed clinical evidence of seizures. Of the rats undergoing EEG monitoring, all animals receiving thrombin showed electrical evidence of seizure activity, whereas none of the control animals exhibited seizure activity. There was no evidence of seizure activity on EEG monitoring when alpha-NAPAP was injected along with the thrombin. In addition, the artificial clots containing thrombin produced agitation and a circling tendency in the rats, along with brain edema. These results indicate that the coagulation cascade is involved in seizure production and increased brain electrical activity, which contribute to the neurological deficits and brain edema formation that are seen with intracerebral hemorrhage.	UNIV MICHIGAN,DEPT SURG NEUROSURG,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS017760, R01NS023870] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-23870, NS-17760] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BERGER AR, 1988, NEUROLOGY, V38, P1363, DOI 10.1212/WNL.38.9.1363; CERVONI L, 1994, NEUROSURG REV, V17, P185, DOI 10.1007/BF00418427; FAUGHT E, 1989, NEUROLOGY, V39, P1089, DOI 10.1212/WNL.39.8.1089; KAPLAN HA, 1961, EPILEPSIA, V2, P111; LANCMAN ME, 1993, EPILEPSIA, V34, P141, DOI 10.1111/j.1528-1157.1993.tb02386.x; Lee KR, 1996, ACTA NEUROCHIR, V138, P396, DOI 10.1007/BF01420301; LEE KR, 1995, J NEUROSURG, V83, P1045, DOI 10.3171/jns.1995.83.6.1045; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; LEE KR, 1994, INTRACRANIAL PRESSUR, V9, P70; LEE KR, 1996, NEUROSURG FOCUS, V1; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LIPTON RB, 1987, J NEUROL, V234, P86, DOI 10.1007/BF00314107; MAFFRAND JP, 1992, NOUV REV FR HEMATOL, V34, P405; MARKWARDT F, 1988, NOUV REV FR HEMATOL, V30, P161; MIRSHAHI M, 1989, BLOOD, V74, P1025; Paxinos G., 1982, RAT BRAIN STEREOTAXI; RICHARDSON E P Jr, 1954, Epilepsia, V3, P49, DOI 10.1111/j.1528-1157.1954.tb03153.x; SEEGERS WH, 1962, PROTHROMBIN, P417; SUNG CY, 1989, J NEUROL NEUROSUR PS, V52, P1273, DOI 10.1136/jnnp.52.11.1273; SUZUKI M, 1992, STROKE, V23, P1181, DOI 10.1161/01.STR.23.8.1181; SVENDSEN L, 1984, THROMB RES, V34, P457, DOI 10.1016/0049-3848(84)90250-0; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093	28	82	84	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1997	87	1					73	78		10.3171/jns.1997.87.1.0073			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XF331	WOS:A1997XF33100011	9202268				2021-06-18	
J	Kossmann, T; Stahel, PF; MorgantiKossmann, MC; Jones, JL; Barnum, SR				Kossmann, T; Stahel, PF; MorgantiKossmann, MC; Jones, JL; Barnum, SR			Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						brain injury; cerebrospinal fluid; complement; blood-brain barrier	CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; ALZHEIMERS-DISEASE; HEAD-INJURY; GENE-EXPRESSION; SERUM; INTERLEUKIN-1; QUANTITATION; RESPONSES; PROTEINS	Immunological events occurring in the central nervous system (CNS) as a result of head trauma are largely unexplored. We report here that the levels of the alternative pathway complement proteins C3 and factor B are elevated in the cerebrospinal fluid (CSF) of head-injured patients. C3 and factor B indices suggest that changes in C3 and factor B levels in CSF are most likely due to altered blood-brain barrier integrity and not to intrathecal synthesis. These data demonstrate, for the first time, elevated levels of complement proteins in CSF of patients with severe traumatic brain injury. Elevated complement levels in brain injury may contribute to secondary damage.	UNIV ZURICH HOSP,DEPT SURG,DIV TRAMA SURG,CH-8091 ZURICH,SWITZERLAND; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV CLIN IMMUNOL & RHEUMATOL,BIRMINGHAM,AL 35294				Morganti-Kossmann, Cristina/0000-0002-0807-2063	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29719] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS029719] Funding Source: NIH RePORTER		AISEN PS, 1994, AM J PSYCHIAT, V151, P1105; BARNUM SR, 1994, J IMMUNOL, V152, P765; BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301; BECKER P, 1987, ANAESTHESIST, V36, P301; BROADWELL RD, 1993, EXP NEUROL, V120, P245, DOI 10.1006/exnr.1993.1059; DAVIS RE, 1993, CRIT REV NEUROBIOL, V7, P41; DUJARDIN BCG, 1985, J IMMUNOL METHODS, V80, P227, DOI 10.1016/0022-1759(85)90024-9; GAILLARD O, 1993, CLIN CHEM, V39, P309; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; JENNETT B, 1975, LANCET, V1, P480; JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KOSSMANN T, 1993, CIRC SHOCK S2, V62, P63; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MORGAN BP, 1993, COMPLEMENT HLTH DISE, P353; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P158; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; OGLESBY TJ, 1988, J IMMUNOL METHODS, V110, P55, DOI 10.1016/0022-1759(88)90082-8; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; REBHUN J, 1991, ANN ALLERGY, V66, P335; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Shin Moon Lee, 1992, P801; Takabayashi T, 1996, J IMMUNOL, V156, P3455; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P391; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P397; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	37	82	82	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	MAR	1997	73	1-2					63	69		10.1016/S0165-5728(96)00164-6			7	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	WM882	WOS:A1997WM88200008	9058760				2021-06-18	
J	Jacobs, A; Put, E; Ingels, M; Put, T; Bossuyt, A				Jacobs, A; Put, E; Ingels, M; Put, T; Bossuyt, A			One-year follow-up of technetium-99m-HMPAO SPECT in mild head injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						regional cerebral blood flow; SPECT; mild head injury; technetium-99m-HMPAO	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; BEHAVIORAL SEQUELAE; CT; MRI	We evaluated the predictive capacity of Tc-99m-HMPAO SPECT for clinical outcome during a follow-up period of 12 mo after mild head injury. Methods: We prospectively evaluated 136 patients with mild head injury who underwent initial SPECT imaging (SPECTO) within 4 wk after the trauma. Re-evaluations were made 2.9-3.3 mo (T3mo), 5.7-6.3 mo (T6mo) and 11.9-12.6 mo (T12mo) postinjury. All patients with an abnormal SPECT underwent a repeat study at the subsequent time of evaluation. Patients with a previously normal SPECT scan did not undergo a repeat study. Clinical reassessments (GUN) were performed as long as the earlier study had been positive or until patients were completely asymptomatic. Results: During all follow-up evaluations, SPECT had a high sensitivity and negative predictive value, increasing from 91% and 89%, respectively, at T3mo to 100% at T6mo and at T12mo. Clinical normalization occurred earlier than scintigraphic normalization. However, at 12 mo postinjury, we observed considerable improvement in the specificity and positive predictive value of SPECT (85% and 83%, respectively). The persistent lesions on the SPECT scan were related to their severity and to localization in the frontal cortex. Conclusion: A normal Tc-99m-HMPAO SPECT scan is a reliable tool in the exclusion of clinical sequelae of mild head injury. At 12 mo postinjury, a positive SPECT study is also a reliable predictor for clinical outcome.	ST FRANCISKUS HOSP,DEPT NEUROSURG,HEUSDEN ZOLDER,BELGIUM; FREE UNIV BRUSSELS HOSP,DEPT NUCL MED,JETTE,BELGIUM	Jacobs, A (corresponding author), VIRGA JESSE HOSP,DEPT NUCL MED,STADSOMVAART 11,B-3500 HASSELT,BELGIUM.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAY BG, 1992, J NUCL MED, V33, P52; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; JACOBS A, 1993, NUCL MED COMMUN, V14, P702, DOI 10.1097/00006231-199308000-00011; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; REID RH, 1990, ACTA NEUROCHIR S, V51, P283; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; ROPER SN, 1991, J NUCL MED, V32, P1684; RUTHERFORD WH, 1977, LANCET, V1, P1; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TIKOFSKY RS, 1994, J NUCL MED, V35, P947	18	82	85	0	0	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 22090-5316	0161-5505			J NUCL MED	J. Nucl. Med.	OCT	1996	37	10					1605	1609					5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	VL581	WOS:A1996VL58100014	8862291				2021-06-18	
J	Taneda, M; Kataoka, K; Akai, F; Asai, T; Sakata, I				Taneda, M; Kataoka, K; Akai, F; Asai, T; Sakata, I			Traumatic subarachnoid hemorrhage as a predictable indicator of delayed ischemic symptoms	JOURNAL OF NEUROSURGERY			English	Article						cerebral ischemia; vasospasm; subarachnoid hemorrhage; head injury; delayed ischemic deficit	CEREBRAL BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; HEAD-INJURY; ANGIOGRAPHIC FINDINGS; ARTERIAL SPASM; VASOSPASM; COMA	This report provides findings of an investigation of the influence of traumatic subarachnoid hemorrhage on the development of delayed cerebral ischemia caused by vasospasm. The authors prospectively studied 130 patients with closed-head trauma, who exhibited subarachnoid blood on admission computerized tomography (CT) scans. Ten (7.7%) of these patients developed delayed ischemic symptoms between Days 4 and 16 after the head injury. They consisted of three (3.0%) of 101 patients with small amounts of subarachnoid blood and seven (24.1%) of 29 patients with massive quanti ties of subarachnoid blood on admission CT scans. In each of the 10 patients, severe vasospasm was demonstrated by angiography performed soon after development of ischemic symptoms. There was a close correlation between the main site of the subarachnoid blood and the location of severe vasospasm. In seven of the patients, follow-up CT scans showed development of focal ischemic areas in the cerebral territories corresponding to the vasospastic arteries. These results demonstrate that traumatic subarachnoid hemorrhage, especially if massive, is a predictable indicator of delayed ischemic symptoms.	KINKI UNIV,SCH MED,CRIT CARE MED CTR,SAYAMA,OSAKA 589,JAPAN	Taneda, M (corresponding author), KINKI UNIV,SCH MED,DEPT NEUROSURG,377-2 OHNO HIGASHI,SAYAMA,OSAKA 589,JAPAN.						ARSENI C, 1971, ACTA NEUROCHIR, V24, P25, DOI 10.1007/BF01403138; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; CHAN KH, 1992, NEUROSURGERY, V30, P697; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FREIDENFELT H, 1963, ACTA RADIOL DIAGN, V1, P278, DOI 10.1177/028418516300100221; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1984, J NEUROSURG, V61, P225, DOI 10.3171/jns.1984.61.2.0225; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; Kostron H, 1985, Neurochirurgia (Stuttg), V28 Suppl 1, P103; LEWIN W, 1968, BRIT J SURG, V55, P321, DOI 10.1002/bjs.1800550502; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Newell D W, 1992, Clin Neurosurg, V39, P348; PASQUALIN A, 1986, NEUROSURGERY, V15, P855; SEILER RW, 1986, J NEUROSURG, V64, P594, DOI 10.3171/jns.1986.64.4.0594; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1967, J NEUROL NEUROSUR PS, V30, P497, DOI 10.1136/jnnp.30.6.497; TANEDA M, 1982, J NEUROSURG, V57, P622, DOI 10.3171/jns.1982.57.5.0622; TEASDALE G, 1974, LANCET, V2, P81; VARDIMAN AB, 1995, AM J NEURORADIOL, V16, P319; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; Wilkins R H, 1977, Clin Neurosurg, V24, P185; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; WILKINS RH, 1980, CEREBRAL ARTERIAL SP, P472; YOSHIHARA M, 1995, J NEUROSURG, V82, P386, DOI 10.3171/jns.1995.82.3.0386	28	82	89	1	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1996	84	5					762	768		10.3171/jns.1996.84.5.0762			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	UG540	WOS:A1996UG54000008	8622149				2021-06-18	
J	SINSON, G; VODDI, M; MCINTOSH, TK				SINSON, G; VODDI, M; MCINTOSH, TK			NERVE GROWTH-FACTOR ADMINISTRATION ATTENUATES COGNITIVE BUT NOT NEUROBEHAVIORAL MOTOR DYSFUNCTION OR HIPPOCAMPAL CELL LOSS FOLLOWING FLUID-PERCUSSION BRAIN INJURY IN RATS	JOURNAL OF NEUROCHEMISTRY			English	Article						FLUID-PERCUSSION INJURY; NERVE GROWTH FACTOR; NEUROTROPHIN; COGNITIVE DYSFUNCTION; TRAUMATIC BRAIN INJURY	NEURONAL DEATH; EXCITOTOXIC LESIONS; CHOLINERGIC NEURONS; FACTOR INFUSION; SEPTAL NEURONS; ADULT-RATS; NGF; TRANSPLANTATION; AMELIORATION; REGENERATION	Lateral fluid-percussion brain injury in rats results in cognitive deficits, motor dysfunction, and selective hippocampal cell loss. Neurotrophic factors have been shown to have potential therapeutic applications in neurodegenerative diseases, and nerve growth factor (NGF) has been shown to be neuroprotective in models of excitotoxicity. This study evaluated the neuroprotective efficacy of intracerebral NGF infusion after traumatic brain injury. Male Sprague-Dawley rats received lateral fluid-percussion brain injury of moderate severity (2.1-2.3 atm). A miniosmotic pump was implanted 24 h after injury to infuse NGF (n = 34) or vehicle (n = 16) directly into the region of maximal cortical injury. Infusions of NGF continued until the animal was killed at 72 h, 1 week, or 2 weeks after injury. Animals were evaluated for cognitive dysfunction (Morris Water Maze) and regional neuronal cell loss (Nissl staining) at each of the three time points. Animals surviving for 1 or 2 weeks were also evaluated for neurobehavioral motor function. Although an improvement in memory scores was not observed at 72 h after injury, animals receiving NGF infusions showed significantly improved memory scores when tested at 1 or 2 weeks after injury compared with injured animals receiving vehicle infusions (p < 0.05). Motor scores and CA3 hippocampal cell loss were not significantly different in any group of NGF-treated animals when compared with controls. These data suggest that NGF administration, in the acute, posttraumatic period following fluid-percussion brain injury, may have potential in improving posttraumatic cognitive deficits.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R55NS026818, R01NS026818] Funding Source: NIH RePORTER		Charles V., 1994, Society for Neuroscience Abstracts, V20, P1103; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DACEY RG, 1993, HEAD INJURY, P159; DEKKER AJ, 1994, NEUROSCIENCE, V60, P299, DOI 10.1016/0306-4522(94)90244-5; DEKKER AJ, 1994, BRAIN RES, V639, P149, DOI 10.1016/0006-8993(94)91775-2; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; FRIDEN PM, 1993, SCIENCE, V259, P373, DOI 10.1126/science.8420006; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; GAROFALO L, 1992, P NATL ACAD SCI USA, V89, P2639, DOI 10.1073/pnas.89.7.2639; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; HAGG T, 1990, J NEUROSCI, V10, P3087; HAGG T, 1993, EXP NEUROL, V119, P37, DOI 10.1006/exnr.1993.1005; HAGG T, 1990, EXP NEUROL, V109, P153, DOI 10.1016/0014-4886(90)90069-5; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN D, 1993, EXP NEUROL, V122, P100, DOI 10.1006/exnr.1993.1111; KAWAJA MD, 1992, J NEUROSCI, V12, P2849; KOLIATSOS VE, 1990, J NEUROSCI, V10, P3801; KORSCHING S, 1993, J NEUROSCI, V13, P2739; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIMONTALCINI R, 1953, J EXP ZOOL, V123, P233, DOI 10.1002/jez.1401230203; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MARKOWSKA AL, 1994, J NEUROSCI, V14, P4815; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OKIYAMA K, 1992, J NEUROSURG, V77, P605; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; SALVANT JB, 1994, J NEUROTRAUM, V12, P139; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares Holly D., 1992, Society for Neuroscience Abstracts, V18, P174; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; VINK R, 1990, J NEUROSCI, V10, P3524; WAYNE DB, 1990, DEV BIOL, V138, P473, DOI 10.1016/0012-1606(90)90213-3; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; WINN SR, 1994, P NATL ACAD SCI USA, V91, P2324, DOI 10.1073/pnas.91.6.2324; YUNSHAO H, 1992, Brain Research, V586, P27	51	82	82	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	NOV	1995	65	5					2209	2216					8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	TA742	WOS:A1995TA74200037	7595509				2021-06-18	
J	PRALL, JA; WINSTON, KR; BRENNAN, R				PRALL, JA; WINSTON, KR; BRENNAN, R			SEVERE SNOWBOARDING INJURIES	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article								Thirty-seven consecutive patients with severe snowboard-related injuries (defined by referral to a Level I trauma centre) were reviewed. The type and mechanism of each injury were examined and found to be similar to those reported for skiers. Mild closed head injuries were common (54 per cent). Head and abdominal injuries were move common among snowboarders than skiers, but chest and skeletal injuries were rare. There were no deaths. Serious snowboarding injury rates were similar to those for serious skiing injuries. The incidence of snowboarding injuries sufficiently severe to require tertiary referral was estimated at 0.03 injuries/1000 snowboarder days. Similar to reports of minor snowboarding injury, these data indicate that injury patterns in more serious snowboarding accidents are quite different from those of serious downhill skiing accidents. Injured snowboarders suffer splenic injuries more often and chest and spinal injuries less often than do skiers, and should be evaluated for blunt injuries with these statistical differences in mind.	UNIV COLORADO,HLTH SCI CTR,DEPT SURG,DIV NEUROSURG,DENVER,CO 80262								0	82	82	0	1	BUTTERWORTH-HEINEMANN LTD	OXFORD	LINACRE HOUSE JORDAN HILL, OXFORD, OXON, ENGLAND OX2 8DP	0020-1383			INJURY	Inj.-Int. J. Care Inj.	OCT	1995	26	8					539	542		10.1016/0020-1383(95)00085-N			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	RZ593	WOS:A1995RZ59300009	8550144				2021-06-18	
J	SCHMIDT, RH; GRADY, MS				SCHMIDT, RH; GRADY, MS			LOSS OF FOREBRAIN CHOLINERGIC NEURONS FOLLOWING FLUID-PERCUSSION INJURY - IMPLICATIONS FOR COGNITIVE IMPAIRMENT IN CLOSED-HEAD INJURY	JOURNAL OF NEUROSURGERY			English	Article						FLUID-PERCUSSION INJURY; TRAUMATIC BRAIN INJURY; ACETYLCHOLINE; CATECHOLAMINE; NUCLEUS BASALIS; SEPTAL NUCLEUS; RAT	CONCUSSIVE BRAIN INJURY; DIFFUSE AXONAL INJURY; ALZHEIMERS-DISEASE; BASAL FOREBRAIN; TEGMENTAL NUCLEUS; NERVOUS-SYSTEM; RAT-BRAIN; PROJECTIONS; MEMORY; HISTOCHEMISTRY	Disturbances in memory, concentration, and problem solving are common after even mild to moderate traumatic brain injury. Because these functions are mediated in part by forebrain cholinergic and catecholaminergic innervation, in this study the authors sought to determine if experimental concussive injury produces detectable morphological damage to these systems. Fluid-percussion head injury, sufficient to cause a 13- to 14-minute loss of righting reflex, was produced in rats that had been anesthetized with halothane. Injury was delivered either at midline or 2 mm off midline and compared with appropriate sham-injured controls. After 11 to 15 days, the rat brains were stained in serial sections for choline acetyltransferase, tyrosine hydroxylase, dopamine beta-hydroxylase, acetylcholinesterase, and nicotinamide adenine dinucleotide phosphate diaphorase. Cell counts were determined for the entire population of ventrobasal forebrain cholinergic cells. Midline injury produced a bilateral loss of cholinergic neurons averaging 36% in area Chi (medial septal nucleus), 45% in Ch2 (nucleus of the diagonal band of Broca), and 41% in Ch4 (nucleus basalis of Meynart), (p less than or equal to 0.05). Lateralized injury resulted in cholinergic neuron loss of similar magnitude ipsilaterally (p less than or equal to 0.05), but a smaller contralateral loss of between 11% and 28%. No loss of neurons was detected in the pontomesencephalic cholinergic groups Ch5 and Ch6. There was no visible effect of head injury on forebrain dopamine or noradrenergic innervation. A significant and apparently selective loss of ventrobasal forebrain cholinergic neurons following brief concussive injury in rats is demonstrated in this study. This type of injury is known to produce significant disturbance in cognitive tasks linked to neocortical and hippocampal cholinergic function. It remains to be determined how this neuron loss occurs, whether it can be prevented with neuroprotective agents, how it affects innervation in target tissues, and whether it occurs in human victims of traumatic brain injury.	UNIV WASHINGTON, DEPT NEUROL SURG, SEATTLE, WA USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS01371] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001371] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ASTONJONES G, 1991, PROG BRAIN RES, V88, P501; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DEKKER AJAM, 1991, NEUROSCI BIOBEHAV R, V15, P299, DOI 10.1016/S0149-7634(05)80008-9; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUBACH M, 1987, NEUROSCI LETT, V75, P205, DOI 10.1016/0304-3940(87)90298-9; FIBIGER HC, 1982, BRAIN RES REV, V4, P327, DOI 10.1016/0165-0173(82)90011-X; FRANCIS PT, 1985, NEW ENGL J MED, V313, P7, DOI 10.1056/NEJM198507043130102; Graham D.I., 1993, HEAD INJURY, P91; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Hagg Theo, 1993, P265; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEPLER DJ, 1985, J NEUROSCI, V5, P866; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Katayama Y, 1988, Brain Inj, V2, P51, DOI 10.3109/02699058809150931; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katayama Y, 1986, Neurol Med Chir (Tokyo), V26, P1, DOI 10.2176/nmc.26.1; KAYAMA Y, 1992, BRAIN RES, V569, P210, DOI 10.1016/0006-8993(92)90632-J; KITT C A, 1988, Society for Neuroscience Abstracts, V14, P631; Kraus JF, 1993, HEAD INJURY, P1; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MARTIN LJ, 1993, J NEUROSCI, V13, P2249; Mesulam M.M., 1988, NEUROTRANSMITTERS CO, P237; MESULAM MM, 1987, ANN NEUROL, V22, P683, DOI 10.1002/ana.410220603; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MIYAMOTO M, 1987, BRAIN RES, V419, P19, DOI 10.1016/0006-8993(87)90564-6; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; PALMER AM, 1990, FASEB J, V4, P2745; Povlishock John T., 1993, P185; RAJKOWSKI J, 1992, NEUR ABST, V18, P538; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SCHERERSINGLER U, 1983, J NEUROSCI METH, V9, P229, DOI 10.1016/0165-0270(83)90085-7; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Steel R.G.D., 1960, PRINCIPLES PROCEDURE, P99; TAGO H, 1986, J HISTOCHEM CYTOCHEM, V34, P1431, DOI 10.1177/34.11.2430009; WAITE JJ, 1993, NEUR ABST, V19, P1231; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398; WILCOX KS, 1989, BRAIN RES BULL, V22, P557, DOI 10.1016/0361-9230(89)90111-1; WOOLF NJ, 1986, BRAIN RES BULL, V16, P603, DOI 10.1016/0361-9230(86)90134-6; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	51	82	85	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	1995	83	3					496	502		10.3171/jns.1995.83.3.0496			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RR001	WOS:A1995RR00100018	7666229				2021-06-18	
J	CORRIGAN, JD; DEMING, R				CORRIGAN, JD; DEMING, R			PSYCHOMETRIC CHARACTERISTICS OF THE COMMUNITY INTEGRATION QUESTIONNAIRE - REPLICATION AND EXTENSION	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article								Psychometric characteristics of the Community Integration Questionnaire (CIQ) were replicated and extended. Retrospective CIQs assessing premorbid functioning were completed at inpatient admission for 461 patients with traumatic brain injury (TBI) or disabilities resulting from other injuries. Data were collected at follow-up from 217 persons. The total score was normally distributed, with premorbid scores showing a slight negative skew. Significant mean differences for premorbid versus follow-up samples were evident for the total score and all three subscales, except TBI home integration. Age and gender had minimal effects on total and subscale scores. Overall, results supported the utility of the CIQ as a measure of handicap following TBI. Problems in the distribution of the productivity subscale suggested that it should not be used independently of the total score. Findings also suggested that retrospective assessment may be a useful method for collecting comparative data and that the CIQ can be used to measure integration in populations other than TBI.	OHIO STATE UNIV,MED CTR,COLUMBUS,OH 43210	CORRIGAN, JD (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,COLUMBUS,OH 43210, USA.		Corrigan, John D./E-2921-2011				Carmines E.G., 1979, RELIABILITY VALIDITY, V17; RIMEL RW, 1990, REHABILITATION ADULT; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLER BS, 1993, BRAIN INJURY REHABIL; World Health Organization, 1980, INT CLASS IMP DIS HA	7	82	82	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1995	10	4					41	53		10.1097/00001199-199508000-00005			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RN010	WOS:A1995RN01000005					2021-06-18	
J	Schwartz, MF; Montgomery, MW; FitzpatrickDeSalme, EJ; Ochipa, C; Coslett, HB; Mayer, NH				Schwartz, MF; Montgomery, MW; FitzpatrickDeSalme, EJ; Ochipa, C; Coslett, HB; Mayer, NH			Analysis of a disorder of everyday action	COGNITIVE NEUROPSYCHOLOGY			English	Article							POSITRON EMISSION TOMOGRAPHY; FRONTAL-LOBE DAMAGE; OBJECT RECOGNITION; ALZHEIMERS-DISEASE; IDEATIONAL APRAXIA; SEMANTIC MEMORY; OPTIC APHASIA; IMPAIRMENTS; AGNOSIA; CORTEX	We present a patient, JK, who developed a profound disturbance of routine action production subsequent to closed head injury. Part I of the study describes the disorder as it was expressed in tasks of everyday living. JK demonstrated the features of frontal apraxia, including extreme vulnerability to object substitution and object misuse. In Part II we carried out a neuropsychological assessment targeted at JK's recognition and understanding of objects and implements. This assessment showed a surprising preservation of low- and high-level vision, as well as semantic knowledge relevant to everyday tasks. It also revealed some areas of weakness, notably in access to semantic memory and gesture recall. It is widely accepted that everyday action tasks are planned and executed automatically, that is, with minimal involvement of executive control processes. JK's defects in the areas of semantic memory and gesture recall may have compromised the automaticity of his action planning, but this alone cannot account for his flagrant everyday-action disorder. We speculate, without direct evidence, that the executive control processes (supervisory attention/working memory) that support non-automatic action planning might also have been compromised in JK. If so, it suggests a new account of frontal apraxia, which rests on a combination of deficits: (1) disruption of the fast, automatic retrieval of information from memory stores relevant to action planning; and (2) pathological depletion of executive resources necessary to plan and execute routine behaviour when automaticity fails.	TEMPLE UNIV,SCH MED,PHILADELPHIA,PA 19122; JAMES A HALEY VET HOSP,TAMPA,FL 33612	Schwartz, MF (corresponding author), MOSS REHABIL RES INST,1200 W TABOR RD,PHILADELPHIA,PA 19141, USA.						Allport Alan, 1987, PERSPECTIVES PERCEPT; Baars BJ., 1992, EXPT SLIPS HUMAN ERR; Baddeley A. D., 1994, Neuropsychology, V8, P485, DOI [10.1037/0894-4105.8.4.485., 10.1037/0894-4105.8.4.485]; BAYLIS GC, 1987, J NEUROSCI, V7, P330; BIEDERMAN I, 1993, UNPUB HIGH LEVEL OBJ; CANAVAN AGM, 1985, J NEUROL NEUROSUR PS, V48, P1049, DOI 10.1136/jnnp.48.10.1049; CHERTKOW H, 1989, BRAIN LANG, V36, P420, DOI 10.1016/0093-934X(89)90078-3; CHERTKOW H, 1990, MODULAR DEFICITS ALZ; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; COSLETT HB, 1989, BRAIN, V112, P1091, DOI 10.1093/brain/112.4.1091; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DERENZI E, 1986, CORTEX, V22, P171, DOI 10.1016/S0010-9452(86)80041-7; DERENZI E, 1968, NEUROPSYCHOLOGIA, V6, P41, DOI 10.1016/0028-3932(68)90037-7; Farah M, 1990, VISUAL AGNOSIA; Fuster J, 1989, PREFRONTAL CORTEX; GOLDMANRAKIC PS, 1987, HDB PHYSL NERVOUS SY, V5; GROSS CG, 1992, PHILOS T ROY SOC B, V335, P3, DOI 10.1098/rstb.1992.0001; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; HEILMAN KM, 1985, CLIN NEUROPSYCHOLOGY; HUMPHREYS GW, 1984, Q J EXP PSYCHOL-A, V36, P385, DOI 10.1080/14640748408402169; HUMPHREYS GW, 1989, VISUAL COGNITION COM; Kaplan E., 1983, BOSTON NAMING TEST; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEHMKUHL G, 1981, CORTEX, V17, P153, DOI 10.1016/S0010-9452(81)80017-2; LIEPMANN H, 1905, TRANSLATIONS LIEPMAN; Luria A. R., 1966, HIGHER CORTICAL FUNC; LURIA AR, 1973, PSYCHOPHYSIOLOGY FRO; MACKAY DG, 1985, NEUROPSYCHOLOGICAL S; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MATTSON ME, 1992, EXPT SLIPS HUMAN ERR; MAYER NH, 1990, NEUROPSYCHOLOGY EVER; Norman D, 1986, CONSCIOUSNESS SELF R, VIV; NORMAN DA, 1981, PSYCHOL REV, V88, P1, DOI 10.1037/0033-295X.88.1.1; OCHIPA C, 1989, ANN NEUROL, V25, P190, DOI 10.1002/ana.410250214; OCHIPA C, 1992, BRAIN, V115, P1061, DOI 10.1093/brain/115.4.1061; POECK K, 1980, CORTEX, V16, P273, DOI 10.1016/S0010-9452(80)80062-1; Poeck K, 1985, NEUROPSYCHOLOGICAL S; Prigatano G. P., 1991, AWARENESS DEFICIT BR; RAPCSAK SZ, 1993, BRAIN COGNITION, V23, P181, DOI 10.1006/brcg.1993.1054; Reason J., 1990, HUMAN ERROR; Reason J. T., 1984, VARIETIES ATTENTION; REASON JT, 1982, ABSENT MINDED PSYCHO; REASON JT, 1979, ASPECTS CONSCIOUSNES, V1; Reed Edward S., 1992, Ecological Psychology, V4, P129, DOI 10.1207/s15326969eco0403_1; RIDDOCH MJ, 1987, COGN NEUROPSYCHOL, V4, P131, DOI 10.1080/02643298708252038; Rothi L. J. G., 1991, FLORIDA APRAXIA BATT; ROTHI LJG, 1991, COGN NEUROPSYCHOL, V8, P443, DOI 10.1080/02643299108253382; ROTHI LJG, 1991, UNPUB FLORIDA APRAXI; ROY EA, 1982, NORMALITY PATHOLOGY; ROY EA, 1983, MEMORY CONTROL ACTIO; Roy EA, 1985, NEUROPSYCHOLOGICAL S; SAFFRAN A, 1994, ATTENTION PERFORMANC, V15; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; SCHWARTZ MF, 1993, J HEAD TRAUMA REHAB, V8, P59, DOI DOI 10.1097/00001199-199303000-00007; SCHWARTZ MF, 1990, MODULAR DEFICITS ALZ; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SIRIGU A, 1991, BRAIN, V114, P2555, DOI 10.1093/brain/114.6.2555; Stuss D.T., 1986, FRONTAL LOBES; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOU; WARRINGTON EK, 1978, PERCEPTION, V7, P695, DOI 10.1068/p070695; WARRINGTON EK, 1982, PHILOS T ROY SOC B, V298, P15, DOI 10.1098/rstb.1982.0069; WARRINGTON EK, 1975, Q J EXP PSYCHOL, V27, P635, DOI 10.1080/14640747508400525; WARRINGTON EK, 1984, MANUAL RECOGNITION M; WHYTE J, 1993, REHABILITATION MED P	68	82	82	2	6	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.		1995	12	8					863	892		10.1080/02643299508251406			32	Psychology; Psychology, Experimental	Psychology	TM093	WOS:A1995TM09300005					2021-06-18	
J	MOONEY, GF; HAAS, LJ				MOONEY, GF; HAAS, LJ			EFFECT OF METHYLPHENIDATE ON BRAIN INJURY-RELATED ANGER	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						ANGER; BRAIN INJURIES; METHYLPHENIDATE	CLOSED HEAD-INJURY; FOLLOW-UP; ADJUSTMENT; BEHAVIOR; TRAUMA		UNIV UTAH, DEPT FAMILY & PREVENTAT MED, SALT LAKE CITY, UT 84132 USA	MOONEY, GF (corresponding author), UNIV UTAH, CTR REHABIL, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.						BARKLEY RA, 1977, J CHILD PSYCHOL PSYC, V18, P137, DOI 10.1111/j.1469-7610.1977.tb00425.x; BRAUN CMJ, 1988, J NEUROLOGICAL REHAB, V2, P109; Brooks D N, 1979, Int Rehabil Med, V1, P160; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GAULTIERI CT, 1988, BRAIN INJURY, V2, P273; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LEZAK M, 1983, NEUROPSYCHOLOGICAL A, P549; LEZAK MD, 1980, 8TH ANN M INT NEUR S; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McNair D.M., 1981, MANUAL PROFILE MOOD; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Spielberger, 1980, PRELIMINARY MANUAL S; SPIELBERGER CD, 1983, ADV PERSONALITY ASSE, V175; STERN JM, 1978, SCAND J REHABIL MED, V10, P7; STEVENSON RD, 1989, PEDIATR CLIN N AM, V36, P1183; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEINSTEIN GS, 1981, J CLIN PSYCHIAT, V42, P120	26	82	84	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1993	74	2					153	160					8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	KL171	WOS:A1993KL17100008	8431099				2021-06-18	
J	CRUZ, J; MINER, ME; ALLEN, SJ; ALVES, WM; GENNARELLI, TA				CRUZ, J; MINER, ME; ALLEN, SJ; ALVES, WM; GENNARELLI, TA			CONTINUOUS MONITORING OF CEREBRAL OXYGENATION IN ACUTE BRAIN INJURY - ASSESSMENT OF CEREBRAL HEMODYNAMIC RESERVE	NEUROSURGERY			English	Article						ARTERIOJUGULAR OXYGEN DIFFERENCE; COMA; FIBEROPTIC MONITORING; HEAD INJURY; HEMODYNAMIC RESERVE; HYPERVENTILATION; INTRACRANIAL PRESSURE	BLOOD-FLOW; COMATOSE PATIENTS; INTRACRANIAL-PRESSURE; HEAD-INJURY; MANNITOL; METABOLISM	A new index of cerebral hemodynamics, cerebral hemodynamic reserve (CHR), was evaluated in 12 comatose adults with severe, acute, traumatic, diffuse swelling of the brain, who underwent continuous monitoring with a fiberoptic catheter of the saturation difference in arteriojugular oxyhemoglobin. CHR was assessed as the ratio of changes in global cerebral oxygen extraction to changes in cerebral perfusion pressure (CPP) as a result of spontaneous increases in intracranial pressure (ICP). During the course of hyperventilation (Pco2 in the range of 20 mm Hg) for ICP control below 20 mm Hg, 34 observations were made over the initial 48 hours postinjury. Despite normal CPP, in 25 of the observations (73.5%), ICP elevations to the range of 20 mm Hg were associated with compromised CHR, as evidenced by decreases in jugular oxygenation directly attributed to the ICP increases. In the remaining nine observations (26.5%), CHR was preserved, as evidenced by no changes or increases in jugular oxygenation when ICP increased. The CHR improved on the second day, suggesting an improved tolerance of the cerebral hemodynamics to ICP increases. Before the ICP elevations, in most of the observations, the global cerebral blood flow was estimated as being optimally decreased (by hypocapnia), in relation to cerebral oxygen consumption. This was reflected by the occurrence of baseline normalized cerebral oxygen extraction. It is concluded that in this group of patients, under circumstances of profound hyperventilation, ICP elevations within the normal CPP range may result in decreased cerebral oxygenation, even when the normal CPP would imply otherwise. It is suggested that CHR assessment may provide information regarding the status of intracranial "tightness," insofar as cerebral circulation and oxygenation are concerned.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR HEAD INJURY,PHILADELPHIA,PA 19104; OHIO STATE UNIV,SCH MED,DIV NEUROL SURG,COLUMBUS,OH 43210; UNIV TEXAS,SCH MED,DEPT ANESTHESIOL,HOUSTON,TX 77025					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803-19] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R 49/CCR303687-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803] Funding Source: NIH RePORTER		BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; BROWN FD, 1979, J NEUROSURG, V50, P423, DOI 10.3171/jns.1979.50.4.0423; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1985, CRIT CARE MED, V13, P284, DOI 10.1097/00003246-198504000-00047; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1986, NEUROTRAUMA TREATMEN, P55; CRUZ J, 1984, 52ND ANN M AM ASS NE; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GRUBB RL, 1975, J NEUROSURG, V43, P385, DOI 10.3171/jns.1975.43.4.0385; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Rappaport Z H, 1981, Prog Neurol Surg, V10, P1, DOI 10.1159/000384765; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81	19	82	82	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	NOV	1991	29	5					743	749		10.1227/00006123-199111000-00017			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GL761	WOS:A1991GL76100017	1961406				2021-06-18	
J	Chen, XR; Wu, SK; Chen, CN; Xie, BY; Fang, ZN; Hu, WP; Chen, JY; Fu, HD; He, HF				Chen, Xiangrong; Wu, Shukai; Chen, Chunnuan; Xie, Baoyuan; Fang, Zhongning; Hu, Weipeng; Chen, Junyan; Fu, Huangde; He, Hefan			Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-kappa B pathway following experimental traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Omega-3 polyunsaturated fatty acid; Microglia; Neuroinflammation; HMGB1/TLR4/NF-kappa B pathway	EXPERIMENTAL SUBARACHNOID HEMORRHAGE; GROUP BOX 1; DOCOSAHEXAENOIC ACID; SIGNALING PATHWAY; ACTIVATION; OMEGA-3-FATTY-ACIDS; EXPRESSION; NEUROPROTECTION; METASTASIS; INCREASE	Background: Microglial activation and the subsequent inflammatory response in the central nervous system play important roles in secondary damage after traumatic brain injury (TBI). High-mobility group box 1 (HMGB1) protein, an important mediator in late inflammatory responses, interacts with transmembrane receptor for advanced glycation end products (RAGE) and toll-like receptors (TLRs) to activate downstream signaling pathways, such as the nuclear factor (NF)-kappa B signaling pathway, leading to a cascade amplification of inflammatory responses, which are related to neuronal damage after TBI. Omega-3 polyunsaturated fatty acid (omega-3 PUFA) is a commonly used clinical immunonutrient, which has antioxidative and anti-inflammatory effects. However, the effects of omega-3 PUFA on HMGB1 expression and HMGB1-mediated activation of the TLR4/NF-kappa B signaling pathway are not clear. Methods: The Feeney DM TBI model was adopted to induce brain injury in rats. Modified neurological severity scores, brain water content, and Nissl staining were employed to determine the neuroprotective effects of omega-3 PUFA supplementation. Assessment of microglial activation in lesioned sites and protein markers for proinflammatory, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6, interferon (IFN)-gamma, and HMGB1 were used to evaluate neuroinflammatory responses and anti-inflammation effects of omega-3 PUFA supplementation. Immunofluorescent staining and western blot analysis were used to detect HMGB1 nuclear translocation, secretion, and HMGB1-mediated activation of the TLR4/NF-kappa B signaling pathway to evaluate the effects of omega-3 PUFA supplementation and gain further insight into the mechanisms underlying the development of the neuroinflammatory response after TBI. Results: It was found that omega-3 PUFA supplementation inhibited TBI-induced microglial activation and expression of inflammatory factors (TNF-alpha, IL-1 beta, IL-6, and IFN-gamma), reduced brain edema, decreased neuronal apoptosis, and improved neurological functions after TBI. We further demonstrated that omega-3 PUFA supplementation inhibited HMGB1 nuclear translocation and secretion and decreased expression of HMGB1 in neurons and microglia in the lesioned areas. Moreover, omega-3 PUFA supplementation inhibited microglial activation and the subsequent inflammatory response by regulating HMGB1 and the TLR4/NF-kappa B signaling pathway. Conclusions: The results of this study suggest that microglial activation and the subsequent neuroinflammatory response as well as the related HMGB1/TLR4/NF-kappa B signaling pathway play essential roles in secondary injury after TBI. Furthermore, omega-3 PUFA supplementation inhibited TBI-induced microglial activation and the subsequent inflammatory response by regulating HMGB1 nuclear translocation and secretion and also HMGB1-mediated activation of the TLR4/NF-kappa B signaling pathway, leading to neuroprotective effects.	[Chen, Xiangrong; Wu, Shukai; Xie, Baoyuan; Fang, Zhongning; Hu, Weipeng; Chen, Junyan] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou 362000, Fujian, Peoples R China; [Chen, Chunnuan] Fujian Med Univ, Affiliated Hosp 2, Dept Neurol, Quanzhou 362000, Fujian, Peoples R China; [Fu, Huangde] YouJiang Med Univ Nationalities, Dept Neurosurg, Affiliated Hosp, Baise 533000, Guangxi Provinc, Peoples R China; [He, Hefan] Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesia, Quanzhou 362000, Fujian, Peoples R China	Fu, HD (corresponding author), YouJiang Med Univ Nationalities, Dept Neurosurg, Affiliated Hosp, Baise 533000, Guangxi Provinc, Peoples R China.; He, HF (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesia, Quanzhou 362000, Fujian, Peoples R China.	xiangrong_chen281@126.com; xiangrong_chen281@126.com; 15860905262@163.com	zhang, chuengji/AAD-4591-2020		funds for Fujian Province Scientific Foundation [2015J01443]; Fujian Province Hygiene Innovation Foundation [2015-CXB-20]	This work was supported by grants from the funds for Fujian Province Scientific Foundation (no. 2015J01443) and Fujian Province Hygiene Innovation Foundation (no. 2015-CXB-20) from Dr. Xiangrong Chen.	Avgousti DC, 2016, NATURE, V535, P173, DOI 10.1038/nature18317; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Chhor V, 2017, BRAIN BEHAV IMMUN, V63, P197, DOI 10.1016/j.bbi.2016.11.001; Chi JH, 2017, EUR J PHARMACOL, V796, P101, DOI 10.1016/j.ejphar.2016.12.026; Corrigan F, 2017, BRAIN BEHAV IMMUN, V64, P124, DOI 10.1016/j.bbi.2017.04.006; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Delattre AM, 2017, MOL NEUROBIOL, V54, P2090, DOI 10.1007/s12035-016-9803-8; Eslami M, 2015, J NEUROIMMUNOL, V289, P143, DOI 10.1016/j.jneuroim.2015.11.003; Genet GF, 2017, J NEUROTRAUM, V34, P1054, DOI 10.1089/neu.2016.4574; Guadagno J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.151; Haruma J, 2016, SCI REP-UK, V6, DOI 10.1038/srep37755; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hopp S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0815-8; Inoue T, 2017, BBA-MOL CELL BIOL L, V1862, P552, DOI 10.1016/j.bbalip.2017.02.010; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Li Y, 2015, NEUROBIOL DIS, V74, P240, DOI 10.1016/j.nbd.2014.11.021; Lu B, 2012, NATURE, V488, P670, DOI 10.1038/nature11290; Lv W, 2016, CANCER LETT, V375, P245, DOI 10.1016/j.canlet.2016.02.005; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Michael-Titus AT, 2014, TRENDS NEUROSCI, V37, P30, DOI 10.1016/j.tins.2013.10.005; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Pu HJ, 2017, CELL TRANSPLANT, V26, P555, DOI [10.3727/096368916X693842, 10.3727/096368916x693842]; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Ren HX, 2017, MOL NEUROBIOL, V54, P3317, DOI 10.1007/s12035-016-9931-1; Scrimgeour AG, 2014, J NEUROTRAUM, V31, P989, DOI 10.1089/neu.2013.3234; Sinha SP, 2017, BRAIN BEHAV IMMUN, V61, P353, DOI 10.1016/j.bbi.2017.01.006; Song NY, 2014, BIOCHEM PHARMACOL, V92, P142, DOI 10.1016/j.bcp.2014.08.030; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Sun MY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11445; Takizawa T, 2017, J CEREBR BLOOD F MET, V37, P890, DOI 10.1177/0271678X16647398; Tremblay ME, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0580-0; Wang DL, 2017, SCI REP-UK, V7, DOI 10.1038/srep46243; Wang Z, 2013, J PINEAL RES, V55, P399, DOI 10.1111/jpi.12087; Weber DJ, 2015, ANTIOXID REDOX SIGN, V23, P1316, DOI 10.1089/ars.2015.6299; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292; Zhou Y, 2016, SCI REP-UK, V6, P1, DOI 10.1038/srep33819; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087915	41	81	94	1	28	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUL 24	2017	14								143	10.1186/s12974-017-0917-3			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	FB4XG	WOS:000406144800001	28738820	DOAJ Gold, Green Published			2021-06-18	
J	Elbin, RJ; Sufrinko, A; Schatz, P; French, J; Henry, L; Burkhart, S; Collins, MW; Kontos, AP				Elbin, R. J.; Sufrinko, Alicia; Schatz, Philip; French, Jon; Henry, Luke; Burkhart, Scott; Collins, Michael W.; Kontos, Anthony P.			Removal From Play After Concussion and Recovery Time	PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; SCHOOL FOOTBALL PLAYERS; 2ND IMPACT SYNDROME; VOLUNTARY EXERCISE; ONLINE VERSION; SYMPTOMS; PRESSURE; WINDOW	OBJECTIVE: Despite increases in education and awareness, many athletes continue to play with signs and symptoms of a sport-related concussion (SRC). The impact that continuing to play has on recovery is unknown. This study compared recovery time and related outcomes between athletes who were immediately removed from play and athletes who continued to play with an SRC. METHODS: A prospective, repeated measures design was used to compare neurocognitive performance, symptoms, and recovery time between 35 athletes (mean +/- SD age, 15.61 +/- 1.65 years) immediately removed after an SRC (REMOVED group) compared with 34 athletes (mean +/- SD age, 15.35 +/- 1.73 years) who continued to play (PLAYED group) with SRC. Neurocognitive and symptom data were obtained at baseline and at 1 to 7 days and 8 to 30 days after an SRC. RESULTS: The PLAYED group took longer to recover than the REMOVED group (44.4 +/- 36.0 vs 22.0 +/- 18.7 days; P = .003) and were 8.80 times more likely to demonstrate protracted recovery (= 21 days) (P < .001). Removal from play status was associated with the greatest risk of protracted recovery (adjusted odds ratio, 14.27; P = .001) compared with other predictors (eg, sex). The PLAYED group exhibited significantly worse neurocognitive and greater symptoms than the REMOVED group. CONCLUSIONS: SRC recovery time may be reduced if athletes are removed from participation. Immediate removal from play is the first step in mitigating prolonged SRC recovery, and these data support current consensus statements and management guidelines.	[Elbin, R. J.] Univ Arkansas, Off Sport Concuss Res, Dept Hlth Human Performance & Recreat, 155 Stadium Dr, Fayetteville, AR 72701 USA; [Sufrinko, Alicia; French, Jon; Henry, Luke; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA USA; [Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Burkhart, Scott] Florida State Univ, Dept Human Sci, Tallahassee Orthoped Clin, Tallahassee, FL 32306 USA	Elbin, RJ (corresponding author), Univ Arkansas, Off Sport Concuss Res, Dept Hlth Human Performance & Recreat, 155 Stadium Dr, Fayetteville, AR 72701 USA.	rjelbin@uark.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	This research was supported in part by a grant to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) to Dr Kontos. Funded by the National Institutes of Health (NIH).	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Centers for Disease Control and Prevention, HEADS; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham R., 2014, SPORTS RELATED CONCU; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; IBM Corp, 2012, IBM SPSS STAT WINDOW; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kroshus E, 2015, J ATHL TRAINING, V50, P944, DOI 10.4085/1062-6050-50.6.03; Kroshus E, 2015, SOC SCI MED, V134, P66, DOI 10.1016/j.socscimed.2015.04.011; Kurowski BG, 2015, J TRAUMA ACUTE CARE, V79, pS21, DOI 10.1097/TA.0000000000000675; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Vagnozzi R, 2013, BRAIN 11, V136, pi1; Vagnozzi R, 2013, BRAIN, V136, DOI 10.1093/brain/awt121; Weinstein E, 2013, J NEUROSURG-PEDIATR, V11, P331, DOI 10.3171/2012.11.PEDS12343; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	42	81	81	0	17	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2016	138	3							e20160910	10.1542/peds.2016-0910			8	Pediatrics	Pediatrics	DW9SE	WOS:000384002100039	27573089	Bronze, Green Published			2021-06-18	
J	Mann, AP; Scodeller, P; Hussain, S; Joo, J; Kwon, E; Braun, GB; Molder, T; She, ZG; Kotamraju, VR; Ranscht, B; Krajewski, S; Teesalu, T; Bhatia, S; Sailor, MJ; Ruoslahti, E				Mann, Aman P.; Scodeller, Pablo; Hussain, Sazid; Joo, Jinmyoung; Kwon, Ester; Braun, Gary B.; Molder, Tarmo; She, Zhi-Gang; Kotamraju, Venkata Ramana; Ranscht, Barbara; Krajewski, Stan; Teesalu, Tambet; Bhatia, Sangeeta; Sailor, Michael J.; Ruoslahti, Erkki			A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries	NATURE COMMUNICATIONS			English	Article							POROUS SILICON NANOPARTICLES; TRAUMATIC BRAIN; BARRIER DISRUPTION; CELL; SULFATE; MODELS; SILVER; EDEMA	Traumatic brain injury (TBI) is a major health and socio-economic problem, but no pharmacological agent is currently approved for the treatment of acute TBI. Thus, there is a great need for advances in this field. Here, we describe a short peptide (sequence CAQK) identified by in vivo phage display screening in mice with acute brain injury. The CAQK peptide selectively binds to injured mouse and human brain, and systemically injected CAQK specifically homes to sites of brain injury in mouse models. The CAQK target is a proteoglycan complex upregulated in brain injuries. Coupling to CAQK increased injury site accumulation of systemically administered molecules ranging from a drug-sized molecule to nanoparticles. CAQK-coated nanoparticles containing silencing oligonucleotides provided the first evidence of gene silencing in injured brain parenchyma by systemically administered siRNA. These findings present an effective targeting strategy for the delivery of therapeutics in clinical management of acute brain injuries.	[Mann, Aman P.; Scodeller, Pablo; Hussain, Sazid; Braun, Gary B.; She, Zhi-Gang; Kotamraju, Venkata Ramana; Ranscht, Barbara; Krajewski, Stan; Ruoslahti, Erkki] Sanford Burnham Prebys Med Discovery Inst, Canc Res Ctr, La Jolla, CA 92037 USA; [Scodeller, Pablo; Molder, Tarmo; Teesalu, Tambet] Univ Tartu, Inst Biomed & Translat Med, Canc Biol Lab, EE-50411 Tartu, Estonia; [Hussain, Sazid] AivoCode, La Jolla, CA 92037 USA; [Joo, Jinmyoung; Sailor, Michael J.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Kwon, Ester; Bhatia, Sangeeta] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA; [Kwon, Ester; Bhatia, Sangeeta] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA; [Kwon, Ester; Bhatia, Sangeeta] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Ruoslahti, Erkki] Univ Calif Santa Barbara, Ctr Nanomed, Santa Barbara, CA 93106 USA; [Ruoslahti, Erkki] Univ Calif Santa Barbara, Dept Cell Mol & Dev Biol, Santa Barbara, CA 93106 USA; [Joo, Jinmyoung] Univ Ulsan, Coll Med, Biomed Engn Res Ctr, Asan Med Ctr, Seoul 05505, South Korea	Ruoslahti, E (corresponding author), Sanford Burnham Prebys Med Discovery Inst, Canc Res Ctr, La Jolla, CA 92037 USA.; Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Ctr Nanomed, Santa Barbara, CA 93106 USA.; Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Dept Cell Mol & Dev Biol, Santa Barbara, CA 93106 USA.	ruoslahti@sbpdiscovery.org	Scodeller, Pablo/AAH-7694-2019; Sailor, Michael J/H-9044-2017	Scodeller, Pablo/0000-0003-0745-2467; Sailor, Michael J/0000-0002-4809-9826; Kwon, Ester/0000-0002-6335-9681	Defense Advanced Research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [HR0011-13-2-0017]; European Research CouncilEuropean Research Council (ERC)European Commission [291910]; Wellcome TrustWellcome TrustEuropean Commission [WT095077MA]; National Multiple Sclerosis Grant [RG-4666-A-2]; NSF SBIR Phase I grantNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1548490]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS047101]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA014051, P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047101] Funding Source: NIH RePORTER	We thank Drs Dieter Zimmermann and William Stallcup, for sharing reagents and for helpful discussions, and Guillermina Garcia for assistance in histology. We also thank Center for Neuroscience & Regenerative Medicine Brain Tissue Repository at the Uniformed Services University of the Health Sciences in Bethesda, MD for sharing human brain tissues. This work was supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement HR0011-13-2-0017. The findings and views expressed are those of the authors and do not reflect the official policy or position of the Department of Defense or the U.S. Government. T.T. was supported by grants from the European Research Council (No. 291910) and Wellcome Trust International Fellowship (WT095077MA). B.R. was funded by the National Multiple Sclerosis Grant RG-4666-A-2. S.H. was supported in part by NSF SBIR Phase I grant (1548490). UCSD School of Medicine Microscopy Core is supported by NINDS NS047101.	Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Braun GB, 2014, NAT MATER, V13, P904, DOI [10.1038/NMAT3982, 10.1038/nmat3982]; Cai WB, 2008, NAT PROTOC, V3, P89, DOI 10.1038/nprot.2007.478; Chen YH, 2009, NAT MED, V15, P1215, DOI 10.1038/nm.2025; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cunningham TL, 2014, J NEUROTRAUM, V31, P505, DOI 10.1089/neu.2013.2965; Dadosh T, 2009, MATER LETT, V63, P2236, DOI 10.1016/j.matlet.2009.07.042; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Fan XM, 2007, PHARM RES-DORDR, V24, P868, DOI 10.1007/s11095-007-9238-z; Fukuda AM, 2013, GENES-BASEL, V4, P435, DOI 10.3390/genes4030435; Gu L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3326; Hill JJ, 2012, P NATL ACAD SCI USA, V109, P9155, DOI 10.1073/pnas.1205697109; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; Hussain S, 2014, SCI REP-UK, V4, DOI 10.1038/srep05232; Joo J, 2015, ACS NANO, V9, P6233, DOI 10.1021/acsnano.5b01594; Joo J, 2014, ADV FUNCT MATER, V24, P5688, DOI 10.1002/adfm.201400587; Kielian T, 2001, J IMMUNOL, V166, P4634, DOI 10.4049/jimmunol.166.7.4634; Kielian T, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-16; Krajewska M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024341; KUROIWA T, 1988, ACTA NEUROPATHOL, V76, P62, DOI 10.1007/BF00687681; Kwok JCF, 2012, INT J BIOCHEM CELL B, V44, P582, DOI 10.1016/j.biocel.2012.01.004; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Navarro JRG, 2013, ANALYST, V138, P583, DOI 10.1039/c2an36135c; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Park JH, 2009, NAT MATER, V8, P331, DOI [10.1038/NMAT2398, 10.1038/nmat2398]; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Pillai DR, 2009, J CEREBR BLOOD F MET, V29, P1846, DOI 10.1038/jcbfm.2009.106; Qin ZT, 2014, PART PART SYST CHAR, V31, P252, DOI 10.1002/ppsc.201300244; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Ruoslahti E, 2012, ADV MATER, V24, P3747, DOI 10.1002/adma.201200454; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; STEWART PA, 1992, J NEUROSCI METH, V41, P75, DOI 10.1016/0165-0270(92)90125-W; Teesalu T, 2012, METHOD ENZYMOL, V503, P35, DOI 10.1016/B978-0-12-396962-0.00002-1; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	44	81	83	1	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	JUN	2016	7								11980	10.1038/ncomms11980			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DQ3NK	WOS:000379108800001	27351915	DOAJ Gold, Green Published			2021-06-18	
J	DiFazio, M; Silverberg, ND; Kirkwood, MW; Bernier, R; Iverson, GL				DiFazio, Marc; Silverberg, Noah D.; Kirkwood, Michael W.; Bernier, Raquel; Iverson, Grant L.			Prolonged Activity Restriction After Concussion: Are We Worsening Outcomes?	CLINICAL PEDIATRICS			English	Article						concussion; mTBI; activity restriction; rest; rehabilitation; treatment	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; MILD HEAD-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; QUALITY-OF-LIFE; BED REST; DEPRESSED AFFECT; TEMPORAL WINDOW; UP-REGULATION; CHILDREN	The current treatment of concussion or mild traumatic brain injury (mTBI) is primarily based on expert consensus. Most clinical practice guidelines advise cognitive and physical rest after injury including withdrawal from normal life activities such as school attendance, sports participation, and technology use until symptoms resolve. Some individuals who sustain an mTBI experience persistent physical, cognitive, and mental health problems. Activity restriction itself may contribute to protracted recovery and other complications. Williamson's Activity Restriction Model of Depression, formulated more than 20 years ago, is central to this hypothesis. We review research evidence for potential harms of prolonged activity restriction and report an mTBI case as an example of how an activity restriction cascade can unfold. According to this model, psychological consequences of removal from validating life activities, combined with physical deconditioning, contribute to the development and persistence of postconcussive symptoms after mTBI in some youth. A modification to mTBI guidelines that emphasizes prompt reengagement in life activities as tolerated is encouraged.	[DiFazio, Marc; Bernier, Raquel] Childrens Natl Hlth Syst, Washington, DC USA; [Silverberg, Noah D.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Aurora, CO USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp Children, Boston, MA USA; [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA	DiFazio, M (corresponding author), 9850 Key West Ave, Rockville, MD 20850 USA.	mdifazio@childrensnational.org		Iverson, Grant/0000-0001-7348-9570	Mooney-Reed Charitable Foundation; Vancouver Coastal Health Research Institute	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GLI acknowledges funding support from the Mooney-Reed Charitable Foundation. NDS receives salary support from the Vancouver Coastal Health Research Institute.	Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANDREASSEN J, 1957, ACTA MED SCAND, V158, P239; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bass P, 2014, CONT PEDIAT; Beaupre M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/924692; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Clayton RB, 2015, J COMPUT-MEDIAT COMM, V20, P119, DOI 10.1111/jcc4.12109; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Craton N, 2014, CURR SPORT MED REP, V13, P201, DOI 10.1249/JSR.0000000000000072; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; DeMatteo C, 2015, CLIN PEDIATR, V54, P783, DOI 10.1177/0009922814567305; DeMatteo C, 2015, CLIN PEDIATR, V54, P152, DOI 10.1177/0009922814558256; Edmed S, 2012, PSYCHIAT RES, V200, P41, DOI 10.1016/j.psychres.2012.05.022; Fainaru S, 2003, ESPN OUTSIDE LINES; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Fortney SM, 2011, COMPR PHYSIOL, P889; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hartman-Maeir A, 2007, DISABIL REHABIL, V29, P559, DOI 10.1080/09638280600924996; Hernandez SE, 2015, J ALTERN COMPLEM MED, V21, P175, DOI 10.1089/acm.2013.0450; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2012, MILD TRAUMATIC BRAIN, P281; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kirkwood MW, 2012, CLIN J SPORT MED, V22, P383, DOI 10.1097/JSM.0b013e31826396fc; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lewinsohn PM, 1997, J ABNORM PSYCHOL, V106, P365, DOI 10.1037/0021-843X.106.3.365; Lewinsohn PM., 1985, THEORETICAL ISSUES B, P331; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; MEERLOO AM, 1949, J NERV MENT DIS, V110, P347, DOI 10.1097/00005053-194911040-00005; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Molton IR, 2014, J HEALTH PSYCHOL, V19, P1025, DOI 10.1177/1359105313483156; Morrissey D, 2014, J TRAUMA ACUTE CARE, V77, pS8, DOI 10.1097/TA.0000000000000331; Moser RS, 2015, BRAIN INJURY, V29, P58, DOI 10.3109/02699052.2014.964771; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Peterson RL, 2015, J NEUROPSYCH CLIN N, V27, P280, DOI 10.1176/appi.neuropsych.14120373; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Short EB, 2010, EVID-BASED COMPL ALT, V7, P121, DOI 10.1093/ecam/nem163; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Smorawinski J, 2001, J APPL PHYSIOL, V91, P249; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Turner AP, 2009, ARCH PHYS MED REHAB, V90, P420, DOI 10.1016/j.apmr.2008.09.558; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2014, PSYCHOL INJ LAW, V7, P245, DOI 10.1007/s12207-014-9201-3; VORIS HC, 1950, AM J SURG, V80, P707, DOI 10.1016/0002-9610(50)90595-2; Walters AS, 1999, CHILD HEALTH CARE, V28, P33, DOI 10.1207/s15326888chc2801_3; Watt J., 1938, AM J SURG, V41, P272; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WILLIAMSON GM, 1995, PSYCHOL AGING, V10, P369, DOI 10.1037/0882-7974.10.3.369; Williamson GM, 2000, HEALTH PSYCHOL, V19, P339, DOI 10.1037//0278-6133.19.4.339; Wilson TD, 2014, SCIENCE, V345, P75, DOI 10.1126/science.1250830; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082	88	81	82	0	24	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	MAY	2016	55	5					443	451		10.1177/0009922815589914			9	Pediatrics	Pediatrics	DJ5FM	WOS:000374232200007	26130391				2021-06-18	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Return to Activity after Concussion Affects Dual-Task Gait Balance Control Recovery	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						SPORT CONCUSSION; GAIT STABILITY; RECOVERY; PHYSICAL ACTIVITY	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; EXECUTIVE FUNCTION; PERFORMANCE; STATEMENT; ATTENTION; PARADIGM; MOTION; LEVEL	Background Recent work has identified deficits in dual-task gait balance control for up to 2 months after adolescent concussion; however, how resumption of preinjury physical activities affects recovery is unknown. Purpose The objective of this study is to examine how return to activity (RTA) affects recovery from concussion on measures of symptom severity, cognition, and balance control during single-task and dual-task walking. Methods Nineteen adolescents with concussion who returned to preinjury activity within 2 months after injury and 19 uninjured, matched controls completed symptom inventories, computerized cognitive testing, and single-task and dual-task gait analyses. Concussion participants were assessed at five time points: within 72 h, 1 wk, 2 wk, 1 month, and 2 months postinjury. Control participants were assessed at the same time points as their matched concussion counterparts. RTA day was documented as the postinjury day in which physical activity participation was allowed. The effect of returning to physical activity was assessed by examining the percent change on each dependent variable across time before and directly after the RTA. Data were analyzed by two-way mixed effects ANOVAs. Results After the RTA day, concussion participants significantly increased their total center-of-mass medial/lateral displacement (P = 0.009, (2)(p) = .175) and peak velocity (P = 0.048, (2)(p) = 0.104) during dual-task walking when compared with pre-RTA data, whereas no changes for the concussion group or between groups were detected on measures of single-task walking, forward movement, or cognition. Conclusions Adolescents with concussion displayed increased center-of-mass medial/lateral displacement and velocity during dual-task walking after RTA, suggesting a regression of recovery in gait balance control. This study reinforces the need for a multifaceted approach to concussion management and continued monitoring beyond the point of clinical recovery.	[Howell, David R.; Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA	Chou, LS (corresponding author), 1240 Univ Oregon, Dept Human Physiol, 122 Esslinger Hall, Eugene, OR 97403 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Howell, David/0000-0002-2955-0191	Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Translational Research Award from University of Oregon; Peace Health Oregon Region; Department of Defense-TATRC Award [W81XWH-11-1-0717]	This work was supported by Veterans Administration subcontract awards (A4842C8 and A4843C), Translational Research Award from the University of Oregon and Peace Health Oregon Region, and the Department of Defense-TATRC Award (W81XWH-11-1-0717).	Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayr U, 2006, PSYCHON B REV, V13, P794, DOI 10.3758/BF03193999; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Resch JE, 2011, J ATHL TRAINING, V46, P170, DOI 10.4085/1062-6050-46.2.170; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Ross LM, 2011, J SPORT REHABIL, V20, P296, DOI 10.1123/jsr.20.3.296; Scherer MR, 2013, PHYS THER, V93, P1254, DOI 10.2522/ptj.20120143; Teel EF, 2014, CLIN NEUROPHYSIOL, V125, P703, DOI 10.1016/j.clinph.2013.08.027; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	35	81	82	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	APR	2015	47	4					673	680		10.1249/MSS.0000000000000462			8	Sport Sciences	Sport Sciences	CE1QU	WOS:000351587800001	25100340				2021-06-18	
J	Diamond, ML; Ritter, AC; Failla, MD; Boles, JA; Conley, YP; Kochanek, PM; Wagner, AK				Diamond, Matthew L.; Ritter, Anne C.; Failla, Michelle D.; Boles, Jennifer A.; Conley, Yvette P.; Kochanek, Patrick M.; Wagner, Amy K.			IL-1 beta associations with posttraumatic epilepsy development: A genetics and biomarker cohort study	EPILEPSIA			English	Article						Posttraumatic epilepsy; Inflammation; Traumatic brain injury; Genetic variation; IL-1 beta	TRAUMATIC BRAIN-INJURY; BINDING CASSETTE TRANSPORTER; RECEPTOR ANTAGONIST; INTERLEUKIN-1-BETA GENE; RISK-FACTORS; RAT MODEL; SEIZURES; SECRETION; INFLAMMATION; POLYMORPHISMS	Objective: Posttraumatic epilepsy (PTE) is a significant complication following traumatic brain injury (TBI), yet the role of genetic variation in modulating PTE onset is unclear. We hypothesized that TBI-induced inflammation likely contributes to seizure development. We assessed whether genetic variation in the interleukin-1beta (IL-1 beta) gene, IL-1 beta levels in cerebrospinal fluid (CSF) and serum, and CSF/serum IL-1 beta ratios would predict PTE development post-TBI. Methods: We investigated PTE development in 256 Caucasian adults with moderate-to-severe TBI. IL-1 beta tagging and functional single nucleotide polymorphisms (SNPs) were genotyped. Genetic variance and PTE development were assessed. Serum and CSF IL-1 beta levels were collected from a subset of subjects (n = 59) during the first week postinjury and evaluated for their associations with IL-1 beta gene variants, and also PTE. Temporally matched CSF/serum IL-1 beta ratios were also generated to reflect the relative contribution of serum IL-1 beta to CSF IL-1 beta. Results: Multivariate analysis showed that higher CSF/serum IL-1 beta ratios were associated with increased risk for PTE over time (p = 0.008). Multivariate analysis for rs1143634 revealed an association between the CT genotype and increased PTE risk over time (p = 0.005). The CT genotype group also had lower serum IL-1 beta levels (p = 0.014) and higher IL-1 beta CSF/serum ratios (p = 0.093). Significance: This is the first report implicating IL-1 beta gene variability in PTE risk and linking (1) IL-1 beta gene variation with serum IL-1 beta levels observed after TBI and (2) IL-1 beta ratios with PTE risk. Given these findings, we propose that genetic and IL-1 beta ratio associations with PTE may be attributable to biologic variability with blood-brain barrier integrity during TBI recovery. These results provide a rationale for further studies (1) validating the impact of genetic variability on IL-1 beta production after TBI, (2) assessing genetically mediated signaling mechanisms that contribute to IL-1 beta CSF/serum associations with PTE, and (3) evaluating targeted IL-1 beta therapies that reduce PTE.	[Diamond, Matthew L.; Ritter, Anne C.; Failla, Michelle D.; Boles, Jennifer A.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Hlth Promot & Dev, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Kochanek, Patrick M/D-2371-2015; Failla, Michelle/AAI-3788-2021	Kochanek, Patrick M/0000-0002-2627-913X; Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162-02, R01NR008424, 5P01NS030318];  [DODW81XWH-071-0701]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424] Funding Source: NIH RePORTER	This work was supported by DODW81XWH-071-0701, NIH R01 HD048162-02, NIH R01NR008424, and NIH 5P01NS030318. Thanks to Sandra Deslouche for support with genotyping, and the subjects and their families for their generous participation. Thanks to the UPMC Trauma Registry for providing some elements of data collection. Thanks to the University of Pittsburgh Cancer Institute for Luminex services.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Boles J, 2013, 2013 ANN S NAT NEUR; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; BROWN R, 1991, CELL IMMUNOL, V132, P84, DOI 10.1016/0008-8749(91)90008-Y; Camargo MC, 2006, CANCER EPIDEM BIOMAR, V15, P1674, DOI 10.1158/1055-9965.EPI-06-0189; Chen HM, 2006, HUM MOL GENET, V15, P519, DOI 10.1093/hmg/ddi469; Chen XP, 2009, J BIOL CHEM, V284, P27857, DOI 10.1074/jbc.M109.000950; Darrah SD, 2013, EPILEPSY RES, V103, P180, DOI 10.1016/j.eplepsyres.2012.07.006; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dominici R, 2002, EXP MOL PATHOL, V73, P139, DOI 10.1006/exmp.2002.2435; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Ferrari D, 1996, J IMMUNOL, V156, P1531; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Formisano R, 2007, BRAIN INJURY, V21, P499, DOI 10.1080/02699050701310994; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Hall SK, 2004, ARTHRITIS RHEUM-US, V50, P1976, DOI 10.1002/art.20310; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holtman L, 2013, EPILEPSIA, V54, P589, DOI 10.1111/epi.12112; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kauffman MA, 2008, GENET MED, V10, P83, DOI 10.1097/GIM.0b013e318161317c; Kolakowsky-Hayner SA, 2013, BRAIN INJURY, V27, P578, DOI 10.3109/02699052.2013.765595; LEE SC, 1993, J IMMUNOL, V150, P2659; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; National Institute of Neurological Disorders and Stroke, 2013, EP RES BENCHM PROGR; Omran A, 2012, EPILEPSIA, V53, P1215, DOI 10.1111/j.1528-1167.2012.03540.x; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; Ravizza T, 2006, EPILEPSIA, V47, P1160, DOI 10.1111/j.1528-1167.2006.00590.x; Rijkers K, 2009, EXP NEUROL, V216, P258, DOI 10.1016/j.expneurol.2008.12.014; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Schmitz G, 1999, PATHOBIOLOGY, V67, P236, DOI 10.1159/000028100; Skinner RA, 2009, BRIT J PHARMACOL, V156, P1115, DOI 10.1111/j.1476-5381.2008.00129.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; VANDERZEE CEE, 1995, J NEUROSCI, V15, P5316; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; Vezzani A, 2008, EPILEPSIA, V49, P24, DOI 10.1111/j.1528-1167.2008.01490.x; von Wedel-Parlow M, 2009, J NEUROCHEM, V111, P111, DOI 10.1111/j.1471-4159.2009.06305.x; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Zhu G, 2006, EPILEPSY RES, V71, P107, DOI 10.1016/j.eplepsyres.2006.05.017; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	55	81	82	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUL	2014	55	7					1109	1119		10.1111/epi.12628			11	Clinical Neurology	Neurosciences & Neurology	AN4YI	WOS:000340595500025	24754437	Green Accepted, Bronze			2021-06-18	
J	Valle, EJ; Allen, CJ; Van Haren, RM; Jouria, JM; Li, H; Livingstone, AS; Namias, N; Schulman, CI; Proctor, KG				Valle, Evan J.; Allen, Casey J.; Van Haren, Robert M.; Jouria, Jassin M.; Li, Hua; Livingstone, Alan S.; Namias, Nicholas; Schulman, Carl I.; Proctor, Kenneth G.			Do all trauma patients benefit from tranexamic acid?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	72nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 18-23, 2013	San Francisco, CA	Amer Assoc Surg Trauma		Hemostasis; resuscitation; transfusion	ACUTE COAGULOPATHY; FIBRINOLYSIS	BACKGROUND: This study tested the hypothesis that early routine use of tranexamic acid (TXA) reduces mortality in a subset of the most critically injured trauma intensive care unit patients. METHODS: Consecutive trauma patients (n = 1,217) who required emergency surgery (OR) and/or transfusions from August 2009 to January 2013 were reviewed. At surgeon discretion, TXA was administered at a median of 97 minutes (1-g bolus then 1-g over 8 hours) to 150 patients deemed high risk for hemorrhagic death. With the use of propensity scores based on age, sex, traumatic brain injury (TBI), mechanism of injury, systolic blood pressure, transfusion requirements, and Injury Severity Score (ISS), these patients were matched to 150 non-TXA patients. RESULTS: The study population was 43 years old, 86% male, 54% penetrating mechanism of injury, 25% TBI, 28 ISS, with 22% mortality. OR was required in 78% at 86 minutes, transfusion was required in 97% at 36 minutes, and 75% received both. For TXA versus no TXA, more packed red blood cells and total fluid were required, and mortality was 27% versus 17% (all p < 0.05). The effects of TXA were similar in those with or without TBI, although ISS, fluid, and mortality were all higher in the TBI group. Mortality associated with TXA was influenced by the timing of administration (p G 0.05), but any benefit was eliminated in those who required more than 2,000-mL packed red blood cells, who presented with systolic blood pressure of less than 120 mm Hg or who required OR (all p G 0.05). CONCLUSION: For the highest injury acuity patients, TXA was associated with increased, rather than reduced, mortality, no matter what time it was administered. This lack of benefit can probably be attributed to the rapid availability of fluids and emergency OR at this trauma center. Prospective studies are needed to further identify conditions that may override the benefits from TXA. (J Trauma Acute Care Surg. 2014; 76: 1373-1378. Copyright (C) 2014 by Lippincott Williams & Wilkins)	Univ Miami, Miller Sch Med, Dewitt Daughtry Family Dept Surg, Div Trauma, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dewitt Daughtry Family Dept Surg, Div Surg Crit Care, Miami, FL 33136 USA	Proctor, KG (corresponding author), Univ Miami, Sch Med, Ryder Trauma Ctr, Div Trauma,Dewitt Daughtry Family Dept Surg, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu	Livingstone, Alan/AAA-4026-2019; Van Haren, Robert/T-8218-2019; Schulman, Carl/AAE-7448-2021	Namias, Nicholas/0000-0001-7021-2250; Schulman, Carl/0000-0001-8899-4350; Allen, Casey/0000-0001-9890-7417			Chapman MP, 2013, J TRAUMA ACUTE CARE, V75, P961, DOI 10.1097/TA.0b013e3182aa9c9f; Faraoni D, 2013, MINERVA ANESTESIOL; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; Morrison JJ, 2013, J TRAUMA ACUTE CARE, V75, P743, DOI 10.1097/TA.0b013e3182a53873; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; Napolitano LM, 2013, J TRAUMA ACUTE CARE, V74, P1575, DOI 10.1097/TA.0b013e318292cc54; Pusateri AE, 2013, SHOCK, V39, P121, DOI 10.1097/SHK.0b013e318280409a; Roberts I, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5839; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Schlimp CJ, 2014, HAMOSTASEOLOGIE, V34, P29, DOI 10.5482/HAMO-13-07-0038; Schochl H, 2013, J TRAUMA ACUTE CARE, V74, P1587, DOI 10.1097/TA.0b013e31828c3171; Schochl H, 2013, CURR OPIN ANESTHESIO, V26, P221, DOI 10.1097/ACO.0b013e32835cca92; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Tranexamic Acid Injection 100 mg/ml NDC 67457-197-10 10 mL single dose vial packages of 10, TRAN AC INJ 100 MG M; Vu Erik Nelson, 2013, Air Med J, V32, P289, DOI 10.1016/j.amj.2013.05.001; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484	18	81	81	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2014	76	6					1373	1378		10.1097/TA.0000000000000242			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AI8FR	WOS:000337145500006	24854303				2021-06-18	
J	George, MS; Raman, R; Benedek, DM; Pelic, CG; Grammer, GG; Stokes, KT; Schmidt, M; Spiegel, C; DeAlmeida, N; Beaver, KL; Borckardt, JJ; Sun, XY; Jain, S; Stein, MB				George, Mark S.; Raman, Rema; Benedek, David M.; Pelic, Christopher G.; Grammer, Geoffrey G.; Stokes, Karen T.; Schmidt, Matthew; Spiegel, Chad; DeAlmeida, Nancy; Beaver, Kathryn L.; Borckardt, Jeffrey J.; Sun, Xiaoying; Jain, Sonia; Stein, Murray B.			A Two-site Pilot Randomized 3 Day Trial of High Dose Left Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for Suicidal Inpatients	BRAIN STIMULATION			English	Article						TMS; Transcranial; Suicide; Prefrontal; Magnetic	LEARNED HELPLESSNESS; MOTOR THRESHOLD; DEPRESSION; CORTEX; PAIN; LITHIUM; PREVENTION; DISORDER; THERAPY; PLACEBO	Background: Suicide attempts and completed suicides are common, yet there are no proven acute medication or device treatments for treating a suicidal crisis. Repeated daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) for 4-6 weeks is a new FDA-approved treatment for acute depression. Some open-label rTMS studies have found rapid reductions in suicidality. Design: This study tests whether a high dose of rTMS to suicidal inpatients is feasible and safe, and also whether this higher dosing might rapidly improve suicidal thinking. This prospective, 2-site, randomized, active sham-controlled (1: 1 randomization) design incorporated 9 sessions of rTMS over 3 days as adjunctive to usual inpatient suicidality treatment. The setting was two inpatient military hospital wards (one VA, the other DOD). Patients: Research staff screened approximately 377 inpatients, yielding 41 adults admitted for suicidal crisis. Because of the funding source, all patients also had either post-traumatic stress disorder, mild traumatic brain injury, or both. TMS methods: Repetitive TMS (rTMS) was delivered to the left prefrontal cortex with a figure-eight solid core coil at 120% motor threshold, 10 Hertz (Hz), 5 second (s) train duration, 10 s intertrain interval for 30 minutes (6000 pulses) 3 times daily for 3 days (total 9 sessions; 54,000 stimuli). Sham rTMS used a similar coil that contained a metal insert blocking the magnetic field and utilized electrodes on the scalp, which delivered a matched somatosensory sensation. Main outcome measure: Primary outcomes were the daily change in severity of suicidal thinking as measured by the Beck Scale of Suicidal Ideation (SSI) administered at baseline and then daily, as well as subjective visual analog scale measures before and after each TMS session. Mixed model repeated measures (MMRM) analysis was performed on modified intent to treat (mITT) and completer populations. Results: This intense schedule of rTMS with suicidal inpatients was feasible and safe. Minimal side effects occurred, none differing by arm, and the 3-day retention rate was 88%. No one died of suicide within the 6 month followup. From the mITT analyses, SSI scores declined rapidly over the 3 days for both groups (sham change -15.3 points, active change -15.4 points), with a trend for more rapid decline on the first day with active rTMS (sham change -6.4 points, active -10.7 points, P = 0.12). This decline was more pronounced in the completers subgroup [sham change -5.9 (95% CI: -10.1, -1.7), active -13 points (95% CI: -18.7, -7.4); P = 0.054]. Subjective ratings of 'being bothered by thoughts of suicide' declined non- significantly more with active rTMS than with sham at the end of 9 sessions of treatment in the mITT analysis [sham change 31.9 (95% CI: 41.7, 22.0), active change 42.5 (95% CI: 53.8, 31.2); P = 0.17]. There was a significant decrease in the completers sample [sham change -24.9 (95% CI: -34.4, -15.3), active change -43.8 (95% CI: -57.2, -30.3); P = 0.028]. Conclusions: Delivering high doses of left prefrontal rTMS over three days (54,000 stimuli) to suicidal inpatients is possible and safe, with few side effects and no worsening of suicidal thinking. The suggestions of a rapid anti-suicide effect (day 1 SSI data, Visual Analogue Scale data over the 3 days) need to be tested for replication in a larger sample. (C) 2014 Elsevier Inc. All rights reserved.	[George, Mark S.; Pelic, Christopher G.; Schmidt, Matthew; Beaver, Kathryn L.; Borckardt, Jeffrey J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA; [George, Mark S.; Pelic, Christopher G.; Schmidt, Matthew; Beaver, Kathryn L.; Borckardt, Jeffrey J.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Div, Charleston, SC 29425 USA; [Benedek, David M.; Grammer, Geoffrey G.; Spiegel, Chad; DeAlmeida, Nancy] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20889 USA; [Raman, Rema; Stokes, Karen T.; Sun, Xiaoying; Jain, Sonia; Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA	George, MS (corresponding author), MUSC, IOP, 502 N,67 President St, Charleston, SC 29425 USA.	georgem@musc.edu		George, Mark/0000-0003-1767-1815	U.S. Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC); DOD INTRuST [W81XWH-08-2-0159]	Funded by U.S. Army Medical Research and Materiel Command (USAMRMC).; Funding mechanism: Contract # W81XWH-08-2-0159, DOD INTRuST.	Amat J, 2008, NEUROSCIENCE, V154, P1178, DOI 10.1016/j.neuroscience.2008.04.005; Anderson B, 2006, J ECT, V22, P49, DOI 10.1097/00124509-200603000-00011; [Anonymous], 2012, MSMR, V19, P2; [Anonymous], 2012, MSMR, V19, P5; Arana AB, 2008, BRAIN STIMUL, V1, P44, DOI 10.1016/j.brs.2007.08.006; Armed Forces Health Surveillance Center (AFHSC), 2012, MSMR, V19, P7; Baratta MV, 2007, NEUROSCIENCE, V146, P1495, DOI 10.1016/j.neuroscience.2007.03.042; Baratta MV, 2008, LEARN MEMORY, V15, P84, DOI 10.1101/lm.800308; Barth Kelly S, 2011, Front Psychiatry, V2, P9, DOI 10.3389/fpsyt.2011.00009; BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; Bluml V, 2013, J PSYCHIATR RES, V47, P407, DOI 10.1016/j.jpsychires.2012.12.002; Borckardt JJ, 2007, PAIN RES MANAG, V12, P287, DOI 10.1155/2007/741897; Borckardt JJ, 2008, BRAIN STIMUL, V1, P52, DOI 10.1016/j.brs.2007.09.003; Borckardt JJ, 2006, ANESTHESIOLOGY, V105, P557, DOI 10.1097/00000542-200609000-00020; Borckardt JJ, 2011, CLIN J PAIN, V27, P486, DOI 10.1097/AJP.0b013e31820d2733; Borckardt JJ, 2011, PAIN, V152, P182, DOI 10.1016/j.pain.2010.10.018; Borckardt JJ, 2009, PAIN MED, V10, P840, DOI 10.1111/j.1526-4637.2009.00657.x; Borckardt JJ, 2006, J ECT, V22, P169, DOI 10.1097/01.yct.0000235923.52741.72; Borckardt JJ, 2009, J ECT, V25, P91, DOI 10.1097/YCT.0b013e318183c6a4; Borckardt JJ, 2008, BRAIN STIMUL, V1, P122, DOI 10.1016/j.brs.2008.04.002; Borckardt JJ, 2013, BRAIN STIMUL; Centers for Disease Control and Prevention (CDC), 2013, MMWR Morb Mortal Wkly Rep, V62, P321; Christianson JP, 2008, STRESS, P1; Cipriani A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3646; Fawcett J, 2013, DEPRESS ANXIETY, V30, P898, DOI 10.1002/da.22058; Fink M, 2013, J ECT; George MS, 2013, CURR OPIN PSYCHIATR, V26, P13, DOI 10.1097/YCO.0b013e32835ab46d; George MS, 2011, AM J PSYCHIAT, V168, P356, DOI 10.1176/appi.ajp.2010.10060864; George MS, 2010, ARCH GEN PSYCHIAT, V67, P507, DOI 10.1001/archgenpsychiatry.2010.46; George MS, 1997, AM J PSYCHIAT, V154, P1752, DOI 10.1176/ajp.154.12.1752; GEORGE MS, 1994, CONVULSIVE THER, V10, P251; George MS, 1994, DEPRESSION, V2, P59, DOI 10.1002/depr.3050020202.; Gold KJ, 2013, GEN HOSP PSYCHIAT, V35, P45, DOI 10.1016/j.genhosppsych.2012.08.005; Hadley D, 2011, J ECT, V27, P18, DOI 10.1097/YCT.0b013e3181ce1a8c; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Holtzheimer PE, 2010, DEPRESS ANXIETY, V27, P960, DOI 10.1002/da.20731; Jollant F, 2011, WORLD J BIOL PSYCHIA, V12, P319, DOI 10.3109/15622975.2011.556200; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kemp J, 2012, SUICIDE DATA REPORT; Larkin GL, 2011, INT J NEUROPSYCHOPH, V14, P1127, DOI 10.1017/S1461145711000629; Madsen T, 2012, J CLIN PSYCHIAT, V73, P144, DOI 10.4088/JCP.10m06473; Martin L, 2013, PAIN MED, V14, P999, DOI 10.1111/pme.12129; MILLER WR, 1975, J ABNORM PSYCHOL, V84, P228, DOI 10.1037/h0076720; Mishory A, 2004, J ECT, V20, P160, DOI 10.1097/00124509-200409000-00007; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Olfson M, 2005, ARCH GEN PSYCHIAT, V62, P1122, DOI 10.1001/archpsyc.62.10.1122; Oquendo MA, 2011, AM J PSYCHIAT, V168, P1050, DOI 10.1176/appi.ajp.2011.11010163; Perlis RH, 2011, AM J PSYCHIAT, V168, P1009, DOI 10.1176/appi.ajp.2011.11081250; Pridmore S, 1998, J ECT, V14, P25; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Roy-Byrne P, 2013, DEPRESS ANXIETY, V30, P893, DOI 10.1002/da.22181; SELIGMAN MEP, 1975, J COMP PHYSIOL PSYCH, V88, P542, DOI 10.1037/h0076431; Stein MB, 2013, DEPRESS ANXIETY, V30, P896, DOI 10.1002/da.22196; Taylor JJ, 2013, NEUROPSYCHOPHARMACOL, V38, P1189, DOI 10.1038/npp.2013.13; Taylor JJ, 2012, PAIN, V153, P1219, DOI 10.1016/j.pain.2012.02.030; Troister Talia, 2008, Curr Psychiatry Rep, V10, P60, DOI 10.1007/s11920-008-0011-8; Vollmayr B, 2001, MOL PSYCHIATR, V6, P471, DOI 10.1038/sj.mp.4000907; Young AH, 2013, EVID-BASED MENT HEAL, V16, P112, DOI 10.1136/eb-2013-101493	58	81	85	0	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	MAY-JUN	2014	7	3					421	431		10.1016/j.brs.2014.03.006			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AG9KZ	WOS:000335739400012	24731434				2021-06-18	
J	Ahmadzadeh, H; Smith, DH; Shenoy, VB				Ahmadzadeh, Hossein; Smith, Douglas H.; Shenoy, Vivek B.			Viscoelasticity of Tau Proteins Leads to Strain Rate-Dependent Breaking of Microtubules during Axonal Stretch Injury: Predictions from a Mathematical Model	BIOPHYSICAL JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; IN-VIVO; SODIUM-CHANNELS; TENSION; BINDING; CELLS; TETRODOTOXIN; DEGENERATION; ELASTICITY; MECHANICS	The unique viscoelastic nature of axons is thought to underlie selective vulnerability to damage during traumatic brain injury. In particular, dynamic loading of axons has been shown to mechanically break microtubules at the time of injury. However, the mechanism of this rate-dependent response has remained elusive. Here, we present a microstructural model of the axonal cytoskeleton to quantitatively elucidate the interaction between microtubules and tau proteins under mechanical loading. Mirroring the axon ultrastructure, the nnicrotubules were arranged in staggered arrays, cross-linked by tau proteins. We found that the viscoelastic behavior specifically of tau proteins leads to mechanical breaking of microtubules at high strain rates, whereas extension of tau allows for reversible sliding of microtubules without any damage at small strain rates. Based on the stiffness and viscosity of tau proteins inferred from single-molecule force spectroscopy studies, we predict the critical strain rate for microtubule breaking to be in the range 22-44 s(-1), in excellent agreement with recent experiments on dynamic loading of micropatterned neuronal cultures. We also identified a characteristic length scale for load transfer that depends on microstructural properties and have derived a phase diagram in the parameter space spanned by loading rate and microtubule length that demarcates those regions where axons can be loaded and unloaded reversibly and those where axons are injured due to breaking of the microtubules.	[Ahmadzadeh, Hossein; Shenoy, Vivek B.] Univ Penn, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Shenoy, VB (corresponding author), Univ Penn, Dept Mat Sci & Engn, 3231 Walnut St, Philadelphia, PA 19104 USA.	vshenoy@seas.upenn.edu			National Science FoundationNational Science Foundation (NSF) [NSF-CMMI-1312392]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS R01-038104, NS P01-056202]; Department of DefenseUnited States Department of Defense [PT110785]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202, R01NS038104] Funding Source: NIH RePORTER	This study was supported by National Science Foundation grant No. NSF-CMMI-1312392 (to V.B.S.), by National Institutes of Health grant Nos. NS R01-038104 and NS P01-056202, and by Department of Defense grant No. PT110785 (to D.H.S.).	Ahmadzadeh H, 2013, J BIOMECH, V46, P2497, DOI 10.1016/j.jbiomech.2013.07.008; Baas PW, 2013, BRAIN, V136, P2937, DOI 10.1093/brain/awt153; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Brady S., 2005, BASIC NEUROCHEMISTRY; Burgoyne R. D, 1991, NEURONAL CYTOSKELETO; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Guo HL, 2006, BIOPHYS J, V90, P2093, DOI 10.1529/biophysj.105.071209; Hinrichs MH, 2012, J BIOL CHEM, V287, P38559, DOI 10.1074/jbc.M112.369785; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; Hui O., 2010, MICR UGIM 2010 18 BI, P1; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kawakami M, 2006, BIOPHYS J, V91, pL16, DOI 10.1529/biophysj.106.085019; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Makrides V, 2004, P NATL ACAD SCI USA, V101, P6746, DOI 10.1073/pnas.0400992101; Peter SJ, 2012, BIOPHYS J, V102, P749, DOI 10.1016/j.bpj.2011.11.4024; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Rajagopalan J, 2010, BIOPHYS J, V99, P3208, DOI 10.1016/j.bpj.2010.09.029; Rosenberg KJ, 2008, P NATL ACAD SCI USA, V105, P7445, DOI 10.1073/pnas.0802036105; Saif T., 2010, MRS P; Schaap IAT, 2007, J STRUCT BIOL, V158, P282, DOI 10.1016/j.jsb.2006.11.010; Singh A, 2009, J NEUROTRAUM, V26, P627, DOI 10.1089/neu.2008.0621; Skotak M, 2012, J NEUROSCI METH, V205, P159, DOI 10.1016/j.jneumeth.2012.01.001; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Wang Y, 2011, EPL-EUROPHYS LETT, V96, DOI 10.1209/0295-5075/96/18003; Wegmann S, 2011, J BIOL CHEM, V286, P20512, DOI 10.1074/jbc.M111.237875; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; YU WQ, 1994, J NEUROSCI, V14, P2818	38	81	82	0	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0006-3495	1542-0086		BIOPHYS J	Biophys. J.	MAR 4	2014	106	5					1123	1133		10.1016/j.bpj.2014.01.024			11	Biophysics	Biophysics	AC4OT	WOS:000332501300015	24606936	Bronze, Green Published			2021-06-18	
J	Didehbani, N; Cullum, CM; Mansinghani, S; Conover, H; Hart, J				Didehbani, Nyaz; Cullum, C. Munro; Mansinghani, Sethesh; Conover, Heather; Hart, John, Jr.			Depressive Symptoms and Concussions in Aging Retired NFL Players	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; Depression; Cognition; Aging; Football; NFL	PROFESSIONAL FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; POSTCONCUSSION SYMPTOMS; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; EARLY ADULTHOOD; UNITED-STATES; HIGH-SCHOOL; IMPACT	We examined the relationship between a remote history of concussions with current symptoms of depression in retired professional athletes. Thirty retired National Football League (NFL) athletes with a history of concussion and 29 age-and IQ-matched controls without a history of concussion were recruited. We found a significant correlation between the number of lifetime concussions and depressive symptom severity using the Beck Depression Inventory II. Upon investigating a three-factor model of depressive symptoms (affective, cognitive, and somatic; Buckley et al., 2001) from the BDI-II, the cognitive factor was the only factor that was significantly related to concussions. In general, NFL players endorsed more symptoms of depression on all three Buckley factors compared with matched controls. Findings suggest that the number of self-reported concussions may be related to later depressive symptomology (particularly cognitive symptoms of depression).	[Didehbani, Nyaz; Mansinghani, Sethesh; Conover, Heather; Hart, John, Jr.] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75230 USA; [Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA	Didehbani, N (corresponding author), Ctr BrainHlth, 2200 W Mockingbird Lane, Dallas, TX 75235 USA.	nyaz.didehbani@utdallas.edu	Cullum, C. Munro/AAC-2496-2019	Cullum, C. Munro/0000-0001-9706-5465; Mansinghani, Sethesh/0000-0001-5861-3764; Didehbani, Nyaz/0000-0001-6121-5759	National Institute of Health/National Institute of AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG12300-19]	This work was partially funded by the National Institute of Health/National Institute of Aging (P30 AG12300-19).	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Buckley TC, 2001, J SUBST ABUSE TREAT, V20, P197, DOI 10.1016/S0740-5472(00)00169-0; Casson IR, 2008, NEUROL CLIN, V26, P217, DOI 10.1016/j.ncl.2007.11.005; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Dave D., 2006, SO EC J, V75, P497, DOI 10.2307/27751397; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delis DC, 2000, CALIFORNIA VERBAL LE; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horn S, 2009, AM J PHYS MED REHAB, V88, P192, DOI 10.1097/PHM.0b013e318198b622; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Kaplan E., 1983, BOSTON NAMING TEST; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraut MA, 2006, COGN BEHAV NEUROL, V19, P177, DOI 10.1097/01.wnn.0000213922.41008.22; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Spreen O., 1998, COMPENDIUM NEUROPSYC; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Turner AP, 2000, BRIT J SPORT MED, V34, P332, DOI 10.1136/bjsm.34.5.332; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Weir Dr, 2009, NATL FOOTBALL LEAGUE; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	48	81	82	0	79	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2013	28	5					418	424		10.1093/arclin/act028			7	Psychology, Clinical; Psychology	Psychology	186CN	WOS:000322019600004	23644673	Green Published, Bronze			2021-06-18	
J	Bachstetter, AD; Rowe, RK; Kaneko, M; Goulding, D; Lifshitz, J; Van Eldik, LJ				Bachstetter, Adam D.; Rowe, Rachel K.; Kaneko, Machi; Goulding, Danielle; Lifshitz, Jonathan; Van Eldik, Linda J.			The p38 alpha MAPK Regulates Microglial Responsiveness to Diffuse Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							PROINFLAMMATORY CYTOKINE PRODUCTION; ATTENUATES SYNAPTIC DYSFUNCTION; PROTEIN-KINASE INHIBITOR; MACROSIALIN MOUSE CD68; UP-REGULATION; NEURON DEGENERATION; AXONAL INJURY; IN-VIVO; ACTIVATION; RECEPTOR	Neuropathology after traumatic brain injury (TBI) is the result of both the immediate impact injury and secondary injury mechanisms. Unresolved post-traumatic glial activation is a secondary injury mechanism that contributes to a chronic state of neuroinflammation in both animal models of TBI and human head injury patients. We recently demonstrated, using in vitro models, that p38 alpha MAPK signaling in microglia is a key event in promoting cytokine production in response to diverse disease-relevant stressors and subsequent inflammatory neuronal dysfunction. From these findings, we hypothesized that the p38 alpha signaling pathway in microglia could be contributing to the secondary neuropathologic sequelae after a diffuse TBI. Mice where microglia were p38 alpha-deficient (p38 alpha KO) were protected against TBI-induced motor deficits and synaptic protein loss. In wild-type (WT) mice, diffuse TBI produced microglia morphological activation that lasted for at least 7 d; however, p38 alpha KO mice failed to activate this response. Unexpectedly, we found that the peak of the early, acute phase cytokine and chemokine levels was increased in injured p38 alpha KO mice compared with injured WT mice. The increased cytokine levels in the p38 alpha KO mice could not be accounted for by more infiltration of macrophages or neutrophils, or increased astrogliosis. By 7 d after injury, the cytokine and chemokine levels remained elevated in injured WT mice but not in p38 alpha KO mice. Together, these data suggest that p38 alpha balances the inflammatory response by acutely attenuating the early proinflammatory cytokine surge while perpetuating the chronic microglia activation after TBI.	[Bachstetter, Adam D.; Kaneko, Machi; Goulding, Danielle; Van Eldik, Linda J.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Rowe, Rachel K.; Van Eldik, Linda J.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Rowe, Rachel K.; Van Eldik, Linda J.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85004 USA; [Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ 85004 USA; [Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ 85004 USA	Van Eldik, LJ (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 800 S Limestone, Lexington, KY 40536 USA.	linda.vaneldik@uky.edu		Bachstetter, Adam/0000-0003-4646-6757; Rowe, Rachel/0000-0002-9034-3159	Alzheimer's Association Zenith awardAlzheimer's Association; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS064247, R01 NS065052, R21 NS072611, R01 NS065052-S, F32 AG037280]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, R21NS072611, R01NS064247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F32AG037280] Funding Source: NIH RePORTER	This work was supported in part by the Alzheimer's Association Zenith award to L.J.V.E. and National Institutes of Health Grant R01 NS064247 to L.J.V.E., Grants R01 NS065052, R21 NS072611, and R01 NS065052-S to J.L., and Grant F32 AG037280 to A. D. B. We thank Dr. Huiping Jiang (Boehringer Ingelheim Pharmaceuticals) and Dr. Jiahuai Han (Scripps Research Institute) for the kind gifts of the knock-out mice; and Edgardo Dimayuga, Jordan Harrison, Janna Neltner, and Bin Xing for assistance with various aspects of this work.	Bachstetter AD, 2012, J NEUROSCI, V32, P10201, DOI 10.1523/JNEUROSCI.1496-12.2012; Bachstetter AD, 2010, AGING DIS, V1, P199; Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Clarke S, 1996, P NATL ACAD SCI USA, V93, P1434, DOI 10.1073/pnas.93.4.1434; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Culbert AA, 2006, J BIOL CHEM, V281, P23658, DOI 10.1074/jbc.M513646200; da Silva RP, 1999, BIOCHEM J, V338, P687, DOI 10.1042/bj3380687; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Ferreira R, 2012, J NEUROCHEM, V120, P93, DOI 10.1111/j.1471-4159.2011.07541.x; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Ghasemlou N, 2010, J NEUROSCI, V30, P13750, DOI 10.1523/JNEUROSCI.2998-10.2010; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heinrichsdorff J, 2008, EMBO REP, V9, P1048, DOI 10.1038/embor.2008.149; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Heit B, 2008, NAT IMMUNOL, V9, P743, DOI 10.1038/ni.1623; Hosmane S, 2012, J NEUROSCI, V32, P7745, DOI 10.1523/JNEUROSCI.0203-12.2012; Huang GH, 2012, NAT IMMUNOL, V13, P152, DOI 10.1038/ni.2207; Hume DA, 2011, J LEUKOCYTE BIOL, V89, P525, DOI 10.1189/jlb.0810472; Isfort K, 2011, J BIOL CHEM, V286, P44776, DOI 10.1074/jbc.M111.289793; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kang YJ, 2008, J IMMUNOL, V180, P5075, DOI 10.4049/jimmunol.180.7.5075; Katayama T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040813; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kim C, 2008, NAT IMMUNOL, V9, P1019, DOI 10.1038/ni.1640; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104; Legos JJ, 2001, BRAIN RES, V892, P70, DOI 10.1016/S0006-8993(00)03228-5; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; Mathur RK, 2004, NAT MED, V10, P540, DOI 10.1038/nm1045; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Penninger JM, 2001, NAT IMMUNOL, V2, P389; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; Stirling DP, 2008, NEUROSCIENCE, V155, P128, DOI 10.1016/j.neuroscience.2008.05.007; Sudduth TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031993; Tanaka T, 2009, J BIOL CHEM, V284, P21626, DOI 10.1074/jbc.M109.005603; Thomas T, 2008, J NEUROCHEM, V105, P2039, DOI 10.1111/j.1471-4159.2008.05310.x; Thuraisingam T, 2010, J INVEST DERMATOL, V130, P278, DOI 10.1038/jid.2009.209; Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wang XK, 2002, J BIOL CHEM, V277, P43968, DOI 10.1074/jbc.M206837200; Xing B, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-84; Xu Z, 2006, LIFE SCI, V79, P1895, DOI 10.1016/j.lfs.2006.06.023; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	72	81	85	0	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 3	2013	33	14					6143	6153		10.1523/JNEUROSCI.5399-12.2013			11	Neurosciences	Neurosciences & Neurology	120QP	WOS:000317186800027	23554495	Green Accepted, Bronze, Green Published			2021-06-18	
J	Liu, XQ; Zhou, CL; Li, YJ; Ji, Y; Xu, GP; Wang, XT; Yan, JL				Liu, Xiaoqi; Zhou, Changlong; Li, Yanjing; Ji, Ye; Xu, Gongping; Wang, Xintao; Yan, Jinglong			SDF-1 Promotes Endochondral Bone Repair during Fracture Healing at the Traumatic Brain Injury Condition	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; HEAD-INJURY; ENHANCED OSTEOGENESIS; IN-VITRO; MYOCARDIAL-INFARCTION; MARROW; GROWTH; MIGRATION; MODEL; RATS	Purposes: The objective of this study was to investigate the role of stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, on bone healing and whether SDF-1 contributes to accelerating bone repair in traumatic brain injury (TBI)/fracture model. Materials and Methods: Real-time polymerase chain reaction and immunohistochemical analysis were used to detect the expression of SDF-1 during the repair of femoral bone in TBI/fracture model. The TBI/fracture model was treated with anti-SDF-1 neutralizing antibody or AMD3100, an antagonist for CXCR4, and evaluated by histomorphometry. In vitro and in vivo migration assays were used to evaluate the functional effect of SDF-1 on primary mesenchymal stem cells. Results: The expression of SDF1 and CXCR4 messenger RNA was increased during the bone healing in TBI/fracture model but was less increased in fracture only model. High expression of SDF-1 protein was observed in the surrounding tissue of the damaged bone. Treated with anti-SDF-1 antibody or AMD3100 could inhibit new bone formation. SDF-1 increased mesenchymal stem cell chemotaxis in vitro in a dose-dependent manner. The in vivo migration study demonstrated that mesenchymal stem cells recruited by SDF-1 participate in endochondral bone repair. Conclusion: The SDF-1/CXCR4 axis plays a crucial role in the accelerating fracture healing under the condition of TBI and contributes to endochondral bone repair.	[Liu, Xiaoqi; Zhou, Changlong; Li, Yanjing; Ji, Ye; Xu, Gongping; Wang, Xintao; Yan, Jinglong] Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Harbin, Peoples R China	Yan, JL (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Harbin, Peoples R China.	yanjlhyd@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [100334]	The National Natural Science Foundation of China (100334) (http://www.nsfc.gov.cn/Portal0/default152.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Beeton CA, 2004, J BONE JOINT SURG BR, V86B, P912, DOI 10.1302/0301-620x.86b6.14176; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Castano-Izquierdo H, 2007, J BIOMED MATER RES A, V82A, P129, DOI 10.1002/jbm.a.31082; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Guo ZK, 2006, STEM CELLS, V24, P992, DOI 10.1634/stemcells.2005-0224; HaraIrie F, 1996, BONE, V18, P29, DOI 10.1016/8756-3282(95)00425-4; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003; Khare G N, 1995, Indian J Med Sci, V49, P281; Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283; Kucia M, 2004, BLOOD CELL MOL DIS, V32, P52, DOI 10.1016/j.bcmd.2003.09.025; Liu XQ, 2012, BIOTECHNOL LETT, V34, P387, DOI 10.1007/s10529-011-0757-7; Ma J, 2005, BASIC RES CARDIOL, V100, P217, DOI 10.1007/s00395-005-0521-z; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mori T, 2004, MOL CANCER THER, V3, P29; Otfinowski Janusz, 1993, Patologia Polska, V44, P133; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood-2004-09-3507; SPENCER RF, 1990, S AFR J SURG, V28, P51; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109; Thevenot PT, 2010, BIOMATERIALS, V31, P3997, DOI 10.1016/j.biomaterials.2010.01.144; Tiyapatanaputi P, 2004, J ORTHOP RES, V22, P1254, DOI 10.1016/j.orthres.2004.03.017; Togel F, 2005, KIDNEY INT, V67, P1772, DOI 10.1111/j.1523-1755.2005.00275.x; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; Wieczorek G, 2003, CELL TISSUE RES, V311, P227, DOI 10.1007/s00441-002-0671-3; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Zhang G, 2007, TISSUE ENG, V13, P2063, DOI 10.1089/ten.2006.0013	35	81	88	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2013	8	1							e54077	10.1371/journal.pone.0054077			10	Multidisciplinary Sciences	Science & Technology - Other Topics	077HS	WOS:000314019100041	23349789	DOAJ Gold, Green Published			2021-06-18	
J	Galanaud, D; Perlbarg, V; Gupta, R; Stevens, RD; Sanchez, P; Tollard, E; de Champfleur, NM; Dinkel, J; Faivre, S; Soto-Ares, G; Veber, B; Cottenceau, V; Masson, F; Tourdias, T; Andre, E; Audibert, G; Schmitt, E; Ibarrola, D; Dailler, F; Vanhaudenhuyse, A; Tshibanda, L; Payen, JF; Le Bas, JF; Krainik, A; Bruder, N; Girard, N; Laureys, S; Benali, H; Puybasset, L				Galanaud, Damien; Perlbarg, Vincent; Gupta, Rajiv; Stevens, Robert D.; Sanchez, Paola; Tollard, Eleonore; de Champfleur, Nicolas Menjot; Dinkel, Julien; Faivre, Sebastien; Soto-Ares, Gustavo; Veber, Benoit; Cottenceau, Vincent; Masson, Francoise; Tourdias, Thomas; Andre, Edith; Audibert, Gerard; Schmitt, Emmanuelle; Ibarrola, Danielle; Dailler, Frederic; Vanhaudenhuyse, Audrey; Tshibanda, Luaba; Payen, Jean-Francois; Le Bas, Jean-Francois; Krainik, Alexandre; Bruder, Nicolas; Girard, Nadine; Laureys, Steven; Benali, Habib; Puybasset, Louis		Neuro Imaging Coma Emergence Recov	Assessment of White Matter Injury and Outcome in Severe Brain Trauma A Prospective Multicenter Cohort	ANESTHESIOLOGY			English	Article							DIFFUSE AXONAL INJURY; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC VALUE; HEAD-INJURY; MRI; CLASSIFICATION; PREDICTION; IMPACT; IMAGE; STATE	Background: Existing methods to predict recovery after severe traumatic brain injury lack accuracy. The aim of this study is to determine the prognostic value of quantitative diffusion tensor imaging (DTI). Methods: In a multicenter study, the authors prospectively enrolled 105 patients who remained comatose at least 7 days after traumatic brain injury. Patients underwent brain magnetic resonance imaging, including DTI in 20 preselected white matter tracts. Patients were evaluated at 1 yr with a modified Glasgow Outcome Scale. A composite DTI score was constructed for outcome prognostication on this training database and then validated on an independent database (n = 38). DTI score was compared with the International Mission for Prognosis and Analysis of Clinical Trials Score. Results: Using the DTI score for prediction of unfavorable outcome on the training database, the area under the receiver operating characteristic curve was 0.84 (95% CI: 0.75-0.91). The DTI score had a sensitivity of 64% and a specificity of 95% for the prediction of unfavorable outcome. On the validation-independent database, the area under the receiver operating characteristic curve was 0.80 (95% CI: 0.54-0.94). On the training database, reclassification methods showed significant improvement of classification accuracy (P < 0.05) compared with the International Mission for Prognosis and Analysis of Clinical Trials score. Similar results were observed on the validation database. Conclusions: White matter assessment with quantitative DTI increases the accuracy of long-term outcome prediction compared with the available clinical/radiographic prognostic score.	[Galanaud, Damien] Hop La Pitie Salpetriere, Dept Neurol, F-75013 Paris, France; [Perlbarg, Vincent; Dinkel, Julien] Univ Paris 06, UMRS, INSERM, Paris, France; [Gupta, Rajiv; Benali, Habib] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Div Neurosci Crit Care, Baltimore, MD USA; [Sanchez, Paola] Hop La Pitie Salpetriere, AP HP, Neurosurg Intens Care Unit, Paris, France; [Tollard, Eleonore] CHU, Dept Neuroradiol, Rouen, France; [de Champfleur, Nicolas Menjot] Guy Chauliac Hospi, Dept Neuroradiol, Montpellier, France; [Faivre, Sebastien] Roger Salengro Hosp, Dept Anesthesia, Lille, France; [Faivre, Sebastien] Roger Salengro Hosp, Surg Intens Care Unit, Lille, France; [Soto-Ares, Gustavo] Roger Salengro Hosp, Dept Neuroradiol, Lille, France; [Veber, Benoit] CHU, Surg Intens Care Unit, Rouen, France; [Tourdias, Thomas] CHU, Dept Neuroradiol, Bordeaux, France; [Masson, Francoise] CHU, Dept Anesthesia, Bordeaux, France; [Masson, Francoise] CHU, Surg Intens Care Unit, Bordeaux, France; [Andre, Edith] Guy Chauliac Hosp, Dept Anesthesia, Montpellier, France; [Andre, Edith] Guy Chauliac Hosp, Intens Care Unit, Montpellier, France; [Audibert, Gerard] CHU, Dept Anesthesia, Nancy, France; [Audibert, Gerard] CHU, Surg Intens Care Unit, Nancy, France; [Schmitt, Emmanuelle] CHU, Dept Neuroradiol, Nancy, France; [Ibarrola, Danielle] Pierre Wertheimer Neurol & Neurosurg Hosp, CERMEP, Bron, France; [Dailler, Frederic] Pierre Wertheimer Neurol & Neurosurg Hosp, Surg Intens Care Unit, Lyon, France; [Vanhaudenhuyse, Audrey] Univ Liege, Cyclotron Res Ctr, Liege, Belgium; [Tshibanda, Luaba] Univ Liege, Dept Neuroradiol, Liege, Belgium; [Payen, Jean-Francois] Michallon Hosp, Dept Anesthesia, La Tronche, France; [Payen, Jean-Francois] Michallon Hosp, Surg Intens Care Unit, La Tronche, France; [Krainik, Alexandre] Michallon Hosp, Dept Neuroradiol, La Tronche, France; [Bruder, Nicolas] La Timone Hosp, Dept Anesthesia, Marseille, France; [Bruder, Nicolas] La Timone Hosp, Intens Care Unit, Marseille, France; [Girard, Nadine] La Timone Hosp, Dept Neuroradiol, Marseille, France; [Puybasset, Louis] Hop La Pitie Salpetriere, AP HP, Neurosurg Intens Care Unit, Paris, France	Galanaud, D (corresponding author), Hop La Pitie Salpetriere, Dept Neurol, 47 Blvd Hop, F-75013 Paris, France.	galanaud@gmail.com	Laureys, Steven/AAN-2097-2021; krainik, alexandre/I-2431-2015; Vanhaudenhuyse, Audrey/AAP-2455-2020; Tourdias, Thomas/K-1209-2019; KRAINIK, Alexandre/L-5874-2014; Payen, Jean-Francois/L-6667-2014; Girard, Nadine/B-7109-2017; Sappey-Marinier, Dominique/L-2925-2014; , Girard/E-8537-2013; Laureys, Steven/A-3349-2011	Laureys, Steven/0000-0002-3096-3807; Tourdias, Thomas/0000-0002-7151-6325; Sappey-Marinier, Dominique/0000-0003-4104-1514; , Girard/0000-0001-8639-9275; DOUSSET, VINCENT/0000-0003-0427-3236	French ministry of health, Paris, France [P051061]; "Agence Nationale de la Recherche," Paris FranceFrench National Research Agency (ANR) [ANR-10-IAIHU-06]	This work was funded by a grant from the French ministry of health (ProjetHospitalier de Recherche Clinique registration #P051061 (2005)), Paris, France, and from the "Agence Nationale de la Recherche," Paris France, for the program " investissements d'avenir" under agreement noANR-10-IAIHU-06 for the Paris Institute of Translational Neurosciences-IHU-A-ICM. Other support was provided from institutional and/or departmental sources.	Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Grubb A, 1996, LANCET, V348, P35, DOI 10.1016/S0140-6736(96)02030-2; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mori S., 2005, MRI ATLAS HUMAN WHIT; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Pagani E, 2010, J MAGN RESON IMAGING, V31, P1458, DOI 10.1002/jmri.22186; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Yanagawa Y, 2009, J TRAUMA, V66, P162, DOI 10.1097/TA.0b013e3181469857	32	81	82	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	DEC	2012	117	6					1300	1310		10.1097/ALN.0b013e3182755558			11	Anesthesiology	Anesthesiology	041PY	WOS:000311414900020	23135261	Bronze			2021-06-18	
J	Katz, E; Wang, J; Privman, M; Halamek, J				Katz, Evgeny; Wang, Joseph; Privman, Marina; Halamek, Jan			Multianalyte Digital Enzyme Biosensors with Built-in Boolean Logic	ANALYTICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; BIOMARKER; SIGNALS; SYSTEMS; PROTEIN; GATES		[Katz, Evgeny; Halamek, Jan] Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA; [Wang, Joseph] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA; [Privman, Marina] SUNY Empire State Coll, Ft Drum, NY 13602 USA	Katz, E (corresponding author), Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA.	ekatz@clarkson.edu; josephwang@ucsd.edu	Wang, Joseph/C-6175-2011		Office of Naval ResearchOffice of Naval Research [N00014-08-1-1202]; NSFNational Science Foundation (NSF) [CBET-1066397, CBET-1066531]; Directorate For EngineeringNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1066531] Funding Source: National Science Foundation	This work was supported by the Office of Naval Research (Award #N00014-08-1-1202) and NSF (Awards #CBET-1066397 and #CBET-1066531). The authors thank all students, postdoctoral researchers, and collaborators who made this interesting research possible.	Beutler E, 2008, BLOOD, V111, P16, DOI 10.1182/blood-2007-04-077412; Borisov SM, 2008, CHEM REV, V108, P423, DOI 10.1021/cr068105t; Calude C.S., 2009, LECT NOTES COMPUTER, V5715; Chuang MC, 2011, CHEM COMMUN, V47, P3087, DOI 10.1039/c0cc05716a; CLARK LC, 1962, ANN NY ACAD SCI, V102, P29, DOI 10.1111/j.1749-6632.1962.tb13623.x; Crowther J. R., 2010, ELISA GUIDEBOOK; de Silva AP, 2007, NAT NANOTECHNOL, V2, P399, DOI 10.1038/nnano.2007.188; Ehrenkranz JRL, 2002, EPIDEMIOLOGY, V13, pS15, DOI 10.1097/00001648-200205001-00003; Halamek J, 2011, ANAL CHEM, V83, P8383, DOI 10.1021/ac202139m; Halamek J, 2010, MOL BIOSYST, V6, P2554, DOI 10.1039/c0mb00153h; Halamek J, 2010, ANALYST, V135, P2249, DOI 10.1039/c0an00270d; Halamkova L, 2012, ANALYST, V137, P1768, DOI 10.1039/c2an00014h; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Katz E, 2012, BIOMOLECULAR INFORM; Katz E., 2012, MOL SUPRAMOLECULAR I; Katz E, 2010, CHEM SOC REV, V39, P1835, DOI 10.1039/b806038j; Khalili H, 2011, CLIN GASTROENT-SER, P47, DOI 10.1007/978-1-60761-866-9_3; Kratz A, 2004, NEW ENGL J MED, V351, P1548, DOI 10.1056/NEJMcpc049016; Kumar V, 2011, ANALYST, V136, P5151, DOI 10.1039/c1an15726d; Lee SY, 2010, J NEUROL, V257, P1708, DOI 10.1007/s00415-010-5608-2; LEECH D, 1994, CHEM SOC REV, V23, P205, DOI 10.1039/cs9942300205; Li ZJ, 2011, CHEM COMMUN, V47, P3060, DOI 10.1039/c0cc05037g; Lusczek E.R., 2011, J BIOANAL BIOMED, V3, P038; Margulies D, 2009, J AM CHEM SOC, V131, P9142, DOI 10.1021/ja900848t; May EE, 2008, IEEE SENS J, V8, P1011, DOI 10.1109/JSEN.2008.923945; Melnikov D, 2010, J PHYS CHEM B, V114, P12166, DOI 10.1021/jp105912e; OLERUD JE, 1976, ARCH INTERN MED, V136, P692, DOI 10.1001/archinte.136.6.692; Privman M, 2011, ACS APPL MATER INTER, V3, P1620, DOI 10.1021/am200165m; Privman V, 2011, ISR J CHEM, V51, P118, DOI 10.1002/ijch.201000066; Privman V, 2010, J PHYS CHEM B, V114, P14103, DOI 10.1021/jp108693m; Rafael SP, 2012, ANAL CHEM, V84, P1076, DOI 10.1021/ac202701c; Renneberg R., 2008, SERIES ADV BIOCH ENG; Ronkainen NJ, 2010, CHEM SOC REV, V39, P1747, DOI 10.1039/b714449k; Sassolas A, 2008, CHEM REV, V108, P109, DOI 10.1021/cr0684467; Schena M., 2002, MICROARRAY ANAL; Steinem C., 2010, SERIES SPRINGER SERI; Stojanovic MN, 2002, J AM CHEM SOC, V124, P3555, DOI 10.1021/ja016756v; Stojanovic MN, 2003, NAT BIOTECHNOL, V21, P1069, DOI 10.1038/nbt862; Strack G, 2010, J PHYS CHEM LETT, V1, P839, DOI 10.1021/jz100070u; Tan KK, 2009, INJURY, V40, P978, DOI 10.1016/j.injury.2009.02.023; Vaidya VS, 2010, BIOMARKERS MED DRUG; van Emon JM, 2006, IMMUNOASSAY OTHER BI; von Maltzahn G, 2007, J AM CHEM SOC, V129, P6064, DOI 10.1021/ja070461l; Wang J, 2008, CHEM REV, V108, P814, DOI 10.1021/cr068123a; Wang J, 2010, ANAL BIOANAL CHEM, V398, P1591, DOI 10.1007/s00216-010-3746-0; Warsinke A, 2009, ANAL BIOANAL CHEM, V393, P1393, DOI 10.1007/s00216-008-2572-0; Willner I, 2000, ANGEW CHEM INT EDIT, V39, P1180, DOI 10.1002/(SICI)1521-3773(20000403)39:7<1180::AID-ANIE1180>3.0.CO;2-E; Win MN, 2008, SCIENCE, V322, P456, DOI 10.1126/science.1160311; Zhou JA, 2011, TALANTA, V83, P955, DOI 10.1016/j.talanta.2010.10.057; Zhou M, 2012, ANGEW CHEM INT EDIT, V51, P2686, DOI 10.1002/anie.201107068; Zhou ND, 2011, ANAL CHIM ACTA, V703, P94, DOI 10.1016/j.aca.2011.07.023; Zourob M, 2010, RECOGNITION RECEPTORS IN BIOSENSORS, P415, DOI 10.1007/978-1-4419-0919-0_11	52	81	81	2	60	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	JUL 3	2012	84	13					5463	5469		10.1021/ac3007076			7	Chemistry, Analytical	Chemistry	966XS	WOS:000305871300003	22656194				2021-06-18	
J	Goeller, J; Wardlaw, A; Treichler, D; O'Bruba, J; Weiss, G				Goeller, Jacques; Wardlaw, Andrew; Treichler, Derrick; O'Bruba, Joseph; Weiss, Greg			Investigation of Cavitation as a Possible Damage Mechanism in Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast wave; cavitation; Dynamic System Mechanics Advance Simulation (DYSMAS); improvised explosive device; shock tube tests; traumatic brain injury	MODEL; COLLAPSE; SHELL	Cavitation was investigated as a possible damage mechanism for war-related traumatic brain injury (TBI) due to an improvised explosive device (IED) blast. When a frontal blast wave encounters the head, a shock wave is transmitted through the skull, cerebrospinal fluid (CSF), and tissue, causing negative pressure at the contrecoup that may result in cavitation. Numerical simulations and shock tube experiments were conducted to determine the possibility of cranial cavitation from realistic IED non-impact blast loading. Simplified surrogate models of the head consisted of a transparent polycarbonate ellipsoid. The first series of tests in the 18-inch-diameter shock tube were conducted on an ellipsoid filled with degassed water to simulate CSF and tissue. In the second series, Sylgard gel, surrounded by a layer of degassed water, was used to represent the tissue and CSF, respectively. Simulated blast overpressure in the shock tube tests ranged from a nominal 10-25 pounds per square inch gauge (psig; 69-170 kPa). Pressure in the simulated CSF was determined by Kulite thin line pressure sensors at the coup, center, and contrecoup positions. Using video taken at 10,000 frames/sec, we verified the presence of cavitation bubbles at the contrecoup in both ellipsoid models. In all tests, cavitation at the contrecoup was observed to coincide temporally with periods of negative pressure. Collapse of the cavitation bubbles caused by the surrounding pressure and elastic rebound of the skull resulted in significant pressure spikes in the simulated CSF. Numerical simulations using the DYSMAS hydrocode to predict onset of cavitation and pressure spikes during cavity collapse were in good agreement with the tests. The numerical simulations and experiments indicate that skull deformation is a significant factor causing cavitation. These results suggest that cavitation may be a damage mechanism contributing to TBI that requires future study.	[Goeller, Jacques; Wardlaw, Andrew; Treichler, Derrick; O'Bruba, Joseph] Adv Technol & Res Corp, Columbia, MD 21046 USA; [Weiss, Greg] Appl Res Associates, Littleton, CO USA	Goeller, J (corresponding author), Adv Technol & Res Corp, 6650 Eli Whitney Dr, Columbia, MD 21046 USA.	jgoeller@atrcorp.com					Alley M.D., 2010, EXPT MODELING EXPLOS; Bailey MR, 2003, ACOUST PHYS+, V49, P369, DOI 10.1134/1.1591291; BENJAMIN TB, 1966, PHILOS TR R SOC S-A, V260, P221, DOI 10.1098/rsta.1966.0046; Brands D.W.A., 1999, P 43 STAPP CAR CRASH, P313; Brennen CE, 2002, J FLUID MECH, V472, P153, DOI 10.1017/S0022112002002288; Chafi S.M., 2007, P IMECE2007 NOV; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; ENGIN AE, 1978, AVIAT SPACE ENVIR MD, V49, P120; FROST D, 1986, J HEAT TRANS-T ASME, V108, P418, DOI 10.1115/1.3246940; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; HICKLING R, 1973, J BIOMECH, V6, P115, DOI 10.1016/0021-9290(73)90081-X; HICKLING R, 1964, PHYS FLUIDS, V7, P7, DOI 10.1063/1.1711058; Johnson E., 2006, 2006012368 SAE INT; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Matsumoto Y., 2003, RENAL STONE CO UNPUB; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; SUH C, 1972, J BIOMECH, V5, P181, DOI 10.1016/0021-9290(72)90054-1; van den Bosch E., 2000, DEV IMPROVED DUMMY H; Ward C, 1980, P 24 STAPP CAR CRASH; WARD JW, 1948, SCIENCE, V107, P349, DOI 10.1126/science.107.2779.349; Wardlaw A, 2010, IFMBE PROC, V32, P34, DOI 10.1007/978-3-642-14998-6_9; Wardlaw Jr A., 2002, P 73 SHOCK VIBR S; Wardlaw Jr A.B., 2003, 2500 NSWC IH TR; Young F.R., 1999, CAVITATION, P143; Zhang L., 2004, THEORY PRACTICE FINA, V126; Ziejewski M., 2009, 21 INT TECHN C ENH S; Ziejewski M., 2007, BRAIN INJ PROF, V4, P10	32	81	85	3	58	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1970	1981		10.1089/neu.2011.2224			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400399	22489674				2021-06-18	
J	Bauer, RM; Iverson, GL; Cernich, AN; Binder, LM; Ruff, RM; Naugle, RI				Bauer, Russell M.; Iverson, Grant L.; Cernich, Alison N.; Binder, Laurence M.; Ruff, Ronald M.; Naugle, Richard I.			Computerized Neuropsychological Assessment Devices: Joint Position Paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology	CLINICAL NEUROPSYCHOLOGIST			English	Article						Computerized testing; neurocognition; neuropsychological test validity	MILD COGNITIVE IMPAIRMENT; TEST-RETEST RELIABILITY; BRAIN-INJURY; PSYCHOLOGICAL-ASSESSMENT; MOOD DISORDERS; CATEGORY TEST; TEST-SCORES; IRAQ-WAR; CONCUSSION; BATTERY	This joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology sets forth our position on appropriate standards and conventions for computerized neuropsychological assessment devices (CNADs). In this paper, we first define CNADs and distinguish them from examiner-administered neuropsychological instruments. We then set forth position statements on eight key issues relevant to the development and use of CNADs in the healthcare setting. These statements address (a) device marketing and performance claims made by developers of CNADs; (b) issues involved in appropriate end-users for administration and interpretation of CNADs; (c) technical (hardware/software/firmware) issues; (d) privacy, data security, identity verification, and testing environment; (e) psychometric development issues, especially reliability and validity; (f) cultural, experiential, and disability factors affecting examinee interaction with CNADs; (g) use of computerized testing and reporting services; and (h) the need for checks on response validity and effort in the CNAD environment. This paper is intended to provide guidance for test developers and users of CNADs that will promote accurate and appropriate use of computerized tests in a way that maximizes clinical utility and minimizes risks of misuse. The positions taken in this paper are put forth with an eye toward balancing the need to make validated CNADs accessible to otherwise underserved patients with the need to ensure that such tests are developed and utilized competently, appropriately, and with due concern for patient welfare and quality of care.	[Bauer, Russell M.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; [Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Cernich, Alison N.] VA Maryland Hlth Care Syst, Baltimore, MD USA; [Binder, Laurence M.] Oregon Hlth & Sci Univ, Portland, OR USA; [Ruff, Ronald M.] San Francisco Clin Neurosci, San Francisco, CA USA; [Naugle, Richard I.] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Bauer, Russell M.; Cernich, Alison N.; Naugle, Richard I.] Amer Acad Clin Neuropsychol, Ann Arbor, MI USA; [Iverson, Grant L.; Binder, Laurence M.; Ruff, Ronald M.] Natl Acad Neuropsychol, Ann Arbor, MI USA	Bauer, RM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, POB 100165 HSC, Gainesville, FL 32610 USA.	rbauer@phhp.ufl.edu		Iverson, Grant/0000-0001-7348-9570	University of FloridaUniversity of Florida [UL1 RR029890]; Canadian government; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029890] Funding Source: NIH RePORTER	Russell M. Bauer, Ph.D. is supported in part by grants UL1 RR029890 to the University of Florida. Grant Iverson has led or been a member of research teams that have received grant funding from test publishing companies, the pharmaceutical industry, and the Canadian government to study the psychometrics of computerized and traditional neuropsychological tests. These companies include AstraZeneca Canada, Lundbeck Canada, Pfizer Canada, ImPACT Applications, Inc., CNS Vital Signs, Psychological Assessment Resources (PAR, Inc.), and the Canadian Institute of Health Research. He is also a co-author on a test published by PAR, Inc. Alison Cernich's views are her own and do not necessarily represent the views of the Department of Veteran's Affairs (VA). The VA had no role in the writing of the article or the decision to submit it for publication. Ronald Ruff has published four tests with Psychological Assessment Resources, Inc. Laurence Binder is the author and publisher of the Portland Digit Recognition Test.	*AM PSYCH ASS, 1986, GUID COMP BAS TESTS; American Psychiatric Association, 1999, STAND ED PSYCH TEST; Anger WK, 1999, J INT NEUROPSYCH SOC, V5, P203, DOI 10.1017/S1355617799533031; [Anonymous], 2007, AM PSYCHOL, V62, P993, DOI 10.1037/0003-066X.62.9.993; APA, 2010, ETH PRINC PSYCH COD; Berger SG, 1997, J CLIN PSYCHOL, V53, P723; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bolfer C, 2010, ARQ NEURO-PSIQUIAT, V68, P282, DOI 10.1590/S0004-282X2010000200025; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brooks BL, 2010, APPL NEUROPSYCHOL, V17, P37, DOI 10.1080/09084280903526083; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Campbell KA, 1999, ASSESSMENT, V6, P21, DOI 10.1177/107319119900600103; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Chamberlain SR, 2011, BIOL PSYCHIAT, V69, P1192, DOI 10.1016/j.biopsych.2010.08.019; Choca J., 1992, CLIN NEUROPSYCHOL, V6, P9, DOI [10.1080/13854049208404112, DOI 10.1080/13854049208404112]; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; CREEGER CP, 1990, BEHAV RES METH INSTR, V22, P34, DOI 10.3758/BF03203120; Cronbach L. J., 1971, ED MEASUREMENT, P443, DOI DOI 10.1037/14353-009; Crook T. H., 2009, NEUROPSYCHOLOGICAL A, P84; Doniger Glen M., 2005, Current Alzheimer Research, V2, P117; Doniger Glen M, 2006, Am J Alzheimers Dis Other Demen, V21, P28; Dorion AA, 2002, NEUROPSYCHOLOGIA, V40, P946, DOI 10.1016/S0028-3932(01)00150-6; Downing S, 2006, HDB TEST DEV; Dwolatzky T, 2004, J MOL NEUROSCI, V24, P33, DOI 10.1385/JMN:24:1:033; Feldstein SN, 1999, CLIN NEUROPSYCHOL, V13, P303, DOI 10.1076/clin.13.3.303.1744; Forster KI, 2003, BEHAV RES METH INS C, V35, P116, DOI 10.3758/BF03195503; Franzen M. D., 1989, RELIABILITY VALIDITY; Franzen MD, 2000, RELIABILITY VALIDITY, V2nd; Gaver W. W., 1991, CHI 1991 P SIGCHI C; Gofen A, 1997, SPATIAL VISION, V10, P361, DOI 10.1163/156856897X00285; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Gualtieri C Thomas, 2006, J Atten Disord, V9, P534, DOI 10.1177/1087054705283758; Gualtieri C Thomas, 2005, Am J Alzheimers Dis Other Demen, V20, P359; Gualtieri C Thomas, 2008, Medscape J Med, V10, P90; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hitchcock E, 2006, TOP STROKE REHABIL, V13, P22, DOI 10.1310/0HWA-DJN8-JUPC-GET1; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2011, J AFFECT DISORDERS, V132, P360, DOI 10.1016/j.jad.2011.03.001; Iverson GL, 2009, J CLIN EXP NEUROPSYC, V31, P594, DOI 10.1080/13803390802372125; KRAMER JJ, 1987, AM PSYCHOL, V42, P889, DOI 10.1037/0003-066X.42.9.889.b; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Matarazzo J. D., 1985, Computers in Human Behaviour, V1, P235, DOI 10.1016/0747-5632(85)90015-9; MATARAZZO JD, 1986, AM PSYCHOL, V41, P96; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; MCINNES WJ, 2001, BEHAV RES METH INSTR, V31, P129; Mclay R, 2010, MIL MED, V175, P945, DOI 10.7205/MILMED-D-09-00237; Messick S., 1989, ED MEASUREMENT, V3, P13, DOI DOI 10.7203/RELIEVE.22.1.8248; Mitrushina M., 2005, HDB NORMATIVE DATA N; Moore JL, 2002, EPILEPSY BEHAV, V3, P92, DOI 10.1006/ebeh.2001.0313; Myors B, 1999, BEHAV RES METH INS C, V31, P322, DOI 10.3758/BF03207727; Naglieri JA, 2004, AM PSYCHOL, V59, P150, DOI 10.1037/0003-066X.59.3.150; Newman TB, 2009, EVIDENCE-BASED DIAGNOSIS, P1, DOI 10.1017/CBO9780511759512; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; OZONOFF D, 1995, LANCET, V346, P860, DOI 10.1016/S0140-6736(95)92706-9; PEDHAZER EJ, 1991, MEASUREMENT DESIGN A; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Plant RR, 2009, BEHAV RES METHODS, V41, P598, DOI 10.3758/BRM.41.3.598; Plant RR, 2004, BEHAV RES METH INS C, V36, P291, DOI 10.3758/BF03195575; Polderman TJC, 2011, CHILD NEUROPSYCHOL, V17, P138, DOI 10.1080/09297049.2010.518142; Raymond PD, 2006, EUR J CARDIO-THORAC, V29, P82, DOI 10.1016/j.ejcts.2005.10.016; Reise SP, 2009, ANNU REV CLIN PSYCHO, V5, P27, DOI 10.1146/annurev.clinpsy.032408.153553; Retzlaff P. D., 2000, CLIN GUIDE NEUROPSYC, P277; Retzlaff PD, 1999, MIL MED, V164, P514; Slick DJ, 2003, CLIN NEUROPSYCHOL, V17, P390, DOI 10.1076/clin.17.3.390.18090; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Sweeney JA, 2000, BIOL PSYCHIAT, V48, P674, DOI 10.1016/S0006-3223(00)00910-0; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Thomas ML, 2011, ASSESSMENT, V18, P291, DOI 10.1177/1073191110374797; Tien Allen Y., 1996, Kaohsiung Journal of Medical Sciences, V12, P479; Tornatore JB, 2005, J NEUROPSYCH CLIN N, V17, P98, DOI 10.1176/appi.neuropsych.17.1.98; Urbina S., 2004, ESSENTIALS PSYCHOL T; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Wild K, 2008, ALZHEIMERS DEMENT, V4, P428, DOI 10.1016/j.jalz.2008.07.003; Wouters H, 2009, DEMENT GERIATR COGN, V28, P486, DOI 10.1159/000250593; Wouters H, 2009, INT J METH PSYCH RES, V18, P118, DOI 10.1002/mpr.283	86	81	83	2	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	2					177	196		10.1080/13854046.2012.663001			20	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	936EO	WOS:000303573900001	22394228	Green Accepted			2021-06-18	
J	Gavett, BE; Cantu, RC; Shenton, M; Lin, AP; Nowinski, CJ; McKee, AC; Stern, RA				Gavett, Brandon E.; Cantu, Robert C.; Shenton, Martha; Lin, Alexander P.; Nowinski, Christopher J.; McKee, Ann C.; Stern, Robert A.			Clinical appraisal of chronic traumatic encephalopathy: current perspectives and future directions	CURRENT OPINION IN NEUROLOGY			English	Article						biomarkers; chronic traumatic encephalopathy; concussion; dementia; traumatic brain injury	MAGNETIC-RESONANCE SPECTROSCOPY; PROFESSIONAL FOOTBALL PLAYERS; LIST LEARNING TEST; BRAIN-INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; OLFACTORY DYSFUNCTION; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION	Purpose of review There are currently no consensus-based clinical diagnostic criteria for chronic traumatic encephalopathy (CTE). This review provides an update on recent literature pertaining to clinically relevant procedures that - presently or in the future - may be useful for the in-vivo detection, characterization, and/or prediction of CTE. Recent findings Preliminary evidence about the clinical manifestations of CTE has been accumulating via post-mortem medical record review and interviews of friends or family members of individuals with neuropathologically documented CTE. This evidence suggests that CTE is manifested clinically by changes in cognition (especially memory and executive functioning, with dementia later in the disease course), mood (especially, depression, apathy, and suicidality), personality and behavior (especially poor impulse control and behavioral disinhibition), and movement (including parkinsonism and signs of motor neuron disease). At the present time, evidence regarding CTE has not been confirmed in a prospective study of a cohort at risk for CTE. Summary On the basis of recent research in the fields of dementia and traumatic brain injury, several in-vivo procedures (including neurological examination, neuropsychological assessment, neuroimaging techniques, and blood and cerebrospinal fluid biomarkers) each have the potential to contribute unique information about the manifestations of CTE, including clinical and preclinical stages. More research is needed to develop a set of consensus diagnostic criteria that provide a reliable and valid indicator of neuropathologically verified CTE. Until such criteria are developed, the clinical assessment of CTE should be informed by modern research that is of relevance to traumatic brain injury and neurodegenerative diseases.	[Stern, Robert A.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Shenton, Martha; Lin, Alexander P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [McKee, Ann C.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Gavett, Brandon E.] Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA	Stern, RA (corresponding author), Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, 72 E Concord St,B-7380, Boston, MA 02118 USA.	bobstern@bu.edu	, Bob/ABA-8507-2020; Shenton, Martha/V-8780-2019	Stern, Robert/0000-0002-5008-077X; Gavett, Brandon/0000-0003-1938-1854	Boston University Alzheimer's Disease Center NIA [P30 AG13846]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078337]; VA Biorepository [CSP 501]; Department of Veterans AffairsUS Department of Veterans Affairs; Sports Legacy Institute; National Operating Committee on Standards for Athletic Equipment; National Football League; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	The study was supported by the Boston University Alzheimer's Disease Center NIA P30 AG13846, supplement 0572063345-5; NIH R01NS078337; the VA Biorepository (CSP 501), funded by the Department of Veterans Affairs; the Sports Legacy Institute; the National Operating Committee on Standards for Athletic Equipment; and by an un-restricted gift from the National Football League.	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brown W S, 1982, Bull Los Angeles Neurol Soc, V47, P91; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Collet S, 2009, B-ENT, P97; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/j.1469-8986.1981.tb01815.x; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Fodero-Tavoletti MT, 2011, BRAIN, V134, P1089, DOI 10.1093/brain/awr038; Galvin JE, 2011, NEUROLOGY, V76, P1797, DOI 10.1212/WNL.0b013e31821ccc83; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, J INT NEUROPSYCH SOC, V16, P651, DOI 10.1017/S1355617710000421; Gavett BE, 2009, J INT NEUROPSYCH SOC, V15, P121, DOI 10.1017/S1355617708090176; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampel H, 2010, EXP GERONTOL, V45, P30, DOI 10.1016/j.exger.2009.10.010; Haschke M, 2007, CLIN CHEM, V53, P489, DOI 10.1373/clinchem.2006.078972; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; HOMBERG V, 1986, ELECTROEN CLIN NEURO, V63, P552, DOI 10.1016/0013-4694(86)90143-4; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jagust WJ, 2009, NEUROLOGY, V73, P1193, DOI 10.1212/WNL.0b013e3181bc010c; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; KRAMER AF, 1988, BIOL PSYCHOL, V26, P231, DOI 10.1016/0301-0511(88)90022-1; Lin A., 2010, NEUROCHEMICAL CHANGE; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; ODONNELL BF, 1987, BIOL PSYCHOL, V24, P23, DOI 10.1016/0301-0511(87)90097-4; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P138, DOI 10.1016/0013-4694(86)90007-6; POLICH J, 1987, ELECTROEN CLIN NEURO, V68, P311, DOI 10.1016/0168-5597(87)90052-9; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Sandford AA, 2006, INT J PEDIATR OTORHI, V70, P1015, DOI 10.1016/j.ijporl.2005.10.013; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Sperling RA, 2010, NEUROMOL MED, V12, P27, DOI 10.1007/s12017-009-8109-7; Stern RA, 2011, WILEY-BL HB BEHAV SC, P369; Talavage T. M., 2010, J NEUROTRAUMA; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vanderstichele H, 2008, BIOMARKERS EARLY DIA, P81; Vemuri P, 2009, NEUROLOGY, V73, P294, DOI 10.1212/WNL.0b013e3181af79fb; Vent J, 2010, BRAIN RES, V1320, P1, DOI 10.1016/j.brainres.2010.01.007; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wu AP, 2008, AM J RHINOL, V22, P606, DOI 10.2500/ajr.2008.22.3238; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075	61	81	81	2	47	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2011	24	6					525	531		10.1097/WCO.0b013e32834cd477			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	845VC	WOS:000296850900002	22045219				2021-06-18	
J	Schatz, P; Moser, RS; Covassin, T; Karpf, R				Schatz, Philip; Moser, Rosemarie Scolaro; Covassin, Tracey; Karpf, Robin			Early Indicators of Enduring Symptoms in High School Athletes With Multiple Previous Concussions	NEUROSURGERY			English	Article						Concussion symptoms; Long-term effects; Post-Concussion Symptom Scale; Postconcussion syndrome	CHRONIC TRAUMATIC ENCEPHALOPATHY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; RISK; RECOVERY; PLAY	BACKGROUND: Despite recent findings of cognitive, emotional, physical, and behavioral symptomatology in retired professional athletes with a history of multiple concussions, there is little systematic research examining these symptoms in high school athletes with a history of concussion. OBJECTIVE: To identify cognitive, emotional, and physical symptoms at baseline in nonconcussed high school athletes based on concussion history. METHODS: A multicenter sample of 616 high school athletes who completed baseline evaluations were assigned to groups based on history of concussion (none, 1, 2, or more previous concussions). The Post-Concussion Symptom Scale was administered as part of a computerized neuropsychological test battery during athletes' preseason baseline evaluations. Cross-sectional analyses were used to examine symptoms reported at the time of baseline neuropsychological testing. RESULTS: High school athletes with a history of 2 or more concussions showed significantly higher ratings of concussion-related symptoms (cognitive, physical, sleep difficulties) than athletes with a history of one or no previous concussions. CONCLUSION: It appears that youth athletes who sustain multiple concussions experience a variety of subtle effects, which may be possible precursors of the future onset of concussion-related difficulties.	[Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Schatz, Philip; Moser, Rosemarie Scolaro] Int Brain Res Fdn, Edison, NJ USA; [Moser, Rosemarie Scolaro] RSM Psychol Ctr LLC, Sports Concuss Ctr New Jersey, Lawrenceville, NJ USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Karpf, Robin] Lawrenceville Sch, Lawrenceville, NJ USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			Center BUAsD, 2010, SEL CSTE CAS 18 YEAR; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Olian C, 2009, STUDY LINKS CONCUSSI; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pardini D., 2004, BR J SPORTS MED, V38, P661; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Schwarz A, 2008, NY TIMES        0924; Schwarz A, 2010, NFL DON 1 MILL DOLL; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	26	81	81	1	31	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2011	68	6					1562	1567		10.1227/NEU.0b013e31820e382e			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	760CK	WOS:000290299700049	21258259	Bronze			2021-06-18	
J	Liesemer, K; Bratton, SL; Zebrack, CM; Brockmeyer, D; Statler, KD				Liesemer, Kate; Bratton, Susan L.; Zebrack, C. Michelle; Brockmeyer, Douglas; Statler, Kimberly D.			Early Post-Traumatic Seizures in Moderate to Severe Pediatric Traumatic Brain Injury: Rates, Risk Factors, and Clinical Features	JOURNAL OF NEUROTRAUMA			English	Article						CT scanning; epilepsy; pediatric brain injury; secondary insult	HEAD-INJURY; CHILDREN; PREDICTORS	We performed a retrospective, observational study at a level I pediatric trauma center of children with moderate-to-severe traumatic brain injury (TBI) from January 2002 to September 2006 to identify clinical and radiographic risk factors for early post-traumatic seizures (EPTS). Two hundred and ninety-nine children ages 0-15 years were evaluated, with 24 excluded because they died before the initial head computed tomography (CT) was obtained (n=20), or because their medical records were missing (n=4). Records were reviewed for accident characteristics, pre-hospital hypoxia or hypotension, initial non-contrast head CT characteristics, seizure occurrence, antiepileptic drug (AED) administration, and outcome. All care was at the discretion of the treating physicians, including the use of AEDs and continuous electroencephalogram (EEG) monitoring in patients receiving neuromuscular blocking agents. The primary outcome was seizure activity during the first 7 days as determined by clinician observation or EEG analysis. Of the 275 patients included in the study, 34 had identified EPTS (12%). Risk factors identified on bivariable analysis included pre-hospital hypoxia, young age, nonaccidental trauma (NAT), severe TBI, impact seizure, and subdural hemorrhage, while receiving an AED was protective. Independent risk factors identified by multivariable analysis were age <2 years (OR 3.0 [95% CI 1.0,8.6]), Glasgow Coma Scale (GCS) score <= 8 (OR 8.7 [95% CI 1.1,67.6]), and NAT as a mechanism of injury (OR 3.4 [95% CI 1.0,11.3]). AED treatment was protective against EPTS (OR 0.2 [95% CI 0.07,0.5]). Twenty-three (68%) patients developed EPTS within the first 12 h post-injury. This early peak in EPTS activity and demonstrated protective effect of AED administration in this cohort suggests that to evaluate the maximal potential benefit among patients at increased risk for EPTS, future research should be randomized and prospective, and should intervene during pre-trauma center care with initiation of continuous EEG monitoring as soon as possible.	[Liesemer, Kate; Bratton, Susan L.] Univ Utah, Sch Med, Salt Lake City, UT 84118 USA; [Liesemer, Kate; Bratton, Susan L.; Statler, Kimberly D.] Primary Childrens Med Ctr, Dept Pediat, Div Crit Care Med, Salt Lake City, UT 84118 USA; [Zebrack, C. Michelle] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Zebrack, C. Michelle] Lucile Packard Childrens Hosp, Div Cardiol & Cardiovasc Intens Care Med, Palo Alto, CA USA; [Brockmeyer, Douglas] Primary Childrens Med Ctr, Dept Pediat, Div Neurosurg, Salt Lake City, UT 84118 USA	Liesemer, K (corresponding author), Univ Utah, Sch Med, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84118 USA.	Kate.Liesemer@utah.edu		Bratton, Susan/0000-0002-4605-8078			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Bruce D A, 1990, Curr Probl Pediatr, V20, P61; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Faul M.D., 2010, TRAUMATIC BRAIN INJU; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006	21	81	89	1	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					755	762		10.1089/neu.2010.1518			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100276	21381863				2021-06-18	
J	Clayton, EH; Garbow, JR; Bayly, PV				Clayton, E. H.; Garbow, J. R.; Bayly, P. V.			Frequency-dependent viscoelastic parameters of mouse brain tissue estimated by MR elastography	PHYSICS IN MEDICINE AND BIOLOGY			English	Article							MAGNETIC-RESONANCE-ELASTOGRAPHY; ACOUSTIC STRAIN WAVES; HEPATIC-FIBROSIS; HUMAN HEART; VISUALIZATION; ELASTICITY; PROSTATE; MODULUS; LIVER; MODEL	Viscoelastic properties of mouse brain tissue were estimated non-invasively, in vivo, using magnetic resonance elastography (MRE) at 4.7 T to measure the dispersive properties of induced shear waves. Key features of this study include (i) the development and application of a novelMR-compatible actuation system which transmits vibratory motion into the brain through an incisor bar, and (ii) the investigation of the mechanical properties of brain tissue over a 1200 Hz bandwidth from 600-1800 Hz. Displacement fields due to propagating shear waves were measured during continuous, harmonic excitation of the skull. This protocol enabled characterization of the true steady-state patterns of shear wave propagation. Analysis of displacement fields obtained at different frequencies indicates that the viscoelastic properties of mouse brain tissue depend strongly on frequency. The average storage modulus (G') increased from approximately 1.6 to 8 kPa over this range; average loss modulus (G '') increased from approximately 1 to 3 kPa. Both moduli were well approximated by a power-law relationship over this frequency range. MRE may be a valuable addition to studies of disease in murine models, and to pre-clinical evaluations of therapies. Quantitative measurements of the viscoelastic parameters of brain tissue at high frequencies are also valuable for modeling and simulation of traumatic brain injury.	[Clayton, E. H.; Bayly, P. V.] Washington Univ, Dept Mech Engn & Mat Sci, St Louis, MO 63130 USA; [Bayly, P. V.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA; [Garbow, J. R.] Washington Univ, Dept Radiol, Biomed Magnet Resonance Lab, St Louis, MO 63110 USA	Clayton, EH (corresponding author), Washington Univ, Dept Mech Engn & Mat Sci, 1 Brookings Dr,Campus Box 1185, St Louis, MO 63130 USA.	clayton@wustl.edu; garbow@wustl.edu; pvb@wustl.edu	Clayton, Erik/A-9263-2012	Bayly, Philip/0000-0003-4303-0704	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS055951]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	Financial support was provided by NIH RO1 NS055951 (Bayly). Dr Mark Conradi supported MR Tx/Rx coil development. Special thanks to colleagues in the Biomedical Magnetic Resonance Laboratory at Washington University for additional assistance. Numerical simulations performed in this study were made	Asbach P, 2008, MAGN RESON MED, V60, P373, DOI 10.1002/mrm.21636; Beltzer AI, 1988, ACOUSTICS SOLIDS; Chopra R, 2009, MAGN RESON MED, V62, P665, DOI 10.1002/mrm.22038; CLAYTON EH, 2010, P INT SOC MAGN RES M, P3400; Diguet E., 2009, P 17 ISMRM C, P714; Elgeti T, 2008, INVEST RADIOL, V43, P762, DOI 10.1097/RLI.0b013e3181822085; Flugge W., 1975, VISCOELASTICITY; Garbow JR, 2008, CONCEPT MAGN RESON B, V33B, P252, DOI 10.1002/cmr.b.20124; Hackbusch W., 1985, MULTIGRID METHODS AP; Hamhaber U, 2007, ACTA BIOMATER, V3, P127, DOI 10.1016/j.actbio.2006.08.007; Kemper J, 2004, ROFO-FORTSCHR RONTG, V176, P1094, DOI 10.1055/s-2004-813279; Kolipaka A, 2010, MAGN RESON MED, V64, P862, DOI 10.1002/mrm.22467; Kolsky H., 1963, STRESS WAVES SOLIDS; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Litwiller DV, 2010, J MAGN RESON IMAGING, V32, P44, DOI 10.1002/jmri.22217; Lockett F.J., 1972, NONLINEAR VISCOELAST; Madsen EL, 2008, PHYS MED BIOL, V53, P5313, DOI 10.1088/0031-9155/53/19/004; Manduca A, 2001, MED IMAGE ANAL, V5, P237, DOI 10.1016/S1361-8415(00)00039-6; MURPHY MC, 2010, P INT SOC MAGN RES M, P2360; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Muthupillai R, 1996, MAGN RESON MED, V36, P266, DOI 10.1002/mrm.1910360214; ODONNELL M, 1981, J ACOUST SOC AM, V69, P696, DOI 10.1121/1.385566; Pattison AJ, 2010, J BIOMECH, V43, P2747, DOI 10.1016/j.jbiomech.2010.06.008; Plewes DB, 2000, PHYS MED BIOL, V45, P1591, DOI 10.1088/0031-9155/45/6/314; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Pritz T, 1999, J SOUND VIB, V228, P1145, DOI 10.1006/jsvi.1999.2495; Robert B, 2009, MAGN RESON MED, V62, P1155, DOI 10.1002/mrm.22124; Romano AJ, 2005, MAGN RESON MED, V54, P893, DOI 10.1002/mrm.20607; Rouviere O, 2006, RADIOLOGY, V240, P440, DOI 10.1148/radiol.2402050606; Sack I, 2009, MAGN RESON MED, V61, P668, DOI 10.1002/mrm.21878; SCHREGEL K, 2010, P INT SOC MAGN RES M, P2134; Sinkus R, 2005, MAGN RESON IMAGING, V23, P159, DOI 10.1016/j.mri.2004.11.060; Sinkus R, 2005, MAGNET RESON MED, V53, P372, DOI 10.1002/mrm.20355; Wuerfel J, 2010, NEUROIMAGE, V49, P2520, DOI 10.1016/j.neuroimage.2009.06.018; Yin M, 2007, CLIN GASTROENTEROL H, V5, P1207, DOI 10.1016/j.cgh.2007.06.012; Yin M, 2007, MAGN RESON MED, V58, P346, DOI 10.1002/mrm.21286	36	81	81	0	13	IOP PUBLISHING LTD	BRISTOL	DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND	0031-9155			PHYS MED BIOL	Phys. Med. Biol.	APR 21	2011	56	8					2391	2406		10.1088/0031-9155/56/8/005			16	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Engineering; Radiology, Nuclear Medicine & Medical Imaging	749PL	WOS:000289480700006	21427486	Green Accepted			2021-06-18	
J	Cooper, DB; Kennedy, JE; Cullen, MA; Critchfield, EN; Amador, RR; Bowles, AO				Cooper, Douglas B.; Kennedy, Jan E.; Cullen, Maren A.; Critchfield, Eda. N.; Amador, Ricardo R.; Bowles, Amy O.			Association between combat stress and post-concussive symptom reporting in OEF/OIF service members with mild traumatic brain injuries	BRAIN INJURY			English	Article						Mild traumatic brain injury; blast injury; post-traumatic stress disorder; post-concussion syndrome	POSTCONCUSSION SYNDROME; PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; BASE RATES; DISORDER; IRAQ; AFGHANISTAN; VETERANS; CRITERIA	Objective: The relationship between combat stress and post-concussive symptoms in service members with mild traumatic brain injuries (mTBI) is poorly understood. It was hypothesized that the co-occurrence of combat stress would have a significant effect on the severity of post-concussive complaints, specifically on emotional and cognitive symptoms. Methods: Four hundred and seventy-two combat-deployed service members with mTBI completed self-report inventories of post-traumatic stress and post-concussive symptoms. Two groups were formed based on post-traumatic stress symptoms (High Combat Stress and Low Combat Stress). Results: A 3-8-fold increase in post-concussive symptoms was observed when comparing the High and Low Combat Stress Groups. Elevations in post-concussive symptom reporting were not limited to emotional and/or cognitive symptoms, but rather were inclusive of all measured post-concussive symptoms. Conclusions: The findings of the present study suggest that non-brain injury-related factors, such as high-levels of combat stress, may impact post-concussive symptom reporting in this population, further confounding the accuracy of the post-concussion syndrome (PCS) diagnosis. Considerable caution should be exercised in making the diagnosis of PCS in concussed service members with co-occurring combat-stress disorders.	[Cooper, Douglas B.] Brooke Army Med Ctr, MCHE DOR TBI, Traumat Brain Injury Serv, Dept Orthoped & Rehabil, Ft Sam Houston, TX 78234 USA; [Kennedy, Jan E.; Cullen, Maren A.; Amador, Ricardo R.] Brooke Army Med Ctr, Def & Vet Brain Injury Ctr, Ft Sam Houston, TX 78234 USA	Cooper, DB (corresponding author), Brooke Army Med Ctr, MCHE DOR TBI, Traumat Brain Injury Serv, Dept Orthoped & Rehabil, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	douglas.cooper2@amedd.army.mil					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; *DEF VET BRAIN INJ, 2008, OP IR FREED OIF OP E; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Interian A, 2004, PSYCHOSOM MED, V66, P141, DOI 10.1097/01.PSY.0000107883.14385.EC; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Lange RT, 2008, CLIN NEUROPSYCHOL, V22, P209, DOI 10.1080/13854040701290062; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCrea M, 2008, MILD TRAUMATIC BRAIN; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Powell GE, 2008, J NEUROL NEUROSUR PS, V79, P237, DOI 10.1136/jnnp.2007.131722; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; TABER KH, 2009, J NEUROPSYCH CLIN N, V21, pR4; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	25	81	82	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2011	25	1					1	7		10.3109/02699052.2010.531692			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700001	21117916				2021-06-18	
J	Tan, M; Zhu, JC; Du, J; Zhang, LM; Yin, HH				Tan, Min; Zhu, Jing-Ci; Du, Jiang; Zhang, Li-Mei; Yin, Hua-Hua			Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic brain-injured patients: a prospective randomized pilot study	CRITICAL CARE			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; NOSOCOMIAL INFECTIONS; DOUBLE-BLIND; SYNBIOTICS; BACTERIA; PROPHYLAXIS; PREBIOTICS; THERAPY	Introduction: Traumatic brain injury (TBI) is associated with a profound immunological dysfunction manifested by a severe shift from T-helper type 1 (Th1) to T-helper type 2 (Th2) response. This predisposes patients to infections, sepsis, and adverse outcomes. Probiotic bacteria have been shown to balance the Th1/Th2 cytokines in allergic murine models and patients. For the present study, we hypothesized that the enteral administration of probiotics would adjust the Th1/Th2 imbalance and improve clinical outcomes in TBI patients. Methods: We designed a prospective, randomized, single-blind study. Patients with severe TBI and Glasgow Coma Scale scores between 5 and 8 were included, resulting in 26 patients in the control group and 26 patients in the probiotic group. All patients received enteral nutrition via a nasogastric tube within 24 to 48 hours following admission. In addition, the probiotic group received 10(9) bacteria of viable probiotics per day for 21 days. The associated serum levels of Th1/Th2 cytokines, Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores, nosocomial infections, length of ICU stay, and 28-day mortality rate were studied. Results: The patients responded to viable probiotics, and showed a significantly higher increase in serum IL-12p70 and IFN gamma levels while also experiencing a dramatic decrease in IL-4 and IL-10 concentrations. APACHE II and SOFA scores were not significantly affected by probiotic treatment. Patients in the probiotic group experienced a decreased incidence of nosocomial infections towards the end of the study. Shorter ICU stays were also observed among patients treated with probiotic therapy. However, the 28-day mortality rate was unaffected. Conclusions: The present study showed that daily prophylactic administration of probiotics could attenuate the deviated Th1/Th2 response induced by severe TBI, and could result in a decreased nosocomial infection rate, especially in the late period.	[Tan, Min] Affiliated Hosp N Sichuan Med Coll, Dept Nursing, Nanchong 637000, Sichuan, Peoples R China; [Tan, Min; Zhu, Jing-Ci; Zhang, Li-Mei; Yin, Hua-Hua] Third Mil Med Univ, Sch Nursing, Chongqing 400038, Peoples R China; [Du, Jiang] Affiliated Hosp N Sichuan Med Coll, Dept Gen Surg, Nanchong 637000, Sichuan, Peoples R China	Zhu, JC (corresponding author), Third Mil Med Univ, Sch Nursing, Chongqing 400038, Peoples R China.	zhujingci2009@163.com			11th 5-year research program of the People's Liberation Army of China [09MA009]	The present work was funded in part by the 11th 5-year research program of the People's Liberation Army of China under Grant No. 09MA009. The authors highly appreciate the great editing effort in the final version of the manuscript by Mr Lawrence Huang and Mr Leon Sun in the National Cancer Institute of the United States. They also would like to thank all staff at the Department of Neurosurgery, Affiliated Hospital of North Sichuan Medical College for their corporation during the study, and the Institute of Rheumatology and Immunology at North Sichuan Medical College for the support in experimental techniques.	Alberda C, 2007, AM J CLIN NUTR, V85, P816; Amaral ACKB, 2005, INTENS CARE MED, V31, P243, DOI 10.1007/s00134-004-2528-6; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Barraud D, 2010, INTENS CARE MED, V36, P1540, DOI 10.1007/s00134-010-1927-0; Bengmark S, 2001, CLIN NUTR, V20, P11, DOI 10.1054/clnu.2000.0111; Besselink MGH, 2008, LANCET, V371, P651, DOI 10.1016/S0140-6736(08)60207-X; Camargo LFA, 2004, CRIT CARE, V8, pR422, DOI 10.1186/cc2965; Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171; Delgado S, 2008, J APPL MICROBIOL, V104, P1119, DOI 10.1111/j.1365-2672.2007.03642.x; DIPIRO JT, 1995, ARCH SURG-CHICAGO, V130, P1159; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Fukushima Y, 2007, BRIT J NUTR, V98, P969, DOI 10.1017/S0007114507764723; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Ghadimi D, 2008, IMMUNOBIOLOGY, V213, P677, DOI 10.1016/j.imbio.2008.02.001; Giamarellos-Bourboulis EJ, 2009, J TRAUMA, V67, P815, DOI 10.1097/TA.0b013e31819d979e; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Husebye E, 2001, AM J PHYSIOL-GASTR L, V280, pG368; Isakow W, 2007, CHEST, V132, P286, DOI 10.1378/chest.06-2156; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knight DJW, 2009, INTENS CARE MED, V35, P854, DOI 10.1007/s00134-008-1368-1; Kotzampassi K, 2006, WORLD J SURG, V30, P1848, DOI 10.1007/s00268-005-0653-1; McNaught CE, 2005, CLIN NUTR, V24, P211, DOI 10.1016/j.clnu.2004.08.008; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Miller AC, 2007, J TRAUMA, V63, P1407, DOI 10.1097/TA.0b013e31815b839e; Mohamadzadeh M, 2005, P NATL ACAD SCI USA, V102, P2880, DOI 10.1073/pnas.0500098102; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Morrow LE, 2010, AM J RESP CRIT CARE, V182, P1058, DOI 10.1164/rccm.200912-1853OC; Morrow LE, 2008, CRIT CARE, V12, DOI 10.1186/cc6927; Nylen ES, 2001, BEST PRACT RES CL EN, V15, P553, DOI 10.1053/beem.2001.0169; Schiavi E, 2011, ALLERGY, V66, P499, DOI 10.1111/j.1398-9995.2010.02501.x; Schultz MJ, 2011, CRIT CARE, V15, DOI 10.1186/cc9963; Siempos II, 2010, CRIT CARE MED, V38, P954, DOI 10.1097/CCM.0b013e3181c8fe4b; Spindler-Vesel A, 2007, JPEN-PARENTER ENTER, V31, P119, DOI 10.1177/0148607107031002119; Sudo N, 2002, CLIN EXP ALLERGY, V32, P1112, DOI 10.1046/j.1365-2222.2002.01430.x; Takahashi N, 2006, BIOSCI BIOTECH BIOCH, V70, P2013, DOI 10.1271/bbb.60260; Watkinson PJ, 2007, CLIN NUTR, V26, P182, DOI 10.1016/j.clnu.2006.07.010; Whelan K, 2010, AM J CLIN NUTR, V91, P687, DOI 10.3945/ajcn.2009.28759; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Wolvers D, 2010, J NUTR, V140, p698S, DOI 10.3945/jn.109.113753	41	81	100	0	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	6							R290	10.1186/cc10579			10	Critical Care Medicine	General & Internal Medicine	969VJ	WOS:000306087200084	22136422	DOAJ Gold, Green Published			2021-06-18	
J	Tefertiller, C; Pharo, B; Evans, N; Winchester, P				Tefertiller, Candace; Pharo, Beth; Evans, Nicholas; Winchester, Patricia			Efficacy of rehabilitation robotics for walking training in neurological disorders: A review	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						gait; locomotor training; multiple sclerosis; neurological disorders; rehabilitation; robotics; spinal cord injury; stroke; traumatic brain injury; walking	BODY-WEIGHT SUPPORT; SPINAL-CORD-INJURY; ELECTROMECHANICAL GAIT TRAINER; ASSISTED TREADMILL WALKING; SUBACUTE STROKE PATIENTS; MULTIPLE-SCLEROSIS; HEMIPARETIC PATIENTS; LOCOMOTOR THERAPY; MECHANIZED GAIT; MUSCLE-ACTIVITY	Robotic technologies are becoming more prevalent for treating neurological conditions in clinical settings. We conducted a literature search of original articles to identify all studies that examined the use of robotic devices for restoring walking function in adults with neurological disorders. We evaluated and rated each study using either the Physiotherapy Evidence Database scale for randomized controlled trials (RCTs) or the Downs and Black scale for non-RCTs. We reviewed 30 articles (14 RCTs, 16 non-RCTs) that examined the effects of locomotor training with robotic assistance in patients following stroke, spinal cord injury (SCI), multiple sclerosis (MS), traumatic brain injury (TBI), and Parkinson disease (PD). This review supports that locomotor training with robotic assistance is beneficial for improving walking function in individuals following a stroke and SCI. Gait speed and endurance were not found to be significantly different among patients with motor incomplete SCI after a variety of locomotor training approaches. Limited evidence demonstrates that locomotor training with robotic assistance is beneficial in populations of patients with MS, TBI, or PD. We discuss clinical implications and decision making in the area of gait rehabilitation for neurological dysfunction.	[Tefertiller, Candace; Pharo, Beth; Evans, Nicholas] Shepherd Ctr, Atlanta, GA USA; [Winchester, Patricia] Mercy Reg Med Ctr, Durango, CO USA	Tefertiller, C (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	ctefertillerc@craighospital.org	Evans, Nicholas/AAT-1330-2020				ALAIMO MA, 1984, J APPL PHYSIOL, V56, P1608; Backus D., 2008, TOP SPINAL CORD INJ, V14, P23, DOI [10.1310/sci1401-23, DOI 10.1310/SCI1401-23]; Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; Barbeau H, 1998, ANN NY ACAD SCI, V860, P377, DOI 10.1111/j.1749-6632.1998.tb09063.x; Beer S, 2008, MULT SCLER J, V14, P231, DOI 10.1177/1352458507082358; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Behrman AL, 2005, PHYS THER, V85, P1356, DOI 10.1093/ptj/85.12.1356; Behrman AL, 2006, PHYS THER, V86, P1406, DOI 10.2522/ptj.20050212; Brown TH, 2005, J HEAD TRAUMA REHAB, V20, P402, DOI 10.1097/00001199-200509000-00002; Colombo G, 2000, J REHABIL RES DEV, V37, P693; Colombo G, 2001, SPINAL CORD, V39, P252, DOI 10.1038/sj.sc.3101154; Dietz V, 2002, BRAIN, V125, P2626, DOI 10.1093/brain/awf273; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Eng Janice J, 2007, Top Spinal Cord Inj Rehabil, V13, P1, DOI 10.1310/sci1301-1; Field-Fote Edelle C, 2005, J Neurol Phys Ther, V29, P127; Forlander DA, 1999, CLIN REHABIL, V13, P97, DOI 10.1191/026921599675502264; Freivogel S, 2008, BRAIN INJURY, V22, P625, DOI 10.1080/02699050801941771; Gardner MB, 1998, PHYS THER, V78, P361, DOI 10.1093/ptj/78.4.361; Giesser B, 2007, MULT SCLER, V13, P224, DOI 10.1177/1352458506070663; Hesse S, 2000, J REHABIL RES DEV, V37, P701; Hesse S, 1999, CLIN REHABIL, V13, P401, DOI 10.1191/026921599673896297; Hesse S, 2000, ARCH PHYS MED REHAB, V81, P1158, DOI 10.1053/apmr.2000.6280; Hesse S, 2004, SPINAL CORD, V42, P346, DOI 10.1038/sj.sc.3101595; Hesse S, 2001, Curr Atheroscler Rep, V3, P287, DOI 10.1007/s11883-001-0021-z; Hesse Stefan, 2003, Adv Neurol, V92, P423; Hicks AL, 2005, SPINAL CORD, V43, P291, DOI 10.1038/sj.sc.3101710; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Hornby TG, 2005, PHYS THER, V85, P52, DOI 10.1093/ptj/85.1.52; Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; Israel JF, 2006, PHYS THER, V86, P1466, DOI 10.2522/ptj.20050266; Krewer C, 2007, GAIT POSTURE, V26, P372, DOI 10.1016/j.gaitpost.2006.10.003; KURTZKE JF, 1994, ANN NEUROL, V36, pS73, DOI 10.1002/ana.410360717; Lam T, 2008, SPINAL CORD, V46, P246, DOI 10.1038/sj.sc.3102134; Lam T, 2008, NEUROREHAB NEURAL RE, V22, P438, DOI 10.1177/1545968308315595; Lamontagne A, 2004, STROKE, V35, P2543, DOI 10.1161/01.STR.0000144685.88760.d7; Lewek MD, 2009, PHYS THER, V89, P829, DOI 10.2522/ptj.20080180; Lo AC, 2008, NEUROREHAB NEURAL RE, V22, P661, DOI 10.1177/1545968308318473; LOVELY RG, 1990, BRAIN RES, V514, P206, DOI 10.1016/0006-8993(90)91417-F; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; Mayr A, 2007, NEUROREHAB NEURAL RE, V21, P307, DOI 10.1177/1545968307300697; McCain KJ, 2008, ARCH PHYS MED REHAB, V89, P684, DOI 10.1016/j.apmr.2007.09.050; Mehrholz J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub2; Miyai I, 2002, ARCH PHYS MED REHAB, V83, P1370, DOI 10.1053/apmr.2002.34603; Miyai I, 2000, ARCH PHYS MED REHAB, V81, P849, DOI 10.1053/apmr.2000.4439; Moreh E, 2009, J REHABIL MED, V41, P88, DOI 10.2340/16501977-0279; Morrison Sarah A, 2007, J Neurol Phys Ther, V31, P50; Moseley AM, 2002, AUST J PHYSIOTHER, V48, P43, DOI 10.1016/S0004-9514(14)60281-6; Neckel ND, 2008, J NEUROENG REHABIL, V5, DOI 10.1186/1743-0003-5-19; Nooijen CFJ, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-36; Peurala SH, 2005, ARCH PHYS MED REHAB, V86, P1557, DOI 10.1016/j.apmr.2005.02.005; Pohl M, 2007, CLIN REHABIL, V21, P17, DOI 10.1177/0269215506071281; Pohl M, 2003, ARCH PHYS MED REHAB, V84, P1760, DOI 10.1016/S0003-9993(03)00433-7; Protas EJ, 2001, ARCH PHYS MED REHAB, V82, P825, DOI 10.1053/apmr.2001.23198; Querry RG, 2008, J REHABIL RES DEV, V45, P175, DOI 10.1682/JRRD.2007.02.0028; Riener R, 2005, MED BIOL ENG COMPUT, V43, P2, DOI 10.1007/BF02345116; Scherer M, 2007, BRAIN INJURY, V21, P93, DOI 10.1080/02699050601149104; Schwartz I, 2009, PM&R, V1, P516, DOI 10.1016/j.pmrj.2009.03.009; SMITH JL, 1983, BIRTH DEFECTS-ORIG, V19, P357; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Tong RK, 2006, ARCH PHYS MED REHAB, V87, P1298, DOI 10.1016/j.apmr.2006.06.016; Tong RKY, 2006, PHYS THER, V86, P1282, DOI 10.2522/ptj.20050183; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Werner C, 2002, STROKE, V33, P2895, DOI 10.1161/01.STR.0000035734.61539.f6; Wernig A, 1998, SPINAL CORD, V36, P744, DOI 10.1038/sj.sc.3100670; WEST SP, 1986, EXP NEUROL, V91, P174, DOI 10.1016/0014-4886(86)90035-X; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Winchester P, 2005, NEUROREHAB NEURAL RE, V19, P313, DOI 10.1177/1545968305281515; Winchester Patricia, 2006, Phys Med Rehabil Clin N Am, V17, P159, DOI 10.1016/j.pmr.2005.10.008; Winchester P, 2009, J SPINAL CORD MED, V32, P63, DOI 10.1080/10790268.2009.11760754; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004	71	81	84	0	41	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2011	48	4					387	416		10.1682/JRRD.2010.04.0055			30	Rehabilitation	Rehabilitation	774GB	WOS:000291372200008	21674390	Bronze			2021-06-18	
J	Wakao, S; Hayashi, T; Kitada, M; Kohama, M; Matsue, D; Teramoto, N; Ose, T; Itokazu, Y; Koshino, K; Watabe, H; Iida, H; Takamoto, T; Tabata, Y; Dezawa, M				Wakao, Shohei; Hayashi, Takuya; Kitada, Masaaki; Kohama, Misaki; Matsue, Dai; Teramoto, Noboru; Ose, Takayuki; Itokazu, Yutaka; Koshino, Kazuhiro; Watabe, Hiroshi; Iida, Hidehiro; Takamoto, Tomoaki; Tabata, Yasuhiko; Dezawa, Mari			Long-term observation of auto-cell transplantation in non-human primate reveals safety and efficiency of bone marrow stromal cell-derived Schwann cells in peripheral nerve regeneration	EXPERIMENTAL NEUROLOGY			English	Article						Mesenchymal stem cells; Monkey; Schwann cells; Nerve regeneration; Peripheral nerve; Transdifferentiation	RAT SPINAL-CORD; OLFACTORY ENSHEATHING GLIA; IN-VITRO; STEM-CELLS; AXONAL REGENERATION; FUNCTIONAL RECOVERY; DIFFERENTIATION; MODEL; GRAFT; STRATEGIES	Based on their differentiation ability, bone marrow stromal cells (MSCs) are a good source for cell therapy. Using a cynomolgus monkey peripheral nervous system injury model, we examined the safety and efficacy of Schwann cells induced from MSCs as a source for auto-cell transplantation therapy in nerve injury. Serial treatment of monkey MSCs with reducing agents and cytokines induced their differentiation into cells with Schwann cell properties at a very high ratio. Expression of Schwann cell markers was confirmed by both immunocytochemistry and reverse transcription-polymerase chain reaction. Induced Schwann cells were used for auto-cell transplantation into the median nerve and followed-up for 1 year. No abnormalities were observed in general conditions. Ki67-immunostaining revealed no sign of massive proliferation inside the grafted tube. Furthermore, (18)F-fluorodeoxygluocose-positron emission tomography scanning demonstrated no abnormal accumulation of radioactivity except in regions with expected physiologic accumulation. Restoration of the transplanted nerve was corroborated by behavior analysis, electrophysiology and histological evaluation. Our results suggest that auto-cell transplantation therapy using MSC-derived Schwann cells is safe and effective for accelerating the regeneration of transected axons and for functional recovery of injured nerves. The practical advantages of MSCs are expected to make this system applicable for spinal cord injury and other neurotrauma or myelin disorders where the acceleration of regeneration is expected to enhance functional recovery. (C) 2010 Elsevier Inc. All rights reserved.	[Dezawa, Mari] Tohoku Univ, Grad Sch Med, Dept Stem Cell Biol & Histol, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Hayashi, Takuya; Teramoto, Noboru; Ose, Takayuki; Koshino, Kazuhiro; Watabe, Hiroshi; Iida, Hidehiro] Natl Cardiovasc Ctr, Res Inst, Adv Med Engn Ctr, Dept Invest Radiol, Osaka 5658565, Japan; [Itokazu, Yutaka] Kyoto Univ, Grad Sch Med, Dept Anat & Neurobiol, Kyoto 6068501, Japan; [Takamoto, Tomoaki; Tabata, Yasuhiko] Kyoto Univ, Inst Frontier Med Sci, Field Tissue Engn, Dept Biomat, Kyoto 6068507, Japan	Dezawa, M (corresponding author), Tohoku Univ, Grad Sch Med, Dept Stem Cell Biol & Histol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	mdezawa@m.tains.tohoku.ac.jp	Hayashi, Takuya/A-1634-2011; Kitada, Masaaki/I-1591-2017; Iida, Hidehiro/D-4582-2011; Iida, Hidehiro/D-5159-2011	Hayashi, Takuya/0000-0001-7639-0197; Kitada, Masaaki/0000-0002-4103-9767; Iida, Hidehiro/0000-0002-7914-3068	National Institute of Biomedical Innovation (NIBIO)National Institute of Biomedical Innovation [05-6]; Ministry of Health, Labor and WelfareMinistry of Health, Labour and Welfare, Japan; Ministry of Education, Culture, Sports, Science and Technology JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [19390074]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21659095] Funding Source: KAKEN	We thank to Dr. J. J. Archelos (Karl-Franzens Universitat, Graz, Austria) for providing us the PO antibody and to Ms. Mori E., Ms. Kotera J. and Ms. Mamiya R. for their technical assistance. This study was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO, 05-6) and by the Health and Labor Sciences Research Grants of "Research on Psychiatric and Neurological Diseases and Mental Health" from the Ministry of Health, Labor and Welfare. The study was also supported by Grant-in-Aid for Scientific Research (B) (19390074) from the Ministry of Education, Culture, Sports, Science and Technology Japan.	Ahmed Z, 1999, SCAND J PLAST RECONS, V33, P393; Al-Sugair A, 1998, SEMIN NUCL MED, V28, P303, DOI 10.1016/S0001-2998(98)80035-4; ARCHIBALD SJ, 1995, J NEUROSCI, V15, P4109; Auba C, 2006, J NEUROSURG, V105, P602, DOI 10.3171/jns.2006.105.4.602; Bunge MB, 2008, J SPINAL CORD MED, V31, P262, DOI 10.1080/10790268.2008.11760720; Bunge MB, 2002, PROG BRAIN RES, V137, P275; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Dezawa M, 2000, PROG RETIN EYE RES, V19, P171, DOI 10.1016/S1350-9462(99)00010-5; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hall S, 2001, J HAND SURG-BRIT EUR, V26, P129, DOI 10.1054/jhsb.2000.0497; HAMACHER K, 1986, J NUCL MED, V27, P235; Hamada K, 2006, ANN NUCL MED, V20, P671; Hess JR, 2007, PLAST RECONSTR SURG, V119, P246, DOI 10.1097/01.prs.0000245341.71666.97; Hill CE, 2006, GLIA, V53, P338, DOI 10.1002/glia.20287; Hisasue S, 2005, J UROLOGY, V173, P286, DOI 10.1097/01.ju.0000141578.84536.80; Ishikawa N, 2009, J BIOMED MATER RES A, V89A, P1118, DOI 10.1002/jbm.a.32389; Jiang L, 2008, NEUROREPORT, V19, P1015, DOI 10.1097/WNR.0b013e3283040efc; Kamada T, 2005, J NEUROPATH EXP NEUR, V64, P37, DOI 10.1093/jnen/64.1.37; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; Kitada M, 2001, GLIA, V36, P364, DOI 10.1002/glia.1123; Kitada M, 2006, GLIA, V54, P35, DOI 10.1002/glia.20354; Lee SJ, 2008, PLAST RECONSTR SURG, V121, P1188, DOI 10.1097/01.prs.0000305563.77782.35; McKay Hart A., 2002, EXP BRAIN RES, V142, P308; Mimura T, 2004, J NEUROSURG, V101, P806, DOI 10.3171/jns.2004.101.5.0806; Mligiliche Nurru L., 2003, Anatomical Science International, V78, P156, DOI 10.1046/j.0022-7722.2003.00056.x; Nagane K, 2009, TISSUE ENG PT A, V15, P1655, DOI 10.1089/ten.tea.2008.0453; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Plant GW, 1998, CELL TRANSPLANT, V7, P381, DOI 10.1016/S0963-6897(98)00016-5; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Radtke Christine, 2009, Eplasty, V9, pe47; Roth TM, 2007, GLIA, V55, P1123, DOI 10.1002/glia.20534; Shimizu S, 2007, BIOCHEM BIOPH RES CO, V359, P915, DOI 10.1016/j.bbrc.2007.05.212; Someya Y, 2008, J NEUROSURG-SPINE, V9, P600, DOI 10.3171/SPI.2008.9.08135; Torigoe K, 1996, EXP NEUROL, V137, P301, DOI 10.1006/exnr.1996.0030; Vukovic J, 2007, NEURON GLIA BIOL, V3, P105, DOI 10.1017/S1740925X07000671; Xu YF, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-21	37	81	84	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUN	2010	223	2			SI		537	547		10.1016/j.expneurol.2010.01.022			11	Neurosciences	Neurosciences & Neurology	597GD	WOS:000277743700034	20153320				2021-06-18	
J	Cho, Y; Shi, RY; Borgens, RB				Cho, Youngnam; Shi, Riyi; Borgens, Richard B.			Chitosan produces potent neuroprotection and physiological recovery following traumatic spinal cord injury	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						chitosan; nanoparticle; nerve tissue engineering; membrane; self assembly	ATOMIC-FORCE MICROSCOPY; POLYETHYLENE-GLYCOL; OXIDATIVE STRESS; SURFACTANT POLOXAMER-188; PHOSPHOLIPID-BILAYER; MOLECULAR REPAIR; BRAIN-INJURY; PC12 CELLS; IN-VITRO; MEMBRANES	Chitosan, a non-toxic biodegradable polycationic polymer with low immunogenicity, has been extensively investigated in various biomedical applications. In this work, chitosan has been demonstrated to seal compromised nerve cell membranes thus serving as a potent neuroprotector following acute spinal cord trauma. Topical application of chitosan after complete transection or compression of the guinea pig spinal cord facilitated sealing of neuronal membranes in ex vivo tests, and restored the conduction of nerve impulses through the length of spinal cords in vivo, using somatosensory evoked potential recordings. Moreover, chitosan preferentially targeted damaged tissues, served as a suppressor of reactive oxygen species ( free radical) generation, and the resultant lipid peroxidation of membranes, as shown in ex vivo spinal cord samples. These findings suggest a novel medical approach to reduce the catastrophic loss of behavior after acute spinal cord and brain injury.	[Cho, Youngnam; Shi, Riyi; Borgens, Richard B.] Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA; [Shi, Riyi; Borgens, Richard B.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Cho, Y (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	cho22@purdue.edu	sadeghi, meisam/K-2389-2018	sadeghi, meisam/0000-0002-8448-0149	General Funds of the Center for Paralysis Research; The State of Indiana	We would like to thank Debra Bohnert for her expert handling of whole animal experiments. We appreciate the excellent illustrations and graphics of Michel Schweinsberg, and financial support from the General Funds of the Center for Paralysis Research, The State of Indiana, and a generous endowment from Mrs Mari Hulman George.	BODMEIER R, 1989, PHARMACEUT RES, V6, P413, DOI 10.1023/A:1015987516796; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; BORGENS RB, 2003, RESTORING FUNCTION I; Brent J, 2001, DRUGS, V61, P979, DOI 10.2165/00003495-200161070-00006; Burcham PC, 2004, MOL PHARMACOL, V65, P655, DOI 10.1124/mol.65.3.655; Burcham PC, 2006, MOL PHARMACOL, V69, P1056, DOI 10.1124/mol.105.018168; Cadichon SB, 2007, J NEUROSURG, V106, P36, DOI 10.3171/ped.2007.106.1.36; Caravati EM, 2005, CLIN TOXICOL, V43, P327, DOI 10.1080/07313820500184971; Cho Y, 2008, SMALL, V4, P1676, DOI 10.1002/smll.200800838; Chung YC, 2004, ACTA PHARMACOL SIN, V25, P932; COLLINS JM, 2006, J SURG RES, V130, P288; Fang N, 2003, BIOMACROMOLECULES, V4, P1596, DOI 10.1021/bm034259w; Fang N, 2001, BIOMACROMOLECULES, V2, P1161, DOI 10.1021/bm015548s; Frim DM, 2004, NEUROREPORT, V15, P171, DOI 10.1097/00001756-200401190-00033; Gan Q, 2007, COLLOID SURFACE B, V59, P24, DOI 10.1016/j.colsurfb.2007.04.009; ILLUM L, 1994, PHARMACEUT RES, V11, P1186, DOI 10.1023/A:1018901302450; Janes KA, 2001, J CONTROL RELEASE, V73, P255, DOI 10.1016/S0168-3659(01)00294-2; Koob AO, 2006, J NEUROSCI RES, V83, P1558, DOI 10.1002/jnr.20837; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; Kumari S, 2008, NAT CELL BIOL, V10, P30, DOI 10.1038/ncb1666; Laverty PH, 2004, J NEUROTRAUM, V21, P1767, DOI 10.1089/neu.2004.21.1767; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Liu-Snyder P, 2007, J EXP BIOL, V210, P1455, DOI 10.1242/jeb.02756; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P219, DOI 10.1002/jnr.20862; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Madihally SV, 1999, BIOMATERIALS, V20, P1133, DOI 10.1016/S0142-9612(99)00011-3; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Pavinatto FJ, 2007, BIOMACROMOLECULES, V8, P1633, DOI 10.1021/bm0701550; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Qaqish RB, 1999, CARBOHYD POLYM, V38, P99, DOI 10.1016/S0144-8617(98)00109-X; Roy K, 1999, NAT MED, V5, P387; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Ueno H, 1999, BIOMATERIALS, V20, P1407, DOI 10.1016/S0142-9612(99)00046-0; Working PK, 1997, ACS SYM SER, V680, P45; Yuan Y, 2004, BIOMATERIALS, V25, P4273, DOI 10.1016/j.biomaterials.2003.11.029; Zuo YY, 2006, PEDIATR RES, V60, P125, DOI 10.1203/01.pdr.0000227558.14024.57	49	81	88	1	23	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0022-0949			J EXP BIOL	J. Exp. Biol.	MAY 1	2010	213	9					1513	1520		10.1242/jeb.035162			8	Biology	Life Sciences & Biomedicine - Other Topics	584XJ	WOS:000276787200023	20400636	Bronze			2021-06-18	
J	Schmidt, S; Kwee, LC; Allen, KD; Oddone, EZ				Schmidt, Silke; Kwee, Lydia Coulter; Allen, Kelli D.; Oddone, Eugene Z.			Association of ALS with head injury, cigarette smoking and APOE genotypes	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Case-control study; US veterans; Candidate gene; Gene-environment interaction; Neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON-DISEASE; TRAUMATIC BRAIN-INJURY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; APOLIPOPROTEIN-E GENOTYPES; WESTERN WASHINGTON-STATE; GULF-WAR VETERANS; E EPSILON 4; ALZHEIMERS-DISEASE; PARKINSON-DISEASE	Objective: An increased risk of ALS has been reported for US veterans, but the cause is unknown. Since head injury and cigarette smoking are two previously implicated environmental risk factors that are more common in military than civilian study populations, we tested their association with ALS in a US veteran study population. Methods: We used logistic regression to examine the association of ALS with head injury and cigarette smoking in 241 incident cases and 597 controls. Since APOE is a plausible ALS candidate gene, we also tested its main effect and its statistical interaction with these environmental exposures. Results: Cigarette smoking was not associated with ALS in this predominantly male and Caucasian population. Veterans who had experienced head injuries during the last 15 years before the reference date had an adjusted odds ratio of 2.33 (95% confidence interval 1.18-4.61), relative to veterans without any head injuries. This association was strongest in APOE-4 carriers. Conclusions: Our results add to the body of evidence suggesting that head injuries may be a risk factor for multiple neurodegenerative diseases, including ALS. We hypothesize that the strength of association between head injuries and ALS may depend upon APOE genotype. (C) 2010 Elsevier B.V. All rights reserved.	[Schmidt, Silke; Kwee, Lydia Coulter] Duke Univ, Med Ctr, Dept Med, Ctr Human Genet, Durham, NC 27710 USA; [Schmidt, Silke; Kwee, Lydia Coulter; Allen, Kelli D.; Oddone, Eugene Z.] Durham VAMC, Epidemiol Res & Informat Ctr, Durham, NC 27705 USA; [Schmidt, Silke; Kwee, Lydia Coulter; Allen, Kelli D.; Oddone, Eugene Z.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Schmidt, S (corresponding author), Duke Univ, Med Ctr, Dept Med, Ctr Human Genet, Box 3445, Durham, NC 27710 USA.	silke.schmidt@duke.edu			National Institutes of Health/National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01 ES 013244]; ALS Association [ALSA 1230]; Department of Veterans AffairsUS Department of Veterans Affairs [CSP 500A, CSP 478]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES013244] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health/National Institute of Environmental Health Sciences [R01 ES 013244] and the ALS Association [ALSA 1230]. The National Registry of Veterans with ALS and its DNA bank were supported by the Office of Research and Development, Cooperative Studies Program, Department of Veterans Affairs [CSP #500A and CSP #478].	AlChalabi A, 1996, LANCET, V347, P159, DOI 10.1016/S0140-6736(96)90343-8; Allen KD, 2008, NEUROEPIDEMIOLOGY, V30, P180, DOI 10.1159/000126910; ARMON C, 1991, NEUROLOGY, V41, P1077, DOI 10.1212/WNL.41.7.1077; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Belli S, 2005, EUR J EPIDEMIOL, V20, P237, DOI 10.1007/s10654-004-6879-7; Bennet AM, 2007, JAMA-J AM MED ASSOC, V298, P1300, DOI 10.1001/jama.298.11.1300; BINAZZI A, 2008, AMYOTROPH LATERAL SC, V16, P1; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; CAMPBELL AM, 1970, J NEUROL NEUROSUR PS, V33, P877, DOI 10.1136/jnnp.33.6.877; Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5; CHANCELLOR AM, 1993, J NEUROL NEUROSUR PS, V56, P1200, DOI 10.1136/jnnp.56.11.1200; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Chio A, 2002, NEUROLOGY, V59, P99, DOI 10.1212/WNL.59.1.99; Chio A, 2008, J NEUROL SCI, V269, P187, DOI 10.1016/j.jns.2007.10.005; CORDELL HJ, 2009, NAT REV GENET   0512; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; DEAPEN DM, 1986, AM J EPIDEMIOL, V123, P790, DOI 10.1093/oxfordjournals.aje.a114308; del Aguila MA, 2003, NEUROLOGY, V60, P813, DOI 10.1212/01.WNL.0000049472.47709.3B; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; FELMUS MT, 1976, NEUROLOGY, V26, P167, DOI 10.1212/WNL.26.2.167; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Frantseva M, 2002, PROG BRAIN RES, V137, P171; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; GRESHAM L S, 1986, Neuroepidemiology, V5, P29, DOI 10.1159/000110810; Haasdijk ED, 2002, NEUROSCI LETT, V335, P29, DOI 10.1016/S0304-3940(02)01159-X; Haley RW, 2003, NEUROLOGY, V61, P750, DOI 10.1212/WNL.61.6.750; Horner RD, 2003, NEUROLOGY, V61, P742, DOI 10.1212/01.WNL.0000069922.32557.CA; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Kamel F, 1999, NEUROEPIDEMIOLOGY, V18, P194, DOI 10.1159/000026211; Kamel F, 2002, EPIDEMIOLOGY, V13, P311, DOI 10.1097/00001648-200205000-00012; Kamel F, 2008, ENVIRON HEALTH PERSP, V116, P943, DOI 10.1289/ehp.11193; Katzman R, 1996, NEUROLOGY, V46, P889; KONDO K, 1981, ARCH NEUROL-CHICAGO, V38, P220, DOI 10.1001/archneur.1981.00510040046007; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li YJ, 2004, NEUROGENETICS, V5, P209, DOI 10.1007/s10048-004-0193-0; Li YJ, 2004, NEUROLOGY, V62, P2005, DOI 10.1212/01.WNL.0000128089.53030.AC; Longstreth WT, 1998, ARCH NEUROL-CHICAGO, V55, P201, DOI 10.1001/archneur.55.2.201; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCulloch CC, 2008, HUM GENET, V123, P257, DOI 10.1007/s00439-008-0466-z; McGuire V, 1996, NEUROLOGY, V47, P571, DOI 10.1212/WNL.47.2.571; McGuire V, 1997, AM J EPIDEMIOL, V145, P1076, DOI 10.1093/oxfordjournals.aje.a009070; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Migliore L, 2009, MUTAT RES-FUND MOL M, V667, P82, DOI 10.1016/j.mrfmmm.2008.10.011; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Morton LM, 2006, AM J EPIDEMIOL, V163, P197, DOI 10.1093/aje/kwj036; MOULARD B, 1996, J NEUROL SCI S   AUG, P34; Nelson LM, 2000, AM J EPIDEMIOL, V151, P156, DOI 10.1093/oxfordjournals.aje.a010183; O'Toole O, 2008, J NEUROL NEUROSUR PS, V79, P30, DOI 10.1136/jnnp.2007.117788; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PIERCERUHLAND R, 1981, ANN CLIN RES, V13, P102; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Popat RA, 2007, AMYOTROPH LATERAL SC, V8, P157, DOI 10.1080/17482960601179456; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; SAVETTIERI G, 1991, NEUROEPIDEMIOLOGY, V10, P242, DOI 10.1159/000110279; Scarmeas N, 2002, NEUROLOGY, V59, P773, DOI 10.1212/WNL.59.5.773; Schmidt S, 2008, NEUROEPIDEMIOLOGY, V30, P191, DOI 10.1159/000126911; Smith RG, 1996, LANCET, V348, P334, DOI 10.1016/S0140-6736(05)64502-3; Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013; Sorenson EJ, 2002, NEUROLOGY, V59, P280, DOI 10.1212/WNL.59.2.280; Tartaglia MC, 2007, ARCH NEUROL-CHICAGO, V64, P232, DOI 10.1001/archneur.64.2.232; Traynor BJ, 1999, NEUROLOGY, V52, P504, DOI 10.1212/WNL.52.3.504; van Es MA, 2009, NAT GENET, V41, P1083, DOI 10.1038/ng.442; Wahner AD, 2007, NEUROLOGY, V69, P1836, DOI 10.1212/01.wnl.0000279519.99344.ad; Weisskopf MG, 2004, AM J EPIDEMIOL, V160, P26, DOI 10.1093/aje/kwh179; Weisskopf MG, 2005, NEUROLOGY, V64, P32, DOI 10.1212/01.WNL.0000148649.17706.D9; Zoccolella S, 2008, J NEUROL NEUROSUR PS, V79, P33, DOI 10.1136/jnnp.2007.118018	71	81	81	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	APR 15	2010	291	1-2					22	29		10.1016/j.jns.2010.01.011			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	582UG	WOS:000276624200005	20129626	Green Accepted			2021-06-18	
J	Sander, AM; Clark, A; Pappadis, MR				Sander, Angelle M.; Clark, Allison; Pappadis, Monique R.			What Is Community Integration Anyway?: Defining Meaning Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community integration; participation; traumatic brain injury	ETHNIC-DIFFERENCES; REHABILITATION; OUTCOMES; PARTICIPATION; QUESTIONNAIRE; SATISFACTION; INDIVIDUALS; WORK; RACE; PERSPECTIVES	Full community integration, or participation in society, is the ultimate goal of rehabilitation and of research conducted in the field of rehabilitation for persons with traumatic brain injury (TBI). Community integration has been traditionally defined by 3 main areas: employment or other productive activity, independent living, and social activity. However, these have not always received equal weighting and attention in clinical or research efforts. Significant gaps remain in our understanding of factors that impact community integration and in our ability to intervene to improve participation for persons with TBI. This article describes 3 main challenges for researchers and rehabilitation professionals. First, a comprehensive meaning of community integration is needed, which includes the viewpoints and preferences of persons with TBI. Second, cultural competence in measurement and intervention is needed. Third, a thorough assessment of environmental factors impacting participation is needed and should be incorporated into research and treatment planning.	[Sander, Angelle M.; Clark, Allison; Pappadis, Monique R.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.; Clark, Allison] Harris Cty Hosp Dist, Baylor Coll Med, Dept Phys Med & Rehabil, Waco, TX USA; [Pappadis, Monique R.] Univ Houston, Grad Coll SocialWork, Houston, TX USA	Sander, AM (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bem.edu	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133 B031117, H133A070043]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grants H133 B031117 and H133A070043).	Almeida J, 2009, SOC SCI MED, V68, P1852, DOI 10.1016/j.socscimed.2009.02.029; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; BOAKE C, 1991, COGNITIVE REHABILITA, pR11; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Brandt E. N., 1997, ENABLING AM ASSESSIN; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Christenson OD, 2006, J LEISURE RES, V38, P475; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Craig Hospital Research Department, 2001, CRAIG HOSP INV ENV F; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; FLOYD MF, 1994, J LEISURE RES, V26, P158; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kamo Y, 2000, SOCIOL PERSPECT, V43, P211, DOI 10.2307/1389794; Kim HK, 1998, J COMP FAM STUD, V29, P313; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Mascialino G, 2009, NEUROREHABILITATION, V24, P29, DOI 10.3233/NRE-2009-0451; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pledger C, 2003, AM PSYCHOL, V58, P279, DOI 10.1037/0003-066X.58.4.279; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M. Foreword, 1990, COMMUNITY INTEGRATIO, pxi; *RRTC COMM INT PER, T7 STAT OF THE SCI C; Saeki S, 2006, J REHABIL MED, V38, P333, DOI 10.1080/16501970600780245; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sander AM, 2009, ARCH PHYS MED REHA E, V90, pE36; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Sarkisian N, 2006, FAM RELAT, V55, P331, DOI 10.1111/j.1741-3729.2006.00408.x; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Struchen M.A., 2005, REHABILITATION TRAUM, P88; *US DOE, 2000, LONG RANG PLAN 1999; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1994, BRAIN INJURY, V8, P647, DOI 10.3109/02699059409151017; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; World Health Organization, 2001, INT CLASS FUNCT DIS; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	61	81	81	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					121	127		10.1097/HTR.0b013e3181cd1635			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000007	20134333				2021-06-18	
J	Nelson, DW; Nystrom, H; MacCallum, RM; Thornquist, B; Lilja, A; Bellander, BM; Rudehill, A; Wanecek, M; Weitzberg, E				Nelson, David W.; Nystrom, Harriet; MacCallum, Robert M.; Thornquist, Bjorn; Lilja, Anders; Bellander, Bo-Michael; Rudehill, Anders; Wanecek, Michael; Weitzberg, Eddie			Extended Analysis of Early Computed Tomography Scans of Traumatic Brain Injured Patients and Relations to Outcome	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography; Glasgow Coma Scale; Glasgow Outcome Scale; outcome; traumatic brain injury	SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; LOGISTIC-REGRESSION; PROGNOSTIC MODELS; ADMISSION CHARACTERISTICS; CLASSIFICATION; IMPACT; SCALE; VALIDATION; MACHINE	Traumatic brain injury (TBI) is responsible for up to 45% of in-hospital trauma mortality. Computed tomography (CT) is central to acute TBI diagnostics, and millions of brain CT scans are conducted yearly worldwide. Though many studies have addressed individual predictors of outcome from findings on CT scans, few have done so from a multivariate perspective. As these parameters are interrelated in a complex manner, there is a need for a better understanding of them in this context. CT scans from 861 TBI patients were reviewed according to an extensive protocol. An extended analysis of CT parameters with respect to outcome was performed using linear and non-linear methods. We identified complex interactions and mutual information in many of the parameters. Variables predicting death differ from those predicting unfavorable versus favorable outcomes (Glasgow Outcome Scale scores of 1-3 versus 4-5 [GOS]). The most important parameter for prediction of unfavorable outcome is the magnitude of midline shift. In fact, this parameter, as a continuous variable, is by itself a better predictor and is better calibrated than the Marshall CT score, even for predicting death. In addition, hematoma volumes are nearly co-linear with midline shift and can be substituted for it. A score of traumatic subarachnoid/intraventricular blood components adds substantially to model calibration. A CT scoring system geared toward dichotomous GOS scores is suggested. CT parameters were found to add 6-10% additional estimated explained variance in the presence of the important clinical variables of age, Glasgow Coma Scale score, and pupillary response. Finally we present a practical clinical "rule of thumb" to help predict the probability of unfavorable outcome using clinical and CT variables.	[Nelson, David W.; Thornquist, Bjorn; Rudehill, Anders; Wanecek, Michael; Weitzberg, Eddie] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, S-17177 Stockholm, Sweden; [Bellander, Bo-Michael] Karolinska Inst, Neurosurg Sect, S-17177 Stockholm, Sweden; [Nystrom, Harriet; Lilja, Anders] Karolinska Inst, Neuroradiol Sect, Dept Clin Neurosci, S-17177 Stockholm, Sweden; [MacCallum, Robert M.] Univ London Imperial Coll Sci Technol & Med, Immunogenom Grp, Div Cell & Mol Biol, London, England	Nelson, DW (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, S-17177 Stockholm, Sweden.	david.nelson@karolinska.se	Wanecek, Michael/AAE-7998-2021		Karolinska Institutet, The Swedish Research CouncilSwedish Research Council; Swedish Cancer and Traffic Injury Fund (CTRF)	Funding for this study was provided in part by the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institutet, funds from the Karolinska Institutet, The Swedish Research Council, The Swedish Cancer and Traffic Injury Fund (CTRF)	Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; Ben-Hur A, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000173; Bertolini G, 2000, J Epidemiol Biostat, V5, P251; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Farin A, 2004, ACT NEUR S, V89, P101; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Hosmer DW, 2002, STAT MED, V21, P2723, DOI 10.1002/sim.1200; Hosmer DW, 1997, STAT MED, V16, P965; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1975, LANCET, V1, P480; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Meier L, 2008, J R STAT SOC B, V70, P53, DOI 10.1111/j.1467-9868.2007.00627.x; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Mjolsness E, 2001, SCIENCE, V293, P2051, DOI 10.1126/science.293.5537.2051; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Platt JC, 1999, ADV LARGE MARGIN CLA; R Development Core Team, 2008, R LANGUAGE ENV STAT; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597, DOI [10.1089/neu.2000.17.597, DOI 10.1089/NEU.2000.17.597]; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188	36	81	82	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					51	64		10.1089/neu.2009.0986			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200004	19698072				2021-06-18	
J	Truelle, JL; Koskinen, S; Hawthorne, G; Sarajuuri, J; Formisano, R; Von Wild, K; Neugebauer, E; Wilson, L; Gibbons, H; Powell, J; Bullinger, M; Hofer, S; Maas, A; Zitnay, G; Von Steinbuechel, N				Truelle, Jean-Luc; Koskinen, Sanna; Hawthorne, Graeme; Sarajuuri, Jaana; Formisano, Rita; Von Wild, Klaus; Neugebauer, Edmund; Wilson, Lindsay; Gibbons, Henning; Powell, Jane; Bullinger, Monika; Hoefer, Stefan; Maas, Andrew; Zitnay, George; Von Steinbuechel, Nicole		Qolibri Task Force	Quality of life after traumatic brain injury: The clinical use of the QOLIBRI, a novel disease-specific instrument	BRAIN INJURY			English	Article						Traumatic brain injury; health-related quality of life; assessment; international; multi-centre study; QOLIBRI	PSYCHIATRIC-DISORDERS; SUBJECTIVE EXPERIENCE; POPULATION NORMS; HOSPITAL ANXIETY; CLOSE RELATIVES; SOCIAL SUPPORT; HEALTH; SATISFACTION; REHABILITATION; QUESTIONNAIRE	Objective: To report the clinical use of the QOLIBRI, a disease-specific measure of health-related quality-of-life (HRQoL) after traumatic brain injury (TBI). Methods: The QOLIBRI, with 37 items in six scales (cognition, self, daily life and autonomy, social relationships, emotions and physical problems) was completed by 795 patients in six languages (Finnish, German, Italian, French, English and Dutch). QOLIBRI scores were examined by variables likely to be influenced by rehabilitation interventions and included socio-demographic, functional outcome, health status and mental health variables. Results: The QOLIBRI was self-completed by 73% of participants and 27% completed it in interview. It was sensitive to areas of life amenable to intervention, such as accommodation, work participation, health status (including mental health) and functional outcome. Conclusion: The QOLIBRI provides information about patient's subjective perception of his/her HRQoL which supplements clinical measures and measures of functional outcome. It can be applied across different populations and cultures. It allows the identification of personal needs, the prioritization of therapeutic goals and the evaluation of individual progress. It may also be useful in clinical trials and in longitudinal studies of TBI recovery.	[Truelle, Jean-Luc; Koskinen, Sanna; Hawthorne, Graeme; Sarajuuri, Jaana; Formisano, Rita; Von Wild, Klaus; Neugebauer, Edmund; Wilson, Lindsay; Gibbons, Henning; Powell, Jane; Bullinger, Monika; Hoefer, Stefan; Maas, Andrew; Zitnay, George; Von Steinbuechel, Nicole; Qolibri Task Force] Univ Hosp, Dept Phys Med & Rehabil, QOLIBRI Task Force TBI Qual Life, F-92380 Garches, France	Truelle, JL (corresponding author), Univ Hosp, Dept Phys Med & Rehabil, QOLIBRI Task Force TBI Qual Life, F-92380 Garches, France.	jean-luc.truelle@wanadoo.fr	Wilson, Lindsay/O-8883-2019; Sarajuuri, Jaana/AAD-8665-2019; Hofer, Stefan/N-8253-2019; Castro-Caldas, Alexandre/M-4156-2013; Hofer, Stefan/B-8393-2008; Wilson, Lindsay/A-3659-2009; Maas, Andrew IR/C-5584-2013; Mancuso, Mauro/J-6773-2018	Wilson, Lindsay/0000-0003-4113-2328; Sarajuuri, Jaana/0000-0002-6432-0295; Hofer, Stefan/0000-0002-6128-3687; Castro-Caldas, Alexandre/0000-0002-9148-3719; Hofer, Stefan/0000-0002-6128-3687; Wilson, Lindsay/0000-0003-4113-2328; Maas, Andrew IR/0000-0003-1612-1264; Mancuso, Mauro/0000-0002-8451-9277; Koskinen, Sanna/0000-0002-3453-5084	EMN (Euroacademia Multidisciplinaria Neurotraumatologica); EBIS (European Brain Injury Society); International Brain Research Foundation Inc; Les Gueules Cassees, France; MAAF Insurance Foundation, France; France Traumatisme Cranien, France; Hannelore Kohl Foundation, Germany; Cerebprotect e.V. Munster, Germany; Homerton Hospital, UK; Victorian Neurotrauma Initiative, Australia	We thank organizations who initiated, encouraged and supported our work in developing the QOLIBRI: the EMN (Euroacademia Multidisciplinaria Neurotraumatologica), the EBIS (European Brain Injury Society), the International Brain Research Foundation Inc, and in France Les Gueules Cassees, the MAAF Insurance Foundation, France Traumatisme Cranien, in Germany the Hannelore Kohl Foundation and Cerebprotect e.V. Munster, in the UK the Homerton Hospital and in Australia the Victorian Neurotrauma Initiative.	*ABS, 1997, NAT HLTH SURV SF 36; Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; AZOUVI P, 2005, ACTA NEUROPSYCHOLOGI, V3, P25; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P93; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; CIURLI P, J INT NEURO IN PRESS; COETZER BR, 2002, J COGN REHABIL, V20, P20; Coetzer R, 2005, INT J REHABIL RES, V28, P361, DOI 10.1097/00004356-200512000-00010; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; English TC, 1904, LANCET, V1, P485; Eriksson G, 2009, J REHABIL MED, V41, P187, DOI 10.2340/16501977-0307; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; FORMISANO R, 2009, CRITICAL CARE, P2254; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Hawley CA, 2008, BRAIN INJURY, V22, P427, DOI 10.1080/02699050802064607; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Hawthorne G, 2006, SOC INDIC RES, V77, P37, DOI 10.1007/s11205-005-5552-1; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoffmann B, 2002, ACT NEUR S, V79, P33; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JENNETT B, 1975, LANCET, V1, P480; Johnstone B, 2009, BRAIN INJURY, V23, P411, DOI 10.1080/02699050902788501; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kaplan RM, 1982, HEALTH PSYCHOL, V1, P61, DOI DOI 10.1037/0278-6133.1.1.61; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kozlowski O., 2002, Annales de Readaptation et de Medecine Physique, V45, P466, DOI 10.1016/S0168-6054(02)00297-0; Lowe SR, 2009, J TRAUMA STRESS, V22, P244, DOI 10.1002/jts.20403; Luo N, 2005, MED CARE, V43, P1078, DOI 10.1097/01.mlr.0000182493.57090.c1; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Martin C, 2001, BRAIN INJURY, V15, P947, DOI 10.1080/02699050110065655; Mathiesen Birgit Bork, 2004, Cogn Neuropsychiatry, V9, P249, DOI 10.1080/13546800344000237; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Oppermann JD, 2004, BRAIN INJURY, V18, P941, DOI 10.1080/02699050410001671919; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; PATRICK DL, 1984, QUALITY LIFE CARDIOV, V1, P53; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Sansoni J, 2007, FINAL REPORT DEMENTI; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P561, DOI 10.1080/09602010500263084; SCHONLE PW, 1995, NEUROL REHABIL, V2, P87; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Sopena S, 2007, BRAIN INJURY, V21, P1063, DOI 10.1080/02699050701630342; *SPSS INC, 2006, STAT PACK SOC SCI V1; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1978, ANESTHESIOLOGY, V49, P225, DOI 10.1097/00000542-197809000-00023; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; The WHOQOL Group, 1993, QUAL LIFE RES, V2, P153, DOI DOI 10.1007/BF00435734; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Truelle JL, 2008, ACTA NEUROCHIR SUPPL, V101, P125; Truelle J-L, 2010, Asian J Neurosurg, V5, P24; TRUELLE JL, 2008, 5 C WORLD FED NEUR 2, P528; TRUELLE JL, 2005, ACTA NEUROPSYCHOLOGI, V3, P6; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; VONSTEINBUECHEL N, 2010, J NEUROTRAU IN PRESS; VONSTEINBUECHEL N, NEUROTRAUMA IN PRESS; WAGNER AK, 1995, QUAL LIFE RES, V4, P169, DOI 10.1007/BF01833610; WARE JE, 1993, SF 36 HLTH SURV MAN; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winter V., 2005, ACTA NEUROPSYCHOL, V3, P36; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; World Health Organization, 2001, INT CLASS FUNCT DIS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599	108	81	81	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	11					1272	1291		10.3109/02699052.2010.506865			20	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MY	WOS:000283198800002	20722501				2021-06-18	
J	Raskin, SA				Raskin, Sarah A.			Memory for Intentions Screening Test: Psychometric Properties and Clinical Evidence	BRAIN IMPAIRMENT			English	Article						prospective memory; memory for intentions	PERFORMED TASKS; BRAIN-INJURY; HIV; IMPAIRMENT; PREDICTORS; INFECTION; PEOPLE	As he field of prospective memory (ProM) research has expanded, recognition of the need to make a clinical diagnosis of ProM difficulties has also increased. In addition, there is increasing interest in understanding in more detail the ways in which ProM deficits differ in populations with different underlying neurological dysfunctions. While questionnaires, naturalistic studies and laboratory studies have all been invaluable in furthering our understanding of ProM, until recently there has not been a standardised clinical measure. The Memory for Intentions Screening Test (MIST) was designed to be a relatively brief clinical measure of ProM in clinical populations. The MIST allows for comparisons of performance with event-based and time-based cues. The MIST also has some items with a short (2-minute) and some with a long (15-minute) delay period. Finally, the MIST contains items that require a verbal response as well as items that require an action response. The MIST has now been used in studies of normal ageing as well as a range of clinical populations, including individuals with traumatic brain injury, individuals with HIV infection and individuals with schizophrenia. The psychometric properties of the MIST have been found to be acceptable. Data from each of the clinical populations that have been administered the MIST demonstrate good specificity and sensitivity of the measure as well as the ability to begin to make comparisons about different patterns of performance between disease types.	[Raskin, Sarah A.] Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; [Raskin, Sarah A.] Trinity Coll, Neurosci Program, Hartford, CT 06106 USA	Raskin, SA (corresponding author), Trinity Coll, Dept Psychol, 300 Summit St, Hartford, CT 06106 USA.	sarah.raskin@trincoll.edu	Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			BASSO MR, 2008, INT NEUR SOC M WAIK; Carey CL, 2006, J CLIN EXP NEUROPSYC, V28, P536, DOI 10.1080/13803390590949494; COCKBURN J, 1994, BRIT J PSYCHOL, V85, P273, DOI 10.1111/j.2044-8295.1994.tb02523.x; COCKBURN J, 1996, PROSPECTIVE MEMORY T; CONTARDO C, RELATIONSHIP P UNPUB; DELISI L, 2006, THESIS E WASHINGTON; EDWARDS C, 2009, COGN NEUR SOC M SAN; Ellis J., 1996, PROSPECTIVE MEMORY T; ENGELKAMP J, 1994, PSYCHOL RES-PSYCH FO, V57, P47, DOI 10.1007/BF00452995; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; Ghaleb H., 2008, COGN NEUR SOC M SAN; GOSHKE T, 1993, J EXPT PSYCHOL LEARN, V19, P1211; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hicks JL, 2000, J EXP PSYCHOL LEARN, V26, P1160, DOI 10.1037/0278-7393.26.5.1160; KARANTZOULIS S, 2008, 36 ANN M INT NEUR SO; KARANTZOULIS S, 2007, 35 ANN M INT NEUR SO; Kliegel M, 2002, PSYCHOL BEITR, V44, P303, DOI DOI 10.1037/0012-1649.44.2.612; KORIAT A, 1990, MEM COGNITION, V18, P568, DOI 10.3758/BF03197099; MAYE J, 2008, NE UND GRAD ORG NEUR; MEACHAM JA, 1982, MEMORY OBSERVED REME; MOSCOVITCH M, 2008, PROSPECTIVE MEMORY C; Pearce R, 2000, THESIS TRINITY COLL; Phillips L. H., 2008, PROSPECTIVE MEMORY C; RASKIN S, 2001, INT NEUR SOC BOST MA; RASKIN S, 2004, COGN NEUR SOC SAN FR; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; RASKIN S, 2003, ANN M INT NEUR SOC H; RASKIN S, 1998, COGN NEUR SOC SAN FR; Schaefer EG, 1998, MEM COGNITION, V26, P644, DOI 10.3758/BF03211384; SETHNA J, 2001, COGN NEUR SOC M SAN; TROSTER A, 2008, INT NEUR SOC M BUEN; TWAMLEY E, 2007, SCHIZOPHRENIA RES, V10; Uttl B, 2001, CONSCIOUS COGN, V10, P451, DOI 10.1006/ccog.2001.0505; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Woods SP, 2008, CLIN NEUROPSYCHOL, V22, P864, DOI 10.1080/13854040701595999; Woods SP, 2008, ARCH CLIN NEUROPSYCH, V23, P257, DOI 10.1016/j.acn.2007.12.006; Woods SP, 2008, NEUROPSYCHOLOGY, V22, P110, DOI 10.1037/0894-4105.22.1.110; Woods SP, 2007, ARCH CLIN NEUROPSYCH, V22, P187, DOI 10.1016/j.acn.2006.12.006; Woods SP, 2007, SCHIZOPHR RES, V90, P344, DOI 10.1016/j.schres.2006.11.005	39	81	81	0	15	AUSTRALIAN ACAD PRESS	BOWEN HILLS	32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA	1443-9646			BRAIN IMPAIR	Brain Impair.	MAY	2009	10	1					23	33		10.1375/brim.10.1.23			11	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	443CQ	WOS:000265888200005					2021-06-18	
J	Lord-Fontaine, S; Yang, F; Diep, Q; Dergham, P; Munzer, S; Tremblay, P; McKerracher, L				Lord-Fontaine, Stephanie; Yang, Fan; Diep, Quy; Dergham, Pauline; Munzer, Scott; Tremblay, Patrick; McKerracher, Lisa			Local Inhibition of Rho Signaling by Cell-Permeable Recombinant Protein BA-210 Prevents Secondary Damage and Promotes Functional Recovery following Acute Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						contusion; neuroprotection; regeneration; Rho GTPase; spinal cord injury	TRAUMATIC BRAIN-INJURY; NEURITE OUTGROWTH; CLOSTRIDIUM-BOTULINUM; LESIONAL EXPRESSION; AXON REGENERATION; C3 EXOENZYME; NOGO-A; GROWTH; KINASE; ACTIVATION	Spinal cord injury (SCI) leads to robust Rho activation at the lesion site. Here, we demonstrate that BA-210, a cell-permeable fusion protein derived from C3 transferase, formulated in fibrin sealant and delivered topically onto the dura matter, diffuses into the spinal cord and inactivates Rho in a dose-dependent manner. Treatment with BA-210 in rats with thoracic spinal cord contusion increased tissue sparing around the lesion area and led to significant improvement of locomotor function. In mice, BA-210 improved functional outcome when treatment was either applied at the time of injury or delayed by 24 h. In both rats and mice, treatment with BA-210 was well tolerated. Rats gained body weight normally, and BA-210 treatment had no impact on the development of allodynia. Inactivating Rho with BA-210 holds promise for treating patients with SCI.	[Lord-Fontaine, Stephanie; Yang, Fan; Diep, Quy; Dergham, Pauline; Munzer, Scott; Tremblay, Patrick; McKerracher, Lisa] BioAxone Therapeut Inc, Montreal, PQ, Canada; [Dergham, Pauline; McKerracher, Lisa] Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ, Canada	Tremblay, P (corresponding author), 1100 Boul Rene Levesque Ouest,25E Etage, Montreal, PQ H3B 5C9, Canada.	tremblay-patrick@videotron.ca			CIHRCanadian Institutes of Health Research (CIHR); NSERCNatural Sciences and Engineering Research Council of Canada (NSERC)	We thank Dr. Louise Laberge-Caouette for her helpful discussions and for her help with spinal cord surgery protocols. We thank Rozica Bolovan, Annie Salesse, Rathna Chaudry, and Charles Essagian for their help with surgery, animal care, histology, and behavioral analysis. We thank Veronique Boulanger for her contributions to the characterization of BA-210. This work was supported by BioAxone Therapeutic and by grants from the CIHR to L. M. Pauline Dergham was the recipient of a NSERC Industrial Fellowship.	Adcock KH, 2004, EUR J NEUROSCI, V20, P1425, DOI 10.1111/j.1460-9568.2004.03573.x; Ahmed Z, 2005, MOL CELL NEUROSCI, V28, P509, DOI 10.1016/j.mcn.2004.11.002; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 2000, PHYS THER, V80, P808, DOI 10.1093/ptj/80.8.808; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bertrand J, 2007, NEUROBIOL DIS, V25, P65, DOI 10.1016/j.nbd.2006.08.008; Bertrand J, 2005, J NEUROSCI, V25, P1113, DOI 10.1523/JNEUROSCI.3931-04.2005; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Conrad S, 2005, J COMP NEUROL, V487, P166, DOI 10.1002/cne.20561; CONSTANTINI S, 1994, J NEUROSURG, V80; Dergham P, 2002, J NEUROSCI, V22, P6570; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Figueroa JD, 2006, J NEUROSCI RES, V84, P1438, DOI 10.1002/jnr.21048; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Fournier AE, 2003, J NEUROSCI, V23, P1416; Genth H, 2003, J BIOL CHEM, V278, P28523, DOI 10.1074/jbc.M301915200; Gingras K, 2004, BIOORG MED CHEM LETT, V14, P4931, DOI 10.1016/j.bmcl.2004.07.025; Guest JD, 1997, J NEUROSCI RES, V50, P888, DOI 10.1002/(SICI)1097-4547(19971201)50:5<888::AID-JNR24>3.0.CO;2-W; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Kassam Amin, 2004, Ear Nose Throat J, V83, P246; Kubo T, 2008, J NEUROCHEM, V105, P113, DOI 10.1111/j.1471-4159.2007.05125.x; Lasko D, 2006, METHOD ENZYMOL, V406, P512, DOI 10.1016/S0076-6879(06)06039-3; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Logan A, 2006, BRAIN, V129, P490, DOI 10.1093/brain/awh706; Macias MY, 2006, EXP NEUROL, V201, P335, DOI 10.1016/j.expneurol.2006.04.035; Madura T, 2004, EMBO REP, V5, P412, DOI 10.1038/sj.embor.7400117; McKerracher L, 2006, J NEUROTRAUM, V23, P309, DOI 10.1089/neu.2006.23.309; McKerracher L, 2004, NAT MED, V10, P1052, DOI 10.1038/nm1004-1052; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Niederost B, 2002, J NEUROSCI, V22, P10368; Nusser N, 2006, CELL SIGNAL, V18, P704, DOI 10.1016/j.cellsig.2005.06.010; Obata K, 2006, NEUROSCI RES, V55, P1, DOI 10.1016/j.neures.2006.01.005; Ozdinler PH, 2001, J COMP NEUROL, V438, P377; Ramer LM, 2004, J NEUROSCI, V24, P10796, DOI 10.1523/JNEUROSCI.3337-04.2004; Romero MI, 2000, J NEUROSCI, V20, P4435, DOI 10.1523/JNEUROSCI.20-12-04435.2000; Rosenzweig ES, 2004, CURR OPIN NEUROL, V17, P121, DOI 10.1097/00019052-200404000-00007; Schwab JM, 2004, GLIA, V47, P377, DOI 10.1002/glia.20031; Schweigreiter R, 2004, MOL CELL NEUROSCI, V27, P163, DOI 10.1016/j.mcn.2004.06.004; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Sung JK, 2003, BRAIN RES, V959, P29, DOI 10.1016/S0006-8993(02)03717-4; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Yamagishi S, 2005, J BIOL CHEM, V280, P20384, DOI 10.1074/jbc.M501945200; Yamashita T, 2005, MOL NEUROBIOL, V32, P105, DOI 10.1385/MN:32:2:105; Zhang YP, 2004, J NEUROSURG, V100, P343, DOI 10.3171/spi.2004.100.4.0343	49	81	87	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2008	25	11					1309	1322		10.1089/neu.2008.0613			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	384BP	WOS:000261718900003	19061375				2021-06-18	
B	Gaertner, DJ; Hallman, TM; Hankenson, FC; Batchelder, MA		Fish, RE; Brown, MJ; Danneman, PJ; Karas, AZ		Gaertner, Diane J.; Hallman, Troy M.; Hankenson, F. Claire; Batchelder, Margaret A.			Anesthesia and Analgesia for Laboratory Rodents	ANESTHESIA AND ANALGESIA IN LABORATORY ANIMALS, 2ND EDITION	American College of Laboratory Animal Medicine Series		English	Article; Book Chapter							MORPHINE-INDUCED ANALGESIA; ADULT MALE-RATS; KETAMINE-XYLAZINE ANESTHESIA; FENTANYL-DROPERIDOL DROPERIDOL; SPRAGUE-DAWLEY RATS; MU-OPIOID-RECEPTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LIPOSOME-ENCAPSULATED OXYMORPHONE; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE		[Gaertner, Diane J.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA; [Hallman, Troy M.] Sch Vet Med, Univ Lab Anim Resources, Philadelphia, PA 19104 USA; [Hankenson, F. Claire] Univ Penn, Sch Vet Med, Univ Lab Anim Resources, Dept Pathobiol, Philadelphia, PA 19104 USA; [Batchelder, Margaret A.] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA	Gaertner, DJ (corresponding author), Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA.						Abbott FV, 1997, VET REC, V140, P553, DOI 10.1136/vr.140.21.553; Abbott FV, 2000, BEHAV BRAIN RES, V112, P177, DOI 10.1016/S0166-4328(00)00179-0; Abram SE, 1997, ANESTHESIOLOGY, V87, P127, DOI 10.1097/00000542-199707000-00017; Adachi YU, 2005, BRIT J ANAESTH, V95, P485, DOI 10.1093/bja/aei213; AKERMAN SBA, 1985, BRIT J ANAESTH, V57, P329, DOI 10.1093/bja/57.3.329; Alexander M, 2005, J SURG RES, V129, P161, DOI 10.1016/j.jss.2005.04.028; Alkire MT, 2005, ANESTHESIOLOGY, V103, P1167, DOI 10.1097/00000542-200512000-00010; Altholtz LY, 2006, J AM ASSOC LAB ANIM, V45, P17; AMOUZADEH HR, 1989, VET HUM TOXICOL, V31, P532; Antunes LM, 2003, EUR J ANAESTH, V20, P800, DOI 10.1097/00003643-200310000-00005; Antunes LM, 2003, VET ANAESTH ANALG, V30, P15, DOI 10.1046/j.1467-2995.2003.00085.x; Arevalo MI, 2004, ANESTH ANALG, V98, P1407, DOI 10.1213/01.ANE.0000107936.69436.5B; Arras M, 2001, COMPARATIVE MED, V51, P443; Asai T, 1998, BRIT J ANAESTH, V80, P814, DOI 10.1093/bja/80.6.814; Attia MA, 2004, INT J PHARM, V276, P11, DOI 10.1016/j.ijpharm.2004.01.041; BACKONJA MM, 1995, NEUROSCI LETT, V196, P61, DOI 10.1016/0304-3940(95)11844-M; Bagis H, 2004, LAB ANIM-UK, V38, P50, DOI 10.1258/00236770460734399; Barr GA, 1999, PAIN, V81, P155, DOI 10.1016/S0304-3959(99)00003-2; Barrett AC, 2002, EUR J PHARMACOL, V452, P163, DOI 10.1016/S0014-2999(02)02274-4; Bartok RE, 1997, J PHARMACOL EXP THER, V282, P769; BARZAGO MM, 1994, LAB ANIM SCI, V44, P648; Bauer DJ, 2003, CONTEMP TOP LAB ANIM, V42, P20; Beagles K, 2004, MOL PHARMACOL, V65, P437, DOI 10.1124/mol.65.2.437; Beiglbock C, 2003, J WILDLIFE DIS, V39, P665, DOI 10.7589/0090-3558-39.3.665; Beirith A, 1998, EUR J PHARMACOL, V345, P233, DOI 10.1016/S0014-2999(98)00026-0; Bekker A, 2006, ANESTH ANALG, V102, P1134, DOI 10.1213/01.ane.0000198637.36539.c1; Ben-Nathan D, 2000, ANN NY ACAD SCI, V917, P944; Benesova O, 2001, EUR NEUROPSYCHOPHARM, V11, P367, DOI 10.1016/S0924-977X(01)00102-X; Bickler PE, 2006, ANESTH ANALG, V103, P419, DOI 10.1213/01.ane.0000223671.49376.b2; Blais V, 2002, ENDOCRINOLOGY, V143, P4820, DOI 10.1210/en.2002-220598; BOHRER H, 1994, LAB ANIM SCI, V44, P326; Bolan EA, 2002, J PHARMACOL EXP THER, V303, P557, DOI 10.1124/jpet.102.035881; Borchard R.E., 1992, INTRO DRUG DOSAGE LA, pix; BRAMMER A, 1993, LAB ANIM, V27, P250, DOI 10.1258/002367793780745354; Branson K. R., 2001, Veterinary pharmacology and therapeutics, P213; BRIGGS SL, 1995, PHARMACOL BIOCHEM BE, V52, P561, DOI 10.1016/0091-3057(95)00140-R; Brown ET, 2005, VISUAL NEUROSCI, V22, P615, DOI 10.1017/S0952523805225105; BROWN JN, 1989, LAB ANIM SCI, V39, P142; Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623-200401000-00017; Brown RH, 1999, J APPL PHYSIOL, V87, P2362; Brown-Woodman PDC, 2004, TOXICOL IN VITRO, V18, P719, DOI 10.1016/j.tiv.2003.12.002; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; BRUGUEROLLE B, 1991, CHRONOBIOL INT, V8, P277, DOI 10.3109/07420529109063932; Brunson D.B., 1997, ANESTHESIA ANALGESIA; BUELKESAM J, 1978, LAB ANIM SCI, V28, P157; Buetow BS, 1999, CONTEMP TOP LAB ANIM, V38, P47; Buzaleh AM, 1996, GEN PHARMACOL, V27, P1009, DOI 10.1016/0306-3623(95)02137-X; CADRANEL JF, 1993, J CLIN GASTROENTEROL, V17, P52, DOI 10.1097/00004836-199307000-00015; CALCAGNETTI DJ, 1990, PHARMACOL BIOCHEM BE, V37, P193, DOI 10.1016/0091-3057(90)90061-L; CALDERONE L, 1986, EXP EYE RES, V42, P331, DOI 10.1016/0014-4835(86)90026-6; Campos AR, 2006, BIOL PHARM BULL, V29, P86, DOI 10.1248/bpb.29.86; Camprodon RAM, 2006, TRANSPLANT P, V38, P1857, DOI 10.1016/j.transproceed.2006.05.005; Cantwell Shauna L., 2001, Veterinary Clinics of North America Exotic Animal Practice, V4, P169; CAPETOLA RJ, 1983, J CLIN PHARMACOL, V23, P545, DOI 10.1002/j.1552-4604.1983.tb01802.x; Castonguay A, 1998, EXP LUNG RES, V24, P605, DOI 10.3109/01902149809087389; Ceccarelli I, 2006, NEUROSCIENCE, V140, P929, DOI 10.1016/j.neuroscience.2006.02.044; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Cetin N, 2005, LAB ANIM-UK, V39, P100, DOI 10.1258/0023677052886510; CHAU TT, 1989, J PHARMACOL EXP THER, V248, P907; Chen Kuan-Ting, 2002, Acta Anaesthesiol Sin, V40, P191; Chen NN, 2002, PROSTAG OTH LIPID M, V67, P143, DOI 10.1016/S0090-6980(01)00185-X; CHILD KJ, 1971, BRIT J ANAESTH, V43, P2, DOI 10.1093/bja/43.1.2-a; Choi SS, 2001, BRAIN RES, V921, P233, DOI 10.1016/S0006-8993(01)03126-2; Christoph T, 2005, EUR J PHARMACOL, V507, P87, DOI 10.1016/j.ejphar.2004.11.052; Chu DK, 2006, J AM ASSOC LAB ANIM, V45, P8; Cicero TJ, 2002, J PHARMACOL EXP THER, V300, P695, DOI 10.1124/jpet.300.2.695; Clark JA, 1997, LAB ANIM SCI, V47, P300; Clark MD, 2004, COMPARATIVE MED, V54, P558; Clifford D. H., 1984, Laboratory animal medicine, P527; Clowry GJ, 2000, LAB ANIM, V34, P260, DOI 10.1258/002367700780384771; COLE DJ, 1990, LAB ANIM SCI, V40, P506; COLPAERT FC, 1987, PAIN, V28, P201, DOI 10.1016/0304-3959(87)90117-5; COLPAERT FC, 1982, LIFE SCI, V31, P67, DOI 10.1016/0024-3205(82)90402-7; Colpaert FC, 2001, PAIN, V91, P33, DOI 10.1016/S0304-3959(00)00413-9; Craft RM, 2003, CLIN J PAIN, V19, P175, DOI 10.1097/00002508-200305000-00005; Craft RM, 2003, PHARMACOL BIOCHEM BE, V75, P235, DOI 10.1016/S0091-3057(03)00076-5; Craft RM, 2001, DRUG ALCOHOL DEPEN, V63, P215, DOI 10.1016/S0376-8716(00)00209-X; Crain SM, 2001, BRAIN RES, V888, P75, DOI 10.1016/S0006-8993(00)03010-9; CRIFO S, 1975, ORL J OTO-RHINO-LARY, V37, P27, DOI 10.1159/000275201; Cruz JI, 1998, LAB ANIM-UK, V32, P18, DOI 10.1258/002367798780559383; CUNNINGHAM MG, 1993, J NEUROSCI METH, V47, P105, DOI 10.1016/0165-0270(93)90026-N; CURL JL, 1983, LAB ANIM, V17, P290, DOI 10.1258/002367783781062361; CURL JL, 1988, LAB ANIM, V22, P309, DOI 10.1258/002367788780746269; D'Amato FR, 1998, BEHAV PHARMACOL, V9, P369; D'Elia M, 2003, CLIN IMMUNOL, V109, P179, DOI 10.1016/S1521-6616(03)00177-3; DADA MO, 1992, LIFE SCI, V51, P29; DALKARA T, 1995, J CEREBR BLOOD F MET, V15, P631, DOI 10.1038/jcbfm.1995.78; DALLEINNE CP, 1982, VET HUM TOXICOL, V24, P410; Danneman PJ, 1997, LAB ANIM SCI, V47, P386; DAVIS A, 1993, AGENTS ACTIONS, V38, pC10, DOI 10.1007/BF01991121; DELMONTE M, 1990, BRIT J PHARMACOL, V99, P582; DeSouza AC, 1997, PHARMACOL BIOCHEM BE, V56, P481, DOI 10.1016/S0091-3057(96)00246-8; Diaz-Reval MI, 2001, ARCH MED RES, V32, P13, DOI 10.1016/S0188-4409(00)00268-X; Dimaculangan D, 2006, J NEUROSURG ANESTH, V18, P78, DOI 10.1097/01.ana.0000194705.67834.09; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Dittmar MS, 2004, COMPARATIVE MED, V54, P652; Doretto MC, 1998, NEUROREPORT, V9, P2415, DOI 10.1097/00001756-199807130-00048; DRETCHEN K, 1971, ANESTHESIOLOGY, V34, P463, DOI 10.1097/00000542-197105000-00024; Drobac E, 2004, PHYSIOL BEHAV, V82, P279, DOI 10.1016/j.physbeh.2004.03.013; DUBOIS M A, 1981, Journal of Microsurgery, V3, P107; DWYER RC, 1994, ANESTHESIOLOGY, V81, P403, DOI 10.1097/00000542-199408000-00019; Easterly ME, 2001, LAB ANIMAL, V30, P46; EBERT B, 1995, NEUROSCI LETT, V187, P165, DOI 10.1016/0304-3940(95)11364-3; Efstathiou JA, 2005, FERTIL STERIL, V83, P171, DOI 10.1016/j.fertnstert.2004.06.058; EGER RP, 1995, CAN J ANAESTH, V42, P173, DOI 10.1007/BF03028273; El Mouedden M, 2005, PHARMACOL BIOCHEM BE, V82, P109, DOI 10.1016/j.pbb.2005.07.016; Elena G, 2003, LAB ANIM-UK, V37, P193, DOI 10.1258/002367703766453038; Elena G, 1997, INT J IMMUNOPHARMACO, V19, P699; Engelhard K, 1999, BRIT J ANAESTH, V83, P415; ENGELHARDT G, 1995, INFLAMM RES, V44, P423, DOI 10.1007/BF01757699; Epemolu O, 2003, ANESTHESIOLOGY, V99, P632, DOI 10.1097/00000542-200309000-00018; Erbil Y, 1998, ACTA CHIR BELG, V98, P245; Erhan E, 2005, METHOD FIND EXP CLIN, V27, P629, DOI 10.1358/mf.2005.27.9.939337; Erichsen HK, 2005, PAIN, V116, P347, DOI 10.1016/j.pain.2005.05.004; FAGIOLI S, 1990, BRAIN RES, V510, P150, DOI 10.1016/0006-8993(90)90743-U; Fang ZX, 1997, ANESTH ANALG, V84, P852, DOI 10.1097/00000539-199704000-00028; Ferrari L, 2005, COMPARATIVE MED, V55, P256; Field K.J., 1988, THESIS LAB ANIMAL ME, P104; FIELD KJ, 1988, LAB ANIM, V22, P255, DOI 10.1258/002367788780746331; FIELD KJ, 1993, LAB ANIM, V27, P258, DOI 10.1258/002367793780745471; Filaretov A A, 1996, Neurosci Behav Physiol, V26, P572, DOI 10.1007/BF02359502; FILE SE, 1988, J PHARM PHARMACOL, V40, P57, DOI 10.1111/j.2042-7158.1988.tb05152.x; FINSTER M, 1972, ANESTHESIOLOGY, V36, P159, DOI 10.1097/00000542-197202000-00017; Fitzpatrick LR, 1999, ALIMENT PHARM THER, V13, P1553; Flecknell P., 1996, LAB ANIMAL ANAESTHES; Flecknell P, 1996, HDB RODENT RABBIT ME; Flecknell P., 1987, LAB ANIMAL ANAESTHES; Flecknell P.A., 1987, J ASS VET ANAESTHETI, V14, P111; FLECKNELL PA, 1991, LAB ANIM, V25, P50, DOI 10.1258/002367791780808239; FLECKNELL PA, 1990, LAB ANIM-UK, V24, P142, DOI 10.1258/002367790780890121; FLECKNELL PA, 1984, LAB ANIM, V18, P143, DOI 10.1258/002367784780891406; Flecknell PA, 1999, LAB ANIM, V33, P169, DOI 10.1258/002367799780578381; FLECKNELL PA, 1993, METHOD ENZYMOL, V225, P16; FLECKNELL PA, 1993, BRIT J ANAESTH, V71, P885, DOI 10.1093/bja/71.6.885; Flecknell PA, 1999, VET REC, V144, P65, DOI 10.1136/vr.144.3.65; FLECKNELL PA, 1984, LAB ANIM, V18, P147, DOI 10.1258/002367784780891226; FLEISCHMAN RW, 1977, LAB ANIM SCI, V27, P238; Flood P, 2002, ANESTHESIOLOGY, V97, P192, DOI 10.1097/00000542-200207000-00027; FORSYTHE DB, 1992, LAB ANIM SCI, V42, P497; FRASE BA, 1989, J WILDLIFE DIS, V25, P444, DOI 10.7589/0090-3558-25.3.444; FU ES, 1995, REGION ANESTH, V20, P291; Furukawa S, 1998, LAB ANIM SCI, V48, P357; Gades NM, 2000, CONTEMP TOP LAB ANIM, V39, P8; GAERTNER DJ, 1987, LAB ANIM SCI, V37, P80; GARDNER DJ, 1995, LAB ANIM SCI, V45, P199; Gaveriaux-Ruff C, 1998, P NATL ACAD SCI USA, V95, P6326, DOI 10.1073/pnas.95.11.6326; GAWRISCH E, 1990, CRIT CARE MED, V18, P1034, DOI 10.1097/00003246-199009000-00022; Genedani S, 1999, EUR J PHARMACOL, V367, P13, DOI 10.1016/S0014-2999(98)00966-2; GIBBS NM, 1989, ANESTHESIOLOGY, V71, P214; Gillingham MB, 2001, CONTEMP TOP LAB ANIM, V40, P21; GILROY BA, 1980, VET MED SM ANIM CLIN, V75, P508; Giraud O, 2000, AM J RESP CRIT CARE, V162, P2278, DOI 10.1164/ajrccm.162.6.9807113; Giraud O, 2003, ANESTHESIOLOGY, V98, P74, DOI 10.1097/00000542-200301000-00015; GLEN JB, 1980, BRIT J ANAESTH, V52, P731, DOI 10.1093/bja/52.8.731; Goecke JC, 2005, COMPARATIVE MED, V55, P37; Gong DH, 1998, ANESTH ANALG, V86, P198, DOI 10.1097/00000539-199801000-00038; Gonzalez MI, 2000, PAIN, V88, P79, DOI 10.1016/S0304-3959(00)00309-2; Gopalan C, 2005, CONTEMP TOP LAB ANIM, V44, P7; Goren S, 2001, J NEUROSURG ANESTH, V13, P113, DOI 10.1097/00008506-200104000-00008; Goto T, 1996, BRIT J ANAESTH, V76, P702; Gotoh H, 2004, EXP ANIM TOKYO, V53, P63, DOI 10.1538/expanim.53.63; Gourine AV, 2003, J PHYSIOL-LONDON, V552, P197, DOI 10.1113/jphysiol.2003.045294; Graham MD, 2004, BIOPHYS J, V86, p48A; GRANADOSSOTO V, 1995, METHOD FIND EXP CLIN, V17, P535; GREEN C J, 1975, Laboratory Animals (London), V9, P161, DOI 10.1258/002367775780994574; GREEN CJ, 1981, LAB ANIM, V15, P163, DOI 10.1258/002367781780959107; GREEN CJ, 1978, LAB ANIM, V12, P85, DOI 10.1258/002367778780953206; Greenwood-Van Meerveld B, 2004, NEUROGASTROENT MOTIL, V16, P46, DOI 10.1111/j.1743-3150.2004.00555.x; Gringauz M, 2001, J Anesth, V15, P204, DOI 10.1007/s005400170004; Groeben H, 2003, BRIT J ANAESTH, V91, P541, DOI 10.1093/bja/aeg222; Gross M. E., 2001, Veterinary pharmacology and therapeutics, P299; Gultekin H, 2006, ADV THER, V23, P39, DOI 10.1007/BF02850345; Gupta A, 2001, PHARMACOL BIOCHEM BE, V68, P635, DOI 10.1016/S0091-3057(00)00475-5; Gupta SK, 2002, SKIN PHARMACOL APPL, V15, P105, DOI 10.1159/000049397; GURTU S, 1994, NEUROREPORT, V5, P715, DOI 10.1097/00001756-199402000-00014; Haberham ZL, 1999, LAB ANIM, V33, P47, DOI 10.1258/002367799780578570; Hacker SO, 2005, CONTEMP TOP LAB ANIM, V44, P7; Haelewyn B, 2004, BRIT J ANAESTH, V92, P552, DOI 10.1093/bja/aeh100; Hahn N, 2005, LAB ANIMAL, V34, P48, DOI 10.1038/laban0205-48; Hall L. W., 2001, VET ANAESTHESIA, P113; Hall TJ, 1996, INFLAMM RES, V45, P299, DOI 10.1007/BF02280995; Hamura H, 2000, JPN J PHARMACOL, V83, P286, DOI 10.1254/jjp.83.286; Hanson CE, 2001, COMPARATIVE MED, V51, P224; Haque SF, 2004, J REPROD DEVELOP, V50, P185, DOI 10.1262/jrd.50.185; Harkness JE, 1995, BIOL MED RABBITS ROD; HART MV, 1984, AM J VET RES, V45, P2328; Haseneder R, 2004, ANESTH ANALG, V98, P1718, DOI 10.1213/01.ANE.0000112309.80017.3F; Hasirci V, 2003, LIFE SCI, V73, P3323, DOI 10.1016/S0024-3205(03)00615-5; HASSAN HG, 1989, REGION ANESTH, V14, P138; HASSAN HG, 1993, ACTA ANAESTH SCAND, V37, P70, DOI 10.1111/j.1399-6576.1993.tb03601.x; Hawk C., 2005, FORMULARY LAB ANIMAL; Hayashi H, 2002, PAEDIATR ANAESTH, V12, P770, DOI 10.1046/j.1460-9592.2002.00883.x; Hayes JH, 1999, LAB ANIM-UK, V33, P16, DOI 10.1258/002367799780578534; Hayes KE, 2000, CONTEMP TOP LAB ANIM, V39, P18; Hayton SM, 1999, LAB ANIM-UK, V33, P243, DOI 10.1258/002367799780578219; Heard D.J., 2004, ANESTHESIA ANALGESIA; Heavner J.E., 1997, AM COLL LAB ANIMAL M; Heavner JE, 2001, COMPARATIVE MED, V51, P500; Hedenqvist P, 2000, LAB ANIM-UK, V34, P244, DOI 10.1258/002367700780384762; Hedenqvist P, 2000, LAB ANIM, V34, P207, DOI 10.1258/002367700780457536; Henke J, 2004, J VET MED A, V51, P259, DOI 10.1111/j.1439-0442.2004.00632.x; HENNING RH, 1993, BRIT J PHARMACOL, V108, P717, DOI 10.1111/j.1476-5381.1993.tb12867.x; Hernandez-Delgadillo GP, 2006, EUR J PHARMACOL, V546, P54, DOI 10.1016/j.ejphar.2006.07.027; Hernandez-Delgadillo GP, 2004, EUR J PHARMACOL, V502, P67, DOI 10.1016/j.ejphar.2004.08.032; Hernandez-Delgadillo GP, 2003, EUR J PHARMACOL, V469, P71, DOI 10.1016/S0014-2999(03)01727-8; Hernandez-Delgadillo GP, 2002, EUR J PHARMACOL, V441, P177, DOI 10.1016/S0014-2999(02)01344-4; Herrero JF, 1996, BRIT J PHARMACOL, V118, P968, DOI 10.1111/j.1476-5381.1996.tb15494.x; Hertl MC, 1998, REGION ANESTH PAIN M, V23, P152, DOI 10.1136/rapm-00115550-199823020-00007; Hildebrand S.V., 1997, PARALYTIC AGENTS; HIRST M, 1984, CAN J PHYSIOL PHARM, V62, P1102, DOI 10.1139/y84-184; HOAR RM, 1969, FED PROC, V28, P1517; Hockertz S, 1996, ARZNEIMITTEL-FORSCH, V46, P1012; Hoff JB, 2006, J AM ASSOC LAB ANIM, V45, P57; HRAPKIEWICZ KL, 1989, LAB ANIM SCI, V39, P338; HSU WH, 1986, J AM VET MED ASSOC, V189, P1040; HSU WH, 1982, EUR J PHARMACOL, V83, P55, DOI 10.1016/0014-2999(82)90285-0; HU C, 1992, LAB ANIM-UK, V26, P15, DOI 10.1258/002367792780809075; Hu GC, 2003, ANESTHESIOLOGY, V98, P712, DOI 10.1097/00000542-200303000-00020; Huang C, 2000, NEUROSCI LETT, V294, P159, DOI 10.1016/S0304-3940(00)01572-X; Huang C, 2002, BRAIN RES, V945, P20, DOI 10.1016/S0006-8993(02)02503-9; Huang Y, 2005, ACTA ANAESTH SCAND, V49, P1544, DOI 10.1111/j.1399-6576.2005.00760.x; HUGHES EW, 1982, CLIN EXP PHARMACOL P, V9, P119, DOI 10.1111/j.1440-1681.1982.tb00788.x; Iltis I, 2005, J MAGN RESON IMAGING, V22, P242, DOI 10.1002/jmri.20352; Imai T, 1998, CAN J ANAESTH, V45, P360, DOI 10.1007/BF03012029; Ingalls CP, 1996, J APPL PHYSIOL, V80, P332; Institute for Laboratory Animal Research (U.S. ) (ILAR). Commission on Life Sciences N. R. C. U. S., 1996, GUID CAR US LAB AN; Institute for Laboratory Animal Research (U. S. ) (ILAR). Committee on Guidelines for the Use of Animals in Neuroscience and Behavioral Research and N. R. Council, 2003, GUID CAR US MAMM NEU; Institute for LaboratoryAnimal Research (U.S. ) (ILAR). Committee on Pain and Distress in Laboratory Animals N. R. C., 1992, REC ALL PAIN DISTR L; Interagency Research Animal Committee (IRAC), 1985, US GOV PRINC UT CAR; Jablonski P, 2002, LAB ANIM-UK, V36, P134, DOI 10.1258/0023677021912415; Jablonski P, 2001, LAB ANIM-UK, V35, P213, DOI 10.1258/0023677011911651; Jacobsen KO, 2004, CONTEMP TOP LAB ANIM, V43, P8; Jacobson C, 2000, LAB ANIM, V34, P202, DOI 10.1258/002367700780457509; Jacobson C, 2001, LAB ANIM-UK, V35, P271, DOI 10.1258/0023677011911598; Jain NK, 2002, LIFE SCI, V70, P2857, DOI 10.1016/S0024-3205(02)01549-7; Jain Subheet, 2005, Current Drug Delivery, V2, P223, DOI 10.2174/1567201054368020; Jang S, 2006, ARCH PHARM RES, V29, P677, DOI 10.1007/BF02968252; Janicki PK, 1996, LIFE SCI, V59, pPL269, DOI 10.1016/0024-3205(96)00477-8; Janssen BJA, 2004, AM J PHYSIOL-HEART C, V287, pH1618, DOI 10.1152/ajpheart.01192.2003; Jaquenod M, 1998, ANESTH ANALG, V86, P1090, DOI 10.1097/00000539-199805000-00036; JAUCHEM JR, 1991, LAB ANIM SCI, V41, P70; Javan M, 2006, BRAIN RES, V1104, P73, DOI 10.1016/j.brainres.2006.05.088; Ji YP, 2006, AM J PHYSIOL-REG I, V291, pR307, DOI 10.1152/ajpregu.00824.2005; Jobin N, 2000, CELL IMMUNOL, V200, P65, DOI 10.1006/cimm.2000.1619; JOHANSEN O, 1994, LAB ANIM, V28, P244, DOI 10.1258/002367794780681723; Jong WMC, 2002, CONTEMP TOP LAB ANIM, V41, P28; Joshi SK, 2006, NEUROSCIENCE, V143, P587, DOI 10.1016/j.neuroscience.2006.08.005; Jou IM, 2000, J APPL PHYSIOL, V89, P1766; Jungwirth B, 2006, ANESTHESIOLOGY, V104, P770, DOI 10.1097/00000542-200604000-00022; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; Kalinichev M, 2001, PSYCHOPHARMACOLOGY, V157, P305, DOI 10.1007/s002130100806; Kanaan SA, 1997, PHARMACOLOGY, V54, P285, DOI 10.1159/000139498; Kanarek RB, 1997, PHARMACOL BIOCHEM BE, V58, P43, DOI 10.1016/S0091-3057(96)00470-4; Kandatsu N, 2005, ANESTHESIOLOGY, V102, P1182, DOI 10.1097/00000542-200506000-00018; KANUI TI, 1990, COMP BIOCHEM PHYS C, V96, P131, DOI 10.1016/0742-8413(90)90057-G; Karas AZ, 2002, LAB ANIMAL, V31, P49; Karuri AR, 1998, BRAIN RES BULL, V47, P205, DOI 10.1016/S0361-9230(98)00072-0; Kashimoto S, 1997, EUR J ANAESTH, V14, P359, DOI 10.1046/j.1365-2346.1997.00092.x; Kastl S, 2004, ADV PHYSIOL EDUC, V28, P29, DOI 10.1152/advan.00008.2003; Katz Y, 2002, J MED VIROL, V66, P576, DOI 10.1002/jmv.2184; Kavaliers M, 1997, BRAIN RES, V766, P11, DOI 10.1016/S0006-8993(97)00521-0; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; KAYSER V, 1991, EUR J PHARMACOL, V195, P37, DOI 10.1016/0014-2999(91)90379-5; Keller C, 2001, INVEST OPHTH VIS SCI, V42, P476; Kennedy BW, 2002, LAB ANIMAL, V31, P34; Kest B, 1999, J PHARMACOL EXP THER, V289, P1370; Kharasch ED, 2006, TOXICOL SCI, V90, P419, DOI 10.1093/toxsci/kfj088; Kharasch ED, 1999, ANESTHESIOLOGY, V91, P1267, DOI 10.1097/00000542-199911000-00017; Kiatchoosakun S, 2001, COMPARATIVE MED, V51, P26; Kilgore JL, 2003, TEX J SCI, V55, P149; Kim H, 2006, TOXICOLOGY, V220, P169, DOI 10.1016/j.tox.2005.12.010; Kim T, 1996, ANESTHESIOLOGY, V85, P331, DOI 10.1097/00000542-199608000-00015; KIPP DE, 1989, INT J VITAM NUTR RES, V59, P172; Kirsch JH, 2002, CONTEMP TOP LAB ANIM, V41, P9; Kissin I, 1996, ANESTH ANALG, V83, P600, DOI 10.1097/00000539-199609000-00029; KLIDE AM, 1967, J PHARMACOL EXP THER, V158, P28; KOBAYASHI K, 1985, EXP ANIM TOKYO, V34, P379, DOI 10.1538/expanim1978.34.4_379; Koblin DD, 1998, ANESTH ANALG, V87, P419, DOI 10.1097/00000539-199808000-00035; Koch VW, 2006, LAB ANIMAL, V35, P27, DOI 10.1038/laban0506-27; Kohler I, 1999, LAB ANIM, V33, P155, DOI 10.1258/002367799780578390; Kolesnikov Y, 1999, J PHARMACOL EXP THER, V290, P247; Kolesnikov YA, 2000, J PHARMACOL EXP THER, V295, P546; Kolesnikov YA, 2003, ANESTH ANALG, V97, P1721, DOI 10.1213/01.ANE.0000087801.20395.97; Komatsu H, 1998, ANESTHESIOLOGY, V89, P1184, DOI 10.1097/00000542-199811000-00019; KOMULAINEN A, 1991, AM J VET RES, V52, P585; Konat GW, 2003, METAB BRAIN DIS, V18, P11, DOI 10.1023/A:1021922500998; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; Koo ST, 2002, PAIN, V99, P423, DOI 10.1016/S0304-3959(02)00164-1; Kopjas NN, 2006, EPILEPSY RES, V69, P87, DOI 10.1016/j.eplepsyres.2005.12.001; Krugner-Higby L, 2003, COMPARATIVE MED, V53, P270; Kubota T, 1999, BRAIN RES, V840, P175, DOI 10.1016/S0006-8993(99)01793-X; KUFOY EA, 1989, EXP EYE RES, V49, P861, DOI 10.1016/S0014-4835(89)80045-4; Kumar SGV, 2006, METHOD FIND EXP CLIN, V28, P419, DOI 10.1358/mf.2006.28.7.1003549; KUPERS R, 1995, PAIN, V60, P137, DOI 10.1016/0304-3959(94)00106-O; Kuratani N, 1996, ANESTH ANALG, V83, P798, DOI 10.1097/00000539-199610000-00025; Laird JMA, 1996, INFLAMM RES, V45, P150, DOI 10.1007/BF02265170; Laird JMA, 1997, INFLAMM RES, V46, P203, DOI 10.1007/s000110050174; Laird JMA, 1998, INFLAMM RES, V47, P389, DOI 10.1007/s000110050349; Langford DJ, 2006, SCIENCE, V312, P1967, DOI 10.1126/science.1128322; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Lawson DM, 2001, CONTEMP TOP LAB ANIM, V40, P18; Leach MC, 2002, VET REC, V150, P808, DOI 10.1136/vr.150.26.808; Leach MC, 2002, COMPARATIVE MED, V52, P249; LEASH AM, 1973, LAB ANIM SCI, V23, P720; Lee SC, 1997, ANESTH ANALG, V84, P810, DOI 10.1097/00000539-199704000-00021; LEEUWIN RS, 1984, BRIT J PHARMACOL, V82, P339, DOI 10.1111/j.1476-5381.1984.tb10768.x; LEGROS J, 1984, ARCH INT PHARMACOD T, V271, P11; Lemke KA, 1996, J AM VET MED ASSOC, V209, P776; Lerche P, 2000, J AM VET MED ASSOC, V217, P485, DOI [10.2460/javma.2000.217.493, 10.2460/javma.2000.217.485]; LEVIN LL, 1986, ANESTH ANALG, V65, P330; LEVINE JD, 1988, J CLIN INVEST, V82, P1574, DOI 10.1172/JCI113768; Liang DY, 2006, PAIN, V121, P232, DOI 10.1016/j.pain.2005.12.026; Lieggi CC, 2005, CONTEMP TOP LAB ANIM, V44, P11; Lieggi CC, 2005, CONTEMP TOP LAB ANIM, V44, P17; LIGHTFOOTE WE, 1978, AM J VET RES, V39, P1061; LILES JH, 1994, J VET PHARMACOL THER, V17, P284, DOI 10.1111/j.1365-2885.1994.tb00247.x; Liles JH, 1998, LAB ANIM, V32, P149, DOI 10.1258/002367798780600025; LIN MT, 1978, CAN J PHYSIOL PHARM, V56, P963, DOI 10.1139/y78-153; LIND RC, 1987, ANESTH ANALG, V66, P222; LIND RC, 1989, ANESTHESIOLOGY, V71, P878, DOI 10.1097/00000542-198912000-00011; Linden RD, 2000, CONTEMP TOP LAB ANIM, V39, P40; Lindsay DS, 2005, J PARASITOL, V91, P1488, DOI 10.1645/GE-732R.1; LIPMAN NS, 1987, LAB ANIM SCI, V37, P474; Liu KS, 2004, BRIT J ANAESTH, V92, P712, DOI 10.1093/bja/aeh126; Loepke AW, 2006, ANESTH ANALG, V102, P75, DOI 10.1213/01.ANE.0000181102.92729.B8; LOOMIS CW, 1989, ANESTHESIOLOGY, V71, P704, DOI 10.1097/00000542-198911000-00013; Lorenz JN, 2002, AM J PHYSIOL-REG I, V282, pR1565, DOI 10.1152/ajpregu.00759.2001; LUCIANO L, 1992, ARCH HISTOL CYTOL, V55, P131, DOI 10.1679/aohc.55.Suppl_131; Lumb W.V., 1984, LUMB JONES VET ANEST; LUNAM CA, 1985, J PHARMACOL EXP THER, V232, P802; Lutz M, 2006, ANESTH ANALG, V102, P984, DOI 10.1213/01.ane.0000198568.79079.4c; MACDONALD E, 1989, ACTA VET SCAND, P77; MAHELOVA O, 1991, PHYSIOL RES, V40, P355; Malik AA, 2002, J ENDOUROL, V16, P605, DOI 10.1089/089277902320913314; MARIANI L, 1978, TOXICOL APPL PHARM, V45, P637, DOI 10.1016/0041-008X(78)90126-6; Martin LBE, 2001, COMPARATIVE MED, V51, P43; Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020; Matson DJ, 2007, J PHARMACOL EXP THER, V320, P194, DOI 10.1124/jpet.106.109736; Matsuura S, 2006, ANESTH ANALG, V102, P1703, DOI 10.1213/01.ane.0000216001.36932.a3; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MCLAUGHLIN CR, 1994, PHARMACOL BIOCHEM BE, V49, P1017, DOI 10.1016/0091-3057(94)90258-5; McLaughlin JP, 2006, NEUROPSYCHOPHARMACOL, V31, P1241, DOI 10.1038/sj.npp.1300872; Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7; Lopez JRM, 2006, EUR J PHARMACOL, V544, P31, DOI 10.1016/j.ejphar.2006.06.041; MEERT TF, 1994, ANESTHESIOLOGY, V81, P677, DOI 10.1097/00000542-199409000-00022; Meert TF, 2005, PHARMACOL BIOCHEM BE, V80, P309, DOI 10.1016/j.pbb.2004.12.002; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; Mellon RD, 2001, DRUG ALCOHOL DEPEN, V62, P141, DOI 10.1016/S0376-8716(00)00184-8; MERTENS J, 1991, EUR ARCH OTO-RHINO-L, V248, P402, DOI 10.1007/BF01463563; MESSIHA FS, 1991, NEUROTOXICOLOGY, V12, P571; Mets B, 1997, ACTA ANAESTH SCAND, V41, P252, DOI 10.1111/j.1399-6576.1997.tb04675.x; Metten P, 2007, BEHAV GENET, V37, P160, DOI 10.1007/s10519-006-9094-3; Meyer RE, 2005, LAB ANIMAL, V34, P47, DOI 10.1038/laban1105-47; Mickley GA, 2006, J AM ASSOC LAB ANIM, V45, P48; MILANES MV, 1984, GEN PHARMACOL, V15, P357, DOI 10.1016/0306-3623(84)90015-6; Millecamps M, 2005, ARTHRITIS RHEUM-US, V52, P3470, DOI 10.1002/art.21403; MIMURA M, 1990, PSYCHOPHARMACOLOGY, V102, P399, DOI 10.1007/BF02244110; MIMURA M, 1992, ACTA ANAESTH SCAND, V36, P460, DOI 10.1111/j.1399-6576.1992.tb03497.x; MISHRA Y, 1992, CAN J ANAESTH, V39, P370, DOI 10.1007/BF03009048; MISHRA Y, 1993, ANESTH ANALG, V77, P780; MISHRA Y, 1992, CLIN EXP PHARMACOL P, V19, P803, DOI 10.1111/j.1440-1681.1992.tb00418.x; MISHRA Y, 1993, CAN J ANAESTH, V40, P32, DOI 10.1007/BF03009315; MISHRA Y, 1993, ANESTH ANALG, V76, P627; MOLINA VA, 1994, PSYCHOPHARMACOLOGY, V114, P433, DOI 10.1007/BF02249333; Molthen RC, 2006, J AM ASSOC LAB ANIM, V45, P88; MORCH ET, 1956, J PHARMACOL EXP THER, V117, P184; Morimoto K, 2001, J VET MED A, V48, P303, DOI 10.1046/j.1439-0442.2001.00360.x; MUIR WW, 1989, HDB VET ANESTHESIA; MULDER JB, 1978, LAB ANIM SCI, V28, P70; MULDER JB, 1978, J AM VET MED ASSOC, V173, P1252; MULDER KJ, 1979, VET MED SM ANIM CLIN, V74, P569; Nadeson R, 2000, PAIN, V88, P31, DOI 10.1016/S0304-3959(00)00300-6; National Institute for Occupational Safety and Health, 1977, CRIT REC STAND OCC E; Nelson CJ, 1997, ANESTH ANALG, V85, P620, DOI 10.1097/00000539-199709000-00024; NEMETH S, 1985, ENDOCRINOL EXP, V19, P91; NEUGEBAUER V, 1994, AGENTS ACTIONS, V41, P62, DOI 10.1007/BF01986396; NEVALAINEN T, 1989, ACTA VET SCAND, P139; NEWTON WM, 1975, LAB ANIM SCI, V25, P597; Nielsen AN, 2004, EUR J PHARMACOL, V487, P93, DOI 10.1016/j.ejphar.2004.01.017; NIELSEN GD, 1985, ACTA PHARMACOL TOX, V56, P165; Nikfar S, 1997, GEN PHARMACOL-VASC S, V29, P583, DOI 10.1016/S0306-3623(96)00575-7; Nishiyama T, 2006, ACTA ANAESTH SCAND, V50, P228, DOI 10.1111/j.1399-6576.2006.00921.x; Njoku D, 1997, ANESTH ANALG, V84, P173, DOI 10.1097/00000539-199701000-00031; Noguchi M, 2005, EUR J PHARMACOL, V513, P229, DOI 10.1016/j.ejphar.2005.01.058; NORRIS ML, 1983, LAB ANIM, V17, P324, DOI 10.1258/002367783781062370; Noseworthy MD, 1997, J BIOCHEM BIOPH METH, V34, P107, DOI 10.1016/S0165-022X(97)01207-4; NOTARNICOLA A, 1983, LIFE SCI, V33, P481, DOI 10.1016/0024-3205(83)90546-5; Obal D, 2003, CAN J ANAESTH, V50, P940, DOI 10.1007/BF03018744; Obal D, 2001, BRIT J ANAESTH, V87, P905, DOI 10.1093/bja/87.6.905; Office of Laboratory Animal Welfare National Institutes of Health, 2002, PUBL HLTH SERV POL H; Ogawa A, 2003, NEUROSCIENCE, V120, P1081, DOI 10.1016/S0306-4522(03)00214-8; OLSON ME, 1988, LAB ANIM SCI, V38, P299; OLSON ME, 1986, J AM VET MED ASSOC, V189, P1035; Omisore NOA, 2004, J ETHNOPHARMACOL, V95, P7, DOI 10.1016/j.jep.2004.05.022; Ordodi VL, 2005, LAB ANIMAL, V34, P37, DOI 10.1038/laban0905-37; Oropeza-Hernandez LF, 2002, PHARMACOL BIOCHEM BE, V72, P937, DOI 10.1016/S0091-3057(02)00767-0; Ortiz MI, 2002, EUR J PHARMACOL, V438, P85, DOI 10.1016/S0014-2999(02)01288-8; OSTROWSKI NL, 1979, PHARMACOL BIOCHEM BE, V11, P673, DOI 10.1016/0091-3057(79)90261-2; Ozdogan UK, 2006, EUR J PHARMACOL, V529, P105, DOI 10.1016/j.ejphar.2005.10.029; Ozdogan UK, 2004, EUR J PHARMACOL, V497, P161, DOI 10.1016/j.ejphar.2004.06.051; Paddleford R R, 1986, Semin Vet Med Surg Small Anim, V1, P249; Padi SSV, 2004, EUR J PHARMACOL, V491, P69, DOI 10.1016/j.ejphar.2004.03.013; Page GG, 2002, J PAIN, V3, P301, DOI 10.1054/jpai.2002.125184; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; Pape M, 2006, ANESTH ANALG, V103, P173, DOI 10.1213/01.ane.0000222634.51192.a4; Paris A, 2005, ANESTH ANALG, V100, P102, DOI 10.1213/01.ANE.0000139355.86522.D1; Park KW, 1998, ANESTH ANALG, V86, P646, DOI 10.1097/00000539-199803000-00039; Park WK, 1996, ANESTHESIOLOGY, V84, P1166, DOI 10.1097/00000542-199605000-00019; Parkhill AL, 2006, INT IMMUNOPHARMACOL, V6, P1013, DOI 10.1016/j.intimp.2006.01.012; PAVONE F, 1989, DEV BRAIN RES, V49, P156, DOI 10.1016/0165-3806(89)90071-0; Payne RS, 2005, BRAIN RES, V1034, P147, DOI 10.1016/j.brainres.2004.12.006; PAYTON AJ, 1993, CORNELL VET, V83, P153; Penderis J, 2005, VET ANAESTH ANALG, V32, P256, DOI 10.1111/j.1467-2995.2005.00183.x; Perez-Garcia CC, 2003, LAB ANIM-UK, V37, P68, DOI 10.1258/002367703762226719; Petzelt C, 2003, LIFE SCI, V72, P1909, DOI 10.1016/S0024-3205(02)02439-6; PHIFER CB, 1986, PHYSIOL BEHAV, V38, P887, DOI 10.1016/0031-9384(86)90058-2; Pick CG, 1996, EUR NEUROPSYCHOPHARM, V6, P201, DOI 10.1016/0924-977X(96)00021-1; PICK CG, 1991, BRAIN RES, V566, P295, DOI 10.1016/0006-8993(91)91712-A; Piersma FE, 1999, LAB ANIM-UK, V33, P328, DOI 10.1258/002367799780487887; Pinardi G, 2005, PHARMACOL BIOCHEM BE, V82, P120, DOI 10.1016/j.pbb.2005.07.017; Plachinta RV, 2003, ANESTHESIOLOGY, V98, P89, DOI 10.1097/00000542-200301000-00017; Planas E, 2003, EUR J PHARMACOL, V482, P223, DOI 10.1016/j.ejphar.2003.09.048; Plate AYA, 2005, ANESTH ANALG, V101, P1063, DOI 10.1213/01.ane.0000166791.30963.ef; Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008; POOLE TB, 1987, UFAW HDB CARE MANAGE; Poonawala T, 2005, WOUND REPAIR REGEN, V13, P165, DOI 10.1111/j.1067-1927.2005.130207.x; Poveda R, 2003, EUR J PAIN, V7, P439, DOI 10.1016/S1090-3801(03)00003-X; Poyhia R, 1999, ANESTH ANALG, V89, P428, DOI 10.1097/00000539-199908000-00033; Prado WA, 2002, BRAZ J MED BIOL RES, V35, P111, DOI 10.1590/S0100-879X2002000100016; Prechel MM, 2000, NEUROCHEM RES, V25, P357, DOI 10.1023/A:1007588903897; Public Health Service (PHS), 2002, POL HUM CAR US LAB A; Puig NR, 1999, REPROD TOXICOL, V13, P361, DOI 10.1016/S0890-6238(99)00031-3; Radde GR, 1996, LAB ANIM-UK, V30, P220, DOI 10.1258/002367796780684935; Rampil IJ, 2006, ANESTH ANALG, V102, P1431, DOI 10.1213/01.ane.0000202384.96269.51; Rampil IJ, 1996, ANESTHESIOLOGY, V85, P129, DOI 10.1097/00000542-199607000-00018; Rana J, 1995, In Vivo, V9, P163; Randolph B C, 1997, Anesth Prog, V44, P11; Rank J., 1989, Scandinavian Journal of Laboratory Animal Science, V16, P115; RAO SB, 1990, INDIAN VET J, V67, P339; Reboucas ECC, 2005, PSYCHOPHARMACOLOGY, V179, P349, DOI 10.1007/s00213-004-2045-x; Redwine KE, 2003, PHARMACOL BIOCHEM BE, V76, P361, DOI 10.1016/j.pbb.2003.08.009; REID WD, 1989, LAB ANIM, V23, P156, DOI 10.1258/002367789780863592; Rembert MS, 2004, LAB ANIM-UK, V38, P55, DOI 10.1258/00236770460734407; Rhodes J, 2001, COMPARATIVE MED, V51, P457; Richardson CA, 2005, ATLA-ALTERN LAB ANIM, V33, P119, DOI 10.1177/026119290503300207; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Rieg T, 2004, N-S ARCH PHARMACOL, V370, P320, DOI 10.1007/s00210-004-0982-x; Robertson Sheilah A., 2001, Veterinary Clinics of North America Exotic Animal Practice, V4, P1; Rodrigues SF, 2006, LIFE SCI, V79, P1630, DOI 10.1016/j.lfs.2006.05.019; Rofael HZ, 2003, TOXICOLOGY, V188, P101, DOI 10.1016/S0300-483X(03)00081-7; Rogers B, 1986, AAOHN J, V34, P574; Roughan JV, 2004, BEHAV PHARMACOL, V15, P461, DOI 10.1097/00008877-200411000-00002; Roughan JV, 1999, LAB ANIM-UK, V33, P234, DOI 10.1258/002367799780578183; Roughan JV, 2003, EUR J PAIN, V7, P397, DOI 10.1016/S1090-3801(02)00140-4; Roughan JV, 2002, LAB ANIM-UK, V36, P322, DOI 10.1258/002367702320162423; Roughan JV, 2001, PAIN, V90, P65, DOI 10.1016/S0304-3959(00)00387-0; Roy S, 2005, J NEUROSCI, V25, P3229, DOI 10.1523/JNEUROSCI.0332-05.2005; RUSSELL GB, 1995, PHARMACOLOGY, V50, P162, DOI 10.1159/000139278; Russell WMS, 1959, PRINCIPLES HUMANE EX; Sabetkasaie M, 2004, EUR J PHARMACOL, V501, P95, DOI 10.1016/j.ejphar.2004.08.010; Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa; SAGE MD, 1985, LAB ANIM SCI, V35, P153; Saito Osamu, 2005, J Anesth, V19, P218, DOI 10.1007/s00540-005-0323-3; Santos ARS, 1998, INFLAMM RES, V47, P302, DOI 10.1007/s000110050333; SARLIS N J, 1991, Middle East Journal of Anesthesiology, V11, P271; Sarraf-Yazdi S, 1999, J NEUROSURG ANESTH, V11, P31, DOI 10.1097/00008506-199901000-00006; Saurer TB, 2006, J NEUROIMMUNOL, V173, P3, DOI 10.1016/j.jneuroim.2005.11.009; SCHAEFER CF, 1984, J APPL PHYSIOL, V56, P533; SCHMIDT WK, 1985, DRUG ALCOHOL DEPEN, V14, P339, DOI 10.1016/0376-8716(85)90066-3; SCHOLER DW, 1986, AM J MED, V80, P34, DOI 10.1016/0002-9343(86)90077-X; SCHULTZ VL, 1995, J BONE MINER RES, V10, P1298; Schwenke DO, 2004, COMPARATIVE MED, V54, P77; Segato FN, 1997, BRAZ J MED BIOL RES, V30, P981, DOI 10.1590/S0100-879X1997000800011; Sendil D, 2003, BIOMATERIALS, V24, P1969, DOI 10.1016/S0142-9612(02)00567-7; Serita R, 2002, BRIT J ANAESTH, V89, P896, DOI 10.1093/bja/aef282; SEVERS WB, 1981, PHARMACOLOGY, V22, P209, DOI 10.1159/000137493; Sharma Sameer, 2005, Indian Journal of Experimental Biology, V43, P498; Sharp J, 2003, CONTEMP TOP LAB ANIM, V42, P22; Sheffels P, 2004, CHEM RES TOXICOL, V17, P1177, DOI 10.1021/tx049899e; Shin Y S, 1992, J Anesth, V6, P1; Shuey DL, 2007, TOXICOL SCI, V96, P162, DOI 10.1093/toxsci/kfl178; SILVERMAN J, 1993, LAB ANIM SCI, V43, P210; SILVERMAN J, 1986, LAB ANIM SCI, V36, P539; Silverman J, 2003, LAB ANIMAL, V32, P19, DOI 10.1038/laban1103-19a; SILVERMAN J, 1983, LAB ANIM SCI, V33, P457; Simpson DP, 1997, LAB ANIM SCI, V47, P519; Sintov AC, 2004, J CONTROL RELEASE, V95, P173, DOI 10.1016/j.jconrel.2003.11.004; Skeehan TM, 1995, J CARDIOTHOR VASC AN, V9, P706, DOI 10.1016/S1053-0770(05)80233-2; SKORNIK WA, 1990, J APPL PHYSIOL, V68, P2536; Sluka KA, 2002, PAIN, V100, P183, DOI 10.1016/S0304-3959(02)00294-4; SMILER KL, 1990, LAB ANIM SCI, V40, P60; SMITH JA, 1993, SEMIN VET MED SURG, V8, P90; Smith JC, 2004, LAB ANIM-UK, V38, P38, DOI 10.1258/00236770460734371; Smith JC, 2003, CONTEMP TOP LAB ANIM, V42, P10; Smith LJ, 2006, COMPARATIVE MED, V56, P487; Smith LJ, 2003, COMPARATIVE MED, V53, P280; Smith MA, 2002, PSYCHOPHARMACOLOGY, V162, P255, DOI 10.1007/s00213-002-1102-6; Smith MA, 2001, PSYCHOPHARMACOLOGY, V156, P445, DOI 10.1007/s002130100750; Smith DE, 1999, CONTEMP TOP LAB ANIM, V38, P84; Smith LJ, 2002, PAIN, V97, P267, DOI 10.1016/S0304-3959(02)00028-3; Smith MA, 2003, PSYCHOPHARMACOLOGY, V168, P426, DOI 10.1007/s00213-003-1471-5; Sonner JM, 1999, ANESTH ANALG, V89, P1030, DOI 10.1097/00000539-199910000-00039; Sonner JM, 2000, ANESTH ANALG, V91, P720, DOI 10.1213/00000539-200009000-00042; SORAHAN T, 1993, BRIT J IND MED, V50, P528; STACKMAN RW, 1992, BEHAV NEURAL BIOL, V57, P233, DOI 10.1016/0163-1047(92)90206-J; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Steffey MA, 2003, AM J VET RES, V64, P470, DOI 10.2460/ajvr.2003.64.470; Sternberg WF, 2005, PAIN, V113, P347, DOI 10.1016/j.pain.2004.11.013; Sternberg WF, 2004, NEUROSCI LETT, V363, P178, DOI 10.1016/j.neulet.2004.04.004; STERNBERG WF, 1995, EUR J ANAESTH, V12, P14; Sternberg WF, 2003, PHYSIOL BEHAV, V78, P375, DOI 10.1016/S0031-9384(03)00015-5; Stevenson GW, 2006, J PAIN, V7, P408, DOI 10.1016/j.jpain.2006.01.447; Stewart LSA, 2003, COMPARATIVE MED, V53, P29; Stewart LSA, 2003, CONTEMP TOP LAB ANIM, V42, P28; Stringer SK, 1996, LAB ANIM SCI, V46, P430; Suganuma T, 1998, BIOL PHARM BULL, V21, P756; Sun FJ, 2003, CONTEMP TOP LAB ANIM, V42, P32; Sunaga H, 2006, ANESTH ANALG, V103, P601, DOI 10.1213/01.ane.0000229720.13815.73; Szczesny G, 2004, LAB ANIM-UK, V38, P64, DOI 10.1258/00236770460734416; Taira Y, 2000, BRIT J ANAESTH, V85, P881, DOI 10.1093/bja/85.6.881; Takada K, 2002, ANESTHESIOLOGY, V96, P1420, DOI 10.1097/00000542-200206000-00022; Takahashi K, 1997, ANESTH ANALG, V85, P347, DOI 10.1097/00000539-199708000-00019; Takahashi M, 2005, REGION ANESTH PAIN M, V30, P351, DOI 10.1016/j.rapm.2005.04.010; Tanaka T, 1993, J Anesth, V7, P75, DOI 10.1007/s0054030070075; TATSUO MAKF, 1994, INFLAMMATION, V18, P399, DOI 10.1007/BF01534437; Taylor J, 1998, EUR J PHARMACOL, V351, P39, DOI 10.1016/S0014-2999(98)00298-2; Taylor R, 2000, CONTEMP TOP LAB ANIM, V39, P14; Terner JM, 2002, PSYCHOPHARMACOLOGY, V163, P183, DOI 10.1007/s00213-002-1143-x; Themistocleous A, 2007, J PAIN, V8, P208, DOI 10.1016/j.jpain.2006.07.003; Thompson AC, 2004, COMPARATIVE MED, V54, P293; Thompson AC, 2006, J AM ASSOC LAB ANIM, V45, P13; Thompson JS, 2002, COMPARATIVE MED, V52, P63; Thornton SR, 1998, DEV BRAIN RES, V105, P269, DOI 10.1016/S0165-3806(97)00185-5; Thurmon J. C., 1996, LUMB JONES VET ANEST, P183; Tokuyama S, 1998, LIFE SCI, V62, P1677, DOI 10.1016/S0024-3205(98)00127-1; Torjman MC, 2005, INT J PHARM, V294, P65, DOI 10.1016/j.ijpharm.2004.12.028; Torres-Lopez JE, 2002, LIFE SCI, V70, P1669, DOI 10.1016/S0024-3205(02)01491-1; Tortorici V, 1996, BRAIN RES, V725, P106, DOI 10.1016/0006-8993(96)00196-5; TORTORICI V, 1994, PAIN, V57, P197, DOI 10.1016/0304-3959(94)90224-0; TOWETT PK, 1993, PHARMACOL BIOCHEM BE, V45, P153, DOI 10.1016/0091-3057(93)90099-F; Tsutsumi YM, 2006, AM J PHYSIOL-HEART C, V291, pH979, DOI 10.1152/ajpheart.00266.2006; Tsutsumi YM, 2006, ANESTHESIOLOGY, V104, P495, DOI 10.1097/00000542-200603000-00017; Turner PV, 2005, COMPARATIVE MED, V55, P175; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; VACCARINO AL, 1988, NEUROSCI LETT, V84, P103, DOI 10.1016/0304-3940(88)90345-X; Vahl TP, 2005, AM J PHYSIOL-ENDOC M, V289, pE823, DOI 10.1152/ajpendo.00122.2005; Vaillancourt C, 1999, EXP NEUROL, V160, P142, DOI 10.1006/exnr.1999.7201; Vanegas H, 2002, CELL MOL NEUROBIOL, V22, P655, DOI 10.1023/A:1021896622089; VANLOVEREN H, 1994, LAB ANIM-UK, V28, P355, DOI 10.1258/002367794780745119; VANPELT LF, 1977, J AM VET MED ASSOC, V171, P842; Veiga APC, 2004, LIFE SCI, V75, P2807, DOI 10.1016/j.lfs.2004.05.028; Vella ET, 2004, COMPARATIVE MED, V54, P202; Vergari A, 2004, Eur Rev Med Pharmacol Sci, V8, P103; Vergari A, 2003, LAB ANIM-UK, V37, P204, DOI 10.1258/002367703766453047; Verma-Gandhu M, 2006, GASTROENTEROLOGY, V130, P1721, DOI 10.1053/j.gastro.2006.01.045; VICKERY B, 1979, PROSTAG LEUKOTR ESS, V2, P325, DOI 10.1016/0161-4630(79)90105-8; VIRTANEN R, 1989, ACTA VET SCAND, P29; Volker D, 2000, LAB ANIM-UK, V34, P423, DOI 10.1258/002367700780387732; Wakeno-Takahashi M, 2005, AM J PHYSIOL-HEART C, V289, pH2585, DOI 10.1152/ajpheart.00400.2005; Walker JS, 2003, ADV EXP MED BIOL, V521, P148; Walker JS, 1996, INFLAMM RES, V45, P557, DOI 10.1007/BF02342227; Wang JJ, 2006, J CONTROL RELEASE, V115, P140, DOI 10.1016/j.jconrel.2006.07.023; WARD GS, 1974, LAB ANIM SCI, V24, P737; Watkins JC, 2006, BRIT J PHARMACOL, V147, pS100, DOI 10.1038/sj.bjp.0706444; Weber NC, 2005, BRIT J PHARMACOL, V144, P123, DOI 10.1038/sj.bjp.0706063; WEICHBROD RH, 1988, LAB ANIM SCI, V38, P296; Weinandy R, 2005, LAB ANIM-UK, V39, P200, DOI 10.1258/0023677053739828; WEINGER MB, 1995, BRIT J ANAESTH, V74, P455, DOI 10.1093/bja/74.4.455; Weiss J, 1999, LAB ANIM, V33, P192, DOI 10.1258/002367799780578417; WEKSLER B, 1994, J APPL PHYSIOL, V76, P1823; Welberg LAM, 2006, J AM ASSOC LAB ANIM, V45, P13; WEST CD, 1987, LAB ANIM, V21, P143, DOI 10.1177/002367728702100211; West JP, 1998, DRUG ALCOHOL DEPEN, V53, P31, DOI 10.1016/S0376-8716(98)00109-4; WHITE WJ, 1987, VET CLIN N AM-SMALL, V17, P989, DOI 10.1016/S0195-5616(87)50102-4; Whiteside GT, 2004, BRIT J PHARMACOL, V141, P85, DOI 10.1038/sj.bjp.0705568; Whittington RA, 2006, ANESTH ANALG, V103, P92, DOI 10.1213/01.ane.0000221488.48352.61; Wiesmann F, 2000, AM J PHYSIOL-HEART C, V278, pH652; Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031; Williams Jon L., 2005, Psychological Record, V55, P3; Wilson AW, 2006, EUR J PAIN, V10, P537, DOI 10.1016/j.ejpain.2005.08.003; WILSON RP, 1992, PHARMACOL BIOCHEM BE, V43, P1129, DOI 10.1016/0091-3057(92)90492-X; Wilson SG, 2003, J PHARMACOL EXP THER, V304, P547, DOI 10.1124/jpet.102.041889; Wixson S.K., 1997, ANESTHESIA ANALGESIA, P166; WIXSON SK, 1987, LAB ANIM SCI, V37, P726; WIXSON SK, 1987, LAB ANIM SCI, V37, P731; WIXSON SK, 1987, LAB ANIM SCI, V37, P736; WIXSON SK, 1987, LAB ANIM SCI, V37, P743; Wood AKW, 2001, ACAD RADIOL, V8, P1136, DOI 10.1016/S1076-6332(03)80727-4; WOOLFOLK DR, 1995, PHARMACOL BIOCHEM BE, V51, P699, DOI 10.1016/0091-3057(94)00440-T; Wright-Williams SL, 2007, PAIN, V130, P108, DOI 10.1016/j.pain.2006.11.003; Yamakage M, 2002, CAN J ANAESTH, V49, P62, DOI 10.1007/BF03020420; Yamasaki A, 2001, BIOCHEM PHARMACOL, V62, P375, DOI 10.1016/S0006-2952(01)00664-5; Yamasaki K, 2003, EXP ANIM TOKYO, V52, P349, DOI 10.1538/expanim.52.349; Yang J, 2006, NEUROSCI RES, V54, P49, DOI 10.1016/j.neures.2005.10.006; Yokoro CM, 2003, BRAZ J MED BIOL RES, V36, P77, DOI 10.1590/S0100-879X2003000100011; Yu JG, 2004, CAN J ANAESTH, V51, P979, DOI 10.1007/BF03018483; Zagon IS, 1998, PHARMACOL BIOCHEM BE, V59, P201, DOI 10.1016/S0091-3057(97)00419-X; Zambricki EA, 2004, COMPARATIVE MED, V54, P49; ZATZMAN ML, 1988, CRYOBIOLOGY, V25, P212, DOI 10.1016/0011-2240(88)90028-4; Zelcer S, 2005, BRAIN RES, V1040, P151, DOI 10.1016/j.brainres.2005.01.070; Zeller W, 1998, LAB ANIM, V32, P407, DOI 10.1258/002367798780599811; Zhan XH, 2006, ANESTHESIOLOGY, V104, P995, DOI 10.1097/00000542-200605000-00016; Zhang RX, 2004, PHARMACOL BIOCHEM BE, V78, P793, DOI 10.1016/j.pbb.2004.05.010; Zhang Y, 2000, ANESTH ANALG, V91, P462, DOI 10.1097/00000539-200008000-00044; Zhao CS, 2004, J PAIN, V5, P104, DOI 10.1016/j.jpain.2003.12.001; Zhao P, 2004, ANESTHESIOLOGY, V101, P695, DOI 10.1097/00000542-200409000-00018; Zhou JX, 2006, ANESTH ANALG, V102, P129, DOI 10.1213/01.ane.0000189612.24147.07; ZHU CB, 1995, ACTA PHARM SINIC, V16, P311; Zuurbier CJ, 2002, AM J PHYSIOL-HEART C, V282, pH2099, DOI 10.1152/ajpheart.01002.2001; Zvara DA, 2006, ANESTH ANALG, V102, P1341, DOI 10.1213/01.ane.0000204357.06219.8c	612	81	82	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS			978-0-12-373898-1; 978-0-12-373898-1	AM COLL LAB			2008							239	297		10.1016/B978-012373898-1.50014-0			59	Veterinary Sciences	Veterinary Sciences	BED52	WOS:000316210000011					2021-06-18	
J	Arimoto, T; Choi, DY; Lu, X; Liu, M; Nguyen, XV; Zheng, NY; Stewart, CA; Kim, HC; Bing, GY				Arimoto, Toyoko; Choi, Dong-Young; Lu, Xin; Liu, Mei; Nguyen, Xuan V.; Zheng, Naiying; Stewart, Charles A.; Kim, Hyoung-Chun; Bing, Guoying			Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra	NEUROBIOLOGY OF AGING			English	Article						lipopolysaccharide (LPS); inflammation; neurodegeneration; dopaminergic neuron; apoptosis; microglia; interleukin-10 (IL-10); Parkinson's disease (PD)	NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; MICROGLIAL ACTIVATION; FACTOR-ALPHA; CELL-DEATH; ALZHEIMERS-DISEASE; PC12 CELLS; INTRANIGRAL INJECTION	Inflammation has been increasingly recognized to play an important role in the pathogenesis of Parkinson's disease (PD). Using immunocytochemistry and electron microscopy, we found that intranigral injection of lipopolysaccharide (LPS) caused marked microglial activation and a dose-dependent selective loss of dopaminergic neurons, which was mediated by apoptosis as evidenced by prominent TUNEL labeling. RNase protection assays revealed that mRNA for Bax, Fas and the pro-inflammatory cytokines interleukin (IL)-1 alpha, IL-1 beta, IL-6 and tumor necrosis factor (TNF)-alpha were significant increased ipsilaterally in LPS-injected side of SN, while expression of the anti-apoptotic gene Bcl-2 was decreased. Osmotic pump infusion of IL-10, a global inhibitor of cytokine synthesis, protected against LPS-induced cell death of dopaminergic neurons, with a corresponding decrease in the number of activated microglia, suggesting that the reduction in microglia-mediated release of inflammatory mediators may contribute to the anti-inflammatory effect of IL-10. Our results provide evidence that LPS induces apoptotic cell death in SNpc, which is likely through the expression of Fas, Bax, caspase-3, and the pro- inflammatory cytokines. (c) 2006 Elsevier Inc. All rights reserved.	Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Natl Inst Environm Studies, Div Environm Hlth Sci, Tsukuba, Ibaraki, Japan; Oklahoma Med Res Fdn, Free Rad Aging Res Program, Oklahoma City, OK 73104 USA; Kangwon Natl Univ, Coll Pharm, Chunchon 200701, South Korea	Bing, GY (corresponding author), Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA.	gbing@pop.uky.edu	Nguyen, Xuan V/G-5532-2012	Nguyen, Xuan V/0000-0002-2617-1938; Bing, Guoying/0000-0003-0609-8152	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39345] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039345] Funding Source: NIH RePORTER		Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Arimoto T, 2003, NEUROBIOL DIS, V12, P35, DOI 10.1016/S0969-9961(02)00017-7; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Becher B, 1996, J NEUROSCI RES, V45, P375; Bing G., 1998, NEUR ABSTR, V24, P44; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Bronstein DM, 1995, BRAIN RES, V704, P112, DOI 10.1016/0006-8993(95)01189-7; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; Castano A, 1998, J NEUROCHEM, V70, P1584; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHAO CC, 1995, DEV NEUROSCI-BASEL, V17, P97, DOI 10.1159/000111278; Cheeran MCJ, 2003, J VIROL, V77, P4502, DOI 10.1128/JVI.77.8.4502-4515.2003; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; Ding MZ, 1997, J BIOL CHEM, V272, P11327; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; DORHEIM MA, 1994, BIOCHEM BIOPH RES CO, V205, P659, DOI 10.1006/bbrc.1994.2716; Dugas N, 1998, CYTOKINE, V10, P680, DOI 10.1006/cyto.1998.0352; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Espey MG, 1997, NEUROREPORT, V8, P431, DOI 10.1097/00001756-199701200-00011; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Froen JF, 2002, BRAIN RES, V942, P87, DOI 10.1016/S0006-8993(02)02700-2; Galea E, 1996, J NEUROIMMUNOL, V64, P19, DOI 10.1016/0165-5728(95)00143-3; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Glabinski AR, 1999, J NEUROVIROL, V5, P623, DOI 10.3109/13550289909021291; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Gunnett C.A., 1999, STROKE, V30, P5; Gunnett CA, 1999, STROKE, V30, P2191, DOI 10.1161/01.STR.30.10.2191; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; Hartmann A, 2002, NEUROLOGY, V58, P308, DOI 10.1212/WNL.58.2.308; He Y, 2001, BRAIN RES, V909, P187, DOI 10.1016/S0006-8993(01)02681-6; Herrera AJ, 2000, NEUROBIOL DIS, V7, P429, DOI 10.1006/nbdi.2000.0289; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; Hu SX, 1999, J LEUKOCYTE BIOL, V65, P815; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; Janabi N, 1998, GLIA, V23, P304; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kingsbury AE, 1998, MOVEMENT DISORD, V13, P877, DOI 10.1002/mds.870130604; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kremlev SG, 2004, J NEUROIMMUNOL, V149, P1, DOI 10.1016/j.jneuroim.2003.11.012; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Ledeboer A, 2000, GLIA, V30, P134, DOI 10.1002/(SICI)1098-1136(200004)30:2<134::AID-GLIA3>3.0.CO;2-3; Lee HO, 2003, CYTOKINE GROWTH F R, V14, P325, DOI 10.1016/S1359-6101(03)00028-5; LEE SC, 1993, J IMMUNOL, V150, P2659; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Lodge PA, 1996, J LEUKOCYTE BIOL, V60, P502; Lu X, 2000, NEUROSCIENCE, V97, P285, DOI 10.1016/S0306-4522(00)00033-6; Marques CP, 2004, GLIA, V47, P358, DOI 10.1002/glia.20045; MATSUO M, 1995, BRAIN RES, V685, P201, DOI 10.1016/0006-8993(95)00490-H; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Mesples B, 2003, DEV BRAIN RES, V141, P25, DOI 10.1016/S0165-3806(02)00636-3; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; MOCHIZUKI H, 1994, NEUROSCI LETT, V170, P191, DOI 10.1016/0304-3940(94)90271-2; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mogi M, 1996, NEUROSCI LETT, V220, P195, DOI 10.1016/S0304-3940(96)13257-2; Molina-Holgado F, 2001, GLIA, V33, P97, DOI 10.1002/1098-1136(200102)33:2<97::AID-GLIA1009>3.0.CO;2-N; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; Ochu EE, 1998, J NEUROCHEM, V70, P2637; Paxinos G, 1998, PACE, V21, P728, DOI 10.1111/j.1540-8159.1998.tb00130.x; Peterson PK, 1997, J INFECT DIS, V175, P478, DOI 10.1093/infdis/175.2.478; RINK A, 1995, AM J PATHOL, V147, P1575; Sawa A, 1997, MOL BRAIN RES, V48, P53, DOI 10.1016/S0169-328X(97)00078-8; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; SELBY G, 1968, J NEUROL SCI, V6, P517, DOI 10.1016/0022-510X(68)90034-8; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; SHIGEMATSU K, 1992, J NEUROSCI RES, V31, P443, DOI 10.1002/jnr.490310306; SPOOREN WP, 1998, NEUROSCIENCE, V85, P53; Spooren WPJM, 1998, NEUROSCIENCE, V85, P649; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Takai N, 1998, J NEUROSCI RES, V54, P214, DOI 10.1002/(SICI)1097-4547(19981015)54:2<214::AID-JNR9>3.0.CO;2-H; Tatton NA, 1998, ANN NEUROL, V44, pS142, DOI 10.1002/ana.410440721; Tatton NA, 1997, NEUROSCIENCE, V77, P1037, DOI 10.1016/S0306-4522(96)00545-3; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Williams K, 1996, NEUROCHEM INT, V29, P55, DOI 10.1016/0197-0186(95)00138-7; Youdim MBH, 1997, SCI AM, V276, P52, DOI 10.1038/scientificamerican0197-52; Zhao ML, 2001, J NEUROIMMUNOL, V115, P182, DOI 10.1016/S0165-5728(00)00463-X	85	81	85	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	JUN	2007	28	6					894	906		10.1016/j.neurobiolaging.2006.04.011			13	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	164SB	WOS:000246253300011	21887889				2021-06-18	
J	Trivedi, MA; Ward, MA; Hess, TM; Gale, SD; Dempsey, RJ; Rowley, HA; Johnson, SC				Trivedi, Mehul A.; Ward, Michael A.; Hess, Timothy M.; Gale, Shawn D.; Dempsey, Robert J.; Rowley, Howard A.; Johnson, Sterling C.			Longitudinal changes in global brain volume between 79 and 409 days after traumatic brain injury: Relationship with duration of coma	JOURNAL OF NEUROTRAUMA			English	Article						brain volume change; injury severity; SIENA	ACCURATE; ATROPHY; MR	Neuropathological and experimental animal studies indicate that traumatic brain injury (TBI) results in long-term, neurodegenerative changes. Structural image evaluation using normalization of atrophy (SIENA) offers an automated analysis of the subtle changes in percent brain volume change (%BVC) associated with TBI. In the present study, SIENA was used to evaluate %BVC in individuals who had sustained a mild to severe TBI. We obtained three-dimensional (3D) TI-weighted anatomical magnetic resonance imaging (MRI) scans approximately 79 days and again 409 days post-injury. TBI patients (n = 37) displayed significantly greater decline in %BVC (-1.43%) relative to a normal comparison group (+0.1%, n = 30). Greater %BVC was associated with longer duration of post-injury coma. These results confirm previous findings from cross-sectional studies and argue that the brain undergoes continued structural change for several months post-injury.	William S Middleton Mem VA Hosp, GRECC, Madison, WI 53705 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurosurg, Madison, WI USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI USA; Barrow Neurol Inst, Dept Clin Neuropsychol, Phoenix, AZ 85013 USA	Johnson, SC (corresponding author), William S Middleton Mem VA Hosp, GRECC, 2500 Overlook Terrace,11G, Madison, WI 53705 USA.	scj@medicine.wisc.edu	Gale, Shawn/M-3144-2013	Gale, Shawn/0000-0002-8989-0964	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH065723-05, R01 MH65723, R01 MH065723, R01 MH065723-06] Funding Source: Medline		BARTSCH AJ, BRAIN, V130, P36; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BIGLER ED, 2005, TXB TRAUMATIC BRAIN, P79, DOI DOI 10.1007/S00417-005-0003-X; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Enzinger C, 2005, NEUROLOGY, V64, P1704, DOI 10.1212/01.WNL.0000161871.83614.BB; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1, P823; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2001, J COMPUT ASSIST TOMO, V25, P466, DOI 10.1097/00004728-200105000-00022; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046	13	81	82	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2007	24	5					766	771		10.1089/neu.2006.0205			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	167YT	WOS:000246489300002	17518532	Green Accepted			2021-06-18	
J	Ariza, M; Pueyo, R; Matarin, MD; Junque, C; Mataro, M; Clemente, I; Moral, P; Poca, MA; Garnacho, A; Sahuquillo, J				Ariza, M.; Pueyo, R.; Matarin, M. del M.; Junque, C.; Mataro, M.; Clemente, I.; Moral, P.; Poca, M. A.; Garnacho, A.; Sahuquillo, J.			Influence of APOE polymorphism on cognitive and behavioural outcome in moderate and severe traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							APOLIPOPROTEIN-E; HEAD-INJURY; ALZHEIMERS-DISEASE; RECOVERY; GENOTYPE; REHABILITATION; ASSOCIATION; EPSILON-4	Aim: To analyse the influence of apolipoprotein (APOE) is an element of 4 status on the cognitive and behavioural functions usually impaired after moderate and severe traumatic brain injury (TBI). Methods: In all, 77 patients with TBI selected from 140 consecutive admissions were genotyped for APOE. Each patient was subjected to neuropsychological and neurobehavioural assessment at least 6 months after injury. Results: Performance of participants carrying the is an element of 4 allele was notably worse on verbal memory (Auditory Verbal Learning Test), motor speed, fine motor coordination, visual scanning, attention and mental flexibility (Grooved Pegboard, Symbol Digit Modalities Test and part B of the Trail Making Test) and showed considerably more neurobehavioural disturbances (Neurobehavioral Rating Scale Revised) than the group without the is an element of 4 allele. Conclusions: In particular, performance on neuropsychological tasks that are presumed to be related to temporal lobe, frontal lobe and white matter integrity is worse in patients with the APOE is an element of 4 allele than in those without it. More neurobehavioural disturbances are observed in APOE is an element of 4 carriers than in APOE is an element of 2 and is an element of 3 carriers.	Univ Barcelona, Dept Psiquiatria & Psicobiol Clin, Barcelona 08035, Spain; IDIBAPS, Barcelona, Spain; Univ Barcelona, Dept Biol Anim, Barcelona 08035, Spain; Vall Hebron Univ Hosp, Dept Neurosurg, Barcelona, Spain; Vall Hebron Univ Hosp, Neurotraumatol Intens Care Unit, Barcelona, Spain	Ariza, M (corresponding author), Univ Barcelona, Dept Psiquiatria & Psicobiol Clin, Passeig Vall Hebron,171, Barcelona 08035, Spain.	marizago7@docd4.ub.edu	Poca, Maria A./B-8475-2008; Matarin, Mar/F-1771-2016; Clemente, I Concepcion/H-5399-2013; Sahuquillo, Juan/B-3577-2008; Junque, Carme/B-4400-2011; Garnacho, Angel/A-9309-2013; Mataro, Maria/B-4524-2011; Moral, Pedro/K-9587-2014; Ariza, Mar/F-2754-2019; Benito, Roser Pueyo/G-3433-2011	Poca, Maria A./0000-0002-3831-0536; Matarin, Mar/0000-0002-4717-5735; Clemente, I Concepcion/0000-0003-0728-0925; Sahuquillo, Juan/0000-0003-0713-5875; Junque, Carme/0000-0002-6381-3063; Mataro, Maria/0000-0002-9946-2656; Moral, Pedro/0000-0001-5072-5892; Benito, Roser Pueyo/0000-0002-8230-8409; Ariza, Mar/0000-0003-1020-6945			Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Mitrushina M., 1999, HDB NORMATIVE DATA N; Rey A., 1959, TEST COPIE REPROD ME; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teasdale TW, 2000, NEUROPSYCHOL REHABIL, V10, P151, DOI 10.1080/096020100389228; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	20	81	86	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2006	77	10					1191	1193		10.1136/jnnp.2005.085167			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	084LX	WOS:000240535500019	16614010	Green Published			2021-06-18	
J	Carlson, AP; Schermer, CR; Lu, SW				Carlson, Andrew P.; Schermer, Carol R.; Lu, Stephen W.			Retrospective evaluation of anemia and transfusion in traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-24, 2005	Atlanta, GA	Amer Assoc Surg Trauma			AUTOLOGOUS BLOOD-TRANSFUSION; SECONDARY SYSTEMIC INSULTS; SEVERE HEAD-INJURY; CEREBRAL HEMODYNAMICS; CANCER-SURGERY; NATURAL-KILLER; MANAGEMENT; HYPOXIA; CARE; METABOLISM	Background: Despite clear evidence in critical care that blood transfusion has an adverse impact on outcome, neurosurgical textbooks still recommend transfusion of patients with traumatic brain injury (TBI) to a hematocrit (HCT) of 30%. There is little empirical evidence to support this practice. The current study addresses transfusion requirements in TBI in terms of neurologic outcome. Methods: Retrospective record review of patients with severe TBI. Outcome measures were Glasgow Coma Scale score (GCS), Glasgow Outcome Score (GOS), and Ranchos Los Amigos Score (RLA) at hospital discharge (D/C); and GOS and Functional Independence Measures at follow-up. Association of outcomes with the number of days the HCT < 30% and lowest measured HCT were evaluated. Results: In all, 169 patients reviewed; 150 with D/C outcome data and 72 with long-term follow-up data. Univariate analysis showed that lowest measured HCT was associated with lower D/C GCS, D/C GOS, and RLA scores. Linear regression showed that more days with HCT < 30% were associated with improved neurologic outcomes measured by GOS (R-2 = 0.424, p < 0.001), GCS (R-2 = 0.381, p < 0.001) and RLA (R-2 = 0.392,p < 0.001) scores on D/C. Both transfusion and lowest measured HCT were significantly associated with all lower outcome scores on D/C. Additional factors with adverse impact on outcome were head Abbreviated Injury Score (AIS), Injury Severity Score, hyperglycemia, and hypotension. Long-term outcomes were only significantly associated with head AIS. Conclusions: Patients with severe TBI should not have a different transfusion threshold than other critical care patients. Prospective studies are needed to evaluate the effects of anemia in TBI.	Univ New Mexico, Dept Surg, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA	Lu, SW (corresponding author), Univ New Mexico, Dept Surg, MSC 10 5610, Albuquerque, NM 87131 USA.	swlu@salud.unm.edu	Carlson, Andrew P/B-4369-2012	Carlson, Andrew P/0000-0003-2189-3699			Bedell Eric, 2002, Anesthesiol Clin North Am, V20, P417, DOI 10.1016/S0889-8537(01)00010-4; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; CZER LSC, 1978, SURG GYNECOL OBSTET, V147, P363; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Goodnough LT, 2003, CRIT CARE MED, V31, pS678, DOI 10.1097/01.CCM.0000100124.50579.D9; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; Heiss MM, 1997, VOX SANG, V73, P237, DOI 10.1046/j.1423-0410.1997.7340237.x; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Lee EJ, 1999, J NEUROL SCI, V164, P117, DOI 10.1016/S0022-510X(99)00068-4; Lee EJ, 2001, J NEUROL SCI, V190, P3, DOI 10.1016/S0022-510X(01)00567-6; Marescal C, 1998, ANN FR ANESTH, V17, P234, DOI 10.1016/S0750-7658(98)80005-1; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; OPELZ G, 1973, TRANSPLANT P, V5, P253; OPELZ G, 1976, TRANSPLANTATION, V22, P380, DOI 10.1097/00007890-197610000-00010; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Winn HR, 2004, YOUMANS NEUROLOGICAL	23	81	88	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2006	61	3					567	571		10.1097/01.ta.0000231768.44727.a2			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	084YL	WOS:000240570200013	16966988				2021-06-18	
J	Leinhase, I; Schmidt, OI; Thurman, JM; Hossini, AM; Rozanski, M; Taha, ME; Scheffler, A; John, T; Smith, WR; Holers, VM; Stahel, PF				Leinhase, Iris; Schmidt, Oliver I.; Thurman, Joshua M.; Hossini, Amir M.; Rozanski, Michal; Taha, Mohy E.; Scheffler, Alice; John, Thilo; Smith, Wade R.; Holers, V. Michael; Stahel, Philip F.			Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	Annual Meeting of the German-Society-for-Trauma-Surgery	OCT 19-22, 2005	Berlin, GERMANY	German Soc Trauma Soc		complement; traumatic brain injury; neuroinflammation; neurodegeneration; gene expression	CLOSED-HEAD INJURY; CENTRAL-NERVOUS-SYSTEM; C5A RECEPTOR; AXONAL INJURY; CRRY-IG; MICE; PROTEIN; ACTIVATION; REGULATOR; DEMYELINATION	The complement system represents an important mediator of neuroinflammation in traumatic brain injury. We have previously shown that transgenic mice with central nervous system-targeted overexpression of Crry, a potent murine complement inhibitor at the level of C3 convertases, are protected from complement-mediated neuropathological sequelae in brain-injured mice. This knowledge was expanded in the present study to a pharmacological approach by the use of a recombinant Crry molecule (termed Crry-Ig) which was recently made available in a chimeric form fused to the non-complement fixing mouse IgG1 Fc region. In a standardized model of closed head injury in mice, the systemic injection of I mg Crry-Ig at I h and 24 h after trauma resulted in a significant neurological improvement for up to 7 days, as compared to vehicle-injected control mice (P < 0.05, repeated measures ANOVA). Furthermore, the extensive neuronal destruction seen in the hippocampal CA3/CA4 sublayers in head-injured mice with vehicle injection only was shown to be preserved - to a similar extent as in "sbam"-operated mice - by the posttraumatic injection of Crry-Ig. Real-time RT-PCR analysis revealed that the post-treatment with Crry-Ig resulted in a significant up-regulation of candidate neuroprotective genes in the injured hemisphere (Bcl-2, C1-Inh, CD55, CD59), as compared to the vehicle control group (P < 0.01, unpaired Student's t test). Increased intracerebral Bcl-2 expression by Crry-Ig treatment was furthermore confirmed at the protein level by Western blot analysis. These data suggest that pharmacological complement inhibition represents a promising approach for attenuation of neuroinflammation and secondary neurodegeneration after head injury. (c) 2006 Elsevier Inc. All rights reserved.	Univ Berlin, Med Sch, Dept Trauma & Reconstruct Surg, D-12200 Berlin, Germany; Univ Colorado, Hlth Sci Ctr, Div Rheumatol, Dept Med, Denver, CO 80309 USA; Univ Colorado, Denver Hlth Med Ctr, Dept Orthoped, Denver, CO 80309 USA	Stahel, PF (corresponding author), Univ Berlin, Med Sch, Dept Trauma & Reconstruct Surg, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	pfstahel@aol.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08DK064790] Funding Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK064790-02] Funding Source: Medline		Alexander JJ, 2003, BBA-MOL BASIS DIS, V1639, P169, DOI 10.1016/j.bbadis.2003.09.005; Baalasubramanian S, 2004, J IMMUNOL, V173, P3684, DOI 10.4049/jimmunol.173.6.3684; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; D'Ambrosio AL, 2001, MOL MED, V7, P367, DOI 10.1007/BF03402183; Davoust N, 1999, GLIA, V27, P162, DOI 10.1002/(SICI)1098-1136(199908)27:2<162::AID-GLIA6>3.0.CO;2-K; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Elf K, 2003, EUR J TRAUMA, V29, P74; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Fecker LF, 2005, J INVEST DERMATOL, V124, P221, DOI 10.1111/j.0022-202X.2004.23572.x; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; FOLEY S, 1993, EUR J IMMUNOL, V23, P1381, DOI 10.1002/eji.1830230630; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Harris CL, 2002, BIOCHEM SOC T, V30, P1019, DOI 10.1042/bst0301019; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kulkarni AP, 2004, ANN NY ACAD SCI, V1035, P147, DOI 10.1196/annals.1332.010; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Mead RJ, 2004, LAB INVEST, V84, P21, DOI 10.1038/labinvest.3700015; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Mizuno M., 2004, Current Drug Targets - Inflammation and Allergy, V3, P87, DOI 10.2174/1568010043483890; Molina H, 2002, CELL MOL LIFE SCI, V59, P220, DOI 10.1007/s00018-002-8418-6; Morgan BP, 2005, XENOTRANSPLANTATION, V12, P258, DOI 10.1111/j.1399-3089.2005.00237.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Quigg RJ, 1998, J IMMUNOL, V160, P4553; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Reed AR, 2002, SAMJ S AFR MED J, V92, P221; Rehrig S, 2001, J IMMUNOL, V167, P5921, DOI 10.4049/jimmunol.167.10.5921; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Rus H, 2005, ANN MED, V37, P97, DOI 10.1080/07853890510007278; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmidt OI., 2004, EUR J TRAUMA, V30, P135, DOI [10.1007/s00068-004-1394-9, DOI 10.1007/S00068-004-1394-9]; Schmidt OI, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-13; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shacka JJ, 2005, CNS NEUROL DISORD-DR, V4, P25, DOI 10.2174/1568007053005127; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Singhrao SK, 1999, LAB INVEST, V79, P1247; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van Beek J, 2005, J IMMUNOL, V174, P2353, DOI 10.4049/jimmunol.174.4.2353; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; WALDMEIER PC, 2003, BIOL PSYCHIAT, V27, P303; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	60	81	82	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUN	2006	199	2					454	464		10.1016/j.expneurol.2006.01.033			11	Neurosciences	Neurosciences & Neurology	063DB	WOS:000238995200026	16545803				2021-06-18	
J	Gurkoff, GG; Giza, CC; Hovda, DA				Gurkoff, GG; Giza, CC; Hovda, DA			Lateral fluid percussion injury in the developing rat causes an acute, mild behavioral dysfunction in the absence of significant cell death	BRAIN RESEARCH			English	Article						cell death; dysfunction; hippocampus; Morris water maze; stereology; traumatic brain injury	TRAUMATIC BRAIN-INJURY; UNBIASED STEREOLOGICAL ESTIMATION; CONTROLLED CORTICAL IMPACT; LONG-TERM POTENTIATION; CEREBRAL-CORTEX; HEAD-INJURY; STATUS EPILEPTICUS; IMMATURE RAT; ENRICHED ENVIRONMENT; GLUCOSE-UTILIZATION	Lateral fluid percussion injury (LFP), a model of mild-moderate concussion, leads to the temporary loss of the capacity for experience-dependent plasticity in developing rats. To determine if this injury-induced loss in capacity for plasticity is due to cell death, we conducted stereological measurements within the cerebral cortex and CA3 of the hippocampus 2 weeks following mild, moderate or severe LFP in the post-natal day 19 (P19) rat. Results indicated that there was no significant change in the absolute number of neurons, regardless of injury severity, in either the ipsilateral cortex (sham = 10.6 +/- 1.7, mild = 11.5 +/- 2.1, moderate = 10.0 +/- 1.0, severe = 10.9 +/- 1.3 million neurons) or CA3 region of the hippocampus (sham = 251 +/- 38, mild = 289 +/- 2, moderate = 245 +/- 48, severe = 255 +/- 62 thousand neurons). Even though there was no evidence of a significant degree of injury-induced cell death, animals exhibited cognitive deficits as revealed in a Morris water maze task (MWM). The MWM results indicated that regardless of injury severity, P19-injured rats exhibited a significant increase in escape latency compared to age-matched shams (injury by day; P < 0.001) and a significant increase in the number of trials needed to reach criterion (P < 0.05). Analysis of a probe trial one week post-MWM training, however, indicated that there was no deficit in storage or recall of the learned behavior as analyzed by platform hits (sham = 2.9 +/- 0.37, mild = 2.0 +/- 0.40, moderate = 1 +/- 0, severe 2.8 +/- 0.62) or percent time spent in, or immediately surrounding, the platform area (sham 13.5 +/- 1.71, mild = 10.8 +/- 2.32, moderate = 12.7 +/- 0, severe = 13.5 +/- 1.69). Taken together, these results indicate that while LFP in P19-injured animals does not lead to significant cell death, it does generate acute, mild deficits in MWM performance. (C) 2006 Elsevier B.V. All rights reserved.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Neurol, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Gurkoff, GG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, Mail Code 703919,Room 18-228 NPI, Los Angeles, CA 90095 USA.	ggurkoff@ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS02197] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DIAMOND MC, 1972, J NEUROBIOL, V3, P47, DOI 10.1002/neu.480030105; DIAMOND MC, 1966, J COMP NEUROL, V128, P117, DOI 10.1002/cne.901280110; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1990, ACT NEUR S, V51, P331; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, NEUROSURGERY, V27, P334; LE HM, 1995, J NEUROTRAUM, V12, P129; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Narkilahti S, 2005, NEUROSCIENCE, V131, P887, DOI 10.1016/j.neuroscience.2004.12.013; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Sankar R, 1998, J NEUROSCI, V18, P8382; Sankar R, 1997, EPILEPSY RES, V28, P129, DOI 10.1016/S0920-1211(97)00040-5; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Skoglund TS, 1996, J NEUROSCI METH, V70, P201, DOI 10.1016/S0165-0270(96)00119-7; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Thompson K, 1998, NEUROSCIENCE, V82, P337; Thompson K, 1997, DEV BRAIN RES, V100, P1, DOI 10.1016/S0165-3806(96)00209-X; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	73	81	84	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 10	2006	1077						24	36		10.1016/j.brainres.2006.01.011			13	Neurosciences	Neurosciences & Neurology	030TZ	WOS:000236659000004	16490184				2021-06-18	
J	Havet-Thomassin, V; Allain, P; Etcharry-Bouyx, F; Le Gall, D				Havet-Thomassin, V; Allain, P; Etcharry-Bouyx, F; Le Gall, D			What about theory of mind after severe brain injury?	BRAIN INJURY			English	Article; Proceedings Paper	Conference on Day of Spring	JUN 04-05, 2004	Angers, FRANCE			traumatic brain injury; theory of mind; executive functions; social cognition	CLOSED-HEAD INJURY; ASPERGER-SYNDROME; SOCIAL COGNITION; NORMAL ADULTS; AUTISM; IMPAIRMENTS; ATTRIBUTION; SCHIZOPHRENIA; DISTURBANCE; INTENTIONS	Background: Behavioural changes are often reported after a severe traumatic brain injury (TBI). These changes are usually a greater burden for relatives than physical or cognitive impairments. This study investigated social cognition in TBI patients using two theory of mind (TOM) tasks. Method: The performances of 17 patients with severe TBI and 17 matched controls were compared on two tasks designed to investigate understanding of other people's mental states: The 'Reading the Mind in the Eyes' test (RME) and the 'Character Intention Task' (CIT). TBI patients and controls were also given several executive function tasks. Results: Compared to healthy controls, patients were impaired in most executive tests and in both TOM tasks. No relationship was found between TOM and executive measures. This is consistent with Rowe's position, who suggested an independence between executive functioning and social cognition. These data suggest that TBI patients may have specific social intelligence disturbances. Conclusion: Future work should employ additional tests of TOM and behavioural ratings and recruit more patients in order to complete analysis.	Ctr Hosp Univ Angers, Dept Psychol, Angers, France	Le Gall, D (corresponding author), Ctr Hosp Univ Angers, Dept Neurol, Unite Neuropsychol, 4 Rue Larrey, F-49933 Angers 01, France.	neuropsychologie@chu-angers.fr		ALLAIN, Philiooe/0000-0003-0668-0986			Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Allain P, 1999, J CLIN EXP NEUROPSYC, V21, P643, DOI 10.1076/jcen.21.5.643.871; Baron-Cohen S, 1999, EUR J NEUROSCI, V11, P1891, DOI 10.1046/j.1460-9568.1999.00621.x; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; BARONCOHEN S, 1994, BRIT J PSYCHIAT, V165, P640, DOI 10.1192/bjp.165.5.640; BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bird CM, 2004, BRAIN, V127, P914, DOI 10.1093/brain/awh108; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525; Brunet Eric, 2003, Cogn Neuropsychiatry, V8, P129, DOI 10.1080/13546800244000256; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FONTAINE A, 1995, NEUROPSYCHOLOGIE TRA, P13; Frith C. D., 1996, COGNITIVE NEUROPSYCH; Happe F, 2001, NEUROPSYCHOLOGIA, V39, P83, DOI 10.1016/S0028-3932(00)00093-2; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HUGHES C, 1993, DEV PSYCHOL, V29, P498, DOI 10.1037/0012-1649.29.3.498; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEGALL D, 1987, NEUROPSY, V4, P257; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PERNER J, 2000, UNDERSTANDING OTHER, P155; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Russell TA, 2000, AM J PSYCHIAT, V157, P2040, DOI 10.1176/appi.ajp.157.12.2040; Sarfati Y, 1997, SCHIZOPHR RES, V25, P199, DOI 10.1016/S0920-9964(97)00025-X; Shallice T, 2001, BRAIN, V124, P247, DOI 10.1093/brain/124.2.247; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; TEASDALE G, 1974, LANCET, V2, P81; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wellman H. M., 1990, CHILDS THEORY MIND; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570	44	81	83	1	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					83	91		10.1080/02699050500340655			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000009	16403703				2021-06-18	
J	Compagnone, C; Murray, GD; Teasdale, GM; Maas, AIR; Esposito, D; Princi, P; D'Avella, D; Servadei, F				Compagnone, C; Murray, GD; Teasdale, GM; Maas, AIR; Esposito, D; Princi, P; D'Avella, D; Servadei, F			The management of patients with intradural post-traumatic mass lesions: A multicenter survey of current approaches to surgical management in 729 patients coordinated by the european brain injury consortium	NEUROSURGERY			English	Article						decompressive cranietomy; intradural mass lesions; surgical management; traumatic brain injury	ACUTE SUBDURAL-HEMATOMA; DECOMPRESSIVE CRANIECTOMY; CONSERVATIVE TREATMENT; EXTRADURAL HEMATOMA; HEAD-INJURY; EVACUATION; HEMORRHAGE; MORTALITY; TRIAL; SCAN	OBJECTIVE: Controversy exists about the indications and timing for surgery in head injured patients with an intradural mass lesion. The aim of this study was to survey contemporary approaches to the treatment of head injured patients with an intradural lesion, placing a particular focus on the utilization of decompressive craniectomy. METHODS: A prospective international survey was conducted over a 3-month period in 67 centers from 24 countries on the neurosurgical management of head injured patients with an intradural mass lesion and/or radiological signs of raised intracranial pressure. Information was obtained about demographic, clinical, and radiological features; surgical management, and mortality at discharge. RESULTS: Over the period of the study, data were collected about 729 patients consecutively admitted to one of the participating centers. The survey included 397 patients with a severe head injury (Glasgow Coma Scale [GCS] 3-8), 155 with a moderate head injury (GCS 9-12) and 143 patients with a mild head injury (GCS 13-15). An operation was performed on 502 patients (69%). Emergency surgery (<24 h) was most frequently performed on 502 patients (69%). Emergency surgery (<24 h) was most frequently performed for patients with an extracerebral mass lesions (subdural hematomas) whereas delayed surgery was most frequently performed for an intracerebral hematoma or contusion. Decompressive craniectomy was performed in a substantial number of patients, either during an emergency procedure (n = 134, 33%) or a delayed procedure (n = 47, 31%). The decompressive procedure was nearly always combined with evacuation of a mass lesion. The size of the decompression was however considered too small in 25% of cases. CONCLUSION: The results provide a contemporary picture of neurosurgical surgical approaches to the management of head injured with an intradural mass lesion and/or signs of raised intracranial pressure in some Neurosurgical Units across the world. The relative benefits of early versus delayed surgery in patients with intraparenchymal lesions and on the indications, technique and benefits of decompressive craniectomy could be topics for future head injury research.	Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy; Osped Gen Provinciale M Bufalini, Div Neurosurg, I-47023 Cesena, Italy; Univ Edinburgh, Sch Med, Div Community Hlth Sci, Edinburgh, Midlothian, Scotland; So Gen Hosp, Inst Neurol Sci, Div Neurosci, Glasgow G51 4TF, Lanark, Scotland; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; Univ Mississippi, Dept Neurosurg, Jackson, MS 39216 USA; CNR, Messina, Italy; Univ Messina, Neurosurg Clin, Messina, Italy	Servadei, F (corresponding author), Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy.	francoservadei@libero.it	; Maas, Andrew I.R./C-5584-2013; Sahuquillo, Juan/B-3577-2008	Splavski, Bruno/0000-0002-4483-9364; Maas, Andrew I.R./0000-0003-1612-1264; Sahuquillo, Juan/0000-0003-0713-5875; Compagnone, Christian/0000-0001-9951-5503; Murray, Gordon/0000-0001-9866-4734; Servadei, Franco/0000-0002-3595-3464			Breasted JH, 1930, E SMITH SURG PAPYRUS; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT R, 1999, TRAUMATIC BRAIN INJU, P81; Cooper P R, 1976, Surg Neurol, V5, P25; CROCE MA, 1994, J TRAUMA, V36, P820, DOI 10.1097/00005373-199406000-00012; Csokay A, 2002, SURG NEUROL, V57, P126, DOI 10.1016/S0090-3019(01)00686-3; DECARPI B, TRACTATUS PERUTILIS; DOE J, 1940, B MED LIBR ASSOC, V28, P165; FRENCH BN, 1977, SURG NEUROL, V7, P171; GRAHAM DI, 1971, LANCET, V1, P265; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HAMILTON M, 1992, AM J NEURORADIOL, V13, P853; HOUNDFIELD GN, 1973, BRIT J RADIOL, V46, P1016, DOI 10.1259/0007-1285-46-552-1016; Hutchinson PJ, 2005, ACTA NEUROCHIR, V147, P1, DOI 10.1007/s00701-004-0400-7; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Mendelow AD, 2005, LANCET, V365, P387; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Munch E, 2000, NEUROSURGERY, V47, P315; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Procaccio F, 2000, J Neurosurg Sci, V44, P1; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Servadei F, 2000, NEUROSURGERY, V46, P70; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412	33	81	89	0	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2005	57	6					1183	1191					9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	991PQ	WOS:000233826300036	16331166				2021-06-18	
J	Walker, WC; Seel, RT; Curtiss, G; Warden, DL				Walker, WC; Seel, RT; Curtiss, G; Warden, DL			Headache after moderate and severe traumatic brain injury: A longitudinal analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 20-24, 2002	ORLANDO, FL	Amer Acad Phys Med & Rehabil		anxiety; brain injuries; depression; headache; rehabilitation	HAMILTON RATING-SCALE; BECK DEPRESSION INVENTORY; POSTTRAUMATIC HEADACHE; CHRONIC PAIN; EPIDEMIOLOGY; DISABILITY; COMPLAINTS; VALIDITY; ANXIETY; STATES	Objectives: To measure longitudinally headache (HA) after moderate and severe traumatic brain injury (TBI) and to examine potential association with demographic, injury, and psychologic factors. Design: Cohort study. Setting: Four Veterans Administration rehabilitation facilities (Minneapolis, Palo Alto, Richmond, Tampa) within the Defense and Veterans Brain Injury Center. Participants: Consecutive patients (military or veteran beneficiaries) with moderate or severe TBI (N = 109) who during acute rehabilitation consented to data collection and who completed 6- and 12-month follow-up evaluations. Interventions: Not applicable. Main Outcome Measures: HA frequency, location, type, and incapacitation levels measured during prospective neurologic assessments. Results: Nearly 38% (41/109) of patients had acute post-traumatic headache (PTHA) symptoms; most often in a frontal location (20/41), most often of daily frequency (31/41), and showing no relation to injury severity, emotional, or demographic variables. Postacutely, PTHA symptom severity declined within the group. Better individual improvement was associated with less anxiety and depression at 6-month follow-up. Almost all subjects (21/22) with PTHA symptoms that persisted into the 6-month follow-up period reported symptoms again at 12-month follow-up. Conclusions: PTHA severity in this sample of persons with moderate and severe TBI showed a pattern of improvement that leveled off by 6 months posthospitalization.	Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; Crawford Res Inst, Sheperd Ctr, Atlanta, GA USA; James A Haley Vet Hosp, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; Def & Vet Brain Injury Ctr, Washington, DC USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Walker, WC (corresponding author), MCV Campus,POB 980661, Richmond, VA 23298 USA.	wc.walker@mail2.vcu.edu	Walker, William C/N-3162-2014; Curtiss, Glenn/ABB-5566-2020				Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Annoni J M, 1992, Disabil Rehabil, V14, P23; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; BECH P, 1975, ACTA PSYCHIAT SCAND, V51, P161, DOI 10.1111/j.1600-0447.1975.tb00002.x; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BROWN C, 1995, PSYCHOL ASSESSMENT, V7, P59; *COMM ACCR REH FAC, 2002, STAND MAN INT GUID M; COOLIGAN R, 1994, J CLIN PSYCHOL, V50, P168; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; DANIEL WW, 1995, BIOSTATISTICS; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; Guy, 1976, ECDEU ASSESSMENT MAN; Hagen C., 1972, LEVELS COGNITIVE FUN; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; HAMMEN CL, 1980, J CONSULT CLIN PSYCH, V48, P126, DOI 10.1037/0022-006X.48.1.126; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hines ME, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P375; Jacobson L, 2001, BONICAS MANAGEMENT P; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; JONES JH, 1992, ARCH PHYS MED REHAB, V73, P145; KNESEVICH JW, 1977, BRIT J PSYCHIAT, V131, P49, DOI 10.1192/bjp.131.1.49; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MOWBRAY RM, 1972, PSYCHOL MED, V2, P272, DOI 10.1017/S0033291700042574; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; PORTER JH, 1986, STAT APPL BEHAV SCI; RAMOSBRIEVA JA, 1988, J PSYCHIAT RES, V22, P21, DOI 10.1016/0022-3956(88)90024-6; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Rasmussen BK, 2001, CEPHALALGIA, V21, P774, DOI 10.1046/j.1468-2982.2001.00248.x; REHM LP, 1985, J PSYCHIAT RES, V19, P31, DOI 10.1016/0022-3956(85)90066-4; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RISKIND JH, 1987, J NERV MENT DIS, V175, P474, DOI 10.1097/00005053-198708000-00005; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SALAZAR AM, 1999, BRAIN INJ SOURCE, V3, P8; STEWART WF, 1994, NEUROLOGY, V44, P24; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; ZIEGLER VE, 1978, BIOL PSYCHIAT, V13, P119; 1988, CEPHALGIA, V8, P1	44	81	81	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2005	86	9					1793	1800		10.1016/j.apmr.2004.12.042			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	962QM	WOS:000231747300014	16181945				2021-06-18	
J	Lu, DY; Mahmood, A; Goussev, A; Schallert, T; Qu, CS; Zhang, ZG; Li, Y; Lu, M; Chopp, M				Lu, DY; Mahmood, A; Goussev, A; Schallert, T; Qu, CS; Zhang, ZG; Li, Y; Lu, M; Chopp, M			Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; atorvastatin; vascular injury; spatial memory; rat	CONTROLLED CORTICAL IMPACT; ENDOTHELIAL NITRIC-OXIDE; HEAD-INJURY; STATINS; ISCHEMIA; STROKE; MICE; INHIBITOR; SYNTHASE; PROTECTS	Object. Atorvastatin, a beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor, has pleiotropic effects, such as promoting angiogenesis, increasing fibrinolysis, and reducing inflammatory responses, and has shown promise in enhancing recovery in animals with traumatic brain injury (TBI) and stroke. The authors tested the effect of atorvastatin on vascular changes after TBI. Methods. Male Wistar rats subjected to controlled cortical impact injury were perfused at different time points with fluorescein isothiocyanate (FITC)-conjugated dextran 1 minute before being killed. Spatial memory function had been measured using a Morris Water Maze test at various points before and after TBI. The temporal profile of intravascular thrombosis and vascular changes was measured on brain tissue sections by using a microcomputer imaging device and a laser confocal microscopy. The study revealed the following results. 1) Vessels in the lesion boundary zone and hippocampal CA3 region showed a variety of damage, morphological alterations, reduced perfusion, and intraluminal microthrombin formation. 2) Atorvastatin enhanced FITC-dextran perfusion of vessels and reduced intravascular coagulation. 3) Atorvastatin promoted the restoration of spatial memory function. Conclusions. These results indicated that atorvastatin warrants investigation as a potential therapeutic drug for TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Biostat, Detroit, MI USA; Univ Texas, Dept Psychol, Austin, TX 78712 USA; Univ Texas, Inst Neurosci, Austin, TX 78712 USA; Oakland Univ, Dept Phys, Rochester, MI USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40225] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline		Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; Amin-Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Biros MH., 1998, EMERGENCY MED CONCEP, P416; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cominacini L, 2003, J AM COLL CARDIOL, V41, P499, DOI 10.1016/S0735-1097(02)02811-5; Dalla Nora E, 2003, J ENDOCRINOL INVEST, V26, P73, DOI 10.1007/BF03345126; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eberlein M, 2001, BRIT J PHARMACOL, V133, P1172, DOI 10.1038/sj.bjp.0704173; Eto M, 2003, ENDOTHELIUM-J ENDOTH, V10, P35, DOI 10.1080/10623320303359; Friedrich DH, 2000, ACTA NEUROCHIR SUPPL, V76, P257; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Gryglewski RJ, 2001, ANN NY ACAD SCI, V947, P229; Honjo M, 2002, ARCH OPHTHALMOL-CHIC, V120, P1707; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Lattimore SU, 2003, STROKE, V34, pE55, DOI 10.1161/01.STR.0000073789.12120.F3; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2003, EUR J CLIN PHARMACOL, V58, P719, DOI 10.1007/s00228-002-0556-0; Laufs U, 2002, BRAIN RES, V942, P23, DOI 10.1016/S0006-8993(02)02649-5; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mason JC, 2003, CLIN SCI, V105, P251, DOI 10.1042/CS20030148; Mason JC, 2002, CIRC RES, V91, P696, DOI 10.1161/01.RES.0000038151.57577.19; MINER ME, 1985, NEUROSURGERY, P1666; Mital S, 2000, AM J PHYSIOL-HEART C, V279, pH2649; Ohyama H, 2001, BRAIN RES, V902, P264, DOI 10.1016/S0006-8993(01)02354-X; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Shovman O, 2002, IMMUNOL RES, V25, P271, DOI 10.1385/IR:25:3:271; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sparks D L, 2002, J Nutr Health Aging, V6, P324; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stumpf C, 2003, CLIN SCI, V105, P45, DOI 10.1042/CS20020359; Yamada K, 1999, BRIT J PHARMACOL, V126, P235, DOI 10.1038/sj.bjp.0702309; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zhang ZG, 1999, J NEUROSCI, V19, P10898	46	81	81	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2004	101	5					813	821		10.3171/jns.2004.101.5.0813			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	873UL	WOS:000225306500013	15540920				2021-06-18	
J	Tate, DG; Forchheimer, MB; Krause, JS; Meade, MA; Bombardier, CH				Tate, DG; Forchheimer, MB; Krause, JS; Meade, MA; Bombardier, CH			Patterns of alcohol and substance use and abuse in persons with spinal cord injury: Risk factors and correlates	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						alcohol abuse; alcohol consumption; rehabilitation; spinal cord injuries; substance abuse	CAGE QUESTIONNAIRE; BRAIN-INJURY; HISTORY; SATISFACTION	Objective: To investigate patterns of alcohol consumption and abuse and substance use among persons with spinal cord injury (SCI), relating these patterns to demographic and injury-related characteristics, as well as to key medical and psychosocial outcomes. Design: Retrospective cross-sectional. Participants: Subjects with traumatic SCI (N=3041) with dates of injury between June 6, 1975, and June 23, 2002, who were interviewed between November 2000 and March 2003. Setting: Sixteen Model Spinal Cord Injury Systems participating in this collaborative study during the 2000-2005 grant cycle. Interventions: Not applicable. Main Outcome Measures: Alcohol consumption, substance use, CAGE questionnaire, Satisfaction With Life Scale, Craig Handicap Assessment Reporting Technique, and pain. Data were analyzed using chi-square tests, analysis of variance, analysis of covariance, and logistic regression models. Results: Fourteen percent of the subjects were classified as likely to have an alcohol abuse issue, based on the CAGE, and 11% reported using illegal drugs or prescription medications for nonmedical reasons. Demographic and injury characteristics were associated with alcohol consumption patterns, abuse, and substance use. At-risk drinkers and substance users tended to be younger, single, male, and less educated. Those who were CAGE positive and substance users reported more pain and lower satisfaction with life. Persons who drank without indication of problem drinking had superior occupation outcomes. Pressure ulcers were associated with substance use. Conclusions: Alcohol abuse and substance use were related to a number of adverse outcomes. The specific role of drinking with increased work activity deserves further exploration.	Univ Michigan, Model Spinal Cord Injury Care Syst, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; Med Univ S Carolina, Coll Hlth Prof, S Carolina Spinal Cord Injury Ctr, Charleston, SC 29425 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Reg Spinal Cord Injury Model Syst, Richmond, VA USA; Univ Washington, Dept Rehabil Med, NW Reg Spinal Cord Injury Syst, Seattle, WA USA	Tate, DG (corresponding author), Univ Michigan, Model Spinal Cord Injury Care Syst, Dept Phys Med & Rehabil, 300 N Ingalls,Rm N12A09, Ann Arbor, MI 48109 USA.	dgtate@umich.edu	Forchheimer, Martin/B-6148-2009	Forchheimer, Martin/0000-0002-7709-9622			*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P175; *AM SPIN INJ ASS, 2000, INT STAND NEUR CLASS, P1; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 1998, ARCH PHYS MED REHAB, V79, P1110, DOI 10.1016/S0003-9993(98)90180-0; CHARLIFUE SW, 1991, ARCH PHYS MED REHAB, V72, P488; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Elliott TR, 1996, ARCH PHYS MED REHAB, V77, P816, DOI 10.1016/S0003-9993(96)90263-4; Elliott TR, 2002, REHABIL PSYCHOL, V47, P278, DOI 10.1037//0090-5550.47.3.278; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; Hawkins DA, 1998, REHABIL PSYCHOL, V43, P219, DOI 10.1037/0090-5550.43.3.219; Hearne R, 2002, J ROY SOC MED, V95, P84, DOI 10.1258/jrsm.95.2.84; HEINEMANN AW, 1995, REHABIL PSYCHOL, V40, P125; HEINEMANN AW, 1990, REHABIL PSYCHOL, V35, P217, DOI 10.1037/h0079065; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1991, ARCH PHYS MED REHAB, V72, P482; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Krause JS, 1999, ARCH PHYS MED REHAB, V80, P1435; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P306, DOI 10.1097/00002060-199907000-00002; *NAT I ALC AB ALC, 2000, NAT I ALC AB ALC PUB; O'Donnell JJ, 1981, ALCOHOL HEALTH RES W, V82, P27; Richards JS, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P11, DOI 10.1037/10361-001; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Stover SL, 1999, ARCH PHYS MED REHAB, V80, P1365, DOI 10.1016/S0003-9993(99)90246-0; TATE DG, 1994, J REHABIL, V60, P31; TATE DG, 1993, AM J PHYS MED REHAB, V72, P192, DOI 10.1097/00002060-199308000-00004; WARE JE, 1993, SF 36 HLTH SURV MAN; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0	33	81	84	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2004	85	11					1837	1847		10.1016/j.apmr.2004.02.022			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	870WO	WOS:000225089700013	15520979				2021-06-18	
J	Whiteneck, G; Brooks, CA; Mellick, D; Harrison-Felix, C; Terrill, MS; Noble, K				Whiteneck, G; Brooks, CA; Mellick, D; Harrison-Felix, C; Terrill, MS; Noble, K			Population-based estimates of outcomes after hospitalization for traumatic brain injury in Colorado	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	brain injuries; outcomes research; population surveillance; rehabilitation	HEAD-INJURY; UNITED-STATES; SEVERITY; SYSTEM; REHABILITATION; VARIABLES; WORSE; MILD	Objective: To determine statewide, population-based outcomes of persons hospitalized with traumatic brain injury (TBI) at 1 year postinjury. Design: Follow-up Survey of a representative cohort. Setting: A statewide, population-based registry and follow-up system for persons hospitalized with TBI. Participants: A total of 1591 adult Coloradoans with moderate and severe injury oversampled, but weighted to be representative of persons hospitalized with TBI (1996-1999) who survived their injuries and completed follow-up telephone interviews at 1 year postinjury. Interventions: Not applicable. Main Outcome Measures: Checklists of symptoms and service utilization, the FIM instrument(TM). the Craig Handicap Assessment and Reporting Technique Short Form, a single-item quality of life (QOL) measure, and a needs assessment checklist. Results: Problematic outcomes occurring at 1 year postinjury included one third or more being bothered by fatigue. feeling irritable or grouchy, having headaches, and experiencing trouble sleeping more frequently than preinjury; 37% reported needing the assistance of another person in physical and/or cognitive activities of daily living; substantial participation restrictions were noted in areas of occupation (30%) and social integration (22%); and 29% responded that their QOL was only fair or poor. Negative outcomes were reported more frequently among individuals who were more severely injured, older, or female. Conclusions: Substantial percentages of people hospitalized with TBI in a population-based sample reported a variety of problematic outcomes at 1 year postinjury.	Craig Hosp, Res Dept, Englewood, CO 80113 USA	Brooks, CA (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	cabrooks@craighospital.org					BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BERGER R, 1998, J CLIN BAS CARDIOL, V1, P19; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; Caplan B, 1996, J HEAD TRAUMA REHAB, V11, P1; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; *CO DEP PUBL HLTH, 2002, INJ COL; Department of Health and Human Services [DHHS], 1989, FED INT HEAD INJ TAS; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P87, DOI 10.1097/00002060-200001000-00017; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; *NAT CTR HLTH STAT, 1998, HLTH US 1998; Rose A., 1993, J ENVIRON DEV, V2, P1, DOI [10.1177/107049659300200102, DOI 10.1177/107049659300200102]; SELMAN U, 1993, ARCH PHYS MED REAHAB, V74, P61; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Sosin DM, 1996, BRAIN INJURY, V10, P47; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Svenson JE, 2001, AM J EMERG MED, V19, P19, DOI 10.1053/ajem.2001.18041; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Thurman DJ., 1995, GUIDELINES SURVEILLA; [Uniform Data System for Medical Rehabilitation State University of New York at Buffalo], 1993, GUID UN DAT SET MED; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Whiteneck G, 2001, COLORADO TRAUMATIC B; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whiteneck GG, 1992, GUIDE USE CHART CRAI; *WHO, 1986, INT CLASS DIS 9 REV; WILLER B, 1990, EPIDEMIOLOGY DISABIL; World Health Organization, 1993, INT CLASS IMP DIS HA	38	81	81	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S73	S81		10.1016/j.apmr.2003.08.107			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	812FL	WOS:000220825300010	15083425				2021-06-18	
J	Rios, M; Perianez, JA; Munoz-Cespedes, JM				Rios, M; Perianez, JA; Munoz-Cespedes, JM			Attentional control and slowness of information processing after severe traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; CARD-SORTING-TEST; WORKING-MEMORY; REACTION-TIME; FOCUSED ATTENTION; PREFRONTAL CORTEX; TASK-PERFORMANCE; FRONTAL LESIONS; DEFICITS; DISORDERS	Attention is a basic cognitive function and a prerequisite for other cognitive processes and is frequently impaired after traumatic brain injury. In the present study, 29 severe traumatic brain injury patients and 30 control subjects completed a battery of three neuropsychological tests of attention (WCST, TMT, Stroop). The aim was to clarify the attentional mechanisms underlying tests performance and to explore the types of attentional impairment after severe traumatic brain injury. Significant differences were found between the control and clinical groups in almost all measures. However, some of these differences disappeared when the speed of information processing was controlled using covariance analysis. In addition, a factor analysis revealed a four-factor solution explaining 89.6% of the variance in the data, i.e. cognitive flexibility, speed of processing, interference and working memory. This result supports the view of at least four different subprocesses of attentional control underlie test performance and allows one to differentiate between high- and low-level processes. The implications for neuropsychological assessment and rehabilitation are discussed.	Univ Nacl Educ Distancia, Fac Psicol, Dept Psicol Basica 2, E-28040 Madrid, Spain; Univ Illes Balears, Dept Psychol, Palma de Mallorca, Spain; Beata Maria Ana Hosp, Brain Damage Unit, Madrid, Spain; Univ Complutense, Dept Basic Psychol 2, E-28040 Madrid, Spain	Rios, M (corresponding author), Univ Nacl Educ Distancia, Fac Psicol, Dept Psicol Basica 2, C Juan del Rosal 10, E-28040 Madrid, Spain.	mrios@psi.uned.es	Rios-Lago, Marcos/C-9568-2012; Perianez, Jose/AAI-3988-2021; Rios-Lago, Marcos/P-6930-2019	Rios-Lago, Marcos/0000-0003-0187-5047; Rios-Lago, Marcos/0000-0003-0187-5047; Perianez, Jose A./0000-0003-4310-4021			ALLPORT A, 1993, ATTENTION PERFORM, V14, P182; Andres P, 2001, J CLIN EXP NEUROPSYC, V23, P225; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; AZOUVI P, 1995, J INT NEUROPSYCH SOC, V1, P213; Baddeley A, 2001, J EXP PSYCHOL GEN, V130, P641, DOI 10.1037//0096-3445.130.4.641; Baddeley AD, 2001, AM PSYCHOL, V56, P851, DOI 10.1037/0003-066X.56.11.851; BADDELEY AD, 1974, RECENT ADV LEARNING, V8, P47, DOI DOI 10.1016/S0079-7421(08)60452-1; BAKE AJ, 2001, CLIN NEUROPSYCHOL, V15, P405; Barcelo F, 2002, NEUROREPORT, V13, P1887, DOI 10.1097/00001756-200210280-00011; Barcelo F, 2000, NEUROPSYCHOLOGIA, V38, P1342, DOI 10.1016/S0028-3932(00)00046-4; Barcelo F, 1998, NEUROREPORT, V9, P747, DOI 10.1097/00001756-199803090-00034; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; Berti S, 2003, EUR J NEUROSCI, V17, P1119, DOI 10.1046/j.1460-9568.2003.02527.x; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Fernandez-Duque D, 2001, J CLIN EXP NEUROPSYC, V23, P74, DOI 10.1076/jcen.23.1.74.1217; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Fristoe NM, 1997, NEUROPSYCHOLOGY, V11, P428, DOI 10.1037/0894-4105.11.3.428; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Godefroy O, 1996, BRAIN COGNITION, V30, P155, DOI 10.1006/brcg.1996.0010; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Heaton R., 1993, WISCONSIN CARD SORTI; Henik A, 1996, J Int Neuropsychol Soc, V2, P467; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Konishi S, 1999, CEREB CORTEX, V9, P745, DOI 10.1093/cercor/9.7.745; Koren D, 1998, NEUROPSYCHOLOGY, V12, P289, DOI 10.1037/0894-4105.12.2.289; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P100, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Monchi O, 2001, J NEUROSCI, V21, P7733; Munoz-Cespedes JM, 2001, REV NEUROLOGIA, V32, P351, DOI 10.33588/rn.3204.2000456; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PICANO JJ, 1992, ARCH CLIN NEUROPSYCH, V7, P271, DOI 10.1016/0887-6177(92)90168-M; Pineda DA, 2000, REV NEUROLOGIA, V31, P1112, DOI 10.33588/rn.3112.2000417; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIST F, 1991, HDB SCHIZOPHRENIA, V5, P241; Robertson I. R., 1999, COGNITIVE NEUROREHAB, P302; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Schmitter-Edgecombe M, 1996, J Int Neuropsychol Soc, V2, P111; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Simpson A, 2000, NEUROPSYCHOLOGY, V14, P310, DOI 10.1037//0894-4105.14.2.310; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2001, ANN NY ACAD SCI, V931, P359; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Spreen O., 1998, COMPENDIUM NEUROPSYC; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TREXLER LE, 1988, BRAIN COGNITION, V8, P291, DOI 10.1016/0278-2626(88)90056-5; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VELTMAN JC, 1996, NEUROPSYCHOLOGY, V10, P1; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Wang LH, 2001, COGNITIVE BRAIN RES, V12, P19, DOI 10.1016/S0926-6410(01)00022-2; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; YELA M, 1968, REV PSICOLOGIA GEN A, V92, P313; ZAHN TP, 1991, J ABNORM CHILD PSYCH, V19, P233, DOI 10.1007/BF00909980; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	80	81	82	1	16	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2004	18	3					257	272		10.1080/02699050310001617442			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900003	14726285				2021-06-18	
J	Zweckberger, K; Stoffel, M; Baethmann, A; Plesnila, N				Zweckberger, K; Stoffel, M; Baethmann, A; Plesnila, N			Effect of decompression craniotomy on increase of contusion volume and functional outcome after controlled cortical impact in mice	JOURNAL OF NEUROTRAUMA			English	Article						craniotomy; functional outcome; intracranial pressure; neuroprotection; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; SURGICAL DECOMPRESSION; MANAGEMENT; CRANIECTOMY; HALOTHANE; RABBITS; MOUSE; EDEMA	If, how, and when decompressive craniotomy should be used for the treatment of increased intracranial pressure after traumatic brain injury are widely discussed clinical subjects. Despite the large number of clinical studies addressing this issue, experimental evidence of a beneficial or detrimental role of decompressive craniotomy after brain trauma is sparse. Therefore, we investigated the influence of craniotomy on intracranial pressure, contusion volume, and functional outcome in a model of traumatic brain injury in mice. Male C57/B16 mice were craniotomized above the right parietal cortex and were subjected to controlled cortical impact injury. In control mice, the craniotomy was closed immediately after trauma, whereas in treated animals the craniotomy was left open. In control mice intracranial pressure (ICP) increased to a.maximum of 23.7 +/- 3.1 mm Hg 6 h after trauma (p < 0.001),while in craniotomized animals; no ICP increase was observed. Twenty-four hours after trauma, the point in time of maximal lesion expansion, contusion volume in craniotomized mice was 40% smaller as compared to controls (18.3 +/- 2.0 vs. 30.2 +/- 3.5 mm(3), p < 0.04). Furthermore, craniotomized mice showed significantly improved motor function in a beam walking task (p < 0.04) and faster recovery of body weight after trauma (p < 0.02). Our results demonstrate that craniotomy blunts post-traumatic ICP increase, significantly reduces secondary brain damage and improves functional outcome after experimental TBI. Careful clinical evaluation of craniotomy as a therapeutic option after TBI in man may therefore be indicated.	Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-8000 Munich, Germany; Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany	Plesnila, N (corresponding author), Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-8000 Munich, Germany.	plesnila@icf.med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019				BAETHMAN A, 1978, NEUROSURG REV, V1, P85; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; Burkert W, 1989, Zentralbl Neurochir, V50, P106; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CUNITZ G, 1976, ANAESTHESIST, V25, P323; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; GAAB M, 1979, CHILD BRAIN, V5, P484; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hans P, 1980, Acta Anaesthesiol Belg, V31 Suppl, P49; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; Kocher T, 1901, HIRNERSCHUTTERUNG HI, P262; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Munch E, 2000, NEUROSURGERY, V47, P315; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Ogawa M, 1974, Med J Osaka Univ, V25, P73; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; RINALDI A, 1990, ACT NEUR S, V51, P394; SCHELLER MS, 1987, ANESTHESIOLOGY, V67, P507, DOI 10.1097/00000542-198710000-00011; ZORNOW MH, 1992, ANESTH ANALG, V75, P232	23	81	83	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2003	20	12					1307	1314		10.1089/089771503322686102			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	756XH	WOS:000187510700003	14748979				2021-06-18	
J	Cornwell, EE; Chang, DC; Phillips, J; Campbell, KA				Cornwell, EE; Chang, DC; Phillips, J; Campbell, KA			Enhanced trauma program commitment at a level I trauma center - Effect on the process and outcome of care	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	74th Annual Meeting of the Pacific-Coast-Surgical-Association	FEB 16-18, 2003	MONTEREY, CALIFORNIA	Pacific Coast Surg Assoc			SEVERELY INJURED PATIENTS; HOUSE; SURGEONS; IMPACT; QUALITY; COST	Hypothesis: With advances in surgical care, the occurrences of major adverse outcomes have become a rare event. The effect of a surgical service can be more comprehensively evaluated by following the Donabedian model, looking at the triad of structure, process, and outcome. It is hypothesized that the implementation of a focused program commitment at a trauma center is associated with improvements in process of care and patient outcomes. Design: Evaluation of prospectively collected information in a trauma registry for the 3-year periods immediately before (1995-1997) and after (1999-2001) the implementation (in 1998) of the full-time trauma. service. Setting: Level I university-affiliated trauma center. Patients: Patients meeting criteria for major trauma. Intervention: The implementation of a full-time trauma service, featuring 24-hour in-house attending coverage, dedicated trauma admitting unit, regular trauma core curriculum, regular multidisciplinary quality assurance meetings, and state designation for level I status. Main Outcome Measures: Process of care measures, including time in the emergency department (ED) and trauma "bypass" hours (ie, time spent in the trauma resuscitation area). Outcome measures, including lengths of stay, overall mortality and mortality, excluding ED deaths. Results: The total number of patients with major trauma increased from 2240 (1995-1997) to 2513 (1999-2001). The average time in the ED for patients going to the operating room, intensive care unit, and observation wards all decreased significantly (84 vs 52 minutes, 197 vs 118 minutes, and 300 vs 140 minutes, respectively; all with P < .01). The number of hours that the trauma center was closed owing to ED overcrowding also decreased significantly, from 56 to 2.7 hours per month (P < .01). After excluding ED deaths, there was a trend on bivariate analyses toward lower overall mortality rates (4.5% vs 3.4%, P = .07) and mortality rates among patients with severe head injury (23.8% vs 17.2%, P = .07). On further analyses with multiple logistic regression, controlling for age, Injury Severity Score, Abbreviated Injury Score (for a head injury) I and admission blood pressure, the later period is associated with a 31% decrease in overall odds of death (P = .047) and a 42% decrease in odds of death among patients with severe head injury (an Abbreviated Injury Score, greater than or equal to3; P = .03). Conclusion: The implementation of a full-time trauma service is associated with improved timeliness of triage and therapeutic interventions and improved patient outcomes.	Johns Hopkins Univ, Sch Med, Div Trauma, Dept Surg, Baltimore, MD 21218 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA	Cornwell, EE (corresponding author), Johns Hopkins Univ Hosp, 600 N Wolfe St,Osler 625, Baltimore, MD 21287 USA.						[Anonymous], 1999, RES OPT CAR INJ PAT; Cohen MM, 1999, J TRAUMA, V46, P1114, DOI 10.1097/00005373-199906000-00028; Demarest GAB, 1999, J TRAUMA, V46, P535, DOI 10.1097/00005373-199904000-00001; DEMETRIADES D, 1995, ARCH SURG-CHICAGO, V130, P216; Dodek P, 2000, AM J MED QUAL, V15, P3, DOI 10.1177/106286060001500102; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Fulda GJ, 2002, J TRAUMA, V53, P494, DOI 10.1097/00005373-200209000-00017; Luchette F, 1997, J TRAUMA, V42, P490, DOI 10.1097/00005373-199703000-00017; Porter JM, 2001, AM SURGEON, V67, P611; ROGERS FB, 1993, J TRAUMA, V34, P871, DOI 10.1097/00005373-199306000-00019; THOMPSON CT, 1992, J TRAUMA, V32, P336, DOI 10.1097/00005373-199203000-00011	11	81	86	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	AUG	2003	138	8					838	842		10.1001/archsurg.138.8.838			5	Surgery	Surgery	709HB	WOS:000184618800005	12912741	Bronze			2021-06-18	
J	Coleman, RD; Rapport, LJ; Ergh, TC; Hanks, RA; Ricker, JH; Millis, SR				Coleman, RD; Rapport, LJ; Ergh, TC; Hanks, RA; Ricker, JH; Millis, SR			Predictors of driving outcome after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	29th Annual Meeting of the International-Neuropsychological-Society	FEB 14-17, 2001	CHICAGO, ILLINOIS	Int Neuropsychol Soc		accidents; traffic; automobile driving; brain injuries; rehabilitation	ALZHEIMERS-DISEASE; CEREBRAL-DAMAGE; RATING-SCALE; REHABILITATION; PERFORMANCE; DRIVERS; DISABILITY; IMPAIRMENT; FITNESS; ABILITY	Objective: To examine predictors of driving status and fitness to drive after traumatic brain injury (TBI). Design: Retrospective and prospective follow-up of a cohort ranging from 4 months to 10 years post-TBI. Setting: A Midwestern, urban university-affiliated rehabilitation hospital. Participants: Seventy-one pairs of adults who had sustained a TBI and their significant others. Interventions: Not applicable. Main Outcome Measures: Driving status (whether the patient resumed driving), driving frequency (estimated miles driven per week), and postinjury driving records compiled by the Department of Motor Vehicles. Results: Logistic and hierarchical regression analyses indicated that the significant other's perceptions of the patient's fitness to drive were the strongest predictor of patients' driving status and driving frequency. However, years postinjury, disability at discharge, and current neuropsychologic functioning best predicted postinjury driving safety as measured by actual incidents. The relation between perception of patients' fitness and actual driving incidents, however, was modest. Conclusions: Neuropsychologic and medical information available by traditional methods showed unique value in predictive driving safety. However, caregiver perception of patients' fitness was the overwhelming determinant of whether and how much patients drive. The bases on which caregivers form their opinions affect the safety of patients and the public. The rehabilitation setting is a unique resource for family education regarding abilities essential to safe driving.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA; Rehabiol Inst Michigan, Detroit, MI USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren, Detroit, MI 48202 USA.			Ricker, Joseph/0000-0003-3415-991X			Bieliauskas LA, 1998, CLIN NEUROPSYCHOL, V12, P206, DOI 10.1076/clin.12.2.206.1994; Boake C., 1998, J INT NEUROPSYCH SOC, V4, P75; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROUWER WH, 1990, TRAUMATIC BRAIN INJU, P89; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; Engum E. S., 1988, COGNITIVE REHABILITA, V6, P34; Fisk GD, 1998, BRAIN INJURY, V12, P683; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Meyers J E, 1999, Appl Neuropsychol, V6, P154, DOI 10.1207/s15324826an0603_3; Michon J.A., 1979, DEALING DANGER SUMMA; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; Ott BR, 2000, DEMENT GERIATR COGN, V11, P153, DOI 10.1159/000017229; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; RAPPORT LJ, 1998, M AM PSYCH ASS AUG 1; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; ROTHKE S, 1989, INT J CLIN NEUROPSYC, V11, P134; Satz P., 1996, COLOR TRAILS TEST; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; SHORE D, 1980, ARCH PHYS MED REHAB, V61, P481; SHUTE GE, 1990, DEV NEUROPSYCHOL, V6, P1, DOI 10.1080/87565649009540445; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; Trobe JD, 1996, ARCH NEUROL-CHICAGO, V53, P411, DOI 10.1001/archneur.1996.00550050033021; VANWOLFFELAAR PC, 1990, DRIVING BEHAV SOCIAL, P564; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; WEBSTER JS, 1995, ARCH PHYS MED REHAB, V76, P924, DOI 10.1016/S0003-9993(95)80068-9; WEBSTER JS, 1994, J CLIN EXP NEUROPSYC, V16, P129, DOI 10.1080/01688639408402623; Wechsler D, 1997, WAIS 3 ADM SCORING M; Withaar FK, 2000, J INT NEUROPSYCH SOC, V6, P480, DOI 10.1017/S1355617700644065	55	81	84	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2002	83	10					1415	1422		10.1053/apmr.2002.35111			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	600NT	WOS:000178397800015	12370878				2021-06-18	
J	Ylvisaker, M; Hanks, R; Johnson-Greene, D				Ylvisaker, M; Hanks, R; Johnson-Greene, D			Perspectives on rehabilitation of individuals with cognitive impairment after brain injury: Rationale for reconsideration of theoretical paradigms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive impairment; cognitive rebabilitation; neuropsychological rehabilitation; traumatic brain injury	EXPRESSIVE VOCABULARY DELAYS; EXECUTIVE FUNCTIONS; LONG-TERM; ATTENTION; BEHAVIOR; METAANALYSIS; CHILDHOOD; CHILDREN; TODDLERS; PROJECT	Background: The frequency of cognitive impairment associated with traumatic brain injury (TBI) has led to the widespread use of cognitive rehabilitation as a discrete rehabilitative service. This service has become controversial in part because of disagreements regarding its theoretical base and implementation procedures, and in part because of insufficient experimental support. Objective: We outline two paradigms for cognitive rehabilitation that are interestingly different, both theoretically and procedurally. These paradigms are defined in relation to the goals of intervention, orientation to assessment, modalities of treatment, organization of treatment, and logistics of service delivery (setting, content, and provider). A rationale for each paradigm is described. Conclusion: We conclude with a call for (a) additional research into the effectiveness of interventions for individuals with cognitive impairment after TBI and (b) clinicians' thoughtful reflection on the foundations of their service.	Coll St Rose, Dept Commun Disorders, Albany, NY USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA	Ylvisaker, M (corresponding author), 1171 Van Antwerp Rd, Schenectady, NY 12309 USA.	ylvisakm@mail.strose.edu					American Speech and Hearing Association, 1995, ASHA S14, V37, P23; Anderson, 1989, TRANSFER COGNITIVE S; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; ASHMAN AF, 1989, COGNITIVE STRATEGIES; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BENYISHAY Y, 1987, NEUROPSYCHOL REHABIL, P165; Berk L.E., 1995, NAEYC RES PRACTICE S, V7; BJORKLUND DF, 1990, CHILDRENS STRATEGIES; BOAKE C, 1989, J HEAD TRAUMA REHAB, V41, P1; BODROVA E, 1996, TOOLS MIND VYGOTSKYA; BRAGA LW, 2000, INT HDB NEUROPSYCHOL; BRONSON M, 2000, SELF REGULATION EARL; BROWN AL, 1992, INTERACTIVE LEARNING; CAMPIONE JC, 1990, DIAGNOSTIC MONITORING OF SKILL AND KNOWLEDGE ACQUISITION, P141; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Carr E.G., 1999, POSITIVE BEHAV SUPPO; Chesnut R, 1999, AHCPR PUBLICATION; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Clancey W.J, 1997, SITUATED COGNITION H; Crepeau F, 1997, NEUROPSYCHOL REHABIL, V7, P147, DOI 10.1080/713755525; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DESHLER DD, 1993, ELEM SCHOOL J, V94, P153, DOI 10.1086/461757; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Engelmann S., 1991, THEORY INSTRUCTION P; EVANS P, 1993, CHARTING AGENDA ED A; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Feeney TJ, 2001, J HEAD TRAUMA REHAB, V16, P61, DOI 10.1097/00001199-200102000-00008; Flavell J. H., 2001, COGNITIVE DEV; Girolametto L, 1999, AM J SPEECH-LANG PAT, V8, P364, DOI 10.1044/1058-0360.0804.364; Girolametto L, 1996, J SPEECH HEAR RES, V39, P1274, DOI 10.1044/jshr.3906.1274; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; HARLEY JP, 1992, NEUROREHABILITATION, V2, P62; Horner R. H., 1988, GEN MAINTENANCE LIFE; Kaiser AP, 1996, TOP EARLY CHILD SPEC, V16, P375, DOI 10.1177/027112149601600307; Kavale K. A., 1999, EFFICACY SPECIAL ED; Kazdin A.E., 1994, HDB PSYCHOTHERAPY BE, P19; KOEGEL LK, 1997, POSITIVE BEHAV SUPPO; LAVE J, 1991, PERSPECTIVES ON SOCIALLY SHARED COGNITION, P63, DOI 10.1037/10096-003; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; MALEC JF, 1996, NEUROLOGY TRAUMA, P231; MANN L, 1979, TRAIL PROCESS HIST P; Meichenbaum D., 1977, COGNITIVE BEHAV MODI; Meichenbaum D, 1998, NURTURING INDEPENDEN; Meier M. J., 1987, NEUROPSYCHOLOGICAL R; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; PALINSCAR AS, 1989, TEACHING UNDERSTANDI, V1; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PRESSLEY M, 1995, EDUC PSYCHOL, V30, P207, DOI 10.1207/s15326985ep3004_6; Robinson TR, 1999, J EDUC PSYCHOL, V91, P195, DOI 10.1037/0022-0663.91.2.195; Rogoff B., 1990, APPRENTICESHIP THINK; Sackett DL, 1995, J ROY SOC MED, V88, P620; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; SCHACTER DL, 1996, SEARCHING MEMORY BRA; Schneider P, 1996, LANG SPEECH HEAR SER, V27, P157, DOI 10.1044/0161-1461.2702.157; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Sternberg RJ., 1993, TRANSFER TRIAL INTEL; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; VANCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Vygotsky L. S., 1978, MIND SOC DEV HIGHER; WEHMAN P, 1990, VOCATIONAL REHABILIT; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; Wertsch J. V., 1981, CONCEPT ACTIVITY SOV; Westby C. E., 1994, LANGUAGE LEARNING DI, P180; *WHO, 1998, COMM LANG FUNCT DIS; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; World Health Organization, 1980, INT CLASS IMP DIS HA; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100	74	81	87	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2002	17	3					191	209		10.1097/00001199-200206000-00002			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	552WE	WOS:000175642400002	12086574				2021-06-18	
J	Floyd, CL; Golden, KM; Black, RT; Hamm, RJ; Lyeth, BG				Floyd, CL; Golden, KM; Black, RT; Hamm, RJ; Lyeth, BG			Craniectomy position affects Morris water maze performance and hippocampal cell loss after parasagittal fluid percussion	JOURNAL OF NEUROTRAUMA			English	Article						animal models; cell death; glial fibrillary acidic protein (GFAP); reactive astrocytes; traumatic brain injury	TRAUMATIC BRAIN-INJURY; BEHAVIORAL-ANALYSIS; ASTROCYTES; MEMORY; RATS; CONSEQUENCES; DAMAGE	Valid and reliable animal models are essential for mechanistic and therapeutic studies of traumatic brain injury (TBI). Therefore, model characterization is a continual and reciprocal process between the experimental laboratory and the clinic. Several excellent experimental models of TBI, including the lateral fluid percussion rat model, are currently in wide use in many neurotrauma laboratories. However, small differences in the position of lateral fluid percussion craniectomy are reported between labs. Additionally, differences in hippocampal cell death have also been reported. Therefore, we hypothesized that small changes in craniectomy position could affect commonly used outcome measures such as vestibulomotor function, Morris water maze (MWM) performance, hippocampal cell loss, and glial fibrillary acidic protein (GFAP) immunoreactivity. Four placements were systematically manipulated: rostral, caudal, medial and lateral. The medial and caudal placements produced significantly greater impairments in the MWM acquisition task over the lateral and rostral placements. The rostral placement produced diffuse cortical damage but little hippocampal cell loss. In contrast, the medial, lateral, and caudal placements produced more mid-dorsally localized cortical damage and significant cell loss in the CA2/CA3 and hilus ipsilateral to the injury site. Furthermore, reactive astrocytosis was more pronounced in the medial, lateral, and caudal placements than in the rostral placement. All craniectomy position groups had similar durations of traumatic unconsciousness and similar impairment on motor tasks. We conclude that small alterations in craniectomy position produce differences in cognitive performance, hippocampal cell loss, and reactive astrocytosis but not in motor performance nor transient unconsciousness.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurol Surg, Richmond, VA 23298 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER		ANNETT LE, 1989, BEHAV BRAIN RES, V31, P231, DOI 10.1016/0166-4328(89)90005-3; Baldwin SA, 1996, GLIA, V16, P266; Bedell EA, 1998, J NEUROTRAUM, V15, P985, DOI 10.1089/neu.1998.15.985; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; DEBRUIN JPC, 1994, BRAIN RES, V652, P323, DOI 10.1016/0006-8993(94)90243-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1987, CENTRAL NERV SYST TR, V4, P1987; MEANEY DF, 1988, FRONTIERS HEAD NECK, P169; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Okimura Y, 1996, J NEUROTRAUM, V13, P385, DOI 10.1089/neu.1996.13.385; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	23	81	84	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					303	316		10.1089/089771502753594873			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900002	11939498				2021-06-18	
J	Rice, AC; Zsoldos, R; Chen, T; Wilson, MS; Alessandri, B; Hamm, RJ; Bullock, MR				Rice, AC; Zsoldos, R; Chen, T; Wilson, MS; Alessandri, B; Hamm, RJ; Bullock, MR			Lactate administration attenuates cognitive deficits following traumatic brain injury	BRAIN RESEARCH			English	Article						Morris water maze; lateral fluid percussion injury	FLUID-PERCUSSION MODEL; HIPPOCAMPAL-LESIONS; GLUCOSE; RAT; NEURONS; GLIA; IMPAIRMENT; IMPACT; TISSUE	Moderately head injured patients often suffer long term neurological sequelae. There is no therapy for brain trauma and current treatments aim only to minimize secondary damage. These secondary effects we often triggered by the inability to re-establish ionic homeostasis after injury, due to large energy demands. Recent reports have demonstrated that neurons are capable of utilizing lactate as an energy source, thus this report examines the usefulness of lactate administration in the attenuation of behavioural deficits following a moderate brain injury. Lactate infusion (i.v.) was started 30 min after lateral fluid percussion injury and continued for 3 h. Cognitive deficits were determined using the Morris water maze. Lactate infused injured animals demonstrated significantly less cognitive deficits than saline infused injured animals. Thus, lactate infusion attenuated the cognitive deficits normally observed in this model, and therefore may provide moderately head injured patients with a treatment to help ameliorate the sequelae. (C) 2002 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23298 USA	Rice, AC (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		Alvarez-Maubecin V, 2000, J NEUROSCI, V20, P4091; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hilton G, 1994, Orthop Nurs, V13, P25, DOI 10.1097/00006416-199407000-00006; IZUMI Y, 1994, NEUROREPORT, V5, P617, DOI 10.1097/00001756-199401000-00021; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Larrabee MG, 1996, J NEUROCHEM, V67, P1726; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MOSER E, 1993, J NEUROSCI, V13, P3916; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Schousboe A, 1997, GLIA, V21, P99; Schurr A, 1998, DEV NEUROSCI-BASEL, V20, P348, DOI 10.1159/000017330; Schurr A, 1999, J NEUROSCI, V19, P34; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tsacopoulos M, 1996, J NEUROSCI, V16, P877	23	81	82	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 22	2002	928	1-2					156	159	PII S0006-8993(01)03299-1	10.1016/S0006-8993(01)03299-1			4	Neurosciences	Neurosciences & Neurology	530TJ	WOS:000174374800017	11844482				2021-06-18	
J	Degeneffe, CE				Degeneffe, CE			Family caregiving and traumatic brain injury	HEALTH & SOCIAL WORK			English	Article						care giving; families; traumatic brain injury	HEAD-INJURY; SOCIAL SUPPORT; ADULTS; RELATIVES; STRESS; DISABILITIES; INDIVIDUALS; ADAPTATION; DISTRESS; PARENTS	This article discusses the extensive challenges faced by those providing long-term care for family members with traumatic brain injury. Areas reviewed include the nature of care needs, stress and burden experienced, and how families cope with caregiving demands. This article concludes with a discussion of what social workers can do to reduce the demands of family caregiving and subsequently, improve caregivers' quality of life.	Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA	Degeneffe, CE (corresponding author), Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA.						ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; *BRAIN INJ ASS INC, 2000, ISS BRIEF TRAUM BRAI; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Carson P, 1993, J Neurosci Nurs, V25, P165; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; Cicirelli V. G., 1982, SIBLING RELATIONSHIP, P267; CORRIGAN JD, 1999, REPORT NIH CONSENSUS, P64; Cunningham JM, 1999, HLTH CARE DISABILITY, P475; DeJong G., 1999, REPORT NIH CONSENSUS, P121; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EAMES P, 1990, REHABILITATION ADULT, P410; *FAM CAR ALL, 1999, LONGT CAR STAT; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gilson SF, 1998, FAM SOC-J CONTEMP H, V79, P188, DOI 10.1606/1044-3894.1818; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; GREENBERG JS, 1993, GERONTOLOGIST, V33, P542, DOI 10.1093/geront/33.4.542; Greenberg JS, 1997, FAM RELAT, V46, P383, DOI 10.2307/585098; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; HARDGROVE H, 1991, HEAD INJURY FAMILY M, P25; HEPWORTH D, 1990, DIRECT SOCIAL WORK P; HOSACK KR, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199504000-00007; JACOB E, 1993, QUALITATIVE RES HIGH, P47; JACOBS HE, 1989, NEUROPSYCHOLOGICAL T, P297; Johnson B P, 1995, J Neurosci Nurs, V27, P113; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kosciulek JF, 1996, J REHABIL, V62, P49; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/0090-5550.39.4.215; KOSCIULEK JF, 1993, J REHABIL, V59, P40; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KREUTZER JS, 1999, REPORT NIH CONSENSUS, P59; Leathem J, 1996, BRAIN INJURY, V10, P27; Lees M., 1988, REHABILITATION SEVER, P166; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVNEH H, 1997, PSYCHOL ADAPTATION C; Lynch R. T., 1986, APPL REHABILITATION, P262; MAITZ EA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199504000-00003; Mathis M, 1984, J Neurosurg Nurs, V16, P36; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; MINTZ MC, 1995, BRAIN INJURY, V9, P173, DOI 10.3109/02699059509008190; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; MUIR CR, 1984, BEHAV ASSESSMENT REB; National Institutes of Health, 1999, REP NIH CONS DEV C R; OLSON D, 1990, FAMILY ADAPTABILITY; ORSILLO SM, 1993, J HEAD TRARMA REHABI, V8, P105; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; Quine S, 1993, Health Soc Work, V18, P114; Quinn P., 1995, J TEACHING SOCIAL WO, V12, P55; Rosenthal M., 1989, TRAUMATIC BRAIN INJU, P191; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; SACHS PR, 1991, TREATING FAMILIES BR; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SARGENT MM, 1997, NEUROPSYCHOLOGICAL T, P183; Spivack Marilyn Price, 1994, J HEAD TRAUMA REHAB, V9, P82; STEBBINS P, 1997, AUSTR J REHABILITATI, V9, P30; WESOLOWSKI MD, 1994, PRACTICAL GUIDE HEAD	60	81	84	0	8	NATL ASSOC SOCIAL WORKERS	WASHINGTON	750 FIRST ST, NE, STE 700, WASHINGTON, DC 20002-4241 USA	0360-7283			HEALTH SOC WORK	Health Soc. Work	NOV	2001	26	4					257	268		10.1093/hsw/26.4.257			12	Social Work	Social Work	497TT	WOS:000172472100006	11758867				2021-06-18	
J	Sarrafzadeh, AS; Peltonen, EE; Kaisers, U; Kuchler, I; Lanksch, WR; Unterberg, AW				Sarrafzadeh, AS; Peltonen, EE; Kaisers, U; Kuchler, I; Lanksch, WR; Unterberg, AW			Secondary insults in severe head injury - Do multiply injured patients do worse?	CRITICAL CARE MEDICINE			English	Article						cerebral hypoxia; head injury; multiple injuries; polytrauma; outcome; secondary insults	BRAIN-TISSUE PO2; CEREBRAL OXYGENATION; TRAUMA; SATURATION; MANAGEMENT; FRACTURE	Objectives: To study the occurrence of secondary insults and the influence of extracranial injuries on cerebral oxygenation and outcome in patients with closed severe head injury (Glasgow Coma Scale score less than or equal to8). Design: Two-year prospective, clinical study. Setting: Two intensive care units in a level III trauma center. Patients: We studied 119 patients. Eighty patients had severe head injury and were divided into two categories: "isolated" severe head injury patients (n = 36, Injury Severity Score < 30), and severe head injury patients with associated extracranial injuries (n = 44, injury Severity Score > 29). Thirty-nine patients with extracranial injuries and no head injury served as the control group. Interventions: After patients were admitted to the intensive care unit, we began continuous multimodal cerebral monitoring of intracranial pressure, mean arterial blood pressure, cerebral perfusion pressure, end-tidal Co-2, brain tissue Po-2 (Licox), jugular bulb oxyhemoglobin saturation in severe head injury patients, and mean arterial blood pressure in the control group. Targets of management included intracranial pressure < 20 mm Hg, cerebral perfusion pressure > 60 mm Hg, Paco(2) > 30 mm Hg, control of cerebral oxygenation, and delayed surgery for non-life-threatening extracranial lesions. Measurements and Main Results: Data were analyzed for critical thresholds. The occurrence of secondary insults (intracranial pressure > 20 mm Hg, mean arterial blood pressure < 70 mm Hg, cerebral perfusion pressure < 60 mm Hg, end-tidal Co-2 <30 torr, brain tissue Po-2 <less than>10 torr, jugular bulb oxyhemoglobin saturation < 50%) was comparable in patients with isolated severe head injury and those with severe head injury with associated extracranial lesions (Abbreviated Injury Scale score less than or equal to5). The duration of intracranial hypertension and arterial hypotension significantly correlated with an unfavorable outcome, independent of the Injury Severity Score. In patients with severe head injury, 1-yr outcome was 29% dead or vegetative, 17% severely disabled, and 54% moderate or good outcome. This was similar to patients with severe head injury and extracranial injuries (31% dead or vegetative, 14% severely disabled, and 56% moderate or goad outcome) and was independent of the Injury Severity Score. Patients with no head injury had less secondary insults (mean arterial blood pressure < 70 mm Hg, p < .01) and a better outcome compared with both severe head injury groups (P < .044). Conclusions: In patients with severe head injury who have targeted management including intracranial pressure- and cerebral perfusion pressure-guided therapy and delayed surgery for extracranial lesions, the occurrence of secondary insults in the intensive care unit and long-term neurological outcome were comparable and independent of the presence of extracranial lesions (Abbreviated Injury Severity level less than or equal to5). A severe head injury is still a major contributor predicting an unfavorable outcome in multiply injured patients.	Humboldt Univ, Dept Neurosurg, D-13353 Berlin, Germany; Humboldt Univ, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany; Humboldt Univ, Inst Biometr, Fac Med, D-13353 Berlin, Germany	Sarrafzadeh, AS (corresponding author), Humboldt Univ, Dept Neurosurg, Charite CampusVirchow Med Ctr,Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					*ABBR INJ SCAL, 1990, REV PLAIN; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bardt TF, 1998, ACT NEUR S, V71, P153; Bardt TF, 1998, ACTA NEUROCHIR, V140, P357, DOI 10.1007/s007010050109; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Bullock MR, 1996, J NEUROTRAUM, V13, P647; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GLENN JN, 1973, J TRAUMA, V13, P958, DOI 10.1097/00005373-197311000-00004; GOBIET W, 1995, ZBL CHIR, V120, P544; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; JENNETT B, 1975, LANCET, V1, P480; Jennett B., 1991, NIMODIPINE PHARM CLI, P225; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McKee MD, 1997, J TRAUMA, V42, P1041, DOI 10.1097/00005373-199706000-00009; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; WELKERLING H, 1991, ZBL CHIR, V116, P1263	32	81	87	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2001	29	6					1116	1123		10.1097/00003246-200106000-00004			8	Critical Care Medicine	General & Internal Medicine	442BY	WOS:000169266400003	11395585				2021-06-18	
J	Gaetz, M; Weinberg, H				Gaetz, M; Weinberg, H			Electrophysiological indices of persistent post-concussion symptoms	BRAIN INJURY			English	Article							MILD HEAD-INJURY; AUDITORY EVOKED-POTENTIALS; TRAUMATIC BRAIN INJURY; AXONAL INJURY; NEUROFILAMENT SUBUNITS; STEM RESPONSES; P300; HYPOTHESIS; SPECTRUM; P-300	Mild head injuries (MHI) including concussion were once considered transient alterations of function that resulted in no long-term structural or functional effects. This opinion has changed somewhat in recent years, based on the scientific evidence and popular cases in the media that suggest MHI can result in damage that can, in some cases, lead to long-term cognitive sequelae. Purpose and methods: An EP/ERP assessment battery is presented as a method for detecting changes in brain function that form the organic basis of persistent post-concussion symptoms (PCS). The primary focus of the paper was directed towards using this battery to determine whether or not brain function in individuals with persistent PCS was different than responses of individuals that comprised a normative database. Results: Visual and auditory ERPs and visual EPs were beyond a 2.5 standard deviation normal limit in young and older groups of individuals with persistent post-concussion symptoms. Conclusions: Evidence of changes in brain function in individuals with persistent post-concussion symptoms is consistent with the position that the post-concussion syndrome has a substantial biological, as opposed to a psychological, basis.	Simon Fraser Univ, Fac Sci Appl, Sch Kinesiol, Brain Behav Lab, Burnaby, BC V5A 1S6, Canada	Gaetz, M (corresponding author), Simon Fraser Univ, Fac Sci Appl, Sch Kinesiol, Brain Behav Lab, Burnaby, BC V5A 1S6, Canada.	gaetz@sfu.ca					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; BENNA P, 1982, ITAL J NEUROL SCI, V3, P281, DOI 10.1007/BF02043575; BERNAD PG, 1988, CLIN ELECTROENCEPHAL, V19, P174; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; DEADWYLER SA, 1987, CRC CR REV CL NEUROB, V2, P335; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; Drake M E Jr, 1996, Electromyogr Clin Neurophysiol, V36, P457; DRAKE ME, 1987, CLIN EVOKED POTENTIA, V5, P19; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; *GUID 9 GUID EV PO, 1994, J CLIN NEUROPHYSIOL, V11, P40; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; JOHNSON R, 1988, BRAIN, V111, P1517, DOI 10.1093/brain/111.6.1517; Kelly JP, 1997, NEUROLOGY, V48, P581; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LHERMITTE F, 1985, ARCH NEUROL-CHICAGO, V42, P567, DOI 10.1001/archneur.1985.04060060069011; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MCCARTHY G, 1982, NEUR ABSTR, V8, P976; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; Misulis K., 1994, SPEHLMANNS EVOKED PO; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; ONOFRJ M, 1991, ACTA NEUROL SCAND, V83, P273, DOI 10.1111/j.1600-0404.1991.tb04700.x; PAPATHANASOPOULOS P, 1994, EUR NEUROL, V34, P268, DOI 10.1159/000117054; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PICTON TW, 1974, ELECTROEN CLIN NEURO, V36, P179, DOI 10.1016/0013-4694(74)90155-2; PICTON TW, 1994, CURR OPIN NEUROBIOL, V4, P256, DOI 10.1016/0959-4388(94)90082-5; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Regan D., 1989, HUMAN BRAIN ELECTROP; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; ROTTEVEEL J, 1990, EVOKED POTENTIAL MAN, P79; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SCHOENHUBER R, 1985, EVOKED POTENTIALS NE, P237; SQUIRES NK, 1983, TUTORIALS EVENT RELA; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANBOXTEL GJM, 1994, BIOL PSYCHOL, V38, P37, DOI 10.1016/0301-0511(94)90048-5; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; WOOD C C, 1985, Society for Neuroscience Abstracts, V11, P879; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	64	81	82	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2000	14	9					815	832					18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	357YT	WOS:000089530300005	11030455				2021-06-18	
J	Graham, DI; Raghupathi, R; Saatman, KE; Meaney, D; McIntosh, TK				Graham, DI; Raghupathi, R; Saatman, KE; Meaney, D; McIntosh, TK			Tissue tears in the white matter after lateral fluid percussion brain injury in the rat: relevance to human brain injury	ACTA NEUROPATHOLOGICA			English	Article						rat; lateral fluid percussion; tissue tears; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; RADIOPATHOLOGIC FEATURES; TRAUMATIC LESIONS; DAMAGE; MR; MILD; IMMEDIATE	A characteristic feature of severe diffuse axonal injury in man is radiological evidence of the "shearing injury triad" represented by lesions, sometimes haemorrhagic, in the corpus callosum, deep white matter and the rostral brain stem. With the exception of studies carried out on the non-human primate, such lesions have not been replicated to date in the multiple and diverse rodent laboratory models of traumatic brain injury. The present report describes tissue tears in the white matter, particularly in the fimbria of Sprague-Dawley rats killed 12, 24, and 48 h and 7 days after lateral fluid percussion brain injury of moderate severity (2.1-2.4 atm). The lesions were most easily seen at 24 h when they appeared as foci of tissue rarefaction in which there were a few polymorphonuclear leucocytes. At the margins of these lesions, large amounts of accumulated amyloid precursor protein (APP) were found in axonal swellings and bulbs. By 1 week post-injury, there was macrophage infiltration with marked astrocytosis and early scar formation. This lesion is considered to be due to severe defomation of white matter and this is the first time that it has been identified reproducibly in a rodent model of head injury under controlled conditions.	Univ Glasgow, Dept Neuropathol, Inst Neurol Sci, So Gen Hosp NHS Trust, Glasgow G51 4TF, Lanark, Scotland; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Graham, DI (corresponding author), Univ Glasgow, Dept Neuropathol, Inst Neurol Sci, So Gen Hosp NHS Trust, Glasgow G51 4TF, Lanark, Scotland.	D.Graham@clinmed.gla.ac.uk		Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P50-NS-08803] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BLUMBERGS PC, 1994, ZENTRALBL NEUROCHIR, V52, P89; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; GEAN AD, 1994, IMAGING HEAD TRAUMA, P207; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1987, P 31 STAPP CAR CRASH, P48; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; GRCEVIC N, 1982, RAD JUGOSL AKAD ZNAN, V402, P265; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pileri SA, 1997, J PATHOL, V183, P116; PILZ P, 1982, J NEUROL NEUROSUR PS, V45, P422, DOI 10.1136/jnnp.45.5.422; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SIMPSON DA, 1989, J TRAUMA, V29, P1519, DOI 10.1097/00005373-198911000-00011; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Yam PS, 1998, J NEUROTRAUM, V15, P441, DOI 10.1089/neu.1998.15.441; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZIMMERMAN RA, 1986, AM J NEURORADIOL, V7, P757	57	81	81	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	FEB	2000	99	2					117	124		10.1007/PL00007414			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	275TA	WOS:000084835200005	10672317				2021-06-18	
J	McCracken, E; Hunter, AJ; Patel, S; Graham, DI; Dewar, D				McCracken, E; Hunter, AJ; Patel, S; Graham, DI; Dewar, D			Calpain activation and cytoskeletal protein breakdown in the corpus callosum of head-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						axonal damage; human; head injury; calpain; cytoskeleton	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; DIFFUSE AXONAL INJURY; FOCAL CEREBRAL-ISCHEMIA; RAT-BRAIN; NEUROFILAMENT SUBUNITS; WHITE-MATTER; BETA-APP; CALCIUM; DAMAGE	Calpain-mediated breakdown of the cytoskeleton has been proposed to contribute to brain damage resulting from head injury, We examined the corpus callosum from patients who died after a blunt head injury in order to determine if there was evidence of these pathophysiological events in a midline myelinated commissure that is susceptible to damage after human head injury. Western blotting revealed marked reductions in the levels of neurofilament triplet proteins 200 and 68kDa in the corpus callosum of head-injured patients compared with control subjects, Neurofilament 200kDa levels were significantly reduced as detected by either phosphorylation-dependent or -independent antibodies, In contrast, there were minimal changes in the levels of beta-tubulin or the microtubule-associated protein, tau, in the head-injured patients, although amyloid precursor protein immunostaining demonstrated axonal damage in 9 of the 10 patients, The inactive 80kDa and active 76kDa subunits of mu-calpain were present in control subjects and head-injured patients, However, there was a significant increase in the levels of calpain-mediated spectrin breakdown products in head-injured patients compared with the control subjects, The results demonstrate that following human blunt head injury, there is a significant degradation of neurofilament proteins and increased levels of calpain-mediated spectrin breakdown products within the corpus callosum, Therefore, our data support the hypothesis that calpain-mediated breakdown of the cytoskeleton may contribute to axonal damage after head injury.	Univ Glasgow, Wellcome Surg Inst, Glasgow, Lanark, Scotland; Univ Glasgow, Hugh Fraser Labs, Glasgow, Lanark, Scotland; SmithKline Beecham Pharmaceut, Neurosci Res, Harlow CM19 5AD, Essex, England; Univ Glasgow, Dept Neuropathol, Glasgow, Lanark, Scotland	McCracken, E (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate, Glasgow, Lanark, Scotland.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DEWAR D, 1995, BRAIN RES, V684, P70, DOI 10.1016/0006-8993(95)00417-O; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FTIZPATRICK MO, 1997, J CEREB BLOOD FLO S1, V17, pS415; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI ZH, 1995, BRAIN RES, V697, P112; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MASLIAH E, 1990, J NEUROSCI, V10, P2113; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OGHAMI T, 1992, NEUROSCI LETT, V136, P75; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SUENAGA T, 1994, ACTA NEUROPATHOL, V87, P450; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Yam PS, 1998, J NEUROTRAUM, V15, P441, DOI 10.1089/neu.1998.15.441	64	81	83	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1999	16	9					749	761		10.1089/neu.1999.16.749			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	241EL	WOS:000082869700001	10521135				2021-06-18	
J	Sander, AM; High, WM; Hannay, HJ; Sherer, M				Sander, AM; High, WM; Hannay, HJ; Sherer, M			Predictors of psychological health in caregivers of patients with closed head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; DISABILITY RATING-SCALE; ALZHEIMERS PATIENTS; COPING STRATEGIES; RELATIVES VIEW; SOCIAL SUPPORT; FAMILY; BURDEN; STRESS; RECOVERY	The purpose of the current study was to investigate the contribution of coping strategies, subjective burden, and social support to psychological health in caregivers. The sample included 69 primary caregivers of patients with severe closed head injuries. There were three groups of caregivers: acute (0-6 months post-injury); intermediate (6 months-1.5 years); and long-term (> 1.5 years). All had participated in rehabilitation. Caregivers completed an interview and series of questionnaires, including the Ways of Coping Questionnaire, Social Support Questionnaire, Subjective Burden Measure, and General Health Questionnaire. The Disability Rating Scale was completed by staff to assess patients' level of functioning at the time of caregivers' assessment. ANOVA revealed no between-group differences in coping style or social support. Multiple regression revealed that greater use of emotion-focused coping was associated with greater emotional distress. Coping style contributed to a greater proportion of the variance in caregivers' psychological health than did patients' level of functioning. Increased satisfaction with social support was associated with less emotional distress. The full model, including group, caregiver gender, emotion-focused coping, social support, patient level of recovery, burden, and the burden x coping interaction accounted for over half of the variance in psychological health. Results support a multidimensional model for explaining caregivers' adjustment.	BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030; INST REHABIL & RES,BRAIN INJURY RES CTR,HOUSTON,TX 77025; UNIV HOUSTON,DEPT PSYCHOL,HOUSTON,TX 77204; BAYLOR COLL MED,DEPT NEUROSURG,HOUSTON,TX 77030	Sander, AM (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,MCV BOX 980542,RICHMOND,VA 23298, USA.			Hannay, H. Julia/0000-0001-7023-912X			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; DILLEHAY RC, 1990, INT J AGING HUM DEV, V30, P263, DOI 10.2190/2P3J-A9AH-HHF4-00RG; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; FOLKMAN S, 1988, MANUAL WAYS COPING; Goldberg DP., 1972, DETECTION PSYCHIATRI; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; HALEY WE, 1987, PSYCHOL AGING, V2, P323, DOI 10.1037/0882-7974.2.4.323; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KOSCIULEK JF, 1994, REHABIL COUNS BULL, V37, P244; KOSCIULEK JF, 1993, J REHABIL, V59, P40; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KREUTZER JS, 1994, BRAIN INJURY, V8, P187; LAZARUS RS, 1988, STRESS APPRAISAL COP; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McCubbin H.I., 1983, SOCIAL STRESS FAMILY, P7, DOI DOI 10.1300/J002V06N01_02; MCCUBBIN HI, 1979, J MARRIAGE FAM, V41, P237, DOI 10.2307/351693; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; PRATT CC, 1985, FAM RELAT, V34, P27, DOI 10.2307/583754; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; STEPHENS MAP, 1988, PSYCHOL AGING, V3, P208, DOI 10.1037/0882-7974.3.2.208; Tarter S B, 1990, Arch Clin Neuropsychol, V5, P15; White N E, 1992, West J Nurs Res, V14, P211, DOI 10.1177/019394599201400208; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	40	81	82	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	APR	1997	11	4					235	249		10.1080/026990597123548			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WQ736	WOS:A1997WQ73600001	9134198				2021-06-18	
J	Corrigan, JD; Bogner, JA; Mysiw, WJ; Clinchot, D; Fugate, L				Corrigan, JD; Bogner, JA; Mysiw, WJ; Clinchot, D; Fugate, L			Systematic bias in outcome studies of persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; COMMUNITY INTEGRATION QUESTIONNAIRE; SUBSTANCE-ABUSE; FOLLOW-UP; 1-YEAR; REHABILITATION; RECOVERY; SCALE; COMA	Objective: (1) Examine systematic biases created by subjects lost at 1-year follow-up in samples of persons with traumatic brain injury; (2) identify potential threats to generalization of outcomes data. Design: A consecutive sample of admissions to acute rehabilitation studied 1 year following discharge. Setting: An inpatient brain injury rehabilitation unit in a large, academic medical center. Subjects: Eighty-eight patients with primary diagnosis of traumatic brain injury. Main Outcome Measures: Subjects were considered lost to follow-up when phone calls, mail, clinic visits, and assistance from family failed to allow contact 1 year after discharge from acute rehabilitation. Potential effects of the biased follow-up sample were examined for seven suboptimal outcomes. Results: A total of 38.6% of subjects were lost to follow-up. Subjects intoxicated at time of injury and those with history of substance abuse were more likely to be lost. Among subjects followed, the likelihood of working or being in school I year after discharge was significantly less for those intoxicated at time of injury and those with a history of substance abuse. Conclusions: Systematic bias in longitudinal studies may result from subjects with substance use problems being lost to follow-up. Population estimates for return to work or school will be overestimated if those lost who have substance use problems resemble those followed. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	OHIO STATE UNIV,DEPT PHYS MED & REHABIL,COLUMBUS,OH 43210			Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011	Clinchot, Daniel/0000-0002-2810-7227			ANSELL BJ, 1989, W NEURO SENSORY STIM; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; CORRIGAN JD, 1996, FUNCTIONAL ASSESSMEN; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MCCUBBIN H, 1987, FAMILY ASSESSMENT IN, P203; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Reitan RM., 1985, HALSTEAD REITAN NEUR; ROSENTHAL M, 1996, TRAUM BRAIN INJ MOD; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; *SUNY BUFF, 1993, UN DAT SYST MED REH; TEASDALE G, 1974, LANCET, V2, P81; THOMAS RL, 1988, TOXIC CONTAMINATION, V3, P1; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, BRAIN INJURY REHABIL, P355	42	81	81	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1997	78	2					132	137		10.1016/S0003-9993(97)90253-7			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	WH072	WOS:A1997WH07200004	9041892				2021-06-18	
J	Prigatano, GP				Prigatano, GP			Behavioral limitations TBI patients tend to underestimate: A replication and extension to patients with lateralized cerebral dysfunction	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN INJURY; ANOSOGNOSIA; AWARENESS; LESIONS	Patients with moderate to severe traumatic brain injury (TBI), as well as patients with lateralized cerebral dysfunction, completed the Patient Competency Rating Scale (PCRS) along with a neuropsychological control group. Relatives or significant others for each patient also rated the patient's abilities on the PCRS. A previous finding that TBT patients overestimate social interaction and emotional control skills was replicated. Patients with right versus left hemisphere lesions also tended to show this same pattern, while the neuropsychological control group did not. Brain dysfunction may increase the tendency to overstate certain behavioral characteristics irrespective of the location of the lesion. Nonneurological factors, however, may also contribute to this phenomenon. In this regard, it may be useful to distinguish between impaired self-awareness versus denial of disability after brain injury.		Prigatano, GP (corresponding author), ST JOSEPHS HOSP,BARROW NEUROL INST,350 W THOMAS RD,PHOENIX,AZ 85013, USA.						ADAMS KM, 1985, J CLIN EXP NEUROPSYC, V7, P445, DOI 10.1080/01688638508401276; Ben-Yishay Y., 1990, REHABILITATION ADULT, P393; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Feher EP., 1991, NEUROPSY NEUROPSY BE, V4, P136; Fleming J., 1995, BRIT J OCCUP THER, V58, P55, DOI DOI 10.1177/030802269505800204; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LORD FM, 1969, PSYCHOL BULL, V72, P336, DOI 10.1037/h0028108; LORD FM, 1967, PSYCHOL BULL, V68, P304, DOI 10.1037/h0025105; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MIZUNO M, 1991, Keio Journal of Medicine, V40, P221; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1995, 10 ANN M SECT NEUR B; PRIGATANO GP, 1995, MANUAL BNI SCREEN HI, P2; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P27; PRIGATANO GP, IN PRESS NEUROPSYCHO; REITAN RM, 1994, CLIN NEUROPSYCHOL, V8, P193, DOI 10.1080/13854049408401557; REITAN RM, 1955, UNPUB MANUAL ADM NEU; ROBINSON RG, 1985, CRC CR REV CL NEUROB, V1, P285; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; SQUIRE LR, 1988, J CLIN EXPT NEUROPSC, V10, P737; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P43; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; VILKKI J, 1991, CORTEX, V27, P203, DOI 10.1016/S0010-9452(13)80124-4; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; WEINSTEIN EA, IN PRESS NEUROPSYCHI	32	81	82	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	1996	10	2					191	201		10.1080/13854049608406680			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	UM880	WOS:A1996UM88000009					2021-06-18	
J	BENZEL, EC; DAY, WT; KESTERSON, L; WILLIS, BK; KESSLER, CW; MODLING, D; HADDEN, TA				BENZEL, EC; DAY, WT; KESTERSON, L; WILLIS, BK; KESSLER, CW; MODLING, D; HADDEN, TA			CIVILIAN CRANIOCEREBRAL GUNSHOT WOUNDS	NEUROSURGERY			English	Article						CRANIOCEREBRAL GUNSHOT WOUND; GUNSHOT WOUND; PENETRATING CRANIOCEREBRAL INJURIES	CEREBRAL MISSILE INJURY; TRAUMATIC ANEURYSM; HEAD-INJURY; BRAIN; PERSPECTIVE; MANAGEMENT; FRAGMENTS; MORTALITY; DEATHS	Experience with 120 patients who incurred a gunshot wound to the head with dural penetration is presented. All of the patients were managed by a standard resuscitation protocol and assigned a clinical grade based on their level of consciousness both at the time of presentation and at 2 to 4 months after injury. Fifty patients (42%) underwent surgery. Twenty-eight patients (23%) had a good recovery, 19 (16%) were moderately disabled, 6 (5%) were severely disabled, and 67 (56%) died. All patients who were alert and awake with a normal or near normal neurological examination at the time of admission survived with a good outcome. All but 4 patients who were comatose at the time of admission died. Nine patients, however, who were not comatose at the time of admission died from potentially preventable causes. In 3 of these patients, a more aggressive diagnostic approach (including cerebral angiography) may have altered their ultimate outcome. An expeditious approach to the trauma victim with a comprehensive management scheme after injury may have altered the course in the remainder of these patients.	LOUISIANA STATE UNIV, SCH MED, DIV NEUROSURG, SHREVEPORT, LA 71105 USA	BENZEL, EC (corresponding author), UNIV NEW MEXICO, SCH MED, DIV NEUROSURG, ALBUQUERQUE, NM 87131 USA.						ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COOPER PR, 1979, NEUROSURGERY, V4, P373, DOI 10.1227/00006123-197905000-00001; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; Cushing H, 1918, BRIT J SURG, V5, P558; Cushing H, 1918, Br Med J, V1, P221; HUBSCHMANN O, 1979, NEUROSURGERY, V5, P285; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1980, NEUROSURGERY, V6, P181, DOI 10.1227/00006123-198002000-00011; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KIRKPATRICK JB, 1978, J NEUROSURG, V49, P185, DOI 10.3171/jns.1978.49.2.0185; LILLARD PL, 1978, SURG NEUROL, V9, P79; MEIROWSKY AM, 1982, J NEUROSURG, V57, P617, DOI 10.3171/jns.1982.57.5.0617; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; ORNATO JP, 1985, J TRAUMA, V25, P575, DOI 10.1097/00005373-198507000-00001; RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; RISH BL, 1980, J NEUROSURG, V53, P772, DOI 10.3171/jns.1980.53.6.0772; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; TEASDALE G, 1974, LANCET, V2, P81; WEST CGH, 1981, SURG NEUROL, V16, P145, DOI 10.1016/0090-3019(81)90117-8	26	81	82	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	1991	29	1					67	72		10.1227/00006123-199107000-00011			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FT164	WOS:A1991FT16400011	1870690				2021-06-18	
J	LEVIN, HS; GROSSMAN, RG; KELLY, PJ				LEVIN, HS; GROSSMAN, RG; KELLY, PJ			APHASIC DISORDER IN PATIENTS WITH CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550							AKBAROVA NA, 1972, ZH NEVOPATOLOGII PSI, V11, P1641; Bender L., 1938, VISUAL MOTOR GESTALT; Benton A., 1968, CORTEX, V4, P344, DOI DOI 10.1016/S0010-9452(68)80018-8; Benton A., 1959, RIGHT LEFT DISCRIMIN; BENTON AL, 1964, J NERV MENT DIS, V139, P110, DOI 10.1097/00005053-196408000-00003; Benton AL, 1967, CORTEX, V3, P32, DOI [10.1016/S0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; LEVIN HS, 1975, J PSYCHOL, V91, P223, DOI 10.1080/00223980.1975.9923946; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; MORSIER GD, 1973, PSYCHIAT CLIN, V6, P226; SPREEN O, 1966, MANUAL NEUROSENSORY	12	81	81	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1976	39	11					1062	1070		10.1136/jnnp.39.11.1062			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	CP283	WOS:A1976CP28300004	1011017	Green Published, Bronze			2021-06-18	
J	Chen, X; Park, YJ; Kang, M; Kang, SK; Koo, J; Shinde, SM; Shin, J; Jeon, S; Park, G; Yan, Y; MacEwan, MR; Ray, WZ; Lee, KM; Rogers, JA; Ahn, JH				Chen, Xiang; Park, Yong Ju; Kang, Minpyo; Kang, Seung-Kyun; Koo, Jahyun; Shinde, Sachin M.; Shin, Jiho; Jeon, Seunghyun; Park, Gayoung; Yan, Ying; MacEwan, Matthew R.; Ray, Wilson Z.; Lee, Kyung-Mi; Rogers, John A.; Ahn, Jong-Hyun			CVD-grown monolayer MoS2 in bioabsorbable electronics and biosensors	NATURE COMMUNICATIONS			English	Article							CHEMICAL-VAPOR-DEPOSITION; TRANSITION-METAL DICHALCOGENIDES; THIN-FILM TRANSISTORS; MOLYBDENUM-DISULFIDE; LAYER MOS2; TRANSIENT ELECTRONICS; GRAIN-BOUNDARIES; GRAPHENE; WS2; INTERCALATION	Transient electronics represents an emerging technology whose defining feature is an ability to dissolve, disintegrate or otherwise physically disappear in a controlled manner. Envisioned applications include resorbable/degradable biomedical implants, hardware-secure memory devices, and zero-impact environmental sensors. 2D materials may have essential roles in these systems due to their unique mechanical, thermal, electrical, and optical properties. Here, we study the bioabsorption of CVD-grown monolayer MoS2, including long-term cytotoxicity and immunological biocompatibility evaluations in biofluids and tissues of live animal models. The results show that MoS2 undergoes hydrolysis slowly in aqueous solutions without adverse biological effects. We also present a class of MoS2-based bioabsorbable and multi-functional sensor for intracranial monitoring of pressure, temperature, strain, and motion in animal models. Such technology offers specific, clinically relevant roles in diagnostic/therapeutic functions during recovery from traumatic brain injury. Our findings support the broader use of 2D materials in transient electronics and qualitatively expand the design options in other areas.	[Chen, Xiang; Park, Yong Ju; Kang, Minpyo; Shinde, Sachin M.; Ahn, Jong-Hyun] Yonsei Univ, Sch Elect & Elect Engn, 50 Yonsei Ro, Seoul 03722, South Korea; [Kang, Seung-Kyun] Korea Adv Inst Sci & Technol, KI Hlth Sci & Technol KIHST, Dept Bio & Brain Engn, Daejeon 34141, South Korea; [Koo, Jahyun; Rogers, John A.] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; [Shin, Jiho; Rogers, John A.] Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; [Jeon, Seunghyun; Park, Gayoung; Lee, Kyung-Mi] Korea Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 02841, South Korea; [Yan, Ying; MacEwan, Matthew R.; Ray, Wilson Z.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Biomed Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Chem, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Mech Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Elect Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Comp Sci, Evanston, IL 60208 USA	Ahn, JH (corresponding author), Yonsei Univ, Sch Elect & Elect Engn, 50 Yonsei Ro, Seoul 03722, South Korea.; Rogers, JA (corresponding author), Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA.; Lee, KM (corresponding author), Korea Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 02841, South Korea.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Biomed Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Chem, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Mech Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Elect Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Simpson Querrey Inst Nano Biotechnol, Ctr Bio Integrated Elect, Dept Comp Sci, Evanston, IL 60208 USA.	kyunglee@korea.ac.kr; jrogers@northwestern.edu; ahnj@yonsei.ac.kr	Rogers, John/L-2798-2016; Kang, Seung-Kyun/L-3053-2017; Chen, Xiang/AAO-6631-2020; Ahn, Jong-Hyun/L-9825-2016; huang, yonggang/O-6236-2019	Chen, Xiang/0000-0001-5100-1482; Ahn, Jong-Hyun/0000-0002-8135-7719; WANG, KE/0000-0003-2004-2745; Koo, Jahyun/0000-0003-1503-0731; Jeon, Seunghyun/0000-0002-4320-2644	National Research Foundation of Korea (NRF) - Korean government (MSIT) [NRF-2015R1A3A2066337, NRF-2016M3A9B6948342]	This work was supported by the National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (NRF-2015R1A3A2066337, NRF-2016M3A9B6948342).	Appel JH, 2016, ACS BIOMATER SCI ENG, V2, P361, DOI 10.1021/acsbiomaterials.5b00467; Bettinger CJ, 2010, ADV MATER, V22, P651, DOI 10.1002/adma.200902322; Camposeo A, 2014, ACS NANO, V8, P10893, DOI 10.1021/nn504720b; Chen CR, 2016, ACS NANO, V10, P10389, DOI 10.1021/acsnano.6b06256; Chen X, 2016, NANOSCALE, V8, P15181, DOI 10.1039/c6nr03318k; Dungey KE, 1998, J CATAL, V175, P129, DOI 10.1006/jcat.1998.1963; Fu KK, 2016, CHEM MATER, V28, P3527, DOI 10.1021/acs.chemmater.5b04931; Gan XR, 2017, BIOSENS BIOELECTRON, V89, P56, DOI 10.1016/j.bios.2016.03.042; Ganatra R, 2014, ACS NANO, V8, P4074, DOI 10.1021/nn405938z; Gao J, 2016, ACS NANO, V10, P2628, DOI 10.1021/acsnano.5b07677; Hao JL, 2017, ADV SCI, V4, DOI 10.1002/advs.201600160; Hwang SW, 2014, ADV MATER, V26, P3905, DOI 10.1002/adma.201306050; Hwang SW, 2013, ADV FUNCT MATER, V23, P4087, DOI 10.1002/adfm.201300127; Irimia-Vladu M, 2010, ADV FUNCT MATER, V20, P4069, DOI 10.1002/adfm.201001031; Jia XT, 2016, ADV FUNCT MATER, V26, P1454, DOI 10.1002/adfm.201503498; Kalantar-zadeh K, 2015, ADV FUNCT MATER, V25, P5086, DOI 10.1002/adfm.201500891; Kang K, 2015, NATURE, V520, P656, DOI 10.1038/nature14417; Kang SK, 2014, ADV FUNCT MATER, V24, P4427, DOI 10.1002/adfm.201304293; Kurapati R, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201605176; Lee G, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700157; Lee W, 2015, SMALL, V11, P6272, DOI 10.1002/smll.201502338; Lee YH, 2012, ADV MATER, V24, P2320, DOI 10.1002/adma.201104798; Lin Z, 2016, 2D MATER, V3, DOI 10.1088/2053-1583/3/4/042001; Ling X, 2014, NANO LETT, V14, P464, DOI 10.1021/nl4033704; Mittal R, 2005, INJURY, V36, P333, DOI 10.1016/j.injury.2004.09.015; Park G, 2014, ADV HEALTHC MATER, V3, P515, DOI 10.1002/adhm.201300220; Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8568; Park K, 2010, ADV FUNCT MATER, V20, P3577, DOI 10.1002/adfm.201001107; Park M, 2016, ADV MATER, V28, P2556, DOI 10.1002/adma.201505124; Park W, 2014, ACS NANO, V8, P4961, DOI 10.1021/nn501019g; Radisavljevic B, 2011, NAT NANOTECHNOL, V6, P147, DOI [10.1038/nnano.2010.279, 10.1038/NNANO.2010.279]; Rong YM, 2015, ACS NANO, V9, P3695, DOI 10.1021/acsnano.5b00852; ROSS S, 1955, J PHYS CHEM-US, V59, P889, DOI 10.1021/j150531a020; Santosh KC, 2015, J APPL PHYS, V117, DOI 10.1063/1.4916536; Tan CL, 2017, CHEM REV, V117, P6225, DOI 10.1021/acs.chemrev.6b00558; Tan MJ, 2016, J MATER CHEM C, V4, P5531, DOI 10.1039/c6tc00678g; Teo WZ, 2014, CHEM-EUR J, V20, P9627, DOI 10.1002/chem.201402680; van der Zande AM, 2013, NAT MATER, V12, P554, DOI [10.1038/NMAT3633, 10.1038/nmat3633]; Wang LF, 2014, J AM CHEM SOC, V136, P6693, DOI 10.1021/ja501686w; Wang XF, 2014, ACS NANO, V8, P11394, DOI 10.1021/nn505501v; Wang ZY, 2016, ENVIRON SCI TECHNOL, V50, P7208, DOI 10.1021/acs.est.6b01881; Wu HH, 2011, ACS NANO, V5, P1276, DOI 10.1021/nn102941b; Wu LB, 2004, BIOMATERIALS, V25, P5821, DOI 10.1016/j.biomaterials.2004.01.038; Yamamoto M, 2013, J PHYS CHEM C, V117, P25643, DOI 10.1021/jp410893e; Yang LM, 2014, NANO LETT, V14, P6275, DOI 10.1021/nl502603d; Yin L, 2015, ADV MATER, V27, P1857, DOI 10.1002/adma.201404579; Yin L, 2014, ADV FUNCT MATER, V24, P645, DOI 10.1002/adfm.201301847; Yin XB, 2014, SCIENCE, V344, P488, DOI 10.1126/science.1250564; Yu KJ, 2016, NAT MATER, V15, P782, DOI [10.1038/NMAT4624, 10.1038/nmat4624]; Zhang J, 2014, ACS NANO, V8, P6024, DOI 10.1021/nn5020819; Zhang LQ, 2016, RSC ADV, V6, P96035, DOI 10.1039/c6ra18188k; Zheng Q, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501478; Zhou W, 2013, NANO LETT, V13, P2615, DOI 10.1021/nl4007479	53	80	81	6	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	APR 27	2018	9								1690	10.1038/s41467-018-03956-9			12	Multidisciplinary Sciences	Science & Technology - Other Topics	GE1WV	WOS:000431008400006	29703901	DOAJ Gold, Green Published			2021-06-18	
J	Deistung, A; Schweser, F; Reichenbach, JR				Deistung, Andreas; Schweser, Ferdinand; Reichenbach, Juergen R.			Overview of quantitative susceptibility mapping	NMR IN BIOMEDICINE			English	Article; Proceedings Paper	4th International Workshop on MRI Phase Contrast and Quantitative Susceptibility Mapping (QSM)	SEP 26-28, 2016	Univ Graz, Graz, AUSTRIA		Univ Graz	magnetic susceptibility; quantitative susceptibility mapping; susceptibility tensor imaging; functional MRI; multiple sclerosis	MULTIPLE-SCLEROSIS LESIONS; BACKGROUND FIELD REMOVAL; TRAUMATIC BRAIN-INJURY; GRADIENT-ECHO MRI; PHASE UNWRAPPING ALGORITHM; SUBCORTICAL GRAY-MATTER; DIFFUSE AXONAL INJURY; NON-HAEMIN IRON; MAGNETIC-SUSCEPTIBILITY; IN-VIVO	Magnetic susceptibility describes the magnetizability of a material to an applied magnetic field and represents an important parameter in the field of MRI. With the recently introduced method of quantitative susceptibility mapping (QSM) and its conceptual extension to susceptibility tensor imaging (STI), the non-invasive assessment of this important physical quantity has become possible with MRI. Both methods solve the ill-posed inverse problem to determine the magnetic susceptibility from local magnetic fields. Whilst QSM allows the extraction of the spatial distribution of the bulk magnetic susceptibility from a single measurement, STI enables the quantification of magnetic susceptibility anisotropy, but requires multiple measurements with different orientations of the object relative to the main static magnetic field. In this review, we briefly recapitulate the fundamental theoretical foundation of QSM and STI, as well as computational strategies for the characterization of magnetic susceptibility with MRI phase data. In the second part, we provide an overview of current methodological and clinical applications of QSM with a focus on brain imaging. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Deistung, Andreas; Reichenbach, Juergen R.] Friedrich Schiller Univ Jena, Jena Univ Hosp, Med Phys Grp, Inst Diagnost & Intervent Radiol, Philosophenweg 3, D-07743 Jena, Germany; [Schweser, Ferdinand] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo Neuroimaging Anal Ctr, Dept Neurol, Buffalo, NY USA; [Schweser, Ferdinand] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, MRI Clin & Translat Res Ctr, Buffalo, NY USA; [Reichenbach, Juergen R.] Friedrich Schiller Univ Jena, Michael Stifel Ctr Data Driven & Simulat Sci Jena, Jena, Germany	Deistung, A; Reichenbach, JR (corresponding author), Friedrich Schiller Univ Jena, Jena Univ Hosp, Med Phys Grp, Inst Diagnost & Intervent Radiol, Philosophenweg 3, D-07743 Jena, Germany.	andreas.deistung@med.uni-jena.de; juergen.reichenbach@med.uni-jena.de	Schweser, Ferdinand/Q-6932-2019; Deistung, Andreas/AAN-9412-2021; Reichenbach, Jurgen R./B-4333-2011	Schweser, Ferdinand/0000-0003-0399-9211; Reichenbach, Jurgen R./0000-0002-2640-0630; Deistung, Andreas/0000-0002-2427-1302	German Research Foundation (DFG)German Research Foundation (DFG) [RE1123/9-2, DE2516/1-1]; International Society for Magnetic Resonance in Medicine (ISMRM); Friedrich Schiller University Jena; Interdisciplinary Center for Clinical Research (IZKF) in Jena, Germany; German Academic Exchange Service (DAAD)Deutscher Akademischer Austausch Dienst (DAAD) [57131995]	We are deeply grateful for support from Berengar W. Lehr, Li Huang, Karsten Sommer, Xiang Feng, Barthelemy Serres, Martin Stenzel, Hans-Joachim Mentzel, Matthias Schwab, Andreas Schafer, Robert Turner, Dagmar Timmann, Jan Klohs, Till Schneider and Alexander Radbruch. We acknowledge funding from the German Research Foundation (DFG, RE1123/9-2, DE2516/1-1), seed grants awarded to F.S. by the International Society for Magnetic Resonance in Medicine (ISMRM) and the Friedrich Schiller University Jena, and a seed grant awarded to A.D. by the Interdisciplinary Center for Clinical Research (IZKF) in Jena, Germany. Support is also acknowledged from the bilateral PPP - USA 2015/2016 program (project 57131995 - Quantitative MRI for Neurological Studies) of the German Academic Exchange Service (DAAD) awarded to JRR.	Abdul-Rahman HS, 2007, APPL OPTICS, V46, P6623, DOI 10.1364/AO.46.006623; Abduljalil AM, 2003, J MAGN RESON IMAGING, V18, P284, DOI 10.1002/jmri.10362; Acosta-Cabronero J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081093; Anderson LJ, 2001, EUR HEART J, V22, P2171, DOI 10.1053/euhj.2001.2822; ANDREWS BT, 1989, NEUROSURGERY, V24, P514, DOI 10.1227/00006123-198904000-00005; [Anonymous], QUANT SUSC MAPP TOOL; Ashkan K, 2007, BRIT J NEUROSURG, V21, P197, DOI 10.1080/02688690701272240; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bahr O, 2011, NEURO-ONCOLOGY, V13, P1020, DOI 10.1093/neuonc/nor099; Bagnato F, 2011, BRAIN, V134, P3599, DOI 10.1093/brain/awr278; Bai Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053237; Balla DZ, 2014, NEUROIMAGE, V100, P112, DOI 10.1016/j.neuroimage.2014.06.011; BEARD JL, 1993, NUTR REV, V51, P157, DOI 10.1111/j.1753-4887.1993.tb03096.x; Berg D, 2002, ARCH NEUROL-CHICAGO, V59, P999, DOI 10.1001/archneur.59.6.999; Berg D, 2008, LANCET NEUROL, V7, P1044, DOI 10.1016/S1474-4422(08)70239-4; BERNSTEIN MA, 1994, MAGN RESON MED, V32, P330, DOI 10.1002/mrm.1910320308; Bianciardi M, 2014, HUM BRAIN MAPP, V35, P2191, DOI 10.1002/hbm.22320; Bilgic B, 2016, QUANTITATIVE SUSCEPT; Bilgic B, 2016, NEUROIMAGE, V125, P1131, DOI 10.1016/j.neuroimage.2015.08.015; Bilgic B, 2015, MAGN RESON MED, V73, P2152, DOI 10.1002/mrm.25347; Bilgic B, 2014, J MAGN RESON IMAGING, V40, P181, DOI 10.1002/jmri.24365; Bilgic B, 2012, NEUROIMAGE, V59, P2625, DOI 10.1016/j.neuroimage.2011.08.077; Bioucas-Dias JM, 2007, IEEE T IMAGE PROCESS, V16, P698, DOI 10.1109/TIP.2006.888351; Blazejewska AI, 2015, J MAGN RESON IMAGING, V41, P1065, DOI 10.1002/jmri.24644; Blazejewska AI, 2013, NEUROLOGY, V81, P534, DOI 10.1212/WNL.0b013e31829e6fd2; Boddaert N, 2007, BLOOD, V110, P401, DOI 10.1182/blood-2006-12-065433; Boesch C, 1997, MAGN RESON MED, V37, P484, DOI 10.1002/mrm.1910370403; Bonekamp D, 2015, MAGN RESON MED, V73, P544, DOI 10.1002/mrm.25144; da Silva CB, 2014, EUR J NEUROL, V21, P1131, DOI 10.1111/ene.12448; Bowen CV, 2002, MAGNET RESON MED, V48, P52, DOI 10.1002/mrm.10192; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; Buch S, 2015, MAGN RESON MED, V73, P2185, DOI 10.1002/mrm.25350; Cavanee WK., 2007, WHO CLASSIFICATION T; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Chandran AS, 2016, J NEUROSURG, V124, P96, DOI 10.3171/2015.1.JNS142066; Chen WW, 2014, RADIOLOGY, V271, P183, DOI 10.1148/radiol.13130353; Chen WW, 2014, RADIOLOGY, V270, P496, DOI 10.1148/radiol.13122640; Chen ZK, 2015, J NEUROSCI METH, V241, P85, DOI 10.1016/j.jneumeth.2014.12.014; Chen ZK, 2013, J NEUROSCI METH, V216, P33, DOI 10.1016/j.jneumeth.2013.03.003; Cheng ZT, 2015, OPT EXPRESS, V23, P32337, DOI 10.1364/OE.23.032337; Cobzas D, 2015, J MAGN RESON IMAGING, V42, P1601, DOI 10.1002/jmri.24951; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Cook DM, 1975, PROPERTIES MATTER, P289; COX IJ, 1986, J MAGN RESON, V70, P163, DOI 10.1016/0022-2364(86)90373-2; Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437; de Rochefort L, 2008, MAGN RESON MED, V60, P1003, DOI 10.1002/mrm.21710; de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187; de Zwart JA, 2002, MAGN RESON MED, V48, P1011, DOI 10.1002/mrm.10303; Deh K, 2015, J MAGN RESON IMAGING, V42, P1592, DOI 10.1002/jmri.24943; Deistung A, 2015, P 23 ANN M ISMRM TOR, P284; Deistung A, 2008, MAGN RESON MED, V60, P1155, DOI 10.1002/mrm.21754; Deistung A, 2006, Z MED PHYS, V16, P261, DOI 10.1078/0939-3889-00324; Deistung A, 2016, CEREBELLUM, V15, P21, DOI 10.1007/s12311-015-0738-9; Deistung A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00710; Deistung A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057924; Deistung A, 2013, NEUROIMAGE, V65, P299, DOI 10.1016/j.neuroimage.2012.09.055; Deistung A, 2009, J MAGN RESON IMAGING, V29, P1478, DOI 10.1002/jmri.21673; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; Di Corato R, 2013, ACS NANO, V7, P7500, DOI 10.1021/nn401095p; Dibb R, 2015, J CARDIOVASC MAGN R, V17, DOI 10.1186/s12968-015-0159-4; Diedrichsen J, 2011, NEUROIMAGE, V54, P1786, DOI 10.1016/j.neuroimage.2010.10.035; Donato Stefano Di, 2012, Handb Clin Neurol, V103, P399, DOI 10.1016/B978-0-444-51892-7.00025-5; Dong JW, 2015, IEEE T MED IMAGING, V34, P531, DOI 10.1109/TMI.2014.2361764; Duerst Y, 2016, MAGN RESON MED, V76, P430, DOI 10.1002/mrm.25838; Durrant CJ, 2003, CONCEPTS MAGN RESO A, V18A, P72, DOI 10.1002/cmr.a.10067; Duyn J, 2013, J MAGN RESON, V229, P198, DOI 10.1016/j.jmr.2012.11.013; Duyn JH, 2007, P NATL ACAD SCI USA, V104, P11796, DOI 10.1073/pnas.0610821104; Eskildsen SF, 2012, NEUROIMAGE, V59, P2362, DOI 10.1016/j.neuroimage.2011.09.012; Fan AP, 2015, NEUROIMAGE, V104, P146, DOI 10.1016/j.neuroimage.2014.09.068; Fan AP, 2014, MAGN RESON MED, V72, P149, DOI 10.1002/mrm.24918; FAUL D, 1984, Radiology, V153, P303; Feng X, 2015, P 23 ANN M ISMRM TOR, P3497; Fernandez-Seara MA, 2000, MAGNET RESON MED, V44, P358, DOI 10.1002/1522-2594(200009)44:3<358::AID-MRM3>3.0.CO;2-I; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fukunaga M, 2010, P NATL ACAD SCI USA, V107, P3834, DOI 10.1073/pnas.0911177107; Gallichan D, 2016, MAGN RESON MED, V75, P1030, DOI 10.1002/mrm.25670; Ghiglia DC, 1996, J OPT SOC AM A, V13, P1999, DOI 10.1364/JOSAA.13.001999; Gierga K, 2009, NEUROPATH APPL NEURO, V35, P515, DOI 10.1111/j.1365-2990.2009.01015.x; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke E.M., 2011, SUSCEPTIBILITY WEIGH; Haacke E M, 1999, MAGNETIC RESONANCE I, P741; Haacke EM, 2015, MAGN RESON IMAGING, V33, P1, DOI 10.1016/j.mri.2014.09.004; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; Hadzhieva M, 2014, NEUROPATH APPL NEURO, V40, P240, DOI 10.1111/nan.12096; HALLGREN B, 1960, J NEUROCHEM, V5, P307, DOI 10.1111/j.1471-4159.1960.tb13369.x; HALLGREN B, 1958, J NEUROCHEM, V3, P41, DOI 10.1111/j.1471-4159.1958.tb12607.x; Hametner S, 2013, ANN NEUROL, V74, P848, DOI 10.1002/ana.23974; Hammond KE, 2008, NEUROIMAGE, V39, P1682, DOI 10.1016/j.neuroimage.2007.10.037; Hammond KE, 2008, ANN NEUROL, V64, P707, DOI 10.1002/ana.21582; Hankins JS, 2009, BLOOD, V113, P4853, DOI 10.1182/blood-2008-12-191643; He NY, 2015, HUM BRAIN MAPP, V36, P4407, DOI 10.1002/hbm.22928; He Q, 2015, P 23 ANN M ISMRM TOR, P1725; He X, 2009, P NATL ACAD SCI USA, V106, P13558, DOI 10.1073/pnas.0904899106; Hebbrecht G, 1999, NUCL INSTRUM METH B, V150, P208, DOI 10.1016/S0168-583X(98)00938-0; Herrmann KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150371; Hinoda T, 2015, INVEST RADIOL, V50, P522, DOI 10.1097/RLI.0000000000000159; HOLT RW, 1994, JMRI-J MAGN RESON IM, V4, P809, DOI 10.1002/jmri.1880040612; Hopkins JA, 1997, MAGNET RESON MED, V37, P494, DOI 10.1002/mrm.1910370404; Huang YL, 2015, NEUROLOGY, V84, P580, DOI 10.1212/WNL.0000000000001237; HWANG SN, 1995, J MAGN RESON SER B, V109, P126, DOI 10.1006/jmrb.1995.0002; Jain M, 2007, DIAMAGNETIC SUSCEPTI; Jain V, 2013, MAGN RESON MED, V70, P785, DOI 10.1002/mrm.24519; Jain V, 2012, MAGN RESON MED, V68, P863, DOI 10.1002/mrm.23282; Jezzard P, 1999, HUM BRAIN MAPP, V8, P80, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<80::AID-HBM2>3.0.CO;2-C; KAWAMURA Y, 1981, MOL CRYST LIQ CRYST, V67, P733; Khabipova D, 2015, P 23 ANN M ISMRM TOR, P929; Khabipova D, 2015, NEUROIMAGE, V107, P163, DOI 10.1016/j.neuroimage.2014.11.038; Kidd D, 1999, BRAIN, V122, P17, DOI 10.1093/brain/122.1.17; Kiselev VG, 2001, MAGN RESON MED, V46, P1113, DOI 10.1002/mrm.1307; Klassen L, 2005, P INT SOC MAGN RESON, V13, P496; Klockgether T, 2011, CURR OPIN NEUROL, V24, P339, DOI 10.1097/WCO.0b013e32834875ba; Klohs J, 2016, J CEREBR BLOOD F MET, V36, P1614, DOI 10.1177/0271678X15621500; Koeppen AH, 2007, ACTA NEUROPATHOL, V114, P163, DOI 10.1007/s00401-007-0220-y; Koeppen AH, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-26; Koeppen AH, 2012, CEREBELLUM, V11, P845, DOI 10.1007/s12311-012-0383-5; Koopmans PJ, 2008, MAGN RESON MATER PHY, V21, P149, DOI 10.1007/s10334-007-0101-3; Kornienko VN, 2009, DIAGNOSTIC NEURORADI; Kressler B, 2010, IEEE T MED IMAGING, V29, P273, DOI 10.1109/TMI.2009.2023787; Langkammer C, 2015, NEUROIMAGE, V111, P622, DOI 10.1016/j.neuroimage.2015.02.041; Langkammer C, 2013, RADIOLOGY, V267, P551, DOI 10.1148/radiol.12120707; Langkammer C, 2012, NEUROIMAGE, V62, P1593, DOI 10.1016/j.neuroimage.2012.05.049; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lee J, 2011, NEUROIMAGE, V54, P2779, DOI 10.1016/j.neuroimage.2010.10.071; Lee J, 2010, P NATL ACAD SCI USA, V107, P5130, DOI 10.1073/pnas.0910222107; Leskovjan AC, 2011, NEUROIMAGE, V55, P32, DOI 10.1016/j.neuroimage.2010.11.073; Leutritz T, 2013, MAGN RESON MED, V69, P263, DOI 10.1002/mrm.24223; LeVine SM, 1997, BRAIN RES, V760, P298, DOI 10.1016/S0006-8993(97)00470-8; Li L, 2004, MAGN RESON MED, V51, P1077, DOI 10.1002/mrm.20054; Li L, 2001, J MAGN RESON, V148, P442, DOI 10.1006/jmre.2000.2267; Li Wei, 2013, J Neurosci Neuroeng, V2, P431; Li W, 2015, NEUROIMAGE, V108, P111, DOI 10.1016/j.neuroimage.2014.12.043; Li W, 2014, HUM BRAIN MAPP, V35, P2698, DOI 10.1002/hbm.22360; Li W, 2014, NMR BIOMED, V27, P219, DOI 10.1002/nbm.3056; Li W, 2012, NEUROIMAGE, V59, P2088, DOI 10.1016/j.neuroimage.2011.10.038; Li X, 2016, J MAGN RESON IMAGING, V43, P463, DOI 10.1002/jmri.24976; Li X, 2014, MAGN RESON MED, V72, P610, DOI 10.1002/mrm.25322; Li X, 2012, NEUROIMAGE, V62, P314, DOI 10.1016/j.neuroimage.2012.04.042; Lim IAL, 2014, NEUROIMAGE, V86, P265, DOI 10.1016/j.neuroimage.2013.09.072; Lin PY, 2015, AM J NEURORADIOL, V36, P467, DOI 10.3174/ajnr.A4137; Liu C, 2016, STI SUITE; Liu CL, 2015, TOMOGRAPHY, V1, P3, DOI 10.18383/j.tom.2015.00136; Liu CL, 2015, J MAGN RESON IMAGING, V42, P23, DOI [10.1002/jmri.24768, 10.3969/j.issn.1001-2400.2015.01.004]; Liu CL, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00011; Liu CL, 2013, NEUROIMAGE, V67, P193, DOI 10.1016/j.neuroimage.2012.10.050; Liu CL, 2011, NEUROIMAGE, V56, P930, DOI 10.1016/j.neuroimage.2011.02.024; Liu CL, 2010, MAGN RESON MED, V63, P1471, DOI 10.1002/mrm.22482; Liu J, 2012, NEUROIMAGE, V59, P2560, DOI 10.1016/j.neuroimage.2011.08.082; Liu J, 2016, J NEUROTRAUM, V33, P10, DOI 10.1089/neu.2014.3856; Liu JM, 2015, MAGN RESON MED, V73, P1654, DOI 10.1002/mrm.25247; Liu S, 2015, P 23 ANN M ISMRM TOR, P3309; Liu T, 2013, RADIOLOGY, V269, P216, DOI 10.1148/radiol.13121991; Liu T, 2013, MAGN RESON MED, V69, P467, DOI 10.1002/mrm.24272; Liu T, 2011, NMR BIOMED, V24, P1129, DOI 10.1002/nbm.1670; Liu T, 2009, MAGN RESON MED, V61, P196, DOI 10.1002/mrm.21828; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Lobel U, 2010, NEURORADIOLOGY, V52, P1167, DOI 10.1007/s00234-010-0771-9; Loktyushin A, 2013, MAGN RESON MED, V70, P1608, DOI 10.1002/mrm.24615; Lonsdale K, 1939, PROC R SOC LON SER-A, V171, P0541, DOI 10.1098/rspa.1939.0083; Lorentz H. A. H. A., 1916, THEORY ELECT ITS APP; Lotfipour AK, 2012, J MAGN RESON IMAGING, V35, P48, DOI 10.1002/jmri.22752; Luo J, 2014, MAGN RESON MED, V71, P1251, DOI 10.1002/mrm.24762; Ma YJ, 2015, MED PHYS, V42, P637, DOI 10.1118/1.4905163; Maderwald S, 2012, NEUROIMAGE, V63, P1421, DOI 10.1016/j.neuroimage.2012.07.063; Mahlknecht P, 2013, NEURODEGENER DIS, V12, P212, DOI 10.1159/000348595; Marques JP, 2005, CONCEPT MAGN RESON B, V25B, P65, DOI 10.1002/cmr.b.20034; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moon Y, 2016, J ALZHEIMERS DIS, V51, P737, DOI 10.3233/JAD-151037; MORRIS CM, 1992, ACTA ANAT, V144, P235; Moser E, 2012, NMR BIOMED, V25, P695, DOI 10.1002/nbm.1794; Murakami Y, 2015, AM J NEURORADIOL, V36, P1102, DOI 10.3174/ajnr.A4260; Nakada T, 2008, J NEUROIMAGING, V18, P125, DOI 10.1111/j.1552-6569.2007.00179.x; Navarro MA, 2012, OPT EXPRESS, V20, P2556, DOI 10.1364/OE.20.002556; Neelavalli J, 2011, MRI SUSCEPTIBILITY W, P17; Neelavalli J, 2009, J MAGN RESON IMAGING, V29, P937, DOI 10.1002/jmri.21693; Nordsmark M, 2005, RADIOTHER ONCOL, V77, P18, DOI 10.1016/j.radonc.2005.06.038; Ogawa S, 1998, ANNU REV BIOPH BIOM, V27, P447, DOI 10.1146/annurev.biophys.27.1.447; Barbosa JHO, 2015, MAGN RESON IMAGING, V33, P559, DOI 10.1016/j.mri.2015.02.021; Patel NK, 2008, STEREOT FUNCT NEUROS, V86, P153, DOI 10.1159/000120427; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Perlmutter JS, 2006, ANNU REV NEUROSCI, V29, P229, DOI 10.1146/annurev.neuro.29.051605.112824; Persson N, 2015, NEUROIMAGE, V122, P385, DOI 10.1016/j.neuroimage.2015.07.050; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; Qin L, 2009, MAGN RESON MED, V62, P924, DOI 10.1002/mrm.22076; Ramos P, 2014, J TRACE ELEM MED BIO, V28, P13, DOI 10.1016/j.jtemb.2013.08.001; Reichenbach JR, 2015, CLIN NEURORADIOL, V25, P225, DOI 10.1007/s00062-015-0432-9; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robinson S, 2014, MAGN RESON MED, V72, P80, DOI 10.1002/mrm.24897; Robinson S, 2011, MAGN RESON MED, V65, P1638, DOI 10.1002/mrm.22753; Robitaille PML, 1998, NMR BIOMED, V11, P263, DOI 10.1002/(SICI)1099-1492(199810)11:6<263::AID-NBM549>3.0.CO;2-0; Rodgers ZB, 2015, NEUROIMAGE, V106, P441, DOI 10.1016/j.neuroimage.2014.10.061; ROEMER PB, 1990, MAGNET RESON MED, V16, P192, DOI 10.1002/mrm.1910160203; Ros C, 2008, 4th European Conference of the International Federation for Medical and Biological Engineering - ECIFMBE 2008, P803; Rudko DA, 2014, RADIOLOGY, V272, P851, DOI 10.1148/radiol.14132475; Salomir R, 2003, CONCEPT MAGN RESON B, V19B, P26, DOI 10.1002/cmr.b.10083; Schafer A, 2012, HUM BRAIN MAPP, V33, P2831, DOI 10.1002/hbm.21404; Schafer A, 2009, NEUROIMAGE, V48, P126, DOI 10.1016/j.neuroimage.2009.05.093; Schafer A, 2014, P 22 M INT SOC MAGN, P3267; Schenck JF, 2005, PROG BIOPHYS MOL BIO, V87, P185, DOI 10.1016/j.pbiomolbio.2004.08.009; Schenck JF, 2003, J NEUROL SCI, V207, P99, DOI 10.1016/S0022-510X(02)00431-8; Schenck JF, 1996, MED PHYS, V23, P815, DOI 10.1118/1.597854; Schneider TM, 2016, OPER NEUROSURG, V12, P330, DOI 10.1227/NEU.0000000000001256; Schofield MA, 2003, OPT LETT, V28, P1194, DOI 10.1364/OL.28.001194; SCHUBERT D, 1995, BIOCHEM BIOPH RES CO, V216, P702, DOI 10.1006/bbrc.1995.2678; Schweser F, 2014, P 22 ANN M ISMRM MIL, P632; Schweser F., 2012, P 20 ANN M ISMRM MEL, P409; Schweser F., 2011, P 19 ANN M ISMRM MON, V19, P2667; Schweser F, 2011, P 19 ANN M ISMRM MON, P1014; Schweser F, 2011, P 19 M INT SOC MAGN, V19, P120; Schweser F, 2016, Z MED PHYS, V26, P6, DOI 10.1016/j.zemedi.2015.10.002; Schweser F, 2013, MAGN RESON MED, V69, P1581, DOI 10.1002/mrm.24405; Schweser F, 2012, NEUROIMAGE, V62, P2083, DOI 10.1016/j.neuroimage.2012.05.067; Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598; SEPULVEDA NG, 1994, IEEE T MAGN, V30, P5062, DOI 10.1109/20.334296; Serres B, 2015, P 23 ANN M ISMRM TOR, P290; Sharma SD, 2015, MAGN RESON MED, V74, P673, DOI 10.1002/mrm.25448; Shi HL, 2007, FRONT BIOSCI-LANDMRK, V12, P1318, DOI 10.2741/2150; Shmueli K, 2011, MAGN RESON MED, V65, P35, DOI 10.1002/mrm.22604; Shmueli K, 2009, MAGN RESON MED, V62, P1510, DOI 10.1002/mrm.22135; Shoamanesh A, 2011, CEREBROVASC DIS, V32, P528, DOI 10.1159/000331466; Silbernagl S, 2001, TASCHENATLAS PHYSL, P88; Smith MA, 2010, J ALZHEIMERS DIS, V19, P363, DOI 10.3233/JAD-2010-1239; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Solbach K, 2014, NEUROIMAGE-CLIN, V6, P93, DOI 10.1016/j.nicl.2014.08.018; Spees WM, 2001, MAGN RESON MED, V45, P533, DOI 10.1002/mrm.1072; St Pierre TG, 2004, NMR BIOMED, V17, P446, DOI 10.1002/nbm.905; Stefanescu MR, 2015, BRAIN, V138, P1182, DOI 10.1093/brain/awv064; Stoffel W., 2012, CELLULAR METABOLISM, P55; Straub S, 2015, 32 ANN SCI M ESMRMB, P178; Straub S, 2016, MAGN RESON MED, V75, P2526, DOI 10.1002/mrm.25812; Stuber C, 2014, NEUROIMAGE, V93, P95, DOI 10.1016/j.neuroimage.2014.02.026; Sun H, 2016, MATLAB SCRIPTS QSM; Sun HF, 2016, MAGN RESON MED, V76, P781, DOI 10.1002/mrm.25919; Sun HF, 2015, MAGN RESON MED, V73, P1932, DOI 10.1002/mrm.25316; Sun HF, 2015, NEUROIMAGE, V105, P486, DOI 10.1016/j.neuroimage.2014.11.010; Sun HF, 2014, MAGN RESON MED, V71, P1151, DOI 10.1002/mrm.24765; Tan H, 2013, 2 WORKSH MRI PHAS CO, P110; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; Terreno E, 2006, MAGN RESON MED, V55, P491, DOI 10.1002/mrm.20793; THULBORN KR, 1982, BIOCHIM BIOPHYS ACTA, V714, P265, DOI 10.1016/0304-4165(82)90333-6; Thunberg P, 2005, MAGN RESON IMAGING, V23, P795, DOI 10.1016/j.mri.2005.06.002; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Topfer R, 2015, MAGN RESON MED, V73, P851, DOI 10.1002/mrm.25148; Ulrich R, 2003, J MAGN RESON, V164, P115, DOI 10.1016/S1090-7807(03)00208-8; van Gelderen P, 2015, MAGN RESON MED, V74, P1388, DOI 10.1002/mrm.25524; Vannesjo SJ, 2015, MAGN RESON MED, V73, P1833, DOI 10.1002/mrm.25303; Versluis MJ, 2010, NEUROIMAGE, V51, P1082, DOI 10.1016/j.neuroimage.2010.03.048; Waldvogel D, 1999, ANN NEUROL, V46, P123, DOI 10.1002/1531-8249(199907)46:1<123::AID-ANA19>3.0.CO;2-H; Walsh DO, 2000, MAGNET RESON MED, V43, P682, DOI 10.1002/(SICI)1522-2594(200005)43:5<682::AID-MRM10>3.0.CO;2-G; Wang Y, 2015, MAGN RESON MED, V73, P82, DOI 10.1002/mrm.25358; Ward R, 2014, LANCET NEUROL, V13, P1045, DOI 10.1016/S1474-4422(14)70117-6; Wei H, 2015, P 23 ANN M ISMRM TOR; Wei HJ, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3501; Wei HJ, 2015, NMR BIOMED, V28, P1294, DOI 10.1002/nbm.3383; Weisberg LA, 1996, ESSENTIALS CLIN NEUR, P356; WEISSKOFF RM, 1992, MAGNET RESON MED, V24, P375, DOI 10.1002/mrm.1910240219; Wen J, 2015, MAGN RESON MED, V73, P195, DOI 10.1002/mrm.25114; Wen Y, 2016, MAGN RESON MED, V75, P823, DOI 10.1002/mrm.25652; Wen Y, 2014, MAGN RESON MED, V72, P1065, DOI 10.1002/mrm.24998; Wengenack TM, 2011, NEUROIMAGE, V54, P113, DOI 10.1016/j.neuroimage.2010.08.033; Wharton S, 2010, NEUROIMAGE, V53, P515, DOI 10.1016/j.neuroimage.2010.06.070; Wharton S, 2010, MAGN RESON MED, V63, P1292, DOI 10.1002/mrm.22334; Wharton S, 2015, MAGN RESON MED, V73, P1258, DOI 10.1002/mrm.25189; Wisnieff C, 2015, MAGN RESON MED, V74, P564, DOI 10.1002/mrm.25420; Wisnieff C, 2013, NEUROIMAGE, V70, P363, DOI 10.1016/j.neuroimage.2012.12.050; Witoszynskyj S, 2009, MED IMAGE ANAL, V13, P257, DOI 10.1016/j.media.2008.10.004; Wolber J, 2000, MAGNET RESON MED, V43, P491, DOI 10.1002/(SICI)1522-2594(200004)43:4<491::AID-MRM1>3.0.CO;2-6; Wong R, 2012, ANN BIOMED ENG, V40, P1328, DOI 10.1007/s10439-011-0482-3; Wood JC, 2005, BLOOD, V106, P1460, DOI 10.1182/blood-2004-10-3982; Wu B, 2012, MAGN RESON MED, V67, P137, DOI 10.1002/mrm.23000; Wu B, 2012, NEUROIMAGE, V59, P297, DOI 10.1016/j.neuroimage.2011.07.019; Wu DM, 2016, MAGN RESON MED, V76, P478, DOI 10.1002/mrm.25878; XIANG QS, 1995, JMRI-J MAGN RESON IM, V5, P529, DOI 10.1002/jmri.1880050509; Xie LK, 2015, MAGN RESON MED, V73, P1270, DOI 10.1002/mrm.25219; Xu B, 2015, MAGN RESON MED, V73, P1540, DOI 10.1002/mrm.25257; Xu B, 2014, MAGN RESON MED, V72, P438, DOI 10.1002/mrm.24937; Yablonskiy DA, 2015, MAGN RESON MED, V73, P757, DOI 10.1002/mrm.25538; Yablonskiy DA, 2012, P NATL ACAD SCI USA, V109, P14212, DOI 10.1073/pnas.1206037109; YAMADA N, 1992, MAGN RESON IMAGING, V10, P559, DOI 10.1016/0730-725X(92)90007-M; Yamada N, 1996, RADIOLOGY, V198, P171, DOI 10.1148/radiology.198.1.8539373; YE FQ, 1995, MAGNET RESON MED, V34, P713, DOI 10.1002/mrm.1910340510; YOUNG IR, 1989, J COMPUT ASSIST TOMO, V13, P490, DOI 10.1097/00004728-198905000-00023; YOUNG IR, 1987, J COMPUT ASSIST TOMO, V11, P2, DOI 10.1097/00004728-198701000-00002; Zaitsev M, 2006, NEUROIMAGE, V31, P1038, DOI 10.1016/j.neuroimage.2006.01.039; Zhang JW, 2015, MAGN RESON MED, V74, P945, DOI 10.1002/mrm.25463; Zheng WL, 2013, NEUROIMAGE, V78, P68, DOI 10.1016/j.neuroimage.2013.04.022; Zhong K, 2008, NEUROIMAGE, V40, P1561, DOI 10.1016/j.neuroimage.2008.01.061; Zhou D, 2014, NMR BIOMED, V27, P312, DOI 10.1002/nbm.3064	295	80	80	3	34	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	APR	2017	30	4			SI				e3569	10.1002/nbm.3569			27	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	EQ5CY	WOS:000398100400004	27434134				2021-06-18	
J	Coughlin, JM; Wang, YH; Minn, I; Bienko, N; Ambinder, EB; Xu, X; Peters, ME; Dougherty, JW; Vranesic, M; Koo, SM; Ahn, HH; Lee, M; Cottrell, C; Sair, HI; Sawa, A; Munro, CA; Nowinski, CJ; Dannals, RF; Lyketsos, CG; Kassiou, M; Smith, G; Caffo, B; Mori, S; Guilarte, TR; Pomper, MG				Coughlin, Jennifer M.; Wang, Yuchuan; Minn, Il; Bienko, Nicholas; Ambinder, Emily B.; Xu, Xin; Peters, Matthew E.; Dougherty, John W.; Vranesic, Melin; Koo, Soo Min; Ahn, Hye-Hyun; Lee, Merton; Cottrell, Chris; Sair, Haris I.; Sawa, Akira; Munro, Cynthia A.; Nowinski, Christopher J.; Dannals, Robert F.; Lyketsos, Constantine G.; Kassiou, Michael; Smith, Gwenn; Caffo, Brian; Mori, Susumu; Guilarte, Tomas R.; Pomper, Martin G.			Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players	JAMA NEUROLOGY			English	Article							18 KDA TSPO; CHRONIC TRAUMATIC ENCEPHALOPATHY; SPORTS-RELATED CONCUSSION; TRANSLOCATOR PROTEIN; MICROGLIAL ACTIVATION; MICROGLIA/MACROPHAGE POLARIZATION; THERAPEUTIC TARGET; INJURY; DISEASE; BINDING	IMPORTANCE Microglia, the resident immune cells of the central nervous system, play an important role in the brain's response to injury and neurodegenerative processes. It has been proposed that prolonged microglial activation occurs after single and repeated traumatic brain injury, possibly through sports-related concussive and subconcussive injuries. Limited in vivo brain imaging studies months to years after individuals experience a single moderate to severe traumatic brain injury suggest widespread persistent microglial activation, but there has been little study of persistent glial cell activity in brains of athletes with sports-related traumatic brain injury. OBJECTIVE To measure translocator protein 18 kDa (TSPO), a marker of activated glial cell response, in a cohort of National Football League (NFL) players and control participants, and to report measures of white matter integrity. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional, case-control study included young active (n = 4) or former (n = 10) NFL players recruited from across the United States, and 16 age-, sex-, highest educational level-, and body mass index-matched control participants. This study was conducted at an academic research institution in Baltimore, Maryland, from January 29, 2015, to February 18, 2016. MAIN OUTCOMES AND MEASURES Positron emission tomography-based regional measures of TSPO using [C-11] DPA-713, diffusion tensor imaging measures of regional white matter integrity, regional volumes on structural magnetic resonance imaging, and neuropsychological performance. RESULTS The mean (SD) ages of the 14 NFL participants and 16 control participants were 31.3 (6.1) years and 27.6 (4.9) years, respectively. Players reported a mean (SD) of 7.0 (6.4) years (range, 1-21 years) since the last self-reported concussion. Using [11C] DPA-713 positron emission tomographic data from 12 active or former NFL players and 11 matched control participants, the NFL players showed higher total distribution volume in 8 of the 12 brain regions examined (P < .004). We also observed limited change in white matter fractional anisotropy and mean diffusivity in 13 players compared with 15 control participants. In contrast, these young players did not differ from control participants in regional brain volumes or in neuropsychological performance. CONCLUSIONS AND RELEVANCE The results suggest that localized brain injury and repair, indicated by higher TSPO signal and white matter changes, may be associated with NFL play. Further study is needed to confirm these findings and to determine whether TSPO signal and white matter changes in young NFL athletes are related to later onset of neuropsychiatric symptoms.	[Coughlin, Jennifer M.; Bienko, Nicholas; Peters, Matthew E.; Dougherty, John W.; Cottrell, Chris; Sawa, Akira; Munro, Cynthia A.; Lyketsos, Constantine G.; Smith, Gwenn; Pomper, Martin G.] Johns Hopkins Med Inst, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Coughlin, Jennifer M.; Wang, Yuchuan; Minn, Il; Ambinder, Emily B.; Xu, Xin; Vranesic, Melin; Koo, Soo Min; Ahn, Hye-Hyun; Lee, Merton; Sair, Haris I.; Dannals, Robert F.; Mori, Susumu; Pomper, Martin G.] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, 600 N Wolfe St, Baltimore, MD 21205 USA; [Munro, Cynthia A.] Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21205 USA; [Nowinski, Christopher J.] Concuss Legacy Fdn, Waltham, MA USA; [Nowinski, Christopher J.] Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Kassiou, Michael] Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; [Kassiou, Michael] Univ Sydney, Discipline Med Radiat Sci, Sydney, NSW, Australia; [Caffo, Brian] Johns Hopkins Med Inst, Dept Biostat, Baltimore, MD 21205 USA; [Guilarte, Tomas R.] Florida Int Univ, Dept Environm & Occupat Hlth, Miami, FL 33199 USA; [Guilarte, Tomas R.] Florida Int Univ, Program Cognit Neurosci & Imaging, Miami, FL 33199 USA	Pomper, MG (corresponding author), Johns Hopkins Med Inst, Dept Radiol & Radiol Sci, 1550 Orleans St,CRB 2,Room 492, Baltimore, MD 21231 USA.	mpomper@jhmi.edu	Coughlin, Jennifer M/O-8179-2018; MINN, IL/L-1812-2018	Coughlin, Jennifer M/0000-0002-2514-9640; MINN, IL/0000-0002-7822-662X; Kassiou, Michael/0000-0002-6655-0529	National Association for Research on Schizophrenia and Depression; Alexander Wilson Schweizer Fellowship; NIEHS from the National Institute of Environmental Health Sciences [ES007062]; GE/NFL Head Health Challenge I; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES007062, R01ES007062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005146, T32AG027668] Funding Source: NIH RePORTER	This study was supported by the National Association for Research on Schizophrenia and Depression (Dr Coughlin), the Alexander Wilson Schweizer Fellowship (Dr Coughlin), grant NIEHS ES007062 from the National Institute of Environmental Health Sciences (Dr Guilarte), and GE/NFL Head Health Challenge I.	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Andersson JLR, 2002, NEUROIMAGE, V16, P177, DOI 10.1006/nimg.2001.1039; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bird JLE, 2010, ATHEROSCLEROSIS, V210, P388, DOI 10.1016/j.atherosclerosis.2009.11.047; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Chauveau F, 2008, EUR J NUCL MED MOL I, V35, P2304, DOI 10.1007/s00259-008-0908-9; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Ching ASC, 2012, INSIGHTS IMAGING, V3, P111, DOI 10.1007/s13244-011-0128-x; Coughlin JM, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.40; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Coughlin JM, 2014, J NEUROVIROL, V20, P219, DOI 10.1007/s13365-014-0239-5; Faria AV, 2010, NEUROIMAGE, V52, P415, DOI 10.1016/j.neuroimage.2010.04.238; Folkersma H, 2011, J NUCL MED, V52, P1235, DOI 10.2967/jnumed.110.084061; Gajawelli N, 2013, WORLD NEUROSURG, V80, P824, DOI 10.1016/j.wneu.2013.10.020; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Green P., 1995, MANUAL ORAL WORD MEM; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Olmos-Alonso A, 2016, BRAIN, V139, P891, DOI 10.1093/brain/awv379; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Owen DRJ, 2011, INT REV NEUROBIOL, V101, P19, DOI 10.1016/B978-0-12-387718-5.00002-X; Papadopoulos V, 2009, EXP NEUROL, V219, P53, DOI 10.1016/j.expneurol.2009.04.016; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Scarf AM, 2011, J NUCL MED, V52, P667, DOI 10.2967/jnumed.110.086629; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Subcommittee QS, 1997, NEUROLOGY, V48, P581; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Team R.D.C, 2014, R LANG ENV STAT COMP; Venneti S, 2013, GLIA, V61, P10, DOI 10.1002/glia.22357; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wright AD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150215; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049; Ziebell JM, 2017, BRAIN BEHAV IMMUN, V59, P1, DOI 10.1016/j.bbi.2016.03.008	48	80	81	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JAN 1	2017	74	1					67	74		10.1001/jamaneurol.2016.3764			8	Clinical Neurology	Neurosciences & Neurology	EK1IK	WOS:000393678800014	27893897	Green Accepted, Bronze			2021-06-18	
J	Kon, AA; Shepard, EK; Sederstrom, NO; Swoboda, SM; Marshall, MF; Birriel, B; Rincon, F				Kon, Alexander A.; Shepard, Eric K.; Sederstrom, Nneka O.; Swoboda, Sandra M.; Marshall, Mary Faith; Birriel, Barbara; Rincon, Fred			Defining Futile and Potentially Inappropriate Interventions: A Policy Statement From the Society of Critical Care Medicine Ethics Committee	CRITICAL CARE MEDICINE			English	Article						decision making; end-of-life care; ethics; ethics consultation; medical futility	TRAUMATIC BRAIN-INJURY; LIFE-SUSTAINING THERAPY; INTENSIVE-CARE; INTRACEREBRAL HEMORRHAGE; HOSPITAL MORTALITY; CARDIAC-ARREST; UNIT PATIENTS; ILL PATIENTS; ACUTE PHYSIOLOGY; SCORE	Objectives: The Society of Critical Care Medicine and four other major critical care organizations have endorsed a seven-step process to resolve disagreements about potentially inappropriate treatments. The multiorganization statement (entitled: An official ATS/AACN/ACCP/ESICM/SCCM Policy Statement: Responding to Requests for Potentially Inappropriate Treatments in Intensive Care Units) provides examples of potentially inappropriate treatments; however, no clear definition is provided. This statement was developed to provide a clear definition of inappropriate interventions in the ICU environment. Design: A subcommittee of the Society of Critical Care Medicine Ethics Committee performed a systematic review of empirical research published in peer-reviewed journals as well as professional organization position statements to generate recommendations. Recommendations approved by consensus of the full Society of Critical Care Medicine Ethics Committees and the Society of Critical Care Medicine Council were included in the statement. Measurements and Main Results: ICU interventions should generally be considered inappropriate when there is no reasonable expectation that the patient will improve sufficiently to survive outside the acute care setting, or when there is no reasonable expectation that the patient's neurologic function will improve sufficiently to allow the patient to perceive the benefits of treatment. This definition should not be considered exhaustive; there will be cases in which life-prolonging interventions may reasonably be considered inappropriate even when the patient would survive outside the acute care setting with sufficient cognitive ability to perceive the benefits of treatment. When patients or surrogate decision makers demand interventions that the clinician believes are potentially inappropriate, the seven-step process presented in the multiorganization statement should be followed. Clinicians should recognize the limits of prognostication when evaluating potential neurologic outcome and terminal cases. At times, it may be appropriate to provide time-limited ICU interventions to patients if doing so furthers the patient's reasonable goals of care. If the patient is experiencing pain or suffering, treatment to relieve pain and suffering is always appropriate. Conclusions : The Society of Critical Care Medicine supports the seven-step process presented in the multiorganization statement. This statement provides added guidance to clinicians in the ICU environment.	[Kon, Alexander A.] Naval Med Ctr San Diego, Pediat Crit Care Med & Healthcare Eth, San Diego, CA 92134 USA; [Kon, Alexander A.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Shepard, Eric K.] Univ Maryland, Sch Med, Anesthesiol & Crit Care Med, Baltimore, MD 21201 USA; [Sederstrom, Nneka O.] MedStar Washington Hosp Ctr, Ctr Eth, Washington, DC USA; [Swoboda, Sandra M.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Swoboda, Sandra M.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA; [Marshall, Mary Faith] Univ Virginia, Sch Med, Ctr Biomed Eth & Humanities, Charlottesville, VA 22908 USA; [Birriel, Barbara] Penn State Univ, Coll Nursing, Hershey, PA USA; [Rincon, Fred] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA	Kon, AA (corresponding author), Naval Med Ctr San Diego, Pediat Crit Care Med & Healthcare Eth, San Diego, CA 92134 USA.; Kon, AA (corresponding author), Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.	kon.sandiego@gmail.com	Sederstrom, Nneka/AAV-8269-2020		GenentechRoche HoldingGenentech	Dr. Kon disclosed other healthcare professional organization activities (President-elect, American Society for Bioethics and Humanities), disclosed government employment, and disclosed serving as an expert witness. Dr. Swoboda disclosed other healthcare professional organization activities (Surgical Infection Society, American Association of Critical-Care Nurses, Society for Simulation in Healthcare, International Nursing Association for Clinical Simulation and Learning member). Dr. Marshall disclosed relationships with providers of healthcare services (Consult for National Institutes of Health, and Academic Health Centers on Issues of Clinical and Research Ethics) and other healthcare professional organization activities (Consultant, National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, and American Society for Bone and Mineral Research). Dr. Rincon disclosed relationships with providers of healthcare services (Otsuka, Bard), disclosed other healthcare professional organization activities (Neurocritical Care Society, American College of Chest Physicians), and received grant support (Genentech Research Grant). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Afessa B, 2004, CHEST, V126, P1905, DOI 10.1378/chest.126.6.1905; [Anonymous], 1995, CMAJ, V153, p1652A; [Anonymous], 2011, RESP REQ NONB TREATM; Barrera R, 2001, J CRIT CARE, V16, P32, DOI 10.1053/jcrc.2001.21794; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Bosslet GT, 2015, AM J RESP CRIT CARE, V191, P1318, DOI 10.1164/rccm.201505-0924ST; BRATTON SL, 1994, ARCH PEDIAT ADOL MED, V148, P167, DOI 10.1001/archpedi.1994.02170020053008; Courtwright A, 2012, HASTINGS CENT REP, V42, P41, DOI 10.1002/hast.51; Cronberg T, 2011, NEUROLOGY, V77, P623, DOI 10.1212/WNL.0b013e31822a276d; Cronberg T, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-45; Curtis JR, 2000, ARCH INTERN MED, V160, P1597, DOI 10.1001/archinte.160.11.1597; Danis M, 1997, CRIT CARE MED, V25, P887; Fanshawe M, 2002, ANAESTH INTENS CARE, V30, P628, DOI 10.1177/0310057X0203000515; Frick S, 2003, CRIT CARE MED, V31, P456, DOI 10.1097/01.CCM.0000049945.69373.7C; Gallo JJ, 2003, J AM GERIATR SOC, V51, P961, DOI 10.1046/j.1365-2389.2003.51309.x; Goodman D, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00162; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Ho KM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003226; Honeybul S, 2011, J NEUROTRAUM, V28, P13, DOI 10.1089/neu.2010.1584; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Huynh TN, 2013, JAMA INTERN MED, V173, P1887, DOI 10.1001/jamainternmed.2013.10261; Ibsen LM, 2002, CRIT CARE MED, V30, pS402, DOI 10.1097/00003246-200211001-00004; Jacobs LM, 2010, J TRAUMA, V69, P1567, DOI 10.1097/TA.0b013e3181f65921; Jox RJ, 2012, J MED ETHICS, V38, P540, DOI 10.1136/medethics-2011-100479; Joynt GM, 2001, INTENS CARE MED, V27, P1459, DOI 10.1007/s001340101041; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Karathanou A, 2011, J NEUROSURG SCI, V55, P173; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; Litton E, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.11.013; Marik PE, 1999, RESUSCITATION, V42, P197, DOI 10.1016/S0300-9572(99)00114-8; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; Metnitz PGH, 2005, INTENS CARE MED, V31, P1336, DOI 10.1007/s00134-005-2762-6; Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5; Mulder M, 2014, CRIT CARE MED, V42, P2493, DOI 10.1097/CCM.0000000000000540; Norris WM, 2005, CHEST, V127, P2180, DOI 10.1378/chest.127.6.2180; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Plows CW, 1999, JAMA-J AM MED ASSOC, V281, P937; Reisfield GM, 2006, RESUSCITATION, V71, P152, DOI 10.1016/j.resuscitation.2006.02.022; Rodriguez KL, 2006, J MED ETHICS, V32, P444, DOI 10.1136/jme.2005.014118; Rodriguez RM, 1997, CRIT CARE MED, V25, P1801, DOI 10.1097/00003246-199711000-00016; Rost NS, 2008, STROKE, V39, P2304, DOI 10.1161/STROKEAHA.107.512202; Schneiderman LJ, 2000, CAMB Q HEALTHC ETHIC, V9, P524, DOI 10.1017/S0963180100904110; Sibbald R, 2007, CAN MED ASSOC J, V177, P1201, DOI 10.1503/cmaj.070144; Sinuff T, 2006, CRIT CARE MED, V34, P878, DOI 10.1097/01.CCM.0000201881.58644.41; SKANDALAKIS LJ, 1989, AM SURGEON, V55, P492; Smith EE, 2010, CIRCULATION, V122, P1496, DOI 10.1161/CIRCULATIONAHA.109.932822; Stein DM, 2012, J TRAUMA ACUTE CARE, V73, P419, DOI 10.1097/TA.0b013e31825ff59a; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Thenayan EAL, 2010, J CRIT CARE, V25, P300, DOI 10.1016/j.jcrc.2009.06.049; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vicente FG, 2004, INTENS CARE MED, V30, P655, DOI 10.1007/s00134-003-2139-7; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Zier LS, 2009, CHEST, V136, P110, DOI 10.1378/chest.08-2753; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	60	80	82	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2016	44	9					1769	1774		10.1097/CCM.0000000000001965			6	Critical Care Medicine	General & Internal Medicine	DT8CZ	WOS:000381718000017	27525995				2021-06-18	
J	Wang, Y; Nelson, LD; LaRoche, AA; Pfaller, AY; Nencka, AS; Koch, KM; McCrea, MA				Wang, Yang; Nelson, Lindsay D.; LaRoche, Ashley A.; Pfaller, Adam Y.; Nencka, Andrew S.; Koch, Kevin M.; McCrea, Michael A.			Cerebral Blood Flow Alterations in Acute Sport-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						arterial spin labeling; cerebral blood flow; concussion; MRI; recovery	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; FOOTBALL PLAYERS; HEAD-INJURY; HIGH-SCHOOL; PERFUSION; RECOVERY; MRI; AUTOREGULATION; RATS	Sport-related concussion (SRC) is a major health problem, affecting millions of athletes each year. While the clinical effects of SRC (e.g., symptoms and functional impairments) typically resolve within several days, increasing evidence suggests persistent neurophysiological abnormalities beyond the point of clinical recovery after injury. This study aimed to evaluate cerebral blood flow (CBF) changes in acute SRC, as measured using advanced arterial spin labeling (ASL) magnetic resonance imaging (MRI). We compared CBF maps assessed in 18 concussed football players (age, 17.8 +/- 1.5 years) obtained within 24 h and at 8 days after injury with a control group of 19 matched non-concussed football players. While the control group did not show any changes in CBF between the two time-points, concussed athletes demonstrated a significant decrease in CBF at 8 days relative to within 24 h. Scores on the clinical symptom (Sport Concussion Assessment Tool 3, SCAT3) and cognitive measures (Standardized Assessment of Concussion [SAC]) demonstrated significant impairment (vs. pre-season baseline levels) at 24 h (SCAT, p < 0.0001; SAC, p < 0.01) but returned to baseline levels at 8 days. Two additional computerized neurocognitive tests, the Automated Neuropsychological Assessment Metrics and Immediate Post-Concussion and Cognitive Testing, showed a similar pattern of changes. These data support the hypothesis that physiological changes persist beyond the point of clinical recovery after SRC. Our results also indicate that advanced ASL MRI methods might be useful for detecting and tracking the longitudinal course of underlying neurophysiological recovery from concussion.	[Wang, Yang; Nencka, Andrew S.; Koch, Kevin M.] Med Coll Wisconsin, Dept Radiol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Wang, Yang; Nencka, Andrew S.; Koch, Kevin M.] Med Coll Wisconsin, Dept Biophys, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; LaRoche, Ashley A.; Pfaller, Adam Y.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA	Wang, Y (corresponding author), Med Coll Wisconsin, Dept Radiol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.; Wang, Y (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.	yangwang@mcw.edu	Koch, Kevin/AAD-6403-2021		NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000055] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER		Alsop DC, 2015, MAGN RESON MED, V73, P102, DOI 10.1002/mrm.25197; Amin-Hanjani S, 2015, J CEREBR BLOOD F MET, V35, P312, DOI 10.1038/jcbfm.2014.203; [Anonymous], 2007, MMWR MORBID MORTAL W, V56, P733; Aslan S, 2010, MAGN RESON MED, V63, P765, DOI 10.1002/mrm.22245; Audenaert K., 2003, MED SCI MONITOR, V9, P112; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Chen G, 2012, NEUROIMAGE, V60, P747, DOI 10.1016/j.neuroimage.2011.12.060; Chen YF, 2011, J MAGN RESON IMAGING, V33, P940, DOI 10.1002/jmri.22345; Choe MC, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0573-9; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Chow HM, 2013, P NATL ACAD SCI USA, V110, P10300, DOI 10.1073/pnas.1217691110; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Detre JA, 2009, CURR OPIN NEUROL, V22, P348, DOI 10.1097/WCO.0b013e32832d9505; Dijkhuizen RM, 2011, TRANSL STROKE RES, V2, P524, DOI 10.1007/s12975-011-0130-0; Doshi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118061; Ellis M. J, 2016, FRONTIERS NEUROLOGY, V7; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gardner AJ, 2015, BRIT J SPORT MED, V49, P1050, DOI 10.1136/bjsports-2014-093901; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Hannawi Yousef, 2016, CURRENT NEUROLOGY NE, V16; Helmick K, 2006, DEFENSE VETERANS BRA; Iadecola C, 2007, NAT NEUROSCI, V10, P1369, DOI 10.1038/nn2003; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Kumar NS, 2014, AM J SPORT MED, V42, P2050, DOI 10.1177/0363546514539449; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2014, PROG NEUROL SURG, V28, P112, DOI 10.1159/000358769; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGoron Anthony J, 2008, BMC Med Imaging, V8, P4, DOI 10.1186/1471-2342-8-4; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Metting Z, 2014, BRAIN COGNITION, V86, P24, DOI 10.1016/j.bandc.2014.01.012; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Okonkwo OC, 2014, CEREB CORTEX, V24, P978, DOI 10.1093/cercor/bhs381; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Vidorreta M, 2013, NEUROIMAGE, V66, P662, DOI 10.1016/j.neuroimage.2012.10.087; Wang DJJ, 2012, STROKE, V43, P1018, DOI 10.1161/STROKEAHA.111.631929; Wang JJ, 2003, MAGN RESON MED, V49, P796, DOI 10.1002/mrm.10437; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Wang Y, 2015, DEV NEUROPSYCHOL, V40, P40, DOI 10.1080/87565641.2014.979927; Wang Y, 2011, NEUROIMAGE, V54, P1188, DOI 10.1016/j.neuroimage.2010.08.043; Wu WC, 2007, MAGN RESON MED, V58, P1020, DOI 10.1002/mrm.21403; Wu WC, 2010, MAGN RESON MED, V64, P1140, DOI 10.1002/mrm.22484; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yengo-Kahn AM, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15611; Zhang R, 2002, CIRCULATION, V106, P1814, DOI 10.1161/01.CIR.0000031798.07790.FE; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	79	80	80	2	41	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2016	33	13					1227	+		10.1089/neu.2015.4072			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DP2QY	WOS:000378336200389	26414315	Green Published			2021-06-18	
J	Gagnon, I; Grilli, L; Friedman, D; Iverson, GL				Gagnon, I.; Grilli, L.; Friedman, D.; Iverson, G. L.			A pilot study of active rehabilitation for adolescents who are slow to recover from sport-related concussion	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						Pediatric; mild traumatic brain injury; children; physiotherapy; sports; post-concussion symptoms; aerobics	TRAUMATIC BRAIN-INJURY; VOLUNTARY EXERCISE; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; NEUROTROPHIC FACTOR; PHYSICAL-EXERCISE; CONTUSION INJURY; TEMPORAL WINDOW; DEPRESSION; SYMPTOMS	The purpose of this study was to examine the effectiveness of an active rehabilitation intervention for adolescents who are slow-to-recover after a sport-related concussion. Ten adolescents (three girls and seven boys) seen at the Montreal Children's Hospital Concussion Clinic participated in this case series. Adolescents who were symptomatic more than 4 weeks after the injury were provided with an active rehabilitation intervention (M=7.9 weeks following injury; range=3.7 to 26.2 weeks). The rehabilitation program includes gradual, closely monitored light aerobic exercise, general coordination exercises, mental imagery, as well as reassurance, normalization of recovery, and stress/anxiety reduction strategies. The program continued until complete symptom resolution and readiness to begin stepwise return to activities. The primary outcome of the study was evolution of post-concussion symptoms. Secondary outcomes included mood, energy, balance, and cognition. After the intervention, post-concussion symptoms significantly decreased for the group of participants. They also had decreased fatigue and improved mood after 6 weeks of initiating the rehabilitation intervention. This case series shows that postconcussive symptoms and functioning in adolescents following sports-related concussion can be improved after participation in an active rehabilitation intervention. The introduction of graded light intensity exercise in the post-acute period following concussion is safe, feasible and appears to have a positive impact on adolescents' functioning.	[Gagnon, I.] McGill Univ, Fac Med, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Gagnon, I.; Grilli, L.; Friedman, D.] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Trauma Ctr, Montreal, PQ, Canada; [Gagnon, I.; Friedman, D.] McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada; [Friedman, D.] Canadian Hosp Injury Reporting & Prevent Program, Montreal, PQ, Canada; [Iverson, G. L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, G. L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, G. L.] Mass Gen Hosp, Children Sports Concuss Program, Boston, MA USA; [Iverson, G. L.] Red Sox Fdn, Boston, MA USA; [Iverson, G. L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Gagnon, I (corresponding author), Montreal Childrens Hosp, Trauma Programs C 833, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.	Isabelle.gagnon8@mcgill.ca	Meijer, Anna/K-5118-2016	Iverson, Grant/0000-0001-7348-9570	Research Institute of the McGill University Health Center; The Montreal Children's Hospital Trauma Programs	We would like to thank the children and their families for participating in this study and The Montreal Children's Hospital Trauma Programs professionals for their support. As well, we wish to thank the Research Institute of the McGill University Health Center for its support of this research.	Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Barbour KA, 2007, J CARDIOPULM REHABIL, V27, P359, DOI 10.1097/01.HCR.0000300262.69645.95; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Bruininks BD, 2006, BRUININKS OSERETSKY; Canadian Pediatric Society, 2006, PAEDIAT CHILD HLTH, V11, P420; CHAOULOFF F, 1989, ACTA PHYSIOL SCAND, V137, P1, DOI 10.1111/j.1748-1716.1989.tb08715.x; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Daley A, 2008, J CLIN PSYCHOL MED S, V15, P140, DOI 10.1007/s10880-008-9105-z; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greenwood BN, 2008, NEUROMOL MED, V10, P81, DOI 10.1007/s12017-008-8029-y; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Herring MP, 2010, ARCH INTERN MED, V170, P321, DOI 10.1001/archinternmed.2009.530; Iverson GL, 2012, MILD TRAUMATIC BRAIN, P281; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lawlor DA, 2001, BMJ-BRIT MED J, V322, P763, DOI 10.1136/bmj.322.7289.763; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lojovich JM, 2010, J HEAD TRAUMA REHAB, V25, P184, DOI 10.1097/HTR.0b013e3181dc78cd; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Merom D, 2008, J ANXIETY DISORD, V22, P959, DOI 10.1016/j.janxdis.2007.09.010; Michelini LC, 2009, EXP PHYSIOL, V94, P947, DOI 10.1113/expphysiol.2009.047449; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Penninx BWJH, 2002, J GERONTOL B-PSYCHOL, V57, pP124, DOI 10.1093/geronb/57.2.P124; Rethorst CD, 2009, SPORTS MED, V39, P491, DOI 10.2165/00007256-200939060-00004; Rimer J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub5; Roemmich JN, 2006, MED SCI SPORT EXER, V38, P1014, DOI 10.1249/01.mss.0000218123.81079.49; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Smits JAJ, 2008, DEPRESS ANXIETY, V25, P689, DOI 10.1002/da.20411; Spielberger CD., 1980, TEST ANXIETY INVENTO; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; van Praag H, 2008, NEUROMOL MED, V10, P128, DOI 10.1007/s12017-008-8028-z; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Vidal PG, 2012, PEDIATR ANN, V41, pE186, DOI 10.3928/00904481-20120827-10; Wang CC, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-23; Youngstedt SD, 2005, CLIN SPORT MED, V24, P355, DOI 10.1016/j.csm.2004.12.003	60	80	81	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	MAR	2016	26	3					299	306		10.1111/sms.12441			8	Sport Sciences	Sport Sciences	DF3MB	WOS:000371247200007	25735821				2021-06-18	
J	Russo, RM; Williams, TK; Grayson, JK; Lamb, CM; Cannon, JW; Clement, NF; Galante, JM; Neff, LP				Russo, Rachel M.; Williams, Timothy K.; Grayson, John Kevin; Lamb, Christopher M.; Cannon, Jeremy W.; Clement, Nathan F.; Galante, Joseph M.; Neff, Lucas P.			Extending the golden hour: Partial resuscitative endovascular balloon occlusion of the aorta in a highly lethal swine liver injury model	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	74th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 09-12, 2015	Las Vegas, NV	Amer Assoc Surg Trauma		Trauma; endovascular; resuscitation; intra-aortic balloon; swine	NONCOMPRESSIBLE TORSO HEMORRHAGE; TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION; ISCHEMIC-STROKE; PORCINE MODEL; BLOOD-FLOW; SHOCK; MORTALITY; HYPERTENSION; SURVIVAL	BACKGROUND Combat-injured patients may require rapid and sustained support during transport; however, the prolonged aortic occlusion produced by conventional resuscitative endovascular balloon occlusion of the aorta (REBOA) may lead to substantial morbidity. Partial REBOA (P-REBOA) may permit longer periods of occlusion by allowing some degree of distal perfusion. However, the ability of this procedure to limit exsanguination is unclear. We evaluated the impact of P-REBOA on immediate survival and ongoing hemorrhage in a highly lethal swine liver injury model. METHODS Fifteen Yorkshire-cross swine were anesthetized, instrumented, splenectomized, and subjected to rapid 10% total blood loss followed by 30% liver amputation. Coagulopathy was created through colloid hemodilution. Randomized swine received no intervention (control), P-REBOA, or complete REBOA (C-REBOA). Central mean arterial pressure (cMAP), carotid blood flow, and blood loss were recorded. Balloons remained inflated in the P-REBOA and C-REBOA groups for 90 minutes followed by graded deflation. The study ended at 180 minutes from onset of hemorrhage or death of the animal. Survival analysis was performed, and data were analyzed using repeated-measures analysis of variance with post hoc pairwise comparisons. RESULTS Mean survival times in the control, P-REBOA, and C-REBOA groups were, 25 21, 86 +/- 40, and 163 +/- 20 minutes, respectively (p < 0.001). Blood loss was greater in the P-REBOA group than the C-REBOA or control groups, but this difference was not significant (4,722 +/- 224, 3,834 +/- 319, 3,818 +/- 37 mL, respectively, p = 0.10). P-REBOA resulted in maintenance of near-baseline carotid blood flow and cMAP, while C-REBOA generated extreme cMAP and prolonged supraphysiologic carotid blood flow. Both experimental groups experienced profound decreases in cMAP following balloon deflation. CONCLUSION In the setting of severe ongoing hemorrhage, P-REBOA increased survival time beyond the golden hour while maintaining cMAP and carotid flow at physiologic levels.	[Russo, Rachel M.; Williams, Timothy K.; Galante, Joseph M.; Neff, Lucas P.] Univ Calif Davis, Med Ctr, Dept Surg, Sacramento, CA 95817 USA; [Russo, Rachel M.; Williams, Timothy K.; Grayson, John Kevin; Lamb, Christopher M.; Neff, Lucas P.] David Grant USAF Med Ctr, Clin Invest Facil, Fairfield, CA USA; [Williams, Timothy K.; Lamb, Christopher M.] David Grant USAF Med Ctr, Dept Vasc & Endovasc Surg, Fairfield, CA USA; [Clement, Nathan F.] David Grant USAF Med Ctr, Dept Pathol, Fairfield, CA USA; [Neff, Lucas P.] David Grant USAF Med Ctr, Dept Gen Surg, Fairfield, CA 94535 USA; [Cannon, Jeremy W.] Univ Penn, Perelman Sch Med, Dept Surg, Philadelphia, PA 19104 USA; [Lamb, Christopher M.] Royal Ctr Def Med, Acad Dept Mil Surg & Trauma, Birmingham, W Midlands, England	Neff, LP (corresponding author), David Grant USAF Med Ctr, Dept Gen Surg, Fairfield, CA 94535 USA.	lucas.neff.2@us.af.mil	Cannon, Jeremy/T-3875-2019	Cannon, Jeremy/0000-0002-2969-9316			Annecke T, 2008, ACTA ANAESTH SCAND, V52, P977, DOI 10.1111/j.1399-6576.2008.01665.x; Avaro JP, 2011, J TRAUMA, V71, P720, DOI 10.1097/TA.0b013e318221a94a; Barmparas G, 2014, J TRAUMA ACUTE CARE, V77, P592, DOI 10.1097/TA.0000000000000382; Biffl WL, 2015, J TRAUMA ACUTE CARE, V78, P1054, DOI 10.1097/TA.0000000000000609; Blackbourne LH, 2010, J TRAUMA, V69, pS1, DOI 10.1097/TA.0b013e3181e4206f; Brenner ML, 2013, J TRAUMA ACUTE CARE, V75, P506, DOI 10.1097/TA.0b013e31829e5416; CoAxia, 2005, NEUROFLO PERF AUGM I; DUNN E, 1977, J SURG RES, V22, P463, DOI 10.1016/0022-4804(77)90028-2; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Eastridge BJ, 2011, J TRAUMA, V71, pS4, DOI 10.1097/TA.0b013e318221147b; Emery DJ, 2011, STROKE, V42, P1135, DOI 10.1161/STROKEAHA.110.607846; Fuller G, 2014, INJURY, V45, P612, DOI 10.1016/j.injury.2013.09.008; GOLDEN MA, 1991, J VASC SURG, V13, P792, DOI 10.1016/0741-5214(91)90043-T; Hammer M, 2009, CEREBROVASC DIS, V28, P406, DOI 10.1159/000235628; Kotwal RS, 2015, JAMA SURG, V30, P1; Lylyk P, 2005, NEUROL RES, V27, pS129, DOI 10.1179/016164105X35512; Markov NP, 2013, SURGERY, V153, P848, DOI 10.1016/j.surg.2012.12.001; Morrison JJ, 2014, J SURG RES, V191, P423, DOI 10.1016/j.jss.2014.04.012; Morrison JJ, 2014, SHOCK, V41, P130, DOI 10.1097/SHK.0000000000000085; Morrison JJ, 2013, J TRAUMA ACUTE CARE, V75, pS263, DOI 10.1097/TA.0b013e318299da0a; Mundasad S., 2015, BBC NEWS; Norii T, 2015, J TRAUMA ACUTE CARE, V78, P721, DOI 10.1097/TA.0000000000000578; Rasmussen TE, 2015, ARMY AL T MAGAZINE, P80; Saito N, 2015, J TRAUMA ACUTE CARE, V78, P897, DOI 10.1097/TA.0000000000000614; Sellmann T, 2012, DTSCH ARZTEBL INT, V109, P849, DOI 10.3238/arztebl.2012.0849; Shuaib A, 2011, STROKE, V42, P1680, DOI 10.1161/STROKEAHA.110.609933; Stannard A, 2013, J TRAUMA ACUTE CARE, V74, P830, DOI 10.1097/TA.0b013e31827a3704; Stannard A, 2011, J TRAUMA, V71, P1869, DOI 10.1097/TA.0b013e31823fe90c; STOKLAND O, 1980, AM J PHYSIOL, V238, pH423; Trauma and Injury Subcommittee, 2015, COMB TRAUM LESS LEAR; White JM, 2011, SURGERY, V150, P400, DOI 10.1016/j.surg.2011.06.010; Winship IR, 2014, J CEREBR BLOOD F MET, V34, P61, DOI 10.1038/jcbfm.2013.162	32	80	82	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2016	80	3					372	378		10.1097/TA.0000000000000940			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DF7XT	WOS:000371571900005	26670114				2021-06-18	
J	Webster, KM; Wright, DK; Sun, MJ; Semple, BD; Ozturk, E; Stein, DG; O'Brien, TJ; Shultz, SR				Webster, Kyria M.; Wright, David K.; Sun, Mujun; Semple, Bridgette D.; Ozturk, Ezgi; Stein, Donald G.; O'Brien, Terence J.; Shultz, Sandy R.			Progesterone treatment reduces neuroinflammation, oxidative stress and brain damage and improves long-term outcomes in a rat model of repeated mild traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Concussion; Chronic traumatic encephalopathy; Animal model; DTI; MRI; Treatment; Microglia; Macrophages; Astrogliosis; Lipid peroxidation	HIGH-DOSE PROGESTERONE; RECURRENT CONCUSSION; ANIMAL-MODEL; IN-VIVO; INFLAMMATORY RESPONSE; COGNITIVE IMPAIRMENT; SYNAPTIC PLASTICITY; LIPID-PEROXIDATION; CLINICAL-TRIAL; MOUSE MODEL	Background: Repeated mild traumatic brain injuries, such as concussions, may result in cumulative brain damage, neurodegeneration and other chronic neurological impairments. There are currently no clinically available treatment options known to prevent these consequences. However, growing evidence implicates neuroinflammation and oxidative stress in the pathogenesis of repetitive mild brain injuries; thus, these may represent potential therapeutic targets. Progesterone has been demonstrated to have potent anti-inflammatory and anti-oxidant properties after brain insult; therefore, here, we examined progesterone treatment in rats given repetitive mild brain injuries via the repeated mild fluid percussion injury model. Methods: Male Long-Evans rats were assigned into four groups: sham injury + vehicle treatment, sham injury + progesterone treatment (8 mg/kg/day), repeated mild fluid percussion injuries + vehicle treatment, and repeated mild fluid percussion injuries + progesterone treatment. Rats were administered a total of three injuries, with each injury separated by 5 days. Treatment was initiated 1 h after the first injury, then administered daily for a total of 15 days. Rats underwent behavioural testing at 12-weeks post-treatment to assess cognition, motor function, anxiety and depression. Brains were then dissected for analysis of markers for neuroinflammation and oxidative stress. Ex vivo MRI was conducted in order to examine structural brain damage and white matter integrity. Results: Repeated mild fluid percussion injuries + progesterone treatment rats showed significantly reduced cognitive and sensorimotor deficits compared to their vehicle-treated counterparts at 12-weeks post-treatment. Progesterone treatment significantly attenuated markers of neuroinflammation and oxidative stress in rats given repeated mild fluid percussion injuries, with concomitant reductions in grey and white matter damage as indicated by MRI. Conclusions: These findings implicate neuroinflammation and oxidative stress in the pathophysiological aftermath of mild brain injuries and suggest that progesterone may be a viable treatment option to mitigate these effects and their detrimental consequences.	[Webster, Kyria M.; Sun, Mujun; Semple, Bridgette D.; Ozturk, Ezgi; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; [Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3010, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Shultz, SR (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au	Stein, Donald/AAJ-5139-2020	Wright, David/0000-0002-7535-8651; Sun, Mujun/0000-0002-9923-9913; O'Brien, Terence/0000-0002-7198-8621	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1062653]; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); NHMRCNational Health and Medical Research Council of Australia	We would like to thank Dr. Iqbal Sayeed (Emory University) for his contributions towards this project. This study was funded by a grant to SRS from the National Health and Medical Research Council (NHMRC # 1062653) and fellowships to SRS from the Canadian Institute of Health Research and NHMRC.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Aebi S, 1999, CANCER CHEMOTH PHARM, V44, P259, DOI 10.1007/s002800050976; Allolio B, 1995, EUR J ENDOCRINOL, V133, P696, DOI 10.1530/eje.0.1330696; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cai J, 2015, NEUROSCI LETT, V600, P238, DOI 10.1016/j.neulet.2015.06.023; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Coughlan T, 2005, J NEUROCHEM, V93, P932, DOI 10.1111/j.1471-4159.2005.03068.x; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Ferrer-Martin RM, 2014, EXP EYE RES, V121, P42, DOI 10.1016/j.exer.2014.02.015; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Howard R.B., 2015, J NEUROTRAUMA; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Ishihara Y, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/343706; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Kadhim HJ, 2009, J INTENSIVE CARE MED, V23, P236; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Robertson CL, 2015, PEDIATR CRIT CARE ME, V16, P236, DOI 10.1097/PCC.0000000000000323; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sheng WS, 2013, NEUROCHEM RES, V38, P2148, DOI 10.1007/s11064-013-1123-z; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2015, BEHAV BRAIN RES, V278, P542, DOI 10.1016/j.bbr.2014.10.050; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Stein DG, 2015, FUTURE NEUROL; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang JP, 2011, MOL MED REP, V4, P319, DOI 10.3892/mmr.2011.418; Whishaw IQ, 1995, HIPPOCAMPUS, V5, P595, DOI 10.1002/hipo.450050610; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zotova E, 2013, BRAIN, V136, P2677, DOI 10.1093/brain/awt210	74	80	81	0	24	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	DEC 18	2015	12								238	10.1186/s12974-015-0457-7			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CZ6SM	WOS:000367231000001	26683475	DOAJ Gold, Green Published			2021-06-18	
J	Fagerholm, ED; Hellyer, PJ; Scott, G; Leech, R; Sharp, DJ				Fagerholm, Erik D.; Hellyer, Peter J.; Scott, Gregory; Leech, Robert; Sharp, David J.			Disconnection of network hubs and cognitive impairment after traumatic brain injury	BRAIN			English	Article						traumatic brain injury; diffusion tensor imaging; betweenness centrality; network hubs; graph theory	FUNCTIONAL CONNECTIVITY; STRUCTURAL CONNECTIVITY; TRACTOGRAPHY; ARCHITECTURE; DYSFUNCTION; SELECTION; ANATOMY; CORTEX	Traumatic brain injury affects brain connectivity by producing traumatic axonal injury. This disrupts the function of large-scale networks that support cognition. The best way to describe this relationship is unclear, but one elegant approach is to view networks as graphs. Brain regions become nodes in the graph, and white matter tracts the connections. The overall effect of an injury can then be estimated by calculating graph metrics of network structure and function. Here we test which graph metrics best predict the presence of traumatic axonal injury, as well as which are most highly associated with cognitive impairment. A comprehensive range of graph metrics was calculated from structural connectivity measures for 52 patients with traumatic brain injury, 21 of whom had microbleed evidence of traumatic axonal injury, and 25 age-matched controls. White matter connections between 165 grey matter brain regions were defined using tractography, and structural connectivity matrices calculated from skeletonized diffusion tensor imaging data. This technique estimates injury at the centre of tract, but is insensitive to damage at tract edges. Graph metrics were calculated from the resulting connectivity matrices and machine-learning techniques used to select the metrics that best predicted the presence of traumatic brain injury. In addition, we used regularization and variable selection via the elastic net to predict patient behaviour on tests of information processing speed, executive function and associative memory. Support vector machines trained with graph metrics of white matter connectivity matrices from the microbleed group were able to identify patients with a history of traumatic brain injury with 93.4% accuracy, a result robust to different ways of sampling the data. Graph metrics were significantly associated with cognitive performance: information processing speed (R-2 = 0.64), executive function (R-2 = 0.56) and associative memory (R-2 = 0.25). These results were then replicated in a separate group of patients without microbleeds. The most influential graph metrics were betweenness centrality and eigenvector centrality, which provide measures of the extent to which a given brain region connects other regions in the network. Reductions in betweenness centrality and eigenvector centrality were particularly evident within hub regions including the cingulate cortex and caudate. Our results demonstrate that betweenness centrality and eigenvector centrality are reduced within network hubs, due to the impact of traumatic axonal injury on network connections. The dominance of betweenness centrality and eigenvector centrality suggests that cognitive impairment after traumatic brain injury results from the disconnection of network hubs by traumatic axonal injury.	[Fagerholm, Erik D.; Hellyer, Peter J.; Scott, Gregory; Leech, Robert; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp Campus, Fac Med, Div Brain Sci,Computat Cognit & Clin Neuroimaging, London, England	Fagerholm, ED (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013; Hellyer, Peter J/F-7112-2013; Leech, Robert/AAE-8254-2019	Hellyer, Peter J/0000-0002-5139-3401; Leech, Robert/0000-0002-5801-6318; Scott, Gregory/0000-0001-8063-5871	MRC (UK) Clinician Scientist FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute of Health Research Professorship [RP-011-048]; National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; MRC DTA studentshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1110783] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	The work has been supported by an MRC (UK) Clinician Scientist Fellowship (D.J.S.) and a National Institute of Health Research Professorship - RP-011-048 (D.J.S.). The research was also supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. This work is also supported by an MRC DTA studentship (E.D.F.).	Andersson J.L., 2007, TR07JA2 FMRIB AN GRO; Baddeley AD, 1994, DOORS PEOPLE TEST VI; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Cawley GC, 2006, IEEE IJCNN, P1661; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Crossley NA, 2014, BRAIN, V137, P2382, DOI 10.1093/brain/awu132; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Gottlich M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077336; Goni J, 2014, P NATL ACAD SCI USA, V111, P833, DOI 10.1073/pnas.1315529111; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hwang K, 2013, CEREB CORTEX, V23, P2380, DOI 10.1093/cercor/bhs227; Jan HT, 2013, IEEE ENG MED BIO, P523, DOI 10.1109/EMBC.2013.6609552; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Li YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070390; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Platt JC, 1999, ADV LARGE MARGIN CLA; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; van den Heuvel MP, 2013, J NEUROSCI, V33, P14489, DOI 10.1523/JNEUROSCI.2128-13.2013; van den Heuvel MP, 2012, P NATL ACAD SCI USA, V109, P11372, DOI 10.1073/pnas.1203593109; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Vives-Gilabert Y, 2013, PSYCHIAT RES-NEUROIM, V214, P322, DOI 10.1016/j.pscychresns.2013.09.009; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Xue KQ, 2014, EPILEPSY RES, V108, P125, DOI 10.1016/j.eplepsyres.2013.10.002; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	43	80	82	1	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUN 1	2015	138		6				1696	1709		10.1093/brain/awv075			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CM9BD	WOS:000357999300031	25808370	Green Published, Other Gold			2021-06-18	
J	Zhu, DC; Covassin, T; Nogle, S; Doyle, S; Russell, D; Pearson, RL; Monroe, J; Liszewski, CM; DeMarco, JK; Kaufman, DI				Zhu, David C.; Covassin, Tracey; Nogle, Sally; Doyle, Scarlett; Russell, Doozie; Pearson, Randolph L.; Monroe, Jeffrey; Liszewski, Christine M.; DeMarco, J. Kevin; Kaufman, David I.			A Potential Biomarker in Sports-Related Concussion: Brain Functional Connectivity Alteration of the Default-Mode Network Measured with Longitudinal Resting-State fMRI over Thirty Days	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; sports-related concussion; resting-state fMRI; diffusion-tensor imaging; default-mode network	SCHOOL FOOTBALL PLAYERS; PHYSICAL STRESS TEST; ALZHEIMERS-DISEASE; INJURY; IMPACT; COLLEGIATE; RECOVERY; EPIDEMIOLOGY; ORGANIZATION; TRACTOGRAPHY	Current diagnosis and monitoring of sports-related concussion rely on clinical signs and symptoms, and balance, vestibular, and neuropsychological examinations. Conventional brain imaging often does not reveal abnormalities. We sought to assess if the longitudinal change of functional and structural connectivity of the default-mode network (DMN) can serve as a potential biomarker. Eight concussed Division I collegiate football student-athletes in season (one participated twice) and 11 control subjects participated in this study. ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) was administered over the course of recovery. High-resolution three dimensional T-1-weighted, T-2*-weighted diffusion-tensor images and resting-state functional magnetic resonance imaging (rs-fMRI) scans were collected from each subject within 24 h, 7 +/- 1 d and 30 +/- 1 d after concussion. Both network based and whole-brain based functional correlation analyses on DMN were performed. ImPACT findings demonstrated significant cognitive impairment across multiple categories and a significant increase of symptom severity on Day 1 following a concussion but full recovery by 6.0 +/- 2.4 d. While the structural connectivity within DMN and gross anatomy appeared unchanged, a significantly reduced functional connectivity within DMN from Day 1 to Day 7 was found in the concussed group in this small pilot study. This reduction was seen in eight of our nine concussion cases. Compared with the control group, there appears a general trend of increased DMN functional connectivity on Day 1, a significant drop on Day 7, and partial recovery on Day 30. The results of this pilot study suggest that the functional connectivity of DMN measured with longitudinal rs-fMRI can serve as a potential biomarker to monitor the dynamically changing brain function after sports-related concussion, even in patients who have shown clinical improvement.	[Zhu, David C.; Doyle, Scarlett; DeMarco, J. Kevin] Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA; [Covassin, Tracey; Nogle, Sally; Monroe, Jeffrey] Michigan State Univ, Dept Intercollegiate Athlet, E Lansing, MI 48824 USA; [Russell, Doozie; Kaufman, David I.] Michigan State Univ, Dept Neurol & Ophthalmol, E Lansing, MI 48824 USA; [Pearson, Randolph L.] Michigan State Univ, Dept Family Med, E Lansing, MI 48824 USA; [Liszewski, Christine M.] Michigan State Univ, Dept Psychiat, E Lansing, MI 48824 USA; [Zhu, David C.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA; [Covassin, Tracey; Nogle, Sally] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Zhu, David C.; Doyle, Scarlett] Michigan State Univ, Cognit Imaging Res Ctr, E Lansing, MI 48824 USA	Zhu, DC (corresponding author), Michigan State Univ, Radiol Bldg,846 Serv Rd, E Lansing, MI 48824 USA.	zhuda@msu.edu			Michigan State University Radiology Pilot Scan Program	The authors thank suggestions from Drs. Erik Shapiro and Eric Eggenberger, concussed subject assessment assistance from Drs. Albert Aniskiewicz, Michael Shingles, Douglas Dietzel and Michael Andary, and support from Head Football Coach Mr. Mark Dantonio at Michigan State University. This work was supported by the Michigan State University Radiology Pilot Scan Program.	Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bey T, 2009, WEST J EMERG MED, V10, P6; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Supekar K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000100; Ward B., 2000, SIMULTANEOUS INFEREN; WARD BD, 2000, DECONVOLUTION ANAL F; WOOLSEY TA, 2003, BRAIN ATLAS VISUAL G; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Zhang HY, 2010, RADIOLOGY, V256, P598, DOI 10.1148/radiol.10091701; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2014, J NEUROIMAGING, V24, P176, DOI 10.1111/j.1552-6569.2012.00768.x; Zhu DC, 2013, J ALZHEIMERS DIS, V34, P969, DOI 10.3233/JAD-121879	53	80	80	0	31	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2015	32	5					327	341		10.1089/neu.2014.3413			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CC0SD	WOS:000350045700005	25116397				2021-06-18	
J	Simpson, SG; Reid, CL				Simpson, Susan G.; Reid, Corinne L.			Therapeutic alliance in videoconferencing psychotherapy: A review	AUSTRALIAN JOURNAL OF RURAL HEALTH			English	Article						rural mental health; telepsychology; videoconferencing; video therapy	FACE-TO-FACE; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; OBSESSIVE-COMPULSIVE DISORDER; TRAUMATIC BRAIN-INJURY; NONINFERIORITY TRIAL; WORKING ALLIANCE; PANIC DISORDER; HEALTH; TELEHEALTH	Psychotherapy services are limited in remote and rural areas in Australia and across the globe. Videoconferencing has become well established as a feasible and acceptable mode of psychological treatment delivery. Therapeutic alliance (TA) is an essential factor underlying successful therapy across therapeutic models. In order to determine the state of knowledge regarding TA in psychotherapy via videoconferencing, a literature review was conducted on research studies that formally measured TA as primary, secondary or tertiary outcome measures over the past 23 years. The databases searched were Medline, PsycArticles, PsycINFO, PsycEXTRA and EMBASE. Searching identified 9915 articles that measured satisfaction, acceptability or therapeutic rapport, of which 23 met criteria for the review. Three studies were carried out in Australia, 11 in USA, 4 in Canada, 3 in Scotland and 2 in England. Studies overwhelmingly supported the notion that TA can be developed in psychotherapy by videoconference, with clients rating bond and presence at least equally as strongly as in-person settings across a range of diagnostic groups. Therapists also rated high levels of TA, but often not quite as high as that of their clients early in treatment. The evidence was examined in the context of important aspects of TA, including bond, presence, therapist attitudes and abilities, and client attitudes and beliefs. Barriers and facilitators of alliance were identified. Future studies should include observational measures of bond and presence to supplement self-report.	[Simpson, Susan G.] Univ S Australia, Psychol Clin, Adelaide, SA 5001, Australia; [Reid, Corinne L.] Murdoch Univ, Sch Psychol & Exercise Sci, Perth, WA, Australia	Simpson, SG (corresponding author), Univ S Australia, Psychol Clin, Magill Campus,GPO Box 2471, Adelaide, SA 5001, Australia.	susan.simpson@unisa.edu.au	Simpson, Susan G/F-3261-2013	Simpson, Susan G/0000-0002-9625-0797			Ackerman SJ, 2001, PSYCHOTHERAPY, V38, P171, DOI 10.1037/0033-3204.38.2.171; Ackerman SJ, 2003, CLIN PSYCHOL REV, V23, P1, DOI 10.1016/s0272-7358(02)00146-0; Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; Alexander L.B., 1986, PSYCHOTHERAPEUTIC PR, P325; Austen S, 2006, J TELEMED TELECARE, V12, P146, DOI 10.1258/135763306776738594; Bachelor A, 1999, HEART AND SOUL OF CHANGE, P133, DOI 10.1037/11132-004; Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924; BARRETTLENNARD GT, 1981, J COUNS PSYCHOL, V28, P91, DOI 10.1037/0022-0167.28.2.91; Bischoff RJ, 2004, CONTEMP FAM THER, V26, P179, DOI 10.1023/B:COFT.0000031242.83259.fa; Bordin E. S., 1979, PSYCHOTHER-THEOR RES, V16, P252, DOI DOI 10.1037/H0085885; Bose U, 2001, J TELEMED TELECARE, V7, pS8, DOI 10.1258/1357633011936804; Bouchard S, 2004, TELEMED J E-HEALTH, V10, P13, DOI 10.1089/153056204773644535; Bouchard S, 2000, CYBERPSYCHOL BEHAV, V3, P999, DOI 10.1089/109493100452264; Bouchard S, 2007, P 10 INT WORKSH PRES; Bouchard S, 2004, 7 ANN M CAN SOC TEL; Bouchard S, 2000, TELEPRESENCE VIDEOCO; Cluver JS, 2005, J TELEMED TELECARE, V11, P157, DOI 10.1258/1357633053688741; Constantino M.J., 2002, COUNSELING BASED PRO, P81; Cowain T, 2001, AUST NZ J PSYCHIAT, V35, P62, DOI 10.1046/j.1440-1614.2001.00853.x; Day SX, 2002, J COUNS PSYCHOL, V49, P499, DOI 10.1037/0022-0167.49.4.499; Dunstan DA, 2012, RURAL REMOTE HEALTH, V12; Dunstan DA, 2012, AUST J RURAL HEALTH, V20, P88, DOI 10.1111/j.1440-1584.2012.01260.x; Elliot R, 1999, QUALITATIVE INTERVIE; Elliott R, 2011, PSYCHOTHERAPY, V48, P43, DOI 10.1037/a0022187; Ertelt TW, 2011, INT J EAT DISORDER, V44, P687, DOI 10.1002/eat.20874; Farber B. A., 2002, PSYCHOTHERAPY RELATI, P175; Frueh BC, 2007, J TELEMED TELECARE, V13, P142, DOI 10.1258/135763307780677604; Frueh BC, 2005, J TELEMED TELECARE, V11, P372, DOI 10.1258/135763305774472060; Garcia-Lizana Francisca, 2010, Prim Care Companion J Clin Psychiatry, V12, DOI 10.4088/PCC.09m00831whi; GASTON L, 1990, PSYCHOTHER, V27, P143, DOI 10.1037/0033-3204.27.2.143; Germain V, 2010, CYBERPSYCH BEH SOC N, V13, P29, DOI 10.1089/cyber.2009.0139; Ghosh G J, 1997, J Telemed Telecare, V3 Suppl 1, P33, DOI 10.1258/1357633971930283; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; Goetter EM, 2013, J OBSESS-COMPULS REL, V2, P137, DOI 10.1016/j.jocrd.2013.01.003; Greenberg LS, 2001, PSYCHOTHERAPY, V38, P380, DOI 10.1037/0033-3204.38.4.380; Greene CJ, 2010, J CONSULT CLIN PSYCH, V78, P746, DOI 10.1037/a0020158; Griffiths L, 2006, J TELEMED TELECARE, V12, P136, DOI 10.1258/135763306776738567; GUBA EG, 1981, ECTJ-EDUC COMMUN TEC, V29, P75; Harvey-Berino J, 1998, BEHAV THER, V29, P505, DOI 10.1016/S0005-7894(98)80046-4; HATCHER RL, 1995, J CONSULT CLIN PSYCH, V63, P636, DOI 10.1037/0022-006X.63.4.636; Himle JA, 2006, BEHAV RES THER, V44, P1821, DOI 10.1016/j.brat.2005.12.010; Hollon SD, 2002, BIOL PSYCHIAT, V52, P610, DOI 10.1016/S0006-3223(02)01384-7; HORVATH A, 2010, EVIDENCE BASED THERA, V121, P5; Horvath A, 1982, INSTRUCTIONAL PSYCHO, P82; Horvath A.O., 1994, WORKING ALLIANCE THE; Horvath A.O., 1981, THESIS U BRIT COLUMB; Horvath AO, 2011, PSYCHOTHERAPY, V48, P9, DOI 10.1037/a0022186; HORVATH AO, 1993, J CONSULT CLIN PSYCH, V61, P561, DOI 10.1037/0022-006X.61.4.561; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; Jerome LW, 2000, PROF PSYCHOL-RES PR, V31, P478, DOI 10.1037//0735-7028.31.5.478; Kolden GG, 2011, PSYCHOTHERAPY, V48, P65, DOI 10.1037/a0022064; Krumm-Heller Roe I, 2006, THESIS FIELDING GRAD; Larsen R. J., 1992, EMOTION, V13, P25; Lincoln Y, 1985, NATURALISTIC ENQUIRY; Maheu MM, 2003, PSYCHOTHERAPY, V40, P20, DOI 10.1037/0033-3204.40.1-2.20; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; Manchanda M, 1998, J TELEMED TELECARE, V4, P53, DOI 10.1258/1357633981931452; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; Millar H, 2009, TELEMENTAL HLTH SCOT; Mohr DC, 2010, ANN BEHAV MED, V40, P89, DOI 10.1007/s12160-010-9203-7; Morgan RD, 2008, J CONSULT CLIN PSYCH, V76, P158, DOI 10.1037/0022-006X.76.1.158; Morland LA, 2010, J CLIN PSYCHIAT, V71, P855, DOI 10.4088/JCP.09m05604blu; Myers KM, 2007, PSYCHIAT SERV, V58, P1493, DOI 10.1176/appi.ps.58.11.1493; Norcross J.C., 2002, PSYCHOTHERAPY RELATI; Norcross JC, 2011, PSYCHOTHERAPY, V48, P4, DOI 10.1037/a0022180; Nutting PA, 2002, J GEN INTERN MED, V17, P103, DOI 10.1046/j.1525-1497.2002.10128.x; OMALLEY SS, 1983, J CONSULT CLIN PSYCH, V51, P581, DOI 10.1037/0022-006X.51.4.581; PINSOF WM, 1986, J MARITAL FAM THER, V12, P137, DOI 10.1111/j.1752-0606.1986.tb01631.x; Porcari CE, 2009, J TELEMED TELECARE, V15, P89, DOI 10.1258/jtt.2008.080612; Rees CS, 2005, PROF PSYCHOL-RES PR, V36, P649, DOI 10.1037/0735-7028.36.6.649; Rees CS, 2004, AUST PSYCHOL, V39, P212, DOI 10.1080/00050060412331295108; Reid C, 2013, EUROPEAN J PERSON CT, V1, P336; REISENZEIN R, 1994, J PERS SOC PSYCHOL, V67, P525, DOI 10.1037/0022-3514.67.3.525; Richardson L, 2011, CAN YOU SEE WHAT I A; Richardson LK, 2009, CLIN PSYCHOL-SCI PR, V16, P323, DOI 10.1111/j.1468-2850.2009.01170.x; Rogers C., 1951, CLIENT CTR THERAPY I; Ruskin PE, 2004, AM J PSYCHIAT, V161, P1471, DOI 10.1176/appi.ajp.161.8.1471; Sadowski W, 2002, HUM FAC ER, P791; Safran J. D., 1991, PSYCHOL ASSESSMENT J, V3, P188, DOI DOI 10.1037/1040-3590.3.2.188; Samstag LW, CORE PROCESSES BRIEF, P187; Schneider PL, 1999, 107 ANN CONV AM PSYC; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Shore JH, 2007, AM J PSYCHIAT, V164, P115, DOI 10.1176/appi.ajp.164.1.115; Simpson S, 2005, CLIN PSYCHOL PSYCHOT, V12, P156, DOI 10.1002/cpp.436; Simpson S, 2001, CLIN PSYCHOL PSYCHOT, V8, P130, DOI 10.1002/cpp.279; Simpson S, 2003, J TELEMED TELECARE, V9, pS37, DOI 10.1258/135763303322196286; Simpson S., 2005, EATING DISORDERS NEW, P99; Simpson S., 2010, USE TECHNOLOGY MENTA, P94; Simpson S, 2006, EUR EAT DISORD REV, V14, P226, DOI 10.1002/erv.686; Simpson S, 2009, BRIT J GUID COUNS, V37, P271, DOI 10.1080/03069880902957007; Simpson Susan G, 2011, Clin Pract Epidemiol Ment Health, V7, P38, DOI 10.2174/1745017901107010038; Simpson SG, 2014, AUST PSYCHOL, V49, P193, DOI 10.1111/ap.12049; Sirey JA, 2001, PSYCHIAT SERV, V52, P1615, DOI 10.1176/appi.ps.52.12.1615; STILES WB, 1984, BRIT J CLIN PSYCHOL, V23, P59, DOI 10.1111/j.2044-8260.1984.tb00627.x; STILES WB, 1994, J COUNS PSYCHOL, V41, P175, DOI 10.1037/0022-0167.41.2.175; Stubbings DR, 2012, THESIS CURTIN U AUST; Tashakkori Abbas, 1998, MIXED METHODOLOGY CO; TICHENOR V, 1989, PSYCHOTHER, V26, P195, DOI 10.1037/h0085419; Tracey T. J., 1989, PSYCHOL ASSESS, V1, P207, DOI [10.1037/1040-3590.1.3.207, DOI 10.1037/1040-3590.1.3.207]; Tuerk PW, 2010, J TRAUMA STRESS, V23, P116, DOI 10.1002/jts.20494; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wampold B. E., 2001, GREAT PSYCHOTHERAPY; Wray B, 2003, 11 AUSTR ASS COGN BE; Wray BT, 2003, THESIS CURTIN U TECH; Yin RK, 1994, CASE STUDY RES DESIG, V2nd; Yuen EK, 2013, J ANXIETY DISORD, V27, P389, DOI 10.1016/j.janxdis.2013.03.002	107	80	82	3	42	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1038-5282	1440-1584		AUST J RURAL HEALTH	Aust. J. Rural Health	DEC	2014	22	6			SI		280	299		10.1111/ajr.12149			20	Public, Environmental & Occupational Health; Nursing	Public, Environmental & Occupational Health; Nursing	AW4GN	WOS:000346239400003	25495622				2021-06-18	
J	Singh, R; Meier, TB; Kuplicki, R; Savitz, J; Mukai, I; Cavanagh, L; Allen, T; Teague, TK; Nerio, C; Polanski, D; Bellgowan, PSF				Singh, Rashmi; Meier, Timothy B.; Kuplicki, Rayus; Savitz, Jonathan; Mukai, Ikuko; Cavanagh, LaMont; Allen, Thomas; Teague, T. Kent; Nerio, Christopher; Polanski, David; Bellgowan, Patrick S. F.			Relationship of Collegiate Football Experience and Concussion With Hippocampal Volume and Cognitive Outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; DEFICITS; PLAYERS; STRESS; IDENTIFICATION; PERFORMANCE; RECOVERY; IMPACT; MODEL	IMPORTANCE Concussion and subconcussive impacts have been associated with short-term disrupted cognitive performance in collegiate athletes, but there are limited data on their long-term neuroanatomic and cognitive consequences. OBJECTIVE To assess the relationships of concussion history and years of football experience with hippocampal volume and cognitive performance in collegiate football athletes. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study conducted between June 2011 and August 2013 at a US psychiatric research institute specializing in neuroimaging among collegiate football players with a history of clinician-diagnosed concussion (n = 25), collegiate football players without a history of concussion (n = 25), and non-football-playing, age-, sex-, and education-matched healthy controls (n = 25). EXPOSURES History of clinician-diagnosed concussion and years of football experience. MAIN OUTCOMES AND MEASURES High-resolution anatomical magnetic resonance imaging was used to quantify brain volumes. Baseline scores on a computerized concussion-related cognitive battery were used for cognitive assessment in athletes. RESULTS Players with and without a history of concussion had smaller hippocampal volumes relative to healthy control participants (with concussion: t(48) = 7.58; P < .001; mean difference, 1788 mu L; 95% CI, 1317-2258 mu L; without concussion: t(48) = 4.35; P < .001, mean difference, 1027 mu L; 95% CI, 556-1498 mu L). Players with a history of concussion had smaller hippocampal volumes than players without concussion (t(48) = 3.15; P < .001; mean difference, 761 mu L; 95% CI, 280-1242 mu L). In both athlete groups, there was a statistically significant inverse relationship between left hippocampal volume and number of years of football played (t(46) = -3.62; P < .001; coefficient = -43.54; 95% CI, -67.66 to -19.41). Behavioral testing demonstrated no differences between athletes with and without a concussion history on 5 cognitive measures but did show an inverse correlation between years of playing football and reaction time (rho(42) = -0.43; 95% CI, -0.46 to -0.40; P = .005). CONCLUSIONS AND RELEVANCE Among a group of collegiate football athletes, there was a significant inverse relationship of concussion and years of football played with hippocampal volume. Years of football experience also correlated with slower reaction time. Further research is needed to determine the temporal relationships of these findings.	[Singh, Rashmi; Meier, Timothy B.; Kuplicki, Rayus; Savitz, Jonathan; Mukai, Ikuko; Bellgowan, Patrick S. F.] Laureate Inst Brain Res, Tulsa, OK 74136 USA; [Kuplicki, Rayus] Univ Tulsa, Tandy Sch Comp Sci, Tulsa, OK 74104 USA; [Savitz, Jonathan; Bellgowan, Patrick S. F.] Univ Tulsa, Fac Community Med, Tulsa, OK 74104 USA; [Cavanagh, LaMont; Allen, Thomas] Univ Oklahoma, Dept Family Med, Oklahoma Sch Community Med, Tulsa, OK USA; [Teague, T. Kent] Univ Oklahoma, Dept Surg, Oklahoma Sch Community Med, Tulsa, OK USA; [Teague, T. Kent] Univ Oklahoma, Dept Psychiat, Oklahoma Sch Community Med, Tulsa, OK USA; [Teague, T. Kent] Univ Oklahoma, Dept Pharmaceut Sci, Oklahoma Coll Pharm, Tulsa, OK USA; [Teague, T. Kent] Oklahoma State Univ, Ctr Hlth Sci, Dept Biochem & Microbiol, Tulsa, OK USA; [Nerio, Christopher; Polanski, David] Univ Tulsa, Dept Athlet, Tulsa, OK 74104 USA	Bellgowan, PSF (corresponding author), Laureate Inst Brain Res, 6655 S Yale Ave, Tulsa, OK 74136 USA.	pbellgowan@laureateinstitute.org	Savitz, Jonathan/C-3088-2009; Teague, T. Kent/A-2527-2008	Savitz, Jonathan/0000-0001-8143-182X; Teague, T. Kent/0000-0002-4680-5440	Laureate Institute for Brain Research; William K. Warren Foundation	This research was conducted using internal funds from the Laureate Institute for Brain Research, which is supported by the William K. Warren Foundation.	Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Erk S, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.57; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Franko E, 2014, HUM BRAIN MAPP, V35, P248, DOI 10.1002/hbm.22170; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McEwen BS, 2001, ANN NY ACAD SCI, V933, P265, DOI 10.1111/j.1749-6632.2001.tb05830.x; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Stein JL, 2012, NAT GENET, V44, P552, DOI 10.1038/ng.2250; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x	30	80	80	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2014	311	18					1883	1888		10.1001/jama.2014.3313			6	Medicine, General & Internal	General & Internal Medicine	AH0GT	WOS:000335798100020	24825643	Bronze			2021-06-18	
J	Eckner, JT; Oh, YK; Joshi, MS; Richardson, JK; Ashton-Miller, JA				Eckner, James T.; Oh, Youkeun K.; Joshi, Monica S.; Richardson, James K.; Ashton-Miller, James A.			Effect of Neck Muscle Strength and Anticipatory Cervical Muscle Activation on the Kinematic Response of the Head to Impulsive Loads	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries; concussion; head kinematics; injury biomechanics; neck muscle activation; neck strength	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; SEGMENT DYNAMIC STABILIZATION; ANKLE TORQUE DEVELOPMENT; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; NCAA CONCUSSION; UNITED-STATES; BIOMECHANICS	Background: Greater neck strength and activating the neck muscles to brace for impact are both thought to reduce an athlete's risk of concussion during a collision by attenuating the head's kinematic response after impact. However, the literature reporting the neck's role in controlling postimpact head kinematics is mixed. Furthermore, these relationships have not been examined in the coronal or transverse planes or in pediatric athletes. Hypotheses: In each anatomic plane, peak linear velocity (V) and peak angular velocity () of the head are inversely related to maximal isometric cervical muscle strength in the opposing direction (H1). Under impulsive loading, V and will be decreased during anticipatory cervical muscle activation compared with the baseline state (H2). Study Design: Descriptive laboratory study. Methods: Maximum isometric neck strength was measured in each anatomic plane in 46 male and female contact sport athletes aged 8 to 30 years. A loading apparatus applied impulsive test forces to athletes' heads in flexion, extension, lateral flexion, and axial rotation during baseline and anticipatory cervical muscle activation conditions. Multivariate linear mixed models were used to determine the effects of neck strength and cervical muscle activation on head V and . Results: Greater isometric neck strength and anticipatory activation were independently associated with decreased head V and after impulsive loading across all planes of motion (all P < .001). Inverse relationships between neck strength and head V and presented moderately strong effect sizes (r = 0.417 to r = 0.657), varying by direction of motion and cervical muscle activation. Conclusion: In male and female athletes across the age spectrum, greater neck strength and anticipatory cervical muscle activation (bracing for impact) can reduce the magnitude of the head's kinematic response. Future studies should determine whether neck strength contributes to the observed sex and age group differences in concussion incidence. Clinical Relevance: Neck strength and impact anticipation are 2 potentially modifiable risk factors for concussion. Interventions aimed at increasing athletes' neck strength and reducing unanticipated impacts may decrease the risk of concussion associated with sport participation.	[Eckner, James T.; Oh, Youkeun K.; Joshi, Monica S.; Richardson, James K.; Ashton-Miller, James A.] Univ Michigan, Ann Arbor, MI 48108 USA	Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu			K12 Career Development Award from the Rehabilitation Medicine Scientist Training Program [5K12HD001097]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: J.T.E. has declared a potential conflict of interest as specified in the AJSM Conflict of Interest Statement. He has received funding for this study through a K12 Career Development Award from the Rehabilitation Medicine Scientist Training Program (5K12HD001097).	Beier G, 1979, DETERMINATION PHYS D; BLANPIED P, 1993, J GERONTOL, V48, pM58, DOI 10.1093/geronj/48.2.M58; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Brooks SV, 1996, J PHYSIOL-LONDON, V497, P573, DOI 10.1113/jphysiol.1996.sp021790; BURDI AR, 1969, J BIOMECH, V2, P267, DOI 10.1016/0021-9290(69)90083-9; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dvir Z, 2008, J MANIP PHYSIOL THER, V31, P518, DOI 10.1016/j.jmpt.2008.08.008; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gregory S., 2013, TIME MAGAZINE; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamilton DF, 2012, BONE JOINT RES, V1, P152, DOI 10.1302/2046-3758.17.2000079; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Jordan A, 1999, SPINE, V24, P1343, DOI 10.1097/00007632-199907010-00012; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lavallee AV, 2013, J BIOMECH, V46, P527, DOI 10.1016/j.jbiomech.2012.09.029; Mansell J, 2005, J ATHL TRAINING, V40, P310; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Newman J A, 2000, Stapp Car Crash J, V44, P215; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Patton DA, 2013, J APPL BIOMECH; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Simoneau M, 2008, J BIOMECH, V41, P2097, DOI 10.1016/j.jbiomech.2008.05.002; Staudte H W, 1994, Eur Spine J, V3, P155, DOI 10.1007/BF02190578; Thelen DG, 1996, J AM GERIATR SOC, V44, P804, DOI 10.1111/j.1532-5415.1996.tb03737.x; Thelen DG, 1996, J GERONTOL A-BIOL, V51, pM226, DOI 10.1093/gerona/51A.5.M226; Thibault LE, 1987, P 31 STAPP CAR CRASH, P267; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Vasavada AN, 1998, SPINE, V23, P412, DOI 10.1097/00007632-199802150-00002; Versace J., 1971, P 15 STAPP CAR CRASH, P771; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029	46	80	80	0	57	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2014	42	3					566	576		10.1177/0363546513517869			11	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AH6EA	WOS:000336222300006	24488820	Green Accepted			2021-06-18	
J	Lin, CJ; Chen, TH; Yang, LY; Shih, CM				Lin, C-J; Chen, T-H; Yang, L-Y; Shih, C-M			Resveratrol protects astrocytes against traumatic brain injury through inhibiting apoptotic and autophagic cell death	CELL DEATH & DISEASE			English	Article						traumatic brain injury; resveratrol; glycogen synthase kinase-3 beta; mitochondrial permeability transition pore; autophagy; apoptosis	GLYCOGEN-SYNTHASE KINASE-3; OXIDATIVE STRESS; IN-VITRO; GLUTAMATE; PERMEABILITY; DEGRADATION; NEURONS; GLYCOGEN-SYNTHASE-KINASE-3-BETA; INVOLVEMENT; ACTIVATION	Traumatic brain injury (TBI) is often caused by accidents that damage the brain. TBI can induce glutamate excitotoxicity and lead to neuronal and glial cell death. In this study, we investigated the mechanism of cell death during the secondary damage caused by TBI in vivo and in vitro, as well as the protective effect of resveratrol (RV). Here we report that glycogen synthase kinase-3 beta (GSK-3 beta) activation and microtubule-associated protein light chain 3 processing were induced in rat brains exposed to TBI. In the in vitro TBI model, apoptotic and autophagic cell death were induced through glutamate-mediated GSK-3b activation in normal CTX TNA2 astrocytes. The GSK-3 beta inhibitor SB216763 or transfection of GSK-3 beta small-interfering RNA increases cell survival. By contrast, overexpression of GSK-3 beta enhanced glutamate excitotoxicity. Administration of RV reduced cell death in CTX TNA2 astrocytes by suppressing reactive oxygen species (ROS)-mediated GSK-3 beta activation, the mechanism by which RV also exerted protective effects in vivo. Mitochondrial damages, including the opening of mitochondrial permeability transition pore (MPTP) and mitochondrial depolarization, were induced by glutamate through the ROS/GSK-3 beta pathway. Moreover, cyclosporine A, an MPTP inhibitor, suppressed mitochondrial damage and the percentages of cells undergoing autophagy and apoptosis and thereby increased cell survival. Taken together, our results demonstrated that cell death occurring after TBI is induced through the ROS/GSK-3 beta/mitochondria signaling pathway and that administration of RV can increase cell survival by suppressing GSK-3 beta-mediated autophagy and apoptosis. Therefore, the results indicated that resveratrol may serve as a potential therapeutic agent in the treatment of TBI.	[Lin, C-J; Yang, L-Y; Shih, C-M] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 110, Taiwan; [Lin, C-J; Shih, C-M] Taipei Med Univ, Sch Med, Dept Biochem, Taipei 110, Taiwan; [Chen, T-H] Cathay Gen Hosp, Div Cardiovasc Surg, Dept Surg, Taipei 106, Taiwan; [Yang, L-Y] Taipei Med Univ, Dept Physiol, Coll Med, Taipei 110, Taiwan; [Shih, C-M] Taipei Med Univ Hosp, Tradit Herbal Med Res Ctr, Taipei 110, Taiwan; [Shih, C-M] Taipei Med Univ Hosp, Ctr Reprod Med & Sci, Taipei 110, Taiwan	Shih, CM (corresponding author), Taipei Med Univ, Sch Med, Dept Biochem, 250 Wu Hsing St, Taipei 110, Taiwan.	cmshih@tmu.edu.tw		Lin, Chien-Ju/0000-0001-5224-3539	Cathay General Hospital [101CGH-TMU-05]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC99-2320-B08-008-MY3]	This work was supported by grants from Cathay General Hospital (101CGH-TMU-05) and the National Science Council (NSC99-2320-B08-008-MY3) to CMS.	Alayev A, 2014, CELL CYCLE, V13, P371, DOI 10.4161/cc.27355; Armour SM, 2009, AGING-US, V1, P515, DOI 10.18632/aging.100056; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Bhat RV, 2002, NEUROSIGNALS, V11, P251, DOI 10.1159/000067423; Chen HC, 2012, SPINE, V37, P470, DOI 10.1097/BRS.0b013e318221e859; Chen ML, 2013, AUTOPHAGY, V9, P2033, DOI 10.4161/auto.26336; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chen ZY, 2010, NEUROSCI LETT, V482, P264, DOI 10.1016/j.neulet.2010.07.052; Cheng HY, 2008, J PHARMACOL SCI, V107, P21, DOI 10.1254/jphs.FP0072394; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Cucciolla V, 2007, CELL CYCLE, V6, P2495, DOI 10.4161/cc.6.20.4815; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Forde JE, 2007, CELL MOL LIFE SCI, V64, P1930, DOI 10.1007/s00018-007-7045-7; Gould TD, 2004, J CLIN PSYCHIAT, V65, P10; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hisano K, 2009, J ANESTH, V23, P363, DOI 10.1007/s00540-009-0766-z; Jeong JK, 2012, NEUROSCI RES, V73, P99, DOI 10.1016/j.neures.2012.03.005; Kanzawa T, 2003, J NEUROSURG, V99, P1047, DOI 10.3171/jns.2003.99.6.1047; Karmarkar SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023493; Kim H, 2009, BIOCHEM BIOPH RES CO, V388, P339, DOI 10.1016/j.bbrc.2009.08.007; Lee KY, 2007, BRAIN RES, V1129, P89, DOI 10.1016/j.brainres.2006.10.055; Leon R, 2009, J NEUROSCI RES, V87, P1185, DOI 10.1002/jnr.21926; Liu CJ, 2011, BRAIN RES, V1374, P100, DOI 10.1016/j.brainres.2010.11.061; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu H, 2013, AUTOPHAGY, V9, P730, DOI 10.4161/auto.24039; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Lv XC, 2012, CAN J PHYSIOL PHARM, V90, P655, DOI [10.1139/Y2012-051, 10.1139/y2012-051]; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Molz S, 2008, NEUROCHEM RES, V33, P27, DOI 10.1007/s11064-007-9402-1; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Obame FN, 2008, J PHARMACOL EXP THER, V326, P252, DOI 10.1124/jpet.108.138008; Pan CL, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S18; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Parr C, 2012, MOL CELL BIOL, V32, P4410, DOI 10.1128/MCB.00930-12; Petit-Paitel A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005491; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Pietra G, 2001, CANCER RES, V61, P8218; Pozo-Guisado E, 2004, INT J CANCER, V109, P167, DOI 10.1002/ijc.11720; Ray SK, 2006, NEUROSCIENCE, V139, P577, DOI 10.1016/j.neuroscience.2005.12.057; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Shin SM, 2009, MOL PHARMACOL, V76, P884, DOI 10.1124/mol.109.058479; Shin SY, 2006, CELL SIGNAL, V18, P601, DOI 10.1016/j.cellsig.2005.06.001; Smith JS, 2000, NEURAL PLAST, V7, P73, DOI 10.1155/NP.2000.73; Thevenod F, 1999, FASEB J, V13, P1751; Varamini B, 2014, INT J FOOD SCI NUTR, V65, P89, DOI 10.3109/09637486.2013.832171; Wang H, 2010, BIOCHEM PHARMACOL, V80, P1386, DOI 10.1016/j.bcp.2010.07.034; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Wang SH, 2009, TOXICOL SCI, V108, P124, DOI 10.1093/toxsci/kfn266; Wu Y, 2007, APOPTOSIS, V12, P1365, DOI 10.1007/s10495-007-0065-9; Yao LL, 2010, AM J PHYSIOL-HEART C, V298, pH1310, DOI 10.1152/ajpheart.00339.2009; Zamin LL, 2006, NEUROBIOL DIS, V24, P170, DOI 10.1016/j.nbd.2006.06.002; Zhang XJ, 2011, AUTOPHAGY, V7, P412, DOI 10.4161/auto.7.4.14541; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao Y, 2012, J CELL PHYSIOL, V227, P639, DOI 10.1002/jcp.22768; Zschocke J, 2011, NEUROPSYCHOPHARMACOL, V36, P1754, DOI 10.1038/npp.2011.57	58	80	85	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	MAR	2014	5								e1147	10.1038/cddis.2014.123			11	Cell Biology	Cell Biology	AE1TW	WOS:000333754100051	24675465	DOAJ Gold, Green Published			2021-06-18	
J	Liu, Q; Qiu, J; Liang, M; Golinski, J; van Leyen, K; Jung, JE; You, Z; Lo, EH; Degterev, A; Whalen, MJ				Liu, Q.; Qiu, J.; Liang, M.; Golinski, J.; van Leyen, K.; Jung, J. E.; You, Z.; Lo, E. H.; Degterev, A.; Whalen, M. J.			Akt and mTOR mediate programmed necrosis in neurons	CELL DEATH & DISEASE			English	Article						necroptosis; neuron; Akt; mTOR; RIPK1; RIPK3	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; AUTOPHAGIC CELL-DEATH; MIXED LINEAGE KINASE; NF-KAPPA-B; TRANSCRIPTION FACTORS; INDUCED ACTIVATION; REACTIVE OXYGEN; RIP1 KINASE	Necroptosis is a newly described form of regulated necrosis that contributes to neuronal death in experimental models of stroke and brain trauma. Although much work has been done elucidating initiating mechanisms, signaling events governing necroptosis remain largely unexplored. Akt is known to inhibit apoptotic neuronal cell death. Mechanistic target of rapamycin (mTOR) is a downstream effector of Akt that controls protein synthesis. We previously reported that dual inhibition of Akt and mTOR reduced acute cell death and improved long term cognitive deficits after controlled-cortical impact in mice. These findings raised the possibility that Akt/mTOR might regulate necroptosis. To test this hypothesis, we induced necroptosis in the hippocampal neuronal cell line HT22 using concomitant treatment with tumor necrosis factor alpha (TNF alpha) and the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. TNF alpha/zVAD treatment induced cell death within 4 h. Cell death was preceded by RIPK1-RIPK3-pAkt assembly, and phosphorylation of Thr-308 and Thr473 of AKT and its direct substrate glycogen synthase kinase-beta b, as well as mTOR and its direct substrate S6 ribosomal protein (S6), suggesting activation of Akt/mTOR pathways. Pretreatment with Akt inhibitor viii and rapamycin inhibited Akt and S6 phosphorylation events, mitochondrial reactive oxygen species production, and necroptosis by over 50% without affecting RIPK1-RIPK3 complex assembly. These data were confirmed using small inhibitory ribonucleic acid-mediated knockdown of AKT1/2 and mTOR. All of the aforementioned biochemical events were inhibited by necrostatin-1, including Akt and mTOR phosphorylation, generation of oxidative stress, and RIPK1-RIPK3-pAkt complex assembly. The data suggest a novel, heretofore unexpected role for Akt and mTOR downstream of RIPK1 activation in neuronal cell death.	[Liu, Q.; Qiu, J.; Liang, M.; Golinski, J.; Whalen, M. J.] Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA 02129 USA; [Liu, Q.; Qiu, J.; Liang, M.; Golinski, J.; van Leyen, K.; Jung, J. E.; Lo, E. H.; Whalen, M. J.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA; [Liu, Q.; Qiu, J.; Liang, M.; Golinski, J.; van Leyen, K.; Jung, J. E.; Lo, E. H.; Whalen, M. J.] Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; [Liu, Q.] Fudan Univ, Shanghai Med Coll, Dept Anat Histol & Embryol, Shanghai 200433, Peoples R China; [Liang, M.] Fudan Univ, Huashan Hosp, Dept Rheumatol, Shanghai 200433, Peoples R China; [van Leyen, K.; Jung, J. E.; Lo, E. H.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Neurol, Charlestown, MA 02129 USA; [van Leyen, K.; Jung, J. E.; Lo, E. H.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Radiol, Charlestown, MA 02129 USA; [You, Z.; Degterev, A.] Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Biochem, Boston, MA 02111 USA	Whalen, MJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, 149 13th St, Charlestown, MA 02129 USA.	MWhalen@Partners.org	van Leyen, Klaus/C-9126-2013	van Leyen, Klaus/0000-0003-1032-3754	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NSO64545]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31371083]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049430] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS 5RO1NSO64545 (MJW) and National Natural Science Foundation of China grant 31371083.	Aki T, 2003, ONCOGENE, V22, P8529, DOI 10.1038/sj.onc.1207197; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Friguls B, 2002, NEUROBIOL DIS, V11, P443, DOI 10.1006/nbdi.2002.0553; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Kitagawa H, 1999, NEUROSCI LETT, V274, P45, DOI 10.1016/S0304-3940(99)00676-X; Komandirov MA, 2011, J MOL NEUROSCI, V45, P229, DOI 10.1007/s12031-011-9499-1; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Li F, 2003, BRAIN RES, V962, P21, DOI 10.1016/S0006-8993(02)03774-5; Li YL, 2008, NEUROSCI LETT, V447, P120, DOI 10.1016/j.neulet.2008.08.037; Los M, 2009, BIOESSAYS, V31, P492, DOI 10.1002/bies.200900005; Lu B, 2006, J IMMUNOL, V176, P6785, DOI 10.4049/jimmunol.176.11.6785; Maddika S, 2008, ONCOGENE, V27, P3060, DOI 10.1038/sj.onc.1210958; Maddika S, 2007, CELL PROLIFERAT, V40, P835, DOI 10.1111/j.1365-2184.2007.00475.x; Maddika S, 2008, J CELL SCI, V121, P979, DOI 10.1242/jcs.009530; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; McNamara CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056576; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nimbalkar D, 2003, CANCER RES, V63, P1034; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Northington FJ, 2011, J CEREBR BLOOD F MET, V31, P178, DOI 10.1038/jcbfm.2010.72; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; O'Donnell MA, 2012, IMMUNOL RES, V54, P214, DOI 10.1007/s12026-012-8321-7; Ohba N, 2004, NEUROSCI LETT, V359, P159, DOI 10.1016/j.neulet.2004.02.029; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Shack S, 2003, MOL CELL BIOL, V23, P2407, DOI 10.1128/MCB.23.7.2407-2414.2003; Shioda N, 2007, NEUROSCIENCE, V148, P221, DOI 10.1016/j.neuroscience.2007.05.040; Song YS, 2008, J CEREBR BLOOD F MET, V28, P1917, DOI 10.1038/jcbfm.2008.80; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Teng X, 2005, BIOORG MED CHEM LETT, V15, P5039, DOI 10.1016/j.bmcl.2005.07.077; van Leyen K, 2008, J NEUROSCI RES, V86, P904, DOI 10.1002/jnr.21543; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Wang HY, 2009, BRAIN RES, V1297, P177, DOI 10.1016/j.brainres.2009.08.054; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Yamanaka K, 2011, J BIOL CHEM, V286, P24666, DOI 10.1074/jbc.M111.236273; Yigitkanli K, 2013, ANN NEUROL, V73, P129, DOI 10.1002/ana.23734; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109	57	80	83	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	FEB	2014	5								e1038	10.1038/cddis.2014.69			10	Cell Biology	Cell Biology	AC0ZJ	WOS:000332223700041	24577082	DOAJ Gold, Green Published			2021-06-18	
J	Chauhan, NB				Chauhan, Neelima B.			Chronic neurodegenerative consequences of traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Traumatic brain injury; traumatic axonal injury; chronic traumatic encephalopathy; dementia pugilistica; amyotrophic lateral sclerosis; Parkinson's disease; Alzheimer's disease; dementia	AMYLOID PRECURSOR PROTEIN; POSTTRAUMATIC-STRESS-DISORDER; HUMAN APOLIPOPROTEIN E4; DIFFUSE AXONAL INJURY; MICROTUBULE-ASSOCIATED PROTEINS; ANTERIOR-PITUITARY DYSFUNCTION; LONG-TERM ACCUMULATION; ALZHEIMERS-DISEASE; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE	Traumatic brain injury (TBI) is a serious public health concern and a major cause of death and disability worldwide. Each year, an estimated 1.7 million Americans sustain TBI of which similar to 52,000 people die, similar to 275,000 people are hospitalized and 1,365,000 people are treated as emergency outpatients. Currently there are similar to 5.3 million Americans living with TBI. TBI is more of a disease process than of an event that is associated with immediate and long-term sensomotor, psychological and cognitive impairments. TBI is the best known established epigenetic risk factor for later development of neurodegenerative diseases and dementia. People sustaining TBI are similar to 4 times more likely to develop dementia at a later stage than people without TBI. Single brain injury is linked to later development of symptoms resembling Alzheimer's disease while repetitive brain injuries are linked to later development of chronic traumatic encephalopathy (CTE) and/or Dementia Pugilistica (DP). Furthermore, genetic background of beta-amyloid precursor protein (APP), Apolipoprotein E (ApoE), presenilin (PS) and neprilysin (NEP) genes is associated with exacerbation of neurodegenerative process after TBI. This review encompasses acute effects and chronic neurodegenerative consequences after TBI.	[Chauhan, Neelima B.] Jesse Brown VA Med Ctr, R&D 151,820 South Damen Ave, Chicago, IL 60612 USA; [Chauhan, Neelima B.] Univ Illinois, Dept Pediat, Chicago, IL USA; [Chauhan, Neelima B.] Univ Illinois, Childrens Hosp, Chicago, IL USA	Chauhan, NB (corresponding author), Jesse Brown VA Med Ctr, R&D 151,820 South Damen Ave, Chicago, IL 60612 USA.	nchauhan@uic.edu			Westside Institute for Science and Education; Department of Pediatrics, University of Illinois at Chicago; Children's Hospital of the University of Illinois, Chicago, IL; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG039625, NS079614]; Westside Institute of Science AMP; Education, Chicago, IL; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation RDUS Department of Veterans Affairs [I0880R]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS079614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG039625] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000880] Funding Source: NIH RePORTER	This material is the result of work supported with resources and use of facilities provided by the Jesse Brown VA medical center Chicago, Chicago, IL. Authors acknowledge the support provided by the Westside Institute for Science and Education; Department of Pediatrics, University of Illinois at Chicago; Children's Hospital of the University of Illinois, Chicago, IL. This work has been supported in part by National Institute of Health (AG039625, NS079614 NBC); by Westside Institute of Science & Education, Chicago, IL; and by Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation R&D (I0880R, NBC).	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Acerini CL, 2007, HORM RES, V68, P14, DOI 10.1159/000110465; Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Al-Bassam J, 2002, J CELL BIOL, V157, P1187, DOI 10.1083/jcb.200201048; Al-Chalabi A, 2012, ACTA NEUROPATHOL, V124, P339, DOI 10.1007/s00401-012-1022-4; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Ali A, 2012, NEUROL RES, V34, P462, DOI 10.1179/1743132812Y.0000000014; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; ASSERY M, 1992, J PROSTHET DENT, V67, P275, DOI 10.1016/0022-3913(92)90467-O; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Back S, 2007, J NEUROSCI RES, V85, P2580, DOI 10.1002/jnr.21239; Bajwa R, 2012, PEDIATR TRANSPLANT, V16, P872, DOI 10.1111/petr.12002; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; Bao X, 2008, ACTA NEUROCHIR SUPPL, V105, P23; Bar-Haim Y, 2007, PSYCHOL BULL, V133, P1, DOI 10.1037/0033-2909.133.1.1; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Baxter D., 2013, ANN NEUROL; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Blain JF, 2006, NEUROBIOL DIS, V21, P505, DOI 10.1016/j.nbd.2005.08.010; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Blissitt Patricia A, 2006, Crit Care Nurs Clin North Am, V18, P321, DOI 10.1016/j.ccell.2006.05.006; Bocksch L., 2001, Current Drug Targets - Cardiovascular and Haematological Disorders, V1, P93, DOI 10.2174/1568006013337944; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Braak H, 2010, ACTA NEUROPATHOL, V120, P67, DOI 10.1007/s00401-010-0683-0; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; Bramlett HM, 2003, EXP NEUROL, V184, P27, DOI 10.1016/S0014-4886(03)00401-1; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brooks J.C., 2013, ARCH PHYS MED REHABI; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Brunholz S, 2012, EXP BRAIN RES, V217, P353, DOI 10.1007/s00221-011-2870-1; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8; Capehart B, 2012, J REHABIL RES DEV, V49, P789, DOI 10.1682/JRRD.2011.10.0185; Capell A, 2002, J BIOL CHEM, V277, P5637, DOI 10.1074/jbc.M109119200; Carlson KF, 2013, BRAIN INJURY, V27, P640, DOI 10.3109/02699052.2013.771795; Carro E, 2002, NAT MED, V8, P1390, DOI 10.1038/nm793; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casano-Sancho P, 2013, CLIN ENDOCRINOL OXF; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Christensen J, 2012, EPILEPSIA, V53, P43, DOI 10.1111/j.1528-1167.2012.03612.x; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dai SS, 2013, J EXP MED, V210, P839, DOI 10.1084/jem.20122196; Dal Monte O, 2013, SOC COGN AFFECT NEUR, V8, P632, DOI 10.1093/scan/nss041; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Dehmelt L, 2005, GENOME BIOL, V6; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Dickson DW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009258; Dickson DW, 2010, INT J CLIN EXP PATHO, V3, P1; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Dumanis SB, 2009, J NEUROSCI, V29, P15317, DOI 10.1523/JNEUROSCI.4026-09.2009; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Ennis N, 2013, NEUROPSYCHOL REHABIL, V23, P1, DOI 10.1080/09602011.2012.712871; Ertekin MV, 2004, BIOL TRACE ELEM RES, V100, P63, DOI 10.1385/BTER:100:1:063; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Evans MC, 2013, MOL CELL NEUROSCI, V53, P34, DOI 10.1016/j.mcn.2012.10.008; Farlow MR, 2004, NEUROLOGY, V63, P1898, DOI 10.1212/01.WNL.0000144279.21502.B7; Ferrer I, 2011, J NEURAL TRANSM, V118, P821, DOI 10.1007/s00702-010-0482-8; Feussner G, 1998, HUM MUTAT, V11, P417, DOI 10.1002/(SICI)1098-1004(1998)11:6<417::AID-HUMU1>3.3.CO;2-X; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Forslund M.V., 2013, ACTA NEUROL SCAND; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gale CR, 2008, ARCH GEN PSYCHIAT, V65, P1410, DOI 10.1001/archpsyc.65.12.1410; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Gatson JW, 2013, J NEUROSURG, V118, P1336, DOI 10.3171/2013.2.JNS121771; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Geser F, 2009, J NEUROL, V256, P1205, DOI 10.1007/s00415-009-5069-7; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Giza CC, 2001, J ATHL TRAINING, V36, P228; GLASS AM, 1980, APPL OPTICS, V19, P276, DOI 10.1364/AO.19.000276; Godoy DA, 2010, NEUROCRIT CARE, V13, P425, DOI 10.1007/s12028-010-9404-8; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goodwin Linda, 2006, J Insur Med, V38, P300; Gotow Takahiro, 2000, Medical Electron Microscopy, V33, P173, DOI 10.1007/s007950000019; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Granieri E, 2000, J NEUROVIROL, V6, pS141; Greco T, 2013, J NEUROTRAUMA; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Halpain S, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-6-224; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hannon MJ, 2011, BEST PRACT RES CL EN, V25, P783, DOI 10.1016/j.beem.2011.06.001; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hinkebein JH, 2003, BRAIN INJURY, V17, P1035, DOI 10.1080/0269905031000110490; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hohl A, 2009, ARQ BRAS ENDOCRINOL, V53, P908, DOI 10.1590/S0004-27302009000800003; Honeybul S, 2011, J NEUROSURG SCI, V55, P343; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Hsieh H.L., 2013, MOL NEUROBIOL; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Huang JH, 2013, NEUROL RES, V35, P221, DOI 10.1179/1743132813Y.0000000178; Huang YD, 2004, J MOL NEUROSCI, V23, P189, DOI 10.1385/JMN:23:3:189; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Itoh T, 2013, BRAIN STRUCT FUNCT, V218, P209, DOI 10.1007/s00429-012-0394-5; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jang SH, 2011, NEUROREHABILITATION, V29, P339, DOI 10.3233/NRE-2011-0710; Janke C, 2011, NAT REV MOL CELL BIO, V12, P773, DOI 10.1038/nrm3227; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kagansky N, 2001, ARCH NEUROL-CHICAGO, V58, P1209, DOI 10.1001/archneur.58.8.1209; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kamal AK, 2003, AM J NEURORADIOL, V24, P895; Kanayama G, 1997, PSYCHIAT CLIN NEUROS, V51, P157, DOI 10.1111/j.1440-1819.1997.tb02379.x; Kang JH, 2012, J NEUROTRAUM, V29, P90, DOI 10.1089/neu.2011.1936; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Khadr SN, 2010, CLIN ENDOCRINOL, V73, P637, DOI 10.1111/j.1365-2265.2010.03857.x; Kim HJ, 2013, NEUROBIOL AGING; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kiris E, 2010, METHOD CELL BIOL, V95, P481, DOI 10.1016/S0091-679X(10)95024-3; Kolakowsky-Hayner SA, 2012, BRAIN INJURY, V26, P1328, DOI 10.3109/02699052.2012.706353; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kouloulas E.J., 2013, INT J REHABIL RES; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; KURLAND LT, 1994, ANN NEUROL, V36, pS33, DOI 10.1002/ana.410360711; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Lariviere RC, 2004, J NEUROBIOL, V58, P131, DOI 10.1002/neu.10270; Lasagna-Reeves CA, 2011, CURR ALZHEIMER RES, V8, P659; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lazarov O, 2005, J NEUROSCI, V25, P2386, DOI 10.1523/JNEUROSCI.3089-04.2005; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lee D, 2013, PEDIATR DRUGS, V15, P151, DOI 10.1007/s40272-013-0009-5; Li XY, 2010, NEUROSCIENCE, V169, P357, DOI 10.1016/j.neuroscience.2010.04.075; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Liraz O, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-16; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Llompart-Pou JA, 2008, NEUROCRIT CARE, V9, P230, DOI 10.1007/s12028-008-9115-6; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Ludolph AC, 2012, CURR OPIN NEUROL, V25, P530, DOI 10.1097/WCO.0b013e328356d328; Luth HJ, 2001, BRAIN RES, V913, P57, DOI 10.1016/S0006-8993(01)02758-5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Masada T, 2000, BRAIN RES, V867, P173, DOI 10.1016/S0006-8993(00)02302-7; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Matenia D, 2009, TRENDS BIOCHEM SCI, V34, P332, DOI 10.1016/j.tibs.2009.03.008; MATUS A, 1990, J PHYSIOL-PARIS, V84, P134; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MCNALLY RJ, 1995, AM J PSYCHIAT, V152, P936; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miller CCJ, 2002, CELL MOL LIFE SCI, V59, P323, DOI 10.1007/s00018-002-8425-7; Miller RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub3; Moon RJ, 2010, J NEUROTRAUM, V27, P1827, DOI 10.1089/neu.2010.1408; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; Munoz A, 2013, CURR OPIN ENDOCRINOL, V20, P354, DOI 10.1097/MED.0b013e32836318ba; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Nelson PT, 2009, J NEUROPATH EXP NEUR, V68, P1, DOI 10.1097/NEN.0b013e3181919a48; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Norwood KW, 2010, CLIN PEDIATR, V49, P1044, DOI 10.1177/0009922810376234; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Oliveros-Juste A, 2002, REV NEUROLOGIA, V34, P448, DOI 10.33588/rn.3405.2001439; Orman JA, 2012, J TRAUMA ACUTE CARE, V73, pS496, DOI 10.1097/TA.0b013e318275473c; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Paglini G, 2000, NEUROCHEM RES, V25, P37, DOI 10.1023/A:1007531230651; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park KD, 2010, BRAIN INJURY, V24, P1330, DOI 10.3109/02699052.2010.506863; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; Pearson WS, 2012, PREHOSP EMERG CARE, V16, P323, DOI 10.3109/10903127.2012.682701; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Poirier J, 2000, ANN NY ACAD SCI, V924, P81; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; POSER CM, 1994, CLIN NEUROL NEUROSUR, V96, P103, DOI 10.1016/0303-8467(94)90042-6; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Qing WG, 2009, J NEUROSURG, V110, P462, DOI 10.3171/2008.4.JNS17512; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Reeves RR, 2012, J PSYCHOSOC NURS MEN, V50, P32, DOI 10.3928/02793695-20120207-02; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Riggio S, 2010, PSYCHIAT CLIN N AM, V33, P807, DOI 10.1016/j.psc.2010.08.004; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rose SR, 2012, PITUITARY, V15, P267, DOI 10.1007/s11102-011-0360-x; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Ross DE, 2013, J NEUROPSYCH CLIN N, V25, P32, DOI 10.1176/appi.neuropsych.11120377; Rubin DC, 2008, PSYCHOL REV, V115, P985, DOI 10.1037/a0013397; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; SHEA TB, 1994, MOL BIOL CELL, V5, P863; Shea TB, 2003, TRENDS NEUROSCI, V26, P397, DOI 10.1016/S0166-2236(03)00199-1; Shea TB, 2009, RESULTS PROBL CELL D, V48, P29, DOI 10.1007/400_2009_8; Sheng JG, 2003, EXP NEUROL, V184, P1053, DOI 10.1016/j.expneurol.2003.08.018; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sherer M., 2013, J HEAD TRAUMA REHABI; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; Singh PP, 2002, HUM BIOL, V74, P673, DOI 10.1353/hub.2002.0057; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Small D H, 1999, J Alzheimers Dis, V1, P275; Small DH, 1998, NEUROCHEM RES, V23, P795, DOI 10.1023/A:1022471729291; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Somali M, 2005, HORM METAB RES, V37, P494, DOI 10.1055/s-2005-870308; Srinivas R, 2010, CHILD NERV SYST, V26, P647, DOI 10.1007/s00381-009-1038-9; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sugerman DE, 2012, J TRAUMA ACUTE CARE, V73, P1491, DOI 10.1097/TA.0b013e3182782675; Tang BL, 2009, CELL ADHES MIGR, V3, P118, DOI 10.4161/cam.3.1.7254; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tanriverdi F, 2010, PITUITARY, V13, P111, DOI 10.1007/s11102-009-0204-0; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, BRAIN INJURY, V21, P433, DOI 10.1080/02699050701311083; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasell R, 2007, BRAIN INJURY, V21, P201, DOI 10.1080/02699050701201854; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Teter B, 2002, J NEUROSCI RES, V68, P331, DOI 10.1002/jnr.10221; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Van den Heuvel C, 2000, J NEUROTRAUM, V17, P1041, DOI 10.1089/neu.2000.17.1041; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Viola-Saltzman M, 2012, NEUROL CLIN, V30, P1299, DOI 10.1016/j.ncl.2012.08.008; Wang JZ, 2008, PROG NEUROBIOL, V85, P148, DOI 10.1016/j.pneurobio.2008.03.002; Wang JZ, 2013, J ALZHEIMERS DIS, V33, pS123, DOI 10.3233/JAD-2012-129031; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Wei W, 2010, NAT NEUROSCI, V13, P190, DOI 10.1038/nn.2476; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820; Xie YY, 2003, J NEUROSCI RES, V73, P557, DOI 10.1002/jnr.10667; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xydakis MS, 2012, ANN NEUROL, V72, P673, DOI 10.1002/ana.23757; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zazulia AR, 1999, STROKE, V30, P1167, DOI 10.1161/01.STR.30.6.1167; Zhang HB, 2006, NEUROL RES, V28, P104, DOI 10.1179/016164106X91960; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319; Zhang YW, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-3; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	363	80	84	1	42	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2014	32	2					337	365		10.3233/RNN-130354			29	Neurosciences	Neurosciences & Neurology	AC4GD	WOS:000332478200011	24398724				2021-06-18	
J	Cho, HJ; Sajja, VSSS; Vandevord, PJ; Lee, YW				Cho, H. J.; Sajja, V. S. S. S.; Vandevord, P. J.; Lee, Y. W.			BLAST INDUCES OXIDATIVE STRESS, INFLAMMATION, NEURONAL LOSS AND SUBSEQUENT SHORT-TERM MEMORY IMPAIRMENT IN RATS	NEUROSCIENCE			English	Article						blast-induced neurotrauma; oxidative stress; inflammation; neuronal loss; novel object recognition; short-term memory impairment	TRAUMATIC BRAIN-INJURY; MICROGLIAL-ACTIVATION; INDUCED NEUROTRAUMA; ALZHEIMERS-DISEASE; SHOCK-WAVE; NEURODEGENERATIVE DISEASES; CHRONIC NEUROINFLAMMATION; INTRACRANIAL-PRESSURE; MULTIPLE-SCLEROSIS; COGNITIVE DEFICITS	Molecular and cellular mechanisms of brain injury after exposure to blast overpressure (BOP) are not clearly known. The present study hypothesizes that pro-oxidative and pro-inflammatory pathways in the brain may be responsible for neuronal loss and behavioral deficits following BOP exposure. Male Sprague-Dawley rats were anesthetized and exposed to calibrated BOP of 129.23 +/- 3.01 kPa while controls received only anesthesia. In situ dihydroethidium fluorescence staining revealed that BOP significantly increased the production of reactive oxygen species in the brain. In addition, real-time reverse transcriptase-polymerase chain reaction, immunofluorescence staining and enzyme-linked immunosorbent assay demonstrated a significant up-regulation of mRNA and protein expressions of pro-inflammatory mediators, such as interferon-gamma and monocyte chemoattractant protein-1, in brains collected from BOP-exposed animals compared with the controls. Furthermore, immunoreactivity of neuronal nuclei in brains indicated that fewer neurons were present following BOP exposure. Moreover, novel object recognition paradigm showed a significant impairment in the short-term memory at 2 weeks following BOP exposure. These results suggest that pro-oxidative and pro-inflammatory environments in the brain could play a potential role in BOP-induced neuronal loss and behavioral deficits. It may provide a foundation for defining a molecular and cellular basis of the pathophysiology of blast-induced neurotrauma (BINT). It will also contribute to the development of new therapeutic approaches selectively targeting these pathways, which have great potential in the diagnosis and therapy of BINT. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Cho, H. J.; Sajja, V. S. S. S.; Vandevord, P. J.; Lee, Y. W.] Virginia Polytech Inst & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA; [Lee, Y. W.] Virginia Polytech Inst & State Univ, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA; [Vandevord, P. J.] Vet Affairs Med Ctr, Salem, VA 24153 USA	Lee, YW (corresponding author), Virginia Polytech Inst & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA.	hjcho79@vt.edu; sujits@vt.edu; pvord@vt.edu; ywlee@vt.edu	Sajja, Sujith/I-5289-2019	Sajja, Sujith/0000-0002-1992-9501; Cho, Hyung Joon/0000-0002-7481-6841			Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P9; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belujon P, 2011, ANN NY ACAD SCI, V1216, P114, DOI 10.1111/j.1749-6632.2010.05896.x; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne TC, 2013, J IMMUNOL, V190, P2241, DOI 10.4049/jimmunol.1200947; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Cechetti F, 2012, BRAIN RES BULL, V87, P109, DOI 10.1016/j.brainresbull.2011.10.006; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Choi K, 2009, CURR NEUROVASC RES, V6, P213, DOI 10.2174/156720209789630375; Diaz A, 2012, J ALZHEIMERS DIS, V30, P505, DOI 10.3233/JAD-2012-111979; Dinel AL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024325; do Nascimento AL, 2012, BRAIN RES, V1470, P98, DOI 10.1016/j.brainres.2012.06.008; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Gao HM, 2011, J NEUROSCI, V31, P1081, DOI 10.1523/JNEUROSCI.3732-10.2011; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hauss-Wegrzyniak B, 1998, BRAIN RES, V780, P294, DOI 10.1016/S0006-8993(97)01215-8; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lee WH, 2010, INT J RADIAT BIOL, V86, P132, DOI 10.3109/09553000903419346; Lee YW, 2003, AM J PHYSIOL-HEART C, V284, pH185, DOI 10.1152/ajpheart.00524.2002; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Li GM, 2013, NEUROL SCI, V34, P963, DOI 10.1007/s10072-012-1173-z; Little AR, 2002, NEUROSCIENCE, V115, P307, DOI 10.1016/S0306-4522(02)00359-7; Liu Y, 2006, J NEUROSCI, V26, P12904, DOI 10.1523/JNEUROSCI.2531-06.2006; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Martino G, 2002, LANCET NEUROL, V1, P499, DOI 10.1016/S1474-4422(02)00223-5; Morley MG, 2010, DISASTER MED PUBLIC, V4, P154, DOI 10.1001/dmp.v4n2.hra10003; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Rauh MJ, 2013, J REHABIL RES DEV, V50, P161, DOI 10.1682/JRRD.2011.11.0212; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Salim S, 2012, ADV PROTEIN CHEM STR, V88, P1, DOI 10.1016/B978-0-12-398314-5.00001-5; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Schofield E, 2003, BRAIN, V126, P827, DOI 10.1093/brain/awg085; Shapiro LA, 2005, NEUROSCIENCE, V136, P823, DOI 10.1016/j.neuroscience.2005.03.059; Smith JE, 2011, PHILOS T R SOC B, V366, P291, DOI 10.1098/rstb.2010.0251; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Stetler RA, 2010, PROG NEUROBIOL, V92, P184, DOI 10.1016/j.pneurobio.2010.05.002; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Takeuchi H, 2006, NEUROBIOL DIS, V22, P33, DOI 10.1016/j.nbd.2005.09.014; Tansey MG, 2010, NEUROBIOL DIS, V37, P510, DOI 10.1016/j.nbd.2009.11.004; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Wang KC, 2013, NEUROSCIENCE, V234, P146, DOI 10.1016/j.neuroscience.2012.12.049; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Wani Imtiaz, 2009, World J Emerg Surg, V4, P46, DOI 10.1186/1749-7922-4-46; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yang GA, 2011, BRAIN PATHOL, V21, P279, DOI 10.1111/j.1750-3639.2010.00445.x; Zhang DM, 2012, NEUROCHEM INT, V61, P1021, DOI 10.1016/j.neuint.2012.07.019; Zhang J, 2013, BEHAV BRAIN RES, V244, P70, DOI 10.1016/j.bbr.2013.01.037	94	80	83	2	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 3	2013	253						9	20		10.1016/j.neuroscience.2013.08.037			12	Neurosciences	Neurosciences & Neurology	252HZ	WOS:000326997100002	23999126				2021-06-18	
J	Cole, WR; Arrieux, JP; Schwab, K; Ivins, BJ; Qashu, FM; Lewis, SC				Cole, Wesley R.; Arrieux, Jacques P.; Schwab, Karen; Ivins, Brian J.; Qashu, Felicia M.; Lewis, Steven C.			TestRetest Reliability of Four Computerized Neurocognitive Assessment Tools in an Active Duty Military Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Reliability; Cognitive screening; Traumatic brain injury; Concussion; Military; NCAT	TRAUMATIC BRAIN-INJURY; TEST-RETEST RELIABILITY; REDICK CLINICAL UTILITY; IMPACT ASSESSMENT; CONCUSSION; NEUROPSYCHOLOGY; PERFORMANCE; MAYERS	Computerized neurocognitive assessment tools (NCATs) are increasingly used for baseline and post-concussion assessments. To date, NCATs have not demonstrated strong testretest reliabilities. Most studies have used non-military populations and different methodologies, complicating the determination of the utility of NCATs in military populations. The testretest reliability of four NCATs (Automated Neuropsychological Assessment Metrics 4 [ANAM4], CNS-Vital Signs, CogState, and Immediate Post-Concussion Assessment and Cognitive Test [ImPACT]) was investigated in a healthy active duty military sample. Four hundred and nineteen Service Members were randomly assigned to take one NCAT and 215 returned after approximately 30 days for retest. Participants deemed to have inadequate effort during one or both testing sessions, according to the NCATs scoring algorithms, were removed from analyses. Each NCAT had at least one reliability score (intraclass correlation) in the adequate range (.70.79), only ImPACT had one score considered high (.80.89), and no scores met very high criteria (.90.99). However, overall testretest reliabilities in four NCATs in a military sample are consistent with reliabilities reported in the literature and are lower than desired for clinical decision-making.	[Cole, Wesley R.; Arrieux, Jacques P.; Lewis, Steven C.] Womack Army Med Ctr, Ft Bragg, NC 28310 USA; [Cole, Wesley R.; Arrieux, Jacques P.; Lewis, Steven C.] DVBIC, Ft Bragg, NC USA; [Schwab, Karen; Ivins, Brian J.; Qashu, Felicia M.] DVBIC, Silver Spring, MD USA	Cole, WR (corresponding author), Womack Army Med Ctr, Dept Brain Injury Med, Ft Bragg, NC 28310 USA.	wesley.r.cole.ctr@mail.mil			Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Henry M. Jacskon Foundation; Womack Army Medical Center	This research was supported by the Defense and Veterans Brain Injury Center and conducted with the oversight and support of the Henry M. Jacskon Foundation and Womack Army Medical Center.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Department of Defence, 2012, DOD POL GUID MAN MIL; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Eonta SE, 2011, AVIAT SPACE ENVIR MD, V82, P34, DOI 10.3357/ASEM.2799.2011; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri C Thomas, 2005, Am J Alzheimers Dis Other Demen, V20, P359; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Leposavic I, 2010, PSYCHIAT DANUB, V22, P149; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Marx RG, 2003, J CLIN EPIDEMIOL, V56, P730, DOI 10.1016/S0895-4356(03)00084-2; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P435, DOI 10.1080/13803395.2012.667790; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Moritz S, 2003, APPL NEUROPSYCHOL, V10, P115, DOI 10.1207/S15324826AN1002_07; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; US Army Traumatic Brain Injury Task Force, 2007, REP SURG GEN	42	80	80	0	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2013	28	7					732	742		10.1093/arclin/act040			11	Psychology, Clinical; Psychology	Psychology	243AS	WOS:000326289300011	23819991	Bronze, Green Published			2021-06-18	
J	Saha, B; Peron, S; Murray, K; Jaber, M; Gaillard, A				Saha, Bhaskar; Peron, Sophie; Murray, Kerren; Jaber, Mohamed; Gaillard, Afsaneh			Cortical lesion stimulates adult subventricular zone neural progenitor cell proliferation and migration to the site of injury	STEM CELL RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; STEM-CELLS; NEURONAL MIGRATION; NEUROBLAST MIGRATION; NEUROTROPHIC FACTOR; DIRECTED MIGRATION; CEREBRAL-CORTEX; VASCULAR NICHE; BLOOD-VESSELS; NEUROGENESIS	The subventricular zone (SVZ) is the principal neurogenic niche present in the adult non-human mammalian brain. Neurons generated in the SVZ migrate along the rostral migratory stream to reach the olfactory bulb. Brain injuries stimulate SVZ neurogenesis and direct migration of new progenitors to the sites of injury. To date, cortical injury-induced adult SVZ neurogenesis in mice remains ambiguous and migration of neural progenitors to the site of injury has not been studied in detail. Here we report that aspiration lesion in the motor cortex induces a transient, but significant increase in the proliferation as well as neurogenesis in the SVZ. New neural progenitors migrate ectopically to the injured area with the assistance of blood vessels and reactive astrocytes. The SVZ origin of these progenitors was further confirmed using lentiviral transduction. In addition, we show that astrocyte-assisted ectopic migration is regulated by CXCR4/SDF-1 signaling pathway. Finally, upon reaching the lesion area, these progenitors differentiate mainly into glial cells and, to a lesser extent, mature neurons. These data provide a detailed account of the changes occurring in the SVZ and the cortex following lesion, and indicate the potential of the endogenous neural progenitors in cortical repair. (C) 2013 Elsevier B.V. All rights reserved.	[Saha, Bhaskar; Peron, Sophie; Jaber, Mohamed; Gaillard, Afsaneh] INSERM, U1084, F-86022 Poitiers, France; [Saha, Bhaskar; Peron, Sophie; Jaber, Mohamed; Gaillard, Afsaneh] Univ Poitiers, F-86022 Poitiers, France; [Murray, Kerren] Inst Pasteur, Migrat & Canc Unit, F-75724 Paris 15, France	Gaillard, A (corresponding author), Univ Poitiers, Expt & Clin Neurosci Lab, INSERM, U1084, Bldg B36,1 Rue Georges Bonnet,BP 633, F-86022 Poitiers, France.	Afsaneh.Gaillard@univ-poitiers.fr		Jaber, Mohamed/0000-0003-2536-1913; Peron, Sophie/0000-0002-7167-4585	Institut de Recherche sur la Moelle epiniere et sur l'Encephale (IRME); Agence Nationale de La RechercheFrench National Research Agency (ANR)European Commission [ANR-09-MNPS-027-01]; FEDEREuropean Commission [33552]; CPER; ANRFrench National Research Agency (ANR)	This work was funded by grants from the Institut de Recherche sur la Moelle epiniere et sur l'Encephale (IRME), and the Agence Nationale de La Recherche ANR-09-MNPS-027-01 (to A.G); FEDER No 33552 and the CPER 5. B.S. is a postdoctoral fellow of ANR. We thank Dr. Andre Goffinet for Reelin antibody, M. Francheteau for technical assistance and staffs of Image'UP platform (University of Poitiers).	ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bagri A, 2002, DEVELOPMENT, V129, P4249; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Bergmann O, 2012, NEURON, V74, P634, DOI 10.1016/j.neuron.2012.03.030; Blizzard CA, 2011, CEREB CORTEX, V21, P281, DOI 10.1093/cercor/bhq091; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Carbonell WS, 2005, J NEUROSCI, V25, P7040, DOI 10.1523/JNEUROSCI.5171-04.2005; Chazal G, 2000, J NEUROSCI, V20, P1446; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Consiglio A, 2004, P NATL ACAD SCI USA, V101, P14835, DOI 10.1073/pnas.0404180101; Courtes S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020430; Decressac M, 2010, EXP NEUROL, V226, P24, DOI 10.1016/j.expneurol.2010.07.022; Dizon MLV, 2006, NEUROSCIENCE, V142, P717, DOI 10.1016/j.neuroscience.2006.06.050; Doetsch F, 1997, J NEUROSCI, V17, P5046; Faiz M, 2008, MOL CELL NEUROSCI, V38, P170, DOI 10.1016/j.mcn.2008.02.002; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gaillard A, 1998, ADV ANAT EMBRYOL CEL, V148, P1; Gaillard A, 2008, M S-MED SCI, V24, P132, DOI 10.1051/medsci/2008242132; Gaillard A, 2007, NAT NEUROSCI, V10, P1294, DOI 10.1038/nn1970; Gaillard A, 2007, CELL ADHES MIGR, V1, P161, DOI 10.4161/cam.1.4.5274; Goings GE, 2002, NEUROSCI LETT, V329, P161, DOI 10.1016/S0304-3940(02)00611-0; GOMEZPINILLA F, 1992, NEUROSCIENCE, V49, P771, DOI 10.1016/0306-4522(92)90355-6; Grubb MS, 2008, J NEUROSCI, V28, P2919, DOI 10.1523/JNEUROSCI.5550-07.2008; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jablonska B, 2010, NAT NEUROSCI, V13, P541, DOI 10.1038/nn.2536; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Kokovay E, 2010, CELL STEM CELL, V7, P163, DOI 10.1016/j.stem.2010.05.019; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Macas J, 2006, J NEUROSCI, V26, P13114, DOI 10.1523/JNEUROSCI.4667-06.2006; Magavi SS, 2000, NATURE, V405, P951; Marti-Fabregas J, 2010, NEUROLOGY, V74, P357, DOI 10.1212/WNL.0b013e3181cbccec; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; Ohtani Y, 1998, NEUROSCI LETT, V249, P163, DOI 10.1016/S0304-3940(98)00425-X; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rodriguez JJ, 2009, NEUROREPORT, V20, P907, DOI 10.1097/WNR.0b013e32832be77d; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; SAHA B, 2012, FRONT CELL NEUROSCI, V0006; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Seidenfaden R, 2006, MOL CELL NEUROSCI, V32, P187, DOI 10.1016/j.mcn.2006.04.003; Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026; Sirko S, 2009, BRAIN, V132, P2252, DOI 10.1093/brain/awp043; Snapyan M, 2009, J NEUROSCI, V29, P4172, DOI 10.1523/JNEUROSCI.4956-08.2009; Stumm R, 2007, J MOL ENDOCRINOL, V38, P377, DOI 10.1677/JME-06-0032; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; Wang CM, 2011, CELL RES, V21, P1534, DOI 10.1038/cr.2011.83; Whitman MC, 2009, J COMP NEUROL, V516, P94, DOI 10.1002/cne.22093; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579; Zhu Y, 2009, DEVELOPMENT, V136, P1919, DOI 10.1242/dev.032276	62	80	85	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1873-5061	1876-7753		STEM CELL RES	Stem Cell Res.	NOV	2013	11	3					965	977		10.1016/j.scr.2013.06.006			13	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology	Cell Biology; Biotechnology & Applied Microbiology	264UA	WOS:000327905300001	23900166				2021-06-18	
J	Arndt, DH; Lerner, JT; Matsumoto, JH; Madikians, A; Yudovin, S; Valino, H; McArthur, DL; Wu, JY; Leung, M; Buxey, F; Szeliga, C; Van Hirtum-Das, M; Sankar, R; Brooks-Kayal, A; Giza, CC				Arndt, Daniel H.; Lerner, Jason T.; Matsumoto, Joyce H.; Madikians, Andranik; Yudovin, Sue; Valino, Hannah; McArthur, David L.; Wu, Joyce Y.; Leung, Michelle; Buxey, Farzad; Szeliga, Conrad; Van Hirtum-Das, Michele; Sankar, Raman; Brooks-Kayal, Amy; Giza, Christopher C.			Subclinical early posttraumatic seizures detected by continuous EEG monitoring in a consecutive pediatric cohort	EPILEPSIA			English	Article						Clinical neurophysiology; Children; Epilepsy; ICU	TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; CRITICALLY-ILL CHILDREN; HEAD-INJURY; NONCONVULSIVE SEIZURES; EPILEPTIFORM ACTIVITY; VIDEO-EEG; EPILEPSY; PREDICTORS; PREVENTION	PurposeTraumatic brain injury (TBI) is an important cause of morbidity and mortality in children, and early posttraumatic seizures (EPTS) are a contributing factor to ongoing acute damage. Continuous video-EEG monitoring (cEEG) was utilized to assess the burden of clinical and electrographic EPTS. MethodsEighty-seven consecutive, unselected (mild - severe), acute TBI patients requiring pediatric intensive care unit (PICU) admission at two academic centers were monitored prospectively with cEEG per established clinical TBI protocols. Clinical and subclinical seizures and status epilepticus (SE, clinical and subclinical) were assessed for their relation to clinical risk factors and short-term outcome measures. Key FindingsOf all patients, 42.5% (37/87) had seizures. Younger age (p=0.002) and injury mechanism (abusive head trauma - AHT, p<0.001) were significant risk factors. Subclinical seizures occurred in 16.1% (14/87), while 6.9% (6/87) had only subclinical seizures. Risk factors for subclinical seizures included younger age (p<0.001), AHT (p<0.001), and intraaxial bleed (p<0.001). SE occurred in 18.4% (16/87) with risk factors including younger age (p<0.001), AHT (p<0.001), and intraaxial bleed (p=0.002). Subclinical SE was detected in 13.8% (12/87) with significant risk factors including younger age (p<0.001), AHT (p=0.001), and intraaxial bleed (p=0.004). Subclinical seizures were associated with lower discharge King's Outcome Scale for Childhood Head Injury (KOSCHI) score (p=0.002). SE and subclinical SE were associated with increased hospital length of stay (p=0.017 and p=0.041, respectively) and lower hospital discharge KOSCHI (p=0.007 and p=0.040, respectively). SignificancecEEG monitoring significantly improves detection of seizures/SE and is the only way to detect subclinical seizures/SE. cEEG may be indicated after pediatric TBI, particularly in younger children, AHT cases, and those with intraaxial blood on computerized tomography (CT).	[Arndt, Daniel H.] Oakland Univ, Beaumont Childrens Hosp, Dept Pediat & Adult Neurol, Royal Oak, MI USA; [Lerner, Jason T.; Matsumoto, Joyce H.; Yudovin, Sue; Wu, Joyce Y.; Szeliga, Conrad; Sankar, Raman; Giza, Christopher C.] Univ Calif Los Angeles, Dept Pediat, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90024 USA; [Lerner, Jason T.; Matsumoto, Joyce H.; Yudovin, Sue; Valino, Hannah; McArthur, David L.; Wu, Joyce Y.; Leung, Michelle; Buxey, Farzad; Sankar, Raman; Giza, Christopher C.] UCLA Brain Injury Res Ctr, Los Angeles, CA USA; [Madikians, Andranik] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Pediat Crit Care, Los Angeles, CA USA; [Valino, Hannah; McArthur, David L.; Leung, Michelle; Buxey, Farzad; Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Van Hirtum-Das, Michele] Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90027 USA; [Brooks-Kayal, Amy] Childrens Hosp Colorado, Div Pediat Neurol, Aurora, CO USA; [Brooks-Kayal, Amy] Univ Colorado, Dept Pediat Neurol & Pharmacol Sci, Aurora, CO USA; [Giza, Christopher C.] Univ Calif Los Angeles, Interdept Program Neurosci, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, Interdept Program Biomed Engn, Los Angeles, CA USA	Lerner, JT (corresponding author), 10833 Le Conte,22-474 MDCC, Los Angeles, CA 90095 USA.	jlerner@mednet.ucla.edu			Thrasher Research Foundation; National Epifellows Foundation; Child Neurology Foundation/Winokur Family Foundation; Epilepsy Foundation of America; Today's and Tomorrow's Children Fund; UCLA Brain Injury Research Center [NS 058489]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013642] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL073980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R34MH089299, R21MH079933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS051637, R01NS051710, P01NS058489, P20NS080199] Funding Source: NIH RePORTER	We thank the following people for their roles in supporting this project: Susan Koh, MD, Pramote Laoprasert, MD, Kelly Knupp, MD, Kristen Park, MD, Mark Tripputi, PhD, Christine Thompson; and EEG technologists: Andrea Duran, Jimmy Nguyen, Bereket Habibda, Pat Oliver, and Sy Turner. Funding was supported primarily by a grant from the Thrasher Research Foundation. Support for D.H.A. was primarily through the National Epifellows Foundation. Additional support from the Child Neurology Foundation/Winokur Family Foundation, Epilepsy Foundation of America, Today's and Tomorrow's Children Fund, and UCLA Brain Injury Research Center (NS 058489) was also greatly appreciated.	Abend NS, 2011, J CLIN NEUROPHYSIOL, V28, P15, DOI 10.1097/WNP.0b013e3182051123; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Barto K., 2012, MUMIN MULTIMODEL INF; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Burnham K.P., 2010, MODEL SELECTION MULT, VSecond edition; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Goldstein JL, 2011, NEUROCRIT CARE, V15, P63, DOI 10.1007/s12028-010-9468-5; Hahn CD, 2011, NEUROLOGY, V76, P1036, DOI 10.1212/WNL.0b013e318211c3dd; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HENDRICK EB, 1968, J TRAUM, V8, P547; JENNETT B, 1973, DEV MED CHILD NEUROL, V15, P56; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Kaindl AM, 2006, CELL MOL LIFE SCI, V63, P399, DOI 10.1007/s00018-005-5348-0; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Maas A, 2011, LANCET NEUROL, V10, P111, DOI 10.1016/S1474-4422(10)70312-4; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Olney JW, 2004, TRENDS PHARMACOL SCI, V25, P135, DOI 10.1016/j.tips.2004.01.002; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; PAGNI CA, 1990, ACT NEUR S, V50, P38; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saengpattrachai M, 2006, EPILEPSIA, V47, P1510, DOI 10.1111/j.1528-1167.2006.00624.x; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wilcox R., 2012, INTRO ROBUST ESTIMAT, V1st; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; WILLMORE LJ, 1978, BRAIN RES, V152, P406, DOI 10.1016/0006-8993(78)90273-1; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	45	80	85	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	OCT	2013	54	10					1780	1788		10.1111/epi.12369			9	Clinical Neurology	Neurosciences & Neurology	227UU	WOS:000325141500011	24032982	Green Accepted			2021-06-18	
J	Monti, JM; Voss, MW; Pence, A; McAuley, E; Kramer, AF; Cohen, NJ				Monti, Jim M.; Voss, Michelle W.; Pence, Ari; McAuley, Edward; Kramer, Arthur F.; Cohen, Neal J.			History of mild traumatic brain injury is associated with deficits in relational memory, reduced hippocampal volume, and less neural activity later in life	FRONTIERS IN AGING NEUROSCIENCE			English	Article						mTBI; hippocampus; aging; relational memory; fMRI	SYNAPTIC PLASTICITY; COGNITIVE DECLINE; EPISODIC MEMORY; DEFAULT NETWORK; OLDER-ADULTS; HEAD-INJURY; AMNESIA; CORTEX; NEUROPATHOLOGY; SEGMENTATION	Evidence suggests that a history of head trauma is associated with memory deficits later in life. The majority of previous research has focused on moderate-to-severe traumatic brain injury (TBI), but recent evidence suggests that even a mild TBI (mTBI) can interact with the aging process and produce reductions in memory performance. This study examined the association of mTBI with memory and the brain by comparing young and middle-aged adults who have had mTBI in their recent (several years ago) and remote (several decades ago) past, respectively, with control subjects on a face-scene relational memory paradigm while they underwent functional magnetic resonance imaging (fMRI). Hippocampal volumes were also examined from high-resolution structural images. Results indicated middle-aged adults with a head injury in their remote past had impaired memory compared to gender, age, and education matched control participants, consistent with previous results in the study of memory, aging, and TBI. The present findings extended previous results by demonstrating that these individuals also had smaller bilateral hippocampi, and had reduced neural activity during memory performance in cortical regions important for memory retrieval. These results indicate that a history of mTBI may be one of the many factors that negatively influence cognitive and brain health in aging.	[Monti, Jim M.; Kramer, Arthur F.; Cohen, Neal J.] Univ Illinois, Dept Psychol, Champaign, IL USA; [Monti, Jim M.; Pence, Ari; McAuley, Edward; Kramer, Arthur F.; Cohen, Neal J.] Univ Illinois, Beckman Inst, Urbana, IL 61801 USA; [Voss, Michelle W.] Univ Iowa, Dept Psychol, Iowa City, IA USA; [McAuley, Edward] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Kramer, Arthur F.; Cohen, Neal J.] Univ Illinois, Neurosci Program, Urbana, IL 61801 USA	Monti, JM (corresponding author), Univ Illinois, Beckman Inst, 405 N Mathews Ave, Urbana, IL 61801 USA.	monti@illinois.edu	Kramer, Arthur/AAB-2937-2019	Kramer, Arthur/0000-0001-5870-2724	Health and Wellness Initiative from the College of Applied Health Sciences at the University of Illinois at Urbana-Champaign; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH062500] Funding Source: NIH RePORTER	This work was supported by funds from a Health and Wellness Initiative from the College of Applied Health Sciences at the University of Illinois at Urbana-Champaign. We thank Steve Broglio for his involvement in an earlier stage of this project, Rebecca Delgado for her assistance intesting participants, and Nancy Dodge and Holly Tracy for assisting in the imaging sessions.	Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Bennett DA, 2012, ANN NEUROL, V72, P599, DOI 10.1002/ana.23654; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bohbot VD, 1998, NEUROPSYCHOLOGIA, V36, P1217, DOI 10.1016/S0028-3932(97)00161-9; Buckner RL, 2004, NEUROIMAGE, V23, P724, DOI 10.1016/j.neuroimage.2004.06.018; Cabeza R, 2008, NAT REV NEUROSCI, V9, P613, DOI 10.1038/nrn2459; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Cohen N.J., 2001, CONDITIONING CONSCIO; Cohen N.J., 1993, MEMORY AMNESIA HIPPO; Cohen NJ, 1999, HIPPOCAMPUS, V9, P83, DOI 10.1002/(SICI)1098-1063(1999)9:1<83::AID-HIPO9>3.0.CO;2-7; CORKIN S, 1989, J NEUROSCI, V9, P3876; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dobbins IG, 2002, NEURON, V35, P989, DOI 10.1016/S0896-6273(02)00858-9; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Erickson KI, 2009, HIPPOCAMPUS, V19, P1030, DOI 10.1002/hipo.20547; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fjell AM, 2013, NEUROBIOL AGING, V34, P2239, DOI 10.1016/j.neurobiolaging.2013.04.006; Foster TC, 2007, AGING CELL, V6, P319, DOI 10.1111/j.1474-9726.2007.00283.x; Fotuhi M, 2009, NAT REV NEUROL, V5, P649, DOI 10.1038/nrneurol.2009.175; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guillozet AL, 2003, ARCH NEUROL-CHICAGO, V60, P729, DOI 10.1001/archneur.60.5.729; Hannula DE, 2006, J NEUROSCI, V26, P8352, DOI 10.1523/JNEUROSCI.5222-05.2006; Hannula DE, 2007, J COGNITIVE NEUROSCI, V19, P1690, DOI 10.1162/jocn.2007.19.10.1690; Head D, 2008, NEUROPSYCHOLOGY, V22, P491, DOI 10.1037/0894-4105.22.4.491; Hirni DI, 2013, NEUROPSYCHOLOGIA, V51, P930, DOI 10.1016/j.neuropsychologia.2013.01.013; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Jagust W, 2013, NEURON, V77, P219, DOI 10.1016/j.neuron.2013.01.002; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy KM, 2012, NEUROIMAGE, V62, P1, DOI 10.1016/j.neuroimage.2012.03.077; Kobayashi Y, 2003, J COMP NEUROL, V466, P48, DOI 10.1002/cne.10883; Konkel A, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.015.2008; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mesulam M. M., 2000, PRINCIPLES BEHAV COG, P439; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Morey RA, 2009, NEUROIMAGE, V45, P855, DOI 10.1016/j.neuroimage.2008.12.033; Noble KG, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00307; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Price JL, 2009, NEUROBIOL AGING, V30, P1026, DOI 10.1016/j.neurobiolaging.2009.04.002; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Raz N, 2010, NEUROIMAGE, V51, P501, DOI 10.1016/j.neuroimage.2010.03.020; Rentz DM, 2011, NEUROPSYCHOLOGIA, V49, P2776, DOI 10.1016/j.neuropsychologia.2011.06.006; Rockland KS, 1999, CEREB CORTEX, V9, P232, DOI 10.1093/cercor/9.3.232; Ryan JD, 2000, PSYCHOL SCI, V11, P454, DOI 10.1111/1467-9280.00288; Serrano F, 2004, AGEING RES REV, V3, P431, DOI 10.1016/j.arr.2004.05.002; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Small SA, 2011, NAT REV NEUROSCI, V12, P585, DOI 10.1038/nrn3085; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Sperling RA, 2009, NEURON, V63, P178, DOI 10.1016/j.neuron.2009.07.003; Staresina BP, 2009, NEURON, V63, P267, DOI 10.1016/j.neuron.2009.06.024; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wagner AD, 2005, TRENDS COGN SCI, V9, P445, DOI 10.1016/j.tics.2005.07.001; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Watson PD, 2013, HIPPOCAMPUS, V23, P570, DOI 10.1002/hipo.22115; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313	67	80	81	0	23	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	AUG 22	2013	5								41	10.3389/fnagi.2013.00041			9	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	206JF	WOS:000323515400001	23986698	DOAJ Gold, Green Published			2021-06-18	
J	Shultz, SR; Cardamone, L; Liu, YR; Hogan, RE; Maccotta, L; Wright, DK; Zheng, P; Koe, A; Gregoire, MC; Williams, JP; Hicks, RJ; Jones, NC; Myers, DE; O'Brien, TJ; Bouilleret, V				Shultz, Sandy R.; Cardamone, Lisa; Liu, Ying R.; Hogan, R. Edward; Maccotta, Luigi; Wright, David K.; Zheng, Ping; Koe, Amelia; Gregoire, Marie-Claude; Williams, John P.; Hicks, Rodney J.; Jones, Nigel C.; Myers, Damian E.; O'Brien, Terence J.; Bouilleret, Viviane			Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?	EPILEPSIA			English	Article						Posttraumatic epilepsy; Lateral fluid percussion injury; MRI; PET; Epileptogenesis	LATE POSTTRAUMATIC SEIZURES; MODEL; MRI; ANXIETY; HIPPOCAMPUS; BEHAVIOR; RISK	Purpose: Posttraumatic epilepsy (PTE) occurs in a proportion of traumatic brain injury (TBI) cases, significantly compounding the disability, and risk of injury and death for sufferers. To date, predictive biomarkers for PTE have not been identified. This study used the lateral fluid percussion injury (LFPI) rat model of TBI to investigate whether structural, functional, and behavioral changes post-TBI relate to the later development of PTE. Methods: Adult male Wistar rats underwent LFPI or sham injury. Serial magnetic resonance (MR) and positron emission tomography (PET) imaging, and behavioral analyses were performed over 6 months postinjury. Rats were then implanted with recording electrodes and monitored for two consecutive weeks using video-electroencephalography (EEG) to assess for PTE. Of the LFPI rats, 52% (n = 12) displayed spontaneous recurring seizures and/or epileptic discharges on the video-EEG recordings. Key Findings: MRI volumetric and signal analysis of changes in cortex, hippocampus, thalamus, and amygdala, F-18-fluorodeoxyglucose (FDG)-PET analysis of metabolic function, and behavioral analysis of cognitive and emotional changes, at 1 week, and 1, 3, and 6 months post-LFPI, all failed to identify significant differences on univariate analysis between the epileptic and nonepileptic groups. However, hippocampal surface shape analysis using large-deformation high-dimensional mapping identified significant changes in the ipsilateral hippocampus at 1 week postinjury relative to baseline that differed between rats that would go onto become epileptic versus those who did not. Furthermore, a multivariate logistic regression model that incorporated the 1 week, and 1 and 3 month F-18-FDG PET parameters from the ipsilateral hippocampus was able to correctly predict the epileptic outcome in all of the LFPI cases. As such, these subtle changes in the ipsilateral hippocampus at acute phases after LFPI may be related to PTE and require further examination. Significance: These findings suggest that PTE may be independent of major structural, functional, and behavioral changes induced by TBI, and suggest that more subtle abnormalities are likely involved. However, there are limitations associated with studying acquired epilepsies in animal models that must be considered when interpreting these results, in particular the failure to detect differences between the groups may be related to the limitations of properly identifying/separating the epileptic and nonepileptic animals into the correct group.	[Shultz, Sandy R.; Cardamone, Lisa; Liu, Ying R.; Zheng, Ping; Koe, Amelia; Jones, Nigel C.; Myers, Damian E.; O'Brien, Terence J.; Bouilleret, Viviane] Univ Melbourne, Dept Med RMH, Parkville, Vic 3050, Australia; [Hogan, R. Edward; Maccotta, Luigi] Washington Univ, Dept Neurol, St Louis, MO USA; [Wright, David K.; Williams, John P.] Florey Inst Neurosci & Mental Hlth, Small Anim MRI Facil, Parkville, Vic, Australia; [Gregoire, Marie-Claude] Australian Nucl Sci & Technol Org, Kirrawee, NSW, Australia; [Hicks, Rodney J.] Peter MacCallum Canc Ctr, Ctr Mol Imaging, Melbourne, Vic, Australia; [Bouilleret, Viviane] CHU Bicetre, APHP, Dept Neurophysiol & Epilepsy, Paris, France	Shultz, SR (corresponding author), Univ Melbourne, Dept Med RMH, 4th Floor Clin Sci Bldg, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au	Myers, Damian E/L-5302-2013; O'Brien, Terence J/L-8102-2013; Bouilleret, viviane/AAQ-5878-2021	Hicks, Rodney/0000-0002-0758-0824; Shultz, Sandy/0000-0002-2525-8775; Maccotta, Luigi/0000-0003-3702-0331; Wright, David/0000-0002-7535-8651; Jones, Nigel/0000-0002-1080-8439; Myers, Damian/0000-0002-7569-9907; O'Brien, Terence/0000-0002-7198-8621; Hogan, Robert/0000-0003-2272-5005	Victorian Government Transport Accident Commission [DP0023]; NHMRC of AustraliaNational Health and Medical Research Council of Australia; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000450, UL1TR000448] Funding Source: NIH RePORTER	We wish to acknowledge the staff of the Howard Florey Institute Small Animal MRI Facility, and the Peter MacCallum Cancer Centre. Funding for this project was provided by the Victorian Government Transport Accident Commission (DP0023). N.J. and T.O. acknowledge the financial support of the NHMRC of Australia.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Beyenburg S, 2005, EPILEPSY BEHAV, V7, P161, DOI 10.1016/j.yebeh.2005.05.014; Bouilleret V, 2011, J MAGN RESON IMAGING, V34, P774, DOI 10.1002/jmri.22669; Bouilleret V, 2009, NEUROIMAGE, V45, P267, DOI 10.1016/j.neuroimage.2008.12.019; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Casteels C, 2006, J NUCL MED, V47, P1858; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Csernansky JG, 1998, P NATL ACAD SCI USA, V95, P11406, DOI 10.1073/pnas.95.19.11406; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio RD, 2005, BRAIN, V132, P2805; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Dudek FE, 2010, EPILEPSY CURR, V10, P91, DOI 10.1111/j.1535-7511.2010.01368.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gardner R, 2005, CLIN ANAT, V18, P481, DOI 10.1002/ca.20183; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Golarai G, 2001, J NEUROSCI, V21, P8523; Hogan RE, 2008, J NEUROL NEUROSUR PS, V79, P636, DOI 10.1136/jnnp.2007.123406; Hogan RE, 2009, J MAGN RESON IMAGING, V29, P1027, DOI 10.1002/jmri.21766; Hogan RE, 2004, BRAIN, V127, P1731, DOI 10.1093/brain/awh197; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Jones NC, 2009, BEHAV BRAIN RES, V203, P81, DOI 10.1016/j.bbr.2009.04.023; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jupp B, 2012, EPILEPSIA, V53, P1233, DOI 10.1111/j.1528-1167.2012.03525.x; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Li HF, 2011, NEUROSCI LETT, V497, P172, DOI 10.1016/j.neulet.2011.02.042; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mishra AM, 2011, NEUROSCI LETT, V497, P194, DOI 10.1016/j.neulet.2011.01.076; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Posener JA, 2003, AM J PSYCHIAT, V160, P83, DOI 10.1176/appi.ajp.160.1.83; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Snyder A. Z., 1996, QUANTIFICATION BRAIN, P131, DOI DOI 10.1016/B978-012389760-2/50028-1; Stroud LM, 2005, BRAIN RES, V1033, P151, DOI 10.1016/j.brainres.2004.11.022; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; van Raay L, 2009, J NEUROSCI METH, V179, P184, DOI 10.1016/j.jneumeth.2009.01.024; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358	53	80	81	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUL	2013	54	7					1240	1250		10.1111/epi.12223			11	Clinical Neurology	Neurosciences & Neurology	173VP	WOS:000321110100013	23718645	Bronze, Green Accepted			2021-06-18	
J	McCauley, SR; Wilde, EA; Miller, ER; Frisby, ML; Garza, HM; Varghese, R; Levin, HS; Robertson, CS; McCarthy, JJ				McCauley, Stephen R.; Wilde, Elisabeth A.; Miller, Emmy R.; Frisby, Melissa L.; Garza, Hector M.; Varghese, Reni; Levin, Harvey S.; Robertson, Claudia S.; McCarthy, James J.			Preinjury Resilience and Mood as Predictors of Early Outcome following Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						anxiety; mood; outcome; postconcussion symptoms; resilience; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; COMPREHENSIVE-SOLDIER-FITNESS; OPERATIONS ENDURING FREEDOM; EMOTIONAL RISK-FACTORS; MINOR HEAD-INJURY; DSM-IV CRITERIA; POSTCONCUSSIONAL DISORDER; PSYCHOLOGICAL-RESILIENCE; PSYCHOMETRIC PROPERTIES	There is significant heterogeneity in outcomes following mild traumatic brain injury (mTBI). While several host factors (age, gender, and preinjury psychiatric history) have been investigated, the influence of preinjury psychological resilience and mood status in conjunction with mild TBI remains relatively unexplored. Euthymic mood and high resilience are potentially protective against anxiety and postconcussion symptoms, but their relative contributions are currently unknown. This prospective study obtained preinjury estimates of resilience and mood measures in addition to measures of anxiety (Acute Stress Disorder Scale and PTSD-Checklist-Civilian form) and postconcussion symptom severity (Rivermead Post Concussion Symptoms Questionnaire) < 24 hours (Baseline), 1 week, and 1 month postinjury in patients with either mTBI (n = 46) or a comparison group with orthopedic injuries not involving the head (OI, n = 29). The groups did not differ on preinjury resilience or mood status at baseline, but differed significantly on measures of anxiety and postconcussion symptom severity at each subsequent study occasion. Multivariate linear regression analyses were conducted to determine if preinjury resilience and mood were significant contributors to anxiety and postconcussion symptoms during the first month postinjury after accounting for other known host factors (e. g., age at injury, gender, and education). Injury group and preinjury mood status were significant predictors for all three dependent variables at each study occasion (all p < 0.007). Preinjury resilience showed a positive trend only for acute stress severity at baseline, but demonstrated significant prediction of all three dependent measures at one week and one month postinjury. These results suggest that preinjury depressed mood and resilience are significant contributors to the severity of postinjury anxiety and postconcussion symptoms, even after accounting for effects of other specific host factors.	[McCauley, Stephen R.; Wilde, Elisabeth A.; Frisby, Melissa L.; Garza, Hector M.; Varghese, Reni; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Frisby, Melissa L.; Garza, Hector M.; Varghese, Reni; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Pediat Radiol, Houston, TX 77030 USA; [Miller, Emmy R.; Levin, Harvey S.; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [McCarthy, James J.] Univ Texas Houston, Sch Med, Dept Emergency Med, Houston, TX USA; [McCarthy, James J.] Mem Hermann Hosp, Dept Emergency Med, Houston, TX USA	McCauley, SR (corresponding author), Baylor Coll Med, Dept Neurol, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	mccauley@bcm.edu			Congressionally Directed Medical Research ProgramsUnited States Department of Defense [W81XWH-08-2-0131, W81XWH-08-0132, W81XWH-08-2-0133]; Department of DefenseUnited States Department of Defense	We sincerely thank the participants for their interest and willingness to take part in this research. This work was supported by W81XWH-08-2-0131 (McCarthy-PI), W81XWH-08-0132 (Robertson-PI), and W81XWH-08-2-0133 (Levin-PI) from the Congressionally Directed Medical Research Programs and the Department of Defense. The information in this article and the article itself have never been published either electronically or in print. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Defense.	Adler AB, 2009, MIL MED, V174, P21, DOI 10.7205/MILMED-D-00-2208; Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Assistant Secretary of Defense for Health Affairs, 2007, HLTH AFF MEM OCT 1 2; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bohn M.J., 1991, PROBLEMS DRUG DEPEND, V119, P233, DOI DOI 10.1037/E496152006-001; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; BRESLAU N, 1995, AM J PSYCHIAT, V152, P529; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casey GW, 2011, AM PSYCHOL, V66, P1, DOI 10.1037/a0021930; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Cornum R, 2011, AM PSYCHOL, V66, P4, DOI 10.1037/a0021420; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Dickstein BD, 2010, MIL MED, V175, P482, DOI 10.7205/MILMED-D-09-00178; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Dolan CA, 2006, MIL MED, V171, P93, DOI 10.7205/MILMED.171.2.93; EVANS RW, 1992, NEUROL CLIN, V10, P815; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Frappell-Cooke W, 2010, OCCUP MED-OXFORD, V60, P645, DOI 10.1093/occmed/kqq149; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Green KT, 2010, J CLIN PSYCHIAT, V71, P823, DOI 10.4088/JCP.09m05780blu; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iversen AC, 2008, PSYCHOL MED, V38, P511, DOI 10.1017/S0033291708002778; Iversen AC, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-68; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; KOBASA SC, 1979, J PERS SOC PSYCHOL, V37, P1, DOI 10.1037/0022-3514.37.1.1; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kozlovsky N, 2008, EUR NEUROPSYCHOPHARM, V18, P107, DOI 10.1016/j.euroneuro.2007.04.009; Kremen WS, 2007, ARCH GEN PSYCHIAT, V64, P361, DOI 10.1001/archpsyc.64.3.361; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; Lester PB, 2011, AM PSYCHOL, V66, P77, DOI 10.1037/a0022083; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lyons JA., 1991, J TRAUMA STRESS, V4, P93, DOI [DOI 10.1007/BF00976011, 10.1002/jts.2490040108, DOI 10.1002/JTS.2490040108]; Maguen S, 2008, MIL MED, V173, P1; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI 10.1023/A:1011157800050; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Miller L, 2001, NEUROREHABILITATION, V16, P109; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Parker RS, 2002, NEUROREHABILITATION, V17, P131; Phillips CJ, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-52; Pietrzak RH, 2011, J AFFECT DISORDERS, V133, P560, DOI 10.1016/j.jad.2011.04.028; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Polusny MA, 2011, PSYCHOL MED, V41, P687, DOI 10.1017/S0033291710002047; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Reivich KJ, 2011, AM PSYCHOL, V66, P25, DOI 10.1037/a0021897; Richardson JD, 2007, CAN J PSYCHIAT, V52, P510, DOI 10.1177/070674370705200809; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUSSELL RW, 1971, TRAUMATIC AMNESIAS; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTTER M, 1985, BRIT J PSYCHIAT, V147, P598, DOI 10.1192/bjp.147.6.598; Sandweiss DA, 2011, ARCH GEN PSYCHIAT, V68, P496, DOI 10.1001/archgenpsychiatry.2011.44; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Sbordone RJ, 2010, PSYCHOL INJ LAW, V3, P63, DOI 10.1007/s12207-010-9066-z; Scherrer JF, 2008, COMPR PSYCHIAT, V49, P297, DOI 10.1016/j.comppsych.2007.11.001; Schok ML, 2010, AGING MENT HEALTH, V14, P328, DOI 10.1080/13607860903228812; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Seligman MEP, 2011, AM PSYCHOL, V66, P82, DOI 10.1037/a0021898; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Slick D., 1997, VICTORIA SYMPTOM VAL; Smith TC, 2008, EPIDEMIOLOGY, V19, P505, DOI 10.1097/EDE.0b013e31816a9dff; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sosin DM, 1996, BRAIN INJURY, V10, P47; STOGNER BL, 2000, DISS ABSTR INT B, V61, P550; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; TEASDALE G, 1974, LANCET, V2, P81; Tedeschi RG, 2011, AM PSYCHOL, V66, P19, DOI 10.1037/a0021896; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; van Zuiden M, 2011, AM J PSYCHIAT, V168, P89, DOI 10.1176/appi.ajp.2010.10050706; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Weathers F, 1993, 9 ANN CONV INT SOC T; Wells TS, 2011, INT REV PSYCHIATR, V23, P144, DOI 10.3109/09540261.2011.558833; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; World Health Organization, 1992, ICD 10 CLASS MENT BE; Young RM, 2002, ALCOHOL ALCOHOLISM, V37, P451, DOI 10.1093/alcalc/37.5.451; Yudko E, 2007, J SUBST ABUSE TREAT, V32, P189, DOI 10.1016/j.jsat.2006.08.002; Zlotnick C, 2001, AM J PSYCHIAT, V158, P1923, DOI 10.1176/appi.ajp.158.11.1923	132	80	82	0	31	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		642	652		10.1089/neu.2012.2393			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500006	23046394				2021-06-18	
J	Mayer, AR; Ling, JM; Yang, Z; Pena, A; Yeo, RA; Klimaj, S				Mayer, Andrew R.; Ling, Josef M.; Yang, Zhen; Pena, Amanda; Yeo, Ronald A.; Klimaj, Stefan			Diffusion Abnormalities in Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							AXONAL INJURY; HEAD-INJURY; COGNITIVE DEFICITS; CORPUS-CALLOSUM; CONCUSSION; CHILDREN; CHILDHOOD; RECOVERY; NEURODEGENERATION; NEUROPATHOLOGY	Pediatric mild traumatic brain injury (pmTBI) is the most prevalent neurological insult in children and is associated with both acute and chronic neurobehavioral sequelae. However, little is known about underlying pathophysiology and how injuries change as a function of recovery. Fractional anisotropy, axial diffusivity, and radial diffusivity were examined in 15 semi-acute pmTBI patients and 15 well-matched controls, with a subset of participants returning for a second visit. A novel analytic strategy was applied to capture spatially heterogeneous white matter injuries (lesions) in addition to standard analyses. Evidence of cognitive dysfunction after pmTBI was observed in the domains of attention (p = 0.02, d = -0.92) and processing speed (p = 0.05, d = -0.73) semi-acutely. Region of interest (ROI) and voxelwise analyses indicated increased anisotropic diffusion for pmTBI patients, with an elevated number of clusters with high anisotropy. Metrics of increased anisotropy were able to objectively classify pmTBI from healthy controls at 90% accuracy but were not associated with neuropsychological deficits. Little evidence of recovery in white matter abnormalities was observed over a 4-month interval in returning patients, indicating that physiological recovery may lag behind subjective reports of normality. Increased anisotropic diffusion has been previously linked with cytotoxic edema after TBI, and the magnitude and duration of these abnormalities appear to be greater in pediatric patients. Current findings suggest that developing white matter may be more susceptible to initial mechanical injury forces and that anisotropic diffusion provides an objective biomarker of pmTBI.	[Mayer, Andrew R.; Ling, Josef M.; Yang, Zhen; Pena, Amanda; Yeo, Ronald A.; Klimaj, Stefan] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87106 USA; [Mayer, Andrew R.; Yang, Zhen; Yeo, Ronald A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Lovelace Biomed & Environm Res Inst, Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	He, Hongbo/H-1815-2013; Klimaj, Stefan/AAV-4060-2020; He, Robert/L-9441-2013		Mind Research Network Grant (Department of Energy Grant) [DE-FG02-99ER62764]	This research was supported by the Mind Research Network Grant (Department of Energy Grant DE-FG02-99ER62764) (A.R.M.).	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Giza CC, 2006, INDIAN J NEUROTRAUM, V3, P19; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reynolds CR., 2004, BEHAV ASSESSMENT SYS, V2nd; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786; Sowell ER, 2002, DEV MED CHILD NEUROL, V44, P4, DOI 10.1017/S0012162201001591; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Storey P, 2007, MAGN RESON MED, V57, P614, DOI 10.1002/mrm.21132; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082	61	80	81	0	18	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC 12	2012	32	50					17961	17969		10.1523/JNEUROSCI.3379-12.2012			9	Neurosciences	Neurosciences & Neurology	055GY	WOS:000312404700004	23238712	Bronze, Green Published			2021-06-18	
J	Sundaramurthy, A; Alai, A; Ganpule, S; Holmberg, A; Plougonven, E; Chandra, N				Sundaramurthy, Aravind; Alai, Aaron; Ganpule, Shailesh; Holmberg, Aaron; Plougonven, Erwan; Chandra, Namas			Blast-Induced Biomechanical Loading of the Rat: An Experimental and Anatomically Accurate Computational Blast Injury Model	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; Finite element model; military injury; rat	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; INDUCED NEUROTRAUMA; SHOCK-WAVES; MECHANISMS; TUBE; OVERPRESSURE; RESPONSES; EXPOSURE; IMPACTS	Blast waves generated by improvised explosive devices (IEDs) cause traumatic brain injury (TBI) in soldiers and civilians. In vivo animal models that use shock tubes are extensively used in laboratories to simulate field conditions, to identify mechanisms of injury, and to develop injury thresholds. In this article, we place rats in different locations along the length of the shock tube (i.e., inside, outside, and near the exit), to examine the role of animal placement location (APL) in the biomechanical load experienced by the animal. We found that the biomechanical load on the brain and internal organs in the thoracic cavity (lungs and heart) varied significantly depending on the APL. When the specimen is positioned outside, organs in the thoracic cavity experience a higher pressure for a longer duration, in contrast to APL inside the shock tube. This in turn will possibly alter the injury type, severity, and lethality. We found that the optimal APL is where the Friedlander waveform is first formed inside the shock tube. Once the optimal APL was determined, the effect of the incident blast intensity on the surface and intracranial pressure was measured and analyzed. Noticeably, surface and intracranial pressure increases linearly with the incident peak overpressures, though surface pressures are significantly higher than the other two. Further, we developed and validated an anatomically accurate finite element model of the rat head. With this model, we determined that the main pathway of pressure transmission to the brain was through the skull and not through the snout; however, the snout plays a secondary role in diffracting the incoming blast wave towards the skull.	[Sundaramurthy, Aravind; Alai, Aaron; Ganpule, Shailesh; Holmberg, Aaron; Plougonven, Erwan; Chandra, Namas] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA	Chandra, N (corresponding author), Univ Nebraska, Dept Mech & Mat Engn, W328-1 NW Nebraska Hall H, Lincoln, NE 68588 USA.	nchandra2@unl.edu	Sundaramurthy, Aravind/O-2047-2019	Sundaramurthy, Aravind/0000-0002-0359-8680	U.S. Army Research Office project "Army-UNL Center of Trauma Mechanics" [W911NF-08-10483]	The authors gratefully acknowledge the financial support under the U.S. Army Research Office project "Army-UNL Center of Trauma Mechanics" (contract no. W911NF-08-10483, Project Manager: Larry Russell, P.I: Namas Chandra). We are grateful to Dr. Maciej Skotak and Dr. Fang Wang for helpful comments on the manuscript.	Abdul-Wahab R., 2011, BIOENG C NEBEC 2011, P1; Ahlers S. T., 2012, FRONT NEUROL, P3; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Anderson J.D, 2001, FUNDAMENTALS AERODYN, V3; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bolander R., 2011, ANN BIOMED ENG, P1; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chandra N., 2011, CONTROLLING SHAPE SH; CHANG KS, 1995, SHOCK WAVES, V5, P33, DOI 10.1007/BF02425034; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Ganpule S, 2012, COMPUT METHOD BIOMEC, V15, P1233, DOI 10.1080/10255842.2011.597353; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Haselbacher A, 2007, AIAA J, V45, P1917, DOI 10.2514/1.23081; Honma H, 2003, SHOCK WAVES, V13, P179, DOI 10.1007/s00193-003-0206-1; Jiang Z, 1999, SHOCK WAVES, V9, P1, DOI 10.1007/s001930050133; Jiang Z, 1998, PHYS FLUIDS, V10, P277, DOI 10.1063/1.869566; Kleinschmit N.N., 2011, THESIS U NEBRASKA LI; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nyein MK, 2011, P NATL ACAD SCI USA, V108, P433, DOI 10.1073/pnas.1018365108; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pena A, 2005, ACT NEUR S, V95, P333; Rafaels K., 2010, THESIS U VIRGINIA; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Teasdale G., 1974, J GERONTOL B-PSYCHOL, V304, P81, DOI DOI 10.1016/S0140-6736(74)91639-0; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhu Feng, 2010, Stapp Car Crash J, V54, P211	41	80	81	2	31	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	13					2352	+		10.1089/neu.2012.2413			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000PU	WOS:000308399900011	22620716				2021-06-18	
J	McDonald, BC; Saykin, AJ; McAllister, TW				McDonald, Brenna C.; Saykin, Andrew J.; McAllister, Thomas W.			Functional MRI of mild traumatic brain injury (mTBI): progress and perspectives from the first decade of studies	BRAIN IMAGING AND BEHAVIOR			English	Article						Episodic memory; Frontal lobes; Functional connectivity; Functional MRI; Mild traumatic brain injury; Working memory	ALTERED WORKING-MEMORY; BOLD RESPONSE; HEAD-INJURY; CONCUSSION; FMRI; ABNORMALITIES; ACTIVATION; SYMPTOMS; RECOVERY; CORTEX	Mild traumatic brain injury (mTBI) represents the great majority of traumatic brain injuries, and is a common medical problem affecting cognitive and vocational functioning as well as quality of life in some individuals. Functional MRI (fMRI) is an important research method for investigating the neuroanatomic substrates of cognitive disorders and their treatment. Surprisingly, however, relatively little research has utilized fMRI to examine alterations in brain functioning after mTBI. This article provides a critical overview of the published fMRI research on mTBI to date. These topics include examination of frontal lobe/executive functions such as working memory, as well as episodic memory and resting state/functional connectivity. mTBI has also been investigated in military populations where studies have focused on effects of blast injury and comorbid conditions such as post-traumatic stress disorder and major depressive disorder. Finally, we address fMRI evaluations of response to behavioral or pharmacological challenges and interventions targeting cognitive and behavioral sequelae of mTBI. The review concludes with identification and discussion of gaps in current knowledge and future directions for fMRI studies of mTBI. The authors conclude that fMRI in combination with related methods can be expected to play an increasing role in research related to studies of pathophysiological mechanisms of the sequelae of mTBI as well as in diagnosis and treatment monitoring.	[McDonald, Brenna C.; Saykin, Andrew J.] Indiana Univ Sch Med, IU Ctr Neuroimaging, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA; [McDonald, Brenna C.; Saykin, Andrew J.; McAllister, Thomas W.] Dartmouth Med Sch, Sect Neuropsychiat, Dept Psychiat, Lebanon, NH USA	McDonald, BC (corresponding author), Indiana Univ Sch Med, IU Ctr Neuroimaging, Dept Radiol & Imaging Sci, 950 W Walnut St,R2 E124, Indianapolis, IN 46202 USA.	mcdonalb@iupui.edu; asaykin@iupui.edu; thomas.w.mcallister@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	National Institute on Disability and Rehabilitation Research [H133G70031, H133000136]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040472]; Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176]; US Department of DefenseUnited States Department of Defense; Indiana Spinal Cord and Traumatic Brain Injury Fund; Indiana Economic Development Corporation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176, R01HD047242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010133, R01AG019771] Funding Source: NIH RePORTER	This research was supported in part by grants from the National Institute on Disability and Rehabilitation Research (H133G70031 and H133000136), the National Institute of Neurological Disorders and Stroke (R01 NS040472), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01 HD048176), the US Department of Defense to the Alzheimer's Disease Neuroimaging Initiative to investigate AD risk after TBI and PTSD, the Indiana Spinal Cord and Traumatic Brain Injury Fund, and the Indiana Economic Development Corporation.	Arnsten A F, 1998, Adv Pharmacol, V42, P764; Arnsten AFT, 2011, BIOL PSYCHIAT, V69, pE89, DOI 10.1016/j.biopsych.2011.01.027; Baugh C. M., 2012, BRAIN IMAGING BEHAV; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Breedlove E. L., 2012, J BIOMECHANICS; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Gamo NJ, 2011, BEHAV NEUROSCI, V125, P282, DOI 10.1037/a0023165; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Lipsky R. H., 2002, J NEUROPSYCHIATRY CL; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayer A. R., 2012, BRAIN IMAGING BEHAV; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister T., 2001, J NEUROPSYCHIATRY CL, V13, P141; McAllister T. W., 2004, J NEUROPSYCHIATRY CL, V16, P240; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2011, INT J PSYCHOPHYSIOL, V82, P107, DOI 10.1016/j.ijpsycho.2011.06.022; McAllister TW, 2011, J NEUROPSYCH CLIN N, V23, P277, DOI 10.1176/appi.neuropsych.23.3.277; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McAllister TW., 2002, J NEUROPSYCHIATRY CL, V14, P116; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rosenbaum S. B., 2012, BRAIN IMAGING BEHAV; Roy MJ, 2010, ANN NY ACAD SCI, V1208, P142, DOI 10.1111/j.1749-6632.2010.05689.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saykin AJ, 1999, BRAIN, V122, P1963, DOI 10.1093/brain/122.10.1963; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S. M., 2012, BRAIN IMAGING BEHAV; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Stevens MC, 2012, BRAIN IMAGING BEHAV; Stulemeijer M, 2010, J NEUROTRAUM, V27, P1585, DOI 10.1089/neu.2010.1298; Talavage T. M., 2010, J NEUROTRAUMA; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	58	80	82	0	46	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		193	207		10.1007/s11682-012-9173-4			15	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900004	22618832	Green Accepted			2021-06-18	
J	Balakathiresan, N; Bhomia, M; Chandran, R; Chavko, M; McCarron, RM; Maheshwari, RK				Balakathiresan, Nagaraja; Bhomia, Manish; Chandran, Raghavendar; Chavko, Mikulas; McCarron, Richard M.; Maheshwari, Radha K.			MicroRNA Let-7i Is a Promising Serum Biomarker for Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; blast overpressure injury; microRNA; serum; traumatic brain injury	NEUROTRAUMA; MECHANISMS; EXPRESSION; STRESS; MODEL	Blast-induced traumatic brain injury (TBI) is of significant concern in soldiers returning from the current conflicts in Iraq and Afghanistan. Incidents of TBI have increased significantly in the current conflicts compared to previous wars, and a majority of these injuries are caused by improvised explosive devices. Currently, no specific technique or biomarker is available for diagnosing TBI when no obvious clinical symptoms are present. MicroRNAs are small RNA (similar to 22nts) molecules that are expressed endogenously and play an important role in regulating gene expression. MicroRNAs have emerged as novel serum diagnostic biomarkers for various diseases. In this study, we studied the effect of blast overpressure injury on the microRNA signatures in the serum of rats. Rats were exposed to three serial 120-kPa blast overpressure exposures through a shockwave tube. Blood and cerebrospinal fluid were collected at various time points after injury, and microRNA modulation was analyzed using real-time PCR. Five microRNAs were significantly modulated in the serum samples of these animals at three time points post-injury. Further, we also found that the levels of microRNA let-7i are also elevated in cerebrospinal fluid post-blast wave exposure. The presence of microRNA in both serum and cerebrospinal fluid immediately after injury makes microRNA let-7i an ideal candidate for further studies of biomarkers in TBI.	[Balakathiresan, Nagaraja; Bhomia, Manish; Chandran, Raghavendar; Maheshwari, Radha K.] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA; [Bhomia, Manish; Chandran, Raghavendar] Birla Inst Technol & Sci, Biol Sci Grp, Pilani, Rajasthan, India; [Chavko, Mikulas; McCarron, Richard M.] USN, Med Res Ctr, Silver Spring, MD USA	Maheshwari, RK (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	radha.maheshwari@usuhs.edu	Chandran, Raghavendar/AAB-9402-2019; Balakathiresan, Nagaraja Sethuraman/O-3213-2019; Bhomia, Manish/C-7683-2015	Chandran, Raghavendar/0000-0002-7915-2810; Bhomia, Manish/0000-0003-2808-9927; Balakathiresan, Nagaraja Sethuraman/0000-0001-5756-6070	Defense Medical Research and Development Program	This work was supported by a grant from the Defense Medical Research and Development Program. The authors are also thankful to Dr. Anuj Sharma for critically reviewing the manuscript, and Dr. Deepti Parashar for her help in real-time PCR assays.	Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Barbato C, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/871313; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Brown BD, 2009, NAT REV GENET, V10, P578, DOI 10.1038/nrg2628; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Cullen DK, 2011, J NEUROTRAUM, V28, P2307, DOI [10.1089/neu.2010.1718, 10.1089/neu.2011.1718]; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Polakis P, 2008, J CELL BIOL, V183, P371, DOI 10.1083/jcb.200810040; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Scholer N, 2010, EXP HEMATOL, V38, P1126, DOI 10.1016/j.exphem.2010.10.004; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Young GB, 2010, CRIT CARE MED, V38, P325, DOI 10.1097/CCM.0b013e3181bfeb89; Zajtchuk R, 1991, CONVENTIONAL WARFARE, P241; Zhang BH, 2009, ENVIRON HEALTH PERSP, V117, P231, DOI 10.1289/ehp.11841	35	80	86	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1379	1387		10.1089/neu.2011.2146			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600012	22352906	Green Published			2021-06-18	
J	De Bonis, P; Frassanito, P; Mangiola, A; Nucci, CG; Anile, C; Pompucci, A				De Bonis, Pasquale; Frassanito, Paolo; Mangiola, Annunziato; Nucci, Carlotta Ginevra; Anile, Carmelo; Pompucci, Angelo			Cranial Repair: How Complicated Is Filling a "Hole''?	JOURNAL OF NEUROTRAUMA			English	Article						autologous bone flap; cranial repair; cranioplasty; custom-made skull prosthesis; decompressive craniectomy	TRAUMATIC BRAIN-INJURY; SINKING SKIN FLAP; DECOMPRESSIVE CRANIECTOMY; DELAYED CRANIOPLASTY; GRAFT INFECTION; BONE-GRAFTS; BLOOD-FLOW; PRESERVATION; DEFECTS; FROZEN	In general, cranioplasty is viewed as a straightforward surgical procedure, and for many years the complications associated with the procedure have been underestimated. We reviewed our 5-year experience consisting of 218 cranioplasties. Study outcomes focused specifically on the occurrence of complications after cranioplasty. Autologous bone-assisted and prosthetic cranioplasties were considered. Variables described by other authors to be associated with complications were studied, including history of previous cranioplasty, wider craniectomy size, bifrontal craniectomy, and delayed cranioplasty. We also analyzed the influence of material used for craniectomy on the occurrence of complications. The overall complication rate was 19.7%. Nineteen cases of infection (8.7%), 5 cases of postoperative wound dehiscence (2.3%), 6 cases of epidural hemorrhage (2.8%), and 13 cases of cranioplasty dislocation (5.9%) were observed. Bifrontal cranioplasties were more frequently associated with complications (p = 0.01; Fisher's exact test) and infection (p < 0.0001; Fisher's exact test). Postoperative wound dehiscence was more frequently observed with hand-made or custom-made cranioplasties compared with autologous cranioplasties (p = 0.02). Early cranioplasty (< 3 months from craniectomy) was significantly associated with cranioplasty dislocation (p = 0.03). Logistical regression analysis showed that the only factor independently associated with complication was the site of cranioplasty (p = 0.01). In particular, patients with a bifrontal cranioplasty had a 2-fold increased risk of complication (CI 95 1.1-3.6, p = 0.017) and a 2.5-fold increased risk of developing infection (CI 95 1.3-4.9, p = 0.009) compared with hemispheric/bihemispheric cranioplasty. Our analysis confirms that cranioplasty is burdened by a significant complication rate. In this context, bifrontal cranioplasty is related to a higher risk of complication and, in particular, infection.	[De Bonis, Pasquale; Frassanito, Paolo; Mangiola, Annunziato; Nucci, Carlotta Ginevra; Anile, Carmelo; Pompucci, Angelo] Catholic Univ, Sch Med, Inst Neurosurg, I-00168 Rome, Italy	Frassanito, P (corresponding author), Catholic Univ, Sch Med, Inst Neurosurg, Largo Agostino Gemelli 8, I-00168 Rome, Italy.	paolo.frassanito@gmail.com	de bonis, pasquale/K-8200-2016; FRASSANITO, Paolo/K-4099-2018; Nucci, Carlotta Ginevra/AAE-4748-2019	de bonis, pasquale/0000-0002-9879-8940; FRASSANITO, Paolo/0000-0003-0071-3126; Nucci, Carlotta Ginevra/0000-0002-9016-7503	Codman; Synthes	Pasquale De Bonis received grants from Codman and from Synthes in 2010.	AZIZ T Z, 1990, British Journal of Neurosurgery, V4, P417, DOI 10.3109/02688699008992764; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Ducic J, 2002, J ORAL MAXIL SURG, V60, P272, DOI 10.1053/joms.2002.30575; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Flannery T, 2001, BRIT J NEUROSURG, V15, P518, DOI 10.1080/02688690120097732; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; Horaczek JA, 2008, NEUROSURGERY, V63, P176, DOI 10.1227/01.NEU.0000312707.25073.CB; Isago T, 2004, ANN PLAS SURG, V53, P288, DOI 10.1097/01.sap.0000106433.89983.72; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Lee CH, 2007, CLIN NEUROL NEUROSUR, V109, P667, DOI 10.1016/j.clineuro.2007.05.015; Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001; Li G, 2008, BRAIN INJURY, V22, P333, DOI 10.1080/02699050801958353; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Neovius E, 2010, J PLAST RECONSTR AES, V63, P1615, DOI 10.1016/j.bjps.2009.06.003; Nievas MNCY, 2006, NEUROL RES, V28, P139, DOI 10.1179/016164106X98008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; POSNICK JC, 1993, NEUROSURGERY, V32, P785, DOI 10.1227/00006123-199305000-00011; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	34	80	80	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1071	1076		10.1089/neu.2011.2116			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100005	22059899				2021-06-18	
J	Sullivan, SJ; Schneiders, AG; Cheang, CW; Kitto, E; Lee, H; Redhead, J; Ward, S; Ahmed, OH; McCrory, PR				Sullivan, S. John; Schneiders, Anthony G.; Cheang, Choon-Wi; Kitto, Emma; Lee, Hopin; Redhead, Jason; Ward, Sarah; Ahmed, Osman H.; McCrory, Paul R.			'What's happening?' A content analysis of concussion-related traffic on Twitter	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; SOCIAL NETWORKS; HEALTH INFORMATION; SUPPORT GROUPS; KNOWLEDGE; FOOTBALL; PLAY; MISCONCEPTIONS; MANAGEMENT	Background Twitter is a rapidly growing social networking site (SNS) with approximately 124 million users worldwide. Twitter allows users to post brief messages ('tweets') online, on a range of everyday topics including those dealing with health and wellbeing. Currently, little is known about how tweets are used to convey information relating to specific injuries, such as concussion, that commonly occur in youth sports. Objective The purpose of this study was to analyse the online content of concussion-related tweets on the SNS Twitter, to determine the concept and context of mild traumatic brain injury as it relates to an online population. Study design A prospective observational study using content analysis. Methods Twitter traffic was investigated over a 7-day period in July 2010, using eight concussion-related search terms. From the 3488 tweets identified, 1000 were randomly selected and independently analysed using a customised coding scheme to determine major content themes. Results The most frequent theme was 'news' (33%) followed by 'sharing personal information/situation' (27%) and 'inferred management' (13%). Demographic data were available for 60% of the sample, with the majority of tweets (82%) originating from the USA, followed by Asia (5%) and the UK (4.5%). Conclusion This study highlights the capacity of Twitter to serve as a powerful broadcast medium for sports concussion information and education.	[Sullivan, S. John] Univ Otago, Sch Physiotherapy, Ctr Physiotherapy Res, Dunedin 9054, New Zealand; [McCrory, Paul R.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia	Sullivan, SJ (corresponding author), Univ Otago, Sch Physiotherapy, Ctr Physiotherapy Res, POB 56, Dunedin 9054, New Zealand.	sjohn.sullivan@otago.ac.nz	McCrory, Paul/Q-8688-2019; Schneiders, Anthony/F-4212-2015	Lee, Hopin/0000-0001-5692-0314; McCrory, Paul/0000-0003-4850-0568; Schneiders, Anthony/0000-0002-1583-3879	International Rugby Board	The authors express their thanks to Andrew Long from the University of Otago Department of Information Science for his guidance on the exploration of Twitter and acknowledge funding support from the International Rugby Board.	Accident Compenstaion Corporation, 2006, ACC1419 SID CONC CHE; Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; [Anonymous], 2010, ECONOMIST; [Anonymous], 2010, MOMSTEAM; [Anonymous], 2010, NY TIMES; [Anonymous], 2010, BOSTON GLOBE; [Anonymous], TWITTER; Baker JR, 2008, CYBERPSYCHOL BEHAV, V11, P747, DOI 10.1089/cpb.2008.0053; Bloom GA, 2008, EUR J SPORT SCI, V8, P295, DOI 10.1080/17461390802251836; Brain Injury New Zealand, CONC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2009, HEADS CONC YOUTH SPO; Chapman RCG, 2010, BRAIN INJURY, V24, P797, DOI 10.3109/02699051003709607; CrunchBase, 2010, TWITT; Deshpande A, 2006, J MENS HLTH GENDER, V3, P332, DOI DOI 10.1016/J.JMHG.2006.09.004; Eysenbach G, 2004, BMJ-BRIT MED J, V328, P1166, DOI 10.1136/bmj.328.7449.1166; Eysenbach G, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.1030; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HERMIDA A, 2010, M C J, V13, P2; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Java A., 2007, P JOINT 9 WEBKDD 1 S; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kostkova P, 2010, INT J INFECT DIS, V14, pE384, DOI 10.1016/j.ijid.2010.02.475; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Miller C. C., 2009, NY TIMES; Nardi BA, 2004, COMMUN ACM, V47, P41, DOI 10.1145/1035134.1035163; Nonnecke B., 2000, CHI 2000 Conference Proceedings. Conference on Human Factors in Computing Systems. CHI 2000. The Future is Here, P73; Papacharissi Z, 2009, NEW MEDIA SOC, V11, P199, DOI 10.1177/1461444808099577; Pew Internet & American Life Project, 2010, UND PART NEWS CONS; Pew Internet & American Life Project, 2009, SOC LIF HLTH INF; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Pulman A, 2009, J NURS HEALTHC CHRON, V1, P245, DOI [10.1111/j.1752-9824.2009.01027.x, DOI 10.1111/J.1752-9824.2009.01027.X]; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Scanfeld D, 2010, AM J INFECT CONTROL, V38, P182, DOI 10.1016/j.ajic.2009.11.004; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Thomas DR, 2003, GEN INDUCTIVE APPROA; Van De Belt TH, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1350; van Uden-Kraan CF, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.992; Viralblog, 2010, TWITT FACTS FIG; Wilson P, 2002, BMJ-BRIT MED J, V324, P598, DOI 10.1136/bmj.324.7337.598; Wrightson P, 1999, APPENDIX 2 MILD HEAD, P182; Wyatt JC, 2005, BRIT MED J, V331, P1391, DOI 10.1136/bmj.331.7529.1391	53	80	80	0	49	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAR	2012	46	4					258	263		10.1136/bjsm.2010.080341			6	Sport Sciences	Sport Sciences	899PO	WOS:000300828500011	21406451				2021-06-18	
J	Xu, S; Zhuo, JC; Racz, J; Shi, D; Roys, S; Fiskum, G; Gullapalli, R				Xu, Su; Zhuo, Jiachen; Racz, Jennifer; Shi, Da; Roys, Steven; Fiskum, Gary; Gullapalli, Rao			Early Microstructural and Metabolic Changes following Controlled Cortical Impact Injury in Rat: A Magnetic Resonance Imaging and Spectroscopy Study	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; diffusion tensor imaging; early changes; MR spectroscopy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SWELLING-ACTIVATED RELEASE; ACUTE PATHOLOGICAL-CHANGES; PROTON MR SPECTROSCOPY; DIFFUSE AXONAL INJURY; ACUTE HEAD-INJURY; N-ACETYLASPARTATE; MITOCHONDRIAL DYSFUNCTION; CHRONIC HYPONATREMIA; OUTCOME PREDICTION	Understanding tissue alterations at an early stage following traumatic brain injury (TBI) is critical for injury management and limiting severe consequences from secondary injury. We investigated the early microstructural and metabolic profiles using in vivo diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (H-1 MRS) at 2 and 4 h following a controlled cortical impact injury in the rat brain using a 7.0 Tesla animal MRI system and compared profiles to baseline. Significant decrease in mean diffusivity (MD) and increased fractional anisotropy (FA) was found near the impact site (hippocampus and bilateral thalamus; p < 0.05) immediately following TBI, suggesting cytotoxic edema. Although the DTI parameters largely normalized on the contralateral side by 4 h, a large inter-individual variation was observed with a trend towards recovery of MD and FA in the ipsilateral hippocampus and a sustained elevation of FA in the ipsilateral thalamus (p < 0.05). Significant reduction in metabolite to total creatine ratios of N-acetylaspartate (NAA, p = 0.0002), glutamate (p = 0.0006), myoinositol (Ins, p = 0.04), phosphocholine and glycerophosphocholine (PCh + GPC, p = 0.03), and taurine (Tau, p = 0.009) were observed ipsilateral to the injury as early as 2 h, while glutamine concentration increased marginally (p = 0.07). These metabolic alterations remained sustained over 4 h after TBI. Significant reductions of Ins (p = 0.024) and Tau (p = 0.013) and marginal reduction of NAA (p = 0.06) were also observed on the contralateral side at 4 h after TBI. Overall our findings suggest significant microstructural and metabolic alterations as early as 2 h following injury. The tendency towards normalization at 4 h from the DTI data and no further metabolic changes at 4 h from MRS suggest an optimal temporal window of about 3 h for interventions that might limit secondary damage to the brain. Results indicate that early assessment of TBI patients using DTI and MRS may provide valuable information on the available treatment window to limit secondary brain damage.	[Xu, Su; Zhuo, Jiachen; Shi, Da; Roys, Steven; Gullapalli, Rao] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Racz, Jennifer; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Racz, Jennifer; Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA	Gullapalli, R (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 S Greene St, Baltimore, MD 21201 USA.	gullapalli@umm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10RR019935]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR019935] Funding Source: NIH RePORTER	This study was supported in part by grants from the National Institutes of Health (1S10RR019935).	Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Arieff A I, 1987, Adv Intern Med, V32, P325; Arnold DL, 1996, MR SPECTROSCOPY CLIN, P139; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bothwell JH, 2001, J NEUROCHEM, V77, P1632, DOI 10.1046/j.1471-4159.2001.00403.x; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Cooper CE, 2000, BIOCHEM SOC T, V28, P121, DOI 10.1042/bst0280121; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUTTON GR, 1991, ANN NY ACAD SCI, V633, P489; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; FRAHM J, 1986, MAGNET RESON MED, V3, P321, DOI 10.1002/mrm.1910030217; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gass A, 2001, J NEUROL SCI, V186, pS15, DOI 10.1016/S0022-510X(01)00487-7; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HAUSSINGER D, 1994, GASTROENTEROLOGY, V107, P1475; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.0.CO;2-6; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kimelberg HK, 1998, CONTRIB NEPHROL, V123, P240, DOI 10.1159/000059916; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Law RO, 1996, BBA-MOL CELL RES, V1314, P34, DOI 10.1016/S0167-4889(96)00070-5; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; OLSON JE, 1995, BRAIN RES, V682, P197, DOI 10.1016/0006-8993(95)00368-Z; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Phillis JW, 1998, BRAIN RES, V780, P352, DOI 10.1016/S0006-8993(97)01352-8; Price WS, 1996, J MAGN RESON SER B, V112, P190, DOI 10.1006/jmrb.1996.0129; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Ross B, 2001, ANAT RECORD, V265, P54, DOI 10.1002/ar.1058; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers D.R., 2007, AM J NEURORADIOL, V29, P51451; Sager TN, 1997, J NEUROCHEM, V68, P675; SANCHEZOLEA R, 1993, NEUROSCI LETT, V156, P141, DOI 10.1016/0304-3940(93)90458-W; SanchezOlea R, 1996, AM J PHYSIOL-CELL PH, V270, pC1703; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2002, ACT NEUR S, V81, P373; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Silver SM, 2006, J NEUROPATH EXP NEUR, V65, P37, DOI 10.1097/01.jnen.0000195938.02292.39; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stein D.G, 2011, NEUROSCIENCE, V14; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; VERBALIS JG, 1991, BRAIN RES, V567, P274, DOI 10.1016/0006-8993(91)90806-7; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; VIDEEN JS, 1995, J CLIN INVEST, V95, P788, DOI 10.1172/JCI117728; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Yoon SJ, 2005, CLIN REHABIL, V19, P209, DOI 10.1191/0269215505cr813oa; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	109	80	82	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2091	2102		10.1089/neu.2010.1739			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500010	21761962	Green Published			2021-06-18	
J	Li, M; Li, F; Luo, CX; Shan, YA; Zhang, LJ; Qian, ZM; Zhu, G; Lin, JK; Feng, H				Li, Mei; Li, Fei; Luo, Chunxia; Shan, Youan; Zhang, Lijun; Qian, Zhongming; Zhu, Gang; Lin, Jiangkai; Feng, Hua			Immediate Splenectomy Decreases Mortality and Improves Cognitive Function of Rats After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Splenectomy; Mortality; Cognitive function; Brain edema	EXPERIMENTAL STROKE; HEAD-INJURY; INFLAMMATION; NEURODEGENERATION; INTERLEUKIN-1; EPIDEMIOLOGY; OUTCOMES; EDEMA	Background: Traumatic brain injury (TBI) is a major health problem all over the world. It frequently causes a considerable social burden because of its high incidence of death and long-term disability, especially in the case of severe TBI. Recent studies revealed that the spleen might contribute to secondary brain injury after ischemia or intracerebral hemorrhage. The purpose of this study was to evaluate the significance of the spleen in traumatic brain edema after severe TBI. Methods: We established a severe TBI model with rats and performed splenectomy to observe the mortality, brain water content, cognitive function (water maze), and cytokines levels, including interleukin (IL)-1 beta, tumor necrosis factor-alpha (TNF-alpha), IL-6, and IL-10, in the blood plasma (enzyme-linked immunosorbent assay) and their mRNA expression levels in injured brain tissue (quantitative reverse transcriptase-polymerase chain reaction). Results: The immediate splenectomy after TBI significantly decreased the death rate from 35.42% to 14.89% and eliminated the brain water content of the injured brain, especially at days 2 and 3. The Morris water maze assessment showed an improved spatial reference memory in rats that underwent both TBI and splenectomy when compared with those in the TBI group, 4 weeks later. Splenectomy reduced the IL-1 beta, TNF-alpha, and IL-6 contents in the blood serum after TBI, and the mRNA expression levels of IL-1 beta, TNF-alpha, and IL-6 in the ipsilateral brain tissue also decreased. Conclusions: Our study demonstrates that splenectomy has a protective effect on rats with severe TBI by inhibiting proinflammatory cytokines, including IL-1 beta, TNF-alpha, and IL-6, both systematically and locally in the injured brain, hence leading to a decreased mortality and improved cognitive function.	[Li, Mei; Li, Fei; Luo, Chunxia; Shan, Youan; Zhang, Lijun; Zhu, Gang; Lin, Jiangkai; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China; [Qian, Zhongming] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China	Feng, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China.	fenghua8888@yahoo.com.cn	Li, Ming/G-3911-2015; Jiang, Rui/P-8022-2015; Jiang, Rui/F-9719-2013	Li, Ming/0000-0002-8545-0726; 	Health Sector Public Welfare fund of China [200802017]	Supported by Health Sector Public Welfare fund of China grant 200802017.	Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gendron A, 2002, BRAIN RES, V955, P85, DOI 10.1016/S0006-8993(02)03368-1; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hurn PD, 2007, J CEREBR BLOOD F MET, V27, P1798, DOI 10.1038/sj.jcbfm.9600482; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Lee ST, 2010, BRAIN RES, V1309, P164, DOI 10.1016/j.brainres.2009.10.076; Liu BY, 2008, NEUROL RES, V30, P594, DOI 10.1179/174313208X310296; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Marshall L F, 2000, Clin Neurosurg, V46, P105; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nujaimin U, 2009, ASIAN J SURG, V32, P157, DOI 10.1016/S1015-9584(09)60387-0; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Petroni G, 2010, J TRAUMA, V68, P564, DOI 10.1097/TA.0b013e3181ce1eed; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Subramanian S, 2009, STROKE, V40, P2539, DOI 10.1161/STROKEAHA.108.543991; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	27	80	85	2	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2011	71	1					141	147		10.1097/TA.0b013e3181f30fc9			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	790RR	WOS:000292607400034	21248654				2021-06-18	
J	Gao, XA; Chen, JH				Gao, Xiang; Chen, Jinhui			Mild Traumatic Brain Injury Results in Extensive Neuronal Degeneration in the Cerebral Cortex	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Dendrite; mTBI; Neural degeneration; Spine; Synapse	CONTROLLED CORTICAL IMPACT; MINOR HEAD-INJURY; MEDIAL PREFRONTAL CORTEX; PYRAMIDAL NEURONS; DENDRITIC SPINES; FUNCTIONAL MRI; FLUORO-JADE; TIME-COURSE; RAT; HIPPOCAMPUS	Mild traumatic brain injury (mTBI) leads to long-term cognitive and emotional difficulties and behavioral disturbances, but the diagnosis and treatment of mTBI have historically been hampered by a lack of evidence-based correlates of these clinical manifestations. Unlike moderate and severe TBI, mTBI does not show significant tissue lesions or cavities in the cortex. Moreover, neuroimaging by magnetic resonance imaging or computed tomography is usually negative, suggesting that the damage is beyond the resolution of current structure-based scanning technologies. Therefore, we investigated the morphologies of spared neurons in the mouse cortex after mTBI in a controlled cortical impact injury model. Our results indicate that, although mTBI caused only a mild extent of cell death, it led to extensive dendrite degeneration and synapse reduction in the cortex in this model. This study sheds light on the neuropathologic consequences of mTBI in humans and suggests that neurodegeneration may be a novel target for developing diagnostic methods and therapeutic approaches for mTBI.	[Chen, Jinhui] Indiana Univ, Dept Neurosurg, Indianapolis, IN 46204 USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ, Cord & Brain Injury Res Grp, Indianapolis, IN 46204 USA; [Chen, Jinhui] Indiana Univ, Stark Neurosci Res Inst, Indianapolis, IN 46204 USA	Chen, JH (corresponding author), Indiana Univ Sch Med, Dept Neurosurg, 980 W Walnut St, Indianapolis, IN 46202 USA.	chen204@iupui.edu	Chen, Jinhui/A-7138-2009	Chen, Jinhui/0000-0002-6864-7121	Indiana Spinal Cord & Brain Injury Research Grants [SCBI 200-12]; Ralph W. and Grace M. Showalter Research Award; Indiana University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER	This work was supported by grants from the Indiana Spinal Cord & Brain Injury Research Grants (SCBI 200-12), the Ralph W. and Grace M. Showalter Research Award, and Indiana University Biological Research Grant to J. Chen.	Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cassidy JD, 2004, J REHABIL MED, V36, P15, DOI 10.1080/16501960410023688; Cerqueira JJ, 2007, CEREB CORTEX, V17, P1998, DOI 10.1093/cercor/bhl108; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; CLINE DM, 1988, ANN EMERG MED, V17, P127, DOI 10.1016/S0196-0644(88)80297-X; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunaevsky A, 1999, P NATL ACAD SCI USA, V96, P13438, DOI 10.1073/pnas.96.23.13438; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao X, 2008, J NEUROTRAUM, V25, P985, DOI 10.1089/neu.2008.0460; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI 10.1089/neu.2008-0744; GARRAWAY M, 1995, LANCET, V345, P1485; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jagoda AS, 2009, J EMERG NURS, V35, P5; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; LIDVALL HF, 1974, LANCET, V2, P1150; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOWDON IMR, 1989, INJURY, V20, P193, DOI 10.1016/0020-1383(89)90109-5; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Petrak LJ, 2005, J COMP NEUROL, V484, P183, DOI 10.1002/cne.20468; Portera-Cailliau C, 2003, J NEUROSCI, V23, P7129, DOI 10.1523/JNEUROSCI.23-18-07129.2003; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Radley JJ, 2004, NEUROSCIENCE, V125, P1, DOI 10.1016/j.neuroscience.2004.01.006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SHOLL D A, 1956, Prog Neurobiol, P324; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tada T, 2006, CURR OPIN NEUROBIOL, V16, P95, DOI 10.1016/j.conb.2005.12.001; UYLINGS HBM, 1994, PROG BRAIN RES, V102, P109; UYLINGS HBM, 1986, J NEUROSCI METH, V18, P127, DOI 10.1016/0165-0270(86)90116-0; Uylings HBM, 2002, NETWORK-COMP NEURAL, V13, P397, DOI 10.1088/0954-898X/13/3/309; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	66	80	80	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2011	70	3					183	191		10.1097/NEN.0b013e31820c6878			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	723BT	WOS:000287481900003	21293299	Green Accepted			2021-06-18	
J	Theeler, BJ; Flynn, FG; Erickson, JC				Theeler, Brett J.; Flynn, Frederick G.; Erickson, Jay C.			Headaches After Concussion in US Soldiers Returning From Iraq or Afghanistan	HEADACHE			English	Article						mild traumatic brain injury; concussion; military; posttraumatic headache	TRAUMATIC BRAIN-INJURY; CHRONIC POSTTRAUMATIC HEADACHES; UNITED-STATES; PREVALENCE; MIGRAINE; HEAD; DISABILITY; INCREASES; VETERANS; IMPACT	Objectives.-To determine the prevalence, characteristics, impact, and treatment patterns of headaches after concussion in US Army soldiers returning from a deployment to Iraq or Afghanistan. Methods.-A cross-sectional study was conducted with a cohort of soldiers undergoing postdeployment evaluation during a 5-month period at the Madigan Traumatic Brain Injury Program at Et. Lewis, WA. All soldiers screening positive for a deployment-related concussion were given a 13-item headache questionnaire. Results.-A total of 1033 (19.6%) of 5270 returning soldiers met criteria for a deployment-related concussion. Among those with a concussion, 957 (97.8%) reported having headaches during the final 3 months of deployment. Posttraumatic headaches, defined as headaches beginning within I week after a concussion, were present in 361 (37%) soldiers. In total, 58% of posttraumatic headaches were classified as migraine. Posttraumatic headaches had a higher attack frequency than nontraumatic headaches, averaging 10 days per month. Chronic daily headache was present in 27% of soldiers with posttraumatic headache compared with 14% of soldiers with nontraumatic headache. Posttraumatic headaches interfered with duty performance in 37% of cases and caused more sick call visits compared with nontraumatic headache. In total, 78% of soldiers with posttraumatic headache used abortive medications, predominantly over-the-counter analgesics, and most perceived medication as effective. Conclusions.-More than 1 in 3 returning military troops who have sustained a deployment-related concussion have headaches that meet criteria for posttraumatic headache. Migraine is the predominant headache phenotype precipitated by a concussion during military deployment. Compared with headaches not directly attributable to head trauma, posttraumatic headaches are associated with a higher frequency of headache attacks and an increased prevalence of chronic daily headache.	[Theeler, Brett J.] USA, Med Corps, Neurol Serv, William Beaumont Army Med Ctr,Dept Med, Ft Bliss, TX USA; [Flynn, Frederick G.] Madigan Traumat Brain Injury Program, Ft Lewis, WA USA; [Erickson, Jay C.] USA, Med Corps, Neurol Serv, Madigan Army Med Ctr,Dept Med, Ft Lewis, WA USA	Theeler, BJ (corresponding author), USA, Med Corps, Neurol Serv, William Beaumont Army Med Ctr,Dept Med, Ft Bliss, TX USA.				Uniformed Services University of the Health Sciences	The Comprehensive National Neuroscience Program at the Uniformed Services University of the Health Sciences.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Armed Forces Health Surveillance Center, 2009, MSMR, V16, P10; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Couch JR, 2009, EUR J NEUROL, V16, DOI 10.1111/j.1468-1331.2008.02362.x; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; DUCKRO PN, 1995, HEADACHE, V35, P7, DOI 10.1111/j.1526-4610.1995.hed3501007.x; Erickson JC, 2009, NEUROLOGY, V72, pA494; Evans RW, 2008, HEADACHE, V48, P1216, DOI 10.1111/j.1526-4610.2008.01216.x; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Formisano R, 2009, J HEADACHE PAIN, V10, P145, DOI 10.1007/s10194-009-0108-4; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Helseth EK, 2008, HEADACHE, V48, P883, DOI 10.1111/j.1526-4610.2007.00962.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lenaerts ME, 2008, CEPHALALGIA, V28, P12, DOI 10.1111/j.1468-2982.2008.01608.x; Lenaerts Marc E, 2004, Curr Treat Options Neurol, V6, P507, DOI 10.1007/s11940-004-0008-5; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Marcus DA, 2003, HEADACHE, V43, P117, DOI 10.1046/j.1526-4610.2003.03028.x; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sheftell FD, 2007, NEUROL SCI, V28, pS203, DOI 10.1007/s10072-007-0777-1; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; STEWART WF, 1991, AM J EPIDEMIOL, V134, P1111, DOI 10.1093/oxfordjournals.aje.a116014; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; Stovner LJ, 2008, NEUROLOGY, V71, P383, DOI 10.1212/01.wnl.0000324088.61277.3f; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2010, HEADACHE, V50, P790, DOI 10.1111/j.1526-4610.2009.01571.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x	32	80	80	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	SEP	2010	50	8					1262	1272		10.1111/j.1526-4610.2010.01700.x			11	Clinical Neurology	Neurosciences & Neurology	645RU	WOS:000281483200003	20553333				2021-06-18	
J	Hartikainen, KM; Waljas, M; Isoviita, T; Dastidar, P; Liimatainen, S; Solbakk, AK; Ogawa, KH; Soimakallio, S; Ylinen, A; Ohman, J				Hartikainen, Kaisa M.; Waljas, Minna; Isoviita, Tuulia; Dastidar, Prasun; Liimatainen, Suvi; Solbakk, Anne-Kristin; Ogawa, Keith H.; Soimakallio, Seppo; Ylinen, Aarne; Ohman, Juha			Persistent symptoms in mild to moderate traumatic brain injury associated with executive dysfunction	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Executive function; Mild traumatic brain injury; Postconcussion syndrome; Head injury; Diffusion tensor imaging; Neuropsychological assessment; Frontal lobes; Mesencephalon; Cognitive performance; Reaction time	ATTENTION; STIMULI; SEVERITY; LESIONS; MEMORY	In order to improve detection of subtle cognitive dysfunction and to shed light on the etiology of persistent symptoms after mild-to-moderate traumatic brain injury (TBI), we employed an experimental executive reaction time (RT) test, standardized neuropsychological tests, and diffusion tensor imaging (DTI). The Executive RT-Test, an Executive Composite Score from standardized neuropsychological tests, and DTI-indices in the midbrain differentiated between patients with persistent symptoms from those fully recovered after mild-to-moderate TBI. We suggest that persistent symptoms in mild-to-moderate TBI may reflect disrupted fronto-striatal network involved in executive functioning, and the Executive RT-Test provides an objective and novel method to detect it.	[Hartikainen, Kaisa M.; Liimatainen, Suvi] Tampere Univ Hosp, Dept Neurol, Tampere 33521, Finland; [Hartikainen, Kaisa M.; Isoviita, Tuulia] Tampere Univ, Fac Med, Dept Physiol, FIN-33101 Tampere, Finland; [Waljas, Minna; Ohman, Juha] Tampere Univ Hosp, Dept Neurosurg, Tampere 33521, Finland; [Dastidar, Prasun; Soimakallio, Seppo] Tampere Univ Hosp, Dept Radiol, Tampere 33521, Finland; [Solbakk, Anne-Kristin] Univ Oslo, Rikshosp, Div Clin Neurosci, Oslo Univ Hosp,Dept Neuropsychiat & Psychosomat M, N-0027 Oslo, Norway; [Ogawa, Keith H.] St Marys Coll Calif, John Magaddino Neurosci Lab, Moraga, CA USA; [Ylinen, Aarne] Finnish Assoc People Phys Disabil, Kapyla Rehabilitat Ctr Synapsia, Helsinki, Finland	Hartikainen, KM (corresponding author), Tampere Univ Hosp, Dept Neurol, BO 2000, Tampere 33521, Finland.	kaisa.hartikainen@pshp.fi		Hartikainen, Kaisa/0000-0001-7278-9635; Ohman, Juha/0000-0002-6592-1367			Adair JC, 1996, NEUROLOGY, V46, P842; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; *CANTAB, 2004, CAMBR NEUR AUT TEST; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; Hanna-Pladdy B, 2007, J Neurol Phys Ther, V31, P119; Hartikainen K. M., 2003, DETECTION CHANGE EVE, P99, DOI DOI 10.1007/978-1-4615-0294-4; Hartikainen KA, 2001, BRAIN COGNITION, V47, P339; Hartikainen KM, 2007, NEUROREPORT, V18, P1929, DOI 10.1097/WNR.0b013e3282f1ca18; Hartikainen KM, 2000, NEUROPSYCHOLOGIA, V38, P1576, DOI 10.1016/S0028-3932(00)00072-5; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morrow LA, 2002, CLIN NEUROPSYCHOL, V16, P373, DOI 10.1076/clin.16.3.373.13850; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; Posner MI, 1998, ATTENTIVE BRAIN, P401; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rosen HJ, 2002, NEUROLOGY, V58, P1608, DOI 10.1212/WNL.58.11.1608; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; SCHNIDER A, 1999, SCI PRACT NEUROPSYCH, P487; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; SOLBAKK AK, 2001, THESIS U OSLO OSLO; SOLBAKK AK, 2000, J CLIN EXPT NEUROPSY, V22, P1; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Turner C, 2004, ACCIDENT ANAL PREV, V36, P93, DOI 10.1016/S0001-4575(02)00131-8; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vuilleumier P, 2001, NEUROREPORT, V12, P1119, DOI 10.1097/00001756-200105080-00014; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	50	80	80	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	7					767	774	PII 919572123	10.1080/13803390903521000			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	631WB	WOS:000280380200010	20198531				2021-06-18	
J	Maerlender, A; Flashman, L; Kessler, A; Kumbhani, S; Greenwald, R; Tosteson, T; McAllister, T				Maerlender, A.; Flashman, L.; Kessler, A.; Kumbhani, S.; Greenwald, R.; Tosteson, T.; McAllister, T.			Examination of the Construct Validity of Impact Computerized Test, Traditional, and Experimental Neuropsychological Measures	CLINICAL NEUROPSYCHOLOGIST			English	Article						ImPACT; Mild TBI; Construct validity; Sports concussion; Computerized neuropsychological testing	TRAUMATIC BRAIN-INJURY; MEMORY; MILD; DYSFUNCTION; VALIDATION; SPORT	Although computerized neuropsychological screening is becoming a standard for sports concussion identification and management, convergent validity studies are limited. Such studies are important for several reasons: reference to established measures is needed to establish validity; examination of the computerized battery relative to a more traditional comprehensive battery will help understand the strengths and limitations of the computer battery; and such an examination will help inform the output of the computerized battery. We compared scores on the ImPACT battery to a comprehensive battery of traditional neuropsychological measures and several experimental measures used in the assessment of sports-related concussion in 54 healthy male athletes. Convergent validity was demonstrated for four of the five ImPACT domain scores. Two cognitive domains often compromised as a result of mild TBI were not directly identified by the ImPACT battery: sustained attention and auditory working memory. Affective symptoms correlated with performance on measures of attention and working memory. In this healthy sample the correlations between the domains covered by ImPACT and the neuropsychological battery supports ImPACT as a useful screening tool for assessing many of the cognitive factors related to mTBI. However, the data suggest other sources of data need to be considered when identifying and managing concussions.	[Maerlender, A.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Lebanon, NH 03756 USA	Maerlender, A (corresponding author), Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	maerlender@dartmouth.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [BRP R01HD048638, RO1NS055020]; National Center for Medical Rehabilitation Research; National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported by National Institute of Health BRP R01HD048638 National Center for Medical Rehabilitation Research, National Institute of Child Health and Development, and National Institute of Health RO1NS055020 National Institute of Health/National Institute of Neurological Disease and Stroke.	Anastasi A, 1997, PSYCHOL TESTING, V7th; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bishop SJ, 2009, NAT NEUROSCI, V12, P92, DOI 10.1038/nn.2242; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Delis DC, 2000, CALIFORNIA VERBAL LE; DELIS DC, 2001, DELISKALPAN EXECUTIV; Derakshan N, 1998, COGNITION EMOTION, V12, P697; Green P., 1995, MANUAL ORAL WORD MEM; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2003, CONSTRUCT VALIDITY I; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Mitrushina M., 2005, HDB NORMATIVE DATA N; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Smith A., 1991, SYMBOL DIGIT MODALIT; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Swick D, 1999, NEUROPSYCHOLOGY, V13, P155, DOI 10.1037/0894-4105.13.2.155	27	80	80	0	40	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	8					1309	1325	PII 927588900	10.1080/13854046.2010.516072			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	685LA	WOS:000284629000005	20924979	Green Accepted, Green Published			2021-06-18	
J	Poddar, R; Paul, S				Poddar, Ranjana; Paul, Surojit			Homocysteine-NMDA receptor-mediated activation of extracellular signal-regulated kinase leads to neuronal cell death	JOURNAL OF NEUROCHEMISTRY			English	Article						Ca2+ influx; cAMP response-element binding protein; extracellular signal-regulated mitogen-activated protein kinase; homocysteine; neuronal cell death; NMDA receptors	D-ASPARTATE RECEPTOR; FOCAL CEREBRAL-ISCHEMIA; ELEMENT-BINDING PROTEIN; METABOTROPIC GLUTAMATE RECEPTORS; TRAUMATIC BRAIN-INJURY; MAP KINASE; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; PLASMA HOMOCYSTEINE; CORTICAL-NEURONS	Hyperhomocysteinemia is an independent risk factor for stroke and neurological abnormalities. However, the underlying cellular mechanisms by which elevated homocysteine can promote neuronal death is not clear. In the present study we have examined the role of NMDA receptor-mediated activation of the extracellular signal-regulated kinase-mitogen-activated protein (ERK-MAP) kinase pathway in homocysteine-dependent neurotoxicity. The study demonstrates that in neurons l-homocysteine-induced cell death was mediated through activation of NMDA receptors. The study also shows that homocysteine-dependent NMDA receptor stimulation and resultant Ca2+ influx leads to rapid and sustained phosphorylation of ERK-MAP kinase. Inhibition of ERK phosphorylation attenuates homocysteine-mediated neuronal cell death thereby demonstrating that activation of ERK-MAP kinase signaling pathway is an intermediate step that couples homocysteine-mediated NMDA receptor stimulation to neuronal death. The findings also show that cAMP response-element binding protein (CREB), a pro-survival transcription factor and a downstream target of ERK, is only transiently activated following homocysteine exposure. The sustained activation of ERK but a transient activation of CREB together suggest that exposure to homocysteine initiates a feedback loop that shuts off CREB signaling without affecting ERK phosphorylation and thereby facilitates homocysteine-mediated neurotoxicity.	[Poddar, Ranjana; Paul, Surojit] Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA	Poddar, R (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Neurol, 1 Univ New Mexico, Albuquerque, NM 87131 USA.	rpoddar@salud.unm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 RR15636]; New Mexico Trust Fund, UNM HSC RAC; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015636] Funding Source: NIH RePORTER	We would like to thank CW Shuttleworth and JA Connor for their helpful comments. This work was supported by the National Institutes of Health Grants P20 RR15636 (Okada, Y.) and New Mexico Trust Fund, UNM HSC RAC (Poddar, R).	Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Austin RC, 2004, CELL DEATH DIFFER, V11, pS56, DOI 10.1038/sj.cdd.4401451; Banko JL, 2004, J NEUROCHEM, V91, P462, DOI 10.1111/j.1471-4159.2004.02734.x; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Blum S, 1999, J NEUROSCI, V19, P3535; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROCH OJ, 1984, J NEUROCHEM, V43, P1755, DOI 10.1111/j.1471-4159.1984.tb06105.x; Cao J, 2005, J CELL BIOL, V168, P117, DOI 10.1083/jcb.200407024; Chandler LJ, 2001, J BIOL CHEM, V276, P2627, DOI 10.1074/jbc.M003390200; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; Coogan AN, 1999, J NEUROPHYSIOL, V81, P103; DAXHELET GA, 1989, ANAL BIOCHEM, V179, P401, DOI 10.1016/0003-2697(89)90152-8; den Heijer T, 2003, BRAIN, V126, P170, DOI 10.1093/brain/awg006; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Duan W, 2002, J NEUROCHEM, V80, P101, DOI 10.1046/j.0022-3042.2001.00676.x; Durkin JP, 1996, J NEUROCHEM, V66, P951; Endres M, 2005, STROKE, V36, P321, DOI 10.1161/01.STR.0000153008.60517.ab; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; Gottfries CG, 1998, J NEURAL TRANSM, V105, P773, DOI 10.1007/s007020050094; Hankey GJ, 2001, CURR OPIN NEUROL, V14, P95, DOI 10.1097/00019052-200102000-00015; Hara T, 2003, J NEUROCHEM, V86, P805, DOI 10.1046/j.1471-4159.2003.01847.x; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Ho PI, 2002, J NEUROSCI RES, V70, P694, DOI 10.1002/jnr.10416; Irving EA, 2000, MOL BRAIN RES, V77, P65, DOI 10.1016/S0169-328X(00)00043-7; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Jara-Prado A, 2003, NEUROTOX RES, V5, P237, DOI 10.1007/BF03033381; Jiang Q, 2000, BRAIN RES, V887, P285, DOI 10.1016/S0006-8993(00)03003-1; Jiang Q, 2000, BRAIN RES, V857, P71, DOI 10.1016/S0006-8993(99)02364-1; Kamath AF, 2006, BLOOD, V107, P591, DOI 10.1182/blood-2005-06-2506; Kim MJ, 2005, NEURON, V46, P745, DOI 10.1016/j.neuron.2005.04.031; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Lazarewicz JW, 2003, NEUROCHEM RES, V28, P259, DOI 10.1023/A:1022329317218; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lenz G, 2005, J BIOL CHEM, V280, P38121, DOI 10.1074/jbc.C500363200; Lesuisse C, 2002, J CEREBR BLOOD F MET, V22, P935, DOI 10.1097/00004647-200208000-00005; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Luchowska E, 2005, J NEUROSCI RES, V79, P375, DOI 10.1002/jnr.20359; Luo JH, 1997, MOL PHARMACOL, V51, P79; Mabuchi T, 2001, J NEUROSCI, V21, P9204, DOI 10.1523/JNEUROSCI.21-23-09204.2001; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miller JW, 1999, NUTR REV, V57, P126; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Obeid R, 2006, FEBS LETT, V580, P2994, DOI 10.1016/j.febslet.2006.04.088; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; Pende M, 1997, J NEUROSCI, V17, P1291; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; PHILLIS JW, 1994, NEUROCHEM RES, V19, P1125, DOI 10.1007/BF00965145; Poddar R, 2001, CIRCULATION, V103, P2717; Robert K, 2005, NEUROSCIENCE, V133, P925, DOI 10.1016/j.neuroscience.2005.03.034; Runden E, 1998, J NEUROSCI, V18, P7296; Sacco RL, 1998, NEUROEPIDEMIOLOGY, V17, P167, DOI 10.1159/000026169; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Shi Q, 2003, J PHARMACOL EXP THER, V305, P131, DOI 10.1124/jpet.102.047092; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; VANDENBERG M, 1995, EUR J CLIN INVEST, V25, P176; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Vincent SR, 1998, SYNAPSE, V29, P29, DOI 10.1002/(SICI)1098-2396(199805)29:1<29::AID-SYN3>3.3.CO;2-T; Wang ZQ, 2004, BRAIN RES, V996, P55, DOI 10.1016/j.brainres.2003.09.074; WATKINS D, 1989, AM J MED GENET, V34, P427, DOI 10.1002/ajmg.1320340320; Waxman EA, 2005, J BIOL CHEM, V280, P29322, DOI 10.1074/jbc.M502080200; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yun HY, 1999, DIABETES RES CLIN PR, V45, P113, DOI 10.1016/S0168-8227(99)00039-X; Yuzaki M, 1999, J NEUROPHYSIOL, V82, P2820; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367; Zieminska E, 2003, NEUROCHEM INT, V43, P481, DOI 10.1016/S0197-0186(03)00038-X; Zoccolella Stefano, 2006, Current Vascular Pharmacology, V4, P237, DOI 10.2174/157016106777698414	79	80	83	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2009	110	3					1095	1106		10.1111/j.1471-4159.2009.06207.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	470IP	WOS:000267968700030	19508427	Green Accepted, Bronze			2021-06-18	
J	Gubern, C; Hurtado, O; Rodriguez, R; Morales, JR; Romera, VG; Moro, MA; Lizasoain, I; Serena, J; Mallolas, J				Gubern, Carme; Hurtado, Olivia; Rodriguez, Rocio; Morales, Jesus R.; Romera, Victor G.; Moro, Maria A.; Lizasoain, Ignacio; Serena, Joaquin; Mallolas, Judith			Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia	BMC MOLECULAR BIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; RT-PCR; EXPERIMENTAL STROKE; ARTERY OCCLUSION; DISEASE-MODELS; ANIMAL-MODEL; RAT-BRAIN; EXPRESSION; NORMALIZATION; NEUROPROTECTION	Background: Studies of gene expression in experimental cerebral ischaemia models can contribute to understanding the pathophysiology of brain ischaemia and to identifying prognostic markers and potential therapeutic targets. The normalization of relative qRT-PCR data using a suitable reference gene is a crucial prerequisite for obtaining reliable conclusions. No validated housekeeping genes have been reported for the relative quantification of the mRNA expression profile activated in in-vitro ischaemic conditions, whereas for the in-vivo model different reference genes have been used. The present study aims to determine the expression stability of ten housekeeping genes (Gapdh, beta 2m, Hprt, Ppia, Rpl13a, Oaz1, 18S rRNA, Gusb, Ywhaz and Sdha) to establish their suitability as control genes for in-vitro and in-vivo cerebral ischaemia models. Results: The expression stability of the candidate reference genes was evaluated using the 2(-Delta CT) method and ANOVA followed by Dunnett's test. For the in-vitro model using primary cultures of rat astrocytes, all genes analysed except for Rpl13a and Sdha were found to have significantly different levels of mRNA expression. These different levels were also found in the case of the in-vivo model of pMCAO in rats except for Hprt, Sdha and Ywhaz mRNA, where the expression did not vary. Sdha and Ywhaz were identified by geNorm and NormFinder as the two most stable genes. Conclusion: We have validated endogenous control genes for qRT-PCR analysis of gene expression in in-vitro and in-vivo cerebral ischaemia models. For normalization purposes, Rpl13a and Sdha are found to be the most suitable genes for the in-vitro model and Sdha and Ywhaz for the in-vivo model. Genes previously used as housekeeping genes for the in-vivo model in the literature were not validated as good control genes in the present study, showing the need for careful evaluation for each new experimental setup.	[Gubern, Carme; Rodriguez, Rocio; Romera, Victor G.; Serena, Joaquin; Mallolas, Judith] Hosp Girona Dr Josep Trueta, Fundacio Privada, Inst Invest Biomed Girona Dr Josep Trueta IDIBGi, Serv Neurol, Girona, Spain; [Hurtado, Olivia; Morales, Jesus R.; Moro, Maria A.; Lizasoain, Ignacio] Univ Complutense Madrid, Fac Med, Dept Farmacol, Madrid, Spain	Mallolas, J (corresponding author), Hosp Girona Dr Josep Trueta, Fundacio Privada, Inst Invest Biomed Girona Dr Josep Trueta IDIBGi, Serv Neurol, Girona, Spain.	cgubern.girona.ics@gencat.cat; olhurtad@med.ucm.es; rociorodriguez.girona.ics@gencat.cat; jrmorales@med.ucm.es; vgromera@gmail.com; neurona@med.ucm.es; ignacio.lizasoain@med.ucm.es; jserena.girona.ics@gencat.cat; jmallolas.girona.ics@gencat.cat	Moro, Maria/K-6396-2014; HURTADO, OLIVIA/E-7248-2012; Lizasoain, Ignacio/K-9844-2014	Moro, Maria/0000-0003-1010-8237; HURTADO, OLIVIA/0000-0001-5735-7092; Lizasoain, Ignacio/0000-0002-6028-7379; Gubern Merida, Carme/0000-0001-8378-4477; , Victor/0000-0002-5424-7362	Spanish Ministry of Science and InnovationSpanish Government; European Regional Development Fund (ERDF)European Commission [CIT 090100-2005-15, CIT 090100-2007-43, CIT 090000-2008-11]; Institut de Salud Carlos III (ISCIII)Instituto de Salud Carlos III [FIS-PI070322, RD06/0026/0005, RD07/0026/2002]; Generalitat de CatalunyaGeneralitat de Catalunya [RDITSCON07-1-0006]; Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR) [2007 BE-100293]	This work was partially supported by the Spanish Ministry of Science and Innovation and the European Regional Development Fund (ERDF) PROFIT grant nos. CIT 090100-2005-15, CIT 090100-2007-43, CIT 090000-2008-11 (J. Mallolas and I. Lizasoain), Spanish Ministry of Science and Innovation, Institut de Salud Carlos III (ISCIII) grant nos. FIS-PI070322 (J. Mallolas), ISCIII retics-RENEVAS-RD06/0026/0005 (MA. Moro) and RD07/0026/2002 (J. Serena) and the Centre d'Innovacio i Desenvolupament Empresarial (CIDEM) of the Generalitat de Catalunya (grant no. RDITSCON07-1-0006). C. Gubern was recipient of a BE grant no. 2007 BE-100293 from the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR).	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Bond BC, 2002, MOL BRAIN RES, V106, P101, DOI 10.1016/S0169-328X(02)00417-5; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; BRINT S, 1988, J CEREBR BLOOD F MET, V8, P474, DOI 10.1038/jcbfm.1988.88; Buga AM, 2008, J CELL MOL MED, V12, P2731, DOI 10.1111/j.1582-4934.2008.00252.x; Candelario-Jalil E, 2008, CURR PHARM DESIGN, V14, P1401, DOI 10.2174/138161208784480216; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Cook NL, 2009, J NEUROSCI RES, V87, P34, DOI 10.1002/jnr.21846; Coulson DTR, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-46; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; Derks NM, 2008, NEUROSCIENCE, V156, P305, DOI 10.1016/j.neuroscience.2008.07.047; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Hurtado O, 2008, NEUROBIOL DIS, V29, P123, DOI 10.1016/j.nbd.2007.08.004; Hurtado O, 2005, NEUROBIOL DIS, V18, P336, DOI 10.1016/j.nbd.2004.10.006; Keyvani K, 2002, J CEREBR BLOOD F MET, V22, P153, DOI 10.1097/00004647-200202000-00003; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Langnaese K, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-53; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mallolas J, 2006, J EXP MED, V203, P711, DOI 10.1084/jem.20051979; Matsushita K, 1998, NEUROSCIENCE, V83, P439, DOI 10.1016/S0306-4522(97)00391-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McNeill RE, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-107; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; Meldgaard M, 2006, J NEUROSCI METH, V156, P101, DOI 10.1016/j.jneumeth.2006.02.008; Morales JR, 2008, CIRCULATION, V118, P1450, DOI 10.1161/CIRCULATIONAHA.108.782300; Rhinn H, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-62; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schwarz DA, 2002, MOL BRAIN RES, V101, P12, DOI 10.1016/S0169-328X(02)00135-3; Sobrado M, 2009, J NEUROSCI, V29, P3875, DOI 10.1523/JNEUROSCI.5529-08.2009; Splegler M, 2007, J NEUROPATH EXP NEUR, V66, P481, DOI 10.1097/01.jnen.0000263875.22306.3c; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P61, DOI 10.1038/jcbfm.1981.7; Tanic N, 2007, J MOL NEUROSCI, V32, P38, DOI 10.1007/s12031-007-0006-7; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Tian YF, 2007, ACTA ANAESTH SCAND, V51, P158, DOI 10.1111/j.1399-6576.2006.01161.x; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034	42	80	81	0	21	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2199			BMC MOL BIOL	BMC Mol. Biol.	JUN 16	2009	10								57	10.1186/1471-2199-10-57			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	469VC	WOS:000267927800001	19531214	Green Published, Other Gold			2021-06-18	
J	Fujita, T; Tozaki-Saitoh, H; Inoue, K				Fujita, Takumi; Tozaki-Saitoh, Hidetoshi; Inoue, Kazuhide			P2Y(1) Receptor Signaling Enhances Neuroprotection by Astrocytes Against Oxidative Stress via IL-6 Release in Hippocampal Cultures	GLIA			English	Article						adenosine triphosphate; cell survival; cytokines; cytoprotection; hippocampus	NECROSIS-FACTOR-ALPHA; FRESHLY ISOLATED ASTROCYTES; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; PC12 CELLS; HYDROGEN-PEROXIDE; GROWTH-FACTOR; SYNAPTIC-TRANSMISSION; GLUTAMATE EXOCYTOSIS; INTERLEUKIN-6 IL-6	Cell survival is a critical issue in the onset and progression of neurodegenerative diseases and following pathological events including ischemia and traumatic brain injury. Oxidative stress is the main cause of cell damage in such pathological conditions. Here, we report that adenosine 5'-triphosphate (ATP) protects hippocampal astrocytes from hydrogen peroxide (H2O2)-evoked oxidative injury in astrocyte monocultures. The effect of ATP was prevented by a selective antagonist of or siRNAs against P2Y(1)R. Interestingly, in astrocyte-neuron cocultures, ATP also produced neuroprotective effects against H2O2-evoked neuronal cell death, whereas ATP did not produce any neuroprotective effects in monocultures. The ATP-induced neuroprotection in cocultures was completely inhibited by silencing of astrocytic P2Y(1)R expression, indicating that ATP acts on astrocytes and enhances their neuroprotective functions by activating P2Y(1)R. Furthermore, this neuroprotective effect was mimicked by applying conditioned medium from astrocytes that had been stimulated by ATP, implying an involvement of diffusible factors from astrocytes. We found that, in both purified astrocyte cultures and astrocyte-neuronal cocultures, ATP and the P2Y(1)R agonist 2-methylthioadenosine 5' diphosphate (2MeSADP) induced the release of interleukin-6 (IL-6), but this did not occur in neuron monocultures. Moreover, exogenous IL-6 produced a neuroprotective effect, and the neuroprotection induced by P2Y(1)R-stimulated astrocytes was prevented in the presence of an anti-IL-6 antibody. Taken together, these results suggest that P2Y(1)R-stimulated astrocytes protect against neuronal damage induced by oxidative stress, and that IL-6 is a crucial signaling molecule released from astrocytes. Thus, activation of P2Y(1)R in astrocytes may rescue neurons from secondary cell death under pathological conditions. (C) 2008 Wiley-Liss, Inc.	[Inoue, Kazuhide] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, Fukuoka 8128582, Japan	Inoue, K (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, 3-1-1 Maidashi Collabostn 11-Rm 410, Fukuoka 8128582, Japan.	inoue@phar.kyushu-u.ac.jp		, hidetoshi/0000-0003-0423-2143	Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21790080] Funding Source: KAKEN	Grant sponsor: Ministry of Education, Science, Sports and Culture of Japan.	Abbracchio MP, 1999, PROG BRAIN RES, V120, P333; Abe K, 1996, J NEUROCHEM, V67, P2074; AGARDH CD, 1991, INT J DEV NEUROSCI, V9, P127, DOI 10.1016/0736-5748(91)90003-5; Aihara H, 2002, BRAIN RES, V952, P31, DOI 10.1016/S0006-8993(02)03185-2; Amadio S, 2002, NEUROPHARMACOLOGY, V42, P489, DOI 10.1016/S0028-3908(01)00197-6; Arthur DB, 2007, J NEUROCHEM, V100, P1257, DOI 10.1111/j.1471-4159.2006.04305.x; Arthur DB, 2006, J NEUROSCI, V26, P3798, DOI 10.1523/JNEUROSCI.5338-05.2006; BANKER GA, 1980, SCIENCE, V209, P809, DOI 10.1126/science.7403847; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Belliveau DJ, 2006, J BIOL CHEM, V281, P20920, DOI 10.1074/jbc.M600026200; Benjelloun N, 1998, CELL MOL BIOL, V44, P579; Bennett GC, 2003, BRIT J PHARMACOL, V139, P279, DOI 10.1038/sj.bjp.0705242; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Bissonnette CJ, 2004, NEUROSCI LETT, V361, P40, DOI 10.1016/j.neulet.2004.01.005; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Burnstock G, 2004, CURR TOP MED CHEM, V4, P793, DOI 10.2174/1568026043451014; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Carlson NG, 1999, J IMMUNOL, V163, P3963; Chen WC, 1998, GLIA, V22, P360, DOI 10.1002/(SICI)1098-1136(199804)22:4<360::AID-GLIA5>3.0.CO;2-7; Cheung KK, 2003, DEV DYNAM, V228, P254, DOI 10.1002/dvdy.10378; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; D'Ambrosi N, 2001, NEUROSCIENCE, V108, P527, DOI 10.1016/S0306-4522(01)00431-6; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Desagher S, 1996, J NEUROSCI, V16, P2553; Domercq M, 2006, J BIOL CHEM, V281, P30684, DOI 10.1074/jbc.M606429200; Fiebich BL, 2005, NEUROCHEM INT, V46, P501, DOI 10.1016/j.neuint.2004.11.009; Fiebich BL, 1996, J NEUROCHEM, V66, P1426; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Franke H, 1999, GLIA, V28, P190, DOI 10.1002/(SICI)1098-1136(199912)28:3<190::AID-GLIA3>3.3.CO;2-S; Franke H, 2006, PHARMACOL THERAPEUT, V109, P297, DOI 10.1016/j.pharmthera.2005.06.002; FUKUDA J, 1983, J NEUROSCI METH, V8, P295, DOI 10.1016/0165-0270(83)90042-0; Giffard RG, 2005, GLIA, V50, P299, DOI 10.1002/glia.20167; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Heine C, 2006, NEUROSCIENCE, V138, P303, DOI 10.1016/j.neuroscience.2005.11.056; Herpers BL, 1999, NEUROREPORT, V10, P2647, DOI 10.1097/00001756-199908200-00038; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Inoue K, 1999, PROG BRAIN RES, V120, P193; Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849; Kawamura M, 2004, J NEUROSCI, V24, P10835, DOI 10.1523/JNEUROSCI.3028-04.2004; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Koizumi S, 2003, P NATL ACAD SCI USA, V100, P11023, DOI 10.1073/pnas.1834448100; Koizumi Schuichi, 2004, Nihon Yakurigaku Zasshi, V123, P389; Lin JHC, 2007, DEV BIOL, V302, P356, DOI 10.1016/j.ydbio.2006.09.017; Liu JSH, 2000, J NEUROSCI, V20, P5292, DOI 10.1523/JNEUROSCI.20-14-05292.2000; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Matsuda S, 1996, NEUROSCI LETT, V204, P109, DOI 10.1016/0304-3940(96)12340-5; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; MATTSON MP, 1990, INT J DEV NEUROSCI, V8, P399, DOI 10.1016/0736-5748(90)90073-B; Mattson MP, 1996, NEUROBIOL AGING, V17, P485, DOI 10.1016/0197-4580(96)00016-4; Moran-Jimenez MJ, 2000, MOL BRAIN RES, V78, P50, DOI 10.1016/S0169-328X(00)00067-X; Nakajima A, 2002, FREE RADICAL BIO MED, V32, P1324, DOI 10.1016/S0891-5849(02)00845-6; Neary JT, 2004, NEUROCHEM RES, V29, P2037, DOI 10.1007/s11064-004-6876-y; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NORRIS JG, 1994, J IMMUNOL, V152, P841; Novak I, 2003, NEWS PHYSIOL SCI, V18, P12, DOI 10.1152/nips.01409.2002; Pavelko KD, 2003, J NEUROSCI, V23, P481; PEARCE B, 1994, BRAIN RES, V660, P329, DOI 10.1016/0006-8993(94)91307-2; Peng YP, 2005, NEUROSCI LETT, V374, P192, DOI 10.1016/j.neulet.2004.10.069; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Pizzi M, 2004, MOL CELL NEUROSCI, V25, P301, DOI 10.1016/j.mcn.2003.10.022; Pousset F, 1999, GLIA, V26, P12, DOI 10.1002/(SICI)1098-1136(199903)26:1<12::AID-GLIA2>3.0.CO;2-S; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rathbone MP, 1999, PROG NEUROBIOL, V59, P663, DOI 10.1016/S0301-0082(99)00017-9; Ryu JK, 2002, NEUROREPORT, V13, P1611, DOI 10.1097/00001756-200209160-00008; Shinozaki Y, 2005, GLIA, V49, P288, DOI 10.1002/glia.20118; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Tabner Brian J., 2001, Current Topics in Medicinal Chemistry, V1, P507, DOI 10.2174/1568026013394822; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Volonte C, 2003, CNS NEUROL DISORD-DR, V2, P403, DOI 10.2174/1568007033482643; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Yamada K, 1997, BRAIN RES BULL, V43, P573, DOI 10.1016/S0361-9230(96)00336-X; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; Zhu YZ, 2004, DEV BRAIN RES, V148, P77, DOI 10.1016/j.devbrainres.2003.10.014; Zhu YZ, 2001, J NEUROCHEM, V77, P530, DOI 10.1046/j.1471-4159.2001.00241.x	82	80	82	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2009	57	3					244	257		10.1002/glia.20749			14	Neurosciences	Neurosciences & Neurology	392BF	WOS:000262277200002	18756525				2021-06-18	
J	Jin, W; Wang, HD; Yan, W; Zhu, L; Hu, ZG; Ding, YS; Tang, K				Jin, Wei; Wang, Handong; Yan, Wei; Zhu, Lin; Hu, Zhigang; Ding, Yasuo; Tang, Ke			Role of Nrf2 in Protection against Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; nuclear factor erythroid 2-related factor 2; oxidative stress; traumatic brain injury	CEREBRAL-ISCHEMIA; ENHANCES SUSCEPTIBILITY; NRF2-DEFICIENT MICE; OXIDATIVE STRESS; IN-VIVO; EXPRESSION; PATHWAY; ANTIOXIDANTS; INDUCTION; REDUCTASE	Previous studies have shown that nuclear factor erythroid 2-related factor 2 (Nrf2) plays a unique role in many physiological stress processes. The present study investigated the role of Nrf2 in modulating traumatic brain injury (TBI)-induced secondary brain injury. Wild-type Nrf2 (+/+) and Nrf2 (-/-)-deficient mice were subjected to a moderately severe weight-drop impact head injury. The absence of Nrf2 function in mice resulted in exacerbated brain injury as shown by the increased severity of neurological deficit, apoptosis, and brain edema at 24 h after TBI. This exacerbation of brain injury in Nrf2-deficient mice was associated with increased mRNA and protein expression of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6), and with decreased mRNA expression and enzymatic activity of antioxidant and detoxifying enzymes including NAD(P) H: quinone oxidoreductase 1 (NQO1) and glutathione S-transferase alpha-1 (GST-alpha 1), compared with their wild-type counterparts after TBI. In combination, these results suggest that Nrf2 plays an important role in protecting TBI-induced secondary brain injury, possibly by regulating inflammatory cytokines and inducing antioxidant and detoxifying enzymes.	[Jin, Wei; Wang, Handong; Zhu, Lin; Hu, Zhigang; Ding, Yasuo; Tang, Ke] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China; [Yan, Wei] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hdwang_jw@yahoo.com.cn		Yan, Wei/0000-0002-1123-0835	Jinling Hospital of Nanjing, China	This work was supported by grants from Jinling Hospital of Nanjing, China. The authors would like to thank Dr. Bo Wu and Dr. Geng-bao Feng for technical assistance.	Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Beaumont A, 2002, ACT NEUR S, V81, P217; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kelly VP, 2000, CANCER RES, V60, P957; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Laxton AW, 2001, NEUROREPORT, V12, P1045, DOI 10.1097/00001756-200104170-00036; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Naga KK, 2007, NEUROL RES, V29, P877, DOI 10.1179/016164107X181842; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Ramsey CP, 2007, J NEUROPATH EXP NEUR, V66, P75, DOI 10.1097/nen.0b013e31802d6da9; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; RIINK A, 1995, AM J PATHOL, V147, P1575; Shah ZA, 2007, NEUROSCIENCE, V147, P53, DOI 10.1016/j.neuroscience.2007.02.066; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Smeyne M, 2007, P NATL ACAD SCI USA, V104, P1977, DOI 10.1073/pnas.0610978104; Stringer JL, 2004, J COMP NEUROL, V471, P289, DOI 10.1002/cne.20048; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	45	80	85	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2009	26	1					131	139		10.1089/neu.2008.0655			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	409OW	WOS:000263516700011	19125683				2021-06-18	
J	Kohl, AD; Wylie, GR; Genova, HM; Hillary, FG; DeLuca, J				Kohl, A. D.; Wylie, G. R.; Genova, H. M.; Hillary, F. G.; DeLuca, J.			The neural correlates of cognitive fatigue in traumatic brain injury using functional MRI	BRAIN INJURY			English	Article						Cognitive fatigue; fMRI; fatigue; basal ganglia; traumatic brain injury	BASAL GANGLIA; HEAD-INJURY; ATTENTION DEFICITS; MENTAL FATIGUE; MEMORY; ACTIVATION; PERFORMANCE; ANATOMY; IMPACT; FMRI	Primary objective: The present study used fMRI (functional magnetic resonance imaging) to objectively assess cognitive fatigue in persons with traumatic brain injury (TBI). It was hypothesized that while performing a cognitive task, TBI participants would show increased brain activity over time, indicative of increased cerebral 'effort' which might manifest as the subjective feeling of cognitive fatigue. Methods and procedures: Functional MRI was used to track brain activity across time while 11 TBI patients with moderate-severe injury and 11 age-matched healthy controls (HCs) performed a modified Symbol Digit Modalities Task (mSDMT). Cognitive fatigue was operationally defined as a relative increase in cerebral activation across time compared to that seen in HCs. ROIs were derived from the Chauduri and Behan model of cognitive fatigue. Main outcomes and results: While performing the mSDMT, participants with a TBI showed increased activity, while HCs subsequently showed decreased activity in several regions including the middle frontal gyrus, superior parietal cortex, basal ganglia and anterior cingulate. Conclusions: Increased brain activity exhibited by participants with a TBI might represent increased cerebral effort which may be manifested as cognitive fatigue. Functional MRI appears to be a potentially useful tool for understanding the neural mechanisms associated with cognitive fatigue in TBI.	[Kohl, A. D.] Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ USA; [Kohl, A. D.; Wylie, G. R.; Genova, H. M.; DeLuca, J.] Kessler Fdn, Res Ctr, W Orange, NJ USA; [Wylie, G. R.; Genova, H. M.; DeLuca, J.] UMDNJ Grad Sch Biomed Sci, Dept Phys Med & Rehabil, Newark, NJ USA; [Wylie, G. R.; Genova, H. M.; DeLuca, J.] UMDNJ New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ USA; [Hillary, F. G.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA	Wylie, GR (corresponding author), Kessler Med Rehabil Res & Educ Ctr, Neuropsychol & Neurosci Lab, 300 Execut Dr,Suite 10, W Orange, NJ 07052 USA.	gwylie@kmrrec.org	Hillary, Frank/AAN-8622-2021		National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 R01 NS049176-01A2]; Henry H. Kessler foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049176] Funding Source: NIH RePORTER	This study was supported in part by a National Institute of Health grant (1 R01 NS049176-01A2) and by the Henry H. Kessler foundation.	AARONSON LS, 1999, IMAGE J NURSING SCH, V31, P41; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Bandettini PA, 1997, HUM BRAIN MAPP, V5, P93; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Centers for Disease Control and Prevention, 2001, INJ FACT BOOK 2001 2; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Christodoulou C, 2005, ISS CLIN COGN NEUROP, P19; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cook DB, 2007, NEUROIMAGE, V36, P108, DOI 10.1016/j.neuroimage.2007.02.033; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; DeLuca J, 2005, ISS CLIN COGN NEUROP, P37; DeLuca J, 2005, ISS CLIN COGN NEUROP, P319; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Duntley SP, 2005, ISS CLIN COGN NEUROP, P209; Elovic EP, 2005, ISS CLIN COGN NEUROP, P89; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Koch K, 2006, BRAIN RES, V1107, P140, DOI 10.1016/j.brainres.2006.06.003; Krupp LB, 1996, CURR OPIN NEUROL, V9, P456, DOI 10.1097/00019052-199612000-00011; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leung HC, 2002, J COGNITIVE NEUROSCI, V14, P659, DOI 10.1162/08989290260045882; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mulert C, 2005, INT J PSYCHOPHYSIOL, V56, P65, DOI 10.1016/j.ijpsycho.2004.10.002; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; PRIGITANO GP, 1975, AWARENESS DEFICITS B; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Schwid SR, 2003, MULT SCLER, V9, P503, DOI 10.1191/1352458503ms946oa; Seger CA, 2006, NEUROSCIENTIST, V12, P285, DOI 10.1177/1073858405285632; Shomstein S, 2006, J NEUROSCI, V26, P435, DOI 10.1523/JNEUROSCI.4408-05.2006; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Vuilleumier P, 2002, NAT NEUROSCI, V5, P491, DOI 10.1038/nn839; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	44	80	81	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	5					420	432	PII 910862632	10.1080/02699050902788519			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439NL	WOS:000265633700006	19408165				2021-06-18	
J	Turner, GR; Levine, B				Turner, Gary R.; Levine, Brian			Augmented neural activity during executive control processing following diffuse axonal injury	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; WORKING-MEMORY PERFORMANCE; PREFRONTAL CORTEX; FMRI DATA; MRI; NEUROPATHOLOGY; MANIPULATION; ACTIVATION; RECOVERY; DEFICITS	Background: Deficits in working memory are commonly observed after traumatic brain injury (TBI), with executive control processes preferentially impacted relative to storage and rehearsal. Previous activation functional neuroimaging investigations of working memory in patients with TBI have reported altered functional recruitment, but methodologic issues including sample heterogeneity (e. g., variability in injury mechanism, severity, neuropathology or chronicity), underspecified definitions of "working memory," and behavioral differences between TBI and control groups have hindered interpretation of these changes. Methods: Executive control processing in working memory was explicitly engaged during fMRI in a sample of carefully selected chronic-stage, moderate-to-severe TBI patients with diffuse axonal injury (DAI) but without focal lesions. Results: Despite equivalent task performance, we observed a pattern of greater recruitment of interhemispheric and intrahemispheric regions of prefrontal cortex (PFC) and posterior cortices in our DAI sample. Enhanced activations were recorded in the left dorsolateral PFC (middle frontal gyrus), right ventrolateral PFC (inferior frontal gyrus), bilateral posterior parietal cortices, and left temporo-occipital junction. Region-of-interest analyses confirmed that these effects were robust across individual patients and could not be attributed to load factors or slowed speed of processing. Conclusions: Augmented functional recruitment in the context of normal behavioral performance may be a neural marker of capacity or efficiency limits that can affect functional outcome after traumatic brain injury with diffuse injury.	[Turner, Gary R.; Levine, Brian] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; [Turner, Gary R.; Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON, Canada	Levine, B (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@rotman-baycrest.on.ca	Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD42385-01] Funding Source: Medline		Baddeley A. D., 1986, WORKING MEMORY; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Courville C. B., 1937, PATHOLOGY CENTRAL 4; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Craik F.I.M., 1986, HUMAN MEMORY COGNITI, P409; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; D'Esposito M, 1999, BRAIN COGNITION, V41, P66, DOI 10.1006/brcg.1999.1096; D'Esposito M, 2006, J INT NEUROPSYCH SOC, V12, P248, DOI 10.1017/S1355617706060322; FUJIWARA E, NEUROPSYCHO IN PRESS; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Kane MJ, 2004, J EXP PSYCHOL GEN, V133, P189, DOI 10.1037/0096-3445.133.2.189; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Petrides M, 1999, EUR J NEUROSCI, V11, P1011, DOI 10.1046/j.1460-9568.1999.00518.x; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Postle BR, 1999, P NATL ACAD SCI USA, V96, P12959, DOI 10.1073/pnas.96.22.12959; Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Zachary R., 1986, SHIPLEY I LIVING SCA	31	80	80	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP 9	2008	71	11					812	818		10.1212/01.wnl.0000325640.18235.1c			7	Clinical Neurology	Neurosciences & Neurology	345ZU	WOS:000259039000007	18779509	Green Published			2021-06-18	
J	Schreiber, S; Barkai, G; Gur-Hartman, T; Peles, E; Tov, N; Dolberg, OT; Pick, CG				Schreiber, Shaul; Barkai, Gabriel; Gur-Hartman, Tamar; Peles, Einat; Tov, Naveh; Dolberg, Ornah T.; Pick, Chaim G.			Long-lasting sleep patterns of adult patients with minor traumatic brain injury (mTBI) and non-mTBI subjects	SLEEP MEDICINE			English	Article						adults; minor traumatic brain injury (mTBI); multiple sleep latency test (MSLT); polysomnography (PSG)	HEAD-INJURY; COGNITIVE IMPAIRMENT; MEMORY CONSOLIDATION; PHASE SYNDROME; DISTURBANCES; COMPLAINTS; RECOVERY; INSOMNIA; MICE; REM	Background: Sleep disturbance is a common subjective complaint of minor traumatic brain-injured (mTBI) patients, but little is known about the characteristics of sleep disturbance in adults years after the injury. Methods: Polysomnographic (PSG) and multiple sleep latency test (MSLT) records of 26 mTBI adult patients with normal brain computerized tomography and negative encephalographic studies, no past history of CNS pathology, no premorbid or present major psychiatric diagnosis, and no sleep apnea syndrome were compared to a matched group of apparently healthy individuals (controls). Results: Sleep patterns were disturbed in the mTBI patients. Their sleep architecture was altered, with significantly higher light-sleep non-rapid eye movement (NREM) stage 2 scores compared to controls (54.5 +/- 13.4% vs. 46.6 +/- 10.40/0, respectively, p = 0.03) and significantly lower REM sleep scores (21.2 +/- 18.4% vs. 25.4 +/- 4.5%, respectively, p = 0.05). The MSLT findings documented significant excessive daytime episodes of falling asleep. Conclusions: Sleep disturbances of adult patients with chronic mTBI may manifest characteristic alterations in both timing and architecture of their sleep patterns. Sleep lab evaluations may help identify subgroups of mTBI patients who would probably benefit from treatment. (C) 2007 Elsevier B.V. All rights reserved.	[Schreiber, Shaul; Barkai, Gabriel; Dolberg, Ornah T.] Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-64239 Tel Aviv, Israel; [Schreiber, Shaul; Barkai, Gabriel; Dolberg, Ornah T.] Tel Aviv Univ, Sackler Fac Med, IL-64239 Tel Aviv, Israel; [Schreiber, Shaul; Barkai, Gabriel; Dolberg, Ornah T.] Neuropsychol Unit Treatment & Rehabil, Tel Aviv, Israel; [Schreiber, Shaul; Barkai, Gabriel; Dolberg, Ornah T.] Neuropsychol Unit Treatment & Rehabil, Jerusalem, Israel; [Gur-Hartman, Tamar; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Peles, Einat] Tel Aviv Sourasky Med Ctr, Dr Miriam & Sheldon G Adelson Clin Drug Abuse Tre, IL-64239 Tel Aviv, Israel; [Tov, Naveh] Bnai Zion Med Ctr, Dept Internal Med C, Haifa, Israel	Schreiber, S (corresponding author), Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-64239 Tel Aviv, Israel.	Shaldsch@tasmc.health.gov.il	Schreiber, Shaul/E-5821-2010; Sanguansri, Luz/B-6630-2011; Pick, Chaim/D-4789-2009	Schreiber, Shaul/0000-0002-2189-0693; Sanguansri, Luz/0000-0003-1908-7604; 			ALEXANDRIA VA, 2005, BRAIN INJ FACTS; Antoniadis EA, 2000, BEHAV BRAIN RES, V114, P219, DOI 10.1016/S0166-4328(00)00290-4; ARMITAGE R, 1995, SLEEP, V18, P334, DOI 10.1093/sleep/18.5.334; AUTRET A, 1990, PRESSE MED, V19, P1833; Autret A, 2001, NEUROPHYSIOL CLIN, V31, P356, DOI 10.1016/S0987-7053(01)00282-9; BEETAR J, 1996, AM J PHYS MED REHABI, V75, P63; Bonnet MH, 2003, SLEEP MED REV, V7, P297, DOI 10.1053/smrv.2001.0245; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; CARSKADON MA, 1994, PRINCIPLES PRACTICE; *CDCP, 2001, TRAUM BRAI INJ US RE; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CZEISLER CA, 1980, SCIENCE, V210, P1264, DOI 10.1126/science.7434029; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; GEORGE B, 1981, NEUROCHIRURGIE, V27, P35; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; KAUFMAN DM, 1995, CLIN NEUROLOGY PSYCH; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LENARD HG, 1970, ACTA PAEDIATR SCAND, V59, P565, DOI 10.1111/j.1651-2227.1970.tb16809.x; Maeda M, 1995, Rinsho Shinkeigaku, V35, P811; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Nagtegaal JE, 1997, FUNCT NEUROL, V12, P345; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PELED R, 1999, HAREFUAH, V137, P432; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; RECHTSCHALTEN A, 1968, NIH PUBLICATION, V204; REGESTEIN QR, 1995, AM J PSYCHIAT, V152, P602; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Rosenthal L, 2005, SLEEP MED, V6, P485, DOI 10.1016/j.sleep.2005.05.012; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; SCHREIBER S, 1998, J NEUROPSYCHIATRY CL, V9, P640; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Siegel JM, 2001, SCIENCE, V294, P1058, DOI 10.1126/science.1063049; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; TRONCOSO JC, 1996, HEAD INJURY POSTCONC; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vertes RP, 2004, NEURON, V44, P135, DOI 10.1016/j.neuron.2004.08.034; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	48	80	81	1	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	JUL	2008	9	5					481	487		10.1016/j.sleep.2007.04.014			7	Clinical Neurology	Neurosciences & Neurology	330BA	WOS:000257913100004	17638592				2021-06-18	
J	Flint, AC; Manley, GT; Gean, AD; Hemphill, JC; Rosenthal, G				Flint, Alexander C.; Manley, Geoffrey T.; Gean, Alisa D.; Hemphill, J. Claude, III; Rosenthal, Guy			Post-operative expansion of hemorrhagic contusions after unilateral decompressive hemicraniectomy in severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; clinical outcomes; clinical trial; decompressive hemicraniectomy; hemorrhagic contusions; hypothermia; subarachnoid hemorrhage	ACUTE INTRACEREBRAL HEMORRHAGE; PREDICTS HEMATOMA EXPANSION; INTRA-CEREBRAL HEMATOMAS; SEVERE HEAD TRAUMA; PROGNOSTIC VALUE; PERFUSION-CT; PROGRESSION; EXTRAVASATION; CRANIECTOMY; CONTRAST	Decompressive hemicraniectomy is commonly performed in patients with traumatic brain injury (TBI) with diffuse brain swelling or refractory raised intracranial pressure. Expansion of hemorrhagic contusions in TBI patients is common, but its frequency following decompressive hemicraniectomy has not been well established. The aim of this retrospective study was to determine the rate of hemorrhagic contusion expansion following unilateral hemicraniectomy in severe TBI, to identify factors associated with contusion expansion, and to examine whether contusion expansion is associated with worsened clinical outcomes. Computed tomography (CT) scans of 40 consecutive patients with non-penetrating TBI who underwent decompressive hemicraniectomy were analyzed. Hemorrhagic contusion volumes were measured on initial, last pre-operative, and first post-operative CT scans. Mortality and 6-month Glasgow Outcome Scale (GOS) score were recorded. Hemorrhagic contusions of any size were present on the initial head CT scan in 48% of patients, but hemorrhagic contusions with a total volume of >5 cc were present in only 10%. New or expanded hemorrhagic contusions of >= 5 cc were observed after hemicraniectomy in 58% of patients. The mean volume of increased hemorrhage among these patients was 37.1 +/- 36.3 cc. The Rotterdam CT score on the initial head CT was strongly associated with the occurrence and the total volume of expanded hemorrhagic contusions following decompressive hemicraniectomy. Expanded hemorrhagic contusion volume greater than 20 cc after hemicraniectomy was strongly associated with mortality and poor 6-month GOS even after controlling for age and initial Glasgow Coma Scale (GCS) score. Expansion of hemorrhagic contusions is common after decompressive hemicraniectomy following severe TBI. The volume of hemorrhagic contusion expansion following hemicraniectomy is strongly associated with mortality and poor outcome. Severity of initial CT findings may predict the risk of contusion expansion following hemicraniectomy, thereby identifying a subgroup of patients who might benefit from therapies aimed at augmenting the coagulation system.	[Flint, Alexander C.; Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, Neurovasc & Neurocrit Care Serv, San Francisco, CA 94143 USA; [Manley, Geoffrey T.; Rosenthal, Guy] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Gean, Alisa D.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Flint, Alexander C.; Manley, Geoffrey T.; Gean, Alisa D.; Hemphill, J. Claude, III; Rosenthal, Guy] Univ Calif San Francisco, USCF Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA	Manley, GT (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, 1001 Potrero Ave, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Flint, Alexander/0000-0002-3721-2694; Hemphill, Claude/0000-0003-4019-7525			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Becker KJ, 1999, STROKE, V30, P2025, DOI 10.1161/01.STR.30.10.2025; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Goldstein JN, 2007, NEUROLOGY, V68, P889, DOI 10.1212/01.wnl.0000257087.22852.21; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MAYER SA, 2007, 16 EUR STROK C GLASG; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; MURRAY L, 2007, 13 INT S INTR PRESS; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006	28	80	87	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2008	25	5					503	512		10.1089/neu.2007.0442			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	303PY	WOS:000256054100007	18346002				2021-06-18	
J	Narayan, RK; Maas, AIR; Marshall, LF; Servadei, F; Skolnick, BE; Tillinger, MN				Narayan, Raj K.; Maas, Andrew I. R.; Marshall, Lawrence F.; Servadei, Franco; Skolnick, Brett E.; Tillinger, Michael N.		rFVIIa Traumatic ICH Study Grp	Recombinant factor VIIA in traumatic intracerebral hemorrhage: Results of a dose-escalation clinical trial	NEUROSURGERY			English	Article						clinical trial; deep vein thrombosis; intracerebral hemorrhage; lesion expansion; recombinant factor VIIa; thromboembolic complications; traumatic brain injury	DEEP VENOUS THROMBOSIS; ACTIVATED FACTOR-VII; SEVERE HEAD-INJURY; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; TIME-COURSE; MANAGEMENT; CT; THROMBOEMBOLISM; COAGULOPATHY	OBJECTIVE: Intracerebral hemorrhages, whether spontaneous or traumatic (tICH), often expand, and an association has been described between hemorrhage expansion and worse clinical outcomes. Recombinant factor VIIa (rFVIIa) is a hemostatic agent that has been shown to limit hemorrhage expansion and which, therefore, could potentially reduce morbidity and mortality in tICH. This first prospective, randomized, placebo-controlled, dose-escalation study evaluated the safety and preliminary effectiveness of rFVIIa to limit tICH progression. METHODS: Patients were enrolled if they had tICH lesions of at least 2 ml on a baseline computed tomographic scan obtained within 6 hours of injury. rFVIIa or placebo was administered within 2.5 hours of the baseline computed tomographic scan but no later than 7 hours after injury. Computed tomographic scans were repeated at 24 and 72 hours. Five escalating dose tiers were evaluated (40, 80, 120, 160, and 200 mu g/kg rFVIIa). Clinical evaluations and adverse events were recorded until Day 15. RESULTS: No significant differences were detected in mortality rate or number and type of adverse events among treatment groups. Asymptomatic deep vein thrombosis, detected on routinely performed ultrasound at Day 3, was observed more frequently in the combined rFVIIa treatment group (placebo, 3%; rFVIIa, 8%; not significant). A nonsignificant trend for rFVIIa dose-response to limit tICH volume increase was observed (placebo, 21.0 ml; rFVIIa, 10.1 ml). CONCLUSION: In this first prospective study of rFVIIa in tICH, there appeared to be less hematoma progression in rFVIIa-treated patients (80-200 mu g/kg) compared with that seen in placebo treated patients. The potential significance of this biological effect on clinical outcomes and the significance of the somewhat higher incidence of ultrasound-detected deep vein thromboses in the rFVIIa-treated group need to be examined in a larger prospective randomized clinical trial.	[Narayan, Raj K.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Maas, Andrew I. R.] Erasmus MC, Rotterdam, Netherlands; [Marshall, Lawrence F.] Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA; [Servadei, Franco] Osped Maggiore Parma, Parma, Italy; [Skolnick, Brett E.; Tillinger, Michael N.] Novo Nordisk AS, Princeton, NJ USA	Narayan, RK (corresponding author), Univ Cincinnati, Univ Hosp, Inst Neurosci, Dept Neurosurg, 231 Albert Sabin Way,POB 670515, Cincinnati, OH 45267 USA.	raj.narayan@uc.edu	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264; Servadei, Franco/0000-0002-3595-3464			Andrews E James Jr, 2005, Ultrasound Q, V21, P213, DOI 10.1097/01.ruq.0000187024.54319.19; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; [Anonymous], 1997, ICH HARM TRIP GUID G; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carlile MC, 2006, J HEAD TRAUMA REHAB, V21, P483, DOI 10.1097/00001199-200611000-00003; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Crowther MA, 2005, J CRIT CARE, V20, P334, DOI 10.1016/j.jcrc.2005.09.011; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Fainardi E, 2004, ACTA NEUROCHIR, V146, P257, DOI 10.1007/s00701-003-0207-y; FUJITSU K, 1990, J NEUROSURG, V73, P518, DOI 10.3171/jns.1990.73.4.0518; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Hawryluk GWJ, 2006, J NEUROSURG, V105, P859, DOI 10.3171/jns.2006.105.6.859; Karadimov D, 2003, J NEUROSURG ANESTH, V15, P330, DOI 10.1097/00008506-200310000-00008; King BS, 2000, SURG CLIN N AM, V80, P855, DOI 10.1016/S0039-6109(05)70100-6; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Levy JH, 2006, TRANSFUSION, V46, P919, DOI 10.1111/j.1537-2995.2006.00824.x; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marion DW, 2006, NEUROSURGERY, V58, P655; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pathak A, 2005, Neurol India, V53, P178; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2000, NEUROSURGERY, V46, P70; Siddique MS, 2002, J NEUROSURG, V96, P86, DOI 10.3171/jns.2002.96.1.0086; Siegel LJ, 2004, ANESTHESIOLOGY, V100, P441, DOI 10.1097/00000542-200402000-00037; Stawicki SP, 2005, AM SURGEON, V71, P387; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wittebole X, 2005, J ELECTROCARDIOL, V38, P77, DOI 10.1016/j.jelectrocard.2004.09.004; World Medical Association General Assembly, 2004, J Int Bioethique, V15, P124; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; Zaaroor M, 2004, SEMIN HEMATOL, V41, P175, DOI 10.1053/j.seminhematol.2003.11.033	45	80	86	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2008	62	4					776	786		10.1227/01.NEU.0000297095.04013.C4			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	294TR	WOS:000255429300014	18496183				2021-06-18	
J	Whalen, MJ; Dalkara, T; You, ZR; Qiu, JH; Bermpohl, D; Mehta, N; Suter, B; Bhide, PG; Lo, EH; Ericsson, M; Moskowitz, MA				Whalen, Michael J.; Dalkara, Turgay; You, Zerong; Qiu, Jianhua; Bermpohl, Daniela; Mehta, Niyati; Suter, Bernhard; Bhide, Pradeep G.; Lo, Eng H.; Ericsson, Maria; Moskowitz, Michael A.			Acute plasmalemma permeability and protracted clearance of injured cells after controlled cortical impact in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; mice; necrosis; plasmalemma; propidium iodide; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DEATH MECHANISMS; HEAD-INJURY; RATS; INHIBITOR; APOPTOSIS; NECROSIS; CULTURES; NEURONS; MOUSE	Cell death after traumatic brain injury (TBI) evolves over days to weeks. Despite advances in understanding biochemical mechanisms that contribute to posttraumatic brain cell death, the time course of cell injury, death, and removal remains incompletely characterized in experimental TBI models. In a mouse controlled cortical impact (CCI) model, plasmalemma permeability to propidium iodide (PI) was an early and persistent feature of posttraumatic cellular injury in cortex and hippocampus. In cortical and hippocampal brain regions known to be vulnerable to traumatic cell death, the number of PI + cells peaked early after CCI, and increased with increasing injury severity in hippocampus but not cortex (P < 0.05). Propidium iodide labeling correlated strongly with hematoxylin and eosin staining in injured cells (r = 0.99, P < 0.001), suggesting that plasmalemma damage portends fatal cellular injury. Using PI pulse labeling to identify and follow the fate of a cohort of injured cells, we found that many PI + cells recovered plasmalemma integrity by 24 h and were terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling negative, but nonetheless disappeared from injured brain by 7 days. Propidium iodide-positive cells in dentate gyrus showed significant ultrastructural damage, including plasmalemma and nuclear membrane damage or overt membrane loss, in all cells when examined by laser capture microdissection and transmission electron microscopy 1 to 24 h after CCI. The data suggest that plasmalemma damage is a fundamental marker of cellular injury after CCI; some injured cells might have an extended window for potential rescue by neuroprotective strategies.	[Whalen, Michael J.; Dalkara, Turgay; You, Zerong; Qiu, Jianhua; Bermpohl, Daniela; Mehta, Niyati; Suter, Bernhard; Bhide, Pradeep G.; Lo, Eng H.; Moskowitz, Michael A.] Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, Charlestown, MA 02129 USA; [Whalen, Michael J.; You, Zerong] Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Whalen, Michael J.; Qiu, Jianhua; Bermpohl, Daniela; Lo, Eng H.; Moskowitz, Michael A.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Suter, Bernhard; Bhide, Pradeep G.; Lo, Eng H.; Moskowitz, Michael A.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; [Ericsson, Maria] Harvard Univ, Sch Med, Electron Microscopy Facil, Boston, MA USA	Whalen, MJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, 149 13th St, Charlestown, MA 02129 USA.	MWhalen@Partners.org	Moskowitz, Michael A/D-9916-2011	Dalkara, Turgay/0000-0003-3943-7819; Bhide, Pradeep/0000-0003-4236-9415	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045776, R01NS053560, R01NS037074, R01NS047447, R01NS043426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA020796] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA020796, R01 DA020796-03] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037074, R01 NS 047447, P30 NS 45776, R01 NS043426-05, P30 NS045776, R01 NS 37074, R01 NS053560, R01 NS043426, R01 NS047447-03, P30 NS045776-06A17807, R01 NS 53560, R01 NS047447] Funding Source: Medline		BERMPOHL D, 2007, IN PRESS J CEREB BLO; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Castejon O. J., 2004, Journal of Submicroscopic Cytology and Pathology, V36, P167; Castejon O. J., 2004, Journal of Submicroscopic Cytology and Pathology, V36, P273; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P499, DOI 10.1007/BF00310026; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hamabe W, 2003, J PHARMACOL EXP THER, V307, P205, DOI 10.1124/jpet.103.053033; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kristensen BW, 2003, BRAIN RES, V964, P264, DOI 10.1016/S0006-8993(02)04080-5; Matsumoto Y, 2004, STROKE, V35, P185, DOI 10.1161/01.STR.0000106910.42815.C2; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saelens X, 2005, J CELL BIOL, V168, P545, DOI 10.1083/jcb.200407162; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Toth Z, 1997, J NEUROSCI, V17, P8106; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	34	80	80	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2008	28	3					490	505		10.1038/sj.jcbfm.9600544			16	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	266DA	WOS:000253410400007	17713463	Green Accepted, Bronze			2021-06-18	
J	Buz, S; Zipfel, B; Mulahasanovic, S; Pasic, M; Weng, Y; Hetzer, R				Buz, Semih; Zipfel, Burkhart; Mulahasanovic, Sead; Pasic, Miralem; Weng, Yuguo; Hetzer, Roland			Conventional surgical repair and endovascular treatment of acute traumatic aortic rupture	EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY			English	Article; Proceedings Paper	20th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery/14th Annual Meeting of the European-Society-of-Thoracic-Surgeons	SEP 10-13, 2006	Stockholm, SWEDEN	European Assoc Cardio Thorac Surg, European Soc Thorac Surg		traumatic aortic rupture; conventional surgery; endovascular stent graft	THORACIC AORTA; DELAYED TREATMENT; INJURIES; MANAGEMENT; MORTALITY	Objective: Endoluminal aortic stent grafting offers a potentially less invasive alternative to open chest surgery, especially in patients with polytrauma. We compare the results of conventional surgical repair and endovascular treatment of traumatic aortic rupture. Methods: Retrospectively, 74 patients with acute traumatic aortic rupture were analyzed. Most of the patients had a rupture limited to the isthmus, and severe associated injuries. Thirty-five patients (6 female, 29 mate, mean age 36 years) underwent surgical repair. Two patients were operated upon without cardiopulmonary bypass. In 39 patients (5 female, 34 mate, mean age 36 years) thoracic endografts were implanted. The delay between trauma and treatment was comparable in the two groups. Results: Hospital mortality was 20% (7 of 35 patients) in the surgical group and 7.7% (3 of 39 patients) in the endovascular group. The most common cause of death in the surgical group was brain death in severe traumatic patients. Ten surgical complications occurred in 5 patients: respiratory insufficiency (n = 3), pulmonary infection (n = 2), recurrent nerve palsy In = 2), repeat thoracotomy (n = 2), and compartment syndrome (n = 1). No patient in this group had paraplegia. Except for one case, which required conversion to conventional surgery, stent-graft implantation was successful in all cases, without peri-interventional complications or procedure-induced paraplegia. In 9 patients the left subclavian artery was covered with the device. Two patients underwent surgical repair 15 days and 4 months after endografting because of injury of the aortic wall by the stent and development of a spurious aneurysm, respectively. Conclusions: In the treatment of traumatic thoracic aortic rupture, the early outcome of patients treated with endovascular stent grafts appears to be better than that with conventional surgical repair. The new technique allows safe and successful repair of this life-threatening injury in the early phase of trauma management. How far this potential benefit is sustained in the tong term remains unclear at present. (c) 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.	[Buz, Semih; Zipfel, Burkhart; Mulahasanovic, Sead; Pasic, Miralem; Weng, Yuguo; Hetzer, Roland] Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, D-13353 Berlin, Germany	Buz, S (corresponding author), Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, Augustburger Pl 1, D-13353 Berlin, Germany.	buz@dhzb.de					Amabile P, 2004, J VASC SURG, V40, P873, DOI 10.1016/j.jvs.2004.08.053; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; Grabenwoger M, 2003, EUR J CARDIO-THORAC, V23, P788, DOI 10.1016/S1010-7940(03)00075-7; HETZER R, 2000, TSCHERNE UNFALLCHIRU, V2, P159; Holmes JH, 2002, ANN THORAC SURG, V73, P1149, DOI 10.1016/S0003-4975(01)03585-8; Hoornweg LL, 2006, J VASC SURG, V43, P1096, DOI 10.1016/j.jvs.2006.01.034; Hunt JP, 1996, J TRAUMA, V40, P547, DOI 10.1097/00005373-199604000-00005; Idu MM, 2005, J ENDOVASC THER, V12, P503, DOI 10.1583/04-1515R.1; Jahromi AS, 2001, J VASC SURG, V34, P1029, DOI 10.1067/mva.2001.120036; Jamieson WRE, 2002, AM J SURG, V183, P571, DOI 10.1016/S0002-9610(02)00851-6; Kuhne CA, 2005, UNFALLCHIRURG, V108, P279, DOI 10.1007/s00113-004-0890-z; Langanay T, 2002, EUR J CARDIO-THORAC, V21, P282, DOI 10.1016/S1010-7940(01)01133-2; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Nicolosi AC, 1996, ANN THORAC SURG, V61, P875, DOI 10.1016/0003-4975(95)01136-6; Ott MC, 2004, J TRAUMA, V56, P565, DOI 10.1097/01.TA.0000114061.69699.A3; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; Pierangeli A, 2000, CARDIOVASC SURG, V8, P280, DOI 10.1016/S0967-2109(00)00015-6; Rousseau H, 2005, J THORAC CARDIOV SUR, V129, P1050, DOI 10.1016/j.jtcvs.2004.12.023; Rousseau H, 1999, CIRCULATION, V99, P498, DOI 10.1161/01.CIR.99.4.498; SMITH RS, 1986, AM J SURG, V152, P660, DOI 10.1016/0002-9610(86)90444-7; VONOPPELL UO, 1994, ANN THORAC SURG, V58, P585, DOI 10.1016/0003-4975(94)92270-5; ZIPFEL B, 1999, THORAC CARDIOVASC S1, V43, P260; Zipfel B, 2007, ANN THORAC SURG, V83, P441, DOI 10.1016/j.athoracsur.2006.09.036	25	80	87	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1010-7940	1873-734X		EUR J CARDIO-THORAC	Eur. J. Cardio-Thorac. Surg.	FEB	2008	33	2					143	149		10.1016/j.ejcts.2007.10.017			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	270XC	WOS:000253752500002	18065235	Bronze			2021-06-18	
J	Hergenroeder, G; Redell, JB; Moore, AN; Dubinsky, WP; Funk, RT; Crommett, J; Clifton, GL; Levine, R; Valadka, A; Dash, PK				Hergenroeder, Georgene; Redell, John B.; Moore, Anthony N.; Dubinsky, William P.; Funk, Robert T.; Crommett, John; Clifton, Guy L.; Levine, Robert; Valadka, Alex; Dash, Pramod K.			Identification of serum biomarkers in brain-injured adults: Potential for predicting elevated intracranial pressure	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; c-reactive protein; intracranial pressure; retinol binding protein 4; secondary pathology; serum amyloid protein A	CEREBROSPINAL-FLUID; PROTEIN BIOMARKERS; CANCER-DETECTION; HEAD-INJURY; MARKERS; PLASMA; HYPERTENSION; CHILDREN; DAMAGE; CHROMATOGRAPHY	Brain injury biornarkers may have clinical utility in stratifying injury severity level, predicting adverse secondary events or outcomes, and monitoring the effectiveness of therapeutic interventions. As a biomarker source, serum offers several advantages over cerebrospinal fluid (CSF), including ease of accessibility and reduced risk to the patient. We screened pooled serum samples obtained from 11 severely injured traumatic brain injury (TBI) patients (Glasgow Coma Scale [GCS] <= 8) and 11 age-, sex- and race-matched volunteers. Two time points-41.5 +/- 4.9 h and 66.3 +/- 6.6 h post-injury-were chosen for the initial screening analysis. Samples were immunodepleted for 12 highly abundant serum proteins, and then labeled with mass-balanced isobaric tags (iTRAQ), and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Identification and quantification of 2455 iTRAQ-labeled peptides that mapped to 160 proteins revealed 31 candidate biomarkers whose serum abundance was altered after injury. Changes in three candidate biomarkers (serum amyloid A, [SAA], c-reactive protein [CRP], retinol binding protein 4 [RBP4]) were verified using independent TBI and healthy volunteer serum samples. Receiver operating characteristic (ROC) curve analysis of CRP and SAA indicated they were robust indicators of injury even at very acute time points. Analysis of serum RBP4 levels at 24-36 h post-injury indicates it may predict subsequent increases in intracranial pressure (ICP) with a sensitivity of 86% and specificity of 88% at 11.6 mu g/mL [n = 7, ICP < 20 mm Hg; n = 8, ICP > 25 mm Hg). Our results support the use of serum as a source for discovery of TBI biomarkers, and indicate that serum biomarkers may have utility for predicting secondary pathologies (e.g., elevated ICP) associated with TBI.	[Redell, John B.; Moore, Anthony N.; Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hergenroeder, Georgene; Funk, Robert T.; Crommett, John; Clifton, Guy L.; Levine, Robert; Valadka, Alex; Dash, Pramod K.] Univ Texas Houston, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; [Hergenroeder, Georgene; Funk, Robert T.; Crommett, John; Clifton, Guy L.; Levine, Robert; Valadka, Alex; Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurosurg, Houston, TX 77225 USA; [Dubinsky, William P.] Univ Texas Houston, Sch Med, Dept Integrat Biol, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Hergenroeder, Georgene/0000-0002-6170-2191; Dash, Pramod/0000-0001-6746-1002	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, R01NS049160] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR02558] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH072933] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, NS049160] Funding Source: Medline		Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Boehm AM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-214; Borovecki F, 2005, P NATL ACAD SCI USA, V102, P11023, DOI 10.1073/pnas.0504921102; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Eastham JA, 2005, NAT CLIN PRACT UROL, V2, P482, DOI 10.1038/ncpuro0321; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kratz A, 2002, AM J CLIN PATHOL, V118, P856, DOI 10.1092/BTWQ5YMYVQ67QK9L; Lachmann HJ, 2007, NEW ENGL J MED, V356, P2361, DOI 10.1056/NEJMoa070265; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; Liotta LA, 2006, J CLIN INVEST, V116, P26, DOI 10.1172/JCI27467; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pieper R, 2003, PROTEOMICS, V3, P422, DOI 10.1002/pmic.200390057; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Posadas EM, 2004, CURR OPIN ONCOL, V16, P478, DOI 10.1097/00001622-200409000-00012; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Taracha E, 2006, CLIN CHEM LAB MED, V44, P1446, DOI 10.1515/CCLM.2006.263; TEASDALE G, 1974, LANCET, V2, P81; Troyer DA, 2004, DIS MARKERS, V20, P117, DOI 10.1155/2004/509276; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wulfkuhle JD, 2003, NAT REV CANCER, V3, P267, DOI 10.1038/nrc1043; Yocum AK, 2005, J PROTEOME RES, V4, P1722, DOI 10.1021/pr0501721; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; ZWEIG MH, 1993, CLIN CHEM, V39, P561	48	80	88	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					79	93		10.1089/neu.2007.0386			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000001	18260791				2021-06-18	
J	Koskinen, S; Alaranta, H				Koskinen, Sanna; Alaranta, Hannu			Traumatic brain injury in Finland 1991-2005: A nationwide register study of hospitalized and fatal TBI	BRAIN INJURY			English	Article						traumatic brain injury; epidemiology; incidence	HEAD-INJURIES; OLDER-ADULTS; EPIDEMIOLOGY; REHABILITATION; MORTALITY; FUTURE; IMPACT	Primary objective: To examine the epidemiology of traumatic brain injury (TBI) in Finland in 1991-2005. Research design: Nationwide population based data of hospitalized and fatal TBI collected from the national registers of Finland. The incidence, age and gender distribution, aetiology, external causes, cursory outcome and mortality are presented. Methods and procedures: The data were collected from the National Hospital Discharge Register of Finland and from the official cause-of-death register of Statistics Finland. Main outcome and results: The average incidence of hospitalized TBI was 101/100 000 population and the mortality rate 18.1/100 000. The incidence increased by 59.4% in the patients aged 70 years or older while the incidence decreased by 2.4% in the younger age groups. The mortality rate decreased in men. The most common external causes were falls. The oldest patients needed 6.8-times longer stay in the hospital than the youngest. After discharge 54% of the patients needed at least occasional care. Conclusions: TBI prevention should be focused to the main groups at risk. The need for further care, rehabilitation and increasing the awareness of TBI is obvious.	[Koskinen, Sanna; Alaranta, Hannu] Kapyla Rehabil Ctr, FI-00251 Helsinki, Finland	Koskinen, S (corresponding author), Kapyla Rehabil Ctr, POB 103, FI-00251 Helsinki, Finland.	sannakos@gmail.com					Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Alaranta H, 2002, SUOM LAAKARILEHTI, V47, P4801; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Engberg AW, 2007, J HEAD TRAUMA REHAB, V22, P221, DOI 10.1097/01.HTR.0000281837.62226.54; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; HONKANEN R, 1990, HOSPITALIZATION DUE; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kannus P, 2001, J CLIN EPIDEMIOL, V54, P597, DOI 10.1016/S0895-4356(00)00346-2; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lexell J, 2007, J HEAD TRAUMA REHAB, V22, P229, DOI 10.1097/01.HTR.0000281838.00344.03; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Servadei F, 2002, J Neurosurg Sci, V46, P111; Sosin DM, 1996, BRAIN INJURY, V10, P47; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	32	80	81	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	3					205	214		10.1080/02699050801938975			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500001	18297592				2021-06-18	
J	Li, L; Lu, J; Tay, SSW; Moochhala, SM; He, BP				Li, Lu; Lu, Jia; Tay, Samuel Sam Wah; Moochhala, Shabbir M.; He, Bei Ping			The function of microglia, either neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro	BRAIN RESEARCH			English	Article						2,5-hexanedione; dual function; microglia; neurodegeneration; neurotoxicity; neuroprotection	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE; SPINAL-CORD; 2,5-HEXANEDIONE-INDUCED CHANGES; ALZHEIMERS-DISEASE; NEURONAL DAMAGE; MOTOR-NEURONS; UP-REGULATION; EXPRESSION; BRAIN	Opposing functions of activated microglia, namely neuroprotection or neurotrophy versus neurodestruction or neurotoxicity, have been observed in a number of experimental models of neurotrauma and neurodegenerative diseases. However, the mechanism(s) involved in the determination of which function activated microglia execute under a given set of conditions still remains to be elucidated. Our current in vitro study has revealed that a neuroprotective/neurotrophic or a neurodestructive/neurotoxic microglial function may be configured by the equilibrium among various microglial factors released into the microenvironment. When NSC-34 neurons were treated with lower concentrations of lipopolysaccharide-stimulated BV-2 microglial conditioned medium (LPS-BVCM), viability of the NSC-34 neurons increased, outgrowth of neuronal processes was promoted, and the formation of 2,5-hexanedione-induced aggregates was prevented. However, when NSC-34 neurons were treated with higher concentrations of the same LPS-BVCM, neuronal viability was reduced, apoptosis was induced and outgrowth of neuronal processes was prevented. Measurement of the cytokines tumor necrotic factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and IL-6 in the LPS-BVCM has shown that the upregulation in expression for each cytokine varied both temporally and quantitatively. It is postulated that an alteration in the concentration of the LPS-BVCM might significantly affect the functional balance of microglial factors in the microenvironment with a resultant different microglial function. (C) 2007 Elsevier B.V. All rights reserved.	Natl Univ Singapore, Dept Anat, Yong Loo Lin Sch Med, Singapore 117597, Singapore; DSO Natl Labs, Def Med & Environm Res Inst, Singapore, Singapore	He, BP (corresponding author), Natl Univ Singapore, Dept Anat, Yong Loo Lin Sch Med, MD10,4 Med Dr, Singapore 117597, Singapore.	anthebp@nus.edu.sg		MOOCHHALA, SHABBIR/0000-0003-4521-3192			Bissonnette CJ, 2004, NEUROSCI LETT, V361, P40, DOI 10.1016/j.neulet.2004.01.005; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; COFFEY PJ, 1990, NEUROSCIENCE, V35, P121, DOI 10.1016/0306-4522(90)90126-O; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DURHAM HD, 1993, NEUROTOXICOLOGY, V14, P387; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; Eriksson C, 2000, CYTOKINE, V12, P423, DOI 10.1006/cyto.1999.0582; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GRAHAM DG, 1995, CRIT REV TOXICOL, V25, P91, DOI 10.3109/10408449509021609; Hao AJ, 2002, NEUROSCIENCE, V112, P889, DOI 10.1016/S0306-4522(02)00144-6; Hao AJ, 2001, NEUROREPORT, V12, P1391, DOI 10.1097/00001756-200105250-00020; Hartley CL, 1997, NEUROPATH APPL NEURO, V23, P364; He BP, 1997, EXP NEUROL, V146, P587, DOI 10.1006/exnr.1997.6561; He BP, 2002, J NEUROIMMUNOL, V128, P31, DOI 10.1016/S0165-5728(02)00141-8; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; Johnson AB, 2006, J NEUROIMMUNOL, V174, P82, DOI 10.1016/j.jneuroim.2006.01.019; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LoPachin RM, 2005, NEUROTOXICOLOGY, V26, P229, DOI 10.1016/j.neuro.2004.09.007; LoPachin RM, 2004, TOXICOL APPL PHARM, V198, P61, DOI 10.1016/j.taap.2004.03.002; Lunemann A, 2006, GLIA, V53, P412, DOI 10.1002/glia.20301; Marron TU, 2005, J NEUROCHEM, V92, P10, DOI 10.1111/j.1471-4159.2004.02836.x; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; NAGATA K, 1993, J NEUROSCI RES, V34, P357, DOI 10.1002/jnr.490340313; Nakajima K, 2001, J NEUROSCI RES, V65, P322, DOI 10.1002/jnr.1157; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; Roy A, 2006, J BIOL CHEM, V281, P14971, DOI 10.1074/jbc.M600236200; Schmuck G, 1996, TOXICOL IND HEALTH, V12, P683, DOI 10.1177/074823379601200507; Shrikant P, 1996, J IMMUNOL, V157, P892; Thomas DM, 2005, FASEB J, V19, P515, DOI 10.1096/fj.05-4873fje; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Wen WY, 2006, NEUROSCI RES, V55, P87, DOI 10.1016/j.neures.2006.02.004; YAO JB, 1992, BRAIN RES, V591, P88, DOI 10.1016/0006-8993(92)90981-E	40	80	83	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 23	2007	1159						8	17		10.1016/j.brainres.2007.04.066			10	Neurosciences	Neurosciences & Neurology	198GD	WOS:000248614100002	17572395				2021-06-18	
J	Shapira, M; Licht, A; Milman, A; Pick, CG; Shohami, E; Eldar-Finkelman, H				Shapira, Moran; Licht, Avital; Milman, Anat; Pick, Chaim G.; Shohami, Esther; Eldar-Finkelman, Hagit			Role of glycogen synthase kinase-3 beta in early depressive behavior induced by mild traumatic brain injury	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; CLOSED-HEAD INJURY; FOCAL CEREBRAL-ISCHEMIA; BETA-CATENIN; HIPPOCAMPAL VOLUME; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; PRIMARY NEURONS; RAT-BRAIN; PROTEIN	Traumatic brain injury (TBI) is a triggering event for a set of pathophysiological changes and concomitant depressive behavior. Glycogen synthase kinase-3 (GSK-3) is a potent in vivo regulator of cell apoptosis and, in addition, is implicated in depressive behavior. In this study, we investigated the role of GSK-3 in the physiological model of mild TBI (mTBI) at both the cellular and behavior levels. mTBI resulted in increased phosphorylation of inhibitory site serine(9) of GSK-3 beta, which coincided with increased serine(473) phosphorylation of its upstream kinase PKB and accumulation of its downstream target beta-catenin in the hippocampus. mTBI induced a depressive behavior which was evident as early as 24 h post-injury. Pretreatment with GSK-3 inhibitors, lithium, or L803-mts prevented mTBI-induced depression. We suggest that mTBI elicits a pro-survival cascade of PKB/GSK-3 beta/ beta-catenin as part of a rehabilitation program. Furthermore, the use of selective GSK-3 inhibitors may have therapeutic benefits in treatment conditions associated with brain injury. (c) 2007 Elsevier Inc. All rights reserved.	Tel Aviv Univ, Sackler Sch Med, Dept Mol Human Genet & Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Anat, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Eldar-Finkelman, H (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Mol Human Genet & Biochem, IL-69978 Tel Aviv, Israel.	heldar@post.tau.ac.il	Eldar-Finkelman, Hagit/AAF-8329-2019; Pick, Chaim/D-4789-2009	Eldar-Finkelman, Hagit/0000-0002-8460-9686; Milman, Anat/0000-0002-8551-4101			Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Bamji SX, 2006, J CELL BIOL, V174, P289, DOI 10.1083/jcb.200601087; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen HM, 2004, SER REMOTE SENS, V3, P3, DOI 10.1142/9789812702630_0001; CHEN S, IN PRESS J CEREB BLO; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Clark RSB, 1997, J NEUROSCI, V17, P9172; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Friguls B, 2001, NEUROREPORT, V12, P3381, DOI 10.1097/00001756-200110290-00046; Gould TD, 2004, INT J NEUROPSYCHOPH, V7, P387, DOI 10.1017/S1461145704004535; Hongisto V, 2003, MOL CELL BIOL, V23, P6027, DOI 10.1128/MCB.23.17.6027-6036.2003; Hye A, 2005, NEUROSCI LETT, V373, P1, DOI 10.1016/j.neulet.2004.10.031; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kaidanovich-Beilin O, 2004, BIOL PSYCHIAT, V55, P781, DOI 10.1016/j.biopsych.2004.01.008; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Leuner B, 2004, J NEUROSCI, V24, P7477, DOI 10.1523/JNEUROSCI.0204-04.2004; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Li XH, 2005, J NEUROCHEM, V92, P701, DOI 10.1111/j.1471-4159.2004.02898.x; Li XH, 2002, BIPOLAR DISORD, V4, P137, DOI 10.1034/j.1399-5618.2002.40201.x; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; RINK A, 1995, AM J PATHOL, V147, P1575; Robinson R G, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p638A; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu X, 2003, NAT NEUROSCI, V6, P1169, DOI 10.1038/nn1132; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	61	80	84	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	APR	2007	34	4					571	577		10.1016/j.mcn.2006.12.006			7	Neurosciences	Neurosciences & Neurology	156NK	WOS:000245656000007	17289399				2021-06-18	
J	Tsubokawa, T; Jadhav, V; Solaroglu, I; Shiokawa, Y; Konishi, Y; Zhang, JH				Tsubokawa, Tamiji; Jadhav, Vikram; Solaroglu, Ihsan; Shiokawa, Yoshiaki; Konishi, Yoshifumi; Zhang, John H.			Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats	STROKE			English	Article						cerebral ischemia; lecithinized superoxide dismutase; neuronal apoptosis; oxidative stress	SPINAL-CORD INJURY; TRAUMATIC BRAIN-INJURY; HYPERBARIC-OXYGEN; OXIDATIVE STRESS; TRANSGENIC MICE; CYTOCHROME-C; ACTIVATION; MODEL; APOPTOSIS; RELEASE	Background and Purpose - Recent studies have shown the antiapoptotic neuroprotective effects of lecithinized superoxide dismutase (PC-SOD) in different forms of brain injury. We tested the effects of PC-SOD in focal cerebral ischemia in the rat middle cerebral artery occlusion model (MCAO). Methods - Adult male Sprague-Dawley rats were treated with PC-SOD (0.3, 1.0, and 3.0 mg/kg) administered intravenously after 90 minutes of occlusion (beginning of reperfusion). Physiological parameters, neurological score, and infarct volume were assessed at 24 and 72 hours in 3 groups of animals: sham-operated (n = 18), MCAO treated with vehicle (n=26), and MCAO treated with PC-SOD (n=37). Oxidative stress was evaluated by malondialdehyde assay, and the apoptotic mechanisms were studied by Western blotting. Results - PC-SOD treatment significantly reduced infarct volume and improved neurological scores at different time points compared with the vehicle-treated group. PC-SOD treatment decreased malondialdehyde levels, cytochrome c, and cleaved caspase 3 expression and increased mitochondrial Bcl-2 expression. Conclusions - Inhibition of oxidative stress with PC-SOD treatment improves outcomes after focal cerebral ischemia. This neuroprotective effect is likely exerted by antiapoptotic mechanisms.	Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA 92354 USA; Kyorin Univ, Sch Med, Tokyo, Japan	Zhang, JH (corresponding author), Loma Linda Univ, Med Ctr, Div Neurosurg, 11234 Anderson St,Rm 2562B, Loma Linda, CA 92354 USA.	johnzhang3910@yahoo.com	tao, li/G-7956-2011; Solaroglu, Ihsan/ABF-7606-2020; Solaroglu, Ihsan/ABE-8816-2020	Solaroglu, Ihsan/0000-0002-9472-1735	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD43120] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45694, NS43338] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD043120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043338, R01NS045694] Funding Source: NIH RePORTER		Calvert JW, 2003, J APPL PHYSIOL, V95, P2072, DOI 10.1152/japplphysiol.00630.2003; Chan PH, 2004, STROKE, V35, P2748, DOI 10.1161/01.STR.0000143325.25610.ac; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chikawa T, 2001, J NEUROTRAUM, V18, P93, DOI 10.1089/089771501750055802; Fujimura M, 2000, J NEUROSCI, V20, P2817; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Hori Y, 1997, JPN J PHARMACOL, V74, P99, DOI 10.1254/jjp.74.99; IGARASHI R, 1994, J PHARMACOL EXP THER, V271, P1672; IGARASHI R, 1992, J PHARMACOL EXP THER, V262, P1214; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; Koo DDH, 2001, KIDNEY INT, V60, P786, DOI 10.1046/j.1523-1755.2001.060002786.x; Kusaka I, 2004, AM J PHYSIOL-HEART C, V286, pH2442, DOI 10.1152/ajpheart.01169.2003; LIU TH, 1989, AM J PHYSIOL, V256, pH589; MEHTA JL, 1990, J CARDIOVASC PHARM, V16, P112, DOI 10.1097/00005344-199007000-00016; Nakauchi K, 1996, J NEUROTRAUM, V13, P573, DOI 10.1089/neu.1996.13.573; Noshita N, 2003, STROKE, V34, P1513, DOI 10.1161/01.STR.0000072986.46924.F4; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P557, DOI 10.1097/00004647-200105000-00010; Saito A, 2003, J NEUROSCI, V23, P1710; Shimmura S, 2003, AM J OPHTHALMOL, V135, P613, DOI 10.1016/S0002-9394(02)02151-7; Takenaga M, 2006, J CONTROL RELEASE, V110, P283, DOI 10.1016/j.jconrel.2005.10.022; Tsubokawa T, 2006, STROKE, V37, P1888, DOI 10.1161/01.STR.0000227259.15506.24; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739; Yunoki M, 2003, SURG NEUROL, V59, P156, DOI 10.1016/S0090-3019(02)01040-6	24	80	87	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAR	2007	38	3					1057	1062		10.1161/01.STR.0000257978.70312.1d			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	140DB	WOS:000244482500046	17272760	Bronze			2021-06-18	
J	Yates, PJ; Williams, WH; Harris, A; Round, A; Jenkins, R				Yates, PJ; Williams, WH; Harris, A; Round, A; Jenkins, R			An epidemiological study of head injuries in a UK population attending an emergency department	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; RISK-FACTORS; ASSOCIATIONS; MORTALITY	We aimed to identify the attendance rate for all head injuries, and for moderate to severe head injury (MSHI), in an emergency department (ED), and related risk factors for MSHI, including age, sex, area of residence, and socioeconomic status (SES). This was a retrospective descriptive epidemiological study of an ED database of head injury attendances over 6 years, carried out in an ED that serves both urban and mixed rural and urban areas, with a wide socioeconomic range, and a total population of 344 600. The main outcome measure was rates of attendance for head injury. Head injury presentations accounted for 3.4% of all attendances per year. An overall rate of 453 per 100 000 was found for all head injuries, of which 40 per 100 000 were moderate to severe (10.9%). Urban residents had significantly greater risk of presenting with MSHI compared with residents of mixed/rural areas. Males were more at risk than females, and children and adolescents had higher risk of MSHI. A high attendance rate of MSHI was found in the 5 year old age group in urban areas for both sexes. A gradient, with higher attendance in groups with lower SES, was observed for children in urban areas, while the gradient was reversed in mixed/rural areas. Head injuries are a relatively common cause of attendance at ED. There is significant variation in attendance with MSHI with regard to sex, age, socioeconomic factors, and type of area of residence. The planning and delivery of preventative and management services may be improved by such analyses.	Univ Exeter, Sch Psychol, Ctr Clin Neuropsychol Res, Exeter EX4 4QG, Devon, England; Royal Devon & Exeter Hosp, NHS Fdn, Mardon Neurorehabil Ctr, Exeter EX2 5DW, Devon, England; Royal Devon & Exeter Hosp, NHS Fdn, Emergency Dept, Exeter EX2 5DW, Devon, England; Publ Hlth Directorate, E Devon PCT, Exeter, Devon, England; Publ Hlth Directorate, Mid Devon PCT, Exeter, Devon, England	Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Ctr Clin Neuropsychol Res, Exeter EX4 4QG, Devon, England.	w.h.williams@ex.ac.uk		williams, huw/0000-0003-0670-2620			Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; *DEP ENV TRANSP RE, 2000, IND MULT DEPR 2000 R; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Lalloo R, 2003, INJURY, V34, P261, DOI 10.1016/S0020-1383(02)00277-2; Lyons RA, 2003, INJ PREV, V9, P33, DOI 10.1136/ip.9.1.33; *NHS CTR COD CLAS, 1996 HLTH SERV GUID; Roberts I, 1996, BRIT MED J, V313, P784; Stella J, 2001, ANZ J SURG, V71, P665, DOI 10.1046/j.1445-1433.2001.02229.x; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; Tennant A, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-21; TENNANT A, 1996, TRAUMATIC BRAIN INJU; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Turner-Stokes L, 2005, J NEUROL NEUROSUR PS, V76, P901, DOI 10.1136/jnnp.2005.066472; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	25	80	81	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2006	77	5					699	701		10.1136/jnnp.2005.081901			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	038QM	WOS:000237238000034	16464899	Green Published			2021-06-18	
J	Harrison-Felix, C; Whiteneck, G; DeVivo, M; Hammond, FM; Jha, A				Harrison-Felix, C; Whiteneck, G; DeVivo, M; Hammond, FM; Jha, A			Causes of death following 1 year postinjury among individuals with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						causes of death; traumatic brain injury	LONG-TERM; LIFE EXPECTANCY; SYSTEMATIC BIAS; MORTALITY; EPILEPSY; ACCURACY; INDEX; ASCERTAINMENT; POPULATION; COMPLETION	Objective: To investigate causes of death in individuals with traumatic brain injury (TBI). Design: Retrospective cohort study Setting: Utilized data from the TBI Model Systems National Database, the Social Security Death Index, death certificates, and the US population age-race-gender-cause-specific mortality rates for 1994. Patients: Two thousand one hundred forty individuals with TBI completing inpatient rehabilitation in I of 15 National Institute on Disability and Rehabilitation Research-funded TBI Model Systems of Care between 1988 and 2001, and surviving past 1 year postinjury. Main Outcome Measures: Primary cause of death based on the International Classification of Diseases - 9th Revision - Clinical Modification-coded death certificates. Results: Individuals with TBI were about 37 times more likely to die of seizures, 12 times more likely to die of septicemia, 4 times more likely to die of pneumonia, and about 3 times more likely to die of other respiratory conditions (excluding pneumonia), digestive conditions, and all external causes of injury/poisoning than were individuals in the general population of similar age, gender, and race. Conclusion: Long-term follow-tip of individuals with TBI should increase vigilance for, and prevention of, diagnoses frequently causing death (circulatory disorders) and diagnoses with a high relative risk of causing death in this population (seizures, septicemia, respiratory and digestive conditions, and external causes of injury).	Craig Hosp, Dept Res, Englewood, CO 80113 USA; Univ Colorado, Hlth Sci Ctr, Dept Rehabil Med, Denver, CO 80202 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; Charlotte Inst Rehabil, Charlotte, NC USA; Denver Hlth Med Ctr, Denver, CO USA	Harrison-Felix, C (corresponding author), Craig Hosp, Dept Res, 3425 S Clarkson Str, Englewood, CO 80113 USA.	charrison-felix@craighospital.org					Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Baguley I, 2000, BRAIN INJURY, V14, P505; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; BRESLOW NE, 1987, INT AGENCY RES CANC, V82; Caplan B, 1996, J HEAD TRAUMA REHAB, V11, P1; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; DeVivo MJ, 2004, BRAIN INJURY, V18, P1155, DOI 10.1080/02699050410001672323; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; DEVIVO MJ, 1995, CHEST, V108, P226, DOI 10.1378/chest.108.1.226; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Ficker DM, 1998, NEUROLOGY, V51, P1270, DOI 10.1212/WNL.51.5.1270; FISHER SG, 1995, AM J EPIDEMIOL, V141, P242, DOI 10.1093/oxfordjournals.aje.a117426; Gordis L., 2000, EPIDEMIOLOGY; HAMMOND F, 2000, ARCH PHYS MED REHAB, V81, P1259; Hammond F. M., 2000, ARCH PHYS MED REHAB, V81, P1260; Hanna N.J, 2002, NATL SENTINEL CLIN A; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; KIRCHER T, 1987, JAMA-J AM MED ASSOC, V258, P349, DOI 10.1001/jama.258.3.349; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Lhatoo SD, 2001, ANN NEUROL, V49, P336; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; Morgan CL, 2002, EPILEPSIA, V43, P1251, DOI 10.1046/j.1528-1157.2002.38701.x; *NAT CTR HLTH STAT, DEATHS 282 SEL CAUS; *NAT CTR HLTH STAT, DEATH RAT 72 SEL CAU; *NAT CTR HLTH STAT, DEATH RAT 113 SEL CA; *NAT CTR HLTH STAT, DEATH RAT 282 SEL CA; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Roberts A.V., 1979, SEVERE ACCIDENTAL HE, P140; Rosenthal M, 1993, J HEAD TRAUMA REHAB, V8, P1; Schnorr TM, 1997, EPIDEMIOLOGY, V8, P321, DOI 10.1097/00001648-199705000-00017; Sesso HD, 2000, AM J EPIDEMIOL, V152, P107, DOI 10.1093/aje/152.2.107; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Sperling MR, 1999, ANN NEUROL, V46, P45, DOI 10.1002/1531-8249(199907)46:1<45::AID-ANA8>3.0.CO;2-I; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Strauss DJ, 2003, NEUROLOGY, V60, P395, DOI 10.1212/WNL.60.3.395; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 2001, HEAD TRAUMA, P327; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US DEP COMM, 1994, CURR POP REP PROJ PO; *US DHHS, 1995, PHYS HDB MED CERT DE; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; Whiteneck G, 2001, COLORADO TRAUMATIC B; 1986, INT CLASSIFICATION D	62	80	80	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2006	21	1					22	33		10.1097/00001199-200601000-00003			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	004WW	WOS:000234784300003	16456389				2021-06-18	
J	Cunningham, AS; Salvador, R; Coles, JP; Chatfield, DA; Bradley, PG; Johnston, AJ; Steiner, LA; Fryer, TD; Aigbirhio, FI; Smielewski, P; Williams, GB; Carpenter, TA; Gillard, JH; Pickard, JD; Menon, DK				Cunningham, AS; Salvador, R; Coles, JP; Chatfield, DA; Bradley, PG; Johnston, AJ; Steiner, LA; Fryer, TD; Aigbirhio, FI; Smielewski, P; Williams, GB; Carpenter, TA; Gillard, JH; Pickard, JD; Menon, DK			Physiological thresholds for irreversible tissue damage in contusional regions following traumatic brain injury	BRAIN			English	Article						traumatic brain injury; CBF; cerebral metabolism; physiological thresholds; prediction	CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; MAGNETIC-RESONANCE-SPECTROSCOPY; HEAD-INJURY; MODERATE HYPERVENTILATION; OXYGEN-CONSUMPTION; PERFUSION-PRESSURE; STROKE PATIENTS; FOCAL ISCHEMIA; METABOLISM	Cerebral ischaemia appears to be an important mechanism of secondary neuronal injury in traumatic brain injury (TBI) and is an important predictor of outcome. To date, the thresholds of cerebral blood flow (CBF) and cerebral oxygen utilization (CMRO2) for irreversible tissue damage used in TBI studies have been adopted from experimental and clinical ischaemic stroke studies. Identification of irreversibly damaged tissue in the acute phase following TBI could have considerable therapeutic and prognostic implications. However, it is questionable whether stroke thresholds are applicable to TBI. Therefore, the aim of this study was to determine physiological thresholds for the development of irreversible tissue damage in contusional and pericontusional regions in TBI, and to determine the ability of such thresholds to accurately differentiate irreversibly damaged tissue. This study involved 14 patients with structural abnormalities on late-stage MRI, all of whom had been studied with O-15 PET within 72 h of TBI. Lesion regions of interest (ROI) and non-lesion ROIs were constructed on late-stage MRIs and applied to co-registered PET maps of CBF, CMRO2 and oxygen extraction fraction (OEF). From the entire population of voxels in non-lesion ROIs, we determined thresholds for the development of irreversible tissue damage as the lower limit of the 95% confidence interval for CBF, CMRO2 and OEF. To test the ability of a physiological variable to differentiate lesion and non-lesion tissue, we constructed probability curves, demonstrating the ability of a physiological variable to predict lesion and non-lesion outcomes. The lower limits of the 95% confidence interval for CBF, CMRO2 and OEF in non-lesion tissue were 15.0 ml/100 ml/min, 36.7 mu mol/100 ml/min and 25.9% respectively. Voxels below these values were significantly more frequent in lesion tissue (all P < 0.005, Mann-Whitney U-test). However, a significant proportion of lesion voxels had values above these thresholds, so that definition of the full extent of irreversible tissue damage would not be possible based upon single physiological thresholds. We conclude that, in TBI, the threshold of CBF below which irreversible tissue damage consistently occurs differs from the classical CBF threshold for stroke (where similar methodology is used to define such thresholds). The CMRO2 threshold is comparable to that reported in the stroke literature. At a voxel-based level, however (and in common with ischaemic stroke), the extent of irreversible tissue damage cannot be accurately predicted by early abnormalities of any single physiological variable.	Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Radiol, Cambridge CB2 2QQ, England	Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Dept Med, Box 93, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Steiner, Luzius/J-1987-2019	Salvador, Raymond/0000-0001-5557-1562; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390] Funding Source: Medline		ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; BARON JC, 1984, J CEREBR BLOOD F MET, V4, P140, DOI 10.1038/jcbfm.1984.22; BARON JC, 1983, J CEREB BLOOD FLOW M, V1, pS1; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Heiss WD, 2000, STROKE, V31, P366, DOI 10.1161/01.STR.31.2.366; Heiss WD, 1998, J CEREBR BLOOD F MET, V18, P1298, DOI 10.1097/00004647-199812000-00004; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; Heiss WD, 2001, BRAIN, V124, P20, DOI 10.1093/brain/124.1.20; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; JENNETT B, 1975, LANCET, V1, P480; Jiang Q, 1997, J NEUROL SCI, V145, P15, DOI 10.1016/S0022-510X(96)00286-9; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; Marchal G, 1996, STROKE, V27, P599, DOI 10.1161/01.STR.27.4.599; MARCHAL G, 1992, ARCH NEUROL-CHICAGO, V49, P1013, DOI 10.1001/archneur.1992.00530340029014; MARCOUX FW, 1982, STROKE, V13, P339, DOI 10.1161/01.STR.13.3.339; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; PHELPS ME, 1979, J NUCL MED, V20, P328; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SETTE G, 1993, STROKE, V24, P2046, DOI 10.1161/01.STR.24.12.2046; Smielewski Peter, 2002, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Warach S, 2001, STROKE, V32, P2460; Wu O, 2001, STROKE, V32, P933, DOI 10.1161/01.STR.32.4.933	59	80	84	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG	2005	128		8				1931	1942		10.1093/brain/awh536			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	948OB	WOS:000230724500021	15888537	Bronze			2021-06-18	
J	Schuster, R; Waxman, K; Sanchez, B; Becerra, S; Chung, R; Conner, S; Jones, T				Schuster, R; Waxman, K; Sanchez, B; Becerra, S; Chung, R; Conner, S; Jones, T			Magnetic resonance imaging is not needed to clear cervical spines in blunt trauma patients with normal computed tomographic results and no motor deficits	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	76th Annual Meeting of the Pacific-Coast-Surgical-Association	FEB 19-20, 2005	Dana Point, CA	Pacific Coast Surg Assoc			RADIOGRAPHY; INJURY; FRACTURES	Hypothesis: Trauma patients with normal motor examination results and normal cervical spine helical computed tomographic (CT) scans with sagittal reconstructions do not have significant cervical spine injury. Design: Prospectively collected registry data. Setting: Level 11 community-based trauma center Patients: All patients admitted to the trauma service from January 1, 1999, to December 31, 2003. Main Outcome Measures: Injury detected by CT and/or magnetic resonance imaging (MRI) of the cervical spine. Neurologic examination and need for surgery were secondary outcomes. Results: During the study period, 2854 trauma patients were admitted, of whom 91.2% had blunt trauma. Of these patients, 56.2% had a closed head injury. One hundred patients had cervical spine and/or spinal cord injuries. Eighty-five patients had a cervical spine injury diagnosed by CT. Fifteen patients had admission neurologic deficits not seen on CT, and 7 of these patients had nonbony abnormalities on MRI. Ninety-three patients had a normal admission motor examination result, a CT result negative for trauma, and persistent cervical spine pain, and were examined with MRI. All MRI examination results were negative for clinically significant injury. Seventeen patients had MRIs that showed degenerative disc disease, and 6 had spinal canal stenosis secondary to ossification. Twelve comatose patients (Glasgow Coma Scale score, < 9), moving all 4 extremities on arrival, with normal CT results of the cervical spine, were examined with MRI. All of these MRI examination results were negative for injury. None of the patients experienced neurologic deterioration. No patient required operative management of spinal injury. Conclusion: Blunt trauma patients with normal motor examination results and normal CT results of the cervical spine do not require further radiologic examination before clearing the cervical spine.	Santa Barbara Cottage Hosp, Dept Surg Educ, Santa Barbara, CA 93102 USA; Santa Barbara Cottage Hosp, Dept Surg, Santa Barbara, CA 93102 USA; Santa Barbara Cottage Hosp, Dept Neurosurg, Santa Barbara, CA 93102 USA	Waxman, K (corresponding author), Santa Barbara Cottage Hosp, Dept Surg Educ, POB 689, Santa Barbara, CA 93102 USA.	kwaxman@sbch.org					Albrecht RM, 2003, AM SURGEON, V69, P261; Barba CA, 2001, J TRAUMA, V51, P652, DOI 10.1097/00005373-200110000-00005; Berne JD, 1999, J TRAUMA, V47, P896, DOI 10.1097/00005373-199911000-00014; Besman A, 2003, AM SURGEON, V69, P1010; BOROCK EC, 1991, J TRAUMA, V31, P1001, DOI 10.1097/00005373-199107000-00021; Crim JR, 2001, SEMIN ULTRASOUND CT, V22, P283, DOI 10.1016/S0887-2171(01)90023-X; Diaz JJ, 2003, J TRAUMA, V55, P658, DOI 10.1097/01.TA.0000088120.99247.4A; Hanson JA, 2002, AM J ROENTGENOL, V178, P1261, DOI 10.2214/ajr.178.5.1781261; Hoffman JR, 1998, ANN EMERG MED, V32, P461, DOI 10.1016/S0196-0644(98)70176-3; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Horn EM, 2004, J NEUROSURG-SPINE, V1, P39, DOI 10.3171/spi.2004.1.1.0039; MARION D, DETERMINATION CERVIC; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; RAVICHANDRAN G, 1982, BRIT MED J, V284, P953, DOI 10.1136/bmj.284.6320.953; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; SANCHEZ B, IN PRESS J TRAUMA; Schenarts PJ, 2001, J TRAUMA, V51, P663, DOI 10.1097/00005373-200110000-00007; Weisskopf M, 2001, EUR SPINE J, V10, P250, DOI 10.1007/s005860000208; WOODRING JH, 1993, J TRAUMA, V34, P32, DOI 10.1097/00005373-199301000-00006	19	80	81	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0004-0010	1538-3644		ARCH SURG-CHICAGO	Arch. Surg.	AUG	2005	140	8					762	765		10.1001/archsurg.140.8.762			4	Surgery	Surgery	951RM	WOS:000230948300013	16103286	Bronze			2021-06-18	
J	Hart, T; Whyte, J; Kim, J; Vaccaro, M				Hart, T; Whyte, J; Kim, J; Vaccaro, M			Executive function and self-awareness of "real-world" behavior and attention deficits following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						executive function; observational rating scales; self-awareness; traumatic brain njury	COGNITIVE-FAILURES-QUESTIONNAIRE; VERBAL FLUENCY TASKS; CLOSED-HEAD-INJURY; IMPAIRED AWARENESS; INDIVIDUAL-DIFFERENCES; FRONTAL-LOBE; CONSCIOUSNESS; REHABILITATION; DISTURBANCES; DYSFUNCTION	Objective: To investigate the relationship between executive function and awareness of real-world behavioral and attentional dysfunction in persons with moderate and severe traumatic brain injury (TBI) and uninjured controls. Design: Observational 2-group study. Participants: Thirty-six persons with moderate to severe TBI and residual cognitive deficits, recruited from therapy programs and the community, and 30 uninjured control participants of similar age, education, gender, and race. Measures: Eight clinical measures of executive function were combined in a composite score, the Executive Composite (EC). Awareness of behavioral and attentional lapses in everyday life was estimated using Self and Significant Other (SO) ratings on the Dysexecutive (DEX) Questionnaire and the Cognitive Failures Questionnaire (CFQ). Results: Participants with TBI scored significantly worse on the EC than control participants and exhibited impaired self-awareness (ISA) compared to controls. Control participants agreed closely with their SOs on both the DEX and CFQ scales, whereas the SOs of TBI participants reported significantly greater degrees of difficulty on both scales than was endorsed by participants with TBI. Low-EC scorers within the TBI group had significantly worse ISA than controls, lending support to the hypothesis that executive function is related to ISA in chronic, moderate to severe TBI. Executive function and discrepancy scores demonstrated a modest but statistically significant association across the sample. Conclusion: Although executive function was associated with ISA in this sample, further research is needed to determine whether executive function deficits contribute in a causal fashion to ISA, and which of the cognitive operations within executive function are responsible for supporting self-awareness.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Moss Rehabil Res Inst, Elkins Pk, PA USA; Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu	Kim, Junghoon John/I-6702-2019; Kim, Junghoon/A-6669-2012	Kim, Junghoon John/0000-0001-5729-8993; Whyte, John/0000-0002-4381-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Baddeley A, 1998, J INT NEUROPSYCH SOC, V4, P523, DOI 10.1017/S135561779800513X; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Benton A., 1994, MULTILINGUAL APHASIA; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hart T, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P133; Heaton R., 1993, WISCONSIN CARD SORTI; Jones GV, 2003, APPL COGNITIVE PSYCH, V17, P861, DOI 10.1002/acp.935; KIM J, IN PRESS J INT NEURO; Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121; Kruger J, 2004, PERS SOC PSYCHOL B, V30, P328, DOI 10.1177/0146167203259932; Larson GE, 1997, BRIT J PSYCHOL, V88, P29, DOI 10.1111/j.2044-8295.1997.tb02618.x; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MEIRAN N, 1994, PERS INDIV DIFFER, V17, P727, DOI 10.1016/0191-8869(94)90042-6; Newman AC, 2000, BRAIN INJURY, V14, P333; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 2003, NEUROPSYCHOL REHABIL, V13, P13, DOI 10.1080/09602010244000282; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigozhin L, 1996, FREE BOUNDARY PROBLE, V10, P2; Randolph C., 1993, NEUROPSYCHOLOGY, V7, P82, DOI [10.1037/0894-4105.7.1.82, DOI 10.1037/0894-4105.7.1.82]; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Reitan RM., 1985, HALSTEAD REITAN NEUR; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; TEASDALE G, 1974, LANCET, V2, P81; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Wagle AC, 1999, COMPR PSYCHIAT, V40, P478, DOI 10.1016/S0010-440X(99)90093-7; Wallace JC, 2003, J BUS PSYCHOL, V17, P503, DOI 10.1023/A:1023452218225; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Wilson BA, 1996, BEHAV ASSESSMENT DYS	56	80	81	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2005	20	4					333	347		10.1097/00001199-200507000-00005			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941MV	WOS:000230219800005	16030440				2021-06-18	
J	Carrick, MM; Tyroch, AH; Youens, CA; Handley, T				Carrick, MM; Tyroch, AH; Youens, CA; Handley, T			Subsequent development of thrombocytopenia and coagulopathy in moderate and severe head injury: Support for serial laboratory examination	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Japanese-Association-for-Acute-Medicine	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma, Japanese Assoc Acute Med		traumatic brain injury; secondary brain insult; thrombocytopenia; coagulopathy	DISSEMINATED INTRAVASCULAR COAGULATION; BRAIN-INJURY; TRAUMA; DISTURBANCES; FIBRINOLYSIS; ACTIVATION; HEMORRHAGE; SYSTEM	Background. Patients with moderate and severe traumatic brain injury (TBI) are at risk for secondary brain insults such as thrombocytopenia and coagulopathy. This study assessed the development of thrombocytopenia and coagulopathy at admission and within the subsequent 72 hours after TBI. Methods: Blunt trauma patients with moderate or severe TBI and an extracranial Abbreviated Injury Scale score less than 3 were reviewed. Data collection included initial and subsequent prothrombin time, partial thromboplastin time, and platelet values. Results: On initial evaluation, thrombocytopenia was present in 14% and coagulopathy in 21% of patients. By the third day, thrombocytopenia and coagulopathy increased to 46% and 41%, respectively. Of patients who died, 67% had thrombocytopenia and 62% had coagulopathy. Conclusion: Patients with moderate and severe TBI are at risk for thrombocytopenia and coagulopathy, not only at admission but also on subsequent laboratory examination. Repeat laboratory evaluation is warranted even if initial results are normal in this population.	Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Texas Tech Univ, Hlth Sci Ctr, El Paso, TX USA	Carrick, MM (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, 1 Baylor Plaza, Houston, TX 77030 USA.	mcarrick@bcm.tmc.edu					AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; AUER LM, 1979, ACTA NEUROCHIR, V49, P219, DOI 10.1007/BF01808961; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; Chesnut R M, 1995, New Horiz, V3, P366; CLARK JA, 1980, J NEUROSURG, V52, P266, DOI 10.3171/jns.1980.52.2.0266; Cortiana M, 1986, J Neurosurg Sci, V30, P133; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; DAWODU ST, 2003, EMEDICINE, V6, P1; DRAYER BP, 1975, JAMA-J AM MED ASSOC, V231, P174, DOI 10.1001/jama.231.2.174; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Keller M S, 2001, Semin Pediatr Surg, V10, P12, DOI 10.1053/spsu.2001.19381; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; May AK, 1997, AM SURGEON, V63, P233; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Murshid WR, 2002, BRIT J NEUROSURG, V16, P362, DOI 10.1080/0268869021000007597; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; PRESTON FE, 1974, J NEUROL NEUROSUR PS, V37, P241, DOI 10.1136/jnnp.37.3.241; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021	35	80	89	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2005	58	4					725	729		10.1097/01.TA.0000159249.68363.78			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	919VS	WOS:000228646300018	15824648				2021-06-18	
J	Larsson, A; Wilhelmsson, U; Pekna, M; Pekny, M				Larsson, A; Wilhelmsson, U; Pekna, M; Pekny, M			Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP(-/-)Vim(-/-) mice	NEUROCHEMICAL RESEARCH			English	Article						neurogenesis; dentate gyrus; hippocampus; astrocytes; intermediate filaments; glial fibrillary acidic protein; vimentin	FIBRILLARY ACIDIC PROTEIN; NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; REACTIVE ASTROCYTES; GLIAL REACTION; MOUSE-BRAIN; VIMENTIN; NEURONS; REGENERATION	In response to central nervous system (CNS) injury, and more discretely so also during aging, astrocytes become reactive and increase their expression of the intermediate. lament proteins glial fibrillary acidic protein (GFAP) and vimentin. Studies of mice deficient in astrocytic intermediate. laments have provided insights into the function of reactive gliosis. Recently we demonstrated robust integration of retinal transplants (1) and increased post-traumatic synaptic regeneration (2) in GFAP(-/-) Vim(-/-) mice, suggesting that modulation of astrocyte activity affects the permissiveness of the CNS environment for regeneration. Neurogenesis in the adult mammalian CNS is restricted to essentially two regions, the hippocampus and the subventricular zone. Here, we assessed neurogenesis in the hippocampus of 18-month-old GFAP(-/-) Vim(-/-) mice. In the granular layer of the dentate gyrus, cell proliferation/survival was 34% higher and neurogenesis 36% higher in GFAP(-/-) Vim(-/-) mice than in wildtype controls. These findings suggest that the adult hippocampal neurogenesis in healthy old mice can be increased by modulating astrocyte reactivity.	Univ Gothenburg, Dept Med Biochem, Sahlgrenska Acad, S-40530 Gothenburg, Sweden	Pekny, M (corresponding author), Univ Gothenburg, Dept Med Biochem, Sahlgrenska Acad, Box 440, S-40530 Gothenburg, Sweden.	Milos.Pekny@medkem.gu.se	Pekna, Marcela/AAM-3261-2021; Pekna, Marcela/AAM-3249-2021	Pekna, Marcela/0000-0003-2734-8237; Pekna, Marcela/0000-0003-2734-8237			Amenta F, 1998, MICROSC RES TECHNIQ, V43, P29, DOI 10.1002/(SICI)1097-0029(19981001)43:1<29::AID-JEMT5>3.0.CO;2-H; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; David JP, 1997, NEUROSCI LETT, V235, P53, DOI 10.1016/S0304-3940(97)00708-8; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Emsley JG, 2004, TRENDS NEUROSCI, V27, P238, DOI 10.1016/j.tins.2004.02.008; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GOSS JR, 1991, NEUROBIOL AGING, V12, P165, DOI 10.1016/0197-4580(91)90056-P; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Imura T, 2003, J NEUROSCI, V23, P2824; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; KOHAMA SG, 1995, NEUROBIOL AGING, V16, P59, DOI 10.1016/0197-4580(95)80008-F; Kurimoto Y, 2001, NEUROSCI LETT, V306, P57, DOI 10.1016/S0304-3940(01)01857-2; Lane EB, 2004, METHOD CELL BIOL, V78, P229; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Mirich JM, 2002, J COMP NEUROL, V454, P361, DOI 10.1002/cne.10426; Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Pekny M, 2004, TRENDS NEUROSCI, V27, P243, DOI 10.1016/j.tins.2004.01.012; PEKNY M, 2004, IN PRESS J PATHOL, V204; Privat A, 2003, GLIA, V43, P91, DOI 10.1002/glia.10249; Quinlan R, 2004, TRENDS NEUROSCI, V27, P241, DOI 10.1016/j.tins.2004.02.009; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Unger JW, 1998, MICROSC RES TECHNIQ, V43, P24, DOI 10.1002/(SICI)1097-0029(19981001)43:1<24::AID-JEMT4>3.0.CO;2-P; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004	34	80	86	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	NOV	2004	29	11					2069	2073		10.1007/s11064-004-6880-2			5	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	876ZS	WOS:000225538200014	15662841				2021-06-18	
J	Falsig, J; Latta, M; Leist, M				Falsig, J; Latta, M; Leist, M			Defined inflammatory states in astrocyte cultures: correlation with susceptibility towards CD95-driven apoptosis	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; astrocyte; CD95; inflammation; nitric oxide; p38	NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; HUMAN FETAL ASTROCYTES; CENTRAL-NERVOUS-SYSTEM; TRANSIENT GLOBAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; HUMAN GLIOMA-CELLS; FAS LIGAND CD95L	A complete cytokine mix (CCM) or its individual components tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interferon-gamma (IFN-gamma) were used to switch resting murine astrocytes to reactive states. The transformation process was characterized by differential up-regulation of interleukin-6 (IL-6), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthetase (iNOS) mRNA and protein and a subsequent release of prostaglandin E2, nitric oxide (NO) and IL-6. Both CD95L and anti-CD95 antibodies triggered caspase activation followed by apoptotic death in fully pro-inflammatory astrocytes, whereas resting cells were totally resistant. Two other death-inducing ligands, TNF and TNF-related apoptosis-inducing ligand (TRAIL) did not induce apoptosis in reactive astrocytes. The switch in astrocyte sensitivity was accompanied by up-regulation of caspase-8 and CD95 as well as the capacity to recruit Fas-associated death domain (FADD) to the activated death receptor complex. Neither CD95-mediated death, nor other inflammatory parameters were affected by inhibition of iNOS or COX, respectively. Accordingly, IFN-gamma was absolutely essential for up-regulation of iNOS, but not for the switch in apoptosis sensitivity. In contrast, p38 kinase activity was identified as an important controller of both the inflammatory reaction and apoptosis both in astrocytes stimulated with CCM and in glia exposed to TNF and IL-1 only.	H Lundbeck & Co AS, Mol Dis Biol, DK-2500 Valby, Denmark; Univ Konstanz, D-7750 Constance, Germany	Falsig, J (corresponding author), H Lundbeck & Co AS, Mol Dis Biol, Ottiliavej 9, DK-2500 Valby, Denmark.		Leist, Marcel/D-2133-2010	Leist, Marcel/0000-0002-3778-8693			Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Becher B, 1998, NEUROSCIENCE, V84, P627, DOI 10.1016/S0306-4522(97)00455-7; Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Bechmann I, 2002, J NEUROIMMUNOL, V132, P60, DOI 10.1016/S0165-5728(02)00311-9; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; Bordin S, 2003, J IMMUNOL, V170, P667, DOI 10.4049/jimmunol.170.2.667; Bowman CC, 2003, GLIA, V43, P281, DOI 10.1002/glia.10256; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Choi C, 1999, J IMMUNOL, V162, P1889; Choi C, 2002, J NEURO-ONCOL, V56, P13, DOI 10.1023/A:1014467626314; Choi C, 2001, CANCER RES, V61, P3084; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Ciccarelli R, 2001, INT J DEV NEUROSCI, V19, P395, DOI 10.1016/S0736-5748(00)00084-8; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Davidson WF, 2002, J IMMUNOL, V169, P6218, DOI 10.4049/jimmunol.169.11.6218; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Dorf ME, 2000, J NEUROIMMUNOL, V111, P109, DOI 10.1016/S0165-5728(00)00371-4; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; Ferrer I, 2001, ACTA NEUROPATHOL, V102, P121; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Harrrison M, 1998, FEBS LETT, V435, P207, DOI 10.1016/S0014-5793(98)01051-5; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Hentze H, 2001, BIOCHEM BIOPH RES CO, V283, P1111, DOI 10.1006/bbrc.2001.4918; Hirst WD, 1999, MOL CELL NEUROSCI, V13, P57, DOI 10.1006/mcne.1998.0731; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; Hua LWL, 2002, J NEUROIMMUNOL, V126, P180, DOI 10.1016/S0165-5728(02)00055-3; Kohji T, 2000, J NEUROIMMUNOL, V106, P165, DOI 10.1016/S0165-5728(00)00238-1; Lee SJ, 2000, J IMMUNOL, V164, P1277, DOI 10.4049/jimmunol.164.3.1277; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Li GL, 2000, ACTA NEUROPATHOL, V100, P75, DOI 10.1007/s004010051195; Loihl AK, 1999, BRAIN RES, V830, P155, DOI 10.1016/S0006-8993(99)01388-8; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; Malipiero U, 1997, EUR J IMMUNOL, V27, P3151, DOI 10.1002/eji.1830271211; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Maslinska D, 1999, FOLIA NEUROPATHOL, V37, P75; MATSUYAMA T, 1994, BRAIN RES, V657, P342, DOI 10.1016/0006-8993(94)90989-X; Mezosi E, 2002, J CLIN ENDOCR METAB, V87, P4264, DOI 10.1210/jc.2002-020111; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; MOLINAHOLGADO F, 1995, GLIA, V15, P167, DOI 10.1002/glia.440150209; Moreau G, 2001, BLOOD, V97, P3069, DOI 10.1182/blood.V97.10.3069; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Piao CS, 2002, MOL BRAIN RES, V107, P137, DOI 10.1016/S0169-328X(02)00456-4; Quirk SM, 2000, BIOL REPROD, V63, P49, DOI 10.1095/biolreprod63.1.49; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Riccioli A, 2000, J IMMUNOL, V165, P743, DOI 10.4049/jimmunol.165.2.743; Saas P, 1999, J IMMUNOL, V162, P2326; Saas P, 2002, NEUROREPORT, V13, P1921, DOI 10.1097/00001756-200210280-00018; Scaffidi C, 1999, METHODS, V17, P287, DOI 10.1006/meth.1999.0742; Shin DH, 2002, J NEUROIMMUNOL, V123, P50, DOI 10.1016/S0165-5728(01)00478-7; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Sola C, 2002, EUR J NEUROSCI, V16, P1275, DOI 10.1046/j.1460-9568.2002.02199.x; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Terrazzino S, 2002, J NEUROIMMUNOL, V124, P45, DOI 10.1016/S0165-5728(02)00013-9; Van Landeghem FKH, 2002, PEDIATR RES, V51, P129, DOI 10.1203/00006450-200202000-00003; Weinstein DE, 1997, CURRENT PROTOCOLS NE; Wosik K, 2001, GLIA, V33, P217, DOI 10.1002/1098-1136(200103)33:3<217::AID-GLIA1020>3.0.CO;2-W	71	80	81	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	JAN	2004	88	1					181	193		10.1046/j.1471-4159.2003.02144.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	753YJ	WOS:000187275700019	14675162				2021-06-18	
J	Glaesser, J; Neuner, F; Lutgehetmann, R; Schmidt, R; Elbert, T				Glaesser, Judith; Neuner, Frank; Luetgehetmann, Ralph; Schmidt, Roger; Elbert, Thomas			Posttraumatic Stress Disorder in patients with traumatic brain injury	BMC PSYCHIATRY			English	Article								Background: Severe traumatic stressors such as war, rape, or life-threatening accidents can result in a debilitating psychopathological development conceptualised as Posttraumatic Stress Disorder (PTSD). Pathological memory formation during an alarm response may set the precondition for PTSD to occur. If true, a lack of memory formation by extended unconsciousness in the course of the traumatic experience should preclude PTSD. Methods: 46 patients from a neurological rehabilitation clinic were examined by means of questionnaires and structured clinical interviews. All patients had suffered a TBI due to an accident, but varied with respect to falling unconscious during the traumatic event. Results: 27% of the sub-sample who were not unconscious for an extended period but only 3% (1 of 31 patients) who were unconscious for more than 12 hours as a result of the accident were diagnosed as having current PTSD (P < .02). Furthermore, intrusive memories proved to be far more frequent in patients who had not been unconscious. This was also the case for other reexperiencing symptoms and for psychological distress and physiological reactivity to reminders of the traumatic event. Conclusion: TBI and PTSD are not mutually exclusive. However, victims of accidents are unlikely to develop a PTSD if the impact to the head had resulted in an extended period of unconsciousness.	[Glaesser, Judith; Neuner, Frank; Elbert, Thomas] Univ Konstanz, Dept Psychol, D-78457 Constance, Germany; [Neuner, Frank; Elbert, Thomas] Vivo, Cupramontana, Italy; [Luetgehetmann, Ralph; Schmidt, Roger] Kliniken Schmieder, D-78464 Constance, Germany	Glaesser, J (corresponding author), Univ Konstanz, Dept Psychol, D-78457 Constance, Germany.	Judith.Glaesser@uni-konstanz.de; Frank.Neuner@uni-konstanz.de; r.luetgehetmann@t-online.de; r.Schmidt@kliniken-schmieder.de; Thomas.Elbert@vivo.org	; Elbert, Thomas/C-8556-2009	Glaesser, Judith/0000-0002-6173-3596; Elbert, Thomas/0000-0003-1332-4939	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG); Lurija-Institute	Supported by the Deutsche Forschungsgemeinschaft and the Lurija-Institute. We thank Christina J. Robert for editorial assistance and helpful comments on the ms.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Elbert T, 2002, NATURE, V419, P883, DOI 10.1038/419883a; Foa E.B., 1995, POSTTRAUMATIC STRESS; Freeman HL, 1999, BRIT J PSYCHIAT, V174, P79; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Gunkel S, 1999, TRAUMA KONFLIKT ZUGA, P48; Harting C., 2000, WECHSLER GEDACHTNIST; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; Maes M, 2000, EUR ARCH PSY CLIN N, V250, P156, DOI 10.1007/s004060070034; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; Neuner F, PSYCHOL TRAUMA UNPUB; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; STEIL R, 1997, POSTTRAUMATISCHE INT; Wittchen H. U., 1997, STRUKTURIERTES KLIN	21	80	83	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-244X			BMC PSYCHIATRY	BMC Psychiatry		2004	4								5	10.1186/1471-244X-4-5			6	Psychiatry	Psychiatry	V22MU	WOS:000208280100005	15113439	DOAJ Gold			2021-06-18	
